PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Aylon, Y; Yabuta, N; Besserglick, H; Buganim, Y; Rotter, V; Nojima, H; Oren, M				Aylon, Y.; Yabuta, N.; Besserglick, H.; Buganim, Y.; Rotter, V.; Nojima, H.; Oren, M.			Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation	ONCOGENE			English	Article						Ras; p53; Lats2; apoptosis	MAMMARY EPITHELIAL-CELLS; DOWN-REGULATION; PROMOTER HYPERMETHYLATION; DNA HYPERMETHYLATION; GENOMIC INSTABILITY; INDUCED SENESCENCE; P53; P16(INK4A); MUTATIONS; CANCER	The Lats2 tumor suppressor protein has been implicated earlier in promoting p53 activation in response to mitotic apparatus stress, by preventing Mdm2-driven p53 degradation. We now report that Lats2 also has a role in an ATR-Chk1-mediated stress check point in response to oncogenic H-Ras. Activated mutant H-Ras triggers the translocation of Lats2 from centrosomes into the nucleus, coupled with an increase in Lats2 protein levels. This leads to the induction of p53 activity, upregulation of proapoptotic genes, downregulation of antiapoptotic genes and eventually apoptotic cell death. Many of the cells that survive apoptosis undergo senescence. However, a fraction of the cells escape this checkpoint mechanism, despite maintaining a high mutant H-Ras expression. These escapers display increased genome instability, as evidenced by a substantial fraction of cells with micronuclei and cells with polyploid genomes. Interestingly, such cells show markedly reduced levels of Lats2, in conjunction with enhanced hypermethylation of the Lats2 gene promoter. Our findings suggest that Lats2 might have an important role in quenching H-Ras-induced transformation, whereas silencing of Lats2 expression might serve as a mechanism to enable tumor progression. Oncogene (2009) 28, 4469-4479; doi:10.1038/onc.2009.270; published online 26 October 2009	[Aylon, Y.; Besserglick, H.; Buganim, Y.; Rotter, V.; Oren, M.] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; [Yabuta, N.; Nojima, H.] Osaka Univ, Microbial Dis Res Inst, Dept Mol Genet, Osaka, Japan	Weizmann Institute of Science; Osaka University	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, 300 Herzl St, IL-76100 Rehovot, Israel.	moshe.oren@weizmann.ac.il		Oren, Moshe/0000-0003-4311-7172	National Cancer Institute [R37 CA40099]; EC [LSHC-CT-2004-503576]; Dr Miriam and Sheldon Adelson Medical Research Foundation; Yad Abraham Center for Cancer Diagnosis and Therapy; NATIONAL CANCER INSTITUTE [R37CA040099] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); EC(European CommissionEuropean Commission Joint Research Centre); Dr Miriam and Sheldon Adelson Medical Research Foundation; Yad Abraham Center for Cancer Diagnosis and Therapy; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Doron Ginsberg, Reuven Agami and Scott Lowe for the generous gift or plasmids and the following people for other help: Lior Golomb (beta-gal staining), Efrat Shema (migration assays) and Sylvia Wilder (excellent technical help). We were supported in part by Grant R37 CA40099 from the National Cancer Institute, EC FP6 Grant LSHC-CT-2004-503576, FP7 funding (ONCOMIRS, agreement 201102), the Dr Miriam and Sheldon Adelson Medical Research Foundation and the Yad Abraham Center for Cancer Diagnosis and Therapy. The EC is not liable for any use that may be made of the information contained herein.	Abulaiti A, 2006, CANCER RES, V66, P10505, DOI 10.1158/0008-5472.CAN-06-2351; Aylon Y, 2006, GENE DEV, V20, P2687, DOI 10.1101/gad.1447006; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bean GR, 2007, CLIN CANCER RES, V13, P6834, DOI 10.1158/1078-0432.CCR-07-0407; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Chang HC, 2006, CANCER RES, V66, P8413, DOI 10.1158/0008-5472.CAN-06-0685; DENKO N, 1995, SOMAT CELL MOLEC GEN, V21, P241, DOI 10.1007/BF02255779; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fikaris AJ, 2006, J BIOL CHEM, V281, P34759, DOI 10.1074/jbc.M606737200; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Jiang KC, 2003, J BIOL CHEM, V278, P25207, DOI 10.1074/jbc.M300070200; Jiang Z, 2006, NEUROSCI RES, V56, P450, DOI 10.1016/j.neures.2006.09.006; Jimenez-Velasco A, 2005, LEUKEMIA, V19, P2347, DOI 10.1038/sj.leu.2403974; Kim JS, 2007, MOL CELL BIOL, V27, P662, DOI 10.1128/MCB.00537-06; Li YF, 2003, ONCOGENE, V22, P4398, DOI 10.1038/sj.onc.1206603; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051; Milyavsky M, 2003, CANCER RES, V63, P7147; Phelps ED, 2006, AM J PHYSIOL-CELL PH, V290, pC352, DOI 10.1152/ajpcell.00050.2005; Ponzio TA, 2007, J NEUROSCI METH, V164, P149, DOI 10.1016/j.jneumeth.2007.04.012; Pruitt K, 2005, J BIOL CHEM, V280, P23363, DOI 10.1074/jbc.M503083200; Reynolds PA, 2006, J BIOL CHEM, V281, P24790, DOI 10.1074/jbc.M604175200; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Shema E, 2008, GENE DEV, V22, P2664, DOI 10.1101/gad.1703008; Strazisar M, 2009, LUNG CANCER, V64, P257, DOI 10.1016/j.lungcan.2008.09.011; Takahashi Y, 2005, CLIN CANCER RES, V11, P1380, DOI 10.1158/1078-0432.CCR-04-1773; Toji S, 2004, GENES CELLS, V9, P383, DOI 10.1111/j.1356-9597.2004.00732.x; Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wang W, 2008, CURR OPIN ONCOL, V20, P90, DOI 10.1097/CCO.0b013e3282f31d6f; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yabuta N, 2007, J BIOL CHEM, V282, P19259, DOI 10.1074/jbc.M608562200	36	49	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	2009	28	50					4469	4479		10.1038/onc.2009.270	http://dx.doi.org/10.1038/onc.2009.270			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DU	19855428	Green Accepted			2022-12-17	WOS:000272876500006
J	Jian, Y; Gao, Z; Sun, J; Shen, Q; Feng, F; Jing, Y; Yang, C				Jian, Y.; Gao, Z.; Sun, J.; Shen, Q.; Feng, F.; Jing, Y.; Yang, C.			RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells	ONCOGENE			English	Article						nucleophosmin; RNA aptamer; p14ARF; p53; apoptosis	PROTEIN B23; BINDING; ARF; NUCLEOLI	Nucleophosmin (NPM) is a multifunctional protein involved in both proliferation and apoptosis. Importantly, NPM negatively regulates p53 and is frequently overexpressed in a wide variety of cancers. To identify inhibitory molecules of NPM, we used an in vitro selection method termed systematic evolution of ligands by exponential enrichment (SELEX) to select RNA aptamers that bind to NPM with high affinity and specificity. The selected RNA aptamers bind to the central acidic region of NPM and affect its oligomerization both in vitro and in vivo. Remarkably, expression of NPM-specific aptamers causes mislocalization of NPM in the nucleoplasm rather than in the nucleolus, suggesting that NPM oligomerization is important for its proper localization. Moreover, p14ARF is mislocalized in the nucleoplasm and p53 is upregulated in cells expressing NPM aptamers. In addition, cancer cells expressing NPM aptamers not only undergo apoptosis on their own, but are more susceptible to apoptosis induced by DNA-damaging agents as well. These results suggest that interfering with NPM oligomerization can inhibit NPM function and aptamers targeting NPM can serve as potential lead for developing anticancer drugs. Oncogene (2009) 28, 4201-4211; doi: 10.1038/onc.2009.275; published online 7 September 2009	[Jian, Y.; Gao, Z.; Sun, J.; Shen, Q.; Jing, Y.; Yang, C.] Chinese Acad Sci, Inst Genet & Dev Biol, Key Lab Mol & Dev Biol, Beijing 100101, Peoples R China; [Feng, F.] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS	Yang, C (corresponding author), Chinese Acad Sci, Inst Genet & Dev Biol, Key Lab Mol & Dev Biol, Datun Rd, Beijing 100101, Peoples R China.	clyang@genetics.ac.cn			National 863 Program [2006AA02Z147]; National Basic Research Program [2006CB504100, 2007CB947201]; National Natural Science Foundation [30871266]; Chinese Academy of Sciences [KSC1-YW-R-70]; CAS 100-Talents Program	National 863 Program(National High Technology Research and Development Program of China); National Basic Research Program(National Basic Research Program of China); National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences(Chinese Academy of Sciences); CAS 100-Talents Program(Chinese Academy of Sciences)	We thank Dr S Luo and Dr D Wu for providing NPM and p14ARF cDNAs; Dr Y Liu for help with protein purification; Dr X Wang for helpful suggestions and critical reading of the paper. This research was supported by grants from National 863 Program (no. 2006AA02Z147), National Basic Research Program (nos. 2006CB504100 and 2007CB947201), National Natural Science Foundation (no. 30871266) and Chinese Academy of Sciences (no. KSC1-YW-R-70). CY was supported by the CAS 100-Talents Program.	Ahn JY, 2005, MOL CELL, V18, P435, DOI 10.1016/j.molcel.2005.04.010; Apte RS, 2008, EXPERT OPIN PHARMACO, V9, P499, DOI [10.1517/14656566.9.3.499, 10.1517/14656566.9.3.499 ]; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Chan PK, 1999, BIOCHEM BIOPH RES CO, V264, P305, DOI 10.1006/bbrc.1999.1255; Chu TC, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl388; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Enomoto T, 2006, J BIOL CHEM, V281, P18463, DOI 10.1074/jbc.M602788200; Gjerset RA, 2006, CELL CYCLE, V5, P686, DOI 10.4161/cc.5.7.2623; Good PD, 1997, GENE THER, V4, P45, DOI 10.1038/sj.gt.3300354; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Ireson CR, 2006, MOL CANCER THER, V5, P2957, DOI 10.1158/1535-7163.MCT-06-0172; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Lee HZ, 2005, INT J CANCER, V113, P971, DOI 10.1002/ijc.20676; Levy-Nissenbaum E, 2008, TRENDS BIOTECHNOL, V26, P442, DOI 10.1016/j.tibtech.2008.04.006; Maiguel DA, 2004, MOL CELL BIOL, V24, P3703, DOI 10.1128/MCB.24.9.3703-3711.2004; McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223; Namboodiri VMH, 2004, STRUCTURE, V12, P2149, DOI 10.1016/j.str.2004.09.017; Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Qi W, 2008, ONCOGENE, V27, P4210, DOI 10.1038/onc.2008.54; Sambrook J, 2001, MOL CLONING LAB MANU; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; SZEBENI A, 1995, BIOCHEMISTRY-US, V34, P8037, DOI 10.1021/bi00025a009; WANG DR, 1994, J BIOL CHEM, V269, P30994; Yang C, 2002, NUCLEIC ACIDS RES, V30, P2251, DOI 10.1093/nar/30.10.2251; Yang CL, 2006, J BIOL CHEM, V281, P9137, DOI 10.1074/jbc.M511742200; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	31	49	51	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2009	28	47					4201	4211		10.1038/onc.2009.275	http://dx.doi.org/10.1038/onc.2009.275			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DQ	19734942				2022-12-17	WOS:000272876100006
J	Kang, BH; Altieri, DC				Kang, B. H.; Altieri, D. C.			Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones	ONCOGENE			English	Review						Hsp90; mitochondrial permeability transition; CypD; protein folding; cancer therapy	PERMEABILITY TRANSITION; CYCLOPHILIN-D; MOLECULAR CHAPERONE; OXIDATIVE STRESS; PROTEIN-1 TRAP-1; PROTECTS CELLS; HUMAN BREAST; APOPTOSIS; PEPTIDES; DISEASE	There is a plethora of attractive drug targets in cancer, but their therapeutic exploitation proved more difficult than expected, and only rarely truly successful. One possibility not often considered in drug discovery is that cancer signaling pathways are not randomly arranged in cells, but orchestrated in specialized subcellular compartments. The identification of heat shock protein-90 (Hsp90) chaperones in mitochondria of tumors, but not most normal tissues, provides an example of a compartmentalized network of cell survival, opening fresh prospects for novel, subcellularly targeted cancer drug discovery. Oncogene (2009) 28, 3681-3688; doi: 10.1038/onc.2009.227; published online 3 August 2009	[Kang, B. H.; Altieri, D. C.] Univ Massachusetts, Sch Med, Dept Canc Biol, Prostate Canc Discovery & Dev Program, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Altieri, DC (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, Prostate Canc Discovery & Dev Program, LRB428,364 Plantat St, Worcester, MA 01605 USA.	dario.altieri@umassmed.edu	Kang, Byoung Heon/E-6165-2010	Kang, Byoung Heon/0000-0001-5902-0549	National Institutes of Health [CA78810, CA90917, CA118005]; NATIONAL CANCER INSTITUTE [R01CA078810, R01CA090917, R01CA118005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054131] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We apologize to all the colleagues, whose work could not be cited due to space limitations. This work was supported by National Institutes of Health grants CA78810, CA90917 and CA118005.	Armstrong JS, 2007, BRIT J PHARMACOL, V151, P1154, DOI 10.1038/sj.bjp.0707288; Baines CP, 2007, NAT CELL BIOL, V9, P550, DOI 10.1038/ncb1575; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Barral JM, 2002, SCIENCE, V295, P669, DOI 10.1126/science.1066648; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Butcher EC, 2005, NAT REV DRUG DISCOV, V4, P461, DOI 10.1038/nrd1754; Cechetto JD, 2000, EXP CELL RES, V260, P30, DOI 10.1006/excr.2000.4983; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cellbio.4.1.155; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Cowen LE, 2005, SCIENCE, V309, P2185, DOI 10.1126/science.1118370; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Deng J, 2007, CANCER CELL, V12, P171, DOI 10.1016/j.ccr.2007.07.001; Drysdale MJ, 2006, CURR OPIN DRUG DISC, V9, P483; Du H, 2008, NAT MED, V14, P1097, DOI 10.1038/nm.1868; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Fantin VR, 2006, ONCOGENE, V25, P4787, DOI 10.1038/sj.onc.1209599; Felts SJ, 2000, J BIOL CHEM, V275, P3305, DOI 10.1074/jbc.275.5.3305; Fernandex-Carneado J, 2005, J AM CHEM SOC, V127, P869, DOI 10.1021/ja044006q; Forte M, 2007, P NATL ACAD SCI USA, V104, P7558, DOI 10.1073/pnas.0702228104; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Gesualdi NM, 2007, STRESS, V10, P342, DOI 10.1080/10253890701314863; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gyurkocza B, 2006, J NATL CANCER I, V98, P1068, DOI 10.1093/jnci/djj300; Halestrap AP, 2009, J MOL CELL CARDIOL, V46, P821, DOI 10.1016/j.yjmcc.2009.02.021; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; Henchcliffe C, 2008, NAT CLIN PRACT NEURO, V4, P600, DOI 10.1038/ncpneuro0924; Hua GQ, 2007, J BIOL CHEM, V282, P20553, DOI 10.1074/jbc.M703196200; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Kang BH, 2007, CELL, V131, P257, DOI 10.1016/j.cell.2007.08.028; Kang BH, 2009, J CLIN INVEST, V119, P454, DOI 10.1172/JCI37613; Koga F, 2006, P NATL ACAD SCI USA, V103, P11318, DOI 10.1073/pnas.0604705103; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kolata G., 2009, NY TIMES        0424; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Leaf C, 2004, FORTUNE, V149, P76; Li RX, 2007, NEOPLASIA, V9, P801, DOI 10.1593/neo.07394; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; Masuda Y, 2004, J BIOL CHEM, V279, P42503, DOI 10.1074/jbc.M404256200; McClellan AJ, 2007, CELL, V131, P121, DOI 10.1016/j.cell.2007.07.036; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Murphy MP, 2008, BBA-BIOENERGETICS, V1777, P1028, DOI 10.1016/j.bbabio.2008.03.029; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; O'Dwyer M E, 2000, Lancet Oncol, V1, P207, DOI 10.1016/S1470-2045(00)00149-2; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Petit A, 2005, J BIOL CHEM, V280, P34025, DOI 10.1074/jbc.M505143200; Pilkington GJ, 2008, SEMIN CANCER BIOL, V18, P226, DOI 10.1016/j.semcancer.2007.12.006; Plescia J, 2005, CANCER CELL, V7, P457, DOI 10.1016/j.ccr.2005.03.035; Price JT, 2005, CANCER RES, V65, P4929, DOI 10.1158/0008-5472.CAN-04-4458; Pridgeon JW, 2007, PLOS BIOL, V5, P1494, DOI 10.1371/journal.pbio.0050172; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Rajasethupathy P, 2005, CURR OPIN CHEM BIOL, V9, P400, DOI 10.1016/j.cbpa.2005.06.008; Rodina A, 2007, NAT CHEM BIOL, V3, P498, DOI 10.1038/nchembio.2007.10; Ross MF, 2004, BIOCHEM J, V383, P457, DOI 10.1042/BJ20041095; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Schein PS, 2006, CLIN CANCER RES, V12, P3243, DOI 10.1158/1078-0432.CCR-06-0329; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Solit DB, 2008, DRUG DISCOV TODAY, V13, P38, DOI 10.1016/j.drudis.2007.10.007; Steensma DP, 2009, J CLIN ONCOL, V27, P1737, DOI 10.1200/JCO.2008.20.6292; Szeto HH, 2008, ANN NY ACAD SCI, V1147, P112, DOI 10.1196/annals.1427.013; Torchilin VP, 2006, ANNU REV BIOMED ENG, V8, P343, DOI 10.1146/annurev.bioeng.8.061505.095735; Tsujimoto Y, 2007, APOPTOSIS, V12, P835, DOI 10.1007/s10495-006-0525-7; van der Greef J, 2005, NAT REV DRUG DISCOV, V4, P961, DOI 10.1038/nrd1904; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Vogler M, 2009, CELL DEATH DIFFER, V16, P360, DOI 10.1038/cdd.2008.137; Voloboueva LA, 2008, J CEREBR BLOOD F MET, V28, P1009, DOI 10.1038/sj.jcbfm.9600600; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Wright GL, 2008, FASEB J, V22, P3264, DOI 10.1096/fj.08-106468; XU LJ, 2009, J CEREBR BLOOD F MET, V29, P365, DOI DOI 10.1038/JCBFM.2008.125; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Zeitlin BD, 2008, J CLIN ONCOL, V26, P4180, DOI 10.1200/JCO.2007.15.7693; Zhao RM, 2007, ADV EXP MED BIOL, V594, P27	81	49	50	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2009	28	42					3681	3688		10.1038/onc.2009.227	http://dx.doi.org/10.1038/onc.2009.227			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	509MY	19648961	Green Accepted			2022-12-17	WOS:000271023200001
J	Sun, J; Khalid, S; Rozakis-Adcock, M; Fantus, IG; Jin, T				Sun, J.; Khalid, S.; Rozakis-Adcock, M.; Fantus, I. G.; Jin, T.			P-21-activated protein kinase-1 functions as a linker between insulin and Wnt signaling pathways in the intestine	ONCOGENE			English	Article						insulin; beta-catenin; Wnt; PAK-1; c-Myc; ChIP	BETA-CATENIN; P21-ACTIVATED KINASE; COLORECTAL-CANCER; DIABETES-MELLITUS; COLON-CANCER; PHOSPHORYLATION; ACTIVATION; PAK1; RAS; EXPRESSION	Hyperinsulinemia and type II diabetes are associated with an increased risk of developing colorectal tumors. We found previously that in intestinal cells, insulin or insulin-like growth factor-1 stimulates c-Myc and cyclin D1 protein expression through both Akt-dependent and Akt-independent mechanisms. The effect of Akt is attributed to the stimulation of c-Myc translation by mammalian target of rapamycin. However, Akt-independent stimulation was, associated with an increase in beta-catenin (beta-cat) in the nucleus and an increased association between beta-cat and T-cell factor binding sites on the c-Myc promoter, detected by chromatin immunoprecipitation. In this study, we show that insulin stimulated the phosphorylation/activation of p-21-activated protein kinase-1 (PAK-1) in an Akt-independent manner in vitro and in an in vivo hyperinsulinemic mouse model. Significantly, shRNA (small hairpin RNA)-mediated PAK-1 knockdown attenuated both basal and insulin-stimulated c-Myc and cyclin D1 expression, associated with a marked reduction in extracellular signal-regulated kinase activation and beta-cat phosphorylation at Ser675. Furthermore, PAK-1 silencing led to a complete blockade of insulin-stimulated beta-cat binding to the c-Myc promoter and cellular growth. Finally, inhibition of MEK, a downstream target of PAK-1, blocked insulin-stimulated nuclear beta-cat accumulation and c-Myc expression. Our observations suggest that PAK-1 serves as an important linker between insulin and Wnt signaling pathways. Oncogene (2009) 28, 3132-3144; doi: 10.1038/onc.2009.167; published online 6 July 2009	[Sun, J.; Khalid, S.; Fantus, I. G.; Jin, T.] Univ Hlth Network, Div Cell & Mol Biol, Toronto, ON M5G 1L7, Canada; [Khalid, S.; Fantus, I. G.] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; [Sun, J.; Khalid, S.; Fantus, I. G.; Jin, T.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Sun, J.; Rozakis-Adcock, M.; Jin, T.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Sun, J.; Khalid, S.; Fantus, I. G.; Jin, T.] Univ Toronto, Dept Physiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto	Jin, T (corresponding author), Univ Hlth Network, Div Cell & Mol Biol, 10-354 Toronto Med Discovery Tower,101 Coll St, Toronto, ON M5G 1L7, Canada.	tianru.jin@utoronto.ca			Banting and Best Diabetes Centre (BBDC); Canadian Institutes of Health Research [MOP-89987]; Canadian Breast Cancer Research Alliance/CIHR [016512]	Banting and Best Diabetes Centre (BBDC); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Research Alliance/CIHR(Canadian Institutes of Health Research (CIHR))	We thank Dr Jeffrey Field (University of Pennsylvania) for providing the dominant negative PAK-1 (K299R), constitutively active PAK-1 (T423E) and control plasmids. JS is a recipient of Banting and Best Diabetes Centre (BBDC) Novo Nordisk graduate studentship (2004-2008). This study was supported by an operating grant from Canadian Institutes of Health Research to TJ (MOP-89987) and a Translational Acceleration Research Grant from the Canadian Breast Cancer Research Alliance/CIHR (# 016512) to IGF.	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Akinmade D, 2008, BRIT J CANCER, V98, P1132, DOI 10.1038/sj.bjc.6604261; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arias-Romero LE, 2008, BIOL CELL, V100, P97, DOI 10.1042/BC20070109; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bustin SA, 2001, TRENDS MOL MED, V7, P447, DOI 10.1016/S1471-4914(01)02104-9; Carter JH, 2004, CLIN CANCER RES, V10, P3448, DOI 10.1158/1078-0432.CCR-03-0210; Chang CK, 2003, DIABETOLOGIA, V46, P595, DOI 10.1007/s00125-003-1109-5; Ching YP, 2007, CANCER RES, V67, P3601, DOI 10.1158/0008-5472.CAN-06-3994; Clements Wilson M, 2003, Clin Colorectal Cancer, V3, P113, DOI 10.3816/CCC.2003.n.018; Clevers H, 2004, CANCER CELL, V5, P5, DOI 10.1016/S1535-6108(03)00339-8; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Dong YF, 2006, J CELL PHYSIOL, V208, P77, DOI 10.1002/jcp.20656; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Elwing JE, 2006, AM J GASTROENTEROL, V101, P1866, DOI 10.1111/j.1572-0241.2006.00651.x; Giovannucci E, 2001, J NUTR, V131, p3109S, DOI 10.1093/jn/131.11.3109S; Giovannucci E, 2007, AM J CLIN NUTR, V86, p836S, DOI 10.1093/ajcn/86.3.836S; He H, 2008, BBA-MOL CELL RES, V1783, P1943, DOI 10.1016/j.bbamcr.2008.04.016; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Jin SH, 2005, J BIOL CHEM, V280, P24698, DOI 10.1074/jbc.M413374200; Jin TR, 2008, CELL SIGNAL, V20, P1697, DOI 10.1016/j.cellsig.2008.04.014; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Lewin HS, 2008, J MED LIBR ASSOC, V96, P155, DOI 10.3163/1536-5050.96.2.155; Li JN, 2005, GASTROENTEROLOGY, V128, P1907, DOI 10.1053/j.gastro.2005.02.067; Li WQ, 2001, J BIOL CHEM, V276, P34728, DOI 10.1074/jbc.M103496200; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu ZY, 2008, J BIOL CHEM, V283, P8723, DOI 10.1074/jbc.M706105200; Ma J, 2004, JNCI-J NATL CANCER I, V96, P546, DOI 10.1093/jnci/djh082; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; OLNES MJ, 1994, BIOTECHNIQUES, V17, P828; Park ER, 2007, CELL SIGNAL, V19, P1488, DOI 10.1016/j.cellsig.2007.01.018; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Qiao M, 2004, J BIOL CHEM, V279, P42709, DOI 10.1074/jbc.M404480200; Rochat A, 2004, MOL BIOL CELL, V15, P4544, DOI 10.1091/mbc.E03-11-0816; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Smith SD, 2008, J CELL SCI, V121, P3729, DOI 10.1242/jcs.027680; Sun J, 2008, CELL SIGNAL, V20, P219, DOI 10.1016/j.cellsig.2007.10.010; Sundberg-Smith LJ, 2005, J BIOL CHEM, V280, P2055, DOI 10.1074/jbc.M406013200; Tang Y, 1998, P NATL ACAD SCI USA, V95, P5139, DOI 10.1073/pnas.95.9.5139; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tran TT, 1996, CANCER EPIDEM BIOMAR, V5, P1013; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Wang PX, 2003, BIOCHEM J, V375, P199, DOI 10.1042/BJ20030579; Yi FH, 2008, ENDOCRINOLOGY, V149, P2341, DOI 10.1210/en.2007-1142; Yi FH, 2005, J BIOL CHEM, V280, P1457, DOI 10.1074/jbc.M411487200; Yoshii S, 2001, MOL CELL BIOL, V21, P6796, DOI 10.1128/MCB.21.20.6796-6807.2001; Zhang Q, 2006, J BIOL CHEM, V281, P10174, DOI 10.1074/jbc.M513008200; Zhou GL, 2004, CANCER BIOL THER, V3, P102, DOI 10.4161/cbt.3.1.691; Zhou GL, 2003, MOL CELL BIOL, V23, P8058, DOI 10.1128/MCB.23.22.8058-8069.2003	67	49	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2009	28	35					3132	3144		10.1038/onc.2009.167	http://dx.doi.org/10.1038/onc.2009.167			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QC	19581924				2022-12-17	WOS:000269515100005
J	Kitagawa, K; Hiramatsu, Y; Uchida, C; Isobe, T; Hattori, T; Oda, T; Shibata, K; Nakamura, S; Kikuchi, A; Kitagawa, M				Kitagawa, K.; Hiramatsu, Y.; Uchida, C.; Isobe, T.; Hattori, T.; Oda, T.; Shibata, K.; Nakamura, S.; Kikuchi, A.; Kitagawa, M.			Fbw7 promotes ubiquitin-dependent degradation of c-Myb: involvement of GSK3-mediated phosphorylation of Thr-572 in mouse c-Myb	ONCOGENE			English	Article						c-Myb; ubiquitin-proteasome; Fbw7; phosphorylation; GSK3	F-BOX PROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; GLYCOGEN-SYNTHASE KINASE-3; T-CELL LEUKEMIA; CYCLIN-E; TUMOR-SUPPRESSOR; FBXW7 ACTS; DIFFERENTIATION; LIGASE; PROTEOLYSIS	Expression of oncoprotein c-Myb oscillates during hematopoiesis and hematological malignancies. Its quantity is not only regulated through transcriptional control but also through the ubiquitin-proteasome pathway, accompanied by phosphorylation, although the mechanisms are poorly understood. In this report, we tried to identify an E3 ubiquitin ligase, which targets c-Myb for ubiquitin-dependent degradation. We found that an F-box protein, Fbw7, interacted with c-Myb, which is mutated in numerous cancers. Fbw7 facilitated ubiquitylation and degradation of c-Myb in intact cells. Moreover, depletion of Fbw7 by RNA interference delayed turnover and increased the abundance of c-Myb in myeloid leukemia cells concomitantly, and suppressed the transcriptional level of gamma-globin, which receives transcriptional repression from c-Myb. In addition, we analysed sites required for both ubiquitylation and degradation of c-Myb. We found that Thr-572 is critical for Fbw7-mediated ubiquitylation in mouse c-Myb using site-directed mutagenesis. Fbw7 recognized the phosphorylation of Thr-572, which was mediated by glycogen synthase kinase 3 (GSK3). In consequence, the c-Myb protein was markedly stabilized by the substitution of Thr-572 to Ala. These observations suggest that SCFFbw7 ubiquitin ligase regulates phosphorylation-dependent degradation of c-Myb protein. Oncogene (2009) 28, 2393-2405; doi:10.1038/onc.2009.111; published online 4 May 2009	[Kitagawa, K.; Hiramatsu, Y.; Uchida, C.; Isobe, T.; Hattori, T.; Oda, T.; Kitagawa, M.] Hamamatsu Univ Sch Med, Dept Biochem 1, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan; [Hiramatsu, Y.] Hamamatsu Univ Sch Med, Dept Surg, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan; [Shibata, K.] Hamamatsu Univ Sch Med, Res Equipment Ctr, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan; [Nakamura, S.] Hamamatsu Univ Sch Med, Dept Internal Med 3, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan; [Kikuchi, A.] Hiroshima Univ, Dept Biochem, Grad Sch Biomed Sci, Minami Ku, Hiroshima, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hiroshima University	Kitagawa, M (corresponding author), Hamamatsu Univ Sch Med, Dept Biochem 1, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	kitamasa@hama-med.ac.jp		Hiramatsu, Yoshihiro/0000-0003-1448-1610	Ministry of Education, Science, Sports, Culture and Technology of Japan; COE program of Hamamatsu University School of Medicine	Ministry of Education, Science, Sports, Culture and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); COE program of Hamamatsu University School of Medicine	We thank Yojiro Kotake, Keiichi I Nakayama, Masaki Matsumoto, Akinobu Matsumoto and Issay Kitabayashi for providing plasmids and useful discussions, and Sayuri Suzuki, Tomomi Abe, Ning Liu, Harumi Shiratori, Daisuke Hiraoka, Daizo Ueno, Yasue Kirita, Tatsuya Kobayashi, Konomi Mizuguchi, Erina Nihashi, Syuhei Iizuka, Daisuke Ichikawa and Naohiro Takamoto for their technical assistance. This study was supported in part by grants from the Ministry of Education, Science, Sports, Culture and Technology of Japan (MK and KK), by a COE program of Hamamatsu University School of Medicine from the Ministry of Education, Science, Sports, Culture and Technology of Japan (MK).	Bies J, 2000, ONCOGENE, V19, P2846, DOI 10.1038/sj.onc.1203613; Bies J, 1999, J VIROL, V73, P2038, DOI 10.1128/JVI.73.3.2038-2044.1999; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; Bies J, 2001, BLOOD CELL MOL DIS, V27, P422, DOI 10.1006/bcmd.2001.0400; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; Clappier E, 2007, BLOOD, V110, P1251, DOI 10.1182/blood-2006-12-064683; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Corradini F, 2005, J BIOL CHEM, V280, P30254, DOI 10.1074/jbc.M504703200; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; Feikova S, 2000, NEOPLASMA, V47, P212; Friedman AD, 2002, J CELL BIOCHEM, V86, P624, DOI 10.1002/jcb.10271; Goto H, 2007, NAT PROTOC, V2, P2574, DOI 10.1038/nprot.2007.374; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hiramatsu Y, 2006, CANCER RES, V66, P8477, DOI 10.1158/0008-5472.CAN-06-1603; Jiang J, 2006, BLOOD, V108, P1077, DOI 10.1182/blood-2006-01-008912; Kanei-Ishii C, 2004, J BIOL CHEM, V279, P44582, DOI 10.1074/jbc.M407831200; Kanei-Ishii C, 2004, GENE DEV, V18, P816, DOI 10.1101/gad.1170604; Kanei-Ishii C, 2008, J BIOL CHEM, V283, P30540, DOI 10.1074/jbc.M804340200; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lahortiga I, 2007, NAT GENET, V39, P593, DOI 10.1038/ng2025; Lieu YK, 2004, P NATL ACAD SCI USA, V101, P14853, DOI 10.1073/pnas.0405338101; Matsumoto A, 2006, BIOCHEM BIOPH RES CO, V350, P114, DOI 10.1016/j.bbrc.2006.09.003; Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808; Minella AC, 2005, CELL CYCLE, V4, P1356, DOI 10.4161/cc.4.10.2058; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Onoyama I, 2007, J EXP MED, V204, P2875, DOI 10.1084/jem.20062299; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; Sakamoto H, 2006, BLOOD, V108, P896, DOI 10.1182/blood-2005-09-3846; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Sharma VM, 2007, CELL CYCLE, V6, P927, DOI 10.4161/cc.6.8.4134; SIEGERT W, 1990, EUR J CANCER, V26, P733, DOI 10.1016/0277-5379(90)90130-L; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Tanji C, 2002, J BIOL CHEM, V277, P36955, DOI 10.1074/jbc.M206210200; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486; Vegiopoulos A, 2006, BLOOD, V107, P4703, DOI 10.1182/blood-2005-07-2968; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Wu RC, 2007, CELL, V129, P1125, DOI 10.1016/j.cell.2007.04.039; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yamamoto H, 2007, GENES CELLS, V12, P1215, DOI 10.1111/j.1365-2443.2007.01128.x	56	49	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	25					2393	2405		10.1038/onc.2009.111	http://dx.doi.org/10.1038/onc.2009.111			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462HS	19421138				2022-12-17	WOS:000267342400004
J	Somanath, PR; Vijai, J; Kichina, JV; Byzova, T; Kandel, ES				Somanath, P. R.; Vijai, J.; Kichina, J. V.; Byzova, T.; Kandel, E. S.			The role of PAK-1 in activation of MAP kinase cascade and oncogenic transformation by Akt	ONCOGENE			English	Article						extracellular signal-regulated MAP kinases; protein kinase B; neoplastic cell transformation; p21-activated kinases	PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; PLASMA-MEMBRANE; SERINE 338; RAF; PHOSPHORYLATION; AKT/PKB; CANCER; CYCLE; DEPENDENCE	The activity of protein kinase B, also known as Akt, is commonly elevated in human malignancies and plays a crucial role in oncogenic transformation. The relationship between Akt and the mitogen-activated protein kinase cascade, which is also frequently associated with oncogenesis, remains controversial. We report here examples of cooperation between Akt and cRaf in oncogenic transformation, which was accompanied by elevated activity of extracellular signal-regulated mitogen-activated protein kinases. The effect of Akt on extracellular signal-regulated kinases depended on the status of p21-activated kinase (PAK). Importantly, disruption of the function of PAK not only uncoupled the activation of Akt from that of extracellular signal-regulated kinases, but also greatly reduced the capacity of Akt to act as a transforming oncogene. For the malignancies with hyperactive Akt, our observations support the role for PAK-1 as a potential target for therapeutic intervention. Oncogene (2009) 28, 2365 2369; doi:10.1038/onc.2009.114; published online 4 May 2009	[Vijai, J.; Kichina, J. V.; Kandel, E. S.] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; [Somanath, P. R.; Byzova, T.] Cleveland Clin, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44106 USA	Roswell Park Cancer Institute; Cleveland Clinic Foundation	Kandel, ES (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, BLSC L3-318,Elm & Carlton St, Buffalo, NY 14263 USA.	eugene.kandel@RoswellPark.org	Joseph, Vijai/J-9158-2013	Joseph, Vijai/0000-0002-7933-151X; Byzova, Tatiana/0000-0002-2615-875X; Rammohan Shenoy, Somanath/0000-0003-3017-0230	Howard Temin Award to ESK; NIH [HL071625]; American Heart Association [0830326N]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071625] Funding Source: NIH RePORTER	Howard Temin Award to ESK; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr Nikolay Neznanov for the Ets-reporter construct, Dr Channing Der for RIE-1 cells, Dr George Stark for the MEF cells and Dr Nissim Hay for various Akt-expressing constructs. This work was supported by the Howard Temin Award to ESK, NIH Grant HL071625 to TB and American Heart Association grant 0830326N to PRS.	Bereiter-Hahn J, 1998, CELL STRUCT FUNCT, V23, P85, DOI 10.1247/csf.23.85; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Galetic I, 2003, J BIOL CHEM, V278, P4416, DOI 10.1074/jbc.M210578200; Gartel AL, 2006, BIOMOL ENG, V23, P17, DOI 10.1016/j.bioeng.2006.01.002; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; McCubrey JA, 2001, CANCER DETECT PREV, V25, P375; McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004; Mirza AM, 2004, MOL CELL BIOL, V24, P10868, DOI 10.1128/MCB.24.24.10868-10881.2004; Mirza AM, 2000, CELL GROWTH DIFFER, V11, P279; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nheu T, 2004, CELL CYCLE, V3, P71; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Shelton JG, 2004, CELL CYCLE, V3, P503; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; Somanath PR, 2009, J CELL PHYSIOL, V218, P394, DOI 10.1002/jcp.21612; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Weinberg RA, 2007, BIOL CANC; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	28	49	52	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	25					2365	2369		10.1038/onc.2009.114	http://dx.doi.org/10.1038/onc.2009.114			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462HS	19421139	Green Accepted			2022-12-17	WOS:000267342400001
J	Shen, J; Vakifahmetoglu, H; Stridh, H; Zhivotovsky, B; Wiman, KG				Shen, J.; Vakifahmetoglu, H.; Stridh, H.; Zhivotovsky, B.; Wiman, K. G.			PRIMA-1(MET) induces mitochondrial apoptosis through activation of caspase-2	ONCOGENE			English	Article						apoptosis; cancer therapy; caspase-2; mutant p53; PRIMA-1(MET)	CYTOCHROME-C RELEASE; MUTANT P53; BREAST-CANCER; CELLS; GENE; RESTORATION; DEATH; PUMA; TRANSCRIPTION; INDUCTION	p53 mutations occur frequently in human tumors. The low-molecular-weight compound PRIMA-1(MET) reactivates mutant p53, induces apoptosis in human tumor cells and inhibits tumor xenograft growth in vivo. Here, we show that PRIMA-1(MET) induces mutant p53-dependent mito-chondria-mediated apoptosis through activation of caspase-2 with subsequent cytochrome c release and further activation of downstream caspase-9 and caspase-3. Inhibition of caspase-2 by a selective inhibitor and/or siRNA prevents cytochrome c release on PRIMA-1(MET) treatment and causes a significant reduction in PRIMA-1(MET)-induced cell death. Our findings highlight a chain of cellular events triggered by PRIMA-1(MET) that lead to apoptotic cell death. This should facilitate further development and optimization of eficient PRIMA-1(MET)-based anticancer drugs.	[Wiman, K. G.] Karolinska Univ Hosp, CCK, Karolinska Inst, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; [Vakifahmetoglu, H.; Zhivotovsky, B.] Karolinska Inst, Inst Environm Med, Div Toxicol, S-10401 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Univ Hosp, CCK, Karolinska Inst, Dept Oncol Pathol, R8-04, SE-17176 Stockholm, Sweden.	klas.wiman@ki.se	Wiman, Klas/AAB-8399-2021; Zhivotovsky, Boris/A-4346-2014	Wiman, Klas/0000-0002-7113-524X; Zhivotovsky, Boris/0000-0002-2238-3482	Swedish and Stockholm Cancer Societies; Swedish Research Council; EU 6th and 7th Framework Programs; Karolinska Institutet	Swedish and Stockholm Cancer Societies; Swedish Research Council(Swedish Research CouncilEuropean Commission); EU 6th and 7th Framework Programs(European Commission); Karolinska Institutet(Karolinska Institutet)	This study was supported by grants from the Swedish and Stockholm Cancer Societies, the Swedish Research Council, the EU 6th and 7th Framework Programs, and Karolinska Institutet. This publication reflects the author's views and not necessarily those of the EC partners. The information in this document is provided as is and no guarantee or warranty is given that the information is fit for any particular purpose. The user thereof uses the information at its sole risk and liability. The Community is not liable for any use that may be made of the information contained herein.	ALSHABANAH OA, 1995, CHEMOTHERAPY, V41, P368, DOI 10.1159/000239369; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; Bykov VJN, 2005, J BIOL CHEM, V280, P30384, DOI 10.1074/jbc.M501664200; Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419; Bykov VJN, 2003, EUR J CANCER, V39, P1828, DOI 10.1016/S0959-8049(03)00454-4; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Guimaraes DP, 2002, BIOCHIMIE, V84, P83, DOI 10.1016/S0300-9084(01)01356-6; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Olivier M, 2006, CLIN CANCER RES, V12, P1157, DOI 10.1158/1078-0432.CCR-05-1029; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tyagi A, 2006, CARCINOGENESIS, V27, P2269, DOI 10.1093/carcin/bgl098; Vakifahmetoglu H, 2006, ONCOGENE, V25, P5683, DOI 10.1038/sj.onc.1209569; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yin XM, 2006, GENE, V369, P7, DOI 10.1016/j.gene.2005.10.038; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	28	49	49	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2008	27	51					6571	6580		10.1038/onc.2008.249	http://dx.doi.org/10.1038/onc.2008.249			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RS	18663359				2022-12-17	WOS:000260501700004
J	Faux, MC; Coates, JL; Catimel, B; Cody, S; Clayton, AHA; Layton, MJ; Burgess, AW				Faux, M. C.; Coates, J. L.; Catimel, B.; Cody, S.; Clayton, A. H. A.; Layton, M. J.; Burgess, A. W.			Recruitment of adenomatous polyposis coli and beta-catenin to axin-puncta	ONCOGENE			English	Article						APC; axin; beta-catenin	WNT-SIGNALING PATHWAY; TUMOR-SUPPRESSOR PROTEIN; F-BOX PROTEIN; SINGLE-PARTICLE TRACKING; PLASMA-MEMBRANE; NEGATIVE REGULATOR; CELL-MIGRATION; APC PROTEIN; IN-VITRO; MICROTUBULES	The adenomatous polyposis coli (APC) tumour suppressor is a multifunctional protein involved in the regulation of Wnt signalling and cytoskeletal dynamics. Little is known about how APC controls these disparate functions. In this study, we have used APC- and axin-fluorescent fusion proteins to examine the interactions between these proteins and show that the functionally distinct populations of APC are also spatially separate. Axin-RFP forms cytoplasmic punctate structures, similar to endogenous axin puncta. Axin-RFP recruits beta-catenin destruction complex proteins, including APC, b-catenin, glycogen synthase kinase-3-beta (GSK3-beta) and casein kinase-1-alpha (CK1-alpha). Recruitment into axin-RFP puncta sequesters APC from clusters at cell extensions and this prevents its microtubule-associated functions. The interaction between APC-GFP and axin-RFP within the cytoplasmic puncta is direct and dramatically alters the dynamic properties of APC-GFP. However, recruitment of APC to axin puncta is not absolutely required for beta-catenin degradation. Instead, formation of axin puncta, mediated by the DIX domain, is required for beta-catenin degradation. An axin Delta DIX mutant did not form puncta, but still mediated recruitment of destruction complex proteins and phosphorylation of beta-catenin. We conclude that there are distinct pools of APC and that the formation of axin puncta, rather than the axin/APC complex, is essential for beta-catenin destruction.	[Faux, M. C.; Coates, J. L.; Catimel, B.; Cody, S.; Clayton, A. H. A.; Layton, M. J.; Burgess, A. W.] Royal Melbourne Hosp, Ludwig Inst Canc Res, Epithelial Biol Lab, Melbourne Tumour Biol Branch, Parkville, Vic 3050, Australia	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Faux, MC (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, Epithelial Biol Lab, Melbourne Tumour Biol Branch, POB 2008, Parkville, Vic 3050, Australia.	maree.faux@ludwig.edu.au		CATIMEL, Bruno/0000-0002-4350-6875	NHMRC program [234703]; NH&MRC RD Wright Research	NHMRC program(National Health and Medical Research Council (NHMRC) of Australia); NH&MRC RD Wright Research(National Health and Medical Research Council (NHMRC) of Australia)	We thank Dr M Prescott, Dr F Costantini and Dr D Capelluto for cDNA constructs. MCF, MJL and AWB are supported by NH&MRC program grant 234703; AHAC is an NH&MRC RD Wright Research Fellow.	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Barth AIM, 2002, J CELL SCI, V115, P1583; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Catimel B, 2006, BIOMED CHROMATOGR, V20, P569, DOI 10.1002/bmc.648; Ciani L, 2004, J CELL BIOL, V164, P243, DOI 10.1083/jcb.200309096; Clayton AHA, 2005, J BIOL CHEM, V280, P30392, DOI 10.1074/jbc.M504770200; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960-9822(03)00370-1; Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318; Dayanandan R, 2003, CELL MOTIL CYTOSKEL, V54, P237, DOI 10.1002/cm.10096; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Faux MC, 2004, J CELL SCI, V117, P427, DOI 10.1242/jcs.00862; Fodde R, 2003, NAT CELL BIOL, V5, P190, DOI 10.1038/ncb0303-190; Hanley QS, 2005, J MICROSC-OXFORD, V218, P62, DOI 10.1111/j.1365-2818.2005.01463.x; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Harte D, 1998, J NONLINEAR SCI, V8, P581, DOI 10.1007/s003329900060; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kita K, 2006, MOL BIOL CELL, V17, P2331, DOI 10.1091/mbc.E05-06-0498; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kroboth K, 2007, MOL BIOL CELL, V18, P910, DOI 10.1091/mbc.E06-03-0179; Langford KJ, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-3; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; Levina E, 2004, ONCOGENE, V23, P4444, DOI 10.1038/sj.onc.1207587; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Magde D, 1999, PHOTOCHEM PHOTOBIOL, V70, P737, DOI 10.1562/0031-8655(1999)070<0737:SDOTFL>2.3.CO;2; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Nathke IS, 2004, ANNU REV CELL DEV BI, V20, P337, DOI 10.1146/annurev.cellbio.20.012103.094541; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Park TJ, 2005, CURR BIOL, V15, P1039, DOI 10.1016/j.cub.2005.04.062; Penman GA, 2005, J CELL SCI, V118, P4741, DOI 10.1242/jcs.02589; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; Sage D, 2005, IEEE T IMAGE PROCESS, V14, P1372, DOI 10.1109/TIP.2005.852787; Sakanaka C, 1999, J BIOL CHEM, V274, P14090, DOI 10.1074/jbc.274.20.14090; Saxton MJ, 1997, ANNU REV BIOPH BIOM, V26, P373, DOI 10.1146/annurev.biophys.26.1.373; Schneikert J, 2007, GUT, V56, P417, DOI 10.1136/gut.2006.093310; Schwarz-Romond T, 2005, J CELL SCI, V118, P5269, DOI 10.1242/jcs.02646; Schwarz-Romond T, 2007, J CELL SCI, V120, P2402, DOI 10.1242/jcs.002956; Schwarz-Romond T, 2007, NAT STRUCT MOL BIOL, V14, P484, DOI 10.1038/nsmb1247; Sharma M, 2006, J BIOL CHEM, V281, P17140, DOI 10.1074/jbc.M513027200; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; SU LK, 1995, CANCER RES, V55, P2972; van Munster EB, 2004, CYTOM PART A, V58A, P185, DOI 10.1002/cyto.a.20013; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Wen Y, 2004, NAT CELL BIOL, V6, P820, DOI 10.1038/ncb1160; Wiechens N, 2004, J BIOL CHEM, V279, P5263, DOI 10.1074/jbc.M307253200; Wilson KM, 1996, J CELL SCI, V109, P2101; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	62	49	49	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2008	27	44					5808	5820		10.1038/onc.2008.205	http://dx.doi.org/10.1038/onc.2008.205			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QC	18591934				2022-12-17	WOS:000259722400005
J	Hassan, M; Alaoui, A; Feyen, O; Mirmohammadsadegh, A; Essmann, F; Tannapfel, A; Gulbins, E; Schulze-Osthoff, K; Hengge, UR				Hassan, M.; Alaoui, A.; Feyen, O.; Mirmohammadsadegh, A.; Essmann, F.; Tannapfel, A.; Gulbins, E.; Schulze-Osthoff, K.; Hengge, U. R.			The BH3-only member Noxa causes apoptosis in melanoma cells by multiple pathways	ONCOGENE			English	Article						apoptosis; melanoma; Noxa; BH3-only proteins	ENDOPLASMIC-RETICULUM; BCL-2 FAMILY; TRIGGERS APOPTOSIS; SIGNALING PATHWAY; GENE-EXPRESSION; UP-REGULATION; C-JUN; DEATH; ACTIVATION; INDUCTION	The molecular causes for resistance of melanoma to apoptosis are currently only partly understood. In the present study, we examined gene transfer and expression of the proapoptotic BH3-only protein Noxa as an alternative approach to chemotherapy and investigated the molecular mechanisms regulating Noxa-induced apoptosis. Noxa gene transfer caused dysregulation of both mitochondria and, as shown for the first time, also the endoplasmic reticulum, resulting in the accumulation of reactive oxygen species. Interestingly, expression of Noxa not only triggered the classical mitochondrial caspase cascade, but also resulted in the activation of apoptosis signal-regulating kinase1 and its downstream effectors c-Jun N-terminal kinase and p38. The activation of these kinases was abolished by antioxidants. Moreover, inhibition of the kinases by RNA interference or pharmacological inhibitors significantly attenuated Noxa-induced apoptosis. Thus, our data provide evidence for the involvement of multiple pathways in Noxa-induced apoptosis that are triggered at mitochondria and the endoplasmic reticulum, and suggest Noxa gene transfer as a complementary approach to chemotherapy.	[Hassan, M.; Alaoui, A.; Mirmohammadsadegh, A.; Hengge, U. R.] Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany; [Feyen, O.] Univ Dusseldorf, Dept Pediat Immunol & Oncol, D-40225 Dusseldorf, Germany; [Essmann, F.; Schulze-Osthoff, K.] Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; [Tannapfel, A.] Ruhr Univ Bochum, Dept Pathol, Bochum, Germany; [Gulbins, E.] Univ Duisburg Essen, Dept Mol Biol, Essen, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Ruhr University Bochum; University of Duisburg Essen	Hengge, UR (corresponding author), Univ Dusseldorf, Dept Dermatol, Moorenstr 5, D-40225 Dusseldorf, Germany.	ulrich.hengge@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013; Hassan, Mohamed/AHE-7565-2022; Essmann, Frank/ABG-7409-2020	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Essmann, Frank/0000-0003-4369-8456				Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; AKAO Y, 1994, CANCER RES, V54, P2468; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chun ACS, 2003, J BIOL CHEM, V278, P37439, DOI 10.1074/jbc.M307185200; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; DENIAUD A, 2007, ONCOGENE, V27, P274; Duan WR, 2003, J PATHOL, V199, P221, DOI 10.1002/path.1289; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Essmann F, 2005, J BIOL CHEM, V280, P37169, DOI 10.1074/jbc.M502052200; Essmann F, 2003, CELL DEATH DIFFER, V10, P1260, DOI 10.1038/sj.cdd.4401301; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gomez-Bougie P, 2007, CANCER RES, V67, P5418, DOI 10.1158/0008-5472.CAN-06-4322; Hassan M, 2005, CELL MOL LIFE SCI, V62, P2015, DOI 10.1007/s00018-005-5172-6; Hassan M, 2005, VIROLOGY, V333, P324, DOI 10.1016/j.virol.2005.01.008; Hassan M, 2004, CELL SIGNAL, V16, P1375, DOI 10.1016/j.cellsig.2004.04.005; Hassan M, 2007, CELL SIGNAL, V19, P301, DOI 10.1016/j.cellsig.2006.07.002; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Horiuchi D, 2003, NEUROSCI RES, V47, P209, DOI 10.1016/S0168-0102(03)00216-5; Hossini AM, 2006, ONCOGENE, V25, P2160, DOI 10.1038/sj.onc.1209253; Hossini AM, 2003, FEBS LETT, V553, P250, DOI 10.1016/S0014-5793(03)01017-2; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oppermann M, 2005, ONCOGENE, V24, P7369, DOI 10.1038/sj.onc.1208890; Pardo J, 2006, J CELL BIOL, V174, P509, DOI 10.1083/jcb.200604044; Perez-Galan P, 2007, BLOOD, V109, P4441, DOI 10.1182/blood-2006-07-034173; Qin JZ, 2006, CANCER RES, V66, P9636, DOI 10.1158/0008-5472.CAN-06-0747; Qin JZ, 2004, MOL CANCER THER, V3, P895; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Samraj AK, 2007, MOL BIOL CELL, V18, P84, DOI 10.1091/mbc.E06-04-0263; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	47	49	51	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4557	4568		10.1038/onc.2008.90	http://dx.doi.org/10.1038/onc.2008.90			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18408751				2022-12-17	WOS:000258077300005
J	Al-Azawi, D; Mc Ilroy, M; Kelly, G; Redmond, AM; Bane, FT; Cocchiglia, S; Hill, ADK; Young, LS				Al-Azawi, D.; Mc Ilroy, M.; Kelly, G.; Redmond, A. M.; Bane, F. T.; Cocchiglia, S.; Hill, A. D. K.; Young, L. S.			Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer	ONCOGENE			English	Article						breast cancer; myc; SRC-1; tamoxifen resistance; Ets-2	CREB-BINDING-PROTEIN; ESTROGEN-RECEPTOR; EXPRESSION; PHOSPHORYLATION; ACTIVATION; GROWTH; COACTIVATORS; PATHWAYS; P300; ER81	Associations between p160 coactivator proteins and endocrine resistance have been described. Though thought to primarily interact with steroid receptors, the p160 proteins can also interact with non-nuclear receptor transcription factors including the MAP kinase effector proteins Ets. Here, we observed that in breast cancer cells resistant and insensitive to endocrine treatment, the growth factor EGF induced Ets-2 but not Ets-1 transcriptional regulation of the oncogene myc. Ets-2 regulation of myc was found to be reliant on the p160 proteins SRC-1 and SRC-3. In support of these molecular observations, strong associations were observed between the transcription factor, Ets-2 and its coactivator SRC-1 (P < 0.01) and the target gene myc (P < 0.0001) in a cohort of breast cancer patients with locally advanced disease. Expression of Ets-2, SRC-1 and c-Myc individually all associated with reduced disease-free survival (P < 0.001, P < 0.001 and P = 0.002 respectively). There was no association between SRC-3 and disease-free survival (P = 0.707). SRC-1 can utilize MAP kinase effector transcription factor Ets-2 to regulate the production of the oncogene myc. These signalling mechanisms maybe important in the development of steroid resistant/independent breast cancer.	[Al-Azawi, D.; Mc Ilroy, M.; Redmond, A. M.; Bane, F. T.; Cocchiglia, S.; Hill, A. D. K.; Young, L. S.] Royal Coll Surgeons Ireland, Dept Surg, Dublin 2, Ireland; [Al-Azawi, D.] Univ Coll Dublin, Sch Med & Med Sci, UCD Conway Inst, Dublin 2, Ireland; [Kelly, G.] Univ Coll Dublin, Sch Math Sci Stat & Actuarial Sci, Dublin 2, Ireland	Royal College of Surgeons - Ireland; University College Dublin; University College Dublin	Young, LS (corresponding author), Royal Coll Surgeons Ireland, Dept Surg Res, Lab 3, 4th Floor,York House,RCSI St Stephens Green, Dublin 2, Ireland.	lyoung@rcsi.ie	Hill, Arnold DK/F-8438-2011; McIlroy, Marie/D-6110-2012; Young, Leonie/D-5631-2012	McIlroy, Marie/0000-0002-0827-8096; Young, Leonie/0000-0002-4904-0367				BRONZERT DA, 1985, ENDOCRINOLOGY, V117, P1409, DOI 10.1210/endo-117-4-1409; BRUNNER N, 1993, CANCER RES, V53, P283; Carbone GM, 2004, NUCLEIC ACIDS RES, V32, P4358, DOI 10.1093/nar/gkh744; CHEVALLIER B, 1993, AM J CLIN ONCOL-CANC, V16, P223, DOI 10.1097/00000421-199306000-00006; Cosgrave N, 2006, J MOL ENDOCRINOL, V37, P377, DOI 10.1677/jme.1.02118; Cui YK, 2006, CANCER RES, V66, P5950, DOI 10.1158/0008-5472.CAN-05-3243; DUKE RC, 1994, FASEB J, V8, P237, DOI 10.1096/fasebj.8.2.8119494; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Foulds CE, 2004, MOL CELL BIOL, V24, P10954, DOI 10.1128/MCB.24.24.10954-10964.2004; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Goel A, 2004, J BIOL CHEM, V279, P14909, DOI 10.1074/jbc.M400036200; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hutcheson IR, 2003, BREAST CANCER RES TR, V81, P81, DOI 10.1023/A:1025484908380; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; MCIIROY M, 2006, ENDOCR-RELAT CANCER, V13, P1135; McNeil CM, 2006, J STEROID BIOCHEM, V102, P147, DOI 10.1016/j.jsbmb.2006.09.028; Myers E, 2005, CLIN CANCER RES, V11, P2111, DOI 10.1158/1078-0432.CCR-04-1192; Nicholson RI, 2004, CLIN CANCER RES, V10, p346S, DOI 10.1158/1078-0432.CCR-031206; Osborne CK, 2005, CLIN CANCER RES, V11, p865S; Papoutsopoulou S, 2000, MOL CELL BIOL, V20, P7300, DOI 10.1128/MCB.20.19.7300-7310.2000; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Shepherd T, 2001, J MAMMARY GLAND BIOL, V6, P129, DOI 10.1023/A:1009576801226; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218	27	49	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2008	27	21					3021	3031		10.1038/sj.onc.1210964	http://dx.doi.org/10.1038/sj.onc.1210964			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059336				2022-12-17	WOS:000255681700009
J	Cangemi, R; Mensah, A; Albertini, V; Jain, A; Mello-Grand, M; Chiorino, G; Catapano, CV; Carbone, GM				Cangemi, R.; Mensah, A.; Albertini, V.; Jain, A.; Mello-Grand, M.; Chiorino, G.; Catapano, C. V.; Carbone, G. M.			Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer	ONCOGENE			English	Article						ETS transcription factor; ESE-3; prostate cancer; tumor suppressor; caspase-3; apoptosis	EPITHELIAL-CELLS; GENE-EXPRESSION; P53 PROMOTER; TARGET GENE; METHYLATION; INHIBITION; APOPTOSIS; SITE; DIFFERENTIATION; IDENTIFICATION	Deregulated expression of ETS transcription factors has emerged as an important event in prostate cancer pathogenesis. Here we show that the expression of epithelial-specific ETS (ESE)-3 factor is frequently reduced at the RNA and protein level in prostate cancer clinical samples compared to normal prostate. In PC3 and DU145 cells, ESE-3 was silenced by methylation of an evolutionarily conserved CpG site in its promoter and treatment with 5-aza-2'-deoxycytidine restored its expression. In a prostate epithelial cell transformation model, methylation of this site was inversely correlated with ESE-3 expression and occurred only in Ras-transformed and tumorigenic cells and not in normal and immortalized cells suggesting that ESE-3 silencing was functionally linked to oncogenic transformation. Consistent with a tumor suppressor function, re-expression of ESE-3 in prostate cancer cells inhibited clonogenic survival and induced apoptotic cell death. ESE-3 increased the level of procaspase-3, a key element in the apoptotic cascade. This effect was mediated at the transcriptional level by direct binding of ESE-3 to the caspase-3 promoter. Collectively, our findings implicate ESE-3 as a candidate tumor suppressor in prostate cancer. Decreased expression of ESE-3 may result in loss of important regulatory mechanisms in prostate epithelial cells and contribute to the pathogenesis of prostate cancer.	[Cangemi, R.; Mensah, A.; Albertini, V.; Jain, A.; Catapano, C. V.; Carbone, G. M.] Oncol Inst So Switzerland, Expt Oncol Lab, CH-6500 Bellinzona, Switzerland; [Mello-Grand, M.; Chiorino, G.] Lab Canc Genom, Fondo Edo Tempia, Biella, Italy	Institute of Oncology Research (IOR)	Carbone, GM (corresponding author), Oncol Inst So Switzerland, Expt Oncol Lab, CH-6500 Bellinzona, Switzerland.	pina.carbone@irb.unisi.ch	Chiorino, Giovanna/K-5037-2016	Chiorino, Giovanna/0000-0002-9502-6400; Catapano, Carlo V./0000-0002-7079-557X; Mensah, Afua Adjeiwaa/0000-0001-8113-3689; Jain, Aklank/0000-0001-5539-3225				Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Carbone GM, 2004, NUCLEIC ACIDS RES, V32, P4358, DOI 10.1093/nar/gkh744; Catapano CV, 2000, BIOCHEMISTRY-US, V39, P5126, DOI 10.1021/bi992185w; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jones B, 2006, EMBO J, V25, P2443, DOI 10.1038/sj.emboj.7601148; Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266; Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986; Laslo P, 2006, CELL, V126, P755, DOI 10.1016/j.cell.2006.06.052; Liu AY, 1997, PROSTATE, V30, P145, DOI 10.1002/(SICI)1097-0045(19970215)30:3<145::AID-PROS1>3.0.CO;2-L; Liu WF, 2002, J BIOL CHEM, V277, P8273, DOI 10.1074/jbc.M110768200; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Pei HP, 2005, CANCER RES, V65, P7205, DOI 10.1158/0008-5472.CAN-04-3566; Petrovics G, 2005, ONCOGENE, V24, P3847, DOI 10.1038/sj.onc.1208518; Pogribny IP, 2000, CANCER RES, V60, P588; ROBERTSON KD, 1995, MOL CELL BIOL, V15, P6150; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Schedin PJ, 2004, ONCOGENE, V23, P1766, DOI 10.1038/sj.onc.1207391; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tugores A, 2001, J BIOL CHEM, V276, P20397, DOI 10.1074/jbc.M010930200; Tummala R, 2006, J CELL BIOCHEM, V97, P766, DOI 10.1002/jcb.20685	26	49	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2877	2885		10.1038/sj.onc.1210953	http://dx.doi.org/10.1038/sj.onc.1210953			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18037958				2022-12-17	WOS:000255502500009
J	Cuende, J; Moreno, S; Bolanos, JP; Almeida, A				Cuende, J.; Moreno, S.; Bolanos, J. P.; Almeida, A.			Retinoic acid downregulates Rae1 leading to APC(Cdh1) activation and neuroblastoma SH-SY5Y differentiation	ONCOGENE			English	Article						retinoic acid; Rae1; Cdh1; Skp2; p27; neuroblastoma	ANAPHASE-PROMOTING COMPLEX; CDK INHIBITOR P27; CELL-CYCLE EXIT; POSTMITOTIC NEURONS; AXONAL GROWTH; S-PHASE; DEGRADATION; P27(KIP1); SKP2; PHOSPHORYLATION	In neuroblastoma cells, retinoic acid induces cell cycle arrest and differentiation through degradation of the F-box protein, Skp2, and stabilization of cyclin-dependent kinase inhibitor, p27. However, the mechanism responsible for retinoic acid-mediated Skp2 destabilization is unknown. Since Skp2 is degraded by anaphase-promoting complex (APC)(Cdh1), here we studied whether retinoic acid promotes differentiation of human SH-SY5Y neuroblastoma cells by modulating Cdh1. We found that retinoic acid induced the nuclear accumulation of Cdh1 that paralleled Skp2 destabilization and p27 accumulation. The mRNA and protein abundance of Rae1-a nuclear export factor that limits APC(Cdh1) activity in mitosis decreased upon retinoic acid-induced inhibition of neuroblastoma cell proliferation. Furthermore, either Rae1 overexpression or Cdh1 inhibition promoted Skp2 accumulation, p27 destabilization and prevented retinoic acid-induced cell cycle arrest and differentiation. Conversely, inhibition of Rae1 accelerated retinoic acid-induced differentiation. Thus, retinoic acid downregulates Rae1, hence facilitating APC(Cdh1)-mediated Skp2 degradation leading to the arrest of cell cycle progression and neuroblastoma differentiation.	[Cuende, J.; Almeida, A.] Hosp Univ Salamanca, Unidad Invest, Inst Estudios Ciencias Salud Castilla & Leon, Salamanca 37007, Spain; [Cuende, J.; Bolanos, J. P.; Almeida, A.] Univ Salamanca, Inst Neurociencias Castilla & Leon, Dept Bioquim & Biol Mol, E-37008 Salamanca, Spain; [Moreno, S.] Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, E-37008 Salamanca, Spain	University of Salamanca; University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Almeida, A (corresponding author), Hosp Univ Salamanca, Unidad Invest, Inst Estudios Ciencias Salud Castilla & Leon, Paseo San Vicente 58-182, Salamanca 37007, Spain.	aaparra@usal.es	Moreno, Sergio/K-3671-2014; 2008, Ibsal/A-1268-2012; ALMEIDA, ANGELES/B-4727-2017; Bolaños, Juan Pedro/M-9518-2019	Moreno, Sergio/0000-0002-8039-1413; ALMEIDA, ANGELES/0000-0003-0485-8904; Bolaños, Juan Pedro/0000-0002-3949-6862				Almeida A, 2005, J NEUROSCI, V25, P8115, DOI 10.1523/JNEUROSCI.1143-05.2005; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Binne UK, 2007, NAT CELL BIOL, V9, P225, DOI 10.1038/ncb1532; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Blower MD, 2005, CELL, V121, P223, DOI 10.1016/j.cell.2005.02.016; Borriello A, 2006, CANCER RES, V66, P4240, DOI 10.1158/0008-5472.CAN-05-2759; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Clagett-Dame M, 2006, J NEUROBIOL, V66, P739, DOI 10.1002/neu.20241; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Encinas M, 2000, J NEUROCHEM, V75, P991, DOI 10.1046/j.1471-4159.2000.0750991.x; Gieffers C, 1999, P NATL ACAD SCI USA, V96, P11317, DOI 10.1073/pnas.96.20.11317; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Jeganathan KB, 2005, NATURE, V438, P1036, DOI 10.1038/nature04221; Konishi Y, 2004, SCIENCE, V303, P1026, DOI 10.1126/science.1093712; Lasorella A, 2006, NATURE, V442, P471, DOI 10.1038/nature04895; Maden M, 2002, NAT REV NEUROSCI, V3, P843, DOI 10.1038/nrn963; Matthay M A, 1999, Chest, V116, p119S; Nakamura M, 2003, CELL DEATH DIFFER, V10, P230, DOI 10.1038/sj.cdd.4401125; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Zancai P, 2005, ONCOGENE, V24, P2483, DOI 10.1038/sj.onc.1208458	27	49	50	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	23					3339	3344		10.1038/sj.onc.1210987	http://dx.doi.org/10.1038/sj.onc.1210987			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18212744				2022-12-17	WOS:000256111400012
J	Howarth, KD; Blood, KA; Ng, BL; Beavis, JC; Chua, Y; Cooke, SL; Raby, S; Ichimura, K; Collins, VP; Carter, NP; Edwards, PAW				Howarth, K. D.; Blood, K. A.; Ng, B. L.; Beavis, J. C.; Chua, Y.; Cooke, S. L.; Raby, S.; Ichimura, K.; Collins, V. P.; Carter, N. P.; Edwards, P. A. W.			Array painting reveals a high frequency of balanced translocations in breast cancer cell lines that break in cancer-relevant genes	ONCOGENE			English	Article						breast cancer; chromosome rearrangements; microarrays	COMPARATIVE GENOMIC HYBRIDIZATION; POLYCYSTIC KIDNEY-DISEASE; CHROMOSOME REARRANGEMENT; CYTOGENETIC ANALYSIS; COLORECTAL CANCERS; MYELOID-LEUKEMIA; DNA MICROARRAYS; PROSTATE-CANCER; GAMMA-HEREGULIN; FUSION GENES	Chromosome translocations in the common epithelial cancers are abundant, yet little is known about them. They have been thought to be almost all unbalanced and therefore dismissed as mostly mediating tumour suppressor loss. We present a comprehensive analysis by array painting of the chromosome translocations of breast cancer cell lines HCC1806, HCC1187 and ZR-75-30. In array painting, chromosomes are isolated by flow cytometry, amplified and hybridized to DNA microarrays. A total of 200 breakpoints were identified and all were mapped to 1Mb resolution on bacterial artificial chromosome (BAC) arrays, then 40 selected breakpoints, including all balanced breakpoints, were further mapped on tiling-path BAC arrays or to around 2 kb resolution using oligonucleotide arrays. Many more of the translocations were balanced at 1Mb resolution than expected, either reciprocal (eight in total) or balanced for at least one participating chromosome (19 paired breakpoints). Second, many of the breakpoints were at genes that are plausible targets of oncogenic translocation, including balanced breaks at CTCF, EP300/p300 and FOXP4. Two gene fusions were demonstrated, TAX1BP1-AHCY and RIF1-PKD1L1. Our results support the idea that chromosome rearrangements may play an important role in common epithelial cancers such as breast cancer.	[Howarth, K. D.; Blood, K. A.; Beavis, J. C.; Chua, Y.; Cooke, S. L.; Raby, S.; Edwards, P. A. W.] Univ Cambridge, Hutchison MRC Res Ctr, Dept Pathol, Cambridge CB2 0XZ, England; [Ng, B. L.; Carter, N. P.] Wellcome Trust Sanger, Cambridge, England; [Ichimura, K.; Collins, V. P.] Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Div Mol Histopathol, Cambridge CB2 0XZ, England	University of Cambridge; Wellcome Trust Sanger Institute; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Edwards, PAW (corresponding author), Univ Cambridge, Hutchison MRC Res Ctr, Dept Pathol, Hills Rd, Cambridge CB2 0XZ, England.	pawe1@cam.ac.uk	Edwards, Paul A/M-8291-2014	Edwards, Paul A/0000-0002-4789-3374	Cancer Research UK [A4392] Funding Source: Medline; Wellcome Trust [077008] Funding Source: Medline; Breast Cancer Now [2005NOV68] Funding Source: Medline	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission); Breast Cancer Now		Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Adeyinka A, 2000, INT J MOL MED, V5, P235; Alsop AE, 2006, CANCER GENET CYTOGEN, V164, P97, DOI 10.1016/j.cancergencyto.2005.09.011; Barlund M, 2002, GENE CHROMOSOME CANC, V35, P311, DOI 10.1002/gcc.10121; BRIAND P, 1987, IN VITRO CELL DEV B, V23, P181, DOI 10.1007/BF02623578; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Chin KT, 2007, CANCER RES, V67, P1072, DOI 10.1158/0008-5472.CAN-06-3053; Davidson JM, 2000, BRIT J CANCER, V83, P1309, DOI 10.1054/bjoc.2000.1458; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delmas P, 2005, PFLUG ARCH EUR J PHY, V451, P264, DOI 10.1007/s00424-005-1431-5; Dorssers LCJ, 1997, INT J CANCER, V72, P700, DOI 10.1002/(SICI)1097-0215(19970807)72:4<700::AID-IJC24>3.0.CO;2-D; Dutrillaux B, 1995, ADV CANCER RES, V67, P59, DOI 10.1016/S0065-230X(08)60710-1; ENGEL LW, 1978, CANCER RES, V38, P3352; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Fiegler H, 2003, J MED GENET, V40, P664, DOI 10.1136/jmg.40.9.664; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L; Gribble SM, 2007, J MED GENET, V44, P51, DOI 10.1136/jmg.2006.044909; Gribble SM, 2005, J MED GENET, V42, P8, DOI 10.1136/jmg.2004.024141; Grigorova M, 2005, CANCER GENET CYTOGEN, V162, P1, DOI 10.1016/j.cancergencyto.2005.03.007; Hahn Y, 2004, P NATL ACAD SCI USA, V101, P13257, DOI 10.1073/pnas.0405490101; Huang AL, 2006, NATURE, V442, P934, DOI [10.1038/nature05084, 10.1038/nature050084]; Huang HE, 2004, CANCER RES, V64, P6840, DOI 10.1158/0008-5472.CAN-04-1762; Ichimura K, 2006, ONCOGENE, V25, P1261, DOI 10.1038/sj.onc.1209156; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Krzywinski M, 2004, NUCLEIC ACIDS RES, V32, P3651, DOI 10.1093/nar/gkh700; Liu XF, 1999, ONCOGENE, V18, P7110, DOI 10.1038/sj.onc.1203136; McMullan TFW, 2002, HUM GENET, V110, P244, DOI 10.1007/s00439-002-0679-5; Mehra R, 2007, MODERN PATHOL, V20, P538, DOI 10.1038/modpathol.3800769; Mitelman F, 2005, GENE CHROMOSOME CANC, V43, P350, DOI 10.1002/gcc.20212; Mitelman F, 2004, NAT GENET, V36, P331, DOI 10.1038/ng1335; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; Morris JS, 1997, GENE CHROMOSOME CANC, V20, P120, DOI 10.1002/(SICI)1098-2264(199710)20:2<120::AID-GCC3>3.0.CO;2-5; Murrell A, 2004, NAT GENET, V36, P889, DOI 10.1038/ng1402; Ng BL, 2006, CYTOM PART A, V69A, P1028, DOI 10.1002/cyto.a.20330; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Persson K, 1999, GENE CHROMOSOME CANC, V25, P115, DOI 10.1002/(SICI)1098-2264(199906)25:2<115::AID-GCC7>3.0.CO;2-2; Pole JCM, 2006, ONCOGENE, V25, P5693, DOI 10.1038/sj.onc.1209570; Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102; Roschke AV, 2003, CANCER RES, V63, P8634; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Seng TJ, 2005, GENE CHROMOSOME CANC, V43, P181, DOI 10.1002/gcc.20181; Shillingford JM, 2006, P NATL ACAD SCI USA, V103, P5466, DOI 10.1073/pnas.0509694103; Silverman J, 2004, GENE DEV, V18, P2108, DOI 10.1101/gad.1216004; Sinclair PB, 2000, BLOOD, V95, P738, DOI 10.1182/blood.V95.3.738.003k21_738_743; Sirivatanauksorn V, 2001, INT J CANCER, V91, P350, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.3.CO;2-3; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Theodorou V, 2007, NAT GENET, V39, P759, DOI 10.1038/ng2034; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Volik S, 2003, P NATL ACAD SCI USA, V100, P7696, DOI 10.1073/pnas.1232418100; Wang XZ, 1999, ONCOGENE, V18, P5718, DOI 10.1038/sj.onc.1202950; Yuasa T, 2002, GENOMICS, V79, P376, DOI 10.1006/geno.2002.6719	55	49	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	23					3345	3359		10.1038/sj.onc.1210993	http://dx.doi.org/10.1038/sj.onc.1210993			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18084325	Green Accepted			2022-12-17	WOS:000256111400013
J	Leotoing, L; Meunier, L; Manin, M; Mauduit, C; Decaussin, M; Verrijdt, G; Claessens, F; Benahmed, M; Veyssiere, G; Morel, L; Beaudoin, C				Leotoing, L.; Meunier, L.; Manin, M.; Mauduit, C.; Decaussin, M.; Verrijdt, G.; Claessens, F.; Benahmed, M.; Veyssiere, G.; Morel, L.; Beaudoin, C.			Influence of nucleophosmin/B23 on DNA binding and transcriptional activity of the androgen receptor in prostate cancer cell	ONCOGENE			English	Article						nucleophosmin/B23; androgen receptor; transcription and prostate cancer	NUCLEOLAR PROTEIN B23; MOUSE VAS-DEFERENS; IN-VITRO; GENE; ACTIVATION; PROMOTER; TRANSACTIVATION; DIFFERENTIATION; IDENTIFICATION; EXPRESSION	The promotion and progression of prostate cancer (PCa) are associated with androgen receptor (AR) signalling. AR functions are modulated by a variety of co-factors amongst which we identified the nucleophosmin (NPM/B23), a member of the histone chaperone family. Here, we show that NPM is overexpressed in PCa compared to normal adjacent tissues. AR and NPM interact in vitro and in vivo, and NPM is critical for androgen-dependent transcriptional activation in LNCaP cells as an anti-NPM siRNA downregulates transcription of a transfected androgen response element (ARE)-containing reporter promoter as well as expression of the endogenous androgen responsive prostate-specific antigen (PSA) gene. By investigating the effect of NPM on AR, we have also observed that NPM enhances AR binding to an ARE in vitro in electrophoretic gel mobility-shift assay experiments. Chromatin immunoprecipitation studies further demonstrated that both AR and NPM associate with AREs of the PSA gene in vivo. Altogether, our data suggest that the molecular histone chaperone NPM could regulate AR functions by promoting assembly of AR-containing regulatory complexes and that high levels of NPM might alter AR functions in PCa.	[Leotoing, L.; Manin, M.; Veyssiere, G.; Morel, L.; Beaudoin, C.] Univ Blaise Pascal Clermont Ferrand II, CNRS, UMR 6547, F-63177 Aubiere, France; [Meunier, L.; Mauduit, C.; Decaussin, M.; Benahmed, M.] Fac Med Lyon Sud, INSERM, U 407, Oullins, France; [Verrijdt, G.; Claessens, F.] Katholieke Univ Leuven, Mol Endocrinol Lab, Louvain, Belgium	Centre National de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA); Institut National de la Sante et de la Recherche Medicale (Inserm); KU Leuven	Morel, L (corresponding author), Univ Blaise Pascal Clermont Ferrand II, CNRS, UMR 6547, 24 Ave Landais, F-63177 Aubiere, France.	laurent.morel@univ-bpclermont.fr	Claessens, Frank/M-8565-2016	Claessens, Frank/0000-0002-8676-7709; meunier, leo/0000-0001-8573-5687				Baron S, 2004, J BIOL CHEM, V279, P14579, DOI 10.1074/jbc.M306143200; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; BOCKER T, 1995, MODERN PATHOL, V8, P226; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Darne CH, 1997, MOL CELL ENDOCRINOL, V132, P13, DOI 10.1016/S0303-7207(97)00116-0; Dhar SK, 2004, J BIOL CHEM, V279, P28209, DOI 10.1074/jbc.M403553200; FABRE S, 1994, J BIOL CHEM, V269, P5857; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Haelens A, 2007, CANCER RES, V67, P4514, DOI 10.1158/0008-5472.CAN-06-1701; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Hsing AW, 2000, INT J CANCER, V85, P60, DOI 10.1002/(SICI)1097-0215(20000101)85:1&lt;60::AID-IJC11&gt;3.0.CO;2-B; Hu YC, 2004, J BIOL CHEM, V279, P33438, DOI 10.1074/jbc.M401781200; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Kim J, 2003, NUCLEIC ACIDS RES, V31, P6741, DOI 10.1093/nar/gkg909; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Leotoing L, 2007, J MOL ENDOCRINOL, V39, P151, DOI 10.1677/JME-07-0021; Liu H, 2007, EMBO REP, V8, P394, DOI 10.1038/sj.embor.7400909; Maiguel DA, 2004, MOL CELL BIOL, V24, P3703, DOI 10.1128/MCB.24.9.3703-3711.2004; Melvin VS, 1999, STEROIDS, V64, P576, DOI 10.1016/S0039-128X(99)00036-7; Morimoto RI, 2002, CELL, V110, P281, DOI 10.1016/S0092-8674(02)00860-7; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Ranganathan S, 1997, PROSTATE, V30, P263, DOI 10.1002/(SICI)1097-0045(19970301)30:4<263::AID-PROS6>3.0.CO;2-M; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Shatkina L, 2003, MOL CELL BIOL, V23, P7189, DOI 10.1128/MCB.23.20.7189-7197.2003; Subong ENP, 1999, PROSTATE, V39, P298; Swaminathan V, 2005, MOL CELL BIOL, V25, P7534, DOI 10.1128/MCB.25.17.7534-7545.2005; SZEBENI A, 1995, BIOCHEMISTRY-US, V34, P8037, DOI 10.1021/bi00025a009; Takemura M, 1999, J BIOCHEM-TOKYO, V125, P904, DOI 10.1093/oxfordjournals.jbchem.a022367; Verrijdt G, 2002, BIOCHEM J, V361, P97, DOI 10.1042/0264-6021:3610097; Volle DH, 2004, MOL ENDOCRINOL, V18, P888, DOI 10.1210/me.2003-0338; Wang L, 2005, PROSTATE, V63, P117, DOI 10.1002/pros.20170; Weng JJ, 2005, BIOCHEM BIOPH RES CO, V335, P826, DOI 10.1016/j.bbrc.2005.07.150	35	49	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2858	2867		10.1038/sj.onc.1210942	http://dx.doi.org/10.1038/sj.onc.1210942			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18037965				2022-12-17	WOS:000255502500007
J	Song, MS; Song, SJ; Kim, SJ; Nakayama, K; Nakayama, KI; Lim, DS				Song, M. S.; Song, S. J.; Kim, S. J.; Nakayama, K.; Nakayama, K. I.; Lim, D-S			Skp2 regulates the antiproliferative function of the tumor suppressor RASSF1A via ubiquitin-mediated degradation at the G(1)-S transition	ONCOGENE			English	Article						Skp2; RASSF1A; cyclin D-Cdk4; ubiquitination; G(1)-S transition	ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE; HUMAN CANCERS; PROTEIN; GENE; PROGRESSION; LIGASE; TRANSCRIPTION; ACCUMULATION; DESTRUCTION	The tumor suppressor RASSF1A is inactivated in many human cancers and is implicated in regulation of microtubule stability, cell cycle progression and apoptosis. However, the precise mechanisms of RASSF1A action and their regulation remain unclear. Here we show that Skp2, an oncogenic subunit of the Skp1-Cul1-F-box ubiquitin ligase complex, interacts with, ubiquitinates, and promotes the degradation of RASSF1A at the G1-S transition of the cell cycle. This Skp2-dependent destruction of RASSF1A requires phosphorylation of the latter on serine-203 by cyclin D-cyclin-dependent kinase 4. Interestingly, mutation of RASSF1A-phosphorylation site Ser(203) to alanine results in a delay in cell cycle progression from G(1) to S phase. Moreover, enforced expression of Skp2 abolishes the inhibitory effect of RASSF1A on cell proliferation. Finally, the delay in G(1)-S progression after Skp2 removal is normalized by depletion of RASSF1A. These findings suggest that the Skp2-mediated degradation of RASSF1A plays an important role in cell proliferation and survival.	[Song, M. S.; Song, S. J.; Kim, S. J.; Lim, D-S] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; [Nakayama, K.] Tohoku Univ, Grad Sch Med, Ctr Translat & Adv Anim Res Human Dis, Div Dev Genet, Sendai, Miyagi 980, Japan; [Nakayama, K. I.] Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 812, Japan	Korea Advanced Institute of Science & Technology (KAIST); Tohoku University; Kyushu University	Lim, DS (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 373-1 Guseong D, Taejon 305701, South Korea.	daesiklim@kaist.ac.kr	Lim, Dae-Sik/C-1599-2011	Lim, Dae-Sik/0000-0003-2356-7555				Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; An HX, 1999, AM J PATHOL, V154, P113, DOI 10.1016/S0002-9440(10)65257-1; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; BARTKOVA J, 1995, ONCOGENE, V10, P775; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bashir T, 2003, ADV CANCER RES, V88, P101, DOI 10.1016/S0065-230X(03)88305-7; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Fenton SL, 2004, CANCER RES, V64, P102, DOI 10.1158/0008-5472.CAN-03-2622; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Harper JW, 2002, TRENDS CELL BIOL, V12, P104, DOI 10.1016/S0962-8924(01)02238-3; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Oh HJ, 2006, CANCER RES, V66, P2562, DOI 10.1158/0008-5472.CAN-05-2951; Pagano M, 2003, CANCER CELL, V4, P251, DOI 10.1016/S1535-6108(03)00243-5; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901; RONG R, 2007, ONCOGENE; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Tommasi S, 2005, CANCER RES, V65, P92; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Yokoi S, 2002, AM J PATHOL, V161, P207, DOI 10.1016/S0002-9440(10)64172-7; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	34	49	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	22					3176	3185		10.1038/sj.onc.1210971	http://dx.doi.org/10.1038/sj.onc.1210971			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071316				2022-12-17	WOS:000255897600010
J	Lee, T; Langford, KJ; Askham, JM; Bruning-Richardson, A; Morrison, EE				Lee, T.; Langford, K. J.; Askham, J. M.; Bruning-Richardson, A.; Morrison, E. E.			MCAK associates with EB1	ONCOGENE			English	Article						EB1; MCAK; APC; microtubule	APC TUMOR-SUPPRESSOR; MICROTUBULE PLUS-END; MAMMALIAN-CELLS; PROTEIN; P150(GLUED); KINESIN; DEPOLYMERIZATION; POLYMERIZATION; DOMAINS	The microtubule ( MT)- associated protein EB1 localizes to and promotes growth at MT plus ends. The MT depolymerizing kinesin MCAK has also been reported to track growing MT plus ends. Here, we confirm that human MCAK colocalizes with EB1 at growing MT ends when expressed as a GFP fusion protein in transfected cells. We show that MCAK associates with the C- terminus of EB1 and EB3 but much less efficiently with RP1. EB1 associates with the N- terminal localization and regulatory domain in MCAK but not with the motor domain of the protein. The interaction is competitive with the binding of other EB1 ligands and does not require MTs. Knockdown of EB1 expression using siRNA impaired the ability of GFP- MCAK to localize to MT tips in transfected cells. We propose that MCAK is targeted to growing MT ends by EB1, that MCAK is held in an inactive conformation when associated with EB1 and that this could provide the basis for a mechanism that facilitates rapid switching between phases of MT growth and depolymerization.	[Lee, T.; Langford, K. J.; Askham, J. M.; Bruning-Richardson, A.; Morrison, E. E.] Univ Leeds, St James Univ Hosp, Leeds Inst Mol Med, Div Canc Med Res,CRUK Clin Ctr Leeds, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Morrison, EE (corresponding author), Univ Leeds, St James Univ Hosp, Leeds Inst Mol Med, Div Canc Med Res,CRUK Clin Ctr Leeds, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	e.e.morrison@leeds.ac.uk		Bruning-Richardson, Anke/0000-0002-9862-9805	Cancer Research UK Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Askham JM, 2002, MOL BIOL CELL, V13, P3627, DOI 10.1091/mbc.E02-01-0061; Banks JD, 2004, CURR BIOL, V14, P2033, DOI 10.1016/j.cub.2004.10.049; Bu W, 2003, J BIOL CHEM, V278, P49721, DOI 10.1074/jbc.M306194200; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Draviam VM, 2006, EMBO J, V25, P2814, DOI 10.1038/sj.emboj.7601168; Ems-McClung SC, 2007, MOL BIOL CELL, V18, P282, DOI 10.1091/mbc.E06-08-0724; Hayashi I, 2005, MOL CELL, V19, P449, DOI 10.1016/j.molcel.2005.06.034; Helenius J, 2006, NATURE, V441, P115, DOI 10.1038/nature04736; Kinoshita K, 2006, J MUSCLE RES CELL M, V27, P107, DOI 10.1007/s10974-005-9045-2; Kline-Smith SL, 2004, MOL BIOL CELL, V15, P1146, DOI 10.1091/mbc.E03-08-0581; Knowlton AL, 2006, CURR BIOL, V16, P1705, DOI 10.1016/j.cub.2006.07.057; Langford KJ, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-3; Lansbergen G, 2006, TRAFFIC, V7, P499, DOI 10.1111/j.1600-0854.2006.00400.x; Maney T, 2001, J BIOL CHEM, V276, P34753, DOI 10.1074/jbc.M106626200; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; Moore AT, 2005, J CELL BIOL, V169, P391, DOI 10.1083/jcb.200411089; Moores CA, 2006, J CELL SCI, V119, P3905, DOI 10.1242/jcs.03224; Morrison EE, 2007, CELL MOL LIFE SCI, V64, P307, DOI 10.1007/s00018-007-6360-3; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; Ohi R, 2007, CURR BIOL, V17, P953, DOI 10.1016/j.cub.2007.04.057; Riess NP, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-17; Tirnauer JS, 2002, MOL BIOL CELL, V13, P3614, DOI 10.1091/mbc.E02-04-0210; Watson P, 2006, J CELL SCI, V119, P2758, DOI 10.1242/jcs.02999	25	49	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2494	2500		10.1038/sj.onc.1210867	http://dx.doi.org/10.1038/sj.onc.1210867			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17968321				2022-12-17	WOS:000254844900014
J	Sirvent, A; Boureux, A; Simon, V; Leroy, C; Roche, S				Sirvent, A.; Boureux, A.; Simon, V.; Leroy, C.; Roche, S.			The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells	ONCOGENE			English	Article						Src; Abl; ERK5; Rac; cell transformation; breast cancer	VASCULAR SMOOTH-MUSCLE; MIDDLE-T-ANTIGEN; C-ABL; FAMILY KINASES; GROWTH-FACTORS; DNA-SYNTHESIS; TRANSCRIPTIONAL ACTIVITY; GENE-EXPRESSION; MYC EXPRESSION; RAC ACTIVATION	The cytoplasmic tyrosine kinase Src has been implicated in signal transduction induced by growth factors and integrins. Src also shows oncogenic activity when deregulated. Accumulating evidence indicates that the tyrosine kinase Abl is an important substrate for Src signalling in normal cells. Here we show that Abl is also required for Src-induced transformation of mouse fibroblasts. Abl does not mediate tyrosine phosphorylation of Stat3 and Shc, two important regulators of Src oncogenic activity. In contrast, Abl controls the activation of the small GTPase Rac for oncogenic signalling and active Rac partly rescued Src transformation in cells with inactive Abl. Moreover, Abl mediates Src-induced extracellular regulated kinase 5 (ERK5) activation to drive cell transformation. Finally, we find that Abl/Rac and Abl/ERK5 pathways also operate in human MCF7 and BT549 breast cancer cells, where neoplastic transformation depends on Src-like activities. Therefore, Abl is an important regulator of Src oncogenic activity both in mouse fibroblasts and in human cancer cells. Targeting these Abl-dependent signalling cascades may be of therapeutic value in breast cancers where Src-like function is important.	CNRS, CRBM, UMR 5237, F-34033 Montpellier, France; IGH, UPR1142 UMII, F-34095 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier	Roche, S (corresponding author), CNRS, CRBM, UMR 5237, BP 5051, F-34033 Montpellier, France.	serge.roche@crbm.cnrs.fr		roche, serge/0000-0003-3413-3859				Barros JC, 2005, J CELL SCI, V118, P1663, DOI 10.1242/jcs.02308; Boureux A, 2005, J CELL SCI, V118, P3717, DOI 10.1242/jcs.02491; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Buschbeck M, 2005, EMBO REP, V6, P63, DOI 10.1038/sj.embor.7400316; Chan AY, 2005, ONCOGENE, V24, P7821, DOI 10.1038/sj.onc.1208909; Chen T, 2006, ANTI-CANCER DRUG, V17, P123, DOI 10.1097/00001813-200602000-00002; Daniels CE, 2004, J CLIN INVEST, V114, P1308, DOI 10.1175/JCI200419603; Deroanne C, 2003, J CELL SCI, V116, P1367, DOI 10.1242/jcs.00308; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; FINN RS, 2007, IN PRESS BREAST CANC; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Franco M, 2006, MOL CELL BIOL, V26, P1932, DOI 10.1128/MCB.26.5.1932-1947.2006; Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514; Garaude J, 2006, J IMMUNOL, V177, P7607, DOI 10.4049/jimmunol.177.11.7607; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kayahara M, 2005, MOL CELL BIOL, V25, P3784, DOI 10.1128/MCB.25.9.3784-3792.2005; Kovalenko M, 1997, BIOCHEMISTRY-US, V36, P6260, DOI 10.1021/bi962553l; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mulloy R, 2003, ONCOGENE, V22, P5387, DOI 10.1038/sj.onc.1206839; Nicholson PR, 2001, EMBO J, V20, P6337, DOI 10.1093/emboj/20.22.6337; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Plattner R, 2003, NAT CELL BIOL, V5, P309, DOI 10.1038/ncb949; Roussidis AE, 2004, ANTICANCER RES, V24, P1445; SEGINA NV, 2007, NATURE, V445, P437; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Sini P, 2004, NAT CELL BIOL, V6, P268, DOI 10.1038/ncb1096; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Suzuki J, 2004, ONCOGENE, V23, P8527, DOI 10.1038/sj.onc.1207894; Tanis KQ, 2003, MOL CELL BIOL, V23, P3884, DOI 10.1128/MCB.23.11.3884-3896.2003; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; Ushio-Fukai M, 2005, CIRC RES, V97, P829, DOI 10.1161/01.RES.0000185322.46009.F5; Veracini L, 2006, J CELL SCI, V119, P2921, DOI 10.1242/jcs.03015; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zipfel PA, 2004, CURR BIOL, V14, P1222, DOI 10.1016/j.cub.2004.07.021; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	44	49	52	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2007	26	52					7313	7323		10.1038/sj.onc.1210543	http://dx.doi.org/10.1038/sj.onc.1210543			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533370	Green Submitted			2022-12-17	WOS:000250955700003
J	Ginestier, C; Adelaide, J; Goncalves, A; Repellini, L; Sircoulomb, F; Letessier, A; Finetti, P; Geneix, J; Charafe-Jauffret, E; Bertucci, F; Jacquemier, J; Viens, P; Birnbaum, D				Ginestier, C.; Adelaiede, J.; Goncalves, A.; Repellini, L.; Sircoulomb, F.; Letessier, A.; Finetti, P.; Geneix, J.; Charafe-Jauffret, E.; Bertucci, F.; Jacquemier, J.; Viens, P.; Birnbaum, D.			ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines	ONCOGENE			English	Article						herceptin; trastuzumab; ERBB2; breast cancer; phosphorylation; tyrosine kinase	ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; 1ST-LINE TREATMENT; PHASE-II; THERAPY; EXPRESSION; HERCEPTIN; EFFICACY; RESISTANCE; COMPLEX	Breast cancers that overexpress the ERBB2 tyrosine kinase receptor may be treated with the recombinant humanized monoclonal anti-ERBB2 antibody trastuzumab (herceptin). However, resistance to this targeted therapy is frequent. We have determined the response of 18 breast tumor cell lines to trastuzumab and compared it with the ERBB2 phosphorylation status using antibodies directed against tyrosine residue 1248. We show that sensitivity to trastuzumab is frequently associated with the expression of a phosphorylated ERBB2 protein.	Inst J Paoli I Calmettes, Ctr Rech Cancerol Marseille, INSERM, UMR599,Dept Oncol Mol, F-13009 Marseille, France; Inst J Paoli I Calmettes, Ctr Rech Cancerol Marseille, INSERM, UMR599,Dept Oncol Med, F-13009 Marseille, France; Univ Mediterranee, Fac Med, Marseille, France; Inst J Paoli I Calmettes, Dept BioPathol, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC)	Birnbaum, D (corresponding author), Inst J Paoli I Calmettes, Ctr Rech Cancerol Marseille, INSERM, UMR599,Dept Oncol Mol, 27 Bd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	Letessier, Anne/M-3431-2017; ADELAIDE, José JA/O-4390-2017; Ginestier, Christophe/M-8828-2017; Charafe-Jauffret, emmanuelle/P-6009-2017; Finetti, Pascal/O-8669-2017	Letessier, Anne/0000-0002-1894-4072; ADELAIDE, José JA/0000-0003-4364-9857; Ginestier, Christophe/0000-0002-7477-3837; Birnbaum, Daniel/0000-0001-7920-9883; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299; Finetti, Pascal/0000-0002-2674-3123				Adelaide J, 2003, GENE CHROMOSOME CANC, V37, P333, DOI 10.1002/gcc.10218; Anastasi S, 2005, ONCOGENE, V24, P4540, DOI 10.1038/sj.onc.1208658; BADACHE A, 2004, NAT CELL BIOL, V6, P515; Baselga J, 2004, SEMIN ONCOL, V31, P51, DOI 10.1053/j.seminoncol.2004.07.022; Baselga J, 2005, J CLIN ONCOL, V23, P2162, DOI 10.1200/JCO.2005.01.014; Bernard-Marty C, 2006, DRUGS, V66, P1577, DOI 10.2165/00003495-200666120-00004; Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Diermeier S, 2005, EXP CELL RES, V304, P604, DOI 10.1016/j.yexcr.2004.12.008; Emens Leisha A, 2005, Am J Ther, V12, P243; ETHIER SP, 1993, CANCER RES, V53, P627; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; Gonzalez-Angulo AM, 2006, ONCOLOGIST, V11, P857, DOI 10.1634/theoncologist.11-8-857; Hudelist G, 2006, INT J CANCER, V118, P1126, DOI 10.1002/ijc.21492; Kauraniemi P, 2004, ONCOGENE, V23, P1010, DOI 10.1038/sj.onc.1207200; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Lee JW, 2006, CLIN CANCER RES, V12, P57, DOI 10.1158/1078-0432.CCR-05-0976; Letessier A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-245; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Mass Robert D, 2005, Clin Breast Cancer, V6, P240, DOI 10.3816/CBC.2005.n.026; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nagy P, 2005, CANCER RES, V65, P473; Nahta R, 2004, CANCER RES, V64, P3981, DOI 10.1158/0008-5472.CAN-03-3900; Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; Pegram MD, 1999, SEMIN ONCOL, V26, P89; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Ramsauer VP, 2003, J BIOL CHEM, V278, P30142, DOI 10.1074/jbc.M303220200; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Tan-Chiu E, 2005, J CLIN ONCOL, V23, P7811, DOI 10.1200/JCO.2005.02.4091; Vogel CL, 2001, ONCOLOGY-BASEL, V61, P37, DOI 10.1159/000055400; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wobus M, 2001, GYNECOL ONCOL, V83, P227, DOI 10.1006/gyno.2001.6369	39	49	50	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7163	7169		10.1038/sj.onc.1210528	http://dx.doi.org/10.1038/sj.onc.1210528			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17525746				2022-12-17	WOS:000250715000011
J	Ollikainen, M; Hannelius, U; Lindgren, CM; Abdel-Rahman, WM; Kere, J; Peltomaki, P				Ollikainen, M.; Hannelius, U.; Lindgren, C. M.; Abdel-Rahman, W. M.; Kere, J.; Peltomaki, P.			Mechanisms of inactivation of MLH1 in hereditary nonpolyposis colorectal carcinoma: a novel approach	ONCOGENE			English	Article						hereditary nonpolyposis colorectal cancer; loss of heterozygosity; promoter methylation; colorectal cancer; endometrial cancer	REPAIR GENE-MUTATIONS; MICROSATELLITE INSTABILITY; HMLH1 PROMOTER; COLON-CANCER; ENDOMETRIAL CARCINOMA; SOMATIC MUTATIONS; PHENOTYPE; PROTEIN; HYPERMETHYLATION; METHYLATION	Mutations in the DNA mismatch repair gene MLH1 are a major cause of hereditary nonpolyposis colorectal cancer (HNPCC). No mutant phenotype is observed before the wild-type (wt) allele is somatically inactivated in target tissue. We addressed the mechanisms of MLH1 inactivation in 25 colorectal (CRC) and 32 endometrial cancers (ECs) from MLH1 mutation carriers (Mut1, in-frame genomic deletion; Mut2, out-of-frame splice site mutation; Mut3, missense mutation). By a quantitative method, matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF), utilizing four intragenic single nucleotide polymorphisms and mutations, loss of heterozygosity (LOH) was present in 31/57 (54.4%) of tumors. The wt allele displayed LOH more often than the mutant allele (23/57 vs 8/57, P = 0.006). For Mut1, LOH was more frequent in CRC than EC (10/11 vs 1/13, P < 0.0001), whereas Mut2 and Mut3 displayed opposite LOH pattern. Moreover, although wt LOH predominated in CRC irrespective of the predisposing mutation, LOH often affected the mutant allele in EC from Mut2 and Mut3 carriers (6/19, 31.6%). MLH1 promoter methylation, which reflected a more widespread hypermethylation tendency, occurred in 4/55 (7.3%) of tumors and was inversely associated with LOH. In conclusion, the patterns of somatic events (LOH and promoter methylation) differ depending on the tissue and germline mutation, which may in part explain the differential tumor susceptibility of different organs in HNPCC. MALDI-TOF provides a novel approach for the detection and quantification of LOH.	Univ Helsinki, Dept Med Genet, Helsinki, Finland; Karolinska Univ Hosp, Karolinska Inst, Clin Res Ctr, Huddinge, Sweden	University of Helsinki; Karolinska Institutet; Karolinska University Hospital	Ollikainen, M (corresponding author), Univ Helsinki, Dept Med Genet, Biomedicum, PO Box 63 Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	Miina.Ollikainen@Helsinki.fi	Ollikainen, Miina E/K-7464-2012; Kere, Juha/AAX-9117-2021; Kere, Juha/A-9179-2008	Ollikainen, Miina E/0000-0003-3661-7400; Kere, Juha/0000-0003-1974-0271; Kere, Juha/0000-0003-1974-0271; Abdel-Rahman, Wael/0000-0002-2149-1043; Lindgren, Cecilia/0000-0002-4903-9374; Peltomaki, Paivi/0000-0001-8819-2980	Wellcome Trust [090532] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Benedet JL, 2000, INT J GYNECOL OBSTET, V70, P209; Cejka P, 2003, EMBO J, V22, P2245, DOI 10.1093/emboj/cdg216; Chadwick RB, 2001, J MED GENET, V38, P461, DOI 10.1136/jmg.38.7.461; Cunningham JM, 1998, CANCER RES, V58, P3455; de Abajo AS, 2006, ONCOGENE, V25, P2124, DOI 10.1038/sj.onc.1209233; De Rosa M, 2000, ONCOGENE, V19, P1719, DOI 10.1038/sj.onc.1203447; de Wind N, 1998, CANCER RES, V58, P248; Deng GR, 1999, CANCER RES, V59, P2029; Dixon LA, 2006, FORENSIC SCI INT, V164, P33, DOI 10.1016/j.forsciint.2005.11.011; Dukes CE, 1932, J PATHOL BACTERIOL, V35, P323, DOI 10.1002/path.1700350303; Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Groves C, 2002, AM J PATHOL, V160, P2055, DOI 10.1016/S0002-9440(10)61155-8; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; ISOLA J, 1994, AM J PATHOL, V145, P1301; Jager AC, 1997, AM J HUM GENET, V61, P129, DOI 10.1086/513896; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Moisio AL, 1996, AM J HUM GENET, V59, P1243; Nagase T, 2000, DNA RES, V7, P347, DOI 10.1093/dnares/7.6.347; Nicolaides NC, 1998, MOL CELL BIOL, V18, P1635, DOI 10.1128/MCB.18.3.1635; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; Ohmae S, 2006, J BIOL CHEM, V281, P20427, DOI 10.1074/jbc.M513212200; Ollikainen M, 2005, J CLIN ONCOL, V23, P4609, DOI 10.1200/JCO.2005.06.055; Peltomaki P, 2004, DIS MARKERS, V20, P269, DOI 10.1155/2004/305058; Peltomaki P, 2001, Fam Cancer, V1, P9, DOI 10.1023/A:1011564720772; Petkovski E, 2005, J FORENSIC SCI, V50, P535; Potocnik U, 2001, CANCER GENET CYTOGEN, V126, P85, DOI 10.1016/S0165-4608(00)00399-X; Protopopov A, 2003, CANCER RES, V63, P404; Raevaara TE, 2005, GASTROENTEROLOGY, V129, P537, DOI 10.1053/j.gastro.2005.06.005; Renkonen E, 2003, J CLIN ONCOL, V21, P3629, DOI 10.1200/JCO.2003.03.181; Satoh J, 2006, J NEUROSCI METH, V152, P278, DOI 10.1016/j.jneumeth.2005.09.015; SCHWWIZER P, 2001, CANCER RES, V61, P2183; Simpkins SB, 1999, HUM MOL GENET, V8, P661, DOI 10.1093/hmg/8.4.661; Suzuki H, 1996, BIOCHEM BIOPH RES CO, V229, P902, DOI 10.1006/bbrc.1996.1900; Takagi Y, 2003, DNA REPAIR, V2, P1135, DOI 10.1016/S1568-7864(03)00134-4; Tannergard P, 1997, HUM GENET, V101, P51, DOI 10.1007/s004390050585; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Utsuno Hajime, 2004, Bull Tokyo Dent Coll, V45, P33, DOI 10.2209/tdcpublication.45.33; van Puijenbroek M, 2005, J MOL DIAGN, V7, P623, DOI 10.1016/S1525-1578(10)60596-X; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wheeler JMD, 2000, J MED GENET, V37, P588, DOI 10.1136/jmg.37.8.588; Wijnen J, 1999, NAT GENET, V23, P142, DOI 10.1038/13773; Yuen ST, 2002, ONCOGENE, V21, P7585, DOI 10.1038/sj.onc.1205968; ZHANG J, 2006, CANCER RES, V66, P559	49	49	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	31					4541	4549		10.1038/sj.onc.1210236	http://dx.doi.org/10.1038/sj.onc.1210236			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17260015				2022-12-17	WOS:000247836100008
J	Cowling, VH; Cole, MD				Cowling, V. H.; Cole, M. D.			E-cadherin repression contributes to c-Myc-induced epithelial cell transformation	ONCOGENE			English	Article						c-Myc; E-cadherin; transformation; epithelial cell; EMT	TRANSCRIPTION FACTOR SNAIL; MESENCHYMAL TRANSITIONS; GENE-EXPRESSION; METASTASIS; GROWTH	c-Myc oncoprotein is overexpressed in a significant proportion of human epithelial cancers, and experimental overexpression of c-Myc in epithelial cells promotes tumour formation. However, it is not known how c-Myc promotes epithelial cell tumour formation. We report that c-Myc expression in human mammary epithelial cells induces a dramatic change in cell morphology, with some characteristics of an 'epithelial to mesenchymal transition'. E-cadherin expression is repressed by a post-transcriptional mechanism in cells expressing c-Myc. Furthermore, E-cadherin repression is necessary for c-Myc-induced cell transformation.	Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Pharmacol, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Genet, Lebanon, NH 03756 USA	Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center	Cole, MD (corresponding author), Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Pharmacol, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	mcole@dartmouth.edu		Cowling, Victoria/0000-0001-7638-4870	MRC [G0700240] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [R01CA080320] Funding Source: NIH RePORTER; Medical Research Council [G0700240] Funding Source: Medline; NCI NIH HHS [CA80320] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; DiRenzo J, 2002, CANCER RES, V62, P89; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; GRAFF JR, 1995, CANCER RES, V55, P5195; Niveditha S R, 2003, Indian J Pathol Microbiol, V46, P579; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822	18	49	50	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3582	3586		10.1038/sj.onc.1210132	http://dx.doi.org/10.1038/sj.onc.1210132			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17146437				2022-12-17	WOS:000246799200014
J	Rother, K; Kirschner, R; Sanger, K; Bohlig, L; Mossner, J; Engeland, K				Rother, K.; Kirschner, R.; Saenger, K.; Boehlig, L.; Moessner, J.; Engeland, K.			p53 downregulates expression of the G(1)/S cell cycle phosphatase Cdc25A	ONCOGENE			English	Article						p53; Cdc25A; G(1) to S transition; repression; tumor suppressor; transcription	SUPPRESSOR PROTEIN P53; P63; HOMOLOG; TRANSCRIPTION; ACTIVATION; PHOSPHORYLATION; P73; IDENTIFICATION; REQUIREMENT; INHIBITION	Overexpression of Cdc25A phosphatase is often observed in cancer and results in poor prognosis. Cdc25A mainly dephosphorylates and thereby activates Cyclin-dependent kinase 2 and thus induces progression in the cell cycle from G(1) to S phase. Here, we demonstrate that the tumor suppressor p53 downregulates expression from the Cdc25A gene. In a p53-inducible cell system, Cdc25A expression on the mRNA and protein level is downregulated upon p53 expression. Promoter-reporter assays show that this regulation is dependent on the Cdc25A promoter. Mutant p53 fails to reduce Cdc25A transcription. In contrast to p53, neither p63 nor p73 can repress Cdc25A transcription. The Cdc25A promoter displays no p53 binding site, and p53 does not bind directly to the promoter DNA as shown by chromatin immunoprecipitation assays. Previously, the contribution of p53 to G1/S arrest has been mostly linked to activating the expression of the Cdk inhibitor p21(WAF1/CIP1). By downregulating Cdc25A expression, p53 may impair transition from G1 to S phase independently of p21(WAF1/CIP1). Therefore, the data suggest that, as long as p53 is intact, Cdc25A transcriptional downregulation might play a role in cancer prevention.	Univ Leipzig, Med Klin & Poliklin 2, Max Burger Forschungszentrum, D-04103 Leipzig, Germany; Univ Leipzig, IZKF, Max Burger Forschungszentrum, D-7010 Leipzig, Germany	Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Leipzig University	Engeland, K (corresponding author), Univ Leipzig, Med Klin & Poliklin 2, Max Burger Forschungszentrum, Johannisallee, D-04103 Leipzig, Germany.	engeland@medizin.uni-leipzig.de	Engeland, Kurt/AAW-9965-2020; Rother, Karen/GQI-3786-2022	Engeland, Kurt/0000-0003-3525-0440; Rother, Karen/0000-0002-0074-7329				Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Broggini M, 2000, ANTICANCER RES, V20, P4835; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Chen MS, 2003, MOL CELL BIOL, V23, P7488, DOI 10.1128/MCB.23.21.7488-7497.2003; Dietz S, 2002, FEBS LETT, V525, P93, DOI 10.1016/S0014-5793(02)03093-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Katoh I, 2000, ONCOGENE, V19, P3126, DOI 10.1038/sj.onc.1203644; Krause K, 2001, BIOCHEM BIOPH RES CO, V284, P743, DOI 10.1006/bbrc.2001.5040; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Lammer C, 1998, J CELL SCI, V111, P2445; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moll UM, 2004, MOL CANCER RES, V2, P371; NAGATA A, 1991, NEW BIOL, V3, P959; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Tschop K, 2006, FEBS J, V273, P1681, DOI 10.1111/j.1742-4658.2006.05184.x; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Wasner M, 2003, GENE, V312, P225, DOI 10.1016/S0378-1119(03)00618-8; Wasner M, 2003, FEBS LETT, V536, P66, DOI 10.1016/S0014-5793(03)00028-0; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhu JH, 1998, CANCER RES, V58, P5061	45	49	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1949	1953		10.1038/sj.onc.1209989	http://dx.doi.org/10.1038/sj.onc.1209989			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001315				2022-12-17	WOS:000245117700012
J	McDermott, SP; Ranheim, EA; Leatherberry, VS; Khwaja, SS; Klos, KS; Alexander, CM				McDermott, S. P.; Ranheim, E. A.; Leatherberry, V. S.; Khwaja, S. S.; Klos, K. S.; Alexander, C. M.			Juvenile syndecan-1 null mice are protected from carcinogen-induced tumor development	ONCOGENE			English	Article						syndecan-1 heparan sulfate proteoglycan; mouse tumor; DMBA	BREAST-CANCER CELLS; PROGENITOR CELLS; HEPARAN-SULFATE; STEM-CELLS; MOUSE; IDENTIFICATION; ACTIVATION; EXPRESSION; INDUCTION; RECOMMENDATIONS	We previously showed that mice with a null mutation in syndecan-1 (Sdc1; CD138) were resistant to Wnt1-induced mammary tumor initiation. The absence of Sdc1 inhibited the increase in the mammary stem cell fraction that is characteristic of preneoplasia in this model. As the tumor precursor cells are recruited from the stem/progenitor cell compartment, tumor development was also inhibited (Liu et al., 2004; PNAS 101, 4158). Although Sdc1(-/-) mice are grossly normal, they are systemically smaller, suggesting that developmental abnormalities may extend further than their mammary glands. We have therefore evaluated the multi-organ response of Sdc1(-/-) mice to carcinogen-induced tumor development (7,12-dimethylbenz[a] anthracene, DMBA), and find these mice to be resistant to tumorigenesis in all the predominant carcinogen-susceptible lineages. Thus, Sdc1(-/-) mice administered DMBA during juvenile development are resistant not only to epithelial tumors, including liver (60-80%) and lung tumors (C57BL6 mice, 60-80%), but also to lymphoma ( over 70%, depending upon strain and carcinogen dose). We demonstrate that CD138 is expressed ( heterogeneously) in the hematopoietic stem cell fraction ( and not only in pre-B and plasma cells), and that tumors arise in both myeloid and lymphoid lineages. Furthermore, carcinogen-induced mammary tumors are bilineal, implying a bipotent precursor cell. Both observations imply that the DMBA-induced tumor precursor cells are drawn from the stem/progenitor fraction, and we suggest that pathogenic activation of these cells could be abnormal in Sdc1(-/-) mice.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Pathol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Alexander, CM (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	alexander@oncology.wisc.edu	McDermott, Sean/I-2978-2013; Ranheim, Erik/AAY-6505-2021	McDermott, Sean/0000-0001-7820-2399; 	NCI NIH HHS [T32 CA09135, CA 90877] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009135, R01CA090877] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAMATSU Y, 1975, J NATL CANCER I, V55, P893, DOI 10.1093/jnci/55.4.893; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bunger MK, 2003, J BIOL CHEM, V278, P17767, DOI 10.1074/jbc.M209594200; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; FLAKS A, 1968, European Journal of Cancer, V4, P579, DOI 10.1016/0014-2964(68)90042-X; Forsberg EC, 2005, PLOS GENET, V1, P281, DOI 10.1371/journal.pgen.0010028; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; Gotte M, 2002, INVEST OPHTH VIS SCI, V43, P1135; Heidel SM, 2000, CANCER RES, V60, P3454; Huntly BJP, 2005, NAT REV CANCER, V5, P311, DOI 10.1038/nrc1592; Kenney Nicholas J., 2001, Journal of Biomedicine and Biotechnology, V1, P133, DOI 10.1155/S1110724301000304; Kramer KL, 2003, ANNU REV GENET, V37, P461, DOI 10.1146/annurev.genet.37.061103.090226; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Liu BY, 2003, ONCOGENE, V22, P9243, DOI 10.1038/sj.onc.1207217; Maeda T, 2006, ONCOGENE, V25, P1408, DOI 10.1038/sj.onc.1209168; Maeda T, 2004, CANCER RES, V64, P612, DOI 10.1158/0008-5472.CAN-03-2439; Mehta RG, 2000, EUR J CANCER, V36, P1275, DOI 10.1016/S0959-8049(00)00100-3; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Paguirigan A, 2006, EUR J CANCER, V42, P1225, DOI 10.1016/j.ejca.2006.01.048; Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100; Ranheim EA, 2005, BLOOD, V105, P2487, DOI 10.1182/blood-2004-06-2334; ROE FJC, 1968, FOOD COSMET TOXICOL, V6, P581, DOI 10.1016/0015-6264(68)90302-7; SHACKLEFORD GM, 1988, P NATL ACAD SCI USA, V85, P9655, DOI 10.1073/pnas.85.24.9655; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stepp MA, 2002, J CELL SCI, V115, P4517, DOI 10.1242/jcs.00128; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; Taylor KR, 2006, FASEB J, V20, P9, DOI 10.1096/fj.05-4682rev; VANLEEUWEN F, 1995, SEMIN CANCER BIOL, V6, P127, DOI 10.1006/scbi.1995.0018; WALTERS MA, 1966, BRIT J CANCER, V20, P148, DOI 10.1038/bjc.1966.17; Whitelock JM, 2005, CHEM REV, V105, P2745, DOI 10.1021/cr010213m	37	49	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2007	26	10					1407	1416		10.1038/sj.onc.1209930	http://dx.doi.org/10.1038/sj.onc.1209930			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16953225				2022-12-17	WOS:000244558800005
J	Bradley, KJ; Bowl, MR; Williams, SE; Ahmad, BN; Partridge, CJ; Patmanidi, AL; Kennedy, AM; Loh, NY; Thakker, RV				Bradley, K. J.; Bowl, M. R.; Williams, S. E.; Ahmad, B. N.; Partridge, C. J.; Patmanidi, A. L.; Kennedy, A. M.; Loh, N. Y.; Thakker, R. V.			Parafibromin is a nuclear protein with a functional monopartite nuclear localization signal	ONCOGENE			English	Article						parathyroid cancer; tumour suppressor gene; uterine tumours; renal tumours; ossifying fibromas	JAW TUMOR SYNDROME; PARATHYROID CARCINOMA; GENE-PRODUCT; HUMAN PAF1; HYPERPARATHYROIDISM; HRPT2; MUTATIONS; RETINOBLASTOMA; IDENTIFICATION; DYSPLASIA	Parafibromin is a nuclear protein with a tumour suppressor role in the development of non-hereditary and hereditary parathyroid carcinomas, and the hyperparathyroidism-jaw tumour (HPT-JT) syndrome, which is associated with renal and uterine tumours. Nuclear localization signal( s), (NLS(s)), of the 61kDa parafibromin remain to be defined. Utilization of computer-prediction programmes, identified five NLSs (three bipartite ( BP) and two monopartite ( MP)). To investigate their functionality, wild-type (WT) and mutant parafibromin constructs tagged with enhanced green fluorescent protein or cMyc were transiently expressed in COS-7 cells, or human embryonic kidney 293 (HEK293) cells, and their subcellular locations determined by confocal fluorescence microscopy. Western blot analyses of nuclear and cytoplasmic fractions from the transfected cells were also performed. WT parafibromin localized to the nucleus and deletions or mutations of the three predicted BP and one of the predicted MP NLSs did not affect this localization. In contrast, deletions or mutations of a MP NLS, at residues 136-139, resulted in loss of nuclear localization. Furthermore, the critical basic residues, KKXR, of this MP NLS were found to be evolutionarily conserved, and over 60% of all parafibromin mutations lead to a loss of this NLS. Thus, an important functional domain of parafibromin, consisting of an evolutionarily conserved MP NLS, has been identified.	Univ Oxford, OCDEM, Nuffield Dept Clin Med, Acad Endocrine Unit,Churchil Hosp, Oxford OX3 7LJ, England; Univ Oxford, Diabet Res Labs, Nuffield Dept Clin Med, Dept Clin Med,Churchill Hosp,OCDEM, Oxford OX3 7LJ, England	University of Oxford; University of Oxford	Thakker, RV (corresponding author), Univ Oxford, OCDEM, Nuffield Dept Clin Med, Acad Endocrine Unit,Churchil Hosp, Oxford OX3 7LJ, England.	rajesh.thakker@ndm.ox.ac.uk		Kennedy, Ann/0000-0003-0290-396X; Piret, Sian/0000-0002-3586-7654; Patmanidi, Alexandra/0000-0003-0773-2020; Bowl, Michael/0000-0001-7971-445X; Thakker, Rajesh/0000-0002-1438-3220	Medical Research Council [G9825289] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G9825289] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bradley KJ, 2006, CLIN ENDOCRINOL, V64, P299, DOI 10.1111/j.1365-2265.2006.02460.x; Bradley KJ, 2005, J INTERN MED, V257, P18, DOI 10.1111/j.1365-2796.2004.01421.x; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Cavaco BM, 2001, QJM-INT J MED, V94, P213, DOI 10.1093/qjmed/94.4.213; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Fontes MRM, 2003, J BIOL CHEM, V278, P27981, DOI 10.1074/jbc.M303275200; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Hahn MA, 2005, ONCOGENE, V24, P6241, DOI 10.1038/sj.onc.1208778; Haven CJ, 2000, J CLIN ENDOCR METAB, V85, P1449, DOI 10.1210/jc.85.4.1449; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Howell VM, 2003, J MED GENET, V40, P657, DOI 10.1136/jmg.40.9.657; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Kennedy AM, 2005, J CLIN INVEST, V115, P2832, DOI 10.1172/JCI22900; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Krauer K, 2004, J GEN VIROL, V85, P165, DOI 10.1099/vir.0.19549-0; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nesbit MA, 2004, J BIOL CHEM, V279, P22624, DOI 10.1074/jbc.M401797200; Quadrini KJ, 2002, J BIOL CHEM, V277, P32243, DOI 10.1074/jbc.M205677200; Rozenblatt-Rosen O, 2005, MOL CELL BIOL, V25, P612, DOI 10.1128/MCB.25.2.612-620.2005; Shattuck TM, 2003, NEW ENGL J MED, V349, P1722, DOI 10.1056/NEJMoa031237; SZABO J, 1995, AM J HUM GENET, V56, P944; Tan MH, 2004, CLIN CANCER RES, V10, P6629, DOI 10.1158/1078-0432.CCR-04-0493; Teh BT, 1996, J CLIN ENDOCR METAB, V81, P4204, DOI 10.1210/jc.81.12.4204; THAKKER RV, 2006, ENDOCRINOLOGY, V2, P1511; Vandenbroucke I, 2004, FEBS LETT, V560, P98, DOI 10.1016/S0014-5793(04)00078-X; Woodard GE, 2005, ONCOGENE, V24, P1272, DOI 10.1038/sj.onc.1208274; Yart A, 2005, MOL CELL BIOL, V25, P5052, DOI 10.1128/MCB.25.12.5052-5060.2005; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588	30	49	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1213	1221		10.1038/sj.onc.1209893	http://dx.doi.org/10.1038/sj.onc.1209893			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16964291				2022-12-17	WOS:000244406400011
J	Iyer, NG; Xian, J; Chin, SF; Bannister, AJ; Daigo, Y; Aparicio, S; Kouzarides, T; Caldas, C				Iyer, N. G.; Xian, J.; Chin, S-F; Bannister, A. J.; Daigo, Y.; Aparicio, S.; Kouzarides, T.; Caldas, C.			p300 is required for orderly G1/S transition in human cancer cells	ONCOGENE			English	Article						RB; retinoblastoma; hyperphosphorylation; Cdk; HCT116	DNA-DAMAGE; C-MYC; RETINOBLASTOMA PROTEIN; G(1) EXIT; IN-VITRO; ACETYLATION; CBP; P53; MUTATIONS; BINDING	The role of the transcriptional coactivator p300 in cell cycle control has not been analysed in detail due to the lack of appropriate experimental systems. We have now examined cell cycle progression of p300-deficient cancer cell lines, where p300 was disrupted either by gene targeting (p300(-) cells) or knocked down using RNAi. Despite significant proliferation defects under normal growth conditions, p300(-) deficient cells progressed rapidly through G1 with premature S-phase entry. Accelerated G1/S transition was associated with early retinoblastoma (RB) hyperphosphorylation and activation of E2F targets. The p300(-) acetylase activity was dispensable since expression of a HAT-deficient p300 mutant reversed these changes. Co-immunoprecipitation showed p300/RB interaction occurs in vivo during G1, and this interaction has two peaks: in early G1 with unphosphorylated RB and in late G1 with phosphorylated RB. In vitro kinase assays showed that p300 directly inhibits cdk6-mediated RB phosphorylation, suggesting p300 acts in early G1 to prevent RB hyperphosphorylation and delay premature S-phase entry. Paradoxically, continued cycling of p300(-) cells despite prolonged serum depletion was observed, and this occurred in association with persistent RB hyperphosphorylation. Altogether, these results suggest that p300 has an important role in G1/S control, possibly by modulating RB phosphorylation.	Univ Cambridge, Canc Genom Program, Hutchison MRC Res Ctr, Dept Oncol, Cambridge CB2 2XZ, England; Univ Cambridge, Wellcome Trust CRUK Gurdon Inst, Cambridge, England	University of Cambridge; University of Cambridge	Caldas, C (corresponding author), Univ Cambridge, Canc Genom Program, Hutchison MRC Res Ctr, Dept Oncol, Hills Rd, Cambridge CB2 2XZ, England.	cc234@cam.ac.uk	Caldas, Carlos/A-7543-2008; Caldas, Carlos/U-7250-2019	Caldas, Carlos/0000-0003-3547-1489; Kouzarides, Tony/0000-0002-8918-4162; Aparicio, Samuel/0000-0002-0487-9599; chin, suet-feung/0000-0001-5697-1082; Bannister, Andrew/0000-0002-6312-4436; Daigo, Yataro/0000-0002-0915-3025				Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Baluchamy S, 2003, P NATL ACAD SCI USA, V100, P9524, DOI 10.1073/pnas.1633700100; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; Dolbeare F, 1990, Methods Cell Biol, V33, P207; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; Iyer NG, 2004, P NATL ACAD SCI USA, V101, P7386, DOI 10.1073/pnas.0401002101; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Kolli S, 2001, P NATL ACAD SCI USA, V98, P4646, DOI 10.1073/pnas.081141998; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Liu L, 1999, MOL CELL BIOL, V19, P1202; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Ozdag H, 2002, BRIT J CANCER, V87, P1162, DOI 10.1038/sj.bjc.6600554; Rajabi HN, 2005, J BIOL CHEM, V280, P361, DOI 10.1074/jbc.M408633200; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Suganuma T, 2002, P NATL ACAD SCI USA, V99, P13073, DOI 10.1073/pnas.192586699; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; WALDMAN T, 1995, CANCER RES, V55, P5187; Ward R, 2005, J MED GENET, V42, P514, DOI 10.1136/jmg.2004.025080; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan ZM, 1999, ONCOGENE, V18, P5714, DOI 10.1038/sj.onc.1202930	33	49	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					21	29		10.1038/sj.onc.1209771	http://dx.doi.org/10.1038/sj.onc.1209771			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16878158				2022-12-17	WOS:000243236500003
J	Brummer, T; Martin, P; Herzog, S; Misawa, Y; Daly, RJ; Reth, M				Brummer, T.; Martin, P.; Herzog, S.; Misawa, Y.; Daly, R. J.; Reth, M.			Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein	ONCOGENE			English	Article						Ras; 14-3-3 proteins; beta-Catenin; E-cadherin; mammary epithelial cells	ACTIVATED PROTEIN-KINASE; WILD-TYPE BRAF; C-RAF; ONCOGENIC MUTATIONS; SIGNALING PATHWAY; COLORECTAL TUMORS; TYROSINE KINASES; HUMAN CANCER; IN-VITRO; PHOSPHORYLATION	The BRAF(V600E) mutation is found in approximately 6% of human cancers and mimics the phosphorylation of the kinase domain activation segment. In wild-type B-Raf (B-Raf(wt)), activation segment phosphorylation is thought to cooperate with negative charges within the N-region for full activation. In contrast to Raf-1, the N-region of B-Raf is constitutively negatively charged owing to the presence of residues D447/D448 and the phosphorylation of S446. Therefore, it has been suggested that this hallmark predisposes B-Raf for oncogenic activation. In this study, we demonstrate that neutralizing mutations of these residues (in particular S446 and S447), or uncoupling of B-Raf from Ras-guanine 5'-triphosphate (GTP), strongly reduce the biological activity of B-Raf in a PC12 cell differentiation assay. We also confirm that S365 is a 14-3-3 binding site, and determine that mutation of this residue rescues the impaired biological activity of B-Raf proteins with a neutralized N-region, suggesting that the N-region opposes a 14-3-3-mediated transition into an inactive conformation. However, in the case of B-Raf(V600E), although complete N-region neutralization resulted in a 2.5-fold reduction in kinase activity in vitro, this oncoprotein strongly induced PC12 differentiation or transformation and epithelial - mesenchymal transition of MCF-10A cells regardless of its N-region charge. Furthermore, the biological activity of B-RafV600E was independent of its ability to bind Ras-GTP. Our analysis identifies important regulatory differences between B-Raf(wt) and B-Raf(V600E) and suggests that B-Raf(V600E) cannot be inhibited by strategies aimed at blocking S446 phosphorylation or Ras activation.	Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; Univ Freiburg, Inst Biol 3, Dept Mol Immunol, D-7800 Freiburg, Germany; Max Planck Inst Immunbiol, D-7800 Freiburg, Germany; Univ Virginia, Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA USA	Garvan Institute of Medical Research; University of Freiburg; Max Planck Society; University of Virginia	Brummer, T (corresponding author), Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	t.brummer@garvan.org.au	Brummer, Tilman/AAA-9428-2020; Brummer, Tilman/B-6218-2016; Daly, Roger J/C-8179-2009	Brummer, Tilman/0000-0003-4387-7905; Brummer, Tilman/0000-0003-4387-7905; Daly, Roger/0000-0002-5739-8027; Herzog, Sebastian/0000-0001-7167-3489				ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Brummer T, 2003, ONCOGENE, V22, P8823, DOI 10.1038/sj.onc.1207185; Brummer T, 2002, EMBO J, V21, P5611, DOI 10.1093/emboj/cdf588; Brummer Tilman, 2004, Methods Mol Biol, V271, P189; Carey KD, 2003, J BIOL CHEM, V278, P3185, DOI 10.1074/jbc.M207014200; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Chong HR, 2003, J BIOL CHEM, V278, P36269, DOI 10.1074/jbc.M212803200; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Dhillon AS, 2003, MOL CELL BIOL, V23, P1983, DOI 10.1128/MCB.23.6.1983-1993.2003; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Emuss V, 2005, CANCER RES, V65, P9719, DOI 10.1158/0008-5472.CAN-05-1683; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Gilles C, 2003, CANCER RES, V63, P2658; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Grbovic OM, 2006, P NATL ACAD SCI USA, V103, P57, DOI 10.1073/pnas.0609973103; Harding A, 2003, J BIOL CHEM, V278, P45519, DOI 10.1074/jbc.M303106200; Hekman M, 2004, J BIOL CHEM, V279, P14074, DOI 10.1074/jbc.M309620200; Hingorani SR, 2003, CANCER RES, V63, P5198; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; Hubbard SR, 2004, CELL, V116, P764, DOI 10.1016/S0092-8674(04)00256-9; Ikenoue T, 2004, CANCER RES, V64, P3428, DOI 10.1158/0008-5472.CAN-03-3591; Ikenoue T, 2003, CANCER RES, V63, P8132; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Light Y, 2002, MOL CELL BIOL, V22, P4984, DOI 10.1128/MCB.22.14.4984-4996.2002; MacNicol MC, 2000, J BIOL CHEM, V275, P3803, DOI 10.1074/jbc.275.6.3803; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mercer K, 2005, CANCER RES, V65, P11493, DOI 10.1158/0008-5472.CAN-05-2211; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Morrison DK, 2004, NATURE, V428, P813, DOI 10.1038/428813a; O'Neill E, 2004, BRIT J CANCER, V90, P283, DOI 10.1038/sj.bjc.6601488; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Tanami H, 2004, ONCOGENE, V23, P8796, DOI 10.1038/sj.onc.1208152; Terai K, 2005, EMBO REP, V6, P251, DOI 10.1038/sj.embor.7400349; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tran NH, 2005, J BIOL CHEM, V280, P16244, DOI 10.1074/jbc.M501185200; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; Tsavachidou D, 2004, CANCER RES, V64, P5556, DOI 10.1158/0008-5472.CAN-04-1669; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Xiang XQ, 2002, J BIOL CHEM, V277, P44996, DOI 10.1074/jbc.M203953200; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yamaguchi T, 2004, J BIOL CHEM, V279, P40419, DOI 10.1074/jbc.M405079200; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhang BH, 2001, J BIOL CHEM, V276, P31620, DOI 10.1074/jbc.M102808200; Zhu J, 2005, MOL BIOL CELL, V16, P4733, DOI 10.1091/mbc.E05-02-0090; Ziogas A, 2005, J BIOL CHEM, V280, P24205, DOI 10.1074/jbc.M413327200	58	49	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2006	25	47					6262	6276		10.1038/sj.onc.1209640	http://dx.doi.org/10.1038/sj.onc.1209640			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16702958				2022-12-17	WOS:000241218200004
J	Gort, EH; Groot, AJ; van de Ven, TLPD; van der Groep, P; Verlaan, I; van Laar, T; van Diest, PJ; van der Wall, E; Shvarts, A				Gort, E. H.; Groot, A. J.; van de Ven, T. L. P. Derks; van der Groep, P.; Verlaan, I.; van Laar, T.; van Diest, P. J.; van der Wall, E.; Shvarts, A.			Hypoxia-inducible factor-1 alpha expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas	ONCOGENE			English	Article						HIF-1 alpha; PI 3-kinase; Akt; hypoxia; breast cancer	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE-B; FACTOR 1-ALPHA; PROLYL HYDROXYLATION; GENE-TRANSCRIPTION; PROSTATE-CANCER; HIF-ALPHA; ACTIVATION; PATHWAY; CELLS	Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is the regulatory subunit of the heterodimeric transcription factor HIF-1 and the key factor in cellular response to low oxygen tension. Expression of HIF-1 alpha protein is associated with poor patient survival and therapy resistance in many types of solid tumors. Insight into HIF-1 alpha regulation in solid tumors is important for therapeutic strategies. In this study, we determined the pathophysiological relevance of HIF-1 alpha regulation by the oncogenic phosphatidylinositol 3'-kinase (PI 3-kinase)/Akt signaling pathway. We modeled the physiology of hypoxic tumor regions by culturing carcinoma cells under low oxygen tension in the absence of serum. We observed that hypoxic induction of HIF-1 alpha protein was decreased by serum deprivation. Overexpression of dominant-active Akt1 restored HIF-1 alpha expression, whereas inhibition of PI 3-kinase activity reduced hypoxic HIF-1 alpha protein levels to a similar extent as serum deprivation. Immunohistochemical analysis of 95 human breast cancers revealed that lack of Akt1 phosphorylation correlates with low HIF-1 alpha levels. To our knowledge, this is the first reported comparison between HIF-1 alpha expression and Akt phosphorylation in human carcinomas. We conclude that Akt activity is physiologically relevant for HIF-1 alpha expression in breast cancer. This implies that HIF-1 alpha function might be therapeutically targeted by inhibition of the PI 3-kinase/Akt pathway.	Univ Med Ctr Utrecht, Dept Pathol, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr Utrecht, Div Internal Med & Dermatol, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	van Diest, PJ (corresponding author), Univ Med Ctr Utrecht, Dept Pathol, POB 85500, NL-3508 GA Utrecht, Netherlands.	p.j.vandiest@azu.nl						Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Birner P, 2000, CANCER RES, V60, P4693; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Dales JP, 2005, INT J CANCER, V116, P734, DOI 10.1002/ijc.20984; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Schmitz KJ, 2004, MODERN PATHOL, V17, P15, DOI 10.1038/modpathol.3800002; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shibata T, 1998, INT J RADIAT ONCOL, V42, P913, DOI 10.1016/S0360-3016(98)00298-3; Skinner HD, 2004, J BIOL CHEM, V279, P45643, DOI 10.1074/jbc.M404097200; Tang TTL, 2003, J BIOL CHEM, V278, P30125, DOI 10.1074/jbc.M302042200; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; van Diest PJ, 2002, BMJ-BRIT MED J, V325, P648, DOI 10.1136/bmj.325.7365.648; Vaupel P, 2005, TRANSFUS CLIN BIOL, V12, P5, DOI 10.1016/j.tracli.2004.11.005; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zhong H, 2000, CANCER RES, V60, P1541; Zhou J, 2004, J BIOL CHEM, V279, P13506, DOI 10.1074/jbc.M310164200	39	49	53	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6123	6127		10.1038/sj.onc.1209643	http://dx.doi.org/10.1038/sj.onc.1209643			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16682946				2022-12-17	WOS:000241101200009
J	Lund, P; Weisshaupt, K; Mikeska, T; Jammas, D; Chen, X; Kuban, RJ; Ungethum, U; Krapfenbauer, U; Herzel, HP; Schafer, R; Walter, J; Sers, C				Lund, P.; Weisshaupt, K.; Mikeska, T.; Jammas, D.; Chen, X.; Kuban, R-J; Ungethum, U.; Krapfenbauer, U.; Herzel, H-P; Schafer, R.; Walter, J.; Sers, C.			Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation	ONCOGENE			English	Article						HRAS(G12V); MEK/ERK signalling; gene expression; CpG methylation; clusterin; Mmp2	PROGRAMMED CELL-DEATH; DNA-METHYLTRANSFERASE; HA-RAS; TRANSFORMED PHENOTYPE; GENE-EXPRESSION; METHYLATION; CANCER; TIMP-2; ACTIVATION; TRANSCRIPTION	Silencing of gene expression by methylation of CpG islands in regulatory elements is frequently observed in cancer. However, an influence of the most common oncogenic signalling pathways onto DNA methylation has not yet been investigated thoroughly. To address this issue, we identified genes suppressed in HRAS-transformed rat fibroblasts but upregulated after treatment with the demethylating agent 5-Aza-2-deoxycytidine and with the MEK1,2 inhibitor U0126. Analysis of gene expression by microarray and Northern blot analysis revealed the MEK/ERK target genes clusterin, matrix metalloproteinase 2 (Mmp2), peptidylpropyl isomerase C-associated protein, syndecan 4, Timp2 and Thbs1 to be repressed in the HRAS-transformed FE-8 cells in a MEK/ERK- and methylation-dependent manner. Hypermethylation of putative regulatory elements in HRAS-transformed cells as compared to immortalized fibroblasts was detected within a CpG island 14.5 kb upstream of clusterin, within the clusterin promoter and within a CpG island of the Mmp2 promoter by bisulphite sequencing. Furthermore, hypermethylation of the clusterin promoter was observed 10 days after induction of HRAS in immortalized rat fibroblasts and a clear correlation between reduced clusterin expression and hypermethlyation could also be observed in distinct rat tissues. These results suggest that silencing of individual genes by DNA methylation is controlled by oncogenic signalling pathways, yet the mechanisms responsible for initial target gene suppression are variable.	Inst Pathol, Lab Mol Tumorpathol, Charite, D-10117 Berlin, Germany; Univ Saarland, Dept Nat Sci, Tech Fac Biol Sci 3 FR 8 3, Inst Genet Epigenet, D-6600 Saarbrucken, Germany; Lab Funct Genome Res, Charite, Berlin, Germany; Humboldt Univ, Inst Theoret Biol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Saarland University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin	Sers, C (corresponding author), Inst Pathol, Lab Mol Tumorpathol, Charite, Schumannstr 20-21, D-10117 Berlin, Germany.	christine.sers@charite.de	Schäfer, Reinhold/AAB-5110-2021; Mikeska, Thomas/B-4876-2008; Sers, Christine/B-5438-2010; Lund, Per G/M-9019-2017; Lund, Per/Q-6737-2017	Mikeska, Thomas/0000-0003-1318-0859; Lund, Per/0000-0002-7457-4360; Sers, christine/0000-0002-6219-1514				Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Behrens P, 2001, PATHOBIOLOGY, V69, P19, DOI 10.1159/000048753; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BOS JL, 1989, CANCER RES, V49, P4682; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Brem R, 2001, ONCOGENE, V20, P2854, DOI 10.1038/sj.onc.1204403; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cappabianca L, 2003, EXP CELL RES, V286, P209, DOI 10.1016/S0014-4827(03)00072-7; Chen TG, 2004, CANCER RES, V64, P7412, DOI 10.1158/0008-5472.CAN-04-2077; Criswell T, 2005, J BIOL CHEM, V280, P14212, DOI 10.1074/jbc.M412569200; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Deryugina EI, 1997, ANTICANCER RES, V17, P3201; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X; Fensterer H, 2004, GENE CHROMOSOME CANC, V39, P224, DOI 10.1002/gcc.20000; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Gadal F, 2003, NUCLEIC ACIDS RES, V31, P5789, DOI 10.1093/nar/gkg762; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Itoh T, 1998, CANCER RES, V58, P1048; Ivanova T, 2004, INT J CANCER, V108, P882, DOI 10.1002/ijc.11652; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; Klock G, 1998, J CELL PHYSIOL, V177, P593, DOI 10.1002/(SICI)1097-4652(199812)177:4<593::AID-JCP10>3.3.CO;2-6; KYPRIANOU N, 1991, CANCER RES, V51, P162; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Laduron S, 2004, NUCLEIC ACIDS RES, V32, P4340, DOI 10.1093/nar/gkh735; Leskov KS, 2003, J BIOL CHEM, V278, P11590, DOI 10.1074/jbc.M209233200; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663; LIU HS, 1992, CANCER RES, V52, P983; Lopes S, 2003, HUM MOL GENET, V12, P295, DOI 10.1093/hmg/ddg022; Lymar ES, 2000, BIOL REPROD, V63, P1341, DOI 10.1095/biolreprod63.5.1341; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; Ordway JM, 2004, ONCOGENE, V23, P3737, DOI 10.1038/sj.onc.1207483; Pucci S, 2004, ONCOGENE, V23, P2298, DOI 10.1038/sj.onc.1207404; Raudies O, 2005, ADV ENZYME REGUL, V45, P63, DOI 10.1016/j.advenzreg.2005.02.004; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; ROSEMBLIT N, 1994, J MOL ENDOCRINOL, V13, P69, DOI 10.1677/jme.0.0130069; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; Scaltriti M, 2004, INT J CANCER, V108, P23, DOI 10.1002/ijc.11496; Scaltriti M, 2004, CANCER RES, V64, P6174, DOI 10.1158/0008-5472.CAN-04-0920; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; Schneider-Stock R, 2005, J PHARMACOL EXP THER, V312, P525, DOI 10.1124/jpet.104.074195; SCHWARTEWALDHOFF I, 1994, ONCOGENE, V9, P899; Sers C, 2002, ADV ENZYME REGUL, V42, P63, DOI 10.1016/S0065-2571(01)00024-3; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Taraboletti G, 2000, FASEB J, V14, P1674; Tchernitsa OI, 2004, ONCOGENE, V23, P4536, DOI 10.1038/sj.onc.1207585; Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Wei G, 2003, ANTICANCER RES, V23, P2173; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	68	49	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4890	4903		10.1038/sj.onc.1209502	http://dx.doi.org/10.1038/sj.onc.1209502			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16568090				2022-12-17	WOS:000239687100007
J	Massimi, P; Narayan, N; Cuenda, A; Banks, L				Massimi, P.; Narayan, N.; Cuenda, A.; Banks, L.			Phosphorylation of the discs large tumour suppressor protein controls its membrane localisation and enhances its susceptibility to HPV E6-induced degradation	ONCOGENE			English	Article						Dlg; HPV; JNK; proteasome	PAPILLOMAVIRUS E6 PROTEINS; PROTEASOME-MEDIATED DEGRADATION; HIGH-RISK; HUMAN HOMOLOG; ADENOVIRUS E4-ORF1; CELL POLARITY; ACTIN MOTOR; MYOSIN-VI; ONCOPROTEINS; EXPRESSION	The Discs Large (Dlg) protein is intimately involved in regulating cell polarity and cell proliferation, and is targeted by the high-risk Human Papillomavirus (HPV) E6 proteins for proteasome-mediated degradation. We show here that exposure of cells to osmotic shock induces the hyperphosphorylation of Dlg and its concomitant accumulation within the cell membrane at sites of cell contact, a process that requires an intact actin. lament network. In addition, hyperphosphorylation of Dlg also renders it more susceptible to degradation induced by the HPV-18 E6 oncoprotein. Mutational analysis of Dlg identifies a region within the first 185 amino acids as being important for this, with phosphorylation on residue S158 being responsible for its enhanced targeting by the E6 oncoprotein. Using specific kinase inhibitors, we show that Jun N-terminal kinase (JNK) is in part responsible for this phosphorylation, and for the subsequent Dlg accumulation at sites of cell contact. These results further support the notion of a complex phosphorylation-dependent regulation of Dlg, both with respect to its precise cellular localisation and to its susceptibility to proteasome-mediated degradation.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Univ Dundee, MRC, Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland; Univ Extremadura, Fac Vet, Dipartimento Bioquim & Biol Mol, Caceres, Spain	International Center for Genetic Engineering & Biotechnology (ICGEB); University of Dundee; Universidad de Extremadura	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org						Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Buss F, 2002, TRAFFIC, V3, P851, DOI 10.1034/j.1600-0854.2002.31201.x; Caruana G, 2001, MOL CELL BIOL, V21, P1475, DOI 10.1128/MCB.21.5.1475-1483.2001; Cavatorta AL, 2004, INT J CANCER, V111, P373, DOI 10.1002/ijc.20275; Fuja TJ, 2004, CANCER RES, V64, P942, DOI 10.1158/0008-5472.CAN-03-2100; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2002, J GEN VIROL, V83, P283, DOI 10.1099/0022-1317-83-2-283; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Guccione E, 2002, VIROLOGY, V293, P20, DOI 10.1006/viro.2001.1290; Hanada T, 2000, J BIOL CHEM, V275, P28774, DOI 10.1074/jbc.M000715200; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mantovani F, 2001, J CELL SCI, V114, P4285; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Nguyen MM, 2003, MOL CELL BIOL, V23, P8970, DOI 10.1128/MCB.23.24.8970-8981.2003; Sabio G, 2005, EMBO J, V24, P1134, DOI 10.1038/sj.emboj.7600578; Song S, 2000, VIROLOGY, V267, P141, DOI 10.1006/viro.1999.0106; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Watson RA, 2003, J CELL SCI, V116, P4925, DOI 10.1242/jcs.00809; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Wu HJ, 2002, J BIOL CHEM, V277, P30928, DOI 10.1074/jbc.M203735200; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	32	49	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4276	4285		10.1038/sj.onc.1209457	http://dx.doi.org/10.1038/sj.onc.1209457			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16532034				2022-12-17	WOS:000239240100003
J	Cuilliere-Dartigues, P; El-Bchiri, J; Krimi, A; Buhard, O; Fontanges, P; Flejou, JF; Hamelin, R; Duval, A				Cuilliere-Dartigues, P.; El-Bchiri, J.; Krimi, A.; Buhard, O.; Fontanges, P.; Flejou, J-F; Hamelin, R.; Duval, A.			TCF-4 isoforms absent in TCF-4 mutated MSI-H colorectal cancer cells colocalize with nuclear CtBP and repress TCF-4-mediated transcription	ONCOGENE			English	Article						TCF-4 isoforms; CtBP; corepressor; alternative splicing; MSI-H cancer; Wnt/Wingless signalling	NONSENSE-MEDIATED DECAY; BETA-CATENIN; MICROSATELLITE INSTABILITY; FRAMESHIFT MUTATIONS; SEQUENCES; GENE	TCF-4 is the main effector of the Wnt/Wingless signalling pathway. As with other TCF/LEF factors, numerous alternative splicings at its 30 end affect its expression. Such a mechanism leads to the synthesis of numerous TCF-4 isoforms among which some contain binding domains for CtBP, an ubiquitous transcriptional corepressor. Of interest, we described a frequent TCF-4 frameshift mutation in mismatch-repair deficient colorectal cancers (MSI-H cancers) that leads to the selective loss of TCF-4 isoforms with CtBP binding abilities. We provide here data that argue for a partial colocalization of CtBP with TCF-4 isoforms containing CtBP binding domains in cellulo, and for a functional role of CtBP in repressing TCF-4 mediated transcription. We also demonstrate that such a colocalization is not observed in MSI-H colorectal cancer cells that harbour the TCF-4 frameshift mutation, and that CtBP is not able to repress TCF-4-mediated transcription in this context. Taken together, our results strongly suggest that CtBP would play a role in regulating TCF-4 mediated transcription upon its binding with some TCF-4 isoforms encoded by alternatively spliced mRNA. They also suggest a role for TCF-4 frameshift mutation during MSI-H colorectal tumour progression, by regulating the relative proportion of the different TCF-4 isoforms.	INSERM, U762, F-75010 Paris, France; Univ Paris 06, F-75005 Paris, France; Hop Tenon, IFR65, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Duval, A (corresponding author), INSERM, U762, 27 Rue Juliette Dodu, F-75010 Paris, France.	alex.duval@cephb.fr						AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; Duval A, 1999, CANCER RES, V59, P4213; Duval A, 2002, CANCER RES, V62, P2447; Duval A, 2000, CANCER RES, V60, P3872; El-Bchiri J, 2005, HUM MOL GENET, V14, P2435, DOI 10.1093/hmg/ddi245; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Hamada F, 2004, DEV CELL, V7, P677, DOI 10.1016/j.devcel.2004.08.022; Holbrook JA, 2004, NAT GENET, V36, P801, DOI 10.1038/ng1403; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jourdan F, 2003, VIRCHOWS ARCH, V443, P115, DOI 10.1007/s00428-003-0833-z; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Ruckert S, 2002, CANCER RES, V62, P3009; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Valenta T, 2003, NUCLEIC ACIDS RES, V31, P2369, DOI 10.1093/nar/gkg346	19	49	50	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4441	4448		10.1038/sj.onc.1209471	http://dx.doi.org/10.1038/sj.onc.1209471			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16547505				2022-12-17	WOS:000239326000007
J	Chan, IH; Privalsky, ML				Chan, I. H.; Privalsky, M. L.			Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs	ONCOGENE			English	Article						nuclear hormone receptors; dominant-negatives; hepatocellular carcinoma; DNA recognition; c-Jun; AP-1	DOMINANT-NEGATIVE ACTIVITY; RETINOIC ACID RECEPTORS; HUMAN HEPATOCELLULAR-CARCINOMA; NUCLEAR RECEPTORS; V-ERBA; TRANSCRIPTIONAL ACTIVATION; RESISTANCE; COREPRESSOR; GENE; EXPRESSION	Aberrant thyroid hormone receptors (TRs) are found in over 70% of the human hepatocellular carcinomas (HCCs) analysed. To better understand the role(s) of these TR mutants in this neoplasia, we analysed a panel of HCC mutant receptors for their molecular properties. Virtually all HCC-associated TR mutants tested retained the ability to repress target genes in the absence of T3, yet were impaired in T3-driven gene activation and functioned as dominant-negative inhibitors of wild-type TR activity. Intriguingly, the HCC TRa1 mutants exerted dominant-negative interference at all T3 concentrations tested, whereas the HCC TR beta 1 mutants were dominant-negatives only at low and intermediate T3 concentrations, reverting to transcriptional activators at higher hormone levels. The relative affinity for the SMRT versus N-CoR corepressors was detectably altered for several of the HCC mutant TRs, suggesting changes in corepressor preference and recruitment compared to wild type. Several of the TR alpha HCC mutations also altered the DNA recognition properties of the encoded receptors, indicating that these HCC TR mutants may regulate a distinct set of target genes from those regulated by wild-type TRs. Finally, whereas wild-type TRs interfere with c-Jun/AP-1 function in a T3-dependent fashion and suppress anchorage-independent growth when ectopically expressed in HepG2 cells, at least certain of the HCC mutants did not exert these inhibitory properties. These alterations in transcriptional regulation and DNA recognition appear likely to contribute to oncogenesis by reprogramming the differentiation and proliferative properties of the hepatocytes in which the mutant TRs are expressed.	Univ Calif Davis, Microbiol Sect, Div Biol Sci, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Privalsky, ML (corresponding author), Univ Calif Davis, Microbiol Sect, Div Biol Sci, 1 Shields Ave, Davis, CA 95616 USA.	mlprivalsky@ucdavis.edu	Chan, Ivan/B-7922-2010	Chan, Ivan/0000-0003-2834-2574	NATIONAL CANCER INSTITUTE [R37CA053394] Funding Source: NIH RePORTER; NCI NIH HHS [R37-CA53394, R37 CA053394, R37 CA053394-13] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ando S, 2001, J CLIN ENDOCR METAB, V86, P5572, DOI 10.1210/jc.86.11.5572; Apriletti JW, 1998, CLIN EXP PHARMACOL P, V25, pS2, DOI 10.1111/j.1440-1681.1998.tb02293.x; BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225; Chatterjee VKK, 1997, HORM RES, V48, P43, DOI 10.1159/000191312; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; Cheng SY, 2003, MOL CELL ENDOCRINOL, V213, P23, DOI 10.1016/j.mce.2003.10.051; DeGroot LJ, 1996, ANN INTERN MED, V125, P623, DOI 10.7326/0003-4819-125-7-199610010-00022; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Farboud B, 2004, MOL ENDOCRINOL, V18, P2839, DOI 10.1210/me.2004-0236; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Garcia-Silva S, 2004, MOL CELL BIOL, V24, P7514, DOI 10.1128/MCB.24.17.7514-7523.2004; Glass CK, 1996, J ENDOCRINOL, V150, P349, DOI 10.1677/joe.0.1500349; Glass CK, 2000, GENE DEV, V14, P121; Gonzalez-Sancho JM, 2003, CANCER LETT, V192, P121, DOI 10.1016/S0304-3835(02)00614-6; Goodson ML, 2005, J BIOL CHEM, V280, P7493, DOI 10.1074/jbc.M411514200; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HuberGieseke T, 1997, ONCOLOGY, V54, P214; Ikeda M, 1996, J BIOL CHEM, V271, P23096, DOI 10.1074/jbc.271.38.23096; Jonas BA, 2004, J BIOL CHEM, V279, P54676, DOI 10.1074/jbc.M410128200; Judelson C, 1996, J BIOL CHEM, V271, P10800, DOI 10.1074/jbc.271.18.10800; Kamiya Y, 2003, ENDOCRINOLOGY, V144, P4144, DOI 10.1210/en.2003-0239; Kamiya Y, 2002, CARCINOGENESIS, V23, P25, DOI 10.1093/carcin/23.1.25; Kato Y, 2004, ENDOCRINOLOGY, V145, P4430, DOI 10.1210/en.2004-0612; Koenig RJ, 1998, THYROID, V8, P703, DOI 10.1089/thy.1998.8.703; Kopp P, 1996, P SOC EXP BIOL MED, V211, P49; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Lee JW, 2002, CANCER LETT, V184, P149, DOI 10.1016/S0304-3835(02)00206-9; Lee MO, 2002, BIOL PHARM BULL, V25, P1298, DOI 10.1248/bpb.25.1298; Lee S, 2005, MOL ENDOCRINOL, V19, P863, DOI 10.1210/me.2004-0210; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; Lin BC, 1997, MOL CELL BIOL, V17, P6131, DOI 10.1128/MCB.17.10.6131; Lin KH, 1997, ENDOCRINOLOGY, V138, P5308, DOI 10.1210/en.138.12.5308; Lin KH, 2001, ENDOCRINOLOGY, V142, P653, DOI 10.1210/en.142.2.653; Lin KH, 1999, MOL CARCINOGEN, V26, P53, DOI 10.1002/(SICI)1098-2744(199909)26:1<53::AID-MC7>3.0.CO;2-Z; Liu Y, 1998, ENDOCRINOLOGY, V139, P4197, DOI 10.1210/en.139.10.4197; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matsushita A, 2000, J ENDOCRINOL, V167, P493, DOI 10.1677/joe.0.1670493; Moehren U, 2004, ESSAYS BIOCHEM, V40, P89, DOI 10.1042/bse0400089; Murata Y, 1998, Nagoya J Med Sci, V61, P103; Nagaya T, 1998, BIOCHEM BIOPH RES CO, V247, P620, DOI 10.1006/bbrc.1998.8854; Nagaya T, 1998, ENDOCR J, V45, P709, DOI 10.1507/endocrj.45.709; Ordentlich P, 2001, CURR TOP MICROBIOL, V254, P101; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Privalsky ML, 2000, MOL CELL ENDOCRINOL, V159, P109, DOI 10.1016/S0303-7207(99)00201-4; Puzianowska-Kuznicka M, 2002, J CLIN ENDOCR METAB, V87, P1120, DOI 10.1210/jc.87.3.1120; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; REFETOFF S, 1993, CLIN LAB MED, V13, P563, DOI 10.1016/S0272-2712(18)30426-8; Ribeiro RCJ, 1998, RECENT PROG HORM RES, V53, P351; Safer JD, 1998, J BIOL CHEM, V273, P30175, DOI 10.1074/jbc.273.46.30175; SANDE S, 1993, J VIROL, V67, P1067, DOI 10.1128/JVI.67.2.1067-1074.1993; SCHMIDT EDL, 1993, BIOCHEM BIOPH RES CO, V192, P151, DOI 10.1006/bbrc.1993.1394; SHARIF M, 1992, ONCOGENE, V7, P953; SISLEY K, 1993, MELANOMA RES, V3, P457, DOI 10.1097/00008390-199311000-00009; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Suriawinata A, 2004, SEMIN LIVER DIS, V24, P77; Tagami T, 1998, ENDOCRINOLOGY, V139, P640, DOI 10.1210/en.139.2.640; Tenbaum S, 1997, INT J BIOCHEM CELL B, V29, P1325, DOI 10.1016/S1357-2725(97)00087-3; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wang CS, 2002, CANCER LETT, V175, P121, DOI 10.1016/S0304-3835(01)00722-4; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; Winter WE, 2001, ANN CLIN LAB SCI, V31, P221; Wong CW, 1998, MOL CELL BIOL, V18, P5724, DOI 10.1128/MCB.18.10.5724; Yen PM, 2003, J ENDOCRINOL INVEST, V26, P780, DOI 10.1007/BF03347365; Yoh SM, 1997, MOL ENDOCRINOL, V11, P470, DOI 10.1210/me.11.4.470; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	72	49	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3576	3588		10.1038/sj.onc.1209389	http://dx.doi.org/10.1038/sj.onc.1209389			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16434963	Green Accepted			2022-12-17	WOS:000238448200010
J	Linghu, H; Tsuda, M; Makino, Y; Sakai, M; Watanabe, T; Ichihara, S; Sawa, H; Nagashima, K; Mochizuki, N; Tanaka, S				Linghu, H.; Tsuda, M.; Makino, Y.; Sakai, M.; Watanabe, T.; Ichihara, S.; Sawa, H.; Nagashima, K.; Mochizuki, N.; Tanaka, S.			Involvement of adaptor protein Crk in malignant feature of human ovarian cancer cell line MCAS	ONCOGENE			English	Article						Crk; C3G; Rac; dock180; siRNA; human cancer	V-CRK; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE-C; ACTIVATION; C3G; MIGRATION; COMPLEX; KINASE; MEMBRANE; ADHESION	Signaling adaptor protein Crk regulates cell motility and growth through its targets Dock180 and C3G, those are the guanine-nucleotide exchange factors (GEFs) for small GTPases Rac and Rap, respectively. Recently, overexpression of Crk has been reported in various human cancers. To de. ne the role for Crk in human cancer cells, Crk expression was targeted in the human ovarian cancer cell line MCAS through RNA interference, resulting in the establishment of three Crk knockdown cell lines. These cell lines exhibited disorganized actin fibers, reduced number of focal adhesions, and abolishment of lamellipodia formation. Decreased Rac activity was demonstrated by pull-down assay and FRET-based time-lapse microscopy, in association with suppression of both motility and invasion by phagokinetic track assay and transwell assay in these cells. Furthermore, Crk knockdown cells exhibited slow growth rates in culture and suppressed anchorage-dependent growth in soft agar. Tumor forming potential in nude mice was attenuated, and intraperitoneal dissemination was not observed when Crk knockdown cells were injected into the peritoneal cavity. These results suggest that the Crk is a key component of focal adhesion and involved in cell growth, invasion, and dissemination of human ovarian cancer cell line MCAS.	Hokkaido Univ, Lab Mol & Cellular Pathol, Sch Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Natl Cardiovasc Ctr Hosp & Res Inst, Osaka, Japan	Hokkaido University; National Cerebral & Cardiovascular Center - Japan	Tanaka, S (corresponding author), Hokkaido Univ, Lab Mol & Cellular Pathol, Sch Med, Kita Ku, N 15,W7, Sapporo, Hokkaido 0608638, Japan.	tanaka@med.hokudai.ac.jp	Tanaka, Shinya/D-3586-2011; Sawa, Hirofumi/F-6954-2012; Sawa, Hirofumi/AAW-8816-2021	Sawa, Hirofumi/0000-0003-2569-2755; 				Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Brugge JS, 1998, NAT GENET, V19, P309, DOI 10.1038/1189; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Chen ZC, 2001, CANCER-AM CANCER SOC, V92, P3068, DOI 10.1002/1097-0142(20011215)92:12<3068::AID-CNCR10149>3.0.CO;2-5; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hemmeryckx B, 2002, ONCOGENE, V21, P3225, DOI 10.1038/sj.onc.1205452; Imaizumi T, 1999, BIOCHEM BIOPH RES CO, V266, P569, DOI 10.1006/bbrc.1999.1869; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Iwahara T, 2003, ONCOGENE, V22, P5946, DOI 10.1038/sj.onc.1206633; Judson PL, 1999, CANCER, V86, P1551, DOI 10.1002/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Liu EB, 2000, CANCER RES, V60, P2361; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUDA M, 1992, J VIROL, V66, P115, DOI 10.1128/JVI.66.1.115-121.1992; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Miller CT, 2003, ONCOGENE, V22, P7950, DOI 10.1038/sj.onc.1206529; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Nagashima KI, 2002, MOL BIOL CELL, V13, P4231, DOI 10.1091/mbc.E02-04-0181; Nishihara H, 2002, BIOCHEM BIOPH RES CO, V296, P716, DOI 10.1016/S0006-291X(02)00931-2; Nishihara H, 2002, CANCER LETT, V180, P55, DOI 10.1016/S0304-3835(01)00763-7; Nishihara H, 2002, BLOOD, V100, P3968, DOI 10.1182/blood-2001-11-0032; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962-8924(98)80005-6; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Takino T, 2003, CANCER RES, V63, P2335; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Tsuda M, 2002, CELL GROWTH DIFFER, V13, P131; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076	38	49	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3547	3556		10.1038/sj.onc.1209398	http://dx.doi.org/10.1038/sj.onc.1209398			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16491127				2022-12-17	WOS:000238448200007
J	Klein, F; Feldhahn, N; Herzog, S; Sprangers, M; Mooster, JL; Jumaa, H; Muschen, M				Klein, F; Feldhahn, N; Herzog, S; Sprangers, M; Mooster, JL; Jumaa, H; Muschen, M			BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells	ONCOGENE			English	Article						lineage commitment; lymphopoiesis; RNA; interference; alternative splicing	EXPRESSION; GENE; RECEPTOR; DIFFERENTIATION; LEUKEMOGENESIS; ISOFORM	Pre-B lymphoblastic leukemia cells carrying a BCR-ABL1 gene rearrangement exhibit an undifferentiated phenotype. Comparing the genome-wide gene expression profiles of normal B-cell subsets and BCR-ABL1(+) pre-B lymphoblastic leukemia cells by SAGE, the leukemia cells show loss of B lymphoid identity and aberrant expression of myeloid lineage-specific molecules. Consistent with this, BCR-ABL1(+) pre-B lymphoblastic leukemia cells exhibit defective expression of IKAROS, a transcription factor needed for early lymphoid lineage commitment. As shown by inducible expression of BCR-ABL1 in human and murine B-cell precursor cell lines, BCR-ABL1 induces the expression of a dominant-negative IKAROS splice variant, termed IK6. Comparing matched leukemia sample pairs from patients before and during therapy with the BCR-ABL1 kinase inhibitor STI571 (Imatinib), inhibition of BCR-ABL1 partially corrected aberrant expression of IK6 and lineage infidelity of the leukemia cells. To elucidate the contribution of IK6 to lineage infidelity in BCR-ABL1(+) cell lines, IK6 expression was silenced by RNA interference. Upon inhibition of IK6, BCR-ABL1(+) leukemia cells partially restored B lymphoid lineage commitment. Therefore, we propose that BCR-ABL1 induces aberrant splicing of IKAROS, which interferes with lineage identity and differentiation of pre-B lymphoblastic leukemia cells.	Univ Dusseldorf, Lab Mol Stem Cell Biol, D-40225 Dusseldorf, Germany; Max Planck Inst Immunobiol, Freiburg, Germany	Heinrich Heine University Dusseldorf; Max Planck Society	Muschen, M (corresponding author), Univ Dusseldorf, Lab Mol Stem Cell Biol, Moorenstr 5,Bldg 14-80, D-40225 Dusseldorf, Germany.	markus.mueschen@uni-duesseldorf.de		Herzog, Sebastian/0000-0001-7167-3489				Busslinger M, 2004, ANNU REV IMMUNOL, V22, P55, DOI 10.1146/annurev.immunol.22.012703.104807; Feldhahn N, 2005, J EXP MED, V201, P1837, DOI 10.1084/jem.20042101; Feldhahn N, 2002, J EXP MED, V196, P1291, DOI 10.1084/jem.20020881; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Jumaa H, 2003, NATURE, V423, P452, DOI 10.1038/nature01608; Kirstetter P, 2002, EUR J IMMUNOL, V32, P720, DOI 10.1002/1521-4141(200203)32:3<720::AID-IMMU720>3.0.CO;2-P; Klein F, 2005, J IMMUNOL, V174, P367, DOI 10.4049/jimmunol.174.1.367; Klein F, 2004, J EXP MED, V199, P673, DOI 10.1084/jem.20031637; Klein F, 2003, P NATL ACAD SCI USA, V100, P6747, DOI 10.1073/pnas.1031503100; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Laurent E, 2001, CANCER RES, V61, P2343; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Muschen M, 2002, P NATL ACAD SCI USA, V99, P10014, DOI 10.1073/pnas.152327399; Nakase K, 2000, CANCER RES, V60, P4062; Perrotti D, 2002, ONCOGENE, V21, P8577, DOI 10.1038/sj.onc.1206085; Salesse S, 2004, LEUKEMIA, V18, P727, DOI 10.1038/sj.leu.2403310; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Tonnelle C, 2001, BLOOD, V98, P2673, DOI 10.1182/blood.V98.9.2673; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484	20	49	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1118	1124		10.1038/sj.onc.1209133	http://dx.doi.org/10.1038/sj.onc.1209133			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16205638				2022-12-17	WOS:000235361000016
J	Stoter, M; Bamberger, AM; Aslan, B; Kurth, M; Speidel, D; Loning, T; Frank, HG; Kaufmann, P; Lohler, J; Henne-Bruns, D; Deppert, W; Knippschild, U				Stoter, M; Bamberger, AM; Aslan, B; Kurth, M; Speidel, D; Loning, T; Frank, HG; Kaufmann, P; Lohler, J; Henne-Bruns, D; Deppert, W; Knippschild, U			Inhibition of casein kinase I delta alters mitotic spindle formation and induces apoptosis in trophoblast cells	ONCOGENE			English	Article						casein kinase I delta; trophoblast; choriocarcinoma; apoptosis; IC261	WILD-TYPE P53; POLYMORPHIC VARIANTS; PROTEIN-KINASES; MOLECULAR-CLONING; CENTROSOME; PHOSPHORYLATION; EXPRESSION; EPSILON; LOCALIZATION; INSTABILITY	The serine/threonine-specific casein kinase I delta (CKI delta) is ubiquitously expressed in all tissues, is p53 dependently induced in stress situations and plays an important role in various cellular processes. Our immunohistochemical analysis of the human placenta revealed strongest expression of CKId in extravillous trophoblast cells and in choriocarcinomas. Investigation of the functional role of CKId in an extravillous trophoblast hybrid cell line revealed that CKId was constitutively localized at the centrosomes and the mitotic spindle. Inhibition of CKId with the CKI-specific inhibitor IC261 led to structural alterations of the centrosomes, the formation of multipolar spindles, the inhibition of mitosis and, in contrast to other cell lines, the induction of apoptosis. Our findings indicate that CKId plays an important role in the mitotic progression and in the survival of cells of trophoblast origin. Therefore, IC261 could provide a new tool in treating choriocarcinomas.	Univ Ulm, Dept Visceral & Transplantat Surg, Ulm, Germany; Univ Hosp Eppendorf, Inst Pathol, Dept Gynecopathol, Hamburg, Germany; Heinrich Pette Inst Expt Virol & Immunol, Hamburg, Germany; Rhein Westfal TH Aachen, Dept Anat 2, Aachen, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Heinrich Pette Institute; RWTH Aachen University	Knippschild, U (corresponding author), Univ Ulm Klinikum, Steinhovelstr 9, D-89075 Ulm, Germany.	uwe.knippschild@medizin.uni-ulm.de	Frank, Hans-Georg/G-6038-2012; Speidel, Daniel/I-4244-2012	Frank, Hans-Georg/0000-0002-3562-138X; 				Bamberger AM, 1997, ENDOCRINE, V6, P111, DOI 10.1007/BF02738953; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Behrend L, 2000, EUR J CELL BIOL, V79, P240, DOI 10.1078/S0171-9335(04)70027-8; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; Bischof P, 2000, HUM REPROD, V15, P51; Bornens M, 1999, METHOD CELL BIOL, V61, P13; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; Chakraborty C, 2002, CAN J PHYSIOL PHARM, V80, P116, DOI 10.1139/Y02-016; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; Frank HG, 2000, CANCER GENET CYTOGEN, V116, P16, DOI 10.1016/S0165-4608(99)00107-7; Funayama H., 1997, PLACENTA, V18, P191; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Izeradjene K, 2004, CANCER RES, V64, P8036, DOI 10.1158/0008-5472.CAN-04-0762; Kalderon D, 2002, TRENDS CELL BIOL, V12, P523, DOI 10.1016/S0962-8924(02)02388-7; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Knippschild U, 1996, ONCOGENE, V13, P1387; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Marchal C, 2002, J CELL SCI, V115, P217; Maritzen T, 2003, EUR J CELL BIOL, V82, P369, DOI 10.1078/0171-9335-00323; Martin-Subero JI, 2003, LEUKEMIA, V17, P2214, DOI 10.1038/sj.leu.2403129; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Milne DM, 2001, EXP CELL RES, V263, P43, DOI 10.1006/excr.2000.5100; Murakami A, 1999, J BIOL CHEM, V274, P3804, DOI 10.1074/jbc.274.6.3804; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Okamura A, 2004, BLOOD, V103, P2997, DOI 10.1182/blood-2003-08-2768; Panek HR, 2000, J CELL SCI, V113, P4545; Pihan GA, 1998, CANCER RES, V58, P3974; Pim D, 2004, INT J CANCER, V108, P196, DOI 10.1002/ijc.11548; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Thomas M, 1999, MOL CELL BIOL, V19, P1092; TUAZON PT, 1991, ADV 2 MESSENGER PHOS, V23, P123; Urbani L, 1999, CURR BIOL, V9, pR315, DOI 10.1016/S0960-9822(99)80201-2; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Winter M, 2004, BIOCHEMISTRY-US, V43, P16356, DOI 10.1021/bi0489255; YAGEL S, 1988, J CELL PHYSIOL, V136, P455, DOI 10.1002/jcp.1041360309; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717; Zhang JR, 1996, BIOCHEMISTRY-US, V35, P16319, DOI 10.1021/bi9614444; Zhao Y, 2004, J BIOL CHEM, V279, P30844, DOI 10.1074/jbc.M404651200; Zimmerman W, 1999, CURR OPIN CELL BIOL, V11, P122, DOI 10.1016/S0955-0674(99)80015-5	50	49	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					7964	7975		10.1038/sj.onc.1208941	http://dx.doi.org/10.1038/sj.onc.1208941			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16027726				2022-12-17	WOS:000233656600003
J	O'Shea, CC				O'Shea, CC			Viruses - seeking and destroying the tumor program	ONCOGENE			English	Review						viruses; oncolytic viral therapy; cancer; transformation; systems biology; adenovirus	HUMAN-PAPILLOMAVIRUS TYPE-16; ADENOVIRUS-INFECTED CELLS; REVERSE-TRANSCRIPTASE PROMOTER; PROTEIN-INTERACTION NETWORKS; E1B 55-KILODALTON PROTEIN; CERVICAL-CARCINOMA CELLS; LATE GENE-EXPRESSION; E2F TARGET GENES; CANCER-THERAPY; MESSENGER-RNA	DNA viruses have enormous utility in cancer research, both as tools for tumor target discovery as well as agents for lytic cancer therapies. This is because there is a profound functional overlap between the DNA viral and tumor cell programs. DNA viruses encode proteins that elicit growth deregulation in infected cells similar to that engendered by mutations in tumor cells. Evolution has refined viral proteins to target the critical cellular hubs that regulate growth. Thus, viral proteins are discriminating biochemical probes that can be used to identify and characterize novel tumor targets. Moreover, the overlap between the DNA viral and tumor programs can also be exploited for the development of lytic cancer therapies. Discovering whether tumor cells selectively complement the replication of viral mutants can reveal novel oncolytic viral therapies, as well as unexpected tumor properties. For example, altered RNA export was recently uncovered as a novel tumor cell property that underlies ONYX-015 replication, a promising oncolytic adenoviral therapy. A perspective is provided on how adenovirus could be systematically exploited to map the requisite role, or indeed the redundancy, of cellular pathways that act in an integrated program to elicit pathological replication. This knowledge has important applications for the rational design of the next generation of oncolytic viruses, as well as the discovery of efficacious combination cancer therapies.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	O'Shea, CC (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St,N315, San Francisco, CA 94115 USA.	coshea@cc.ucsf.edu						Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Avruch J, 2005, CURR OPIN CLIN NUTR, V8, P67, DOI 10.1097/00075197-200501000-00010; BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Barber GN, 2005, ONCOGENE, V24, P7710, DOI 10.1038/sj.onc.1209042; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Benedict CA, 2001, J BIOL CHEM, V276, P3270, DOI 10.1074/jbc.M008218200; Benedict CA, 2001, VIROLOGY, V289, P1, DOI 10.1006/viro.2001.1109; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Bischof O, 2005, MOL CELL BIOL, V25, P1013, DOI 10.1128/MCB.25.3.1013-1024.2005; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Branton PE, 2001, ONCOGENE, V20, P7855, DOI 10.1038/sj.onc.1204862; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Chiocca EA, 2002, NAT REV CANCER, V2, P938, DOI 10.1038/nrc948; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; Cuesta R, 2004, J VIROL, V78, P7707, DOI 10.1128/JVI.78.14.7707-7716.2004; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Dobbelstein M, 2004, CURR TOP MICROBIOL, V273, P291; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Eisenberg E, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.138701; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Foddis R, 2002, ONCOGENE, V21, P1434, DOI 10.1038/sj.onc.1205203; Freeman-Cook LL, 2005, ONCOGENE, V24, P7756, DOI 10.1038/sj.onc.1209039; Frese KK, 2003, ONCOGENE, V22, P710, DOI 10.1038/sj.onc.1206151; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Gewin L, 2004, GENE DEV, V18, P2269, DOI 10.1101/gad.1214704; Glaunsinger BA, 2001, EMBO J, V20, P5578, DOI 10.1093/emboj/20.20.5578; Goodrum FD, 1999, J VIROL, V73, P7474, DOI 10.1128/JVI.73.9.7474-7488.1999; Goodrum FD, 1997, J VIROL, V71, P548, DOI 10.1128/JVI.71.1.548-561.1997; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hann B, 2003, J VIROL, V77, P11588, DOI 10.1128/JVI.77.21.11588-11595.2003; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Hart LS, 2005, J BIOL CHEM, V280, P1474, DOI 10.1074/jbc.M409934200; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; HAYES BW, 1990, J VIROL, V64, P2732, DOI 10.1128/JVI.64.6.2732-2742.1990; HEGDE RS, 1995, J CELL PHYSIOL, V165, P186, DOI 10.1002/jcp.1041650122; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; HO YS, 1982, VIROLOGY, V122, P109, DOI 10.1016/0042-6822(82)90381-6; Hobom U, 2004, J VIROL, V78, P7685, DOI 10.1128/JVI.78.14.7685-7697.2004; Horner SM, 2004, J VIROL, V78, P4063, DOI 10.1128/JVI.78.8.4063-4073.2004; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; Huang SL, 2001, CANCER RES, V61, P3373; Huang W, 1998, J VIROL, V72, P225, DOI 10.1128/JVI.72.1.225-235.1998; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Ito A, 2003, HISTOL HISTOPATHOL, V18, P1313, DOI 10.14670/HH-18.1313; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Johnson L, 2002, CANCER CELL, V1, P325, DOI 10.1016/S1535-6108(02)00060-0; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kirn D, 2001, EXPERT OPIN BIOL TH, V1, P525, DOI 10.1517/14712598.1.3.525; Ko D, 2005, ONCOGENE, V24, P7763, DOI 10.1038/sj.onc.1209048; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; Kyo S, 2002, ONCOGENE, V21, P688, DOI 10.1038/sj.onc.1205163; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; Lichtenstein DL, 2004, INT REV IMMUNOL, V23, P75, DOI 10.1080/08830180490265556; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Liu Y, 2001, ONCOGENE, V20, P2514, DOI 10.1038/sj.onc.1204364; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Lu ZM, 2004, J BIOL CHEM, V279, P35664, DOI 10.1074/jbc.M403385200; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Martin MED, 1999, MOL CELL BIOL, V19, P3403; Mathis JM, 2005, ONCOGENE, V24, P7775, DOI 10.1038/sj.onc.1209044; McCormick F, 2005, ONCOGENE, V24, P7817, DOI 10.1038/sj.onc.1209064; McCormick F, 2003, CANCER BIOL THER, V2, pS157; McMurray HR, 2003, J VIROL, V77, P9852, DOI 10.1128/JVI.77.18.9852-9861.2003; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mohr I, 2005, ONCOGENE, V24, P7697, DOI 10.1038/sj.onc.1209053; Moule MG, 2004, P NATL ACAD SCI USA, V101, P14063, DOI 10.1073/pnas.0405533101; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; Nemunaitis J, 2000, CANCER RES, V60, P6359; Nilsson CE, 2001, EMBO J, V20, P864, DOI 10.1093/emboj/20.4.864; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; O'Connor RJ, 2000, J VIROL, V74, P5819, DOI 10.1128/JVI.74.13.5819-5824.2000; O'Shea C, 2005, EMBO J, V24, P1211, DOI 10.1038/sj.emboj.7600597; O'Shea CC, 2005, CELL CYCLE, V4, P449, DOI 10.4161/cc.4.3.1555; O'Shea CC, 2005, CELL CYCLE, V4, P883, DOI 10.4161/cc.4.7.1791; O'Shea CC, 2005, CANCER CELL, V8, P61, DOI 10.1016/j.ccr.2005.06.009; O'Shea CC, 2005, CURR OPIN GENET DEV, V15, P18, DOI 10.1016/j.gde.2004.12.010; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Perez D, 2003, J VIROL, V77, P2651, DOI 10.1128/JVI.77.4.2651-2662.2003; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Psyrri A, 2004, CANCER RES, V64, P3079, DOI 10.1158/0008-5472.CAN-03-3739; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; Reid T, 2002, CANCER RES, V62, P6070; Ries S, 2002, BRIT J CANCER, V86, P5, DOI 10.1038/sj.bjc.6600006; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; Rudin CM, 2003, J CLIN ONCOL, V21, P4546, DOI 10.1200/JCO.2003.03.544; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Russell WC, 2000, J GEN VIROL, V81, P2573, DOI 10.1099/0022-1317-81-11-2573; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; Seidel ER, 1997, BRIT J PHARMACOL, V120, P571, DOI 10.1038/sj.bjp.0700936; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Shen YQ, 2001, J VIROL, V75, P4297, DOI 10.1128/JVI.75.9.4297-4307.2001; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shmulevitz M, 2005, ONCOGENE, V24, P7720, DOI 10.1038/sj.onc.1209041; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; Tarakanova VL, 2003, J VIROL, V77, P9324, DOI 10.1128/JVI.77.17.9324-9336.2003; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Thorne SH, 2005, J VIROL, V79, P581, DOI 10.1128/JVI.79.1.581-591.2005; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; Tollefson AE, 2003, J VIROL, V77, P7764, DOI 10.1128/JVI.77.14.7764-7778.2003; Tollefson AE, 2001, J VIROL, V75, P8875, DOI 10.1128/JVI.75.19.8875-8887.2001; Tollefson AE, 1998, NATURE, V392, P726, DOI 10.1038/33712; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Turnell AS, 1999, J VIROL, V73, P2074, DOI 10.1128/JVI.73.3.2074-2083.1999; Veldman T, 2003, P NATL ACAD SCI USA, V100, P8211, DOI 10.1073/pnas.1435900100; Verma SC, 2004, J VIROL, V78, P10348, DOI 10.1128/JVI.78.19.10348-10359.2004; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wagner A, 2003, P ROY SOC B-BIOL SCI, V270, P457, DOI 10.1098/rspb.2002.2269; Walsh D, 2005, J VIROL, V79, P8057, DOI 10.1128/JVI.79.13.8057-8064.2005; Walsh D, 2004, GENE DEV, V18, P660, DOI 10.1101/gad.1185304; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WEINBERG DH, 1986, J VIROL, V57, P833, DOI 10.1128/JVI.57.3.833-838.1986; Weitzman MD, 2005, ONCOGENE, V24, P7686, DOI 10.1038/sj.onc.1209063; Weitzman MD, 2004, DNA REPAIR, V3, P1165, DOI 10.1016/j.dnarep.2004.03.018; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Working PK, 2005, ONCOGENE, V24, P7792, DOI 10.1038/sj.onc.1209045; YEN A, 1979, SCIENCE, V204, P1315, DOI 10.1126/science.451539; YODER SS, 1986, J VIROL, V60, P779, DOI 10.1128/JVI.60.2.779-781.1986; Yook SH, 2004, PROTEOMICS, V4, P928, DOI 10.1002/pmic.200300636; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Yu YJ, 2002, J VIROL, V76, P3731, DOI 10.1128/JVI.76.8.3731-3738.2002; Yuan H, 2002, J VIROL, V76, P10685, DOI 10.1128/JVI.76.21.10685-10691.2002; Yueh A, 2000, GENE DEV, V14, P414; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	180	49	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7640	7655		10.1038/sj.onc.1209047	http://dx.doi.org/10.1038/sj.onc.1209047			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299526	Green Submitted			2022-12-17	WOS:000233372600002
J	Ito, H; Iwamoto, I; Morishita, R; Nozawa, Y; Narumiya, S; Asano, T; Nagata, KI				Ito, H; Iwamoto, I; Morishita, R; Nozawa, Y; Narumiya, S; Asano, T; Nagata, KI			Possible role of Rho/Rhotekin signaling in mammalian septin organization	ONCOGENE			English	Article						septin; Sept9; Rho; Rhotekin; actin	NUCLEOTIDE EXCHANGE FACTOR; RHO-GTPASES; FAMILY; PROTEINS; CELLS	There is growing evidence for crosstalk between septin. laments and actin cytoskeleton which is regulated by Rho family of GTPases. Here we show that active Rho disrupts septin filament structures in rat embryonic fibroblast REF52 cells. Among Rho effector molecules tested, Rhotekin induced morphological changes of septin. laments similar to those by activated Rho. The center region of Rhotekin was sufficient for the septin reorganization in the cells, and likely to interact indirectly with the C-terminal half of a septin Sept9b, where a GTPase domain is located. Rhotekin and Sept9b are colocalized mainly in perinuclear regions in serum-starved REF52 cells. Upon stimulation with lysophosphatidic acid, they translocated to actin stress fibers in 10 min and then redistributed again to cytoplasm after 90 min treatment. In neuroblastoma Neuro2a cells, Rhotekin and Sept9b were enriched in the tip of neurites, a location where cortical actin reorganization is induced upon stimulation with lysophosphatidic acid. Taken together, we propose that Rhotekin is a novel regulator organizing mammalian septin structures and provide a new link between the septin and Rho-signaling.	Aichi Human Serv Ctr, Dept Mol Neurobiol, Inst Dev Res, Kamiya, Kasugai 4800392, Japan; Gifu Int Inst Biotechnol, Gifu 5040838, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Nagata, KI (corresponding author), Aichi Human Serv Ctr, Dept Mol Neurobiol, Inst Dev Res, Kamiya, Kasugai 4800392, Japan.	knagata@inst-hsc.jp		Ito, Hidenori/0000-0002-6527-477X				Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Faty M, 2002, CURR GENET, V41, P123, DOI 10.1007/s00294-002-0304-0; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Govek EE, 2005, GENE DEV, V19, P1, DOI 10.1101/gad.1256405; Hall PA, 2004, J PATHOL, V204, P489, DOI 10.1002/path.1654; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Joberty G, 2001, NAT CELL BIOL, V3, P861, DOI 10.1038/ncb1001-861; Kartmann B, 2001, J CELL SCI, V114, P839; Kinoshita M, 2003, J BIOCHEM, V134, P491, DOI 10.1093/jb/mvg182; Kinoshita M, 2002, DEV CELL, V3, P791, DOI 10.1016/S1534-5807(02)00366-0; Nagata K, 2004, J BIOL CHEM, V279, P55895, DOI 10.1074/jbc.M406153200; Nagata K, 2003, J BIOL CHEM, V278, P18538, DOI 10.1074/jbc.M205246200; Nagata KI, 2005, ONCOGENE, V24, P65, DOI 10.1038/sj.onc.1208101; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Sheffield PJ, 2003, J BIOL CHEM, V278, P3483, DOI 10.1074/jbc.M209701200; Togashi H, 2000, J BIOL CHEM, V275, P29570, DOI 10.1074/jbc.M003726200; Trimble WS, 1999, J MEMBRANE BIOL, V169, P75, DOI 10.1007/s002329900519	19	49	54	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7064	7072		10.1038/sj.onc.1208862	http://dx.doi.org/10.1038/sj.onc.1208862			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007136				2022-12-17	WOS:000232833200008
J	Kim, H; Laing, M; Muller, W				Kim, H; Laing, M; Muller, W			c-Src-null mice exhibit defects in normal mammary gland development and ER alpha signaling	ONCOGENE			English	Article						estrogen receptor; c-Src; mammary gland	ESTROGEN-RECEPTOR-ALPHA; GROWTH-FACTOR RECEPTOR; BREAST-CANCER; ESTRADIOL-RECEPTOR; INDEPENDENT ACTIVATION; TARGETED DISRUPTION; SURVIVAL SIGNAL; KINASE PATHWAY; PHOSPHORYLATION; TYROSINE	The c-Src tyrosine kinase has been implicated to play an integral role in modulating growth factor receptor, integrin and steroid receptor function. One class of steroid receptors that c-Src modulates is the estrogen receptor a (ER alpha). Although there is strong biochemical evidence supporting a role for c-Src in ER alpha signaling, the consequence of this association is unclear at the biological level. To explore the significance of c-Src in ER alpha signaling, we studied the development of various reproductive organs that are dependent on ER alpha in c-Srcdeficient mice. We show that the loss of the c-Src tyrosine kinase correlates with defects in ductal development as well as in uterine and ovarian development. Genetic and biochemical analyses of c-Src-deficient mammary epithelial cells also revealed defects in the ability of mammary epithelial cells to activate a number of signaling pathways in response to exogenous estrogen stimulation. Taken together, these studies demonstrate that c-Src plays a role in ER alpha signaling in vivo.	McMaster Univ, Dept Med Sci, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4K1, Canada	McMaster University; McMaster University; McMaster University	Muller, W (corresponding author), McGill Univ, Royal Victoria Hosp, Dept Med, Mol Oncol Grp, Room H5-63A,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	william.muller@mcgill.ca						Arnold SF, 1997, MOL ENDOCRINOL, V11, P48, DOI 10.1210/me.11.1.48; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; ARNOLD SF, 1995, J BIOL CHEM, V270, P30205; BISWAS R, 1987, CANCER RES, V47, P3509; Brisken C, 2000, GENE DEV, V14, P650; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Carlomagno C, 1996, J CLIN ONCOL, V14, P2702, DOI 10.1200/JCO.1996.14.10.2702; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Chan TO, 2002, CANCER CELL, V1, P181, DOI 10.1016/S1535-6108(02)00033-8; Cunha GR, 1997, J MAMMARY GLAND BIOL, V2, P393, DOI 10.1023/A:1026303630843; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; De Placido S, 1998, BREAST CANCER RES TR, V52, P55, DOI 10.1023/A:1006159001039; DENTON RR, 1992, J BIOL CHEM, V267, P7263; DiDomenico M, 1996, CANCER RES, V56, P4516; Fan MY, 2004, MOL ENDOCRINOL, V18, P2603, DOI 10.1210/me.2004-0164; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Jackson D, 1997, J CELL SCI, V110, P1261; Jackson-Fisher AJ, 2004, P NATL ACAD SCI USA, V101, P17138, DOI 10.1073/pnas.0407057101; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; Lahooti H, 1995, J STEROID BIOCHEM, V55, P305, DOI 10.1016/0960-0760(95)00188-3; LAHOOTI H, 1994, MOL ENDOCRINOL, V8, P182, DOI 10.1210/me.8.2.182; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LIPPMAN M, 1976, CANCER RES, V36, P4595; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MIGLIACCIO A, 1993, ONCOGENE, V8, P2183; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; MIGLIACCIO A, 1986, EMBO J, V5, P2867, DOI 10.1002/j.1460-2075.1986.tb04581.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Montagna C, 2002, ONCOGENE, V21, P890, DOI 10.1038/sj.onc.1205146; Morelli C, 2003, ONCOGENE, V22, P4007, DOI 10.1038/sj.onc.1206436; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Newman SP, 2000, ONCOGENE, V19, P490, DOI 10.1038/sj.onc.1203416; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Reid G, 2002, CELL MOL LIFE SCI, V59, P821, DOI 10.1007/s00018-002-8470-2; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Schomberg DW, 1999, ENDOCRINOLOGY, V140, P2733, DOI 10.1210/en.140.6.2733; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Tepera SB, 2003, J CELL SCI, V116, P1137, DOI 10.1242/jcs.00334; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427; Wiesen JF, 1999, DEVELOPMENT, V126, P335; Yudt MR, 1999, BIOCHEMISTRY-US, V38, P14146, DOI 10.1021/bi9911132; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	64	49	50	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5629	5636		10.1038/sj.onc.1208718	http://dx.doi.org/10.1038/sj.onc.1208718			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16007215				2022-12-17	WOS:000231296100009
J	Li, JP; Wang, EF; Rinaldo, F; Datta, K				Li, JP; Wang, EF; Rinaldo, F; Datta, K			Upregulation of VEGF-C by androgen depletion: the involvement of IGFIR-FOXO pathway	ONCOGENE			English	Article						VEGF-C; prostate cancer; metastasis; androgen; IGF-IR	ENDOTHELIAL-GROWTH-FACTOR; LYMPH-NODE METASTASIS; REFRACTORY PROSTATE-CANCER; FACTOR RECEPTOR-3; TRANSCRIPTION FACTORS; TUMOR ANGIOGENESIS; SIGNALING PATHWAY; TYROSINE KINASES; FAMILY-MEMBER; CELL-DEATH	Androgen ablation therapy is eventually followed by a more metastatic and androgen-refractory stage of prostate cancer. The detailed molecular mechanism of this gradual transition is not clearly understood. Recent reports correlate the high abundance of vascular endothelial growth factor-C (VEGF-C) to the lymph node metastasis seen in human prostate cancer (Tsurusaki et al., 1999). In this study, we report that androgen ablation in LNCaP cells augment the transcriptional upregulation of VEGF-C and the downregulation of the IGF-IR pathway, due to androgen withdrawal, is a potential mechanism for this observed VEGF-C transcription. Forkhead transcription factor FOXO-1, activated by SIRT-1, was identified as the downstream molecule within this pathway. Furthermore, the VEGF-C-induced increase of Bag-IL expression in LNCaP cells suggests that VEGF-C plays a role in the androgen-independent reactivation of the androgen receptor, resulting in androgen-refractory prostate cancer growth.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Datta, K (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW,Gugg 1401B, Rochester, MN 55905 USA.	datta.kaustubh@mayo.edu			NCHHSTP CDC HHS [1 PSOCA91956-3] Funding Source: Medline	NCHHSTP CDC HHS		Achen MG, 2002, GROWTH FACTORS, V20, P99, DOI 10.1080/08977190290031969; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Arnold JT, 2005, AM J PHYSIOL-ENDOC M, V288, pE573, DOI 10.1152/ajpendo.00454.2004; Baron S, 2004, J BIOL CHEM, V279, P14579, DOI 10.1074/jbc.M306143200; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Castoria G, 2004, STEROIDS, V69, P517, DOI 10.1016/j.steroids.2004.05.001; Chilov D, 1997, J BIOL CHEM, V272, P25176, DOI 10.1074/jbc.272.40.25176; Clarijs R, 2001, INVEST OPHTH VIS SCI, V42, P1422; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Datta K, 2000, J BIOL CHEM, V275, P20700, DOI 10.1074/jbc.M909970199; DeMeyts P, 1995, ANN NY ACAD SCI, V766, P388, DOI 10.1111/j.1749-6632.1995.tb26688.x; DENIS L, 1993, CANCER, V72, P3888, DOI 10.1002/1097-0142(19931215)72:12+<3888::AID-CNCR2820721726>3.0.CO;2-B; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dias S, 2002, BLOOD, V99, P2179, DOI 10.1182/blood.V99.6.2179; Dvorak HF, 2000, SEMIN PERINATOL, V24, P75, DOI 10.1016/S0146-0005(00)80061-0; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Epstein JI, 1996, AM J SURG PATHOL, V20, P286, DOI 10.1097/00000478-199603000-00004; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Gustavsson H, 2005, PROSTATE, V62, P364, DOI 10.1002/pros.20145; Hashimoto I, 2001, BRIT J CANCER, V85, P93, DOI 10.1054/bjoc.2001.1846; HATVA E, 1995, AM J PATHOL, V146, P368; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Jia YT, 2004, WORLD J GASTROENTERO, V10, P3261, DOI 10.3748/wjg.v10.i22.3261; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kang HY, 2004, J BONE MINER RES, V19, P1181, DOI 10.1359/JBMR.040306; KELLER SR, 1993, MOL REPROD DEV, V35, P346, DOI 10.1002/mrd.1080350405; Kimura Y, 2003, ONCOL REP, V10, P1747; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kubo H, 2000, BLOOD, V96, P546; KYPRIANOU N, 1990, CANCER RES, V50, P3748; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Marchio S, 1999, J BIOL CHEM, V274, P27617, DOI 10.1074/jbc.274.39.27617; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Neuchrist C, 2003, HEAD NECK-J SCI SPEC, V25, P464, DOI 10.1002/hed.10235; Nicholson B, 2004, J CELL BIOCHEM, V91, P125, DOI 10.1002/jcb.10772; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Oh WK, 1998, J UROLOGY, V160, P1220, DOI 10.1016/S0022-5347(01)62501-1; Olofsson B, 1999, CURR OPIN BIOTECH, V10, P528, DOI 10.1016/S0958-1669(99)00024-5; Pepper MS, 2001, CLIN CANCER RES, V7, P462; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Plymate SR, 2004, PROSTATE, V61, P276, DOI 10.1002/pros.20099; Ruohola JK, 1999, MOL CELL ENDOCRINOL, V149, P29, DOI 10.1016/S0303-7207(99)00003-9; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shatkina L, 2003, MOL CELL BIOL, V23, P7189, DOI 10.1128/MCB.23.20.7189-7197.2003; Sipos B, 2004, AM J PATHOL, V165, P1187, DOI 10.1016/S0002-9440(10)63379-2; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Steiner H, 2004, EUR J CANCER, V40, P1066, DOI 10.1016/j.ejca.2003.11.033; Stewart RJ, 2001, J UROLOGY, V165, P688, DOI 10.1097/00005392-200102000-00095; Tang YC, 2003, CANCER RES, V63, P1166; Tsurusaki T, 1999, BRIT J CANCER, V80, P309, DOI 10.1038/sj.bjc.6690356; Veikkola T, 2000, CANCER RES, V60, P203; Wang Zhong-liang, 2004, Sichuan Da Xue Xue Bao Yi Xue Ban, V35, P47; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823; Zeng YP, 2004, CLIN CANCER RES, V10, P5137, DOI 10.1158/1078-0432.CCR-03-0434	70	49	51	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5510	5520		10.1038/sj.onc.1208693	http://dx.doi.org/10.1038/sj.onc.1208693			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15897888				2022-12-17	WOS:000231222300011
J	Korkola, JE; Houldsworth, J; Dobrzynski, D; Olshen, AB; Reuter, VE; Bosl, GJ; Chaganti, RSK				Korkola, JE; Houldsworth, J; Dobrzynski, D; Olshen, AB; Reuter, VE; Bosl, GJ; Chaganti, RSK			Gene expression-based classification of nonseminomatous male germ cell tumors	ONCOGENE			English	Article						testicular germ cell tumors; expression microarray; histologic classification	CARCINOMA-CELLS; DIFFERENTIATION; IDENTIFICATION; ENDODERM; PATTERNS; ANTIGENS; CLONING; CANCER	Male adult germ cell tumors (GCTs) comprise two major histologic groups: seminomas and nonseminomas. Non-seminomatous GCTs (NSGCTs) can be further divided into embryonal carcinoma (EC), teratoma (T), yolk sac tumor (YS), and choriocarcinoma (CC) on the basis of the lineage differentiation that they exhibit. NSGCTs frequently present as mixed tumors consisting of two or more histological subtypes, often limiting correlative studies of clinical and molecular features to histology. We sought to develop a molecular classifier that could predict the predominant histologic subtype within mixed NSGCT tumor samples. The expression profiles of 84 NSGCTs ( 42 pure and 42 mixed) and normal age- matched testes were obtained using Affymetrix microarrays. Using prediction analysis for microarrays, we identified 146 transcripts that classified the histology of pure NSGCTs samples with 93% accuracy. When applied to mixed NSGCTs, the classifier predicted a histology that was consistent with one of the reported components in 93% of cases. Among the predictive transcripts were CGB ( high in CC), LCN2 (high in T), BMP2 (high in YS), and POU5F1 (high in EC). Thus, the expression-based classifier accurately assigned a single predominant histology to mixed NSGCTs, and identified transcripts differentially expressed between histologic components with relevance to NSGCT differentiation.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Chaganti, RSK (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Rm K618, New York, NY 10021 USA.	chagantr@mskcc.org		, James/0000-0002-0030-6216; Bosl, George/0000-0002-7842-6584				BO M, 1992, J BIOL CHEM, V267, P3179; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Brinkmann U, 1999, CANCER RES, V59, P1445; Clark AT, 2004, STEM CELLS, V22, P169, DOI 10.1634/stemcells.22-2-169; COOPER S, 1988, DEVELOPMENT, V104, P565; Coucouvanis E, 1999, DEVELOPMENT, V126, P535; Crease DJ, 1998, P NATL ACAD SCI USA, V95, P4398, DOI 10.1073/pnas.95.8.4398; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Houldsworth J, 2002, CELL GROWTH DIFFER, V13, P257; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Looijenga LHJ, 2003, CANCER RES, V63, P2244; MARKEN JS, 1992, P NATL ACAD SCI USA, V89, P3503, DOI 10.1073/pnas.89.8.3503; MOSTOFI FK, 2000, COMPREHENSIVE TXB GE; Sinner D, 2004, DEVELOPMENT, V131, P3069, DOI 10.1242/dev.01176; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; ULBRIGHT TM, 1993, AM J SURG PATHOL, V17, P1075, DOI 10.1097/00000478-199311000-00001; Zakin L, 2000, P NATL ACAD SCI USA, V97, P14388, DOI 10.1073/pnas.011513398; ZHAO ZY, 1995, HUM MOL GENET, V4, P589, DOI 10.1093/hmg/4.4.589	21	49	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5101	5107		10.1038/sj.onc.1208694	http://dx.doi.org/10.1038/sj.onc.1208694			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15870693				2022-12-17	WOS:000230816900009
J	Koch, A; Mancini, A; El Bounkari, O; Tamura, T				Koch, A; Mancini, A; El Bounkari, O; Tamura, T			The SH2-domian-containing inositol 5-phosphatase (SHIP)-2 binds to c-Met directly via tyrosine residue 1356 and involves hepatocyte growth factor (HGF)-induced lamellipodium formation, cell scattering and cell spreading	ONCOGENE			English	Article						SHIP-2; c-Met tyrosine kinase; lamellipodium formation; cell scattering; actin rearrangement	MULTIFUNCTIONAL DOCKING SITE; FACTOR-RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; POLYPHOSPHATE 5-PHOSPHATASE; PROTEIN; SHIP2; KINASE; IDENTIFICATION; ADHESION; 3-KINASE	Recently, evidence has been accumulating that inositol and phosphatidylinositol polyphosphate play important roles in a variety of signal transduction systems including membrane traffic, actin cytoskeleton rearrangement and cell motility. In this paper, we show for the first time that the SH2-domain-containing inositol 5-phosphatase (SHIP)-2 binds directly to the hepatocyte growth factor (HGF/SF) receptor, c-Met, via phosphotyrosine 1356. HGF induces the breakdown of cell junctions and the dispersion of colonies of epithelial cells including MDCK cells. Whereas only few lamellipodia are observed in MDCK cells 2 min after stimulation with HGF, both SHIP-2- and SHIP-1-overexpressing cells form large, broad lamellipodia. The number of lamellipodia is 2-4-fold greater than that of mock-transfected MDCK cells in the same time period and SHIP is found to colocalize with actin at the leading edge. Furthermore, overexpression of a catalytic inactive mutant of SHIP-2 suppresses HGF-potentiated cell scattering and cell spreading, although these mutant-expressing cells form enhanced number of lamellipodia 2 min after HGF stimulation. Interestingly, cells expressing a mutant lacking the proline-rich domain of SHIP-2 at the C-terminal form few lamellipodia, but still spread and scatter upon stimulation with HGF at a reduced rate. These data suggest that phosphatase activity is required for HGF-mediated cell spreading and scattering but not for alteration of lamellipodium formation, while the proline-rich region influences lamellipodium formation. Furthermore, treatment with 10 mu M of phosphatidylinositol 3(PI3) kinase inhibitor, LY294002, abrogates HGF-induced cell scattering of SHIP-2-overexpressing cells but not parental HEK293 cells, suggesting that a balance between PI3 kinase and SHIP is important for cell motility.	Hannover Med Sch, Inst Biochem, D-30623 Hannover, Germany	Hannover Medical School	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE 4310,Carl Neuberg Str 1, D-30623 Hannover, Germany.	tamura.teruko@mh-hannover.de						Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bouscary D, 2003, BLOOD, V101, P3436, DOI 10.1182/blood-2002-07-2332; Dyson JM, 2003, BLOOD, V102, P940, DOI 10.1182/blood-2002-09-2897; Dyson JM, 2001, J CELL BIOL, V155, P1065, DOI 10.1083/jcb.200104005; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; Giuriato S, 2003, BIOCHEM J, V376, P199, DOI 10.1042/BJ20030581; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Kawamura K, 2004, J BIOL CHEM, V279, P54862, DOI 10.1074/jbc.M408057200; Khoury H, 2001, ONCOGENE, V20, P788, DOI 10.1038/sj.onc.1204166; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Koch A, 2000, FEBS LETT, V469, P72, DOI 10.1016/S0014-5793(00)01242-4; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; Mancini A, 2002, ONCOGENE, V21, P1477, DOI 10.1038/sj.onc.1205224; Muraille E, 1999, BIOCHEM J, V342, P697, DOI 10.1042/0264-6021:3420697; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PELICCI G, 1995, ONCOGENE, V10, P1631; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Pesesse X, 2001, J BIOL CHEM, V276, P28348, DOI 10.1074/jbc.M103537200; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Prasad N, 2002, J CELL SCI, V115, P3807, DOI 10.1242/jcs.00070; Prasad N, 2001, MOL CELL BIOL, V21, P1416, DOI 10.1128/MCB.21.4.1416-1428.2001; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; Stefan M, 2001, J BIOL CHEM, V276, P3017, DOI 10.1074/jbc.M009333200; STOKER M, 1985, J CELL SCI, V77, P209; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; Tsujishita Y, 2001, CELL, V105, P379, DOI 10.1016/S0092-8674(01)00326-9; Vollenweider P, 1999, MOL CELL BIOL, V19, P1081; Wang YJ, 2004, J IMMUNOL, V173, P6820, DOI 10.4049/jimmunol.173.11.6820; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720	36	49	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3436	3447		10.1038/sj.onc.1208558	http://dx.doi.org/10.1038/sj.onc.1208558			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735664				2022-12-17	WOS:000229038800006
J	Summers, MK; Bothos, J; Halazonetis, TD				Summers, MK; Bothos, J; Halazonetis, TD			The CHFR mitotic checkpoint protein delays cell cycle progression by excluding Cyclin B1 from the nucleus	ONCOGENE			English	Article						CHFR; cyclin B1; checkpoint; prophase; mitosis	HISTONE H3 PHOSPHORYLATION; CHROMOSOME MISSEGREGATION; EPIGENETIC INACTIVATION; ENVELOPE BREAKDOWN; STRESS CHECKPOINT; MAMMALIAN-CELLS; CPG ISLAND; FHA DOMAIN; AURORA-B; SPINDLE	CHFR, a novel checkpoint gene inactivated in human cancer, delays chromosome condensation in cells treated with microtubule poisons. To understand the molecular mechanism for this delay, we characterized cells with inactivated CHFR and stably transfected derivatives expressing the wild-type gene. After exposure to microtubule poisons, the CHFR-expressing cells arrested transiently in early prophase with a characteristic ruffled morphology of the nuclear envelope and no signs of chromosome condensation. Several markers suggested that Cyclin A/Cdc2 had been activated, whereas Aur-ora-A and -B and Cyclin B1/Cdc2 were inactive. Further, Cyclin B1 was excluded from the nucleus. Ectopic expression of Cyclin B1 with a mutant nuclear export sequence induced chromosome condensation, and thus overcame the CHFR checkpoint. We conclude that the mechanism by which CHFR delays chromosome condensation involves inhibition of accumulation of Cyclin B1 in the nucleus.	Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Philadelphia, PA 19104 USA; Univ Penn, Cell & Mol Biol Program, Biomed Grad Studies, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania	Halazonetis, TD (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.	halazonetis@wistar.upenn.edu	Halazonetis, Thanos/D-7923-2011		NATIONAL CANCER INSTITUTE [T32CA009677, R01CA089630, T32CA009171] Funding Source: NIH RePORTER; NCI NIH HHS [CA09171, CA09677, CA89630] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Basu J, 1999, J CELL BIOL, V146, P13, DOI 10.1083/jcb.146.1.13; Beaudouin J, 2002, CELL, V108, P83, DOI 10.1016/S0092-8674(01)00627-4; Bertholon J, 2003, ONCOGENE, V22, P8956, DOI 10.1038/sj.onc.1207078; Bothos J, 2003, ONCOGENE, V22, P7101, DOI 10.1038/sj.onc.1206831; BULLOUGH WS, 1951, PROC R SOC SER B-BIO, V138, P562, DOI 10.1098/rspb.1951.0041; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chaturvedi P, 2002, CANCER RES, V62, P1797; Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Erson AE, 2004, MOL CARCINOGEN, V39, P26, DOI 10.1002/mc.10161; Georgatos SD, 1997, J CELL SCI, V110, P2129; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; JHA MN, 1994, CANCER RES, V54, P5011; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mariatos G, 2003, CANCER RES, V63, P7185; Matsusaka T, 2004, J CELL BIOL, V166, P507, DOI 10.1083/jcb.200401139; MCINTOSH JR, 1989, SCIENCE, V246, P622; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Rieder CL, 2000, CURR BIOL, V10, P1067, DOI 10.1016/S0960-9822(00)00678-3; Salina D, 2002, CELL, V108, P97, DOI 10.1016/S0092-8674(01)00628-6; Satoh A, 2003, CANCER RES, V63, P8606; Schneider U, 1999, BIOCHEMISTRY-US, V38, P4620, DOI 10.1021/bi9827060; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shibata Y, 2002, CARCINOGENESIS, V23, P1695, DOI 10.1093/carcin/23.10.1695; Stavridi ES, 2002, STRUCTURE, V10, P891, DOI 10.1016/S0969-2126(02)00776-1; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; Woo RA, 2003, CELL CYCLE, V2, P316, DOI 10.4161/cc.2.4.468; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang J, 2001, J BIOL CHEM, V276, P3604, DOI 10.1074/jbc.M008151200	55	49	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2589	2598		10.1038/sj.onc.1208428	http://dx.doi.org/10.1038/sj.onc.1208428			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15674323				2022-12-17	WOS:000228356700001
J	Begum, S; Emani, N; Cheung, A; Wilkins, O; Der, S; Hamel, PA				Begum, S; Emani, N; Cheung, A; Wilkins, O; Der, S; Hamel, PA			Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR	ONCOGENE			English	Article						Pax3; Pax3/ FKHR; microarray; gene targets; rhabdomyosarcoma	HORMONE-RELATED PROTEIN; PAX3-FKHR FUSION PROTEIN; NEURAL CREST MIGRATION; DNA-BINDING; WAARDENBURG SYNDROME; PAIRED-DOMAIN; ALVEOLAR RHABDOMYOSARCOMA; TWISTED GASTRULATION; TRANSCRIPTIONAL ACTIVATOR; EMBRYONIC-DEVELOPMENT	The oncogenic fusion protein, Pax3/FKHR, is a more potent transcription factor relative to its normal counterpart, Pax3. Since Pax3 induced a mesenchymal to epithelial transition (MET) in human SaOS-2 osteosarcomas, we hypothesized that Pax3/FKHR would also induce a morphological change in SaOS-2 cells. We demonstrate here that Pax3/FKHR more potently induces a MET in SaOS-2 cells than Pax3. This greater potency was further evident where Pax3/FKHR, but not Pax3, induced a morphological alteration in U2-OS osteosarcoma cells. By microarray analysis, we determined that Pax3/FKHR altered the expression of gene targets in a manner quantitatively and qualitatively distinct from Pax3. Three classes of genes were identified: (i) genes induced or repressed by Pax3 and Pax3/FKHR, (ii) genes induced or repressed by Pax3/FKHR but not Pax3 and (iii) genes induced by Pax3/FKHR but repressed by Pax3. Chromatin immunoprecipitations confirmed the direct binding of Pax3/FKHR to the promoter region of several factors including cannabinoid receptor-1, EPHA2 and EPHA4. Verification of the microarray data also revealed coordinate alteration in the expression of factors involved in BMP4 signalling. Regulation of gene expression by Pax3 and Pax3/FKHR is, however, cell-type specific. BMP4 expression, for example, was repressed by both Pax3 and Pax3/FKHR in SaOS-2 cells, while in the rhabdomyosarcoma, RD, Pax3/FKHR, but not Pax3, induced BMP4 expression. Thus, our data reveal that Pax3/FKHR regulates a distinct but overlapping set of genes relative to Pax3 and that the global set of Pax3 and Pax3/FKHR gene targets is cell-type specific.	Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada	University of Toronto	Hamel, PA (corresponding author), Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, 1 Kings Coll Circle,6318 Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	paul.hamel@utoronto.ca	Wilkins, Olivia/AGG-7629-2022; Xiao, Yang/B-5668-2012	Wilkins, Olivia/0000-0001-9762-7069				Anderson J, 1999, GENE CHROMOSOME CANC, V26, P275, DOI 10.1002/(SICI)1098-2264(199912)26:4<275::AID-GCC1>3.0.CO;2-3; Anderson J, 2001, AM J PATHOL, V159, P1089, DOI 10.1016/S0002-9440(10)61784-1; Ba-Charvet KTN, 1999, NEURON, V22, P463, DOI 10.1016/S0896-6273(00)80702-3; BALDWIN CT, 1994, HUM MUTAT, V3, P205, DOI 10.1002/humu.1380030306; Barrios A, 2003, CURR BIOL, V13, P1571, DOI 10.1016/j.cub.2003.08.030; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Blake J, 2003, HISTOL HISTOPATHOL, V18, P529, DOI 10.14670/HH-18.529; BOBER E, 1994, DEVELOPMENT, V120, P603; BOUIZAR Z, 1993, CANCER RES, V53, P5076; Buckley NE, 1998, NEUROSCIENCE, V82, P1131; Bundred NJ, 1996, ANN ROY COLL SURG, V78, P354; Cao Y, 2000, J BIOL CHEM, V275, P9854, DOI 10.1074/jbc.275.13.9854; CHALEPAKIS G, 1994, NUCLEIC ACIDS RES, V22, P3131, DOI 10.1093/nar/22.15.3131; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; Chang CB, 2001, NATURE, V410, P483, DOI 10.1038/35068583; Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159; Conway SJ, 1997, CARDIOVASC RES, V36, P163, DOI 10.1016/S0008-6363(97)00172-7; Conway SJ, 1997, DEVELOPMENT, V124, P505; De Bellard ME, 2002, DEV BIOL, V249, P121, DOI 10.1006/dbio.2002.0756; DIETRICH S, 1993, MECH DEVELOP, V44, P189, DOI 10.1016/0925-4773(93)90067-8; Dunbar ME, 1999, J MAMMARY GLAND BIOL, V4, P21, DOI 10.1023/A:1018700502518; Durbin L, 1998, GENE DEV, V12, P3096, DOI 10.1101/gad.12.19.3096; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; Farquharson C, 2001, ENDOCRINOLOGY, V142, P4131, DOI 10.1210/en.142.9.4131; Foley J, 2001, DEVELOPMENT, V128, P513; Fortin AS, 1997, HUM MOL GENET, V6, P1781, DOI 10.1093/hmg/6.11.1781; Fredericks William J., 2001, Cancer Letters, V162, pS23, DOI 10.1016/S0304-3835(00)00649-2; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GERARD M, 1995, CR ACAD SCI III-VIE, V318, P57; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; HOTH CF, 1993, AM J HUM GENET, V52, P455; Hu HY, 1999, NEURON, V23, P703, DOI 10.1016/S0896-6273(01)80029-5; Johnson J, 2001, DEV BIOL, V229, P176, DOI 10.1006/dbio.2000.9969; Kaestner KH, 2000, GENE DEV, V14, P142; Kawasaki H, 1998, J PEDIAT HEMATOL ONC, V20, P327, DOI 10.1097/00043426-199807000-00009; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Khan J, 1998, CANCER RES, V58, P5009; Kissin M W, 1993, Eur J Surg Oncol, V19, P134; Koblar SA, 2000, J NEUROBIOL, V42, P437, DOI 10.1002/(SICI)1097-4695(200003)42:4<437::AID-NEU5>3.3.CO;2-F; Kwang SJ, 2002, DEVELOPMENT, V129, P527; Lagutina I, 2002, MOL CELL BIOL, V22, P7204, DOI 10.1128/MCB.22.20.7204-7216.2002; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Libura J, 2002, BLOOD, V100, P2597, DOI 10.1182/blood-2002-01-0031; Luo T, 2001, INT J DEV BIOL, V45, P681; Mayanil CSK, 2000, J BIOL CHEM, V275, P23259, DOI 10.1074/jbc.M002975200; Mayanil CSK, 2001, J BIOL CHEM, V276, P49299, DOI 10.1074/jbc.M107933200; Park GT, 2002, NUCLEIC ACIDS RES, V30, P515, DOI 10.1093/nar/30.2.515; Popkin DL, 2003, P NATL ACAD SCI USA, V100, P14309, DOI 10.1073/pnas.1835673100; Poser I, 2004, HISTOL HISTOPATHOL, V19, P173, DOI 10.14670/HH-19.173; Relaix F, 2003, GENE DEV, V17, P2950, DOI 10.1101/gad.281203; Ross JJ, 2001, NATURE, V410, P479, DOI 10.1038/35068578; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; Schubert FR, 2001, DEV DYNAM, V222, P506, DOI 10.1002/dvdy.1211; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; SEBAG M, 1994, AM J PHYSIOL, V267, pC723, DOI 10.1152/ajpcell.1994.267.3.C723; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Song ZH, 2000, J PHARMACOL EXP THER, V294, P204; SUBLETT JE, 1995, ONCOGENE, V11, P545; TASSABEHJI M, 1994, HUM MOL GENET, V3, P1069, DOI 10.1093/hmg/3.7.1069; Terzic J, 1999, INT J DEV BIOL, V43, P501; TREMBLAY P, 1995, DEV BIOL, V171, P317, DOI 10.1006/dbio.1995.1284; Tremblay P, 1998, DEV BIOL, V203, P49, DOI 10.1006/dbio.1998.9041; UNDERHILL DA, 1995, P NATL ACAD SCI USA, V92, P3692, DOI 10.1073/pnas.92.9.3692; Underhill DA, 1997, J BIOL CHEM, V272, P14175, DOI 10.1074/jbc.272.22.14175; Vachtenheim J, 1999, CELL MOL BIOL, V45, P1075; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Wardle FC, 1999, DEV BIOL, V206, P63, DOI 10.1006/dbio.1998.9127; Wardle FC, 1999, MECH DEVELOP, V86, P75, DOI 10.1016/S0925-4773(99)00114-8; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Wiggan O, 2002, J CELL SCI, V115, P517; Wiggan O, 2002, J CELL SCI, V115, P531; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; Xia SJJ, 2002, CANCER BIOL THER, V1, P97, DOI 10.4161/cbt.51; Yu K, 2000, DEVELOPMENT, V127, P2143	84	49	53	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1860	1872		10.1038/sj.onc.1208315	http://dx.doi.org/10.1038/sj.onc.1208315			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688035				2022-12-17	WOS:000227542000005
J	Dahm-Daphi, J; Hubbe, P; Horvath, F; El-Awady, RA; Bouffard, KE; Powell, SN; Willers, H				Dahm-Daphi, J; Hubbe, P; Horvath, F; El-Awady, RA; Bouffard, KE; Powell, SN; Willers, H			Nonhomologous end-joining of site-specic but not of radiation-induced DNA double-strand breaks is reduced in the presence of wild-type p53	ONCOGENE			English	Article						p53; double-strand break; nonhomologous end-joining; radiation; I-SceI	HOMOLOGOUS RECOMBINATION; POTENTIAL MECHANISM; GENOMIC STABILITY; IN-VITRO; REPAIR; SUPPRESSION; RADIOSENSITIVITY; PROTEINS; FIDELITY; CELLS	Nonhomologous end-joining (NHEJ) of DNA double-strand breaks (DSBs) entails two principal mechanisms: modi. cation of DNA ends prior to ligation (error-prone rejoining) or precise ligation without modi. cation if the DNA ends are complementary (error-free repair). Error-prone rejoining is mutagenic, because it can lead to destruction of coding sequence or to chromosomal aberrations, and therefore must be tightly regulated. Previous studies on the role of the p53 tumor suppressor in the regulation of NHEJ have yielded conflicting results, but a rigorous analysis of NHEJ proficiency and fidelity in a purely chromosomal context has not been carried out. To this end, we created novel repair plasmid substrates that integrate into the genome. DSBs generated by the I-SceI endonuclease within these substrates were repaired by either error-prone rejoining or precise ligation. We found that the expression of wild-type p53 inhibited any repair-associated DNA sequence deletion, including a more than 250-fold inhibition of error-prone rejoining events compared to p53-null cells, while any promoting effect of p53 on precise ligation could not be directly evaluated. The role of p53 in NHEJ appeared to involve a direct transactivation-independent mechanism, possibly restricting DNA end-modi. cation by blocking the annealing of single strands along flanking stretches of microhomology. The inhibition of error-prone rejoining by p53 did not apply to the rejoining of DSBs induced by ionizing radiation. In conclusion, our data suggest that p53 restricts the mutagenic effects of NHEJ without compromising repair proficiency or cell survival, thereby maintaining genomic stability.	Univ Hamburg, Hosp Eppendorf, Dept Radiotherapy & Radiat Oncol, Expt Radiat Oncol Lab, D-20246 Hamburg, Germany; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol,Lab Mol & Cellular Radiat Biol, Charlestown, MA 02129 USA	University of Hamburg; Harvard University; Massachusetts General Hospital	Dahm-Daphi, J (corresponding author), Univ Klinikum Hamburg Eppendorf, Klin Strahlentherapie & Radioonkol, Martinstr 52, D-20246 Hamburg, Germany.	dahm@uke.uni-hamburg.de			NATIONAL CANCER INSTITUTE [R01CA058985] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58985] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achanta G, 2001, CANCER RES, V61, P8723; Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Allen C, 2003, DNA REPAIR, V2, P1147, DOI 10.1016/S1568-7864(03)00139-3; Bill CA, 1997, MUTAT RES-DNA REPAIR, V385, P21, DOI 10.1016/S0921-8777(97)00040-2; Boehden GS, 2003, ONCOGENE, V22, P4111, DOI 10.1038/sj.onc.1206632; Bohnke A, 2004, INT J RADIAT BIOL, V80, P53, DOI 10.1080/09553000310001642902; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; BRYANT PE, 1987, INT J RADIAT BIOL, V52, P537, DOI 10.1080/09553008714552041; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; CHANG C, 1993, CANCER RES, V53, P1244; Dahm-Daphi J, 2000, STRAHLENTHER ONKOL, V176, P278, DOI 10.1007/s000660050010; DahmDaphi J, 1997, INT J RADIAT BIOL, V72, P171, DOI 10.1080/095530097143392; DiBiase SJ, 1999, INT J RADIAT ONCOL, V45, P743, DOI 10.1016/S0360-3016(99)00229-1; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dikomey E, 1998, INT J RADIAT BIOL, V73, P269, DOI 10.1080/095530098142365; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; El-Awady RA, 2003, BRIT J CANCER, V89, P593, DOI 10.1038/sj.bjc.6601133; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Guirouilh-Barbat J, 2004, MOL CELL, V14, P611, DOI 10.1016/j.molcel.2004.05.008; HENNER WD, 1983, J BIOL CHEM, V258, P711; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; Iwabuchi K, 2003, J BIOL CHEM, V278, P36487, DOI 10.1074/jbc.M304066200; Izumi T, 2003, TOXICOLOGY, V193, P43, DOI 10.1016/S0300-483X(03)00289-0; Lee JW, 2004, J BIOL CHEM, V279, P805, DOI 10.1074/jbc.M307913200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lieber MR, 2004, DNA REPAIR, V3, P817, DOI 10.1016/j.dnarep.2004.03.015; Lin YF, 2003, DNA REPAIR, V2, P1, DOI 10.1016/S1568-7864(02)00183-0; LIU LF, 1983, J BIOL CHEM, V258, P5365; Ma JL, 2003, MOL CELL BIOL, V23, P8820, DOI 10.1128/MCB.23.23.8820-8828.2003; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; Okorokov AL, 2002, CARCINOGENESIS, V23, P549, DOI 10.1093/carcin/23.4.549; PFEIFFER P, 1994, MOL CELL BIOL, V14, P888, DOI 10.1128/MCB.14.2.888; Pfeiffer P, 2000, MUTAGENESIS, V15, P289, DOI 10.1093/mutage/15.4.289; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; POWELL SN, 1995, CANCER RES, V55, P1643; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Rogers-Bald M, 2000, INT J RADIAT BIOL, V76, P23, DOI 10.1080/095530000138970; Romanova LY, 2004, ONCOGENE, V23, P9025, DOI 10.1038/sj.onc.1207982; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; Tang W, 1999, CANCER RES, V59, P2562; Vilenchik MM, 2003, P NATL ACAD SCI USA, V100, P12871, DOI 10.1073/pnas.2135498100; Willers H, 2004, BRIT J CANCER, V90, P1297, DOI 10.1038/sj.bjc.6601729; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Willers H, 2001, CARCINOGENESIS, V22, P1757, DOI 10.1093/carcin/22.11.1757; Yang TT, 1997, ONCOGENE, V14, P1511, DOI 10.1038/sj.onc.1200979; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004	54	49	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1663	1672		10.1038/sj.onc.1208396	http://dx.doi.org/10.1038/sj.onc.1208396			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15688024				2022-12-17	WOS:000227345100002
J	Abu-Amero, KK; Alzahrani, AS; Zou, MJ; Shi, YF				Abu-Amero, KK; Alzahrani, AS; Zou, MJ; Shi, YF			High frequency of somatic mitochondrial DNA mutations in human thyroid carcinomas and complex I respiratory defect in thyroid cancer cell lines	ONCOGENE			English	Article						mitochondria; mutation; thyroid neoplasm; respiratory function	TUMORS; NUCLEAR; GENOME; CHAIN; VARIANTS; DISEASE; MELAS	Significant progress has been made to elucidate the molecular mechanisms that determine thyroid tumor development and progression. However, most investigations have mainly focused on the genetic alterations of nuclear DNA. The potential role of mitochondrial DNA (mtDNA) mutations in thyroid tumorigenesis is not well defined. In the present study, we investigated the frequency of mtDNA mutations in 24 thyroid tumor specimens (19 primary papillary thyroid carcinomas (PTC), one follicular thyroid carcinoma, and four multinodular hyperplasias) and four thyroid cancer cell lines by sequencing the entire coding regions of mitochondrial genome. Among the 19 PTC samples tested, seven (36.8%) had somatic mutations. Somatic mtDNA mutations were also detected in one of four multinodular hyperplasias examined. All the thyroid tumor cell lines carried sequence variations that change amino acid and have not been reported previously as normal sequence variants. Flow cytometry analysis of mitochondria respiratory function in the thyroid tumor cell lines revealed a severe defect in mitochondrial complex I activity. The majority of the mutations was involved in genes located in the complex I of the mitochondrial genome. The mutations were either A-->G or C-->T transitions, often resulting in a change of a moderately or highly conserved amino acid of their corresponding protein. These data suggest that mtDNA mutations may play an important role in the thyroid tumorigenesis. Given that mtDNA mutation is present in the benign multinodular hyperplasia, it might be involved in the early stage of tumor development.	King Faisal Specialist Hosp & Res Ctr, Dept Genet MBC 03, Riyadh 11211, Saudi Arabia; King Faisal Specialist Hosp & Res Ctr, Dept Med, Riyadh 11211, Saudi Arabia	King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center	Shi, YF (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Genet MBC 03, POB 3354, Riyadh 11211, Saudi Arabia.	yufei@kfshrc.edu.sa	Alzahrani, Ali S/L-3664-2017; Shi, Yufei/ABG-5228-2020	Alzahrani, Ali S/0000-0003-4294-3624; Shi, Yufei/0000-0002-6999-0191				Abu-Amero K, 2004, CLIN GENET, V66, P569, DOI 10.1111/j.1399-0004.2004.00365.x; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Bosley TM, 2004, NEUROLOGY, V63, P1305, DOI 10.1212/01.WNL.0000140696.34117.95; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Chagnon P, 1999, AM J MED GENET, V85, P20, DOI 10.1002/(SICI)1096-8628(19990702)85:1<20::AID-AJMG6>3.0.CO;2-K; Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; FARID NR, 1994, ENDOCR REV, V15, P202, DOI 10.1210/er.15.2.202; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Hartman P, 2004, MECH AGEING DEV, V125, P417, DOI 10.1016/j.mad.2004.02.007; Jeronimo C, 2001, ONCOGENE, V20, P5195, DOI 10.1038/sj.onc.1204646; Jones JB, 2001, CANCER RES, V61, P1299; Liu VWS, 2001, CANCER RES, V61, P5998; Maximo V, 2002, AM J PATHOL, V160, P1857, DOI 10.1016/S0002-9440(10)61132-7; MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; Parrella P, 2001, CANCER RES, V61, P7623; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967; Schmutzler C, 2000, EUR J ENDOCRINOL, V143, P15, DOI 10.1530/eje.0.1430015; Segev DL, 2003, SURG ONCOL, V12, P69, DOI 10.1016/S0960-7404(03)00037-9; Setterfield K, 2002, MITOCHONDRION, V1, P437, DOI 10.1016/S1567-7249(02)00008-9; Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759; Singh KK, 2004, ANN NY ACAD SCI, V1019, P260, DOI 10.1196/annals.1297.043; Stefaneanu L, 1979, Endocrinologie, V17, P233; Takano T, 2000, BRIT J CANCER, V83, P1495, DOI 10.1054/bjoc.2000.1483; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Williams AJ, 1999, J CHILD NEUROL, V14, P518, DOI 10.1177/088307389901400807; Yeh JJ, 2000, ONCOGENE, V19, P2060, DOI 10.1038/sj.onc.1203537	30	49	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1455	1460		10.1038/sj.onc.1208292	http://dx.doi.org/10.1038/sj.onc.1208292			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608681				2022-12-17	WOS:000227092600015
J	Lui, WO; Foukakis, T; Liden, J; Thoppe, SR; Dwight, T; Hoog, A; Zedenius, J; Wallin, G; Reimers, M; Larsson, C				Lui, WO; Foukakis, T; Liden, J; Thoppe, SR; Dwight, T; Hoog, A; Zedenius, J; Wallin, G; Reimers, M; Larsson, C			Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPAR gamma fusion oncogene	ONCOGENE			English	Article						follicular thyroid carcinomas; fusion oncogene; PAX8-PPAR gamma; expression array	ACTIVATED-RECEPTOR-GAMMA; TRANSLATIONAL CONTROL; BRAF MUTATIONS; PPAR-GAMMA; CANCER; GENE; TUMORS; REARRANGEMENTS; GROWTH; DIFFERENTIATION	The demonstration of the PAX8-PPARgamma fusion oneogene in a subset of follicular thyroid tumors provides a new and promising starting point to dissect the molecular genetic events involved in the development of this tumor form. In the present study, we compared the gene expression profiles of follicular thyroid carcinomas (FTCs) bearing a PAX8-PPAR7 fusion against FTCs that lack this fusion. Using unsupervised clustering and multidimensional sealing analyses, we show that FTCs possessing a PAX8-wPPARgamma fusion have a highly uniform and distinct gene expression signature that clearly distinguishes them from FTCs without the fusion. The PAX8-PPARgamma(+) FTCs grouped in a defined cluster, where highly ranked genes were mostly associated with signal transduction, cell growth and translation control. Notably, a large number of ribosomal protein and translation-associated genes were concurrently underexpressed in the FTCs with the fusion. Taken together, our findings further support that follicular carcinomas with a PAX8-PPAR7 rearrangement constitute a distinct biological entity. The current data represent one step to elucidate the molecular pathways in the development of FTCs with the specific PAX8-PPARgamma fusion.	Karolinska Univ Hosp, Dept Mol Med, SE-17176 Stockholm, Sweden; Karolinska Univ Hosp, Surg Sci Ctr, SE-14186 Huddinge, Sweden; Karolinska Univ Hosp, Dept Surg Sci, SE-17176 Stockholm, Sweden; Novum, Dept Biosci, SE-14157 Huddinge, Sweden; Karolinska Univ Hosp, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; NCI, Mol Pharmacol Lab, Bethesda, MD 20892 USA	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lui, WO (corresponding author), Stanford Univ, Sch Med, Dept Pathol, 300 Pasteur Dr,Lane Bldg,L313, Stanford, CA 94305 USA.	weng-onn.lui@cmm.ki.se	Lui, Weng-Onn/X-5957-2019; Lui, Weng-Onn/G-6703-2013	Lui, Weng-Onn/0000-0003-4717-4473; Lui, Weng-Onn/0000-0003-4717-4473; Foukakis, Theodoros/0000-0001-8952-9987; Dwight, Trisha/0000-0003-1943-4514				Aldred MA, 2003, ONCOGENE, V22, P3412, DOI 10.1038/sj.onc.1206400; Aman P, 1999, SEMIN CANCER BIOL, V9, P303, DOI 10.1006/scbi.1999.0130; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Cheung L, 2003, J CLIN ENDOCR METAB, V88, P354, DOI 10.1210/jc.2002-021020; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; Durig J, 2003, BLOOD, V101, P2748, DOI 10.1182/blood-2002-09-2683; Dwight T, 2003, J CLIN ENDOCR METAB, V88, P4440, DOI 10.1210/jc.2002-021690; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Fajas L, 2001, J MOL ENDOCRINOL, V27, P1, DOI 10.1677/jme.0.0270001; FOUKAKIS T, 2004, IN PRESS INT J ONCOL; Frattini M, 2004, ONCOGENE, V23, P7436, DOI 10.1038/sj.onc.1207980; French CA, 2003, AM J PATHOL, V162, P1053, DOI 10.1016/S0002-9440(10)63902-8; Gimm O, 2001, CANCER LETT, V163, P143, DOI 10.1016/S0304-3835(00)00697-2; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HIDINGER CE, 1998, HISTOLOGICAL TYPING; Kimura ET, 2003, CANCER RES, V63, P1454; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; LUI WO, 2003, CURR OPIN ENDOCRINOL, V10, P176; Mansen A, 1996, BIOCHEM BIOPH RES CO, V222, P844, DOI 10.1006/bbrc.1996.0832; Marques AR, 2002, J CLIN ENDOCR METAB, V87, P3947, DOI 10.1210/jc.87.8.3947; Martelli ML, 2002, J CLIN ENDOCR METAB, V87, P4728, DOI 10.1210/jc.2001-012054; Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P2318, DOI 10.1210/jc.2002-021907; Nikiforova MN, 2002, AM J SURG PATHOL, V26, P1016, DOI 10.1097/00000478-200208000-00006; Ohta K, 2001, J CLIN ENDOCR METAB, V86, P2170, DOI 10.1210/jc.86.5.2170; Pierotti MA, 2001, CANCER LETT, V166, P1, DOI 10.1016/S0304-3835(01)00439-6; POLEEV A, 1992, DEVELOPMENT, V116, P611; Senyuk V, 2002, ONCOGENE, V21, P3232, DOI 10.1038/sj.onc.1205436; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Ying H, 2003, CANCER RES, V63, P5274; ZUTSU K, 2002, ONCOGENE, V21, P2695	39	49	52	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1467	1476		10.1038/sj.onc.1208135	http://dx.doi.org/10.1038/sj.onc.1208135			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608688				2022-12-17	WOS:000227092600017
J	Andrechek, ER; White, D; Muller, WJ				Andrechek, ER; White, D; Muller, WJ			Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth	ONCOGENE			English	Article						ErbB2; mammary gland; mouse models; epithelium	TRANSGENIC MICE REVEALS; GROWTH-FACTOR RECEPTOR; HUMAN-BREAST-CANCER; NEU ONCOGENE; LOBULOALVEOLAR DEVELOPMENT; EXPRESSION; AMPLIFICATION; NEU/ERBB-2; LACTATION; TUMORS	The ErbB2 receptor tyrosine kinase has been implicated as a critical growth factor receptor in both normal development and cancer. Amplification and overexpression of this receptor is observed in 20-30% of all human breast cancers and is inversely correlated with patient survival. Studies with transgenic mice have established that elevated expression of erbB2 in mammary epithelium can directly induce mammary carcinomas. Although these studies confirmed a role for ErbB2 in breast cancer induction, the precise role of ErbB2 in normal mammary gland development remained to be elucidated due to the embryonic lethality associated with the null mutation. Here, we demonstrate that the mammary-specific ablation of erbB2 through Cre-mediated recombination leads to a striking ductal elongation defect. In addition to the observed elongation defect, we noted that branching in the adult mammary gland was also reduced. Despite these perturbations in virgin mammary gland morphogenesis, targeted disruption of erbB2 had little impact on the ability of these animals to lactate. Taken together, these observations indicate that erbB2 plays a critical role in the initial stages of mammary gland morphogenesis.	McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McMaster Univ, Dept Biol, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Med Sci, Hamilton, ON L8S 4K1, Canada	McGill University; Royal Victoria Hospital; McMaster University; McMaster University	Muller, WJ (corresponding author), McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	william.muller@mcgill.ca		Andrechek, Eran/0000-0002-8680-3423				Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Andrechek ER, 2003, CANCER RES, V63, P4920; Andrechek ER, 2002, MOL CELL BIOL, V22, P4714, DOI 10.1128/MCB.22.13.4714-4722.2002; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHAILLET JR, 1995, GENE DEV, V9, P1177, DOI 10.1101/gad.9.10.1177; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; Jones FE, 1999, ONCOGENE, V18, P3481, DOI 10.1038/sj.onc.1202698; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Mukherjee S, 2000, ONCOGENE, V19, P5982, DOI 10.1038/sj.onc.1203964; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Sebastian J, 1998, CELL GROWTH DIFFER, V9, P777; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Zhou H, 2001, ONCOGENE, V20, P6009, DOI 10.1038/sj.onc.1204830	22	49	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					932	937		10.1038/sj.onc.1208230	http://dx.doi.org/10.1038/sj.onc.1208230			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15580295				2022-12-17	WOS:000226577100018
J	Vidal, CI; Mintz, PJ; Lu, K; Ellis, LM; Manenti, L; Giavazzi, R; Gershenson, DM; Broaddus, R; Liu, JS; Arap, W; Pasqualini, R				Vidal, CI; Mintz, PJ; Lu, K; Ellis, LM; Manenti, L; Giavazzi, R; Gershenson, DM; Broaddus, R; Liu, JS; Arap, W; Pasqualini, R			An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients	ONCOGENE			English	Article						antibodies; heat-shock proteins; HSP90; ovarian cancer; phage display	HEAT-SHOCK-PROTEIN; PROGNOSTIC-FACTORS; EXPRESSION; AUTOANTIBODIES; CARCINOMA; ANTIGENS; DISPLAY; MARKERS; SURFACE; HSP90	To gain insight into the mechanisms of molecular recognition and humoral immune response in ovarian cancer, we used fingerprinting, a phage display-based combinatorial selection to isolate peptide ligands to tumor-related antibodies present in ascites from patients with advanced disease. First, we have isolated a consensus motif (sequence CVPELGHEC) in 86% of the peptides screened; this enriched motif was selected from a total of 108-109 unique random sequences present in the library. Next, we identified the heat-shock protein 90 kDa (HSP90) as the native antigen mimicked by the motif. Finally, we evaluated the expression of HSP90 and the presence of antibodies against the HSP90-mimic peptide in a large panel of ovarian cancer patients and controls. In tissue microarrays, we show that the expression of HSP90 is ubiquitous. However, the corresponding humoral immune response against HSP90 is restricted to a subset of patients with stage IV disease. Together, these results show that screening humoral response can identify tumor antigens that may serve as molecular targets in ovarian cancer. Recognition of such relevant proteins in the immunobiology of malignant tumors may lead to the development of therapies.	Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Mario Negri Inst Pharmacol Res, Dept Oncol, Lab Biol & Therapy Metastasis, I-24125 Bergamo, Italy; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Arap, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	warap@mdanderson.org; rpasqual@mdanderson.org	Giavazzi, Raffaella/J-7424-2018; Giavazzi, Raffaella/ABB-9768-2020	Giavazzi, Raffaella/0000-0001-5249-8208	NCI NIH HHS [CA836393] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Barbas C. F., 2001, PHAGE DISPLAY LAB MA; BOOKMAN MA, 2000, PRINCIPLES PRACTICE, P403; BRINTON LA, 2000, PRINCIPLES PRACTICE, P3; BUICK RN, 1985, CANCER RES, V45, P3668; COHEN IR, 1990, ISRAEL J MED SCI, V26, P673; Conroy SE, 1998, EUR J CANCER, V34, P942; Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Kenderov A, 2002, CLIN EXP IMMUNOL, V129, P169, DOI 10.1046/j.1365-2249.2002.01887.x; Luo LY, 2002, BRIT J CANCER, V87, P339, DOI 10.1038/sj.bjc.6600439; Maggino T, 2000, EUR J GYNAECOL ONCOL, V21, P64; Marsden DE, 2000, SEMIN SURG ONCOL, V19, P11, DOI 10.1002/1098-2388(200007/08)19:1<11::AID-SSU3>3.0.CO;2-3; Meyer T, 2000, BRIT J CANCER, V82, P1535; Mintz PJ, 2003, NAT BIOTECHNOL, V21, P57, DOI 10.1038/nbt774; Neckers L, 2003, NATURE, V425, P357, DOI 10.1038/425357a; Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SRIVASTAVA PK, 2001, PRINCIPLES PRACTICE, P1; Taylor DD, 1998, ONCOL REP, V5, P1519; Trieb K, 2000, BRIT J CANCER, V82, P85, DOI 10.1054/bjoc.1999.0881; Witkin SS, 2001, EUR J GYNAECOL ONCOL, V22, P249	24	49	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8859	8867		10.1038/sj.onc.1208082	http://dx.doi.org/10.1038/sj.onc.1208082			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480432				2022-12-17	WOS:000225354600001
J	Hartman, J; Muller, P; Foster, JS; Wimalasena, J; Gustafsson, JA; Strom, A				Hartman, J; Muller, P; Foster, JS; Wimalasena, J; Gustafsson, JA; Strom, A			HES-1 inhibits 17 beta-estradiol and heregulin-beta 1-mediated upregulation of E2F-1	ONCOGENE			English	Article						all-trans retinoic acid; cell cycle; T47D; HES-6; HERP; NPAT; cyclin E	BREAST-CANCER CELLS; TRANSCRIPTION FACTOR E2F1; TRANS-RETINOIC ACID; CYCLE PROGRESSION; ESTROGEN-RECEPTOR; S-PHASE; EXPRESSION; GENE; DIFFERENTIATION; PROLIFERATION	We have previously shown that expression of the transcription factor HES-1 is required for the growth-inhibitory effect of all-trans retinoic acid on MCF-7 cells. In this study, we have used T47D cells with tetracyclin-regulated expression of wild-type or a dominant-negative form of HES-1. Expression of HES-1 in T47D cells inhibited G(1)/S-phase transition and activation of Cdk2 elicited by estrogen. Estrogen treatment of T47D cells caused increased expression of E2F-1, and this expression was inhibited by cotreatment with all-trans retinoic acid. We show that the effect is mediated through HES-1, which directly downregulates E2F-1 expression through a CACGAG-site within the E2F-1 promoter. Furthermore, proliferation caused by heregulin-beta1 treatment of T47D cells was inhibited by all-trans retinoic acid and this effect was mediated by HES-1. Interestingly, heregulin-beta1-mediated upregulation of E2F-1 expression was directly inhibited by HES-1 through the same CACGAG-site as seen with estrogen-stimulated induction. In addition, we found that two important downstream target genes of estrogen and heregulin-beta1 that are regulated through E2F-1, cyclin E and NPAT, were both regulated in a similar fashion by all-trans retinoic acid, and these effects were antagonized by dominant-negative HES-1. These findings establish that HES-1 inhibits both estrogen- and heregulin-beta1-stimulated growth of breast cancer cells, and further suggest that growth inhibition induced in these cells by all-trans retinoic acid occurs via HES-1-mediated downregulation of E2F-1 expression.	Karolinska Inst, Novum, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden; Univ Tennessee, Med Ctr, Grad Sch Med, Dept Obstet & Gynecol, Knoxville, TN 37920 USA; Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden	Karolinska Institutet; University of Tennessee System; University of Tennessee Health Science Center; Karolinska Institutet	Strom, A (corresponding author), Karolinska Inst, Novum, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden.	anders.strom@biosci.ki.se	Hartman, Johan/N-1406-2015	Hartman, Johan/0000-0002-6500-8527				Bae SK, 2000, DEVELOPMENT, V127, P2933; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Gao G, 2003, MOL CELL BIOL, V23, P2821, DOI 10.1128/MCB.23.8.2821-2833.2003; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; Jhabvala-Romero F, 2003, ONCOGENE, V22, P8178, DOI 10.1038/sj.onc.1206912; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MARTE BM, 1995, ONCOGENE, V10, P167; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Muller P, 2002, J BIOL CHEM, V277, P28376, DOI 10.1074/jbc.C200340200; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nygard M, 2003, MOL ENDOCRINOL, V17, P79, DOI 10.1210/me.2002-0107; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shen WH, 2004, J BIOL CHEM, V279, P7438, DOI 10.1074/jbc.M310264200; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Strom A, 2000, ONCOGENE, V19, P5951, DOI 10.1038/sj.onc.1203990; Swearingen ML, 2003, CANCER LETT, V198, P229, DOI 10.1016/S0304-3835(03)00313-6; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Tang CK, 1996, CANCER RES, V56, P3350; TSUTSUI T, 1987, CARCINOGENESIS, V8, P1715, DOI 10.1093/carcin/8.11.1715; Wang Q, 2000, CANCER RES, V60, P2040; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	35	49	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8826	8833		10.1038/sj.onc.1208139	http://dx.doi.org/10.1038/sj.onc.1208139			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467735				2022-12-17	WOS:000225165100012
J	Neary, CL; Nesterova, M; Cho, YS; Cheadle, C; Becker, KG; Cho-Chung, YS				Neary, CL; Nesterova, M; Cho, YS; Cheadle, C; Becker, KG; Cho-Chung, YS			Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion	ONCOGENE			English	Article						cAMP-dependent protein kinase; cancer; gene therapy; DNA microarray; confocal microscopy	RI-ALPHA SUBUNIT; RII(BETA) REGULATORY SUBUNIT; CANCER CELL-GROWTH; CYCLIC-AMP; CATALYTIC SUBUNIT; RESPONSE ELEMENT; GENE-EXPRESSION; BREAST-CANCER; AUTOPHOSPHORYLATION SITE; PROSTATE-CANCER	The cAMP-dependent protein kinase types I (PKA-I) and II (PKA-II), composed of identical catalytic ( C) subunits but distinct regulatory ( R) subunits (RI versus RII), are expressed in a balance of cell growth and differentiation. Distortion of this balance may underlie tumorigenesis and tumor growth. Here, we used PC3M prostate carcinoma cells as a model to overexpress wild type and mutant R and C subunit genes and examined the effects of differential expression of these genes on tumor growth. Only the RIIbeta and mutant RIalpha-P (a functional mimic of RIIbeta) transfectants exhibited growth inhibition in vitro, reverted phenotype, and apoptosis, and inhibited in vivo tumor growth. DNA microarrays demonstrated that RIIbeta and RIalpha-P overexpression upregulated a cluster of differentiation genes, while downregulating transformation and proliferation signatures. Overexpression of RIalpha and Calpha, which upregulated PKA-I, elicited the expression signatures opposite that elicited by RIIbeta overexpression. Total colocalization of Calpha and RIIbeta seen by confocal microscopy in the RIIbeta cell nucleus supports the opposed genomic regulation demonstrated between Calpha and RIIbeta cells. Differential expression of PKA R subunits may therefore serve as a tumor-target-based gene therapy for PC3M prostate and other cancers.	NCI, Cellular Biochem Sect, Basic Res Lab, NIH, Bethesda, MD 20892 USA; NIA, DNA Array Unit, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Cho-Chung, YS (corresponding author), NCI, Cellular Biochem Sect, Basic Res Lab, NIH, 9000 Rockville Pike,Bldg 10,Room 5B05, Bethesda, MD 20892 USA.	yc12b@nih.gov		Becker, Kevin/0000-0002-6794-6656; Neary, Catherine/0000-0003-0562-7913; /0000-0002-6224-6685	NCI NIH HHS [N02-BC76512/C2700212] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; ALPER O, 1999, ONCOGENE, V218, P55; Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; BEEBE SJ, 1986, ENZYMES, V17, P43; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BRADBURY AW, 1994, BRIT J CANCER, V69, P738, DOI 10.1038/bjc.1994.139; BUDILLON A, 1995, P NATL ACAD SCI USA, V92, P10634, DOI 10.1073/pnas.92.23.10634; Cho YS, 2002, P NATL ACAD SCI USA, V99, P15626, DOI 10.1073/pnas.242617799; Cho YS, 2002, CLIN CANCER RES, V8, P607; Cho YS, 2001, P NATL ACAD SCI USA, V98, P9819, DOI 10.1073/pnas.171314398; Cho YS, 2000, P NATL ACAD SCI USA, V97, P835, DOI 10.1073/pnas.97.2.835; Cho-Chung Yoon S., 1999, Frontiers in Bioscience, V4, pd898, DOI 10.2741/Cho-Chung; ChoChung YS, 1995, CRIT REV ONCOL HEMAT, V21, P33, DOI 10.1016/1040-8428(94)00166-9; ChoChung YS, 1997, ANTISENSE NUCLEIC A, V7, P217, DOI 10.1089/oli.1.1997.7.217; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; CLEGG CH, 1989, J BIOL CHEM, V264, P20140; Conkright MD, 2003, MOL CELL, V11, P1101, DOI 10.1016/S1097-2765(03)00134-5; Cvijic ME, 2000, CLIN CANCER RES, V6, P2309; DURGERIAN S, 1989, J BIOL CHEM, V264, P9807; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Huntington JT, 2004, J BIOL CHEM, V279, P33168, DOI 10.1074/jbc.M405102200; Lee GR, 1999, MOL CELL BIOCHEM, V195, P77, DOI 10.1023/A:1006934113439; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; MILLER WR, 1993, BREAST CANCER RES TR, V26, P89, DOI 10.1007/BF00682703; Neary CL, 2001, ONCOGENE, V20, P8019, DOI 10.1038/sj.onc.1204992; Nesterova M, 2000, CLIN CANCER RES, V6, P3434; Nesterova M, 1996, EUR J BIOCHEM, V235, P486, DOI 10.1111/j.1432-1033.1996.00486.x; NESTEROVA M, 1995, NAT MED, V1, P528, DOI 10.1038/nm0695-528; Nesterova M, 2000, ANTISENSE NUCLEIC A, V10, P423, DOI 10.1089/oli.1.2000.10.423; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NOWAK I, 1987, EUR J BIOCHEM, V167, P27, DOI 10.1111/j.1432-1033.1987.tb13300.x; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; OTTEN AD, 1991, J BIOL CHEM, V266, P23074; Park YG, 1999, J BIOL CHEM, V274, P1573, DOI 10.1074/jbc.274.3.1573; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Srivastava RK, 1999, MOL CELL BIOCHEM, V195, P25, DOI 10.1023/A:1006990231186; Srivastava RK, 1998, P NATL ACAD SCI USA, V95, P6687, DOI 10.1073/pnas.95.12.6687; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; TAYLOR SS, 1988, FASEB J, V2, P2677, DOI 10.1096/fasebj.2.11.3294077; Tortora G, 2002, ANN NY ACAD SCI, V968, P139, DOI 10.1111/j.1749-6632.2002.tb04332.x; TORTORA G, 1990, J BIOL CHEM, V265, P18067; Wang H, 1999, P NATL ACAD SCI USA, V96, P13989, DOI 10.1073/pnas.96.24.13989; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358	44	49	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8847	8856		10.1038/sj.onc.1208165	http://dx.doi.org/10.1038/sj.onc.1208165			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480415				2022-12-17	WOS:000225165100015
J	Florin, L; Hummerich, L; Dittrich, BT; Kokocinski, F; Wrobel, G; Gack, S; Schorpp-Kistner, M; Werner, S; Hahn, M; Lichter, P; Szabowski, A; Angel, P				Florin, L; Hummerich, L; Dittrich, BT; Kokocinski, F; Wrobel, G; Gack, S; Schorpp-Kistner, M; Werner, S; Hahn, M; Lichter, P; Szabowski, A; Angel, P			Identification of novel AP-1 target genes in fibroblasts regulated during cutaneous wound healing	ONCOGENE			English	Article						expression profiling; Jun; mesenchyme; microarray; skin	NF-KAPPA-B; C-JUN; GROWTH-FACTORS; IN-VITRO; DIFFERENTIAL EXPRESSION; TISSUE; BETA; JNK; TRANSCRIPTION; LOCALIZATION	Mesenchymal - epithelial interactions are increasingly considered to be of vital importance for epithelial homeostasis and regeneration. In skin, the transcription factor AP-1 was shown to be critically involved in the communication between keratinocytes and dermal. broblasts. After skin injury, the release of IL-1 from keratinocytes induces the activity of the AP-1 subunits c-Jun and JunB in. broblasts leading to a global change in gene expression. To identify AP-1 target genes in. broblasts, which are involved in the process of cutaneous repair, we performed gene expression pro. ling of wild-type, c-jun- and junB-deficient. broblasts in response to IL-1, mimicking the initial phase of wound healing. Using a 15K cDNA collection, over 1000 genes were found to be Jun-dependent and additional 300 clones showed IL-1 responsiveness. Combinatorial evaluation allowed for the dissection of the specific contribution of either AP-1 subunit to gene regulation. Besides previously identified genes that are involved in cutaneous repair, we have identified novel genes regulated during wound healing in vivo and showed their expression by. broblasts on wound sections. The identification of novel Jun target genes should provide a basis for understanding the molecular mechanisms underlying mesenchymal - epithelial interactions and the critical contribution of AP-1 to tissue homeostasis and repair.	Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Mol Genet, D-69120 Heidelberg, Germany; ETH, Inst Cell Biol, CH-8093 Zurich, Switzerland	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Swiss Federal Institutes of Technology Domain; ETH Zurich	Angel, P (corresponding author), Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	p.angel@dkfz.de		Werner, Sabine/0000-0001-7397-8710; Kokocinski, Felix/0000-0002-8472-9207				Andrecht S, 2002, J BIOL CHEM, V277, P35961, DOI 10.1074/jbc.M202847200; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Beer HD, 1997, J INVEST DERMATOL, V109, P132, DOI 10.1111/1523-1747.ep12319188; Bodo M, 1998, CYTOKINE, V10, P353, DOI 10.1006/cyto.1997.0301; Brown DL, 1997, AM J PATHOL, V151, P715; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Cowland JB, 1997, GENOMICS, V45, P17, DOI 10.1006/geno.1997.4896; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Diehl F, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf078; Elson DA, 2000, CANCER RES, V60, P6189; Fassler R, 1996, EXP CELL RES, V222, P111, DOI 10.1006/excr.1996.0014; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; Grose R, 2002, DEVELOPMENT, V129, P2303; Haroon ZA, 1999, FASEB J, V13, P1787, DOI 10.1096/fasebj.13.13.1787; Herrlich P, 2001, ONCOGENE, V20, P2465, DOI 10.1038/sj.onc.1204388; Hubner G, 1996, CYTOKINE, V8, P548, DOI 10.1006/cyto.1996.0074; Iwata M, 1999, HISTOCHEM CELL BIOL, V112, P283, DOI 10.1007/s004180050449; Kargul GJ, 2001, NAT GENET, V28, P17, DOI 10.1038/ng0501-17; Ko MSH, 2000, DEVELOPMENT, V127, P1737; Ko MSH, 1998, HUM MOL GENET, V7, P1967, DOI 10.1093/hmg/7.12.1967; Kralova J, 1996, ONCOGENE, V12, P2595; Lansdown ABG, 2002, WOUND REPAIR REGEN, V10, P130, DOI 10.1046/j.1524-475X.2002.20101.x; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; Li GC, 2003, DEV CELL, V4, P865, DOI 10.1016/S1534-5807(03)00159-X; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Liaw L, 1998, J CLIN INVEST, V101, P1468; Mann A, 2001, J INVEST DERMATOL, V117, P1382, DOI 10.1046/j.0022-202x.2001.01600.x; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; Muro AF, 2003, J CELL BIOL, V162, P149, DOI 10.1083/jcb.200212079; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; Saika S, 2000, J BIOL CHEM, V275, P2607, DOI 10.1074/jbc.275.4.2607; Sayani K, 2000, HISTOPATHOLOGY, V36, P262; Scheid A, 2000, PEDIATR SURG INT, V16, P232, DOI 10.1007/s003830050735; Schena M, 1996, BIOESSAYS, V18, P427, DOI 10.1002/bies.950180513; Schlingemann J, 2003, INT J CANCER, V104, P699, DOI 10.1002/ijc.11008; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shiina T, 2001, IMMUNOGENETICS, V53, P649, DOI 10.1007/s00251-001-0376-x; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Soo C, 2000, AM J PATHOL, V157, P423, DOI 10.1016/S0002-9440(10)64555-5; SULLIVAN KM, 1995, J PEDIATR SURG, V30, P198, DOI 10.1016/0022-3468(95)90560-X; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Thorey IS, 2004, J BIOL CHEM, V279, P26674, DOI 10.1074/jbc.M311467200; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Wankell M, 2001, J ENDOCRINOL, V171, P385, DOI 10.1677/joe.0.1710385; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; WILLIAMS DH, 1992, BIOCHIM BIOPHYS ACTA, V1180, P9, DOI 10.1016/0925-4439(92)90020-N; Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534-5807(03)00161-8	62	49	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7005	7017		10.1038/sj.onc.1207938	http://dx.doi.org/10.1038/sj.onc.1207938			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273721				2022-12-17	WOS:000223885100002
J	Jonckheere, N; Perrais, M; Mariette, C; Batra, SK; Aubert, JP; Pigny, P; Van Seuningen, I				Jonckheere, N; Perrais, M; Mariette, C; Batra, SK; Aubert, JP; Pigny, P; Van Seuningen, I			A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis	ONCOGENE			English	Article						MUC4; pancreatic cancer; TGF-beta; transcription; mucin; Smad4; acetylation	GROWTH-FACTOR-BETA; DPC4 INACTIVATION; CANCER; EXPRESSION; PROMOTER; INDUCTION; SEQUENCE; CELLS	MUC4 encodes a large transmembrane mucin that is overexpressed in pancreatic adenocarcinomas. The molecular mechanisms responsible for that altered pattern of expression are unknown. TGF-beta, a pleiotropic cytokine, regulates numerous genes involved in pancreatic carcinogenesis via activation of the Smads proteins and MUC4 promoter is rich in Smad-binding elements. Our aim was to study whether the regulation of MUC4 expression by TGF-beta in pancreatic cancer cells was strictly dependent on Smad4 activity. Three pancreatic cancer cell lines, CAPAN-1 (MUC4 + /Smad4-), CAPAN-2 (MUC4 + /Smad4+) and PANC-1 (MUC4-/Smad4 +), were used. By RT-PCR, transfection assays and immunohistochemistry, we show that (i) both MUC4 mRNA and apomucin expression are upregulated by TGF-beta, (ii) Smad2 positively cooperates with Smad4 to activate the promoter, (iii) activation of Smad4 by exogenous TGF-beta induces Smad4 binding to the promoter, (iv) Smad7 and c-ski both inhibit activation by Smad4. When Smad4 is mutated and inactive, TGF-beta activates MUC4 expression via MAPK, PI3K and PKA signaling pathways. Absence of expression in PANC-1 cells is due to historic deacetylation. Altogether, these results indicate that upregulation of MUC4 by TGF-beta is restricted to well-differentiated pancreatic cancer cells, and point out a novel mechanism for TGF-beta as a key molecule in targeting MUC4 overexpression in pancreatic adenocarcinomas.	INSERM, U560, F-59045 Lille, France; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Eppley Canc Ctr, Omaha, NE USA	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Nebraska System; University of Nebraska Medical Center	Van Seuningen, I (corresponding author), INSERM, U560, Place Verdun, F-59045 Lille, France.	isabelvs@lille.inserm.fr	VAN SEUNINGEN, Isabelle/N-6176-2016; Jonckheere, Nicolas/J-6028-2013	VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; Jonckheere, Nicolas/0000-0002-0496-0661	NCI NIH HHS [R01 CA78590] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; BALAGUE C, 1995, GASTROENTEROLOGY, V109, P953, DOI 10.1016/0016-5085(95)90406-9; Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; Carraway KL, 2000, FRONT BIOSCI, V5, pD95, DOI 10.2741/Carraway; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; Choudhury A, 2000, J BIOCHEM-TOKYO, V128, P233, DOI 10.1093/oxfordjournals.jbchem.a022746; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811; HOLLINGSWORTH MA, 1994, INT J CANCER, V57, P198, DOI 10.1002/ijc.2910570212; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Hruban RH, 2001, J GASTROINTEST SURG, V5, P583, DOI 10.1016/S1091-255X(01)80099-8; Huguier M, 1999, AM J SURG, V177, P257, DOI 10.1016/S0002-9610(99)00003-3; Kim YS, 1999, ANN ONCOL, V10, P51, DOI 10.1023/A:1008332602541; Lichtenstein D R, 1995, Gastrointest Endosc Clin N Am, V5, P237; Mariette C, 2004, BIOCHEM J, V377, P701, DOI 10.1042/BJ20031132; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mesquita P, 2003, J BIOL CHEM, V278, P51549, DOI 10.1074/jbc.M309019200; Miyaki M, 2003, BIOCHEM BIOPH RES CO, V306, P799, DOI 10.1016/S0006-291X(03)01066-0; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Moniaux N, 2001, FRONT BIOSCI-LANDMRK, V6, pD1192, DOI 10.2741/Moniaux; Park Hee-Ug, 2003, Pancreas, V26, pe48, DOI 10.1097/00006676-200304000-00022; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Roberts AB, 2002, CYTOKINE GROWTH F R, V13, P3, DOI 10.1016/S1359-6101(01)00027-2; Sakorafas GH, 2000, CANCER TREAT REV, V26, P29, DOI 10.1053/ctrv.1999.0144; Schutte M, 1999, ANN ONCOL, V10, P56, DOI 10.1023/A:1008336703450; Schutte M, 1996, CANCER RES, V56, P2527; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Sipos B, 2003, VIRCHOWS ARCH, V442, P444, DOI 10.1007/s00428-003-0784-4; Soto P, 2003, J BIOL CHEM, V278, P20338, DOI 10.1074/jbc.M301886200; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Van Seuningen I, 2000, BIOCHEM J, V348, P675; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; Wilentz RE, 2000, CANCER RES, V60, P2002	38	49	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5729	5738		10.1038/sj.onc.1207769	http://dx.doi.org/10.1038/sj.onc.1207769			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15184872	Green Published			2022-12-17	WOS:000222629800002
J	Wang, LG; Ossowski, L; Ferrari, AC				Wang, LG; Ossowski, L; Ferrari, AC			Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line	ONCOGENE			English	Article						androgen receptor; suppressor element; androgen-independent prostate cancer	GENE PROMOTER; HISTONE ACETYLATION; LNCAP CELLS; EXPRESSION; TRANSCRIPTION; BINDING; PROTEIN; INHIBITION; CARCINOMA; ANTIGEN	Androgen receptor (AR) overexpression is one of the characteristics of prostate cancer ( PC) that progresses to hormone independence. An androgen-independent ( AI) derivative, with much higher AR-mRNAand protein levels than the parental LNCaP cell line, whose proliferation was androgen dependent ( AD), was used to explore the mechanism of AR overexpression. We found that a suppressor element (ARS), previously identified in mouse AR and located in the 5'-untranslated region of human AR gene, malfunctions in AI cells. Transfection of constructs that included ARS element into AD cells reduced the transactivating activities of both AR promoter and a heterologous SV40 promoter. The deletion of ARS resulted in an eightfold increase in AR-promoter activity in AD cells, but had no effect in AI cells. Moreover, the nuclear extracts of AD cells contained proteins that produced a specific, ARS-binding complex, while this complex appeared to have been lost from AI cells. Most importantly, treatment of AI cells with a demethylating agent or histone deacetylase inhibitors restored the lost ARS-binding complex. The restoration of the complex coincided with a reduced expression of AR-mRNA and protein and a reduced rate of AR-gene transcription, determined by nuclear run-on experiment. Thus, epigenetic transcriptional silencing of the suppressor protein(s) may be responsible for AR overexpression in AI cells, and its reversal in hormone-independent PC may normalize AR levels and restore their hormone dependence.	Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Ferrari, AC (corresponding author), Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, Box 1129,1 Gustave Levy Pl, New York, NY 10029 USA.	Anna.Ferrari@mssm.edu			NATIONAL CANCER INSTITUTE [R01CA098135, R01CA040758] Funding Source: NIH RePORTER; NCI NIH HHS [CA9813501, CA-40758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banerjee PP, 2001, ENDOCRINOLOGY, V142, P4066, DOI 10.1210/en.142.9.4066; Baxevanis AD, 2002, NUCLEIC ACIDS RES, V30, P1, DOI 10.1093/nar/30.1.1; BLOK LJ, 1992, MOL CELL ENDOCRINOL, V88, P153, DOI 10.1016/0303-7207(92)90020-7; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; BRUCHOVSKY N, 1990, CANCER RES, V50, P2275; BUETTER R, 1994, GEN BANK; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chen S, 1997, MOL ENDOCRINOL, V11, P3, DOI 10.1210/me.11.1.3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; Culig Z, 2002, ENDOCR-RELAT CANCER, V9, P155, DOI 10.1677/erc.0.0090155; Debes JD, 2002, CANCER LETT, V187, P1, DOI 10.1016/S0304-3835(02)00413-5; DEWINTER JAR, 1994, AM J PATHOL, V144, P735; DEWINTER JAR, 1994, J HISTOCHEM CYTOCHEM, V42, P125, DOI 10.1177/42.1.8263324; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Eder IE, 2000, CANCER GENE THER, V7, P997, DOI 10.1038/sj.cgt.7700202; FABER PW, 1991, J BIOL CHEM, V266, P10743; Ferrari AC, 2001, CANCER, V91, P2039, DOI 10.1002/1097-0142(20010601)91:11<2039::AID-CNCR1230>3.3.CO;2-I; Gao M, 1999, J CELL PHYSIOL, V179, P336, DOI 10.1002/(SICI)1097-4652(199906)179:3<336::AID-JCP11>3.0.CO;2-Q; Geck P, 2000, P NATL ACAD SCI USA, V97, P10185, DOI 10.1073/pnas.97.18.10185; Gregory CW, 1998, CANCER RES, V58, P5718; GROSSMANN ME, 1995, J BIOL CHEM, V270, P10968, DOI 10.1074/jbc.270.18.10968; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; HOBISCH A, 1995, CANCER RES, V55, P3068; ISAACS JT, 1981, CANCER RES, V41, P5070; KUMAR MV, 1994, NUCLEIC ACIDS RES, V22, P3693, DOI 10.1093/nar/22.18.3693; Kumar VL, 2002, ASIAN J ANDROL, V4, P229; Latil A, 2001, CANCER RES, V61, P1919; LEO ME, 1991, J UROLOGY, V145, P802, DOI 10.1016/S0022-5347(17)38456-2; Linja MJ, 2001, CANCER RES, V61, P3550; LOIDL P, 1994, CHROMOSOMA, V103, P441; McPhaul MJ, 2002, RECENT PROG HORM RES, V57, P181, DOI 10.1210/rp.57.1.181; MIZOKAMI A, 1994, J BIOL CHEM, V269, P25655; PARTIN AW, 1990, J UROLOGY, V143, P747, DOI 10.1016/S0022-5347(17)40079-6; PETROS JA, 1993, UROL CLIN N AM, V20, P749; REIGMAN PHJ, 1989, BIOCHEM BIOPH RES CO, V159, P95, DOI 10.1016/0006-291X(89)92409-1; Song CS, 1999, MOL ENDOCRINOL, V13, P1487, DOI 10.1210/me.13.9.1487; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; SUPAKAR PC, 1993, J BIOL CHEM, V268, P26400; Takane KK, 1996, MOL CELL ENDOCRINOL, V119, P83, DOI 10.1016/0303-7207(96)03800-2; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; Wang LG, 2001, CANCER RES, V61, P7544; Wang LG, 1997, CANCER RES, V57, P714; WANG LG, 1994, CELL GROWTH DIFFER, V5, P1243; White RD, 1997, EUR UROL, V31, P1; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zhou J, 2001, CANCER METAST REV, V20, P351, DOI 10.1023/A:1015504015302	50	49	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5175	5184		10.1038/sj.onc.1207654	http://dx.doi.org/10.1038/sj.onc.1207654			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15156193				2022-12-17	WOS:000222382500007
J	Zhang, ZQ; Wang, Y; Yao, RS; Li, J; Yan, Y; La Regina, M; Lemon, WL; Grubbs, CL; Lubet, RA; You, M				Zhang, ZQ; Wang, Y; Yao, RS; Li, J; Yan, Y; La Regina, M; Lemon, WL; Grubbs, CL; Lubet, RA; You, M			Cancer chemopreventive activity of a mixture of Chinese herbs (antitumor B) in mouse lung tumor models	ONCOGENE			English	Article						antitumor B; lung cancer; chemoprevention; A/J mice; transgenic mice; p53; Ink4a/Arf	BREAST-CANCER CELLS; FEMALE A/J MICE; BETA-SITOSTEROL; ALPHA-SUBUNITS; G13 PROTEINS; GREEN TEA; TUMORIGENESIS; CARCINOGENESIS; PHYTOSTEROLS; INHIBITION	Antitumor B (ATB), also known as Zeng Sheng Ping, is a Chinese herbal mixture composed of six plants. Previously, clinical studies have shown a significant chemopreventive efficacy of ATB against human esophageal and lung cancers. In the present study, A/J mice harboring a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf and treated with benzo[a] pyrene were used to investigate the chemopreventive effects of ATB on chemically induced lung tumorigenesis. Mice with various genotypes treated with ATB displayed a significant reduction in lung tumor multiplicity and tumor load. Treatment with ATB resulted in an approximately 40% decrease in tumor multiplicity and a 70% decrease in tumor load in both wild-type mice and in mice with a loss of the Ink4a/Arf tumor suppressor genes. Interestingly, ATB decreased tumor multiplicity and volume by 50 and 90%, respectively, in mice with a dominant-negative p53 and in mice with both a p53 mutation and deletion of Ink4a/Arf. Kras2 mutation analysis of the lung tumors revealed that tumors harbored mutations in the 12th codon of Kras2. There were no differences in either the incidence or types of mutations between tumors treated with or without ATB. Oligonucleotide array analysis revealed 284 genes that were differentially expressed in mouse lung tumors as compared to the normal lung, and it was found that 114 out of these 284 genes changed their expression toward the normal levels in tumors treated with ATB. Most of the genes modulated by ATB belong to several cellular signaling pathways, including Notch (Notch homolog 2, manic fringe homolog), growth factor (FGF intracellular-binding protein, PDGFalpha), G protein-Ras-MAPK (MAPK3, MAP3K4, rab3A, Rap1, RSG5, PKCh), ubiquitin- proteasome (CDC34, Cullin1, 26S proteasome), and apoptosis (BAD promoter, caspase 3). These results suggest that ATB is an effective chemopreventive against mouse lung tumorigenesis. Furthermore, ATB exhibited an enhanced inhibitory effect in animals harboring genetic alterations (Kras2, p53, and Ink4a/Arf), which are often seen in human lung adenocarcinomas.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Comparat Med, St Louis, MO 63110 USA; Univ Alabama, Chemoprevent Ctr, Dept Surg, Birmingham, AL 35295 USA; NCI, Chemoprevent Branch, Bethesda, MD 20892 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Washington University (WUSTL); University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, Campus Box 8109,660 S Euclid Ave, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu						Awad AB, 2001, NUTR CANCER, V40, P157, DOI 10.1207/S15327914NC402_12; Awad AB, 2000, J NUTR, V130, P2127, DOI 10.1093/jn/130.9.2127; Awad AB, 2000, ANTICANCER RES, V20, P821; Awad AB, 2000, NUTR CANCER, V36, P74, DOI 10.1207/S15327914NC3601_11; Awad AB, 2000, INT J MOL MED, V5, P541; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Castonguay A, 1998, EXP LUNG RES, V24, P605, DOI 10.3109/01902149809087389; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fan X, 1993, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V15, P71; Hansen H H, 1999, Cancer Chemother Biol Response Modif, V18, P336; LIN P, 1990, Proceedings of the Chinese Academy of Medical Sciences and the Peking Union Medical College, V5, P121; Markel P, 1997, NAT GENET, V17, P280, DOI 10.1038/ng1197-280; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Minna JD, 1989, CANCER PRINCIPLES PR, P591; MORSE MA, 1991, CANCER RES, V51, P1846; RAICHT RF, 1980, CANCER RES, V40, P403; RAO AV, 1992, NUTR CANCER, V18, P43, DOI 10.1080/01635589209514203; SHI ST, 1994, CANCER RES, V54, P4641; von Holtz RL, 1998, NUTR CANCER, V32, P8, DOI 10.1080/01635589809514709; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wang Y, 2003, CANCER RES, V63, P4389; Wattenberg LW, 1996, CANCER RES, V56, P5132; Wattenberg LW, 1997, CARCINOGENESIS, V18, P2015, DOI 10.1093/carcin/18.10.2015; You M, 1998, HEMATOL ONCOL CLIN N, V12, P1037, DOI 10.1016/S0889-8588(05)70040-X; Zhang ZQ, 2003, ONCOGENE, V22, P6257, DOI 10.1038/sj.onc.1206630; Zhang ZQ, 2000, CANCER RES, V60, P901; Zhang ZQ, 2002, ONCOGENE, V21, P5960, DOI 10.1038/sj.onc.1205725	29	49	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3841	3850		10.1038/sj.onc.1207496	http://dx.doi.org/10.1038/sj.onc.1207496			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021904				2022-12-17	WOS:000221242500011
J	Kumari, A; Schultz, N; Helleday, T				Kumari, A; Schultz, N; Helleday, T			p53 protects from replication-associated DNA double-strand breaks in mammalian cells	ONCOGENE			English	Article						RAD51; p53; mouse embryonic fibroblasts; stalled DNA replication forks; DNA double-strand breaks; etoposide; hydroxyurea; thymidine	WILD-TYPE P53; INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; DEOXYRIBONUCLEOSIDE TRIPHOSPHATE POOLS; HOLLIDAY JUNCTIONS; MUTANT P53; SYNAPTONEMAL COMPLEXES; EMBRYONIC LETHALITY; HUMAN RAD51; C-ABL; DAMAGE	Genetic instability caused by mutations in the p53 gene is generally thought to be due to a loss of the DNA damage response that controls checkpoint functions and apoptosis. Cells with mutant p53 exhibit high levels of homologous recombination (HR). This could be an indirect consequence of the loss of DNA damage response or p53 could have a direct role in HR. Here, we report that p53-/- mouse embryonic fibroblasts (MEFs) exhibit higher levels of the RAD51 protein and increased level of spontaneous RAD51 foci Agents that stall replication forks, for example, hydroxyurea (HU), potently induce HR repair and RAD51 foci. To test if the increase in RAD51 foci in p53-/- MEFs was due to an increased level of damage during replication, we measured the formation of DNA double-strand breaks (DSBs) in p53+/+ and p53-/- MEFs following treatments with HU. We found that HU induced DSBs only in p53-/- MEFs, indicating that p53 is involved in a pathway to protect stalled replication forks from being collapsed into a substrate for HR. Also, p53 is upregulated in response to agents that inhibit DNA replication, which supports our hypothesis. Finally, we observed that the DSBs produced in p53-/- MEFs did not result in a permanent arrest of replication and that they were repaired. Altogether, we suggest that the effect of p53 on HR and RAD51 levels and foci can be explained by the idea that p53 suppresses formation of recombinogenic lesions.	Univ Sheffield, Sch Med, Inst Canc Studies, Sheffield S10 2RX, S Yorkshire, England; Stockholm Univ, Arrhenius Lab, Dept Genet & Cellular Toxicol, S-10691 Stockholm, Sweden	University of Sheffield; Stockholm University	Helleday, T (corresponding author), Univ Sheffield, Sch Med, Inst Canc Studies, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	t.helleday@sheffield.ac.uk	Helleday, Thomas/D-5224-2013; Schultz, Niklas/AFQ-8244-2022	Helleday, Thomas/0000-0002-7384-092X				Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BIANCHI V, 1986, J BIOL CHEM, V261, P6037; BJURSELL G, 1973, J BIOL CHEM, V248, P3904; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Chehab NH, 2000, GENE DEV, V14, P278; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; Cox MM, 2001, ANNU REV GENET, V35, P53, DOI 10.1146/annurev.genet.35.102401.090016; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; Flygare J, 1998, FEBS LETT, V427, P247, DOI 10.1016/S0014-5793(98)00433-5; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Huang YY, 1999, MOL CELL BIOL, V19, P2986; Janz C, 2002, ONCOGENE, V21, P2130, DOI 10.1038/sj.onc.1205292; Janz C, 2002, ONCOGENE, V21, P5929, DOI 10.1038/sj.onc.1205757; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Lundin C, 2003, J MOL BIOL, V328, P521, DOI 10.1016/S0022-2836(03)00313-9; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Raderschall E, 2002, J CELL SCI, V115, P153; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Shieh SY, 2000, GENE DEV, V14, P289; Shu ZG, 1999, MOL CELL BIOL, V19, P8686; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Strumberg D, 2000, MOL CELL BIOL, V20, P3977, DOI 10.1128/MCB.20.11.3977-3987.2000; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Subramanian D, 2002, NUCLEIC ACIDS RES, V30, P2427, DOI 10.1093/nar/30.11.2427; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Taylor WR, 1999, ONCOGENE, V18, P283, DOI 10.1038/sj.onc.1202516; Willers H, 2000, INT J RADIAT BIOL, V76, P1055; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; Zhang H, 1999, CANCER RES, V59, P3021; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5	46	49	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2324	2329		10.1038/sj.onc.1207379	http://dx.doi.org/10.1038/sj.onc.1207379			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14743204				2022-12-17	WOS:000220427700006
J	Al-Mohanna, MA; Manogaran, PS; Al-Mukhalafi, Z; Al-Hussein, KA; Aboussekhra, A				Al-Mohanna, MA; Manogaran, PS; Al-Mukhalafi, Z; Al-Hussein, KA; Aboussekhra, A			The tumor suppressor p16(INK4a) gene is a regulator of apoptosis induced by ultraviolet light and cisplatin	ONCOGENE			English	Article						apoptosis; Bax; cisplatin; p16(INK4a); UV damage	CELL-CYCLE ARREST; P53-DEPENDENT APOPTOSIS; BAX EXPRESSION; RNA-POLYMERASE; GROWTH ARREST; DNA-REPAIR; P53; BCL-2; SKIN; P16(CDKN2A)	p16(INK4a) (hereafter referred to as p16), a major cyclin-dependent kinase (CDK) inhibitor, is the product of a tumor-suppressor gene that has been found inactivated in different cancer types. In the present study, we sought to investigate the role of p16 in apoptosis induced by ultraviolet light (the most important etiological cause of skin cancer) and cisplatin (an anticancer DNA damaging agent). It is clearly shown that p16-compromised osteosarcoma U2OS cell line and p16-/- mouse embryo fibroblasts are sensitive to UV-induced apoptosis, as compared to their respective isogenic p16-expressing cells (EH1, EH2) and p16 +/+, indicating that p16 protects cells from undergoing apoptosis in response to UV light. Importantly, this reduction in UV-mediated apoptosis was associated with downregulation of the proapoptotic Bax protein, with no effect on Bcl-2 expression, suggesting that this antiapoptotic role of p16 is mediated via the intrinsic-mitochondrial pathway. On the other hand, p16 sensitized cells to cisplatin-mediated apoptosis through Bcl-2 decline. Interestingly, only proliferating but not G1-arrested EH1 cells underwent apoptosis in response to the anticancer drug. These novel findings provide further insight into the role of p16 in carcinogenesis, and has potential implications for future therapy strategies.	King Faisal Specialist Hosp & Res Ctr, BMR, Riyadh 11211, Saudi Arabia	King Faisal Specialist Hospital & Research Center	Aboussekhra, A (corresponding author), King Faisal Specialist Hosp & Res Ctr, BMR, MBC 03,POB 3354, Riyadh 11211, Saudi Arabia.	aboussekhra@kfshrc.edu.sa						Abrahams PJ, 1998, MUTAT RES-DNA REPAIR, V407, P189, DOI 10.1016/S0921-8777(98)00009-3; Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; Al-Mohanna MA, 2001, CARCINOGENESIS, V22, P573, DOI 10.1093/carcin/22.4.573; Allan LA, 1999, ONCOGENE, V18, P5403, DOI 10.1038/sj.onc.1202931; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Amundson SA, 2000, CANCER RES, V60, P6101; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; Canman CE, 1998, ONCOGENE, V16, P957, DOI 10.1038/sj.onc.1201612; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; EVANS DL, 1994, CANCER RES, V54, P1596; Gonzalez VM, 2001, MOL PHARMACOL, V59, P657, DOI 10.1124/mol.59.4.657; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Grim J, 1997, CLIN CANCER RES, V3, P2415; Haluska FG, 1998, J CLIN ONCOL, V16, P670, DOI 10.1200/JCO.1998.16.2.670; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Katsuda K, 2002, ONCOGENE, V21, P2108, DOI 10.1038/sj.onc.1205272; Ljungman M, 1996, ONCOGENE, V13, P823; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; Milligan A, 1998, MUTAT RES-FUND MOL M, V422, P43, DOI 10.1016/S0027-5107(98)00174-2; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Moriwaki SI, 1997, CANCER RES, V57, P4637; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Pavey S, 1999, CANCER RES, V59, P4185; Pavey S, 2002, CANCER RES, V62, P875; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; SORENSON CM, 1988, CANCER RES, V48, P4484; SORENSON CM, 1988, CANCER RES, V48, P6703; Stone S, 1996, CANCER RES, V56, P3199; Tamm I, 2002, CANCER GENE THER, V9, P641, DOI 10.1038/sj.cgt.7700480; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; Zornig M., 2001, BIOCHIM BIOPHYS ACTA, V1551, P1	49	49	54	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					201	212		10.1038/sj.onc.1206927	http://dx.doi.org/10.1038/sj.onc.1206927			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712225				2022-12-17	WOS:000187895300021
J	Wu, YZ; Diab, I; Zhang, XP; Izmailova, ES; Zehner, ZE				Wu, YZ; Diab, I; Zhang, XP; Izmailova, ES; Zehner, ZE			Stat3 enhances vimentin gene expression by binding to the antisilencer element and interacting with the repressor protein, ZBP-89	ONCOGENE			English	Article						Stat3; ZBP-89; Sp1; repressor; activator	TRANSCRIPTION FACTOR ZBP-89; BREAST-CANCER CELLS; ZINC-FINGER PROTEIN; C-JUN; GROWTH-REGULATION; TUMOR-CELLS; PROMOTER; ACTIVATION; SP1; IDENTIFICATION	Vimentin exhibits a complex pattern of developmental- and tissue-specific expression and is aberrantly expressed in most metastatic tumors. The human vimentin promoter contains multiple DNA elements, some of which enhance gene expression and one that inhibits. A silencer element (at -319) binds the repressor ZBP-89. Further upstream (at <LF>-757) is an element, which acts positively in the presence of the silencer element and, thus, is referred to as an antisilencer (ASE). Previously, we showed that Stat1alpha binds to this element upon induction by IFN-gamma. However, substantial binding and reporter gene activity was still present in nontreated cells. Here, we have found that Stat3 binds to the ASE element in vitro. Transfection experiments in COS-1 cells with various vimentin promoter-reporter constructs show that gene activity is dependent upon the cotransfection and activation of Stat3. Moreover, activated Stat3 can overcome ZBP-89 repression. Coimmunoprecipitation studies demonstrate that Stat3 and ZBP-89 can interact and confocal microscopy detects these factors to be colocalized in the nucleus. Moreover, a correlation exists between the presence of activated Stat3 and vimentin expression in MDA-MB-231 cells, which is lacking in MCF7 cells where vimentin is not expressed. In the light of these results, we propose that the interaction of Stat3 and ZBP-89 may be crucial for overcoming the effects of the repressor ZBP-89, which suggests a novel mode for Stat3 gene activation.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Zehner, ZE (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA.	zezehner@vcu.edu		Izmailova, Elena/0000-0002-7150-1748; Diab, Iman/0000-0002-4017-5804	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045422] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45422] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bai LC, 2000, J BIOL CHEM, V275, P30725, DOI 10.1074/jbc.M004249200; Bai LG, 2001, MOL CELL BIOL, V21, P4670, DOI 10.1128/MCB.21.14.4670-4683.2001; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; BUSSEMAKERS MJG, 1992, BIOCHEM BIOPH RES CO, V182, P1254, DOI 10.1016/0006-291X(92)91866-O; CAREY I, 1995, CELL GROWTH DIFFER, V6, P899; Chen JH, 1996, ONCOGENE, V13, P1667; Cheng PY, 2000, BIOCHEMISTRY-US, V39, P4347, DOI 10.1021/bi992298f; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dobretsova A, 1999, J NEUROCHEM, V72, P2227, DOI 10.1046/j.1471-4159.1999.0722227.x; DUPREY P, 1995, INT J DEV BIOL, V39, P443; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FRANKE WW, 1979, EXP CELL RES, V123, P25, DOI 10.1016/0014-4827(79)90418-X; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gilles C, 2003, CANCER RES, V63, P2658; GILLES C, 1996, BREAST J, V2, P83; Hasegawa T, 1999, BIOCHEM BIOPH RES CO, V256, P249, DOI 10.1006/bbrc.1999.0275; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; HSIEH TC, 1995, EXP CELL RES, V218, P137, DOI 10.1006/excr.1995.1140; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Izmailova ES, 1999, GENE, V235, P69, DOI 10.1016/S0378-1119(99)00209-7; Izmailova ES, 1999, GENE, V230, P111, DOI 10.1016/S0378-1119(99)00046-3; Izmailova ES, 2000, J INTERF CYTOK RES, V20, P13, DOI 10.1089/107999000312694; Keates AC, 2001, J BIOL CHEM, V276, P43713, DOI 10.1074/jbc.M107838200; Law DJ, 1998, MAMM GENOME, V9, P165, DOI 10.1007/s003359900711; Law GL, 1998, J BIOL CHEM, V273, P19955, DOI 10.1074/jbc.273.32.19955; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LILIENBAUM A, 1993, J BIOL CHEM, V268, P2180; Lim CP, 2001, J BIOL CHEM, V276, P21004, DOI 10.1074/jbc.M007592200; Malone CS, 2001, GENE, V268, P9, DOI 10.1016/S0378-1119(01)00430-9; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; Meyer T, 2002, EXP CELL RES, V272, P45, DOI 10.1006/excr.2001.5405; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; PARRY D A D, 1992, Current Opinion in Cell Biology, V4, P94, DOI 10.1016/0955-0674(92)90064-J; Passantino R, 1998, J BIOL CHEM, V273, P484, DOI 10.1074/jbc.273.1.484; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Remington MC, 1997, BIOCHEM BIOPH RES CO, V237, P230, DOI 10.1006/bbrc.1997.7119; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; RITTLING SR, 1987, MOL CELL BIOL, V7, P3908, DOI 10.1128/MCB.7.11.3908; RITTLING SR, 1989, NUCLEIC ACIDS RES, V17, P1619, DOI 10.1093/nar/17.4.1619; SALVETTI A, 1993, MOL CELL BIOL, V13, P89, DOI 10.1128/MCB.13.1.89; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Sehgal PB, 2000, CELL SIGNAL, V12, P525, DOI 10.1016/S0898-6568(00)00098-X; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SOMMERS CL, 1989, CANCER RES, V49, P4258; SOMMERS CL, 1992, CANCER RES, V52, P190; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STOVER DM, 1992, MOL CELL BIOL, V12, P2230, DOI 10.1128/MCB.12.5.2230; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; Wieczorek E, 2000, J BIOL CHEM, V275, P12879, DOI 10.1074/jbc.275.17.12879; Wu YZ, 2003, ONCOGENE, V22, P8891, DOI 10.1038/sj.onc.1206898; Yamada A, 2001, J BIOL CHEM, V276, P18082, DOI 10.1074/jbc.M008387200; Ye S, 1999, FEBS LETT, V450, P268, DOI 10.1016/S0014-5793(99)00509-8; Yoo JY, 2001, J BIOL CHEM, V276, P26421, DOI 10.1074/jbc.M009935200; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhang XP, 2003, NUCLEIC ACIDS RES, V31, P2900, DOI 10.1093/nar/gkg380	63	49	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					168	178		10.1038/sj.onc.1207003	http://dx.doi.org/10.1038/sj.onc.1207003			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712222				2022-12-17	WOS:000187895300018
J	Zhou, MX; Gu, LB; Zhu, NX; Woods, WG; Findley, HW				Zhou, MX; Gu, LB; Zhu, NX; Woods, WG; Findley, HW			Transfection of a dominant-negative mutant NF-kappa B inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53	ONCOGENE			English	Article						IkB; p53; apoptosis; leukemia	CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTORS; CANCER-CELLS; ALPHA; DEGRADATION; EXPRESSION; RESISTANCE; LYMPHOMA; GROWTH; PROLIFERATION	To investigate the possible role of inhibiting NF-kB activation in sensitizing tumor cells to chemotherapy-induced apoptosis, we transfected the dominant-negative mutant inhibitor of NF-kB (IkBm) into the EU-1 cell line, an acute lymphoblastic leukemia (ALL) line with constitutive NF-kB activation. Overexpression of IkBm significantly reduced constitutive NF-kB activity in EU-1 cells, resulting in decreased cell growth. In response to apoptosis induced by chemotherapeutic drugs, IkBm-transfected cells (EU-1/IkBm) exhibited increased sensitivity to vincristine (VCR), whereas sensitivity to doxorubicin (Dox) was not changed as compared to neo-transfected control (EU-1/neo) cells. To further evaluate the link between IkBm and sensitivity to Dox and VCR, we demonstrated that both endogenous IkBalpha and ectopic IkBm bind to p53. In response to Dox, the cytosolic p53. IkBalpha complex rapidly dissociated due to downregulation of IkBalpha. However, the p53. IkBm complex did not dissociate under these conditions. Although treatment of EU-1/IkBm cells with Dox increased the expression of p53, the nondissociating p53. IkBm complex resulted in decreased p53 function, as demonstrated by absence of cell-cycle arrest and induction of p53 target genes. Contrastingly, VCR-induced cell death neither down-regulated IkBalpha nor induced p53, as shown by the lack of NF-kB activation and p53-mediated gene expression in VCR-treated cells. Our data suggest that IkBm simultaneously downregulates NF-kB activation and sequesters p53 in the cytoplasm, thus enhancing NF-kB-regulated apoptosis but blocking p53-dependent apoptosis.	Emory Univ, Sch Med, Div Pediat Hematol Oncol BMT, Dept Pediat, Atlanta, GA 30322 USA	Emory University	Zhou, MX (corresponding author), Emory Univ, Sch Med, Div Pediat Hematol Oncol BMT, Dept Pediat, 2040 Ridgewood Dr NE, Atlanta, GA 30322 USA.	mzhou@emory.edu			NATIONAL CANCER INSTITUTE [R01CA082323] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA82323] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Bentires-Alj M, 1999, CANCER RES, V59, P811; Chandra J, 1998, BLOOD, V92, P4220, DOI 10.1182/blood.V92.11.4220.423k49_4220_4229; Chang NS, 2002, J BIOL CHEM, V277, P10323, DOI 10.1074/jbc.M106607200; Conway RM, 1998, EUR J CANCER, V34, P1741, DOI 10.1016/S0959-8049(98)00234-2; Doerre S, 1999, J IMMUNOL, V163, P269; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; Findley HW, 1997, BLOOD, V89, P2986, DOI 10.1182/blood.V89.8.2986; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Groninger E, 2000, BRIT J HAEMATOL, V111, P875, DOI 10.1046/j.1365-2141.2000.02420.x; Gugasyan R, 2000, IMMUNOL REV, V176, P134; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; HWANG S, 1995, CANCER BIOCHEM BIOPH, V14, P265; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; JORDAN MA, 1991, CANCER RES, V51, P2212; Kawai H, 1999, CANCER RES, V59, P6038; Kordes U, 2000, LEUKEMIA, V14, P399, DOI 10.1038/sj.leu.2401705; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Lorenzo E, 2002, J BIOL CHEM, V277, P10883, DOI 10.1074/jbc.M107442200; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Orlowski RZ, 1998, CANCER RES, V58, P4342; Post A, 1998, J NEUROSCI, V18, P8236; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schauer SL, 1998, J IMMUNOL, V160, P4398; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; VAN AD, 1996, SCIENCE, V274, P787; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WU HY, 1994, J BIOL CHEM, V269, P20067; ZHOU MX, 1994, LEUKEMIA, V8, P659	45	49	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8137	8144		10.1038/sj.onc.1206911	http://dx.doi.org/10.1038/sj.onc.1206911			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603254				2022-12-17	WOS:000186403400008
J	Chauhan, D; Li, GL; Sattler, M; Podar, K; Mitsiades, C; Mitsiades, N; Munshi, N; Hideshima, T; Anderson, KC				Chauhan, D; Li, GL; Sattler, M; Podar, K; Mitsiades, C; Mitsiades, N; Munshi, N; Hideshima, T; Anderson, KC			Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells	ONCOGENE			English	Article						multiple myeloma; apoptosis; superoxide; cytochrome c; Smac (second mitochondrial activator of caspases); 2-methoxyestradiol; dexamethasone	MEDIATED APOPTOSIS; CANCER-CELLS; CYTOCHROME-C; ACTIVATION; RESISTANCE; INDUCTION; MECHANISM; PROTEIN; SMAC	Superoxide (O-2(-)) radicals have been linked to apoptosis. Here, we show that 2-methoxyestradiol (2ME2)-induced apoptosis in multiple myeloma ( MM) cells is associated with O-2(-) generation, whereas dexamethasone (Dex)induced apoptosis occurs without concurrent increase in O-2(-). In contrast, both these agents decrease mitochondrial transmembrane potential (Deltapsi(m)). Treatment of MM cells with an antioxidant N-acetyl-L-cysteine blocks 2ME2, but not Dex-induced apoptosis as well as release of mitochondrial proteins cytochrome c (cyto c) and Smac. Taken together, these results demonstrate that there are at least two distinct apoptotic pathways: one dependent on O-2(-), which is induced by 2ME2 and is associated with release of cyto c and Smac; and the other an independent of O-2(-), which is triggered by Dex and associated with Smac release.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Anderson, KC (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02215 USA.		Podar, Klaus/ABD-1112-2020; Munshi, Nikhil/ABE-2338-2021	Podar, Klaus/0000-0002-7414-3632; 	NCI NIH HHS [CA 78373] Funding Source: Medline; PHS HHS [50947] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bossy-Wetzel E, 1999, MUTAT RES-DNA REPAIR, V434, P243, DOI 10.1016/S0921-8777(99)00032-4; Chauhan D, 2002, BLOOD, V100, P2187, DOI 10.1182/blood-2002-02-0376; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; Ding M, 2002, MOL CELL BIOCHEM, V234, P81, DOI 10.1023/A:1015901232124; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Du J, 2001, FREE RADICAL BIO MED, V31, P469, DOI 10.1016/S0891-5849(01)00611-6; Dussmann H, 2003, J BIOL CHEM, V278, P12645, DOI 10.1074/jbc.M210826200; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Li NY, 2003, FREE RADICAL BIO MED, V34, P465, DOI 10.1016/S0891-5849(02)01325-4; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Matsuyama S, 2000, CELL DEATH DIFFER, V7, P1155, DOI 10.1038/sj.cdd.4400779; Ng CP, 2002, PROSTATE, V53, P286, DOI 10.1002/pros.10155; Poot M, 1999, CYTOMETRY, V35, P311, DOI 10.1002/(SICI)1097-0320(19990401)35:4<311::AID-CYTO3>3.3.CO;2-5; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang ZL, 1999, CANCER RES, V59, P1259; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	23	49	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6296	6300		10.1038/sj.onc.1206734	http://dx.doi.org/10.1038/sj.onc.1206734			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679868				2022-12-17	WOS:000185506200019
J	Rippe, V; Drieschner, N; Meiboom, M; Escobar, HM; Bonk, U; Belge, G; Bullerdiek, J				Rippe, V; Drieschner, N; Meiboom, M; Escobar, HM; Bonk, U; Belge, G; Bullerdiek, J			Identification of a gene rearranged by 2p21 aberrations in thyroid adenomas	ONCOGENE			English	Article						2p21 aberrations; thyroid adenomas; THADA; fusion gene	CYTOGENETIC FINDINGS; TUMORS; TRANSLOCATION; 19Q13	Thyroid adenomas belong to the cytogenetically best investigated human epithelial tumors. Cytogenetic studies of about 450 benign lesions allow one to distinguish between different cytogenetic subgroups. Two chromosomal regions, that is, 19q13 and 2p21, are frequently rearranged in these tumors. Although 2p21 aberrations only account for about 10% of the benign thyroid tumors with clonal cytogenetic deviations, 2p21 rearrangements belong to the most common cytogenetic rearrangements in epithelial tumors due to the high frequency of these benign lesions. The 2p21 breakpoint region recently has been delineated to a region of 450 kbp, but the gene affected by the cytogenetic rearrangements still has escaped detection. Positional cloning and 3' RACE-PCR allowed us to clone that gene which we will refer to as thyroid adenoma associated (THADA) gene. In cells from two thyroid adenomas characterized by translocations t(2;20;3) (p21;q11.2;p25) and t(2;7)(p21;p15), respectively, we performed 3'-RACE-PCRs and found two fusions of THADA with a sequence derived from chromosome band 3p25 or with a sequence derived from chromosome band 7p15. The THADA gene spans roughly 365 kbp and, based on preliminary results, encodes a death receptor-interacting protein.	Univ Bremen, Ctr Human Genet, D-28359 Bremen, Germany; Cent Hosp Bremen Nord, Inst Pathol, Bremen, Germany	University of Bremen	Bullerdiek, J (corresponding author), Univ Bremen, Ctr Human Genet, Leobener Str ZHG, D-28359 Bremen, Germany.	bullerdiek@uni-breinen.de	Murua Escobar, Hugo/A-1294-2012; Rippe, Volkhard/I-1927-2013	Rippe, Volkhard/0000-0001-8758-6013				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARTNITZKE S, 1989, CANCER GENET CYTOGEN, V39, P65, DOI 10.1016/0165-4608(89)90230-6; BELGE G, 1992, CELL BIOL INT REP, V16, P339, DOI 10.1016/S0309-1651(06)80139-6; Belge G, 1998, CANCER GENET CYTOGEN, V101, P42, DOI 10.1016/S0165-4608(97)00057-5; Belge G, 2001, CYTOGENET CELL GENET, V93, P48, DOI 10.1159/000056947; Berner JM, 1997, ONCOGENE, V14, P2935, DOI 10.1038/sj.onc.1201135; Bol S, 2001, CYTOGENET CELL GENET, V95, P189, DOI 10.1159/000059344; Bol S, 1999, CANCER GENET CYTOGEN, V114, P75, DOI 10.1016/S0165-4608(99)00028-X; BONDESON L, 1989, CANCER, V64, P680, DOI 10.1002/1097-0142(19890801)64:3<680::AID-CNCR2820640319>3.0.CO;2-I; BULLERDIEK J, 1987, CANCER GENET CYTOGEN, V24, P205, DOI 10.1016/0165-4608(87)90100-2; DALCIN P, 1992, CANCER GENET CYTOGEN, V60, P99, DOI 10.1016/0165-4608(92)90244-3; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; KIEVITS T, 1990, CYTOGENET CELL GENET, V53, P134, DOI 10.1159/000132913; Rippe V, 1999, GENE CHROMOSOME CANC, V26, P229, DOI 10.1002/(SICI)1098-2264(199911)26:3<229::AID-GCC7>3.0.CO;2-J; TEYSSIER JR, 1990, CANCER GENET CYTOGEN, V50, P249, DOI 10.1016/0165-4608(90)90184-C	16	49	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6111	6114		10.1038/sj.onc.1206867	http://dx.doi.org/10.1038/sj.onc.1206867			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955091				2022-12-17	WOS:000185137800021
J	Guerra, B; Issinger, OG; Wang, JYJ				Guerra, B; Issinger, OG; Wang, JYJ			Modulation of human checkpoint kinase Chk1 by the regulatory beta-subunit of protein kinase CK2	ONCOGENE			English	Article						protein kinase CK2; Chk1; protein phosphorylation	DNA-DAMAGE CHECKPOINT; KAPPA-B-ALPHA; CRYSTAL-STRUCTURE; CASEIN KINASE-2; CELL-CYCLE; CK2-BETA SUBUNIT; FISSION YEAST; PHOSPHORYLATION; PROLIFERATION; ADAPTATION	Protein kinase CK2 is a serine/threonine protein kinase involved in various aspects of cellular regulation. The regulatory beta-subunit of CK2 exerts a central role not only in mediating formation of tetrameric CK2 complexes but also as a docking partner for several protein kinases. In this study, CK2beta is found to interact with the human cell cycle checkpoint kinase Chk1. The Chk1-interacting region of CK2beta is localized at the C-terminus and the complex between CK2beta and Chk1 is devoid of the catalytic CK2alpha-subunit. The interaction between CK2beta and Chk1 leads to an increase in the Cdc25C phosphorylation activity of Chk1. The screening of several cell lines has revealed that the association between CK2beta and Chk1 also occurs in vivo at a different degree. Collectively, these studies confirm the implication of the regulatory beta-subunit of protein kinase CK2 in cell cycle regulation and identify a novel mechanism for the activation of Chk1 protein kinase.	Univ Calif San Diego, Div Biol Sci 0322, La Jolla, CA 92093 USA; Univ So Denmark, Inst Biochem & Mol Biol, DK-5230 Odense, Denmark	University of California System; University of California San Diego; University of Southern Denmark	Guerra, B (corresponding author), Univ Calif San Diego, Div Biol Sci 0322, La Jolla, CA 92093 USA.			Guerra, Barbara/0000-0003-1136-2413	NCI NIH HHS [R01 CA043054, CA43054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043054, R37CA043054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; BOLDYREFF B, 1993, BIOCHEMISTRY-US, V32, P12672, DOI 10.1021/bi00210a016; Bren GD, 2000, J MOL BIOL, V297, P1245, DOI 10.1006/jmbi.2000.3630; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; Graham KC, 2000, J BIOL CHEM, V275, P5003, DOI 10.1074/jbc.275.7.5003; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Hagemann C, 1997, FEBS LETT, V403, P200, DOI 10.1016/S0014-5793(97)00011-2; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; Liu QH, 2000, GENE DEV, V14, P1448; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; Niefind K, 1998, EMBO J, V17, P2451, DOI 10.1093/emboj/17.9.2451; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Takai H, 2000, GENE DEV, V14, P1439; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Zhang CJ, 2002, ONCOGENE, V21, P3754, DOI 10.1038/sj.onc.1205467; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	28	49	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					4933	4942		10.1038/sj.onc.1206721	http://dx.doi.org/10.1038/sj.onc.1206721			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902976				2022-12-17	WOS:000184578900001
J	Aboulkassim, TO; LaRue, H; Lemieux, P; Rousseau, F; Fradet, Y				Aboulkassim, TO; LaRue, H; Lemieux, P; Rousseau, F; Fradet, Y			Alteration of the PATCHED locus in superficial bladder cancer	ONCOGENE			English	Article						chromosome 9; LOH; bladder cancer tumour-suppressor gene; PATCHED gene; RT-PCR	BASAL-CELL CARCINOMAS; FANCONI-ANEMIA POLYPEPTIDE; TUMOR-SUPPRESSOR; HUMAN HOMOLOG; SIGNALING PATHWAY; SONIC HEDGEHOG; GENE; CANDIDATE; CHROMOSOME-9; MICE	Chromosome 9 alterations are the most frequently encountered cytologic anomalies in urothelial carcinoma (UC). We previously screened 139 low-stage UCs for loss of heterozygosity on chromosome 9, and identified five distinct regions likely to harbour tumour-suppressor genes. The present study focused on deletion mapping in the 9q22 region with 11 additional microsatellite markers. New deletions in the 9q22 region were found in five tumours. Deletion mapping allowed us to identify a 0.5 CM common minimal region of deletion between markers D9S280 and D9S1809, encompassing PATCHED (PTC), a gene identified as a tumour suppressor in basal cell carcinoma and in medulloblastoma. A marker located in the first intron of this gene showed the highest percentage of deletion (45%). cDNA sequencing in 15 tumours with deletion of PTC showed no mutation in the remaining allele. However, average expression of PTC mRNA measured by semiquantitative RT-PCR was significantly decreased in tumours with LOH in the 9q22 region, compared to normal urothelium (P = 0.04), while it showed marked fluctuations in tumours without deletion. Our results suggest that the PTC gene is a putative suppressor at the 9q22 locus and that haploinsufficiency of this gene may be an early event in the development of papillary bladder tumours.	Univ Laval, Hotel Dieu, Ctr Rech & Cancerol, Quebec City, PQ G1K 7P4, Canada; CHU Quebec, Hop St Francois Assise, Unite Rech Genet Humaine & Mol, Quebec City, PQ, Canada	Laval University; Laval University	Fradet, Y (corresponding author), Univ Laval, Hotel Dieu, Ctr Rech & Cancerol, Quebec City, PQ G1K 7P4, Canada.			Fradet, Yves/0000-0002-7581-2500				Bale AE, 2001, HUM MOL GENET, V10, P757, DOI 10.1093/hmg/10.7.757; CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1993, CANCER RES, V53, P1230; Calzada-Wack J, 2002, CARCINOGENESIS, V23, P727, DOI 10.1093/carcin/23.5.727; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Czerniak B, 1999, ONCOGENE, V18, P1185, DOI 10.1038/sj.onc.1202385; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GIBSON RA, 1993, HUM MOL GENET, V2, P35, DOI 10.1093/hmg/2.1.35; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hornigold N, 1999, ONCOGENE, V18, P2657, DOI 10.1038/sj.onc.1202854; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kallassy M, 1997, CANCER RES, V57, P4731; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Kupfer GM, 1997, BLOOD, V90, P1047, DOI 10.1182/blood.V90.3.1047.1047_1047_1054; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Maurice D, 2001, J BIOL CHEM, V276, P43175, DOI 10.1074/jbc.M105895200; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Simoneau M, 1999, ONCOGENE, V18, P157, DOI 10.1038/sj.onc.1202277; Simoneau M, 2000, ONCOGENE, V19, P6317, DOI 10.1038/sj.onc.1204022; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TANAKA M, 1995, CANCER RES, V55, P3228; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8; Velickovic M, 2002, MODERN PATHOL, V15, P479, DOI 10.1038/modpathol.3880551; Wicking C, 1999, ONCOGENE, V18, P7844, DOI 10.1038/sj.onc.1203282; Wu Q, 1996, INT J CANCER, V65, P840, DOI 10.1002/(SICI)1097-0215(19960315)65:6<840::AID-IJC22>3.0.CO;2-6; Xie JW, 1997, CANCER RES, V57, P2369; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P6712, DOI 10.1073/pnas.91.14.6712; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847; Zurawel RH, 2000, GENE CHROMOSOME CANC, V28, P77, DOI 10.1002/(SICI)1098-2264(200005)28:1<77::AID-GCC9>3.0.CO;2-Y	35	49	58	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2967	2971		10.1038/sj.onc.1206513	http://dx.doi.org/10.1038/sj.onc.1206513			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771948				2022-12-17	WOS:000182824800012
J	Alisi, A; Giambartolomei, S; Cupelli, F; Merlo, P; Fontemaggi, G; Spaziani, A; Balsano, C				Alisi, A; Giambartolomei, S; Cupelli, F; Merlo, P; Fontemaggi, G; Spaziani, A; Balsano, C			Physical and functional interaction between HCV core protein and the different p73 isoforms	ONCOGENE			English	Article						HCV; core p53; p73; p21(WAF1/CIP1); HCC	HEPATITIS-C VIRUS; KAPPA-B ACTIVATION; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTIONAL ACTIVITY; P53-RELATED PROTEIN; HUMAN HEPATOCYTES; RNA HELICASE; DNA-BINDING; P53; APOPTOSIS	Hepatitis C virus (HCV) core protein is a structural viral protein that packages the viral genomic RNA. In addition to this function, HCV core also modulates a number of cellular regulatory functions. In fact, HCV core protein has been found to modulate the expression of the cyclin-dependent inhibitor p21(WAF1/CIP1) and to promote both apoptosis and cell proliferation through its physical interaction with p53. Here, we studied the ability of HCV core to bind the p53-related p73 protein, its isoforms and its deletion mutants. We found that HCV core co-immunoprecipitated with p73 in HepG2 and SAOS-2 cells. Deletion mutational analysis of p73 indicates that the domain involved in HCV core binding is located between amino-acid residues 321-353. We also demonstrate that p73/core interaction results in the nuclear translocation of HCV core protein either in the presence of the p73 or or p73 beta tumor-suppressor proteins. In addition, the interaction with HCV core protein prevents p73 alpha, but not p73 beta dependent cell growth arrest in a p53-dependent manner. Our findings demonstrate that HCV core protein may directly influence the various p73 functions, thus playing a role in HCV pathogenesis.	Fdn Andrea Cesalpino, Med Clin 1, I-00161 Rome, Italy; Univ Aquila, Dip MISP, I-67100 Laquila, Italy; Regina Elena Inst Canc Res, I-00158 Rome, Italy	University of L'Aquila; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Balsano, C (corresponding author), Policlin Umberto 1, Med Clin 1, Viale Policlin 155, I-00161 Rome, Italy.		Merlo, Paola/K-5330-2014; Fontemaggi, Giulia/K-9702-2016; Balsano, Clara/AAK-9870-2020; Alisi, Anna/A-6469-2010	Merlo, Paola/0000-0003-0105-7044; Fontemaggi, Giulia/0000-0001-8332-8842; Balsano, Clara/0000-0002-9615-7031; Alisi, Anna/0000-0001-7241-6329				Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Basu A, 2002, VIROLOGY, V298, P53, DOI 10.1006/viro.2002.1460; Colombo M, 1999, J HEPATOL, V31, P25, DOI 10.1016/S0168-8278(99)80370-5; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Francesco R, 1999, J HEPATOL, V31, P47, DOI 10.1016/S0168-8278(99)80374-2; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Giambartolomei S, 2001, ONCOGENE, V20, P2606, DOI 10.1038/sj.onc.1204372; Hayashi J, 1999, INTERVIROLOGY, V42, P205, DOI 10.1159/000024962; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kaida A, 2000, ONCOGENE, V19, P827, DOI 10.1038/sj.onc.1203387; Koike K, 2002, ONCOLOGY-BASEL, V62, P29, DOI 10.1159/000048273; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Lu W, 1999, VIROLOGY, V264, P134, DOI 10.1006/viro.1999.9979; Maillard P, 2001, J VIROL, V75, P8240, DOI 10.1128/JVI.75.17.8240-8250.2001; Mamiya N, 1999, J BIOL CHEM, V274, P15751, DOI 10.1074/jbc.274.22.15751; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Otsuka M, 2000, J BIOL CHEM, V275, P34122, DOI 10.1074/jbc.M000578200; Park KJ, 2002, J BIOL CHEM, V277, P13122, DOI 10.1074/jbc.M111599200; Prabhu NS, 1998, INT J ONCOL, V13, P5; Ray RB, 1996, VIROLOGY, V226, P176, DOI 10.1006/viro.1996.0644; Ray RB, 1998, GENE, V208, P331, DOI 10.1016/S0378-1119(98)00030-4; Ray RB, 2000, VIROLOGY, V271, P197, DOI 10.1006/viro.2000.0295; Reichelt M, 1999, ARCH VIROL, V144, P621, DOI 10.1007/s007050050530; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shi ST, 2002, VIROLOGY, V292, P198, DOI 10.1006/viro.2001.1225; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Takamatsu Manabu, 2001, Kobe Journal of Medical Sciences, V47, P97; TANNAPFEL A, 1999, J NATL CANCER I, V79, P164; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Tsutsumi T, 2002, HEPATOLOGY, V35, P937, DOI 10.1053/jhep.2002.32470; Uchida M, 2002, HEPATOL RES, V22, P297, DOI 10.1016/S1386-6346(02)00005-0; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Yamanaka T, 2002, BIOCHEM BIOPH RES CO, V294, P528, DOI 10.1016/S0006-291X(02)00508-9; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zemel R, 2002, DIGEST DIS SCI, V47, P716, DOI 10.1023/A:1014767311799; Zeng YX, 1996, ONCOGENE, V12, P1557; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	45	49	54	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2573	2580		10.1038/sj.onc.1206333	http://dx.doi.org/10.1038/sj.onc.1206333			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730672				2022-12-17	WOS:000182569000005
J	She, QB; Ma, WY; Wang, MF; Kaji, A; Ho, CT; Dong, ZG				She, QB; Ma, WY; Wang, MF; Kaji, A; Ho, CT; Dong, ZG			Inhibition of cell transformation by resveratrol and its derivatives: differential effects and mechanisms involved	ONCOGENE			English	Article						resveratrol; resveratrol derivatives; cell transformation; p53; PI-3K/Akt; chemoprevention	ACTIVATOR PROTEIN-1 ACTIVATION; PHOSPHATIDYLINOSITOL KINASE; APOPTOSIS; GROWTH; CHEMOPREVENTION; P53; PRODUCT; PATHWAY; ARREST; PHOSPHORYLATION	Resveratrol, a constituent of grapes and other foods, has been reported to be a potential cancer chemopreventive agent. Our previous study showed that the antitumor activity of resveratrol occurs through mitogen-activated protein kinases-mediated p53 activation and induction of apoptosis. To develop more effective agents with fewer side effects for the chemoprevention of cancer, we investigated the effect of resveratrol and its structurally related derivatives on epidermal growth factor (EGF)-induced cell transformation. Our results provided the first evidence that one of the resveratrol derivatives exerted a more potent inhibitory effect than resveratrol on EGF-induced cell transformation, but had less cytotoxic effects on normal nontransformed cells. Compared to resveratrol, this compound also caused cell cycle arrest in the G1 phase, but did not induce p53 activation and apoptosis. Furthermore, this compound, but not resveratrol, markedly inhibited EGF-induced phosphatidylinositol-3 kinase (PI-3K) and Akt activation. Collectively, these data suggested that the higher antitumor effect of the compound compared to resveratrol, may act through a different mechanism by mainly targeting PI-3K/Akt signaling pathways.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA	University of Minnesota System; Rutgers State University New Brunswick	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	Wang, Mingfu/AAT-3292-2021	Wang, Mingfu/0000-0003-1469-3963; She, Qing-Bai/0000-0002-7207-0599	NATIONAL CANCER INSTITUTE [R01CA077646, R01CA081064, R37CA081064] Funding Source: NIH RePORTER; NCI NIH HHS [CA77646, CA81064] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adhami VM, 2001, BIOCHEM BIOPH RES CO, V288, P579, DOI 10.1006/bbrc.2001.5819; Ahmad N, 2001, CLIN CANCER RES, V7, P1466; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Clement MV, 1998, BLOOD, V92, P996; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; COUGHLIN SR, 1989, SCIENCE, V243, P1191; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Della Ragione F, 1998, BIOCHEM BIOPH RES CO, V250, P53, DOI 10.1006/bbrc.1998.9263; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dong ZG, 1999, ANTICANCER RES, V19, P3743; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Hsieh TC, 1999, EXP CELL RES, V249, P109, DOI 10.1006/excr.1999.4471; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1997, CANCER RES, V57, P2873; Huang CS, 1997, P NATL ACAD SCI USA, V94, P11957, DOI 10.1073/pnas.94.22.11957; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; Kelloff GJ, 2000, J NUTR, V130, p467S, DOI 10.1093/jn/130.2.467S; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Park JW, 2001, CARCINOGENESIS, V22, P1633, DOI 10.1093/carcin/22.10.1633; Prives C, 1999, J PATHOL, V187, P112; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; She QB, 2000, FEBS LETT, V469, P163, DOI 10.1016/S0014-5793(00)01273-4; She QB, 2002, MOL CARCINOGEN, V33, P244, DOI 10.1002/mc.10041; She QB, 2001, CANCER RES, V61, P1604; Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Surh YJ, 1999, CANCER LETT, V140, P1, DOI 10.1016/S0304-3835(99)00039-7; Tsai SH, 1999, BRIT J PHARMACOL, V126, P673, DOI 10.1038/sj.bjp.0702357; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang MF, 1999, J AGR FOOD CHEM, V47, P3974, DOI 10.1021/jf990382w; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	38	49	53	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2143	2150		10.1038/sj.onc.1206370	http://dx.doi.org/10.1038/sj.onc.1206370			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687016				2022-12-17	WOS:000182066900008
J	Wu, WS				Wu, WS			ERK signaling pathway is involved in p15(INK4b)/p16(INK4a) expression and HepG2 growth inhibition triggered by TPA and Saikosaponin a	ONCOGENE			English	Article						ERK; p15(INK4b); p16(INK4a); growth inhibition	CELL-CYCLE ARREST; ACTIVATED PROTEIN-KINASES; BREAST-CANCER CELLS; TUMOR SUPPRESSION; RETINOIC ACID; ONCOGENIC RAS; PROLIFERATION; P15(INK4B); AP-1; SENESCENCE	The signal pathway mediating induction of p15(INK4b) and p16(INK4)a during HepG2 growth inhibition triggered by the phorbol ester tumor promoter TPA (12-O-tetradecanoyl-phorbol 13-acetate) and the Chinese herb Saikosaponin a was investigated. Western blot of three activated forms of mitogen-activated protein kinase (MAPK) (p-ERK, p-JNK and p-p38) demonstrated that phosphorylation of ERK is dramatically induced (11.6-fold) by TPA during 15 min to 1 h and significantly induced (2.5-fold) by Saikosaponin alpha at 30 min, whereas phosphorylation of JNK was induced only by TPA during 30 min to I h. Phosphorylation of p38 was not induced by either drug. During this period, phosphorylation of one of the downstream transcriptional factors of MAPK cascade, ATF2, was 3.2- and 2.0-fold induced by TPA and Saikosaponin a, respectively, whereas that of another transcriptional factor, c-jun, was induced by TPA only. On the other hand, expressions of proto-oncogene c-jun, junB and c-fos were induced by TPA and Saikosaponin a during 30 min to 6 h of treatment. Pretreatment of 20 mug/ml PD98059, an inhibitor of MEK which is the upstream kinase of ERK, prevents the TPA- and Saikosaponin a-triggered HepG2 growth inhibition by 50 and 30%, respectively, accompanied by a 50 - 85% decrease of the P15(INK4b)/ p16(INK4a) RNAs and proteins induced by both drugs. Inductions of c-fos RNA by both drugs and c-jun phosphorylation by TPA were also significantly reduced by PD98059 pretreatment. In addition, AP-1 DNA-binding assay using nonisotopic capillary electrophoresis and laser-induced fluorescence (CE/LIF) demonstrated that the AP-1-related DNA-binding activity was significantly induced by TPA and Saikosaponin a, which can be reduced by PD98059 pretreatment. These results suggested that activation of ERK together with its downstream transcriptional machinery mediated p15(INK4b) and p16(INK4a) expression that led to HepG2 growth inhibition.	TZU CHI Univ, Dept Med Technol, Hualien 970, Taiwan	Tzu Chi University	Wu, WS (corresponding author), TZU CHI Univ, Dept Med Technol, 701,Chung Yang Rd,Sec 3, Hualien 970, Taiwan.	wuws@mail.tcu.edu.tw	Wu, Wen-Sheng/AAN-9078-2020					Agadir A, 1999, J BIOL CHEM, V274, P29779, DOI 10.1074/jbc.274.42.29779; Baek MJ, 2000, CANCER, V89, P60, DOI 10.1002/1097-0142(20000701)89:1<60::AID-CNCR9>3.0.CO;2-3; Bosch M, 1998, J BIOL CHEM, V273, P22145, DOI 10.1074/jbc.273.34.22145; Campbell I, 2000, CANCER GENE THER, V7, P1270, DOI 10.1038/sj.cgt.7700226; Cocolakis E, 2001, J BIOL CHEM, V276, P18430, DOI 10.1074/jbc.M010768200; DAM HV, 2001, ONCOGENE, V20, P2453; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FATIMA MG, 2001, ONCOGENE, V20, P2378; FOULDS GJ, 1998, NUCLEIC ACIDS RES, V26, P4404; Franklin CC, 1995, ONCOGENE, V11, P2365; Fuxe J, 2000, CELL GROWTH DIFFER, V11, P373; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Halfter H, 1999, Mol Cell Biol Res Commun, V1, P109, DOI 10.1006/mcbr.1999.0117; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; Hochholdinger F, 1999, MOL CELL BIOL, V19, P8052; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kavanagh KT, 2001, J CELL BIOCHEM, V82, P387, DOI 10.1002/jcb.1164; Kimura A, 1999, CANCER RES, V59, P5133; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1998, CURR OPIN GENET DEV, V8, P43, DOI 10.1016/S0959-437X(98)80060-9; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Onishi T, 2000, ANTICANCER RES, V20, P3075; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Robson CN, 1999, J ENDOCRINOL, V160, P257, DOI 10.1677/joe.0.1600257; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Verlinden L, 2000, CANCER RES, V60, P2673; Wang JH, 2000, SEP PURIF TECHNOL, V19, P11, DOI 10.1016/S1383-5866(99)00078-7; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Weber E, 1999, INT J CANCER, V80, P935, DOI 10.1002/(SICI)1097-0215(19990315)80:6<935::AID-IJC21>3.0.CO;2-E; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wu WS, 2001, BIOCHEM BIOPH RES CO, V285, P183, DOI 10.1006/bbrc.2001.5152; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; Zauberman A, 1997, ONCOGENE, V15, P1705, DOI 10.1038/sj.onc.1201348	44	49	59	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2003	22	7					955	963		10.1038/sj.onc.1206237	http://dx.doi.org/10.1038/sj.onc.1206237			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592382				2022-12-17	WOS:000180926100001
J	Chau, CH; Chen, KY; Deng, HT; Kim, KJ; Hosoya, K; Terasaki, T; Shih, HM; Ann, DK				Chau, CH; Chen, KY; Deng, HT; Kim, KJ; Hosoya, K; Terasaki, T; Shih, HM; Ann, DK			Coordinating Etk/Bmx activation and VEGF upregulation to promote cell survival and proliferation	ONCOGENE			English	Article						Etk; VEGF; autocrine; survival; proliferation	ENDOTHELIAL GROWTH-FACTOR; FOCAL ADHESION KINASE; BMX TYROSINE KINASE; PROSTATE-CANCER CELLS; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3'-KINASE; SIGNAL-TRANSDUCTION; FAMILY KINASES; PH-DOMAIN; EXPRESSION	Etk/Bmx, a member of the Tee family of non-receptor tyrosine kinase, is characterized by an N-terminal PH domain and has recently been shown to be involved in the regulation of various cellular processes, including proliferation, differentiation, motility and apoptosis. Since VEGF and the activation of its signaling pathway have been implicated in modulating a variety of biological responses, we characterized the role of Etk-dependent signaling pathways involved in the upregulation of VEGF expression, and explored the functional implications of this enhancement in sustaining cell proliferation and survival. Using Northern and Western analyses, transient transfections, and pharmacological agents, we demonstrate that Elk activation alone is sufficient to transcriptionally induce VEGF expression, independent of the previously identified hypoxia response element (HRE), in both Pa-4 epithelial and TR-BBB endothelial cells under normoxia. In addition, Elk utilizes both MEK/ERK and PI3-K/Pak1 signaling pathways in concert to activate VEGF transcription. Functionally, Etk activation elicits a profound stimulatory effect on TR-BBB cell proliferation and formation of capillary-like networks in Matrigel containing reduced levels of growth factors. Finally, antisense oligonucleotides against either endogenous VEGF or Etk abrogate the proliferation of Elk-activated TR-BBB cells, and exogenous VEGF treatment stimulates endogenous Elk tyrosine phosphorylation in HUVECs. Taken together, these results indicate that VEGF is both an Etk downstream target gene and an Elk upstream activator, constituting a reciprocal Etk-VEGF autoregulatory loop. These findings, to our knowledge, are the first delineation of a network of positive feedforward signaling pathways that converge on the Etk-VEGF axis, causally associating Elk-mediation of VEGF induction with enhanced cellular processes in both epithelial and endothelial cells.	Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Tohoku Univ, Grad Sch Pharmaceut Sci, Dept Mol Biopharm & Genet, Aoba Ku, Sendai, Miyagi 9808578, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Toyama 9300194, Japan; Natl Hlth Res Inst, Div Mol & Genomic Med, Taipei 11529, Taiwan; Univ So Calif, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Will Rogers Inst, Pulm Res Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90033 USA; Univ So Calif, Dept Physiol & Biophys, Los Angeles, CA 90033 USA; Univ So Calif, Dept Med, Los Angeles, CA 90033 USA	University of Southern California; Tohoku University; University of Toyama; National Health Research Institutes - Taiwan; University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Ann, DK (corresponding author), Univ So Calif, Dept Mol Pharmacol & Toxicol, Hlth Sci Campus,PSC-210B,1985 Zonal Ave, Los Angeles, CA 90033 USA.		Shih, Hsiu-Ming/S-7023-2018; Terasaki, Tetsuya/K-6730-2012	Terasaki, Tetsuya/0000-0002-6332-7575	NHLBI NIH HHS [R01 HL 38658, R01 HL 64365] Funding Source: Medline; NIDCR NIH HHS [R01 DE 10742, DE 07211, R01 DE 14183] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064365, R01HL038658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014183] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498; Dias S, 2002, BLOOD, V99, P2179, DOI 10.1182/blood.V99.6.2179; Dunk C, 2001, AM J PATHOL, V158, P265, DOI 10.1016/S0002-9440(10)63965-X; Ekman N, 1997, CIRCULATION, V96, P1729, DOI 10.1161/01.CIR.96.6.1729; Ekman N, 2000, ONCOGENE, V19, P4151, DOI 10.1038/sj.onc.1203763; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gotoh I, 1999, J BIOL CHEM, V274, P11874, DOI 10.1074/jbc.274.17.11874; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Hamm-Alvarez SF, 2001, AM J PHYSIOL-CELL PH, V280, pC1657, DOI 10.1152/ajpcell.2001.280.6.C1657; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jui HY, 2000, J BIOL CHEM, V275, P41124, DOI 10.1074/jbc.M007772200; Kanellis J, 2000, AM J PHYSIOL-RENAL, V278, pF905, DOI 10.1152/ajprenal.2000.278.6.F905; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Li DX, 1997, J BIOL CHEM, V272, P25062, DOI 10.1074/jbc.272.40.25062; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; Mahajan S, 1999, J BIOL CHEM, V274, P9587, DOI 10.1074/jbc.274.14.9587; Mao CD, 2001, J BIOL CHEM, V276, P26180, DOI 10.1074/jbc.M101188200; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Parrizas M, 1997, J BIOL CHEM, V272, P154; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rajantie I, 2001, MOL CELL BIOL, V21, P4647, DOI 10.1128/MCB.21.14.4647-4655.2001; RAK J, 1995, CANCER RES, V55, P4575; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Terasaki T, 2001, BIOL PHARM BULL, V24, P111, DOI 10.1248/bpb.24.111; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; Vega-Diaz B, 2001, J INVEST DERMATOL, V116, P525, DOI 10.1046/j.1523-1747.2001.01294.x; Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091; Wen X, 2000, Adv Dent Res, V14, P76; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Wu YM, 2001, J BIOL CHEM, V276, P17672, DOI 10.1074/jbc.M010964200; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200	57	49	52	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8817	8829		10.1038/sj.onc.1206032	http://dx.doi.org/10.1038/sj.onc.1206032			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483534				2022-12-17	WOS:000179734400015
J	Coquelle, A; Rozier, L; Dutrillaux, B; Debatisse, M				Coquelle, A; Rozier, L; Dutrillaux, B; Debatisse, M			Induction of multiple double-strand breaks within an hsr by meganuclease I-SceI expression or fragile site activation leads to formation of double minutes and other chromosomal rearrangements	ONCOGENE			English	Article						I-SceI meganuclease; mammalian gene amplification; double-strand break repair; fragile sites; hypoxia; chromosomal rearrangements	DIHYDROFOLATE-REDUCTASE GENE; CHINESE-HAMSTER CELLS; TUMOR PROGRESSION; TRANSIENT HYPOXIA; SOLID TUMORS; CAD GENES; AMPLIFICATION; CANCER; TRANSLOCATIONS; INSTABILITY	Gene amplification is frequently associated with tumor progression, hence, understanding the underlying mechanisms is important. The study of in vitro model systems indicated that different initial mechanisms accumulate amplified copies within the chromosomes (hsr) or on extra-chromosomal elements (dmin). It has long been suggested that formation of dmin could also occur following hsr breakdown. In order to check this hypothesis, we developed an approach based on the properties of the I-SceI meganuclease, which induces targeted DNA double-strand breaks. A clone containing an I-SceI site, integrated by chance close to an endogenous dhfr gene locus, was used to select for methotrexate resistant mutants. We recovered clones in which the I-SceI site was passively co-amplified with the dhfr gene within the same hsr. We show that I-SceI-induced hsr breakdown leads to the formation of dmin and creates different types of chromosomal rearrangements, including inversions. This demonstrates, for the first time, a direct relationship between double-strand breaks and inversions. Finally, we show that activation of fragile sites by aphidicolin or hypoxia in hsr-containing cells also generates dmin and a variety of chromosomal rearrangements. This may constitute a valuable model to study the consequences of breaks induced in hsr of cancer cells in vivo.	Inst Curie, CNRS, UMR 147, Unit Cytogenet Mol & Oncol, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite	Debatisse, M (corresponding author), Inst Curie, CNRS, UMR 147, Unit Cytogenet Mol & Oncol, 26 Rue Ulm, F-75248 Paris 05, France.		Coquelle, Arnaud/AAE-5425-2020					BALABANMALENBAU.G, 1981, CANCER GENET CYTOGEN, V2, P339; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Brizel DM, 1996, CANCER RES, V56, P941; CARROLL SM, 1988, MOL CELL BIOL, V8, P1525, DOI 10.1128/MCB.8.4.1525; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; Fang JM, 2001, GENE CHROMOSOME CANC, V30, P292, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1095>3.0.CO;2-F; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Knudson AG, 2000, ANNU REV GENET, V34, P1, DOI 10.1146/annurev.genet.34.1.1; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; LEBEAU MM, 1986, BLOOD, V67, P849; LUK CK, 1990, J NATL CANCER I, V82, P684, DOI 10.1093/jnci/82.8.684; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; McClintock B, 1942, P NATL ACAD SCI USA, V28, P458, DOI 10.1073/pnas.28.11.458; Nowell P, 1998, NAT MED, V4, P1107, DOI 10.1038/2598; Perucca-Lostanlen D, 1997, CYTOGENET CELL GENET, V79, P88, DOI 10.1159/000134689; Pipiras E, 1998, EMBO J, V17, P325, DOI 10.1093/emboj/17.1.325; RICE GC, 1986, P NATL ACAD SCI USA, V83, P5978, DOI 10.1073/pnas.83.16.5978; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; RUIZ JC, 1988, MOL CELL BIOL, V8, P4302, DOI 10.1128/MCB.8.10.4302; Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303; Schwab M, 1999, SEMIN CANCER BIOL, V9, P319, DOI 10.1006/scbi.1999.0126; Singer MJ, 2000, P NATL ACAD SCI USA, V97, P7921, DOI 10.1073/pnas.130194897; Smith DI, 1998, INT J ONCOL, V12, P187; SMITH KA, 1992, P NATL ACAD SCI USA, V89, P5427, DOI 10.1073/pnas.89.12.5427; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; TOLEDO F, 1993, CURR BIOL, V3, P255, DOI 10.1016/0960-9822(93)90175-N; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; TRASK BJ, 1989, GENE DEV, V3, P1913, DOI 10.1101/gad.3.12a.1913; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	39	49	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7671	7679		10.1038/sj.onc.1205880	http://dx.doi.org/10.1038/sj.onc.1205880			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400009				2022-12-17	WOS:000178756200006
J	Hu, YC; Sidransky, D; Ahrendt, SA				Hu, YC; Sidransky, D; Ahrendt, SA			Molecular detection approaches for smoking associated tumors	ONCOGENE			English	Article						molecular detection; tumor; smoking; PCR; mutation; microsatellite instability; methylation	SQUAMOUS-CELL CARCINOMA; BRONCHOALVEOLAR LAVAGE FLUID; BLADDER-CANCER; LUNG-CANCER; MICROSATELLITE ALTERATIONS; PROMOTER HYPERMETHYLATION; CIGARETTE-SMOKING; GENE-MUTATIONS; RAS MUTATIONS; P53 MUTATIONS	Smoking is directly responsible for approximately 90% of lung cancers and is also strongly associated with cancers of the head and neck, esophagus and urinary bladder. Our growing understanding of the molecular changes that underlie cancer progression has contributed to the development of novel molecular approaches for the detection of cancer. In this study, we review a number of recent studies that have used molecular techniques to detect neoplastic DNA from lung, head and neck, esophagus and bladder cancer. The majority of these approaches are based on polymerase chain reaction (PCR) based assays. These PCR-based techniques can detect a few clonal cancer cells containing a specific DNA mutation, microsatellite alteration, or CpG island methylation among an excess background of normal cells. The ability to accurately detect a small number of malignant cells in a wide range of clinical specimens including sputum, saliva, bronchoalveolar lavage fluid, urine, serum, plasma, or tissue has significant implications for screening high-risk individuals (such as cigarette smokers) for cancer.	Univ Rochester, Dept Surg, Rochester, NY 14642 USA; Johns Hopkins Med Inst, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA	University of Rochester; Johns Hopkins University; Johns Hopkins Medicine	Ahrendt, SA (corresponding author), Univ Rochester, Dept Surg, 601 Elmwood Ave, Rochester, NY 14642 USA.	steven_ahrendt@urmc.rochester.edu		Ahrendt, Steven/0000-0002-3029-2126				Ahrendt S A, 1999, Surg Oncol Clin N Am, V8, P641; Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332; Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Ahrendt SA, 2000, CANCER RES, V60, P3155; Ahrendt SA, 1999, P NATL ACAD SCI USA, V96, P7382, DOI 10.1073/pnas.96.13.7382; Barrett MT, 1999, NAT GENET, V22, P106, DOI 10.1038/8816; BERLIN NI, 1984, AM REV RESPIR DIS, V130, P545; BLOT WJ, 1988, CANCER RES, V48, P3282; BLOT WJ, 1994, SEMIN ONCOL, V21, P403; BOYLE JO, 1994, AM J SURG, V168, P429, DOI 10.1016/S0002-9610(05)80092-3; BOYLE JO, 1993, CANCER RES, V53, P4477; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; BURCH JD, 1989, INT J CANCER, V44, P622, DOI 10.1002/ijc.2910440411; Califano J, 1999, J NATL CANCER I, V91, P599, DOI 10.1093/jnci/91.7.599; CARBONE D, 1992, AM J MED, V93, pS13, DOI 10.1016/0002-9343(92)90621-H; Chen XQ, 1996, NAT MED, V2, P1033; CLAVEL J, 1989, INT J CANCER, V44, P605, DOI 10.1002/ijc.2910440408; DAVIDSON TM, 1981, OTOLARYNG HEAD NECK, V89, P244, DOI 10.1177/019459988108900219; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; Doll R, 1998, Stat Methods Med Res, V7, P87, DOI 10.1191/096228098668199908; Esteller M, 1999, CANCER RES, V59, P67; FIELDING LP, 1992, CANCER, V70, P2367, DOI 10.1002/1097-0142(19921101)70:9<2367::AID-CNCR2820700927>3.0.CO;2-B; FITZGERALD JM, 1995, J NATL CANCER I, V87, P129, DOI 10.1093/jnci/87.2.129; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; HARTGE P, 1987, J NATL CANCER I, V78, P1119; Hemstreet GP, 2001, JNCI-J NATL CANCER I, V93, P427, DOI 10.1093/jnci/93.6.427; Hibi K, 2001, CLIN CANCER RES, V7, P3135; Hu N, 2000, GENE CHROMOSOME CANC, V27, P217, DOI 10.1002/(SICI)1098-2264(200003)27:3<217::AID-GCC1>3.0.CO;2-A; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; MILLS NE, 1995, J NATL CANCER I, V87, P1056, DOI 10.1093/jnci/87.14.1056; Miyake H, 1998, INT J CANCER, V79, P560, DOI 10.1002/(SICI)1097-0215(19981218)79:6<560::AID-IJC2>3.0.CO;2-X; MORRISON AS, 1984, J UROLOGY, V131, P650, DOI 10.1016/S0022-5347(17)50559-5; Mourah S, 1998, INT J CANCER, V79, P629, DOI 10.1002/(SICI)1097-0215(19981218)79:6<629::AID-IJC13>3.3.CO;2-T; MURPHY WM, 1984, CANCER, V53, P1555, DOI 10.1002/1097-0142(19840401)53:7<1555::AID-CNCR2820530723>3.0.CO;2-G; NARUKE T, 1988, J THORAC CARDIOV SUR, V96, P440; Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035; NAWROZ H, 1994, CANCER RES, V54, P1152; Okamoto I, 1998, J NATL CANCER I, V90, P307, DOI 10.1093/jnci/90.4.307; Palmisano WA, 2000, CANCER RES, V60, P5954; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; Rosas SLB, 2001, CANCER RES, V61, P939; Sanchez-Cespedes M, 2001, CANCER RES, V61, P7015; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Sardi I, 2000, GENE CHROMOSOME CANC, V29, P201, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1031>3.0.CO;2-X; SHOPLAND DR, 1991, JNCI-J NATL CANCER I, V83, P1142, DOI 10.1093/jnci/83.16.1142; Sidransky D, 1997, SCIENCE, V278, P1054, DOI 10.1126/science.278.5340.1054; Sidransky D, 1995, J Natl Cancer Inst Monogr, P27; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; Smith SD, 2001, JAMA-J AM MED ASSOC, V285, P324, DOI 10.1001/jama.285.3.324; Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621; Strauss GM, 1997, CHEST, V111, P754, DOI 10.1378/chest.111.3.754; Swana HS, 1999, NEW ENGL J MED, V341, P452, DOI 10.1056/NEJM199908053410614; Taylor JA, 1998, CANCER RES, V58, P3603; Usadel H, 2002, CANCER RES, V62, P371; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Yakubovskaya MS, 1995, INT J CANCER, V63, P810, DOI 10.1002/ijc.2910630611	61	49	51	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7289	7297		10.1038/sj.onc.1205805	http://dx.doi.org/10.1038/sj.onc.1205805			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379873				2022-12-17	WOS:000178618000003
J	Lauritsen, KJ; List, HJ; Reiter, R; Wellstein, A; Riegel, AT				Lauritsen, KJ; List, HJ; Reiter, R; Wellstein, A; Riegel, AT			A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells	ONCOGENE			English	Article						AIBl; coactivator; breast cancer; antiestrogen; all-trans retinoic acid; TGF-beta	GROWTH-FACTOR-BETA; DEPENDENT ACTIVATION; EXPRESSION; GENE; HORMONE; AMPLIFICATION; TRANSCRIPTION; INVASIVENESS; POSITIVITY; INHIBITION	AIB1 (amplified in breast cancer 1) is a nuclear receptor coactivator gene amplified and overexpressed in breast cancer. However, the mechanisms by which AIB1 is regulated are unclear. Here we show that 17beta-estradiol represses AIB1 mRNA and protein expression in MCF-7 human breast cancer cells primarily by suppressing AIB1 gene transcription. Estrogen levels present in fetal calf serum are sufficient to maintain AIB1 mRNA and protein at low basal levels, and this repression is reversed by the addition of antiestrogens or all-trans retinoic acid. Interestingly, cycloheximide inhibition experiments revealed that secondary protein synthesis was necessary to induce AIB1 expression by antiestrogens and retinoids. Experiments with TGF-beta and TGF-beta blocking antibodies demonstrated that this growth factor modulates AIB1 expression and showed that the antiestrogen and retinoid induction of AIB1 gene expression is mediated at least in part through TGF-beta. These data reveal a mechanism of estrogen-induced down-modulation of the overall hormone sensitivity of cells through feedback inhibition of coactivator gene expression. These data also suggest that antiestrogens can shift the sensitivity of cells to nonestrogenic proliferative signaling by increasing cellular levels of AIB1 This effect may play a role in breast cancer progression and resistance to drug treatment.	Georgetown Univ, Vincent T Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA; Georgetown Univ, Vincent T Lombardi Canc Ctr, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Riegel, AT (corresponding author), Georgetown Univ, Vincent T Lombardi Canc Ctr, Dept Oncol, E307,3970 Reservoir Rd, Washington, DC 20007 USA.			Wellstein, Anton/0000-0002-0570-4950				Akiyama N, 2000, MOL CELL BIOL, V20, P3266, DOI 10.1128/MCB.20.9.3266-3273.2000; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bai JW, 2000, CELL, V103, P1047, DOI 10.1016/S0092-8674(00)00208-7; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Bouras T, 2001, CANCER RES, V61, P903; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; Degitz SJ, 1998, TERATOLOGY, V58, P197, DOI 10.1002/(SICI)1096-9926(199811)58:5<197::AID-TERA6>3.0.CO;2-8; Dumont N, 2000, BREAST CANCER RES, V2, P125, DOI 10.1186/bcr44; Farina AR, 1998, INT J CANCER, V75, P721; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Guan XY, 1996, CANCER RES, V56, P3446; Jakowlew SB, 2000, PEPTIDES, V21, P1831, DOI 10.1016/S0196-9781(00)00344-2; KAREY KP, 1988, CANCER RES, V48, P4083; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; Koli KM, 1997, J BIOL CHEM, V272, P8296, DOI 10.1074/jbc.272.13.8296; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Li H, 1998, J BIOL CHEM, V273, P5948, DOI 10.1074/jbc.273.10.5948; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LIPPMAN ME, 1975, NATURE, V256, P592, DOI 10.1038/256592a0; List HJ, 2001, J BIOL CHEM, V276, P23763, DOI 10.1074/jbc.M102397200; List HJ, 2001, BREAST CANCER RES TR, V68, P21, DOI 10.1023/A:1017910924390; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Nephew KP, 2000, BIOL REPROD, V63, P361, DOI 10.1095/biolreprod63.2.361; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; ONATE SA, 1995, SCIENCE, V270, P1354; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Reiter R, 2001, J BIOL CHEM, V276, P39736, DOI 10.1074/jbc.M104744200; Sakakura C, 2000, INT J CANCER, V89, P217; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Walfish PG, 1997, P NATL ACAD SCI USA, V94, P3697, DOI 10.1073/pnas.94.8.3697; Wang DH, 1999, J BIOL CHEM, V274, P12840, DOI 10.1074/jbc.274.18.12840; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200	43	49	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7147	7155		10.1038/sj.onc.1205943	http://dx.doi.org/10.1038/sj.onc.1205943			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370804				2022-12-17	WOS:000178504600002
J	Tsimbouri, P; Drotar, ME; Coy, JL; Wilson, JB				Tsimbouri, P; Drotar, ME; Coy, JL; Wilson, JB			bcl-x(L) and RAG genes are induced and the response to IL-2 enhanced in E mu EBNA-1 transgenic mouse lymphocytes	ONCOGENE			English	Article						EBV; EBNA-1; IL-2; Bcl-x(L); transgenic mice; lymphoma	EPSTEIN-BARR-VIRUS; EXPRESSION; MICE; DNA; SURVIVAL; CELLS	We have described transgenic mice expressing Epstein-Barr virus (EBV) nuclear antigen-1 (EBNA-1) in B-cells which show a predisposition to lymphoma. To investigate the underlying oncogenic mechanisms, we have cross bred transgenic strains of mice, examined the pre-tumour B-cell phenotype and investigated the expression levels of selected cellular genes as a response to EBNA-1 expression. We have found that bcl-X-L and the recombination activating genes (RAG) 1 and 2 are induced in pre-neoplastic samples of EBNA-1 expressing mice. Induction of bcl-x(L) may explain the observed redundancy in lymphomagenesis between transgenic EBNA-1 and bcl-2. In addition, bone marrow cells derived from the EmuEBNA-1 mice show a greater capacity for cultured growth compared to controls, particularly in the presence of IL-2. Notably, bcl-x(L) expression is responsive to IL-2. These data shed new light on the potential contribution of EBNA-1 to EBV associated tumorigenicity as well as to the viral life cycle and open a potential avenue for therapeutic intervention.	Univ Glasgow, Div Mol Genet, Inst Biomed & Life Sci, Glasgow G11 6NU, Lanark, Scotland	University of Glasgow	Wilson, JB (corresponding author), Univ Glasgow, Div Mol Genet, Inst Biomed & Life Sci, Glasgow G11 6NU, Lanark, Scotland.	Joanna.Wilson@bio.gla.ac.uk	Wilson, Joanna B/B-4466-2009; Tsimbouri, Penelope/F-4373-2010	Tsimbouri, Penelope/0000-0001-5124-7458				ADAMS JM, 1992, CANCER SURV, V15, P119; Berns A, 1999, CANCER RES, V59, p1773S; Bonnet M, 1999, J NATL CANCER I, V91, P1376, DOI 10.1093/jnci/91.16.1376; Gaffen SL, 2001, CYTOKINE, V14, P63, DOI 10.1006/cyto.2001.0862; ISCOVE NN, 1974, J CELL PHYSIOL, V83, P309, DOI 10.1002/jcp.1040830218; Kang MS, 2001, P NATL ACAD SCI USA, V98, P15233, DOI 10.1073/pnas.211556598; Kapoor P, 2001, EMBO J, V20, P222, DOI 10.1093/emboj/20.1.222; Kawa K, 2000, INT J HEMATOL, V71, P108; Kelsoe G, 1995, ADV IMMUNOL, V60, P267, DOI 10.1016/S0065-2776(08)60587-8; Kube D, 1999, J VIROL, V73, P1630, DOI 10.1128/JVI.73.2.1630-1636.1999; KUHNHALLEK I, 1995, BLOOD, V85, P1289, DOI 10.1182/blood.V85.5.1289.bloodjournal8551289; Lee MA, 1999, J VIROL, V73, P2974, DOI 10.1128/JVI.73.4.2974-2982.1999; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Meru N, 2001, INT J CANCER, V92, P75, DOI 10.1002/1097-0215(200102)9999:9999&lt;::AID-IJC1163&gt;3.0.CO;2-M; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; RICKINSON AB, 1996, FIELDS VIROLOGY, P2360; SRINIVAS SK, 1995, J VIROL, V69, P8155, DOI 10.1128/JVI.69.12.8155-8158.1995; Tsimbouri P, 2001, Methods Mol Biol, V174, P411; Tuscano JM, 1996, BLOOD, V88, P1359, DOI 10.1182/blood.V88.4.1359.bloodjournal8841359; Wilson J B, 1992, Curr Top Microbiol Immunol, V182, P375; Wilson J B, 2001, Methods Mol Biol, V174, P361; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; WILSON JB, 1997, EBV REPORT, V4, P63; Wu H, 2000, EMBO REP, V1, P140, DOI 10.1093/embo-reports/kvd026	25	49	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5182	5187		10.1038/sj.onc.1205490	http://dx.doi.org/10.1038/sj.onc.1205490			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140768				2022-12-17	WOS:000176975900016
J	Dubina, MV; Iatckii, NA; Popov, DE; Vasil'ev, SV; Krutovskikh, VA				Dubina, MV; Iatckii, NA; Popov, DE; Vasil'ev, SV; Krutovskikh, VA			Connexin 43, but not connexin 32, is mutated at advanced stages of human sporadic colon cancer	ONCOGENE			English	Article						gap junctions; connexin 43; connexin 32; colon cancer; mutations	GAP JUNCTION PROTEINS; CARDIAC MYOCYTES; GROWTH-CONTROL; MUTATIONS; GENE; EXPRESSION; TUMORS; COMMUNICATION; LOCALIZATION; DOMAIN	The membrane-spanning connexin proteins form microscopic intercellular channels that directly connect the cytoplasms of adjacent cells and as such have been implicated in maintenance of tissue homeostasis. They are considered to act as tumor suppressors since their function or expression is frequently aberrant in tumor cells. Several mechanisms appear to be involved in this, but irreversible mutational alterations have not yet been proved to be among them. In this study we have demonstrated for the first time that connexin 43 but not connexin 32 is specifically and quite frequently mutated in human colon sporadic adenocarcinomas. All tumor-associated mutations led to a shift of reading frame and were located in the multifunctional carboxyl-terminal domain of the protein. Expression of mutated connexin 43 protein was restricted to invasive structures of tumors. These findings suggest that mutational alterations of connexin 43 are involved in advanced stages of progression of human colon cancer towards malignancy.	St Petersburg State Pavlov Med Univ, Dept Pathophysiol, St Petersburg, Russia; St Petersburg State Pavlov Med Univ, Dept Surg Dis, St Petersburg, Russia; Int Agcy Res Canc, Unit Gene Environm Interact, F-69372 Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC)	Krutovskikh, VA (corresponding author), St Petersburg State Pavlov Med Univ, Dept Pathophysiol, St Petersburg, Russia.		Dubina, Michael/E-1888-2014	Dubina, Michael/0000-0002-6606-3309; Popov, Dmitry/0000-0001-9112-0232				Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; FISHMAN GI, 1991, GENOMICS, V10, P250, DOI 10.1016/0888-7543(91)90507-B; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Jamieson S, 1998, J PATHOL, V184, P37, DOI 10.1002/(SICI)1096-9896(199801)184:1<37::AID-PATH966>3.0.CO;2-D; Jin CS, 2000, METHODS, V20, P219, DOI 10.1006/meth.1999.0939; Krutovskikh V, 2000, MUTAT RES-REV MUTAT, V462, P197, DOI 10.1016/S1383-5742(00)00037-5; Krutovskikh V, 1996, CARCINOGENESIS, V17, P1761, DOI 10.1093/carcin/17.8.1761; KRUTOVSKIKH V, 1994, INT J CANCER, V56, P87; Krutovskikh VA, 2000, ONCOGENE, V19, P505, DOI 10.1038/sj.onc.1203340; Lamartine J, 2000, NAT GENET, V26, P142, DOI 10.1038/79851; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; MESNIL M, 1995, CANCER RES, V55, P629; Nelis E, 1999, HUM MUTAT, V13, P11, DOI 10.1002/(SICI)1098-1004(1999)13:1<11::AID-HUMU2>3.0.CO;2-A; NEVEU MJ, 1994, J CELL SCI, V107, P83; Richard G, 1998, NAT GENET, V20, P366, DOI 10.1038/3840; Saito T, 1997, CANCER RES, V57, P375; Saito T, 2000, INT J CANCER, V86, P67, DOI 10.1002/(SICI)1097-0215(20000401)86:1<67::AID-IJC10>3.0.CO;2-1; Stergiopoulos K, 1999, CIRC RES, V84, P1144, DOI 10.1161/01.RES.84.10.1144; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; White TW, 1998, NATURE, V394, P630, DOI 10.1038/29202; WILGENBUS KK, 1992, INT J CANCER, V51, P522, DOI 10.1002/ijc.2910510404; Xia JH, 1998, NAT GENET, V20, P370, DOI 10.1038/3845; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199	25	49	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4992	4996		10.1038/sj.onc.1205630	http://dx.doi.org/10.1038/sj.onc.1205630			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118378				2022-12-17	WOS:000176874800014
J	Oh, IH; Eaves, CJ				Oh, IH; Eaves, CJ			Overexpression of a dominant negative form of STAT3 selectively impairs hematopoietic stem cell activity	ONCOGENE			English	Article						dominant negative STAT3; stem cells; hematopoiesis; gp-130; self-renewal	ADULT BONE-MARROW; SELF-RENEWAL; INTERLEUKIN-6 FAMILY; QUANTITATIVE ASSAY; IN-VITRO; ACTIVATION; DIFFERENTIATION; GP130; EXPANSION; CYTOKINES	STAT3 is a key downstream signaling intermediate of gp130, a receptor previously shown to activate hematopoietic stem cell (HSC) self-renewal divisions. These findings prompted us to investigate if the STAT3 pathway is important to HSC activity in vivo. Initial semi-quantitative RT-PCR analyses showed STAT3 to be expressed at slightly higher levels in primitive subsets of both human and murine adult bone marrow cells. To test the effect of abrogating STAT3 activity in HSCs, primitive murine fetal liver cells were transduced at high efficiency with either a bicistronic dominant-negative (dn) or wild-type (wt) STAT3-IRES-GFP retrovirus. Dn STAT3-transduced HSCs showed markedly and permanently reduced in vivo lympho-myeloid reconstituting ability relative to co-transplanted non-transduced HSCs or HSCs transduced with a control (GFP-only) vector. In contrast, the activity of dn STAT3-transduced cells with short term in vivo (CFU-S) or in vitro (CFC) proliferation potential was not affected. Overexpression of wt-STAT3 had very little effect on either HSCs or shorter term progenitors. These findings suggest HSCs express non-limiting levels of STAT3 which, nevertheless, play an important stage-specific and non-redundant role in maintaining the function of HSCs stimulated to divide in adult marrow tissue.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 1L3, Canada	British Columbia Cancer Agency; University of British Columbia	Eaves, CJ (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 601 W 10th Ave,10th Ave, Vancouver, BC V5Z 1L3, Canada.							Audet J, 2001, P NATL ACAD SCI USA, V98, P1757, DOI 10.1073/pnas.98.4.1757; BERNAD A, 1994, IMMUNITY, V1, P725, DOI 10.1016/S1074-7613(94)80014-6; Biethahn S, 1999, EXP HEMATOL, V27, P885, DOI 10.1016/S0301-472X(99)00017-X; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Chakraborty A, 1998, LEUKEMIA LYMPHOMA, V30, P433, DOI 10.3109/10428199809057555; Chakraborty A, 1996, BLOOD, V88, P2442, DOI 10.1182/blood.V88.7.2442.bloodjournal8872442; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Conneally E, 1997, P NATL ACAD SCI USA, V94, P9836, DOI 10.1073/pnas.94.18.9836; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FRASER CC, 1992, P NATL ACAD SCI USA, V89, P1968, DOI 10.1073/pnas.89.5.1968; Hennemann B, 2000, HUM GENE THER, V11, P43, DOI 10.1089/10430340050016148; Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; LEMIEUX ME, 1995, BLOOD, V86, P1339, DOI 10.1182/blood.V86.4.1339.bloodjournal8641339; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Oh IH, 2000, BLOOD, V96, P4160, DOI 10.1182/blood.V96.13.4160.h8004160_4160_4168; Peters M, 1997, J EXP MED, V185, P755, DOI 10.1084/jem.185.4.755; Petzer AL, 1996, P NATL ACAD SCI USA, V93, P1470, DOI 10.1073/pnas.93.4.1470; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Rebel V I, 1996, J Hematother, V5, P25, DOI 10.1089/scd.1.1996.5.25; Rebel VI, 1996, BLOOD, V87, P3500, DOI 10.1182/blood.V87.8.3500.bloodjournal8783500; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SZILVASSY SJ, 1990, P NATL ACAD SCI USA, V87, P8736, DOI 10.1073/pnas.87.22.8736; SZILVASSY SJ, 2001, METHODS MOL MED HEMA, P167; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Thomas TE, 1999, METHODS, V17, P202, DOI 10.1006/meth.1998.0731; Wang JCY, 1997, BLOOD, V89, P3919, DOI 10.1182/blood.V89.11.3919; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Zandstra PW, 1997, P NATL ACAD SCI USA, V94, P4698, DOI 10.1073/pnas.94.9.4698; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	36	49	49	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4778	4787		10.1038/sj.onc.1205592	http://dx.doi.org/10.1038/sj.onc.1205592			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101416				2022-12-17	WOS:000176716300007
J	Zink, D; Mayr, C; Janz, C; Wiesmuller, L				Zink, D; Mayr, C; Janz, C; Wiesmuller, L			Association of p53 and MSH2 with recombinative repair complexes during S phase	ONCOGENE			English	Article						BRCA1-associated surveillance complex; Rad50; Rad51; replication-associated homologous recombination; tumor suppressor	INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; WILD-TYPE P53; SACCHAROMYCES-CEREVISIAE MSH2; HUMAN RAD51 PROTEIN; LARGE-T-ANTIGEN; MISMATCH REPAIR; DNA-DAMAGE; CELL-CYCLE; IN-VIVO; REPLICATION FIDELITY	Our previous recombination and biochemical analyses have led to the hypothesis that the tumor suppressor p53 monitors homologous recombination, a function which was previously attributed to the mismatch repair protein MSH2. Here, we show that a certain fraction of p53 is concentrated within discrete nuclear foci of cells synchronized in G1 phase, a pattern which becomes even more pronounced in S phase, especially after gamma-ray treatment. p53 foci show some colocalization with MSH2 within distinct foci during G1 phase, while dots formed by BRCA1 display an independent localization pattern. In S phase nuclei, p53 foci almost completely colocalize with MSH2 foci and associate with the recombination surveillance factor BRCA1 in irradiated S phase cells. These p53 and MSH2 foci also show significant overlaps with foci of the recombination enzymes Rad50 and Rad51, which for the first time unveiled recombination-related functions of p53 in replicating cells. During S phase, p53 and MSH2 are maximally active in binding to early recombination intermediates, and coexist within the same nuclear DNA-protein complexes. Our data suggest that p53 is linked similarly to homologous recombination as MSH2 and provide further evidence for the new concept of a dual role of p53 in the regulation of growth and repair.	Univ Ulm, Frauenklin & Poliklin, D-89075 Ulm, Germany; LMU Munchen, Inst Anthropol & Human Genet, D-80336 Munich, Germany	Ulm University; University of Munich	Wiesmuller, L (corresponding author), Univ Ulm, Frauenklin & Poliklin, Prittwitzstr 43, D-89075 Ulm, Germany.							Abraham J, 2000, J MOL BIOL, V295, P853, DOI 10.1006/jmbi.1999.3415; Alani E, 1997, J MOL BIOL, V265, P289, DOI 10.1006/jmbi.1996.0743; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Durant ST, 1999, CURR BIOL, V9, P51, DOI 10.1016/S0960-9822(99)80047-5; Eils R, 1996, J CELL BIOL, V135, P1427, DOI 10.1083/jcb.135.6.1427; Evans E, 2000, MOL CELL, V5, P789, DOI 10.1016/S1097-2765(00)80319-6; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Flores-Rozas H, 2000, TRENDS BIOCHEM SCI, V25, P196, DOI 10.1016/S0968-0004(00)01568-1; Flygare J, 1996, BBA-MOL CELL RES, V1312, P231, DOI 10.1016/0167-4889(96)00040-7; Gebow D, 2000, MOL CELL BIOL, V20, P4028, DOI 10.1128/MCB.20.11.4028-4035.2000; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; Janz C, 2002, ONCOGENE, V21, P2130, DOI 10.1038/sj.onc.1205292; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; Lambert S, 1999, MUTAT RES-DNA REPAIR, V433, P159, DOI 10.1016/S0921-8777(99)00004-X; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Lin XJ, 2000, MOL PHARMACOL, V58, P1222, DOI 10.1124/mol.58.6.1222; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Marsischky GT, 1999, J BIOL CHEM, V274, P7200, DOI 10.1074/jbc.274.11.7200; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Scherer SJ, 2000, J BIOL CHEM, V275, P37469, DOI 10.1074/jbc.M006990200; SCHIRMBECK R, 1989, J VIROL, V63, P2308, DOI 10.1128/JVI.63.5.2308-2316.1989; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Tashiro S, 1996, ONCOGENE, V12, P2165; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Venkitaraman AR, 1999, SCIENCE, V286, P1100, DOI 10.1126/science.286.5442.1100; Wang Y, 2000, GENE DEV, V14, P927; WHITBY MC, 1995, EMBO J, V14, P3302, DOI 10.1002/j.1460-2075.1995.tb07337.x; Wiesmuller L, 1996, J VIROL, V70, P737; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	66	49	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4788	4800		10.1038/sj.onc.1205614	http://dx.doi.org/10.1038/sj.onc.1205614			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101417				2022-12-17	WOS:000176716300008
J	Manzano, RG; Montuenga, LM; Dayton, M; Dent, P; Kinoshita, I; Vicent, S; Gardner, GJ; Nguyen, PM; Choi, YH; Trepel, J; Auersperg, N; Birrer, MJ				Manzano, RG; Montuenga, LM; Dayton, M; Dent, P; Kinoshita, I; Vicent, S; Gardner, GJ; Nguyen, PM; Choi, YH; Trepel, J; Auersperg, N; Birrer, MJ			CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential	ONCOGENE			English	Article						MKP-1; ovarian; cancer; phosphatases; growth; motility	PROTEIN-TYROSINE PHOSPHATASES; IMMEDIATE-EARLY GENE; MAP KINASE; IN-VIVO; CONSTITUTIVE ACTIVATION; EXTRACELLULAR-MATRIX; DNA-SYNTHESIS; CELL-LINES; GROWTH; MKP-1	Although early stage ovarian cancer can be effectively treated with surgery and chemotherapy, the majority of cases present with advanced disease, which remains essentially incurable. Unfortunately, little is known about the genes important for the development and progression of this disease. In this study, the expression of 68 phosphatases was determined in immortalized ovarian epithelial cells (IOSE) and compared to ovarian cancer cell lines. CL100, a dual specificity phosphatase, displayed 10-25-fold higher expression in normal compared to malignant ovarian cell lines. Immunohistochemical staining of normal ovaries and 68 ovarian cancer specimens confirmed this differential expression. Re-expression of CL100 in ovarian cancer cells decreased adherent and nonadherent cell growth and induced phenotypic changes including loss of filopodia and lamellipodia with an associated decrease in cell motility. Induced expression of CL100 in ovarian cancer cells suppressed intraperitoneal tumor growth in nude mice. These results show for the first time that CL100 expression is altered in human ovarian cancer, that CL100 expression changes cell morphology and motility, and that it suppresses intraperitoneal growth of human ovarian epithelial cancer. These data suggest that down-regulation of CL100 may play a role in the progression of human ovarian cancer.	NCI, Cell & Canc Biol Dept, Rockville, MD 20850 USA; Louisiana State Univ, Med Ctr, Dept Med, Shreveport, LA 71130 USA; Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Dept Radiat Oncol, Richmond, VA 23298 USA; Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC V6H 3V5, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Virginia Commonwealth University; University of British Columbia	Birrer, MJ (corresponding author), NCI, Cell & Canc Biol Dept, 9610 Med Ctr Dr, Rockville, MD 20850 USA.		Vicent, Silvestre/K-4261-2017; Montuenga, Luis M/AAF-7783-2020	Vicent, Silvestre/0000-0002-9457-6881; Montuenga, Luis M/0000-0002-8739-1387; Gonzalez Manzano, Ramon/0000-0003-2266-6965	NCI NIH HHS [CA88906] Funding Source: Medline; NIDDK NIH HHS [DK52825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088906] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Auer KL, 1998, BIOCHEM J, V336, P551, DOI 10.1042/bj3360551; BARNEA G, 1994, J BIOL CHEM, V269, P14349; Birrer MJ, 1999, CANCER RES, V59, P5270; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; CHARLES CH, 1992, ONCOGENE, V7, P187; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; CLIBY W, 1993, CANCER RES, V53, P2393; Dayton MA, 1997, RECEPT SIGNAL TRANS, V7, P241; DEVESA SS, 1995, JNCI-J NATL CANCER I, V87, P175, DOI 10.1093/jnci/87.3.175; DODSON MK, 1993, CANCER RES, V53, P4456; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hendricks DT, 1997, CANCER RES, V57, P2112; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Loda M, 1996, AM J PATHOL, V149, P1553; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; MAINESBANDIERA SL, 1992, AM J OBSTET GYNECOL, V167, P729, DOI 10.1016/S0002-9378(11)91579-8; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; Ozols Robert F., 1997, P919; Sabichi AL, 1998, J NATL CANCER I, V90, P597, DOI 10.1093/jnci/90.8.597; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Watsuji T, 1997, BIOCHEM BIOPH RES CO, V234, P769, DOI 10.1006/bbrc.1997.6705; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Wiener JR, 1996, GYNECOL ONCOL, V61, P233, DOI 10.1006/gyno.1996.0131; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5	37	49	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 27	2002	21	28					4435	4447		10.1038/sj.onc.1205542	http://dx.doi.org/10.1038/sj.onc.1205542			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080474	Green Published			2022-12-17	WOS:000176317100009
J	Hatzi, E; Murphy, C; Zoephel, A; Rasmussen, H; Morbidelli, L; Ahorn, H; Kunisada, K; Tontsch, U; Klenk, M; Yamauchi-Takihara, K; Ziche, M; Rofstad, EK; Schweigerer, L; Fotsis, T				Hatzi, E; Murphy, C; Zoephel, A; Rasmussen, H; Morbidelli, L; Ahorn, H; Kunisada, K; Tontsch, U; Klenk, M; Yamauchi-Takihara, K; Ziche, M; Rofstad, EK; Schweigerer, L; Fotsis, T			N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth	ONCOGENE			English	Article						N-myc; IL-6; STAT3; endothelial cell; neuroblastoma	DNA-BINDING; INTERLEUKIN-6; EXPRESSION; CELLS; ACTIVATION; GENE; INDUCTION; PROTEIN; STAT3; TRANSFORMATION	Angiogenesis is an indispensable prerequisite for the progression and metastasis of solid malignancies. Tumor angiogenesis appears to be governed by alterations of tumor suppressor or oncogenes operant in a broad range of tumors. We have addressed this issue in neuroblastoma, a malignancy characterized by the near-exclusive amplification and overexpression of the N-Myc oncogene. Here, we report that N-Myc overexpression results in down-regulation of interleukin-6 (IL-6) and that IL-6 is an inhibitor of endothelial cell proliferation and VEGF-induced rabbit corneal angiogenesis. STAT3 is instrumental for IL-6 activity as infection with adeno-viruses expressing a phosphorylation deficient STAT3 mutant renders endothelial cells insensitive to the antiproliferative action of IL-6. Finally, though IL-6 does not influence neuroblastoma cell growth, IL-6-expressing xenograft tumors in mice exhibit reduced neovascularization and suppressed growth. Our data shed new light on the mechanisms by which N-myc oncogene amplification enhances the malignant phenotype in neuroblastomas.	Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece; Ioannina Biomed Res Inst, Ioannina, Greece; Boehringer Ingelheim Austria GmbH, Vienna, Austria; Norwegian Radium Hosp, Inst Canc Res, Dept Biophys, Oslo, Norway; Univ Siena, Inst Pharmacol Sci, I-53100 Siena, Italy; Osaka Univ, Grad Sch Med, Dept Mol Med, Suita, Osaka, Japan; Univ Essen Gesamthsch, Kinderklin, Abt Hamatol Onkol & Endokrinol, Essen, Germany	University of Ioannina; Foundation for Research & Technology - Hellas (FORTH); Boehringer Ingelheim; University of Oslo; University of Siena; Osaka University; University of Duisburg Essen	Fotsis, T (corresponding author), Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece.	thfotsis@cc.uoi.gr	Morbidelli, Lucia/AAC-7858-2020; Murphy, Carol/ABE-4282-2021; Morbidelli, Lucia/K-4053-2016	Murphy, Carol/0000-0003-1353-8558; Morbidelli, Lucia/0000-0001-8148-7049				Ambrosino C, 1997, J BIOL CHEM, V272, P14883, DOI 10.1074/jbc.272.23.14883; Bannasch D, 1999, ONCOGENE, V18, P6810, DOI 10.1038/sj.onc.1203090; Bartoli M, 2000, J BIOL CHEM, V275, P33189, DOI 10.1074/jbc.C000318200; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Breit S, 2000, CANCER RES, V60, P4596; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Danielsen T, 1998, INT J CANCER, V76, P836, DOI 10.1002/(SICI)1097-0215(19980610)76:6<836::AID-IJC12>3.0.CO;2-0; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Fee D, 2000, CYTOKINE, V12, P655, DOI 10.1006/cyto.1999.0599; Fotsis T, 1997, CANCER RES, V57, P2916; Fotsis T, 1999, EUR J BIOCHEM, V263, P757, DOI 10.1046/j.1432-1327.1999.00575.x; GRADYLEOPARDI EF, 1986, CANCER RES, V46, P3196; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Guo QM, 2000, CANCER RES, V60, P5922; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HILLER S, 1991, ONCOGENE, V6, P969; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Mac SM, 2000, MOL CARCINOGEN, V29, P76, DOI 10.1002/1098-2744(200010)29:2<76::AID-MC4>3.0.CO;2-Y; Matsui H, 1999, CARDIOVASC RES, V42, P104, DOI 10.1016/S0008-6363(98)00285-5; Megeney LA, 1996, DEV GENET, V19, P139, DOI 10.1002/(SICI)1520-6408(1996)19:2<139::AID-DVG5>3.0.CO;2-A; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; OHE Y, 1993, BRIT J CANCER, V67, P939, DOI 10.1038/bjc.1993.174; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; Rofstad EK, 2000, CANCER RES, V60, P4932; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	40	49	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3552	3561		10.1038/sj.onc.1205440	http://dx.doi.org/10.1038/sj.onc.1205440			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032857				2022-12-17	WOS:000175793700006
J	Bluteau, O; Beaudoin, JC; Pasturaud, P; Belghiti, J; Franco, D; Bioulac-Sage, P; Laurent-Puig, P; Zucman-Rossi, J				Bluteau, O; Beaudoin, JC; Pasturaud, P; Belghiti, J; Franco, D; Bioulac-Sage, P; Laurent-Puig, P; Zucman-Rossi, J			Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping	ONCOGENE			English	Article						hepatocellular carcinoma; loss of heterozygosity; chromosome 4; mutation; alcohol intake	PRIMARY LIVER-CANCER; MUTATIONS; PROTEIN; GENE; HETEROZYGOSITY; DISEASE; 4Q	One of the most frequent deletions in hepatocellular carcinoma (HCC) is that involving the long arm of chromosome 4 (30 to 70% of the cases). These chromosomal deletions are closely related to hepatitis B virus (HBV) infection. A tumor suppressor gene (TSG) located on 4q has been proposed in liver carcinogenesis, but has not been identified as yet. Despite previous LOH studies focused on 4q in HCC, a clear minimal common region of deletion (MCRD) could not be delimited. To further investigate the role of chromosome 4q LOH in the pathogenesis of HCC, 85 microsatellite markers spanning chromosome 4q were systematically analysed in a series of 154 well-characterized primary liver tumors. In 59 tumors (38%), LOHs were observed for at least two adjacent markers. Analysis of 31 tumors demonstrating a partial or interstitial 4q deletion allowed to define three MCRDs of 15, 9 and 8 Mb at the 4q22, 4q34 and 4q35 regions, respectively. Seven putative candidate genes located in 4q22, DAPP1, BMPR1B, PKD2, HERC3, SMARCAD1, CEB1 and ENH were screened for mutations but no somatic alterations were identified. Search for relationships between the specific regions of deletion and clinical parameters showed a significant association between loss of the 4q34-35 region with alcohol intake (P=0.005) and with high grade of differentiation (P=0.02). These results are in contrast with the close association between HBV infection and the whole 4q LOH and reveal heterogeneity of 4q LOH in relation to different risk factors. In the light of these new findings, which link different 4q LOH regions to different etiologic factors, the molecular mechanisms underlying 4q deletions in HCC and the targeted gene(s) remain to be identified.	Ctr Etud Polymorphisme Humain, INSERM, U434, F-75010 Paris, France; Hop Beaujon, F-92110 Clichy, France; Hop Antoine Beclere, F-92140 Clamart, France; Hop Pellegrin, F-33000 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; CHU Bordeaux	Zucman-Rossi, J (corresponding author), Ctr Etud Polymorphisme Humain, INSERM, U434, 27 Rue Juliette Dodu, F-75010 Paris, France.	Zucman@cephb.fr	Laurent-Puig, Pierre/K-3641-2019; zucman-rossi, Jessica/B-5098-2009; Bluteau, Olivier/T-9907-2017; laurent-puig, pierre/B-2226-2013; bluteau, olivier/A-8844-2008	Laurent-Puig, Pierre/0000-0001-8475-5459; zucman-rossi, Jessica/0000-0002-5687-0334; Bluteau, Olivier/0000-0002-6943-8858; laurent-puig, pierre/0000-0001-8475-5459; 				Adra CN, 2000, GENOMICS, V69, P162, DOI 10.1006/geno.2000.6281; Bando K, 1999, GENE CHROMOSOME CANC, V25, P284, DOI 10.1002/(SICI)1098-2264(199907)25:3<284::AID-GCC11>3.0.CO;2-I; Bluteau O, 1999, GASTROEN CLIN BIOL, V23, P1225; Boige V, 1997, CANCER RES, V57, P1986; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; Cruz C, 2001, FEBS LETT, V488, P74, DOI 10.1016/S0014-5793(00)02371-1; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; Deuffic S, 1998, LANCET, V351, P214, DOI 10.1016/S0140-6736(05)78179-4; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.3.CO;2-N; Marchio AS, 2000, ONCOGENE, V19, P3733, DOI 10.1038/sj.onc.1203713; Mitsui K, 1999, BIOCHEM BIOPH RES CO, V266, P115, DOI 10.1006/bbrc.1999.1777; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Piao Z, 1998, INT J CANCER, V79, P356, DOI 10.1002/(SICI)1097-0215(19980821)79:4<356::AID-IJC8>3.0.CO;2-U; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; TaylorRobinson SD, 1997, LANCET, V350, P1142, DOI 10.1016/S0140-6736(05)63789-0; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; Wong N, 2000, CLIN CANCER RES, V6, P4000; Yeh SH, 1996, GASTROENTEROLOGY, V110, P184, DOI 10.1053/gast.1996.v110.pm8536855; ZHANG X, 1994, CANCER RES, V54, P4177	27	49	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1225	1232		10.1038/sj.onc.1205197	http://dx.doi.org/10.1038/sj.onc.1205197			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850842				2022-12-17	WOS:000173729400010
J	Muller, M				Muller, M			Telomerase: Its clinical relevance in the diagnosis of bladder cancer	ONCOGENE			English	Article						telomerase; bladder cancer; diagnosis; hTR; hTERT	TRANSITIONAL-CELL-CARCINOMA; TRANSCRIPTASE MESSENGER-RNA; CATALYTIC SUBUNIT GENE; VOIDED URINE SAMPLES; MICROSATELLITE ANALYSIS; UROTHELIAL CANCER; EXFOLIATED CELLS; POTENTIAL MARKER; EARLY EVENT; EXPRESSION	More than 50 years ago, Papanicolaou recognized the importance of a non-invasive technique for the diagnosis and follow-up of patients with carcinoma of the urinary bladder. Cystoscopy, however, has remained the 'gold standard' since no currently available non-invasive method can compete with cystoscopy's sensitivity and specificity. The detection of the ribonucleoprotein telomerase or the telomerase subunits human telomerase RNA (hTR) and human telomerase reverse transcriptase (hTERT) in urine samples offer new diagnostic perspectives. The present article presents a review of publications in the literature and evaluates their clinical relevance. The experimental studies reported to date are very promising and show that telomerase exactly fulfils the requirements for a good diagnostic marker for carcinoma of the urinary bladder. The diagnostic application remains in an experimental stage and telomerase is still several steps away for routine use as a clinical parameter. The remaining steps leading to its routine clinical application will be discussed.	Free Univ Berlin, Klinikum Benjamin Franklin, Dept Urol, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Muller, M (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Dept Urol, Hindenburgdamm 30, D-12200 Berlin, Germany.							ABEL PD, 1988, BRIT J UROL, V62, P103, DOI 10.1111/j.1464-410X.1988.tb04286.x; Arai Y, 2000, CLIN CHIM ACTA, V296, P35, DOI 10.1016/S0009-8981(00)00202-3; Avilion AA, 1996, CANCER RES, V56, P645; Bialkowska-Hobrzanska H, 2000, MOL DIAGN, V5, P267, DOI 10.1054/modi.2000.20314; Cassel A, 2001, J UROLOGY, V166, P841, DOI 10.1016/S0022-5347(05)65848-X; Dalbagni G, 1997, CLIN CANCER RES, V3, P1593; de Kok JB, 2000, CLIN CHEM, V46, P2014; De Kok JB, 2000, INT J CANCER, V87, P217, DOI 10.1002/1097-0215(20000715)87:2<217::AID-IJC10>3.0.CO;2-2; de Kok JB, 2000, CLIN CHEM, V46, P313; DUNCAN RE, 1977, J UROLOGY, V118, P43, DOI 10.1016/S0022-5347(17)57880-5; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GAMARRA MC, 1984, UROLOGY, V23, P23, DOI 10.1016/S0090-4295(84)80110-7; Gelmini S, 2000, CLIN CANCER RES, V6, P2771; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Heine B, 1998, J PATHOL, V185, P139, DOI 10.1002/(SICI)1096-9896(199806)185:2<139::AID-PATH79>3.0.CO;2-L; HENEY NM, 1983, J UROLOGY, V130, P1083, DOI 10.1016/S0022-5347(17)51695-X; Hiyama T, 1999, VIRCHOWS ARCH, V434, P483, DOI 10.1007/s004280050372; Ito H, 1998, CLIN CANCER RES, V4, P2807; Ito H, 1998, CLIN CANCER RES, V4, P1603; Kamata S, 1996, BRIT J UROL, V78, P704, DOI 10.1046/j.1464-410X.1996.01957.x; Kavaler E, 1998, CANCER, V82, P708, DOI 10.1002/(SICI)1097-0142(19980215)82:4<708::AID-CNCR14>3.0.CO;2-1; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, EUR J CANCER, V33, P781, DOI 10.1016/S0959-8049(97)00057-9; Kinoshita H, 1997, J NATL CANCER I, V89, P724, DOI 10.1093/jnci/89.10.724; Kitsukawa SI, 1999, INT J ONCOL, V15, P505; Kriegmair M, 1996, J UROLOGY, V155, P105, DOI 10.1016/S0022-5347(01)66559-5; Kuniyasu H, 1997, JPN J CANCER RES, V88, P103, DOI 10.1111/j.1349-7006.1997.tb00353.x; Kyo S, 1997, AM J CLIN PATHOL, V107, P555; Lancelin F, 2000, BJU INT, V85, P526, DOI 10.1046/j.1464-410x.2000.00466.x; Lee DH, 1998, CLIN CANCER RES, V4, P535; Lin Y, 1996, CLIN CANCER RES, V2, P929; Linn JF, 1997, INT J CANCER, V74, P625, DOI 10.1002/(SICI)1097-0215(19971219)74:6<625::AID-IJC12>3.3.CO;2-4; Maitra A, 2001, CANCER CYTOPATHOL, V93, P73, DOI 10.1002/1097-0142(20010225)93:1<73::AID-CNCR9010>3.0.CO;2-I; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; Mayfield MP, 1998, INT J MOL MED, V1, P835; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MORRISON AS, 1984, J UROLOGY, V131, P650, DOI 10.1016/S0022-5347(17)50559-5; Muller M, 1998, CLIN CANCER RES, V4, P1949; Muller M, 1996, INT J ONCOL, V9, P1169; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; PAPANICOLAOU GN, 1945, SCIENCE, V101, P519, DOI 10.1126/science.101.2629.519; Rahat MA, 1999, CANCER, V85, P919; Ramakumar S, 1999, J UROLOGY, V161, P388, DOI 10.1016/S0022-5347(01)61899-8; Rehn L, 1895, ARCH KLIN CHIR, V50, P588; Sallinen P, 1997, AM J PATHOL, V150, P1159; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Soder AI, 1997, ONCOGENE, V14, P1013, DOI 10.1038/sj.onc.1201066; Wu YY, 2000, CLIN CHIM ACTA, V293, P199, DOI 10.1016/S0009-8981(99)00238-7; YAMAMOTO M, 1992, CANCER RES, V52, P5329; Yashima K, 1997, J CLIN PATHOL, V50, P110, DOI 10.1136/jcp.50.2.110; Yokota K, 1998, BRIT J UROL, V82, P727, DOI 10.1046/j.1464-410x.1998.00827.x; Yoshida K, 1997, CANCER, V79, P362, DOI 10.1002/(SICI)1097-0142(19970115)79:2<362::AID-CNCR20>3.0.CO;2-Y	53	49	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					650	655		10.1038/sj.onc.1205071	http://dx.doi.org/10.1038/sj.onc.1205071			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850792				2022-12-17	WOS:000173390500019
J	Sepehr, A; Taniere, P; Martel-Planche, G; Zia'ee, AA; Rastgar-Jazii, F; Yazdanbod, M; Etemad-Moghadam, G; Kamangar, F; Saidi, F; Hainaut, P				Sepehr, A; Taniere, P; Martel-Planche, G; Zia'ee, AA; Rastgar-Jazii, F; Yazdanbod, M; Etemad-Moghadam, G; Kamangar, F; Saidi, F; Hainaut, P			Distinct pattern of TP53 mutations in squamous cell carcinoma of the esophagus in Iran	ONCOGENE			English	Article; Proceedings Paper	16th Meeting of the European-Association-for-Cancer-Research	JUN 02, 2000	HALKIDIKI HELLAS, GREECE	European Assoc Canc Res		esophagus; neoplasms; Iran; p53; COX-2	TUMOR-SUPPRESSOR GENE; P53 MUTATIONS; NITRIC-OXIDE; PRECANCEROUS LESIONS; CANCER; EXPRESSION; CYCLOOXYGENASE-2; CARCINOGENESIS; AMPLIFICATION; CHINA	Extremely high rates of squamous cell carcinoma of the esophagus (SCCE), are observed in Iran,, reflecting unknown, genetic and/or epidemiological risk factors. Among genetic alterations, in SCCE,: TP53: mutations are the most frequent, vary among populations, and may provide clues on etiological mechanisms. We have analysed mutations in TP53 (exons 5-8): in 98 SCCE from Iran by temporal temperature get electrophoresis and direct sequencing. We found 58, mutations, in 49 patients, (50%,), with a high prevalence of C to T transitions at CpG dinucleotides (29.3%). The TP53 mutation pattern in Iran was significantly different from that observed in SCCEs from high incidence areas of China and Western Europe (P=0.007)., Moreover, the prevalence of mutations at A:T base pairs, (transitions and transversions) was higher in men than in women (38.7%, vs 11.1%, P=0.033). COX-2 overexpression was, detected in 69% of the cases evaluated (24/35), without significant association with TP53, mutation. Accumulation of nitrotyrosine, a marker of protein damage by excess, levels of nitric oxide, was observed in tumor cells, in six of 16 cases analysed. These results are consistent with the hypothesis that several factors are involved in TP53 mutagenesis, in Iran., These factors include a baseline of chronic inflammatory stress, which may have a multiplicative impact on the sensitivity of esophageal cells to exogenous factors of risk.	IARC, Grp Mol Carcinogenesis, F-69008 Lyon, France; Univ Tehran, Inst Biochem & Biophys, Tehran, Iran; NRCGEB, Tehran, Iran; Univ Tehran Med Sci, Dept Surg, Tehran, Iran; Iran Mehr Hosp, Dept Pathol, Tehran, Iran; Iran Mehr Hosp, Dept Surg, Tehran, Iran; Johns Hopkins Univ, Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA	World Health Organization; International Agency for Research on Cancer (IARC); University of Tehran; Tehran University of Medical Sciences; Johns Hopkins University	Hainaut, P (corresponding author), Int Agcy Res Canc, Grp Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				Ambs S, 1999, J NATL CANCER I, V91, P86, DOI 10.1093/jnci/91.1.86; AUDREZET MP, 1993, CANCER RES, V53, P5745; Barnas C, 1997, INT J CANCER, V71, P79, DOI 10.1002/(SICI)1097-0215(19970328)71:1<79::AID-IJC14>3.0.CO;2-4; Biramijamal F, 2001, CANCER RES, V61, P3119; Cai YYC, 2000, CARCINOGENESIS, V21, P683, DOI 10.1093/carcin/21.4.683; Chazotte-Aubert L, 2000, BIOCHEM BIOPH RES CO, V267, P609, DOI 10.1006/bbrc.1999.2003; COOKMOZAFFARI PJ, 1979, BRIT J CANCER, V39, P293, DOI 10.1038/bjc.1979.54; *COUNC INT ORG MED, 1993, CIOMS INT ETH GUID B; ESTEVE A, 1993, MOL CARCINOGEN, V8, P306, DOI 10.1002/mc.2940080414; Fosslien E, 2000, ANN CLIN LAB SCI, V30, P3; FRIESEN M, 1985, MUTAT RES, V150, P177, DOI 10.1016/0027-5107(85)90114-9; GAO HK, 1994, CANCER RES, V54, P4342; Hainaut P, 2000, ADV CANCER RES, V77, P81; Harsch A, 2000, CHEM RES TOXICOL, V13, P1342, DOI 10.1021/tx000140m; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; HEWER T, 1978, LANCET, V2, P494; HOLLSTEIN MC, 1991, CANCER RES, V51, P4102; HORMOZDIARI H, 1975, CANCER RES, V35, P3493; Kato H, 2000, CANCER LETT, V153, P121, DOI 10.1016/S0304-3835(00)00358-X; KMET J, 1972, SCIENCE, V175, P846, DOI 10.1126/science.175.4024.846; Leung WK, 2001, BRIT J CANCER, V84, P335, DOI 10.1054/bjoc.2000.1607; LIANG YY, 1995, INT J CANCER, V61, P611, DOI 10.1002/ijc.2910610505; Lung ML, 1996, CANCER EPIDEM BIOMAR, V5, P277; MAHBOUBI E, 1973, BRIT J CANCER, V28, P192, DOI 10.1038/bjc.1973.138; Montesano R, 1996, INT J CANCER, V69, P225, DOI 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6; Munoz N, 1996, CANC EPIDEMIOLOGY PR, P681; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; Ratnasinghe D, 1999, ANTICANCER RES, V19, P171; Robert V, 2000, CARCINOGENESIS, V21, P563, DOI 10.1093/carcin/21.4.563; Rugge M, 1997, CANCER EPIDEM BIOMAR, V6, P171; Saidi F, 2000, BRIT J CANCER, V83, P1249, DOI 10.1054/bjoc.2000.1414; Shamma A, 2000, CLIN CANCER RES, V6, P1229; Shi ST, 1999, CARCINOGENESIS, V20, P591, DOI 10.1093/carcin/20.4.591; Shi ST, 1996, CARCINOGENESIS, V17, P2131, DOI 10.1093/carcin/17.10.2131; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Taniere P, 2000, INT J CANCER, V88, P223, DOI 10.1002/1097-0215(20001015)88:2&lt;223::AID-IJC12&gt;3.0.CO;2-G; Taniere P, 2001, BRIT J CANCER, V85, P721, DOI 10.1054/bjoc.2001.1990; Taniere P, 2001, AM J PATHOL, V158, P33, DOI 10.1016/S0002-9440(10)63941-7; Zimmermann KC, 1999, CANCER RES, V59, P198	39	49	66	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7368	7374		10.1038/sj.onc.1204912	http://dx.doi.org/10.1038/sj.onc.1204912			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704866				2022-12-17	WOS:000171894200009
J	Steele, IA; Edmondson, RJ; Bulmer, JN; Bolger, BS; Leung, HY; Davies, BR				Steele, IA; Edmondson, RJ; Bulmer, JN; Bolger, BS; Leung, HY; Davies, BR			Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer	ONCOGENE			English	Article						FGF receptor 2; ovarian cancer; ovarian surface epithelium	FIBROBLAST-GROWTH-FACTOR; E-CADHERIN EXPRESSION; SURFACE EPITHELIUM; PROSTATE-CANCER; CELLS; KERATINOCYTE; FAMILY; SPECIFICITY; CARCINOMAS; TISSUES	Epithelial ovarian cancers (EOCs) arise in the Ovarian Surface Epithelium (OSE). This tissue is a simple, poorly committed mesothelium which exhibits characteristics of epithelial and mesenchymal cells when grown in culture. In contrast, EOCs frequently exhibit properties of complex epithelial tissues of the female reproductive tract, such as oviductal, endometrial and cervical epithelia, and show induction of expression of epithelial markers such as E-cadherin. Fibroblast Growth Factor Receptor 2 isoform IIIb (FGF receptor 2-IIIb) is a spliced variant of FGF receptor 2 that binds the ligands FGF-1 and FGF-7 with high affinity, and is expressed exclusively by epithelial cells. We have studied the expression of FGF receptor 2-IIIb and its ligands in primary cultures of normal human OSE, EOC cell lines and snap frozen tissue from EOCs. Expression of FGF receptor 2-IIIb mRNA is undetectable in normal OSE, but is expressed in 16/20 (80%) of EOCs. FGFs 1 and 7 mRNAs are expressed in normal OSE, whilst only 4/20 (20%) and 12/20 (60%) of EOCs demonstrated expression for these ligands respectively. However, FGF-7 protein was detected in 70% (mean level = 0.7 ng/ml) of ascitic fluids obtained from patients with EOC. FGFs 1 and 7 stimulate DNA synthesis in EOC cell lines that express FGF receptor 2-IIlb. Moreover, DNA synthesis in these cell lines can be partially blocked by blocking antisera to FGFs 1 and 7. It is suggested that induction of expression of FGF receptor 2-IIIb may play a role in the development of EOCs by rendering the OSE susceptible to paracrine and/or autocrine stimulation by its requisite FGF ligands.	Newcastle Univ, Sch Med, Dept Surg, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Royal Victoria Infirm, Dept Pathol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Queen Elizabeth Hosp, No Gynaecol Oncol Ctr, Gateshead, Tyne & Wear, England; Royal Victoria Infirm, Dept Obstet & Gynaecol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK	Davies, BR (corresponding author), Newcastle Univ, Sch Med, Dept Surg, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	B.R.Davies@ncl.ac.uk		Edmondson, Richard/0000-0003-2553-4423; Leung, Hing Y./0000-0002-3933-3975				Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bast RC, 1995, J CELL BIOCHEM, P219; BERCHUCK A, 1993, CANCER, V71, P545; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CRICKARD K, 1994, GYNECOL ONCOL, V55, P277, DOI 10.1006/gyno.1994.1290; Davies BR, 1998, HISTOPATHOLOGY, V32, P69; De Medina SGD, 1999, ONCOGENE, V18, P5722, DOI 10.1038/sj.onc.1202958; DIBLASIO AM, 1993, AM J OBSTET GYNECOL, V169, P1517, DOI 10.1016/0002-9378(93)90428-L; Dyck HG, 1996, INT J CANCER, V69, P429, DOI 10.1002/(SICI)1097-0215(19961220)69:6<429::AID-IJC1>3.0.CO;2-6; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; HERNANDEZ E, 1989, MANUAL GYNECOLOGIC C, P57; INOUE M, 1992, AM J CLIN PATHOL, V98, P76, DOI 10.1093/ajcp/98.1.76; KLUG TL, 1984, CANCER RES, V44, P1048; KRUK PA, 1990, LAB INVEST, V63, P132; KRUK PA, 1994, EXP CELL RES, V215, P97, DOI 10.1006/excr.1994.1320; Leung HY, 1997, ONCOGENE, V15, P1115, DOI 10.1038/sj.onc.1201256; Lu WQ, 1999, J BIOL CHEM, V274, P12827, DOI 10.1074/jbc.274.18.12827; MainesBandiera SL, 1997, INT J GYNECOL PATHOL, V16, P250, DOI 10.1097/00004347-199707000-00010; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Mehta PB, 2000, J UROLOGY, V164, P2151, DOI 10.1016/S0022-5347(05)66988-1; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Ong A, 2000, INT J CANCER, V85, P430, DOI 10.1002/(SICI)1097-0215(20000201)85:3<430::AID-IJC21>3.0.CO;2-Q; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PARROTT JA, 1994, ENDOCRINOLOGY, V135, P569, DOI 10.1210/en.135.2.569; PETERS KG, 1992, DEVELOPMENT, V114, P233; RESTA L, 1993, OBSTET GYNECOL, V82, P181; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Scully RE, 1995, J CELL BIOCHEM, P208; SCULLY RE, 1977, AM J PATHOL, V87, P686; SCULLY RE, 1992, OVARIAN CANCER, V2, P199; Sundfeldt K, 1997, INT J CANCER, V74, P275, DOI 10.1002/(SICI)1097-0215(19970620)74:3<275::AID-IJC7>3.3.CO;2-V; VEATCH AL, 1994, INT J CANCER, V58, P393, DOI 10.1002/ijc.2910580315; Westermann AM, 1997, CANCER TREAT REV, V23, P113, DOI 10.1016/S0305-7372(97)90024-4; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; YOUNG RH, 1989, DIAGNOSTIC SURGICAL, P1655	38	49	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2001	20	41					5878	5887		10.1038/sj.onc.1204755	http://dx.doi.org/10.1038/sj.onc.1204755			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593393				2022-12-17	WOS:000171037200011
J	Zhong, J; Troppmair, J; Rapp, UR				Zhong, J; Troppmair, J; Rapp, UR			Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondria	ONCOGENE			English	Article						Raf; Bcl-2; apoptosis; mitochondria	NF-KAPPA-B; INDUCED APOPTOSIS; FAMILY PROTEINS; KINASE RAF-1; DEATH; EXPRESSION; MICE; PHOSPHORYLATION; TRANSFORMATION; TRANSLOCATION	Bcl-2 family proteins play a critical role in the regulation of cell survival by controlling the activation of the cell death executing caspase machinery. Recent work demonstrated that they also provide a link between growth factor signaling and cell survival control. Raf-1 has been identified initially as an essential component of the mitogenic Ras-Raf-MEK-ERK cascade. However, expression of oncogenic Raf-1 also efficiently suppresses apoptotic cell death. This process requires mitochondrial translocation of Raf-1 which can be achieved either by co-expression of the anti-apoptotic protein Bcl-2 or by fusion with the transmembrane domain of the yeast outer mitochondrial membrane protein Mas 70p. It is currently unclear how mitochondrial Raf-1 prevents apoptosis. One possible mechanism involves the phosphorylation of the pro-apoptotic protein Bad resulting in the restoration of Bcl-2 function. Alternatively, the role of Bcl-2 could be limited to the mitochondrial translocation of Raf-1 and survival signaling by Raf-1 is Bcl-2 independent. To test for the mutual requirement of Raf-1 and Bcl-2 in apoptosis suppression the individual proteins were singly tested for survival activity in a genetic background which precludes the expression of the other. The results obtained in these studies demonstrate that ablation of Raf-1 or Bcl-2 expression in fibroblast cells significantly increases the sensitivity towards doxorubicin induced cell death. Reversion of the mutant phenotype could be achieved in either case by introducing a functional bcl-2 gene or a mitochondria targeted version of oncogenic Raf-1, demonstrating that each protein by itself is sufficient to confer protection. Our data thus suggest the existence of two separate pathways of survival signaling at the mitochondria controlled either by Bcl-2 or by Raf-1.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany	University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Versbacher Str 5, D-97078 Wurzburg, Germany.			Troppmair, Jakob/0000-0002-0611-3837				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hagemann D, 1999, ONCOGENE, V18, P1391, DOI 10.1038/sj.onc.1202431; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Lau QC, 1998, ONCOGENE, V16, P1899, DOI 10.1038/sj.onc.1201709; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Naumann U, 1997, Recent Results Cancer Res, V143, P237; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Troppmair J, 1998, ONCOGENE, V17, P685, DOI 10.1038/sj.onc.1201981; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; WRIGHT SC, 1994, FASEB J, V8, P654, DOI 10.1096/fasebj.8.9.8005393; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	44	49	52	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4807	4816		10.1038/sj.onc.1204614	http://dx.doi.org/10.1038/sj.onc.1204614			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521192				2022-12-17	WOS:000170271800005
J	Malkin, D; Chilton-MacNeill, S; Meister, LA; Sexsmith, E; Diller, L; Garcea, RL				Malkin, D; Chilton-MacNeill, S; Meister, LA; Sexsmith, E; Diller, L; Garcea, RL			Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome	ONCOGENE			English	Article						Li-Fraumeni syndrome; p53; SV40 polyomavirus; tumor initiation	GERMLINE P53 MUTATIONS; WILD-TYPE P53; T-ANTIGEN; TRANSGENIC MICE; CHOROID-PLEXUS; BRAIN-TUMORS; CANCER; GENE; FAMILIES; SIMIAN-VIRUS-40	Inactivation of wild-type p53 tumor suppressor function is the primary mechanism of tumor initiation in Li-Fraumeni syndrome (LFS) individuals with germline p53 mutations. Tumors derived from LFS patients frequently retain the normal p53 allele, suggesting that alternative mechanisms in addition to gene deletion must be involved in inactivating wild-type p53 protein. DNA tumor viruses, such as SV40, target p53 for inactivation through the action of viral oncoproteins. We studied the probands from two unrelated LFS families, each of whom presented with multiple malignant neoplasms. Patient 1 developed an embryonal rhabdomyosarcoma (RMS) and a choroid plexus carcinoma (CPC), while patient 2 developed a CPC and subsequently presented with both an osteosarcoma (OS) and renal cell carcinoma (RCC). We utilized DNA sequence analysis and immunohistochemistry to determine p53 gene status in the germline and tumors, as well as evidence for SV40 T-antigen oncoprotein expression. Each patient harbored a heterozygous germline p53 mutation at codons 175 and 273, respectively. In patient 1, the normal p53 gene was lost while the mutant p53 allele was reduced to homozygosity in the RMS. Both normal and mutant genes were maintained in the CPC. In patient 2, normal and mutant p53 alleles were retained in both the CPC and RCC. Both specific PCR and immunostaining detected SV40 T-antigen in both CPCs and the RCC. In addition to chromosomal alterations, epigenetic mechanisms may disrupt p53 function during tumorigenesis. In two LFS patients, we found SV40 DNA sequences and viral T-antigen expression that could account for inactivation of the normal p53 protein. Inactivation of p53 or other tumor suppressors by viral proteins may contribute to tumor formation in specific tissues of genetically susceptible individuals.	Univ Toronto, Hosp Sick Children, Dept Pediat, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada; Joe DiMaggio Childrens Hosp, Div Pediat Hematol, Hollywood, FL USA; Dana Farber Canc Inst, Dept Pediat, Div Oncol, Boston, MA 02115 USA; Univ Colorado, Sch Med, Childrens Hosp, Dept Pediat,Sect Hematol Oncol, Denver, CO 80218 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Harvard University; Dana-Farber Cancer Institute; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Malkin, D (corresponding author), Univ Toronto, Hosp Sick Children, Dept Pediat, Div Hematol Oncol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Malkin, David/AAW-8715-2021					BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; BRUGIERES L, 1993, CANCER RES, V53, P452; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Carbone M, 1996, ONCOGENE, V13, P527; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; CARPENTER DB, 1982, J NEUROSURG, V56, P722, DOI 10.3171/jns.1982.56.5.0722; CHEN JD, 1992, ONCOGENE, V7, P1167; CRAWFORD L, 1982, J VIROL, V42, P612, DOI 10.1128/JVI.42.2.612-620.1982; DILLER L, 1995, J CLIN INVEST, V95, P1606, DOI 10.1172/JCI117834; Dobbelstein M, 1998, J GEN VIROL, V79, P3079, DOI 10.1099/0022-1317-79-12-3079; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; Flaegstad T, 1999, CANCER RES, V59, P1160; FREBOURG T, 1995, AM J HUM GENET, V56, P608; JOLLY KW, 1994, ONCOGENE, V9, P97; Kleihues P, 1997, AM J PATHOL, V150, P1; KRAMER S, 1983, J NATL CANCER I, V70, P49; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; LI FP, 1988, CANCER RES, V48, P5358; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1998, GENETIC BASIS HUMAN, P393; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MCINTYRE JF, 1994, J CLIN ONCOL, V12, P925, DOI 10.1200/JCO.1994.12.5.925; Mendoza SM, 1998, ONCOGENE, V17, P2457, DOI 10.1038/sj.onc.1202179; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; PACKER RJ, 1992, CANCER, V69, P580, DOI 10.1002/1097-0142(19920115)69:2<580::AID-CNCR2820690250>3.0.CO;2-O; PENG HQ, 1993, CANCER RES, V53, P3574; Sedlacek Z, 1998, BRIT J CANCER, V77, P1034, DOI 10.1038/bjc.1998.172; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; VANDYKE TA, 1987, J VIROL, V61, P2029, DOI 10.1128/JVI.61.6.2029-2032.1987; Varley JM, 1997, ONCOGENE, V14, P865, DOI 10.1038/sj.onc.1201041; Varley JM, 1997, CANCER RES, V57, P3245; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; YUASA H, 1993, NEUROSURGERY, V32, P131, DOI 10.1227/00006123-199301000-00021	36	49	50	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4441	4449		10.1038/sj.onc.1204583	http://dx.doi.org/10.1038/sj.onc.1204583			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494139				2022-12-17	WOS:000170074900001
J	Hamer, G; Gademan, IS; Kal, HB; de Rooij, DG				Hamer, G; Gademan, IS; Kal, HB; de Rooij, DG			Role for c-Abl and p73 in the radiation response of male germ cells	ONCOGENE			English	Article						c-Abl; p73; p63; cytoplasm; testis; ionizing radiation	TYROSINE KINASE; DNA-DAMAGE; DIFFERENTIATING SPERMATOGONIA; APOPTOTIC RESPONSE; INDUCE APOPTOSIS; X-IRRADIATION; MOUSE TESTIS; P53; EXPRESSION; PROTEIN	p53 plays a central role in the induction of apoptosis of spermatogonia in response to ionizing radiation. In p53(-/) testes, however, spermatogonial apoptosis still can be induced by ionizing radiation, so p53 independent apoptotic pathways must exist in spermatogonia, Here we show that the p53 homologues p63 and p73 are present in the testis and that p73, but not p63, is localized in the cytoplasm of spermatogonia, Unlike p53, neither p63 nor p73 protein levels were found to increase after a dose of 4 Gy of X-rays, Although p73 protein levels did not increase, its interaction with the nonreceptor tyrosine kinase c-Abl and its phosphorylation on tyrosine residues did. c-Abl and p73 co-localize in the cytoplasm of spermatogonia and spermatocytes and in the residual bodies. Furthermore, c-Abl protein levels increase after irradiation. p63 was not found to colocalize or interact with c-Abl neither before nor after irradiation. In conclusion, in the testis ionizing radiation elevates cytoplasmic c-Abl that in turn interacts with p73, This may represent an additional, cytoplasmic, apoptotic pathway. Although less efficient than the p53 route, this pathway may cause spermatogonial apoptosis as observed in p53 deficient mice.	UMCU, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; UMCU, Dept Radiotherapy, NL-3584 CX Utrecht, Netherlands	Unilever; Utrecht University; Utrecht University Medical Center; Unilever; Utrecht University; Utrecht University Medical Center	Hamer, G (corresponding author), UMCU, Dept Cell Biol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.		de Rooij, D.G./AAW-1195-2021	de Rooij, Dirk/0000-0003-3932-4419; Hamer, Geert/0000-0002-9583-6796				Agami R, 1999, NATURE, V399, P809; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beumer TL, 1997, MOL REPROD DEV, V47, P240, DOI 10.1002/(SICI)1098-2795(199707)47:3&lt;240::AID-MRD2&gt;3.0.CO;2-L; Beumer TL, 1998, CELL DEATH DIFFER, V5, P669, DOI 10.1038/sj.cdd.4400396; Blanco-Rodriguez J, 1999, BIOL REPROD, V61, P1541, DOI 10.1095/biolreprod61.6.1541; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; Gobe GC, 1999, INT J RADIAT BIOL, V75, P973, DOI 10.1080/095530099139737; Gong JG, 1999, NATURE, V399, P806; Hasegawa M, 1997, RADIAT RES, V147, P457, DOI 10.2307/3579503; Hasegawa M, 1998, RADIAT RES, V149, P263, DOI 10.2307/3579959; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kharbanda S, 1998, ONCOGENE, V16, P1773, DOI 10.1038/sj.onc.1201934; Levrero M, 2000, J CELL SCI, V113, P1661; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; OAKBERG EF, 1960, INT J RADIAT BIOL RE, V2, P196, DOI 10.1080/09553006014550211; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sjoblom T, 1996, ONCOGENE, V12, P2499; Soengas MS, 2000, NAT GENET, V26, P391, DOI 10.1038/82497; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; VANDERMEER Y, 1992, RADIAT RES, V130, P296, DOI 10.2307/3578374; VANDERMEER Y, 1992, RADIAT RES, V130, P289, DOI 10.2307/3578373; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; White E, 1999, NATURE, V399, P734, DOI 10.1038/21539; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zipfel PA, 2000, J IMMUNOL, V165, P6872, DOI 10.4049/jimmunol.165.12.6872	41	49	56	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4298	4304		10.1038/sj.onc.1204568	http://dx.doi.org/10.1038/sj.onc.1204568			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466610				2022-12-17	WOS:000169912600003
J	O'Neil, J; Billa, M; Oikemus, S; Kelliher, M				O'Neil, J; Billa, M; Oikemus, S; Kelliher, M			The DNA binding activity of TAL-1 is not required to induce leukemia/lymphoma in mice	ONCOGENE			English	Article						Tal-1; E2A; leukemia	LOOP-HELIX PROTEINS; T-CELL LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; KINASE II-ALPHA; IN-VIVO; TRANSCRIPTION FACTOR; VASCULAR DEVELOPMENT; ENHANCER-BINDING; TRANSGENIC MICE; ID PROTEINS	Activation of the basic helix-loop-helix (bHLH) gene TAL-1 (or SCL) is the most frequent gain-of-function mutation in pediatric T cell acute lymphoblastic leukemia (T-ALL), Similarly, mis-expression of tal-1 in the thymus of transgenic mice results in the development of clonal T cell lymphoblastic leukemia. To determine the mechanism(s) of tal-1-induced leukemogenesis, we created transgenic mice expressing a DNA binding mutant of tal-1, Surprisingly, these mice develop disease, demonstrating that the DNA binding properties of tal-1 are not required to induce leukemia/lymphoma in mice. However, wild type tal-1 and the DNA binding mutant both form stable complexes with E2A proteins. In addition, tal-1 stimulates differentiation of CDS-single positive thymocytes but inhibits the development of CD4-single positive cells: effects also observed in E2A-deficient mice. Our study suggests that the bHLH protein tal-1 contributes to leukemia by interfering with E2A protein function(s).	Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Kelliher, M (corresponding author), BioTech, 373 Plantat St, Worcester, MA 01605 USA.				NATIONAL CANCER INSTITUTE [R01CA096899] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; Anderson KP, 1998, J BIOL CHEM, V273, P14347, DOI 10.1074/jbc.273.23.14347; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; Begley CG, 1999, BLOOD, V93, P2760; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; Cohen-Kaminsky S, 1998, EMBO J, V17, P5151, DOI 10.1093/emboj/17.17.5151; CONDORELLI G, 1995, BLOOD, V86, P164, DOI 10.1182/blood.V86.1.164.bloodjournal861164; Condorelli GL, 1996, CANCER RES, V56, P5113; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DOYLE K, 1994, J BIOL CHEM, V269, P12099; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; Huang SM, 1999, ONCOGENE, V18, P4958, DOI 10.1038/sj.onc.1202889; Johnson SE, 1996, MOL CELL BIOL, V16, P1604; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Littlewood TD., 1998, HELIX LOOP HELIX TRA; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Park ST, 1998, J BIOL CHEM, V273, P7030, DOI 10.1074/jbc.273.12.7030; Porcher C, 1999, DEVELOPMENT, V126, P4603; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; Visvader JE, 1997, P NATL ACAD SCI USA, V94, P13707, DOI 10.1073/pnas.94.25.13707; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; Vyas P, 1999, DEVELOPMENT, V126, P2799; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898	47	49	49	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3897	3905		10.1038/sj.onc.1204519	http://dx.doi.org/10.1038/sj.onc.1204519			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439353				2022-12-17	WOS:000169494700015
J	Ganiatsas, S; Dow, R; Thompson, A; Schulman, B; Germain, D				Ganiatsas, S; Dow, R; Thompson, A; Schulman, B; Germain, D			A splice variant of Skp2 is retained in the cytoplasm and fails to direct cyclin D1 ubiquitination in the uterine cancer cell line SK-UT	ONCOGENE			English	Article						cyclin D1; SCF; ubiquitination; p27	F-BOX; RETINOBLASTOMA PROTEIN; TRANSGENIC MICE; LIGASE COMPLEX; BREAST-CANCER; HUMAN CUL-1; DEGRADATION; P27(KIP1); P27; ACCUMULATION	Cyclin D1 is an important regulator of the transition from G1 into S phase of the cell cycle. The level to which cyclin D1 accumulates is tightly regulated. One mechanism contributing to the control of cyclin D1 levels is the regulation of its ubiquitination, SK-UT-1B cells are deficient in the degradation of D-type cyclins, We show here that p27, a substrate of the SCFSkp2 ubiquitin Ligase complex, is coordinately stabilized in SK-UT-IB cells. Further, we show that expression of Skp2 in SK-UT-IB cells rescues the cyclin D1 and p27 degradation defect observed in this cell line. These results therefore indicate that the SCFSkp2 ubiquitin ligase complex affects the ubiquitination of cyclin D1, In addition, we show that SK-UT-LB cells express a novel splice variant of Skp2 that localizes to the cytoplasm and that cyclin D1 ubiquitination takes place in the nucleus. We propose that the translocation of Skp2 into the nucleus is required for the ubiquitination of cyclin DI and that the absence of the SCFSkp2 complex in the nucleus of SK-UT-IB cells is the mechanism underlying the ubiquitination defect observed in this cell line, Finally, our data indicates that differential splicing of F-box proteins may represent an additional level of regulation of the F-box mediated ubiquitination pathway.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Peter Maccallum Cancer Center; University of Melbourne; Memorial Sloan Kettering Cancer Center	Germain, D (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, St Andrews Pl, Melbourne, Vic 3002, Australia.							Amati B, 1999, NAT CELL BIOL, V1, pE91, DOI 10.1038/12087; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Dealy MJ, 1999, NAT GENET, V23, P245, DOI 10.1038/13886; Demetrick DJ, 1996, CYTOGENET CELL GENET, V73, P104, DOI 10.1159/000134318; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Swanson C, 2000, P NATL ACAD SCI USA, V97, P7796, DOI 10.1073/pnas.97.14.7796; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wang YS, 1999, CURR BIOL, V9, P1191, DOI 10.1016/S0960-9822(00)80024-X; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welcker M, 1996, ONCOGENE, V13, P419; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	39	49	53	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3641	3650		10.1038/sj.onc.1204501	http://dx.doi.org/10.1038/sj.onc.1204501			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439327				2022-12-17	WOS:000169400200005
J	Nishiyama, H; Gill, JH; Pitt, E; Kennedy, W; Knowles, MA				Nishiyama, H; Gill, JH; Pitt, E; Kennedy, W; Knowles, MA			Negative regulation of G(1)/S transition by the candidate bladder tumour suppressor gene DBCCR1	ONCOGENE			English	Article						transitional cell carcinoma; DBCCR1; cell cycle	CELL-CYCLE; TGF-BETA; CANCER; DELETION; PROTEIN; LOCUS; RETINOBLASTOMA; METHYLATION; 9Q32-Q33; REGION	Deletion of all or part of chromosome 9q is the most common genetic alteration in all stages and grades of bladder cancer. DBCCR1 (deleted in bladder cancer chromosome region candidate I) maps to the chromosome region 9q32-33, a candidate tumour suppressor locus for bladder cancer, Although no mutations of DBCCR1 have been detected in bladder tumours, expression of DBCCR1 is silenced by promoter hypermethylation in 50% of bladder cancer cell lines analysed. Here we sought to provide functional evidence to authenticate DBCCR1 as a tumour suppressor using gene-transfer methods. Exogenous expression of DBCCR1 protein or an HA epitope-tagged fusion protein, HA-DBCCR1 in NIH3T3 cells and human bladder tumour cell lines resulted in suppression of proliferation. Cell cycle analyses in NIH3T3 cells revealed that DBCCR1-mediated growth inhibition,vas due to an increase in the number of cells in the G(1) phase of the cell cycle, The levels of apoptosis were not altered. These results demonstrate a role for DBCCR1 in cell cycle control, thereby supporting the hypothesis that this is the tumour suppressor gene targeted by 9q32-33 deletion in bladder cancer. Oncogene (2001) 20, 2956-2964.	St Jamess Univ Hosp, Imperial Canc Res Fund, Ctr Clin, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Knowles, MA (corresponding author), St Jamess Univ Hosp, Imperial Canc Res Fund, Ctr Clin, Beckett St, Leeds LS9 7TF, W Yorkshire, England.			Knowles, Margaret/0000-0002-9363-8657; Gill, Jason/0000-0002-7564-7787				CAIRNS P, 1993, ONCOGENE, V8, P1083; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; HABUCHI T, 2001, IN PRESS ONCOGENE; Hartmann A, 1999, AM J PATHOL, V154, P721, DOI 10.1016/S0002-9440(10)65318-7; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; Nishiyama H, 1999, GENE CHROMOSOME CANC, V26, P171, DOI 10.1002/(SICI)1098-2264(199910)26:2<171::AID-GCC10>3.3.CO;2-2; Nishiyama H, 1997, J CELL BIOL, V137, P899, DOI 10.1083/jcb.137.4.899; Nishiyama H, 1999, GENOMICS, V59, P335, DOI 10.1006/geno.1999.5891; *OFF NAT STAT, 1996, MB1961 ONS; OLUMI AF, 1990, CANCER RES, V50, P7081; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Pestov DG, 1999, BIOTECHNIQUES, V26, P102, DOI 10.2144/99261st04; Ravitz MJ, 1997, ADV CANCER RES, V71, P165, DOI 10.1016/S0065-230X(08)60099-8; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Salem C, 2000, CANCER RES, V60, P2473; Simoneau M, 1999, ONCOGENE, V18, P157, DOI 10.1038/sj.onc.1202277; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569; WU SQ, 1991, CANCER RES, V51, P3323	28	49	53	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2956	2964		10.1038/sj.onc.1204432	http://dx.doi.org/10.1038/sj.onc.1204432			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420708				2022-12-17	WOS:000168901800011
J	Schlichter, U; Burk, O; Worpenberg, S; Klempnauer, KH				Schlichter, U; Burk, O; Worpenberg, S; Klempnauer, KH			The chicken Pdcd4 gene is regulated by v-Myb	ONCOGENE			English	Article						v-myb oncogene; target gene; differential display; Pdcd4	RECEPTOR FUSION PROTEIN; 2 DIFFERENT MECHANISMS; C-MYB; MIM-1 GENE; CELL-LINES; TOPOISOMERASE INHIBITORS; SYNERGISTIC ACTIVATION; MYELOMONOCYTIC CELLS; TRANS-ACTIVATION; MYELOID CELLS	The retroviral oncogene v-myb encodes a transcription factor (v-Myb) which is responsible for the ability of avian myeloblastosis virus (AMV) to transform mlyelomonocytic cells. v-Myb is thought to disrupt the differentiation of myelomonocytic cells by affecting the expression of specific target genes. To identify such genes we have analysed the gene expression in a myelomonocytic chicken cell Line that carries an estrogen inducible version of v-Myb by differential display, Here me describe the identification of the chicken homolog of the mouse Pdcd4 gene as a novel v-Myb target gene. Pdcd4 is also known as MA-3, TIS and H731 and has recently been shown to suppress the transformation of epidermal cells by tumor promoters. Our results provide the first evidence that v-Myb directly regulates the expression of a potential tumor suppressor gene.	Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.							AKIYAMA Y, 1974, BIKEN J, V17, P105; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; CHEN LC, 1983, MOL CELL BIOL, V3, P1077, DOI 10.1128/MCB.3.6.1077; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; DESBIENS X, 1991, DEVELOPMENT, V111, P699; Ess KC, 1999, ONCOGENE, V18, P1103, DOI 10.1038/sj.onc.1202387; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Lahti JM, 1999, METHODS, V17, P305, DOI 10.1006/meth.1999.0744; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Maruo A, 1999, INT IMMUNOL, V11, P1371, DOI 10.1093/intimm/11.9.1371; Matsuhashi Sachiko, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P109; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mink S, 1999, BBA-GENE STRUCT EXPR, V1447, P175, DOI 10.1016/S0167-4781(99)00168-2; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Onishi Y, 1996, BIOCHEM BIOPH RES CO, V228, P7, DOI 10.1006/bbrc.1996.1609; Onishi Y, 1998, GENE, V215, P453, DOI 10.1016/S0378-1119(98)00313-8; PLAZA S, 1995, ONCOGENE, V10, P329; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; QUEVA C, 1992, DEVELOPMENT, V114, P125; Rosenthal MA, 1996, CELL GROWTH DIFFER, V7, P961; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Sitzmann J, 1995, ONCOGENE, V11, P2273; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Wagner C, 1998, MAR BIOL, V131, P411, DOI 10.1007/s002270050334; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Worpenberg S, 1997, ONCOGENE, V15, P213, DOI 10.1038/sj.onc.1201179	52	49	55	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					231	239		10.1038/sj.onc.1204071	http://dx.doi.org/10.1038/sj.onc.1204071			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313950				2022-12-17	WOS:000166410900010
J	Skalsky, YM; Ajuh, PM; Parker, C; Lamond, AI; Goodwin, G; Cooper, CS				Skalsky, YM; Ajuh, PM; Parker, C; Lamond, AI; Goodwin, G; Cooper, CS			PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors	ONCOGENE			English	Article						TFE3; PRCC; transcription activation; pre-mRNA splicing	HELIX-LOOP-HELIX; ACTIVATOR INHIBITOR-1 GENE; BETA-INDUCED TRANSCRIPTION; CELL CARCINOMA; BINDING PROTEIN; SMAD PROTEINS; RNA-BINDING; DNA-BINDING; TRANSLOCATION; P54(NRB)	In papillary renal cell carcinomas the TFE3 transcription factor becomes fused to the PSF and NonO pre-mRNA splicing factors and most commonly to a protein of unknown function designated PRCC, In this: study we have examined the ability of the resulting PRCC-TFE3 and NonO-TFE3 fusions to activate transcription from the plasminogen activator inhibitor-1 (PAI-1) promoter. The results shea that only fusion to PRCC enhanced transcriptional activation, indicating that the ability to enhance the level of transcription from endogenous TFE3 promoters is not a consistent feature of TFE3 fusions, In investigations of the normal function of PRCC,ve observed that PRCC expressed as a green fluorescent fusion protein colocalizes within the nucleus with Sm pre-RNA splicing factors. It was also found that endogenous PRCC is coimmunoprecipitated by antibodies that recognize a variety of pre-mRNA splicing factors including SC35, PRL1 and CDC5. Association with the cellular splicing machinery is therefore, a common feature of the proteins that become fused to TFE3 in papillary renal cell carcinomas.	Inst Canc Res, Mol Carcinogenesis Sect, Haddow Labs, Sutton SM2 5NG, Surrey, England; Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland	University of London; Institute of Cancer Research - UK; University of Dundee	Skalsky, YM (corresponding author), Inst Canc Res, Mol Carcinogenesis Sect, Haddow Labs, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.			Lamond, Angus/0000-0001-6204-6045				ANGLARD P, 1992, CANCER RES, V52, P348; ARTANDI SE, 1995, NUCLEIC ACIDS RES, V23, P3865, DOI 10.1093/nar/23.19.3865; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Basu A, 1997, MOL CELL BIOL, V17, P677, DOI 10.1128/MCB.17.2.677; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; Bernstein HS, 1997, J BIOL CHEM, V272, P5833, DOI 10.1074/jbc.272.9.5833; BRODY E, 1985, SCIENCE, V228, P963, DOI 10.1126/science.3890181; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; Chanas-Sacre G, 1999, J NEUROSCI RES, V57, P62, DOI 10.1002/(SICI)1097-4547(19990701)57:1<62::AID-JNR7>3.0.CO;2-Y; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; DEJONG B, 1986, CANCER GENET CYTOGEN, V21, P165, DOI 10.1016/0165-4608(86)90042-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; FU XD, 1995, RNA, V1, P663; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; Groenen PMA, 1998, GENOMICS, V49, P218, DOI 10.1006/geno.1998.5254; Groenen PMA, 1996, GENOMICS, V38, P141, DOI 10.1006/geno.1996.0609; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Kreivi JP, 1996, CURR BIOL, V6, P802, DOI 10.1016/S0960-9822(02)00599-7; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; McDonald WH, 1999, MOL CELL BIOL, V19, P5352; MELONI AM, 1993, CANCER GENET CYTOGEN, V65, P1, DOI 10.1016/0165-4608(93)90050-V; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; OKEEFE RT, 1994, J CELL BIOL, V124, P249, DOI 10.1083/jcb.124.3.249; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; REEVES BR, 1989, ONCOGENE, V4, P373; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Shinozaki A, 1999, INT J BIOCHEM CELL B, V31, P1279, DOI 10.1016/S1357-2725(99)00101-6; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; Tian G, 1999, MOL CELL BIOL, V19, P2946; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 2000, ONCOGENE, V19, P69, DOI 10.1038/sj.onc.1203255; YANG YS, 1993, MOL CELL BIOL, V13, P5593, DOI 10.1128/MCB.13.9.5593	44	49	50	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					178	187		10.1038/sj.onc.1204056	http://dx.doi.org/10.1038/sj.onc.1204056			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313942				2022-12-17	WOS:000166410900005
J	Ladendorff, NE; Wu, S; Lipsick, JS				Ladendorff, NE; Wu, S; Lipsick, JS			BS69, an adenovirus E1A-associated protein, inhibits the transcriptional activity of c-Myb	ONCOGENE			English	Article						Myb; BS69; corepressor; MYND domain	DNA-BINDING DOMAIN; ACUTE MYELOID-LEUKEMIA; V-MYB; B-MYB; 2-HYBRID SYSTEM; A-MYB; HISTONE DEACETYLASE; COACTIVATOR CBP; GENE-EXPRESSION; FUSION PARTNER	The carboxyl terminus of c-Myb contains a negative regulatory domain that is absent in the v-Myb oncoprotein, but conserved among all the known Myb proteins of animals. This domain inhibits transcriptional activation by c-Myb in animal cells, but not in budding yeast, suggesting that additional protein(s) present in animal cells but not yeast are required for this negative regulatory function. A yeast two-hybrid screen identified BS69, an adenovirus E1A-associated protein, as interacting with the carboxy-terminal region of c-Myb, BS69 contains regions of similarity to the PHD finger, the bromodomain, and the MYND domain, all of which are found in other proteins present in high molecular weight complexes that regulate transcription and/or modify chromatin structure. Further study showed that BS69 inhibited the transcriptional activity of c-Myb, that this inhibition was specific, that it mapped to the carboxyl termini of the two proteins and that it was dose-dependent. A direct interaction between these two proteins was observed in vitro, Furthermore, the 289R E1A protein could inhibit the BS69-mediated decrease in transcriptional activation by c-Myb, By analogy with the inhibition of the Rb/E2F regulatory axis by EIA, we propose that a BS69/Myb regulatory circuit may also be a target of disruption during oncogenesis.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University	Lipsick, JS (corresponding author), Stanford Univ, Sch Med, Dept Pathol, 300 Pasteur Dr, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007290] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA65609] Funding Source: Medline; NIAID NIH HHS [T32 AI07290] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CHEN RH, 1995, ONCOGENE, V11, P1771; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Coffman JA, 1997, DEVELOPMENT, V124, P4717; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; Dubendorff JW, 1999, ONCOGENE, V18, P3452, DOI 10.1038/sj.onc.1202679; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; Fu SL, 1996, J VIROL, V70, P5600, DOI 10.1128/JVI.70.8.5600-5610.1996; Fu SL, 1997, CELL GROWTH DIFFER, V8, P35; Ganter B, 1999, ADV CANCER RES, V76, P21, DOI 10.1016/S0065-230X(08)60773-3; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gibbons RJ, 1997, NAT GENET, V17, P146, DOI 10.1038/ng1097-146; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; HATEBOER G, 1995, EMBO J, V14, P3159, DOI 10.1002/j.1460-2075.1995.tb07318.x; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; Kiewitz A, 1997, FEBS LETT, V415, P258, DOI 10.1016/S0014-5793(97)01134-4; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Lipsick JS, 1996, ONCOGENE, V13, P223; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Masselink H, 2000, ONCOGENE, V19, P1538, DOI 10.1038/sj.onc.1203421; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Saville MK, 1998, ADV CANCER RES, V72, P109; SENECA S, 1993, ONCOGENE, V8, P2335; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Tomita A, 1998, LEUKEMIA, V12, P1422, DOI 10.1038/sj.leu.2401113; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	53	49	52	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					125	132		10.1038/sj.onc.1204048	http://dx.doi.org/10.1038/sj.onc.1204048			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244510				2022-12-17	WOS:000166361400014
J	Ducret, C; Maira, SM; Lutz, Y; Wasylyk, B				Ducret, C; Maira, SM; Lutz, Y; Wasylyk, B			The ternary complex factor Net contains two distinct elements that mediate different responses to MAP kinase signalling cascades	ONCOGENE			English	Article						docking; phosphorylation; Ras; transcription; repression; export	ACTIVATED PROTEIN-KINASES; TRANSCRIPTION FACTOR PHO4; CYCLIN-CDK COMPLEX; C-JUN; TRANSDUCTION PATHWAY; SIGNALING SPECIFICITY; UV-LIGHT; HA-RAS; DOMAIN; JNK	The ternary complex factors (TCFs), Elk-1, Sap-1a and Net, are key integrators of the transcriptional response to different signalling pathways. Classically, three MAP kinase pathways, involving ERK, JNK, and p38, transduce various extracellular stimuli to the nucleus. Net is a repressor that is converted into an activator by Ras/ERK signalling. Net is also exported from the nucleus in response to stress stimuli transduced through the JNK pathway, leading to relief from repression. Here we show that ERK and p38 bind to the D box and that binding is required for phosphorylation of the adjacent C-terminally located C-domain, The D box as web as the phosphorylation sites in the C-domain (the DC element) are required for transcription activation by Pas. On the other hand, JNK binds to the J box in the middle of the protein, and binding is required for phosphorylation of the adjacent EXport motif. Both the binding and phosphorylation sites (the JEX element) are important for Net export. In conclusion, specific targeting of Net by MAP kinase pathways involves two different docking sites and phosphorylation of two different domains. These two elements, DC and JEX, mediate two distinct functional responses.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch Graffenstaden, France.		Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Ducret C, 1999, MOL CELL BIOL, V19, P7076; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Sprague GF, 1998, GENE DEV, V12, P2817, DOI 10.1101/gad.12.18.2817; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	46	49	51	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2000	19	44					5063	5072		10.1038/sj.onc.1203892	http://dx.doi.org/10.1038/sj.onc.1203892			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042694				2022-12-17	WOS:000089930100003
J	Yoshida, S; Kaneita, Y; Aoki, Y; Seto, M; Mori, S; Moriyama, M				Yoshida, S; Kaneita, Y; Aoki, Y; Seto, M; Mori, S; Moriyama, M			Identification of heterologous translocation partner genes fused to the BCL6 gene in diffuse large B-cell lymphomas: 5 '-RACE and LA-PCR analyses of biopsy samples	ONCOGENE			English	Article						BCL6; translocation; hypermutation; lymphoma	NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; SOMATIC HYPERMUTATION; BURKITT-LYMPHOMA; CHROMOSOMAL BREAKPOINT; 3Q27 TRANSLOCATION; MOLECULAR-CLONING; ONCOGENE; LOCUS; PROTEIN	In order to elucidate the molecular mechanism(s) for BCL6 translocation, we identified translocational partner genes by subjecting clinical biopsy samples from patients with non-Hodgkin's lymphoma to 5'-rapid amplification of cDNA ends (5'-RACE). Sequence analysis of the 5'-RACE product revealed that the BCL6 gene was fused to the J segment of the immunoglobulin heavy chain (IgH) gene in about half of the cases, but in the other half, it was fused to heterologous partners, including the MHC class II transactivator (CIITA), pim-1, eukaryotic initiation factor 4AII (ejf4AII), transferrin receptor (TFRR) and ikaros genes, Since analyses using genomic long and accurate (LA)-PCR revealed that the breakpoints in the partner gene mere confined to the first intron or the second exon in all cases, the promoter and the first exon of the BCL6 gene mere replaced by the promoter and the first or both the first and second exon of the partner gene, The breakpoint Banking sequences had no recombination signal sequences (RSSs) or chi sequences and were homologous with the switch region only when the BCL6 gene was fused to the IgH gene, suggesting that BCL6 translocation cannot be explained solely by mistakes of V(D)J, or chi-mediated or class-switch recombination, but rather another mechanism may also be required to explain the molecular mechanism for the promiscuous BCL6 translocation.	Univ Tokyo, Inst Med Sci, Dept Pathol, Tokyo, Japan; Aichi Canc Inst, Lab Chemotherapy, Nagoya, Aichi, Japan; Tottori Univ, Fac Med, Sch Life Sci, Dept Mol Biol, Tottori 6838503, Japan	University of Tokyo; Aichi Cancer Center; Tottori University	Moriyama, M (corresponding author), Tottori Univ, Fac Med, Sch Life Sci, Dept Mol Biol, 86 Nishimachi, Tottori 6838503, Japan.							Akasaka T, 1997, CANCER RES, V57, P7; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BASTARD C, 1994, BLOOD, V83, P2423; BENARDIN F, 1997, ONCOGENE, V14, P849; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DALLAFAVERA R, 1993, CAUSES CONSEQUENCES, P313; DALLERY E, 1995, ONCOGENE, V10, P2171; GAIDANO G, 1998, BIOL HIGH GRADE MALI, P353; Galieque-Zouitina S, 1996, LEUKEMIA, V10, P579; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; HARRIS NL, 1994, BLOOD, V84, P1361; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Klein U, 1998, IMMUNOL REV, V162, P261; MIKI T, 1994, BLOOD, V83, P217; MIKI T, 1994, BLOOD, V83, P26; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; Ohno H, 1997, LEUKEMIA LYMPHOMA, V27, P53, DOI 10.3109/10428199709068271; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; SUZUKI K, 1994, JPN J CANCER RES, V85, P911, DOI 10.1111/j.1349-7006.1994.tb02968.x; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1993, HUMAN B CELL NEOPLAS, P333; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZUTTER MM, 1998, BIOL LOW GRADE MALIG, P337	33	49	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7994	7999		10.1038/sj.onc.1203293	http://dx.doi.org/10.1038/sj.onc.1203293			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637510				2022-12-17	WOS:000084634600008
J	Maung, K; Easty, DJ; Hill, SP; Bennett, DC				Maung, K; Easty, DJ; Hill, SP; Bennett, DC			Requirement for focal adhesion kinase in tumor cell adhesion	ONCOGENE			English	Article						FAK; tyrosine kinase; melanoma; antisense oligonucleotides; focal adhesion	PROTEIN-TYROSINE KINASE; NORMAL HUMAN MELANOCYTES; SIGNAL-TRANSDUCTION; MALIGNANT-MELANOMA; EXPRESSION; PP125(FAK); PHOSPHORYLATION; FIBRONECTIN; APOPTOSIS; MATRIX	Focal adhesion kinase (FAK) is a nonreceptor protein tyrosine kinase and a major phosphotyrosine-containing protein. FAK is found in cell-matrix attachment sites (focal adhesions), and is activated on integrin-ligand binding and by other signaling pathways. Several roles have been proposed for FAK; here we report a novel function. We observed abundant FAK protein in all human melanoma cell lines tested except COLO839, a line that grows predominantly in suspension and was derived from peripheral blood. Five adherent lines, isolated from solid metastases in the same patient as COLO839, did express FAK. We derived four adherent sublines from COLO839. These did express FAK, even when plated on bacteriological plastic, to which they did not adhere. Thus, substrate attachment was not required for FAK expression. Three of the adherent sublines were then grown in the presence of antisense oligonucleotides to the initial FAK coding sequence. All showed substantially reduced FAK expression and, interestingly, the cells largely detached from the substrate while continuing to grow. Similar results were obtained with an independent melanoma line, DX3. Thus, FAK expression appears to be required by melanoma cells for substrate adhesion.	St George Hosp, Sch Med, Dept Anat & Dev Biol, London SW17 0RE, England	St Georges University London	Bennett, DC (corresponding author), St George Hosp, Sch Med, Dept Anat & Dev Biol, Cranmer Terrace, London SW17 0RE, England.		Bennett, Dorothy C/C-2418-2008	Bennett, Dorothy C/0000-0002-3639-7527				AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Crooke ST, 1996, ANNU REV PHARMACOL, V36, P107, DOI 10.1146/annurev.pa.36.040196.000543; EASTY DJ, 1993, J INVEST DERMATOL, V101, P679, DOI 10.1111/1523-1747.ep12371675; EASTY DJ, 1995, INT J CANCER, V60, P129, DOI 10.1002/ijc.2910600119; Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FURUTA Y, 1995, ONCOGENE, V11, P1989; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Ilic D, 1997, J CELL SCI, V110, P401; ILLC D, 1995, NATURE, V377, P539; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEE ST, 1993, ONCOGENE, V8, P3403; MIELE ME, 1994, EXP CELL RES, V214, P231, DOI 10.1006/excr.1994.1253; MORSE HG, 1993, CANCER GENET CYTOGEN, V69, P108, DOI 10.1016/0165-4608(93)90083-X; Otey CA, 1996, INT REV CYTOL, V167, P161, DOI 10.1016/S0074-7696(08)61347-9; OWENS LV, 1995, CANCER RES, V55, P2752; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROZENGURT E, 1995, CANCER SURV, V24, P81; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCOTT G, 1995, EXP CELL RES, V219, P197, DOI 10.1006/excr.1995.1219; Scott G, 1997, J INVEST DERMATOL, V108, P147, DOI 10.1111/1523-1747.ep12332650; Shibata K, 1998, CANCER RES, V58, P900; Sonoda Y, 1997, BIOCHEM BIOPH RES CO, V241, P769, DOI 10.1006/bbrc.1997.7895; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; VANDENOORD JJ, 1994, AM J PATHOL, V145, P294; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; ZHANG XA, 1995, GENE, V160, P219, DOI 10.1016/0378-1119(95)00153-W	38	49	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6824	6828		10.1038/sj.onc.1203094	http://dx.doi.org/10.1038/sj.onc.1203094			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597292				2022-12-17	WOS:000083792000026
J	Darbinian, N; Gallia, GL; Kundu, M; Shcherbik, N; Tretiakova, A; Giordano, A; Khalili, K				Darbinian, N; Gallia, GL; Kundu, M; Shcherbik, N; Tretiakova, A; Giordano, A; Khalili, K			Association of Pur alpha and E2F-1 suppresses transcriptional activity of E2F-1	ONCOGENE			English	Article						single-stranded DNA binding protein; Pur alpha; E2F-1; protein-protein interaction	SINGLE-STRANDED-DNA; CELLULAR PROTEINS YB-1; BINDING PROTEIN; RETINOBLASTOMA PROTEIN; CONTROL ELEMENT; TUMOR-ANTIGEN; CYCLE CONTROL; GENE; REPLICATION; COMPONENTS	Protein-protein interaction can play an important role in the control of several biological events including gene transcription, replication and cell proliferation. E2F-1 is a DNA-binding transcription factor which, upon interaction with its target DNA sequence, induces expression of several S phase specific genes allowing progression of the cell cycle. Evidently, the activity of this protein is modulated by its cellular partner, pRb, which in the hypophosphorylated form, binds to E2F-1 and inactivates its transcriptional ability. In this study, we have demonstrated that expression of a sequence-specific single-stranded DNA binding protein, Pur alpha, in cells decreases the ability of E2F-1 to exert its transcriptional activity upon the responsive promoter derived from DHFR, Results from band shift experiments revealed that while Pur alpha does not recognize the double-stranded DNA fragment containing the E2F-1 binding site, it has the ability to inhibit E2F-1 interaction with its target DNA sequence. Results from GST pull-down assays and the combined immunoprecipitation/Western blot analysis of nuclear extracts revealed a direct association of E2F-1 with Pur alpha in the absence of the DNA molecule containing the E2F-1 binding site, The association of Pur alpha with E2F-1 may increase the stability of E2F-1, as a higher level of E2F-1 was detected in cells coexpressing Pur alpha and E2F-1, The importance of these observations with respect to the role of Pur alpha in the control of cell cycle progression is discussed.	Med Coll Penn & Hahnemann Univ, Sch Med, Ctr Neurovirol & Neurooncol, Philadelphia, PA 19102 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Sbarro Inst Canc Res, Philadelphia, PA 19107 USA	Drexel University; Jefferson University	Khalili, K (corresponding author), Med Coll Penn & Hahnemann Univ, Sch Med, Ctr Neurovirol & Neurooncol, 245 N 15th St,MS 406, Philadelphia, PA 19102 USA.		Kundu, Mondira/N-8139-2018; Giordano, Antonio/F-1927-2010	Kundu, Mondira/0000-0001-9946-2472; Giordano, Antonio/0000-0002-5959-016X				BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; CHEN NN, 1995, J VIROL, V69, P5843, DOI 10.1128/JVI.69.9.5843-5848.1995; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAAS S, 1995, J CELL BIOL, V130, P1171, DOI 10.1083/jcb.130.5.1171; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; Krachmarov CP, 1996, P NATL ACAD SCI USA, V93, P14112, DOI 10.1073/pnas.93.24.14112; Kundu M, 1997, J BIOL CHEM, V272, P29468, DOI 10.1074/jbc.272.47.29468; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; MA ZW, 1994, GENE, V149, P311, DOI 10.1016/0378-1119(94)90167-8; NEVINS JR, 1992, SCIENCE, V258, P424; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zambrano N, 1997, BIOCHEM J, V328, P293, DOI 10.1042/bj3280293	17	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6398	6402		10.1038/sj.onc.1203011	http://dx.doi.org/10.1038/sj.onc.1203011			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597240				2022-12-17	WOS:000083934100025
J	Bulavin, DV; Tararova, ND; Aksenov, ND; Pospelov, VA; Pospelova, TV				Bulavin, DV; Tararova, ND; Aksenov, ND; Pospelov, VA; Pospelova, TV			Deregulation of p53/p21(Cip1/Waf1) pathway contributes to polyploidy and apoptosis of E1A+cHa-ras transformed cells after gamma-irradiation	ONCOGENE			English	Article						transformation; E1A; cHa-ras; p53/Rb-pathway; G1/S and G2/M checkpoints	ANTICANCER AGENTS; DNA-REPLICATION; E7 ONCOPROTEIN; E1A PROTEINS; ADENOVIRUS; P21; P53; TRANSCRIPTION; ARREST; P21(CIP1/WAF1)	The p53/p21(CiP1/Waf1)-dependent checkpoint control of G1/S and G2/M phases of the cell cycle in response to DNA damage is an important mechanism of genome stability maintenance in normal cells. In many tumor cells, due to frequent point mutations and deletions of p53, the stringent control of the cell cycle and apoptosis is compromised. We have examined the cell cycle control and cell death of the rat embryo fibroblast cells (REF) transformed by E1A + cHa-ras oncogenes and expressing wild type p53, Gamma-irradiation at a dosage of 6 Gy has been used to analyse the p53-dependent transactivation of the target p21(cip1/waf1) gene and the levels of activity of cyclin-dependent kinases, Our results show that the cell cycle inhibitors p21(Cip1/Waf1) and p27(KIP) accumulate in response to irradiation both in REF and E1A+cHa-ras cells. In contrast to normal REF cells, the accumulation of p21(Cip1\Waf1) and p27(KIP) inhibitors, however, does not lead to inhibition of Cdk2 and cyclins E, A-associated kinase activities and to a G1/S block in E1A+cHa-ras cells. It is unlikely that the lack of inhibitory function of p21(Cip1/Waf1) can be explained by its inability to bind Cdk2 and Cdk4 kinases or PCNA, Moreover, the p21(Cip1/Waf1)-associated kinase activity is increased upon gamma-irradiation of E1A + cHa-ras cells. We suggest that inactivation of p21(Cip1/Waf1) may be accounted for by its interaction with E1A oncoproducts as the inhibitor is detected in immunoprecipitates using E1A-specific antibodies. During a temporary G2/M delay induced by gamma-irradiation, E1A+cHa-ras transformants continue DNA replication, which leads to accumulation of polyploid cells with lobulated nuclei and micronuclei, Thus, DNA damage of E1A + cHa-ras transformed cells, with a combination of functionally active wild type p53 and inactive p21(Cip1/Waf1), contributes to formation of polyploid cells which then die due to apoptosis.	Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Pospelova, TV (corresponding author), Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia.		Aksenov, Nikolay D/F-1679-2017					Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHOU T, 1993, ONCOGENE, V8, P1765; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Duyndam MCA, 1996, J VIROL, V70, P5852, DOI 10.1128/JVI.70.9.5852-5859.1996; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kranenburg O, 1996, J VIROL, V70, P7804, DOI 10.1128/JVI.70.11.7804-7810.1996; Kurash YK, 1998, MOL BIOL+, V32, P308; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUDBERG AS, 1993, MOL CELL BIOL, V18, P753; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; Nakajima T, 1998, J BIOL CHEM, V273, P20036, DOI 10.1074/jbc.273.32.20036; NEVINS JR, 1992, SCIENCE, V258, P424; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Orlovskaya EI, 1997, MOL BIOL+, V31, P184; Poon RYC, 1998, ONCOGENE, V16, P1333, DOI 10.1038/sj.onc.1201897; POSPELOV VA, 1994, CELL GROWTH DIFFER, V5, P187; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEKIYA T, 1985, JPN J CANCER RES, V76, P851; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SPITOVSKY D, 1994, J VIROL, V72, P975; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zerfass K, 1996, J VIROL, V70, P2637, DOI 10.1128/JVI.70.4.2637-2642.1996	38	49	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	1999	18	41					5611	5619		10.1038/sj.onc.1202945	http://dx.doi.org/10.1038/sj.onc.1202945			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523840				2022-12-17	WOS:000083016500001
J	Schrantz, N; Blanchard, DA; Auffredou, MT; Sharma, S; Leca, G; Vazquez, A				Schrantz, N; Blanchard, DA; Auffredou, MT; Sharma, S; Leca, G; Vazquez, A			Role of caspases and possible involvement of retinoblastoma protein during TGF beta-mediated apoptosis of human B lymphocytes	ONCOGENE			English	Article						B lymphocytes; apoptosis; TGF beta; caspases; retinoblastoma protein	PROGRAMMED CELL-DEATH; GROWTH FACTOR-BETA; S-PHASE ENTRY; CPP32-LIKE PROTEASES; TRANSFORMING GROWTH-FACTOR-BETA-1; POLY(ADP-RIBOSE) POLYMERASE; TRANSCRIPTION FACTOR; MAMMALIAN HOMOLOG; FAMILY PROTEASES; RAT HEPATOCYTES	In this study, we investigated the involvement of caspases in TGF beta-induced apoptosis in human B cells. Our results show that TGF beta-mediated nuclear fragmentation, observed in the Epstein-Barr virus-negative Burkitt's Lymphoma cell line BL41, was abolished in the presence of the tripeptide caspase inhibitor zVAD-fmk or the specific caspase-3 inhibitor DEVD-fmk. Other apoptotic manifestations such as cell shrinkage, surface phosphatidylserine expression and chromatin condensation were strongly inhibited by zVAD-fmk but only partially by DEVD-fmk. This suggests that other caspases in addition to caspase-3 control these apoptotis-associated features. Specific activation of caspase-3 during TGF beta-induced apoptosis was demonstrated by the DEVD-fmk-sensitive expression of the active p17 subunit of caspase-3 and by in vivo cleavage of PARP. In addition, TGP beta treatment of BL41 promoted the expression of both dephosphorylated and truncated forms of the retinoblastoma protein. Inhibition of caspase-3 activity abolished both nuclear fragmentation and expression of the truncated retinoblastoma protein, without modifying the G1 cell cycle arrest induced by TGF beta. Our data thus demonstrate that TGF beta-induced apoptosis of lymphoma B lymphocytes is dependent on caspase activation and involves caspase-dependent cleavage of the retinoblastoma protein.	IPSC, INSERM, U131, F-92140 Clamart, France; Ctr Claude Bernard CJF 95 2, F-92140 Clamart, France; Women & Infants Hosp Rhode Isl, Dept Pediat, Providence, RI 02908 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Women & Infants Hospital Rhode Island	Vazquez, A (corresponding author), IPSC, INSERM, U131, 32 Rue Carnets, F-92140 Clamart, France.							Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; An B, 1996, CANCER RES, V56, P438; Anel A, 1997, J IMMUNOL, V158, P1999; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Berry DE, 1996, ONCOGENE, V12, P1809; CHAOUCHI N, 1995, ONCOGENE, V11, P1615; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; CHUANG LY, 1994, ANTICANCER RES, V14, P147; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fan GS, 1996, ONCOGENE, V12, P1909; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; KATO J, 1993, GENE DEV, V7, P331; KEHRL JH, 1986, J IMMUNOL, V137, P3855; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; LOMO J, 1995, J IMMUNOL, V154, P1634; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NEVINS JR, 1992, SCIENCE, V258, P424; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shiokawa D, 1997, FEBS LETT, V413, P99, DOI 10.1016/S0014-5793(97)00887-9; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Tan XQ, 1997, J BIOL CHEM, V272, P9613; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wang H, 1996, ONCOGENE, V13, P373; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	58	49	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3511	3519		10.1038/sj.onc.1202718	http://dx.doi.org/10.1038/sj.onc.1202718			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376529				2022-12-17	WOS:000080850600009
J	Tsubakimoto, K; Matsumoto, K; Abe, H; Ishii, J; Amano, M; Kaibuchi, K; Endo, T				Tsubakimoto, K; Matsumoto, K; Abe, H; Ishii, J; Amano, M; Kaibuchi, K; Endo, T			Small GTPase RhoD suppresses cell migration and cytokinesis	ONCOGENE			English	Article						small GTPase; Rho family; actin cytoskeleton; cell motility; cytokinesis	ACTIN STRESS FIBERS; PROTO-ONCOGENE PRODUCT; FOCAL ADHESIONS; BINDING PROTEIN; REGULATED EXPRESSION; HEMATOPOIETIC-CELLS; SMOOTH-MUSCLE; IN-VIVO; KINASE; GENE	Rho family small GTPases regulate organization of the actin cytoskeleton, Among them, RhoA plays essential roles in the formation of the actin stress fibers, the associated focal adhesions, and the contractile rings necessary for cytokinesis, Recently, RhoD, a novel member of Rho family has been identified. The amino acid sequences of its effector domain is distinct from those of the other Rho family proteins, suggesting its unique cellular functions. Introduction of the constitutively active form of RhoD(G26V) into fibroblasts by microinjection or transfection resulted in disassembly of the actin stress fibers and the focal adhesions, whereas the dominant negative form of RhoD(G26V) did not affect these structures. The degree of cell migration assessed by the phagokinetic tracks on a substrate covered with gold particles was diminished by the expression of RhoD(G26V) but not by RhoD(T31K). Thus, cytoskeletal alterations including the loss of stress fibers and focal adhesions by RhoD seems to lead to the retardation of cell migration. Transfection of RhoD(G26V) cDNA into cultured cells also induced multinucleation, Moreover, RhoD(G26V) microinjected into fertilized eggs and embryos of Xenopus laevis caused cleavage arrest only in the injected cells, and the uncleaved cells contained multiple nuclei. These results imply that RhoD does not affect nuclear division but can interfere with cytokinesis presumably by preventing the formation of the actin-based contractile ring. Enhancement of the stress fibers by RhoA or RhoA-activating lysophosphatidic acid was reversed by the transfection of RhoD cDNA, Accordingly, the cellular functions of RhoD are likely to be antagonistic to those of RhoA.	Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan; Nara Inst Sci & Technol, Div Signal Transduct, Nara 6300101, Japan	Chiba University; Nara Institute of Science & Technology	Endo, T (corresponding author), Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan.		Amano, Mutsuki/M-4820-2014	Amano, Mutsuki/0000-0002-0662-1524				AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; del Peso L, 1997, ONCOGENE, V15, P3047; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Dutartre H, 1996, J CELL SCI, V109, P367; ENDO T, 1982, BIOCHEM BIOPH RES CO, V107, P1467, DOI 10.1016/S0006-291X(82)80164-2; Endo T, 1996, J BIOL CHEM, V271, P27855, DOI 10.1074/jbc.271.44.27855; Endo T, 1998, J CELL SCI, V111, P1081; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Foster R, 1996, MOL CELL BIOL, V16, P2689; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leung T, 1996, MOL CELL BIOL, V16, P5313; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; MANSER E, 1995, METHOD ENZYMOL, V256, P130; Marks PW, 1996, GENOMICS, V38, P13, DOI 10.1006/geno.1996.0586; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MOLL J, 1991, ONCOGENE, V6, P863; MORII N, 1995, METHOD ENZYMOL, V256, P196; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Nakamura T, 1996, BIOCHEM BIOPH RES CO, V226, P688, DOI 10.1006/bbrc.1996.1415; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; SEGADE F, 1995, J IMMUNOL, V154, P2384; SELF AJ, 1993, ONCOGENE, V8, P655; SHIRSAT NV, 1990, ONCOGENE, V5, P769; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	64	49	53	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2431	2440		10.1038/sj.onc.1202604	http://dx.doi.org/10.1038/sj.onc.1202604			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229194	Bronze			2022-12-17	WOS:000079703300003
J	Schmidt, M; Maurer-Gebhard, M; Groner, B; Kohler, G; Brochmann-Santos, G; Wels, W				Schmidt, M; Maurer-Gebhard, M; Groner, B; Kohler, G; Brochmann-Santos, G; Wels, W			Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors	ONCOGENE			English	Article						epidermal growth factor receptor; EGFR-vIII; monoclonal antibody 14E1; single chain Fv; immunotoxin	GROWTH-FACTOR RECEPTOR; PSEUDOMONAS EXOTOXIN; MONOCLONAL-ANTIBODIES; LUNG CARCINOMAS; TYROSINE KINASE; FV-FRAGMENTS; EXPRESSION; MUTANT; TUMORS; CELLS	Cytotoxic strategies which are directed to tumor-associated antigens might be most beneficial for cancer patients with minimal tumor load such as in an adjuvant setting after initial therapy, We have recently described a highly potent single chain antibody-toxin, scFv(14E1)-ETA, which consists of the variable domains of the antibody 14E1 genetically fused to a truncated form of Pseudomonas exotoxin A. ScFv(14E1)-ETA specifically recognizes the human epidermal growth factor receptor (EGFR) and the oncogenically activated receptor variant EGFRvIII, which have been implicated in the development of various human malignancies. Here we have investigated the antimetastatic activity of bacterially expressed scFv(14E1)-ETA and its disulfide-stabilized derivative ds-scFv(14E1)-ETA in a novel model for disseminated disease which is based on murine renal carcinoma cells subsequently transfected with the E. coli P-galactosidase gene, and human full-length or variant EGFR cDNAs, Intravenous injection of these Renca-lacZ/EGFR and Renca-lacZ/EGFRvIII cells in syngenic Balb/c mice led to the formation of pulmonary metastases which were readily detectable upon excision of the lungs and X-gal staining, Systemic treatment of mice with scFv(14E1)-ETA resulted in the complete suppression of Renca-lacZ/EGFRvIII metastasis formation and drastically reduced the number of pulmonary Renca-lacZ/EGFR tumor nodules, The ds-scFv(14E1)-ETA derivative where the antibody variable regions are connected by an artificial disulfide bond displayed improved thermal stability at physiological temperature but due to reduced cytotoxic activity was less potent than the original scFv(14E1)-ETA in metastasis suppression.	Georg Speyer Haus Inst Biomed Res, D-60596 Frankfurt, Germany; Tumor Biol Ctr, Inst Expt Canc Res, D-79106 Freiburg, Germany; Univ Freiburg, Dept Pathol, D-79104 Freiburg, Germany	University of Freiburg	Wels, W (corresponding author), Georg Speyer Haus Inst Biomed Res, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.			Wels, Winfried/0000-0001-9858-3643				Altenschmidt U, 1997, INT J CANCER, V73, P117, DOI 10.1002/(SICI)1097-0215(19970926)73:1<117::AID-IJC18>3.0.CO;2-D; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; Fan Zhen, 1998, Current Opinion in Oncology, V10, P67, DOI 10.1097/00001622-199801000-00011; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; Groner B, 1997, INT J CANCER, V70, P682, DOI 10.1002/(SICI)1097-0215(19970317)70:6<682::AID-IJC10>3.0.CO;2-C; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; HILLS D, 1995, INT J CANCER, V63, P537, DOI 10.1002/ijc.2910630414; HUMPHREY PA, 1988, CANCER RES, V48, P2231; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; Kabat EA, 1991, SEQUENCES PROTEINS I; Lorimer IAJ, 1996, P NATL ACAD SCI USA, V93, P14815, DOI 10.1073/pnas.93.25.14815; Luo Dong, 1995, Journal of Biochemistry (Tokyo), V118, P825; Maurer-Gebhard M, 1998, CANCER RES, V58, P2661; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; MURPHY GP, 1973, JNCI-J NATL CANCER I, V50, P1013, DOI 10.1093/jnci/50.4.1013; OGATA M, 1992, J BIOL CHEM, V267, P25396; Pai LH, 1996, NAT MED, V2, P350, DOI 10.1038/nm0396-350; Pantel K, 1996, CURR TOP MICROBIOL, V213, P1; PANTEL K, 1993, JNCI-J NATL CANCER I, V85, P1419, DOI 10.1093/jnci/85.17.1419; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; Reiter Y, 1996, NAT BIOTECHNOL, V14, P1239, DOI 10.1038/nbt1096-1239; Schmidt M, 1998, INT J CANCER, V75, P878, DOI 10.1002/(SICI)1097-0215(19980316)75:6<878::AID-IJC10>3.3.CO;2-U; Schmidt M, 1997, BRIT J CANCER, V75, P1575, DOI 10.1038/bjc.1997.270; Spyridonidis A, 1998, BLOOD, V91, P1820, DOI 10.1182/blood.V91.5.1820.1820_1820_1827; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; WELS W, 1995, INT J CANCER, V60, P137, DOI 10.1002/ijc.2910600120; Wels W, 1996, CURR TOP MICROBIOL, V213, P113; WELS W, 1992, CANCER RES, V52, P6310; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; YAMAZAKI H, 1990, JPN J CANCER RES, V81, P773, DOI 10.1111/j.1349-7006.1990.tb02644.x; Young NM, 1995, FEBS LETT, V377, P135, DOI 10.1016/0014-5793(95)01325-3	32	49	89	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1711	1721		10.1038/sj.onc.1202489	http://dx.doi.org/10.1038/sj.onc.1202489			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208432				2022-12-17	WOS:000079025000006
J	Biden, KG; Simms, LA; Cummings, M; Buttenshaw, R; Schoch, E; Searle, J; Gobe, G; Jass, JR; Meltzer, SJ; Leggett, BA; Young, J				Biden, KG; Simms, LA; Cummings, M; Buttenshaw, R; Schoch, E; Searle, J; Gobe, G; Jass, JR; Meltzer, SJ; Leggett, BA; Young, J			Expression of bcl-2 protein is decreased in colorectal adenocarcinomas with microsatellite instability	ONCOGENE			English	Article						bcl-2; apoptosis; microsatellite instability; colorectal adenocarcinoma	PROGRAMMED CELL-DEATH; C-MYB; CANCER; P53; APOPTOSIS; GENE; SURVIVAL; COLON; POLYMORPHISM; INHIBITION	Bcl-2 is known to inhibit apoptosis and is thought to play a role in colorectal tumour development. Studies of the promoter region of bcl-2 have indicated the presence of a p53 responsive element which downregulates bcl-2 expression, Since p53 is commonly mutated in colorectal cancers, but rarely in those tumours showing microsatellite instability (MSI), the aim of this study was to examine the relationship of bcl-2 protein expression to MSI, as well as to other clinicopathological and molecular variables, in colorectal adenocarcinomas. Expression of bcl-2 was analysed by immunohistochemistry in 71 colorectal cancers which had been previously assigned to three classes depending upon their levels of MSI. MSI-high tumours demonstrated instability in three or more of six microsatellite markers tested, MSI-low tumours in one or two of six, and MSI-null in none of six, Bcl-2 expression in tumours was quantified independently by two pathologists and assigned to one of five categories, with respect to the number of cells which showed positive staining: 0, up to 5%; 1, 6-25%; 2, 26-50%; 3, 51-75%; and 4, greater than or equal to 76%, Bcl-2 negative tumours were defined as those with a score of 0. Bcl-2 protein expression was tested for association with clinicopathological stage, differentiation level, tumour site, age, sex, survival, evidence of p53 inactivation and MSI level, A significant association was found between bcl-2 expression and patient survival (P = 0.012, Gehan Wilcoxon test). Further, a significant reciprocal relationship was found between bcl-2 expression and the presence of MSI (P = 0.012, Wilcoxon rank sum test). We conclude that bcl-2 expressing colorectal cancers are more likely to be MSI-null, and to be associated with improved patient survival.	Royal Brisbane Hosp Fdn Clin Res Ctr, Conjoint Gastroenterol Lab, Brisbane, Qld, Australia; Royal Brisbane Hosp, Dept Pathol, Brisbane, Qld 4029, Australia; Univ Queensland, Dept Pathol, Brisbane, Qld, Australia; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Greenbaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Grad Program Mol & Cell Biol, Baltimore, MD 21201 USA; Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA	Royal Brisbane & Women's Hospital; University of Queensland; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center	Biden, KG (corresponding author), RBHRF, Clin Res Ctr, Conjoint Gastroenterol Lab, Bancroft Ctr, 300 Herston Rd, Brisbane, Qld 4029, Australia.		Cummings, Margaret/B-5747-2011; Young, Joanne P/H-7774-2014; Young, Joanne P/B-9981-2011; Leggett, Barbara A/D-3579-2011; Gobe, Glenda C/G-2315-2010	Cummings, Margaret/0000-0002-7657-0240; Simms, Lisa/0000-0002-5387-7397; Leggett, Barbara/0000-0003-2062-7380	NATIONAL CANCER INSTITUTE [R01CA077057, R01CA067497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER; NCI NIH HHS [CA67497, CA77057] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEDI A, 1995, CANCER RES, V55, P1811; BJERKESET T, 1987, DIS COLON RECTUM, V30, P934, DOI 10.1007/BF02554279; BRONNER MP, 1995, AM J PATHOL, V146, P20; Cottu PH, 1996, ONCOGENE, V13, P2727; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; HAGUE A, 1994, ONCOGENE, V9, P3367; HENRIKSEN R, 1995, BRIT J CANCER, V72, P1324, DOI 10.1038/bjc.1995.509; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Jass JR, 1998, GUT, V42, P673, DOI 10.1136/gut.42.5.673; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; Kaklamanis L, 1996, J PATHOL, V179, P10; KASTAN MB, 1991, CANCER RES, V51, P6304; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lukish JR, 1998, ANN SURG, V227, P51, DOI 10.1097/00000658-199801000-00008; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIYASHITA T, 1994, CANCER RES, V54, P3131; OFNER D, 1995, BRIT J CANCER, V72, P981, DOI 10.1038/bjc.1995.446; OLSCHWANG S, 1991, HUM GENET, V86, P369; PIETENPOL JA, 1994, CANCER RES, V54, P3714; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; Simms LA, 1998, ONCOGENE, V17, P2003, DOI 10.1038/sj.onc.1202109; Simms LA, 1997, ONCOGENE, V14, P2613, DOI 10.1038/sj.onc.1201094; SINICROPE FA, 1995, CANCER RES, V55, P237; Sun XF, 1996, APMIS, V104, P35, DOI 10.1111/j.1699-0463.1996.tb00683.x; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thompson MA, 1997, ONCOGENE, V14, P1715, DOI 10.1038/sj.onc.1201007; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Vairo G, 1996, ONCOGENE, V13, P1511; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Watson AJM, 1996, BRIT J CANCER, V73, P889, DOI 10.1038/bjc.1996.178; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686	35	49	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1245	1249		10.1038/sj.onc.1202413	http://dx.doi.org/10.1038/sj.onc.1202413			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022131				2022-12-17	WOS:000078510700014
J	Uchida, H; Downing, JR; Miyazaki, Y; Frank, R; Zhang, J; Nimer, SD				Uchida, H; Downing, JR; Miyazaki, Y; Frank, R; Zhang, J; Nimer, SD			Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter	ONCOGENE			English	Article						transcription; repression; TEL-AML1	ACUTE LYMPHOBLASTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; ACUTE LYMPHOCYTIC-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; T(8-21) FUSION PROTEIN; ACUTE MYELOID-LEUKEMIA; HUMAN RECOMBINANT IL-3; CORE BINDING-FACTOR; MYELOPROLIFERATIVE DISORDERS; CHROMOSOMAL TRANSLOCATION	A cytogenetically cryptic (12;21) translocation is the most common molecular abnormality identified in childhood acute lymphoblastic leukemia (ALL), and it generates a chimeric TEL-AML1 protein. Fusion of the Helix-Loop-Helix (HLH) (also called the pointed) domain of TEL to AML1 has been suggested to convert AML1 from a transcriptional activator to a repressor. To define the structural features of this chimeric protein required for repression, we analysed the transcriptional activity of a series of TEL-AML1 mutants on the AML1-responsive interleukin-3 (IL-3) promoter, potentially relevant gene target. Our results demonstrate that TEL-AML1 represses basal IL-3 promoter activity in lymphoid cells, and deletion mutant analysis identified three distinct domains of TEL-AML1 that are required for repression; the HLH (pointed) motif contained in the TEL portion of TEL-AML1, and both the runt homology domain (Rhd) and the 74 amino acids downstream of the Rhd that are present in the AML1 portion of the fusion protein. Although AML1B (and a shorter AML1 isoform, AML1A) have transcriptional activating activity on the IL-3 promoter, fusion of the AML1 gene to the TEL gene generates a repressor of IL-3 expression. Consistent with this activity, freshly isolated human ALL cells that contain TEL-AML1 do not express IL-3.	Mem Sloan Kettering Canc Ctr, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38109 USA	Memorial Sloan Kettering Cancer Center; St Jude Children's Research Hospital	Nimer, SD (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Mol Aspects Hematopoiesis, 1275 York Ave, New York, NY 10021 USA.		Downing, James R./N-8102-2018		NCI NIH HHS [CA 70388] Funding Source: Medline; NIDDK NIH HHS [DK43025, DK 52208] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052208, R56DK052208, R01DK043025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguiar RCT, 1996, BRIT J HAEMATOL, V95, P673, DOI 10.1046/j.1365-2141.1996.d01-1946.x; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; BUIJS A, 1995, ONCOGENE, V10, P1511; CANN AJ, 1988, ONCOGENE, V3, P123; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; ERICKSON P, 1992, BLOOD, V80, P1825; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Frank R, 1995, ONCOGENE, V11, P2667; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GRIMALDI JC, 1989, BLOOD, V73, P2081; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; KINASHI T, 1988, P NATL ACAD SCI USA, V85, P4473, DOI 10.1073/pnas.85.12.4473; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; LENNY N, 1995, ONCOGENE, V11, P1761; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; McLean TW, 1996, BLOOD, V88, P4252; MEEKER TC, 1990, BLOOD, V76, P285; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; Miyazaki Y, 1996, ONCOGENE, V13, P1721; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; NIMER SD, 1995, STEM CELLS, V13, P324, DOI 10.1002/stem.5530130402; NUCIFORA G, 1995, BLOOD, V86, P1; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, CANCER RES, V57, P564; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Raynaud S, 1996, LEUKEMIA, V10, P1529; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; ROGERS SY, 1994, EXP HEMATOL, V22, P593; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Shih LY, 1996, LEUKEMIA, V10, P1456; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; TADMORI W, 1989, J IMMUNOL, V142, P1950; Uchida H, 1997, J IMMUNOL, V158, P2251; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WOLIN M, 1993, ONCOGENE, V8, P1905; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; XIA X, 1992, J IMMUNOL, V148, P491; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0; Yonemura Y, 1996, P NATL ACAD SCI USA, V93, P4040, DOI 10.1073/pnas.93.9.4040; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	54	49	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					1015	1022		10.1038/sj.onc.1202383	http://dx.doi.org/10.1038/sj.onc.1202383			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023677				2022-12-17	WOS:000078510600018
J	Oehrl, W; Kardinal, C; Ruf, S; Adermann, K; Groffen, J; Feng, GS; Blenis, J; Tan, TH; Feller, SM				Oehrl, W; Kardinal, C; Ruf, S; Adermann, K; Groffen, J; Feng, GS; Blenis, J; Tan, TH; Feller, SM			The germinal center kinase (GCK)-related protein kinases HPK1 and KHS are candidates for highly selective signal transducers of Crk family adapter proteins	ONCOGENE			English	Article						Crk; CRKL; SH3; HPK1; KHS; kinase; adapter	N-TERMINAL KINASE; PROLINE-RICH SEQUENCES; SRC HOMOLOGY-3 DOMAINS; CELL ANTIGEN RECEPTOR; SH3 DOMAIN; C-CRK; GROWTH-FACTOR; EXCHANGE FACTOR; TYROSINE PHOSPHORYLATION; JUN KINASE	Adapter proteins function by mediating the rapid and specific assembly of multi-protein complexes during the signal transduction which guards proliferation, differentiation and many functions of higher eukaryotic cells, To understand their functional roles in different cells it is important to identify the selectively interacting proteins in these cells. Two novel candidates for signalling partners of Crk family adapter proteins, the hematopoietic progenitor kinase 1 (HPK1) and the kinase homologous to SPS1/STE20 (KHS), were found to bind with great selectivity to the first SH3 domains of c-Crk and CRKL. While KHS bound exclusively to Crk family proteins, HPK1 also interacted with both SH3 domains of Grb2 and weakly with Nck, but not with more than 25 other SH3 domains tested. The interaction of HPK1 with c-Crk and CRKL was studied in more detail. HPK1-binding to the first SH3 domain of CRKL is direct and occurs via proline-rich motifs in the C-terminal, non-catalytic portion of HPK1. In vitro complexes were highly stable and in vivo complexes of c-Crk and CRKL with HPK1 were detectable by co-immnnoprecipitation with transiently transfected cells but also with endogenous proteins. Furthermore, c-Crk II and, to a lesser extent, CRKL were substrates for HPK1, These results make it likely that HPK1 and KHS participate in the signal transduction of Crk family adapter proteins in certain cell types.	Univ Wurzburg, Oncol Mol Lab, Inst Med Radiat & Cell Res, MSZ, D-97078 Wurzburg, Germany; Lower Saxony Inst Peptide Res, IPF, D-30625 Hannover, Germany; Childrens Hosp, Dept Mol Pathol, Los Angeles, CA 90027 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	University of Wurzburg; Children's Hospital Los Angeles; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Harvard University; Harvard Medical School; Baylor College of Medicine	Feller, SM (corresponding author), Univ Wurzburg, Oncol Mol Lab, Inst Med Radiat & Cell Res, MSZ, D-97078 Wurzburg, Germany.		Heisterkamp, Nora/C-1698-2012; Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010	Heisterkamp, Nora/0000-0003-2769-2273; Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049875] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI38649] Funding Source: Medline; NIGMS NIH HHS [R01-GM49875] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FELLER SM, 1995, METHOD ENZYMOL, V255, P369; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FORD AM, 1992, BLOOD, V79, P1962, DOI 10.1182/blood.V79.8.1962.bloodjournal7981962; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HATZ P, 1994, J BIOL CHEM, V269, P16802; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Husson H, 1997, ONCOGENE, V14, P2331, DOI 10.1038/sj.onc.1201074; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Okada S, 1996, J BIOL CHEM, V271, P25533, DOI 10.1074/jbc.271.41.25533; Osada S, 1997, ONCOGENE, V14, P2047, DOI 10.1038/sj.onc.1201043; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; Sattler M, 1996, ONCOGENE, V12, P839; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Schwartz RH, 1997, CURR OPIN IMMUNOL, V9, P351, DOI 10.1016/S0952-7915(97)80081-7; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Smit L, 1996, ONCOGENE, V13, P381; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Tari AM, 1997, BIOCHEM BIOPH RES CO, V235, P383, DOI 10.1006/bbrc.1997.6791; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Torres M, 1996, ONCOGENE, V12, P77; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang BL, 1996, ONCOGENE, V13, P1379; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	58	49	51	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	1998	17	15					1893	1901		10.1038/sj.onc.1202108	http://dx.doi.org/10.1038/sj.onc.1202108			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788432				2022-12-17	WOS:000076423500002
J	Badache, A; Muja, N; De Vries, GH				Badache, A; Muja, N; De Vries, GH			Expression of Kit in neurofibromin-deficient human Schwann cells: role in Schwann cell hyperplasia associated with type 1 neurofibromatosis	ONCOGENE			English	Article						neurofibromatosis; Schwann cells; c-kit proto-oncogene; stem cell factor; growth factors	PERIPHERAL-NERVE; TYROSINE KINASE; C-KIT; GENE; TUMOR; PROLIFERATION; PROTEIN; GROWTH; TYRPHOSTINS; SEQUENCE	Type 1 Neurofibromatosis (NF1) is characterized by the formation of neurofibromas, benign tumors composed mainly of Schwann cells, which can turn malignant to form neurofibrosarcomas. Neurofibromin, the protein product of the Nf1 gene, is believed to act as a tumor suppressor, accelerating the conversion of the oncogene Ras to its inactive form. The absence of neurofibromin could therefore lead to higher Ras activity in Schwann cells, resulting in uncontrolled growth through a cascade of events not yet elucidated. We describe the abnormal expression of high levels of the Kit tyrosine kinase receptor in both NF1-derived Schwann cell lines and tissue, as compared to primary Schwann cells or schwannoma-derived cells. High levels of Kit expression in the neurofibrosarcoma-derived Schwann cells correlate with a decrease in neurofibromin expression. Using inhibitors of tyrosine kinase receptors, we found that proliferation of the neurofibrosarcoma-derived cells is dependent: upon activation of a subclass of tyrosine-kinase receptors. The proliferation of these cells is not dependent upon an autocrine loop involving typical Schwann cell mitogens. Finally, the proliferation of the neurofibrosarcoma-derived Schwann cells can be increased by stimulation with Kit ligand. These data implicate Kit as one of the components leading to the Schwann cell hyperplasia observed in NF1.	Loyola Univ, Dept Anat Cell Biol & Neurobiol, Chicago, IL 60611 USA; Hines VA Hosp, Hines, IL 60141 USA	Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital	Badache, A (corresponding author), Loyola Univ, Dept Anat Cell Biol & Neurobiol, Chicago, IL 60611 USA.		Badache, Ali/Q-6098-2017	Badache, Ali/0000-0001-7710-2505				BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BLEECHMAN JM, 1993, J BIOL CHEM, V268, P4399; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DATSON MM, 1992, NEURON, V8, P415; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DUCATMAN BS, 1986, CANCER-AM CANCER SOC, V57, P2006, DOI 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6; FLEMING TP, 1992, ONCOGENE, V7, P1355; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; Guha A, 1996, ONCOGENE, V12, P507; GUTMANN DH, 1993, J NEUROSCI RES, V36, P216, DOI 10.1002/jnr.490360212; Halling KC, 1996, AM J CLIN PATHOL, V106, P282; He JL, 1997, P NATL ACAD SCI USA, V94, P3954, DOI 10.1073/pnas.94.8.3954; HINES SJ, 1995, CELL GROWTH DIFFER, V6, P769; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KIM HA, 1995, ONCOGENE, V11, P325; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; Lee MMS, 1996, J NEUROSCI RES, V46, P204; LEVITZKI A, 1991, TRENDS PHARMACOL SCI, V12, P171, DOI 10.1016/0165-6147(91)90538-4; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; NITTA T, 1994, NEUROSURGERY, V34, P309, DOI 10.1227/00006123-199402000-00014; RICCARDI VM, 1991, NEW ENGL J MED, V324, P1283, DOI 10.1056/NEJM199105023241812; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RYAN JJ, 1994, J NEUROSCI RES, V37, P415, DOI 10.1002/jnr.490370314; Sudhalter J, 1996, GLIA, V17, P28, DOI 10.1002/(SICI)1098-1136(199605)17:1<28::AID-GLIA3>3.0.CO;2-3; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WILLIAMS DE, 1992, DEV BIOL, V151, P368, DOI 10.1016/0012-1606(92)90176-H; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x	31	49	51	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					795	800		10.1038/sj.onc.1201978	http://dx.doi.org/10.1038/sj.onc.1201978			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715282				2022-12-17	WOS:000075337200015
J	Maru, Y; Yamaguchi, S; Shibuya, M				Maru, Y; Yamaguchi, S; Shibuya, M			Flt-1, a receptor for vascular endothelial growth factor, has transforming and morphogenic potentials	ONCOGENE			English	Article						Flt-1; VEGF; BCR-ABL; tyrosine kinase; transformation	BCR-ABL ONCOGENE; TYROSINE KINASE; SIGNAL-TRANSDUCTION; V-ABL; PHILADELPHIA-CHROMOSOME; C-ABL; PROTEIN; ACTIVATION; LEUKEMIA; DOMAIN	A paradox of Flt-1, a tyrosine kinase receptor for vascular endothelial growth factor (VEGF), is that the ligand cannot activate the receptor to stimulate growth of cells that exogenously overexpress the receptor. In order to find Flt-1 kinase-dependent biological systems, we obtained for the first time activated forms of the Flt-1 kinase in a ligand-independent manner. Replacement of the ABL sequences in the human leukemia oncoprotein BCR-ABL with the cytoplasmic domain of Flt-1 (BCR-FLT) followed by a retroviral random mutagenesis scheme gave constitutively active artificial chimera BCR-FLTm with mutations within the Flt-1 sequence. Like BCR-ABL it could, but not the original BCR-FLT, transform Rat1 fibroblasts, abrogate cytokine dependence in Ba/F3 cells, and induce neurite-like structures in neuronal PC12 cells. Interestingly, Rat1 cells transformed by BCR-FLTm formed tube-like structures in basement membrane matrix. BCR-FLTm retroviruses may be a very useful tool to investigate an as yet uncovered functions of the Flt-1 kinase.	Univ Tokyo, Inst Med Sci, Dept Genet, Tokyo, Japan	University of Tokyo	Maru, Y (corresponding author), Univ Tokyo, Inst Med Sci, Dept Genet, Tokyo, Japan.							AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Ahmed A, 1997, LAB INVEST, V76, P779; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FREEMAN AE, 1973, P NATL ACAD SCI USA, V70, P2415, DOI 10.1073/pnas.70.8.2415; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; Maru Y, 1996, EXP CELL RES, V229, P438, DOI 10.1006/excr.1996.0389; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MATHEYPREVOT B, 1988, MOL CELL BIOL, V8, P234, DOI 10.1128/MCB.8.1.234; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; NILSEN T, 1995, CELL, V41, P719; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PAJUSOLA K, 1992, CANCER RES, V52, P5738; Parmar K, 1996, J VIROL, V70, P1009, DOI 10.1128/JVI.70.2.1009-1015.1996; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; Raffel GD, 1996, J BIOL CHEM, V271, P4640; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; SEETHARAM L, 1995, ONCOGENE, V10, P135; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065-230X(08)60716-2; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Ziche M, 1997, LAB INVEST, V76, P517	58	49	50	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2585	2595		10.1038/sj.onc.1201786	http://dx.doi.org/10.1038/sj.onc.1201786			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632135				2022-12-17	WOS:000073698200003
J	Bongarzone, I; Vigano, E; Alberti, L; Borrello, MG; Pasini, B; Greco, A; Mondellini, P; Smith, DP; Ponder, BAJ; Romeo, G; Pierotti, MA				Bongarzone, I; Vigano, E; Alberti, L; Borrello, MG; Pasini, B; Greco, A; Mondellini, P; Smith, DP; Ponder, BAJ; Romeo, G; Pierotti, MA			Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation	ONCOGENE			English	Article						RET; MEN2B; GDNF	MEDULLARY-THYROID CARCINOMA; NEOPLASIA TYPE 2B; TYROSINE KINASE; ADAPTER PROTEINS; C-RET; PROTOONCOGENE; DISEASE; RECEPTOR; GERMLINE; 2A	Germline mutations of RET gene, encoding a receptor tyrosine kinase, have been associated with the MEN2A and MEN2B inherited cancer syndromes, In MEN2A mutations affecting cysteine residues in the extracellular domain of the receptor cause constitutive activation of the tyrosine kinase by the formation of disulfide-bonded homodimers. In MEN2B a single mutation in the tyrosine kinase domain (Met918Thr) has been identified. This mutation does not lead to dimer formation, but has been shown (both biologically and biochemically) to cause ligand-independent activation of the Ret protein, but to a lesser extent than MEN2A mutations. Intramolecular activation by cis-autophosphorylation of RetMEN2B monomers has been proposed as a model for activation, although alternative mechanisms can be envisaged, Here we show that the activity of RetMEN2B can be increased by stable dimerization of the receptor. Dimerization was achieved experimentally by constructing a double mutant receptor with a MEN2A mutation (Cys634Arg) in addition to the MEN2B mutation, and by chronic exposure of RetMEN2B-expressing cells to the Ret ligand GDNF. In both cases full activation of RetMEN2B, measured by 'in vitro' transfection assays and biochemical parameters, was seen. These results indicate that the MEN2B phenotype could be influenced by the tissue distribution or concentration of Ret ligand(s).	Ist Nazl Tumori, Div Expt Oncol A, I-20133 Milan, Italy; Ist Nazl Tumori, Sci Direct, I-20133 Milan, Italy; Univ Cambridge, CRC, Human Canc Genet Res Grp, Cambridge CB2 2QQ, England; Int Agcy Res Canc, F-69372 Lyon 08, France	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Cambridge; World Health Organization; International Agency for Research on Cancer (IARC)	Bongarzone, I (corresponding author), Ist Nazl Tumori, Div Expt Oncol A, Via Venezian 1, I-20133 Milan, Italy.		Pierotti, Marco Alessandro/AAC-4728-2022; Pasini, Barbara/AHI-2004-2022; Greco, Angela/C-1953-2017; Bongarzone, Italia/B-9544-2017; Borrello, Maria Grazia/C-3161-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Pasini, Barbara/0000-0002-4373-1212; Greco, Angela/0000-0003-2994-0349; Bongarzone, Italia/0000-0003-2530-9170; Borrello, Maria Grazia/0000-0002-6854-2848				Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; Borrello MG, 1995, ONCOGENE, V11, P2419; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec PL, 1996, DEVELOPMENT, V122, P349; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Eng C, 1996, CANCER RES, V56, P2167; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Marsh DJ, 1996, CANCER RES, V56, P1241; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; Ponder BAJ, 1996, ADV CANCER RES, V70, P179, DOI 10.1016/S0065-230X(08)60875-1; Rizzo C, 1996, J BIOL CHEM, V271, P29497, DOI 10.1074/jbc.271.46.29497; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Suvanto P, 1997, HUM MOL GENET, V6, P1267, DOI 10.1093/hmg/6.8.1267; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1997, J NEUROSCI, V17, P3554; Widenfalk J, 1997, J NEUROSCI, V17, P8506	34	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2295	2301		10.1038/sj.onc.1201759	http://dx.doi.org/10.1038/sj.onc.1201759			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620546				2022-12-17	WOS:000073428000001
J	Falasca, M; Iurisci, C; Carvelli, A; Sacchetti, A; Corda, D				Falasca, M; Iurisci, C; Carvelli, A; Sacchetti, A; Corda, D			Release of the mitogen lysophosphatidylinositol from H-Ras-transformed fibroblasts; a possible mechanism of autocrine control of cell proliferation	ONCOGENE			English	Article						lysophospholipids; glycerophosphoinositols; inositol 1 : 2-cyclic phosphate; lipid metabolism; ras oncogene; thyroid cells	THYROID EPITHELIAL-CELLS; AORTIC ENDOTHELIAL-CELLS; LYMPHOCYTE-T ACTIVATION; MURINE SARCOMA-VIRUS; PROTEIN-KINASE-C; PHOSPHOLIPASE-C; INOSITOL 2-PHOSPHATE; SIGNALING PATHWAYS; ADENYLATE-CYCLASE; IONOPHORE A23187	Lysophosphatidylinositol (LysoPtdIns) is formed by a constitutively-active phosphoinositide-specific phospholipase A(2) in Ras-transformed cells and can stimulate cell proliferation. To evaluate whether LysoPtdIns could function as an autocrine modulator of cell growth, we examined whether LysoPtdIns can be released in the medium of Ras-transformed FRT-Fibro fibroblasts and thyroid cells. Here, we report that LysoPtdIns accumulates in the extracellular space of these lines and reaches levels up to tenfold higher than in the case of normal cells. Moreover, the ionophore A23187 increased the levels of the lysolipid in the extracellular medium. Extracellular LysoPtdIns was rapidly hydrolyzed to inositol 1:2-cyclic phosphate. LysoPtdIns induced thymidine incorporation in FRT-Fibro Ha-Ras fibroblasts, whereas inositol cyclic 1:2-cyclic phosphate did not affect cell growth per se, nor did it interfere with the LysoPtdIns mitogenic activity. We hypothesize that in Ras-transformed fibroblasts the formation and release of LysoPtdIns may function as an autocrine mechanism that participates in the Ras-dependent stimulation of cell growth.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Chieti, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Corda, D (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Via Nazl, I-66030 Santa Maria Imbaro, Chieti, Italy.		Corda, Daniela/K-6385-2016; Sacchetti, Andrea/H-8763-2019; Falasca, Marco/S-4020-2016	Corda, Daniela/0000-0002-3614-751X; Falasca, Marco/0000-0002-9801-7235				ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; ALONSO T, 1990, BIOCHEM BIOPH RES CO, V171, P14, DOI 10.1016/0006-291X(90)91349-W; AMBESIIMPIOMBAT.FS, 1989, FRTL 5 TODAY; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; ASAOKA Y, 1991, BIOCHEM BIOPH RES CO, V178, P1378, DOI 10.1016/0006-291X(91)91046-F; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; BARAN DT, 1988, ENDOCRINOLOGY, V122, P930, DOI 10.1210/endo-122-3-930; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BICKNELL R, 1988, P NATL ACAD SCI USA, V85, P5961, DOI 10.1073/pnas.85.16.5961; BILLAH MM, 1982, J BIOL CHEM, V257, P5196; BIRRELL GB, 1995, BIOCHEM BIOPH RES CO, V211, P318, DOI 10.1006/bbrc.1995.1813; CHIARIOTTI L, 1992, ONCOGENE, V7, P2507; COLETTA G, 1983, MOL CELL BIOL, V3, P2099; Corda D, 1996, ANTICANCER RES, V16, P1341; DAWSON RMC, 1971, BIOCHEM J, V122, P605, DOI 10.1042/bj1220605; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Falasca M, 1997, MOL BIOL CELL, V8, P443, DOI 10.1091/mbc.8.3.443; FALASCA M, 1995, ONCOGENE, V10, P2113; Falasca M, 1996, EUR J BIOCHEM, V241, P386, DOI 10.1111/j.1432-1033.1996.00386.x; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; FRANCEL P, 1988, BIOCHEM BIOPH RES CO, V152, P724, DOI 10.1016/S0006-291X(88)80098-6; FUSCO A, 1981, INT J CANCER, V28, P655, DOI 10.1002/ijc.2910280519; FUSCO A, 1982, CANCER RES, V42, P618; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GRAHAM RA, 1987, J BIOL CHEM, V262, P35; HONG SL, 1985, THROMB RES, V38, P1; HONG SL, 1982, J BIOL CHEM, V257, P7151; IACOVELLI L, 1993, J BIOL CHEM, V268, P20402; IMAGAWA W, 1995, EXP CELL RES, V216, P178, DOI 10.1006/excr.1995.1022; KAYA H, 1989, J BIOL CHEM, V264, P4972; KIM JW, 1989, BIOCHEM BIOPH RES CO, V163, P177, DOI 10.1016/0006-291X(89)92117-7; KOLAROVIC L, 1986, ANAL BIOCHEM, V156, P244, DOI 10.1016/0003-2697(86)90179-X; LAMBERT TL, 1986, J BIOL CHEM, V261, P5288; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; MARCOCCI C, 1983, J ENDOCRINOL INVEST, V6, P463, DOI 10.1007/BF03348346; MARTIN TM, 1986, J BIOL CHEM, V262, P13086; METZ SA, 1986, BIOCHEM BIOPH RES CO, V138, P720, DOI 10.1016/S0006-291X(86)80556-3; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; ROSS TS, 1991, J BIOL CHEM, V266, P9086; ROSS TS, 1991, J BIOL CHEM, V266, P851; ROSS TS, 1992, J BIOL CHEM, V267, P19924; SASAKAWA N, 1995, BIOCHEM PHARMACOL, V50, P137, DOI 10.1016/0006-2952(95)00059-9; SEKAR MC, 1993, BIOCHEM BIOPH RES CO, V192, P1079, DOI 10.1006/bbrc.1993.1527; SMITH DM, 1992, J LEUKOCYTE BIOL, V52, P670, DOI 10.1002/jlb.52.6.670; TING AE, 1991, EUR J CELL BIOL, V56, P401; TING AE, 1990, J BIOL CHEM, V265, P5337; VALENTE WA, 1983, ENDOCRINOLOGY, V112, P71, DOI 10.1210/endo-112-1-71; VALITUTTI S, 1991, CELL SIGNAL, V3, P321, DOI 10.1016/0898-6568(91)90061-X; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; VOLWERK JJ, 1992, J CELL PHYSIOL, V151, P613, DOI 10.1002/jcp.1041510322; WEILTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099; ZOELLER RA, 1987, J BIOL CHEM, V262, P17212	55	49	51	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2357	2365		10.1038/sj.onc.1201758	http://dx.doi.org/10.1038/sj.onc.1201758			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620553				2022-12-17	WOS:000073428000008
J	Bertolotto, C; Bille, K; Ortonne, JP; Ballotti, R				Bertolotto, C; Bille, K; Ortonne, JP; Ballotti, R			In B16 melanoma cells, the inhibition of melanogenesis by TPA results from PKC activation and diminution of microphthalmia binding to the M-box of the tyrosinase promoter	ONCOGENE			English	Article						tyrosinase; TPA; PKC; cAMP; microphthalmia	PROTEIN-KINASE-C; NORMAL HUMAN MELANOCYTES; MESSENGER-RNA LEVELS; STIMULATING HORMONE; DOWN-REGULATION; RETINOIC ACID; MAMMALIAN TYROSINASE; GENE-PRODUCT; EXPRESSION; ALPHA	In B16 melanoma cells, cAMP-induced melanogenesis is inhibited by the tumor promoting phorbol ester, TPA, However, the role of PKC activation or depletion in the inhibition of melanogenesis by TPA remains controversial, In this report, using specific PKC inhibitors, ne demonstrated that PKC inhibition does not impair cAMP-induced melanin synthesis and tyrosinase expression, Further, the inhibition of melanogenesis by TPA results from a decrease of the tyrosinase promoter transcriptional activity and this effect is mimicked by over-expression of a constitutively active form of PKC alpha, These findings clearly demonstrate that PKC activation accounts for the inhibition of melanin synthesis by TPA, Additional experiments were undertaken to elucidate the mechanism by which TPA inhibits the tyrosinase gene transcription, Deletions and mutation in the tyrosinase promoter showed that TPA acts on a M-box which is involved in tissue-specific expression and regulation ba cAMP of the tyrosinase gene, We showed that TPA decreases the binding of microphthalmia, a basic helix-loop-helix transcription factor, to the M-box. Since microphthalmia, strongly stimulates the transcriptional activity of the promoter we propose that TPA, through PKC activation, decreases microphthalmia binding to the M-box of the tyrosinase promoter, thereby leading to a reduced tyrosinase expression and melanogenesis inhibition.					Bertolotto, Corine/AAF-6634-2021; Bertolotto-Ballotti, Corine/O-2155-2016; BALLOTTI, Robert/F-8825-2013	Bertolotto, Corine/0000-0001-6971-7753; BALLOTTI, Robert/0000-0002-7322-4908				ABDELMALEK Z, 1992, J CELL PHYSIOL, V150, P416, DOI 10.1002/jcp.1041500226; ABERDAM E, 1993, J CELL SCI, V106, P1015; ANDO H, 1995, J CELL PHYSIOL, V163, P608, DOI 10.1002/jcp.1041630322; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; BROOKS G, 1993, J BIOL CHEM, V268, P23868; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; FRIEDMANN PS, 1990, J CELL PHYSIOL, V142, P334, DOI 10.1002/jcp.1041420216; FULLER BB, 1990, MOL CELL ENDOCRINOL, V72, P81, DOI 10.1016/0303-7207(90)90097-R; FULLER BB, 1979, LIFE SCI, V24, P2405, DOI 10.1016/0024-3205(79)90448-X; GANSS R, 1994, J BIOL CHEM, V269, P29808; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; GRUBER JR, 1995, EXP CELL RES, V221, P377, DOI 10.1006/excr.1995.1388; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HUNT G, 1994, J CELL SCI, V107, P205; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; JIMENEZ M, 1988, P NATL ACAD SCI USA, V85, P3830, DOI 10.1073/pnas.85.11.3830; KOBAYASHI T, 1994, EMBO J, V13, P5818, DOI 10.1002/j.1460-2075.1994.tb06925.x; KUZUMAKI T, 1993, EXP CELL RES, V207, P33, DOI 10.1006/excr.1993.1159; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; Mahalingam H, 1996, J CELL PHYSIOL, V168, P549, DOI 10.1002/(SICI)1097-4652(199609)168:3<549::AID-JCP7>3.0.CO;2-P; Oka M, 1996, J INVEST DERMATOL, V106, P377, DOI 10.1111/1523-1747.ep12343168; OKA M, 1993, J INVEST DERMATOL, V100, pS204, DOI 10.1111/1523-1747.ep12465200; OKA M, 1995, J INVEST DERMATOL, V105, P567, DOI 10.1111/1523-1747.ep12323485; PARK HY, 1993, J BIOL CHEM, V268, P11742; Park HY, 1996, EXP CELL RES, V227, P70, DOI 10.1006/excr.1996.0251; STOCKER KM, 1991, DEVELOPMENT, V111, P635; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0; YAVUZER U, 1995, ONCOGENE, V10, P123; YOKOYAMA K, 1994, J BIOL CHEM, V269, P27080; YOKOYAMA K, 1994, BBA-GENE STRUCT EXPR, V1217, P317, DOI 10.1016/0167-4781(94)90292-5	33	49	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1665	1670		10.1038/sj.onc.1201685	http://dx.doi.org/10.1038/sj.onc.1201685			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582014				2022-12-17	WOS:000072807600004
J	O'Rourke, DM; Nute, EJL; Davis, JG; Wu, CJ; Lee, A; Murali, R; Zhang, HT; Qian, XL; Kao, CC; Greene, MI				O'Rourke, DM; Nute, EJL; Davis, JG; Wu, CJ; Lee, A; Murali, R; Zhang, HT; Qian, XL; Kao, CC; Greene, MI			Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly	ONCOGENE			English	Article						heterodimer; mutant epidermal growth factor receptor; p185neu; trans-receptor inhibition	GROWTH-FACTOR RECEPTOR; NEU DIFFERENTIATION FACTOR; TYROSINE KINASE-ACTIVITY; NECROSIS-FACTOR RECEPTOR; SIGNAL-TRANSDUCTION; INTERMOLECULAR ASSOCIATION; EXTRACELLULAR DOMAIN; HUMAN GLIOBLASTOMAS; DOWN-REGULATION; POINT MUTATION	Mutant Epidermal Growth Factor Receptor (EGFR) oncoproteins lacking most of subdomains I and II of the extracellular region, a deletion which includes most of the first of two cysteine-rich sequences, have been observed in multiple human epithelial tumors, including malignant gliomas, These EGFR oncoproteins, designated Delta EGFR or EGFRvIII, confer increased tumorigenicity in vivo and are often coexpressed with full-length EGFR in human tumors, We have expressed an ectodomain-derived, carboxyl-terminal deletion mutant of the p185neu oncogene (T691stop) in human glioblastoma cells coexpressing endogenous EGFR and activated Delta EGFR oncoproteins, The p185neu ectodomain-derived mutant forms heterodimers with Delta EGFR proteins and reduces the phosphotyrosine content and kinase activity of Delta EGFR monomers, As a consequence of T691stop neu expression and surface localization, cell proliferation in conditions of full growth and reduced serum and anchorage-independent growth in soft agar was reduced in glioblastoma cells expressing either endogenous EGFR alone or coexpressing EGFR and elevated levels of Delta EGFRs. T691stop neu mutant receptors abrogate the dramatic growth advantage conferred by Delta EGFR in vivo, suggesting that physical associations primarily between subdomains III and IV of the p185neu and EGFR ectodomains are sufficient to modulate signaling from activated EGFR complexes, Receptor-based inhibitory strategies exploit the thermodynamic preference for erbB ectodomains to heterodimerize, thereby creating erbB receptor assemblies which are defective in signaling and do not internalize. Pharmaceuticals which mimic the p185neu ectodomain may therefore have important therapeutic applications in advanced human malignancies expressing erbB receptors.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Canc, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	O'Rourke, DM (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 252 John Morgan Bldg,36th & Hamilton Walk, Philadelphia, PA 19104 USA.		O'Rourke, Donald/AAC-3376-2021	Murali, Ramachandran/0000-0002-8384-2793; O'Rourke, Donald/0000-0002-8479-7314; Zhang, Hongtao/0000-0001-9173-0049				Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARTER TH, 1994, CRIT REV ONCOGENESIS, V5, P389, DOI 10.1615/CritRevOncog.v5.i4.40; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; GROUSPORTA D, 1997, EMBO J, V16, P1647; GUY PM, 1992, J BIOL CHEM, V267, P13851; HALEY JD, 1989, ONCOGENE, V4, P273; Han YC, 1996, CANCER RES, V56, P3859; HE J, 1995, CANCER RES, V55, P4833; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELIN K, 1991, J BIOL CHEM, V266, P8363; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; KOHDA D, 1993, J BIOL CHEM, V268, P1976; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; LEVEA CM, 1993, RECEPTOR, V3, P293; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Louis DN, 1997, BRAIN PATHOL, V7, P755, DOI 10.1111/j.1750-3639.1997.tb01062.x; MASUI H, 1991, CANCER RES, V51, P6170; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1996, ONCOGENE, V13, P85; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; MURRAYRUST J, 1993, STRUCTURE, V1, P153, DOI 10.1016/0969-2126(93)90029-G; MYERS JN, 1992, RECEPTOR, V2, P1; NAISMITH JH, 1995, J BIOL CHEM, V270, P13303, DOI 10.1074/jbc.270.22.13303; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NISHIKAWA R, 1995, CANCER RES, V55, P1941; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; ORourke DM, 1997, P ASSOC AM PHYSICIAN, V109, P209; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; QIAN XL, 1995, ONCOGENE, V10, P211; Qian XL, 1996, ONCOGENE, V13, P2149; QIAN XL, 1994, ONCOGENE, V9, P1507; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; REIST CJ, 1995, CANCER RES, V55, P4375; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SOROKIN A, 1995, ONCOGENE, V11, P1531; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WARD CW, 1995, PROTEINS, V22, P141, DOI 10.1002/prot.340220207; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wikstrand CJ, 1997, CANCER RES, V57, P4130; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Worthylake R, 1997, J BIOL CHEM, V272, P8594, DOI 10.1074/jbc.272.13.8594	67	49	53	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1197	1207		10.1038/sj.onc.1201635	http://dx.doi.org/10.1038/sj.onc.1201635			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528862				2022-12-17	WOS:000072336000011
J	Sokolowski, M; Zhao, CP; Tan, W; Schwartz, S				Sokolowski, M; Zhao, CP; Tan, W; Schwartz, S			AU-rich mRNA instability elements on human papillomavirus type 1 late mRNAs and c-fos mRNAs interact with the same cellular factors	ONCOGENE			English	Article						HPV-1; c-fos; RNA stability; hnRNPC	HUMAN-IMMUNODEFICIENCY-VIRUS; MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; OPEN READING FRAME; REV GENE-PRODUCT; 3'-UNTRANSLATED REGION; BINDING PROTEINS; DNA-REPLICATION; NUCLEAR; SEQUENCE	Expression levels of human papillomavirus type 1 late genes are determined in part by an AU-rich inhibitory sequence in the 3' untranslated region on the late mRNAs. Fine mapping of the AU rich inhibitory sequence revealed that it mapped to a 57 nucleotide sequence, consisting of an AU-rich region containing two AUUUA motifs and a U-rich region containing three UUUUU motifs. An internal deletion showed that the U-rich region was required for inhibition, Point mutations in the AUUUA- and UUUUU-motifs inactivated the inhibitory sequence. Analysis of the stability of mRNAs containing the AU-rich sequence in sense or anti-sense orientation showed that mRNAs containing the AU-rich sequence in sense orientation had reduced half life. Analysis of RNA-protein interactions revealed that binding to the inhibitory sequence of three poly(U) binding proteins (38, 44 and 46 kDa) correlated with inhibition and that the same proteins bind to the AU-rich mRNA instability element in the 3' untranslated region on the human c-fos mRNA. We speculate that the human papillomavirus late mRNAs, produced from several hundred copies of the virus genome present in infected cells, compete with the c-fos mRNAs for destabilizing cellular factors and that this may lead to elevated Fos protein levels in human papillomavirus infected cells.	KAROLINSKA INST, MICROBIOL & TUMORBIOL CTR, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet				Sokolowski, Marcus/0000-0003-3931-1810				BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; CHEN CM, 1991, J BIOL CHEM, V266, P7754; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOU ZF, 1994, NUCLEIC ACIDS RES, V22, P2525, DOI 10.1093/nar/22.13.2525; CHOW LT, 1994, INTERVIROLOGY, V37, P150, DOI 10.1159/000150373; DANOS O, 1982, EMBO J, V1, P231, DOI 10.1002/j.1460-2075.1982.tb01152.x; DietrichGoetz W, 1997, P NATL ACAD SCI USA, V94, P163, DOI 10.1073/pnas.94.1.163; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; ENG AM, 1985, J CUTAN PATHOL, V12, P46, DOI 10.1111/j.1600-0560.1985.tb00429.x; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISHER C, 1991, DEVELOPMENT, V111, P253; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; FURTH PA, 1994, MOL CELL BIOL, V14, P5278, DOI 10.1128/MCB.14.8.5278; FURTH PA, 1991, J VIROL, V65, P5806, DOI 10.1128/JVI.65.11.5806-5812.1991; GORLACH M, 1994, J BIOL CHEM, V269, P23074; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grassmann K, 1996, J VIROL, V70, P2339, DOI 10.1128/JVI.70.4.2339-2349.1996; GRUSSENDORF EI, 1979, ARCH DERMATOL RES, V264, P55, DOI 10.1007/BF00417279; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HOWLEY P M, 1990, P1625; HOWLEY PM, 1991, FUNDAMENTAL VIROLOGY, V2, P743; JENSON AB, 1980, J NATL CANCER I, V64, P495; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; KENNEDY IM, 1991, J VIROL, V65, P2093, DOI 10.1128/JVI.65.4.2093-2097.1991; KENNEDY IM, 1990, J VIROL, V64, P1825, DOI 10.1128/JVI.64.4.1825-1829.1990; LAIMINS LA, 1993, INFECT AGENT DIS, V2, P74; LAMBERT PF, 1991, J VIROL, V65, P3417, DOI 10.1128/JVI.65.7.3417-3420.1991; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; LUUKKONEN BGM, 1995, J VIROL, V69, P4086, DOI 10.1128/JVI.69.7.4086-4094.1995; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; NAKAMAKI T, 1995, J CELL PHYSIOL, V165, P484, DOI 10.1002/jcp.1041650306; RAYMOND V, 1989, ONCOGENE RES, V4, P861; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; RUTHER U, 1989, ONCOGENE, V4, P861; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STAKNIS D, 1994, MOL CELL BIOL, V14, P2994, DOI 10.1128/MCB.14.5.2994; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; TAN W, 1995, J VIROL, V69, P2932, DOI 10.1128/JVI.69.5.2932-2945.1995; TAN W, 1995, J VIROL, V69, P5607, DOI 10.1128/JVI.69.9.5607-5620.1995; TUREK LP, 1994, ADV VIRUS RES, V44, P305, DOI 10.1016/S0065-3527(08)60332-2; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WENNBORG A, 1995, P NATL ACAD SCI USA, V92, P7322, DOI 10.1073/pnas.92.16.7322; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931; ZAIDI SHE, 1995, J BIOL CHEM, V270, P17292, DOI 10.1074/jbc.270.29.17292; Zhao CP, 1996, J VIROL, V70, P3659, DOI 10.1128/JVI.70.6.3659-3667.1996; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	57	49	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	1997	15	19					2303	2319		10.1038/sj.onc.1201415	http://dx.doi.org/10.1038/sj.onc.1201415			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393875	Bronze			2022-12-17	WOS:A1997YE15700005
J	Bates, NP; Hurst, HC				Bates, NP; Hurst, HC			An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression	ONCOGENE			English	Article						ERBB2; oestrogen repression; ERBB3; DNase I hypersensitive sites	HUMAN-BREAST-CANCER; GROWTH-FACTOR-RECEPTOR; NEGATIVE REGULATORY ELEMENTS; HER-2 NEU ONCOGENE; CELL-LINE MCF-7; ESTROGEN-RECEPTOR; C-ERBB-2 ONCOPROTEIN; PROTEIN EXPRESSION; POOR SURVIVAL; GENE	Overexpression of the ERBB2 gene in human breast cancer is associated with a poor prognosis and resistance to hormonal treatment and chemotherapy. Oestrogen receptor (ER) positive tumour-derived cell lines are known to express relatively low levels of ERBB2 protein under oestrogenic conditions, but markedly higher levels following withdrawal of oestrogens or administration of tamoxifen. Expression of the closely related ERBB3 gene, which co-operates with ERBB2 in cellular transformation, is now shown to respond to oestrogenic manipulation in a similar way, both responses being mediated largely by transcriptional changes. Six previously undescribed DNase I hypersensitive sites occur within the first intron of ERBB2 in cells that overexpress the gene. A 409 base pair DNA fragment containing one of these sites conferred ER dependent oestrogen inhibition on the ERBB2 promoter in two types of transient transfection assay. DNase I footprinting revealed four separate transcription factor binding sites within this fragment consistent with a role as a transcriptional enhancer. These findings implicate intron 1 sequences in the control of ERBB2 expression for the first time and demonstrate that one site within this region is involved in mediating the transcriptional response to oestrogens. Additionally, there is likely to be synergism between ERBB2 and ERBB3 signalling when both are overexpressed in response to oestrogen inhibition, thereby driving transformed cell behaviour.	HAMMERSMITH HOSP,IMPERIAL CANC RES FUND,MOL ONCOL UNIT,LONDON W12 0NN,ENGLAND	Cancer Research UK; Imperial College London								ADNANE J, 1989, ONCOGENE, V4, P1389; ALIMANDI M, 1995, ONCOGENE, V10, P1813; ANTONIOTTI S, 1994, BRIT J CANCER, V70, P1095, DOI 10.1038/bjc.1994.454; BATES NP, 1996, CLIN GENE ANAL MANIP, P332; BERCHUCK A, 1990, CANCER RES, V50, P4087; BORG A, 1990, CANCER RES, V50, P4332; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHEN YY, 1994, ONCOGENE, V9, P2269; CHRYSOGELOS SA, 1993, NUCLEIC ACIDS RES, V21, P5736, DOI 10.1093/nar/21.24.5736; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DARBRE P, 1983, CANCER RES, V43, P349; DATI C, 1990, ONCOGENE, V5, P1001; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; DSOUZA B, 1993, ONCOGENE, V8, P1797; *EARL BREAST CANC, 1992, LANCET, V339, P1; *EARL BREAST CANC, 1992, LANCET, V339, P71; GASPARINI G, 1992, J CLIN ONCOL, V10, P686, DOI 10.1200/JCO.1992.10.5.686; GASPARINI G, 1994, EUR J CANCER, V30A, P16, DOI 10.1016/S0959-8049(05)80010-3; GROOTECLAES M, 1994, CANCER RES, V54, P4193; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HALL PA, 1990, J PATHOL, V161, P195, DOI 10.1002/path.1711610305; HAYWARD JL, 1977, EUR J CANCER, V13, P89, DOI 10.1016/0014-2964(77)90234-1; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; JAKOWLEW SB, 1984, NUCLEIC ACIDS RES, V12, P2861, DOI 10.1093/nar/12.6.2861; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; MILLER SJ, 1994, INT J ONCOL, V4, P599; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; POWLES TJ, 1990, EUR J CANCER, V26, P680, DOI 10.1016/0277-5379(90)90116-B; PRESS MF, 1993, CANCER RES, V53, P4960; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; READ LD, 1990, CANCER RES, V50, P3947; ROBERTS S, 1992, EMBO J, V11, P1085, DOI 10.1002/j.1460-2075.1992.tb05147.x; RUSSELL KS, 1992, CANCER RES, V52, P6624; SARKAR FH, 1994, J BIOL CHEM, V269, P12285; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SKINNER A, 1993, ONCOGENE, V8, P3393; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEIN B, 1995, MOL CELL BIOL, V15, P4971; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TSU JY, 1985, NUCLEIC ACIDS RES, V13, P2485; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WARRI AM, 1991, INT J CANCER, V49, P616, DOI 10.1002/ijc.2910490425; WRIGHT C, 1989, CANCER RES, V49, P2087; WRIGHT C, 1992, BRIT J CANCER, V65, P118, DOI 10.1038/bjc.1992.22; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YOKOTA J, 1986, LANCET, V1, P765; YONEMURA Y, 1991, CANCER, V67, P2914, DOI 10.1002/1097-0142(19910601)67:11<2914::AID-CNCR2820671134>3.0.CO;2-G	63	49	51	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					473	481		10.1038/sj.onc.1201368	http://dx.doi.org/10.1038/sj.onc.1201368			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242384				2022-12-17	WOS:A1997XM23800012
J	Delia, D; Goi, K; Mizutani, S; Yamada, T; Aiello, A; Fontanella, E; Lamorte, G; Iwata, S; Ishioka, C; Krajewski, S; Reed, JC; Pierotti, MA				Delia, D; Goi, K; Mizutani, S; Yamada, T; Aiello, A; Fontanella, E; Lamorte, G; Iwata, S; Ishioka, C; Krajewski, S; Reed, JC; Pierotti, MA			Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations	ONCOGENE			English	Article						p53; p21(wafl); p34(CDC2); cell cycle; apoptosis	TUMOR-SUPPRESSOR P53; DNA-DAMAGING AGENTS; EPSTEIN-BARR-VIRUS; HUMAN B-CELLS; P53-DEPENDENT APOPTOSIS; THYMOCYTE APOPTOSIS; BCL-2 FAMILY; BINDING-SITE; BAX GENE; IN-VITRO	The radiation response was investigated in two lymphoblastoid cell lines (LBC) derived from families with heterozygous germ-line missense mutations of p53 at codon 282 (LBC282) and 286 (LBC286), and compared to cells with wt/wt p53(LBC-N). By gel retardation assays, we show that p53-containing nuclear extracts from irradiated LBC282 and LBC286 markedly differ in their ability to bind to a p53 DNA consensus sequence, the former generating a shifted band whose intensity is 30-40% that of LBC-N, the latter generating an almost undetectable band. Unlike LBC286, which fail to arrest in G(1) after irradiation, LBC282 have an apparently normal G(1)/S checkpoint, as they arrest in G(1) like LBC-N. While in LBC-N, accumulation of p53 and transactivation of p21(WAF1) increase rapidly and markedly by 3 h after exposure to gamma-radiation, in LBC286 there is only a modest accumulation of p53 and a significantly delayed and quantitatively reduced transactivation of p21(WAF1). Instead, in LBC282 while p53 levels rise little after irradiation, p21(WAF1) levels increase rapidly and significantly as in normal LBC. Apoptotic cells present 48 h after irradiation account for 32% in LBC-N, 8-9% in LBC282 and 5-7% in LBC286, while the dose of gamma-radiation required for killing 50% of cells (LD50) is 400 rads, 1190 rads and 3190 rads, respectively, hence indicating that the heterozygous mutations of p53 at codon 282 affects radioresistance and survival, but not the G(1)/S cell cycle control. In all LBC tested, radiation-induced apoptosis occurs in all phases of the cell cycle and appears not to directly involve changes in the levels of the apoptosis-associated proteins bcl-2, bax and mcl-1. Both basal as well as radiation-induced p53 and p21(WAF1) proteins are detected by Western blotting of FACS-purified G(1), S and G(2)/M fractions from the three cell lines. p34(CDC2-Tyr15), the inactive form of p34(CDC2) kinase phosphorylated on Tyr15, is found in S and G(2)/M fractions, but not in G(1). However, 24 h after irradiation, its levels in these fractions diminish appreciably in LBC-N but not in the radioresistant LBC286 and LBC282. Concomitantly, p34(CDC2) histone H1 kinase activity increases in the former, but not in the latter cell lines, hence suggesting a role for this protein in radiation-induced cell death. Altogether, this study shows that, in cells harbouring heterozygous mutations of p53, the G, checkpoint is not necessarily disrupted, and this may be related to the endogenous p53 heterocomplexes having lost or not the capacity to bind DNA (and therefore transactivate target genes). Radiation-induced cell death is not cell cycle phase specific, does not involve the regulation of bcl-2, bax or mcl-1, but is associated with changes in the phosphorylation state and activation of p34(CDC2) kinase.	NATL CHILDRENS MED RES CTR, DEPT VIROL, SETAGAYA KU, TOKYO 154, JAPAN; FONDAZ MATARELLI, MILAN, ITALY; TOHOKU UNIV, INST DEV AGING & CANC, AOBA KU, SENDAI, MIYAGI 980, JAPAN; BURNHAM INST, CTR CANC RES, LA JOLLA, CA 92037 USA	National Center for Child Health & Development - Japan; Tohoku University; Sanford Burnham Prebys Medical Discovery Institute	Delia, D (corresponding author), IST NAZL TUMORI, DIV OSA, VIA VENEZIAN 1, I-20133 MILAN, ITALY.		Aiello, Antonella/C-3290-2017; Pierotti, Marco Alessandro/AAC-4728-2022	Aiello, Antonella/0000-0002-1932-7113; Pierotti, Marco Alessandro/0000-0002-7431-8332; Lamorte, Giuseppe/0000-0001-9377-7537	NCI NIH HHS [CA 60181] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060181] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; BIRCH JM, 1994, EUR J CANCER, V30A, P1935, DOI 10.1016/0959-8049(94)00383-G; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Davis P, 1996, ONCOGENE, V13, P1315; DELIA D, 1993, CANCER RES, V53, P6036; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENDRESEN PC, 1995, CYTOMETRY, V20, P162, DOI 10.1002/cyto.990200209; FAN SJ, 1994, CANCER RES, V54, P5824; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FOURNEL S, 1995, FEBS LETT, V367, P188, DOI 10.1016/0014-5793(95)00532-E; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; Kitada S, 1996, ONCOGENE, V12, P187; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI Y, 1994, ONCOGENE, V9, P2261; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARTIN SJ, 1995, SCIENCE, V269, P106, DOI 10.1126/science.7604270; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; NIEWOLIK D, 1995, ONCOGENE, V10, P881; NORBURY C, 1994, BIOCHEM BIOPH RES CO, V202, P1400, DOI 10.1006/bbrc.1994.2086; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; OCONNOR PM, 1993, CANCER RES, V53, P4776; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PELLOQUIN F, 1986, IN VITRO CELL DEV B, V22, P689; Pocard M, 1996, ONCOGENE, V12, P875; REYNOLDS JE, 1994, CANCER RES, V54, P6348; ROLLEY N, 1995, ONCOGENE, V11, P763; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEWART N, 1995, ONCOGENE, V10, P109; Thomas A, 1996, ONCOGENE, V12, P1055; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; WADA H, 1994, LEUKEMIA, V8, P53; WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	59	49	51	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 8	1997	14	18					2137	2147		10.1038/sj.onc.1201050	http://dx.doi.org/10.1038/sj.onc.1201050			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174049	Green Published			2022-12-17	WOS:A1997WX93800002
J	Charest, A; Wagner, J; Kwan, M; Tremblay, ML				Charest, A; Wagner, J; Kwan, M; Tremblay, ML			Coupling of the murine protein tyrosine phosphatase PEST to the epidermal growth factor (EGF) receptor through a Src homology 3 (SH3) domain-mediated association with Grb2	ONCOGENE			English	Article						SH3 domain; Grb2; PTPase; EGF receptor; p120	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; HEMATOPOIETIC-CELL PHOSPHATASE; GUANINE-NUCLEOTIDE EXCHANGE; SIGNALING GENE SEM-5; BACULOVIRUS VECTOR; KINASE SUBSTRATE; ADAPTER PROTEIN; BINDING-SITE; RAS; SOS	The involvement of murine protein tyrosine phosphatase-PEST (MPTP-PEST) in signal transduction pathways is suggested by its ability to dephosphorylate phosphotyrosine residues, its interaction with the adaptor protein SHC and by the presence of five proline-rich stretches in its non-catalytic carboxyl terminus, Proline-rich sequences have been identified as binding sites for Src homology 3 (SH3) domains found in proteins associated with signal transduction events. The ability of these sequences to act as SH3 domain recognition motifs was investigated using bacterially expressed SH3 domains derived from several different signalling proteins. In vitro binding assays indicate that four of these proline-rich sequences constitute specific binding sites for both SH3 domains of the adaptor molecule Grb2, Wild type Grb2, but not Grb2 proteins corresponding to loss-of-function mutants in the Caenorhabditis elegans sem-5 protein, associate with MPTP-PEST in vivo. Experiments in EGF receptor expressing cells show that the interaction between MPTP-PEST and Grb2 results in the binding of this complex to activated EGF receptors. In addition, identification of putative substrate(s) of MPTP-PEST have revealed a candidate protein of similar to 120 kDa which is tyrosine phosphorylated upon EGF stimulation. Together, these results describe a novel SH3 domain-dependent recruitment of a protein tyrosine phosphatase to an activated receptor tyrosine kinase and establish a potential role for MPTP-PEST in signalling pathways at the molecular level.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA	McGill University								AMARNEH B, 1995, MOL CELL ENDOCRINOL, V109, pR1, DOI 10.1016/0303-7207(95)03524-B; AUSUBEL FM, 1995, CURR PROTO MOL BIOL; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHAREST A, 1995, GENOMICS, V28, P501, DOI 10.1006/geno.1995.1181; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HORSTMAN DA, 1995, PROTEIN EXPRES PURIF, V6, P278, DOI 10.1006/prep.1995.1036; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI X, 1995, GENOMICS, V28, P442, DOI 10.1006/geno.1995.1173; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2369; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sambrook KJ, 1989, MOL CLONING LAB MANU; SERTH J, 1992, BIOCHEMISTRY-US, V31, P6361, DOI 10.1021/bi00143a001; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; YANG SS, 1995, J BIOL CHEM, V270, P18212, DOI 10.1074/jbc.270.31.18212; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	48	49	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1643	1651		10.1038/sj.onc.1201008	http://dx.doi.org/10.1038/sj.onc.1201008			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135065				2022-12-17	WOS:A1997WR89300002
J	Chen, HJ; Ke, YQ; Oates, AJ; Barraclough, R; Rudland, PS				Chen, HJ; Ke, YQ; Oates, AJ; Barraclough, R; Rudland, PS			Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line	ONCOGENE			English	Article						human metastasis-inducing DNAs; rat mammary cells; osteopontin regulation	CALCIUM-BINDING PROTEIN; HUMAN-BREAST-CANCER; TRANSFECTION; OSTEOPONTIN; BENIGN; TUMOR; ONCOGENES; SEQUENCE; GENE; FIBROBLASTS	Benign rat mammary epithelial cells transfected with restriction enzyme-fragmented DNA from a human malignant metastatic cell line (Ca2-83) produces transfectants that yield metastatic tumours in syngeneic rats. The six metastasis-inducing DNAs (Met-DNAs) that have been isolated from such transfectants are subgene in size and do not code for any expressed mRNAs, but correspond to potential regulatory regions of human DNA from malignant, metastatic cells. In pilot studies the one Met-DNA tested is detectable in some human breast tumours but not in normal tissue. Transfection of all six Met-DNAs singly into the benign mammary epithelial cells causes enhanced expression of osteopontin, whilst transfection of cDNA for osteopontin also induces the metastatic state. These results show that short regulatory DNAs exist in human cancer cells that can induce metastatic spread via a common effector gene, osteopontin, in model rat mammary cell lines.	UNIV LIVERPOOL, SCH BIOL SCI, CANC & POLIO RES FUND LABS, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND	University of Liverpool			Barraclough, Roger/AAH-6516-2020	Barraclough, Roger/0000-0002-7203-1194				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; ANATHAWASWAMY HN, 1988, J CELL BIOCHEM, V36, P137; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BEHREND EI, 1994, CANCER RES, V54, P832; BRIAND P, 1987, IN VITRO CELL DEV B, V23, P181, DOI 10.1007/BF02623578; CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; DAVIES BR, 1993, ONCOGENE, V8, P999; Davies BR, 1996, INT J CANCER, V65, P104; DAVIES BR, 1994, CANCER RES, V54, P2785; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; ENGEL LW, 1978, CANCER RES, V38, P3352; FELDINGHABERMANN B, 1992, J BIOL CHEM, V267, P5070; FENG B, 1995, CLIN EXP METASTAS, V13, P453, DOI 10.1007/BF00118184; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; FISHER MS, 1981, CANCER RES, V41, P3018; GARDNER HAR, 1994, ONCOGENE, V9, P2321; GIBBINS JR, 1991, ANTICANCER RES, V11, P129; JAMIESON S, 1990, INT J CANCER, V46, P1071, DOI 10.1002/ijc.2910460621; JAMIESON S, 1990, PATHOBIOLOGY, V58, P329, DOI 10.1159/000163605; KAMBY C, 1990, CANCER TREAT REV, V17, P37, DOI 10.1016/0305-7372(90)90075-Q; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MURRAY MJ, 1981, CELL, V25, P355, DOI 10.1016/0092-8674(81)90054-4; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Oates AJ, 1996, ONCOGENE, V13, P97; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; RADLERPOHL A, 1988, INT J CANCER, V41, P840, DOI 10.1002/ijc.2910410611; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; RUDLAND PS, 1985, CANCER RES, V45, P3864; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; TARIN D, 1988, CIBA F SYMP, V141, P149; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0	43	49	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	1997	14	13					1581	1588		10.1038/sj.onc.1200993	http://dx.doi.org/10.1038/sj.onc.1200993			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129149				2022-12-17	WOS:A1997WQ54800009
J	Martin, A; Duffy, PA; Liossis, C; GomezMunoz, A; OBrien, L; Stone, JC; Brindley, DN				Martin, A; Duffy, PA; Liossis, C; GomezMunoz, A; OBrien, L; Stone, JC; Brindley, DN			Increased concentrations of phosphatidate, diacylglycerol and ceramide in ras- and tyrosine kinase (fps)-transformed fibroblasts	ONCOGENE			English	Article						ceramides; diacylglycerol kinase; phosphatidate phosphohydrolase; phospholipase D	PHOSPHOLIPASE-D ACTIVITY; GTPASE ACTIVATING PROTEIN; CELL-PERMEABLE CERAMIDES; XENOPUS-LAEVIS OOCYTES; DNA-SYNTHESIS; SIGNAL-TRANSDUCTION; PHOSPHATIDYLCHOLINE METABOLISM; QUANTITATIVE MEASUREMENT; TRANSFORMED FIBROBLASTS; LYSOPHOSPHATIDIC ACID	Concentrations of the bioactive lipids, phosphatidate and diacylglycerol, increased with time in culture in ras- and tyrosine kinase (fps)-transformed fibroblasts but not in control fibroblasts, On Day 3, diacylglycerol and phosphatidate concentrations were about 3.3- and 5.5-fold higher respectively in the Pas-transformed compared to control fibroblasts. These concentrations in fps-transformed fibroblasts were increased about twofold. The changes in phosphatidate and diacylglycerol resulted from enhanced phospholipid turnover rather than from synthesis de novo, The increased ratio of phosphatidate to diacylglycerol is explained by decreased activities of two distinct phosphatidate phosphohydrolases and increased diacylglycerol kinase in Pas-transformed fibroblasts. Ceramide concentrations were about 2.5- and threefold higher in the fps- and ras-transformed cells respectively on Day 3 compared to the controls, Incubating control fibroblasts from Days 1 to 3 with phosphatidylcholine-specific phospholipase C increased diacylglycerol, phosphatidate and ceramide concentrations, and decreased Mg2+-independent-phosphatidate phosphohydrolase activity, 8-(4-chlorophenylthio)-cAMP had a cytostatic effect in Pas-transformed cells, it decreased the concentrations of phosphatidate and diacylglycerol, but increased that of ceramide, The consequences of increased ceramide and phosphatidate concentrations in Pas-transformed cells are discussed in relation to signal transduction, cell division and the transformed phenotype.	UNIV ALBERTA, LIPID & LIPOPROT RES GRP, SIGNAL TRANSDUCT LABS, HERITAGE MED RES CTR 357, EDMONTON, AB T6G 2S2, CANADA; UNIV ALBERTA, DEPT BIOCHEM, HERITAGE MED RES CTR 357, EDMONTON, AB T6G 2S2, CANADA	University of Alberta; University of Alberta				GOMEZ MUNOZ, ANTONIO/0000-0002-2539-016X				ALAM MS, 1995, BIOCHEM BIOPH RES CO, V207, P460, DOI 10.1006/bbrc.1995.1210; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BOS JL, 1989, CANCER RES, V49, P4682; Brindley DN, 1996, CHEM PHYS LIPIDS, V80, P45, DOI 10.1016/0009-3084(96)02545-5; BRINDLEY DN, 1987, CRC SERIES ENZYME BI, V1, P1; CARNERO A, 1994, J CELL BIOCHEM, V54, P478, DOI 10.1002/jcb.240540415; CARNERO A, 1994, ONCOGENE, V9, P1387; CHIARUGI V, 1989, BIOCHEM BIOPH RES CO, V164, P816, DOI 10.1016/0006-291X(89)91532-5; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; DAVIES SA, 1989, BIOCHIM BIOPHYS ACTA, V1013, P173, DOI 10.1016/0167-4889(89)90046-3; DIAZMECO MT, 1991, J BIOL CHEM, V266, P22597; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; ELDAR H, 1993, J BIOL CHEM, V268, P12560; Fiske CH, 1925, J BIOL CHEM, V66, P375; FU T, 1992, BIOCHEM J, V283, P347, DOI 10.1042/bj2830347; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; GOMEZMUNOZ A, 1995, MOL PHARMACOL, V47, P883; GUAN KL, 1994, CELL SIGNAL, V6, P581, DOI 10.1016/0898-6568(94)90041-8; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUANG C, 1992, BIOCHIM BIOPHYS ACTA, V1127, P242, DOI 10.1016/0005-2760(92)90227-M; HUANG CF, 1990, J BIOL CHEM, V265, P17468; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; JONES GA, 1993, J BIOL CHEM, V268, P20845; KENNERLY DA, 1987, J BIOL CHEM, V262, P16305; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEMAITRE RN, 1990, BIOCHEM J, V266, P291, DOI 10.1042/bj2660291; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MARTIN A, 1991, METHOD ENZYMOL, V197, P553; MARTIN A, 1986, BIOCHIM BIOPHYS ACTA, V876, P581, DOI 10.1016/0005-2760(86)90047-0; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MARTIN A, 1994, SIGNAL ACTIVATED PHO, P139; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MORGAN AR, 1974, BIOCH BIOPHYS RES CO, V61; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; MURPHY SK, 1994, BIOCHEM BIOPH RES CO, V205, P1121, DOI 10.1006/bbrc.1994.2782; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; Nakamura Y, 1996, J IMMUNOL, V156, P256; PATERSON A, 1991, BIOCHEM J, V280, P829, DOI 10.1042/bj2800829; PREISS J, 1986, J BIOL CHEM, V261, P8597; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; PRICE BD, 1989, J BIOL CHEM, V264, P16638; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TAGLIAFERRI P, 1988, J BIOL CHEM, V263, P409; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VENABLE ME, 1994, J BIOL CHEM, V269, P26040; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; WAKELAM MJO, 1991, BIOCH SOC S, V56, P103; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5	74	49	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	1997	14	13					1571	1580		10.1038/sj.onc.1200987	http://dx.doi.org/10.1038/sj.onc.1200987			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129148				2022-12-17	WOS:A1997WQ54800008
J	Casola, S; Pedone, PV; Cavazzana, AO; Basso, G; Luksch, R; dAmore, ESG; Carli, M; Bruni, CB; Riccio, A				Casola, S; Pedone, PV; Cavazzana, AO; Basso, G; Luksch, R; dAmore, ESG; Carli, M; Bruni, CB; Riccio, A			Expression and parental imprinting of the H19 gene in human rhabdomyosarcoma	ONCOGENE			English	Article						genomic imprinting; 11p15 LOH; pediatric cancer	GROWTH-FACTOR-II; WILMS-TUMOR; ALVEOLAR RHABDOMYOSARCOMA; MATERNAL ALLELES; RNA; LOCUS; IGF2; HEPATOBLASTOMA; TUMORIGENESIS; METHYLATION	The expression of Insulin-like Growth Factor 2 (IGF-2) and H19, two genes located on human chromosome 11p15 and provided with cell growth modulating activity, is regulated by parental imprinting, in that the activity of their alleles is dependent on the parental origin. Parental bias in the genetic alterations of chromosome 11p15 observed in several pediatric cancers suggests the involvement of imprinted genes in tumor development. We have previously reported that the number of functional IGF-2 alleles is frequently increased in rhabdomyosarcoma (RMS), as a consequence of either relaxation of imprinting (LOI) or gene duplication. Here we show that the expression of the H19 gene is significantly suppressed with respect to normal muscle tissue in 13 out of 15 rhabdomyosarcomas with embryonal histology (ERMS) and in three out of 11 rhabdomyosarcomas classified as alveolar subtype (ARMS). Since a growth-inhibitory activity has been found associated with the H19 gene, the extinction of its expression can contribute to RMS development. Parental imprinting of the H19 gene was found conserved in all informative RMSs, including those whose IGF-2 imprinting was relaxed, indicating that LOI is a gene-specific event. Seven ERMSs and one ARMS displaying low H19 RNA levels showed an underrepresentation of the expressed allele in their genotype. This result is consistent with the paternal imprinting of the H19 gene and with the preferential loss of the maternal 11p15 alleles in these neoplasms. Low H19 expression was also found in four out of eight RMSs retaining the heterozygosity at 11p15, but showing IGF-2 LOI. These findings suggest that the genetic and epigenetic alterations affecting chromosome 11p15 in a high number of RMSs cause deregulation of more than one imprinted gene, possibly affecting tumor growth, including the extinction of H19 expression and an increase in the number of active IGF-2 alleles.	CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOL & PATOL CELLULARE & MOL,I-80131 NAPLES,ITALY; UNIV NAPLES 2,FAC SCI AMBIENTALI,NAPLES,ITALY; UNIV ROMA TOR VERGATA,IST ANAT PATOL,ROME,ITALY; UNIV PADUA,CLIN PEDIAT 2,DIV ONCOEMATOL,PADUA,ITALY; UNIV PADUA,IST ANAT PATOL,PADUA,ITALY; IST NAZL TUMORI,I-20133 MILAN,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita della Campania Vanvitelli; University of Rome Tor Vergata; University of Padua; University of Padua; Fondazione IRCCS Istituto Nazionale Tumori Milan			Riccio, Andrea/A-4991-2015; Cerrato, Flavia/O-8315-2015; Luksch, Roberto/K-2206-2016; Casola, Stefano/AAN-8319-2021; Riccio, Andrea/AAY-7571-2020; Casola, Stefano/O-3922-2014	Riccio, Andrea/0000-0001-7990-3576; Cerrato, Flavia/0000-0003-3794-3021; Luksch, Roberto/0000-0002-7203-4176; Casola, Stefano/0000-0001-5580-0986; Riccio, Andrea/0000-0001-7990-3576; Pedone, Paolo Vincenzo/0000-0002-0828-5843; BASSO, GIUSEPPE/0000-0002-2634-9302				ALBRECHT S, 1994, CANCER RES, V54, P5041; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BARR FG, 1995, JAMA-J AM MED ASSOC, V273, P553, DOI 10.1001/jama.273.7.553; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; CASOLA S, 1995, ONCOGENE, V11, P711; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTOFORI G, 1995, NAT GENET, V10, P196, DOI 10.1038/ng0695-196; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIS RJ, 1994, CANCER RES, V54, P2869; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; ELBADRY OM, 1990, CELL GROWTH DIFFER, V84, P829; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Ferracini R, 1996, ONCOGENE, V12, P1697; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; Hoovers JMN, 1995, P NATL ACAD SCI USA, V92, P12456, DOI 10.1073/pnas.92.26.12456; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; Kondo M, 1996, ONCOGENE, V12, P1365; LEIBOVITCH MP, 1995, ONCOGENE, V10, P251; LEIBOVITCH MP, 1991, BIOCHEM BIOPH RES CO, V180, P1241, DOI 10.1016/S0006-291X(05)81329-4; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LI XR, 1995, ONCOGENE, V11, P221; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NEWTON WA, 1995, CURRENT TOPICS PATHO, V89; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; PAL N, 1990, ONCOGENE, V5, P1665; Pappo Alberto S., 1995, Current Opinion in Oncology, V7, P361, DOI 10.1097/00001622-199507000-00012; PEDONE PV, 1994, J BIOL CHEM, V269, P23970; PEDONE PV, 1994, HUM MOL GENET, V3, P1117, DOI 10.1093/hmg/3.7.1117; PFEIFER K, 1994, GENE DEV, V8, P1867, DOI 10.1101/gad.8.16.1867; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAINIER S, 1995, CANCER RES, V55, P1836; RAINIER S, 1994, JNCI-J NATL CANCER I, V86, P753, DOI 10.1093/jnci/86.10.753; Sambrook J, 1989, MOL CLONING LAB MANU; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SCRABLE H, 1989, GENE CHROMOSOME CANC, V1, P23, DOI 10.1002/gcc.2870010106; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; VANHEYNINGEN V, 1995, CYTOGENET CELL GENET, V69, P128, DOI 10.1159/000133953; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; YUN K, 1992, LAB INVEST, V67, P653; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	51	49	51	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1503	1510		10.1038/sj.onc.1200956	http://dx.doi.org/10.1038/sj.onc.1200956			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136994				2022-12-17	WOS:A1997WT58400013
J	Venkatachalam, S; Denissenko, M; Wani, AA				Venkatachalam, S; Denissenko, M; Wani, AA			Modulation of (+/-)-anti-BPDE mediated p53 accumulation by inhibitors of protein kinase C and poly(ADP-ribose) polymerase	ONCOGENE			English	Article						DNA damage; p53 induction; apoptosis; cell cycle arrest	PERIPHERAL-BLOOD LYMPHOCYTES; DNA-DAMAGING AGENTS; ATAXIA-TELANGIECTASIA; HUMAN-CELLS; IONIZING-RADIATION; MOLECULAR CONTROLS; HUMAN FIBROBLASTS; SUPPRESSOR GENES; STRAND BREAKS; G(1) ARREST	The rapid accumulation of the p53 gene product is considered to be an important component of the cellular response to a variety of genotoxins, In order to gain insights on the biochemical pathways leading to p53 stabilization, the effect of (+/-) 7,8-dihydroxy-anti-9, 10-epoxy-7,8,9,10-tetrahydrobenzo(a)-pyrene [(+/-)-anti-BPDE] induced DNA damage on p53 protein levels was investigated in various repair-proficient and repair-deficient human cells, Brief exposure of normal human fibroblasts to 0.05-1 mu M (+/-)-anti-BPDE resulted in elevated p53 protein levels as compared to the constitutive levels of control sells, The rapid induction response, detectable within a few hours, was sustained up to a period of at least 24 h, Repair-proficient and repair-deficient (XPA) human lymphoblastoid cells showed a similar response, The poly(ADP-ribose) polymerase inhibitor, 3-aminobenzamide (3-AB), diminished the p53 induction response by concomitantly decreasing the extent of (+/-)-anti-BPDE induced DNA damage in cells pretreated with the inhibitor, However, the direct involvement of poly ADP-ribosylation was also apparent as 3-AB was able to attenuate (similar to 50%) the p53 response by post-damage inhibitor treatment of the cells, Inhibition:of cellular DNA replication by hydroxyurea and AraC, in the presence or absence of DNA damage, also resulted in rapid p53 accumulation in repair-deficient cells, On the contrary, inhibition of protein kinase C (PKC) by calphostin-C led to an abrogation of (+/-)-anti-BPDE mediated p53 induction, Analysis of the downstream effects of carcinogen treatment showed that the lymphoblastoid cells undergo DNA fragmentation indicative of apoptosis while fibroblasts exhibit cell cycle arrest at the G(1)-S boundary.	OHIO STATE UNIV,DEPT RADIOL,COLUMBUS,OH 43210; OHIO STATE UNIV,BIOCHEM PROGRAM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006074, R01ES002388] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES6074, ES2388] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABRAHAMS PJ, 1995, MUTAT RES-DNA REPAIR, V336, P169, DOI 10.1016/0921-8777(94)00049-C; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BAE IS, 1995, CANCER RES, V55, P2387; BERGER NA, 1981, BIOCHEMISTRY-US, V20, P3610, DOI 10.1021/bi00515a047; BERGER NA, 1980, BIOCHEMISTRY-US, V19, P289, DOI 10.1021/bi00543a006; BJELOGRLIC NM, 1994, CARCINOGENESIS, V15, P771, DOI 10.1093/carcin/15.4.771; CANMAN CE, 1994, COLD SPRING HARB SYM, V59, P277, DOI 10.1101/SQB.1994.059.01.032; CARSON DA, 1986, EXP CELL RES, V164, P273, DOI 10.1016/0014-4827(86)90028-5; CHATTERJEE S, 1994, MOL CELL BIOCHEM, V138, P61, DOI 10.1007/BF00928444; CONNEY AH, 1982, CANCER RES, V42, P4875; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FAN SJ, 1994, CANCER RES, V54, P5824; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; GIBSONDAMBROSIO RE, 1986, IN VITRO CELL DEV B, V22, P529; GRANA X, 1995, ONCOGENE, V11, P211; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GUENGERICH FP, 1988, CANCER RES, V48, P2946; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL PA, 1993, ONCOGENE, V8, P203; HARRIS CC, 1991, CANCER RES, V51, pS5023; HESS R, 1994, TOXICOL LETT, V72, P43, DOI 10.1016/0378-4274(94)90008-6; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; KASPIN LC, 1996, IN PRESS PAH; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUMAR M, 1995, BIOCHEM BIOPH RES CO, V214, P744, DOI 10.1006/bbrc.1995.2348; KURIAN P, 1992, CARCINOGENESIS, V13, P489, DOI 10.1093/carcin/13.3.489; LAUTIER D, 1993, MOL CELL BIOCHEM, V122, P171, DOI 10.1007/BF01076101; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIU M, 1995, ONCOGENE, V10, P1955; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MOLINARI M, 1995, ONCOGENE, V10, P1849; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OSBORNE MR, 1981, CARCINOGENESIS, V2, P553, DOI 10.1093/carcin/2.6.553; PHILLIPS DH, 1983, NATURE, V303, P468, DOI 10.1038/303468a0; Price BD, 1996, CANCER RES, V56, P246; PRICE BD, 1994, CANCER RES, V54, P896; PRICE BD, 1993, ONCOGENE, V8, P3055; PRICE BD, 1993, ONCOGENE, V8, P305; Sancar A, 1995, ANNU REV GENET, V29, P69, DOI 10.1146/annurev.ge.29.120195.000441; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STIERUM RH, 1995, CARCINOGENESIS, V16, P2765, DOI 10.1093/carcin/16.11.2765; STIERUM RH, 1994, CARCINOGENESIS, V15, P745, DOI 10.1093/carcin/15.4.745; VENKATACHALAM S, 1995, CARCINOGENESIS, V16, P2029, DOI 10.1093/carcin/16.9.2029; VENKATACHALAM S, 1993, BIOCHEM BIOPH RES CO, V197, P722, DOI 10.1006/bbrc.1993.2539; VENKATACHALAM S, 1994, CARCINOGENESIS, V15, P565, DOI 10.1093/carcin/15.4.565; WALKER PR, 1994, EXP CELL RES, V213, P100, DOI 10.1006/excr.1994.1178; WHITACRE CM, 1995, CANCER RES, V55, P3697; ZHANG W, 1994, CANCER RES, V54, P4448	60	49	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					801	809		10.1038/sj.onc.1200890	http://dx.doi.org/10.1038/sj.onc.1200890			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047387				2022-12-17	WOS:A1997WJ11200006
J	Merchant, AK; Loney, TL; Maybaum, J				Merchant, AK; Loney, TL; Maybaum, J			Expression of wild-type p53 stimulates an increase in both Bax and Bcl-x(L) protein content in HT29 cells	ONCOGENE			English	Article						p53; Bax; Bcl-x; programmed cell death; HT29	CHEMOTHERAPY-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR P53; IN-VIVO; DNA FRAGMENTATION; BCL-2 EXPRESSION; CANCER-CELLS; C-MYC; CYCLE; DEATH; GENE	It has been shown previously that wild-type p53 activity can simultaneously up-regulate Bax, a protein which predisposes cells to programmed cell death (PCD), and down-regulate Bcl-2, a protein which antagonizes PCD. These findings have been interpreted to suggest that correction of the mutant p53 status of some tumor cells may be a means of increasing their sensitivity to chemotherapeutic agents, by increasing their likelihood of undergoing PCD. We show here that when wild-type p53 activity is expressed in HT29 human colon cancer cells by use of a temperature sensitive p53 mutant, Bax levels rise, but so do levels of Bcl-x(L) protein. These observations indicate that Bcl-2 and Bcl-x(L) are regulated differently in response to wild-type p53 activity and that, while correction of mutant p53 phenotype may effectively kill cells having Bcl-2 as their major defense against PCD, this is not necessarily the case in cells using Bcl-x(L) as their primary defense	UNIV MICHIGAN, SCH MED, DEPT PHARMACOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [P01CA042761, R01CA056663] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA42761, R01-CA56663] Funding Source: Medline; NIGMS NIH HHS [2T32 GM07767] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BAGWELL CB, 1979, J HISTOCHEM CYTOCHEM, V27, P293, DOI 10.1177/27.1.374589; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; CANMAN CE, 1992, P NATL ACAD SCI USA, V89, P10474, DOI 10.1073/pnas.89.21.10474; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; DOLE MG, 1995, CANCER RES, V55, P2576; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FORGUELAFITTE ME, 1989, CANCER RES, V49, P6566; HAGUE A, 1994, ONCOGENE, V9, P3367; HALDAR S, 1994, CANCER RES, V54, P2095; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PARK JR, 1994, BLOOD, V84, P440; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SCHOTT AF, 1995, ONCOGENE, V11, P1389; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SINICROPE FA, 1995, CANCER RES, V55, P237; STEWART BW, 1994, JNCI-J NATL CANCER I, V86, P1286, DOI 10.1093/jnci/86.17.1286; STEWART N, 1995, ONCOGENE, V10, P109; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tang HYK, 1996, CANCER CHEMOTH PHARM, V37, P486, DOI 10.1007/s002800050416; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WILLINGHAM MC, 1994, J HISTOCHEM CYTOCHEM, V42, P441, DOI 10.1177/42.4.7907352; Wu GS, 1996, CLIN CANCER RES, V2, P623; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; ZHAN QM, 1994, ONCOGENE, V9, P3743	39	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2631	2637						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000137				2022-12-17	WOS:A1996VZ65400013
J	Novak, U; Nice, E; Hamilton, JA; Paradiso, L				Novak, U; Nice, E; Hamilton, JA; Paradiso, L			Requirement for Y706 of the murine (or Y708 of the human) CSF-1 receptor for STAT1 activation in response to CSF-1	ONCOGENE			English	Article						CSF-1; STAT proteins; CSF-1 receptor	STIMULATING FACTOR-I; PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; GROWTH-FACTOR RECEPTORS; TRANSCRIPTION FACTOR; INTERFERON-GAMMA; C-FOS; PHOSPHATIDYLINOSITOL 3-KINASE; CYTOKINE RECEPTORS; FDC-P1 CELLS	Using FDC-P1 derived cell lines which ectopically express either the wild type or mutant forms of the murine CSF-1 receptor in which individual tyrosine residues have been replaced with phenylalanine, we analysed the requirement for tyrosine residues of the receptor for the activation of STAT proteins in response to CSF-1, We found Y706 to be required for efficient activation of STAT1. The activation of STAT3 was not affected by the mutation of Y706 to phenylalanine. The addition of phosphopeptides spanning Y708 of the human CSF-1 receptor (identical with the sequence surrounding Y706 of the murine receptor) to electrophoretic mobility shift assays led to competition of the formation of STAT1 containing complexes, SIF-B and SIF-C with the DNA probe, These phosphopeptides did, however, not affect the formation of the STAT3 containing complex, SIF-A, with the probe. Replacement of Y807 with phenylalanine led to a complete block of activation of all STAT proteins in response to CSF-1, however, this phosphotyrosine does not appear to represent a STAT binding site of the receptor as a phosphopeptide spanning Y809 of the human CSF-1 receptor could not compete any STAT/DNA complex formation in electrophoretic mobility shift assays.	ROYAL MELBOURNE HOSP,TUMOUR BIOL BRANCH,LUDWIG INST CANC RES,PARKVILLE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Novak, U (corresponding author), UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT MED,MELBOURNE,VIC 3050,AUSTRALIA.		Nice, Edouard C/B-1026-2011	Hamilton, John A/0000-0002-9493-9224				ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NICHOLSON SA, 1996, IN PRESS J BIOL CHEM; Novak U, 1996, J BIOL CHEM, V271, P18350, DOI 10.1074/jbc.271.31.18350; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; PLUZNIK DH, 1965, J CELL COMPAR PHYSL, V66, P319, DOI 10.1002/jcp.1030660309; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; ROSNET O, 1991, ONCOGENE, V6, P1641; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	46	49	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2607	2613						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000134				2022-12-17	WOS:A1996VZ65400010
J	Obata, M; Nishimori, H; Ogawa, K; Lee, GH				Obata, M; Nishimori, H; Ogawa, K; Lee, GH			Identification of the Par2 (Pulmonary adenoma resistance) locus on mouse chromosome 18, a major genetic determinant for lung carcinogen resistance in BALB/cByJ mice	ONCOGENE			English	Article						lung tumor; resistance gene; urethane; mouse	K-RAS ONCOGENE; TUMOR SUSCEPTIBILITY; INTESTINAL NEOPLASIA; COLORECTAL CANCERS; ACTIVATION; MAP; PROTOONCOGENE; MUTATIONS; MODIFIER; LOSSES	The A/J mouse strain is 14 times more susceptible to urethane-induction of lung carcinogenesis than the BALB/cByJ strain (BALE). The relative resistance of BALE is dominant over the high sensitivity of A/J, since (BALBxA/J)F-1 mice are phenotypically similar to the parental BALE mice. BALE mice must thus possess modifier genes suppressing phenotypic expression of the Pas (Pulmonary adenoma susceptibility) genes, which are known to be dominant genetic determinants for lung carcinogenesis in A/J mice. In order to genetically dissect the dominant resistance of the BALB mouse, we performed a linkage analysis to chromosomally map modifier genes by using 130 (A/JxBALB)F(1)xA/J backcross mice. Each backcross mouse was injected i.p. with urethane (1 mg/g bw) at 6 weeks of age and lung tumors were enumerated after 120 days. When the backcross mice were genotyped at multiple simple sequence repeat marker loci distributed on all the chromosomes, a significant linkage between the presence of a BALE allele and resistance to lung tumor induction was found on distal chromosome 18 (maximum LOD = 12.2). Thus, distal chromosome 18 of the BALE mouse contains a modifier gene for lung carcinogenesis: The locus, designated Par2 (Pulmonary adenoma resistance), accounted for 38% of the phenotypic variance in the backcross population, indicating a major role in protection against lung tumor development.	ASAHIKAWA MED COLL,DEPT PATHOL,ASAHIKAWA,HOKKAIDO 078,JAPAN	Asahikawa Medical College								ATCHLEY WR, 1991, SCIENCE, V254, P554, DOI 10.1126/science.1948030; BELINSKY SA, 1989, CANCER RES, V49, P5305; CHEN B, 1994, P NATL ACAD SCI USA, V91, P1589, DOI 10.1073/pnas.91.4.1589; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DRAGANI TA, 1991, CANCER RES, V51, P6299; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; FIJNEMAN RJA, 1994, ONCOGENE, V9, P1417; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HEGI ME, 1994, CANCER RES, V54, P6257; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JOHNSON KR, 1994, MAMM GENOME, V5, pS259; JUSTICE MJ, 1992, GENOMICS, V13, P1281, DOI 10.1016/0888-7543(92)90047-V; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1989, GENETICS, V121, P185; LEE GH, 1987, HEPATOLOGY, V7, P937, DOI 10.1002/hep.1840070524; LEE GH, 1995, GENETICS, V139, P387; LEE GH, 1995, CARCINOGENESIS, V16, P1993, DOI 10.1093/carcin/16.8.1993; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MALKINSON AM, 1985, J NATL CANCER I, V75, P971, DOI 10.1093/jnci/75.5.971; MALKINSON AM, 1984, J NATL CANCER I, V73, P925; MALKINSON AM, 1983, J NATL CANCER I, V70, P931; Manenti G, 1996, NAT GENET, V12, P455, DOI 10.1038/ng0496-455; MANENTI G, 1995, GENOMICS, V29, P438, DOI 10.1006/geno.1995.9984; OREFFO VI, 1996, SPEC C AM ASS CANC R, pA34; PITOT HC, 1987, CARCINOGENESIS, V8, P1491, DOI 10.1093/carcin/8.10.1491; RYAN J, 1987, J NATL CANCER I, V79, P1351; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SUZUKI Y, 1990, ONCOGENE, V5, P1037; WISEMAN RW, 1994, P NATL ACAD SCI USA, V91, P3759, DOI 10.1073/pnas.91.9.3759; Wright S., 1968, EVOLUTION GENETICS P, P373; YAMAMOTO F, 1984, NUCLEIC ACIDS RES, V12, P8873, DOI 10.1093/nar/12.23.8873; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804	41	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1599	1604						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895504				2022-12-17	WOS:A1996VM88700003
J	Yang, YM; Dolan, LR; Ronai, Z				Yang, YM; Dolan, LR; Ronai, Z			Expression of dominant negative CREB reduces resistance to radiation of human melanoma cells	ONCOGENE			English	Article						AP1; CREB; dominant negative; melanoma; radiation	ULTRAVIOLET-LIGHT; DNA DAMAGE; PROTEIN; TRANSCRIPTION; P53; IRRADIATION; ACTIVATION; TGACAACA; COMPLEX; KINASE	u.v.-responsive element (URE)-binding proteins were found to include members of the AP1 and ATF transcription factor families, To elucidate the functional contribution of URE-bound proteins to the characteristics of human melanoma, we have used a dominant negative CREB cDNA which is mutated within the DNA-binding domain and cloned into a mammalian expression vector driven by the RSV promoter (KCREB), As such, KCREB is still capable of heterodimerizing with its associated proteins, Set, due to its poor binding affinity to DNA it out competes transcriptional activity mediated by those proteins, Human melanoma cells (MeWo) were transfected with KCREB and three clones, designated K1, K2, and K10 which express KCREB transcripts were then selected for further characterization. When tested for binding activities in gel shift assays, proteins prepared from the three clones exhibited a different set of complexes than the parent MeWo and control MeWo(neo) cells (transfected with empty expression vector) under normal growth conditions, and after u.v.-irradiation, Using CAT vector, driven by a tetramer URE construct, revealed a striking decrease in transcriptional activity in each of the three clones before as well as after u.v.-irradiation, When tested for radiation resistance MeWo cells were found to exhibit 42% survival to a u.v.-dose of 16 J/m(2), whereas, K1, K2 and K10 exhibited only 10.2, 3.9 and 4.2% survival, respectively, Exposure to 2 Gy of X-radiation led to 62.1% survival of MeWo as compared with 18.5% of K1 and 7.7% and 6.5% of K2 and K10, respectively, While no significant differences were noticed in their growth rate, all three clones exhibited fewer, and smaller colonies in soft agar, when compared with parent cells, These findings indicate that through their transcriptional activities, CREB and its associated proteins play an important role in the acquisition of characteristic phenotypes of human melanoma cells including resistance to u.v.-irradiation.	AMER HLTH FDN,MOL CARCINOGENESIS PROGRAM,VALHALLA,NY 10595	American Health Foundation				RONAI, ZEEV/0000-0002-3859-0400; Reinhart, Lisa/0000-0001-6266-3342	NCI NIH HHS [CA51995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051995, R01CA051995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; CHOI HS, 1991, J BIOL CHEM, V266, P11858; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FORNACE AJ, 1992, ANNU REV GENET, V26, P505; GUIFFRE L, 1988, CANCER, V61, P1132; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HERLYN M, 1992, CUTANEOUS MELANOMA, P82; HERRLICH P, 1994, CURR OPIN CELL BIOL, V6, P425, DOI 10.1016/0955-0674(94)90036-1; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KASTAN MB, 1991, CANCER RES, V51, P6304; KENNY JJ, 1994, VIROLOGY, V200, P220, DOI 10.1006/viro.1994.1180; KISSTOTH E, 1993, NUCLEIC ACIDS RES, V21, P3677, DOI 10.1093/nar/21.16.3677; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEONARDO AD, 1994, GENE DEV, V8, P2540; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; NARAYAN S, 1995, BIOCHEMISTRY-US, V34, P73, DOI 10.1021/bi00001a009; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RONAI Z, 1994, ENVIRON MOL MUTAGEN, V23, P157, DOI 10.1002/em.2850230302; RONAI Z, 1992, INDUCIBLE RESPONSES, P97; RONAI ZA, 1990, CANCER RES, V50, P5374; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; RUTBERG SE, 1992, NUCLEIC ACIDS RES, V20, P4305, DOI 10.1093/nar/20.16.4305; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; THOMPSON FJ, 1994, J GEN VIROL, V75, P545, DOI 10.1099/0022-1317-75-3-545; TSUCHIYA H, 1989, JPN J CANCER RES, V80, P1246, DOI 10.1111/j.1349-7006.1989.tb01661.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WANDA T, 1991, J VIROL, V65, P557; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; WOLOSHIN PI, 1992, MOL ENDOCRINOL, V6, P1725, DOI 10.1210/me.6.10.1725; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; YANG YM, 1993, CELL GROWTH DIFFER, V4, P595; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	46	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2223	2233						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668349				2022-12-17	WOS:A1996UP28300022
J	Knippschild, U; Oren, M; Deppert, W				Knippschild, U; Oren, M; Deppert, W			Abrogation of wild-type p53 mediated growth-inhibition by nuclear exclusion	ONCOGENE			English	Article						nuclear-cytoplasmic transport; tumor suppressor p53	TUMOR SUPPRESSOR GENE; AUTOREGULATORY FEEDBACK LOOP; LARGE-T-ANTIGEN; CELL-CYCLE; MDM2 GENE; PROTEIN; TRANSPORT; MUTANT; EXPRESSION; CANCER	We used clone 6 cells (rat embryo fibroblasts transformed by the temperature sensitive mutant p53(val135) and an activated H-ras-gene (Michalovitz et al., 1990)), growth arrested at 32 degrees C, as a model to analyse whether and how transformed cells, growth-arrested by an overexpressed wild-type p53, might overcome p53-mediated growth inhibition, When clone 6 cells were kept at 32 degrees C for about 2 weeks, foci of cells appeared which grew temperature-independent. Analysis of individual clones of such cell demonstrated that the ectopically expressed tsp53-gene had not been altered by an additional mutation, but that the tsp53 in these cells at 32 degrees C had lost its ability to upregulate expression of the p53 target genes waf1 and mdm2. This loss of p53-specific transactivation correlated with nuclear exclusion of the tsp53 at 32 degrees C, which was most likely mediated by cytoplasmic retention of the tsp53 protein via short-lived anchor proteins, Cytoplasmic retention of the tsp53 at 32 degrees C was also observed in PC12 pheochromocytoma cells ectopically expressing tsp53(val135), there occurring without specific selection, Also in these exclusion of the tsp53 correlated with mediated growth inhibition, Nuclear exclusion of p53 thus might serve as an epigenetic mechanism to eliminate the growth-inhibitory function of p53.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Heinrich Pette Institute; University of Hamburg; Weizmann Institute of Science					NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R0I CA 40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHANG FJ, 1993, AM J GASTROENTEROL, V88, P174; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; Deppert W., 1993, MOL CELL BIOL METHOD, P27; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELKIND NB, 1995, ONCOGENE, V11, P841; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; FUKUSAWA K, 1991, MOL CELL BIOL, V11, P3472; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; JUVEN T, 1993, ONCOGENE, V8, P3411; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KALTHOFF H, 1993, ONCOGENE, V8, P289; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; LADANYI M, 1993, CANCER RES, V53, P16; LAIMINS LA, 1993, INFECT AGENT DIS, V2, P74; LANDERS JE, 1994, ONCOGENE, V9, P2745; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LANE DP, 1992, NATURE, V359, P486, DOI 10.1038/359486b0; LANFORD RE, 1982, VIROLOGY, V119, P169, DOI 10.1016/0042-6822(82)90074-5; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LANFORD RE, 1985, VIROLOGY, V147, P72, DOI 10.1016/0042-6822(85)90228-4; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OTTO A, 1993, ONCOGENE, V8, P2591; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; Prives C, 1993, CURR OPIN CELL BIOL, V5, P214, DOI 10.1016/0955-0674(93)90105-Y; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; Sambrook J, 1989, J SAMBROOK MOL CLONI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SELTER H, 1994, INT J BIOCHEM, V26, P145, DOI 10.1016/0020-711X(94)90139-2; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STAUFENBIEL M, 1984, J CELL BIOL, V98, P1886, DOI 10.1083/jcb.98.5.1886; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TAKAHASHI K, 1994, ONCOGENE, V9, P183; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, J BIOL CHEM, V269, P10923; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZERRAHN J, 1992, ONCOGENE, V7, P1371	78	49	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1755	1765						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622896				2022-12-17	WOS:A1996UG45800018
J	BOUKAMP, P; PETER, W; PASCHEBERG, U; ALTMEIER, S; FASCHING, C; STANBRIDGE, EJ; FUSENIG, NE				BOUKAMP, P; PETER, W; PASCHEBERG, U; ALTMEIER, S; FASCHING, C; STANBRIDGE, EJ; FUSENIG, NE			STEP-WISE PROGRESSION IN HUMAN SKIN CARCINOGENESIS IN-VITRO INVOLVES MUTATIONAL INACTIVATION OF P53, RAS(H) ONCOGENE ACTIVATION AND ADDITIONAL CHROMOSOME LOSS	ONCOGENE			English	Article						RAS-ONCOGENE; HUMAN KERATINOCYTES; MALIGNANT TRANSFORMATION; P53 MUTATION; CHROMOSOME 15	SQUAMOUS-CELL CARCINOMAS; NEOPLASTIC TRANSFORMATION; HUMAN KERATINOCYTES; VIRAL INTEGRATION; FRAGILE SITES; GENE; CANCER; EXPRESSION; LINE; HYBRIDIZATION	Two mechanisms relevant for skin carcinogenesis in man are mutational inactivation of p53 and oncogenic activation of c-ras(H) gene. Previously, we transfected c-ras(H) oncogene into human skin keratinocytes (HaCaT) with u.v.-typic mutations in both p53 alleles, which produced benign and malignant tumorigenic clones, expressing similar amounts of mutant Pas protein, Here we show that neither the ras integration site nor the karyotypic changes affects the formation of the benign or malignant tumorigenic phenotype, From the original malignant HaCaT-ras clone we took single human chromosomes, carrying the c-ras(H) oncogene and transferred them by microcell mediated chromosome transfer into genetically different untransfected nontumorigenic HaCaT cells, This novel approach identified the genetic background of the recipient cell as a critical determinant for the resulting tumor phenotype, Exhibiting similar oncogene expression, microcell hybrids from early passage cells remained nontumorigenic or formed benign tumors, while those with more cytogenetic aberrations (later passages) and loss of >1 copy of chromosome 15 became malignant. Since aberrations in chromosome 15 were also detected in three of five human skin carcinoma lines this study provides evidence that p53 and c-ras(H) mutations are early events of human skin carcinogenesis, while loss of gene(s) on chromosome 15 is a late event.	UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine	BOUKAMP, P (corresponding author), GERMAN CANC RES CTR,DIV CARCINOGENESIS & DIFFERENTIAT,NEUENHEIMER FELD 280,D-69009 HEIDELBERG,GERMANY.		Pascheberg, Ulrich/GON-9981-2022		NCI NIH HHS [CA19401] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA019401, R01CA019401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMBROS PF, 1986, CHROMOSOMA, V94, P11, DOI 10.1007/BF00293525; ANANTHASWAMY HN, 1992, PROG CLIN BIOL RES, V376, P61; BOS JL, 1989, CANCER RES, V49, P4682; BOUKAMP P, 1982, JNCI-J NATL CANCER I, V68, P415; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOUKAMP P, 1994, KERATINOCYTE HDB, P485; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRISSETTE JL, 1993, MOL CARCINOGEN, V7, P21, DOI 10.1002/mc.2940070105; CANNIZZARO LA, 1988, CANCER GENET CYTOGEN, V33, P93, DOI 10.1016/0165-4608(88)90054-4; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COROMINAS M, 1989, P NATL ACAD SCI USA, V86, P6372, DOI 10.1073/pnas.86.16.6372; DEAMBROSIS A, 1992, CANCER GENET CYTOGEN, V60, P1, DOI 10.1016/0165-4608(92)90223-U; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P4322; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; FRIEND KK, 1976, SOMAT CELL GENET, V2, P183, DOI 10.1007/BF01542631; FUSENIG NE, 1991, ORAL CANC, P218; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; GAME SM, 1992, INT J CANCER, V52, P461, DOI 10.1002/ijc.2910520322; GANTT R, 1987, CANCER RES, V47, P1390; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDEGENT JE, 1985, J HISTOCHEM CYTOCHEM, V33, P1241, DOI 10.1177/33.12.2415575; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEHMAN TA, 1903, CARCINOGENESIS, V14, P833; MCKENNA WG, 1988, SCIENCE, V241, P1325, DOI 10.1126/science.3045971; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; PARSHAD R, 1994, CARCINOGENESIS, V88, P524; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; POPESCU NC, 1990, HUM GENET, V84, P383; QUINN AG, 1994, J INVEST DERMATOL, V102, P300, DOI 10.1111/1523-1747.ep12371786; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; STANBRIDGE EJ, 1992, CANCER SURV, V12, P5; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TILGEN W, 1983, CANCER RES, V43, P5995; VANDERRIET P, 1994, CANCER RES, V54, P25; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	47	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					961	969						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675455				2022-12-17	WOS:A1995RU79800017
J	MAGGIRWAR, SB; HARHAJ, E; SUN, SC				MAGGIRWAR, SB; HARHAJ, E; SUN, SC			ACTIVATION OF NF-KAPPA-B/REL BY TAX INVOLVES DEGRADATION OF I-KAPPA-B-ALPHA AND IS BLOCKED BY A PROTEASOME INHIBITOR	ONCOGENE			English	Note						TAX; HTLV-I; NF-KAPPA-B; I-KAPPA-B-ALPHA; PROTEIN PHOSPHORYLATION; PROTEASOME INHIBITOR	T-CELL LEUKEMIA; VIRUS TYPE-I; RECEPTOR GENE-EXPRESSION; HTLV-I; TRANSCRIPTION FACTOR; NUCLEAR-LOCALIZATION; PRECURSOR P105; DNA-BINDING; C-REL; PROTEINS	The tax gene product of the human T-cell leukemia virus type I (HTLV-I) induces the nuclear expression and biological function of the NF-kappa B/Rel family of host transcription factors although the underlying mechanism remains unclear, In the present study, we demonstrate that Tax-mediated activation of NF-kappa B/Rel can be inhibited by a proteasome inhibitor, suggesting the involvement of proteolytic reactions in this Tax-specific activation pathway. Transient transfection and reporter gene assays have revealed that Tax overrides the inhibitory function of I kappa B alpha in both F9 embryonal cells and Jurkat T cells. Moreover, Tax-mediated inactivation of I kappa B alpha requires a 16 amino acid sequence element located at the N-terminal region (amino acid 21-36) of I kappa B alpha, which is also required for tumor necrosis factor alpha-induced degradation of this inhibitory protein. We further demonstrate that the proteasome inhibitor also blocks the degradation of I kappa B alpha observed in HTLV-I-infected T cells. Interestingly, inhibition of I kappa B alpha degradation in these cells led to the accumulation of a phosphorylated form of I kappa B alpha. Together, these studies suggest that Tax activation of NF-kappa B/Rel may involve induction of phosphorylation and subsequent proteasome-mediated degradation of the inhibitor I kappa B alpha.	PENN STATE UNIV,COLL MED,MILTON S HERSHEY MED CTR,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health								ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1990, MOL ASPECTS CELLULAR, P409; BALLARD D W, 1989, New Biologist, V1, P83; BALLARD DW, 1986, SCIENCE, V241, P1652; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHEN ISY, 1985, SCIENCE, V229, P54, DOI 10.1126/science.2990037; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CRENON I, 1993, ONCOGENE, V8, P867; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GESSAIN A, 1985, LANCET, V2, P407; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HIRAI H, 1992, ONCOGENE, V7, P1737; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MUNOZ E, 1994, J VIROL, V68, P8035; NAUMANN M, 1993, ONCOGENE, V8, P2275; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OSAME M, 1986, LANCET, V1, P1031; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1046; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WATANABE M, 1993, ONCOGENE, V8, P2949; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	57	49	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					993	998						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675460				2022-12-17	WOS:A1995RU79800022
J	SANCHEZPRIETO, R; LLEONART, M; CAJAL, SRY				SANCHEZPRIETO, R; LLEONART, M; CAJAL, SRY			LACK OF CORRELATION BETWEEN P53 PROTEIN LEVEL AND SENSITIVITY TO DNA-DAMAGING AGENTS IN KERATINOCYTES CARRYING ADENOVIRUS E1A MUTANTS	ONCOGENE			English	Article						ONCOGENES; ADENOVIRUS E1A; E1A MUTANTS; DRUG RESISTANCE; APOPTOSIS; P53	WILD-TYPE P53; CELL-DEATH; TUMOR-SUPPRESSOR; APOPTOSIS; TRANSFORMATION; INDUCTION; GENE; EXPRESSION; CHECKPOINT; ONCOGENE	p53 tumor suppressor protein is required for efficient execution of apoptosis after DNA-damage in many cell systems. Since the oncogene E1a confers susceptibility to DNA-damaging agents and stabilizes p53 protein, we investigate whether the sensitivity to anticancer drugs of E1a-expressing cells was mediated by binding to a specific set of cellular proteins (p60, p105, p107 and p300) and related to the induction of apoptosis and the level of p53 protein. We studied the effect of cisplatin (CDDP), doxorubicin (DOX) and ionizing radiation (RX) on murine keratinocytes (PAM 212) transfected by the wild type E1a oncogene or several E1a mutants which bind to different subsets of cellular proteins. Keratinocytes transfected with the mutant d1787N (which binds to p60, p105, p107 and p300) showed a lethality in response to CDDP (10 mu g ml(-1)) fourfold higher than controls and threefold higher in response to DOX and radiation (5 grays). The sensitivity of keratinocytes carrying the mutant NTd1598 (binding to p105, p107 and p60) to DNA-damaging agents was similar to that of control keratinocytes, while mutant d1992/947 (binding only to p300) were resistant to CDDP and RX but sensitive to DOX. Apoptosis (after 24 h) studied by DNA fragmentation and flow cytometry was only observed in cells carrying the wild type E1a or the mutant d1787N. After treatment with DNA-damaging agents, p53 protein expression increased in all the cell lines and no rE1ation to sensitivity to anticancer agents or induction of apoptosis was observed. From these results, we conclude that cell sensitivity to cisplatin and ionizing radiation induced by the E1a oncogene requires binding to p105, p107 and p300 cellular proteins, while sensitivity to Doxorubicin requires binding only to p300. Interestingly, p53 protein levels were related to the binding to the p300 protein. The high levels of p53 after CDDP and DOX in the mutant d1922/947, which are only sensitive to DOX, suggest that E1a oncogene products may induce sensitivity to DNA-damaging agents by p53-related and unrelated pathways.	CLIN PUERTA DE HIERRO,DEPT PATHOL,E-28035 MADRID,SPAIN	Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda			Prieto, Ricardo/AAZ-7221-2021; Ramon y Cajal, Santiago/H-4955-2016; Sanchez-Prieto, Ricardo/AAY-4271-2021	Ramon y Cajal, Santiago/0000-0002-3867-1390; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Lleonart Pajarin, Matilde/0000-0002-6196-7405				ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BARBEAU D, 1994, ONCOGENE, V9, P359; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CAJAL SRY, 1994, AM J PATHOL, V145, P846; CHU G, 1994, J BIOL CHEM, V269, P787; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; ELDEIRY WS, 1994, CANCER RES, V54, P1169; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS CA, 1993, CANCER RES, V53, P1735; FERNANDEZSARABI.MJ, 1993, NATURE, V366, P274; FLORINCHRISTENS.M, 1993, EXP CELL RES, V207, P57; FREEDMAN CA, 1980, PHARMACOLOGY, V20, P133; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LOWE SW, 1994, J EXP MED, V266, P807; MARCHETTI E, 1994, INT J ONCOL, V5, P611; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P1295; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; RAFF MC, 1993, SCIENCE, V262, P694; SANCHEZPRIETO R, 1995, INT J CANCER, V60, P235; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	46	49	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					675	682						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651731				2022-12-17	WOS:A1995RQ46900009
J	MOASSER, MM; REUTER, VE; DMITROVSKY, E				MOASSER, MM; REUTER, VE; DMITROVSKY, E			OVEREXPRESSION OF THE RETINOIC ACID RECEPTOR-GAMMA DIRECTLY INDUCES TERMINAL DIFFERENTIATION OF HUMAN EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article						RETINOIC ACID; DIFFERENTIATION; EMBRYONAL CARCINOMA; EPISOMAL VECTOR; RAR-GAMMA	ACUTE PROMYELOCYTIC LEUKEMIA; TERATOCARCINOMA STEM-CELLS; EPSTEIN-BARR VIRUS; GRANULOCYTIC DIFFERENTIATION; NUCLEAR RECEPTORS; EXPRESSION; ALPHA; GENE; MOUSE; ISOFORMS	All-trans retinoic acid (RA) exerts profound effects on the growth and differentiation of normal, embryonic, and malignant cells. The effects of RA are mediated through multiple members of the retinoic acid receptor (RAR) and retinoid X receptor (RXR) families of nuclear transcription factors, The RARs and RXRs exhibit specific patterns of expression during development and in adult tissues suggesting tissue or cell-type specific functions. Using NTera2/clone D1 (NT2/D1) human embryonal carcinoma cells as a model, we report that the RA induced terminal differentiation of these cells into a neuronal phenotype is characterized by an increase in expression of RAR alpha, RAR beta, RAR gamma, and a slight induction of RXR alpha. TO study the role of these receptors in the differentiation process we individually overexpressed RAR alpha, beta, gamma and RXR alpha in NT2/D1 cells by cDNA transfection. Using induced cDNA expression by episomal vector amplification we show that RAR gamma overexpression causes the terminal mesenchymal differentiation of these cells,while over-expresssion of RAR alpha, beta and RXR alpha has no observed maturation or growth inhibitory effects. Over-expression of these receptors in the derived RA resistant subclone NT2/D1-R1 showed phenotypic changes characteristic of RA response in RAR gamma transfectants. These studies indicate that of the retinoid receptors expressed in RA-treated NT2/D1 cells, it is the upregulation of RAR gamma that specifically induces the terminal differentiation of these cells.	MEM HOSP,DEPT MED,MOLEC MED LAB,NEW YORK,NY 10021; MEM HOSP,DEPT PATHOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,DEPT MOLEC PHARMACOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,THERAPEUT PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [1R01-CA54494-03, T32-CA-09512-10] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054494, T32CA009512] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1987, J CELL BIOCHEM, V35, P321, DOI 10.1002/jcb.240350407; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREITMAN TR, 1981, BLOOD, V57, P1000; CANFIELD V, 1990, MOL CELL BIOL, V10, P1367, DOI 10.1128/MCB.10.4.1367; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MADER S, 1993, J BIOL CHEM, V268, P591; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANIATIS T, 1989, COLD SPRING HARBOR L; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MERRIMAN RL, 1979, CANCER RES, V39, P1661; MOASSER MM, 1994, ONCOGENE, V9, P833; MOON RC, 1983, CANCER RES, V43, P24696; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SAMANIEGO F, 1990, GENE CHROMOSOME CANC, V1, P289, DOI 10.1002/gcc.2870010406; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x	41	49	49	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1537	1543						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731708				2022-12-17	WOS:A1995QU68100009
J	VALENZUELA, DM; ROJAS, E; GRIFFITHS, JA; COMPTON, DL; GISSER, M; IP, NY; GOLDFARB, M; YANCOPOULOS, GD				VALENZUELA, DM; ROJAS, E; GRIFFITHS, JA; COMPTON, DL; GISSER, M; IP, NY; GOLDFARB, M; YANCOPOULOS, GD			IDENTIFICATION OF FULL-LENGTH AND TRUNCATED FORMS OF EHK-3, A NOVEL MEMBER OF THE EPH RECEPTOR TYROSINE KINASE FAMILY	ONCOGENE			English	Article						RECEPTOR TYROSINE KINASE; EPH GENE FAMILY; EHK-3; NEURAL EXPRESSION	RAT TRKC; PROTEIN; GENE; ENCODES; NEUROTROPHIN-3; HINDBRAIN; MOUSE	Factors that bind and activate receptor tyrosine kinases are known to play key roles during development and in the adult, The Eph-related receptors constitute the largest known family of receptor tyrosine kinases, Members of the Eph family exhibit intriguing patterns of expression in the embryo, implicating them in a variety of developmental processes, and their expression is often restricted to particular subpopulations of postmitotic neurons in the adult, We describe the identification and characterization of a novel member of the Eph receptor family, which we have termed Ehk-3 for Eph Homologous Kinase 3, Ehk-3 displays all the major structural features shared by other members of the Eph family, including a cysteine-rich region and tandem fibronectin type-III domains in its extracellular portion, Ehk-3 is expressed in two forms in a developmentally-regulated fashion: a conventional full-length version containing the intracellular tyrosine kinase domain, as well as a truncated form that lacks this domain, Both forms of Ehk-3 are quite restricted to the nervous system in the adult, but Ehk-3 is more widely expressed in the embryo, suggesting that Ehk-3 mediates different functions during development and in the adult.			VALENZUELA, DM (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.							BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; FROHMAN MA, 1990, PCR PROTOCOLS; GILARDIHEBENSTREIT, 1992, ONCOGENE, V7, P2499; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NIETO MA, 1992, DEVELOPMENT, V116, P1137; SAJJADI FG, 1991, NEW BIOL, V3, P769; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9	21	49	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1573	1580						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731712				2022-12-17	WOS:A1995QU68100013
J	GU, ZM; PIM, D; LABRECQUE, S; BANKS, L; MATLASHEWSKI, G				GU, ZM; PIM, D; LABRECQUE, S; BANKS, L; MATLASHEWSKI, G			DNA-DAMAGE INDUCED P53 MEDIATED TRANSCRIPTION IS INHIBITED BY HUMAN PAPILLOMAVIRUS TYPE-18 E6	ONCOGENE			English	Article							PRIMARY HUMAN KERATINOCYTES; WILD-TYPE P53; TRANSFORMING ACTIVITY; CERVICAL-CANCER; E5 GENE; CELLS; PROTEIN; TRANSACTIVATION; SEQUENCES; IDENTIFICATION	Cervical cancer is similar to other human cancers in that it develops through a multistep process. However, infection with oncogenic human papillomaviruses (HPVs) is believed to be essential for the initiation of this disease. Although HPV may play a central role in the early stages of neoplasia, the accumulation of mutations in an assortment of genes precedes the development of malignant cervical carcinoma. The mechanisms by which abnormalities accumulate are various, but it is possible that viral proteins are involved. In particular, the viral E6 oncoprotein has been shown to interact with the cellular tumour suppressor protein p53, which is involved in DNA damage repair pathways. Hence, E6 may contribute to the genomic instability through this interaction with p53. We have tested this hypothesis by monitoring the effects of E6 upon DNA damage induced p53 transcriptional activity. This study shows that HPV-18 E6 inhibits p53 transcriptional activity following genotoxic stress with UV radiation. No effect was observed when a mutant E6 unable to direct the degradation of p53 was included in this assay. These results suggest that continued E6 expression may contribute to the accumulation of DNA damage associated with the progression of cervical cancer.	MCGILL UNIV, INST PARASITOL, ST ANNE DE BELLEVUE H9X 3V9, PQ, CANADA; MCGILL UNIV, CTR CANC, MONTREAL, PQ, CANADA; INT CTR GENET ENGN & BIOTECHNOL, I-34012 TRIESTE, ITALY	McGill University; McGill University; International Center for Genetic Engineering & Biotechnology (ICGEB)								AUERSPERG N, 1964, J NATL CANCER I, V32, P135; BANKS L, 1990, ONCOGENE, V5, P1383; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; CHEN SL, 1990, J VIROL, V64, P3226, DOI 10.1128/JVI.64.7.3226-3233.1990; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRANCO EL, 1993, INFECT MED, V10, P57; HALL PA, 1993, ONCOGENE, V8, P203; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LORINCZ AT, 1992, OBSTET GYNECOL, V79, P328, DOI 10.1097/00006250-199203000-00002; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MUNGER K, 1989, J VIROL, V63, P4417; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIM D, 1992, ONCOGENE, V7, P27; PONTEN J, 1967, INT J CANCER, V2, P434, DOI 10.1002/ijc.2910020505; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; TOMMASINO M, 1993, ONCOGENE, V8, P195; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	42	49	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					629	633						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290274				2022-12-17	WOS:A1994MW24800031
J	HOWARD, JC; YOUSEFI, S; CHEONG, G; BERNSTEIN, A; BENDAVID, Y				HOWARD, JC; YOUSEFI, S; CHEONG, G; BERNSTEIN, A; BENDAVID, Y			TEMPORAL-ORDER AND FUNCTIONAL-ANALYSIS OF MUTATIONS WITHIN THE FLI-1 AND P53 GENES DURING THE ERYTHROLEUKEMIAS INDUCED BY F-MULV	ONCOGENE			English	Article								The erythroleukemias induced by Friend murine leukemia virus (F-MuLV) result from the accumulation of a number of genetic changes, including activation of the Fli-1 proto-oncogene and inactivation of the p53 tumor suppressor gene. We have determined the temporal order of mutation of the genes involved in this multistage malignancy, by serial in vivo transplantation of F-MuLV induced primary erythroleukemias into syngenic Balb/c mice. These primary tumors are capable of growing when transplanted into syngenic mice, but die after several days of in vitro culture. From the transplanted tumors grown in syngenic mice, erythropoietin-dependent cell lines were established in culture that are clonally related to cells in the primary tumors. We show that retroviral insertional activation of the Fli-1 ets family member is the first detectable genetic event in F-MuLV induced primary erythroleukemias. Mutations in the p53 gene were observed in the Epo-dependent celt lines but not in the transplanted erythroleukemias used to establish these cell lines in culture. These data suggest that activation of Fli-1 plays an important role in the early stages of F-MuLV-induced leukemia, perhaps by altering the self-renewal probabilities of erythroid progenitor cells and that p53 mutations immortalize these cells, enabling them to grow in vitro in the presence of Epo.	SUNNYBROOK HLTH SCI CTR S218, DIV CANC RES, REICHMANN RES BLDG, 2075 BAYVIEW AVE, TORONTO M4N 3M5, ONTARIO, CANADA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto			Yousefi, Shida/AAU-7986-2020; Yousefi, Shida/L-9689-2016	Yousefi, Shida/0000-0002-9855-4305; Yousefi, Shida/0000-0002-9855-4305				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DAVID YB, 1988, ONCOGENE, V3, P179; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HANKINS WD, 1989, ANN NY ACAD SCI, V554, P21, DOI 10.1111/j.1749-6632.1989.tb22405.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINO M, 1991, MOL CELL BIOL, V11, P5527, DOI 10.1128/MCB.11.11.5527; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LACOMBE C, 1991, J BIOL CHEM, V266, P6952; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MCDONALD J, 1987, MOL CELL BIOL, V7, P365, DOI 10.1128/MCB.7.1.365; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; ROVINSKI B, 1988, ONCOGENE, V2, P445; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; SLINGERLAND JM, 1991, BLOOD, V77, P1500; TSUNEFUMI S, 1982, J CELL PHYSL, V1, P185; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZHANG LQ, 1993, ONCOGENE, V8, P1621	40	49	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2721	2729						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378083				2022-12-17	WOS:A1993LX34300013
J	HERMANN, T; HOFFMANN, B; PIEDRAFITA, FJ; ZHANG, XK; PFAHL, M				HERMANN, T; HOFFMANN, B; PIEDRAFITA, FJ; ZHANG, XK; PFAHL, M			V-ERBA REQUIRES AUXILIARY PROTEINS FOR DOMINANT NEGATIVE ACTIVITY	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; AVIAN ERYTHROBLASTOSIS VIRUS; ACID-RESPONSIVE ELEMENT; DNA-BINDING DOMAIN; RETINOIC-ACID; C-ERBA; CELL-TRANSFORMATION; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; ALPHA-MYOSIN	The avian v-erbA protein is an important example of a dominant negative oncogene. It has been identified as a highly mutated form of its cellular homolog, the thyroid hormone receptor alpha (TR-alpha), and its biological activity has been correlated with its repressor function on certain receptor-regulated genes. Although v-erbA has lost the hormone responsiveness of its cellular homolog, it has retained DNA-binding activity, and it has been implied that this function is required for repression and transformation. Here we demonstrate that v-erbA forms heterodimers with the retinoid X receptor (RXR-alpha). Only heteromeric v-erbA-RXR-alpha complexes show DNA-binding strong enough to account for its potent repressor function. In addition, v-erbA-RXR-alpha heterodimers specifically bind natural thyroid hormone-responsive elements (TREs) but not retinoic acid-responsive elements (RAREs). Repression of TRE-controlled gene expression by v-erbA requires the presence of RXR-alpha with the natural TREs tested. In contrast, natural RAREs investigated here do not bind the v-erbA-RXR-alpha heterodimer and also are not significantly repressed by v-erbA. Carboxy-terminal mutations that abolish verbA-RXR-alpha heterodimer formation also abolish v-erbA repressor activity. These data suggest that interaction of v-erbA with RXRs or similar auxiliary receptors is essential for the dominant negative activity of the v-erbA oncogene.	LA JOLLA CANC RES FDN, CANC RES CTR, 10901 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035083] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35083] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; BRENT G A, 1989, New Biologist, V1, P329; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEBUIRE B, 1984, SCIENCE, V224, P1456, DOI 10.1126/science.6328658; DESBOIS C, 1991, ONCOGENE, V6, P2129; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FORMAN B M, 1990, New Biologist, V2, P587; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GRAUPNER G, 1991, MOL ENDOCRINOL, V5, P365, DOI 10.1210/mend-5-3-365; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HERMANN T, 1991, CELL REGUL, V2, P565, DOI 10.1091/mbc.2.7.565; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, J MOL ENDOCRINOL, V4, P1734; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; HUSMANN M, 1992, BIOCHEM BIOPH RES CO, V187, P1558, DOI 10.1016/0006-291X(92)90480-9; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LEHMANN JM, 1991, NUCLEIC ACIDS RES, V19, P573, DOI 10.1093/nar/19.3.573; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; ROSEN ED, 1991, MOL CELL ENDOCRINOL, V78, pC83, DOI 10.1016/0303-7207(91)90175-R; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SEALY L, 1983, VIROLOGY, V130, P155, DOI 10.1016/0042-6822(83)90125-3; SELMI S, 1991, J BIOL CHEM, V266, P11589; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; YANGYEN HF, 1991, NEW BIOL, V3, P1206; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	76	49	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					55	65						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8093812				2022-12-17	WOS:A1993KN00500007
J	LONGSTREET, M; MILLER, B; HOWE, PH				LONGSTREET, M; MILLER, B; HOWE, PH			LOSS OF TRANSFORMING GROWTH FACTOR-BETA-1 (TGF-BETA-1)-INDUCED GROWTH ARREST AND P34(CDC2) REGULATION IN RAS-TRANSFECTED EPITHELIAL-CELLS	ONCOGENE			English	Article							CDC2 PROTEIN-KINASE; FACTOR-BETA; TGF-BETA; C-MYC; RETINOBLASTOMA PROTEIN; HISTONE-H1 KINASE; INHIBITION; PHOSPHORYLATION; PROLIFERATION; EXPRESSION	Transforming growth factor beta-1 (TGF-beta-1) is a potent inhibitor of mink lung epithelial (CCL64) cell growth in culture. The fact that many transformed epithelial cells have escaped from negative growth control by TGF-beta-1 suggests that transfected epithelial cells may be an appropriate model for investigating the growth-inhibitory mechanism of TGF-beta-1. We transfected CCL64 cells with a mouse c-myc oncogene (pSVc-myc1), a mutated Harvey-ras (Ha-ras) oncogene, or a combination of both. The results indicate that cells transfected with c-myc alone exhibit normal morphology and maintain sensitivity to TGF-beta-1 growth arrest, but are unable to form colonies in soft agar in the presence or absence of FGF-beta-1. Cells transfected with Ha-ras, or co-transfected with c-myc, display a transformed morphology, grow spontaneously under anchorage-independent conditions and acquire a complete resistance to growth inhibition by TGF-beta-1. Affinity cross-linking of [I-125]TGF-beta-1 to cell-surface receptors from these transfectants revealed that all three TGF-beta receptor types were present and no significant differences in [I-125]TGF-beta-1 labeling of these receptors was observed. Since we have previously demonstrated that modulation of p34cdc2 kinase is a marker for TGF-beta-1 growth inhibition, we investigated p34cdc2 activity in the CCL64 transfected clones. The results show that in the control CCL64 cells and in the myc-transfected clones TGF-beta-1 regulation of p34cdc2 activity is maintained. In the ras- and ras + myc-transfected cells p34cdc2 phosphorylation and histone HI kinase activity is significantly increased and regulation by TGF-beta-1 is lost.	CLEVELAND CLIN,RES INST,DEPT CELL BIOL,NC1-145,CLEVELAND,OH 44106	Cleveland Clinic Foundation					NCI NIH HHS [CA-55536] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055536, R29CA055536] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COFFEY RJ, 1986, CANCER RES, V44, P2230; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; HADDOW S, 1991, ONCOGENE, V6, P1465; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HOUCK KA, 1989, ONCOGENE, V4, P19; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HOWE PH, 1990, BIOCHEM J, V266, P537, DOI 10.1042/bj2660537; HOWE PH, 1989, CANCER RES, V49, P6024; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEOF EB, 1987, MOL CELL BIOL, V7, P2649, DOI 10.1128/MCB.7.7.2649; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; Maniatis T., 1982, MOL CLONING; MANNING AM, 1991, ONCOGENE, V6, P1471; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; SHIPLEY GD, 1986, CANCER RES, V46, P2068; STROM SC, 1991, DIGEST DIS SCI, V5, P642; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	38	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1549	1556						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630817				2022-12-17	WOS:A1992JE81300011
J	ITOH, F; ISHIZAKA, Y; TAHIRA, T; YAMAMOTO, M; MIYA, A; IMAI, K; YACHI, A; TAKAI, S; SUGIMURA, T; NAGAO, M				ITOH, F; ISHIZAKA, Y; TAHIRA, T; YAMAMOTO, M; MIYA, A; IMAI, K; YACHI, A; TAKAI, S; SUGIMURA, T; NAGAO, M			IDENTIFICATION AND ANALYSIS OF THE RET PROTOONCOGENE PROMOTER REGION IN NEUROBLASTOMA CELL-LINES AND MEDULLARY-THYROID CARCINOMAS FROM MEN2A-PATIENTS	ONCOGENE			English	Article							FACTOR RECEPTOR GENE; MESSENGER-RNA; MOLECULAR-CLONING; EXPRESSION; DNA; PROTOONCOGENE; TRANSCRIPTION; SEQUENCES; VECTORS; TRANSFORMATION	The human ret proto-oncogene (proto-ret), encoding a receptor tyrosine kinase, is highly expressed in neuroblastomas, medullary thyroid carcinomas (MTCs) and pheochromocytomas, which are all tumors of cells originating from the neural crest. In studies on the transcription mechanism of proto-ret, we identified the transcription start site and the promoter region by chloramphenicol acetyl transferase (CAT) assay. A sequence upstream from the transcription start site (- 167 to + 98 bp) showed definite promoter activity in both proto-ret mRNA-positive neuroblastoma NB39-nu cells and proto-ret mRNA-negative HeLa cells. The promoter sequence had a high GC content and contained four tandemly repeated GC boxes without a TATA box. Putative binding sequences for SP-1, AP-2 and epidermal growth factor receptor-specific transcription factor (ETF) and also the transcription-suppressing factor, GC factor (GCF), were found in the repeated GC box region. Southern blot analysis of DNAs of neuroblastoma cell lines and primary MTCs showed that the high proto-ret expression in these tumors is not caused by gross genetic changes in the promoter region, suggesting the possible involvement of a region(s) other than the sequence from - 167 to + 98 bp or a minor genetic change(s) in the promoter region.	NATL CANC CTR,DIV CARCINOGENESIS,1-1 TSUKIJI-5,CHUO KU,TOKYO 104,JAPAN; OSAKA UNIV,SCH MED,DEPT SURG 2,FUKUSHIMA KU,OSAKA 553,JAPAN; SAPPORO MED COLL,DEPT INTERNAL MED 1,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,DIV MED GENET,FUKUSHIMA KU,OSAKA 553,JAPAN	National Cancer Center - Japan; Osaka University; Sapporo Medical University; Osaka University								ARAKI E, 1987, J BIOL CHEM, V262, P16186; ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GREEN MR, 1980, CELL, V22, P231, DOI 10.1016/0092-8674(80)90171-3; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; IKEDA I, 1990, ONCOGENE, V5, P1291; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; ITOH F, 1989, Tumor Research, V24, P1; KAGEYAMA R, 1988, P NATL ACAD SCI USA, V85, P5016, DOI 10.1073/pnas.85.14.5016; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; LAU YF, 1983, P NATL ACAD SCI-BIOL, V80, P5225, DOI 10.1073/pnas.80.17.5225; MAEKAWA T, 1989, J BIOL CHEM, V264, P5488; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MIYAZAKI J, 1989, GENE, V79, P269; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1990, ONCOGENE, V5, P1595; SZENTIRMAY Z, 1990, ONCOGENE, V5, P701; TAHIRA T, 1991, ONCOGENE, V6, P2333; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; YAMAMOTO F, 1988, ONCOGENE RES, V3, P125; YAMAMOTO M, 1991, JPN J CLIN ONCOL, V21, P149; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	38	49	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1201	1206						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1350670				2022-12-17	WOS:A1992HU64200018
J	TADOKORO, K; FUJII, H; OHSHIMA, A; KAKIZAWA, Y; SHIMIZU, K; SAKAI, A; SUMIYOSHI, K; INOUE, T; HAYASHI, Y; YAMADA, M				TADOKORO, K; FUJII, H; OHSHIMA, A; KAKIZAWA, Y; SHIMIZU, K; SAKAI, A; SUMIYOSHI, K; INOUE, T; HAYASHI, Y; YAMADA, M			INTRAGENIC HOMOZYGOUS DELETION OF THE WT1-GENE IN WILMS-TUMOR	ONCOGENE			English	Article							CHROMOSOME-11; GENE; 11P13; LOCUS; DNA; HETEROZYGOSITY; ASSOCIATION; MUTATION; ALLELES; CANCER	One example of intragenic homozygous deletion of the WT1 gene on chromosome 11p13 was found after screening 42 samples of Wilms' tumor DNA from Japanese patients. After construction of a restriction map for the genomic sequence covering the 3' half of the gene, the deletion was analysed at the nucleotide sequence level. The deletion occurred in the patient's germline on his paternal chromosome, and most of the short arm of his maternal chromosome 11 was subsequently lost in the tumor. The size of the deletion was about 8 kb, removing exons 6 and 7 and resulting in premature termination. The deletion seemed to be created by recombination between short homologous sequences found in an Alu repeat, with a 16-bp duplication left at the junction. This case conforms to a two-hit model for the genesis of a certain group of tumors, and supports the hypothesis that WT1 is one of the recessive oncogenes responsible for Wilms' tumor.	NIHON UNIV,COLL AGR & VET MED,NUCLE ACID SCI LAB,FUJISAWA,KANAGAWA 252,JAPAN; UNIV TOKYO,FAC MED,DEPT PEDIAT,TOKYO 113,JAPAN; NATL CHILDRENS HOSP,TOKYO 154,JAPAN	Nihon University; University of Tokyo; National Center for Child Health & Development - Japan	TADOKORO, K (corresponding author), NATL CHILDRENS HOSP,MED RES CTR,3-35-31 TAISHIDO,TOKYO 154,JAPAN.							ALBERTINI RJ, 1990, ANNU REV GENET, V24, P305; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HUFF V, 1991, AM J HUM GENET, V48, P997; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; JELINEK WR, 1982, ANNU REV BIOCHEM, V51, P813, DOI 10.1146/annurev.bi.51.070182.004121; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; PAL N, 1990, ONCOGENE, V5, P1665; Parkin D., 1988, INT INCIDENCE CHILDH, V1st; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P3753, DOI 10.1093/nar/19.13.3753; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RICCARDI VM, 1978, PEDIATRICS, V61, P604; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P2514, DOI 10.1093/nar/19.9.2514; TADOKORO K, 1991, NUCLEIC ACIDS RES, V24, P6967; WADEY RB, 1990, ONCOGENE, V5, P901; WAZIRI M, 1983, J PEDIATR-US, V102, P873, DOI 10.1016/S0022-3476(83)80014-6; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4036, DOI 10.1093/nar/18.13.4036; YAMADA M, 1985, P NATL ACAD SCI USA, V82, P3567, DOI 10.1073/pnas.82.11.3567; YAMADA M, 1982, GENE, V18, P309; YAMADA M, 1988, JPN J CANCER RES, V79, P670, DOI 10.1111/j.1349-7006.1988.tb02219.x	31	49	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1215	1221						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1350671				2022-12-17	WOS:A1992HU64200020
J	MAZARS, GR; JEANTEUR, P; LYNCH, HT; LENOIR, G; THEILLET, C				MAZARS, GR; JEANTEUR, P; LYNCH, HT; LENOIR, G; THEILLET, C			NUCLEOTIDE-SEQUENCE POLYMORPHISM IN A HOTSPOT MUTATION REGION OF THE P53 GENE	ONCOGENE			English	Note							PROTEIN; CANCER	By screening for mutations in the p53 coding sequence by means of single-strand conformation polymorphism (SSCP) in a series of breast tumors we detected a novel polymorphism. This change in the SSCP pattern was detected in 6.2% of the tumor DNAs analysed and implied an A to G substitution at the last base of codon 213, thus representing a neutral change. First suspecting a somatic mutation we confirmed its presence in matched sets of DNAs from normal tissues. Extending our study to a series of 60 ovarian carcinomas and 70 healthy blood donors we noticed that this polymorphism represented only 3% and 2.6% respectively. We wondered if the difference in frequency in the breast cancer population might not be related to familial breast cancer and analysed 26 DNAs from patients showing predisposition to the disease. Two patients presented this polymorphism and one corresponding kindred was analysed, revealing a mendelian mode of transmission but no correlation with the cancer phenotype.	UNIV MONTPELLIER 2,BIOL MOLEC LAB,CNRS,URA 1191,F-34060 MONTPELLIER,FRANCE; UNIV LYON 1,INT AGCY RES CANC,F-69373 LYONS 2,FRANCE; CREIGHTON UNIV,DEPT PREVENT MED,OMAHA,NE 68178	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; World Health Organization; International Agency for Research on Cancer (IARC); Creighton University			Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759				BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CARBONE D, 1991, ONCOGENE, V6, P1691; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MAZARS R, 1991, ONCOGENE, V6, P1685; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0	10	49	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					781	782						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565474				2022-12-17	WOS:A1992HQ68200023
J	GOLDFARB, M; DEED, R; MACALLAN, D; WALTHER, W; DICKSON, C; PETERS, G				GOLDFARB, M; DEED, R; MACALLAN, D; WALTHER, W; DICKSON, C; PETERS, G			CELL-TRANSFORMATION BY INT-2 - A MEMBER OF THE FIBROBLAST GROWTH-FACTOR FAMILY	ONCOGENE			English	Article							PROTO-ONCOGENE INT-2; NUCLEOTIDE-SEQUENCE; SARCOMA DNA; FACTOR CDNA; 3T3 CELLS; MOUSE; GENE; EXPRESSION; FGF; HST	The sequence similarities between Int-2 and members of the fibroblast growth factor (FGF) family have prompted functional as well as structural comparisons with other FGFs. Here we examine the ability of int-2 sequences to induced morphological transformation of NIH3T3 cells, a characteristic property of the secreted FGFs, such as FGF-5 and Hst1/kFGF. Despite encoding a short signal sequence, which directs the product to the secretory pathway, mouse int-2 DNA is incapable of inducing foci of transformation in the standard transfection assay. However, when transfected cells are enriched by coselection with the neomycin resistance gene, a proportion of the int-2-expressing cells display a transformed phenotype, including the ability to grow as colonies in soft agar and in defined medium. Analyses of int-2 RNA and protein in these cells suggest that transformation by int-2 may require a threshold level of expression, and that the subsequent phenotype is dependent on the level of int-2 protein present in the cells.	ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND LABS,DOMINION HOUSE,59 BARTHOLOMEW CLOSE,LONDON EC1A 7BE,ENGLAND; COLUMBIA UNIV,DEPT BIOCHEM,NEW YORK,NY 10032; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; University of London; Queen Mary University London; Columbia University; Cancer Research UK								ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BLAM SB, 1988, ONCOGENE, V3, P129; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BROOKES S, 1989, NUCLEIC ACIDS RES, V17, P4037, DOI 10.1093/nar/17.11.4037; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DELAPEYRIERE O, 1990, ONCOGENE, V5, P823; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIXON M, 1989, MOL CELL BIOL, V9, P4896, DOI 10.1128/MCB.9.11.4896; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GOSPODAROWICZ D, 1974, P NATL ACAD SCI USA, V71, P4648, DOI 10.1073/pnas.71.12.4648; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LOBB RL, 1989, ANAL BIOCHEM, V154, P1; MARICS I, 1989, ONCOGENE, V4, P335; MERLO GR, 1990, CELL GROWTH DIFFER, V1, P463; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; PATERNO GD, 1989, DEVELOPMENT, V106, P79; Peters G, 1987, CELLULAR MOL BIOL MA, P307; QUARTO N, 1989, ONCOGENE RES, V5, P101; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; THOMAS KA, 1988, TRENDS BIOCHEM SCI, V13, P327, DOI 10.1016/0968-0004(88)90098-9; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V157, P618, DOI 10.1016/S0006-291X(88)80295-X; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	48	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					65	71						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1846956				2022-12-17	WOS:A1991EY03900009
J	ZHAO, X; SINGH, B; BATTEN, BE				ZHAO, X; SINGH, B; BATTEN, BE			THE ROLE OF C-MOS PROTO-ONCOPROTEIN IN MAMMALIAN MEIOTIC MATURATION	ONCOGENE			English	Article							KINASE-ACTIVITY; DEVELOPMENTAL REGULATION; OOCYTE MATURATION; ONCOGENE PRODUCT; MOUSE-TISSUES; GERM-CELLS; V-MOS; EXPRESSION; EGGS; TRANSCRIPTS	The developmentally regulated expression of c-mos oncogene has led to the speculation that this gene may be involved in gametogenesis and early development. To directly test this possibility, we have used an electric field mediated transfer method to introduce an antibody against the c-mos gene product into living immature mouse oocytes. Control oocytes exposed to the electric field without antibody, non-immune IgG, or c-mos antibody pre-absorbed with the mos peptide underwent normal germinal vesicle breakdown (GVBD) (90%) and formed a polar body by 8 h. Oocytes transferred with antibody against c-mos product underwent GVBD, and chromosome condensation as judged by Hoechst 33258 staining. However, antibody transferred oocytes did not form a polar body. Confocal fluorescence microscopy using antibodies against tubulin demonstrated that 90% of the oocytes that received antibody against c-mos did not assemble a meiotic spindle. In a few instances an abnormal spindle-like structure did form. Electron microscopy confirmed that the nuclear envelope disassembled and revealed many microtubules in a disorganized manner. Western blot analysis showed the presence of p39c-mos in mouse mature oocytes, spermatocytes and granulosa cells. These results suggest a role for c-mos in regulating the assembly and/or function of the spindle during meiotic division in murine.	OHIO STATE UNIV,DEPT ANAT,COLUMBUS,OH 43210; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030	Ohio State University; University of Texas System; UTMD Anderson Cancer Center								BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; CYERT MS, 1988, CELL, V53, P185, DOI 10.1016/0092-8674(88)90380-7; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GARD DL, 1987, J CELL BIOL, V105, P2203, DOI 10.1083/jcb.105.5.2203; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; HASHIMOTO N, 1988, DEV BIOL, V126, P242, DOI 10.1016/0012-1606(88)90135-2; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1988, ONCOGENE, V3, P225; HOGAN B, 1986, MANIPULATING MANIPUL; KESHET E, 1988, ONCOGENE, V2, P235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MINSHULL J, 1989, VIROLOGY, V56, P947; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; MUTTER GL, 1988, EMBO J, V7, P683, DOI 10.1002/j.1460-2075.1988.tb02863.x; OGISO Y, 1986, BIOCHEM BIOPH RES CO, V140, P477, DOI 10.1016/0006-291X(86)90757-6; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHOLEY J M, 1985, Journal of Cell Biology, V101, p31A; SETH A, 1987, P NATL ACAD SCI USA, V84, P3560, DOI 10.1073/pnas.84.11.3560; SINGH B, 1986, VIROLOGY, V152, P502, DOI 10.1016/0042-6822(86)90156-X; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; Zhao X., 1989, TECHNIQUES J METHODS, V1, P37; ZHAO X, 1990, IN PRESS ONCOGENE	38	49	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					43	49						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1825139				2022-12-17	WOS:A1991EY03900006
J	SCHROEDER, C; RAYNOSCHEK, C; FUHRMANN, U; DAMM, K; VENNSTROM, B; BEUG, H				SCHROEDER, C; RAYNOSCHEK, C; FUHRMANN, U; DAMM, K; VENNSTROM, B; BEUG, H			THE V-ERB A ONCOGENE CAUSES REPRESSION OF ERYTHROCYTE-SPECIFIC GENES AND AN IMMATURE, ABERRANT DIFFERENTIATION PHENOTYPE IN NORMAL ERYTHROID PROGENITORS	ONCOGENE			English	Article									INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY; KAROLINSKA INST,DEPT MOLEC BIOL,CMB,S-10401 STOCKHOLM 60,SWEDEN	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); European Molecular Biology Laboratory (EMBL); Karolinska Institutet								BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; BEUG H, 1981, VIROLOGY, V111, P201, DOI 10.1016/0042-6822(81)90665-6; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1977, EXP CELL RES, V107, P417, DOI 10.1016/0014-4827(77)90363-9; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BEUG H, 1985, MODERN TRENDS HUMA 6, V29, P290; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FORREST D, 1990, IN PRESS ONCOGENE; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUHRMANN U, 1989, GENE DEV, V3, P2027; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1982, BIOCHIM BIOPHYS ACTA, V651, P245, DOI 10.1016/0304-419X(82)90014-2; HAYMAN MJ, 1982, J CELL BIOCHEM, V18, P351, DOI 10.1002/jcb.1982.240180308; HIHARA H, 1983, J NATL CANCER I, V70, P891; KAHN P, 1984, P NATL ACAD SCI-BIOL, V81, P7122, DOI 10.1073/pnas.81.22.7122; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KAHN P, 1986, P HAMBURG, P41; KHAZAIE K, 1988, EMBO J, V7, P3067; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KOWENZ E, 1986, MODERN TRENDS HUMA 7, V31, P199; MAIHLE N J, 1988, Biochimica et Biophysica Acta, V948, P287; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; SAMARUT J, 1980, J CELL PHYSIOL, V105, P553, DOI 10.1002/jcp.1041050320; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHMIDT JA, 1986, CELL, V46, P41, DOI 10.1016/0092-8674(86)90858-5; SEALY L, 1983, VIROLOGY, V130, P155, DOI 10.1016/0042-6822(83)90125-3; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, IN PRESS CELL	42	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1990	5	10					1445	1453						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	1979159				2022-12-17	WOS:A1990EK50200002
J	KUMAR, R; MEDINA, D; SUKUMAR, S				KUMAR, R; MEDINA, D; SUKUMAR, S			ACTIVATION OF H-RAS ONCOGENES IN PRENEOPLASTIC MOUSE MAMMARY TISSUES	ONCOGENE			English	Article									SALK INST BIOL STUDIES, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA; BAYLOR UNIV, DEPT CELL BIOL, HOUSTON, TX 77030 USA; SQUIBB INST MED RES, DEPT MOLEC BIOL, PRINCETON, NJ 08543 USA	Salk Institute; Baylor University					NATIONAL CANCER INSTITUTE [R01CA033369, R01CA048943] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101, CA33369, CA48943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN PR, 1981, CELL, V26, P129, DOI 10.1016/0092-8674(81)90041-6; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIGGER CAH, 1989, P NATL ACAD SCI USA, V86, P2291, DOI 10.1073/pnas.86.7.2291; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; CARDIFF RD, 1988, ONCOGENE, V3, P205; CARDIFF RD, 1984, ADV CANCER RES, V42, P167, DOI 10.1016/S0065-230X(08)60458-3; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; DANIELS CW, 1971, FED PROC, V34, P64; DEOME KB, 1959, CANCER RES, V19, P515; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DIPPLE A, 1983, CANCER RES, V43, P4132; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; GRAHAM R, 1976, VIROLOGY, V54, P536; KUMAR R, 1989, ONCOGENE RES, V4, P235; KUMAR R, 1988, ONCOGENE, V3, P647; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MEDINA D, 1987, J NATL CANCER I, V79, P569; MEDINA D, 1988, CARCINOGENESIS, V9, P1113, DOI 10.1093/carcin/9.7.1113; PINCUS MR, 1987, P NATL ACAD SCI USA, V84, P8375, DOI 10.1073/pnas.84.23.8375; SUKUMAR S, 1989, CURR TOP MICROBIOL, V148, P93; SUKUMAR S, 1990, P NATL ACAD SCI USA, V87, P718, DOI 10.1073/pnas.87.2.718; SUKUMAR S, 1988, SCIENCE, V240, P524, DOI 10.1126/science.3282307; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	26	49	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1990	5	8					1271	1277						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	2118247				2022-12-17	WOS:A1990DX36100023
J	SOBCZAK, J; MECHTI, N; TOURNIER, MF; BLANCHARD, JM; DUGUET, M				SOBCZAK, J; MECHTI, N; TOURNIER, MF; BLANCHARD, JM; DUGUET, M			C-MYC AND C-FOS GENE-REGULATION DURING MOUSE-LIVER REGENERATION	ONCOGENE			English	Article									CNRS, UA 1191, BIOCHIM PROT LAB, F-34060 MONTPELLIER, FRANCE; CNRS, UA 1191, BIOL MOLEC LAB, F-34060 MONTPELLIER, FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	SOBCZAK, J (corresponding author), UNIV PARIS 06, ENZYMOL ACIDES NUCLEIQUES LAB, CNRS, URA 555, 96 BLVD RASPAIL, F-75006 PARIS, FRANCE.			Sobczak, Joelle/0000-0001-7180-2789				BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLANCHARD JM, 1988, BIOCHIMIE, V70, P877, DOI 10.1016/0300-9084(88)90228-3; BLANCHARD JM, 1988, LYMPHOCYTE ACTIVATIO, P339; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; BUCHER NLR, 1982, COLD SPRING HARBOR C, V9, P15; BUSCHER M, 1988, ONCOGENE, V3, P301; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; Higgins GM, 1931, ARCH PATHOL, V12, P186; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; KINDY MS, 1987, MOL CELL BIOL, V7, P2857, DOI 10.1128/MCB.7.8.2857; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MULLER R, 1985, BIOCHIM BIOPHYS ACTA, V823, P207; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; SARIBAN E, 1988, MOL CELL BIOL, V8, P340, DOI 10.1128/MCB.8.1.340; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SOBCZAK J, 1989, EUR J BIOCHEM, V180, P49, DOI 10.1111/j.1432-1033.1989.tb14613.x; SOBCZAK J, 1986, BIOCHIMIE, V68, P957, DOI 10.1016/S0300-9084(86)80039-6; THOMPSON NL, 1986, CANCER RES, V46, P3111; TOURKINE N, 1989, ONCOGENE, V4, P973; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x	54	49	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1989	4	12					1503	1508						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2512526				2022-12-17	WOS:A1989CB65900013
J	GONZALEZCADAVID, NF; ZHOU, D; BATTIFORA, H; BARELI, M; CLINE, MJ				GONZALEZCADAVID, NF; ZHOU, D; BATTIFORA, H; BARELI, M; CLINE, MJ			DIRECT SEQUENCING ANALYSIS OF EXON-1 OF THE C-K-RAS GENE SHOWS A LOW-FREQUENCY OF MUTATIONS IN HUMAN PANCREATIC ADENOCARCINOMAS	ONCOGENE			English	Article											GONZALEZCADAVID, NF (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DIV HEMATOL ONCOL,FACTOR BLDG 11-151,LOS ANGELES,CA 90024, USA.							ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARELI M, 1989, BLOOD, V73, P281; BARELI M, 1989, IN PRESS BRIT J HAEM; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; PEDERSENBJERGAARD J, 1988, CANCER RES, V48, P1812; ROCHLITZ DF, 1988, DNA, V1, P515; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1988, CANCER RES, V48, P5738; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; VANTVEER LJ, 1988, ONCOGENE, V2, P157; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	19	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1137	1140						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2674856				2022-12-17	WOS:A1989AM53100013
J	YI, TL; WILLMAN, CL				YI, TL; WILLMAN, CL			CLONING OF THE MURINE C-FGR PROTO-ONCOGENE CDNA AND INDUCTION OF C-FGR EXPRESSION BY PROLIFERATION AND ACTIVATION FACTORS IN NORMAL BONE MARROW-DERIVED MONOCYTIC CELLS	ONCOGENE			English	Article									UNIV NEW MEXICO,SCH MED,CTR CANC,DEPT CELL BIOL,900 CAMINO SALUD NE,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT PATHOL,ALBUQUERQUE,NM 87131	University of New Mexico; University of New Mexico					NIDDK NIH HHS [KII DK-01284] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001284] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS DO, 1987, IMMUNOL REV, V97, P5, DOI 10.1111/j.1600-065X.1987.tb00514.x; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DALESSIO JM, 1987, FOCUS, V9, P1; FALK LA, 1988, J IMMUNOL, V140, P2652; GRABSTEIN KH, 1986, SCIENCE, V232, P506, DOI 10.1126/science.3083507; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HORIGUCHI J, 1987, BLOOD, V69, P1259; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; INOUE K, 1987, ONCOGENE, V1, P301; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KLEMSZ MJ, 1987, NUCLEIC ACIDS RES, V15, P9600, DOI 10.1093/nar/15.22.9600; KOERNER TJ, 1987, J IMMUNOL, V139, P239; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MALISSEN M, 1983, SCIENCE, V221, P750, DOI 10.1126/science.6410508; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MORRISSEY PJ, 1987, J IMMUNOL, V139, P1113; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; NAHARRO G, 1983, J VIROL, V47, P611, DOI 10.1128/JVI.47.3.611-619.1983; PAWSON T, 1988, ONCOGENE, V3, P491; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TRONICK SR, 1985, P NATL ACAD SCI USA, V82, P6595, DOI 10.1073/pnas.82.19.6595; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; WARREN MK, 1986, J IMMUNOL, V137, P2281; WILLMAN CL, 1987, P NATL ACAD SCI USA, V84, P4480, DOI 10.1073/pnas.84.13.4480; WILLMAN CL, IN PRESS J EXP MED; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	43	49	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1081	1087						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2674853				2022-12-17	WOS:A1989AM53100005
J	ROTH, WK; WERNER, S; SCHIRREN, CG; HOFSCHNEIDER, PH				ROTH, WK; WERNER, S; SCHIRREN, CG; HOFSCHNEIDER, PH			DEPLETION OF PDGF FROM SERUM INHIBITS GROWTH OF AIDS-RELATED AND SPORADIC KAPOSIS SARCOMA-CELLS IN CULTURE	ONCOGENE			English	Article									UNIV MUNICH,DERMATOL KLIN,D-8000 MUNICH 2,FED REP GER	University of Munich	ROTH, WK (corresponding author), MAX PLANCK INST BIOCHEM,VIRUSFORSCH ABT,KLOPFERSPITZ 18A,D-8033 MARTINSRIED,FED REP GER.			Werner, Sabine/0000-0001-7397-8710				ALBINI A, 1988, J CELL BIOCHEM, V36, P369, DOI 10.1002/jcb.240360406; BETSHOLTZ C, 1984, J CELL PHYSIOL, V118, P203, DOI 10.1002/jcp.1041180213; CHIU IM, 1984, CELL, V37, P123; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DICORLETO PE, 1983, P NATL ACAD SCI-BIOL, V80, P1919, DOI 10.1073/pnas.80.7.1919; GOTTLIEB GJ, 1982, HUM PATHOL, V13, P882, DOI 10.1016/S0046-8177(82)80047-6; HAVERKOS HW, 1985, NEW ENGL J MED, V312, P1518; Kaposi M., 1872, ARCH DERMATOL SYPHIL, V4, P265, DOI 10.1007/BF01830024; LITTLE D, 1986, J PATHOL, V149, P89, DOI 10.1002/path.1711490203; Maniatis T., 1982, MOL CLONING; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; ROTH WK, 1988, INT J CANCER, V42, P767, DOI 10.1002/ijc.2910420523; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	14	49	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					483	487						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2541390				2022-12-17	WOS:A1989U567700013
J	TAKADA, S; KOIKE, K				TAKADA, S; KOIKE, K			ACTIVATED N-RAS GENE WAS FOUND IN HUMAN HEPATOMA TISSUE BUT ONLY IN A SMALL FRACTION OF THE TUMOR-CELLS	ONCOGENE			English	Article									JAPANESE FDN CANC RES,INST CANC,DEPT GENE RES,KAMI IKEBUKURO 1-37-1,TOSHIMA KU,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research								BOS JL, 1984, NUCLEIC ACIDS RES, V12, P9155, DOI 10.1093/nar/12.23.9155; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CHANG EH, 1982, P NATL ACAD SCI-BIOL, V79, P4848, DOI 10.1073/pnas.79.16.4848; Cooper G M, 1984, Biochim Biophys Acta, V738, P9, DOI 10.1016/0304-419X(84)90017-9; COOPER GM, 1982, SCIENCE, V217, P801, DOI 10.1126/science.6285471; DER CJ, 1983, CELL, V32, P201, DOI 10.1016/0092-8674(83)90510-X; DUESBERG PH, 1985, SCIENCE, V228, P669, DOI 10.1126/science.3992240; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GU JR, 1986, SCI CHINA SER B, V29, P173; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; JELINEK WR, 1980, P NATL ACAD SCI-BIOL, V77, P1398, DOI 10.1073/pnas.77.3.1398; KOIKE K, 1983, NUCLEIC ACIDS RES, V11, P5391, DOI 10.1093/nar/11.16.5391; Maxam A M, 1980, Methods Enzymol, V65, P499; NOTARIO V, 1984, CANCER CELLS ONCOGEN, P425; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SHEN WPV, 1987, ONCOGENE, V1, P157; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P383, DOI 10.1073/pnas.80.2.383; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TOKSOZ D, 1987, ONCOGENE, V1, P409; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; YAGINUMA K, 1987, J VIROL, V61, P1808, DOI 10.1128/JVI.61.6.1808-1813.1987; YAGINUMA K, 1984, JPN J CANCER RES, V75, P743; YUASA Y, 1984, P NATL ACAD SCI-BIOL, V81, P3670, DOI 10.1073/pnas.81.12.3670; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0	32	49	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					189	193						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2538792				2022-12-17	WOS:A1989U567500010
J	ZECHEL, C; SCHLEENBECKER, U; ANDERS, A; ANDERS, F				ZECHEL, C; SCHLEENBECKER, U; ANDERS, A; ANDERS, F			V-ERBB RELATED SEQUENCES IN XIPHOPHORUS THAT MAP TO MELANOMA DETERMINING MENDELIAN LOCI AND OVEREXPRESS IN A MELANOMA CELL-LINE	ONCOGENE			English	Article											ZECHEL, C (corresponding author), UNIV GIESSEN,INST GENET,D-6300 GIESSEN,FED REP GER.							AHUJA MR, 1979, EXPERIENTIA, V35, P28, DOI 10.1007/BF01917856; ANDERS A, 1978, BIOCHIM BIOPHYS ACTA, V516, P61, DOI 10.1016/0304-419X(78)90004-5; Anders A., 1973, P33; ANDERS A, 1985, PIGMENT CELL 1985, P315; ANDERS F, 1967, EXPERIENTIA, V23, P1, DOI 10.1007/BF02142235; ANDERS F, 1984, ADV CANCER RES, V42, P191, DOI 10.1016/S0065-230X(08)60459-5; ANDERS F, 1985, MODERN TRENDS HUMAN, V4, P228; ANDERS F, 1982, BIOCH DIFFERENTIATIO, P91; Anders F., 1987, CUTANEOUS MELANOMA, P351; ANDERS F, 1980, SKIN VERTEBRATES, P211; ANDERS F, 1981, SHORT TERM TESTS CHE, P399; ATZ JAMES W., 1962, ZOOLOGICA [NEW YORK], V47, P153; BARNEKOW A, 1982, CANCER RES, V42, P2429; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Breider H, 1938, Z WISS ZOOL ABT A, V151, P243; CARPENTER G, 1983, P NATL ACAD SCI-BIOL, V80, P5627, DOI 10.1073/pnas.80.18.5627; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHROMCZYNSKI P, 1984, BIOCHEM BIOPH RES CO, V122, P340; FRISCHAUF AM, 1980, NUCLEIC ACIDS RES, V8, P5541, DOI 10.1093/nar/8.23.5541; GORDON M, 1963, FISHES LABORTORY ANI, P345; GORDON M, 1959, PIGMENT CELL BIOL, P215; GORDON M, 1947, J NATL CANCER I, V7, P87; GUO LH, 1983, NUCLEIC ACIDS RES, V11, P5521, DOI 10.1093/nar/11.16.5521; HENZE M, 1977, COMP BIOCH PHYSL B, V56, P33; HUNTER T, 1984, JNCI-J NATL CANCER I, V73, P773; HUNTER T, 1986, NATURE, V322, P14, DOI 10.1038/322014a0; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; Kallman K.D., 1975, P81; KERSTEN H, 1983, BIOCH CLIN ASPECTS P, P367; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KOLLINGER G, 1979, J CANCER RES CLIN, V95, P239, DOI 10.1007/BF00410645; KUHN C, 1979, IN VITRO CELL DEV B, V15, P537, DOI 10.1007/BF02618156; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIN CR, 1984, SCIENCE, V224, P843, DOI 10.1126/science.6326261; Maniatis T., 1982, MOL CLONING; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; Radda A.C., 1980, Aquaria (St Gallen), V27, P39; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; REYNOLDS FH, 1981, NATURE, V292, P259, DOI 10.1038/292259a0; ROSEN D E, 1979, Bulletin of the American Museum of Natural History, V162, P267; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARTL M, 1985, INT J CANCER, V36, P199, DOI 10.1002/ijc.2910360212; SCHARTL M, 1982, CANCER RES, V42, P4222; SCHWAB M, 1978, EXPERIENTIA, V34, P780, DOI 10.1007/BF01947324; SCHWAB M, 1981, NEOPLASMA COMP PATHO, P451; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; STERNBERG N, 1977, GENE, V1, P255, DOI 10.1016/0378-1119(77)90049-X; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VENNSTROM B, 1980, J VIROL, V36, P575; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VIELKIND U, 1977, Z KREBSFORSCHUNG, V80, P285; WAKAMATSU Y, 1981, CANCER RES, V41, P679; XU YH, 1984, P NATL ACAD SCI-BIOL, V81, P7308, DOI 10.1073/pnas.81.23.7308; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; YAMAMOTO T, 1986, CANCER RES, V46, P414; Zander C. D., 1967, Mitteilungen der Hamburgischen Zoologischen Museum und Institut, V64, P87; ZANDER C D, 1969, Mitteilungen aus dem Hamburgischen Zoologischen Museum und Institut, V66, P241	61	49	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					605	617						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	2484016				2022-12-17	WOS:A1988R516300018
J	HERRMANN, CH; DERY, CV; MATHEWS, MB				HERRMANN, CH; DERY, CV; MATHEWS, MB			TRANSACTIVATION OF HOST AND VIRAL GENES BY THE ADENOVIRUS E1B 19K TUMOR-ANTIGEN	ONCOGENE			English	Article									COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory					NCI NIH HHS [CA13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESTROM P, 1980, CELL, V19, P671, DOI 10.1016/S0092-8674(80)80044-4; ANDERSON CW, 1974, P NATL ACAD SCI USA, V71, P2756, DOI 10.1073/pnas.71.7.2756; ANDERSON CW, 1984, J VIROL, V50, P387, DOI 10.1128/JVI.50.2.387-396.1984; BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; BABISS LE, 1984, J VIROL, V52, P389, DOI 10.1128/JVI.52.2.389-395.1984; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BERGER SL, 1985, NUCLEIC ACIDS RES, V13, P1413, DOI 10.1093/nar/13.4.1413; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BERK AJ, 1986, CANCER SURV, V5, P367; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BERNARDS R, 1986, VIROLOGY, V150, P126, DOI 10.1016/0042-6822(86)90272-2; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BOS JL, 1983, EMBO J, V2, P73, DOI 10.1002/j.1460-2075.1983.tb01383.x; BOS JL, 1981, CELL, V27, P121, DOI 10.1016/0092-8674(81)90366-4; CARLOCK LR, 1981, J VIROL, V40, P657, DOI 10.1128/JVI.40.3.657-664.1981; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; CHOW LT, 1979, J MOL BIOL, V134, P265, DOI 10.1016/0022-2836(79)90036-6; DERY CV, 1987, ONCOGENE, V2, P15; ESCHE H, 1980, J MOL BIOL, V142, P399, DOI 10.1016/0022-2836(80)90279-X; FLINT SJ, 1976, VIROLOGY, V72, P456, DOI 10.1016/0042-6822(76)90174-4; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GAYNOR RB, 1985, SCIENCE, V230, P447, DOI 10.1126/science.2996135; GAYNOR RB, 1984, P NATL ACAD SCI-BIOL, V81, P1193, DOI 10.1073/pnas.81.4.1193; Gluzman Y., 1982, EUKARYOTIC VIRAL VEC, P187; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1978, VIROLOGY, V86, P10, DOI 10.1016/0042-6822(78)90003-X; GRAHAM FL, 1974, COLD SPRING HARB SYM, V39, P637, DOI 10.1101/SQB.1974.039.01.077; GREEN M, 1983, J VIROL, V48, P604, DOI 10.1128/JVI.48.3.604-615.1983; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; HEARING P, 1985, MOL CELL BIOL, V5, P3214, DOI 10.1128/MCB.5.11.3214; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HOEFFLER WK, 1985, CELL, V41, P955, DOI 10.1016/S0092-8674(85)80076-3; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HURWITZ DR, 1985, P NATL ACAD SCI USA, V82, P163, DOI 10.1073/pnas.82.1.163; JOCHEMSEN AG, 1986, J VIROL, V59, P684, DOI 10.1128/JVI.59.3.684-691.1986; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KITCHINGMAN GR, 1980, J MOL BIOL, V137, P23, DOI 10.1016/0022-2836(80)90155-2; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEWIS JB, 1980, CELL, V21, P303, DOI 10.1016/0092-8674(80)90138-5; Logan J, 1984, CANCER CELL, V2, P527; LUCHER LA, 1984, VIROLOGY, V132, P217, DOI 10.1016/0042-6822(84)90106-5; LUPKER JH, 1981, J VIROL, V37, P524, DOI 10.1128/JVI.37.1.524-529.1981; MATSUO T, 1982, VIROLOGY, V118, P456, DOI 10.1016/0042-6822(82)90366-X; MCKINNON RD, 1982, GENE, V19, P33, DOI 10.1016/0378-1119(82)90186-X; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; MONTELL C, 1984, MOL CELL BIOL, V4, P966, DOI 10.1128/MCB.4.5.966; MONTELL C, 1982, NATURE, V295, P380, DOI 10.1038/295380a0; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; NATARAJAN V, 1986, NUCLEIC ACIDS RES, V14, P9445, DOI 10.1093/nar/14.23.9445; NEVINS JR, 1982, CELL, V29, P913, DOI 10.1016/0092-8674(82)90453-6; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; NEVINS JR, 1979, J VIROL, V32, P727, DOI 10.1128/JVI.32.3.727-733.1979; OSBORNE TF, 1984, MOL CELL BIOL, V4, P1293, DOI 10.1128/MCB.4.7.1293; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; PETTERSSON U, 1977, CELL, V12, P741, DOI 10.1016/0092-8674(77)90274-4; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; RICCIARDI RP, 1981, P NATL ACAD SCI-BIOL, V78, P6121, DOI 10.1073/pnas.78.10.6121; ROWE DT, 1984, J GEN VIROL, V65, P585, DOI 10.1099/0022-1317-65-3-585; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SENEAR AW, 1986, MOL CELL BIOL, V6, P1253, DOI 10.1128/MCB.6.4.1253; SOLNICK D, 1982, J VIROL, V42, P106, DOI 10.1128/JVI.42.1.106-113.1982; SPECTOR DJ, 1978, J MOL BIOL, V126, P395, DOI 10.1016/0022-2836(78)90048-7; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; STILLMAN B, 1986, CANCER SURV, V5, P389; SUBRAMANIAN T, 1985, MOL CELL BIOL, V5, P3297, DOI 10.1128/MCB.5.11.3297; SUBRAMANIAN T, 1984, J BIOL CHEM, V259, P1777; SUBRAMANIAN T, 1984, J VIROL, V52, P336, DOI 10.1128/JVI.52.2.336-343.1984; SVENSSON C, 1984, EMBO J, V3, P789, DOI 10.1002/j.1460-2075.1984.tb01886.x; TREISMAN R, 1983, P NATL ACAD SCI-BIOL, V80, P7428, DOI 10.1073/pnas.80.24.7428; VANDENELSEN P, 1983, VIROLOGY, V131, P242, DOI 10.1016/0042-6822(83)90549-4; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VANDEREB AJ, 1977, GENE, V2, P115, DOI 10.1016/0378-1119(77)90012-9; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VIRTANEN A, 1985, J VIROL, V54, P383, DOI 10.1128/JVI.54.2.383-391.1985; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WEEKS DL, 1983, MOL CELL BIOL, V3, P1222, DOI 10.1128/MCB.3.7.1222; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; WHITE E, 1986, MOL CELL BIOL, V6, P3763, DOI 10.1128/MCB.6.11.3763; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Williams J., 1986, CANC CELLS, V4, P275; WILSON MC, 1981, J MOL BIOL, V148, P231, DOI 10.1016/0022-2836(81)90537-4; WINBERG G, 1984, EMBO J, V3, P1907, DOI 10.1002/j.1460-2075.1984.tb02066.x; WU BJ, 1986, MOL CELL BIOL, V6, P2994, DOI 10.1128/MCB.6.8.2994; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629	93	49	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	2	1					25	35						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	L4813	2963990				2022-12-17	WOS:A1987L481300004
J	Liang, LY; Patel, O; Janes, PW; Murphy, JM; Lucet, IS				Liang, Lung-Yu; Patel, Onisha; Janes, Peter W.; Murphy, James M.; Lucet, Isabelle S.			Eph receptor signalling: from catalytic to non-catalytic functions	ONCOGENE			English	Review							TYROSINE PHOSPHORYLATION SITES; SAM DOMAIN; LIGAND ACTIVATION; CRYSTAL-STRUCTURE; TUMOR-SUPPRESSOR; CELL-ADHESION; KINASE; EXPRESSION; PROMOTES; JUXTAMEMBRANE	Eph receptors, the largest subfamily of receptor tyrosine kinases, are linked with proliferative disease, such as cancer, as a result of their deregulated expression or mutation. Unlike other tyrosine kinases that have been clinically targeted, the development of therapeutics against Eph receptors remains at a relatively early stage. The major reason is the limited understanding on the Eph receptor regulatory mechanisms at a molecular level. The complexity in understanding Eph signalling in cells arises due to following reasons: (1) Eph receptors comprise 14 members, two of which are pseudokinases, EphA10 and EphB6, with relatively uncharacterised function; (2) activation of Eph receptors results in dimerisation, oligomerisation and formation of clustered signalling centres at the plasma membrane, which can comprise different combinations of Eph receptors, leading to diverse downstream signalling outputs; (3) the non-catalytic functions of Eph receptors have been overlooked. This review provides a structural perspective of the intricate molecular mechanisms that drive Eph receptor signalling, and investigates the contribution of intra-and inter-molecular interactions between Eph receptors intracellular domains and their major binding partners. We focus on the non-catalytic functions of Eph receptors with relevance to cancer, which are further substantiated by exploring the role of the two pseudokinase Eph receptors, EphA10 and EphB6. Throughout this review, we carefully analyse and reconcile the existing/conflicting data in the field, to allow researchers to further the current understanding of Eph receptor signalling.	[Liang, Lung-Yu; Patel, Onisha; Murphy, James M.; Lucet, Isabelle S.] Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia; [Liang, Lung-Yu; Patel, Onisha; Murphy, James M.; Lucet, Isabelle S.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3052, Australia; [Janes, Peter W.] Olivia Newton John Canc Res Inst, 145 Studley Rd, Heidelberg, Vic 3084, Australia	Walter & Eliza Hall Institute; University of Melbourne; La Trobe University; Olivia Newton-John Cancer Research Institute	Murphy, JM; Lucet, IS (corresponding author), Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia.; Murphy, JM; Lucet, IS (corresponding author), Univ Melbourne, Dept Med Biol, Parkville, Vic 3052, Australia.	jamesm@wehi.edu.au; lucet.i@wehi.edu.au	Liang, Lung-Yu/AAC-6505-2019; Murphy, James/B-4863-2017	Murphy, James/0000-0003-0195-3949; lucet, isabelle/0000-0002-8563-8753; Patel, Onisha/0000-0001-6701-7139	Australian Cancer Research Foundation; Cancer Council of Victoria; Walter and Eliza Hall Institute; Melbourne Research Scholarship; NHMRC [1105754]	Australian Cancer Research Foundation; Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Walter and Eliza Hall Institute; Melbourne Research Scholarship; NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	This work is supported by the Australian Cancer Research Foundation (to LYL, OP and IL), and the Cancer Council of Victoria (to PWJ). IL acknowledges support from the Walter and Eliza Hall Institute. LYL is supported by Melbourne Research Scholarship. JMM is grateful to the NHMRC for fellowship support (1105754). We acknowledge the NHMRC IRIISS and the Victorian State Government Operational Infrastructure Support Scheme.	Aasheim HC, 2005, BBA-GEN SUBJECTS, V1723, P1, DOI 10.1016/j.bbagen.2005.01.011; Akada M, 2014, CELL SIGNAL, V26, P2879, DOI 10.1016/j.cellsig.2014.08.031; Arnato KR, 2014, J CLIN INVEST, V124, P2037, DOI 10.1172/JCI72522; Astin JW, 2010, NAT CELL BIOL, V12, P1194, DOI 10.1038/ncb2122; Atapattu L, 2014, CELL ADHES MIGR, V8, P294, DOI 10.4161/19336918.2014.970026; Bhushan L, 2014, CANCER GENOM PROTEOM, V11, P239; Bin Fang W, 2005, ONCOGENE, V24, P7859, DOI 10.1038/sj.onc.1208937; Bin Fang W, 2008, J BIOL CHEM, V283, P16017, DOI 10.1074/jbc.M709934200; Borthakur S, 2014, J BIOL CHEM, V289, P19694, DOI 10.1074/jbc.M114.567602; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Carvalho RF, 2006, NAT NEUROSCI, V9, P322, DOI 10.1038/nn1655; Cho WCS, 2012, PLOS ONE, V7; Dai DD, 2014, BBA-PROTEINS PROTEOM, V1844, P1729, DOI 10.1016/j.bbapap.2014.07.002; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Davis TL, 2008, STRUCTURE, V16, P873, DOI 10.1016/j.str.2008.03.008; Day BW, 2013, CANCER CELL, V23, P238, DOI 10.1016/j.ccr.2013.01.007; Dionne U, 2018, MOL CELL, V70, P995, DOI 10.1016/j.molcel.2018.05.013; Dong MM, 2018, BIOPHYS J, V115, P865, DOI 10.1016/j.bpj.2018.06.031; Fox BP, 2006, BIOCHEM BIOPH RES CO, V340, P268, DOI 10.1016/j.bbrc.2005.11.174; Freywald A, 2002, J BIOL CHEM, V277, P3823, DOI 10.1074/jbc.M108011200; Fu DY, 2010, HUM PATHOL, V41, P48, DOI 10.1016/j.humpath.2009.06.007; Han DC, 2002, J BIOL CHEM, V277, P45655, DOI 10.1074/jbc.M203165200; Himanen JP, 2001, NATURE, V414, P933, DOI 10.1038/414933a; Himanen JP, 2010, P NATL ACAD SCI USA, V107, P10860, DOI 10.1073/pnas.1004148107; Holmberg J, 2000, NATURE, V408, P203, DOI 10.1038/35041577; Jacobsen AV, 2017, BIOCHEM SOC T, V45, P665, DOI 10.1042/BST20160331; Janes PW, 2011, J CELL BIOL, V195, P1033, DOI 10.1083/jcb.201104037; Janes PW, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000215; Jiang J, 2015, SCI REP-UK, V5, DOI 10.1038/srep11765; Jorgensen C, 2009, SCIENCE, V326, P1502, DOI 10.1126/science.1176615; Kalo MS, 1999, BIOCHEMISTRY-US, V38, P14396, DOI 10.1021/bi991628t; Kalo MS, 2001, J BIOL CHEM, V276, P38940, DOI 10.1074/jbc.M105815200; Kao TJ, 2011, NEURON, V71, P76, DOI 10.1016/j.neuron.2011.05.031; Koshikawa N, 2015, CANCER RES, V75, P3327, DOI 10.1158/0008-5472.CAN-14-2798; Kullander K, 2001, NEURON, V29, P73, DOI 10.1016/S0896-6273(01)00181-7; Kwon A, 2018, J BIOL CHEM, V293, P5102, DOI 10.1074/jbc.RA117.001296; Lawrenson ID, 2002, J CELL SCI, V115, P1059; Lee J, 2015, STEM CELL REP, V5, P480, DOI 10.1016/j.stemcr.2015.09.001; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Li G, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1675; Li SB, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.507; Li SB, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1025-3; Li Y, 2017, ONCOTARGET, V8, P30344, DOI 10.18632/oncotarget.15910; Lim BK, 2008, NAT NEUROSCI, V11, P160, DOI 10.1038/nn2033; Lisabeth EM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009159; Littlefield P, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005786; Locard-Paulet M, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aac5820; Luo HY, 2012, J BIOL CHEM, V287, P6819, DOI 10.1074/jbc.M111.293365; Mateo-Lozano S, 2017, SCI REP-UK, V7, DOI 10.1038/srep43702; Matsuoka H, 2005, J BIOL CHEM, V280, P29355, DOI 10.1074/jbc.M500010200; McDonell LM, 2015, HUM MOL GENET, V24, pR60, DOI 10.1093/hmg/ddv254; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009; Muller-Tidow C, 2005, CANCER RES, V65, P1778, DOI 10.1158/0008-5472.CAN-04-3388; Murphy JM, 2017, CURR OPIN STRUC BIOL, V47, P95, DOI 10.1016/j.sbi.2017.07.004; Murphy JM, 2014, BIOCHEM J, V457, P323, DOI 10.1042/BJ20131174; Murphy JM, 2018, KINASE DRUG DISCOVER, P359; Nagano K, 2014, J CONTROL RELEASE, V189, P72, DOI 10.1016/j.jconrel.2014.06.010; Nagano K, 2014, BIOCHEM BIOPH RES CO, V450, P545, DOI 10.1016/j.bbrc.2014.06.007; Nagano K, 2013, CANCER MED-US, V2, P972, DOI 10.1002/cam4.156; Nievergall E, 2012, CELL MOL LIFE SCI, V69, P1813, DOI 10.1007/s00018-011-0900-6; Noberini R, 2012, CELL ADHES MIGR, V6, P102, DOI 10.4161/cam.19620; Ojosnegros S, 2017, P NATL ACAD SCI USA, V114, P13188, DOI 10.1073/pnas.1713564114; Oricchio E, 2011, CELL, V147, P554, DOI 10.1016/j.cell.2011.09.035; Palmer A, 2002, MOL CELL, V9, P725, DOI 10.1016/S1097-2765(02)00488-4; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Peng LB, 2014, J MOL HISTOL, V45, P555, DOI 10.1007/s10735-014-9577-0; Pesti S, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-36; Reiterer V, 2014, TRENDS CELL BIOL, V24, P489, DOI 10.1016/j.tcb.2014.03.008; Rohani N, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001955; Sahin M, 2005, NEURON, V46, P191, DOI 10.1016/j.neuron.2005.01.030; Schaupp A, 2014, J CELL BIOL, V204, P409, DOI 10.1083/jcb.201305037; Seiradake E, 2013, NAT STRUCT MOL BIOL, V20, P958, DOI 10.1038/nsmb.2617; Seiradake E, 2010, NAT STRUCT MOL BIOL, V17, P398, DOI 10.1038/nsmb.1782; Shi W, 2019, J BIOL CHEM, V294, P6871, DOI 10.1074/jbc.RA118.005767; Shi X, 2017, TRANSLATIONAL MED CO, V2, P7; Shi XJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep45084; Shintani T, 2006, NAT NEUROSCI, V9, P761, DOI 10.1038/nn1697; Singh DR, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0017-7; Singh DR, 2017, BBA-MOL CELL RES, V1864, P31, DOI 10.1016/j.bbamcr.2016.10.011; Singh DR, 2015, BIOCHEM J, V471, P101, DOI 10.1042/BJ20150433; Singla N, 2011, CHEM BIOL, V18, P361, DOI 10.1016/j.chembiol.2011.01.011; Song W, 2017, ONCOGENE, V36, P5620, DOI 10.1038/onc.2017.170; Song WQ, 2014, CANCER RES, V74, P2444, DOI 10.1158/0008-5472.CAN-13-2136; Stallaert W, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aat0114; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Staquicini FI, 2015, J BIOL CHEM, V290, P7345, DOI 10.1074/jbc.M114.630525; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Sugiyama N, 2013, J CELL BIOL, V201, P467, DOI 10.1083/jcb.201205176; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Toosi BM, 2018, ONCOGENE, V37, P4073, DOI 10.1038/s41388-018-0228-x; Truitt L, 2010, CANCER RES, V70, P1141, DOI 10.1158/0008-5472.CAN-09-1710; Vail ME, 2014, CANCER RES, V74, P4470, DOI 10.1158/0008-5472.CAN-14-0218; Wang X, 2019, HEPATOLOGY, V69, P573, DOI 10.1002/hep.29792; Wang Y, 2018, ELIFE, V7, DOI 10.7554/eLife.35677; Wang YJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19215-2; Wiesner S, 2006, EMBO J, V25, P4686, DOI 10.1038/sj.emboj.7601315; Wilkinson DG, 2014, CELL ADHES MIGR, V8, P339, DOI 10.4161/19336918.2014.970007; Wimmer-Kleikamp SH, 2008, BLOOD, V112, P721, DOI 10.1182/blood-2007-11-121681; Wimmer-Kleikamp SH, 2004, J CELL BIOL, V164, P661, DOI 10.1083/jcb.200312001; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; Xu K, 2013, P NATL ACAD SCI USA, V110, P14634, DOI 10.1073/pnas.1311000110; Yang NY, 2011, CELL SIGNAL, V23, P201, DOI 10.1016/j.cellsig.2010.09.004; Yeddula N, 2015, P NATL ACAD SCI USA, V112, pE6476, DOI 10.1073/pnas.1520110112; Yin Y, 2004, NEUROSCI RES, V48, P285, DOI 10.1016/j.neures.2003.11.009; Yu J, 2010, CLIN CANCER RES, V16, P2275, DOI 10.1158/1078-0432.CCR-09-2000; Zelinski DP, 2001, CANCER RES, V61, P2301; Zhao J, 2017, NEUROSCIENCE, V347, P11, DOI 10.1016/j.neuroscience.2017.01.038; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823	111	48	50	9	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2019	38	39					6567	6584		10.1038/s41388-019-0931-2	http://dx.doi.org/10.1038/s41388-019-0931-2			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JA5AQ	31406248	hybrid			2022-12-17	WOS:000487856000001
J	Han, W; Gao, S; Barrett, D; Ahmed, M; Han, D; Macoska, JA; He, HH; Cai, C				Han, W.; Gao, S.; Barrett, D.; Ahmed, M.; Han, D.; Macoska, J. A.; He, H. H.; Cai, C.			Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer	ONCOGENE			English	Article							SPLICE VARIANTS; INCREASED SURVIVAL; GENE-EXPRESSION; TUMORIGENESIS; ENZALUTAMIDE; ABIRATERONE; CELLS; DEPRIVATION; METABOLISM; ACTIVATION	Androgen receptor (AR) is a transcriptional activator that, in prostate cells, stimulates gene expression required for various cellular functions, including metabolisms and proliferation. AR signaling is also essential for the development of hormone-dependent prostate cancer (PCa) and its activity can be blocked by androgen-deprivation therapies (ADTs). Although PCa patients initially respond well to ADTs, the cancer inevitably relapses and progresses to lethal castration-resistant prostate cancer (CRPC). Although AR activity is generally restored in CRPC despite the castrate level of androgens, it is unclear whether AR signaling is significantly reprogrammed. In this study, we examined the AR cistrome in a PCa cell line-derived CRPC model using integrated bioinformatical analyses. Significantly, we found that the AR cistrome is largely retained in the CRPC stage. In particular, AR-mediated lipid biosynthesis is highly conserved and reactivated during the progression to CRPC, and increased level of lipid synthesis is associated with poor prognosis. The restoration of lipid biosynthetic pathways is partially due to the increased expression of AR splice variants. Blocking lipid/cholesterol synthesis in AR variants-expressing CRPC cell line and xenograft models markedly reduces tumor growth through inhibition of mTOR pathway. Silencing the expression of a fatty acid elongase, ELOVL7, also leads to the regression of CRPC xenograft tumors. These results demonstrate the importance of reactivation of AR-regulated lipid biosynthetic pathways in driving CRPC progression, and suggest that ADTs may be therapeutically enhanced by blocking lipid biosynthetic pathways.	[Han, W.; Gao, S.; Barrett, D.; Han, D.; Macoska, J. A.; Cai, C.] Univ Massachusetts, Ctr Personalized Canc Therapy, 100 Morrissey Blvd,ISC 4-4720, Boston, MA 02125 USA; [Ahmed, M.; He, H. H.] Univ Hlth Network, Princess Margaret Canc Ctr, 101 Coll St, Toronto, ON M5G 1L7, Canada; [He, H. H.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Massachusetts System; University of Massachusetts Boston; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Cai, C (corresponding author), Univ Massachusetts, Ctr Personalized Canc Therapy, 100 Morrissey Blvd,ISC 4-4720, Boston, MA 02125 USA.; He, HH (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, 101 Coll St, Toronto, ON M5G 1L7, Canada.	hansenhe@uhnresearch.ca; changmeng.cai@umb.edu	Han, Wanting/AEX-5349-2022; He, Hansen/ABD-8439-2020; Cai, Changmeng/AAE-6835-2020; Han, Wanting/GQA-5728-2022	Han, Wanting/0000-0002-2173-3647; He, Hansen/0000-0003-2898-3363; Cai, Changmeng/0000-0002-8701-2586; Gao, Shuai/0000-0002-7304-8801	NIH [R00 CA166507]; NIH (SPORE in Prostate Cancer) [P50 CA090381-13]; DOD [W81XWH-15-1-0554, W81XWH-15-1-0519, W81XWH-16-1-0445]; CIHR [142246]; Prostate Cancer Canada [RS2016-1022]; NSERC [498706]; CCSRI [703800]; Princess Margaret Cancer Foundation; NATIONAL CANCER INSTITUTE [P50CA090381, R00CA166507] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH (SPORE in Prostate Cancer)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); CIHR(Canadian Institutes of Health Research (CIHR)); Prostate Cancer Canada; NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); CCSRI; Princess Margaret Cancer Foundation(University of Toronto); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by grants from NIH (R00 CA166507 to CC, and SPORE in Prostate Cancer P50 CA090381-13), DOD (W81XWH-15-1-0554 to SG, and W81XWH-15-1-0519 and W81XWH-16-1-0445 to CC), CIHR (142246 to HHH), Prostate Cancer Canada (RS2016-1022 to HHH), NSERC (498706 to HHH), CCSRI (703800 to HHH) and Princess Margaret Cancer Foundation (to HHH). We thank Dr Steven P Balk (Beth Israel Deaconess Medical Center) for the advice of experiment design and Drs Myles Brown and X Shirley Liu (Dana-Farber Cancer Institute) for the support of bioinformatical analyses.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Ananthanarayanan V, 2005, PROSTATE, V63, P341, DOI 10.1002/pros.20196; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Cai CM, 2013, J CLIN INVEST, V123, P1109, DOI 10.1172/JCI66666; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Cai CM, 2011, CANCER RES, V71, P6503, DOI 10.1158/0008-5472.CAN-11-0532; Cai CM, 2009, CANCER RES, V69, P6027, DOI 10.1158/0008-5472.CAN-09-0395; Chan SC, 2015, NUCLEIC ACIDS RES, V43, P5880, DOI 10.1093/nar/gkv262; Chen SY, 2006, P NATL ACAD SCI USA, V103, P15969, DOI 10.1073/pnas.0604193103; Chen Y, 2013, NAT MED, V19, P1023, DOI 10.1038/nm.3216; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Dehm SM, 2006, J BIOL CHEM, V281, P27882, DOI 10.1074/jbc.M605002200; Dehm SM, 2011, ENDOCR-RELAT CANCER, V18, pR183, DOI 10.1530/ERC-11-0141; Evans AJ, 2003, J CLIN PATHOL, V56, P892, DOI 10.1136/jcp.56.12.892; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Green SM, 2012, MOL CELL ENDOCRINOL, V360, P3, DOI 10.1016/j.mce.2011.09.046; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Harshman LC, 2015, JAMA ONCOL, V1, P495, DOI 10.1001/jamaoncol.2015.0829; He HSHS, 2010, NAT GENET, V42, P343, DOI 10.1038/ng.545; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Kochuparambil ST, 2011, J PHARMACOL EXP THER, V336, P496, DOI 10.1124/jpet.110.174870; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Li YM, 2011, CANCER RES, V71, P2108, DOI 10.1158/0008-5472.CAN-10-1998; Liu LL, 2014, ONCOGENE, V33, P3140, DOI 10.1038/onc.2013.284; Lu CX, 2013, TRANSL ANDROL UROL, V2, P178, DOI 10.3978/j.issn.2223-4683.2013.09.08; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Migita T, 2009, JNCI-J NATL CANCER I, V101, P519, DOI 10.1093/jnci/djp030; Mills IG, 2014, NAT REV CANCER, V14, P187, DOI 10.1038/nrc3678; Padanad MS, 2016, CELL REP, V16, P1614, DOI 10.1016/j.celrep.2016.07.009; Pomerantz MM, 2015, NAT GENET, V47, P1346, DOI 10.1038/ng.3419; Pon D, 2015, CURR ATHEROSCLER REP, V17, DOI 10.1007/s11883-014-0474-5; Ryan CJ, 2013, NEW ENGL J MED, V368, P1458, DOI 10.1056/NEJMc1301594; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Sharma NL, 2013, CANCER CELL, V23, P35, DOI 10.1016/j.ccr.2012.11.010; Sivaprasad U, 2006, MOL CANCER THER, V5, P2310, DOI 10.1158/1535-7163.MCT-06-0175; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Tamura K, 2009, CANCER RES, V69, P8133, DOI 10.1158/0008-5472.CAN-09-0775; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Xu YY, 2006, CANCER RES, V66, P7783, DOI 10.1158/0008-5472.CAN-05-4472; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Yu ZY, 2014, CLIN CANCER RES, V20, P1590, DOI 10.1158/1078-0432.CCR-13-1863; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Zhuang LY, 2005, J CLIN INVEST, V115, P959	47	48	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					710	721		10.1038/onc.2017.385	http://dx.doi.org/10.1038/onc.2017.385			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059155	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000424628100003
J	Wada, M; Canals, D; Adada, M; Coant, N; Salama, MF; Helke, KL; Arthur, JS; Shroyer, KR; Kitatani, K; Obeid, LM; Hannun, YA				Wada, M.; Canals, D.; Adada, M.; Coant, N.; Salama, M. F.; Helke, K. L.; Arthur, J. S.; Shroyer, K. R.; Kitatani, K.; Obeid, L. M.; Hannun, Y. A.			P38 delta MAPK promotes breast cancer progression and lung metastasis by enhancing cell proliferation and cell detachment	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; EPITHELIAL-SPECIFIC DISRUPTION; TRANSGENIC MOUSE MODEL; GROWTH; P38-DELTA; INVASION; EXPRESSION; P38-GAMMA; TUMORIGENESIS; LOCALIZATION	The protein p38 mitogen-activated protein kinase (MAPK) delta isoform (p38 delta) is a poorly studied member of the MAPK family. Data analysis from The Cancer Genome Atlas database revealed that p38 delta is highly expressed in all types of human breast cancers. Using a human breast cancer tissue array, we confirmed elevation in cancer tissue. The breast cancer mouse model, MMTV-PyMT (PyMT), developed breast tumors with lung metastasis; however, mice deleted in p38 delta (PyMT/p38 delta(-/-)) exhibited delayed primary tumor formation and highly reduced lung metastatic burden. At the cellular level, we demonstrate that targeting of p38 delta in breast cancer cells, MCF-7 and MDA-MB-231 resulted in a reduced rate of cell proliferation. In addition, cells lacking p38 delta also displayed an increased cell-matrix adhesion and reduced cell detachment. This effect on cell adhesion was molecularly supported by the regulation of the focal adhesion kinase by p38 delta in the human breast cell lines. These studies define a previously unappreciated role for p38 delta in breast cancer development and evolution by regulating tumor growth and altering metastatic properties. This study proposes MAPK p38 delta protein as a key factor in breast cancer. Lack of p38 delta resulted in reduced primary tumor size and blocked the metastatic potential to the lungs.	[Wada, M.; Canals, D.; Adada, M.; Coant, N.; Salama, M. F.; Obeid, L. M.; Hannun, Y. A.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; [Canals, D.; Adada, M.; Obeid, L. M.; Hannun, Y. A.] SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA; [Salama, M. F.] Mansoura Univ, Dept Biochem, Fac Vet Med, Mansoura, Egypt; [Helke, K. L.] Med Univ South Carolina, Dept Comparat Med, Charleston, SC USA; [Arthur, J. S.] Univ Dundee, Sch Life Sci, MRC Prot Phosphorylat Unit, Dundee, Scotland; [Shroyer, K. R.] SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; [Kitatani, K.] Tohoku Univ, Grad Sch Med, Tohoku Med Megabank Org, Sendai, Miyagi, Japan; [Kitatani, K.] Tohoku Univ, Grad Sch Med, Dept Obstet & Gynecol, Sendai, Miyagi, Japan; [Obeid, L. M.] Northport VA Med Ctr, Northport, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Egyptian Knowledge Bank (EKB); Mansoura University; Medical University of South Carolina; University of Dundee; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Tohoku University; Tohoku University	Hannun, YA (corresponding author), SUNY Stony Brook, Stony Brook Canc Ctr, Hlth Sci Ctr, L-4,182, Stony Brook, NY 11794 USA.	yusuf.hannun@sbumed.org	Kitatani, Kazuyuki/H-7100-2019; Canals, Daniel/AAW-1998-2021; Canals, Daniel/AAJ-8176-2021; Salama, Mohamed/S-3493-2019; Salama, Mohamed F/C-9010-2017	Kitatani, Kazuyuki/0000-0002-8516-6135; Canals, Daniel/0000-0002-9293-5123; Salama, Mohamed/0000-0002-0002-9108; Salama, Mohamed F/0000-0002-0002-9108; COANT, Nicolas/0000-0001-9237-2132; Helke, Kris/0000-0001-9746-0764; Arthur, Simon/0000-0002-8135-1958; Adada, Mohamad/0000-0002-2988-2081	National Cancer Institute [R01-CA87584]; NIH [CA087584]; NATIONAL CANCER INSTITUTE [R01CA087584, P01CA097132] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Eiji Suzuki (Fukushima Medical University), Dr Tatiana Efimova (Washington University), Dr Patricia Watson, Dr Dennis K. Watson and George Washington (Medical University of South Carolina), Dr Hideki Furuya, Dr Toshihiko Kawamori (University of Hawaii), Dr Vincent Yang and members of his laboratory, Mallory Korman, Dr Luisa Escobar-Hoyos, Dr Kai Wang, Dr Chiara Luberto, Dr Achraf Shamsedine, Dr Monica Garcia-Barros, Dr Jean-Philip Truman, Maria Hernandez, Dr Ashley Snider and Dr Magali Trayssac (Stony Brook University) for helpful technical advice and/or assistance. This work is supported by the National Cancer Institute (R01-CA87584). These studies were supported by NIH Grant CA087584.	Adada MM, 2015, FASEB J, V29, P4654, DOI 10.1096/fj.15-274340; Arold ST, 2011, CURR OPIN STRUC BIOL, V21, P808, DOI 10.1016/j.sbi.2011.09.008; Aust S, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-67; Chen L, 2009, CANCER RES, V69, P8853, DOI 10.1158/0008-5472.CAN-09-1636; Choi YK, 2013, CANCER GENOM PROTEOM, V10, P265; Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; del Reino P, 2014, CANCER RES, V74, P6150, DOI 10.1158/0008-5472.CAN-14-0870; Dethlefsen C, 2013, BREAST CANCER RES TR, V138, P657, DOI 10.1007/s10549-013-2488-z; Fluck MM, 2009, MICROBIOL MOL BIOL R, V73, P542, DOI 10.1128/MMBR.00009-09; Gandy KAO, 2013, FASEB J, V27, P3155, DOI 10.1096/fj.13-228460; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Ittner A, 2012, J EXP MED, V209, P2229, DOI 10.1084/jem.20120677; Jones LM, 2016, CANCER RES, V76, P1416, DOI 10.1158/0008-5472.CAN-15-2770; Junttila MR, 2007, ONCOGENE, V26, P5267, DOI 10.1038/sj.onc.1210332; Kesson EM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2718; Kitatani K, 2009, J BIOL CHEM, V284, P12979, DOI 10.1074/jbc.M809500200; Kohler BA, 2015, JNCI-J NATL CANCER I, V107, P1975, DOI DOI 10.1093/JNCI/DJV048; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Liu Y, 2013, SCI REP-UK, V3, DOI 10.1038/srep03098; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Luo M, 2009, CANCER RES, V69, P466, DOI 10.1158/0008-5472.CAN-08-3078; McAllister SS, 2014, NAT CELL BIOL, V16, P717, DOI 10.1038/ncb3015; O'Callaghan Carol, 2014, Int J Cell Biol, V2014, P272689, DOI 10.1155/2014/272689; O'Callaghan C, 2013, INT J ONCOL, V43, P405, DOI 10.3892/ijo.2013.1968; OWENS LV, 1995, CANCER RES, V55, P2752; Place AE, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2912; Provenzano PP, 2008, AM J PATHOL, V173, P1551, DOI 10.2353/ajpath.2008.080308; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; Risco A, 2012, P NATL ACAD SCI USA, V109, P11200, DOI 10.1073/pnas.1207290109; Sabio G, 2005, EMBO J, V24, P1134, DOI 10.1038/sj.emboj.7600578; Schindler EM, 2009, CANCER RES, V69, P4648, DOI 10.1158/0008-5472.CAN-08-4455; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792; Tan FLS, 2010, INT J CANCER, V126, P2353, DOI 10.1002/ijc.24944; Zhong J, 2011, LUNG CANCER, V73, P166, DOI 10.1016/j.lungcan.2010.12.003	36	48	48	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6649	6657		10.1038/onc.2017.274	http://dx.doi.org/10.1038/onc.2017.274			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28783172	Green Accepted			2022-12-17	WOS:000416049200013
J	Peters, AA; Jamaludin, SYN; Yapa, KTDS; Chalmers, S; Wiegmans, AP; Lim, HF; Milevskiy, MJG; Azimi, I; Davis, FM; Northwood, KS; Pera, E; Marcial, DL; Dray, E; Waterhouse, NJ; Cabot, PJ; Gonda, TJ; Kenny, PA; Brown, MA; Khanna, KK; Roberts-Thomson, SJ; Monteith, GR				Peters, A. A.; Jamaludin, S. Y. N.; Yapa, K. T. D. S.; Chalmers, S.; Wiegmans, A. P.; Lim, H. F.; Milevskiy, M. J. G.; Azimi, I.; Davis, F. M.; Northwood, K. S.; Pera, E.; Marcial, D. L.; Dray, E.; Waterhouse, N. J.; Cabot, P. J.; Gonda, T. J.; Kenny, P. A.; Brown, M. A.; Khanna, K. K.; Roberts-Thomson, S. J.; Monteith, G. R.			Oncosis and apoptosis induction by activation of an overexpressed ion channel in breast cancer cells	ONCOGENE			English	Article							NEURONAL DEGENERATION; MOLECULAR-MECHANISMS; PROSTATE-CANCER; CALCIUM; DEATH; EXPRESSION; NECROSIS; TUMORS; CONSEQUENCES; HOMEOSTASIS	The critical role of calcium signalling in processes related to cancer cell proliferation and invasion has seen a focus on pharmacological inhibition of overexpressed ion channels in specific cancer subtypes as a potential therapeutic approach. However, despite the critical role of calcium in cell death pathways, pharmacological activation of overexpressed ion channels has not been extensively evaluated in breast cancer. Here we define the overexpression of transient receptor potential vanilloid 4 (TRPV4) in a subgroup of breast cancers of the basal molecular subtype. We also report that pharmacological activation of TRPV4 with GSK1016790A reduced viability of two basal breast cancer cell lines with pronounced endogenous overexpression of TRPV4, MDA-MB-468 and HCC1569. Pharmacological activation of TRPV4 produced pronounced cell death through two mechanisms: apoptosis and oncosis in MDA-MB-468 cells. Apoptosis was associated with PARP-1 cleavage and oncosis was associated with a rapid decline in intracellular ATP levels, which was a consequence of, rather than the cause of, the intracellular ion increase. TRPV4 activation also resulted in reduced tumour growth in vivo. These studies define a novel therapeutic strategy for breast cancers that overexpress specific calcium permeable plasmalemmal ion channels with available selective pharmacological activators.	[Peters, A. A.; Jamaludin, S. Y. N.; Yapa, K. T. D. S.; Chalmers, S.; Lim, H. F.; Azimi, I.; Davis, F. M.; Pera, E.; Marcial, D. L.; Cabot, P. J.; Gonda, T. J.; Roberts-Thomson, S. J.; Monteith, G. R.] Univ Queensland, Sch Pharm, 20 Cornwall St, Brisbane, Qld 4102, Australia; [Wiegmans, A. P.] QIMR Berghofer Med Res Inst, Tumour Microenvironm Lab, Brisbane, Qld, Australia; [Milevskiy, M. J. G.; Northwood, K. S.; Brown, M. A.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld, Australia; [Azimi, I.; Davis, F. M.; Monteith, G. R.] Univ Queensland, Translat Res Inst, Mater Res Inst, Brisbane, Qld, Australia; [Dray, E.] Queensland Univ Technol, Translat Res Inst, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia; [Dray, E.] Queensland Univ Technol, Translat Res Inst, Sch Biomed Sci, Brisbane, Qld, Australia; [Waterhouse, N. J.; Khanna, K. K.] QIMR Berghofer Med Res Inst, Signal Transduct Lab, Brisbane, Qld, Australia; [Kenny, P. A.] Gunderson Med Fdn, Kabara Canc Res Inst, La Crosse, WI USA; [Jamaludin, S. Y. N.] Univ Sultan Zainal Abidin, Fac Med, Kuala Terengganu, Terengganu, Malaysia	University of Queensland; QIMR Berghofer Medical Research Institute; University of Queensland; Mater Research; University of Queensland; Queensland University of Technology (QUT); Queensland University of Technology (QUT); QIMR Berghofer Medical Research Institute; Universiti Sultan Zainal Abidin	Monteith, GR (corresponding author), Univ Queensland, Sch Pharm, 20 Cornwall St, Brisbane, Qld 4102, Australia.	gregm@uq.edu.au	Brown, Melissa A/F-1451-2010; Dray, Eloise/AAD-5147-2021; Davis, Felicity M/P-1387-2016; Peters, Amelia A/E-4254-2010; Cabot, Peter John/B-2424-2013; Monteith, Gregory/B-1626-2008; Chalmers, Silke/GQH-6183-2022; Peters, Amelia/AAP-3886-2021; Roberts-Thomson, Sarah J/B-4282-2011; Chalmers, Silke/Q-5731-2019; Roberts-Thomson, Sarah/W-5676-2019; Azimi, Iman/E-2043-2011; Dray, Eloise/E-3938-2012	Davis, Felicity M/0000-0001-9112-118X; Cabot, Peter John/0000-0003-1778-3753; Monteith, Gregory/0000-0002-4345-530X; Peters, Amelia/0000-0002-0700-7817; Roberts-Thomson, Sarah J/0000-0001-8202-5786; Roberts-Thomson, Sarah/0000-0001-8202-5786; Azimi, Iman/0000-0001-9477-9999; Khanna, Kum Kum/0000-0001-8650-5381; Northwood, Korinne/0000-0001-6268-547X; Gonda, Thomas/0000-0002-8792-3021; Dray, Eloise/0000-0001-6793-9838; Jamaludin, Siti Yusrina Nadihah/0000-0002-8006-1406; Chalmers, Silke/0000-0002-5874-7540; Brown, Melissa/0000-0002-2830-9259	National Health and Medical Research Council of Australia [1079671]; Cancer Council Queensland [1042819]; Mater Foundation; Australian Government; Ministry of Higher Education Malaysia Scholarship; NBCF fellowship [ECR13-04]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Queensland(Cancer Council Queensland); Mater Foundation; Australian Government(Australian GovernmentCGIAR); Ministry of Higher Education Malaysia Scholarship; NBCF fellowship	This work was supported by the National Health and Medical Research Council of Australia (1079671) and Cancer Council Queensland (1042819). We are grateful to Sunil Lakhani and The Brisbane Breast Bank (The University of Queensland Centre for Clinical Research, Brisbane, Australia) for providing the MDA-MB-468 and BT-20 cell lines and RNA from 184A1, 184B5, MCF10A and Bre-80-hTERT cells for this study. GM is supported by the Mater Foundation. The Translational Research Institute is supported by a grant from the Australian Government. SYNJ was funded by the Ministry of Higher Education Malaysia Scholarship. ED is the recipient of a NBCF fellowship (ECR13-04).	Adapala RK, 2016, ONCOGENE, V35, P314, DOI 10.1038/onc.2015.83; Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; Aung CS, 2009, CARCINOGENESIS, V30, P1962, DOI 10.1093/carcin/bgp223; Aydar E, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-23; Azimi I, 2016, MOL ONCOL, V10, P166, DOI 10.1016/j.molonc.2015.09.006; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Cardaci S, 2012, J BIOENERG BIOMEMBR, V44, P17, DOI 10.1007/s10863-012-9422-7; Chen RB, 2014, UROL ONCOL-SEMIN ORI, V32, P524, DOI 10.1016/j.urolonc.2013.05.011; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Clarke C, 2013, CARCINOGENESIS, V34, P2300, DOI 10.1093/carcin/bgt208; Curry MC, 2012, J BIOL CHEM, V287, P28598, DOI 10.1074/jbc.M112.364737; Czifra G, 2009, J CANCER RES CLIN, V135, P507, DOI 10.1007/s00432-008-0482-3; Del Nagro C, 2014, J BIOL CHEM, V289, P35182, DOI 10.1074/jbc.M114.580159; Ding X, 2010, JNCI-J NATL CANCER I, V102, P1052, DOI 10.1093/jnci/djq217; Dubois C, 2014, CANCER CELL, V26, P19, DOI 10.1016/j.ccr.2014.04.025; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; El Boustany C, 2008, HEPATOLOGY, V47, P2068, DOI 10.1002/hep.22263; Feng MY, 2010, CELL, V143, P84, DOI 10.1016/j.cell.2010.08.040; Frandsen SK, 2012, CANCER RES, V72, P1336, DOI 10.1158/0008-5472.CAN-11-3782; Franken J, 2014, BRIT J PHARMACOL, V171, P2537, DOI 10.1111/bph.12502; Garcia-Elias A, 2014, HANDB EXP PHARMACOL, V222, P293, DOI 10.1007/978-3-642-54215-2_12; GOLDSBY RA, 1963, BIOCHEMISTRY-US, V2, P1142, DOI 10.1021/bi00905a041; Gradilone SA, 2010, GASTROENTEROLOGY, V139, P304, DOI 10.1053/j.gastro.2010.04.010; Haas BE, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-61; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; Jo AO, 2016, P NATL ACAD SCI USA, V113, P3885, DOI 10.1073/pnas.1515895113; Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Laing RJ, 2016, NEUROSCIENTIST, V22, P171, DOI 10.1177/1073858414567884; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lee WH, 2016, SCI REP-UK, V6, DOI 10.1038/srep27903; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Mahieu F, 2007, J BIOL CHEM, V282, P3325, DOI 10.1074/jbc.M605213200; MAJNO G, 1995, AM J PATHOL, V146, P3; Middelbeek J, 2012, CANCER RES, V72, P4250, DOI 10.1158/0008-5472.CAN-11-3863; Monteith GR, 2012, J BIOL CHEM, V287, P31666, DOI 10.1074/jbc.R112.343061; Peters AA, 2012, MOL CANCER THER, V11, P2158, DOI 10.1158/1535-7163.MCT-11-0965; Pinton P, 2008, ONCOGENE, V27, P6407, DOI 10.1038/onc.2008.308; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Presson AP, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-230; Rivenbark AG, 2013, AM J PATHOL, V183, P1113, DOI 10.1016/j.ajpath.2013.08.002; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Shi Y, 2009, GUT, V58, P1443, DOI 10.1136/gut.2009.181735; Solvang HK, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-197; Thorneloe KS, 2008, J PHARMACOL EXP THER, V326, P432, DOI 10.1124/jpet.108.139295; Thorneloe KS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004276; Trump BF, 1997, TOXICOL PATHOL, V25, P82, DOI 10.1177/019262339702500116; Weerasinghe P, 2012, EXP MOL PATHOL, V93, P302, DOI 10.1016/j.yexmp.2012.09.018; Willette RN, 2008, J PHARMACOL EXP THER, V326, P443, DOI 10.1124/jpet.107.134551; Wojda U, 2008, IUBMB LIFE, V60, P575, DOI 10.1002/iub.91; Wu TTL, 2014, CELL CALCIUM, V56, P59, DOI 10.1016/j.ceca.2014.04.006; Yang SL, 2009, ONCOGENE, V28, P1320, DOI 10.1038/onc.2008.475; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Zhang L, 2004, CANCER RES, V64, P8365, DOI 10.1158/0008-5472.CAN-04-2146; Zhuang LY, 2002, LAB INVEST, V82, P1755, DOI 10.1097/01.LAB.0000043910.41414.E7; Zong WX, 2006, GENE DEV, V20, P1, DOI 10.1101/gad.1376506	58	48	51	2	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6490	6500		10.1038/onc.2017.234	http://dx.doi.org/10.1038/onc.2017.234			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28759041				2022-12-17	WOS:000415622900012
J	Unger, C; Kramer, N; Unterleuthner, D; Scherzer, M; Burian, A; Rudisch, A; Stadler, M; Schlederer, M; Lenhardt, D; Riedl, A; Walter, S; Wernitznig, A; Kenner, L; Hengstschlger, M; Schler, J; Sommergruber, W; Dolznig, H				Unger, C.; Kramer, N.; Unterleuthner, D.; Scherzer, M.; Burian, A.; Rudisch, A.; Stadler, M.; Schlederer, M.; Lenhardt, D.; Riedl, A.; Walter, S.; Wernitznig, A.; Kenner, L.; Hengstschlger, M.; Schler, J.; Sommergruber, W.; Dolznig, H.			Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; SMOOTH MUSCLE ACTIN; FACTOR-I RECEPTOR; COLORECTAL-CANCER; TUMOR MICROENVIRONMENT; CARCINOMA-CELLS; INSULIN; EXPRESSION; MYOFIBROBLASTS; FIBROBLASTS	The insulin-like growth factor (IGF) 2/IGF1 receptor (IGF1R) signaling axis has an important role in intestinal carcinogenesis and overexpression of IGF2 is an accepted risk factor for colorectal cancer (CRC) development. Genetic amplifications and loss of imprinting contribute to the upregulation of IGF2, but insufficiently explain the extent of IGF2 expression in a subset of patients. Here, we show that IGF2 was specifically induced in the tumor stroma of CRC and identified cancer-associated fibroblasts (CAFs) as the major source. Further, we provide functional evidence that stromal IGF2, via the paracrine IGF1R/insulin receptor axis, activated pro-survival AKT signaling in CRC cell lines. In addition to its effects on malignant cells, autocrine IGF2/IGF1R signaling in CAFs induced myofibroblast differentiation in terms of alpha-smooth muscle actin expression and contractility in floating collagen gels. This was further augmented in concert with transforming growth factor-beta (TGF beta) signaling suggesting a cooperative mechanism. However, we demonstrated that IGF2 neither induced TGF beta/smooth muscle actin/mothers against decapentaplegic (SMAD) signaling nor synergized with TGF beta to hyperactivate this pathway in two dimensional and three dimensional cultures. IGF2-mediated physical matrix remodeling by CAFs, but not changes in extracellular matrix-modifying proteases or other secreted factors acting in a paracrine manner on/in cancer cells, facilitated subsequent tumor cell invasion in organotypic co-cultures. Consistently, colon cancer cells co-inoculated with CAFs expressing endogenous IGF2 in mouse xenograft models exhibited elevated invasiveness and dissemination capacity, as well as increased local tumor regrowth after primary tumor resection compared with conditions with IGF2-deficient CAFs. In line, expression of IGF2 correlated with elevated relapse rates and poor survival in CRC patients. In agreement with our results, high-level coexpression of IGF2 and TGF beta was predicting adverse outcome with higher accuracy than increased expression of the individual genes alone. Taken together, we demonstrate that stromainduced IGF2 promotes colon cancer progression in a paracrine and autocrine manner and propose IGF2 as potential target for tumor stroma cotargeting strategies.	[Unger, C.; Kramer, N.; Unterleuthner, D.; Scherzer, M.; Burian, A.; Stadler, M.; Riedl, A.; Walter, S.; Hengstschlger, M.; Dolznig, H.] Med Univ Vienna, Inst Med Genet, Waehringer Str 10, A-1090 Vienna, Austria; [Rudisch, A.; Riedl, A.; Wernitznig, A.; Sommergruber, W.] Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; [Schlederer, M.; Kenner, L.] Med Univ Vienna, Inst Clin Pathol, Vienna, Austria; [Lenhardt, D.; Schler, J.] Oncotest GmbH, Flughafen 12, Freiburg, Germany; [Kenner, L.] Ludwig Boltzmann Inst Canc Res, Vienna, Austria; [Kenner, L.] Univ Vet Med Vienna, Inst Lab Anim Pathol, Vienna, Austria; [Scherzer, M.] Karolinska Inst, Solnavagen 1, S-17177 Solna, Sweden; [Stadler, M.] Deutsch Krebsforschungszentrum DKFZ, Neuenheimer Feld 280, D-69120 Heidelberg, Germany	Medical University of Vienna; Boehringer Ingelheim; Medical University of Vienna; Oncotest GmbH; Ludwig Boltzmann Institute; University of Veterinary Medicine Vienna; Karolinska Institutet; Helmholtz Association; German Cancer Research Center (DKFZ)	Unger, C; Dolznig, H (corresponding author), Med Univ Vienna, Inst Med Genet, Waehringer Str 10, A-1090 Vienna, Austria.	christine.unger@meduniwien.ac.at; helmut.dolznig@meduniwien.ac.at	Dolznig, Helmut/L-7005-2015	Dolznig, Helmut/0000-0002-6063-3585; Kramer, Nina/0000-0002-9058-8076; Kenner, Lukas/0000-0003-2184-1338				Albrengues J, 2014, CELL REP, V7, P1664, DOI 10.1016/j.celrep.2014.04.036; Arora PD, 1999, AM J PATHOL, V154, P871, DOI 10.1016/S0002-9440(10)65334-5; Baba Y, 2010, GASTROENTEROLOGY, V139, P1855, DOI 10.1053/j.gastro.2010.07.050; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Brouwer-Visser J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100165; Buck E, 2010, MOL CANCER THER, V9, P2652, DOI 10.1158/1535-7163.MCT-10-0318; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Charbonney E, 2011, MOL BIOL CELL, V22, P4472, DOI 10.1091/mbc.E11-04-0335; Chen WJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4472; Chitnis MM, 2008, CLIN CANCER RES, V14, P6364, DOI 10.1158/1078-0432.CCR-07-4879; Church DN, 2012, ONCOGENE, V31, P3635, DOI 10.1038/onc.2011.526; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; DARBY I, 1990, LAB INVEST, V63, P21; De Boeck A, 2013, GUT, V62, P550, DOI 10.1136/gutjnl-2011-301393; De Groot JWB, 2007, ENDOCR-RELAT CANCER, V14, P979, DOI 10.1677/ERC-07-0161; De Wever O, 2004, FASEB J, V18, P1016, DOI 10.1096/fj.03-1110fje; De Wever O, 2008, INT J CANCER, V123, P2229, DOI 10.1002/ijc.23925; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Dolznig H, 2011, AM J PATHOL, V179, P487, DOI 10.1016/j.ajpath.2011.03.015; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Friedbichler K, 2014, MOL CANCER THER, V13, P399, DOI 10.1158/1535-7163.MCT-13-0598; Fukuda I, 2006, GROWTH HORM IGF RES, V16, P211, DOI 10.1016/j.ghir.2006.05.003; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Gao J, 2011, CANCER RES, V71, P1029, DOI 10.1158/0008-5472.CAN-10-2274; Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; Greenall SA, 2013, J BIOL CHEM, V288, P59, DOI 10.1074/jbc.M112.432013; Harper J, 2006, CANCER RES, V66, P1940, DOI 10.1158/0008-5472.CAN-05-2036; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Hinz B, 2007, AM J PATHOL, V170, P1807, DOI 10.2353/ajpath.2007.070112; Hu YP, 2008, CANCER RES, V68, P8004, DOI 10.1158/0008-5472.CAN-08-0280; Hylander BL, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-110; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kaneda A, 2005, CANCER RES, V65, P11236, DOI 10.1158/0008-5472.CAN-05-2959; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Kobayashi T, 2006, BIOCHEM BIOPH RES CO, V339, P290, DOI 10.1016/j.bbrc.2005.10.209; Lee JH, 2014, J NANOMATER, V2014, DOI 10.1155/2014/567827; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Liles JS, 2011, BRIT J CANCER, V105, P523, DOI 10.1038/bjc.2011.263; Livingstone C, 2013, ENDOCR-RELAT CANCER, V20, pR321, DOI 10.1530/ERC-13-0231; Loboda A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-9; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453; Masszi A, 2004, AM J PATHOL, V165, P1955, DOI 10.1016/S0002-9440(10)63247-6; Medico E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8002; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nishida N, 2012, CLIN CANCER RES, V18, P3054, DOI 10.1158/1078-0432.CCR-11-1078; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Park JH, 2014, ANN ONCOL, V25, P644, DOI 10.1093/annonc/mdt593; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Pollak M, 2012, CLIN CANCER RES, V18, P40, DOI 10.1158/1078-0432.CCR-11-0998; Raykha C, 2013, BBA-MOL BASIS DIS, V1832, P1511, DOI 10.1016/j.bbadis.2013.04.018; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Riedemann J, 2006, ENDOCR-RELAT CANCER, V13, pS33, DOI 10.1677/erc.1.01280; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rosner M, 2010, NAT PROTOC, V5, P1081, DOI 10.1038/nprot.2010.74; Rudisch A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124283; Rupp C, 2015, ONCOGENE, V34, P815, DOI 10.1038/onc.2014.18; Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; SINGER C, 1995, CANCER RES, V55, P2448; Singh P, 1998, GASTROENTEROLOGY, V114, P1221, DOI 10.1016/S0016-5085(98)70428-7; Singh SK, 2008, GROWTH FACTORS, V26, P92, DOI 10.1080/08977190802057258; Small EM, 2012, J CARDIOVASC TRANSL, V5, P794, DOI 10.1007/s12265-012-9397-0; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taya S, 2001, J CELL BIOL, V155, P809, DOI 10.1083/jcb.200106139; Tojo M, 2005, CANCER SCI, V96, P791, DOI 10.1111/j.1349-7006.2005.00103.x; Tsujino T, 2007, CLIN CANCER RES, V13, P2082, DOI 10.1158/1078-0432.CCR-06-2191; Ulanet DB, 2010, P NATL ACAD SCI USA, V107, P10791, DOI 10.1073/pnas.0914076107; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Wang HB, 2015, EXP CELL RES, V338, P214, DOI 10.1016/j.yexcr.2015.09.016; Zanella ER, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010445; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	87	48	49	2	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5341	5355		10.1038/onc.2017.116	http://dx.doi.org/10.1038/onc.2017.116			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28534511				2022-12-17	WOS:000411382100002
J	Hanley, MP; Hahn, MA; Li, AX; Wu, X; Lin, J; Wang, J; Choi, AH; Ouyang, Z; Fong, Y; Pfeifer, GP; Devers, TJ; Rosenberg, DW				Hanley, M. P.; Hahn, M. A.; Li, A. X.; Wu, X.; Lin, J.; Wang, J.; Choi, A. H.; Ouyang, Z.; Fong, Y.; Pfeifer, G. P.; Devers, T. J.; Rosenberg, D. W.			Genome-wide DNA methylation profiling reveals cancer-associated changes within early colonic neoplasia	ONCOGENE			English	Article							ABERRANT CRYPT FOCI; CPG ISLAND METHYLATION; TUMOR-SUPPRESSOR GENES; COLORECTAL-CANCER; EXPRESSION; HYPERMETHYLATION; CELLS; HYPOMETHYLATION; TRANSCRIPTION; MUTATION	Colorectal cancer (CRC) is characterized by genome-wide alterations to DNA methylation that influence gene expression and genomic stability. Less is known about the extent to which methylation is disrupted in the earliest stages of CRC development. In this study, we have combined laser-capture microdissection with reduced representation bisulfite sequencing to identify cancer-associated DNA methylation changes in human aberrant crypt foci (ACF), the earliest putative precursor to CRC. Using this approach, methylation profiles have been generated for 10 KRAS-mutant ACF and 10 CRCs harboring a KRAS mutation, as well as matched samples of normal mucosa. Of 811 differentially methylated regions (DMRs) identified in ACF, 537 (66%) were hypermethylated and 274 (34%) were hypomethylated. DMRs located within intergenic regions were heavily enriched for AP-1 transcription factor binding sites and were frequently hypomethylated. Furthermore, gene ontology analysis demonstrated that DMRs associated with promoters were enriched for genes involved in intestinal development, including homeobox genes and targets of the Polycomb repressive complex 2. Consistent with their role in the earliest stages of colonic neoplasia, 75% of the loci harboring methylation changes in ACF were also altered in CRC samples, though the magnitude of change at these sites was lesser in ACF. Although aberrant promoter methylation was associated with altered gene expression in CRC, this was not the case in ACF, suggesting the insufficiency of methylation changes to modulate gene expression in early colonic neoplasia. Altogether, these data demonstrate that DNA methylation changes, including significant hypermethylation, occur more frequently in early colonic neoplasia than previously believed, and identify epigenomic features of ACF that may provide new targets for cancer chemoprevention or lead to the development of new biomarkers for CRC risk.	[Hanley, M. P.; Rosenberg, D. W.] UConn Hlth, Sch Med, Ctr Mol Med, Farmington, CT USA; [Hanley, M. P.; Rosenberg, D. W.] UConn Hlth, Dept Genet & Genome Sci, Farmington, CT USA; [Hahn, M. A.; Choi, A. H.; Fong, Y.] City Hope Natl Med Ctr, Dept Surg, Duarte, CA USA; [Li, A. X.] City Hope Natl Med Ctr, Dept Informat Sci, Duarte, CA USA; [Wu, X.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, Duarte, CA USA; [Lin, J.; Ouyang, Z.] Jackson Lab Genom Med, Farmington, CT USA; [Wang, J.] City Hope Natl Med Ctr, Beckman Res Inst, Integrat Genom Core, Duarte, CA USA; [Ouyang, Z.] Univ Connecticut, Inst Syst Genom, Farmington, CT USA; [Pfeifer, G. P.] Van Andel Res Inst, Ctr Epigenet, Grand Rapids, MI USA; [Devers, T. J.] UConn Hlth, Sch Med, Div Gastroenterol, Farmington, CT USA; [Rosenberg, D. W.] UConn Hlth, Neag Comprehens Canc Ctr, Colon Canc Prevent Program, Farmington, CT USA	City of Hope; City of Hope; City of Hope; Beckman Research Institute of City of Hope; Jackson Laboratory; City of Hope; Beckman Research Institute of City of Hope; University of Connecticut; Van Andel Institute	Rosenberg, DW (corresponding author), Univ Connecticut, Ctr Hlth, 263 Farmington Ave, Farmington, CT 06030 USA.	rosenberg@uchc.edu	Lin, Jianan/T-7238-2019; Lin, Jianan/AAV-1954-2020	Lin, Jianan/0000-0003-3894-6902	NIH [CA159976, CA084469, CA160965]; NATIONAL CANCER INSTITUTE [R01CA160965, P30CA034196, R01CA084469, R01CA159976] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grant CA159976 to DWR, and NIH grants CA084469 and CA160965 to GPP.	Ahlquist T, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-94; American Cancer Society, 2016, CANC FACTS FIG 2016; Ashida Reiko, 2005, Inflammopharmacology, V13, P113, DOI 10.1163/156856005774423935; Bariol C, 2003, AM J PATHOL, V162, P1361, DOI 10.1016/S0002-9440(10)63932-6; Beggs AD, 2013, J PATHOL, V229, P697, DOI 10.1002/path.4132; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Benoit YD, 2012, J CELL SCI, V125, P3454, DOI 10.1242/jcs.102061; Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969; Bhatlekar S, 2014, J MOL MED, V92, P811, DOI 10.1007/s00109-014-1181-y; Campbell JD, 2016, CANCER PREV RES, V9, P119, DOI 10.1158/1940-6207.CAPR-16-0024; Chai H, 2009, ANN CLIN LAB SCI, V39, P331; Chan AOO, 2002, AM J PATHOL, V160, P1823, DOI 10.1016/S0002-9440(10)61128-5; Drew DA, 2014, MOL CANCER RES, V12, P823, DOI 10.1158/1541-7786.MCR-13-0624; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI 10.2217/EPI.09.33; Enroth S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-450; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Fluge O, 2009, BRIT J CANCER, V101, P1282, DOI 10.1038/sj.bjc.6605333; Freschi G, 2005, INT J MOL MED, V16, P581; Greenspan EJ, 2006, CARCINOGENESIS, V27, P1316, DOI 10.1093/carcin/bgi373; Gu HC, 2011, NAT PROTOC, V6, P468, DOI 10.1038/nprot.2010.190; Haberland M, 2009, GENE DEV, V23, P1625, DOI 10.1101/gad.1809209; Hahn MA, 2015, METHODS MOL BIOL, V1238, P273, DOI 10.1007/978-1-4939-1804-1_14; Hahn MA, 2014, CANCER RES, V74, P3617, DOI 10.1158/0008-5472.CAN-13-3147; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hill ME, 1999, MOL ENDOCRINOL, V13, P1474, DOI 10.1210/me.13.9.1474; Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Inoue A, 2015, BRIT J CANCER, V112, P403, DOI 10.1038/bjc.2014.545; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Karlsson L, 2000, DEVELOPMENT, V127, P3457; Kawakami K, 2006, BRIT J CANCER, V94, P593, DOI 10.1038/sj.bjc.6602940; Kong HK, 2012, J BIOL CHEM, V287, P38889, DOI 10.1074/jbc.M112.394270; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Noordermeer D, 2011, SCIENCE, V334, P222, DOI 10.1126/science.1207194; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Ormestad M, 2006, DEVELOPMENT, V133, P833, DOI 10.1242/dev.02252; Pabst O, 1999, DEVELOPMENT, V126, P2215; Rada-Iglesias A, 2009, EPIGENETICS-US, V4, P107, DOI 10.4161/epi.4.2.8038; Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104; Rosenberg DW, 2007, CANCER RES, V67, P3551, DOI 10.1158/0008-5472.CAN-07-0343; Sakai E, 2014, WORLD J GASTROENTERO, V20, P978, DOI 10.3748/wjg.v20.i4.978; Sarabi MM, 2015, CELL BIOCHEM FUNCT, V33, P427, DOI 10.1002/cbf.3126; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shen LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI 10.1073/pnas.0704652104; Silviera ML, 2012, CANCER PREV RES, V5, P374, DOI 10.1158/1940-6207.CAPR-11-0336; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233; VanDussen KL, 2012, DEVELOPMENT, V139, P488, DOI 10.1242/dev.070763; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yagi K, 2012, AM J PATHOL, V180, P616, DOI 10.1016/j.ajpath.2011.10.010; Yagi K, 2010, CLIN CANCER RES, V16, P21, DOI 10.1158/1078-0432.CCR-09-2006; Zimmerman SG, 2010, DEV BIOL, V340, P54, DOI 10.1016/j.ydbio.2010.01.021	57	48	49	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5035	5044		10.1038/onc.2017.130	http://dx.doi.org/10.1038/onc.2017.130			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28459462	Green Accepted			2022-12-17	WOS:000408768800008
J	Sun, H; Peng, Z; Tang, H; Xie, D; Jia, Z; Zhong, L; Zhao, S; Ma, Z; Gao, Y; Zeng, L; Luo, R; Xie, K				Sun, H.; Peng, Z.; Tang, H.; Xie, D.; Jia, Z.; Zhong, L.; Zhao, S.; Ma, Z.; Gao, Y.; Zeng, L.; Luo, R.; Xie, K.			Loss of KLF4 and consequential downregulation of Smad7 exacerbate oncogenic TGF-beta signaling in and promote progression of hepatocellular carcinoma	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; MESENCHYMAL TRANSITION; POOR-PROGNOSIS; CROSS-TALK; EXPRESSION; BLOCKS; TARGET; KRUPPEL-LIKE-FACTOR-4; HEPATOCARCINOGENESIS; METASTASIS	Hyperactivation of transforming growth factor-beta ( TGF-alpha) signaling pathway is a common feature of hepatocellular carcinoma (HCC) progression. However, the driver factors leading to enhanced TGF-beta activity are not well characterized. Here, we explore the mechanisms that loss of Kruppel-like factor 4 (KLF4) exacerbates oncogenic TGF-beta signaling in human HCC. The expression of KLF4 and TGF-beta signaling components in primary HCC and their clinicopathologic relevance and significance was evaluated by using tissue microarray and immunohistochemistry. Cellular and molecular impacts of altered KLF4 expression and TGF-beta signaling were determined using immunofluorescence, western blot, reverse-transcriptase PCR, chromatin immunoprecipitation and promoter reporter assays. Loss of KLF4 expression in primary HCC closely correlated with decreased Smad7 expression, increased p-Smad2/3 expression and independently predicts reduced overall and relapse-free survival after surgery. TGF-beta signaling components were expressed in most HCC cells, and activation of TGF-beta signaling promoted cell migration and invasion. Enforced KLF4 expression blocked TGF-beta signal transduction and inhibited cell migration and invasion via activation of Smad7 transcription, whereas deletion of its C-terminal zinc-finger domain diminished this effect. KLF4 protein physically interacts with the Smad7 promoter. Promoter deletion and point mutation analyses revealed that a region between nucleotides -15bp and -9bp of the Smad7 promoter was required for the induction of Smad7 promoter activity by KLF4. Our data indicate that KLF4 suppresses oncogenic TGF-beta signaling by activation of Smad7 transcription, and that loss of KLF4 expression in primary HCC may contribute to activation of oncogenic TGF-beta signaling and subsequent tumor progression.	[Sun, H.; Jia, Z.; Xie, K.] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA; [Sun, H.; Peng, Z.; Zhong, L.; Zhao, S.] Shanghai Gen Hosp, Dept Gen Surg, 85 Wujin Rd, Shanghai 200080, Peoples R China; [Tang, H.] Shanghai Jiao Tong Univ, Dept Pathol, Affiliated Shanghai Gen Hosp, Shanghai, Peoples R China; [Xie, D.; Gao, Y.] Tongji Univ, Sch Med, Dept Oncol, Shanghai East Hosp, Shanghai, Peoples R China; [Xie, D.; Gao, Y.] Tongji Univ, Sch Med, Tumor Inst, Shanghai East Hosp, Shanghai, Peoples R China; [Ma, Z.] Fudan Univ, Liver Transplantat Sect, Ctr Organ Transplantat, Shanghai, Peoples R China; [Zeng, L.; Luo, R.] Southern Med Univ, Tumor Hosp, Guangzhou, Guangdong, Peoples R China	University of Texas System; UTMD Anderson Cancer Center; Shanghai Jiao Tong University; Tongji University; Tongji University; Fudan University; Southern Medical University - China	Peng, Z (corresponding author), Shanghai Gen Hosp, Dept Gen Surg, 85 Wujin Rd, Shanghai 200080, Peoples R China.; Luo, R (corresponding author), Southern Med Univ, Tumor Hosp, Guangzhou, Guangdong, Peoples R China.; Xie, K (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Unit 1644, 1515 Holcombe Blvd, Houston, TX 77030 USA.	xczmd@sjtu.edu.cn; luorc02@vip.163.com; kepxie@mdanderson.org			National Institutes of Health [R01-CA129956, R01-CA148954]; National Natural Science Foundation of China [81101623]; Science and Technology Commission of Shanghai Municipality [81101623, 81672846]; NATIONAL CANCER INSTITUTE [R01CA129956, R01CA148954, R01CA195651] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Don Norwood for editorial comments. The work is supported in part by grants R01-CA129956 and R01-CA148954 from the National Institutes of Health (K Xie), grant # 81101623 from the National Natural Science Foundation of China and grant # 81101623 and # 81672846 from Science and Technology Commission of Shanghai Municipality (H Sun).	Baek HJ, 2011, HEPATOLOGY, V53, P1676, DOI 10.1002/hep.24128; Chen YW, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-181; Ding Bo, 2015, Asian Pac J Cancer Prev, V16, P3629; Feinberg MW, 2005, J BIOL CHEM, V280, P38247, DOI 10.1074/jbc.M509378200; Fleming NI, 2013, CANCER RES, V73, P725, DOI 10.1158/0008-5472.CAN-12-2706; Fransvea E, 2009, HEPATOLOGY, V49, P839, DOI 10.1002/hep.22731; Giannelli G, 2014, CANCER RES, V74, P1890, DOI 10.1158/0008-5472.CAN-14-0243; Hu B, 2007, AM J RESP CELL MOL, V36, P78, DOI 10.1165/rcmb.2006-0043OC; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Li Q, 2012, GASTROENTEROLOGY, V143, P799, DOI 10.1053/j.gastro.2012.05.043; Lin TH, 2015, CLIN CANCER RES, V21, P3678, DOI 10.1158/1078-0432.CCR-14-1954; Lin ZS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043593; Matsuzaki K, 2000, CANCER RES, V60, P1394; Mazzocca A, 2012, CURR PHARM DESIGN, V18, P4148, DOI 10.2174/138161212802430431; Mazzocca A, 2010, HEPATOLOGY, V51, P523, DOI 10.1002/hep.23285; Mazzocca A, 2009, HEPATOLOGY, V50, P1140, DOI 10.1002/hep.23118; Meindl-Beinker NM, 2012, DIGEST DIS, V30, P514, DOI 10.1159/000341704; Mima K, 2012, CANCER RES, V72, P3414, DOI 10.1158/0008-5472.CAN-12-0299; Morris SM, 2012, HEPATOLOGY, V55, P121, DOI 10.1002/hep.24653; Park YN, 2004, HEPATO-GASTROENTEROL, V51, P396; Reichl P, 2012, CURR PHARM DESIGN, V18, P4135, DOI 10.2174/138161212802430477; Senturk S, 2010, HEPATOLOGY, V52, P966, DOI 10.1002/hep.23769; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Stolfi C, 2013, INT J MOL SCI, V14, P23774, DOI 10.3390/ijms141223774; Sun HC, 2011, ONCOL REP, V25, P1533, DOI 10.3892/or.2011.1230; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wang J, 2013, J PATHOL, V230, P441, DOI 10.1002/path.4206; Wei DY, 2008, CANCER RES, V68, P4631, DOI 10.1158/0008-5472.CAN-07-5953; Wei DY, 2016, CANCER CELL, V29, P324, DOI 10.1016/j.ccell.2016.02.005; Xia HP, 2013, HEPATOLOGY, V58, P629, DOI 10.1002/hep.26369; Yan XH, 2011, BIOCHEM J, V434, P1, DOI 10.1042/BJ20101827; Yan XH, 2009, ACTA BIOCH BIOPH SIN, V41, P263, DOI 10.1093/abbs/gmp018; Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016; Zhang YD, 2013, MATH PROBL ENG, V2013, DOI 10.1155/2013/705238; Zhou AD, 2016, NAT CELL BIOL, V18, P954, DOI 10.1038/ncb3396; Zhu HB, 2013, HEPATOLOGY, V58, P2012, DOI 10.1002/hep.26587	36	48	49	0	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					2957	2968		10.1038/onc.2016.447	http://dx.doi.org/10.1038/onc.2016.447			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	28192402	Green Accepted			2022-12-17	WOS:000402000400004
J	Wang, SH; Chang, JS; Hsiao, JR; Yen, YC; Jiang, SS; Liu, SH; Chen, YL; Shen, YY; Chang, JY; Chen, YW				Wang, S-H; Chang, J. S.; Hsiao, J-R; Yen, Y-C; Jiang, S. S.; Liu, S-H; Chen, Y-L; Shen, Y-Y; Chang, J-Y; Chen, Y-W			Tumour cell-derived WNT5B modulates in vitro lymphangiogenesis via induction of partial endothelial-mesenchymal transition of lymphatic endothelial cells	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA CELLS; SIGNALING PATHWAY; NODE METASTASIS; BINDING-PROTEIN; BREAST-CANCER; PROLIFERATION; EXPRESSION; PROMOTES; ANGIOGENESIS; VASCULATURE	Metastasis of the cervical lymph nodes frequently leads to poor survival of patients with oral squamous cell carcinoma (OSCC). The underlying mechanisms of lymph node metastasis are unclear. Wingless-type MMTV integration site family, member 5B (WNT5B), one component of the WNT signal pathway, was markedly up-regulated in OSCC sublines with high potential of lymphatic metastasis compared to that in OSCC cells with low nodal metastasis. Increased WNT5B mRNA was demonstrated in human OSCC tissues in comparison with adjacent non-tumorous tissues. Interestingly, the high level of WNT5B protein in serum was associated with lymph node metastasis in OSCC patients. Knockdown of WNT5B expression in OSCC sublines did not affect tumour growth but impaired lymph node metastasis and tumour lymphangiogenesis of orthotopic transplantation. Conditioned medium from WNT5B knockdown cells reduced the tube formation of lymphatic endothelial cells (LECs). In contrast, recombinant WNT5B enhanced the tube formation, permeability and migration of LECs. In LECs stained with phalloidin, the morphology of those treated with recombinant WNT5B changed from flat to spindle-like. Recombinant WNT5B also increased alpha-smooth muscle actin and inhibited the expression of vascular endothelial-cadherin but retained characteristics of endothelial cells. The results suggest that WNT5B functions in the partial endothelial-mesenchymal transition (EndoMT). Furthermore, WNT5B-induced tube formation was impaired in the LECs following the knockdown of EndoMT-related transcription factor, SNAIL or SLUG. The WNT5B-induced expression of Snail or Slug was abolished by IWR-1-endo and Rac1 inhibitors, which are involved in the WNT/beta-catenin and planar cell polarity pathways, respectively. Collectively, the data suggest that WNT5B induces tube formation by regulating the expression of Snail and Slug proteins through activation of canonical and non-canonical WNT signalling pathways.	[Wang, S-H; Yen, Y-C; Jiang, S. S.; Liu, S-H; Chen, Y-L; Chen, Y-W] Natl Hlth Res Inst, Natl Inst Canc Res, 35 Keyan Rd, Zhunan Town 35053, Miaoli County, Taiwan; [Chang, J. S.] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan; [Hsiao, J-R] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Otolaryngol, Coll Med, Tainan, Taiwan; [Shen, Y-Y] Natl Hlth Res Inst, Pathol Core Lab, Miaoli, Taiwan; [Chang, J-Y] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan; [Chen, Y-W] China Med Univ, Grad Inst Basic Med Sci, PhD Program Aging, Taichung, Taiwan	National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; National Cheng Kung University; National Cheng Kung University Hospital; National Health Research Institutes - Taiwan; National Cheng Kung University; National Cheng Kung University Hospital; China Medical University Taiwan	Chen, YW (corresponding author), Natl Hlth Res Inst, Natl Inst Canc Res, 35 Keyan Rd, Zhunan Town 35053, Miaoli County, Taiwan.	ywc@nhri.org.tw	Chang, Jeffrey Shu-Ming/AAR-4161-2020; Chen, Ya-Wen/AAG-7549-2019; Jiang, Shih Sheng/J-9671-2019	Chang, Jeffrey Shu-Ming/0000-0002-3236-6205; Chen, Ya-Wen/0000-0002-6080-8859; Jiang, Shih Sheng/0000-0003-1909-437X	NSC [NSC 97-3112-B-001-016]; Ministry of Science and Technology [MOST 104-2314-B-400-014, NHRI CA-104-PP-04, MOHW105-TDU-B-212-112015]; National Health Research Institutes; Ministry of Health and Welfare, Taiwan	NSC(Ministry of Science and Technology, Taiwan); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); National Health Research Institutes(National Health Research Institutes, Japan); Ministry of Health and Welfare, Taiwan	The authors thank Dr Wen-Chun Hung (National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan) for providing technical support and reagents and Pathology Core Laboratory (National Health Research Institutes, Miaoli, Taiwan) for the scoring of immunohistochemistry staining. RNAi reagents were obtained from the National RNAi Core Facility located at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, supported by the National Research Program for Genomic Medicine Grants of NSC (NSC 97-3112-B-001-016). We are also grateful to the Tissue Bank, Research Center of Clinical Medicine, National Cheng Kung University Hospital for providing clinical samples. This study was supported by grants MOST 104-2314-B-400-014, NHRI CA-104-PP- 04 and MOHW105-TDU-B-212-112015 from Ministry of Science and Technology, National Health Research Institutes and Ministry of Health and Welfare, Taiwan, respectively.	Achen MG, 2008, ANN NY ACAD SCI, V1131, P225, DOI 10.1196/annals.1413.020; Andre P, 2012, J BIOL CHEM, V287, P44518, DOI 10.1074/jbc.M112.414441; Buttler K, 2013, DEV BIOL, V381, P365, DOI 10.1016/j.ydbio.2013.06.028; Chen YW, 2008, CANCER RES, V68, P476, DOI 10.1158/0008-5472.CAN-07-1960; Chen YW, 2007, CANCER RES, V67, P7589, DOI 10.1158/0008-5472.CAN-07-0381; Cheng CW, 2008, BIOCHEM BIOPH RES CO, V365, P285, DOI 10.1016/j.bbrc.2007.10.166; Cooley BC, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3006927; Dale TC, 1998, BIOCHEM J, V329, P209; Dejana E, 2010, CIRC RES, V107, P943, DOI 10.1161/CIRCRESAHA.110.223750; Deraz EM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025438; Dieterich LC, 2016, ADV DRUG DELIVER REV, V99, P148, DOI 10.1016/j.addr.2015.12.011; Festing Michael F W, 2002, ILAR J, V43, P244; Ghiabi P, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0386-3; Goodwin AM, 2007, GROWTH FACTORS, V25, P25, DOI 10.1080/08977190701272933; Green JL, 2008, TRENDS CELL BIOL, V18, P536, DOI 10.1016/j.tcb.2008.08.006; Hong YK, 2003, CELL TISSUE RES, V314, P85, DOI 10.1007/s00441-003-0747-8; Kanazawa A, 2005, BIOCHEM BIOPH RES CO, V330, P505, DOI 10.1016/j.bbrc.2005.03.007; Kato S, 2014, CANCER SCI, V105, P281, DOI 10.1111/cas.12336; Kestler HA, 2008, PHILOS T R SOC B, V363, P1333, DOI 10.1098/rstb.2007.2251; Kokudo T, 2008, J CELL SCI, V121, P3317, DOI 10.1242/jcs.028282; Lee CH, 2013, J PATHOL, V230, P298, DOI 10.1002/path.4173; Liao CT, 2009, INT J RADIAT ONCOL, V73, P764, DOI 10.1016/j.ijrobp.2008.05.004; Lin F, 2012, IUBMB LIFE, V64, P717, DOI 10.1002/iub.1059; Lin ZS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043593; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Macheda ML, 2012, J BIOL CHEM, V287, P29312, DOI 10.1074/jbc.M112.362681; Mangioni S, 2005, J CLIN ENDOCR METAB, V90, P5349, DOI 10.1210/jc.2005-0272; Masckauchan TNH, 2006, MOL BIOL CELL, V17, P5163, DOI 10.1091/mbc.E06-04-0320; Miyahara M, 2007, CANCER-AM CANCER SOC, V110, P1287, DOI 10.1002/cncr.22900; Nicenboim J, 2015, NATURE, V522, P56, DOI 10.1038/nature14425; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Pan MR, 2009, J CELL SCI, V122, P3358, DOI 10.1242/jcs.050005; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Sleeman JP, 2009, INT J CANCER, V125, P2747, DOI 10.1002/ijc.24702; Stacker SA, 2014, NAT REV CANCER, V14, P159, DOI 10.1038/nrc3677; Takeshita A, 2014, INT J ONCOL, V44, P59, DOI 10.3892/ijo.2013.2172; Tobler NE, 2006, J LEUKOCYTE BIOL, V80, P691, DOI 10.1189/jlb.1105653; Welch-Reardon KM, 2015, ARTERIOSCL THROM VAS, V35, P303, DOI 10.1161/ATVBAHA.114.303220; Welch-Reardon KM, 2014, J CELL SCI, V127, P2017, DOI 10.1242/jcs.143420; Xu XB, 2015, J BIOL CHEM, V290, P16653, DOI 10.1074/jbc.M115.636944; Yang LX, 2014, BMC CANCER, V14, DOI [10.1186/1471-2407-14-228, 10.1186/1471-2407-14-124]; Yang YZ, 2003, DEVELOPMENT, V130, P1003, DOI 10.1242/dev.00324; Yen YC, 2015, ONCOTARGET, V6, P41837, DOI 10.18632/oncotarget.5995; Yen YC, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-6; Zeisberg EM, 2007, CANCER RES, V67, P10123, DOI 10.1158/0008-5472.CAN-07-3127; Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613	47	48	50	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1503	1515		10.1038/onc.2016.317	http://dx.doi.org/10.1038/onc.2016.317			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27593938				2022-12-17	WOS:000397458100005
J	Hein, AL; Post, CM; Sheinin, YM; Lakshmanan, I; Natarajan, A; Enke, CA; Batra, SK; Ouellette, MM; Yan, Y				Hein, A. L.; Post, C. M.; Sheinin, Y. M.; Lakshmanan, I.; Natarajan, A.; Enke, C. A.; Batra, S. K.; Ouellette, M. M.; Yan, Y.			RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment	ONCOGENE			English	Article							NF-KAPPA-B; POTENTIAL THERAPEUTIC TARGET; SIGNALING PATHWAYS; GAMMA-IRRADIATION; DNA-REPAIR; TRASTUZUMAB RESISTANCE; IONIZING-RADIATION; COLORECTAL-CANCER; ERK ACTIVATION; CYCLE ARREST	Radiation therapy is a staple approach for cancer treatment, whereas radioresistance of cancer cells remains a substantial clinical problem. In response to ionizing radiation (IR) induced DNA damage, cancer cells can sustain/activate pro-survival signaling pathways, leading to apoptotic resistance and induction of cell cycle checkpoint/DNA repair. Previous studies show that Rac1 GTPase is overexpressed/hyperactivated in breast cancer cells and is associated with poor prognosis. Studies from our laboratory reveal that Rac1 activity is necessary for G2/M checkpoint activation and cell survival in response to IR exposure of breast and pancreatic cancer cells. In this study, we investigated the effect of Rac1 on the survival of breast cancer cells treated with hyperfractionated radiation (HFR), which is used clinically for cancer treatment. Results in this report indicate that Rac1 protein expression is increased in the breast cancer cells that survived HFR compared with parental cells. Furthermore, this increase of Rac1 is associated with enhanced activities of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and nuclear factor-.B (NF-.B) signaling pathways and increased levels of anti-apoptotic protein Bcl-xL and Mcl-1, which are downstream targets of ERK1/2 and NF-.B signaling pathways. Using Rac1-specific inhibitor and dominant-negative mutant N17Rac1, here we demonstrate that Rac1 inhibition decreases the phosphorylation of ERK1/2 and inhibitory kappa Ba (I kappa Ba), as well as the levels of Bcl-xL and Mcl-1 protein in the HFR-selected breast cancer cells. Moreover, inhibition of Rac1 using either small molecule inhibitor or dominant-negative N17Rac1 abrogates clonogenic survival of HFR-selected breast cancer cells and decreases the level of intact poly(ADP-ribose) polymerase, which is indicative of apoptosis induction. Collectively, results in this report suggest that Rac1 signaling is essential for the survival of breast cancer cells subjected to HFR and implicate Rac1 in radioresistance of breast cancer cells. These studies also provide the basis to explore Rac1 as a therapeutic target for radioresistant breast cancer cells.	[Hein, A. L.; Post, C. M.; Enke, C. A.; Yan, Y.] Univ Nebraska Med Ctr, Dept Radiat Oncol, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA; [Sheinin, Y. M.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Lakshmanan, I.; Batra, S. K.; Yan, Y.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE USA; [Natarajan, A.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE USA; [Ouellette, M. M.] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Yan, Y (corresponding author), Univ Nebraska Med Ctr, Dept Radiat Oncol, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA.	yyan@unmc.edu		Hein, Ashley/0000-0002-3309-2218; Post, Carl/0000-0003-1018-693X; Natarajan, Amarnath/0000-0001-5067-0203; lakshmanan, Imayavaramban/0000-0003-1733-2223	Pilot Project [5P30GM106397, P50CA127297]; NATIONAL CANCER INSTITUTE [P50CA127297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM106397] Funding Source: NIH RePORTER	Pilot Project; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Vimla Band for 76N cells and Dr Toren Finkel for Ad.N17Rac1 and Ad. dl312 adenoviral vectors. This work was supported, in parts, by Pilot Project Funding from 5P30GM106397 to YY and AN, and P50CA127297 to SKB, MMO and YY.	Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Arnold Christoph R, 2014, Oncoscience, V1, P513; Baldwin AS, 2012, IMMUNOL REV, V246, P327, DOI 10.1111/j.1600-065X.2012.01095.x; Bid HK, 2013, MOL CANCER THER, V12, P1925, DOI 10.1158/1535-7163.MCT-13-0164; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; Bosco EE, 2009, CELL MOL LIFE SCI, V66, P370, DOI 10.1007/s00018-008-8552-x; Brown JH, 2006, CIRC RES, V98, P730, DOI 10.1161/01.RES.0000216039.75913.9e; Bussink J, 2008, LANCET ONCOL, V9, P288, DOI 10.1016/S1470-2045(08)70073-1; Cai ZL, 2011, INT J RADIAT BIOL, V87, P1135, DOI 10.3109/09553002.2011.622033; Charafe-Jaufrret E, 2004, J PATHOL, V202, P265, DOI 10.1002/path.1515; Chen BPC, 2012, CANCER LETT, V327, P103, DOI 10.1016/j.canlet.2011.12.004; Cuadrado A, 2014, J BIOL CHEM, V289, P15244, DOI 10.1074/jbc.M113.540633; DeSantis C, 2014, CANC TREATMENT SURVI, P3; Dokmanovic M, 2009, MOL CANCER THER, V8, P1557, DOI 10.1158/1535-7163.MCT-09-0140; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Espinha G, 2015, MOL CELL BIOCHEM, V404, P281, DOI 10.1007/s11010-015-2388-0; Fiebig AA, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-213; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gonzalez E, 2006, J BIOL CHEM, V281, P3210, DOI 10.1074/jbc.M510434200; Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Hein AL, 2014, INT J ONCOL, V45, P1813, DOI 10.3892/ijo.2014.2614; Jiang DH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092398; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kunz M, 2014, EUR J CELL BIOL, V93, P1, DOI 10.1016/j.ejcb.2013.12.002; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Leve F, 2012, J CELL BIOCHEM, V113, P2549, DOI 10.1002/jcb.24153; Magne N, 2006, CANCER LETT, V231, P158, DOI 10.1016/j.canlet.2005.01.022; Moore KA, 1997, BIOCHEM J, V326, P17, DOI 10.1042/bj3260017; Munshi Anupama, 2013, Genes Cancer, V4, P401, DOI 10.1177/1947601913485414; Murga C, 2002, ONCOGENE, V21, P207, DOI 10.1038/sj.onc.1205036; Myant KB, 2013, CELL STEM CELL, V12, P761, DOI 10.1016/j.stem.2013.04.006; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Opferman JT, 2016, FEBS J, V283, P2661, DOI 10.1111/febs.13472; Pessetto ZY, 2012, BREAST CANCER RES TR, V134, P511, DOI 10.1007/s10549-012-2079-4; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sahlberg SH, 2014, TUMOR BIOL, V35, P3525, DOI 10.1007/s13277-013-1465-9; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Shiao YH, 2000, CANCER EPIDEM BIOMAR, V9, P631; Shimura T, 2011, INT J RADIAT ONCOL, V80, P540, DOI 10.1016/j.ijrobp.2010.12.065; Skvortsov S, 2014, BRIT J CANCER, V110, P2677, DOI 10.1038/bjc.2014.221; Skvortsova I, 2015, SEMIN CANCER BIOL, V35, P39, DOI 10.1016/j.semcancer.2015.09.009; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Sooman L, 2013, CANCER CHEMOTH PHARM, V72, P329, DOI 10.1007/s00280-013-2197-7; Subik K, 2010, BREAST CANCER-BASIC, V4, P35; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Toulany M, 2012, MOL CANCER RES, V10, P945, DOI 10.1158/1541-7786.MCR-11-0592; Valerie K, 2007, MOL CANCER THER, V6, P789, DOI 10.1158/1535-7163.MCT-06-0596; Wang W, 2015, CURR MED CHEM, V22, P264; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95; Wertheimer E, 2012, CELL SIGNAL, V24, P353, DOI 10.1016/j.cellsig.2011.08.011; Wetterskog D, 2014, ONCOGENE, V33, P966, DOI 10.1038/onc.2013.41; Yan Y, 2007, ONCOGENE, V26, P4689, DOI 10.1038/sj.onc.1210268; Yan Y, 2005, ONCOGENE, V24, P3285, DOI 10.1038/sj.onc.1208492; Yan Y, 2002, J BIOL CHEM, V277, P33422, DOI 10.1074/jbc.M201147200; Yan Y, 2014, ONCOTARGET, V5, P10251, DOI 10.18632/oncotarget.2500; Yan Y, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3164; Zhao XS, 2010, P NATL ACAD SCI USA, V107, P14146, DOI 10.1073/pnas.1009030107; Zhao Y, 2011, CANCER LETT, V313, P54, DOI 10.1016/j.canlet.2011.08.023	62	48	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2016	35	49					6319	6329		10.1038/onc.2016.163	http://dx.doi.org/10.1038/onc.2016.163			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TJ	27181206	Green Accepted			2022-12-17	WOS:000390247000005
J	Zhao, C; Chen, X; Zang, D; Lan, X; Liao, S; Yang, C; Zhang, P; Wu, J; Li, X; Liu, N; Liao, Y; Huang, H; Shi, X; Jiang, L; Liu, X; He, Z; Dou, QP; Wang, X; Liu, J				Zhao, C.; Chen, X.; Zang, D.; Lan, X.; Liao, S.; Yang, C.; Zhang, P.; Wu, J.; Li, X.; Liu, N.; Liao, Y.; Huang, H.; Shi, X.; Jiang, L.; Liu, X.; He, Z.; Dou, Q. P.; Wang, X.; Liu, J.			A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy	ONCOGENE			English	Article							ANTIRHEUMATIC AGENT AURANOFIN; ACID INDUCES APOPTOSIS; MYELOID-LEUKEMIA CELLS; GAMBOGIC ACID; 26S PROTEASOME; IN-VITRO; DEGRADATION; RECRUITMENT; IMPAIRMENT; ACTIVATION	Based on the central role of the ubiquitin-proteasome system (UPS) in the degradation of cellular proteins, proteasome inhibition has been considered an attractive approach for anticancer therapy. Deubiquitinases (DUBs) remove ubiquitin conjugates from diverse substrates; therefore, they are essential regulators of the UPS. DUB inhibitors, especially the inhibitors of proteasomal DUBs are becoming a research hotspot in targeted cancer therapy. Previous studies have shown that metal complexes, such as copper and zinc complexes, can induce cancer cell apoptosis through inhibiting UPS function. Moreover, we have found that copper pyrithione inhibits both 19S proteasome-associated DUBs and 20S proteasome activity with a mechanism distinct from that of the classical 20S proteasome inhibitor bortezomib. In the present study, we reveal that (i) nickel pyrithione complex (NiPT) potently inhibits the UPS via targeting the 19S proteasome-associated DUBs (UCHL5 and USP14), without effecting on the 20S proteasome; (ii) NiPT selectively induces proteasome inhibition and apoptosis in cultured tumor cells and cancer cells from acute myeloid leukemia human patients; and (iii) NiPT inhibits proteasome function and tumor growth in nude mice. This study, for the first time, uncovers a nickel complex as an effective inhibitor of the 19S proteasomal DUBs and suggests a potentially new strategy for cancer treatment.	[Zhao, C.; Chen, X.; Zang, D.; Lan, X.; Liao, S.; Yang, C.; Zhang, P.; Wu, J.; Li, X.; Liu, N.; Liao, Y.; Huang, H.; Shi, X.; Jiang, L.; Wang, X.; Liu, J.] Guangzhou Med Univ, Dept Pathophysiol, Prot Modificat & Degradat Lab, State Key Lab Resp Dis, Dongfeng Xi Rd 195, Guangzhou 510182, Guangdong, Peoples R China; [Liu, N.] Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou Res Inst Cardiovasc Dis, Guangzhou, Guangdong, Peoples R China; [Liu, X.] Henan Univ, Coll Chem & Chem Engn, Inst Environm & Analyt Sci, Kaifeng, Peoples R China; [Liu, X.] Key Lab Nat Drug & Immune Engn Henan Prov, Kaifeng, Peoples R China; [He, Z.] Guangzhou Med Univ, Canc Hosp, Guangzhou, Guangdong, Peoples R China; [He, Z.] Guangzhou Med Univ, Canc Res Inst, Guangzhou, Guangdong, Peoples R China; [Dou, Q. P.] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Mol Therapeut Program, Detroit, MI USA; [Dou, Q. P.] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI USA; [Dou, Q. P.] Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI USA; [Dou, Q. P.] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI USA; [Wang, X.] Univ South Dakota, Sanford Sch Med, Div Basic Biomed Sci, Vermillion, SD 57069 USA	Guangzhou Medical University; State Key Laboratory of Respiratory Disease; Guangzhou Medical University; Henan University; Guangzhou Medical University; Guangzhou Medical University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University; Wayne State University; Wayne State University; University of South Dakota	Liu, J (corresponding author), Guangzhou Med Univ, Dept Pathophysiol, Prot Modificat & Degradat Lab, State Key Lab Resp Dis, Dongfeng Xi Rd 195, Guangzhou 510182, Guangdong, Peoples R China.	jliu@gzhmu.edu.cn	Chen, Xin/ABJ-3846-2022; Wang, Xuejun/K-8874-2013; Wang, Xuejun/AAT-9490-2021	Chen, Xin/0000-0003-3668-4830; Wang, Xuejun/0000-0001-9267-1343; Wang, Xuejun/0000-0001-9267-1343; Dou, Qingping/0000-0002-6465-1473	National High Technology Research and Development Program of China [2006AA02Z4B5]; NSFC [81272451/H1609, 81472762/H1609]; MOE [20134423110002]; Guangdong Key Laboratory of Urology [2010A060801016]; US NIH [HL072166, HL085629]; NATIONAL CANCER INSTITUTE [R21CA184788] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072166, R01HL085629] Funding Source: NIH RePORTER	National High Technology Research and Development Program of China(National High Technology Research and Development Program of China); NSFC(National Natural Science Foundation of China (NSFC)); MOE(Ministry of Higher Education & Scientific Research (MHESR)); Guangdong Key Laboratory of Urology; US NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital and Sun Yat-Sen University for flow cytometry detection. This work was supported by the National High Technology Research and Development Program of China (2006AA02Z4B5), NSFC (81272451/H1609, 81472762/H1609), MOE (20134423110002) and Guangdong Key Laboratory of Urology (2010A060801016) (to JL) and in part by US NIH grants HL072166 and HL085629 (to XW).	Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; Atasever B, 2010, INVEST NEW DRUG, V28, P421, DOI 10.1007/s10637-009-9272-2; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Burger AM, 2004, EUR J CANCER, V40, P2217, DOI 10.1016/j.ejca.2004.07.006; Chen D, 2011, CURR CANCER DRUG TAR, V11, P239, DOI 10.2174/156800911794519752; Chen D, 2007, CANCER RES, V67, P9258, DOI 10.1158/0008-5472.CAN-07-1813; Chen JN, 2004, TOXICOL APPL PHARM, V197, P40, DOI 10.1016/j.taap.2004.02.004; Chen X, 2014, ONCOTARGET, V5, P9118, DOI 10.18632/oncotarget.2361; Cvek B, 2008, J MED CHEM, V51, P6256, DOI 10.1021/jm8007807; D'Arcy P, 2011, NAT MED, V17, P1636, DOI 10.1038/nm.2536; Dayal S, 2009, J BIOL CHEM, V284, P5030, DOI 10.1074/jbc.M805871200; Denkhaus E, 2002, CRIT REV ONCOL HEMAT, V42, P35, DOI 10.1016/S1040-8428(01)00214-1; Dinning AJ, 1998, J APPL MICROBIOL, V85, P132; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Florea Ana-Maria, 2011, Cancers (Basel), V3, P1351, DOI 10.3390/cancers3011351; Fraile JM, 2012, ONCOGENE, V31, P2373, DOI 10.1038/onc.2011.443; Frezza M, 2009, INORG CHEM, V48, P5928, DOI 10.1021/ic900276g; Huang HB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049062; Huang HB, 2010, CELL RES, V20, P1372, DOI 10.1038/cr.2010.123; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; Koulich E, 2008, MOL BIOL CELL, V19, P1072, DOI 10.1091/mbc.E07-10-1040; Li XF, 2013, CELL REP, V3, P211, DOI 10.1016/j.celrep.2012.11.023; Liu JB, 2006, FASEB J, V20, P362, DOI 10.1096/fj.05-4869fje; Liu NN, 2014, ONCOTARGET, V5, P5453, DOI 10.18632/oncotarget.2113; Liu NN, 2014, SCI REP-UK, V4, DOI 10.1038/srep05240; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; Milacic V, 2008, TOXICOL APPL PHARM, V231, P24, DOI 10.1016/j.taap.2008.03.009; Pabla N, 2008, J BIOL CHEM, V283, P6572, DOI 10.1074/jbc.M707568200; Paramore A, 2003, NAT REV DRUG DISCOV, V2, P611, DOI 10.1038/nrd1159; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Sacco JJ, 2010, IUBMB LIFE, V62, P140, DOI 10.1002/iub.300; Shi XP, 2015, SCI REP-UK, V5, DOI 10.1038/srep09694; Shi XP, 2014, CLIN CANCER RES, V20, P151, DOI 10.1158/1078-0432.CCR-13-1063; Singhal S, 2008, BMC BIOCHEM, V9, DOI 10.1186/1471-2091-9-S1-S3; Tailler M, 2012, ONCOGENE, V31, P3536, DOI 10.1038/onc.2011.521; Tan J, 2010, BIOMETALS, V23, P1075, DOI 10.1007/s10534-010-9353-x; Tian Z, 2014, BLOOD, V123, P706, DOI 10.1182/blood-2013-05-500033; Todi SV, 2011, TRENDS NEUROSCI, V34, P370, DOI 10.1016/j.tins.2011.05.004; Ventii KH, 2008, BIOCHEM J, V414, P161, DOI 10.1042/BJ20080798; Verani CN, 2012, J INORG BIOCHEM, V106, P59, DOI 10.1016/j.jinorgbio.2011.09.003; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Yang HJ, 2009, INT J CANCER, V124, P2450, DOI 10.1002/ijc.24195; Yao TT, 2006, NAT CELL BIOL, V8, P994, DOI 10.1038/ncb1460	45	48	49	2	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5916	5927		10.1038/onc.2016.114	http://dx.doi.org/10.1038/onc.2016.114			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27086925	Green Accepted			2022-12-17	WOS:000387560800010
J	Bhattacharya, S; Chalk, AM; Ng, AJM; Martin, TJ; Zannettino, AC; Purton, LE; Lu, J; Baker, EK; Walkley, CR				Bhattacharya, S.; Chalk, A. M.; Ng, A. J. M.; Martin, T. J.; Zannettino, A. C.; Purton, L. E.; Lu, J.; Baker, E. K.; Walkley, C. R.			Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death	ONCOGENE			English	Article							TARGETING ROCK1; POOR-PROGNOSIS; MOUSE MODEL; KINASE; MICRORNA-148A; PROGRESSION; RIP1; GENE; HYPERMETHYLATION; IDENTIFICATION	Osteosarcoma (OS) is the most common cancer of bone and the 5th leading cause of cancer-related death in young adults. Currently, 5-year survival rates have plateaued at similar to 70% for patients with localized disease. Those with disseminated disease have an similar to 20% 5-year survival. An improved understanding of the molecular genetics of OS may yield new approaches to improve outcomes for OS patients. To this end, we applied murine models that replicate human OS to identify and understand dysregulated microRNAs (miRNAs) in OS. miRNA expression patterns were profiled in murine primary osteoblasts, osteoblast cultures and primary OS cell cultures (from primary and paired metastatic locations) isolated from two genetically engineered murine models of OS. The differentially expressed miRNA were further assessed by a cross-species comparison with human osteoblasts and OS cultures. We identified miR-155-5p and miR-148a-3p as deregulated in OS. miR-155-5p suppression or miR-148a-3p overexpression potently reduced proliferation and induced apoptosis in OS cells, yet strikingly, did not impact normal osteoblasts. To define how these miRNAs regulated OS cell fate, we used an integrated computational approach to identify putative candidate targets and then correlated these with the cell biological impact. Although we could not resolve the mechanism through which miR-148a-3p impacts OS, we identified that miR-155-5p overexpression suppressed its target Ripk1 (receptor (TNFRSF)-interacting serine-threonine kinase 1) expression, and miR-155-5p inhibition elevated Ripk1 levels. Ripk1 is directly involved in apoptosis/necroptosis. In OS cells, small interfering RNA against Ripk1 prevented cell death induced by the sequestration of miR-155-5p. Collectively, we show that miR-148a-3p and miR-155-5p are species-conserved deregulated miRNA in OS. Modulation of these miRNAs was specifically toxic to tumor cells but not normal osteoblasts, raising the possibility that these may be tractable targets for miRNA-based therapies for OS.	[Bhattacharya, S.; Chalk, A. M.; Ng, A. J. M.; Martin, T. J.; Purton, L. E.; Baker, E. K.; Walkley, C. R.] Univ Melbourne, St Vincents Hosp, St Vincents Inst Med Res, Fitzroy, Vic, Australia; [Zannettino, A. C.] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic, Australia; [Zannettino, A. C.] Univ Adelaide, Fac Hlth Sci, Sch Med, Myeloma Res Lab, Adelaide, SA, Australia; [Purton, L. E.; Walkley, C. R.] South Australian Hlth & Med Res Inst, Canc Theme, Adelaide, SA, Australia; [Lu, J.] St Vincents Inst Med Res, ACRF Rat Drug Discovery Ctr, Fitzroy, Vic, Australia; [Baker, E. K.; Walkley, C. R.] Yale Univ, Dept Genet, New Haven, CT USA; [Baker, E. K.; Walkley, C. R.] Yale Univ, Yale Stem Cell Ctr, New Haven, CT USA	St Vincent's Hospital Melbourne; St. Vincent's Institute of Medical Research; University of Melbourne; St Vincent's Hospital Melbourne; University of Melbourne; University of Adelaide; South Australian Health & Medical Research Institute (SAHMRI); St. Vincent's Institute of Medical Research; Yale University; Yale University	Walkley, CR (corresponding author), St Vincents Inst, 9 Princes St, Fitzroy, Vic 3065, Australia.	cwalkley@svi.edu.au	Purton, Louise/AAI-8956-2021; Walkley, Carl/AAO-6021-2020; Chalk, Alistair/O-3522-2019; Ng, Alvin/AAQ-5759-2020	Purton, Louise/0000-0001-6593-3168; Walkley, Carl/0000-0002-4784-9031; Chalk, Alistair/0000-0002-9630-6236; Zannettino, Andrew/0000-0002-6646-6167	National Health and Medical Research Council (NHMRC), Australia; Cancer Council of Victoria; Cure Cancer Australia Foundation; 5point foundation; Zig Inge Foundation; NHMRC Career Development Award; NHMRC Dora Lush postgraduate scholarship; Victorian State Government OIS Program; Phillip Desbrow Senior Research Fellow of the Leukaemia Foundation	National Health and Medical Research Council (NHMRC), Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Cure Cancer Australia Foundation; 5point foundation; Zig Inge Foundation; NHMRC Career Development Award(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Dora Lush postgraduate scholarship(National Health and Medical Research Council (NHMRC) of Australia); Victorian State Government OIS Program; Phillip Desbrow Senior Research Fellow of the Leukaemia Foundation	We thank A Pfeiffer (University of Bonn) for providing the miR-155-5p sponge, control sponge and miR-155-5p overexpression vector. We thank A Gupte for technical assistance; C Hawkins for discussion and comments; the BioResource Facility (St Vincent's Hospital) for housing and care of experimental animals, and M Thomson (SVI Flow Cytometry Facility) for help with FACS analysis. This work was supported by grants from the National Health and Medical Research Council (NHMRC), Australia (CW and TJM), Cancer Council of Victoria (CW and EB); Cure Cancer Australia Foundation (EB); 5point foundation (EB); Zig Inge Foundation (CW); NHMRC Career Development Award (CW); NHMRC Dora Lush postgraduate scholarship (SB); in part by the Victorian State Government OIS Program (to St. Vincent's Institute); CW was the Phillip Desbrow Senior Research Fellow of the Leukaemia Foundation.	Allan EH, 2003, J CELL BIOCHEM, V90, P158, DOI 10.1002/jcb.10614; Atkins GJ, 2002, BONE, V31, P448, DOI 10.1016/S8756-3282(02)00858-X; Babar IA, 2012, P NATL ACAD SCI USA, V109, pE1695, DOI 10.1073/pnas.1201516109; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Batanian JR, 2002, J CLIN PATHOL-MOL PA, V55, P389, DOI 10.1136/mp.55.6.389; Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776; Cheng CJ, 2015, NATURE, V518, P107, DOI 10.1038/nature13905; Dohi O, 2013, INT J ONCOL, V42, P411, DOI 10.3892/ijo.2012.1724; Dondelinger Y, 2015, MOL CELL, V60, P63, DOI 10.1016/j.molcel.2015.07.032; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Geller David S, 2010, Clin Adv Hematol Oncol, V8, P705; Gougelet A, 2011, INT J CANCER, V129, P680, DOI 10.1002/ijc.25715; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; Hanoun N, 2010, CLIN CHEM, V56, P1107, DOI 10.1373/clinchem.2010.144709; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Houghton PJ, 2007, PEDIATR BLOOD CANCER, V49, P928, DOI 10.1002/pbc.21078; Hu H, 2012, ONCOL LETT, V4, P1037, DOI 10.3892/ol.2012.866; Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106; Janssen HLA, 2013, NEW ENGL J MED, V368, P1685, DOI 10.1056/NEJMoa1209026; Jones KB, 2012, CANCER RES, V72, P1865, DOI 10.1158/0008-5472.CAN-11-2663; Jouan-Lanhouet S, 2012, CELL DEATH DIFFER, V19, P2003, DOI 10.1038/cdd.2012.90; Kansara M, 2007, DNA CELL BIOL, V26, P1, DOI 10.1089/dna.2006.0505; Kelly AD, 2013, GENOME MED, V5, DOI 10.1186/gm406; Kim S, 2010, CANCER SCI, V101, P2425, DOI 10.1111/j.1349-7006.2010.01697.x; Kobayashi T, 2008, P NATL ACAD SCI USA, V105, P1949, DOI 10.1073/pnas.0707900105; Lauvrak SU, 2013, BRIT J CANCER, V109, P2228, DOI 10.1038/bjc.2013.549; Li JP, 2013, MOL CELL BIOCHEM, V380, P277, DOI 10.1007/s11010-013-1682-y; Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105; Lu J, 2008, DEV CELL, V14, P843, DOI 10.1016/j.devcel.2008.03.012; Lv HC, 2014, EXP THER MED, V8, P1575, DOI 10.3892/etm.2014.1942; Ma WL, 2014, TUMOR BIOL, V35, P12467, DOI 10.1007/s13277-014-2565-x; Mirabello L, 2009, CANCER-AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121; Mutsaers AJ, 2013, BONE, V55, P166, DOI 10.1016/j.bone.2013.02.016; Neale G, 2008, CLIN CANCER RES, V14, P4572, DOI 10.1158/1078-0432.CCR-07-5090; Neilsen PM, 2013, ONCOGENE, V32, P2992, DOI 10.1038/onc.2012.305; Ofengeim D, 2013, NAT REV MOL CELL BIO, V14, P727, DOI 10.1038/nrm3683; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; PARKIN DM, 1988, INT J CANCER, V42, P511, DOI 10.1002/ijc.2910420408; Png KJ, 2011, GENE DEV, V25, P226, DOI 10.1101/gad.1974211; Sarver AL, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Sun JX, 2014, ONCOTARGETS THER, V7, P853, DOI 10.2147/OTT.S60888; Tam W, 1997, MOL CELL BIOL, V17, P1490, DOI 10.1128/MCB.17.3.1490; Tang MJ, 2013, ONCOTARGETS THER, V6, P833, DOI 10.2147/OTT.S40080; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Wang Y, 2013, MOL CELL BIOCHEM, V384, P105, DOI 10.1007/s11010-013-1786-4; Wu XY, 2013, INT J MED SCI, V10, P676, DOI 10.7150/ijms.5528; Yang J, 2013, MOL CELL BIOCHEM, V381, P9, DOI 10.1007/s11010-013-1677-8; Yen CC, 2009, INT J ONCOL, V35, P775, DOI 10.3892/ijo_00000390; Yuan J, 2009, CANCER INVEST, V27, P435, DOI 10.1080/07357900802491477; Zhang M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127386; Zhao GY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053906; Zheng BQ, 2011, CLIN CANCER RES, V17, P7574, DOI 10.1158/1078-0432.CCR-11-1714; Zhu A, 2012, MED ONCOL, V29, P2701, DOI 10.1007/s12032-011-0134-3	57	48	50	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5282	5294		10.1038/onc.2016.68	http://dx.doi.org/10.1038/onc.2016.68			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	27041566				2022-12-17	WOS:000386053000007
J	Liu, W; Li, H; Hong, SH; Piszczek, GP; Chen, W; Rodgers, GP				Liu, W.; Li, H.; Hong, S-H; Piszczek, G. P.; Chen, W.; Rodgers, G. P.			Olfactomedin 4 deletion induces colon adenocarcinoma in ApcMin/+ mice	ONCOGENE			English	Article							NF-KAPPA-B; INTESTINAL EPITHELIAL-CELLS; BETA-CATENIN EXPRESSION; STAPHYLOCOCCUS-AUREUS; COLORECTAL-CANCER; HGC-1; ACTIVATION; OLFM4; DIFFERENTIATION; SUSCEPTIBILITY	Colon carcinogenesis is a multiple-step process involving the accumulation of a series of genetic and epigenetic alterations. The most commonly initiating event of intestinal carcinogenesis is mutation of the adenomatous polyposis coli (APC) gene, which leads to activation of the Wnt/beta-catenin pathway. Olfactomedin 4 (OLFM4) has emerged as an intestinal stem-cell marker, but its biological function in the intestine remains to be determined. Here we show that Olfm4 deletion induced colon adenocarcinoma in the distal colon of Apc(Min/+) mice. Mechanistically, we found that OLFM4 is a target gene of the Wnt/beta-catenin pathway and can downregulate beta-catenin signaling by competing with Wnt ligands for binding to Frizzled receptors, as well as by inhibition of the Akt-GSK-3 beta (Akt-glycogen synthase kinase-3 beta) pathway. We have shown that both Wnt and nuclear factor-kappa B (NF-kappa B) signaling were boosted in tumor tissues of Apc Olfm4 double-mutant mice. These data establish OLFM4 as a critical negative regulator of the Wnt/beta-catenin and NF-kappa B pathways that inhibits colon-cancer development initiated by APC mutation. In addition, Olfm4 deletion significantly enhanced intestinal-crypt proliferation and inflammation induced by azoxymethane/dextran sodium sulfate. Thus, OLFM4 has an important role in the regulation of intestinal inflammation and tumorigenesis, and could be a potential therapeutic target for intestinal malignant tumors. Unlike the human colonic epithelium, the mouse colonic epithelium does not express OLFM4, but nevertheless, systemic OLFM4 deletion promotes colon tumorigenesis and that loss from mucosal neutrophils may have a role to play.	[Liu, W.; Li, H.; Hong, S-H; Rodgers, G. P.] NHLBI, Mol & Clin Hematol Branch, NIH, Bldg 10,Room 9N119,9000 Rockville Pike, Bethesda, MD 20892 USA; [Hong, S-H] Natl Canc Ctr, Canc Genom Branch, Goyang Si, Gyeonggi Do, South Korea; [Piszczek, G. P.] NHLBI, Biochem & Biophys Ctr, Bldg 10, Bethesda, MD 20892 USA; [Chen, W.] NIDDK, Genom Core Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Cancer Center - Korea (NCC); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Rodgers, GP (corresponding author), NHLBI, Mol & Clin Hematol Branch, NIH, Bldg 10,Room 9N119,9000 Rockville Pike, Bethesda, MD 20892 USA.	gr5n@nih.gov	Piszczek, Grzegorz/GYU-2029-2022		intramural research fund of the National Institutes of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL006004, ZIGHL006020, ZICHL000338] Funding Source: NIH RePORTER	intramural research fund of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr Michael A Eckhaus, National Institutes of Health, for the pathology assistance and Dr Ivan Ding, National Institutes of Health, for helpful suggestions and review of our manuscript. This study was supported by the intramural research fund of the National Institutes of Health.	Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Besson D, 2011, MOL CELL PROTEOMICS, V10, DOI [10.1074/mcp.M111.009712-1, 10.1074/mcp.M111.009712]; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Chin KL, 2008, BRIT J HAEMATOL, V143, P421, DOI 10.1111/j.1365-2141.2008.07368.x; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; Dinarello CA, 2010, CANCER METAST REV, V29, P317, DOI 10.1007/s10555-010-9229-0; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Gersemann M, 2012, J CROHNS COLITIS, V6, P425, DOI 10.1016/j.crohns.2011.09.013; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inomata M, 1996, CANCER RES, V56, P2213; Kaler P, 2009, CANCER MICROENVIRON, V2, P69, DOI 10.1007/s12307-009-0030-y; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kavandi L, 2012, J CELL BIOCHEM, V113, P3143, DOI 10.1002/jcb.24191; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kwon HS, 2009, MOL CELL BIOL, V29, P2139, DOI 10.1128/MCB.01274-08; Liu WL, 2008, CLIN CANCER RES, V14, P1041, DOI 10.1158/1078-0432.CCR-07-4125; Liu WL, 2006, EXP CELL RES, V312, P1785, DOI 10.1016/j.yexcr.2006.02.011; Liu WL, 2013, J CLIN INVEST, V123, P3751, DOI 10.1172/JCI68453; Liu WL, 2012, J IMMUNOL, V189, P2460, DOI 10.4049/jimmunol.1103179; Liu WL, 2010, BLOOD, V116, P4938, DOI 10.1182/blood-2009-10-246439; Liu WL, 2010, P NATL ACAD SCI USA, V107, P11056, DOI 10.1073/pnas.1001269107; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nakaya N, 2008, J NEUROSCI, V28, P7900, DOI 10.1523/JNEUROSCI.0617-08.2008; Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Rosenbauer F, 2004, BLOOD, V103, P4294, DOI 10.1182/blood-2003-08-2688; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Seko N, 2010, EXP THER MED, V1, P73, DOI 10.3892/etm_00000013; Shinozaki S, 2001, GUT, V48, P623, DOI 10.1136/gut.48.5.623; Van der Flier LG, 2009, GASTROENTEROLOGY, V137, P15, DOI 10.1053/j.gastro.2009.05.035; VanDussen KL, 2012, DEVELOPMENT, V139, P488, DOI 10.1242/dev.070763; Vlantis K, 2011, J CLIN INVEST, V121, P2781, DOI 10.1172/JCI45349; Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003; Zhang JC, 2002, GENE, V283, P83, DOI 10.1016/S0378-1119(01)00763-6	42	48	48	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5237	5247		10.1038/onc.2016.58	http://dx.doi.org/10.1038/onc.2016.58			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	26973250	Green Published, hybrid			2022-12-17	WOS:000386053000003
J	O'Hayre, M; Inoue, A; Kufareva, I; Wang, Z; Mikelis, CM; Drummond, RA; Avino, S; Finkel, K; Kalim, KW; DiPasquale, G; Guo, F; Aoki, J; Zheng, Y; Lionakis, MS; Molinolo, AA; Gutkind, JS				O'Hayre, M.; Inoue, A.; Kufareva, I.; Wang, Z.; Mikelis, C. M.; Drummond, R. A.; Avino, S.; Finkel, K.; Kalim, K. W.; DiPasquale, G.; Guo, F.; Aoki, J.; Zheng, Y.; Lionakis, M. S.; Molinolo, A. A.; Gutkind, J. S.			Inactivating mutations in GNA13 and RHOA in Burkitt's lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the G alpha(13)/RhoA axis in B cells	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTORS; HETEROTRIMERIC G-PROTEINS; SOMATIC MUTATIONS; UVEAL MELANOMA; ALPHA-SUBUNIT; P115 RHOGEF; G12 FAMILY; MIGRATION; GTPASE; ACTIVATION	G proteins and their cognate G protein-coupled receptors (GPCRs) function as critical signal transduction molecules that regulate cell survival, proliferation, motility and differentiation. The aberrant expression and/or function of these molecules have been linked to the growth, progression and metastasis of various cancers. As such, the analysis of mutations in the genes encoding GPCRs, G proteins and their downstream targets provides important clues regarding how these signaling cascades contribute to malignancy. Recent genome-wide sequencing efforts have unveiled the presence of frequent mutations in GNA13, the gene encoding the G protein G alpha(13), in Burkitt's lymphoma and diffuse large B-cell lymphoma (DLBCL). We found that mutations in the downstream target of G alpha(13), RhoA, are also present in Burkitt's lymphoma and DLBCL. By multiple complementary approaches, we now show that that these cancer-specific GNA13 and RHOA mutations are inhibitory in nature, and that the expression of wild-type G alpha(13) in B-cell lymphoma cells with mutant GNA13 has limited impact in vitro but results in a remarkable growth inhibition in vivo. Thus, although G alpha(13) and RhoA activity has previously been linked to cellular transformation and metastatic potential of epithelial cancers, our findings support a tumor suppressive role for G alpha(13) and RhoA in Burkitt's lymphoma and DLBCL.	[O'Hayre, M.; Wang, Z.; Avino, S.; Finkel, K.; Molinolo, A. A.; Gutkind, J. S.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA; [Inoue, A.; Aoki, J.] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi, Japan; [Inoue, A.] Japan Sci & Technol Agcy JST, PRESTO, Kawaguchi, Saitama, Japan; [Kufareva, I.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA; [Mikelis, C. M.] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Biomed Sci, Amarillo, TX USA; [Drummond, R. A.; Lionakis, M. S.] NIAID, Fungal Pathogenesis Unit, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; [Avino, S.] Univ Calabria, Dept Pharm Hlth & Nutr Sci, Arcavacata Di Rende, Cs, Italy; [Kalim, K. W.; Guo, F.; Zheng, Y.] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [DiPasquale, G.] Natl Inst Dent & Craniofacial Res, Mol Physiol & Therapeut Branch, NIH, Bethesda, MD USA; [Aoki, J.] Japan Agcy Med Res & Dev, Core Res Evolut Sci & Technol AMED CREST, AMED, Chiyoda Ku, Tokyo, Japan; [Gutkind, J. S.] UC San Diego Moores Canc Ctr, Dept Pharmacol, 3855 Hlth Sci Dr,0803, La Jolla, CA 92093 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Tohoku University; Japan Science & Technology Agency (JST); University of California System; University of California San Diego; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Calabria; Cincinnati Children's Hospital Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), UC San Diego Moores Canc Ctr, Dept Pharmacol, 3855 Hlth Sci Dr,0803, La Jolla, CA 92093 USA.	sgutkind@ucsd.edu	Mikelis, Constantinos/AGF-9423-2022; Lionakis, Michail/J-8840-2017; Gutkind, J. Silvio/J-1201-2016; Drummond, Rebecca/I-3155-2019	Lionakis, Michail/0000-0003-4994-9500; Gutkind, J. Silvio/0000-0002-5150-4482; Drummond, Rebecca/0000-0001-5424-7074; Kufareva, Irina/0000-0001-9083-7039; Aoki, Junken/0000-0001-9435-1896	National Institute of Dental and Craniofacial Research intramural program at NIH; PRESTO from JST; AMED-CREST from AMED; Division of Intramural Research, NIAID, NIH; NIH [R01 GM071872, R01 AI118985]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001175, R01AI118985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071872] Funding Source: NIH RePORTER	National Institute of Dental and Craniofacial Research intramural program at NIH; PRESTO from JST(Japan Science & Technology Agency (JST)); AMED-CREST from AMED; Division of Intramural Research, NIAID, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by the National Institute of Dental and Craniofacial Research intramural program at NIH. We thank Maria S Degese for her help with immunohistochemistry. AI was funded by PRESTO from JST. JA was funded by AMED-CREST from AMED. We thank Miho Morikawa for technical assistance with the TGF alpha shedding assay. RAD and MSL are supported by the Division of Intramural Research, NIAID, NIH. IK is supported by NIH grants R01 GM071872 and R01 AI118985.	Armbruster BN, 2007, P NATL ACAD SCI USA, V104, P5163, DOI 10.1073/pnas.0700293104; Bachman KE, 2005, CURR OPIN ONCOL, V17, P49, DOI 10.1097/01.cco.0000143682.45316.ae; Cattoretti G, 2009, CANCER RES, V69, P8686, DOI 10.1158/0008-5472.CAN-09-1110; Cools J, 2014, NAT GENET, V46, P320, DOI 10.1038/ng.2937; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Garcia-Marcos M, 2015, J BIOL CHEM, V290, P6697, DOI 10.1074/jbc.R114.613414; Green JA, 2011, NAT IMMUNOL, V12, P672, DOI 10.1038/ni.2047; Gutkind JS, 1998, CONT ENDOCRINOL, V6, P101; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Inoue A, 2012, NAT METHODS, V9, P1021, DOI [10.1038/NMETH.2172, 10.1038/nmeth.2172]; Inoue A, 2011, EMBO J, V30, P4248, DOI 10.1038/emboj.2011.296; Jaffe ES, 2011, HEMATOL-AM SOC HEMAT, P506, DOI 10.1182/asheducation-2011.1.506; Juneja J, 2009, BRIT J PHARMACOL, V158, P32, DOI 10.1111/j.1476-5381.2009.00180.x; Kelly P, 2007, BIOCHEMISTRY-US, V46, P6677, DOI 10.1021/bi700235f; Kelly P, 2006, J BIOL CHEM, V281, P26483, DOI 10.1074/jbc.M604376200; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kufareva I, 2011, STRUCTURE, V19, P1108, DOI 10.1016/j.str.2011.05.012; Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Love C, 2012, NAT GENET, V44, P1321, DOI 10.1038/ng.2468; Manso R, 2014, BLOOD, V123, P2893, DOI 10.1182/blood-2014-02-555946; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Menon MP, 2012, CANCER J, V18, P411, DOI 10.1097/PPO.0b013e31826aee97; Mikelis CM, 2013, J BIOL CHEM, V288, P12232, DOI 10.1074/jbc.M112.428599; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Muppidi JR, 2014, NATURE, V516, P254, DOI 10.1038/nature13765; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Palomero T, 2014, NAT GENET, V46, P166, DOI 10.1038/ng.2873; Qin L, 2015, SCIENCE, V347, P1117, DOI 10.1126/science.1261064; Rasheed SAK, 2013, J BIOL CHEM, V288, P7986, DOI 10.1074/jbc.M112.437749; Rohde M, 2014, GENE CHROMOSOME CANC, V53, P911, DOI 10.1002/gcc.22202; Roschewski M, 2014, NAT REV CLIN ONCOL, V11, P12, DOI 10.1038/nrclinonc.2013.197; Sakata-Yanagimoto M, 2014, NAT GENET, V46, P171, DOI 10.1038/ng.2872; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Wang ZY, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju215; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Yagi H, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002221; Yoo HY, 2014, NAT GENET, V46, P371, DOI 10.1038/ng.2916	47	48	49	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3771	3780		10.1038/onc.2015.442	http://dx.doi.org/10.1038/onc.2015.442			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26616858	Green Accepted			2022-12-17	WOS:000380753200003
J	Arts, FA; Chand, D; Pecquet, C; Velghe, AI; Constantinescu, S; Hallberg, B; Demoulin, JB				Arts, F. A.; Chand, D.; Pecquet, C.; Velghe, A. I.; Constantinescu, S.; Hallberg, B.; Demoulin, J-B			PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib	ONCOGENE			English	Article							GASTROINTESTINAL STROMAL TUMORS; BASAL GANGLIA CALCIFICATION; RECEPTOR TYROSINE KINASES; CELL-TRANSFORMATION; ACTIVATING MUTATION; OF-FUNCTION; GROWTH; GENE; GAIN; DISORDERS	Recently, germline and somatic heterozygous mutations in the platelet-derived growth factor receptor beta (PDGFRB) have been associated with familial infantile myofibromatosis (IM), which is characterized by soft tissue tumors, and overgrowth syndrome, a disease that predisposes to cancer. These mutations have not been functionally characterized. In the present study, the activity of three PDGFRB mutants associated with familial IM (R561C, P660T and N666K) and one PDGFRB mutant found in patients with overgrowth syndrome (P584R) was tested in various models. The P660T mutant showed no difference with the wild-type receptor, suggesting that it might represent a polymorphic variant unrelated to the disease. By contrast, the three other mutants were constitutively active and able to transform NIH3T3 and Ba/F3 cells to different extents. In particular, the germline mutant identified in overgrowth syndrome, P584R, was a stronger oncogene than the germline R561C mutant associated with myofibromatosis. The distinct phenotypes associated with these two mutations could be related to this difference of potency. Importantly, all activated mutants were sensitive to tyrosine kinase inhibitors such as imatinib, nilotinib and ponatinib. In conclusion, the PDGFRB mutations previously identified in familial IM and overgrowth syndrome activate the receptor in the absence of ligand, supporting the hypothesis that these mutations cause the diseases. Moreover, imatinib seems to be a promising treatment for patients carrying these mutations. To our knowledge, these are the first confirmed gain-of-function point mutations of PDGFRB in human cancer.	[Arts, F. A.; Pecquet, C.; Velghe, A. I.; Constantinescu, S.; Demoulin, J-B] Catholic Univ Louvain, Duve Inst, Ave Hippocrate 75,Box B1-74-05, B-1200 Brussels, Belgium; [Chand, D.; Hallberg, B.] Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Dept Med Biochem & Cell Biol, Gothenburg, Sweden; [Chand, D.] Umea Univ, Dept Mol Biol, Umea, Sweden; [Pecquet, C.; Constantinescu, S.] Ludwig Inst Canc Res, Brussels, Belgium	Universite Catholique Louvain; University of Gothenburg; Umea University; Ludwig Institute for Cancer Research	Demoulin, JB (corresponding author), Catholic Univ Louvain, Duve Inst, Ave Hippocrate 75,Box B1-74-05, B-1200 Brussels, Belgium.	jb.demoulin@uclouvain.be		Demoulin, Jean-Baptiste/0000-0002-8016-6689; Christian, Pecquet/0000-0002-8623-3483; Constantinescu, Stefan N./0000-0002-8599-2699	FRS-FNRS - Televie [7.4501.13 F]	FRS-FNRS - Televie(Fonds de la Recherche Scientifique - FNRS)	We would like to thank Nicolas Dauguet for cell sorting, and Anabelle Decottignies, Guy Warnier and Laure Dumoutier for generous donation of reagents. We are grateful to Ahmed Essaghir for statistical analysis. FAA is the recipient of a fellowship from FRS-FNRS - Televie (grant number 7.4501.13 F).	Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Ang P, 2004, CUTIS, V73, P229; Arts FA, 2015, J CELL MOL MED, V19, P239, DOI 10.1111/jcmm.12443; Barker KT, 2003, EUR J HUM GENET, V11, P665, DOI 10.1038/sj.ejhg.5201026; BRACKO M, 1992, CANCER-AM CANCER SOC, V69, P1294; Cheung YH, 2013, AM J HUM GENET, V92, P996, DOI 10.1016/j.ajhg.2013.04.026; Chiara F, 2004, J BIOL CHEM, V279, P42516, DOI 10.1074/jbc.M406051200; CHUNG EB, 1981, CANCER, V48, P1807, DOI 10.1002/1097-0142(19811015)48:8<1807::AID-CNCR2820480818>3.0.CO;2-G; Corless CL, 2005, J CLIN ONCOL, V23, P5357, DOI 10.1200/JCO.2005.14.068; David M, 2007, BLOOD, V109, P61, DOI 10.1182/blood-2006-05-024828; Demoulin JB, 2000, CANCER RES, V60, P3971; Demoulin JB, 2003, ONCOGENE, V22, P1763, DOI 10.1038/sj.onc.1206253; Demoulin JB, 2014, CYTOKINE GROWTH F R, V25, P273, DOI 10.1016/j.cytogfr.2014.03.003; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heldin CH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-97; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; KEATING MT, 1989, J BIOL CHEM, V264, P9129; Lacerda LD, 2014, RADIOL RES PRACT, V2014, DOI 10.1155/2014/947451; Li-Wan-Po A, 2010, EUR J CLIN PHARMACOL, V66, P369, DOI 10.1007/s00228-009-0779-4; Lindhurst MJ, 2011, NEW ENGL J MED, V365, P611, DOI 10.1056/NEJMoa1104017; Linhares ND, 2014, GENET MOL RES, V13, P6287, DOI 10.4238/2014.August.15.11; Looman C, 2007, INT J DEV BIOL, V51, P361, DOI 10.1387/ijdb.072301cl; Martignetti JA, 2013, AM J HUM GENET, V92, P1001, DOI 10.1016/j.ajhg.2013.04.024; Mashiah J, 2014, J AM ACAD DERMATOL, V71, P264, DOI 10.1016/j.jaad.2014.03.035; Medves S, 2010, LEUKEMIA, V24, P1052, DOI 10.1038/leu.2010.13; Medves S, 2011, HAEMATOL-HEMATOL J, V96, P1406, DOI 10.3324/haematol.2011.040147; Miklossy J, 2005, ACTA NEUROPATHOL, V109, P643, DOI 10.1007/s00401-005-1007-7; Millot F, 2014, EUR J CANCER, V50, P3206, DOI 10.1016/j.ejca.2014.10.007; Nakahara M, 1998, GASTROENTEROLOGY, V115, P1090, DOI 10.1016/S0016-5085(98)70079-4; Nicolas G, 2013, BRAIN, V136, P3395, DOI 10.1093/brain/awt255; Nicolas G, 2013, NEUROLOGY, V80, P181, DOI 10.1212/WNL.0b013e31827ccf34; Noel LA, 2014, MOL ONCOL, V8, P728, DOI 10.1016/j.molonc.2014.02.003; Schonherr C, 2011, BIOCHEM J, V440, P405, DOI 10.1042/BJ20101796; Soriano P, 1997, DEVELOPMENT, V124, P2691; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Toffalini F, 2010, BLOOD, V116, P2429, DOI 10.1182/blood-2010-04-279752; Velghe AI, 2014, ONCOGENE, V33, P2568, DOI 10.1038/onc.2013.218; Verstraete K, 2012, NAT REV CANCER, V12, P753, DOI 10.1038/nrc3371; WISWELL TE, 1985, PEDIATRICS, V76, P981; Zand DJ, 2004, AM J MED GENET A, V126A, P261, DOI 10.1002/ajmg.a.20598	40	48	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3239	3248		10.1038/onc.2015.383	http://dx.doi.org/10.1038/onc.2015.383			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26455322				2022-12-17	WOS:000378306400003
J	Koufaris, C; Valbuena, GN; Pomyen, Y; Tredwell, GD; Nevedomskaya, E; Lau, CHE; Yang, T; Benito, A; Ellis, JK; Keun, HC				Koufaris, C.; Valbuena, G. N.; Pomyen, Y.; Tredwell, G. D.; Nevedomskaya, E.; Lau, C-H E.; Yang, T.; Benito, A.; Ellis, J. K.; Keun, H. C.			Systematic integration of molecular profiles identifies miR-22 as a regulator of lipid and folate metabolism in breast cancer cells	ONCOGENE			English	Article							DIFFERENTIAL EXPRESSION ANALYSIS; ATP-CITRATE LYASE; TUMOR-SUPPRESSOR; BIOCONDUCTOR PACKAGE; MICRORNA-22; CONTRIBUTES; MODEL; PROLIFERATION; TRANSCRIPTION; SIGNATURE	Dysregulated microRNA (miRNA) mediate malignant phenotypes, including metabolic reprogramming. By performing an integrative analysis of miRNA and metabolome data for the NCI-60 cell line panel, we identified an miRNA cluster strongly associated with both c-Myc expression and global metabolic variation. Within this cluster the cancer-associated and cardioprotective miR-22 was shown to repress fatty acid synthesis and elongation in tumour cells by targeting ATP citrate lyase and fatty acid elongase 6, as well as impairing mitochondrial one-carbon metabolism by suppression of methylene tetrahydrofolate dehydrogenase/cyclohydrolase. Across several data sets, expression of these target genes were associated with poorer outcomes in breast cancer patients. Importantly, a beneficial effect of miR-22 on clinical outcomes in breast cancer was shown to depend on the expression levels of the identified target genes, demonstrating the relevance of miRNA/mRNA interactions to disease progression in vivo. Our systematic analysis establishes miR-22 as a novel regulator of tumour cell metabolism, a function that could contribute to the role of this miRNA in cellular differentiation and cancer development. Moreover, we provide a paradigmatic example of effect modification in outcome analysis as a consequence of miRNA-directed gene targeting, a phenomenon that could be exploited to improve patient prognosis and treatment.	[Koufaris, C.; Valbuena, G. N.; Pomyen, Y.; Tredwell, G. D.; Lau, C-H E.; Yang, T.; Benito, A.; Ellis, J. K.; Keun, H. C.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Surg & Canc, Div Canc, London, England; [Koufaris, C.] Cyprus Inst Neurol & Genet, Dept Cytogenet & Genom, Nicosia, Cyprus; [Pomyen, Y.] Chulabhorn Res Inst, Translat Res Unit, Bangkok, Thailand; [Nevedomskaya, E.] Leiden Univ, Med Ctr, Ctr Prote & Metabol, Leiden, Netherlands; [Keun, H. C.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Ctr Syst Oncol & Canc Innovat, London, England	Imperial College London; Chulabhorn Research Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Imperial College London	Keun, HC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Div Canc, Inst Reprod & Dev Biol,Hammersmith Hosp, London W12 0NN, England.	h.keun@imperial.ac.uk	Koufaris, Costas/ABW-5036-2022; Lau, ChungHo/K-3557-2019; Tredwell, Greg/L-2294-2015	Koufaris, Costas/0000-0002-1222-5130; Lau, ChungHo/0000-0002-3602-8326; Tredwell, Greg/0000-0002-0020-5626; Benito, Adrian/0000-0002-8088-9537; Pomyen, Yotsawat/0000-0002-1070-3047; Valbuena, Gabriel/0000-0001-6825-7214	European Community's Seventh Framework Programme-Health project DETECTIVE [266838]; Cancer Research UK programme grant [A15115]; EC project Euro-MOTOR [259867]; UK Biotechnology and Biological Sciences Research Council (BBSRC) PhD studentship [BB/F529270/1]; Royal Thai Government Scholarship; UK MRC PhD studentship (Imperial College London Faculty of Medicine Doctoral Training Award); EC project HeCaTos [602156]; Medical Research Council [1416153] Funding Source: researchfish	European Community's Seventh Framework Programme-Health project DETECTIVE; Cancer Research UK programme grant(Cancer Research UK); EC project Euro-MOTOR; UK Biotechnology and Biological Sciences Research Council (BBSRC) PhD studentship; Royal Thai Government Scholarship; UK MRC PhD studentship (Imperial College London Faculty of Medicine Doctoral Training Award); EC project HeCaTos; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	HK, CK, GT and JE acknowledge support by the European Community's Seventh Framework Programme-Health (FP7/2007-2013) project DETECTIVE (grant agreement number 266838). HK and JE are also supported by Cancer Research UK programme grant A15115. HK and GV are supported by the EC FP7/2007-2013 project Euro-MOTOR (grant agreement number 259867). CHL is supported by a UK Biotechnology and Biological Sciences Research Council (BBSRC) PhD studentship (grant number BB/F529270/1 for the Institute of Chemical Biology (Imperial College London) Doctoral Training Centre). YP is supported by a Royal Thai Government Scholarship. TY is supported by a UK MRC PhD studentship (Imperial College London Faculty of Medicine Doctoral Training Award). AB is supported by the EC FP7/20132018 project HeCaTos (grant agreement number 602156). We also acknowledge valuable discussions with Dr Charlotte Bevan, Professor Charles Coombes, Dr Jake Bundy, Professor Nigel Gooderham and Dr Tim Ebbels.	Alvarez-Diaz S, 2012, HUM MOL GENET, V21, P2157, DOI 10.1093/hmg/dds031; Anastasiou D, 2012, NAT CHEM BIOL, V8, P839, DOI 10.1038/NCHEMBIO.1060; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Behrends V, 2011, ANAL BIOCHEM, V415, P206, DOI 10.1016/j.ab.2011.04.009; Bylesjo M, 2007, PLANT J, V52, P1181, DOI 10.1111/j.1365-313X.2007.03293.x; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Christodoulou F, 2010, NATURE, V463, P1084, DOI 10.1038/nature08744; Doria ML, 2014, FASEB J, V28, P4247, DOI 10.1096/fj.14-249672; Duarte NC, 2007, P NATL ACAD SCI USA, V104, P1777, DOI 10.1073/pnas.0610772104; Eichner LJ, 2010, CELL METAB, V12, P352, DOI 10.1016/j.cmet.2010.09.002; Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236; Farazi TA, 2011, CANCER RES, V71, P4443, DOI 10.1158/0008-5472.CAN-11-0608; Frezza C, 2011, NATURE, V477, P225, DOI 10.1038/nature10363; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Guillou H, 2010, PROG LIPID RES, V49, P186, DOI 10.1016/j.plipres.2009.12.002; Gurha P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075882; Gurha P, 2012, CIRCULATION, V125, P2751, DOI 10.1161/CIRCULATIONAHA.111.044354; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Helton JC, 2006, RELIAB ENG SYST SAFE, V91, P1175, DOI 10.1016/j.ress.2005.11.017; Huang ZP, 2013, CIRC RES, V112, P1234, DOI 10.1161/CIRCRESAHA.112.300682; Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; KELLEHER JK, 1992, AM J PHYSIOL, V262, pE118, DOI 10.1152/ajpendo.1992.262.1.E118; Kirwan GM, 2012, ANAL CHEM, V84, P7064, DOI 10.1021/ac301269r; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kong LM, 2014, CANCER RES, V74, P3764, DOI 10.1158/0008-5472.CAN-13-3555; Kuchen S, 2010, IMMUNITY, V32, P828, DOI 10.1016/j.immuni.2010.05.009; Lehtinen L, 2013, ONCOTARGET, V4, P48, DOI 10.18632/oncotarget.756; Liu W, 2012, P NATL ACAD SCI USA, V109, P8983, DOI 10.1073/pnas.1203244109; LligonaTrulla L, 1997, J LIPID RES, V38, P1454; Lu TP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042390; Marzi MJ, 2012, J CELL BIOL, V199, P77, DOI 10.1083/jcb.201206033; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; Meiri E, 2010, NUCLEIC ACIDS RES, V38, P6234, DOI 10.1093/nar/gkq376; Migita T, 2014, INT J CANCER, V135, P37, DOI 10.1002/ijc.28652; Millard P, 2012, BIOINFORMATICS, V28, P1294, DOI 10.1093/bioinformatics/bts127; Muir K, 2013, CANCER RES, V73, P4722, DOI 10.1158/0008-5472.CAN-12-3797; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; National Cancer Institute, MOL TARG DAT NCI NIH; Nilsson R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4128; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Pandey DP, 2009, MOL CELL BIOL, V29, P3783, DOI 10.1128/MCB.01875-08; Patel JB, 2011, ONCOGENE, V30, P1290, DOI 10.1038/onc.2010.510; Pike ST, 2010, J BIOL CHEM, V285, P4612, DOI 10.1074/jbc.M109.079855; Polioudakis D, 2013, NUCLEIC ACIDS RES, V41, P2239, DOI 10.1093/nar/gks1452; Rantalainen M, 2006, J PROTEOME RES, V5, P2642, DOI 10.1021/pr060124w; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Shin M, 2014, J BIOL CHEM, V289, P15507, DOI 10.1074/jbc.M114.555573; Sokilde R, 2011, MOL CANCER THER, V10, P375, DOI 10.1158/1535-7163.MCT-10-0605; Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026; Song SJ, 2013, CELL STEM CELL, V13, P87, DOI 10.1016/j.stem.2013.06.003; Stein SE, 1999, J AM SOC MASS SPECTR, V10, P770, DOI 10.1016/S1044-0305(99)00047-1; Tedeschi PM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.393; Therneau T. M, 2020, SURVIVAL SURVIVAL AN; Trygg J, 2002, J CHEMOMETR, V16, P283, DOI 10.1002/cem.724; Trygg J, 2003, J CHEMOMETR, V17, P53, DOI 10.1002/cem.775; Tsuchiya N, 2011, CANCER RES, V71, P4628, DOI 10.1158/0008-5472.CAN-10-2475; Vecchione A, 2013, P NATL ACAD SCI USA, V110, P9845, DOI 10.1073/pnas.1305472110; Volinia S, 2013, P NATL ACAD SCI USA, V110, P7413, DOI 10.1073/pnas.1304977110; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Wilson CL, 2005, BIOINFORMATICS, V21, P3683, DOI 10.1093/bioinformatics/bti605; Xiong J, 2010, ONCOGENE, V29, P4980, DOI 10.1038/onc.2010.241; Xu D, 2011, J CELL BIOL, V193, P409, DOI 10.1083/jcb.201010100; Xu XD, 2012, J CELL PHYSIOL, V227, P1391, DOI 10.1002/jcp.22852; Zaidi N, 2012, CANCER RES, V72, P3709, DOI 10.1158/0008-5472.CAN-11-4112; Zhang J, 2010, BRIT J CANCER, V103, P1215, DOI 10.1038/sj.bjc.6605895; Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033	74	48	51	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2766	2776		10.1038/onc.2015.333	http://dx.doi.org/10.1038/onc.2015.333			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26477310	Green Submitted			2022-12-17	WOS:000377472700010
J	Bousquet, E; Calvayrac, O; Mazieres, J; Lajoie-Mazenc, I; Boubekeur, N; Favre, G; Pradines, A				Bousquet, E.; Calvayrac, O.; Mazieres, J.; Lajoie-Mazenc, I.; Boubekeur, N.; Favre, G.; Pradines, A.			RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition	ONCOGENE			English	Article							PROTEIN PHOSPHATASE 2A; TYROSINE PHOSPHORYLATION; INCREASED EXPRESSION; CANCER; AKT; CARCINOMA; SUBUNIT; GROWTH; SLUG; TRANSFORMATION	Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide, which is mainly due to its high risk of metastatic dissemination. One critical point of this process is the ability of cancer cells to detach from the primary tumor and migrate through the extracellular matrix; however, the underlying molecular mechanisms are not yet fully understood. In the present study, we identified the small GTPase RhoB as a key regulator of bronchial cell morphology in a three-dimensional (3D) matrix. RhoB loss, which is frequently observed during lung cancer progression, induced an epithelial-mesenchymal transition (EMT) characterized by an increased proportion of invasive elongated cells in 3D. The process was mediated by Slug induction and E-cadherin repression. In addition, downregulation of RhoB induced Akt1 activation, which in turn activated Rac1 through the guanine-exchange factor Trio to control cell shape rearrangement. Further, we provide evidence that RhoB interacted with and positively regulates phosphatase PP2A through the recruitment of its regulatory subunit B55, which was found to be crucial for Akt dephosphorylation. B55 inhibition completely suppressed RhoB-mediated PP2A regulation. Finally, we show that PP2A inactivation, by targeting either its catalytic or its regulatory B55 subunit, completely reversed RhoB-dependent morphological changes and also fully prevented the ability of RhoB to decrease the invasiveness of bronchial cells. Altogether, these results highlight a novel signaling axis and describe new molecular mechanisms that could explain the tumor suppressor role of RhoB in lung cancer. Therefore, we propose that RhoB could be responsible for early metastatic prevention by inhibiting the EMT-derived invasiveness of lung cells through the control of PP2A activity.	[Bousquet, E.; Calvayrac, O.; Mazieres, J.; Lajoie-Mazenc, I.; Boubekeur, N.; Favre, G.; Pradines, A.] INSERM, UMR 1037, CRCT, Toulouse, France; [Bousquet, E.; Calvayrac, O.; Mazieres, J.; Lajoie-Mazenc, I.; Boubekeur, N.; Favre, G.; Pradines, A.] Univ Toulouse 3, F-31062 Toulouse, France; [Bousquet, E.; Calvayrac, O.; Lajoie-Mazenc, I.; Boubekeur, N.; Favre, G.; Pradines, A.] Inst Claudius Regaud, Dept Biol, Toulouse, France; [Mazieres, J.] CHU Toulouse, Dept Pneumol, Hop Larrey, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; UNICANCER; Institut Claudius Regaud; CHU de Toulouse	Pradines, A (corresponding author), Inst Univ Canc Toulouse Oncopole, 1 Ave Irene Joliot Curie, F-31059 Toulouse, France.	pradines.anne@iuct-oncopole.fr	Pradines, Anne/M-3935-2014; Lajoie-Mazenc, Isabelle/M-4636-2014; MAZIERES, JULIEN/M-3986-2014; FAVRE, Gilles/K-9189-2014; Calvayrac, Olivier/A-7145-2016	Pradines, Anne/0000-0002-2449-678X; FAVRE, Gilles/0000-0002-2344-1883; Calvayrac, Olivier/0000-0002-0908-8323; MAZIERES, JULIEN/0000-0002-5921-7613	INSERM (Institut National de la Sante et de la Recherche Medicale); Groupe de Recherche Institut Claudius Regaud; Foundation Recherche et Innovation Therapeutique en Cancerologie; INCa (Institut National du Cancer) France	INSERM (Institut National de la Sante et de la Recherche Medicale)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Groupe de Recherche Institut Claudius Regaud; Foundation Recherche et Innovation Therapeutique en Cancerologie; INCa (Institut National du Cancer) France	We are grateful to Professor Alain Puisieux (CRCL, Lyon, France) for his helpful comments on the manuscript. We thank Remi Gence for helping with recombinant proteins. This work was supported by grants from INSERM (Institut National de la Sante et de la Recherche Medicale), Groupe de Recherche Institut Claudius Regaud, the Foundation Recherche et Innovation Therapeutique en Cancerologie and INCa (Institut National du Cancer) France.	Adnane J, 2002, CLIN CANCER RES, V8, P2225; Barber Mark A, 2006, Bull Cancer, V93, pE44; Bellovin DI, 2006, ONCOGENE, V25, P6959, DOI 10.1038/sj.onc.1209682; Benefield Janet, 1997, Invasion and Metastasis, V17, P210; Bousquet E, 2009, CANCER RES, V69, P6092, DOI 10.1158/0008-5472.CAN-08-4147; Bustelo XR, 2012, BIOESSAYS, V34, P748, DOI 10.1002/bies.201200041; Calvayrac O, 2014, CLIN CANCER RES, V20, P6541, DOI 10.1158/1078-0432.CCR-14-0506; Carpenter RL, 2014, ONCOGENE, V34, P546; CHEN J, 1994, J BIOL CHEM, V269, P7957; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Cordonnier T, 2015, INT J CANCER, V136, pE496, DOI 10.1002/ijc.29122; DeGeer J, 2013, MOL CELL BIOL, V33, P739, DOI 10.1128/MCB.01264-12; Delord JP, 2010, BRIT J CANCER, V103, P61, DOI 10.1038/sj.bjc.6605699; Fenouille N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040378; Fortin SP, 2012, MOL CANCER RES, V10, P958, DOI 10.1158/1541-7786.MCR-11-0616; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gerald D, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3824; Grise F, 2012, HEPATOLOGY, V55, P1766, DOI 10.1002/hep.25568; Ho HH, 2013, TOXICOL APPL PHARM, V266, P76, DOI 10.1016/j.taap.2012.10.019; Jackson Jodi, 1997, Invasion and Metastasis, V17, P199; Kazerounian S, 2013, CANCER RES, V73, P50, DOI 10.1158/0008-5472.CAN-11-3055; Kuo YC, 2008, J BIOL CHEM, V283, P1882, DOI 10.1074/jbc.M709585200; Lee WJ, 2007, PROTEOMICS, V7, P206, DOI 10.1002/pmic.200600480; Li YY, 2014, IUBMB LIFE, V66, P507, DOI 10.1002/iub.1285; Li Yong, 2011, Genes Cancer, V2, P880, DOI 10.1177/1947601911433129; Liao Y, 2010, AM J TRANSL RES, V2, P19; Lin CH, 2014, MOL CELL BIOCHEM, V395, P135, DOI 10.1007/s11010-014-2119-y; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Mamouni K, 2014, MOL CELL BIOL, V34, P3144, DOI 10.1128/MCB.01525-13; Mao KP, 2014, SCI WORLD J, DOI 10.1155/2014/908326; Mazieres J, 2004, CLIN CANCER RES, V10, P2742, DOI 10.1158/1078-0432.CCR-03-0149; Mazieres J, 2005, EXP CELL RES, V304, P354, DOI 10.1016/j.yexcr.2004.10.019; Merikallio H, 2014, INT J CLIN EXP PATHO, V7, P5846; Nakada N, 2005, CELL PHYSIOL BIOCHEM, V15, P19, DOI 10.1159/000083635; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rintoul RC, 2001, LANCET ONCOL, V2, P437, DOI 10.1016/S1470-2045(00)00421-6; Rocher G, 2007, J BIOL CHEM, V282, P5468, DOI 10.1074/jbc.M609712200; Ruvolo PP, 2011, LEUKEMIA, V25, P1711, DOI 10.1038/leu.2011.146; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Sato N, 2007, INT J CANCER, V120, P543, DOI 10.1002/ijc.22328; Schmidt Susanne, 2014, Small GTPases, V5, pe29769, DOI 10.4161/sgtp.29769; Sents W, 2013, FEBS J, V280, P644, DOI 10.1111/j.1742-4658.2012.08579.x; Seshacharyulu P, 2013, CANCER LETT, V335, P9, DOI 10.1016/j.canlet.2013.02.036; Shi-wen X, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007438; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; van Rijssel J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029912; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Vega FM, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0085-y; Wang SW, 2003, ONCOGENE, V22, P6204, DOI 10.1038/sj.onc.1206653; Wheeler AP, 2007, EXP CELL RES, V313, P3505, DOI 10.1016/j.yexcr.2007.07.014; Zhang DQ, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-241; Zhang YZ, 2011, MOL CELL BIOCHEM, V357, P363, DOI 10.1007/s11010-011-0907-1; Zhou JT, 2011, INT J CANCER, V128, P1057, DOI 10.1002/ijc.25445	58	48	48	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1760	1769		10.1038/onc.2015.240	http://dx.doi.org/10.1038/onc.2015.240			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26148238	Green Published			2022-12-17	WOS:000373610400003
J	Dickreuter, E; Eke, I; Krause, M; Borgmann, K; van Vugt, MA; Cordes, N				Dickreuter, E.; Eke, I.; Krause, M.; Borgmann, K.; van Vugt, M. A.; Cordes, N.			Targeting of beta 1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; CONTEXTUAL SYNTHETIC LETHALITY; FOCAL ADHESION KINASE; EXTRACELLULAR-MATRIX; INHIBITION; INTEGRINS; PATHWAY; KU; PROLIFERATION; FIBRONECTIN	beta 1 Integrin-mediated cell-extracellular matrix interactions allow cancer cell survival and confer therapy resistance. It was shown that inhibition of beta 1 integrins sensitizes cells to radiotherapy. Here, we examined the impact of beta 1 integrin targeting on the repair of radiation-induced DNA double-strand breaks (DSBs). beta 1 Integrin inhibition was accomplished using the monoclonal antibody AIIB2 and experiments were performed in three-dimensional cell cultures and tumor xenografts of human head and neck squamous cell carcinoma (HNSCC) cell lines. AIIB2, X-ray irradiation, small interfering RNA-mediated knockdown and Olaparib treatment were performed and residual DSB number, protein and gene expression, non-homologous end joining (NHEJ) activity as well as clonogenic survival were determined. beta 1 Integrin targeting impaired repair of radiogenic DSB (gamma H2AX/53BP1, pDNA-PKcs T2609 foci) in vitro and in vivo and reduced the protein expression of Ku70, Rad50 and Nbs1. Further, we identified Ku70, Ku80 and DNA-PKcs but not poly(ADP-ribose) polymerase (PARP)-1 to reside in the beta 1 integrin pathway. Intriguingly, combined inhibition of beta 1 integrin and PARP using Olaparib was significantly more effective than either treatment alone in non-irradiated and irradiated HNSCC cells. Here, we support beta 1 integrins as potential cancer targets and highlight a regulatory role for beta 1 integrins in the repair of radiogenic DNA damage via classical NHEJ. Further, the data suggest combined targeting of beta 1 integrin and PARP as promising approach for radiosensitization of HNSCC.	[Dickreuter, E.; Eke, I.; Krause, M.; Cordes, N.] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Fac Med, OncoRay Natl Ctr Radiat Res Oncol, D-01062 Dresden, Germany; [Dickreuter, E.; Eke, I.; Krause, M.; Cordes, N.] Helmholtz Zentrum Dresden Rossendorf, D-01314 Dresden, Germany; [Eke, I.; Krause, M.; Cordes, N.] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Radiat Oncol, D-01062 Dresden, Germany; [Krause, M.; Cordes, N.] Helmholtz Zentrum Dresden Rossendorf, Inst Radiooncol, D-01314 Dresden, Germany; [Krause, M.; Cordes, N.] German Canc Consortium DKTK, D-01307 Dresden, Germany; [Krause, M.; Cordes, N.] German Canc Res Ctr, Heidelberg, Germany; [Borgmann, K.] Univ Med Ctr Hamburg Eppendorf, Clin Radiotherapy & Radiooncol, Lab Radiobiol & Expt Radiooncol, Hamburg, Germany; [van Vugt, M. A.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR); Technische Universitat Dresden; Carl Gustav Carus University Hospital; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Groningen	Cordes, N (corresponding author), Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Fac Med, OncoRay Natl Ctr Radiat Res Oncol, Fetscherstr 74-PF 41, D-01307 Dresden, Germany.	Nils.Cordes@OncoRay.de	; Eke, Iris/B-9251-2016	Krause, Mechthild/0000-0003-1776-9556; Eke, Iris/0000-0002-3591-019X; Cordes, Nils/0000-0001-5684-629X	Deutsche Krebshilfe e.V. [108976]; EFRE Europaische Fonds fur regionale Entwicklung, Europa fordert Sachsen [100066308]	Deutsche Krebshilfe e.V.(Deutsche Krebshilfe); EFRE Europaische Fonds fur regionale Entwicklung, Europa fordert Sachsen	The research and authors were funded in part by the Deutsche Krebshilfe e.V. (108976 to N.C.) and the EFRE Europaische Fonds fur regionale Entwicklung, Europa fordert Sachsen (100066308). We are grateful to R Grenman for providing HNSCC cell lines, DD Schlaepfer for providing mouse FAK cDNA and J Stark for providing NHEJ reporter plasmids. We further thank I Lange for performing real-time PCR experiments, L Stolz-Kieslich and A Zielinski for technical assistance and I Kurth for help with FACS analysis. We appreciate critical reading of the manuscript by E Hammond and A Vehlow.	Albert M, 2012, RADIOTHER ONCOL, V104, P230, DOI 10.1016/j.radonc.2012.06.010; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Barkan D, 2010, EUR J CANCER, V46, P1181, DOI 10.1016/j.ejca.2010.02.027; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Borgmann K, 2004, INT J RADIAT ONCOL, V58, P445, DOI 10.1016/j.ijrobp.2003.09.036; Chan N, 2010, CANCER RES, V70, P8045, DOI 10.1158/0008-5472.CAN-10-2352; Chan N, 2010, CLIN CANCER RES, V16, P4553, DOI 10.1158/1078-0432.CCR-10-0527; Chapman JR, 2012, MOL CELL, V47, P497, DOI 10.1016/j.molcel.2012.07.029; Cheng Q, 2011, NUCLEIC ACIDS RES, V39, P9605, DOI 10.1093/nar/gkr656; Couto CAM, 2011, J CELL BIOL, V194, P367, DOI 10.1083/jcb.201012132; Eke I, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju419; Eke I, 2015, SEMIN CANCER BIOL, V31, P65, DOI 10.1016/j.semcancer.2014.07.009; Eke I, 2013, CANCER RES, V73, P5869, DOI 10.1158/0008-5472.CAN-13-0344; Eke I, 2013, CANCER RES, V73, P297, DOI 10.1158/0008-5472.CAN-12-2021; Eke I, 2012, INT J RADIAT ONCOL, V84, pE515, DOI 10.1016/j.ijrobp.2012.06.012; Eke I, 2012, J CLIN INVEST, V122, P1529, DOI 10.1172/JCI61350; Estrugo D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000269; Hammel M, 2010, J BIOL CHEM, V285, P1414, DOI 10.1074/jbc.M109.065615; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hehlgans S, 2007, BBA-REV CANCER, V1775, P163, DOI 10.1016/j.bbcan.2006.09.001; Hehlgans S, 2012, INT J RADIAT ONCOL, V83, pE669, DOI 10.1016/j.ijrobp.2012.01.065; Hehlgans S, 2009, RADIOTHER ONCOL, V92, P371, DOI 10.1016/j.radonc.2009.08.001; Helleday T, 2005, CELL CYCLE, V4, P1176, DOI 10.4161/cc.4.9.2031; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jean C, 2011, ONCOGENE, V30, P2697, DOI 10.1038/onc.2011.27; Jean C, 2014, J CELL BIOL, V204, P247, DOI 10.1083/jcb.201307067; Jones CB, 2001, MOL PHARMACOL, V59, P69, DOI 10.1124/mol.59.1.69; Klein TJ, 2010, SEMIN RADIAT ONCOL, V20, P282, DOI 10.1016/j.semradonc.2010.05.006; Kotter A, 2014, MOL ONCOL, V8, P1616, DOI 10.1016/j.molonc.2014.06.008; Krajewska M, 2013, ONCOGENE, V32, P3001, DOI 10.1038/onc.2012.296; Krause M, 2007, RADIOTHER ONCOL, V83, P316, DOI 10.1016/j.radonc.2007.04.014; Kumareswaran R, 2012, J CELL SCI, V125, P189, DOI 10.1242/jcs.092262; Mahaney BL, 2009, BIOCHEM J, V417, P639, DOI 10.1042/BJ20080413; Mansour WY, 2013, DNA REPAIR, V12, P1134, DOI 10.1016/j.dnarep.2013.10.005; Mansour WY, 2010, NUCLEIC ACIDS RES, V38, P6065, DOI 10.1093/nar/gkq387; Mladenov E, 2011, MUTAT RES-FUND MOL M, V711, P61, DOI 10.1016/j.mrfmmm.2011.02.005; Park CC, 2008, CANCER RES, V68, P4398, DOI 10.1158/0008-5472.CAN-07-6390; Peng YL, 2002, CANCER RES, V62, P6400; Rose JL, 2007, J PHARMACOL EXP THER, V321, P318, DOI 10.1124/jpet.106.113498; Serrels A, 2012, INT J CANCER, V131, P287, DOI 10.1002/ijc.26351; Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Spagnolo L, 2006, MOL CELL, V22, P511, DOI 10.1016/j.molcel.2006.04.013; Storch K, 2010, CANCER RES, V70, P3925, DOI 10.1158/0008-5472.CAN-09-3848; Tomar A, 2009, CURR OPIN CELL BIOL, V21, P676, DOI 10.1016/j.ceb.2009.05.006; Tutt ANJ, 2005, COLD SH Q B, V70, P139, DOI 10.1101/sqb.2005.70.012; Vandersickel V, 2010, J RADIAT RES, V51, P633, DOI 10.1269/jrr.10033; Williams GJ, 2010, DNA REPAIR, V9, P1299, DOI 10.1016/j.dnarep.2010.10.001; Yan H, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-50	50	48	48	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1353	1362		10.1038/onc.2015.212	http://dx.doi.org/10.1038/onc.2015.212			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26073085				2022-12-17	WOS:000372196400002
J	Xi, G; Hayes, E; Lewis, R; Ichi, S; Mania-Farnell, B; Shim, K; Takao, T; Allender, E; Mayanil, CS; Tomita, T				Xi, G.; Hayes, E.; Lewis, R.; Ichi, S.; Mania-Farnell, B.; Shim, K.; Takao, T.; Allender, E.; Mayanil, C. S.; Tomita, T.			CD133 and DNA-PK regulate MDR1 via the PI3K-or Akt-NF-kappa B pathway in multidrug-resistant glioblastoma cells in vitro	ONCOGENE			English	Article							CANCER STEM-CELLS; DEPENDENT PROTEIN-KINASE; ASCITES TUMOR-CELLS; DRUG-RESISTANCE; GENE-EXPRESSION; GLIOMA-CELLS; PI3K/AKT PATHWAY; SIGNALING PATHWAY; MALIGNANT GLIOMA; GLYCOPROTEIN	Chemotherapy is an adjuvant treatment for glioblastomas, however, chemotherapy remains palliative because of the development of multidrug resistance (MDR). Following prolonged chemotherapy, MDR protein 1 (MDR1) and CD133 increase in recurrent glioblastomas. CD133 positive (CD133+) glioma cancer stem-like cells (GCSCs) markedly promote drug resistance and exhibit increased DNA damage repair capability; thus they have a key role in determining tumor chemosensitivity. Although CD133, DNA-dependent protein kinase (DNA-PK), and MDR1 are elevated in CD133+ GCSCs, the relationship among these molecules has not been elucidated. In this study, MDR glioblastoma cell lines were created in response to prolonged doxorubicin chemotherapy. CD133, DNA-PK and MDR1 were markedly elevated in these cells. CD133 and DNA-PK may increase MDR1 via the phosphatidylinositol-3-kinase (PI3K)-Akt signal pathway. PI3K downstream targets Akt and nuclear factor (NF)-kappa B, which interacts with the MDR1 promoter, were also elevated in these cells. Downregulation of CD133 and DNA-PK by small interfering RNA, or inhibition of PI3K or Akt, decreased Akt, NF-kappa B and MDR1 expression. The results indicate that CD133 and DNA-PK regulate MDR1 through the PI3K- or Akt-NF-kappa B signal pathway. Consequently, a novel chemotherapeutic regimen targeting CD133 and DNA-PK in combination with traditional protocols may increase chemotherapeutic efficacy and improve prognosis for individuals who present with glioblastoma.	[Xi, G.; Hayes, E.; Lewis, R.; Ichi, S.; Shim, K.; Takao, T.; Allender, E.; Mayanil, C. S.; Tomita, T.] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Stanley Manne Childrens Res Inst,Div Pediat Neuro, Chicago, IL 60611 USA; [Xi, G.; Tomita, T.] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Falk Brain Tumor Ctr, Chicago, IL 60611 USA; [Ichi, S.; Shim, K.; Takao, T.; Allender, E.; Mayanil, C. S.] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Dev Biol Program,Stanley Manne Childrens Res Inst, Chicago, IL 60611 USA; [Mania-Farnell, B.] Purdue Univ Calumet, Dept Biol Sci, Hammond, IN USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Purdue University System; Purdue University	Xi, G (corresponding author), Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Stanley Manne Childrens Res Inst, 225 East Chicago Ave,POB 28, Chicago, IL 60611 USA.	gxi@luriechildrens.org; ttomita@luriechildrens.org			Rory David Deutsch Foundation; Surgical Neuro-oncology Research Fund of Ann & Robert H Lurie Children's Hospital (A&RLCH) of Chicago; Dr Ralph and Marian C Falk Medical Research Trust	Rory David Deutsch Foundation; Surgical Neuro-oncology Research Fund of Ann & Robert H Lurie Children's Hospital (A&RLCH) of Chicago; Dr Ralph and Marian C Falk Medical Research Trust	We are grateful to Dr Hao Luo for helpful suggestions and Drs Nimrod Miller and Yuping Derek Li for critical reading this article. This project was supported by the Rory David Deutsch Foundation, the Surgical Neuro-oncology Research Fund of Ann & Robert H Lurie Children's Hospital (A&RLCH) of Chicago, and the Dr Ralph and Marian C Falk Medical Research Trust.	Abe T, 1998, J NEURO-ONCOL, V40, P11, DOI 10.1023/A:1005954406809; ABE T, 1994, INT J CANCER, V58, P860; Angelastro JM, 2010, MOL CANCER RES, V8, P1105, DOI 10.1158/1541-7786.MCR-09-0383; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Bahr O, 2003, BRAIN PATHOL, V13, P482; Balik V, 2009, CELL MOL NEUROBIOL, V29, P845, DOI 10.1007/s10571-009-9366-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barancik M, 2006, EUR J PHARM SCI, V29, P426, DOI 10.1016/j.ejps.2006.08.006; Barr MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054193; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106; Bleau AM, 2009, CELL CYCLE, V8, P2936; Bolderson E, 2009, CLIN CANCER RES, V15, P6314, DOI 10.1158/1078-0432.CCR-09-0096; Borst P, 2013, J CLIN INVEST, V123, P4131, DOI 10.1172/JCI70430; Choi BH, 2008, CANCER LETT, V259, P111, DOI 10.1016/j.canlet.2007.10.003; DANO K, 1973, BIOCHIM BIOPHYS ACTA, V323, P466, DOI 10.1016/0005-2736(73)90191-0; de Faria GP, 2008, CANCER INVEST, V26, P883, DOI 10.1080/07357900801975264; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Decleves X, 2002, INT J CANCER, V98, P173, DOI 10.1002/ijc.10135; Facchino S, 2010, J NEUROSCI, V30, P10096, DOI 10.1523/JNEUROSCI.1634-10.2010; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FEUN LG, 1994, J NEURO-ONCOL, V20, P165, DOI 10.1007/BF01052726; Freitas DP, 2014, INT J CANCER, V134, P1270, DOI 10.1002/ijc.28478; Frosina G, 2009, MOL CANCER RES, V7, P989, DOI 10.1158/1541-7786.MCR-09-0030; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Guo Y, 2011, HISTOPATHOLOGY, V59, P763, DOI 10.1111/j.1365-2559.2011.03993.x; Hambardzumyan D, 2008, STEM CELL REV, V4, P203, DOI 10.1007/s12015-008-9021-5; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hsu FM, 2012, TRANSL CANCER RES, V1, P22, DOI 10.3978/j.issn.2218-676X.2012.04.01; HUET S, 1992, BRIT J CANCER, V65, P538, DOI 10.1038/bjc.1992.111; Hussein D, 2011, NEURO-ONCOLOGY, V13, P70, DOI 10.1093/neuonc/noq144; Jin X, 2013, BIOCHEM BIOPH RES CO, V433, P496, DOI 10.1016/j.bbrc.2013.03.021; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Kao GD, 2007, J BIOL CHEM, V282, P21206, DOI 10.1074/jbc.M703042200; KEIZER HG, 1989, CANCER RES, V49, P2988; Kuo MT, 2002, ONCOGENE, V21, P1945, DOI 10.1038/sj.onc.1205117; Lee PC, 2013, ONCOGENE, V32, P1144, DOI 10.1038/onc.2012.133; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Lin X, 2012, NEOPLASMA, V59, P248, DOI 10.4149/neo_2012_032; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Liu QH, 2009, J NEURO-ONCOL, V94, P1, DOI 10.1007/s11060-009-9919-z; Liu T, 2010, MOL CELL BIOCHEM, V340, P265, DOI 10.1007/s11010-010-0426-5; Liu YP, 2013, CANCER RES, V73, P406, DOI 10.1158/0008-5472.CAN-12-1733; Ma L, 2010, ACTA BIOCH BIOPH SIN, V42, P593, DOI 10.1093/abbs/gmq067; Mannervik B, 1981, Methods Enzymol, V77, P231; MARQUARDT D, 1992, CANCER RES, V52, P3157; MATSUMOTO T, 1991, J NEUROSURG, V74, P460, DOI 10.3171/jns.1991.74.3.0460; Mirkin BL, 2005, ONCOGENE, V24, P4965, DOI 10.1038/sj.onc.1208671; Mould E, 2014, BIOCHEM PHARMACOL, V88, P58, DOI 10.1016/j.bcp.2014.01.001; Nakai E, 2009, CANCER INVEST, V27, P901, DOI 10.3109/07357900801946679; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Robey RW, 2007, CANCER METAST REV, V26, P39, DOI 10.1007/s10555-007-9042-6; Seo SB, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-199; Shimura T, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.12; SKOVSGAARD T, 1978, CANCER RES, V38, P1785; Stupp R, 2006, ONCOLOGIST, V11, P165, DOI 10.1634/theoncologist.11-2-165; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Tacar O, 2013, J PHARM PHARMACOL, V65, P157, DOI 10.1111/j.2042-7158.2012.01567.x; Tamura K, 2013, J NEUROSURG, V119, P1145, DOI 10.3171/2013.7.JNS122417; Tazzari PL, 2007, LEUKEMIA, V21, P427, DOI 10.1038/sj.leu.2404523; VANDERBLIEK AM, 1988, CANCER RES, V48, P5927; Wei YY, 2013, P NATL ACAD SCI USA, V110, P6829, DOI 10.1073/pnas.1217002110; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Xi GF, 2014, NANOMED-NANOTECHNOL, V10, P381, DOI 10.1016/j.nano.2013.07.013; Zhong XL, 2007, BIOCHEMISTRY-US, V46, P5766, DOI 10.1021/bi700063b	67	48	50	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					241	250		10.1038/onc.2015.78	http://dx.doi.org/10.1038/onc.2015.78			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25823028				2022-12-17	WOS:000368193900010
J	Wu, H; Zheng, J; Deng, J; Zhang, L; Li, N; Li, W; Li, F; Lu, J; Zhou, Y				Wu, H.; Zheng, J.; Deng, J.; Zhang, L.; Li, N.; Li, W.; Li, F.; Lu, J.; Zhou, Y.			LincRNA-uc002yug.2 involves in alternative splicing of RUNX1 and serves as a predictor for esophageal cancer and prognosis	ONCOGENE			English	Article							GENOME-WIDE ASSOCIATION; SQUAMOUS-CELL CARCINOMA; LONG NONCODING RNA; SUSCEPTIBILITY LOCI; LUNG-CANCER; GENE; CHINESE; PROLIFERATION; TRANSCRIPTION; METASTASIS	Long intergenic noncoding RNAs (lincRNAs) have critical regulatory roles in cancer biology; however, the contributions of lincRNAs to esophageal squamous cell carcinoma (ESCC) have been infrequently explored. The aim of this study was to explore the contribution of lincRNAs, located at ESCC susceptibility loci identified by genome-wide association studies, to the risk and prognosis of ESCC. The associations between lincRNAs and the risk and prognosis of ESCC were analyzed in 358 diagnosed patients from eastern China, and the findings were validated in 326 additional patients from southern China. Functional relevance of lincRNAs was further examined by biochemical assays. We found that lincRNA-uc002yug.2 was commonly overexpressed in ESCC compared with paired peritumoral tissue in eastern and southern Chinese populations. The expression levels of lincRNA-uc002yug.2 in ESCC might be a prognostic factor for survival. Moreover, lincRNA-uc002yug.2 promoted a combination of RUNX1 and alternative splicing (AS) factors in the nucleus to produce more RUNX1 alpha, the short isoform and inhibitor of RUNX1, and reduce CEBP alpha (CCAAT/enhancer-binding protein-alpha) gene expression, thereby promoting ESCC progression. These results indicated that lincRNA-uc002yug.2 might involve in AS of RUNX1/AML1 and serve as a predictor for esophageal cancer and prognosis.	[Wu, H.; Zheng, J.; Deng, J.; Li, N.; Li, W.; Li, F.; Zhou, Y.] Soochow Univ, Coll Med, Dept Genet, Suzhou 215123, Peoples R China; [Zhang, L.] Soochow Univ, Affiliated Hosp 2, Dept Radiotherapy & Oncol, Suzhou 215123, Peoples R China; [Lu, J.] Guangzhou Med Univ, State Key Lab Resp Dis, Inst Chem Carcinogenesis, Guangzhou, Guangdong, Peoples R China	Soochow University - China; Soochow University - China; Guangzhou Medical University; State Key Laboratory of Respiratory Disease	Zhou, Y (corresponding author), Soochow Univ, Coll Med, Dept Genet, Renai Rd 199,Bldg 401,Room 1418, Suzhou 215123, Peoples R China.	zhouyifeng@suda.edu.cn		Zhang, Liyuan/0000-0002-7469-1743	National Scientific Foundation of China [81001278, 81171895, 81472630, 81072366]; Priority Academic Program Development of Jiangsu Higher Education Institutions, Jiangsu Provincial Natural Science Foundation [BK2011297]; Jiangsu Province Science and Technology Support Program [BE2012648]; Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry [20101561]	National Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions, Jiangsu Provincial Natural Science Foundation; Jiangsu Province Science and Technology Support Program; Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry(Scientific Research Foundation for the Returned Overseas Chinese Scholars)	This study was supported by the National Scientific Foundation of China grants 81001278, 81171895, 81472630 and 81072366; a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions, Jiangsu Provincial Natural Science Foundation (No. BK2011297); Jiangsu Province Science and Technology Support Program (No. BE2012648) and the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry (No. 20101561).	Abnet CC, 2010, NAT GENET, V42, P764, DOI 10.1038/ng.649; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777; Chimge NO, 2013, ONCOGENE, V32, P2121, DOI 10.1038/onc.2012.328; Cui R, 2009, GASTROENTEROLOGY, V137, P1768, DOI 10.1053/j.gastro.2009.07.070; Dinger Marcel E., 2009, Briefings in Functional Genomics & Proteomics, V8, P407, DOI 10.1093/bfgp/elp038; Dulak AM, 2012, CANCER RES, V72, P4383, DOI 10.1158/0008-5472.CAN-11-3893; Gibb EA, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-38; Girard N, 2013, P NATL ACAD SCI USA, V110, P13522, DOI 10.1073/pnas.1310067110; Guo H, 2012, BLOOD, V119, P4408, DOI 10.1182/blood-2011-12-397091; Han H, 2013, NATURE, V498, P241, DOI 10.1038/nature12270; Hu N, 2005, CANCER RES, V65, P2542, DOI 10.1158/0008-5472.CAN-04-3247; Huarte M, 2010, HUM MOL GENET, V19, pR152, DOI 10.1093/hmg/ddq353; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Jin GF, 2012, AM J HUM GENET, V91, P928, DOI 10.1016/j.ajhg.2012.09.009; Kumar M, 2013, INT J CANCER, V132, P2032, DOI 10.1002/ijc.27880; Kuwano H, 2005, SURG TODAY, V35, P7, DOI 10.1007/s00595-004-2885-3; Liu X, 2009, LEUKEMIA, V23, P739, DOI 10.1038/leu.2008.350; Luco RF, 2011, CURR OPIN GENET DEV, V21, P366, DOI 10.1016/j.gde.2011.03.004; Manolio TA, 2008, J CLIN INVEST, V118, P1590, DOI 10.1172/JCI34772; Martianov I, 2007, NATURE, V445, P666, DOI 10.1038/nature05519; Muller C, 2004, J BIOL CHEM, V279, P7353, DOI 10.1074/jbc.M312709200; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Sato A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057013; Scheitz CJF, 2012, EMBO J, V31, P4124, DOI 10.1038/emboj.2012.270; St Kapranov P, 2010, BMC BIOL, V8, P149; Sun M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-68; Sun SY, 2010, NAT STRUCT MOL BIOL, V17, P306, DOI 10.1038/nsmb.1750; Szumilo Justyna, 2009, Pol Merkur Lekarski, V26, P82; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Tsuzuki S, 2007, PLOS MED, V4, P880, DOI 10.1371/journal.pmed.0040172; Ulitsky I, 2011, CELL, V147, P1537, DOI 10.1016/j.cell.2011.11.055; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wang LD, 2010, NAT GENET, V42, P759, DOI 10.1038/ng.648; Wang XT, 2008, NATURE, V454, P126, DOI 10.1038/nature06992; Willingham AT, 2005, SCIENCE, V309, P1570, DOI 10.1126/science.1115901; Wu C, 2013, NAT GENET, V45, P632, DOI 10.1038/ng.2638; Wu C, 2012, NAT GENET, V44, P1090, DOI 10.1038/ng.2411; Wu C, 2011, NAT GENET, V43, P679, DOI 10.1038/ng.849; Yamabuki T, 2006, INT J ONCOL, V28, P1375; Yang Howard H., 2008, V141, P23; Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021	45	48	50	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4723	4734		10.1038/onc.2014.400	http://dx.doi.org/10.1038/onc.2014.400			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25486427				2022-12-17	WOS:000360931500006
J	Choi, MJ; Cho, KH; Lee, S; Bae, YJ; Jeong, KJ; Rha, SY; Choi, EJ; Park, JH; Kim, JM; Lee, JS; Mills, GB; Lee, HY				Choi, M. J.; Cho, K. H.; Lee, S.; Bae, Y. J.; Jeong, K. J.; Rha, S. Y.; Choi, E. J.; Park, J. H.; Kim, J. M.; Lee, J-S; Mills, G. B.; Lee, H. Y.			hTERT mediates norepinephrine-induced Slug expression and ovarian cancer aggressiveness	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; NF-KAPPA-B; TELOMERASE ACTIVITY; CHRONIC STRESS; CELLS; SRC; ACTIVATION; PROMOTES; KINASE; TARGET	Stress hormones have been implicated in both tumor initiation and progression. Human telomerase reverse transcriptase (hTERT) is overexpressed in cancer cells and associated with malignant tumor progression and poor outcome. We thus sought to determine whether the stress hormone norepinephrine (NE) could induce hTERT expression and subsequently ovarian cancer progression. Unexpectedly, NE induced hTERT transcript and protein expression, and subsequently ovarian cancer cell invasion. Pharmacologic inhibition of beta 2-adrenergic receptor 2 and protein kinase A, as well as silencing of hypoxia-inducible factor-1 alpha and c-Myc expression, profoundly attenuated NE-induced hTERT expression. Strikingly, stimulation of the cells with NE or ectopic expression of hTERT induced expression of Slug, ovarian cancer cell epithelial-mesenchymal transition (EMT) and invasion. Silencing of hTERT expression abrogated NE-induced ovarian cancer cell invasion, EMT and Slug expression. In addition, silencing of Slug expression significantly inhibited NE-and hTERT-induced ovarian cancer cell EMT and invasion. Moreover, continuous exposure to NE was sufficient to enhance in vivo hTERT expression and metastasis of ovarian cancer cells to the lung. Finally, we provide evidence that hTERT links Src to Slug expression in NE-induced ovarian cancer EMT and metastasis. We thus demonstrate a novel role of hTERT in stress hormone-induced ovarian cancer aggressiveness through inducing Slug, providing novel biomarkers and potential therapeutic targets for ovarian cancer.	[Choi, M. J.; Cho, K. H.; Bae, Y. J.; Lee, H. Y.] Konyang Univ, Dept Pharmacol, Myunggok Med Res Inst, Coll Med, Taejon 302718, South Korea; [Lee, S.; Park, J. H.] Konyang Univ, Dept Biochem, Coll Med, Myunggok Med Res Inst, Taejon 302718, South Korea; [Jeong, K. J.; Lee, J-S; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Rha, S. Y.; Lee, H. Y.] Yonsei Univ, Coll Med, Yonsei Canc Res Inst, Seoul, South Korea; [Choi, E. J.] Konyang Univ, Dept Optometry, Coll Med Sci, Taejon 302718, South Korea; [Kim, J. M.] Chungnam Natl Univ, Sch Med, Canc Res Inst, Reg Canc Ctr, Taejon, South Korea; [Kim, J. M.] Chungnam Natl Univ, Sch Med, Infect Signaling Network Res Ctr, Taejon, South Korea	Konyang University; Konyang University Hospital; Konyang University; Konyang University Hospital; University of Texas System; UTMD Anderson Cancer Center; Yonsei University; Yonsei University Health System; Konyang University; Chungnam National University; Chungnam National University	Lee, HY (corresponding author), Konyang Univ, Dept Pharmacol, Coll Med, 821 Med Sci Bldg,681 Gasuwon Dong, Taejon 302718, South Korea.	hoi@konyang.ac.kr	Jeong, Kangjin/HGT-9268-2022	Choi, Eun Jung/0000-0002-5020-3055; KIM, JIN MAN/0000-0003-0905-9730; Choi, Moonjung/0000-0002-7218-4924; Rha, Sun Young/0000-0002-2512-4531	National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea [121182]; National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [2011-0015761, 2013R1A1A2A10059565]; NATIONAL CANCER INSTITUTE [P50CA083639] Funding Source: NIH RePORTER	National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of KoreaNational Research Foundation of Korea); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Professor Bong-Kyeong Oh (KonKuk University, Seoul, South Korea) for a plasmid-containing hTERT, Sun Hee Leem (Dong-A University, Pusan, Korea) for hTERT promoter and Seong-Lan Yu for experimental support. This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (121182) and Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011-0015761, 2013R1A1A2A10059565).	Armaiz-Pena GN, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2413; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Chakroborty D, 2009, CANCER RES, V69, P3727, DOI 10.1158/0008-5472.CAN-08-4289; Chao C, 2007, ONCOGENE, V26, P1013, DOI 10.1038/sj.onc.1209862; Chida Y, 2008, NAT CLIN PRACT ONCOL, V5, P466, DOI 10.1038/ncponc1134; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; Fredriksson JM, 2000, J BIOL CHEM, V275, P13802, DOI 10.1074/jbc.275.18.13802; Ghosh A, 2012, NAT CELL BIOL, V14, P1270, DOI 10.1038/ncb2621; Ghosh JS, 2012, APPL MICROBIOL BIOT, V93, P753, DOI 10.1007/s00253-011-3471-4; Goldstein DS, 2010, CLIN AUTON RES, V20, P331, DOI 10.1007/s10286-010-0065-7; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hassan S, 2013, J CLIN INVEST, V123, P874, DOI 10.1172/JCI63324; Higgins DF, 2007, J CLIN INVEST, V117, P3810, DOI 10.1172/JCI30487; Jeong KJ, 2012, ONCOGENE, V31, P4279, DOI 10.1038/onc.2011.595; KEMP VH, 1989, RES NURS HEALTH, V12, P331, DOI 10.1002/nur.4770120509; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kyo S, 1999, INT J CANCER, V80, P804; Lambertini E, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-13; Lara HE, 2001, ENDOCRINE, V15, P187, DOI 10.1385/ENDO:15:2:187; Lee J, 2006, CLIN CANCER RES, V12, P6351, DOI 10.1158/1078-0432.CCR-06-1252; Liu Z, 2013, ONCOGENE, V32, P4203, DOI 10.1038/onc.2012.441; Low KC, 2013, TRENDS BIOCHEM SCI, V38, P426, DOI 10.1016/j.tibs.2013.07.001; Lutgendorf SK, 2003, CLIN CANCER RES, V9, P4514; McEwen BS, 2002, NEUROBIOL AGING, V23, P921, DOI 10.1016/S0197-4580(02)00027-1; Meng E, 2012, GYNECOL ONCOL, V124, P598, DOI 10.1016/j.ygyno.2011.11.018; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nilsson MB, 2007, J BIOL CHEM, V282, P29919, DOI 10.1074/jbc.M611539200; Palm D, 2006, INT J CANCER, V118, P2744, DOI 10.1002/ijc.21723; Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137; Park SY, 2011, ONCOGENE, V30, P1351, DOI 10.1038/onc.2010.517; Park SY, 2011, INT J CANCER, V128, P2306, DOI 10.1002/ijc.25589; RILEY V, 1975, SCIENCE, V189, P465, DOI 10.1126/science.168638; Sakai D, 2005, DEV GROWTH DIFFER, V47, P471, DOI 10.1111/j.1440-169X.2005.00821.x; Saul AN, 2005, JNCI-J NATL CANCER I, V97, P1760, DOI 10.1093/jnci/dji401; Schmidt C, 1996, Eur J Med Res, V1, P528; Seo JH, 2010, CANCER LETT, V288, P50, DOI 10.1016/j.canlet.2009.06.023; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Sloan EK, 2010, CANCER RES, V70, P7042, DOI 10.1158/0008-5472.CAN-10-0522; Sood AK, 2006, CLIN CANCER RES, V12, P369, DOI 10.1158/1078-0432.CCR-05-1698; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Wang YP, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-12; Wiener JR, 2003, GYNECOL ONCOL, V88, P73, DOI 10.1006/gyno.2002.6851; Wolfer A, 2011, CANCER RES, V71, P2034, DOI 10.1158/0008-5472.CAN-10-3776; Yang EV, 2006, CANCER RES, V66, P10357, DOI 10.1158/0008-5472.CAN-06-2496; Yatabe N, 2004, ONCOGENE, V23, P3708, DOI 10.1038/sj.onc.1207460; Yu ST, 2009, INT J ONCOL, V35, P329, DOI 10.3892/ijo_00000344; Zhang C, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000106	51	48	50	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3402	3412		10.1038/onc.2014.270	http://dx.doi.org/10.1038/onc.2014.270			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25151968				2022-12-17	WOS:000356871700006
J	Tuthill, MH; Montinaro, A; Zinngrebe, J; Prieske, K; Draber, P; Prieske, S; Newsom-Davis, T; von Karstedt, S; Graves, J; Walczak, H				Tuthill, M. H.; Montinaro, A.; Zinngrebe, J.; Prieske, K.; Draber, P.; Prieske, S.; Newsom-Davis, T.; von Karstedt, S.; Graves, J.; Walczak, H.			TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells	ONCOGENE			English	Article							OVARIAN-CANCER; TUMORICIDAL ACTIVITY; PANCREATIC-CANCER; INDUCED APOPTOSIS; LUNG-CANCER; IN-VIVO; CONATUMUMAB; RESISTANCE; COMBINATION; INHIBITION	Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in cancer cells while sparing normal tissues. Despite promising preclinical results, few patients responded to treatment with recombinant TRAIL (Apo2L/Dulanermin) or TRAIL-R2-specific antibodies, such as conatumumab (AMG655). It is unknown whether this was due to intrinsic TRAIL resistance within primary human cancers or insufficient agonistic activity of the TRAIL-receptor (TRAIL-R)-targeting drugs. Fc gamma receptors (Fc gamma R)-mediated crosslinking increases the cancer-cell-killing activity of TRAIL-R2-specific antibodies in vivo. We tested this phenomenon using Fc gamma R-expressing immune cells from patients with ovarian cancer. However, even in the presence of high numbers of Fc gamma R-expressing immune cells, as found in ovarian cancer ascites, AMG655-induced apoptosis was not enabled to any significant degree, indicating that this concept may not translate into clinical use. On the basis of these results, we next set out to determine whether AMG655 possibly interferes with apoptosis induction by endogenous TRAIL, which could be expressed by immune cells. To do so, we tested how AMG655 affected apoptosis induction by recombinant TRAIL. This, however, resulted in the surprising discovery of a striking synergy between AMG655 and non-tagged TRAIL (Apo2L/TRAIL) in killing cancer cells. This combination was as effective in killing cancer cells as highly active recombinant isoleucine-zipper-tagged TRAIL (iz-TRAIL). The increased killing efficiency was due to enhanced formation of the TRAIL death-inducing signalling complex, enabled by concomitant binding of Apo2L/TRAIL and AMG655 to TRAIL-R2. The synergy of AMG655 with Apo2L/TRAIL extended to primary ovarian cancer cells and was further enhanced by combination with the proteasome inhibitor bortezomib or a second mitochondrial-derived activator of caspases (SMAC) mimetic. Importantly, primary human hepatocytes were not killed by the AMG655-Apo2L/TRAIL combination, also not when further combined with bortezomib or a SMAC mimetic. We therefore propose that clinical-grade non-tagged recombinant forms of TRAIL, such as dulanermin, could be combined with antibodies such as AMG655 to introduce a highly active TRAIL-R2-agonistic therapy into the cancer clinic.	[Tuthill, M. H.; Montinaro, A.; Zinngrebe, J.; Prieske, K.; Draber, P.; Prieske, S.; Newsom-Davis, T.; von Karstedt, S.; Walczak, H.] Univ London Imperial Coll Sci Technol & Med, Dept Med, Tumour Immunol Unit, London, England; [Tuthill, M. H.] Univ London Imperial Coll Sci Technol & Med, Ctr Clin Sci, MRC, London, England; [Graves, J.] Amgen Inc, Seattle, WA USA	Imperial College London; Imperial College London; Amgen	Walczak, H (corresponding author), UCL, Inst Canc, Room 416,Paul OGorman Bldg,72 Huntley St, London WC1E 6DD, England.	h.walczak@ucl.ac.uk	Draber, Peter/G-3141-2014; Walczak, Henning/AAV-2214-2020	Draber, Peter/0000-0001-8658-4614; Walczak, Henning/0000-0002-6312-4591	Medical Research Council [MC_EX_G0802342]; Cancer Research UK [C33499/A10950]; Ovarian Cancer Action; Association for International Cancer Research; Cancer Research UK [10950] Funding Source: researchfish; MRC [MC_EX_G0802342] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Ovarian Cancer Action(Ovarian Cancer Action); Association for International Cancer Research; Cancer Research UK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank the patients and the staff at Imperial College Healthcare NHS Trust for providing and collecting the ovarian cancer ascites samples for this research. AMG655 was kindly provided by AMGEN Inc. (Thousand Oaks, CA, USA). We thank B Vogelstein and R Youle for providing cell lines. We also thank Dr C Kantari for technical advice and helpful discussions. This work has been funded by the Medical Research Council by providing a Clinical Research Training Fellowship for MHT (MC_EX_G0802342), Cancer Research UK, (C33499/A10950), Ovarian Cancer Action, and the Association for International Cancer Research. The SMAC mimetic compound SM083 (also known as SM 9a) was synthesised and kindly provided by P Seneci and L Manzoni.	Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Ganten TM, 2006, CLIN CANCER RES, V12, P2640, DOI 10.1158/1078-0432.CCR-05-2635; Ganten TM, 2005, HEPATOLOGY, V42, P588, DOI 10.1002/hep.20807; Gieffers C, 2013, MOL CANCER THER, V12, P2735, DOI 10.1158/1535-7163.MCT-13-0323; Gillissen B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.67; Goncharenko-Khaider N, 2010, ONCOGENE, V29, P5523, DOI 10.1038/onc.2010.288; Haynes NM, 2010, J IMMUNOL, V185, P532, DOI 10.4049/jimmunol.0903624; Herbst RS, 2010, CLIN CANCER RES, V16, P5883, DOI 10.1158/1078-0432.CCR-10-0631; Herbst RS, 2010, J CLIN ONCOL, V28, P2839, DOI 10.1200/JCO.2009.25.1991; Kaplan-Lefko PJ, 2010, CANCER BIOL THER, V9, P618, DOI 10.4161/cbt.9.8.11264; Kindler HL, 2012, ANN ONCOL, V23, P2834, DOI 10.1093/annonc/mds142; Koschny R, 2007, HEPATOLOGY, V45, P649, DOI 10.1002/hep.21555; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Lecis D, 2012, BIOORGAN MED CHEM, V20, P6709, DOI 10.1016/j.bmc.2012.09.041; Leinster DA, 2012, J PATHOL, V227, P136, DOI 10.1002/path.4002; Lemke J, 2014, CELL DEATH DIFFER, V21, P491, DOI 10.1038/cdd.2013.179; Newsom-Davis T, 2009, APOPTOSIS, V14, P607, DOI 10.1007/s10495-009-0321-2; Paz-Ares L, 2013, J THORAC ONCOL, V8, P329, DOI 10.1097/JTO.0b013e31827ce554; Petrucci E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035073; Plummer R, 2007, CLIN CANCER RES, V13, P6187, DOI 10.1158/1078-0432.CCR-07-0950; Saulle E, 2007, APOPTOSIS, V12, P635, DOI 10.1007/s10495-006-0025-9; Soria JC, 2011, J CLIN ONCOL, V29, P4442, DOI 10.1200/JCO.2011.37.2623; Taieb J, 2006, NAT MED, V12, P214, DOI 10.1038/nm1356; Vogler M, 2008, CANCER RES, V68, P7956, DOI 10.1158/0008-5472.CAN-08-1296; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wilson NS, 2011, CANCER CELL, V19, P101, DOI 10.1016/j.ccr.2010.11.012	27	48	50	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2138	2144		10.1038/onc.2014.156	http://dx.doi.org/10.1038/onc.2014.156			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909167	Green Accepted			2022-12-17	WOS:000353173400013
J	Tsai, LH; Wu, JY; Cheng, YW; Chen, CY; Sheu, GT; Wu, TC; Lee, H				Tsai, L-H; Wu, J-Y; Cheng, Y-W; Chen, C-Y; Sheu, G-T; Wu, T-C; Lee, H.			The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss	ONCOGENE			English	Article							BET BROMODOMAIN INHIBITION; ZINC-FINGER GENE; C-MYC; CANCER PROGRESSION; PREDICTS SURVIVAL; TUMOR-SUPPRESSOR; MUTATIONS; METASTASIS; EXPRESSION; TRANSCRIPTION	Liver kinase B1 (LKB1) loss in lung adenocarcinoma is commonly caused by genetic mutations, but these mutations rarely occur in Asian patients. We recently reported wild-type LKB1 loss via the alteration of NKX2-1/p53-axis-promoted tumor aggressiveness and predicted poor outcomes in cases of lung adenocarcinoma. The mechanistic action of wild-type LKB1 loss within tumor progression remains unknown. The suppression of MYC by LKB1 controls epithelial organization; therefore, we hypothesize that MYC expression can be increased via wild-type LKB1 loss and promotes tumor progression. Here, MYC transcription is upregulated by LKB1-loss-mediated MZF1 expression. The wild-type LKB1-loss-mediated MZF1/MYC axis is responsible for soft-agar growth, migration and invasion in lung adenocarcinoma cells. Moreover, wild-type LKB1 loss-induced cell invasiveness was markedly suppressed by MYC inhibitors (10058-F4 and JQ1). Patients with low-LKB1/high-MZF1 or low-LKB1/high-MYC tumors have shorter overall survival and relapse-free-survival periods than patients with high-LKB1/low-MZF1 or high-LKB1/low-MYC tumors. In summary, MZF1-mediated MYC expression may promote tumor progression, resulting in poor outcomes in cases of lung adenocarcinoma with low-wild-type-LKB1 tumors.	[Tsai, L-H; Sheu, G-T] Chung Shan Med Univ, Inst Med, Taichung 40201, Taiwan; [Wu, J-Y] Tzu Chi Univ, Buddhist Tzu Chi Gen Hosp, Dept Surg, Taichung Branch, Hualien, Taiwan; [Wu, J-Y] Tzu Chi Univ, Coll Med, Hualien, Taiwan; [Cheng, Y-W; Lee, H.] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, Taipei 115, Taiwan; [Chen, C-Y] China Med Univ Hosp, Dept Surg, Taichung, Taiwan; [Wu, T-C] Chung Shan Med Univ Hosp, Dept Internal Med, Taichung 40201, Taiwan	Chung Shan Medical University; Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; Tzu Chi University; Tzu Chi University; Taipei Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan; Chung Shan Medical University; Chung Shan Medical University Hospital	Lee, H (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, Inst Canc Biol & Drug Discovery, Room 5,12th Floor F Bldg,Pk St, Taipei 115, Taiwan.	hl@tmu.edu.tw	Sheu, Gwo-Tarng/H-8855-2019	Sheu, Gwo-Tarng/0000-0002-1299-3375	National Science Council of Taiwan, ROC [NSC1-100-2314-B-038-043-MY3]	National Science Council of Taiwan, ROC(Ministry of Science and Technology, Taiwan)	This work was jointly supported by grants from the National Science Council (NSC1-100-2314-B-038-043-MY3) of Taiwan, ROC.	Bin Cho K, 2010, CANCER LETT, V293, P230, DOI 10.1016/j.canlet.2010.01.013; Cheng YW, 2007, CANCER RES, V67, P10686, DOI 10.1158/0008-5472.CAN-07-1461; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Feng Y, 2012, CANCER RES, V72, P6502, DOI 10.1158/0008-5472.CAN-12-1909; Fernandez P, 2004, ONCOGENE, V23, P5084, DOI 10.1038/sj.onc.1207665; Gao YJ, 2010, P NATL ACAD SCI USA, V107, P18892, DOI 10.1073/pnas.1004952107; Gong FR, 2011, NUCLEIC ACIDS RES, V39, P4640, DOI 10.1093/nar/gkr023; Gu Y, 2012, ONCOGENE, V31, P469, DOI 10.1038/onc.2011.247; HROMAS R, 1991, J BIOL CHEM, V266, P14183; HROMAS R, 1995, CANCER RES, V55, P3610; Huang MJ, 2006, EXP HEMATOL, V34, P1480, DOI 10.1016/j.exphem.2006.06.019; Ischenko I, 2013, P NATL ACAD SCI USA, V110, P3937, DOI 10.1073/pnas.1219592110; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kim MJ, 2010, CANCER GENET CYTOGEN, V196, P204, DOI 10.1016/j.cancergencyto.2009.09.020; Koivunen JP, 2008, BRIT J CANCER, V99, P245, DOI 10.1038/sj.bjc.6604469; Liu H, 2012, NAT CELL BIOL, V14, P567, DOI 10.1038/ncb2491; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Makowski L, 2008, BRIT J CANCER, V99, P683, DOI 10.1038/sj.bjc.6604515; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Miyaki M, 2000, CANCER RES, V60, P6311; Mudduluru G, 2010, MOL CANCER RES, V8, P159, DOI 10.1158/1541-7786.MCR-09-0326; Onozato R, 2007, CANCER SCI, V98, P1747, DOI 10.1111/j.1349-7006.2007.00585.x; Ossipova O, 2003, NAT CELL BIOL, V5, P889, DOI 10.1038/ncb1048; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; Partanen JI, 2012, P NATL ACAD SCI USA, V109, pE388, DOI 10.1073/pnas.1120421109; Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Scott KD, 2007, CANCER RES, V67, P5622, DOI 10.1158/0008-5472.CAN-07-0762; Shimamura T, 2013, CLIN CANCER RES, V19, P6183, DOI 10.1158/1078-0432.CCR-12-3904; Steger DJ, 2008, MOL CELL BIOL, V28, P2825, DOI 10.1128/MCB.02076-07; Sun YH, 2010, J CLIN ONCOL, V28, P4616, DOI 10.1200/JCO.2010.29.6038; Sung WW, 2011, CLIN CANCER RES, V17, P5991, DOI 10.1158/1078-0432.CCR-11-0227; Tsai LH, 2014, ONCOGENE, V33, P3851, DOI 10.1038/onc.2013.353; Wang HB, 2007, MOL CANCER THER, V6, P2399, DOI 10.1158/1535-7163.MCT-07-0005; Wolfer A, 2010, P NATL ACAD SCI USA, V107, P3698, DOI 10.1073/pnas.0914203107; Wu DW, 2011, CLIN CANCER RES, V17, P1895, DOI 10.1158/1078-0432.CCR-10-2316; Wu DW, 2010, CANCER RES, V70, P10392, DOI 10.1158/0008-5472.CAN-10-2341; Wu HH, 2010, ONCOGENE, V29, P4330, DOI 10.1038/onc.2010.178	39	48	48	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1641	1649		10.1038/onc.2014.118	http://dx.doi.org/10.1038/onc.2014.118			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24793789				2022-12-17	WOS:000351848400004
J	Vassilopoulos, A; Chisholm, C; Lahusen, T; Zheng, H; Deng, CX				Vassilopoulos, A.; Chisholm, C.; Lahusen, T.; Zheng, H.; Deng, C-X			A critical role of CD29 and CD49f in mediating metastasis for cancer-initiating cells isolated from a Brca1-associated mouse model of breast cancer	ONCOGENE			English	Article						CD29; CD49f; CSCs; EMT; cancer metastasis	EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; BRCA1; IDENTIFICATION; SUSCEPTIBILITY; EXPRESSION; MECHANISMS; SIGNATURE; MARKERS; TUMORS	Cancer metastasis is a lethal problem that claims the lives of over 90% of cancer patients. In this study, we have investigated metastatic potential of cancer stem cells (CSCs) isolated from mammary tumors of a Brca1-mutant mouse model. Our data indicated that CSCs, which are enriched in CD24(+)CD29(+)/CD49f(+) cell population, displayed much higher migration ability than CD24(-)CD29(-)/CD49f (-) cells in tissue culture and enhanced metastatic potential in allograft-nude mice. CD24(+)CD29(+) cells maintained the ability to differentiate and reconstitute heterogeneity in the metastatic tumors whereas CD24(-)CD29(-) cells could not. Corresponding to their enhanced metastatic ability, CD24(+)CD29(+) cells exhibited features of the epithelial to mesenchymal transition. Finally, using short hairpin RNA to knock down CD29 and/or CD49f in metastatic cancer cells, we demonstrated that while acute knockdown of CD29 or CD49f alone slightly decreased cell migration ability, knockdown of both genes generated a profound effect to block their migration, revealing an overlapping, yet critical function of both genes in the migration of CSCs. Our findings indicate that in addition to serving as markers of CSCs, CD29 and CD49f may also serve as potential therapeutic targets for cancer metastasis.	[Vassilopoulos, A.; Chisholm, C.; Lahusen, T.; Zheng, H.; Deng, C-X] NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Deng, CX (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA.	chuxiad@bdg10.niddk.nih.gov	deng, chuxia/N-6713-2016		Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases; National Institutes of Health, USA	Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank members of the Deng lab for critical reading of the manuscript. This work was supported by the Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; Ali HR, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3061; Baccelli I, 2012, J CELL BIOL, V198, P281, DOI 10.1083/jcb.201202014; Brody LC, 1998, MEDICINE, V77, P208, DOI 10.1097/00005792-199805000-00006; Dave B, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr2938; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Deng CX, 2003, HUM MOL GENET, V12, pR113, DOI 10.1093/hmg/ddg082; Deng CX, 2000, BIOESSAYS, V22, P728; Deng CX, 2002, ENVIRON MOL MUTAGEN, V39, P171, DOI 10.1002/em.10069; Diaz-Cruz Edgar S, 2010, Breast Dis, V32, P85, DOI 10.3233/BD-2010-0308; Dine J, 2013, CANCER METAST REV, V32, P25, DOI 10.1007/s10555-012-9403-7; Drost RM, 2009, BRIT J CANCER, V101, P1651, DOI 10.1038/sj.bjc.6605350; Eccles DM, 2005, LANCET ONCOL, V6, P705, DOI 10.1016/S1470-2045(05)70318-1; Foroni C, 2012, CANCER TREAT REV, V38, P689, DOI 10.1016/j.ctrv.2011.11.001; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gritsenko PG, 2012, J PATHOL, V226, P185, DOI 10.1002/path.3031; Hale JS, 2012, CELL ADHES MIGR, V6, P346, DOI 10.4161/cam.21294; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hu YF, 2009, INT J BIOL SCI, V5, P20; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Lahlou H, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2905; Lanza DG, 2012, TUMOR BIOL, V33, P1997, DOI 10.1007/s13277-012-0459-3; Lathia JD, 2011, CELL STEM CELL, V8, P482, DOI 10.1016/j.stem.2011.04.013; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NICOLSON GL, 1992, ONCOL RES, V4, P389; Nielsen PK, 2001, J BIOL CHEM, V276, P10906, DOI 10.1074/jbc.M008743200; NIESSEN CM, 1994, J CELL SCI, V107, P543; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Podsypanina K, 2008, SCIENCE, V321, P1841, DOI 10.1126/science.1161621; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Song LL, 2007, EXPERT OPIN BIOL TH, V7, P431, DOI 10.1517/14712598.7.4.431; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vassilopoulos A, 2008, INT J BIOL SCI, V4, P133, DOI 10.7150/ijbs.4.133; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Zhang JR, 2005, MOL CANCER RES, V3, P531, DOI 10.1158/1541-7786.MCR-05-0192; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353	47	48	51	1	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5477	5482		10.1038/onc.2013.516	http://dx.doi.org/10.1038/onc.2013.516			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24317509				2022-12-17	WOS:000345120700010
J	Fujiya, M; Konishi, H; Kamel, MKM; Ueno, N; Inaba, Y; Moriichi, K; Tanabe, H; Ikuta, K; Ohtake, T; Kohgo, Y				Fujiya, M.; Konishi, H.; Kamel, M. K. Mohamed; Ueno, N.; Inaba, Y.; Moriichi, K.; Tanabe, H.; Ikuta, K.; Ohtake, T.; Kohgo, Y.			microRNA-18a induces apoptosis in colon cancer cells via the autophagolysosomal degradation of oncogenic heterogeneous nuclear ribonucleoprotein A1	ONCOGENE			English	Article						microRNAs; heterogeneous nuclear ribonucleoproteins; colon cancer; apoptosis; autophagy; ubiquitin	POSTTRANSCRIPTIONAL REGULATION; COLORECTAL-CANCER; NONCODING RNAS; C-ELEGANS; GENE; MUTATIONS; RAS; EXPRESSION; PROLIFERATION; TUMORIGENESIS	It is well known that microRNAs (miRs) are abnormally expressed in various cancers and target the messenger RNAs (mRNAs) of cancer-associated genes. While (miRs) are abnormally expressed in various cancers, whether miRs directly target oncogenic proteins is unknown. The present study investigated the inhibitory effects of miR-18a on colon cancer progression, which was considered to be mediated through its direct binding and degradation of heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1). An MTT assay and xenograft model demonstrated that the transfection of miR-18a induced apoptosis in SW620 cells. A binding assay revealed direct binding between miR-18a and hnRNP A1 in the cytoplasm of SW620 cells, which inhibited the oncogenic functions of hnRNP A1. A competitor RNA, which included the complementary sequence of the region of the miR-18a-hnRNP A1 binding site, repressed the effects of miR-18a on the induction of cancer cell apoptosis. In vitro single and in vivo double isotope assays demonstrated that miR-18a induced the degradation of hnRNP A1. An immunocytochemical study of hnRNP A1 and LC3-II and the inhibition of autophagy by 3-methyladenine and ATG7, p62 and BAG3 siRNA showed that miR-18a and hnRNP A1 formed a complex that was degraded through the autophagolysosomal pathway. This is the first report showing a novel function of a miR in the autophagolysosomal degradation of an oncogenic protein resulting from the creation of a complex consisting of the miR and a RNA-binding protein, which suppressed cancer progression.	[Fujiya, M.; Konishi, H.; Kamel, M. K. Mohamed; Ueno, N.; Inaba, Y.; Moriichi, K.; Tanabe, H.; Ikuta, K.; Ohtake, T.; Kohgo, Y.] Asahikawa Med Coll, Dept Med, Div Gastroenterol & Hematol Oncol, Asahikawa, Hokkaido 0788510, Japan	Asahikawa Medical College	Fujiya, M (corresponding author), Asahikawa Med Coll, Dept Med, Div Gastroenterol & Hematol Oncol, 2-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan.	fjym@asahikawa-med.ac.jp	Kohgo, Yutaka/AAN-4863-2020	Tanabe, Hiroki/0000-0001-9029-5081	Grants-in-Aid for Scientific Research [24790671] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; Eiring AM, 2010, CELL, V140, P652, DOI 10.1016/j.cell.2010.01.007; Eulalio A, 2008, CELL, V132, P9, DOI 10.1016/j.cell.2007.12.024; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; Guan RJ, 1999, GASTROENTEROLOGY, V116, P1063, DOI 10.1016/S0016-5085(99)70009-0; Guil S, 2007, NAT STRUCT MOL BIOL, V14, P591, DOI 10.1038/nsmb1250; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hope NR, 2011, HUM PATHOL, V42, P393, DOI 10.1016/j.humpath.2010.08.006; Jo OD, 2008, J BIOL CHEM, V283, P23274, DOI 10.1074/jbc.M801185200; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kettern N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016398; Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Liu WH, 2009, GASTROENTEROLOGY, V136, P683, DOI 10.1053/j.gastro.2008.10.029; Mattick JS, 2001, MOL BIOL EVOL, V18, P1611, DOI 10.1093/oxfordjournals.molbev.a003951; Michlewski G, 2008, MOL CELL, V32, P383, DOI 10.1016/j.molcel.2008.10.013; Motoyama K, 2009, INT J ONCOL, V34, P1069, DOI 10.3892/ijo_00000233; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Qased A, 2013, MOL MED REP, V7, P559, DOI 10.3892/mmr.2012.1214; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638; Tao J, 2012, MOL MED REP, V5, P167, DOI 10.3892/mmr.2011.591; Thiele BJ, 2004, CIRC RES, V95, P1058, DOI 10.1161/01.RES.0000149166.33833.08; Tsuchiya N, 2011, CANCER RES, V71, P4628, DOI 10.1158/0008-5472.CAN-10-2475; Ushigome M, 2005, INT J ONCOL, V26, P635; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Wu JM, 2012, CARCINOGENESIS, V33, P519, DOI 10.1093/carcin/bgr304; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107; Yu YJ, 2012, CARCINOGENESIS, V33, P68, DOI 10.1093/carcin/bgr246; Zhang Y, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-23; Zhao YC, 2011, BREAST CANCER RES TR, V127, P69, DOI 10.1007/s10549-010-0972-2	38	48	48	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2014	33	40					4847	4856		10.1038/onc.2013.429	http://dx.doi.org/10.1038/onc.2013.429			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0EH	24166503				2022-12-17	WOS:000343240100006
J	Lim, KS; Lim, KJ; Price, AC; Orr, BA; Eberhart, CG; Bar, EE				Lim, K. S.; Lim, K. J.; Price, A. C.; Orr, B. A.; Eberhart, C. G.; Bar, E. E.			Inhibition of monocarboxylate transporter-4 depletes stem-like glioblastoma cells and inhibits HIF transcriptional response in a lactate-independent manner	ONCOGENE			English	Article						hypoxia; monocarboxylate transporter-4; stem cells; glioma	HYPOXIA-INDUCIBLE FACTORS; MALIGNANT GLIOMA; LACTIC-ACID; OXYGEN; GROWTH; EXPRESSION; MCT4; ACTIVATION; EXPANSION; PATHWAY	Hypoxic regions are frequent in glioblastoma (GBM), the most common type of malignant adult brain tumor, and increased levels of tumor hypoxia have been associated with worse clinical outcomes. To unmask genes important in hypoxia, we treated GBM neurospheres in hypoxia and identified monocarboxylate transporter-4 (MCT4) as one of the most upregulated genes. To investigate the clinical importance of MCT4 in GBM, we examined clinical outcomes and found that MCT4 overexpression is associated with shorter patient survival. Consistent with this, MCT4 upregulation correlated with the aggressive mesenchymal subset of GBM, and MCT4 downregulation correlated with the less aggressive G-CIMP (Glioma CpG Methylator Phenotype) subset of GBM. Immunohistochemical analysis of tissue microarrays confirmed that MCT4 protein levels were increased in high-grade as compared with lower-grade astrocytomas, further suggesting that MCT4 is a clinically relevant target. To test the requirement for MCT4 in vitro, we transduced neurospheres with lentiviruses encoding short-hairpin RNAs (shRNAs) against MCT4, resulting in growth inhibition of 50-80% under hypoxia in two lines. MCT4 knockdown was associated with a decreased percentage of cells expressing the stem-cell marker CD133 and increased apoptotic fraction. We also found that flow-sorted CD133-positive cells had almost sixfold higher MCT4 levels than CD133-negative cells, suggesting that the stem-like population might have a greater requirement for MCT4. Most importantly, MCT4 silencing also slowed GBM intracranial xenograft growth in vivo. Interestingly, whereas MCT4 is a well-characterized lactate exporter, we found that both intracellular and extracellular lactate levels did not change following MCT4 silencing, suggesting a novel lactate export-independent mechanism for growth inhibition in GBMs. To identify this potential mechanism, we performed microarray analysis on control and shMCT4-expressing neurospheres and found a dramatic reduction in the expression of multiple Hypoxia-Inducible Factor (HIF)-regulated genes following MCT4 knockdown. The overall reduction in HIF transcriptional response was further validated using a hypoxia response element (HRE)dependent green-fluorescent protein (GFP) reporter line.	[Lim, K. S.; Lim, K. J.; Price, A. C.; Eberhart, C. G.; Bar, E. E.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Orr, B. A.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; [Eberhart, C. G.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; [Eberhart, C. G.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Bar, E. E.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA	Johns Hopkins University; St Jude Children's Research Hospital; Johns Hopkins University; Johns Hopkins University; Case Western Reserve University	Bar, EE (corresponding author), Case Western Reserve Univ, Sch Med, Dept Neurol Surg, Robbins Bldg,Room E750A,10900 Euclid Ave, Cleveland, OH 44106 USA.	eli.bar@case.edu	Orr, Brent/N-8068-2018		Brain Tumor Funders Collaborative;  [R01 NS55089]; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS055089] Funding Source: NIH RePORTER	Brain Tumor Funders Collaborative; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the Brain Tumor Funders Collaborative and R01 NS55089.	Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007-0166; Bar EE, 2011, BRAIN PATHOL, V21, P119, DOI 10.1111/j.1750-3639.2010.00460.x; Bar EE, 2010, AM J PATHOL, V177, P1491, DOI 10.2353/ajpath.2010.091021; Cheng C, 2012, CELL ONCOL, V35, P217, DOI 10.1007/s13402-012-0081-9; Chiche J, 2012, INT J CANCER, V130, P1511, DOI 10.1002/ijc.26125; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Colen CB, 2011, NEOPLASIA, V13, P620, DOI 10.1593/neo.11134; Collins PC, 1998, BIOTECHNOL PROGR, V14, P466, DOI 10.1021/bp980032e; Dimmer KS, 2000, BIOCHEM J, V350, P219, DOI 10.1042/0264-6021:3500219; Ehtesham M, 2007, ONCOGENE, V26, P5752, DOI 10.1038/sj.onc.1210359; Estrada JC, 2012, CELL DEATH DIFFER, V19, P743, DOI 10.1038/cdd.2011.172; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Fan X, 2010, STEM CELLS, V28, P5, DOI 10.1002/stem.254; Fang J, 2006, MOL PHARMACOL, V70, P2108, DOI 10.1124/mol.106.026245; Fox JEM, 2000, J PHYSIOL-LONDON, V529, P285, DOI 10.1111/j.1469-7793.2000.00285.x; Froberg MK, 2001, NEUROREPORT, V12, P761, DOI 10.1097/00001756-200103260-00030; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gong AH, 2012, CANCER RES, V72, P5658, DOI 10.1158/0008-5472.CAN-12-0953; Grabmaier K, 2004, ONCOGENE, V23, P5624, DOI 10.1038/sj.onc.1207764; Heddleston JM, 2010, BRIT J CANCER, V102, P789, DOI 10.1038/sj.bjc.6605551; Heddleston JM, 2009, CELL CYCLE, V8, P3274, DOI 10.4161/cc.8.20.9701; Hu YY, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-82; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; Kita Y, 2011, ANN SURG ONCOL, V18, P261, DOI 10.1245/s10434-010-1271-1; Kobayashi M, 2005, BIOL PHARM BULL, V28, P1197, DOI 10.1248/bpb.28.1197; Le Floch R, 2011, P NATL ACAD SCI USA, V108, P16663, DOI 10.1073/pnas.1106123108; Li KKW, 2009, HUM PATHOL, V40, P1234, DOI 10.1016/j.humpath.2009.02.003; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Lin Q, 2008, GENE REGUL SYST BIO, V2, P43; Mathupala SP, 2004, NEUROSURGERY, V55, P1410, DOI 10.1227/01.NEU.0000143034.62913.59; Miranda-Goncalves V, 2013, NEURO-ONCOLOGY, V15, P172, DOI 10.1093/neuonc/nos298; Pistollato F, 2007, MOL CELL NEUROSCI, V35, P424, DOI 10.1016/j.mcn.2007.04.003; Pistollato F, 2009, STEM CELLS, V27, P7, DOI 10.1634/stemcells.2008-0402; Purow BW, 2005, CANCER RES, V65, P2353, DOI 10.1158/0008-5472.CAN-04-1890; Schietke R, 2010, J BIOL CHEM, V285, P6658, DOI 10.1074/jbc.M109.042424; Seidel S, 2010, BRAIN, V133, P983, DOI 10.1093/brain/awq042; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Stiehl DP, 2012, ONCOGENE, V31, P2283, DOI 10.1038/onc.2011.417; Szeto MD, 2009, CANCER RES, V69, P4502, DOI 10.1158/0008-5472.CAN-08-3884; Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vordermark D, 2001, NEOPLASIA, V3, P527, DOI 10.1038/sj.neo.7900192; Wang Q, 2013, MOL BIOL REP, V40, P3723, DOI 10.1007/s11033-012-2448-4; Westerman KA, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-96; Westfall SD, 2008, STEM CELLS DEV, V17, P869, DOI 10.1089/scd.2007.0240; Zhang KL, 2012, J NEUROIMMUNE PHARM, V7, P740, DOI 10.1007/s11481-012-9359-y; Zhang XP, 2008, MOL CELL BIOCHEM, V307, P101, DOI 10.1007/s11010-007-9589-0; Zhou YF, 2011, J BIOL CHEM, V286, P32843, DOI 10.1074/jbc.M111.260935; Zhu LL, 2011, CELL REPROGRAM, V13, P113, DOI 10.1089/cell.2010.0043	49	48	48	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2014	33	35					4433	4441		10.1038/onc.2013.390	http://dx.doi.org/10.1038/onc.2013.390			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MR	24077291	Green Accepted			2022-12-17	WOS:000341157800008
J	Tian, TV; Tomavo, N; Huot, L; Flourens, A; Bonnelye, E; Flajollet, S; Hot, D; Leroy, X; de Launoit, Y; Duterque-Coquillaud, M				Tian, T. V.; Tomavo, N.; Huot, L.; Flourens, A.; Bonnelye, E.; Flajollet, S.; Hot, D.; Leroy, X.; de Launoit, Y.; Duterque-Coquillaud, M.			Identification of novel TMPRSS2: ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2	ONCOGENE			English	Article						prostate cancer; TMPRSS2: ERG fusion; migration; invasion; MMP9; PLXNA2	GENE FUSION; MATRIX METALLOPROTEINASES; MESENCHYMAL TRANSITION; CELL INVASION; TUMOR-CELLS; EXPRESSION; RESISTANT; FAMILY; MATRIX-METALLOPROTEINASE-9; HETEROGENEITY	Prostate cancer (PCa) is one of the major public health problems in Western countries. Recently, the TMPRSS2: ERG gene fusion, which results in the aberrant expression of the transcription factor ERG, has been shown to be the most common gene rearrangement in PCa. Previous studies have determined the contributions of this fusion in PCa disease initiation and/or progression in vitro and in vivo. In this study on TMPRSS2: ERG regulation in PCa, we used an androgen receptor and TMPRSS2: ERG fusion double-negative PCa cell model: PC3c. In three cell clones with different TMPRSS2: ERG expression levels, ectopic expression of the fusion resulted in significant induction of cell migration and invasion in a dose-dependent manner. In agreement with this phenotype, high-throughput microarray analysis revealed that a set of genes, functionally associated with cell motility and invasiveness, were deregulated in a dose-dependent manner in TMPRSS2: ERG-expressing cells. Importantly, we identified increased MMP9 (Metalloproteinase 9) and PLXNA2 (Plexin A2) expression in TMPRSS2: ERG-positive PCa samples, and their expression levels were significantly correlated with ERG expression in a PCa cohort. In line with these findings, there was evidence that TMPRSS2: ERG directly and positively regulates MMP9 and PLXNA2 expression in PC3c cells. Moreover, PLXNA2 upregulation contributed to TMPRSS2: ERG-mediated enhancements of PC3c cell migration and invasion. Furthermore, and importantly, PLXNA2 expression was upregulated in metastatic PCa tumors compared with localized primary PCa tumors. This study provides novel insights into the role of the TMPRSS2: ERG fusion in PCa metastasis.	[Tian, T. V.; Tomavo, N.; Flourens, A.; Flajollet, S.; de Launoit, Y.; Duterque-Coquillaud, M.] CNRS, UMR8161, Inst Biol Lille, F-59021 Lille, France; [Tian, T. V.; Tomavo, N.; Huot, L.; Flourens, A.; Flajollet, S.; Hot, D.; de Launoit, Y.; Duterque-Coquillaud, M.] Inst Pasteur, IFR142, F-59019 Lille, France; [Tian, T. V.; Tomavo, N.; Huot, L.; Flourens, A.; Flajollet, S.; Hot, D.; Leroy, X.; de Launoit, Y.; Duterque-Coquillaud, M.] Univ Lille Nord France, Lille, France; [Tian, T. V.; Leroy, X.] Univ Droit & Sante Lille II, Fac Med Henri Warembourg, Lille, France; [Huot, L.; Hot, D.] CNRS, UMR8204, INSERM U1019, Ctr Infect & Immunite Lille, Lille, France; [Bonnelye, E.] INSERM, U1033, F-69008 Lyon, France; [Leroy, X.] CHRU Lille, Inst Pathol, F-59037 Lille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille	Duterque-Coquillaud, M (corresponding author), CNRS, UMR8161, Inst Biol Lille, 1 Rue Prof Calmette,BP447, F-59021 Lille, France.	martine.duterque@ibl.fr	Bonnelye, Edith/AAT-9134-2021; TIAN, TIAN/O-1726-2015; Hot, David/M-6775-2016	de Launoit, Yvan/0000-0003-1837-9808; TIAN, TIAN/0000-0002-9906-0980; Duterque-Coquillaud, Martine/0000-0003-3943-5629; Hot, David/0000-0002-2361-0616	Centre national de la recherche scientifique (CNRS); La Ligue contre le Cancer (Comite ' du Pas-de- Calais); Institut national du cancer [INCa_4419]; Institut Pasteur of Lille/ Nord-Pas-de-Calais Regional Council (Region Nord- Pas-de-Calais); Association pour la recherche sur le cancer (ARC)	Centre national de la recherche scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); La Ligue contre le Cancer (Comite ' du Pas-de- Calais); Institut national du cancer(Institut National du Cancer (INCA) France); Institut Pasteur of Lille/ Nord-Pas-de-Calais Regional Council (Region Nord- Pas-de-Calais)(Region Hauts-de-France); Association pour la recherche sur le cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer)	We would like to thank A Fradet, M Le Jeune, M Holder, C Delliaux, G Boulay, M Dubuissez, I Loison, Z Kherrouche and N Malaquin for their excellent technical advices; D Lacorre and E Werkmeister from the BioImaging Center Lille Nord de France for their technical assistance; E Lelievre and D Leprince for their stimulating discussions; and C Engel- Gautier for her critical reading of the manuscript. We also like to thank the local Tumor Tissue Bank (Tumorothe` que), Regional Reference Oncology Center (CRRC) ( Head, Pr. MC Copin) in Lille, France. This work was supported by grants from the Centre national de la recherche scientifique (CNRS), La Ligue contre le Cancer (Comite ' du Pas-de- Calais) and the Institut national du cancer (INCa_4419). TV Tian is a recipient of PhD fellowships from the Institut Pasteur of Lille/ Nord-Pas-de-Calais Regional Council (Region Nord- Pas-de-Calais) and the Association pour la recherche sur le cancer (ARC).	Andreoiu M, 2010, HUM PATHOL, V41, P781, DOI 10.1016/j.humpath.2010.02.011; Attard G, 2008, ONCOGENE, V27, P253, DOI 10.1038/sj.onc.1210640; Attard G, 2009, CANCER RES, V69, P2912, DOI 10.1158/0008-5472.CAN-08-3667; Barry M, 2007, UROLOGY, V70, P630, DOI 10.1016/j.urology.2007.08.032; Becker-Santos DD, 2012, CARCINOGENESIS, V33, P2558, DOI 10.1093/carcin/bgs285; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Blanc V, 2011, PROSTATE, V71, P649, DOI 10.1002/pros.21281; Brown CB, 2001, DEVELOPMENT, V128, P3071; Capparuccia L, 2009, J CELL SCI, V122, P1723, DOI 10.1242/jcs.030197; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Castellano G, 2008, CLIN CANCER RES, V14, P7470, DOI 10.1158/1078-0432.CCR-08-0870; Cheng L, 1998, J NATL CANCER I, V90, P233, DOI 10.1093/jnci/90.3.233; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Chng KR, 2012, EMBO J, V31, P2810, DOI 10.1038/emboj.2012.112; Clark J, 2007, ONCOGENE, V26, P2667, DOI 10.1038/sj.onc.1210070; Demichelis F, 2007, ONCOGENE, V26, P4596, DOI 10.1038/sj.onc.1210237; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; dos Reis ST, 2009, J UROLOGY, V181, P2320, DOI 10.1016/j.juro.2009.01.012; FitzGerald LM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-230; Flajollet S, 2009, J IMMUNOL, V183, P6948, DOI 10.4049/jimmunol.0902053; Fradet A, 2010, BONE, V47, pS289, DOI 10.1016/j.bone.2010.01.224; Franco M, 2008, EMBO REP, V9, P865, DOI 10.1038/embor.2008.139; Furusato B, 2010, PROSTATE CANCER P D, V13, P228, DOI 10.1038/pcan.2010.23; Gopalan A, 2009, CANCER RES, V69, P1400, DOI 10.1158/0008-5472.CAN-08-2467; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guo CC, 2012, HUM PATHOL, V43, P644, DOI 10.1016/j.humpath.2011.06.018; Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008-5472.CAN-10-0244; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hance MW, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.389015; Hanzawa M, 2000, CARCINOGENESIS, V21, P1079, DOI 10.1093/carcin/21.6.1079; Hermans KG, 2009, CLIN CANCER RES, V15, P6398, DOI 10.1158/1078-0432.CCR-09-1176; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Hoogland AM, 2012, MODERN PATHOL, V25, P471, DOI 10.1038/modpathol.2011.176; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Kato T, 2012, BIOCHEM BIOPH RES CO, V417, P966, DOI 10.1016/j.bbrc.2011.12.047; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Kodo K, 2009, P NATL ACAD SCI USA, V106, P13933, DOI 10.1073/pnas.0904744106; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kunderfranco P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010547; Le Jeune M, 2010, EXP CELL RES, V316, P203, DOI 10.1016/j.yexcr.2009.10.002; Leshem O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021650; Macintosh CA, 1998, CANCER RES, V58, P23; Mehra R, 2008, CANCER RES, V68, P3584, DOI 10.1158/0008-5472.CAN-07-6154; Mehra R, 2007, CANCER RES, V67, P7991, DOI 10.1158/0008-5472.CAN-07-2043; Minner S, 2013, MODERN PATHOL, V26, P106, DOI 10.1038/modpathol.2012.130; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Nakamura Y, 2004, J IMMUNOL, V172, P1945, DOI 10.4049/jimmunol.172.3.1945; Nam RK, 2007, BRIT J CANCER, V97, P1690, DOI 10.1038/sj.bjc.6604054; Nam RK, 2007, CANCER BIOL THER, V6, P40, DOI 10.4161/cbt.6.1.3489; Nese N, 2010, ANAL QUANT CYTOL, V32, P90; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482; Perner S, 2010, UROLOGY, V75, P762, DOI 10.1016/j.urology.2009.10.010; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Rubin MA, 2011, J CLIN ONCOL, V29, P3659, DOI 10.1200/JCO.2011.35.1916; Sakurai-Yageta M, 2008, J CELL BIOL, V181, P985, DOI 10.1083/jcb.200709076; Saramaki OR, 2008, CLIN CANCER RES, V14, P3395, DOI 10.1158/1078-0432.CCR-07-2051; Scher HI, 2011, J CLIN ONCOL, V29, P3695, DOI 10.1200/JCO.2011.35.8648; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Squire JA, 2011, ADV CANCER RES, V112, P183, DOI 10.1016/B978-0-12-387688-1.00007-7; Steffan JJ, 2012, J BIOL CHEM, V287, P29968, DOI 10.1074/jbc.M112.379396; Stott SL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000403; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Toyofuku T, 2008, DEV BIOL, V321, P251, DOI 10.1016/j.ydbio.2008.06.028; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Vlaeminck-Guillem V, 2000, MECH DEVELOP, V91, P331, DOI 10.1016/S0925-4773(99)00272-5; Wang JH, 2008, CANCER RES, V68, P8516, DOI 10.1158/0008-5472.CAN-08-1147; Wang JH, 2006, CANCER RES, V66, P8347, DOI 10.1158/0008-5472.CAN-06-1966; Wei GH, 2010, EMBO J, V29, P2147, DOI 10.1038/emboj.2010.106; Wong OGW, 2007, P NATL ACAD SCI USA, V104, P19040, DOI 10.1073/pnas.0702544104; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhou C, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-11; Zong Y, 2009, P NATL ACAD SCI USA, V106, P12465, DOI 10.1073/pnas.0905931106	80	48	51	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2204	2214		10.1038/onc.2013.176	http://dx.doi.org/10.1038/onc.2013.176			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23708657	Green Submitted, Green Published			2022-12-17	WOS:000334996000006
J	Wardwell-Ozgo, J; Dogruluk, T; Gifford, A; Zhang, Y; Heffernan, TP; van Doorn, R; Creighton, CJ; Chin, L; Scott, KL				Wardwell-Ozgo, J.; Dogruluk, T.; Gifford, A.; Zhang, Y.; Heffernan, T. P.; van Doorn, R.; Creighton, C. J.; Chin, L.; Scott, K. L.			HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome	ONCOGENE			English	Article						HOXA1; melanoma; metastasis; MITF; TGF beta	BETA; MITF; THICKNESS; SURVIVAL; ROLES; CELLS	Melanoma is a highly lethal malignancy notorious for its aggressive clinical course and eventual resistance to existing therapies. Currently, we possess a limited understanding of the genetic events driving melanoma progression, and much effort is focused on identifying pro-metastatic aberrations or perturbed signaling networks that constitute new therapeutic targets. In this study, we validate and assess the mechanism by which homeobox transcription factor A1 (HOXA1), a pro-invasion oncogene previously identified in a metastasis screen by our group, contributes to melanoma progression. Transcriptome and pathway profiling analyses of cells expressing HOXA1 reveals upregulation of factors involved in diverse cytokine pathways that include the transforming growth factor beta (TGF beta) signaling axis, which we further demonstrate to be required for HOXA1-mediated cell invasion in melanoma cells. Transcriptome profiling also shows HOXA1's ability to potently downregulate expression of microphthalmia-associated transcription factor (MITF) and other genes required for melanocyte differentiation, suggesting a mechanism by which HOXA1 expression de-differentiates cells into a pro-invasive cell state concomitant with TGF beta activation. Our analysis of publicly available data sets indicate that the HOXA1-induced gene signature successfully categorizes melanoma specimens based on their metastatic potential and, importantly, is capable of stratifying melanoma patient risk for metastasis based on expression in primary tumors. Together, these validation data and mechanistic insights suggest that patients whose primary tumors express HOXA1 are among a high-risk metastasis subgroup that should be considered for anti-TGF beta therapy in adjuvant settings. Moreover, further analysis of HOXA1 target genes in melanoma may reveal new pathways or targets amenable to therapeutic intervention.	[Wardwell-Ozgo, J.; Dogruluk, T.; Gifford, A.; Scott, K. L.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Zhang, Y.; Creighton, C. J.; Scott, K. L.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Heffernan, T. P.; Chin, L.] Univ Texas MD Anderson Canc Ctr, Inst Appl Canc Sci, Houston, TX 77030 USA; [van Doorn, R.] Leiden Univ, Med Ctr, Dept Dermatol, Leiden, Netherlands; [Chin, L.] Dept Genom Med, Houston, TX USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Scott, KL (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, One Baylor Plaza,BCM225, Houston, TX 77030 USA.	kls1@bcm.edu		Dogruluk, Turgut/0000-0002-9212-9471; Wardwell-Ozgo, Joanna/0000-0002-5295-1604; van Doorn, Remco/0000-0002-7019-6673	American Cancer Society; Baylor College of Medicine; NIH [RO1 CA93947, U01 CA84313]; NATIONAL CANCER INSTITUTE [U01CA084313, R01CA093947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008231, T32GM008307] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); Baylor College of Medicine; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	KLS was supported by the American Cancer Society, and this work was supported by departmental seed funds to KLS from Baylor College of Medicine. This work was also supported by grants from the NIH (RO1 CA93947, U01 CA84313) to LC.	Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Creighton CJ, 2008, J CLIN ONCOL, V26, P4078, DOI 10.1200/JCO.2007.13.4429; Criscione VD, 2010, J INVEST DERMATOL, V130, P793, DOI 10.1038/jid.2009.328; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Gavalas A, 2001, DEVELOPMENT, V128, P3017; Gimotty PA, 2007, J CLIN ONCOL, V25, P1129, DOI 10.1200/JCO.2006.08.1463; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Jeffs AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008461; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kaminska B, 2005, ACTA BIOCHIM POL, V52, P329; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Lekmine F, 2007, BIOCHEM BIOPH RES CO, V354, P830, DOI 10.1016/j.bbrc.2007.01.075; Maeda K, 2005, INT J CANCER, V114, P436, DOI 10.1002/ijc.20706; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Mohammad KS, 2011, CANCER RES, V71, P175, DOI 10.1158/0008-5472.CAN-10-2651; Nishimura EK, 2010, CELL STEM CELL, V6, P130, DOI 10.1016/j.stem.2009.12.010; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Remacle S, 2002, NUCLEIC ACIDS RES, V30, P2663, DOI 10.1093/nar/gkf372; Scott KL, 2011, CANCER CELL, V20, P92, DOI 10.1016/j.ccr.2011.05.025; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Svingen T, 2006, HEREDITY, V97, P88, DOI 10.1038/sj.hdy.6800847; Timar J, 2010, CLIN EXP METASTAS, V27, P371, DOI 10.1007/s10585-010-9307-2; Tuong W, 2012, DERMATOL CLIN, V30, P113, DOI 10.1016/j.det.2011.08.006; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Winnepenninckx VR, 2006, JNCI-J NATL CANCER I, V98, P472, DOI 10.1093/jnci/djj103; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	35	48	48	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					1017	1026		10.1038/onc.2013.30	http://dx.doi.org/10.1038/onc.2013.30			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23435427	Green Accepted			2022-12-17	WOS:000331933200009
J	Xie, X; Piao, L; Bullock, BN; Smith, A; Su, T; Zhang, M; Teknos, TN; Arora, PS; Pan, Q				Xie, X.; Piao, L.; Bullock, B. N.; Smith, A.; Su, T.; Zhang, M.; Teknos, T. N.; Arora, P. S.; Pan, Q.			Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma	ONCOGENE			English	Article						human papillomavirus; anticancer therapeutics; p53; p300; head and neck cancer	HUMAN-PAPILLOMAVIRUS TYPE-16; E6 ONCOPROTEIN; CERVICAL-CANCER; STRUCTURAL BASIS; STEM-CELLS; PROTEIN; ACETYLATION; ACTIVATION; UBIQUITINATION; IDENTIFICATION	The incidence of human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) has rapidly increased over the past 30 years, prompting the suggestion that an epidemic maybe on the horizon. Therefore, there is a clinical need to develop alternate therapeutic strategies to manage the growing number of HPV-positive HNSCC patients. High-risk HPV E6 inactivates p53 through two distinct mechanisms; association with E6AP to degrade p53 and association with p300 to block p300-mediated p53 acetylation and activation. In this study, we determined if targeting the E6-p300 interaction is an effective approach to reactivate p53 in HPV-positive HNSCC. Ectopic expression of the CH1 domain of p300 in HPV-positive HNSCC blocks the association between E6 and p300, increases total and acetylated p53 levels and enhances p53 transcriptional activity. Moreover, expression of p21, miR-34a and miR-200c are increased, demonstrating functional p53 reactivation. CH1 overexpression in HPV-positive HNSCC has a global anticancer effect resulting in a decrease in cell proliferation and clonogenic survival and an increase in apoptosis. The in vivo tumor-initiating ability of HPV-positive HNSCC is severely compromised with CH1 overexpression, in part through a reduction in the cancer-initiating cell population. A novel small-molecule CH1 inhibitor, CH1iB, reactivates p53 and potentiates the anticancer activity of cis-platinum in HPV-positive HNSCC cells. Our work shows that CH1-domain inhibitors represent a novel class of p53-reactivation therapeutics for managing HPV-positive HNSCC patients.	[Xie, X.; Piao, L.; Smith, A.; Su, T.; Zhang, M.; Teknos, T. N.; Pan, Q.] Ohio State Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, Columbus, OH 43210 USA; [Xie, X.; Piao, L.; Smith, A.; Su, T.; Zhang, M.; Teknos, T. N.; Pan, Q.] Arthur G James Canc Hosp, Columbus, OH USA; [Xie, X.; Piao, L.; Smith, A.; Su, T.; Zhang, M.; Teknos, T. N.; Pan, Q.] Ohio State Univ, Ctr Comprehens Canc, Richard J Solove Res Inst, Columbus, OH 43210 USA; [Bullock, B. N.; Arora, P. S.] NYU, Dept Chem, New York, NY 10003 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; New York University	Pan, Q (corresponding author), Ohio State Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, 442 Tzagournis Med Res,420 West 12th Ave, Columbus, OH 43210 USA.	Quintin.Pan@osumc.edu	Reever, Larson/H-9685-2019; Arora, Paramjit/AAR-3086-2020; Pan, Quintin/E-3808-2011	Reever, Larson/0000-0002-5692-4793; 	National Institutes of Health [R01CA135096, R01GM073943]; Mary E. and John W. Alford Cancer Research Endowment Fund; Joan Bisesi Fund for Head and Neck Oncology Research; Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [P30CA016058, R01CA135096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073943] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mary E. and John W. Alford Cancer Research Endowment Fund; Joan Bisesi Fund for Head and Neck Oncology Research; Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by National Institutes of Health grants R01CA135096 (to QP) and R01GM073943 (to PSA); Mary E. and John W. Alford Cancer Research Endowment Fund; The Michelle Theado Memorial Grant from the Joan Bisesi Fund for Head and Neck Oncology Research; and Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University Comprehensive Cancer Center.	Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Balz V, 2003, CANCER RES, V63, P1188; Beerheide W, 2000, BIOORGAN MED CHEM, V8, P2549, DOI 10.1016/S0968-0896(00)00193-0; Beerheide W, 1999, J NATL CANCER I, V91, P1211, DOI 10.1093/jnci/91.14.1211; BeerRomero P, 1997, ONCOGENE, V14, P595, DOI 10.1038/sj.onc.1200872; Chang CJ, NAT CELL BIOL MAR, p[13, 317]; Chen YC, 2009, BIOCHEM BIOPH RES CO, V385, P307, DOI 10.1016/j.bbrc.2009.05.048; Choi YJ, NAT CELL BIOL, P1353; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Clay MR, 2010, HEAD NECK-J SCI SPEC, V32, P1195, DOI 10.1002/hed.21315; Courtete J, 2007, MOL CANCER THER, V6, P1728, DOI 10.1158/1535-7163.MCT-06-0808; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hammarstedt L, 2006, INT J CANCER, V119, P2620, DOI 10.1002/ijc.22177; Henchey LK, 2010, J AM CHEM SOC, V132, P941, DOI 10.1021/ja9082864; Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Kawamura T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311; Klussmann JP, 2003, AM J PATHOL, V162, P747, DOI 10.1016/S0002-9440(10)63871-0; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Koivusalo R, 2006, CANCER RES, V66, P11817, DOI 10.1158/0008-5472.CAN-06-2185; Laz TH, 2012, VACCINE, V30, P3534, DOI 10.1016/j.vaccine.2012.03.067; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Licitra Lisa, 2006, Curr Opin Otolaryngol Head Neck Surg, V14, P95, DOI 10.1097/01.moo.0000193170.23956.5f; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Munoz N, 2010, JNCI-J NATL CANCER I, V102, P325, DOI 10.1093/jnci/djp534; Pan Q, 2009, EXPERT OPIN PHARMACO, V10, P2291, DOI 10.1517/14656560903136754; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Patgiri A, 2008, ACCOUNTS CHEM RES, V41, P1289, DOI 10.1021/ar700264k; Patgiri A, 2010, NAT PROTOC, V5, P1857, DOI 10.1038/nprot.2010.146; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Reiter PL, 2011, VACCINE, V29, P5595, DOI 10.1016/j.vaccine.2011.06.020; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shiboski CH, 2005, CANCER-AM CANCER SOC, V103, P1843, DOI 10.1002/cncr.20998; Sigurdsson K, 2009, ACTA OBSTET GYN SCAN, V88, P27, DOI 10.1080/00016340802566770; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Sturgis EM, 2007, CANCER-AM CANCER SOC, V110, P1429, DOI 10.1002/cncr.22963; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Utikal J, 2009, NATURE, V460, P1145, DOI 10.1038/nature08285; Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741; White JS, 2007, ORAL ONCOL, V43, P701, DOI 10.1016/j.oraloncology.2006.09.001; Zhao CY, 2010, CANCER RES, V70, P3372, DOI 10.1158/0008-5472.CAN-09-2787; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	49	48	52	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					1037	1046		10.1038/onc.2013.25	http://dx.doi.org/10.1038/onc.2013.25			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23474763	Green Accepted			2022-12-17	WOS:000331933200011
J	You, X; Liu, F; Zhang, T; Lv, N; Liu, Q; Shan, C; Du, Y; Kong, G; Wang, T; Ye, L; Zhang, X				You, X.; Liu, F.; Zhang, T.; Lv, N.; Liu, Q.; Shan, C.; Du, Y.; Kong, G.; Wang, T.; Ye, L.; Zhang, X.			Hepatitis B virus X protein upregulates Lin28A/Lin28B through Sp-1/c-Myc to enhance the proliferation of hepatoma cells	ONCOGENE			English	Article						hepatitis B virus X protein; Lin28A; Lin28B; proliferation; hepatocellular carcinoma	C-MYC; PROMOTES TRANSFORMATION; LET-7 MICRORNA; MESSENGER-RNA; EXPRESSION; LIN28; BINDING; GROWTH; IDENTIFICATION; ACTIVATION	Hepatitis B virus X protein (HBx) plays critical roles in the pathogenesis of hepatocellular carcinoma (HCC). Here, we were interested in knowing whether the oncogene Lin28A and its homolog Lin28B are involved in the hepatocarcinogenesis mediated by HBx. We showed that the expression levels of Lin28A and Lin28B were increased in clinical HCC tissues, HepG2.2.15 cell line and liver tissues of p21-HBx transgenic mice. Interestingly, the expression levels of HBx were positively associated with those of Lin28A/Lin28B in clinical HCC tissues. Moreover, the overexpression of HBx resulted in the upregulation of Lin28A/Lin28B in hepatoma HepG2/H7402 cell lines by transient transfection, suggesting that HBx was able to upregulate Lin28A and Lin28B. Then, we examined the mechanism by which HBx upregulated Lin28A and Lin28B. We identified that the promoter region of Lin28A regulated by HBx was located at nt -235/-66 that contained Sp-1 binding element. Co-immunoprecipitation showed that HBx was able to interact with Sp-1 in HepG2-X cells. Moreover, chromatin immunoprecipitation (ChIP) demonstrated that HBx could bind to the promoter of Lin28A, which failed to work when Sp-1 was silenced. Electrophoretic mobility shift assay (EMSA) further identified that HBx was able to interact with Sp-1 element in Lin28A promoter via transcription factor Sp-1. In addition, we found that c-Myc was involved in the activation of Lin28B mediated by HBx. In function, Lin28A/Lin28B played important roles in HBx-enhanced proliferation of hepatoma cells in vitro and in vivo. In conclusion, HBx activates Lin28A/Lin28B through Sp-1/c-Myc in hepatoma cells. Lin28A/Lin28B serves as key driver genes in HBx-induced hepatocarcinogenesis.	[You, X.; Zhang, T.; Lv, N.; Shan, C.; Du, Y.; Kong, G.; Wang, T.; Zhang, X.] Nankai Univ, Coll Life Sci, Key Lab Mol Microbiol & Technol, Minist Educ,Dept Canc Res, Tianjin 300071, Peoples R China; [Liu, F.; Liu, Q.; Ye, L.] Nankai Univ, Coll Life Sci, Dept Biochem, Tianjin 300071, Peoples R China	Nankai University; Nankai University	Zhang, X (corresponding author), Nankai Univ, Coll Life Sci, Key Lab Mol Microbiol & Technol, Inst Mol Biol,Minist Educ,Dept Canc Res, 94 Weijin Rd, Tianjin 300071, Peoples R China.	yelihong@nankai.edu.cn; zhangxd@nankai.edu.cn	Zhang, Tao/F-4366-2018; Shan, changliang/L-9029-2016	Zhang, Tao/0000-0002-4749-6774; You, Xiaona/0000-0001-9996-1466	National Basic Research Program of China (973 Program) [2009CB521702]; National Natural Science Foundation of China [81071624, 81272218]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Dr Xiao Yang (from the Genetic Laboratory of Development and Diseases, Institute of Biotechnology, Beijing, People's Republic of China) for kindly providing the HBx transgenic mice. This work was supported in part by National Basic Research Program of China (973 Program, No. 2009CB521702) and National Natural Science Foundation of China (No. 81071624, 81272218).	Abdelrahim M, 2004, CANCER RES, V64, P6740, DOI 10.1158/0008-5472.CAN-04-0713; Ali N, 2011, J VIROL, V85, P12292, DOI 10.1128/JVI.05920-11; Arbuthnot P, 2001, INT J EXP PATHOL, V82, P77, DOI 10.1111/j.1365-2613.2001.iep178.x; Arzumanyan A, 2011, CANCER RES, V71, P3701, DOI 10.1158/0008-5472.CAN-10-3951; Cao DF, 2011, HUM PATHOL, V42, P710, DOI 10.1016/j.humpath.2010.09.007; Carmona S, 2006, MOL THER, V13, P411, DOI 10.1016/j.ymthe.2005.10.013; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Du YM, 2012, J BIOL CHEM, V287, P26302, DOI 10.1074/jbc.M112.342113; Fang H, 2005, MOL BRAIN RES, V136, P1, DOI 10.1016/j.molbrainres.2004.12.024; Guo YQ, 2006, GENE, V384, P51, DOI 10.1016/j.gene.2006.07.011; Hamano R, 2012, BRIT J CANCER, V106, P1415, DOI 10.1038/bjc.2012.90; Helland A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018064; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Kim HH, 2009, GENE DEV, V23, P1743, DOI 10.1101/gad.1812509; King CE, 2011, ONCOGENE, V30, P4185, DOI 10.1038/onc.2011.131; King CE, 2011, CANCER RES, V71, P4260, DOI 10.1158/0008-5472.CAN-10-4637; Kong GY, 2011, ACTA PHARMACOL SIN, V32, P1173, DOI 10.1038/aps.2011.52; Kong GY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019518; Li L, 2012, HEPATOLOGY, V56, P1380, DOI 10.1002/hep.25891; Li WH, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-45; Liang LH, 2010, HEPATOLOGY, V52, P1731, DOI 10.1002/hep.23904; Liu QY, 2011, J BIOL CHEM, V286, P17168, DOI 10.1074/jbc.M110.167783; Michielsen P, 2011, ACTA GASTRO-ENT BELG, V74, P4; Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108; Ng SA, 2011, J GASTROENTEROL, V46, P974, DOI 10.1007/s00535-011-0415-9; Pan L, 2011, MOL CELL BIOCHEM, V355, P257, DOI 10.1007/s11010-011-0862-x; Peng S, 2010, ONCOGENE, V29, P2153, DOI 10.1038/onc.2009.500; Piskounova E, 2008, J BIOL CHEM, V283, P21310, DOI 10.1074/jbc.C800108200; Piskounova E, 2011, CELL, V147, P1066, DOI 10.1016/j.cell.2011.10.039; Polesskaya A, 2007, GENE DEV, V21, P1125, DOI 10.1101/gad.415007; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Qiu CH, 2010, NUCLEIC ACIDS RES, V38, P1240, DOI 10.1093/nar/gkp1071; Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006; Sakurai M, 2012, J STEROID BIOCHEM, V131, P101, DOI 10.1016/j.jsbmb.2011.10.007; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shan CL, 2011, CARCINOGENESIS, V32, P1190, DOI 10.1093/carcin/bgr106; Shan CL, 2010, CELL RES, V20, P563, DOI 10.1038/cr.2010.49; Shona JK, 2009, VIRUS RES, V139, P14, DOI 10.1016/j.virusres.2008.09.006; Sze KMF, 2011, HEPATOLOGY, V53, P1558, DOI 10.1002/hep.24232; Tang H, 2006, CANCER SCI, V97, P977, DOI 10.1111/j.1349-7006.2006.00299.x; Tang H, 2009, HEPATOLOGY, V49, P60, DOI 10.1002/hep.22581; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Wang Q, 2010, NEOPLASIA, V12, P103, DOI 10.1593/neo.91298; Wang YL, 2004, HEPATOLOGY, V39, P318, DOI 10.1002/hep.20076; Wang YC, 2010, CARCINOGENESIS, V31, P1516, DOI 10.1093/carcin/bgq107; Wu HY, 2011, J AGR FOOD CHEM, V59, P1713, DOI 10.1021/jf1045624; Xu BS, 2009, NUCLEIC ACIDS RES, V37, P4256, DOI 10.1093/nar/gkp372; Xu BS, 2009, RNA, V15, P357, DOI 10.1261/rna.1368009; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhang T, 2012, HEPATOLOGY, V56, P2051, DOI 10.1002/hep.25899; Zhang XD, 2005, J MED VIROL, V77, P374, DOI 10.1002/jmv.20466; Zhang XD, 2005, J LAB CLIN MED, V145, P98, DOI 10.1016/j.lab.2004.11.018	52	48	50	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					449	460		10.1038/onc.2012.618	http://dx.doi.org/10.1038/onc.2012.618			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23318446				2022-12-17	WOS:000330214600006
J	Guan, D; Factor, D; Liu, Y; Wang, Z; Kao, HY				Guan, D.; Factor, D.; Liu, Yu; Wang, Z.; Kao, H-Y			The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein	ONCOGENE			English	Article						UHRF1; PML; ubiquitination; cell migration; capillary tube formation	HEMI-METHYLATED DNA; BREAST-CANCER; SRA DOMAIN; PML; LIGASE; RECOGNITION; GENE; ICBP90; ALPHA; ACETYLATION	The promyelocytic leukemia (PML) protein is a tumor suppressor originally identified in acute promyelocytic leukemia and implicated in tumorigenesis in multiple forms of cancer. Here, we demonstrate that the PML protein undergoes ubiquitination-mediated degradation facilitated by an E3 ligase UHRF1 (ubiquitin-like with PHD and RING finger domains 1), which is commonly upregulated in various human malignancies. Furthermore, UHRF1 negatively regulates PML protein accumulation in primary human umbilical vein endothelial cells (HUVECs), HEK 293 cells and cancer cells. Knockdown of UHRF1 upregulates whereas ectopic overexpression of UHRF1 downregulates protein abundance of endogenous or exogenous PML, doing so through its binding to the N-terminus of PML. Overexpression of wild-type UHRF1 shortens PML protein half-life and promotes PML polyubiquitination, whereas deletion of the RING domain or coexpression of the dominant-negative E2 ubiquitin-conjugating enzyme, E2D2, attenuates this modification to PML. Finally, knockdown of UHRF1 prolongs PML half-life and increases PML protein accumulation, yet inhibits cell migration and in vitro capillary tube formation, whereas co-knockdown of PML compromises this inhibitory effect. These findings suggest that UHRF1 promotes the turnover of PML protein, and thus targeting UHRF1 to restore PML-mediated tumor suppression represents a promising, novel, anticancer strategy.	[Guan, D.; Factor, D.; Liu, Yu; Kao, H-Y] Dept Biochem, Cleveland, OH 44106 USA; [Guan, D.; Factor, D.; Liu, Yu; Kao, H-Y] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Wang, Z.] Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; [Wang, Z.; Kao, H-Y] Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH USA; [Wang, Z.; Kao, H-Y] Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Kao, HY (corresponding author), Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.	hxk43@cwru.edu		Factor, Daniel/0000-0002-3200-7560	NIH [R01 DK078965, HL093269]; Case Comprehensive Cancer Center Program in Aging and Energy Balance, NCI [P20 CA103767, CA127590];  [T32HD07104]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007104] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA150964, R01CA127590, P20CA103736, P30CA043703] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL093269] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062985, R01DK078965] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Case Comprehensive Cancer Center Program in Aging and Energy Balance, NCI; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr David Samols for his comments on the manuscript. D Factor is supported by training Grant T32HD07104. This project is supported by the NIH through R01 DK078965, HL093269 and Case Comprehensive Cancer Center Program in Aging and Energy Balance, NCI P20 CA103767 to H-Y Kao and CA127590 to Z Wang.	Alhosin M, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-41; Arita K, 2008, NATURE, V455, P818, DOI 10.1038/nature07249; Avvakumov GV, 2008, NATURE, V455, P822, DOI 10.1038/nature07273; Babbio F, 2012, ONCOGENE, V31, P4878, DOI 10.1038/onc.2011.641; Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939; Boutell C, 2005, J VIROL, V79, P12342, DOI 10.1128/JVI.79.19.12342-12354.2005; Canning M, 2004, J BIOL CHEM, V279, P38160, DOI 10.1074/jbc.M402885200; Cheng XW, 2012, J BIOL CHEM, V287, P23356, DOI 10.1074/jbc.M112.340505; Citterio E, 2004, MOL CELL BIOL, V24, P2526, DOI 10.1128/MCB.24.6.2526-2535.2004; Daskalos A, 2010, CANCER, V117, P1027; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462; Fanelli M, 2004, J BIOL CHEM, V279, P5374, DOI 10.1074/jbc.M306407200; Felle M, 2011, NUCLEIC ACIDS RES, V39, P8355, DOI 10.1093/nar/gkr528; Gao CZ, 2008, MOL BIOL CELL, V19, P3020, DOI 10.1091/mbc.E07-11-1203; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hashimoto H, 2008, NATURE, V455, P826, DOI 10.1038/nature07280; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Hu LL, 2011, CELL RES, V21, P1374, DOI 10.1038/cr.2011.124; Jeanblanc M, 2005, ONCOGENE, V24, P7337, DOI 10.1038/sj.onc.1208878; Jenkins Y, 2005, MOL BIOL CELL, V16, P5621, DOI 10.1091/mbc.E05-03-0194; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Jin W, 2010, BREAST CANCER RES TR, V123, P359, DOI 10.1007/s10549-009-0652-2; Khurana S, 2011, J BIOL CHEM, V286, P1850, DOI 10.1074/jbc.M110.162107; Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li XL, 2011, INT J RADIAT BIOL, V87, P263, DOI 10.3109/09553002.2011.530335; Lim JH, 2011, J BIOL CHEM, V286, P44403, DOI 10.1074/jbc.M111.289512; Louria-Hayon I, 2009, CELL DEATH DIFFER, V16, P1156, DOI 10.1038/cdd.2009.31; Ma HH, 2012, P NATL ACAD SCI USA, V109, P4828, DOI 10.1073/pnas.1116349109; Nady N, 2011, J BIOL CHEM, V286, P24300, DOI 10.1074/jbc.M111.234104; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Rajakumara E, 2011, MOL CELL, V43, P275, DOI 10.1016/j.molcel.2011.07.006; Reineke EL, 2008, MOL CELL BIOL, V28, P997, DOI 10.1128/MCB.01848-07; Reineke EL, 2010, J BIOL CHEM, V285, P9485, DOI 10.1074/jbc.M109.063362; Reineke EL, 2009, INT J BIOL SCI, V5, P366; Sabatino L, 2012, ONCOGENE, V31, P5061, DOI 10.1038/onc.2012.3; Sarkari F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016598; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; TERRIS B, 1995, CANCER RES, V55, P1590; Un F, 2006, ANTICANCER RES, V26, P2761; Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053; Unoki M, 2010, BRIT J CANCER, V103, P217, DOI 10.1038/sj.bjc.6605717; Unoki M, 2009, BRIT J CANCER, V101, P98, DOI 10.1038/sj.bjc.6605123; Unoki M, 2009, BIOCHEM PHARMACOL, V78, P1279, DOI 10.1016/j.bcp.2009.05.035; van Wijk SJL, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.55; Wang DY, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3017; Wang F, 2012, ANN SURG ONCOL, V19, P2753, DOI 10.1245/s10434-011-2194-1; Xie S, 2012, J MOL BIOL, V415, P318, DOI 10.1016/j.jmb.2011.11.012; Yan F, 2011, CANCER BIOTHER RADIO, V26, P183, DOI 10.1089/cbr.2010.0886; Yang GL, 2012, MED ONCOL, V29, P842, DOI 10.1007/s12032-011-9983-z; Yuan WC, 2011, CANCER CELL, V20, P214, DOI 10.1016/j.ccr.2011.07.008	53	48	52	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3819	3828		10.1038/onc.2012.406	http://dx.doi.org/10.1038/onc.2012.406			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22945642	Green Accepted			2022-12-17	WOS:000323210200004
J	Kalari, S; Jung, M; Kernstine, KH; Takahashi, T; Pfeifer, GP				Kalari, S.; Jung, M.; Kernstine, K. H.; Takahashi, T.; Pfeifer, G. P.			The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells	ONCOGENE			English	Article						DNA methylation; small cell lung cancer; differentiation; epigenetics	TUMOR-SUPPRESSOR GENE; CPG ISLAND; EPIGENETIC INACTIVATION; MOLECULAR-GENETICS; EXPRESSION; FAMILY; IDENTIFICATION; AMPLIFICATION; HYPERMETHYLATION; NEUROBLASTOMA	Small cell lung cancer (SCLC) is a disease characterized by aggressive clinical behavior and lack of effective therapy. Owing to its tendency for early dissemination, only a third of patients have limited-stage disease at the time of diagnosis. SCLC is thought to derive from pulmonary neuroendocrine cells. Although several molecular abnormalities in SCLC have been described, there are relatively few studies on epigenetic alterations in this type of tumor. Here, we have used methylation profiling with the methylated-CpG island recovery assay in combination with microarrays and conducted the first genome-scale analysis of methylation changes that occur in primary SCLC and SCLC cell lines. Among the hundreds of tumor-specifically methylated genes discovered, we identified 73 gene targets that are methylated in >77% of primary SCLC tumors, most of which have never been linked to aberrant methylation in tumors. These methylated targets have potential for biomarker development for early detection and therapeutic management of SCLC. SCLC cell lines had a greater number of hypermethylated genes than primary tumors. Gene ontology analysis indicated a significant enrichment of methylated genes functioning as transcription factors and in processes of neuronal differentiation. Motif analysis of tumor-specific methylated regions identified enrichment of binding sites for several neural cell fate-specifying transcription factors including NEUROD1, HAND1, ZNF423 and REST. We hypothesize that two potential mechanisms, loss of cell fate-determining transcription factors by methylation of their promoters and functional inactivation of their corresponding genomic-binding sites by DNA methylation, can promote a differentiation defect of neuroendocrine cells thus enhancing the ability of tumor progenitor cells to transition toward SCLC.	[Kalari, S.; Jung, M.; Pfeifer, G. P.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA; [Kernstine, K. H.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Surg, Duarte, CA 91010 USA; [Takahashi, T.] Nagoya Univ, Grad Sch Med, Div Mol Carcinogenesis, Nagoya, Aichi 4648601, Japan	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; Nagoya University	Pfeifer, GP (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA.	gpfeifer@coh.org	Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001	National Institutes of Health grant [CA084469]; NATIONAL CANCER INSTITUTE [R01CA084469] Funding Source: NIH RePORTER	National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Steven Bates for culturing SCLC cell lines. This work was supported by the National Institutes of Health grant CA084469 to GPP and by generous funds from an anonymous donor.	Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Coulson JM, 2005, CURR BIOL, V15, pR665, DOI 10.1016/j.cub.2005.08.032; Coulson JM, 2000, CANCER RES, V60, P1840; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Fischer B, 2007, CANCER TREAT REV, V33, P391, DOI 10.1016/j.ctrv.2007.01.006; Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859; Hahn MA, 2008, CANCER RES, V68, P10280, DOI 10.1158/0008-5472.CAN-08-1957; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Holzel M, 2010, CELL, V142, P218, DOI 10.1016/j.cell.2010.06.004; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang SD, 2009, CANCER CELL, V15, P328, DOI 10.1016/j.ccr.2009.02.023; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; Kalari S, 2010, ADV GENET, V70, P277, DOI [10.1016/B978-0-12-380866-0.60010-1, 10.1016/S0065-2660(10)70010-9]; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Kreisler A, 2010, ONCOGENE, V29, P5828, DOI 10.1038/onc.2010.321; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Lee NH, 2007, HYPERTENSION, V50, P1126, DOI 10.1161/HYPERTENSIONAHA.107.093138; Lerman MI, 2000, CANCER RES, V60, P6116; Linhart C, 2008, GENOME RES, V18, P1180, DOI 10.1101/gr.076117.108; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; Majumder S, 2006, CELL CYCLE, V5, P1929, DOI 10.4161/cc.5.17.2982; Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165; Modi S, 2000, ONCOGENE, V19, P4632, DOI 10.1038/sj.onc.1203815; Neptune ER, 2008, J BIOL CHEM, V283, P21160, DOI 10.1074/jbc.M708692200; Park KS, 2011, CELL CYCLE, V10, P2806, DOI 10.4161/cc.10.16.17012; Piper M, 2010, J NEUROSCI, V30, P9127, DOI 10.1523/JNEUROSCI.6167-09.2010; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Qureshi IA, 2010, CELL CYCLE, V9, P4477, DOI 10.4161/cc.9.22.13973; Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104; Rauch TA, 2008, P NATL ACAD SCI USA, V105, P252, DOI 10.1073/pnas.0710735105; Rauch TA, 2010, METHODS, V52, P213, DOI 10.1016/j.ymeth.2010.03.004; Rauch Tibor A., 2009, V507, P65, DOI 10.1007/978-1-59745-522-0_6; Rauch TA, 2009, P NATL ACAD SCI USA, V106, P671, DOI 10.1073/pnas.0812399106; Reinert T, 2011, CLIN CANCER RES, V17, P5582, DOI 10.1158/1078-0432.CCR-10-2659; Rodriguez J, 2008, P NATL ACAD SCI USA, V105, P19809, DOI 10.1073/pnas.0810133105; Sato M, 2007, J THORAC ONCOL, V2, P327, DOI 10.1097/01.JTO.0000263718.69320.4c; Sattler M, 2003, SEMIN ONCOL, V30, P57, DOI 10.1053/sonc.2003.50019; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Smith LT, 2006, P NATL ACAD SCI USA, V103, P982, DOI 10.1073/pnas.0510171102; Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716; Sunaga N, 2004, CANCER RES, V64, P4277, DOI 10.1158/0008-5472.CAN-03-3941; SUTHERLAND K, 2011, TLS TIMES LIT S 0422, P19; Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341; TAKAHASHI T, 1989, CANCER RES, V49, P2683; Takeshima H, 2009, GENOME RES, V19, P1974, DOI 10.1101/gr.093310.109; Toedling J, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-221; Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; Warming S, 2006, MOL CELL BIOL, V26, P6913, DOI 10.1128/MCB.02255-05; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Wu XW, 2010, CANCER RES, V70, P2718, DOI 10.1158/0008-5472.CAN-09-3631; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	55	48	48	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2013	32	30					3559	3568		10.1038/onc.2012.362	http://dx.doi.org/10.1038/onc.2012.362			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	188UQ	22907430	Green Accepted			2022-12-17	WOS:000322220800009
J	Zhen, C; Chen, L; Zhao, Q; Liang, B; Gu, YX; Bai, ZF; Wang, K; Xu, X; Han, QY; Fang, DF; Wang, SX; Zhou, T; Xia, Q; Gong, WL; Wang, N; Li, HY; Jin, BF; Man, JH				Zhen, C.; Chen, L.; Zhao, Q.; Liang, B.; Gu, Y-X; Bai, Z-f; Wang, K.; Xu, X.; Han, Q-y; Fang, D-f; Wang, S-x; Zhou, T.; Xia, Q.; Gong, W-l; Wang, N.; Li, H-Y; Jin, B-F; Man, J-h			Gankyrin promotes breast cancer cell metastasis by regulating Rac1 activity	ONCOGENE			English	Article						Gankyrin; Rac; RhoA; adhesion; metastasis	GROWTH-FACTOR RECEPTOR; RHO-GTPASES; MIGRATION; ADHESION; OVEREXPRESSION; DEGRADATION; ONCOPROTEIN; INVASION; INACTIVATION; ACTIVATION	Tumor metastasis is responsible for most cancer patients' deaths. Understanding the mechanism of metastasis is crucial for improving the cure rate for cancer. Here, we report that Gankyrin, a chaperone of ubiquitin-proteasome, has an essential role in breast cancer metastasis. We find that Gankyrin is highly overexpressed in human breast cancers and the expression correlates strongly with lymph node metastasis. Knocking down Gankyrin expression in highly metastatic human breast cancer cells significantly decreases cancer cell migration and invasion. Furthermore, we demonstrate that depletion of Gankyrin inhibits intrinsic Rac1 activity and induces large focal adhesions. Overexpression of Gankyrin accelerates focal adhesion turnover and increases cell migration. Notably, reduction of Gankyrin expression in mouse mammary tumor cell significantly decreases tumor metastasis to lung in animal models. Therefore, our findings suggest that Gankyrin is crucial for breast cancer metastasis and highlight the potential of Gankyrin as a therapeutic target for tumor metastasis.	[Zhen, C.; Chen, L.; Zhao, Q.; Liang, B.; Gu, Y-X; Bai, Z-f; Wang, K.; Xu, X.; Han, Q-y; Fang, D-f; Wang, S-x; Zhou, T.; Xia, Q.; Gong, W-l; Wang, N.; Li, H-Y; Jin, B-F; Man, J-h] Natl Ctr Biomed Anal, Beijing 100850, Peoples R China		Jin, BF (corresponding author), Natl Ctr Biomed Anal, 27 Tai Ping Rd, Beijing 100850, Peoples R China.	jinbaofeng73@hotmail.com; jianghong_man@hotmail.com	FANG, DIFENG/G-7796-2018	FANG, DIFENG/0000-0003-2105-6743	Major Research Plan of the National Natural Science Foundation of China [91029733]; National Basic Research Program of China [2012CB910700]; China National Natural Science Foundation [81001174, 81171918]; Beijing Municipal Science and Technology Commission [2010B040]	Major Research Plan of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); China National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Beijing Municipal Science and Technology Commission(Beijing Municipal Science & Technology Commission)	This work was supported by grants from the Major Research Plan of the National Natural Science Foundation of China (No. 91029733), National Basic Research Program of China (2012CB910700), China National Natural Science Foundation (No. 81001174 and No. 81171918), Beijing Municipal Science and Technology Commission (2010B040).	Boulter E, 2010, NAT CELL BIOL, V12, P477, DOI 10.1038/ncb2049; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Dawson S, 2006, TRENDS CELL BIOL, V16, P229, DOI 10.1016/j.tcb.2006.03.001; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Frank SR, 2006, EMBO J, V25, P1848, DOI 10.1038/sj.emboj.7601092; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hirsch DS, 2006, CANCER RES, V66, P3523, DOI 10.1158/0008-5472.CAN-05-1547; Jin BF, 2006, J PROTEOME RES, V5, P2815, DOI 10.1021/pr060283f; Katsumi A, 2002, J CELL BIOL, V158, P153, DOI 10.1083/jcb.200201105; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Lee KW, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-158; Li Z, 2008, J BIOL CHEM, V283, P7007, DOI 10.1074/jbc.M706992200; Machacek M, 2009, NATURE, V461, P99, DOI 10.1038/nature08242; Man JH, 2010, J CLIN INVEST, V120, P2829, DOI 10.1172/JCI42542; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Minard ME, 2004, BREAST CANCER RES TR, V84, P21, DOI 10.1023/B:BREA.0000018421.31632.e6; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Ortiz CM, 2008, INT J CANCER, V122, P325, DOI 10.1002/ijc.23106; Pan X, 2011, NAT MED, V17, P708, DOI 10.1038/nm.2369; Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957; Ridley AJ, 2001, J CELL SCI, V114, P2713; Roelofs J, 2009, NATURE, V459, P861, DOI 10.1038/nature08063; Saeki Y, 2009, CELL, V137, P900, DOI 10.1016/j.cell.2009.05.005; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Sun W, 2011, HEPATOLOGY, V54, P1259, DOI 10.1002/hep.24530; Tang SH, 2010, CANCER BIOL THER, V9, P88, DOI 10.4161/cbt.9.2.10283; Wang SZE, 2006, CANCER RES, V66, P9591, DOI 10.1158/0008-5472.CAN-06-2071; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wu KM, 2008, P NATL ACAD SCI USA, V105, P6924, DOI 10.1073/pnas.0802085105; Yang CF, 2006, MOL CELL BIOL, V26, P831, DOI 10.1128/MCB.26.3.831-842.2006; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019	38	48	50	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2013	32	29					3452	3460		10.1038/onc.2012.356	http://dx.doi.org/10.1038/onc.2012.356			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AZ	22890318				2022-12-17	WOS:000322014900006
J	Koese, M; Rentero, C; Kota, BP; Hoque, M; Cairns, R; Wood, P; de Muga, SV; Reverter, M; Alvarez-Guaita, A; Monastyrskaya, K; Hughes, WE; Swarbrick, A; Tebar, F; Daly, RJ; Enrich, C; Grewal, T				Koese, M.; Rentero, C.; Kota, B. P.; Hoque, M.; Cairns, R.; Wood, P.; Vila de Muga, S.; Reverter, M.; Alvarez-Guaita, A.; Monastyrskaya, K.; Hughes, W. E.; Swarbrick, A.; Tebar, F.; Daly, R. J.; Enrich, C.; Grewal, T.			Annexin A6 is a scaffold for PKC alpha to promote EGFR inactivation	ONCOGENE			English	Article						annexin A6; scaffold; PKC alpha; EGF receptor	EPIDERMAL-GROWTH-FACTOR; PROTEIN-KINASE-C; FACTOR RECEPTOR PHOSPHORYLATION; INTRACELLULAR TRAFFICKING; CHOLESTEROL TRANSPORT; MEMBRANE-BINDING; CARCINOMA-CELLS; 79 AKAP79; CANCER; VI	Protein kinase C alpha (PKC alpha) can phosphorylate the epidermal growth factor receptor (EGFR) at threonine 654 (T654) to inhibit EGFR tyrosine phosphorylation (pY-EGFR) and the associated activation of downstream effectors. However, upregulation of PKC alpha in a large variety of cancers is not associated with EGFR inactivation, and factors determining the potential of PKC alpha to downregulate EGFR are yet unknown. Here, we show that ectopic expression of annexin A6 (AnxA6), a member of the Ca2+ and phospholipid-binding annexins, strongly reduces pY-EGFR levels while augmenting EGFR T654 phosphorylation in EGFR overexpressing A431, head and neck and breast cancer cell lines. Reduced EGFR activation in AnxA6 expressing A431 cells is associated with reduced EGFR internalization and degradation. RNA interference (RNAi)-mediated PKC alpha knockdown in AnxA6 expressing A431 cells reduces T654-EGFR phosphorylation, but restores EGFR tyrosine phosphorylation, clonogenic growth and EGFR degradation. These findings correlate with AnxA6 interacting with EGFR, and elevated AnxA6 levels promoting PKC alpha membrane association and interaction with EGFR. Stable expression of the cytosolic N-terminal mutant AnxA6(1-175), which cannot promote PKC alpha membrane recruitment, does not increase T654-EGFR phosphorylation or the association of PKC alpha with EGFR. AnxA6 overexpression does not inhibit tyrosine phosphorylation of the T654A EGFR mutant, which cannot be phosphorylated by PKC alpha. Most strikingly, stable plasma membrane anchoring of AnxA6 is sufficient to recruit PKC alpha even in the absence of EGF or Ca2+. In summary, AnxA6 is a new PKC alpha scaffold to promote PKC alpha-mediated EGFR inactivation through increased membrane targeting of PKC alpha and EGFR/PKC alpha complex formation.	[Koese, M.; Kota, B. P.; Hoque, M.; Cairns, R.; Wood, P.; Grewal, T.] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia; [Rentero, C.; Vila de Muga, S.; Reverter, M.; Alvarez-Guaita, A.; Tebar, F.; Enrich, C.] Univ Barcelona, Fac Med, Dept Biol Cellular Immunol & Neurociencies, IDIBAPS, Barcelona 08036, Spain; [Monastyrskaya, K.] Univ Bern, Dept Clin Res, Urol Res Lab, Bern, Switzerland; [Hughes, W. E.; Swarbrick, A.; Daly, R. J.] St Vincents Hosp, Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia	University of Sydney; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Bern; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Enrich, C (corresponding author), Univ Barcelona, Fac Med, Dept Biol Cellular, Casanova 143, Barcelona 08036, Spain.	enrich@ub.edu; thomas.grewal@sydney.edu.au	Rentero Alfonso, Carles/L-4430-2017; Hoque, Monira/AAN-5715-2020; Köse, Meryem/K-7399-2013; Tebar, Francesc/H-1498-2015; Swarbrick, Alexander/E-6107-2010	Rentero Alfonso, Carles/0000-0003-4684-0278; Köse, Meryem/0000-0002-3391-3418; Tebar, Francesc/0000-0002-9522-9726; Swarbrick, Alexander/0000-0002-3051-5676; Hughes, William/0000-0002-7149-3987; Alvarez-Guaita, Anna/0000-0002-9248-2275; Enrich, Carlos/0000-0003-0382-2993; Daly, Roger/0000-0002-5739-8027; Grewal, Thomas/0000-0002-7937-8887; Monastyrskaya, Katia/0000-0003-2042-1139; Cairns, Rose/0000-0002-8946-5079	National Health and Medical Research Council of Australia (NHMRC) [510293, 510294]; University of Sydney [2010-02681]; Consolider-Ingenio from Ministerio de Innovacion, Ciencia y Tecnologia [CSD2009-00016]; Fundacio Marato TV3 (Barcelona, Spain) [PI040236]; NHMRC; National Heart Foundation (NHF)/NHMRC postgraduate scholarship; Beatriu de Pinos fellowship (Generalitat de Catalunya); Ministerio de Educacion y Ciencia, Spain; Ministerio de Innovacion, Ciencia y Tecnologia; Cancer Institute NSW; National Breast Cancer Foundation; (FPI mobility Program) at the laboratory of TG (Sydney, Australia);  [BFU2009-10335];  [BFU2009-13526]	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); University of Sydney(University of Sydney); Consolider-Ingenio from Ministerio de Innovacion, Ciencia y Tecnologia; Fundacio Marato TV3 (Barcelona, Spain); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); National Heart Foundation (NHF)/NHMRC postgraduate scholarship; Beatriu de Pinos fellowship (Generalitat de Catalunya)(Generalitat de Catalunya); Ministerio de Educacion y Ciencia, Spain(Spanish Government); Ministerio de Innovacion, Ciencia y Tecnologia; Cancer Institute NSW; National Breast Cancer Foundation; (FPI mobility Program) at the laboratory of TG (Sydney, Australia); ; 	This study was supported by grants to TG from the National Health and Medical Research Council of Australia (NHMRC; 510293, 510294) and the University of Sydney (2010-02681). CE is supported by BFU2009-10335, Consolider-Ingenio CSD2009-00016 from Ministerio de Innovacion, Ciencia y Tecnologia and PI040236 from Fundacio Marato TV3 (Barcelona, Spain). FT is supported by BFU2009-13526. RJD and AS would like to acknowledge funding from the NHMRC. PW is a recipient of a co-funded National Heart Foundation (NHF)/NHMRC postgraduate scholarship. CR is grateful to the Beatriu de Pinos fellowship (Generalitat de Catalunya). SV is thankful to Ministerio de Educacion y Ciencia, Spain, (FPI mobility Program) for a short-term fellowship at the laboratory of TG (Sydney, Australia). MR and AA are supported by fellowships from Ministerio de Innovacion, Ciencia y Tecnologia. AS is supported by Early Career Fellowships from the Cancer Institute NSW and the National Breast Cancer Foundation.	Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Assender JW, 2007, J CLIN PATHOL, V60, P1216, DOI 10.1136/jcp.2006.041616; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Boultwood J, 2002, BLOOD, V99, P4638, DOI 10.1182/blood.V99.12.4638; BOWEN S, 1991, J BIOL CHEM, V266, P1162; Claperon A, 2007, ONCOGENE, V26, P3143, DOI 10.1038/sj.onc.1210408; Collazos A, 2011, BIOCHEM J, V438, P535, DOI 10.1042/BJ20110521; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; Cubells L, 2008, J BIOL CHEM, V283, P10174, DOI 10.1074/jbc.M706618200; Cubells L, 2007, TRAFFIC, V8, P1568, DOI 10.1111/j.1600-0854.2007.00640.x; Davis AJ, 1996, J BIOL CHEM, V271, P24333, DOI 10.1074/jbc.271.40.24333; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P4080, DOI 10.1073/pnas.82.12.4080; de Diego I, 2002, J BIOL CHEM, V277, P32187, DOI 10.1074/jbc.M205499200; Dubois T, 1996, BBA-MOL CELL RES, V1313, P290, DOI 10.1016/0167-4889(96)00102-4; Enrich C, 2011, BBA-MOL CELL RES, V1813, P935, DOI 10.1016/j.bbamcr.2010.09.015; FABBRO D, 1986, CANCER RES, V46, P2720; Faux MC, 1999, BIOCHEM J, V343, P443, DOI 10.1042/0264-6021:3430443; Ferguson KM, 2008, ANNU REV BIOPHYS, V37, P353, DOI 10.1146/annurev.biophys.37.032807.125829; Frankel LB, 2007, BREAST CANCER RES TR, V104, P165, DOI 10.1007/s10549-006-9399-1; Freye-Minks C, 2003, BIOCHEMISTRY-US, V42, P620, DOI 10.1021/bi026742h; FRIEDMAN B, 1989, P NATL ACAD SCI USA, V86, P812, DOI 10.1073/pnas.86.3.812; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Gold MG, 2011, P NATL ACAD SCI USA, V108, P6426, DOI 10.1073/pnas.1014400108; Grewal T, 2000, J BIOL CHEM, V275, P33806, DOI 10.1074/jbc.M002662200; Grewal T, 2005, ONCOGENE, V24, P5809, DOI 10.1038/sj.onc.1208743; Grewal T, 2006, CURR SIGNAL TRANSD T, V1, P147, DOI 10.2174/157436206777012066; Grewal T, 2010, INT J BIOCHEM CELL B, V42, P580, DOI 10.1016/j.biocel.2009.12.020; Grewal T, 2009, CELL SIGNAL, V21, P847, DOI 10.1016/j.cellsig.2009.01.031; Groves JT, 2010, NAT STRUCT MOL BIOL, V17, P659, DOI 10.1038/nsmb.1844; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; IWASHITA S, 1984, J BIOL CHEM, V259, P2559; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Johannsdottir HK, 2006, INT J CANCER, V119, P1052, DOI 10.1002/ijc.21934; Kheifets V, 2007, PHARMACOL RES, V55, P467, DOI 10.1016/j.phrs.2007.04.014; Kheifets V, 2006, J BIOL CHEM, V281, P23218, DOI 10.1074/jbc.M602075200; Kim J, 2011, ONCOGENE, V30, P323, DOI 10.1038/onc.2010.415; KING CS, 1986, J BIOL CHEM, V261, P73; Lanzetti L, 2008, TRAFFIC, V9, P2011, DOI 10.1111/j.1600-0854.2008.00816.x; LIVNEH E, 1988, MOL CELL BIOL, V8, P2302, DOI 10.1128/MCB.8.6.2302; Llado A, 2008, MOL BIOL CELL, V19, P17, DOI 10.1091/mbc.E07-05-0411; LUND KA, 1990, J BIOL CHEM, V265, P20517; McNulty DE, 2011, J BIOL CHEM, V286, P15010, DOI 10.1074/jbc.M111.227694; Minashima T, 2012, J BIOL CHEM, V287, P14803, DOI 10.1074/jbc.M111.297861; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Monastyrskaya K, 2009, J BIOL CHEM, V284, P17227, DOI 10.1074/jbc.M109.004457; MORRISON P, 1993, J BIOL CHEM, V268, P15536; Orth JD, 2006, CANCER RES, V66, P3603, DOI 10.1158/0008-5472.CAN-05-2916; Pierga JY, 2007, BRIT J CANCER, V96, P341, DOI 10.1038/sj.bjc.6603483; Pines G, 2010, FEBS LETT, V584, P2699, DOI 10.1016/j.febslet.2010.04.019; Podszywalow-Bartnicka P, 2010, J CELL BIOCHEM, V111, P168, DOI 10.1002/jcb.22685; Pons M, 2001, FEBS LETT, V501, P69, DOI 10.1016/S0014-5793(01)02635-7; Prevostel C, 2000, J CELL SCI, V113, P2575; Rentero C, 2006, CELL SIGNAL, V18, P1006, DOI 10.1016/j.cellsig.2005.08.008; Reverter M, 2011, MOL BIOL CELL, V22, P4108, DOI 10.1091/mbc.E11-04-0332; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; RON D, 1994, J BIOL CHEM, V269, P21395; Sakwe AM, 2011, EXP CELL RES, V317, P823, DOI 10.1016/j.yexcr.2010.12.008; Santiskulvong C, 2007, CELL SIGNAL, V19, P1348, DOI 10.1016/j.cellsig.2007.01.006; Schmitz-Peiffer C, 1998, BIOCHEM J, V330, P675, DOI 10.1042/bj3300675; SMYTHE E, 1994, J CELL BIOL, V124, P301, DOI 10.1083/jcb.124.3.301; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Steinberg SF, 2008, PHYSIOL REV, V88, P1341, DOI 10.1152/physrev.00034.2007; Stern KA, 2007, MOL CELL BIOL, V27, P888, DOI 10.1128/MCB.02356-05; Stewart JR, 2005, MOL CANCER THER, V4, P726, DOI 10.1158/1535-7163.MCT-05-0013; Strzelecka-Kiliszek A, 2008, J CELL BIOCHEM, V104, P418, DOI 10.1002/jcb.21632; Tebar F, 2002, MOL BIOL CELL, V13, P2057, DOI 10.1091/mbc.01-12-0571; THEOBALD J, 1995, BRIT J CANCER, V71, P786, DOI 10.1038/bjc.1995.152; Timpson P, 2007, CANCER RES, V67, P9304, DOI 10.1158/0008-5472.CAN-07-0798; Tonetti DA, 2003, BRIT J CANCER, V88, P1400, DOI 10.1038/sj.bjc.6600923; de Muga SV, 2009, ONCOGENE, V28, P363, DOI 10.1038/onc.2008.386; Wang XQ, 2007, CANCER RES, V67, P9986, DOI 10.1158/0008-5472.CAN-07-1300; Warren CM, 2006, CELL SIGNAL, V18, P923, DOI 10.1016/j.cellsig.2005.12.007; Xu TR, 2004, FEBS LETT, V570, P20, DOI 10.1016/j.febslet.2004.05.080	74	48	50	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2013	32	23					2858	2872		10.1038/onc.2012.303	http://dx.doi.org/10.1038/onc.2012.303			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	22797061				2022-12-17	WOS:000320369100006
J	Carloni, V; Mazzocca, A; Mello, T; Galli, A; Capaccioli, S				Carloni, V.; Mazzocca, A.; Mello, T.; Galli, A.; Capaccioli, S.			Cell fusion promotes chemoresistance in metastatic colon carcinoma	ONCOGENE			English	Article						colon cancer therapy; RhoA; GTP-binding protein alpha 13; tetraspanin CD81/CD9; FOLFOX; ADAM10	TUMOR-CELLS; PROTEINS; OXALIPLATIN; CD81; FLUOROURACIL; LEUCOVORIN; ACTIVATION; FAMILY; BREAST; CANCER	Chemoresistance is an important concern in the treatment of metastatic colon cancer. It may emerge through selection of clones that are inherently resistant from the outset or through mechanisms acquired during treatment. Cell fusion represents an efficient means of rapid phenotypic evolution that make cells with new properties at a rate exceeding that achievable by random mutagenesis. Here, we first identified a number of proteins involved in cell fusion using a shotgun proteomics approach, then we investigated the role of these proteins namely tetraspanin CD81/CD9, ADAM10, GTP-binding protein alpha 13, radixin, myosin regulatory light chain and RhoA in the regulation of colon cancer cell fusion. We also found a previously unrecognized role of ADAM10, G alpha 13 and RhoA in promoting cell fusion. Finally, we show that the occurrence of cell fusion in a metastatic model of colon carcinoma causes the appearance of cells resistant to both 5-fluorouracil and oxaliplatin. These findings highlight the importance of cell fusion in cancer progression and raise significant implications for overcoming chemoresistance in metastatic colon cancer.	[Carloni, V.] Univ Florence, DENOthe, Dept Internal Med, Ctr Res Transfer & High Educ, I-50134 Florence, Italy; [Mazzocca, A.] Univ Bari, Sch Med, Dept Emergency & Organ Transplantat, Sect Internal Med Allergol & Clin Immunol, Bari, Italy; [Mello, T.; Galli, A.] Univ Florence, Dept Clin Pathophysiol, Gastroenterol Unit, I-50134 Florence, Italy; [Capaccioli, S.] Univ Florence, Dept Expt Pathol & Oncol, I-50134 Florence, Italy	University of Florence; Universita degli Studi di Bari Aldo Moro; University of Florence; University of Florence	Carloni, V (corresponding author), Univ Florence, DENOthe, Dept Internal Med, Ctr Res Transfer & High Educ, Largo Brambilla 3, I-50134 Florence, Italy.	v.carloni@dmi.unifi.it	Mello, Tommaso/I-4715-2012; Galli, Andrea/AAC-1623-2019; Mello, Tommaso/AAO-7831-2021	Mello, Tommaso/0000-0002-6192-6902; Mello, Tommaso/0000-0002-6192-6902; MAZZOCCA, Antonio/0000-0003-0940-7352; Galli, Andrea/0000-0001-5416-6290	Ente Cassa di Risparmio di Firenze	Ente Cassa di Risparmio di Firenze(Fondazione Cassa Risparmio Firenze)	We thank Peter Altevogt and Joaquin Teixido for important reagents used in this study. This work was supported by grant from Ente Cassa di Risparmio di Firenze.	Alberts SR, 2005, J CLIN ONCOL, V23, P9243, DOI 10.1200/JCO.2005.07.740; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; BORST P, 1993, PHARMACOL THERAPEUT, V60, P289, DOI 10.1016/0163-7258(93)90011-2; Carloni V, 2004, ONCOGENE, V23, P1566, DOI 10.1038/sj.onc.1207287; Chen EH, 2005, SCIENCE, V308, P369, DOI 10.1126/science.1104799; COLE SPC, 1994, CANCER RES, V54, P5902; Duelli D, 2003, CANCER CELL, V3, P445, DOI 10.1016/S1535-6108(03)00114-4; Duelli D, 2007, NAT REV CANCER, V7, P968, DOI 10.1038/nrc2272; Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866; FORTUNA MB, 1990, CANCER LETT, V55, P109, DOI 10.1016/0304-3835(90)90019-T; FORTUNA MB, 1989, INT J CANCER, V44, P731, DOI 10.1002/ijc.2910440430; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Johansson CB, 2008, NAT CELL BIOL, V10, P575, DOI 10.1038/ncb1720; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Khatib AM, 2005, AM J PATHOL, V167, P749, DOI 10.1016/S0002-9440(10)62048-2; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Lu X, 2009, CANCER RES, V69, P8536, DOI 10.1158/0008-5472.CAN-09-2159; Lu X, 2009, P NATL ACAD SCI USA, V106, P9385, DOI 10.1073/pnas.0900108106; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Mazzocca A, 2008, GASTROENTEROLOGY, V135, P244, DOI 10.1053/j.gastro.2008.03.024; Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958; Paluch E, 2006, TRENDS CELL BIOL, V16, P5, DOI 10.1016/j.tcb.2005.11.003; Parthasarathy V, 2009, IMMUNOLOGY, V127, P237, DOI 10.1111/j.1365-2567.2008.02945.x; Pawelek JM, 2008, NAT REV CANCER, V8, P377, DOI 10.1038/nrc2371; Samimi G, 2005, CANCER CHEMOTH PHARM, V55, P1, DOI 10.1007/s00280-004-0819-9; Tachibana I, 1999, J CELL BIOL, V146, P893, DOI 10.1083/jcb.146.4.893; Takeda Y, 2003, J CELL BIOL, V161, P945, DOI 10.1083/jcb.200212031; Vaiskunaite R, 2000, J BIOL CHEM, V275, P26206, DOI 10.1074/jbc.M001863200; WAGHORNE C, 1988, CANCER RES, V48, P6109; WAKELING WF, 1994, CELL BIOL INT, V18, P207, DOI 10.1006/cbir.1994.1063; White JM, 2003, CURR OPIN CELL BIOL, V15, P598, DOI 10.1016/j.ceb.2003.08.001; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720	35	48	48	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2013	32	21					2649	2660		10.1038/onc.2012.268	http://dx.doi.org/10.1038/onc.2012.268			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22751128	Green Published			2022-12-17	WOS:000319806700006
J	Cheng, JC; Chang, HM; Leung, PCK				Cheng, J-C; Chang, H-M; Leung, P. C. K.			Egr-1 mediates epidermal growth factor-induced downregulation of E-cadherin expression via Slug in human ovarian cancer cells	ONCOGENE			English	Article						EGF; Egr-1; E-cadherin; ovarian cancer	FINGER TRANSCRIPTION FACTOR; MESENCHYMAL TRANSITION; FACTOR RECEPTOR; RESPONSE-1 PROTEIN; TUMOR; SNAIL; ACTIVATION; BINDING; MOUSE; SP1	Loss of the cell adhesion protein E-cadherin increases the invasive capability of ovarian cancer cells. We have previously shown that epidermal growth factor (EGF) downregulates E-cadherin and induces ovarian cancer cell invasion through the H2O2/p38 MAPK-mediated upregulation of the E-cadherin transcriptional repressor Snail. However, the molecular mechanisms underlying the EGF-induced downregulation of E-cadherin are not fully understood. In the current study, we demonstrated that treatment of two ovarian cancer cell lines, SKOV3 and OVCAR5, with EGF induced the expression of the transcription factor Egr-1, and this induction was abolished by small interfering RNA (siRNA)-mediated depletion of the EGF receptor. EGF-induced Egr-1 expression required the activation of the ERK1/2 and PI3K/Akt signaling pathways and was unrelated to EGF-induced H2O2 production and activation of the p38 MAPK pathway. Moreover, depletion of Egr-1 with siRNA abolished the EGF-induced downregulation of E-cadherin and increased cell invasion. Interestingly, siRNA depletion of Egr-1 attenuated the EGF-induced expression of Slug, but not that of Snail. Moreover, chromatin immunoprecipitation (ChIP) analysis showed that Slug is a target gene of Egr-1. These results provide evidence that Egr-1 is a mediator that is involved in the EGF-induced downregulation of E-cadherin and increased cell invasion. Our results also demonstrate that EGF activates two independent signaling pathways, which are the H2O2/p38 MAPK-mediated upregulation of Snail expression and the Egr-1-mediated upregulation of Slug expression. These two signaling pathways contribute to the EGF-induced downregulation of E-cadherin, which subsequently increases the invasive capability of ovarian cancer cells. Oncogene (2013) 32, 1041-1049; doi:10.1038/onc.2012.127; published online 16 April 2012	[Cheng, J-C; Chang, H-M; Leung, P. C. K.] Univ British Columbia, Child & Family Res Inst, Dept Obstet & Gynaecol, Vancouver, BC V6H 3V5, Canada	Child & Family Research Institute; University of British Columbia	Leung, PCK (corresponding author), Univ British Columbia, Child & Family Res Inst, Dept Obstet & Gynaecol, Room 2H-30,4490 Oak St, Vancouver, BC V6H 3V5, Canada.	peter.leung@ubc.ca	Cheng, Jung-Chien/T-4258-2019; Chang, Hsun-Ming/M-8584-2018	Cheng, Jung-Chien/0000-0002-5399-9327; Leung, Peter/0000-0003-3152-3800	Canadian Institutes of Health Research; Child & Family Research Institute Senior Investigator Award; BC Foundation for Non-Animal Research-Evelyn Martin Memorial Fellowship	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Child & Family Research Institute Senior Investigator Award; BC Foundation for Non-Animal Research-Evelyn Martin Memorial Fellowship	This work was supported by grants from Canadian Institutes of Health Research to PCKL. PCKL is the recipient of a Child & Family Research Institute Senior Investigator Award. JCC is the recipient of BC Foundation for Non-Animal Research-Evelyn Martin Memorial Fellowship.	Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Baron V, 2003, ANN NY ACAD SCI, V1002, P197, DOI 10.1196/annals.1281.024; Barr S, 2008, CLIN EXP METASTAS, V25, P685, DOI 10.1007/s10585-007-9121-7; Bartlett JMS, 1996, BRIT J CANCER, V73, P301, DOI 10.1038/bjc.1996.53; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Bouchard F, 2010, BLOOD, V116, P759, DOI 10.1182/blood-2009-12-257030; Cabodi S, 2009, J CELL PHYSIOL, V218, P294, DOI 10.1002/jcp.21603; CAO XM, 1993, J BIOL CHEM, V268, P16949; Cheng JC, 2010, MOL ENDOCRINOL, V24, P1569, DOI 10.1210/me.2010-0034; Dahl KDC, 2008, CANCER RES, V68, P4606, DOI 10.1158/0008-5472.CAN-07-5046; Darai E, 1997, HUM PATHOL, V28, P922, DOI 10.1016/S0046-8177(97)90007-1; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Grotegut S, 2006, EMBO J, V25, P3534, DOI 10.1038/sj.emboj.7601213; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; Jones N, 2003, J CELL PHYSIOL, V196, P326, DOI 10.1002/jcp.10308; Kaufmann K, 2001, J NEUROL SCI, V189, P83, DOI 10.1016/S0022-510X(01)00562-7; Kim CG, 2007, CELL SIGNAL, V19, P1290, DOI 10.1016/j.cellsig.2007.01.008; Kuo PL, 2011, J CELL PHYSIOL, V226, P1224, DOI 10.1002/jcp.22445; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Mayer SI, 2009, J CELL SCI, V122, P3340, DOI 10.1242/jcs.048272; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Niikura H, 1997, INT J GYNECOL PATHOL, V16, P60, DOI 10.1097/00004347-199701000-00010; Pecina-Slaus N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-17; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Salah Z, 2007, CANCER RES, V67, P9835, DOI 10.1158/0008-5472.CAN-07-1886; SHINGU T, 1994, J BIOL CHEM, V269, P32551; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tsai JC, 2001, AM J PHYSIOL-GASTR L, V281, pG1271, DOI 10.1152/ajpgi.2001.281.5.G1271; Tsunoda T, 1999, BIOINFORMATICS, V15, P622, DOI 10.1093/bioinformatics/15.7.622; VEATCH AL, 1994, INT J CANCER, V58, P393, DOI 10.1002/ijc.2910580315; Vergara D, 2010, CANCER LETT, V291, P59, DOI 10.1016/j.canlet.2009.09.017; Woo MMM, 2007, IN VITRO CELL DEV-AN, V43, P7, DOI 10.1007/s11626-006-9002-4; Xu ZH, 2010, BIOCHEM BIOPH RES CO, V401, P376, DOI 10.1016/j.bbrc.2010.09.059	44	48	49	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2013	32	8					1041	1049		10.1038/onc.2012.127	http://dx.doi.org/10.1038/onc.2012.127			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22508482				2022-12-17	WOS:000316523200011
J	Origanti, S; Cai, SR; Munir, AZ; White, LS; Piwnica-Worms, H				Origanti, S.; Cai, S-R; Munir, A. Z.; White, L. S.; Piwnica-Worms, H.			Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells	ONCOGENE			English	Article						cell cycle; checkpoints; apoptosis; cancer	ONCOGENE-INDUCED SENESCENCE; S-PHASE; POTENT INHIBITOR; CDK INHIBITORS; DEFECTIVE P53; CHECKPOINT; UCN-01; CDC25A; 7-HYDROXYSTAUROSPORINE; PHOSPHORYLATION	Cell cycle checkpoints ensure genome integrity and are frequently compromised in human cancers. A therapeutic strategy being explored takes advantage of checkpoint defects in p53-deficient tumors in order to sensitize them to DNA-damaging agents by eliminating Chk1-mediated checkpoint responses. Using mouse models, we demonstrated that p21 is a key determinant of how cells respond to the combination of DNA damage and Chk1 inhibition (combination therapy) in normal cells as well as in tumors. Loss of p21 sensitized normal cells to the combination therapy much more than did p53 loss and the enhanced lethality was partially blocked by CDK inhibition. In addition, basal pools of p21 (p53 independent) provided p53 null cells with protection from the combination therapy. Our results uncover a novel p53-independent function for p21 in protecting cells from the lethal effects of DNA damage followed by Chk1 inhibition. As p21 levels are low in a significant fraction of colorectal tumors, they are predicted to be particularly sensitive to the combination therapy. Results reported in this study support this prediction. Oncogene (2013) 32, 577-588; doi:10.1038/onc.2012.84; published online 19 March 2012	[Origanti, S.; Cai, S-R; Munir, A. Z.; White, L. S.; Piwnica-Worms, H.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; [Origanti, S.; Cai, S-R; Munir, A. Z.; White, L. S.; Piwnica-Worms, H.] Washington Univ, Sch Med, BRIGHT Inst, St Louis, MO 63110 USA; [Piwnica-Worms, H.] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Piwnica-Worms, H (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Box 8228,660 South Euclid Ave, St Louis, MO 63110 USA.	hpiwnica@wustl.edu	Piwnica-Worms, Helen/C-5214-2012	Origanti, Sofia/0000-0002-6953-0160	NIH [GM047017]; KOMEN Foundation; Washington University [P50 CA94056]; NATIONAL CANCER INSTITUTE [P50CA094056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047017] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); KOMEN Foundation(Susan G. Komen Breast Cancer Foundation); Washington University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr B Vogelstein for providing the HCT116 cell lines. This study was supported in part by NIH GM047017, the KOMEN Foundation and P50 CA94056 to the Molecular Imaging Center at Washington University. HP-W is a Research Professor of the American Cancer Society.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Eastman A, 2004, J CELL BIOCHEM, V91, P223, DOI 10.1002/jcb.10699; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fikaris AJ, 2006, J BIOL CHEM, V281, P34759, DOI 10.1074/jbc.M606737200; Fracasso PM, 2011, CANCER CHEMOTH PHARM, V67, P1225, DOI 10.1007/s00280-010-1410-1; Gilad O, 2010, CANCER RES, V70, P9693, DOI 10.1158/0008-5472.CAN-10-2286; Goga A, 2007, NAT MED, V13, P820, DOI 10.1038/nm1606; Goloudina A, 2003, CELL CYCLE, V2, P473, DOI 10.4161/cc.2.5.482; Hassepass I, 2003, J BIOL CHEM, V278, P29824, DOI 10.1074/jbc.M302704200; Kohn EA, 2002, J BIOL CHEM, V277, P26553, DOI 10.1074/jbc.M202040200; Kohn EA, 2003, CANCER RES, V63, P31; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Levesque AA, 2008, MOL CANCER THER, V7, P252, DOI 10.1158/1535-7163.MCT-07-2066; Levesque AA, 2007, CARCINOGENESIS, V28, P13, DOI 10.1093/carcin/bgl214; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Perez RP, 2006, CLIN CANCER RES, V12, P7079, DOI 10.1158/1078-0432.CCR-06-0197; Raynaud FI, 2004, MOL CANCER THER, V3, P353; Rodriguez R, 2006, MOL BIOL CELL, V17, P402, DOI 10.1091/mbc.E05-07-0594; Sedelnikova OA, 2003, CANCER BIOL THER, V2, P233; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimuta K, 2002, EMBO J, V21, P3694, DOI 10.1093/emboj/cdf357; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Tapia C, 2006, AM J SURG PATHOL, V30, P83, DOI 10.1097/01.pas.0000183572.94140.43; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tse AN, 2007, CLIN CANCER RES, V13, P591, DOI 10.1158/1078-0432.CCR-06-1424; Cespedes MV, 2007, AM J PATHOL, V170, P1077, DOI 10.2353/ajpath.2007.060773; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Zabludoff SD, 2008, MOL CANCER THER, V7, P2955, DOI 10.1158/1535-7163.MCT-08-0492; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	39	48	49	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2013	32	5					577	588		10.1038/onc.2012.84	http://dx.doi.org/10.1038/onc.2012.84			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22430210	Green Accepted, Green Published			2022-12-17	WOS:000316164700005
J	Su, PH; Lin, YW; Huang, RL; Liao, YP; Lee, HY; Wang, HC; Chao, TK; Chen, CK; Chan, MWY; Chu, TY; Yu, MH; Lai, HC				Su, P-H; Lin, Y-W; Huang, R-L; Liao, Y-P; Lee, H-Y; Wang, H-C; Chao, T-K; Chen, C-K; Chan, M. W. Y.; Chu, T-Y; Yu, M-H; Lai, H-C			Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer	ONCOGENE			English	Article						protein tyrosine phosphatase receptor type R; DNA methyltransferase; mitogen-activated protein kinase; metastasis; methylation; cervical cancer	PROTEIN-TYROSINE PHOSPHATASES; TO-MESENCHYMAL TRANSITION; RISK HUMAN-PAPILLOMAVIRUS; DNA METHYLATION MARKERS; EPITHELIAL-CELLS; E-CADHERIN; INTRAEPITHELIAL NEOPLASIA; INDUCED CARCINOGENESIS; ONCOGENE EXPRESSION; MOTOR COORDINATION	Epigenetic modifications are a driving force in carcinogenesis. However, their role in cancer metastasis remains poorly understood. The present study investigated the role of DNA methylation in the cervical cancer metastasis. Here, we report evidence of the overexpression of DNA methyltransferases 3B (DNMT3B) in invasive cervical cancer and of the inhibition of metastasis by DNMT3B interference. Using methyl-DNA immunoprecipitation coupled with microarray analysis, we found that the protein tyrosine phosphatase receptor type R (PTPRR) was silenced through DNMT3B-mediated methylation in the cervical cancer. PTPRR inhibited p44/42 MAPK signaling, the expression of the transcription factor AP1, human papillomavirus (HPV) oncogenes E6/E7 and DNMTs. The methylation status of PTPRR increased in cervical scrapings (n = 358) in accordance with disease severity, especially in invasive cancer. Methylation of the PTPRR promoter has an important role in the metastasis and may be a biomarker of invasive cervical cancer. Oncogene (2013) 32, 15-26; doi:10.1038/onc.2012.29; published online 13 February 2012	[Huang, R-L; Lee, H-Y; Wang, H-C; Yu, M-H; Lai, H-C] Natl Def Med Ctr, Triserv Gen Hosp, Dept Obstet & Gynecol, Taipei City 114, Taiwan; [Su, P-H; Lai, H-C] Natl Def Med Ctr, Lab Epigenet & Canc Stem Cells, Taipei City 114, Taiwan; [Lin, Y-W] Natl Def Med Ctr, Dept Microbiol & Immunol, Taipei City 114, Taiwan; [Liao, Y-P; Chen, C-K; Lai, H-C] Natl Def Med Ctr, Grad Inst Life Sci, Taipei City 114, Taiwan; [Chao, T-K] Triserv Gen Hosp, Dept Pathol, Taipei, Taiwan; [Chan, M. W. Y.] Natl Chung Cheng Univ, Dept Life Sci, Min Hsiung, Chia Yi, Taiwan; [Chu, T-Y] Tzu Chi Univ, Dept Obstet & Gynecol, Hualien, Taiwan; [Su, P-H; Lai, H-C] Natl Def Med Ctr, Grad Inst Med Sci, Taipei City 114, Taiwan	National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; National Defense Medical Center; National Defense Medical Center; Tri-Service General Hospital; National Chung Cheng University; Tzu Chi University; National Defense Medical Center	Lai, HC (corresponding author), Natl Def Med Ctr, Triserv Gen Hosp, Dept Obstet & Gynecol, 5F,325,Sec 2,Cheng Gong Rd, Taipei City 114, Taiwan.	hclai@ndmctsgh.edu.tw	Chan, Michael/F-9615-2018	Chan, Michael/0000-0003-1431-322X; Chu, Tang-Yuan/0000-0003-2717-2681; Huang, Rui Lan/0000-0001-6458-4672; Chan, Michael/0000-0003-0314-2437	National Science Council, Taiwan, ROC [NSC98-2314-B-016-030-MY3]; Tri-Service General Hospital [TSGH-C100-010-014-S01, TSGH-C100-010-014-S02]; Teh-Tzer Study Group for Human Medical Research Foundation	National Science Council, Taiwan, ROC(Ministry of Science and Technology, Taiwan); Tri-Service General Hospital; Teh-Tzer Study Group for Human Medical Research Foundation	This work was supported by Grant NSC98-2314-B-016-030-MY3 from the National Science Council, Taiwan, ROC (to H-CL); Grant TSGH-C100-010-014-S01 (to M-HY) and TSGH-C100-010-014-S02 (H-CL) from the Tri-Service General Hospital and Teh-Tzer Study Group for Human Medical Research Foundation (to H-CL).	Ahluwalia A, 2001, GYNECOL ONCOL, V82, P299, DOI 10.1006/gyno.2001.6284; Amara K, 2010, CANCER SCI, V101, P1722, DOI 10.1111/j.1349-7006.2010.01569.x; Berger JC, 2005, CANCER BIOL THER, V4, P805, DOI 10.4161/cbt.4.8.1865; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; Branca M, 2004, AM J CLIN PATHOL, V122, P902, DOI 10.1309/VQXFT880JXC7QD2W; Burgers WA, 2007, ONCOGENE, V26, P1650, DOI 10.1038/sj.onc.1209950; Buschbeck M, 2002, J BIOL CHEM, V277, P29503, DOI 10.1074/jbc.M202149200; BUTZ K, 1993, J VIROL, V67, P6476, DOI 10.1128/JVI.67.11.6476-6486.1993; Caberg JHD, 2008, CARCINOGENESIS, V29, P1441, DOI 10.1093/carcin/bgn145; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Chirivi RGS, 2007, J NEUROCHEM, V101, P829, DOI 10.1111/j.1471-4159.2006.04398.x; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Chung MT, 2009, GYNECOL ONCOL, V112, P646, DOI 10.1016/j.ygyno.2008.10.026; Chung MT, 2009, GYNECOL ONCOL, V112, P301, DOI 10.1016/j.ygyno.2008.10.004; de Wilde J, 2008, CELL ONCOL, V30, P77; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fujisawa T, 2011, INT J CANC; Girault I, 2003, CLIN CANCER RES, V9, P4415; Gu W, 2011, CANCER GENE THER, V18, P897, DOI 10.1038/cgt.2011.58; Hellner K, 2009, VIROLOGY, V391, P57, DOI 10.1016/j.virol.2009.05.036; Hickson JA, 2006, CANCER RES, V66, P2264, DOI 10.1158/0008-5472.CAN-05-3676; Horiguchi K, 2009, J BIOL CHEM, V284, P245, DOI 10.1074/jbc.M804777200; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jin BL, 2009, CANCER RES, V69, P7412, DOI 10.1158/0008-5472.CAN-09-0116; Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651; Kikuchi K, 1996, VIRUS GENES, V13, P45, DOI 10.1007/BF00576977; Kwon O, 2010, CARCINOGENESIS; Kyo S, 1997, J GEN VIROL, V78, P401, DOI 10.1099/0022-1317-78-2-401; Lai HC, 2010, CANCER; Lai HC, 2008, INT J CANCER, V123, P161, DOI 10.1002/ijc.23519; Laurson J, 2010, CARCINOGENESIS, V31, P918, DOI 10.1093/carcin/bgq027; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Lemieux E, 2009, INT J CANCER, V125, P1575, DOI 10.1002/ijc.24485; Lichtig H, 2010, VIROLOGY, V396, P47, DOI 10.1016/j.virol.2009.10.011; Lin YW, 2009, J CANCER RES CLIN, V135, P1665, DOI 10.1007/s00432-009-0613-5; Liu CY, 2009, J PATHOL, V219, P222, DOI 10.1002/path.2589; Menigatti M, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-124; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Motiwala T, 2004, P NATL ACAD SCI USA, V101, P13844, DOI 10.1073/pnas.0405451101; Narisawa-Saito M, 2007, CANCER SCI, V98, P1505, DOI 10.1111/j.1349-7006.2007.00546.x; Nephew KP, 2009, GYNECOL ONCOL, V112, P291, DOI 10.1016/j.ygyno.2008.12.016; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Noordman Yvet E, 2006, J Mol Signal, V1, P4, DOI 10.1186/1750-2187-1-4; Nussenzweig MC, 2004, NAT MED, V10, P1304, DOI 10.1038/nm1204-1304; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; Paschos K, 2010, TRENDS MICROBIOL, V18, P439, DOI 10.1016/j.tim.2010.07.003; Prusty BK, 2005, INT J CANCER, V113, P951, DOI 10.1002/ijc.20668; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rodenhiser DI, 2009, CLIN EXP METASTAS, V26, P5, DOI 10.1007/s10585-008-9166-2; Rodriguez-Sastre MA, 2005, GYNECOL ONCOL, V97, P330, DOI 10.1016/j.ygyno.2004.12.062; Sankpal NV, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3070; Schmitt I, 2009, CEREBELLUM, V8, P71, DOI 10.1007/s12311-009-0118-4; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Shi HD, 2003, CANCER RES, V63, P2164; Sova P, 2006, CANCER EPIDEM BIOMAR, V15, P114, DOI 10.1158/1055-9965.EPI-05-0323; Strippoli R, 2008, DIS MODEL MECH, V1, P264, DOI 10.1242/dmm.001321; Szalmas A, 2009, SEMIN CANCER BIOL, V19, P144, DOI 10.1016/j.semcancer.2009.02.011; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1; Veeriah S, 2009, P NATL ACAD SCI USA, V106, P9435, DOI 10.1073/pnas.0900571106; Wang SS, 2008, CANCER RES, V68, P2489, DOI 10.1158/0008-5472.CAN-07-3194; Weng YI, 2009, METHODS MOL BIOL, V590, P165, DOI 10.1007/978-1-60327-378-7_10; Wentzensen N, 2009, GYNECOL ONCOL, V112, P293, DOI 10.1016/j.ygyno.2008.10.012; WHO/ICO, 2010, HUM PAP REL CANC WOR; Wilting S, 2006, J PATHOL, V209, P220, DOI 10.1002/path.1966; Woodman CBJ, 2007, NAT REV CANCER, V7, P11, DOI 10.1038/nrc2050; Yaqinuddin A, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-13; zur Hausen H, 2001, JNCI-J NATL CANCER I, V93, P252	74	48	49	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					15	26		10.1038/onc.2012.29	http://dx.doi.org/10.1038/onc.2012.29			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22330137				2022-12-17	WOS:000313029500002
J	Maruani, DM; Spiegel, TN; Harris, EN; Shachter, AS; Unger, HA; Herrero-Gonzalez, S; Holz, MK				Maruani, D. M.; Spiegel, T. N.; Harris, E. N.; Shachter, A. S.; Unger, H. A.; Herrero-Gonzalez, S.; Holz, M. K.			Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation	ONCOGENE			English	Article						S6K1; mTOR; estrogen; rapamycin; breast cancer	RECEPTOR-ALPHA BINDING; 17Q23 AMPLICON; COPY NUMBER; KINASE; PROTEIN; ACTIVATION; REVEALS; TARGET; GENES; SITES	The 40S ribosomal S6 kinase 1 (S6K1) is an important regulator of cell growth. Expression of S6K1 is often elevated in breast cancer cells. However, the transcriptional mechanism of S6K1 overexpression is not understood. In this report, we demonstrate that estrogen activates expression of S6K1 via estrogen receptor (ER) a in ER-positive breast cancer cells. We also show that estrogen acts on the proximal promoter of the S6K1 gene in a mechanism involving the transcriptional factor GATA-3. Finally, we provide data that support the importance of estrogenic regulation of S6K1 expression in breast cancer cell proliferation. S6K1 directly phosphorylates and regulates ligand-independent activity of ER alpha, while ERa upregulates S6K1 expression. This S6K1-ER alpha relationship creates a positive feed-forward loop in control of breast cancer cell proliferation. Furthermore, the co-dependent association between S6K1 and ER alpha may be exploited in the development of targeted breast cancer therapies. Oncogene (2012) 31, 5073-5080; doi:10.1038/onc.2011.657; published online 30 January 2012	[Maruani, D. M.; Spiegel, T. N.; Harris, E. N.; Shachter, A. S.; Unger, H. A.; Holz, M. K.] Yeshiva Univ, Stern Coll Women, Dept Biol, New York, NY 10016 USA; [Herrero-Gonzalez, S.] Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10467 USA; [Holz, M. K.] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA	Yeshiva University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Holz, MK (corresponding author), Yeshiva Univ, Stern Coll Women, Dept Biol, 245 Lexington Ave, New York, NY 10016 USA.	mholz@yu.edu		Spiegel Strauss, Tirtza/0000-0002-3485-0850	NIH [CA151112]; Atol Charitable Trust; Wendy Will Case Cancer Fund; Yeshiva University; S Daniel Abraham Honors Program of Yeshiva University; NATIONAL CANCER INSTITUTE [R15CA151112] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Atol Charitable Trust; Wendy Will Case Cancer Fund; Yeshiva University; S Daniel Abraham Honors Program of Yeshiva University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank W Lee Kraus for expression constructs and Jonathan Backer for help with kinase assays. We are especially grateful to Matthew Gamble and members of his laboratory for assistance and guidance with ChIP assays. We also like to acknowledge Antonio Di Cristofano for scientific generosity and help with animal experiments. We also thank Fannie F Seligman, Faygel Beren and Miriam Ciner for technical assistance. This work was founded by grants to MKH from NIH (CA151112), Atol Charitable Trust, Wendy Will Case Cancer Fund and Yeshiva University. TNS, ENH, ASS and HAU received support from the S Daniel Abraham Honors Program of Yeshiva University.	[Anonymous], 1992, Lancet, V339, P1; Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; Baselga J, 2009, J CLIN ONCOL, V27, P2630, DOI 10.1200/JCO.2008.18.8391; Becker MA, 2011, MOL ENDOCRINOL, V25, P516, DOI 10.1210/me.2010-0373; Bhat-Nakshatri P, 2008, MOL CELL BIOL, V28, P7487, DOI 10.1128/MCB.00799-08; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Couch FJ, 1999, CANCER RES, V59, P1408; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Ellis M, 2004, ONCOLOGIST, V9, P20, DOI 10.1634/theoncologist.9-suppl_3-20; Fenton TR, 2011, INT J BIOCHEM CELL B, V43, P47, DOI 10.1016/j.biocel.2010.09.018; Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003; Frizzell KM, 2009, J BIOL CHEM, V284, P33926, DOI 10.1074/jbc.M109.023879; Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497; Gruber CJ, 2004, TRENDS ENDOCRIN MET, V15, P73, DOI 10.1016/j.tem.2004.01.008; Han W, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-92; Hu XL, 2009, MOL CANCER RES, V7, P511, DOI 10.1158/1541-7786.MCR-08-0107; Hua S, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.25; Ikeda K, 2004, ARCH HISTOL CYTOL, V67, P435, DOI 10.1679/aohc.67.435; Jiang Shoulei, 2010, Hormones & Cancer, V1, P11, DOI 10.1007/s12672-010-0006-x; Johnston SRD, 2011, BREAST CANCER RES TR, V128, P607, DOI 10.1007/s10549-010-1207-2; Lacroix M, 2004, MOL CELL ENDOCRINOL, V219, P1, DOI 10.1016/j.mce.2004.02.021; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Sathya G, 1997, MOL ENDOCRINOL, V11, P1994, DOI 10.1210/me.11.13.1994; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133; van der Hage JA, 2004, BRIT J CANCER, V90, P1543, DOI 10.1038/sj.bjc.6601741; Yamnik RL, 2010, FEBS LETT, V584, P124, DOI 10.1016/j.febslet.2009.11.041; Yamnik RL, 2009, J BIOL CHEM, V284, P6361, DOI 10.1074/jbc.M807532200; Zhang Y, 2009, CANCER RES, V69, P3795, DOI 10.1158/0008-5472.CAN-08-4596	35	48	49	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	49					5073	5080		10.1038/onc.2011.657	http://dx.doi.org/10.1038/onc.2011.657			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	049RK	22286763	Green Accepted			2022-12-17	WOS:000312000900003
J	Kudo, K; Gavin, E; Das, S; Amable, L; Shevde, LA; Reed, E				Kudo, K.; Gavin, E.; Das, S.; Amable, L.; Shevde, L. A.; Reed, E.			Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair	ONCOGENE			English	Article						Gli1; ERCC1; XPD; XRCC1; cisplatin; ovarian cancer	MESSENGER-RNA LEVELS; NUCLEOTIDE EXCISION-REPAIR; HEDGEHOG PATHWAY; GENE-EXPRESSION; CANCER-CELLS; RESISTANCE; SURVIVAL; TRANSCRIPTION; EXPOSURE; TISSUES	The transcription of ERCC1 and other nucleotide excision repair (NER) genes is strongly influenced by c-jun. C-jun is transcriptionally regulated by Gli proteins of the Hedgehog pathway. We therefore studied the possible relationships between Gli1, c-jun, and the upregulation of ERCC1, XPD and XRCC1 in cisplatin-resistant human ovarian cancer cells. We studied the paired human ovarian cancer cell lines A2780 and A2780-CP70. We used a shRNA construct that specifically degrades Gli1 message. Genes we assessed for mRNA and/or protein levels included: c-jun, ERCC1, XPD, XRCC1, Gli1, Gli2, SHH, IHH, GAPDH and a-tubulin. Platinum-DNA adduct repair was assessed by atomic absorbance spectrometry with Zeeman background correction. Use of the anti-Gli1 shRNA in cisplatin-resistant cells resulted in a block of the cell's ability to upregulate genes in response to cisplatin treatment, including: c-jun, ERCC1, XPD and XRCC1. This block in upregulation of c-jun was concurrent with a change in the phosphorylation pattern of the c-jun protein, shifting that pattern from a Ser63/73 dominant pattern, to a Thr91/93 dominant pattern. A2780-CP70 cells were treated at their cisplatin IC50, and DNA repair was assessed after pretreatment with anti-Gli1 shRNA or scrambled shRNA control. Control cells repaired 78% of platinum-DNA adducts at 12 h, compared with 33% repair in cells pretreated with anti-Gli1 shRNA resulting in a 2.4-fold difference. Pretreatment of A2780-CP70 cells with anti-Gli1 shRNA resulted in supra-additive cell killing with cisplatin; shifting the cisplatin IC50 (half maximal inhibitory concentration) from 30 mu M to 5 mu M. Pretreatment of these cells with cyclopamine did not shift the cisplatin IC50. We conclude that the transcriptional protein Gli1 is important in the upregulation of these three DNA repair genes in human ovarian cancer cells, and that Gli1 strongly influences platinum-DNA adduct repair, and cellular sensitivity to cisplatin. This Gli1 role has c-jun as an intermediate in the pathway. In all, inhibition of Gli1 by a specific shRNA inhibits the upregulation of c-jun Ser63/73, and also inhibits the upregulation of three genes essential to NER (ERCC1, XPD) and base excision repair (XRCC1).	[Kudo, K.; Gavin, E.; Das, S.; Amable, L.; Shevde, L. A.; Reed, E.] Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36604 USA	University of South Alabama	Reed, E (corresponding author), Univ S Alabama, Mitchell Canc Inst, 1660 Springhill Ave, Mobile, AL 36604 USA.	eddiereed@usouthal.edu			Mitchell Cancer Institute, University of South Alabama, Mobile	Mitchell Cancer Institute, University of South Alabama, Mobile	This work was supported by funds from two endowments at the Mitchell Cancer Institute, University of South Alabama, Mobile: the Abraham Mitchell endowment, and the Point Clear Charities endowment.	Altaha R, 2004, INT J MOL MED, V14, P959; Bellmunt J, 2007, ANN ONCOL, V18, P522, DOI 10.1093/annonc/mdl435; Bhattacharya R, 2008, CLIN CANCER RES, V14, P7659, DOI 10.1158/1078-0432.CCR-08-1414; Bonovich M, 2002, CANCER GENE THER, V9, P62, DOI 10.1038/sj/cgt/7700409; Chang HH, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-6; Cobo M, 2007, J CLIN ONCOL, V25, P2747, DOI 10.1200/JCO.2006.09.7915; DABHOLKAR M, 1993, MUTAT RES, V293, P151, DOI 10.1016/0921-8777(93)90066-P; Dabholkar M, 2000, BIOCHEM PHARMACOL, V60, P1611, DOI 10.1016/S0006-2952(00)00448-2; DABHOLKAR M, 1992, J NATL CANCER I, V84, P1512, DOI 10.1093/jnci/84.19.1512; DABHOLKAR M, 1994, J CLIN INVEST, V94, P703, DOI 10.1172/JCI117388; Dabholkar MD, 1996, MOL CARCINOGEN, V17, P1, DOI 10.1002/(SICI)1098-2744(199609)17:1<1::AID-MC1>3.0.CO;2-M; DABHOLKAR MD, 1995, CANCER RES, V55, P1261; Das S, 2009, J BIOL CHEM, V284, P22888, DOI 10.1074/jbc.M109.021949; Desouza LA, 2011, ENDOCRINOLOGY, V152, P1989, DOI 10.1210/en.2010-1396; Kim MK, 2008, CLIN CANCER RES, V14, P4225, DOI 10.1158/1078-0432.CCR-07-4848; Kriyak TC, 2011, GYNECOL ONCOL, V122, P121, DOI 10.1016/j.ygyno.2011.03.027; Laner-Plamberger S, 2009, ONCOGENE, V28, P1639, DOI 10.1038/onc.2009.10; Li Q, 1999, CELL MOL LIFE SCI, V55, P456, DOI 10.1007/s000180050302; Li QD, 1998, J BIOL CHEM, V273, P23419, DOI 10.1074/jbc.273.36.23419; Li QD, 1999, BIOCHEM PHARMACOL, V57, P347, DOI 10.1016/S0006-2952(98)00291-3; Liao XY, 2009, CARCINOGENESIS, V30, P131, DOI 10.1093/carcin/bgn230; Lord RVN, 2002, CLIN CANCER RES, V8, P2286; Metzger R, 1998, J CLIN ONCOL, V16, P309, DOI 10.1200/JCO.1998.16.1.309; Mimnaugh EG, 2000, BIOCHEM PHARMACOL, V60, P1343, DOI 10.1016/S0006-2952(00)00455-X; PARKER RJ, 1991, J CLIN INVEST, V87, P772, DOI 10.1172/JCI115080; Raivich G, 2008, J NEUROCHEM, V107, P898, DOI 10.1111/j.1471-4159.2008.05684.x; Reed E, 2003, CLIN CANCER RES, V9, P5299; Reed E, 2005, CLIN CANCER RES, V11, P6100, DOI 10.1158/1078-0432.CCR-05-1083; Reed E, 1998, CANCER TREAT REV, V24, P331, DOI 10.1016/S0305-7372(98)90056-1; REED E, 1988, ATOM SPECTROSC, V9, P93; Reed E, 1998, CYTOTECHNOLOGY, V27, P187, DOI 10.1023/A:1008016922425; Reed E, 2008, CANC PRINCIPLES PRAC, P419; REED E, 2006, CANC CHEMOTHERAPY BI, P332; Reed E, 2006, NEW ENGL J MED, V355, P1054, DOI 10.1056/NEJMe068162; Reed E, 2010, CLIN CANCER RES, V16, P4511, DOI 10.1158/1078-0432.CCR-10-0528; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Shirota Y, 2001, J CLIN ONCOL, V19, P4298, DOI 10.1200/JCO.2001.19.23.4298; Song Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017687; Sugahara F, 2011, DEVELOPMENT, V138, P1217, DOI 10.1242/dev.059360; Theunissen JW, 2009, CANCER RES, V69, P6007, DOI 10.1158/0008-5472.CAN-09-0756; Verhoeven EEA, 2000, J BIOL CHEM, V275, P5120, DOI 10.1074/jbc.275.7.5120; Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360; Von Hoff DD, 2009, CANCER CELL, V16, P7, DOI 10.1016/j.ccr.2009.06.011; Wei J, 2008, BRIT J CANCER, V98, P1398, DOI 10.1038/sj.bjc.6604317; WESTERVELD A, 1984, NATURE, V310, P425, DOI 10.1038/310425a0; Xu HL, 1998, PLANT J, V13, P823, DOI 10.1046/j.1365-313X.1998.00081.x; ZHEN WP, 1992, MOL CELL BIOL, V12, P3689, DOI 10.1128/MCB.12.9.3689; Zhong XS, 2000, INT J ONCOL, V17, P375	48	48	52	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	44					4718	4724		10.1038/onc.2011.610	http://dx.doi.org/10.1038/onc.2011.610			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032MW	22266871				2022-12-17	WOS:000310724400007
J	Huang, Z; Cheng, Y; Chiu, PM; Cheung, FMF; Nicholls, JM; Kwong, DLW; Lee, AWM; Zabarovsky, ER; Stanbridge, EJ; Lung, HL; Lung, ML				Huang, Z.; Cheng, Y.; Chiu, P. M.; Cheung, F. M. F.; Nicholls, J. M.; Kwong, D. L-W; Lee, A. W. M.; Zabarovsky, E. R.; Stanbridge, E. J.; Lung, H. L.; Lung, M. L.			Tumor suppressor Alpha B-crystallin (CRYAB) associates with the cadherin/catenin adherens junction and impairs NPC progression-associated properties	ONCOGENE			English	Article						Alpha B-crystallin; nasopharyngeal carcinoma; E-cadherin; beta-catenin	EPSTEIN-BARR-VIRUS; NASOPHARYNGEAL EPITHELIAL-CELLS; LYMPH-NODE METASTASIS; DOWN-REGULATION; MESENCHYMAL TRANSITIONS; MOLECULAR-MECHANISMS; DECREASED EXPRESSION; GENE-EXPRESSION; BETA-CATENIN; CARCINOMA	Alpha B-crystallin (CRYAB) maps within the nasopharyngeal carcinoma (NPC) tumor-suppressive critical region 11q22-23 and its downregulation is significantly associated with the progression of NPC. However, little is known about the functional impact of CRYAB on NPC progression. In this study we evaluated the NPC tumor-suppressive and progression-associated functions of CRYAB. Activation of CRYAB suppressed NPC tumor formation in nude mice. Overexpression of CRYAB affected NPC progression-associated phenotypes such as loss of cell adhesion, invasion, interaction with the tumor microenvironment, invasive protrusion formation in three dimensional Matrigel culture, as well as expression of epithelial-mesenchymal transition-associated markers. CRYAB mediates this ability to suppress cancer progression by inhibition of E-cadherin cytoplasmic internalization and maintenance of beta-catenin in the membrane that subsequently reduces the levels of expression of critical downstream targets such as cyclin-D1 and c-myc. Both ectopically expressed and recombinant CRYAB proteins were associated with endogenous E-cadherin and beta-catenin, and, thus, the cadherin/catenin adherens junction. The CRYAB alpha-crystallin core domain is responsible for the interaction of CRYAB with both E-cadherin and beta-catenin. Taken together, these results indicate that CRYAB functions to suppress NPC progression by associating with the cadherin/catenin adherens junction and modulating the beta-catenin function. Oncogene (2012) 31, 3709-3720; doi:10.1038/onc.2011.529; published online 12 December 2011	[Huang, Z.; Cheng, Y.; Chiu, P. M.; Kwong, D. L-W; Lung, H. L.; Lung, M. L.] Univ Hong Kong, Dept Clin Oncol, Pokfulam, Hong Kong, Peoples R China; [Cheung, F. M. F.] Pamela Youde Nethersole Eastern Hosp, Dept Clin Pathol, Hong Kong, Peoples R China; [Nicholls, J. M.] Univ Hong Kong, Dept Pathol, Hong Kong, Peoples R China; [Lee, A. W. M.] Pamela Youde Nethersole Eastern Hosp, Dept Clin Oncol, Hong Kong, Peoples R China; [Huang, Z.; Cheng, Y.; Chiu, P. M.; Kwong, D. L-W; Lung, H. L.; Lung, M. L.] Univ Hong Kong, Ctr Canc Res, Hong Kong, Peoples R China; Karolinska Inst, Dept Microbiol,Tumor & Cell Biol, Stockholm, Sweden; [Zabarovsky, E. R.] Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Stockholm, Sweden; [Zabarovsky, E. R.] Russian Acad Sci, Engelhardt Inst Mol Biol, Lab Struct & Funct Genom, Moscow, Russia; [Stanbridge, E. J.] Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA	University of Hong Kong; Pamela Youde Nethersole Eastern Hospital; University of Hong Kong; Pamela Youde Nethersole Eastern Hospital; University of Hong Kong; Karolinska Institutet; Karolinska Institutet; Sodersjukhuset Hospital; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; University of California System; University of California Irvine	Lung, HL (corresponding author), Univ Hong Kong, Dept Clin Oncol, Room L2-23,2-F Lab Block,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	hllung2@hku.hk; mlilung@hku.hk	Lung, Maria Li/C-4495-2009; Nicholls, John Malcolm/C-4375-2009; /E-9853-2010	Lung, Maria Li/0000-0003-2559-3626; Nicholls, John Malcolm/0000-0001-7217-7444; /0000-0002-2472-1879	Research Grants Council; University Grants Council of Hong Kong Special Administrative Region, People's Republic of China [AoE/M-06/08]; University of Hong Kong Seed Funding Programme for Basic Research; Swedish Cancer Society; Swedish Research Council; Swedish Institute; Karolinska Institute	Research Grants Council(Hong Kong Research Grants Council); University Grants Council of Hong Kong Special Administrative Region, People's Republic of China; University of Hong Kong Seed Funding Programme for Basic Research(University of Hong Kong); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Institute; Karolinska Institute(Karolinska Institutet)	We thank Patrick Vicart for the pcDNA3-CRYAB construct. We acknowledge the funding support from the Research Grants Council grants, and the University Grants Council of Hong Kong Special Administrative Region, People's Republic of China, for AoE/M-06/08 to MLL; The University of Hong Kong Seed Funding Programme for Basic Research to HLL; and the Swedish Cancer Society, the Swedish Research Council, the Swedish Institute and Karolinska Institute to ERZ. We acknowledge the Area of Excellence Hong Kong NPC Research Tissue Bank for the NPC specimens and tissue blocks.	Cheng Y, 2000, GENE CHROMOSOME CANC, V28, P82, DOI 10.1002/(SICI)1098-2264(200005)28:1<82::AID-GCC10>3.0.CO;2-8; Chetty R, 2008, ADV ANAT PATHOL, V15, P234, DOI 10.1097/PAP.0b013e31817bf566; Cheung AKL, 2009, P NATL ACAD SCI USA, V106, P14478, DOI 10.1073/pnas.0900198106; Cheung ST, 1999, INT J CANCER, V83, P121, DOI 10.1002/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F; Chou J, 2008, HEAD NECK-J SCI SPEC, V30, P946, DOI 10.1002/hed.20833; Ghosh JG, 2007, INT J BIOCHEM CELL B, V39, P1804, DOI 10.1016/j.biocel.2007.04.027; Ghosh JG, 2007, BIOCHEMISTRY-US, V46, P6308, DOI 10.1021/bi700149h; Green KJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000125; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915; Hui ABY, 1996, CANCER RES, V56, P3225; Kong QL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000940; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Leung ACC, 2008, INT J CANCER, V122, P587, DOI 10.1002/ijc.23144; Li HM, 2006, INT J CANCER, V119, P1567, DOI 10.1002/ijc.22032; Li JF, 2004, ONCOGENE, V23, P5941, DOI 10.1038/sj.onc.1207789; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Lin JC, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-105; Lo AKF, 2003, LAB INVEST, V83, P697, DOI 10.1097/01.LAB.0000067480.44925.10; Lo KW, 2000, CANCER RES, V60, P3348; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Lung HL, 2005, ONCOGENE, V24, P6525, DOI 10.1038/sj.onc.1208812; Lung HL, 2008, INT J CANCER, V122, P1288, DOI 10.1002/ijc.23259; Lung HL, 2006, CANCER RES, V66, P9385, DOI 10.1158/0008-5472.CAN-06-0590; Lung HL, 2010, INT J CANCER, V127, P304, DOI 10.1002/ijc.25047; Maddala R, 2005, EXP CELL RES, V306, P203, DOI 10.1016/j.yexcr.2005.01.026; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Ohto-Fujita E, 2007, CELL STRESS CHAPERON, V12, P163, DOI 10.1379/CSC-255.1; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; Simon S, 2007, J BIOL CHEM, V282, P34276, DOI 10.1074/jbc.M703267200; Solares CA, 2010, OTOLARYNG HEAD NECK, V142, pS15, DOI 10.1016/j.otohns.2009.12.001; Stronach EA, 2003, CANCER RES, V63, P8648; Takashi M, 1998, UROL RES, V26, P395, DOI 10.1007/s002400050075; Thedieck C, 2008, J MOL BIOL, V378, P145, DOI 10.1016/j.jmb.2008.02.008; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thomson S, 2011, CLIN EXP METASTAS, V28, P137, DOI 10.1007/s10585-010-9367-3; Wong VCL, 2011, BRIT J CANCER, V104, P841, DOI 10.1038/bjc.2011.25; Wong VCL, 2012, INT J CANCER, V130, P83, DOI 10.1002/ijc.25970; Zhang JJ, 2010, CELL CYCLE, V9, P4848, DOI 10.4161/cc.9.24.14136; ZHANG SH, 1983, INT J CANCER, V31, P587, DOI 10.1002/ijc.2910310509; Zheng Z, 1999, HUM PATHOL, V30, P458, DOI 10.1016/S0046-8177(99)90123-5	43	48	49	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	32					3709	3720		10.1038/onc.2011.529	http://dx.doi.org/10.1038/onc.2011.529			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	990TF	22158051				2022-12-17	WOS:000307653800005
J	Pringle, LM; Young, R; Quick, L; Riquelme, DN; Oliveira, AM; May, MJ; Chou, MM				Pringle, L. M.; Young, R.; Quick, L.; Riquelme, D. N.; Oliveira, A. M.; May, M. J.; Chou, M. M.			Atypical mechanism of NF-kappa B activation by TRE17/ubiquitin-specific protease 6 (USP6) oncogene and its requirement in tumorigenesis	ONCOGENE			English	Article						TRE17; USP6; aneurysmal bone cyst; NF-kappa B; I kappa B	ANEURYSMAL BONE-CYST; IKK-BETA; P65 PHOSPHORYLATION; SIGNALING PATHWAY; ANGIOTENSIN-II; KINASE ALPHA; CANCER; SERINE-536; TRANSCRIPTION; UBIQUITIN	The NF-kappa B transcription factor has a central role in diverse processes, including inflammation, proliferation and cell survival, and its activity is dysregulated in diseases such as autoimmunity and cancer. We recently identified the TRE17/ubiquitin-specific protease 6 (USP6) oncogene as the first deubiquitinating enzyme to activate NF-kappa B. TRE17/USP6 is translocated and overexpressed in aneurysmal bone cyst (ABC), a pediatric tumor characterized by extensive bone degradation and inflammatory recruitment. In the current study, we explore the mechanism by which TRE17 induces activation of NF-kappa B, and find that it activates the classical NF-kappa B pathway through an atypical mechanism that does not involve I kappa B degradation. TRE17 co-precipitates with I kappa B kinase (IKK), and IKK activity is augmented in stable cell lines overexpressing TRE17, in a USP-dependent manner. Optimal activation of NF-kappa B by TRE17 requires both catalytic subunits of IKK, distinguishing its mechanism from the classical and non-canonical pathways, which require either IKK beta or IKK alpha, respectively. TRE17 stimulates phosphorylation of p65 at serine 536, a modification that has been associated with enhanced transcriptional activity and nuclear retention. Induction of S536 phosphorylation by TRE17 requires both IKK alpha and IKK beta, as well as the IKK gamma/NEMO regulatory subunit of IKK. We further demonstrate that TRE17(long) is highly tumorigenic when overexpressed in NIH3T3 fibroblasts, and that inhibition of NF-kappa B significantly attenuates tumor formation. In summary, these studies uncover an unexpected signaling mechanism for activation of classical NF-kappa B by TRE17. They further reveal a critical role for NF-kappa B in TRE17-mediated tumorigenesis, and suggest that NF-kappa B inhibitors may function as effective therapeutic agents in the treatment of ABC. Oncogene (2012) 31, 3525-3535; doi:10.1038/onc.2011.520; published online 14 November 2011	[Pringle, L. M.; Young, R.; Quick, L.; Riquelme, D. N.; Chou, M. M.] Childrens Hosp Philadelphia, Dept Pathol & Lab, Philadelphia, PA 19104 USA; [Pringle, L. M.; Young, R.; Quick, L.; Riquelme, D. N.; Chou, M. M.] Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Oliveira, A. M.] Mayo Clin, Dept Pathol & Lab Med, Rochester, MN USA; [Oliveira, A. M.] Mayo Fdn, Rochester, MN USA; [May, M. J.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; [May, M. J.] Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Mayo Clinic; Mayo Clinic; University of Pennsylvania; University of Pennsylvania	Chou, MM (corresponding author), Childrens Hosp Philadelphia, Dept Pathol & Lab, ARC 816E, Philadelphia, PA 19104 USA.	mmc@mail.med.upenn.edu		May, Michael/0000-0002-2485-3716	National Institutes of Health [RO1 CA081415, P30 AS050950]; National Service Research Award Grant [F31CA126488]; NATIONAL CANCER INSTITUTE [F31CA126488, R01CA081415] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL096642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR050950] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Service Research Award Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by the National Institutes of Health Grant RO1 CA081415 (to MMC) and Grant P30 AS050950 (Penn Center for Musculoskeletal Disorders). This work was also supported by the National Service Research Award Grant F31CA126488 (to LMP).	BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Calzado MA, 2007, CURR MED CHEM, V14, P367, DOI 10.2174/092986707779941113; Choudhary S, 2007, MOL ENDOCRINOL, V21, P2203, DOI 10.1210/me.2006-0465; Cottalorda J, 2007, ARCH ORTHOP TRAUM SU, V127, P105, DOI 10.1007/s00402-006-0223-5; Dobrovolskaia MA, 2005, CURR CANCER DRUG TAR, V5, P325, DOI 10.2174/1568009054629645; Douillette A, 2006, J BIOL CHEM, V281, P13275, DOI 10.1074/jbc.M512815200; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; Hansberger MW, 2007, J VIROL, V81, P1360, DOI 10.1128/JVI.01860-06; Harhaj EW, 2011, CELL RES, V21, P22, DOI 10.1038/cr.2010.166; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hu J, 2004, CARCINOGENESIS, V25, P1991, DOI 10.1093/carcin/bgh198; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Khandaker NA, 2004, J IMMUNOL, V173, P6965; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lau AW, 2010, J BIOL CHEM, V285, P37111, DOI 10.1074/jbc.M110.175133; Lee DF, 2008, CLIN CANCER RES, V14, P5656, DOI 10.1158/1078-0432.CCR-08-0123; Liu S, 2008, CELL RES, V21, P6; Mankin HJ, 2005, J CLIN ONCOL, V23, P6756, DOI 10.1200/JCO.2005.15.255; Martinu L, 2004, MOL CELL BIOL, V24, P9752, DOI 10.1128/MCB.24.22.9752-9762.2004; Masuda-Robens JM, 2003, MOL CELL BIOL, V23, P2151, DOI 10.1128/MCB.23.6.2151-2161.2003; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; Mendenhall WM, 2006, AM J CLIN ONCOL-CANC, V29, P311, DOI 10.1097/01.coc.0000204403.13451.52; NAKAMURA T, 1992, ONCOGENE, V7, P733; Oliveira AM, 2005, ONCOGENE, V24, P3419, DOI 10.1038/sj.onc.1208506; Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827; Oliveira AM, 2004, AM J PATHOL, V165, P1773, DOI 10.1016/S0002-9440(10)63432-3; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rollins BJ, 2006, EUR J CANCER, V42, P760, DOI 10.1016/j.ejca.2006.01.002; Saccomanni B, 2008, ARCH ORTHOP TRAUM SU, V128, P1145, DOI 10.1007/s00402-007-0477-6; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Sasaki CY, 2005, J BIOL CHEM, V280, P34538, DOI 10.1074/jbc.M504943200; Shen CL, 2005, J BIOL CHEM, V280, P35967, DOI 10.1074/jbc.M505220200; Shimada H, 2010, J BIOL CHEM, V285, P12536, DOI 10.1074/jbc.M109.099630; Sitcheran R, 2008, MOL CELL BIOL, V28, P5061, DOI 10.1128/MCB.00578-08; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Skaug B, 2009, ANNU REV BIOCHEM, V78, P769, DOI 10.1146/annurev.biochem.78.070907.102750; Solt LA, 2007, J BIOL CHEM, V282, P8724, DOI 10.1074/jbc.M609613200; Sun WJ, 2009, CELL SIGNAL, V21, P1488, DOI 10.1016/j.cellsig.2009.05.007; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Ye Y, 2010, ONCOGENE, V29, P3619, DOI 10.1038/onc.2010.116	48	48	49	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	30					3525	3535		10.1038/onc.2011.520	http://dx.doi.org/10.1038/onc.2011.520			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	979UA	22081069	Green Submitted, Green Accepted			2022-12-17	WOS:000306844100005
J	Sasaki, Y; Kamei, D; Ishikawa, Y; Ishii, T; Uematsu, S; Akira, S; Murakami, M; Hara, S				Sasaki, Y.; Kamei, D.; Ishikawa, Y.; Ishii, T.; Uematsu, S.; Akira, S.; Murakami, M.; Hara, S.			Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis	ONCOGENE			English	Article						mPGES-1; colon cancer; prostaglandin E-2; macrophage	HYPERPLASTIC GASTRIC TUMORS; CANCER; MICE; EXPRESSION; CYCLOOXYGENASE-2; AZOXYMETHANE; INFLAMMATION; PHYSIOLOGY; ROFECOXIB; DELETION	Accumulating evidence indicates that cyclooxygenase (COX)-2-derived prostaglandin (PG) E-2 is involved in the development of various tumors, including colorectal cancer. However, the precise contribution of microsomal PGE synthase (mPGES)-1, a terminal enzyme that acts downstream of COX-2 in the PGE(2)-biosynthetic pathway, to multiple processes of tumor development is not yet fully understood. Here, we show the pro-tumorigenic role of mPGES-1 in chemical carcinogen-induced colon carcinogenesis and intrasplenic tumor transplantation models. Genetic deletion of mPGES-1 significantly reduced both the total number and size of colorectal polyps at 18 weeks after azoxymethane administration with reduced nuclear translocation of beta-catenin, altered expression profiles of chemokines/cytokines and increased production of anti-tumorigenic PGs, prostaglandin D-2 and prostacyclin in tumor tissues. At an early stage (6 weeks), mPGES-1 deficiency significantly reduced the number of aberrant crypt foci, while its transgenic overexpression increased the number. Furthermore, the growth of intrasplenically transplanted tumor cells was suppressed in mPGES-1 knockout (KO) mice. Co-culture of tumor cells with bone marrow-derived macrophages (BM-M Phi s) isolated from wild-type (WT) mice resulted in the induction of mPGES-1 in BM-M Phi s and increased the growth of tumor cells in vitro, whereas mPGES-1-null BM-M Phi s failed to facilitate tumor growth. The adoptive transfer of WT BM-M Phi s into mPGES-1 KO mice restored the growth of transplanted tumor cells, indicating that mPGES-1 in M Phi s is important for the growth of adjacent tumor cells. Taken together, our findings suggest that the inhibition of mPGES-1 is an alternative therapeutic target for colorectal and possibly other cancers.	[Hara, S.] Showa Univ, Sch Pharm, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan; [Kamei, D.] Showa Univ, Sch Pharm, Dept Res & Dev Innovat Med Needs, Tokyo 1428555, Japan; [Ishikawa, Y.; Ishii, T.] Toho Univ, Sch Med, Dept Pathol, Tokyo, Japan; [Uematsu, S.; Akira, S.] Osaka Univ, Dept Host Def, Microbial Dis Res Inst, Osaka, Japan; [Murakami, M.] Tokyo Metropolitan Inst Med Sci, Lipid Metab Project, Tokyo 113, Japan	Showa University; Showa University; Toho University; Osaka University; Tokyo Metropolitan Institute of Medical Science	Hara, S (corresponding author), Showa Univ, Sch Pharm, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	haras@pharm.showa-u.ac.jp	Akira, Shizuo/C-3134-2009		Ministry of Education, Sports, Science, Culture and Technology of Japan; Japan Society for the Promotion of Science for Young Scientists; PRESTO from the Japan Science and Technology Agency; Grants-in-Aid for Scientific Research [21689015, 22116005] Funding Source: KAKEN	Ministry of Education, Sports, Science, Culture and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); PRESTO from the Japan Science and Technology Agency; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by Grants-in-Aid for Scientific Research; by a Private University High Technology Research Center Project matching-fund subsidy from the Ministry of Education, Sports, Science, Culture and Technology of Japan; and by a Showa University Special Grant-in-Aid for Innovative Collaborative Research Projects. D Kamei was supported by Research Fellowships from the Japan Society for the Promotion of Science for Young Scientists. M Murakami was supported by PRESTO from the Japan Science and Technology Agency.	Ban JO, 2010, CHEM-BIOL INTERACT, V188, P75, DOI 10.1016/j.cbi.2010.06.001; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Boulet L, 2004, J BIOL CHEM, V279, P23229, DOI 10.1074/jbc.M400443200; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Casos K, 2011, MICROVASC RES, V81, P261, DOI 10.1016/j.mvr.2011.01.006; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Cathcart MC, 2010, BBA-REV CANCER, V1805, P153, DOI 10.1016/j.bbcan.2010.01.006; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Golijanin D, 2004, CLIN CANCER RES, V10, P1024, DOI 10.1158/1078-0432.CCR-1032-3; Guda K, 2004, ONCOGENE, V23, P3813, DOI 10.1038/sj.onc.1207489; Hanaka H, 2009, P NATL ACAD SCI USA, V106, P18757, DOI 10.1073/pnas.0910218106; Hara S, 2010, BIOCHIMIE, V92, P651, DOI 10.1016/j.biochi.2010.02.007; Hembruff Stacey L, 2009, Cancer Ther, V7, P254; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kamata H, 2010, BIOMED PHARMACOTHER, V64, P409, DOI 10.1016/j.biopha.2010.01.017; Kamei D, 2003, J BIOL CHEM, V278, P19396, DOI 10.1074/jbc.M213290200; Kamei D, 2004, J BIOL CHEM, V279, P33684, DOI 10.1074/jbc.M400199200; Kamei D, 2010, BIOCHEM J, V425, P361, DOI 10.1042/BJ20090045; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; Keith RL, 2004, CANCER RES, V64, P5897, DOI 10.1158/0008-5472.CAN-04-1070; Lavergne E, 2004, J IMMUNOL, V173, P3755, DOI 10.4049/jimmunol.173.6.3755; Mancini JA, 2001, J BIOL CHEM, V276, P4469, DOI 10.1074/jbc.M006865200; Mansure JJ, 2009, CANCER BIOL THER, V8, P1; Murakami M, 2004, PROG LIPID RES, V43, P3, DOI 10.1016/S0163-7827(03)00037-7; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Nakanishi M, 2008, CANCER RES, V68, P3251, DOI 10.1158/0008-5472.CAN-07-6100; Nakanishi M, 2011, CANCER PREV RES, V4, P1198, DOI 10.1158/1940-6207.CAPR-11-0188; Nakatani Y, 2007, J HEALTH SCI, V53, P251, DOI 10.1248/jhs.53.251; Nambiar PR, 2003, INT J ONCOL, V22, P145; Ohtsuki M, 2006, J BIOL CHEM, V281, P36420, DOI 10.1074/jbc.M607975200; Osawa E, 2003, GASTROENTEROLOGY, V124, P361, DOI 10.1053/gast.2003.50067; Oshima H, 2004, EMBO J, V23, P1669, DOI 10.1038/sj.emboj.7600170; Oshima M, 2005, CANCER RES, V65, P9147, DOI 10.1158/0008-5472.CAN-05-1936; Park JM, 2007, CANCER RES, V67, P881, DOI 10.1158/0008-5472.CAN-05-3767; Qian XS, 2011, J BIOL CHEM, V286, P2111, DOI 10.1074/jbc.M110.154971; Robinson SC, 2003, CANCER RES, V63, P8360; Samuelsson B, 2007, PHARMACOL REV, V59, P207, DOI 10.1124/pr.59.3.1; Scher JU, 2005, CLIN IMMUNOL, V114, P100, DOI 10.1016/j.clim.2004.09.008; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Singh B, 2007, J SURG RES, V140, P220, DOI 10.1016/j.jss.2007.01.039; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Thompson EA, 2007, MOL CELLS, V24, P167; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809	47	48	50	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	24					2943	2952		10.1038/onc.2011.472	http://dx.doi.org/10.1038/onc.2011.472			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960LD	21986945				2022-12-17	WOS:000305388400004
J	Basile, KJ; Abel, EV; Aplin, AE				Basile, K. J.; Abel, E. V.; Aplin, A. E.			Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells	ONCOGENE			English	Article						RAF inhibitor; ERK1/2; FOXD3; chemotherapeutic resistance	BRAF MUTATIONS; NEURAL CREST; SELF-RENEWAL; STEM-CELLS; KINASE; CANCER; INHIBITION; PLURIPOTENCY; REQUIREMENT; APOPTOSIS	Melanoma cells driven by mutant v-raf murine sarcoma viral oncogene homolog B1 (B-RAF) are highly resistant to chemotherapeutic treatments. Recent phase 1 results with PLX4032/RG7204/vemurafenib, which selectively inhibits B-RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)1/2 signaling in mutant B-RAF cells, has given encouragement to this struggling field. Nearly all patients in the phase 1-3 studies saw at least some response and the overall response rates ranged from 48 and 81%. However, despite initial tumor shrinkage, most responders in the trial experienced tumor relapse over time. These findings indicate that both intrinsic and acquired resistance may affect the clinical efficacy of PLX4032. It is critical to optimize PLX4032 activity to improve response rates and understand why some patients with the B-RAF mutation do not respond. We have previously shown that the stemness factor, Forkhead box D3 (FOXD3), is upregulated following inhibition of B-RAF-MEK signaling in mutant B-RAF melanoma cells. Here, we show that upregulation of FOXD3 following treatment with PLX4032 and PLX4720 (the non-clinical tool compound for PLX4032) confers resistance to cell death. Small interfering RNA-mediated knockdown of FOXD3 significantly enhanced the cell death response after PLX4032/4720 treatment in mutant B-RAF melanoma cell lines. Additionally, upregulation of FOXD3 after PLX4720 treatment was attenuated in non-adherent conditions and correlated with enhanced cell death. Ectopic expression of FOXD3 in non-adherent cells significantly reduced cell death in response to PLX4720 treatment. Together, these data indicate that upregulation of FOXD3 is an adaptive response to RAF inhibitors that promotes a state of drug resistance. Oncogene (2012) 31, 2471-2479; doi: 10.1038/onc.2011.424; published online 26 September 2011	[Basile, K. J.; Abel, E. V.; Aplin, A. E.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA; [Aplin, A. E.] Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Aplin, AE (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, 233 S 10th St,BLSB 524, Philadelphia, PA 19107 USA.	Andrew.Aplin@KimmelCancerCenter.Org			National Institutes of Health [GM067893, CA125103]; American Cancer Society [RSG-08-03-01-CSM]; Joanna M Nicolay Melanoma Foundation; National Cancer Institute [1P30CA56036]; NATIONAL CANCER INSTITUTE [R01CA160495, P30CA056036, R01CA125103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067893] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Joanna M Nicolay Melanoma Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Gideon Bollag (Plexxikon, Berkeley, CA, USA) for providing PLX4720, Dr Meenhard Herlyn (Wistar Institute, Philadelphia, PA, USA) for WM melanoma cell lines, and Dr Fred Kaplan for critical comments on this paper. This work was supported by National Institutes of Health (GM067893, CA125103), American Cancer Society (RSG-08-03-01-CSM) and a Joanna M Nicolay Melanoma Foundation scholarship. The Kimmel Cancer Center is supported by National Cancer Institute Support Grant 1P30CA56036.	Abel EV, 2010, CANCER RES, V70, P2891, DOI 10.1158/0008-5472.CAN-09-3139; Aplin AE, 2011, J INVEST DERMATOL, V131, P1817, DOI 10.1038/jid.2011.147; Boisvert-Adamo K, 2006, ONCOGENE, V25, P4848, DOI 10.1038/sj.onc.1209493; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Hanna LA, 2002, GENE DEV, V16, P2650, DOI 10.1101/gad.1020502; Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108; Hoeflich KP, 2009, CANCER RES, V69, P3042, DOI 10.1158/0008-5472.CAN-08-3563; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liber D, 2010, CELL STEM CELL, V7, P114, DOI 10.1016/j.stem.2010.05.020; Liu Y, 2008, STEM CELLS, V26, P2475, DOI 10.1634/stemcells.2008-0269; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mundell NA, 2011, DEVELOPMENT, V138, P641, DOI 10.1242/dev.054718; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Pan GJ, 2006, FASEB J, V20, P1730, DOI 10.1096/fj.05-5543fje; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Ribas A, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.8509; Shao YP, 2010, CANCER RES, V70, P6670, DOI 10.1158/0008-5472.CAN-09-4471; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Smalley KSM, 2010, NEW ENGL J MED, V363, P876, DOI 10.1056/NEJMe1005370; Sutton J, 1996, J BIOL CHEM, V271, P23126, DOI 10.1074/jbc.271.38.23126; Teng L, 2008, DEVELOPMENT, V135, P1615, DOI 10.1242/dev.012179; Thomas AJ, 2008, PIGM CELL MELANOMA R, V21, P598, DOI 10.1111/j.1755-148X.2008.00506.x; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Wang YF, 2007, CLIN CANCER RES, V13, P4934, DOI 10.1158/1078-0432.CCR-07-0665	33	48	48	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	19					2471	2479		10.1038/onc.2011.424	http://dx.doi.org/10.1038/onc.2011.424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21996740	Green Accepted			2022-12-17	WOS:000303985300009
J	Woo, JK; Choi, Y; Oh, SH; Jeong, JH; Choi, DH; Seo, HS; Kim, CW				Woo, J. K.; Choi, Y.; Oh, S-H; Jeong, J-H; Choi, D-H; Seo, H-S; Kim, C-W			Mucin 1 enhances the tumor angiogenic response by activation of the AKT signaling pathway	ONCOGENE			English	Article						breast cancer; angiogenesis; MUC1; PI3K/AKT; VEGF	ENDOTHELIAL-GROWTH-FACTOR; FACTOR EXPRESSION; ANTIGEN-EXPRESSION; FACTOR RECEPTOR; FACTOR-I; INDUCTION; PHOSPHORYLATION; METASTASIS; INHIBITION; SUGGESTS	Although the hyper-glycosylated transmembrane protein Mucin 1 (MUC1) is aberrantly overexpressed in human breast carcinoma, the biological significance of MUC1 overexpression is unclear. This study showed that MUC1 expression promoted the synthesis and secretion of vascular endothelial growth factor (VEGF) through the AKT signaling pathway. Increase VEGF production through MUC1 expression had a number of effect. First, MUC1 transfection increased expression of VEGF in breast cancer cells. Second, MUC1-mediated VEGF induction was attenuated by a chemical inhibitor of AKT or MUC1 knock-down by MUC1 siRNA. Third, MUC1 expression led to the activation of insulin-like growth factor-1 receptor, which correlated with VEGF expression. In addition, when MDA-MB-231 human breast cancer cells were directly injected into NOD/SCID mice, MUC1 expression accelerated xenograft tumor growth in vivo. Finally, MUC1 expression enhanced tumor growth and angiogenesis in a PyMT-MMTV/hMUC1 transgenic mouse model. Concurrent with these results, analysis of a human tissue microarray identified a high correlation between MUC1 and VEGF expression in human breast carcinoma. The current report is the first to demonstrate that MUC1 expression promotes angiogenesis in human breast cancer in vivo and in vitro. Oncogene (2012) 31, 2187-2198; doi:10.1038/onc.2011.410; published online 19 September 2011	[Woo, J. K.; Kim, C-W] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110799, South Korea; [Woo, J. K.; Choi, Y.; Choi, D-H; Kim, C-W] Seoul Natl Univ, Coll Med, Tumor Immun Med Res Ctr, Seoul 110799, South Korea; [Woo, J. K.; Choi, Y.; Choi, D-H; Kim, C-W] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110799, South Korea; [Oh, S-H] Gachon Univ Med & Sci, Coll Pharm, Inchon, South Korea; [Jeong, J-H] Korea Inst Radiol & Med Sci, Res Ctr Radiotherapy, Seoul, South Korea; [Seo, H-S] Kyung Hee Univ, Dept Oriental Med, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Gachon University; Korea Institute of Radiological & Medical Sciences; Kyung Hee University	Kim, CW (corresponding author), Seoul Natl Univ, Coll Med, Dept Pathol, 28 Yeongeon Dong, Seoul 110799, South Korea.	cwkim@snu.ac.kr	Kim, Chul-Woo/F-7008-2011	Woo, Jong Kyu/0000-0002-3374-6488	Ministry of Knowledge Economy (MOST) [10035353]; Korean Science and Engineering Foundation (KOSEF) through the Tumor Immunity Medical Research Center at Seoul National University college of Medicine, Republic of Korea	Ministry of Knowledge Economy (MOST)(Ministry of Trade, Industry & Energy (MOTIE), Republic of Korea); Korean Science and Engineering Foundation (KOSEF) through the Tumor Immunity Medical Research Center at Seoul National University college of Medicine, Republic of Korea(Korea Science and Engineering Foundation)	We are grateful to Drs Dong-Young Noh and Hyeong-Gon Moon for providing the human breast cancer tissues microarray. This work was supported in part by grants from the R&D Project, the Ministry of Knowledge Economy (MOST, 10035353) and the Korean Science and Engineering Foundation (KOSEF) through the Tumor Immunity Medical Research Center at Seoul National University college of Medicine, Republic of Korea	BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; Borgstrom P, 1996, CANCER RES, V56, P4032; Brayman Melissa, 2004, Reprod Biol Endocrinol, V2, P4, DOI 10.1186/1477-7827-2-4; Cho JA, 2005, INT J CANCER, V114, P613, DOI 10.1002/ijc.20757; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Duffy MJ, 2000, INT J BIOL MARKER, V15, P330, DOI 10.1177/172460080001500410; Duraisamy S, 2007, INT J ONCOL, V31, P671; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Feldkamp MM, 1999, INT J CANCER, V81, P118, DOI 10.1002/(SICI)1097-0215(19990331)81:1<118::AID-IJC20>3.0.CO;2-5; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Fessler SP, 2009, BREAST CANCER RES TR, V118, P113, DOI 10.1007/s10549-009-0412-3; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Geddis AE, 2006, EXP HEMATOL, V34, P82, DOI 10.1016/j.exphem.2005.09.008; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811; Giatromanolaki A, 2000, CLIN CANCER RES, V6, P1917; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hattrup CL, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1515; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Kimura T, 2000, INT J ONCOL, V16, P55; KOHNO N, 1992, CHEST, V102, P117, DOI 10.1378/chest.102.1.117; Kucab Jill E, 2003, Breast Dis, V17, P41; Kurmasheva RT, 2009, CANCER RES, V69, P7662, DOI 10.1158/0008-5472.CAN-09-1693; Lee HY, 2005, J NATL CANCER I, V97, P1695, DOI 10.1093/jnci/dji377; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; Mikami Y, 2009, BIOCHEM BIOPH RES CO, V379, P1060, DOI 10.1016/j.bbrc.2009.01.002; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Morgillo F, 2006, CANCER RES, V66, P10100, DOI 10.1158/0008-5472.CAN-06-1684; Okajima E, 2000, BIOCHEM BIOPH RES CO, V270, P108, DOI 10.1006/bbrc.2000.2386; Papadopoulos I, 2001, CLIN CANCER RES, V7, P1533; Parrizas M, 1997, J BIOL CHEM, V272, P154; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Pochampalli MR, 2007, ONCOGENE, V26, P1693, DOI 10.1038/sj.onc.1209976; Pochampalli MR, 2007, CANCER RES, V67, P6591, DOI 10.1158/0008-5472.CAN-06-4518; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Pollak MN, 2004, NOVART FDN SYMP, V262, P265, DOI DOI 10.1002/0470869976.CH6; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Poulaki V, 2003, J CLIN ENDOCR METAB, V88, P5392, DOI 10.1210/jc.2003-030389; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Ren J, 2006, MOL CANCER RES, V4, P873, DOI 10.1158/1541-7786.MCR-06-0204; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Sakamoto H, 1997, HUM PATHOL, V28, P1056, DOI 10.1016/S0046-8177(97)90059-9; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; Tang YC, 2003, CANCER RES, V63, P1166; Wang Bao-Feng, 2009, Zhongguo Zhong Xi Yi Jie He Za Zhi, V29, P425; Wei XL, 2006, MOL CELL, V21, P295, DOI 10.1016/j.molcel.2005.11.030; Werner H, 2000, CELL MOL LIFE SCI, V57, P932, DOI 10.1007/PL00000735; Yin L, 2007, J BIOL CHEM, V282, P257, DOI 10.1074/jbc.M610156200; Yoshiji H, 1997, CANCER RES, V57, P3924; Yu H, 2007, BIOCHEM BIOPH RES CO, V361, P946, DOI 10.1016/j.bbrc.2007.07.114; Yuen JSP, 2007, ONCOGENE, V26, P6499, DOI 10.1038/sj.onc.1210474	55	48	50	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	17					2187	2198		10.1038/onc.2011.410	http://dx.doi.org/10.1038/onc.2011.410			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21927028				2022-12-17	WOS:000303415900007
J	Smirnova, T; Zhou, ZN; Flinn, RJ; Wyckoff, J; Boimel, PJ; Pozzuto, M; Coniglio, SJ; Backer, JM; Bresnick, AR; Condeelis, JS; Hynes, NE; Segall, JE				Smirnova, T.; Zhou, Z. N.; Flinn, R. J.; Wyckoff, J.; Boimel, P. J.; Pozzuto, M.; Coniglio, S. J.; Backer, J. M.; Bresnick, A. R.; Condeelis, J. S.; Hynes, N. E.; Segall, J. E.			Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis	ONCOGENE			English	Article						ErbB3; breast cancer; metastasis; in vivo invasion; intravasation; PI3-Kinase	MAMMARY-TUMORS; ERBB2/ERBB3 CORECEPTOR; LUNG-CANCER; INTRAVASATION; ERBB3; INVASION; RECEPTOR; KINASE; INHIBITION; EXPRESSION	Many malignancies show increased expression of the epidermal growth factor (EGF) receptor family member ErbB3 (HER3). ErbB3 binds heregulin beta-1 (HRG beta 1) and forms a heterodimer with other ErbB family members, such as ErbB2 (HER2) or EGF receptor (EGFR; HER1), enhancing phosphorylation of specific C-terminal tyrosine residues and activation of downstream signaling pathways. ErbB3 contains six YXXM motifs that bind the p85 subunit of phosphoinositide 3 (PI3)-kinase. Previous studies demonstrated that overexpression of ErbB3 in mammary tumor cells can significantly enhance chemotaxis to HRG beta 1 and overall metastatic potential. We tested the hypothesis that ErbB3-mediated PI3-kinase signaling is critical for heregulin-induced motility, and therefore crucial for ErbB3-mediated invasion, intravasation and metastasis. The tyrosines in the six YXXM motifs on the ErbB3 C-terminus were replaced with phenylalanine. In contrast to overexpression of the wildtype ErbB3, overexpression of the mutant ErbB3 did not enhance chemotaxis towards HRGb1 in vitro or in vivo. We also observed reduced tumor cell motility in the primary tumor by multiphoton microscopy, as well as a dramatically reduced ability of these cells to cross the endothelium and intravasate into the circulation. Moreover, whereas mutation of the ErbB3 C-terminus had no effect on tumor growth, it had a dramatic effect on spontaneous metastatic potential. Treatment with the PI3-kinase inhibitor PIK-75 similarly inhibited motility and invasion in vitro and in vivo. Our results indicate that stimulation of the early metastatic steps of motility and invasion by ErbB3 requires activation of the PI3-kinase pathway by the ErbB3 receptor. Oncogene (2012) 31, 706-715; doi:10.1038/onc.2011.275; published online 4 July 2011	[Smirnova, T.; Zhou, Z. N.; Wyckoff, J.; Boimel, P. J.; Coniglio, S. J.; Condeelis, J. S.; Segall, J. E.] Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10801 USA; [Flinn, R. J.; Backer, J. M.] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10801 USA; [Wyckoff, J.; Condeelis, J. S.; Segall, J. E.] Albert Einstein Coll Med, Gruss Lipper Ctr Biophoton, Bronx, NY 10801 USA; [Pozzuto, M.; Bresnick, A. R.] Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10801 USA; [Hynes, N. E.] Friedrich Miescher Inst Biomed Res, Basel, Switzerland	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Friedrich Miescher Institute for Biomedical Research	Segall, JE (corresponding author), Albert Einstein Coll Med, Dept Anat & Struct Biol, Price 201,1300 Morris Pk Ave, Bronx, NY 10801 USA.	jeffrey.segall@einstein.yu.edu		Boimel, Pamela/0000-0002-9771-1700	NIH [CA77522, CA100324, CA1U01105490, RO1 GM55692, P01 CA100324]; NATIONAL CANCER INSTITUTE [P01CA100324, U01CA105490, R01CA077522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055692, T32GM007288] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank John Koland and the members of the Segall, Condeelis, Cox, Hodgson, and Hynes laboratories for comments and suggestions. JES is the Betty and Sheldon Feinberg Senior Faculty Scholar in Cancer Research. This work was supported by grants from the NIH (JES: CA77522 and CA100324); CA1U01105490 and CA100324 (JS Condeelis and J Wyckoff); RO1 GM55692 (JB); NIH P01 CA100324 (JB and ARB).	Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Amin DN, 2010, SEMIN CELL DEV BIOL, V21, P944, DOI 10.1016/j.semcdb.2010.08.007; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Burgess AW, 2008, GROWTH FACTORS, V26, P263, DOI 10.1080/08977190802312844; Cain RJ, 2009, BIOL CELL, V101, P13, DOI 10.1042/BC20080079; Campbell MR, 2010, CLIN CANCER RES, V16, P1373, DOI 10.1158/1078-0432.CCR-09-1218; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chausovsky A, 2000, ONCOGENE, V19, P878, DOI 10.1038/sj.onc.1203410; Chaussade C, 2007, BIOCHEM J, V404, P449, DOI 10.1042/BJ20070003; Chiu CG, 2010, ANN SURG, V251, P1107, DOI 10.1097/SLA.0b013e3181dbb77e; Di Cosimo S, 2010, NAT REV CLIN ONCOL, V7, P139, DOI 10.1038/nrclinonc.2009.234; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Fujimoto N, 2005, CANCER RES, V65, P11478, DOI 10.1158/0008-5472.CAN-05-1977; Hayakawa M, 2007, BIOORGAN MED CHEM, V15, P5837, DOI 10.1016/j.bmc.2007.05.070; Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200; Hernandez L, 2009, METHODS MOL BIOL, V571, P227, DOI 10.1007/978-1-60761-198-1_15; Hernandez L, 2009, CANCER RES, V69, P3221, DOI 10.1158/0008-5472.CAN-08-2871; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Iivanainen E, 2007, EXP CELL RES, V313, P2896, DOI 10.1016/j.yexcr.2007.03.042; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kalinowski A, 2010, FASEB J, V24, P2567, DOI 10.1096/fj.08-129072; Kedrin D, 2009, CLIN CANCER RES, V15, P3733, DOI 10.1158/1078-0432.CCR-08-2163; Ky B, 2009, CIRCULATION, V120, P310, DOI 10.1161/CIRCULATIONAHA.109.856310; NERI A, 1982, J NATL CANCER I, V68, P507; Olayioye MA, 2001, EXP CELL RES, V267, P81, DOI 10.1006/excr.2001.5242; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Sassen A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1843; Schade B, 2007, CANCER RES, V67, P7579, DOI 10.1158/0008-5472.CAN-06-4724; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; Vijapurkar U, 2003, EXP CELL RES, V284, P291, DOI 10.1016/S0014-4827(02)00040-X; Wyckoff JB, 2000, CANCER RES, V60, P2504; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Xue CS, 2006, CANCER RES, V66, P1418, DOI 10.1158/0008-5472.CAN-05-0550; Zhang JF, 2006, ARTERIOSCL THROM VAS, V26, pE23, DOI 10.1161/01.ATV.0000202661.61837.93	37	48	49	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	6					706	715		10.1038/onc.2011.275	http://dx.doi.org/10.1038/onc.2011.275			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21725367	Green Accepted			2022-12-17	WOS:000300222100004
J	Lu, Y; Muller, M; Smith, D; Dutta, B; Komurov, K; Iadevaia, S; Ruths, D; Tseng, JT; Yu, S; Yu, Q; Nakhleh, L; Balazsi, G; Donnelly, J; Schurdak, M; Morgan-Lappe, S; Fesik, S; Ram, PT; Mills, GB				Lu, Y.; Muller, M.; Smith, D.; Dutta, B.; Komurov, K.; Iadevaia, S.; Ruths, D.; Tseng, J-T; Yu, S.; Yu, Q.; Nakhleh, L.; Balazsi, G.; Donnelly, J.; Schurdak, M.; Morgan-Lappe, S.; Fesik, S.; Ram, P. T.; Mills, G. B.			Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling	ONCOGENE			English	Article						AKT; MAPK; proteomics; signaling networks; siRNA	RIBOSOMAL S6 KINASE; CANCER CELL-LINES; TUBEROUS-SCLEROSIS; BREAST-CANCER; PI3K PATHWAY; GROWTH; PHOSPHORYLATION; INHIBITION; PROTEIN; TSC2	To identify regulators of intracellular signaling, we targeted 541 kinases and kinase-related molecules with small interfering RNAs (siRNAs), and determined their effects on signaling with a functional proteomics reverse-phase protein array (RPPA) platform assessing 42 phospho and total proteins. The kinome-wide screen demonstrated a strong inverse correlation between phosphorylation of AKT and mitogen-activated protein kinase (MAPK) with 115 genes that, when targeted by siRNAs, demonstrated opposite effects on MAPK and AKT phosphorylation. Network-based analysis identified the MAPK subnetwork of genes along with p70S6K and FRAP1 as the most prominent targets that increased phosphorylation of AKT, a key regulator of cell survival. The regulatory loops induced by the MAPK pathway are dependent on tuberous sclerosis complex 2 but demonstrate a lesser dependence on p70S6K than the previously identified FRAP1 feedback loop. The siRNA screen also revealed novel bi-directionality in the AKT and GSK3 (Glycogen synthase kinase 3) interaction, whereby genetic ablation of GSK3 significantly blocks AKT phosphorylation, an unexpected observation as GSK3 has only been predicted to be downstream of AKT. This method uncovered novel modulators of AKT phosphorylation and facilitated the mapping of regulatory loops. Oncogene (2011) 30, 4567-4577; doi: 10.1038/onc.2011.164; published online 13 June 2011	[Lu, Y.; Muller, M.; Smith, D.; Dutta, B.; Komurov, K.; Iadevaia, S.; Tseng, J-T; Yu, S.; Yu, Q.; Balazsi, G.; Ram, P. T.; Mills, G. B.] UT MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77054 USA; [Ruths, D.; Nakhleh, L.] Rice Univ, Dept Comp Sci, Houston, TX USA; [Donnelly, J.; Schurdak, M.; Morgan-Lappe, S.; Fesik, S.] Abbott Labs, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA	University of Texas System; UTMD Anderson Cancer Center; Rice University; Abbott Laboratories	Ram, PT (corresponding author), UT MD Anderson Canc Ctr, Dept Syst Biol, 7435 Fannin St, Houston, TX 77054 USA.	pram@mdanderson.org		Balazsi, Gabor/0000-0002-6865-5818; Ram, Prahlad/0000-0003-4739-3166; Schurdak, Mark/0000-0002-1146-3268	Kleberg Center for Molecular Markers; Komen Foundation [SU2C-AACR- DT0209]; NIH [CCSG P30CA16672, T90DK070109, R01CA125109, P01CA099031, P50CA083639, U54 CA112970]; NIH Foundation [DPA86424-444938]; GBM; NIH CCTS; Komen fellowship [KG101547]; PTR; DOD [BC044268]; Seed Funding Program Collaborative Advances in Biomedical Computing (CAMC); John and Ann Doerr Fund; NATIONAL CANCER INSTITUTE [P50CA098258, R01CA125109, U54CA112970, P01CA099031, P30CA016672, P50CA083639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T90DK070109] Funding Source: NIH RePORTER	Kleberg Center for Molecular Markers; Komen Foundation(Susan G. Komen Breast Cancer Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Foundation; GBM; NIH CCTS; Komen fellowship; PTR; DOD(United States Department of Defense); Seed Funding Program Collaborative Advances in Biomedical Computing (CAMC); John and Ann Doerr Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Drs Kwiatkowski and J Woodgett for the knock out TSC2 and GSK3 cells, respectively. This study was funded in part by the Kleberg Center for Molecular Markers, the Komen Foundation, StandUp to Cancer/AmericanAssociation for Cancer Research Dream Team Translational Cancer Research Grant, Grant No. SU2C-AACR- DT0209, NIH CCSG P30CA16672, NIH Foundation DPA86424-444938 to BD and GBM, NIH CCTS support to DS, NIH T90DK070109 fellowship to J-TT and SI, Komen fellowship KG101547 to KK and PTR, DOD BC044268 and NIH R01CA125109 to PTR, NIH P01CA099031 and P50CA083639 to GBM, and U54 CA112970 to PTR and GBM. LN was supported by the Seed Funding Program Collaborative Advances in Biomedical Computing (CAMC), funded by the John and Ann Doerr Fund for Computational Biomedicine.	Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Avruch J, 2006, ONCOGENE, V25, P6361, DOI 10.1038/sj.onc.1209882; Ballif BA, 2005, P NATL ACAD SCI USA, V102, P667, DOI 10.1073/pnas.0409143102; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Buck E, 2008, CANCER RES, V68, P8322, DOI 10.1158/0008-5472.CAN-07-6720; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Iadevaia S, 2010, CANCER RES, V70, P6704, DOI 10.1158/0008-5472.CAN-10-0460; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Komurov K, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000889; Komurov K, 2010, J BIOL CHEM, V285, P21134, DOI 10.1074/jbc.M110.137828; Kwiatkowski DJ, 2005, HUM MOL GENET, V14, pR251, DOI 10.1093/hmg/ddi260; Li WQ, 1999, ONCOGENE, V18, P6564, DOI 10.1038/sj.onc.1203065; Lin X, 2007, ONCOGENE, V26, P3972, DOI 10.1038/sj.onc.1210166; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Ma'ayan A, 2005, SCIENCE, V309, P1078, DOI 10.1126/science.1108876; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Morgan-Lappe S, 2006, ONCOGENE, V25, P1340, DOI 10.1038/sj.onc.1209169; Morgan-Lappe SE, 2007, CANCER RES, V67, P4390, DOI 10.1158/0008-5472.CAN-06-4132; Muller M, 2008, FASEB J, V22, P1393, DOI 10.1096/fj.07-9100com; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Ruths D, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000005; Ruths D, 2008, BMC SYST BIOL, V2, DOI 10.1186/1752-0509-2-76; Sarthy AV, 2007, MOL CANCER THER, V6, P269, DOI 10.1158/1535-7163.MCT-06-0560; Song JJ, 2005, J CELL BIOL, V170, P61, DOI 10.1083/jcb.200502070; Tahir SK, 2007, CANCER RES, V67, P1176, DOI 10.1158/0008-5472.CAN-06-2203; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Zheng M, 2008, CANCER RES, V68, P7570, DOI 10.1158/0008-5472.CAN-08-0632	37	48	51	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 10	2011	30	45					4567	4577		10.1038/onc.2011.164	http://dx.doi.org/10.1038/onc.2011.164			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	846IO	21666717	Green Accepted			2022-12-17	WOS:000296890700004
J	Shao, H; Cai, L; Grichnik, JM; Livingstone, AS; Velazquez, OC; Liu, ZJ				Shao, H.; Cai, L.; Grichnik, J. M.; Livingstone, A. S.; Velazquez, O. C.; Liu, Z-J			Activation of Notch1 signaling in stromal fibroblasts inhibits melanoma growth by upregulating WISP-1	ONCOGENE			English	Article						tumor microenvironment; melanoma; fibroblasts; Notch; WISP-1	EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-GROWTH; CANCER-THERAPY; BREAST-CANCER; LUNG-CANCER; ANGIOGENESIS; CELLS; PROGRESSION; DLL4; DIFFERENTIATION	The tumor microenvironment is emerging as an important target for cancer therapy. Fibroblasts (Fbs) within the tumor stroma are critically involved in promoting tumor growth and angiogenesis through secretion of soluble factors, synthesis of extracellular matrix and direct cell-cell interaction. In this work, we aim to alter the biological activity of stromal Fbs by modulating the Notch1 signaling pathway. We show that Fbs engineered to constitutively activate the Notch1 pathway significantly inhibit melanoma growth and tumor angiogenesis. We determine that the inhibitory effect of 'Notch-engineered' Fbs is mediated by increased secretion of Wnt-induced secreted protein-1 (WISP-1) as the effects of Notch1 activation in Fbs are reversed by shRNA-mediated blockade of WISP-1. When 'Notch-engineered' Fbs are co-grafted with melanoma cells in SCID mice, shRNA-mediated blockade of WISP-1 reverses the tumor-suppressive phenotype of the 'Notch-engineered' Fbs, significantly increases melanoma growth and tumor angiogenesis. Consistent with these findings, supplement of recombinant WISP-1 protein inhibits melanoma cell growth in vitro. In addition, WISP-1 is modestly expressed in melanoma-activated Fbs but highly expressed in inactivated Fbs. Evaluation of human melanoma skin biopsies indicates that expression of WISP-1 is significantly lower in melanoma nests and surrounding areas filled with infiltrated immune cells than in the adjacent dermis unaffected by the melanoma. Overall, our study shows that constitutive activation of the Notch1 pathway confers Fbs with a suppressive phenotype to melanoma growth, partially through WISP-1. Thus, targeting tumor stromal Fbs by activating Notch signaling and/or increasing WISP-1 may represent a novel therapeutic approach to combat melanoma. Oncogene (2011) 30, 4316-4326; doi: 10.1038/onc.2011.142; published online 25 April 2011	[Liu, Z-J] Univ Miami, Sylvester Comprehens Canc Ctr, Sch Med, Dept Surg, Miami, FL 33136 USA; [Shao, H.; Cai, L.; Livingstone, A. S.; Velazquez, O. C.; Liu, Z-J] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA; [Cai, L.] Hangzhou Red Cross Hosp, Hangzhou, Zhejiang, Peoples R China; [Grichnik, J. M.] Univ Miami, Miller Sch Med, Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami	Liu, ZJ (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, Sch Med, Dept Surg, RMSB 1046,1600 NW 10th Ave, Miami, FL 33136 USA.	zliu@med.miami.edu	Livingstone, Alan/AAA-4026-2019; Grichnik, James/R-3887-2019	Grichnik, James/0000-0002-9185-0056; Shao, Hongwei/0000-0001-9770-4132	James & Esther King Biomedical Research Program [08KN-10]; Bankhead-Coley Cancer Research [09BN-11]	James & Esther King Biomedical Research Program; Bankhead-Coley Cancer Research	We thank Dr M Herlyn for providing the melanoma cells (1205Lu, WM35, WM3248, Sbcl2, WM278 and WM3899) and Dr G McNamara for laser-scanning confocal microscopy. The work of Dr Liu was supported by grants from the James & Esther King Biomedical Research Program (08KN-10) and the Bankhead-Coley Cancer Research Program (09BN-11).	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Anton K, 2009, CURR PHARM BIOTECHNO, V10, P185, DOI 10.2174/138920109787315088; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Chen PP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000534; Crawford Y, 2009, CANCER CELL, V15, P21, DOI 10.1016/j.ccr.2008.12.004; Davies SR, 2007, ANN SURG ONCOL, V14, P1909, DOI 10.1245/s10434-007-9376-x; Dufraine J, 2008, ONCOGENE, V27, P5132, DOI 10.1038/onc.2008.227; Hayward SW, 2001, CANCER RES, V61, P8135; Ishikawa Y, 2008, ONCOGENE, V27, P6164, DOI 10.1038/onc.2008.216; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Li YW, 2008, NAT PROTOC, V3, P1703, DOI 10.1038/nprot.2008.172; Liu ZJ, 2010, ANN SURG, V252, P625, DOI 10.1097/SLA.0b013e3181f5a079; Liu ZJ, 2009, J CELL BIOCHEM, V106, P984, DOI 10.1002/jcb.22091; Liu ZJ, 2006, CANCER RES, V66, P4182, DOI 10.1158/0008-5472.CAN-05-3589; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; LIU ZJ, 2005, MOL BIOL CUTANEOUS M; Lorusso G, 2008, HISTOCHEM CELL BIOL, V130, P1091, DOI 10.1007/s00418-008-0530-8; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Mailhos C, 2001, DIFFERENTIATION, V69, P135, DOI 10.1046/j.1432-0436.2001.690207.x; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Midwood KS, 2004, INT J BIOCHEM CELL B, V36, P1031, DOI 10.1016/j.biocel.2003.12.003; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Pinnix CC, 2009, CANCER RES, V69, P5312, DOI 10.1158/0008-5472.CAN-08-3767; Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313; Sakamoto K, 2002, J BIOL CHEM, V277, P29399, DOI 10.1074/jbc.M203727200; SAPPINO AP, 1988, INT J CANCER, V41, P707, DOI 10.1002/ijc.2910410512; Soon LL, 2003, J BIOL CHEM, V278, P11465, DOI 10.1074/jbc.M210945200; Tanaka S, 2001, ONCOGENE, V20, P5525, DOI 10.1038/sj.onc.1204723; Thurston G, 2007, NAT REV CANCER, V7, P327, DOI 10.1038/nrc2130; Urs S, 2008, AM J PATHOL, V173, P865, DOI 10.2353/ajpath.2008.080006; Yin L, 2010, BIOCHEM PHARMACOL, V80, P690, DOI 10.1016/j.bcp.2010.03.026; Zeisberg M, 2008, FRONT BIOSCI, V13, P6991	40	48	50	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	42					4316	4326		10.1038/onc.2011.142	http://dx.doi.org/10.1038/onc.2011.142			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HP	21516124				2022-12-17	WOS:000296356400003
J	Hollander, MC; Maier, CR; Hobbs, EA; Ashmore, AR; Linnoila, RI; Dennis, PA				Hollander, M. C.; Maier, C. R.; Hobbs, E. A.; Ashmore, A. R.; Linnoila, R. I.; Dennis, P. A.			Akt1 deletion prevents lung tumorigenesis by mutant K-ras	ONCOGENE			English	Article						Akt1; Akt3; K-ras; lung	PLECKSTRIN HOMOLOGY DOMAIN; GLUCOSE-HOMEOSTASIS; ONCOGENIC MUTATION; THERAPEUTIC TARGET; TUMOR-DEVELOPMENT; MICE LACKING; ACTIVATION; CANCER; IDENTIFICATION; GROWTH	K-ras mutations are associated with smoking-induced lung cancer and poor clinical outcomes. In mice, K-ras mutations are sufficient to induce lung tumors, which require phosphoinoside-3-kinase (PI3K) and further downstream, mammalian target of rapamycin (mTOR) activation. However, the roles of individual Akt isoforms that link PI3K and mTOR are unknown. Here, we show that deletion of Akt1 but not Akt2 or Akt3 prevents lung tumorigenesis in a tobacco carcinogen-induced model and a genetic model. Akt1 deletion prevented tumor initiation as well as tumor progression, coincident with decreased Akt signaling in tumor tissues. In contrast, deletion of Akt3 increased tumor multiplicity in the carcinogen model and increased tumor size in the genetic model. Fibroblasts lacking Akt1 are resistant to transformation by mutant K-ras and stimulation by epidermal growth factor. Human lung cancer cells with mutant K-ras and diminished Akt1 levels fail to grow in vivo. These data suggest that Akt1 is the primary Akt isoform activated by mutant K-ras in lung tumors, and that Akt3 may oppose Akt1 in lung tumorigenesis and lung tumor progression. Given that Akt inhibitors in clinical development as cancer therapeutics are not isoform selective, these studies support specific targeting of Akt1 to mitigate the effects of mutant K-ras in lung cancer. Oncogene (2011) 30, 1812-1821; doi:10.1038/onc.2010.556; published online 17 January 2011	[Hollander, M. C.; Maier, C. R.; Hobbs, E. A.; Ashmore, A. R.; Dennis, P. A.] NCI, Med Oncol Branch, NIH, Bethesda, MD 20889 USA; [Linnoila, R. I.] NCI, Cell & Canc Biol Branch, NIH, Bethesda, MD 20889 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Dennis, PA (corresponding author), NCI, Med Oncol Branch, NIH, NNMC8-5101,8901 Wisconsin Ave, Bethesda, MD 20889 USA.	pdennis@mail.nih.gov			NIH; NATIONAL CANCER INSTITUTE [ZIASC010292, ZIABC010450, ZIASC000167, ZIABC010748, P30CA006973] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This project was funded through the NIH intramural research program.	Askham JM, 2010, ONCOGENE, V29, P150, DOI 10.1038/onc.2009.315; BELINSKY SA, 1989, CANCER RES, V49, P5305; Bulavin DV, 2003, MOL CELL BIOL, V23, P3859, DOI 10.1128/MCB.23.11.3859-3871.2003; Buzzi F, 2010, MOL CELL BIOL, V30, P601, DOI 10.1128/MCB.00719-09; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chen ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Cicenas J, 2008, INT J BIOL MARKER, V23, P1, DOI 10.1177/172460080802300101; Cully M, 2008, CELL, V133, P1292, DOI 10.1016/j.cell.2008.06.020; Dannemann N, 2010, INT J CANCER, V127, P239, DOI 10.1002/ijc.25012; Davies MA, 2008, BRIT J CANCER, V99, P1265, DOI 10.1038/sj.bjc.6604637; DiRenzo J, 2002, CANCER RES, V62, P89; Dummler B, 2006, MOL CELL BIOL, V26, P8042, DOI 10.1128/MCB.00722-06; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Friday BB, 2005, BBA-REV CANCER, V1756, P127, DOI 10.1016/j.bbcan.2005.08.001; Gills JJ, 2009, CURR ONCOL REP, V11, P102, DOI 10.1007/s11912-009-0016-4; Gonzalez E, 2009, CELL CYCLE, V8, P2502, DOI 10.4161/cc.8.16.9335; Granville CA, 2007, CLIN CANCER RES, V13, P2281, DOI 10.1158/1078-0432.CCR-06-2570; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hollander MC, 2008, NEOPLASIA, V10, P866, DOI 10.1593/neo.08406; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jiang HL, 2009, BIOMATERIALS, V30, P5844, DOI 10.1016/j.biomaterials.2009.07.017; John LCH, 2001, BRIT J BIOMED SCI, V58, P159; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Ju XM, 2007, P NATL ACAD SCI USA, V104, P7438, DOI 10.1073/pnas.0605874104; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Lin L, 1998, EXP LUNG RES, V24, P481, DOI 10.3109/01902149809087382; Macdonald JS, 2005, INVEST NEW DRUG, V23, P485, DOI 10.1007/s10637-005-2908-y; Madhunapantula SV, 2009, PIGM CELL MELANOMA R, V22, P400, DOI 10.1111/j.1755-148X.2009.00585.x; Malanga D, 2008, CELL CYCLE, V7, P665, DOI 10.4161/cc.7.5.5485; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Ricarte-Filho JC, 2009, CANCER RES, V69, P4885, DOI 10.1158/0008-5472.CAN-09-0727; Robertson GP, 2005, CANCER METAST REV, V24, P273, DOI 10.1007/s10555-005-1577-9; Ruiz MIG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001722; Shoji K, 2009, BRIT J CANCER, V101, P145, DOI 10.1038/sj.bjc.6605109; Skeen JE, 2006, CANCER CELL, V10, P269, DOI 10.1016/j.ccr.2006.08.022; Steelman LS, 2008, EXPERT OPIN THER TAR, V12, P1139, DOI [10.1517/14728222.12.9.1139, 10.1517/14728222.12.9.1139 ]; Swift S, 2001, Curr Protoc Immunol, VChapter 10, DOI 10.1002/0471142735.im1017cs31; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Tsurutani J, 2006, J CLIN ONCOL, V24, P306, DOI 10.1200/JCO.2005.02.4133; West KA, 2004, CANCER RES, V64, P446, DOI 10.1158/0008-5472.CAN-03-3241; WITSCHI HP, 1981, TOXICOLOGY, V21, P95, DOI 10.1016/0300-483X(81)90120-7; Xu CX, 2008, AM J RESP CRIT CARE, V178, P60, DOI 10.1164/rccm.200707-1022OC; Zilberman DE, 2009, CANCER GENET CYTOGEN, V191, P34, DOI 10.1016/j.cancergencyto.2009.01.009	49	48	49	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	15					1812	1821		10.1038/onc.2010.556	http://dx.doi.org/10.1038/onc.2010.556			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21242979	Green Accepted			2022-12-17	WOS:000289512200008
J	Samuel, S; Fan, F; Dang, LH; Xia, L; Gaur, P; Ellis, LM				Samuel, S.; Fan, F.; Dang, L. H.; Xia, L.; Gaur, P.; Ellis, L. M.			Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells	ONCOGENE			English	Article						VEGF; chemosensitivity; colorectal cancer; autocrine; intracrine; apoptosis	PERMEABILITY FACTOR; TUMOR-CELLS; FACTOR RECEPTOR-1; VEGF; APOPTOSIS; BCL-2; PROLIFERATION; ANGIOGENESIS; EXPRESSION; LETHALITY	Although the effects of vascular endothelial growth factor (VEGF) on angiogenesis and vascular function are well known, the effects of VEGF on tumor cell function remain to be elucidated. We studied phenotypic changes in human colorectal cancer (CRC) cells with homozygous deletion of VEGF alleles to determine the potential direct role of VEGF on tumor cell function. Loss of VEGF expression led to significantly decreased cell growth and increased spontaneous apoptosis in CRC cells (P < 0.01). Loss of VEGF also increased the in vitro sensitivity of cells to the cytotoxic effects of the chemotherapeutic drug 5-fluorouracil, as shown by increased apoptosis (P < 0.05). These effects were mediated via upregulation of the pro-apoptotic mediators caspase-3, cleaved PARP and Bax and downregulation of the pro-survival mediator survivin. Our findings suggest a novel and distinct function of VEGF in mediating autocrine/intracrine CRC cell survival. Oncogene (2011) 30, 1205-1212; doi:10.1038/onc.2010.496; published online 8 November 2010	[Ellis, L. M.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Unit 173, Houston, TX 77230 USA; [Dang, L. H.] Univ Florida, Dept Med, Div Hematol Oncol, Gainesville, FL USA; [Gaur, P.; Ellis, L. M.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77230 USA	University of Texas System; UTMD Anderson Cancer Center; State University System of Florida; University of Florida; University of Texas System; UTMD Anderson Cancer Center	Ellis, LM (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Unit 173, 515 Holcombe Blvd,POB 173, Houston, TX 77230 USA.	lellis@mdanderson.org	Khaitan, Puja/AAQ-6413-2020	Khaitan, Puja/0000-0001-8654-062X	NIH Cancer Center [CA016672]; RE 'Bob' Smith Fund for Cancer Research; NIH [CCSG CA016672, T32 CA09599, R01 CA112390]; William C Liedtke Chair in Cancer Research; NATIONAL CANCER INSTITUTE [T32CA009599, R21CA159270, P30CA016672, R01CA112390] Funding Source: NIH RePORTER	NIH Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RE 'Bob' Smith Fund for Cancer Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); William C Liedtke Chair in Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Cytometry and Cellular Imaging Core Facility at M. D. Anderson Cancer Center (funded by NIH Cancer Center Support Grant CA016672) for assistance with data analysis using the flow cytometers. We thank Sunita Patterson (Department of Scientific Publications) for manuscript editing and Rita Hernandez for editorial assistance. This work was supported by the RE 'Bob' Smith Fund for Cancer Research (SS), NIH grants CCSG CA016672, T32 CA09599 (PG), R01 CA112390 (LME), and the William C Liedtke Chair in Cancer Research.	Bachelder RE, 2001, CANCER RES, V61, P5736; Barr MP, 2008, INT J ONCOL, V32, P41; BROWN LF, 1997, EXS, V79, P233; Calvani M, 2008, CANCER RES, V68, P285, DOI 10.1158/0008-5472.CAN-07-5564; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dang DT, 2006, CANCER RES, V66, P1684, DOI 10.1158/0008-5472.CAN-05-2887; Dias S, 2002, BLOOD, V99, P2532, DOI 10.1182/blood.V99.7.2532; Escudier B, 2009, J CLIN ONCOL, V27, P3312, DOI 10.1200/JCO.2008.19.5511; Fan F, 2005, ONCOGENE, V24, P2647, DOI 10.1038/sj.onc.1208246; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Hutchings H, 2003, FASEB J, V17, P1520, DOI 10.1096/fj.02-0691fje; Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054; Lee TH, 2007, PLOS MED, V4, P1101, DOI 10.1371/journal.pmed.0040186; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Masuda K, 2008, PLOS MED, V5, P805, DOI 10.1371/journal.pmed.0050094; Nor JE, 2001, CANCER RES, V61, P2183; Pidgeon GP, 2001, BRIT J CANCER, V85, P273, DOI 10.1054/bjoc.2001.1876; Rini BI, 2008, J CLIN ONCOL, V26, P5422, DOI 10.1200/JCO.2008.16.9847; Santos SCR, 2004, BLOOD, V103, P3883, DOI 10.1182/BLOOD-2003-05-1634; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Vincent L, 2005, CANCER RES, V65, P3185, DOI 10.1158/0008-5472.CAN-04-3598	31	48	51	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1205	1212		10.1038/onc.2010.496	http://dx.doi.org/10.1038/onc.2010.496			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21057529	Green Accepted			2022-12-17	WOS:000288202400007
J	Maretzky, T; Zhou, W; Huang, XY; Blobel, CP				Maretzky, T.; Zhou, W.; Huang, X-Y; Blobel, C. P.			A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17	ONCOGENE			English	Article						ADAM17; Src; EGF receptor; EGF-receptor ligands; protein ectodomain shedding; ERK	NECROSIS-FACTOR-ALPHA; UP-REGULATED EXPRESSION; GROWTH-FACTOR-ALPHA; CONVERTING-ENZYME; DISINTEGRIN; CLEAVAGE; TRANSACTIVATION; INACTIVATION; COEXPRESSION; ACTIVATION	ADAM17 (a disintegrin and metalloproteinase 17, also referred to as TNF alpha converting enzyme or TACE) is a cell-surface metalloproteinase that regulates signaling via the epidermal growth factor receptor (EGFR) and has important roles in diseases such as cancer and rheumatoid arthritis. ADAM17 can be activated by stimulation of several tyrosine kinase receptors, raising questions about whether oncogenic tyrosine kinases could also enhance EGFR signaling and activation of extracellular signal-regulated kinase (ERK) via stimulation of ADAM17. The main goal of this study was to evaluate the role of Src in activating ADAM17. We provide evidence that a constitutively active transforming form of Src, the E378G mutant, as well as v-Src enhance ADAM17-mediated shedding of the EGFR ligand TGF alpha. Moreover, we demonstrate that constitutive shedding of TGF alpha can be reduced by inhibition of Src in several cell lines, including COS7, MCF7 (the human breast cancer cell line), PAE (a pig aortic endothelial cell line) and HaCaT (the human keratinocyte cell line) cells. Src(E378G)-stimulated shedding of TGF alpha is abolished in Adam17(-/-) cells, but can be rescued by wild-type (wt) ADAM17 and a mutant ADAM17 lacking its cytoplasmic domain. These findings demonstrate that ADAM17 is the principal TGF alpha sheddase that is activated by Src in a manner that does not require the cytoplasmic domain of ADAM17. Finally, we show that stimulation of ADAM17 by Src(E378G) leads to enhanced paracrine signaling via release of EGFR ligands into the culture supernatant. These results raise the possibility that activation of ADAM17 by oncogenic forms of Src can aid in promoting tumorigenesis by enhancing signaling via the EGFR and ERK in an autocrine and paracrine manner. Enhanced autocrine signaling could further activate tumor cells expressing oncogenic mutants of Src, whereas paracrine signaling could stimulate EGFR and ERK signaling in surrounding non-transformed cells such as stromal cells, thereby contributing to crosstalk between tumor cells and stromal cells. Oncogene (2011) 30, 611-618; doi: 10.1038/onc.2010.443; published online 27 September 2010	[Maretzky, T.; Zhou, W.; Blobel, C. P.] Cornell Univ, Hosp Special Surg, Weill Med Coll, Arthrit & Tissue Degenerat Program, New York, NY 10021 USA; [Huang, X-Y] Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA	Cornell University; Cornell University	Blobel, CP (corresponding author), Cornell Univ, Hosp Special Surg, Weill Med Coll, Arthrit & Tissue Degenerat Program, 535 E 70th St, New York, NY 10021 USA.	blobelc@hss.edu	Maretzky, Thorsten/GSN-2981-2022; Maretzky, Thorsten/AEN-1915-2022	Maretzky, Thorsten/0000-0003-1282-6080; Zhou, Wenhui/0000-0002-3857-8567	NIH [R01 GM64750]; Emerald Foundation; Tri-Institutional MD/PhD Program Gateway Program; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064750] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Emerald Foundation; Tri-Institutional MD/PhD Program Gateway Program; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by NIH R01 GM64750, and TM was supported by the Emerald Foundation. WZ was supported by the Tri-Institutional MD/PhD Program Gateway Program. We are grateful to Drs Daniel Lundell and Xioada Niu from the Schering Plough Research Institute in Kenilworth, NJ, for providing SP26, and to Dr Robert Waltermire from Bristol-Myers Squibb for DPC333, and to Andreas Ludwig at the University of Aachen, Germany, for providing GI254023X.	Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blanchot-Jossic F, 2005, J PATHOL, V207, P156, DOI 10.1002/path.1814; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; COOPER JA, 1983, J VIROL, V48, P752, DOI 10.1128/JVI.48.3.752-764.1983; Egeblad M, 2005, COLD SH Q B, V70, P383, DOI 10.1101/sqb.2005.70.007; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Horiuchi K, 2007, J IMMUNOL, V179, P2686, DOI 10.4049/jimmunol.179.5.2686; Horiuchi K, 2007, MOL BIOL CELL, V18, P176, DOI 10.1091/mbc.E06-01-0014; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Le Gall SM, 2009, MOL BIOL CELL, V20, P1785, DOI 10.1091/mbc.E08-11-1135; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Mazzola RD, 2008, BIOORG MED CHEM LETT, V18, P5809, DOI 10.1016/j.bmcl.2008.09.045; McGowan PM, 2008, ANN ONCOL, V19, P1075, DOI 10.1093/annonc/mdm609; Merchant NB, 2008, CLIN CANCER RES, V14, P1182, DOI 10.1158/1078-0432.CCR-07-1216; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Murphy G, 2008, NAT REV CANCER, V8, P929, DOI 10.1038/nrc2459; Nakagawa M, 2009, CANCER SCI, V100, P654, DOI 10.1111/j.1349-7006.2009.01089.x; Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Qian MX, 2007, DRUG METAB DISPOS, V35, P1916, DOI 10.1124/dmd.107.015933; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Sahin Umut, 2006, V327, P99; Sternlicht MD, 2005, DEVELOPMENT, V132, P3923, DOI 10.1242/dev.01966; Sun YT, 2007, EMBO J, V26, P53, DOI 10.1038/sj.emboj.7601502; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Swendeman S, 2008, CIRC RES, V103, P916, DOI 10.1161/CIRCRESAHA.108.184416; Tanaka Y, 2005, CLIN CANCER RES, V11, P4783, DOI 10.1158/1078-0432.CCR-04-1426; Van Schaeybroeck S, 2008, CANCER RES, V68, P8312, DOI 10.1158/0008-5472.CAN-07-6736; Weskamp G, 2010, CIRC RES, V106, P932, DOI 10.1161/CIRCRESAHA.109.207415; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang Q, 2006, P NATL ACAD SCI USA, V103, P6901, DOI 10.1073/pnas.0509719103; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	36	48	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					611	618		10.1038/onc.2010.443	http://dx.doi.org/10.1038/onc.2010.443			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	20871631	Green Accepted			2022-12-17	WOS:000286922300009
J	Xia, M; Knezevic, D; Vassilev, LT				Xia, M.; Knezevic, D.; Vassilev, L. T.			p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation	ONCOGENE			English	Article						p53; MDM2; p21; apoptosis; cell cycle	GROWTH ARREST; TRANSCRIPTIONAL ACTIVATION; INHIBITORY-ACTIVITY; SPINDLE CHECKPOINT; SURVIVIN; PATHWAY; MDM2; THERAPY; GENE; PHOSPHORYLATION	p21(Waf1/Cip1) is a p53 transcription target implicated in both major functions of the tumor suppressor-cell cycle arrest and apoptosis. It is a potent inhibitor of the key cyclin-dependent kinases (CDK1-4), and has been thought to be the main mediator of p53-dependent G1 and G2 arrest. However, an increasing body of information suggests that in addition to its cell-cycle inhibitory activity, p21 can affect p53-dependent apoptosis. These data have been obtained from experiments in which p53 is activated primarily by genotoxic stress. In this study, we use the selective MDM2 antagonist, nutlin-3a, as a nongenotoxic p53 activator and show that the cell-cycle arrest function of p21 is dependent on the cellular context. In most cancer cell lines, p53-dependent p21 induction is essential for cell-cycle arrest, but in some, p21 is dispensable. Depletion of p21 did not increase the apoptotic response to nutlin-3a in all seven cancer cell lines tested and p21 overexpression did not protect apoptosis-sensitive lines from death. p21 was found to mediate nutlin-induced p53-dependent downregulation of another antiapoptotic protein, survivin, without significantly affecting the apoptotic outcome. Taken together our results suggest that p21 induction does not affect the apoptotic response to nongenotoxic p53 activation. Oncogene (2011) 30, 346-355; doi:10.1038/onc.2010.413; published online 27 September 2010	[Xia, M.; Knezevic, D.; Vassilev, L. T.] Hoffmann La Roche Inc, Discovery Oncol, Roche Res Ctr, Nutley, NJ 07110 USA	Roche Holding	Vassilev, LT (corresponding author), Hoffmann La Roche Inc, Discovery Oncol, Roche Res Ctr, 340 Kingsland St, Nutley, NJ 07110 USA.	lyubomir.vassilev@roche.com						Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Altieri DC, 2008, ONCOGENE, V27, P6276, DOI 10.1038/onc.2008.303; Altieri Dario C, 2003, Prog Cell Cycle Res, V5, P447; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Chan TA, 2000, GENE DEV, V14, P1584; Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222; Dohi T, 2007, MOL CELL, V27, P17, DOI 10.1016/j.molcel.2007.06.004; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Enge M, 2009, CANCER CELL, V15, P171, DOI 10.1016/j.ccr.2009.01.019; Ferrandiz N, 2009, DNA REPAIR, V8, P390, DOI 10.1016/j.dnarep.2008.12.001; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; HARPER JW, 1993, CELL, V75, P805; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Janicke RU, 2007, CELL CYCLE, V6, P407; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; Perkins ND, 2002, CELL CYCLE, V1, P39, DOI 10.4161/cc.1.1.98; Qi GY, 2009, ONCOL REP, V22, P557, DOI 10.3892/or_00000471; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sohn D, 2006, CANCER RES, V66, P11254, DOI 10.1158/0008-5472.CAN-06-1569; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Tian H, 2000, CANCER RES, V60, P679; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Xia MX, 2008, CELL CYCLE, V7, P1604, DOI 10.4161/cc.7.11.5929; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang H, 2003, MOL CANCER THER, V2, P1023; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	44	48	48	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					346	355		10.1038/onc.2010.413	http://dx.doi.org/10.1038/onc.2010.413			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20871630				2022-12-17	WOS:000286418800009
J	Kang, X; Li, J; Zou, Y; Yi, J; Zhang, H; Cao, M; Yeh, ETH; Cheng, J				Kang, X.; Li, J.; Zou, Y.; Yi, J.; Zhang, H.; Cao, M.; Yeh, E. T. H.; Cheng, J.			PIASy stimulates HIF1 alpha SUMOylation and negatively regulates HIF1 alpha activity in response to hypoxia	ONCOGENE			English	Article						HIF1 alpha; hypoxia; PIASy; SUMOylation	TRANSCRIPTIONAL ACTIVITY; INDUCIBLE-FACTOR; TUMOR ANGIOGENESIS; CONJUGATING ENZYME; SUMO MODIFICATION; GENE-ACTIVATION; NUCLEAR-BODIES; HIF-ALPHA; PROTEIN; FAMILY	Hypoxia-inducible factor-1 alpha (HIF1 alpha) is a crucial regulator of the cellular response to hypoxia through its regulation of genes that control erythropoiesis, angiogenesis and anaerobic metabolism. We have previously shown that HIF1 alpha stability is regulated by SUMOylation under the hypoxic condition. However, how HIF1 alpha became SUMOylated during hypoxia is still unknown. In this study we identify PIASy as a specific E3 ligase for hypoxia-induced HIF1 alpha SUMOylation. Hypoxia promotes translocation of HIF1 alpha to the nucleus to facilitate its binding to PIASy, enabling the conjugation of HIF1 alpha by SUMO1. We further show that PIASy negatively regulates hypoxia-induced HIF1 alpha stability and transactivation. Knocking down PIASy increases the angiogenic activity of endothelial cells. Moreover, we show an inverse relationship between expression of PIASy and tumor angiogenesis in colon cancer. Thus, we define an important role of PIASy in hypoxia signaling through promoting HIF1 alpha SUMOylation. Oncogene (2010) 29, 5568-5578; doi:10.1038/onc.2010.297; published online 26 July 2010	[Cheng, J.] Shanghai Jiao Tong Univ, Shanghai Canc Inst, Dept Mol & Cell Biol, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200025, Peoples R China; [Kang, X.; Li, J.; Zou, Y.; Yi, J.; Cao, M.; Cheng, J.] Shanghai Jiao Tong Univ, Key Lab Cell Differentiat & Apoptosis, E Inst Shanghai Municipal Educ Commiss, Chinese Minist Educ,Sch Med, Shanghai 200025, Peoples R China; [Zhang, H.] Chinese Acad Med Sci, Canc Hosp, Dept Abdominal Surg, Beijing 100037, Peoples R China; [Zhang, H.] Peking Union Med Coll, Beijing 100021, Peoples R China; [Yeh, E. T. H.] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA; [Yeh, E. T. H.] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; University of Texas System; UTMD Anderson Cancer Center; Saint Lukes Episcopal Hospital; Texas Heart Institute	Cheng, J (corresponding author), Shanghai Jiao Tong Univ, Shanghai Canc Inst, Dept Mol & Cell Biol, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200025, Peoples R China.	jkcheng@shsmu.edu.cn			National Natural Science Foundation of China [30772462, 30800579]; National Key Scientific Program in China [2009CB918403]; State Key Laboratory of Oncogenes and Related Genes [91-08-06]; E-Institutes of Shanghai Municipal Education Commission [E09013]; NIH [CA239520]; NATIONAL CANCER INSTITUTE [R01CA139520] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Scientific Program in China; State Key Laboratory of Oncogenes and Related Genes; E-Institutes of Shanghai Municipal Education Commission; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by National Natural Science Foundation of China (30772462, to JC; 30800579 to XK), National Key Scientific Program in China (2009CB918403, to JC), State Key Laboratory of Oncogenes and Related Genes (91-08-06, to JC), E-Institutes of Shanghai Municipal Education Commission (E09013, to JC) and NIH grants (CA239520, to ETHY). ETHY is the McNair Scholar of the Texas Heart Institute, St Luke Episcopal Hospital.	Bae SH, 2004, BIOCHEM BIOPH RES CO, V324, P394, DOI 10.1016/j.bbrc.2004.09.068; Berta MA, 2007, BIOCHEM BIOPH RES CO, V360, P646, DOI 10.1016/j.bbrc.2007.06.103; Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010; Branzei D, 2006, CELL, V127, P509, DOI 10.1016/j.cell.2006.08.050; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carbia-Nagashima A, 2007, CELL, V131, P309, DOI 10.1016/j.cell.2007.07.044; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carter S, 2007, NAT CELL BIOL, V9, P428, DOI 10.1038/ncb1562; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Comerford KM, 2003, P NATL ACAD SCI USA, V100, P986, DOI 10.1073/pnas.0337412100; Dawlaty MM, 2008, CELL, V133, P103, DOI 10.1016/j.cell.2008.01.045; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gruber M, 2006, CURR OPIN HEMATOL, V13, P169, DOI 10.1097/01.moh.0000219663.88409.35; Hari KL, 2001, GENE DEV, V15, P1334, DOI 10.1101/gad.877901; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Mabb AM, 2006, NAT CELL BIOL, V8, P986, DOI 10.1038/ncb1458; Matsuura T, 2005, EXP CELL RES, V308, P65, DOI 10.1016/j.yexcr.2005.04.022; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Rogers RS, 2003, J BIOL CHEM, V278, P30091, DOI 10.1074/jbc.M301344200; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Shao RJ, 2004, FEBS LETT, V569, P293, DOI 10.1016/j.febslet.2004.05.079; Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; van Hagen M, 2010, NUCLEIC ACIDS RES, V38, P1922, DOI 10.1093/nar/gkp1157; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Yeh ETH, 2009, J BIOL CHEM, V284, P8223, DOI 10.1074/jbc.R800050200	44	48	54	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	41					5568	5578		10.1038/onc.2010.297	http://dx.doi.org/10.1038/onc.2010.297			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20661221				2022-12-17	WOS:000282946900004
J	Yan, Y; Cao, PT; Greer, PM; Nagengast, ES; Kolb, RH; Mumby, MC; Cowan, KH				Yan, Y.; Cao, P. T.; Greer, P. M.; Nagengast, E. S.; Kolb, R. H.; Mumby, M. C.; Cowan, K. H.			Protein phosphatase 2A has an essential role in the activation of gamma-irradiation-induced G2/M checkpoint response	ONCOGENE			English	Article						PP2A; ATM/ATR; Chk1/2; irradiation and G2/M arrest	CELL-CYCLE CHECKPOINTS; DNA-DAMAGE CHECKPOINT; IONIZING-RADIATION; SERINE/THREONINE PHOSPHATASES; OKADAIC ACID; CALYCULIN-A; PHOSPHORYLATION; KINASE; ATR; CHK1	G2/M checkpoint activation after DNA damage results in G2/M cell cycle arrest that allows time for DNA repair before the entry of cells into mitosis. Activation of G2/M checkpoint involves a series of signaling events, which include activation of ataxia telangiectecia-mutated and Rad3-related (ATR) and Chk1 kinases and inhibition of Cdc2/Cyclin B activity. Studies presented in this report show that serine (Ser)/threonine (Thr) protein phosphatase 2A (PP2A) has an important role in G2/M checkpoint activation in response to gamma-irradiation (IR) exposure. Using PP2A inhibitors, as well as siRNA targeting various forms of Ser/Thr protein phosphatases, results presented in this report show that specific PP2A inhibition abrogates IR-induced activation of ATR and Chk1 kinases, as well as phosphorylation of Cdc2-Tyr15, and attenuates IR-induced G2/M arrest. These results suggest an important regulation of PP2A on IR-induced G2/M checkpoint signaling response. Oncogene (2010) 29, 4317-4329; doi:10.1038/onc.2010.187; published online 24 May 2010	[Yan, Y.; Cao, P. T.; Greer, P. M.; Nagengast, E. S.; Kolb, R. H.; Cowan, K. H.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Mumby, M. C.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA	University of Nebraska System; University of Nebraska Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas	Cowan, KH (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA.	kcowan@unmc.edu		Kolb, Ryan/0000-0001-6305-2885	Nebraska [DHHS-LB506, 2007-45]; NCI [NCI T32 CA009476]; NCI Cancer Center Support Grant [P30CA036727]; NATIONAL CANCER INSTITUTE [P30CA036727, T32CA009476] Funding Source: NIH RePORTER	Nebraska; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Michel Ouellette for providing HPNE cells, Dr Helen Piwnica Worms for GST-Cdc25C construct, Dr Charles Kuzynski, Victoria Smith and Megan Michalak for assistance on the flow cytometry analysis, and Dr Janina Baranowska-Kortylewicz for assistance on the operation of Mark I 68A Cesium-137 Irradiator. This work was supported by Nebraska DHHS-LB506 grant 2007-45 to YY, NCI Training Grant (NCI T32 CA009476) to RK and NCI Cancer Center Support Grant (P30CA036727) to KC.	Ahn JY, 2000, CANCER RES, V60, P5934; Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521-4141(2000012)30:12<3422::AID-IMMU3422>3.0.CO;2-J; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Cho US, 2007, PLOS BIOL, V5, P1810, DOI 10.1371/journal.pbio.0050202; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1991, METHOD ENZYMOL, V201, P389; Cohen PTW, 2002, J CELL SCI, V115, P241; Essmann F, 2004, CANCER RES, V64, P7065, DOI 10.1158/0008-5472.CAN-04-1082; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Jang YJ, 2007, J BIOL CHEM, V282, P2473, DOI 10.1074/jbc.M605480200; Janssens IA, 2005, BIOGEOSCIENCES, V2, P15, DOI 10.5194/bg-2-15-2005; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Janssens V, 2008, TRENDS BIOCHEM SCI, V33, P113, DOI 10.1016/j.tibs.2007.12.004; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Lee KM, 2005, LAB INVEST, V85, P1003, DOI 10.1038/labinvest.3700298; Leung-Pineda V, 2006, MOL CELL BIOL, V26, P7529, DOI 10.1128/MCB.00447-06; Li G, 2007, J BIOL CHEM, V282, P7287, DOI 10.1074/jbc.M607951200; Li HH, 2007, EMBO J, V26, P402, DOI 10.1038/sj.emboj.7601519; Li HH, 2004, MOL CELL, V13, P867, DOI 10.1016/S1097-2765(04)00123-6; Liu QH, 2000, GENE DEV, V14, P1448; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; McConnell JL, 2009, MOL PHARMACOL, V75, P1249, DOI 10.1124/mol.108.053140; Nagasawa H, 1998, CANCER RES, V58, P2036; O'Connell MJ, 2005, J CELL SCI, V118, P1, DOI 10.1242/jcs.01626; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Pankov R, 2003, J BIOL CHEM, V278, P18671, DOI 10.1074/jbc.M300879200; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sarkaria JN, 1999, CANCER RES, V59, P4375; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Strack S, 2004, J BIOL CHEM, V279, P47732, DOI 10.1074/jbc.M408015200; Swingle Mark, 2007, V365, P23; TAKAI A, 1995, BIOCHEM J, V306, P657, DOI 10.1042/bj3060657; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu Bo, 2004, Methods Mol Biol, V281, P283; Yan Y, 2007, ONCOGENE, V26, P4689, DOI 10.1038/sj.onc.1210268; Yan Y, 2005, ONCOGENE, V24, P3285, DOI 10.1038/sj.onc.1208492; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	49	48	54	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2010	29	30					4317	4329		10.1038/onc.2010.187	http://dx.doi.org/10.1038/onc.2010.187			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20498628	Green Accepted			2022-12-17	WOS:000280547900008
J	Barone, I; Iacopetta, D; Covington, KR; Cui, Y; Tsimelzon, A; Beyer, A; Ando, S; Fuqua, SAW				Barone, I.; Iacopetta, D.; Covington, K. R.; Cui, Y.; Tsimelzon, A.; Beyer, A.; Ando, S.; Fuqua, S. A. W.			Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity	ONCOGENE			English	Article						breast cancer; estrogen receptor; K303R mutant ER alpha; aromatase inhibitors resistance; s305 ER alpha phosphorylation; IGF-1-signaling pathway	HUMAN-BREAST-CANCER; GROWTH-FACTOR-I; TAMOXIFEN RESISTANCE; DEOXYRIBONUCLEIC-ACID; HINGE REGION; MUTATION; KINASE; CELLS; ACTIVATION; BINDING	We earlier identified a lysine to arginine transition at residue 303 (K303R) in estrogen receptor alpha (ER alpha) in invasive breast cancers, which confers resistance to the aromatase inhibitor (AI) anastrozole (Ana) when expressed in MCF-7 breast cancer cells. Here, we show that AI resistance arises through an enhanced cross talk of the insulin-like growth factor receptor-1 (IGF-1R)/insulin receptor substrate (IRS)-1/Akt pathway with ER alpha, and the serine (S) residue 305 adjacent to the K303R mutation has a key function in mediating this cross talk. The ERa S305 residue is an important site that modifies response to tamoxifen; thus, we questioned whether this site could also influence AI response. We generated stable transfectants-expressing wild-type, K303R ER alpha or a double K303R/S305A mutant receptor, and found that the AI-resistant phenotype associated with expression of the K303R mutation was dependent on activation of S305 within the receptor. Ana significantly reduced growth in K303R/S305A-expressing cells. Preventing S305 phosphorylation with a blocking peptide inhibited IGF-1R/IRS-1/Akt activation and also restored AI sensitivity. Our data suggest that the K303R mutation and the S305 ER alpha residue may be a novel determinant of AI response in breast cancer, and blockade of S305 phosphorylation represents a new therapeutic strategy for treating tumors resistant to hormone therapy. Oncogene (2010) 29, 2404-2414; doi:10.1038/onc.2009.520; published online 25 January 2010	[Fuqua, S. A. W.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Breast Ctr, Houston, TX 77030 USA; [Barone, I.; Iacopetta, D.; Covington, K. R.; Cui, Y.; Tsimelzon, A.; Beyer, A.; Fuqua, S. A. W.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Barone, I.; Ando, S.] Univ Calabria, Ctr Sanit, I-87036 Cosenza, Italy; [Ando, S.] Univ Calabria, Dept Cellular Biol, I-87036 Cosenza, Italy	Baylor College of Medicine; Baylor College of Medicine; University of Calabria; University of Calabria	Fuqua, SAW (corresponding author), Baylor Coll Med, Lester & Sue Smith Breast Ctr, Breast Ctr, BCM 600,1 Baylor Plaza, Houston, TX 77030 USA.	sfuqua@bcm.edu	Iacopetta, Domenico/H-4242-2014	Iacopetta, Domenico/0000-0001-5179-7118; BARONE, Ines/0000-0002-9769-1615	NCI [RO1 CA72038]; NATIONAL CANCER INSTITUTE [R01CA072038] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI RO1 CA72038 to SAWF. We thank Mrs. Robin Sample for excellent administrative assistance.	Agoulnik IU, 2004, J CLIN ENDOCR METAB, V89, P6340, DOI 10.1210/jc.2004-0114; ARTEAGA CL, 1989, CANCER RES, V49, P6237; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Barone I, 2009, CANCER RES, V69, P4724, DOI 10.1158/0008-5472.CAN-08-4194; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brenet F, 2009, ONCOGENE, V28, P128, DOI 10.1038/onc.2008.376; Burtrum D, 2003, CANCER RES, V63, P8912; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Conway K, 2005, BREAST CANCER RES, V7, pR871, DOI 10.1186/bcr1315; Cui Y, 2004, CANCER RES, V64, P9199, DOI 10.1158/0008-5472.CAN-04-2126; Deeb A, 2008, J CLIN ENDOCR METAB, V93, P3691, DOI 10.1210/jc.2008-0737; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; Faus H, 2006, BIOMED PHARMACOTHER, V60, P520, DOI 10.1016/j.biopha.2006.07.082; Fontenot DR, 2007, BIOCHEM BIOPH RES CO, V363, P901, DOI 10.1016/j.bbrc.2007.09.046; Foulstone E, 2005, J PATHOL, V205, P145, DOI 10.1002/path.1712; Fuqua SAW, 2000, CANCER RES, V60, P4026; Giordano C, 2010, BREAST CANCER RES TR, V119, P71, DOI 10.1007/s10549-009-0334-0; Haelens A, 2007, CANCER RES, V67, P4514, DOI 10.1158/0008-5472.CAN-06-1701; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Herynk MH, 2007, CLIN CANCER RES, V13, P3235, DOI 10.1158/1078-0432.CCR-06-2608; Herynk MH, 2006, MOL CANCER THER, V5, P3023, DOI 10.1158/1535-7163.MCT-06-0394; Holm C, 2009, J PATHOL, V217, P372, DOI 10.1002/path.2455; Jelovac D, 2005, CANCER RES, V65, P5380, DOI 10.1158/0008-5472.CAN-04-4502; Kim MY, 2006, MOL ENDOCRINOL, V20, P1479, DOI 10.1210/me.2005-0531; Ksiezak-Reding H, 2003, BBA-MOL BASIS DIS, V1639, P159, DOI 10.1016/j.bbadis.2003.09.001; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Likhite VS, 2006, MOL ENDOCRINOL, V20, P3120, DOI 10.1210/me.2006-0068; MANNING BD, 2002, SCI STKE, pPE49; Martin LA, 2003, J BIOL CHEM, V278, P30458, DOI 10.1074/jbc.M305226200; MCGUIRE WL, 1992, J NATL CANCER I, V84, P1336, DOI 10.1093/jnci/84.17.1336; Michalides R, 2004, CANCER CELL, V5, P597, DOI 10.1016/j.ccr.2004.05.016; Nakajima H, 2008, BREAST CANCER-TOKYO, V15, P65, DOI 10.1007/s12282-007-0018-8; Rayala SK, 2006, CANCER RES, V66, P1694, DOI 10.1158/0008-5472.CAN-05-2922; Rayala SK, 2007, BIOMED PHARMACOTHER, V61, P408, DOI 10.1016/j.biopha.2007.05.006; Romano A, 2006, GYNECOL ONCOL, V101, P287, DOI 10.1016/j.ygyno.2005.10.040; Sabnis GJ, 2005, CANCER RES, V65, P3903, DOI 10.1158/0008-5472.CAN-04-4092; Sachdev D, 2004, J BIOL CHEM, V279, P5017, DOI 10.1074/jbc.M305403200; Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080; Salerno M, 1999, INT J CANCER, V81, P299; Santen RJ, 2005, J STEROID BIOCHEM, V95, P155, DOI 10.1016/j.jsbmb.2005.04.025; Schiff R, 2004, CLIN CANCER RES, V10, p331S, DOI 10.1158/1078-0432.CCR-031212; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Song RX, 2004, P NATL ACAD SCI USA, V101, P2076, DOI 10.1073/pnas.0308334100; Staka CM, 2005, ENDOCR-RELAT CANCER, V12, pS85, DOI 10.1677/erc.1.01006; Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022; Tharakan R, 2008, MOL CELL ENDOCRINOL, V295, P70, DOI 10.1016/j.mce.2008.07.018; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; Varricchio L, 2007, MOL CANCER RES, V5, P1213, DOI 10.1158/1541-7786.MCR-07-0150; WISEMAN LR, 1993, EUR J CANCER, V29A, P2256, DOI 10.1016/0959-8049(93)90218-5	50	48	50	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	16					2404	2414		10.1038/onc.2009.520	http://dx.doi.org/10.1038/onc.2009.520			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20101208	Green Accepted			2022-12-17	WOS:000276951500009
J	Liu, G; Xirodimas, DP				Liu, G.; Xirodimas, D. P.			NUB1 promotes cytoplasmic localization of p53 through cooperation of the NEDD8 and ubiquitin pathways	ONCOGENE			English	Article						NEDDylation; ubiquitination; NUB1; p53; Mdm2; cytoplasmic localization	RING-FINGER DOMAIN; NUCLEAR; NEDDYLATION; DEGRADATION; BINDING; PROTEIN; MDM2; AUTOPHAGY	Non-covalent recognition of ubiquitin (Ub) and ubiquitin-like molecules (Ubls) by interacting proteins has an important role in the regulation of protein function and initiation of signalling events. In addition, growing evidence suggests that regulation of p53 subcellular localization contributes to the biological outcome of the p53 response. Cytoplasmic p53 is shown to promote apoptosis and inhibit the induction of autophagy. In this study we show that NEDD8 ultimate buster 1 (NUB1), a non-covalent interactor of the Ubl NEDD8 (neural precursor cell expressed, developmentally downregulated 8), controls the localization of p53. Expression of NUB1 leads to decreased modification of p53 with NEDD8 and stimulation of p53 ubiquitination. The biological outcome is the cytoplasmic localization and inhibition of the transcriptional activity of p53. Although the effects of NUB1 on p53 depend on NEDDylation and the murine double minute 2 (Mdm2) E3-ligase, the cooperation of NEDD8 with ubiquitin is required. The data identify a role for NEDD8 in controlling p53 localization and suggest that NEDD8 can control protein function through its non-covalent recognition by interacting proteins. Oncogene (2010) 29, 2252-2261; doi: 10.1038/onc.2009.494; published online 25 January 2010	[Xirodimas, D. P.] Univ Dundee, Sch Life Sci, Wellcome Trust Ctr Gene Regulat & Express, Div Gene Regulat & Express,Coll Life Sci, Dundee DD1 5EH, Angus, Scotland	University of Dundee	Xirodimas, DP (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Ctr Gene Regulat & Express, Div Gene Regulat & Express,Coll Life Sci, Dow St, Dundee DD1 5EH, Angus, Scotland.	d.xirodimas@dundee.ac.uk		Liu, Geng/0000-0002-9293-0461; Xirodimas, Dimitris/0000-0001-9275-1140				Abida WM, 2007, J BIOL CHEM, V282, P1797, DOI 10.1074/jbc.M609001200; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Carter S, 2007, NAT CELL BIOL, V9, P428, DOI 10.1038/ncb1562; Carter S, 2009, CURR OPIN GENET DEV, V19, P18, DOI 10.1016/j.gde.2008.11.010; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Coutts AS, 2009, DNA REPAIR, V8, P483, DOI 10.1016/j.dnarep.2009.01.008; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Dohmesen C, 2008, CELL CYCLE, V7, P222, DOI 10.4161/cc.7.2.5185; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Hipp MS, 2004, J BIOL CHEM, V279, P16503, DOI 10.1074/jbc.M310114200; Hurley JH, 2006, BIOCHEM J, V399, P361, DOI 10.1042/BJ20061138; Kamitani T, 2001, J BIOL CHEM, V276, P46655, DOI 10.1074/jbc.M108636200; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Kirkin V, 2007, CURR OPIN CELL BIOL, V19, P199, DOI 10.1016/j.ceb.2007.02.002; Kito K, 2001, J BIOL CHEM, V276, P20603, DOI 10.1074/jbc.M100920200; Laine A, 2006, MOL CELL BIOL, V26, P8901, DOI 10.1128/MCB.01156-06; Lee JT, 2010, CELL DEATH DIFFER, V17, P86, DOI 10.1038/cdd.2009.77; LEE KAW, 1994, CELL BIOL LAB HDB, V1, P668; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498; Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Oh W, 2006, J BIOL CHEM, V281, P17457, DOI 10.1074/jbc.M601857200; Rabut G, 2008, EMBO REP, V9, P969, DOI 10.1038/embor.2008.183; Schmidtke G, 2006, J BIOL CHEM, V281, P20045, DOI 10.1074/jbc.M603063200; Speidel D, 2006, ONCOGENE, V25, P940, DOI 10.1038/sj.onc.1209126; Sundqvist A, 2009, EMBO REP, V10, P1132, DOI 10.1038/embor.2009.178; Tanji K, 2005, BIOCHEM BIOPH RES CO, V337, P116, DOI 10.1016/j.bbrc.2005.09.014; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Tatham MH, 2009, NAT PROTOC, V4, P1363, DOI 10.1038/nprot.2009.128; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Xirodimas DP, 2008, BIOCHEM SOC T, V36, P802, DOI 10.1042/BST0360802; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314	44	48	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	15					2252	2261		10.1038/onc.2009.494	http://dx.doi.org/10.1038/onc.2009.494			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101219				2022-12-17	WOS:000276685200010
J	Mishra, PJ; Ha, L; Rieker, J; Sviderskaya, EV; Bennett, DC; Oberst, MD; Kelly, K; Merlino, G				Mishra, P. J.; Ha, L.; Rieker, J.; Sviderskaya, E. V.; Bennett, D. C.; Oberst, M. D.; Kelly, K.; Merlino, G.			Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation	ONCOGENE			English	Article						anchorage-independent growth; BRaf; melanoma; NRas; PI3K; RalGEF	CELLULAR-TRANSFORMATION; MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; SIGNALING PATHWAYS; BRAF MUTATIONS; CANCER; GTPASES; CELLS; ACTIVATION; MIGRATION	Cutaneous malignant melanoma is considered one of the most deadly human cancers, based on both its penchant for metastatic spread and its typical resistance to currently available therapy. Long known to harbor oncogenic NRAS mutations, melanomas were more recently reported to be frequent bearers of activating mutations in BRAF, one of the effectors situated downstream of wild-type NRAS. NRAS and BRAF mutations are rarely found in the same melanoma, suggesting that they may possess important overlapping oncogenic activities. Here, we compare and contrast the oncogenic roles of the three major NRas downstream effectors, Raf, phosphatidylinositol 3-kinase (PI3K) and Ral guanine exchange factor (RalGEF), using genetically engineered Arf-deficient immortalized mouse melanocytes as a model system. Although no single downstream pathway could recapitulate all of the consequences of oncogenic NRas expression, our data indicate a prominent role for BRaf and PI3K in melanocyte senescence and invasiveness, respectively. More surprisingly, we discovered that constitutive RalGEF activation had a major impact on several malignant phenotypes, particularly anchorage-independent growth, indicating that this often overlooked pathway should be more carefully evaluated as a possible therapeutic target. Oncogene (2010) 29, 2449-2456; doi:10.1038/onc.2009.521; published online 1 February 2010	[Mishra, P. J.; Ha, L.; Rieker, J.; Merlino, G.] NCI, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA; [Ha, L.] US FDA, Div Monoclonal Antibody, Ctr Drug Evaluat & Res, Bethesda, MD 20014 USA; [Sviderskaya, E. V.; Bennett, D. C.] Univ London, Div Basic Med Sci, London, England; [Oberst, M. D.; Kelly, K.] NCI, Cell & Canc Biol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); University of London; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Merlino, G (corresponding author), NCI, Lab Canc Biol & Genet, NIH, Bldg 37,Room 5002,37 Convent Dr, Bethesda, MD 20892 USA.	gmerlino@helix.nih.gov	Bennett, Dorothy C/C-2418-2008; Sviderskaya, Elena V/D-2419-2009	Bennett, Dorothy C/0000-0002-3639-7527; 	NCI [N01-CO-12400]; National Institutes of Health; Wellcome Trust [078327]; NATIONAL CANCER INSTITUTE [ZIABC010607, ZIABC008756] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Christopher Counter (Duke University) for useful discussions, and for communicating data before publication. We acknowledge Dr Paul Khavari (Stanford University) for gifting the NRas, PI3K and BRaf retroviral vectors, and Drs Frederique Zindy and Charles Sherr (St Jude Children's Research Hospital) for the Arf-deficient mouse skins from which the immortalized melanocytes were generated. The PEP7 and PEP8H antibodies were a gift from Dr Vince Hearing (NCI). The pEF-CAAX-Raf-1 vector was a gift from Dr Silvio J Gutkind (NIH/NIDCR). This work was supported in part by the Intramural Research Program of the NCI, National Institutes of Health, in part by NCI Contract N01-CO-12400, and in part by Wellcome Trust Program Grant 078327 (to EVS).	ALBINI A, 1987, CANCER RES, V47, P3239; Bennett DC, 2008, PIGM CELL MELANOMA R, V21, P27, DOI 10.1111/j.1755-148X.2007.00433.x; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Brose MS, 2002, CANCER RES, V62, P6997; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Chudnovsky Y, 2005, NAT GENET, V37, P745, DOI 10.1038/ng1586; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dahl C, 2007, APMIS, V115, P1161, DOI 10.1111/j.1600-0463.2007.apm_855.xml.x; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Gorter DJJ, 2008, BLOOD, V111, P3364, DOI 10.1182/blood-2007-08-106583; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Falsetti SC, 2007, MOL CELL BIOL, V27, P8003, DOI 10.1128/MCB.00057-07; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Freedberg DE, 2008, JNCI-J NATL CANCER I, V100, P784, DOI 10.1093/jnci/djn157; Goel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Omholt K, 2007, MELANOMA RES, V17, P410, DOI 10.1097/CMR.0b013e3282ef4178; Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2002, CANCER CELL, V2, P5, DOI 10.1016/S1535-6108(02)00089-2; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Recio JA, 2002, CANCER RES, V62, P6724; Rosse C, 2006, MOL CELL BIOL, V26, P727, DOI 10.1128/MCB.26.2.727-734.2006; Smith SC, 2007, CLIN CANCER RES, V13, P3803, DOI 10.1158/1078-0432.CCR-06-2419; Stiles BL, 2009, INT J BIOCHEM CELL B, V41, P757, DOI 10.1016/j.biocel.2008.09.022; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Virador VM, 1999, ANAL BIOCHEM, V270, P207, DOI 10.1006/abio.1999.4090; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Yin JJ, 2007, MOL CELL BIOL, V27, P7538, DOI 10.1128/MCB.00955-07	41	48	49	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	16					2449	2456		10.1038/onc.2009.521	http://dx.doi.org/10.1038/onc.2009.521			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20118982	Green Accepted			2022-12-17	WOS:000276951500013
J	Anastasiadou, E; Boccellato, F; Vincenti, S; Rosato, P; Bozzoni, I; Frati, L; Faggioni, A; Presutti, C; Trivedi, P				Anastasiadou, E.; Boccellato, F.; Vincenti, S.; Rosato, P.; Bozzoni, I.; Frati, L.; Faggioni, A.; Presutti, C.; Trivedi, P.			Epstein-Barr virus encoded LMP1 downregulates TCL1 oncogene through miR-29b	ONCOGENE			English	Article						EBV; microRNA; TCL1; LMP1; mir-29b	LATENT MEMBRANE PROTEIN-1; B-CELL LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; ENDEMIC BURKITTS-LYMPHOMA; GENE-EXPRESSION; KAPPA-B; DNA METHYLTRANSFERASES; GROWTH TRANSFORMATION; MICRORNA MIR-146A; T-CELLS	Epstein-Barr virus (EBV) encoded latent membrane protein 1 (LMP1) is noted for its transforming potential. Yet, it also acts as a cytostatic and growth-relenting factor in Burkitt's lymphoma (BL) cells. The underlying molecular mechanisms of the growth inhibitory property of LMP1 have remained largely unknown. In this study, we show that LMP1 negatively regulates a major oncogene, TCL1, in diffuse large B-cell lymphoma (DLBCL) and BL cells. MicroRNA (miR) profiling of LMP1 transfectants showed that among others, miR-29b, is upregulated. LMP1 diminished TCL1 by inducing miR-29b through C-terminus activation region 1 (CTAR1) and CTAR2. miR-29b locked nucleic acid (LNA) antisense oligonucleotide transfection into LMP1-expressing cells reduced miR-29b expression and consequently reconstituted TCL1, suggesting that LMP1 negatively regulates TCL1 through miR-29b upregulation. The miR-29b increase by LMP1 was due to an increase in the cluster pri-miR-29b1-a transcription, derived from human chromosome 7. Using pharmacological inhibitors, we found that p38 mitogen-activated protein kinase-activating function of LMP1 is important for this effect. The ability of LMP1 to negatively regulate TCL1 through miR-29b might underlie its B-cell lymphoma growth antagonistic property. As LMP1 is also important for B-cell transformation, we suggest that the functional dichotomy of this viral protein may depend on a combination of levels of its expression, lineage and differentiation of the target cells and regulation of miRs, which then directs the outcome of the cellular response. Oncogene (2010) 29, 1316-1328; doi:10.1038/onc.2009.439; published online 7 December 2009	[Anastasiadou, E.; Boccellato, F.; Rosato, P.; Frati, L.; Faggioni, A.; Trivedi, P.] Univ Roma La Sapienza, Dept Expt Med & Pathol, Ist Pasteur Fdn Cenci Bolognetti, I-00161 Rome, Italy; [Vincenti, S.; Bozzoni, I.; Presutti, C.] Univ Roma La Sapienza, Dept Genet & Mol Biol, I-00161 Rome, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome; Sapienza University Rome	Trivedi, P (corresponding author), Univ Roma La Sapienza, Dept Expt Med & Pathol, Ist Pasteur Fdn Cenci Bolognetti, Viale Regina Elena 324, I-00161 Rome, Italy.	Pankaj.Trivedi@uniroma1.it	Anastasiadou, Eleni/AAI-1845-2020; Frati, Luigi/ABI-7437-2020; ANASTASIADOU, ELENI/AAU-6080-2021; Vincenti, Sara/N-6007-2018	ANASTASIADOU, ELENI/0000-0003-0212-6734; PRESUTTI, Carlo/0000-0003-3837-2275; bozzoni, irene/0000-0002-3485-8537; Vincenti, Sara/0000-0003-3692-1947; Boccellato, Francesco/0000-0001-6013-7154	MIUR; Associazione Italiana per la ricerca sul Cancro (AIRC); Ministero della Salute; Pasteur Cenci-Bolognetti Foundation; Fondazione Italiana per la sclerosi multipla (FISM); European Union [LSHB-CT-2004 005276]; SIROCCO [037900]	MIUR(Ministry of Education, Universities and Research (MIUR)); Associazione Italiana per la ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero della Salute(Ministry of Health, Italy); Pasteur Cenci-Bolognetti Foundation(Istituto Pasteur Italia Fondazione Cenci Bolognetti); Fondazione Italiana per la sclerosi multipla (FISM)(Fondazione Italiana Sclerosi Multipla (FISM)); European Union(European Commission); SIROCCO	We thank V Licursi, V Del Vescovo and Dr R Negri's group members for help with microarray scanning facility and statistical analysis. We thank Dr Martin Rowe (Birmingham University, UK) for providing mutant LMP1 plasmids and comments. Dr Michael Teitell (UCLA, Los Angeles) and Dr Stefanie Gofflot (University of Liege, Belgium) are acknowledged for supplying TCL1 promoter reporter constructs and SUDH4 DLBCL cell line, respectively. This work was supported by grants from MIUR and Associazione Italiana per la ricerca sul Cancro (AIRC), progetto strategico ISS 9ACF/1 of Ministero della Salute, Pasteur Cenci-Bolognetti Foundation, Fondazione Italiana per la sclerosi multipla (FISM), Sixth Research Framework Programme of the European Union, Project RIGHT (LSHB-CT-2004 005276) and SIROCCO (037900).	ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; Amini RM, 2002, LEUKEMIA LYMPHOMA, V43, P2179, DOI 10.1080/1042819021000032917; BAICHWAL VR, 1988, ONCOGENE, V2, P461; Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328; Bell AI, 2006, J GEN VIROL, V87, P2885, DOI 10.1099/vir.0.81906-0; Bhaumik D, 2008, ONCOGENE, V27, P5643, DOI 10.1038/onc.2008.171; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; Boccellato F, 2007, J VIROL, V81, P2274, DOI 10.1128/JVI.01822-06; Calin GA, 2007, J CLIN INVEST, V117, P2059, DOI 10.1172/JCI32577; Cameron JE, 2008, J VIROL, V82, P1946, DOI 10.1128/JVI.02136-07; Cardinaud B, 2009, LEUKEMIA, V23, P2174, DOI 10.1038/leu.2009.125; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; CUOMO L, 1992, INT J CANCER, V51, P949, DOI 10.1002/ijc.2910510619; Dirmeier U, 2005, ONCOGENE, V24, P1711, DOI 10.1038/sj.onc.1208367; Dirmeier U, 2003, CANCER RES, V63, P2982; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Horenstein MG, 1997, BLOOD, V90, P1186, DOI 10.1182/blood.V90.3.1186; Hoyer KK, 2002, P NATL ACAD SCI USA, V99, P14392, DOI 10.1073/pnas.212410199; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Kawanishi M, 1997, VIROLOGY, V228, P244, DOI 10.1006/viro.1996.8370; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kiss C, 2003, P NATL ACAD SCI USA, V100, P4813, DOI 10.1073/pnas.0730710100; Kuppers R, 2005, NAT REV CANCER, V5, P251, DOI 10.1038/nrc1589; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lam N, 2004, J VIROL, V78, P1657, DOI 10.1128/JVI.78.4.1657-1664.2004; Lam N, 2003, EMBO J, V22, P3027, DOI 10.1093/emboj/cdg284; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lay JD, 2003, J BIOMED SCI, V10, P146, DOI 10.1159/000068077; Maruo S, 2001, J GEN VIROL, V82, P2373, DOI 10.1099/0022-1317-82-10-2373; Motsch N, 2007, RNA BIOL, V4, P131, DOI 10.4161/rna.4.3.5206; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; OHNO S, 1984, J EXP MED, V159, P1762, DOI 10.1084/jem.159.6.1762; Pajic A, 2001, INT J CANCER, V93, P810, DOI 10.1002/ijc.1404; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 2006, CANCER RES, V66, P11590, DOI 10.1158/0008-5472.CAN-06-3613; Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X; Rahadiani N, 2008, BIOCHEM BIOPH RES CO, V377, P579, DOI 10.1016/j.bbrc.2008.10.007; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Said JW, 2001, LAB INVEST, V81, P555, DOI 10.1038/labinvest.3780264; Sandberg ML, 2000, J VIROL, V74, P9755, DOI 10.1128/JVI.74.20.9755-9761.2000; Schultheiss U, 2001, EMBO J, V20, P5678, DOI 10.1093/emboj/20.20.5678; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; Shair KHY, 2007, PLOS PATHOG, V3, P1669, DOI 10.1371/journal.ppat.0030166; Tao Q, 1998, BLOOD, V91, P1373, DOI 10.1182/blood.V91.4.1373; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; Tsai CN, 2002, P NATL ACAD SCI USA, V99, P10084, DOI 10.1073/pnas.152059399; VIRGILIO L, 1993, P NATL ACAD SCI USA, V90, P9275, DOI 10.1073/pnas.90.20.9275; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; Wang S, 1996, CANCER RES, V56, P4610; Yin QY, 2008, J BIOL CHEM, V283, P2654, DOI 10.1074/jbc.M708218200	59	48	49	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1316	1328		10.1038/onc.2009.439	http://dx.doi.org/10.1038/onc.2009.439			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19966860				2022-12-17	WOS:000275170600007
J	Humtsoe, JO; Kramer, RH				Humtsoe, J. O.; Kramer, R. H.			Differential epidermal growth factor receptor signaling regulates anchorage-independent growth by modulation of the PI3K/AKT pathway	ONCOGENE			English	Article						cell-cell adhesion; EGFR; PI3K/AKT	SQUAMOUS-CELL CARCINOMA; FACTOR EGF RECEPTOR; HYPOXIA-INDUCIBLE FACTOR; E-CADHERIN; PHOSPHATIDYLINOSITOL 3-KINASE; INTERCELLULAR-ADHESION; TYROSINE KINASE; CYCLIN D1; DEPENDENT REGULATION; CONTACT FORMATION	Tumor cells are capable of surviving loss of nutrients and anchorage in hostile microenvironments. Under these conditions, adapting to specific signaling pathways may shift the balance between growth and cellular dormancy. Here, we report a mechanism by which epidermal growth factor receptor (EGFR) differentially modulates the phosphatidylinositol 30-kinase (PI3K)/AKT pathway in cellular stress conditions. When carcinoma cells were cultured as multicellular aggregates (MCA), cyclin D1 was induced through a serum-dependent EGFR activating pathway, triggering cell proliferation. The expression of cyclin D1 required both EGFR-mediated ERK and AKT activation. In serum-starved MCAs, EGFR activation was associated with active ERK1/2, but not AKT, and failed to induce cyclin D1. Analysis revealed that, under serum-starved conditions, EGFR-Y1086 residue was poorly autophosphorylated and this correlated with failure to phosphorylate Gab1. Accordingly, the EGFR activation failed to induce EGFR/PI3K complex formation or AKT activation, preventing cyclin D1 induction. Furthermore, we show that in serum-starved MCA, expression of constitutively active AKT re-established cyclin D1 expression and induced proliferation in an EGFR-dependent manner. Thus, modulation of the PI3K/AKT pathway by context-dependent EGFR signaling may regulate tumor cell growth and dormancy. Oncogene (2010) 29, 1214-1226; doi: 10.1038/onc.2009.419; published online 23 November 2009	[Humtsoe, J. O.; Kramer, R. H.] Univ Calif San Francisco, Dept Cell & Tissue Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kramer, RH (corresponding author), Univ Calif San Francisco, Dept Cell & Tissue Biol, 521 Parnassus Ave,Room C-640,Box 0640, San Francisco, CA 94143 USA.	randall.kramer@ucsf.edu			NIH [R01 DE11436]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011436] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr KK Wary (UIC, Chicago) for the insightful discussions and comments, Dr SM Troyanovsky (Washington University, St Louis) for providing the E-cadherin constructs, Dr D Stokoe (UCSF, San Francisco) for the GFP-AKT constructs, L Lee and B Situ for their assistance in preparing the paper. This work was supported by NIH grant R01 DE11436.	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Alt-Holland A, 2005, SEMIN CANCER BIOL, V15, P84, DOI 10.1016/j.semcancer.2004.08.007; Bates RC, 2000, CRIT REV ONCOL HEMAT, V36, P61, DOI 10.1016/S1040-8428(00)00077-9; BERNARD O, 1987, P NATL ACAD SCI USA, V84, P2125, DOI 10.1073/pnas.84.8.2125; Bill HM, 2004, MOL CELL BIOL, V24, P8586, DOI 10.1128/MCB.24.19.8586-8599.2004; Bourguignon LYW, 2006, J BIOL CHEM, V281, P14026, DOI 10.1074/jbc.M507734200; Cabodi S, 2004, BIOCHEM SOC T, V32, P438, DOI 10.1042/BST0320438; Cai WJ, 2006, P NATL ACAD SCI USA, V103, P13801, DOI 10.1073/pnas.0600362103; Chen QM, 2004, BIOCHEM BIOPH RES CO, V315, P850, DOI 10.1016/j.bbrc.2004.01.143; Chitaev NA, 1998, J CELL BIOL, V142, P837, DOI 10.1083/jcb.142.3.837; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fournier AK, 2008, J CELL SCI, V121, P226, DOI 10.1242/jcs.017012; Friedrich J, 2007, INT J RADIAT BIOL, V83, P849, DOI 10.1080/09553000701727531; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723; Goodwin M, 2003, J BIOL CHEM, V278, P20533, DOI 10.1074/jbc.M213171200; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Humtsoe JO, 2003, EMBO J, V22, P1539, DOI 10.1093/emboj/cdg165; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jo H, 2008, MOL CELL BIOL, V28, P4285, DOI 10.1128/MCB.01240-07; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kang HG, 2007, CANCER RES, V67, P3094, DOI 10.1158/0008-5472.CAN-06-3259; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Kawano K, 2001, EXP CELL RES, V262, P180, DOI 10.1006/excr.2000.5083; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; Lawlor ER, 2002, ONCOGENE, V21, P307, DOI 10.1038/sj.onc.1205053; Lenferink AEG, 2001, CANCER RES, V61, P6583; LeVea CM, 2004, EXP CELL RES, V297, P272, DOI 10.1016/j.yexcr.2004.03.026; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; Mattoon DR, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-24; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Nurmenniemi S, 2009, AM J PATHOL, V175, P1281, DOI 10.2353/ajpath.2009.081110; Onishi A, 2008, EXP CELL RES, V314, P377, DOI 10.1016/j.yexcr.2007.09.018; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Pore N, 2006, CANCER RES, V66, P3197, DOI 10.1158/0008-5472.CAN-05-3090; Ranganathan AC, 2006, CELL CYCLE, V5, P1799, DOI 10.4161/cc.5.16.3109; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Santini MT, 2000, CRIT REV ONCOL HEMAT, V36, P75, DOI 10.1016/S1040-8428(00)00078-0; Schmidt MHH, 2003, P NATL ACAD SCI USA, V100, P6505, DOI 10.1073/pnas.1031790100; Schneider MR, 2009, J CELL PHYSIOL, V218, P460, DOI 10.1002/jcp.21635; Shen XD, 2004, AM J PATHOL, V165, P1315, DOI 10.1016/S0002-9440(10)63390-1; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; Singh AB, 2007, J BIOL CHEM, V282, P32890, DOI 10.1074/jbc.M702677200; Thelemann A, 2005, MOL CELL PROTEOMICS, V4, P356, DOI 10.1074/mcp.M400118-MCP200; Walker JL, 2005, CANCER METAST REV, V24, P383, DOI 10.1007/s10555-005-5130-7; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0	49	48	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1214	1226		10.1038/onc.2009.419	http://dx.doi.org/10.1038/onc.2009.419			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19935697	Green Accepted			2022-12-17	WOS:000274912100012
J	Yoo, Y; Ho, HJ; Wang, C; Guan, JL				Yoo, Y.; Ho, H. J.; Wang, C.; Guan, J-L			Tyrosine phosphorylation of cofilin at Y68 by v-Src leads to its degradation through ubiquitin-proteasome pathway	ONCOGENE			English	Article						cofilin; protein phosphorylation; protein degradation; cell spreading	FOCAL ADHESION KINASE; ACTIN DEPOLYMERIZING FACTOR; CELL-MIGRATION; CANCER-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; DOWN-REGULATION; N-WASP; ADF/COFILIN; DYNAMICS; MOTILITY	Cofilin is a major regulator of actin dynamics involved in the regulation of cell spreading and migration through its actin depolymerizing and severing activities. v-Src is an activated Src tyrosine kinase and a potent oncogene known to phosphorylate a variety of cellular proteins in cell transformation process including altered cell adhesion, spreading and migration. Recently, it has been suggested that cofilin is a potential substrate of v-Src (Rush et al., 2005). Here, we show direct tyrosine phosphorylation of cofilin by v-Src and identify Y68 as the major phosphorylation site. Cofilin phosphorylation at Y68 did not change its activity per se, but induced increased ubiquitination of cofilin and its degradation through the proteosome pathway. Furthermore, the negative effect of cofilin on cellular F-actin contents was inhibited by coexpression of v-Src, whereas that of cofilin mutant Y68F (Y68 mutated to F) was not affected, suggesting that v-Src-mediated cofilin phosphorylation at Y68 is required for the degradation of cofilin in vivo. Lastly, inhibition of cell spreading by v-Src was rescued partially by coexpression of cofilin, and to a greater extent by the Y68F mutant, which is not subjected to v-Src-induced degradation through phosphorylation, suggesting that v-Src-mediated changes in cell spreading is, at least in part, through inhibiting the function of cofilin through phosphorylating it at Y68. Together, these results suggest a novel mechanism by which cofilin is regulated by v-Src through tyrosine phosphorylation at Y68 that triggers the degradation of cofilin through ubiquitination proteosome pathway and consequently inhibits cofilin activity in reducing cellular F-actin contents and cell spreading. Oncogene (2010) 29, 263-272; doi:10.1038/onc.2009.319; published online 5 October 2009	[Yoo, Y.; Ho, H. J.; Wang, C.; Guan, J-L] Univ Michigan, Sch Med, Dept Internal Med, Div Mol Med & Genet, Ann Arbor, MI 48109 USA; [Guan, J-L] Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Guan, JL (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, Div Mol Med & Genet, Ann Arbor, MI 48109 USA.	jlguan@umich.edu	wang, chenran/N-6629-2013		NIH [GM48050]; NATIONAL CANCER INSTITUTE [R01CA150926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048050] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to Dr Xiaoyang Wu for discussions during the initial stages of the project. We thank our colleagues Huijun Wei, Ming Luo, Huaping Fan, Fei Liu, Chenran Wang, Richard Liang, Ann Park and Xiaofeng Zhao for their critical reading of the paper and helpful comments. This research was supported by NIH grant GM48050 to J-L Guan.	Abbi S, 2002, MOL BIOL CELL, V13, P3178, DOI 10.1091/mbc.E02-05-0295; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Bailly M, 2003, CURR BIOL, V13, pR128, DOI 10.1016/S0960-9822(03)00072-1; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bamburg JR, 2002, TRENDS CELL BIOL, V12, P598, DOI 10.1016/S0962-8924(02)02404-2; Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Bianchi F, 2006, P NATL ACAD SCI USA, V103, P18981, DOI 10.1073/pnas.0605821103; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Caswell PT, 2006, TRAFFIC, V7, P14, DOI 10.1111/j.1600-0854.2005.00362.x; Chaar Z, 2006, J BIOL CHEM, V281, P28193, DOI 10.1074/jbc.M605665200; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Christopher RA, 2000, INT J MOL MED, V5, P575; Condeelis J, 2001, TRENDS CELL BIOL, V11, P288, DOI 10.1016/S0962-8924(01)02008-6; Cooper LA, 2003, MOL CELL BIOL, V23, P8030, DOI 10.1128/MCB.23.22.8030-8041.2003; Dawe HR, 2003, CURR BIOL, V13, P252, DOI 10.1016/S0960-9822(03)00040-X; Defilippi P, 2006, TRENDS CELL BIOL, V16, P257, DOI 10.1016/j.tcb.2006.03.003; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Gan BY, 2005, J CELL BIOL, V170, P379, DOI 10.1083/jcb.200411106; Gungabissoon RA, 2003, J HISTOCHEM CYTOCHEM, V51, P411, DOI 10.1177/002215540305100402; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Huang TY, 2006, CURR OPIN CELL BIOL, V18, P26, DOI 10.1016/j.ceb.2005.11.005; Hunter T, 2007, MOL CELL, V28, P730, DOI 10.1016/j.molcel.2007.11.019; Ichetovkin I, 2002, CURR BIOL, V12, P79, DOI 10.1016/S0960-9822(01)00629-7; KELLIE S, 1986, EXP CELL RES, V165, P216, DOI 10.1016/0014-4827(86)90546-X; LaLonde DP, 2005, J BIOL CHEM, V280, P21680, DOI 10.1074/jbc.m500752200; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lin R, 2006, CELL COMMUN ADHES, V13, P199, DOI 10.1080/15419060600848516; Martinez-Moczygemba M, 2007, J LEUKOCYTE BIOL, V81, P1137, DOI 10.1189/jlb.0706465; Meberg PJ, 2000, MOL NEUROBIOL, V21, P97, DOI 10.1385/MN:21:1-2:097; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Ono S, 2003, BIOCHEMISTRY-US, V42, P13363, DOI 10.1021/bi034600x; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Rogers SL, 2003, J CELL BIOL, V162, P1079, DOI 10.1083/jcb.200303023; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Samstag Y, 1996, J IMMUNOL, V156, P4167; Scaglioni PP, 2006, CELL, V126, P269, DOI 10.1016/j.cell.2006.05.041; SHRIVER K, 1981, J CELL BIOL, V89, P525, DOI 10.1083/jcb.89.3.525; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tsumura Y, 2005, BIOCHEM J, V387, P627, DOI 10.1042/BJ20041181; Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6; Tursun B, 2005, GENE DEV, V19, P2307, DOI 10.1101/gad.1340605; Wakatsuki T, 2003, J CELL SCI, V116, P1617, DOI 10.1242/jcs.00340; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Wu XY, 2004, J BIOL CHEM, V279, P9565, DOI 10.1074/jbc.M310739200; Yan D, 2006, J CELL BIOL, V174, P415, DOI 10.1083/jcb.200511028; Yap CT, 2005, CELL MOTIL CYTOSKEL, V60, P153, DOI 10.1002/cm.20053; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yoo YD, 2006, J BIOL CHEM, V281, P15352, DOI 10.1074/jbc.M511825200; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	62	48	55	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					263	272		10.1038/onc.2009.319	http://dx.doi.org/10.1038/onc.2009.319			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19802004	Green Accepted			2022-12-17	WOS:000273650000009
J	Nguyen, A; Chang, ACM; Reddel, RR				Nguyen, A.; Chang, A. C. M.; Reddel, R. R.			Stanniocalcin-1 acts in a negative feedback loop in the prosurvival ERK1/2 signaling pathway during oxidative stress	ONCOGENE			English	Article						stanniocalcin-1; STC1; ERK1/2; oxidative stress; PD98059; apoptosis	DIFFERENTIAL GENE-EXPRESSION; ELEVATED EXPRESSION; PROTEIN; GROWTH; CELLS; RECEPTOR; OXYGEN; IDENTIFICATION; SENSITIVITY; ACTIVATION	Mammalian Stanniocalcin-1 (STC1) is a glycoprotein that has been implicated in various biological processes including angiogenesis. Aberrant STC1 expression has been reported in breast, ovarian and prostate cancers, but the significance of this is not well understood. Here, we report that oxidative stress caused a 40-fold increase in STC1 levels in mouse embryo. broblasts (MEFs). STC1(-/-) MEFs were resistant to growth inhibition and cell death induced by H2O2 or by 20% O-2 ( which is hyperoxic for most mammalian cells); this is the first phenotype reported for STC1-null cells. STC1(-/-) cells had higher levels of activated MEK and ERK1/2 than their wild-type (WT) counterparts, and these levels were all reduced by stable expression of exogenous STC1 in STC1(-/-) cells. Furthermore, pharmacological inhibition by PD98059 or UO126 of MEK and therefore of ERK1/2 activation restored sensitivity of STC1(-/-) cells to oxidative stress. We also found that H2O2- induced STC1 expression in WT cells was abolished by inhibition of ERK1/2 activation. Thus, the ERK1/2 signaling pathway upregulates STC1 expression, which in turn downregulates the level of activated MEK and consequently ERK1/2 in a novel negative feedback loop. Therefore, STC1 expression downregulates prosurvival ERK1/2 signaling and reduces survival under conditions of oxidative stress. Oncogene (2009) 28, 1982-1992; doi:10.1038/onc.2009.65; published online 6 April 2009	[Nguyen, A.; Chang, A. C. M.; Reddel, R. R.] Childrens Med Res Inst, Canc Res Unit, Westmead, NSW 2145, Australia; [Nguyen, A.; Chang, A. C. M.; Reddel, R. R.] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia	Children's Medical Research Institute - Australia; University of Sydney	Reddel, RR (corresponding author), Childrens Med Res Inst, Canc Res Unit, 214 Hawkesbury Rd, Westmead, NSW 2145, Australia.	rreddel@cmri.usyd.edu.au	Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107	Australian Postgraduate Award; Carcinogenesis Fellowship of the Cancer Council NSW; National Health and Medical Research Council of Australia Senior Principal Research Fellowship	Australian Postgraduate Award(Australian Government); Carcinogenesis Fellowship of the Cancer Council NSW(Cancer Council New South Wales); National Health and Medical Research Council of Australia Senior Principal Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	This study was supported by an Australian Postgraduate Award, the Carcinogenesis Fellowship of the Cancer Council NSW and a National Health and Medical Research Council of Australia Senior Principal Research Fellowship.	Adayev T, 2003, BBA-MOL CELL RES, V1640, P85, DOI 10.1016/S0167-4889(03)00023-5; Arrington ED, 2000, FREE RADICAL BIO MED, V29, P1166, DOI 10.1016/S0891-5849(00)00439-1; Bai XC, 2002, BIOCHEM J, V363, P395, DOI 10.1042/0264-6021:3630395; Bell SE, 2001, J CELL SCI, V114, P2755; Benn SC, 2004, NAT REV NEUROSCI, V5, P686, DOI 10.1038/nrn1477; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; Bouras T, 2002, CANCER RES, V62, P1289; Chang ACM, 2005, MOL CELL BIOL, V25, P10604, DOI 10.1128/MCB.25.23.10604-10610.2005; Chang ACM, 2003, ENDOCR-RELAT CANCER, V10, P359, DOI 10.1677/erc.0.0100359; CHANG ACM, 1995, MOL CELL ENDOCRINOL, V112, P241, DOI 10.1016/0303-7207(95)03601-3; Chang ACM, 1996, MOL CELL ENDOCRINOL, V124, P185, DOI 10.1016/S0303-7207(96)03929-9; Di Micco R, 2008, CELL CYCLE, V7, P3601, DOI 10.4161/cc.7.22.7152; Ellard JP, 2007, MOL CELL ENDOCRINOL, V264, P90, DOI 10.1016/j.mce.2006.10.008; Filvaroff EH, 2002, ENDOCRINOLOGY, V143, P3681, DOI 10.1210/en.2001-211424; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fujiwara Y, 2000, INT J ONCOL, V16, P799; Ismail RS, 2000, CANCER RES, V60, P6744; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jellinek DA, 2000, BIOCHEM J, V350, P453, DOI 10.1042/0264-6021:3500453; Jiang WQ, 2000, J ENDOCRINOL, V165, P457, DOI 10.1677/joe.0.1650457; Joensuu K, 2008, CANCER LETT, V265, P76, DOI 10.1016/j.canlet.2008.02.022; Kahn J, 2000, AM J PATHOL, V156, P1887, DOI 10.1016/S0002-9440(10)65062-6; Kanellis J, 2004, AM J PHYSIOL-RENAL, V286, pF356, DOI 10.1152/ajprenal.00138.2003; Koizumi K, 2007, CIRC J, V71, P796, DOI 10.1253/circj.71.796; Lai KP, 2007, BIOCHEM BIOPH RES CO, V356, P968, DOI 10.1016/j.bbrc.2007.03.074; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Lee IH, 2008, J BIOL CHEM, V283, P6312, DOI 10.1074/jbc.M706878200; Long H, 2003, CELL PHYSIOL BIOCHEM, V13, P401, DOI 10.1159/000075128; Madsen KL, 1998, AM J PHYSIOL-GASTR L, V274, pG96, DOI 10.1152/ajpgi.1998.274.1.G96; McCudden CR, 2002, J BIOL CHEM, V277, P45249, DOI 10.1074/jbc.M205954200; Okabe H, 2001, CANCER RES, V61, P2129; Olsen HS, 1996, P NATL ACAD SCI USA, V93, P1792, DOI 10.1073/pnas.93.5.1792; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Sheikh-Hamad D, 2000, AM J PHYSIOL-RENAL, V278, pF417, DOI 10.1152/ajprenal.2000.278.3.F417; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SUNDELL K, 1992, J COMP PHYSIOL B, V162, P489; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VANDERKOOI JM, 1991, AM J PHYSIOL, V260, pC1131, DOI 10.1152/ajpcell.1991.260.6.C1131; Varghese R, 2002, ENDOCRINOLOGY, V143, P868, DOI 10.1210/en.143.3.868; Wagner GF, 1997, J BONE MINER RES, V12, P165, DOI 10.1359/jbmr.1997.12.2.165; WAGNER GF, 1988, GEN COMP ENDOCR, V72, P237, DOI 10.1016/0016-6480(88)90206-7; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Westberg JA, 2007, AM J PHYSIOL-HEART C, V293, pH1766, DOI 10.1152/ajpheart.00017.2007; Westberg JA, 2007, STROKE, V38, P1025, DOI 10.1161/01.STR.0000258113.67252.fa; Wu SF, 2006, J BIOL CHEM, V281, P5120, DOI 10.1074/jbc.M506667200; Xu Jianming, 2005, Curr Protoc Mol Biol, VChapter 28, DOI 10.1002/0471142727.mb2801s70; Yeung HY, 2005, ENDOCRINOLOGY, V146, P4951, DOI 10.1210/en.2005-0365; Yeung HY, 2003, ENDOCRINOLOGY, V144, P4446, DOI 10.1210/en.2003-0504; Yoshiko Y, 2003, ENDOCRINOLOGY, V144, P4134, DOI 10.1210/en.2003-0130; Zhang KZ, 2000, P NATL ACAD SCI USA, V97, P3637, DOI 10.1073/pnas.070045897	51	48	50	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2009	28	18					1982	1992		10.1038/onc.2009.65	http://dx.doi.org/10.1038/onc.2009.65			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442DT	19347030				2022-12-17	WOS:000265820900005
J	Goransson, M; Andersson, MK; Forni, C; Stahlberg, A; Andersson, C; Olofsson, A; Mantovani, R; Aman, P				Goransson, M.; Andersson, M. K.; Forni, C.; Stahlberg, A.; Andersson, C.; Olofsson, A.; Mantovani, R.; Aman, P.			The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappa B target genes by interaction with NFKBIZ	ONCOGENE			English	Article						MLS/RCLS; FUS; DDIT3; NF-kappa B; NFKBIZ; sarcoma	RNA-BINDING PROTEIN; TLS-CHOP; EXPRESSION PATTERNS; GENOMIC STRUCTURE; FUS/TLS-CHOP; TRANSCRIPTION; EWS; ZETA; INTERLEUKIN-6; TRANSLOCATION	FUS (also called TLS), EWSR1 and TAF15 (also called TAF2N) are related genes involved in tumor type-specific fusion oncogenes in human malignancies. The FUS-DDIT3 fusion oncogene results from a t(12;16)(q13;p11) chromosome translocation and has a causative role in the initiation of myxoid/round cell liposarcomas (MLS/RCLS). The FUS-DDIT3 protein induces increased expression of the CAAT/enhancer-binding protein (C/EBP) and nuclear factor-kappa B (NF-kappa)-controlled gene IL8, and the N-terminal FUS part is required for this activation. Chromatin immunoprecipitation analysis showed that FUS-DDIT3 binds the IL8 promoter. Expression studies of the IL8 promoter harboring a C/EBP-NF-kappa B composite site pinpointed the importance of NF-kappa B for IL8 expression in FUS-DDIT3-expressing cells. We therefore probed for possible interaction of FUS-DDIT3 with members of the NF-kappa B family. The nuclear factor NFKBIZ colocalizes with FUS-DDIT3 in nuclear structures, and immunoprecipitation experiments showed that FUS-DDIT3 binds the C-terminal of NFKBIZ. We also report that additional NF-kappa B-controlled genes are upregulated at the mRNA level in FUS-DDIT3-expressing cell lines and they can be induced by NFKBIZ. Taken together, the results indicate that FUS-DDIT3 deregulates some NF-kappa B-controlled genes through interactions with NFKBIZ. Similar mechanisms may be a part of the transformation process in other tumor types carrying FUS, EWSR1 and TAF15 containing fusion oncogenes.	[Goransson, M.; Andersson, M. K.; Andersson, C.; Olofsson, A.; Aman, P.] Univ Gothenburg, LLCR, Dept Pathol, Sahlgrenska Acad, SE-41345 Gothenburg, Sweden; [Forni, C.; Mantovani, R.] Univ Milan, Dipartimento Sci Biomol & Biotecnol, Milan, Italy; [Stahlberg, A.] Univ Gothenburg, Sahlgrenska Acad, Ctr Brain Repair & Rehabil, Dept Clin Neurosci & Rehabil, SE-41345 Gothenburg, Sweden	University of Gothenburg; University of Milan; University of Gothenburg	Aman, P (corresponding author), Univ Gothenburg, LLCR, Dept Pathol, Sahlgrenska Acad, Gula Straket 8, SE-41345 Gothenburg, Sweden.	pierre.aman@llcr.med.gu.se		Stahlberg, Anders/0000-0003-4243-0191; Aman, Pierre/0000-0002-1482-8875	Inga-Britt and Arne Lundberg Research Foundation; Swedish Cancer Society; Assar Gabrielssons Research Foundation; Johan Jansson Foundation for Cancer Research; AIRC; Swedish Research Council	Inga-Britt and Arne Lundberg Research Foundation; Swedish Cancer Society(Swedish Cancer Society); Assar Gabrielssons Research Foundation; Johan Jansson Foundation for Cancer Research; AIRC(Fondazione AIRC per la ricerca sul cancro); Swedish Research Council	We thank Ulric Pedersen for image processing. This work was supported by grants from the Inga-Britt and Arne Lundberg Research Foundation, the Swedish Cancer Society, Assar Gabrielssons Research Foundation and the Johan Jansson Foundation for Cancer Research. RM was supported by an AIRC grant. AS is supported by a postdoctoral fellowship award from the Swedish Research Council.	AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; Basile A, 1997, J BIOL CHEM, V272, P8172, DOI 10.1074/jbc.272.13.8172; BIEGEL JA, 1993, GENE CHROMOSOME CANC, V7, P119, DOI 10.1002/gcc.2870070210; Bratt T, 2000, BBA-PROTEIN STRUCT M, V1482, P318, DOI 10.1016/S0167-4838(00)00154-0; Brinckerhoff CE, 2000, CLIN CANCER RES, V6, P4823; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Chen ZD, 1998, NUCLEIC ACIDS RES, V26, P1126, DOI 10.1093/nar/26.4.1126; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DIFFIN F, 1994, J CLIN PATHOL, V47, P562, DOI 10.1136/jcp.47.6.562; Engstrom K, 2006, AM J PATHOL, V168, P1642, DOI 10.2353/ajpath.2006.050872; Goransson M, 2005, INT J CANCER, V115, P556, DOI 10.1002/ijc.20893; Goransson M, 2002, EXP CELL RES, V278, P125, DOI 10.1006/excr.2002.5566; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Kitamura H, 2000, FEBS LETT, V485, P53, DOI 10.1016/S0014-5793(00)02185-2; Kovar H, 2005, SEMIN CANCER BIOL, V15, P189, DOI 10.1016/j.semcancer.2005.01.004; KOVAR H, 1994, KLIN PADIATR, V206, P196, DOI 10.1055/s-2008-1046605; Law Warren J., 2006, Briefings in Functional Genomics & Proteomics, V5, P8, DOI 10.1093/bfgp/ell015; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Matsuo S, 2007, BIOCHEM J, V405, P605, DOI 10.1042/BJ20061797; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Morohoshi F, 1998, GENE, V221, P191, DOI 10.1016/S0378-1119(98)00463-6; Motoyama M, 2005, J BIOL CHEM, V280, P7444, DOI 10.1074/jbc.M412738200; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Nakopoulou L, 1999, HUM PATHOL, V30, P436, DOI 10.1016/S0046-8177(99)90120-X; OHNO T, 1993, CANCER RES, V53, P5859; Oikawa K, 2006, AM J SURG PATHOL, V30, P351; Olofsson A, 2004, INT J ONCOL, V25, P1349; Panagopoulos I, 1996, ONCOGENE, V12, P489; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; Perez-Losada J, 2000, ONCOGENE, V19, P6015, DOI 10.1038/sj.onc.1204018; Perez-Losada J, 2000, ONCOGENE, V19, P2413, DOI 10.1038/sj.onc.1203572; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; Riggi N, 2006, CANCER RES, V66, P7016, DOI 10.1158/0008-5472.CAN-05-3979; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; Schwarzbach MHM, 2004, ONCOGENE, V23, P6798, DOI 10.1038/sj.onc.1207840; Stahlberg A, 2004, CLIN CHEM, V50, P509, DOI 10.1373/clinchem.2003.026161; Sun SC, 2003, CANCER METAST REV, V22, P405, DOI 10.1023/A:1023733231406; Thelin-Jarnum S, 1999, INT J CANCER, V83, P30, DOI 10.1002/(SICI)1097-0215(19990924)83:1<30::AID-IJC6>3.0.CO;2-4; Thelin-Jarnum S, 2002, INT J CANCER, V97, P446, DOI 10.1002/ijc.1632; Totzke G, 2006, J BIOL CHEM, V281, P12645, DOI 10.1074/jbc.M511956200; Trinh DV, 2008, J MOL BIOL, V379, P122, DOI 10.1016/j.jmb.2008.03.060; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vincenti MP, 1998, ARTHRITIS RHEUM, V41, P1987, DOI 10.1002/1529-0131(199811)41:11<1987::AID-ART14>3.3.CO;2-#; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zinszner H, 1997, ONCOGENE, V14, P451, DOI 10.1038/sj.onc.1200854	50	48	51	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					270	278		10.1038/onc.2008.378	http://dx.doi.org/10.1038/onc.2008.378			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18850010				2022-12-17	WOS:000262501100010
J	Sayan, AE; Sayan, BS; Gogvadze, V; Dinsdale, D; Nyman, U; Hansen, TM; Zhivotovsky, B; Cohen, GM; Knight, RA; Melino, G				Sayan, A. E.; Sayan, B. S.; Gogvadze, V.; Dinsdale, D.; Nyman, U.; Hansen, T. M.; Zhivotovsky, B.; Cohen, G. M.; Knight, R. A.; Melino, G.			p73 and caspase-cleaved p73 fragments localize to mitochondria and augment TRAIL-induced apoptosis	ONCOGENE			English	Article						p73; mitochondria; p53; transcription independent; apoptosis; TRAIL	C-ABL; PROTEIN STABILITY; TUMOR-SUPPRESSOR; REGULATES P73; P53; TRANSACTIVATION; ACTIVATION; DEGRADATION; CARCINOMA; ABSENCE	The p73 protein, a member of the p53 family, has both developmental and tumorigenic functions. Here we show that p73 is cleaved by caspase-3 and -8 both in vitro and in vivo during apoptosis elicited by DNA-damaging drugs and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor ligation. TAp73 and some of its cleavage products are localized to mitochondria. siRNA-mediated downregulation of p73 expression induced a small but significant change in the susceptibility of HCT116 cells to TRAIL-induced apoptosis. A transcription-deficient mutant of TAp73 enhanced TRAIL-induced apoptosis suggesting that p73 protein has transcriptionin-dependent functions during death receptor-mediated apoptosis. Additionally, recombinant p73 protein induced cytochrome c release from isolated mitochondria providing evidence that nonnuclear p73 may have additional functions in the progression of apoptosis.	[Sayan, A. E.; Sayan, B. S.; Dinsdale, D.; Hansen, T. M.; Cohen, G. M.; Knight, R. A.; Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; [Gogvadze, V.; Nyman, U.; Zhivotovsky, B.] Karolinska Inst, Inst Environm Med, Div Toxicol, S-10401 Stockholm, Sweden	University of Leicester; Karolinska Institutet	Melino, G (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,Lancaster Rd,POB 138, Leicester LE1 9HN, Leics, England.	gm89@leicester.ac.uk	Zhivotovsky, Boris/A-4346-2014; Nyman, Ulrika/D-3708-2013; Gogvadze, Vladimir/A-4392-2014; SAYAN, A. EMRE/H-7330-2012	Zhivotovsky, Boris/0000-0002-2238-3482; SAYAN, A. EMRE/0000-0002-5291-1485	Medical Research Council [MC_U132670600] Funding Source: Medline; MRC [MC_U132670600] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agami R, 1999, NATURE, V399, P809; Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P994, DOI 10.1038/sj.cdd.4401908; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Essmann F, 2005, J BIOL CHEM, V280, P37169, DOI 10.1074/jbc.M502052200; Gong JG, 1999, NATURE, V399, P806; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Lamkanfi M, 2007, CELL DEATH DIFFER, V14, P44, DOI 10.1038/sj.cdd.4402047; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Luthi AU, 2007, CELL DEATH DIFFER, V14, P641, DOI 10.1038/sj.cdd.4402103; MacLachan TK, 2002, P NATL ACAD SCI USA, V99, P9492, DOI 10.1073/pnas.132241599; Mahyar-Roemer M, 2004, ONCOGENE, V23, P6226, DOI 10.1038/sj.onc.1207637; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Munarriz E, 2005, BIOCHEM BIOPH RES CO, V333, P954, DOI 10.1016/j.bbrc.2005.05.188; Oberst A, 2005, BIOCHEM BIOPH RES CO, V331, P707, DOI 10.1016/j.bbrc.2005.03.158; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Sayan AE, 2001, ONCOGENE, V20, P5111, DOI 10.1038/sj.onc.1204669; Sayan AE, 2005, BIOCHEM BIOPH RES CO, V330, P186, DOI 10.1016/j.bbrc.2005.02.145; Sayan BS, 2007, P NATL ACAD SCI USA, V104, P10871, DOI 10.1073/pnas.0700761104; Sayan BS, 2006, J BIOL CHEM, V281, P13566, DOI 10.1074/jbc.M512467200; Schembri L, 2007, NAT METHODS, V4, P107, DOI 10.1038/nmeth0207-107; Sigal A, 2000, CANCER RES, V60, P6788; Stiewe T, 2002, CANCER RES, V62, P3598; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Zaika AI, 1999, CANCER RES, V59, P3257	43	48	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4363	4372		10.1038/onc.2008.64	http://dx.doi.org/10.1038/onc.2008.64			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18362891				2022-12-17	WOS:000257691100011
J	Loveridge, CJ; MacDonald, ADH; Thoms, HC; Dunlop, MG; Stark, LA				Loveridge, C. J.; MacDonald, A. D. H.; Thoms, H. C.; Dunlop, M. G.; Stark, L. A.			The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappa B	ONCOGENE			English	Article						chemoprevention; colon cancer; aspirin; cell adhesion; nucleolus; cell death	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRANSCRIPTIONAL REGULATION; EXPRESSION; APOPTOSIS; CHEMOPREVENTION; ICAM-1; CELLS; GENE; RELA	Understanding the mechanisms that underlie the antitumour activity of non-steroidal anti-inflammatory drugs (NSAIDs) against colorectal cancer will allow the development of more effective and specific chemopreventative agents. Modulation of the NF-kappa B pathway has been implicated as a key effector of the antitumour effect of aspirin, but the effects of non-aspirin NSAIDs on this pathway have yet to be fully defined. Here, we demonstrate that sulindac, sulindac sulfone and indomethacin activate the NF-kappa B pathway in colorectal cancer cells, as determined by western blot analysis of cytoplasmic levels of I kappa B alpha and immunocytochemical analysis of nuclear NF-kappa B/RelA. Furthermore, we show that all of these NSAIDs induce nucleolar translocation of the RelA subunit of NF-kappa B. Using RelA deleted for the previously described nucleolar localization signal, we demonstrate that this response is causally involved in the apoptotic effects of these agents. Finally, we demonstrate that NSAID-mediated nucleolar translocation of RelA is associated with downregulation of NF-kappa B-driven transcription and of the NF-kappa B target gene, ICAM-1. These data identify nucleolar translocation of RelA and the associated repression of the NF-kappa B-driven transcription as a central molecular mechanism of NSAID-mediated growth inhibition and apoptosis. As well as providing new understanding of the molecular determinants of RelA function, these findings also have relevance to the development of novel chemotherapeutic and chemopreventative agents.	Univ Edinburgh, Canc Res Ctr, Colon Canc Genet Grp, Sch Clin & Mol Med, Edinburgh EH4 2XU, Midlothian, Scotland; Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Stark, LA (corresponding author), Univ Edinburgh, Edinburgh Canc Res Ctr, Colon Canc Genet Grp, MRC,Human Genet Unit,Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland.	lesley.stark@hgu.mrc.ac.uk	Dunlop, Malcolm G/F-1973-2011	Dunlop, Malcolm G/0000-0002-3033-5851; Loveridge, Carolyn/0000-0002-6237-8661	Cancer Research UK [C48/A6361, C20658/A6656, C348/A3758] Funding Source: Medline; Medical Research Council [MC_U127527198] Funding Source: Medline; MRC [MC_U127527198] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BRANDLI DW, 1991, CLIN PHARMACOL THER, V50, P650, DOI 10.1038/clpt.1991.203; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Din FVN, 2004, BRIT J CANCER, V91, P381, DOI 10.1038/sj.bjc.6601913; DIPPOLD W, 1993, GUT, V34, P1593, DOI 10.1136/gut.34.11.1593; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; Gardner SH, 2004, BRIT J CANCER, V91, P153, DOI 10.1038/sj.bjc.6601901; Grau MV, 2006, BASIC CLIN PHARMACOL, V98, P281, DOI 10.1111/j.1742-7843.2006.pto_294.x; Hoffmann A, 2006, ONCOGENE, V25, P6706, DOI 10.1038/sj.onc.1209933; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Stark LA, 2005, MOL CELL BIOL, V25, P5985, DOI 10.1128/MCB.25.14.5985-6004.2005; Stark LA, 2001, FASEB J, V15, P1273, DOI 10.1096/fj.00-0529fje; Stark LA, 2007, CARCINOGENESIS, V28, P968, DOI 10.1093/carcin/bgl220; Sun YJ, 2005, MOL CANCER THER, V4, P51; Thoms HC, 2007, CANCER RES, V67, P1660, DOI 10.1158/0008-5472.CAN-06-1038; Vainer B, 2006, SCAND J GASTROENTERO, V41, P318, DOI 10.1080/00365520510024241; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407	19	48	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2008	27	18					2648	2655		10.1038/sj.onc.1210891	http://dx.doi.org/10.1038/sj.onc.1210891			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	18059344				2022-12-17	WOS:000255057000014
J	Bader, AG; Vogt, PK				Bader, A. G.; Vogt, P. K.			Phosphorylation by Akt disables the anti-oncogenic activity of YB-1	ONCOGENE			English	Article						translation; p50; dbpb; NSEP1; PI3K; mRNA binding	BOX-BINDING PROTEIN-1; COLD-SHOCK DOMAIN; MESSENGER-RNA; CATALYTIC SUBUNIT; BREAST-CANCER; TRANSFORMATION; TRANSCRIPTION; 3-KINASE; KINASE	The Y box-binding protein 1 ( YB-1) is a DNA/ RNA-binding protein that regulates mRNA transcription and translation. It is a major component of free messenger ribonucleoprotein particles and, at higher concentrations, blocks protein synthesis. In chicken embryo fibroblasts, overexpression of YB-1 confers a specific resistance to oncogenic cellular transformation by phosphoinositide 3-kinase ( PI3K) or Akt/ PKB. Recent studies have identified ed YB-1 as a direct substrate of Akt. The functional significance of Akt-mediated phosphorylation remains largely unknown. We generated YB-1 mutants in the Akt phosphorylation consensus sequence to explore the effect of phosphorylated YB-1 in PI3K-induced transformation. In contrast to wild-type YB-1, the phosphomimetic S99E mutant no longer interferes with cellular transformation. This mutant has reduced affinity for the cap of mRNAs and fails to inhibit cap-dependent translation. The data suggest that phosphorylation by Akt disables the inhibitory activity of YB-1 and thereby enhances the translation of transcripts that are necessary for oncogenesis. Overexpression of wild-type YB-1 overrides inactivation by Akt and maintains inhibition of protein synthesis and resistance to transformation.	[Bader, A. G.; Vogt, P. K.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Bader, AG (corresponding author), Asuragen Inc, R&D, 2150 Woodward St, Austin, TX 78744 USA.	abader@asuragen.com	Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500				Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Bader AG, 2003, P NATL ACAD SCI USA, V100, P12384, DOI 10.1073/pnas.2135336100; Bader AG, 2005, MOL CELL BIOL, V25, P2095, DOI 10.1128/MCB.25.6.2095-2106.2005; Bader AG, 2006, CURR CANCER THER REV, V2, P31, DOI 10.2174/157339406775471786; Basaki Y, 2007, ONCOGENE, V26, P2736, DOI 10.1038/sj.onc.1210084; Bergmann S, 2005, CANCER RES, V65, P4078, DOI 10.1158/0008-5472.CAN-04-4056; BOUVET P, 1995, J BIOL CHEM, V270, P28297; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Evdokimova V, 2006, MOL CELL BIOL, V26, P277, DOI 10.1128/MCB.26.1.277-292.2006; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kloks CPAM, 2002, J MOL BIOL, V316, P317, DOI 10.1006/jmbi.2001.5334; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; Sorokin AV, 2005, EMBO J, V24, P3602, DOI 10.1038/sj.emboj.7600830; Stenina OI, 2001, P NATL ACAD SCI USA, V98, P7277, DOI 10.1073/pnas.121592298; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590	19	48	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1179	1182		10.1038/sj.onc.1210719	http://dx.doi.org/10.1038/sj.onc.1210719			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17704806				2022-12-17	WOS:000253136700018
J	Song, LP; Zhang, J; Wu, SF; Huang, Y; Zhao, Q; Cao, JP; Wu, YL; Wang, LS; Chen, GQ				Song, L-P; Zhang, J.; Wu, S-F; Huang, Y.; Zhao, Q.; Cao, J-P; Wu, Y-L; Wang, L-S; Chen, G-Q			Hypoxia-inducible factor-1 alpha-induced differentiation of myeloid leukemic cells is its transcriptional activity independent	ONCOGENE			English	Article						leukemia; differentiation; HIF-1 alpha; C/EBP alpha	PHOSPHOLIPID SCRAMBLASE-1 GENE; TEL-ARNT FUSION; OXYGEN-TENSION; RETINOIC ACID; C/EBP-ALPHA; EXPRESSION; ARREST; TRANSLOCATION	Hypoxia or hypoxia mimetic has been shown to induce differentiation together with the accumulation of hypoxia-inducible factor-1 alpha (HIF-1 alpha) protein of myeloid leukemic cells and normal hematopoietic progenitors. To provide direct evidence for the role of HIF-1 alpha in acute myeloid leukemia (AML) cell differentiation and its mechanisms, we generated myeloid leukemic U937T transformants, in which HIF-1 alpha was tightly induced by tetracycline withdrawal. The results showed that the conditional HIF-1 alpha induction triggered granulocytic differentiation of these transformants, while the suppression of HIF-1 alpha expression by specific short hairpin RNAs (shRNAs) effectively inhibited hypoxia-induced differentiation of U937 cells, as evidenced by morphology, maturation-related antigens as well as expressions of myeloid differentiation signatures and hematopoietic cells- specific cytokine receptors. The specific shRNAs-inhibited expression of HIF-1 beta, an essential partner for transcription activity of HIF-1 alpha failed, while the inhibition of hematopoietic differentiation-critical CCAAT/enhancer-binding protein-a (C/EBPa) significantly eliminated HIF-1 alpha-mediated myeloid leukemic cell differentiation. Collectively, this work provided several lines of direct evidence for the role of HIF-1 alpha protein through its nontranscriptional activity in myeloid cell differentiation, in which C/EBP alpha elicitsa role as an effector downstream to HIF-1 alpha. These discoveries would shed new insights for understanding mechanisms underlying leukemogenesis and designing the new therapeutic strategy for differentiation induction of AML.	[Song, L-P; Zhang, J.; Wu, S-F; Zhao, Q.; Cao, J-P; Chen, G-Q] SJTU SM, Chinese Acad Sci, Grad Sch, Shanghai, Peoples R China; [Song, L-P; Zhang, J.; Wu, S-F; Zhao, Q.; Cao, J-P; Chen, G-Q] SJTU SM, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai, Peoples R China; [Huang, Y.; Wu, Y-L; Wang, L-S; Chen, G-Q] SJTU SM, Chinese Minist Educ, Key Lab Cell Differentiat & Apoptosis, Dept Pathophysiol, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Chen, GQ (corresponding author), Chinese Minist Educ, Key Lab Cell Differentiat & Apoptosis, Dept Pathophysiol, Shanghai 200025, Peoples R China.	chengq@shsmu.edu.cn						Barreda DR, 2004, DEV COMP IMMUNOL, V28, P509, DOI 10.1016/j.dci.2003.09.010; Boer J, 1998, MOL CELL BIOL, V18, P1236, DOI 10.1128/MCB.18.3.1236; Chen GQ, 1997, BLOOD, V89, P3345; Cheng LRL, 2006, FOLIA PHONIATR LOGO, V58, P5, DOI 10.1159/000090474; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Hong SH, 2004, J BIOL CHEM, V279, P16996, DOI 10.1074/jbc.M311752200; Huang Y, 2006, ONCOGENE, V25, P6618, DOI 10.1038/sj.onc.1209677; Huang Y, 2003, LEUKEMIA, V17, P2065, DOI 10.1038/sj.leu.2403141; James SY, 1997, BIOCHEM PHARMACOL, V54, P625, DOI 10.1016/S0006-2952(97)00195-0; Jiang Y, 2005, LEUKEMIA, V19, P1239, DOI 10.1038/sj.leu.2403734; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Liu W, 2006, BLOOD, V107, P698, DOI 10.1182/blood-2005-03-1278; Mueller BU, 2006, CURR OPIN HEMATOL, V13, P7, DOI 10.1097/01.moh.0000190110.08156.96; Nguyen-Khac F, 2006, ONCOGENE, V25, P4840, DOI 10.1038/sj.onc.1209503; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Rosenbauer F, 2005, BLOOD, V106, P1519, DOI 10.1182/blood-2005-02-0717; Salomon-Nguyen F, 2000, P NATL ACAD SCI USA, V97, P6757, DOI 10.1073/pnas.120162297; Scortegagna M, 2003, BLOOD, V102, P1634, DOI 10.1182/blood-2003-02-0448; SCOTT LM, 1992, BLOOD, V80, P1725; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305; Suh HC, 2006, BLOOD, V107, P4308, DOI 10.1182/blood-2005-06-2216; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Thrash-Bingham CA, 1999, JNCI-J NATL CANCER I, V91, P143, DOI 10.1093/jnci/91.2.143; Zhao KW, 2004, BLOOD, V104, P3731, DOI 10.1182/blood-2004-04-1630	25	48	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					519	527		10.1038/sj.onc.1210670	http://dx.doi.org/10.1038/sj.onc.1210670			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637739				2022-12-17	WOS:000252426100012
J	Cuenin, S; Tinel, A; Janssens, S; Tschopp, J				Cuenin, S.; Tinel, A.; Janssens, S.; Tschopp, J.			p53-induced protein with a death domain (PIDD) isoforms differentially activate nuclear factor-kappaB and caspase-2 in response to genotoxic stress	ONCOGENE			English	Article						PIDD; DNA repair; NF-kappa B; caspase-2	DNA-DAMAGE; B ACTIVATION; INDUCED APOPTOSIS; MITOCHONDRIA; NEMO; ATM	Cellsres pond to DNA damage in a complex way and the fate of damaged cells depends on the balance between pro-and antiapoptotic signals. This is of crucial importance in cancer as genotoxic stress is implied both in oncogenesis and in classical tumor therapies. p53-induced protein with a death domain (PIDD), initially described as a p53-inducible gene, is one of the molecular switches able to activate a survival or apoptotic program. Two isoforms of PIDD, PIDD ( isoform 1) and LRDD ( isoform 2), have already been reported and we describe here a third isoform. These three isoforms are differentially expressed in tissues and cell lines. Genotoxic stress only affects PIDD isoform 3 mRNA levels, whereas isoforms 1 and 2 mRNA levels remain unchanged. All isoforms are capable of activating nuclear factor-kappaB in response to genotoxic stress, but only isoform 1 interacts with RIP-associated ICH-1/CED-3 homologous protein with a death domain and activates caspase-2. Isoform 2 counteracts the pro-apoptotic function of isoform 1, whereas isoform 3 enhances it. Thus, the differential splicing of PIDD mRNA leads to the formation of at least three proteins with antagonizing/agonizing functions, thereby regulating cell fate in response to DNA damage.	[Cuenin, S.; Tinel, A.; Janssens, S.; Tschopp, J.] Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland	University of Lausanne	Tschopp, J (corresponding author), Univ Lausanne, Dept Biochem, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	jurg.tschopp@unil.ch	Janssens, Sophie/HHN-1756-2022					Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Campbell KJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-101; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hay RT, 2004, NAT CELL BIOL, V6, P89, DOI 10.1038/ncb0204-89; Ho WC, 2005, CANCER RES, V65, P4273, DOI 10.1158/0008-5472.CAN-04-3494; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Janssens S, 2006, CELL DEATH DIFFER, V13, P773, DOI 10.1038/sj.cdd.4401843; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Katzenberger RJ, 2006, MOL CELL BIOL, V26, P9256, DOI 10.1128/MCB.01125-06; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Mabb AM, 2006, NAT CELL BIOL, V8, P986, DOI 10.1038/ncb1458; Pick R, 2006, BIOCHEM BIOPH RES CO, V349, P1329, DOI 10.1016/j.bbrc.2006.08.176; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Telliez JB, 2000, BBA-PROTEIN STRUCT M, V1478, P280, DOI 10.1016/S0167-4838(00)00029-7; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tinel A, 2007, EMBO J, V26, P197, DOI 10.1038/sj.emboj.7601473; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049	21	48	49	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2008	27	3					387	396		10.1038/sj.onc.1210635	http://dx.doi.org/10.1038/sj.onc.1210635			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17637755				2022-12-17	WOS:000252256000015
J	Zhen, Y; Sorensen, VS; Jin, Y; Suo, Z; Wiedlocha, A				Zhen, Y.; Sorensen, V. S.; Jin, Y.; Suo, Z.; Wiedlocha, A.			Indirubin-3 '-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK	ONCOGENE			English	Article						indirubin-3 '-monoxime; FGFR1; p38 MAPK; ERK1/2; CDK2; cell proliferation	ACTIVATED PROTEIN-KINASE; CELL MYELOPROLIFERATIVE DISORDER; CHINESE ANTILEUKEMIA MEDICINE; THR-160 PHOSPHORYLATION; INDIRUBIN DERIVATIVES; HEPARAN-SULFATE; TRANSLOCATION; APOPTOSIS; RECEPTOR; MECHANISMS	Indirubin-3'-monoxime is a derivative of the bis-indole alkaloid indirubin, an active ingredient of a traditional Chinese medical preparation that exhibits anti-inflammatory and anti-leukemic activities. Indirubin-3'-monoxime is mainly recognized as an inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase-3. It inhibits proliferation of cultured cells, mainly through arresting the cells in the G1/S or G2/M phase of the cell cycle. Here, we report that indirubin-3'-monoxime is able to inhibit proliferation of NIH/3T3 cells by specifically inhibiting autophosphorylation of fibroblast growth factor receptor 1(FGFR1), blocking in this way the receptor-mediated cell signaling. Indirubin-3'-monoxime inhibits the activity of FGFR1 at a concentration lower than that required for inhibition of phosphorylation of CDK2 and retinoblastoma protein and cell proliferation stimulated by fetal calf serum. The ability of indirubin-3'-monoxime to inhibit FGFR1 signa ling was similar to that of the FGFR1 inhibitor SU5402. In addition, we found that indirubin-3'-monoxime activates long-term p38 mitogen-activated protein kinase activity, which stimulates extracellular signal-regulated kinase 1/2 in a way unrelated to the activity of FGFR1. Furthermore, we show that indirubin-3'- monoxime can inhibit proliferation of the myeloid leukemia cell line KG-1a through inhibition of the activity of the FGFR1 tyrosine kinase. The data presented here demonstrate previously unknown activities of indirubin-3'-monoxime that may have clinical implications.	Univ Oslo, Norwegian Radium Hosp, Natl Hosp, Inst Canc Res,Dept Biochem, N-0310 Oslo, Norway; Univ Oslo, Norwegian Radium Hosp, Natl Hosp, Inst Canc Res,Dept Pathol, N-0310 Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway	Wiedlocha, A (corresponding author), Univ Oslo, Norwegian Radium Hosp, Natl Hosp, Inst Canc Res,Dept Biochem, N-0310 Oslo, Norway.	antoni.wiedlocha@rr-research.no						Adachi J, 2001, J BIOL CHEM, V276, P31475, DOI 10.1074/jbc.C100238200; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chaffanet M, 1998, ONCOGENE, V16, P945, DOI 10.1038/sj.onc.1201601; Chiariello M, 2000, BIOCHEM J, V349, P869, DOI 10.1042/bj3490869; Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007; Davies TG, 2001, STRUCTURE, V9, P389, DOI 10.1016/S0969-2126(01)00598-6; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Furdui CM, 2006, MOL CELL, V21, P711, DOI 10.1016/j.molcel.2006.01.022; Gu TL, 2006, BLOOD, V108, P4202, DOI 10.1182/blood-2006-06-026666; Guasch G, 2001, MOL CELL BIOL, V21, P8129, DOI 10.1128/MCB.21.23.8129-8142.2001; Heredia A, 2005, AIDS, V19, P2087, DOI 10.1097/01.aids.0000194805.74293.11; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; IMAMURA T, 1994, EXP CELL RES, V215, P363, DOI 10.1006/excr.1994.1353; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; Jautelat R, 2005, CHEMBIOCHEM, V6, P531, DOI 10.1002/cbic.200400108; Kang YJ, 2006, J BIOL CHEM, V281, P26225, DOI 10.1074/jbc.M606800200; Keenan SM, 2001, J BIOL CHEM, V276, P22404, DOI 10.1074/jbc.M100409200; Kosmopoulou MN, 2004, EUR J BIOCHEM, V271, P2280, DOI 10.1111/j.1432-1033.2004.04173.x; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lents NH, 2002, J BIOL CHEM, V277, P47469, DOI 10.1074/jbc.M207425200; Lin XH, 1999, DEVELOPMENT, V126, P3715; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MACDONALD D, 1995, LEUKEMIA, V9, P1628; Marko D, 2001, BRIT J CANCER, V84, P283, DOI 10.1054/bjoc.2000.1546; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; Nguyen DT, 2006, FREE RADICAL BIO MED, V41, P1225, DOI 10.1016/j.freeradbiomed.2006.06.026; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Polychronopoulos P, 2004, J MED CHEM, V47, P935, DOI 10.1021/jm031016d; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Ribas J, 2006, ONCOGENE, V25, P6304, DOI 10.1038/sj.onc.1209648; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; SANDVIG K, 1982, J BIOL CHEM, V257, P7504; Sethi G, 2006, J BIOL CHEM, V281, P23425, DOI 10.1074/jbc.M602627200; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Xie YB, 2004, NEUROSCI LETT, V367, P355, DOI 10.1016/j.neulet.2004.06.044; Yu ZP, 2000, TOXICOL APPL PHARM, V168, P200, DOI 10.1006/taap.2000.9033; ZHAN X, 1993, J BIOL CHEM, V268, P9611	46	48	54	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6372	6385		10.1038/sj.onc.1210473	http://dx.doi.org/10.1038/sj.onc.1210473			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17533378				2022-12-17	WOS:000249737600002
J	Zhu, MJ; Ou, WB; Fletcher, CDM; Cohen, P; Demetri, GD; Fletcher, JA				Zhu, M-J; Ou, W-B; Fletcher, C. D. M.; Cohen, P. S.; Demetri, G. D.; Fletcher, J. A.			KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance	ONCOGENE			English	Article						KIT; PDGFRA; kinase; interaction; signal transduction	OF-FUNCTION MUTATIONS; C-KIT; IMATINIB MESYLATE; ACTIVATION; CELL; KINASE; SURVIVAL; PROLIFERATION; MECHANISMS; INHIBITOR	Most gastrointestinal stromal tumors (GISTs) express oncogenic and constitutively active forms of the KIT or platelet-derived growth factor receptor alpha (PDGFRA) receptor tyrosine kinase proteins, and these kinase oncoproteins serve as targets for effective therapies. Given that mutant KIT oncoproteins serve crucial transforming roles in GISTs, we evaluated interactions with the KIT oncoproteins and determined signaling pathways that are dependent on KIT oncogenic activation in GISTs. Tyrosine-phosphorylated KIT oncoproteins interacted with PDGFRA, PDGFRB, phosphatidylinositol 3-kinase (PI3-K) and PKC theta in GIST cells, and these interactions were abolished by KIT inhibition with imatinib or PKC412 or KIT RNAi. Notably, tyrosine-phosphorylated PDGFRA was prominent in frozen GIST tumors expressing KIT oncoproteins, suggesting that KIT-mediated PDGFRA phosphorylation is an efficient and biologically consequential mechanism in GISTs. Activated signaling intermediates were identified by immuno affinity purification of tyrosine-phosphorylated proteins in GIST cells before and after treatment with KIT inhibitors, and these analyses show that GRB2, SHC, CBL and MAPK activation are largely KIT dependent in GISTs, whereas PI3-K, STAT1 and STAT3 activation are partially KIT dependent. In addition, we found that phosphorylation of several tyrosine kinase proteinsincluding JAK1 and EPHA4 -did not depend on KIT activation. Likewise, paxillin activation was independent of the KIT oncogenic signal. These studies identify signaling pathways that can provide both KIT-dependent and KIT-independent therapeutic synergies in GIST, and thereby highlight clinical strategies that might consolidate GIST therapeutic response to KIT/PDGFRA inhibition.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Novartis Oncol, Florham Pk, NJ USA; Dana Farber Canc Inst, Ludwig Ctr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Novartis; Harvard University; Dana-Farber Cancer Institute	Zhu, MJ (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	mzhu2@partners.org	Ou, Wen-Bin/J-1142-2019	, Wenbin/0000-0002-6311-9442				Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; Duensing A, 2004, CANCER RES, V64, P5127, DOI 10.1158/0008-5472.CAN-04-0559; Fabbro D, 2000, ANTI-CANCER DRUG DES, V15, P17; Hallek M, 1996, BRIT J HAEMATOL, V94, P5, DOI 10.1046/j.1365-2141.1996.6102053.x; Heinrich MC, 2002, HUM PATHOL, V33, P484, DOI 10.1053/hupa.2002.124124; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; HERBST R, 1995, BIOCHEMISTRY-US, V34, P5971, DOI 10.1021/bi00017a026; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; Medeiros F, 2004, AM J SURG PATHOL, V28, P889, DOI 10.1097/00000478-200407000-00007; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; Otto KG, 2001, BLOOD, V97, P3662, DOI 10.1182/blood.V97.11.3662; Rubin BP, 2001, CANCER RES, V61, P8118; Saucier C, 2002, ONCOGENE, V21, P1800, DOI 10.1038/sj.onc.1205261; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378	22	48	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2007	26	44					6386	6395		10.1038/sj.onc.1210464	http://dx.doi.org/10.1038/sj.onc.1210464			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452978				2022-12-17	WOS:000249737600003
J	Whitwam, T; VanBrocklin, MW; Russo, ME; Haak, PT; Bilgili, D; Resau, JH; Koo, HM; Holmen, SL				Whitwam, T.; VanBrocklin, M. W.; Russo, M. E.; Haak, P. T.; Bilgili, D.; Resau, J. H.; Koo, H-M; Holmen, S. L.			Differential oncogenic potential of activated RAS isoforms in melanocytes	ONCOGENE			English	Article						RAS; MYC; melanocytes; transformation	C-MYC; H-RAS; N-RAS; TUMOR SUPPRESSION; GENE-EXPRESSION; INK4A LOCUS; K-RAS; MELANOMA; PHOSPHORYLATION; GROWTH	RAS genes are mutated in approximately 30% of all human cancers. Interestingly, there exists a strong bias in favor of mutation of only one of the three major RAS genes in tumors of different cellular origins. NRAS mutations occur in approximately 20% of human melanomas, whereas HRAS and KRAS mutations are rare in this disease. To de. ne the mechanism(s) responsible for this preference in melanocytes, we compared the transformation efficiencies of mutant NRAS and KRAS in immortal, non-transformed Ink4a/Arf-deficient melanocytes. NRAS mutation leads to increased cellular proliferation and is potently tumorigenic. In contrast, KRAS mutation does not enhance melanocyte proliferation and is only weakly tumorigenic on its own. Although both NRAS and KRAS activate mitogen-activated protein kinase signaling, only NRAS enhances MYC activity in these cells. Our data suggest that the activity of specific RAS isoforms is context-dependent and provide a possible explanation for the prevalence of NRAS mutations in melanoma. In addition, understanding this mechanism will have important implications for cancer therapies targeting RAS pathways.	Van Andel Res Inst, Mol Med & Virol Grp, Grand Rapids, MI USA; Van Andel Res Inst, Lab Pharmacogenet, Grand Rapids, MI USA; Van Andel Res Inst, Lab Microarray, Grand Rapids, MI USA; No Illinois Univ, Dept Math Sci, De Kalb, IL 60115 USA	Van Andel Institute; Van Andel Institute; Van Andel Institute; Northern Illinois University	Holmen, SL (corresponding author), Nevada Canc Inst, Translat Res Div, 10441 W Twain Ave, Las Vegas, NV 89135 USA.	sholmen@nvcancer.org						Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; AROCA P, 1993, J BIOL CHEM, V268, P25650; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Goel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Holmen SL, 2005, CANCER RES, V65, P8250, DOI 10.1158/0008-5472.CAN-05-1173; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kim K, 2002, CANCER RES, V62, P1241; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MAHER J, 1995, ONCOGENE, V11, P1639; Prior IA, 2001, J CELL SCI, V114, P1603; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sviderskaya EV, 2002, JNCI-J NATL CANCER I, V94, P446; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	31	48	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4563	4570		10.1038/sj.onc.1210239	http://dx.doi.org/10.1038/sj.onc.1210239			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17297468				2022-12-17	WOS:000247836100010
J	Nagai, H; Sugito, N; Matsubara, H; Tatematsu, Y; Hida, T; Sekido, Y; Nagino, M; Nimura, Y; Takahashi, T; Osada, H				Nagai, H.; Sugito, N.; Matsubara, H.; Tatematsu, Y.; Hida, T.; Sekido, Y.; Nagino, M.; Nimura, Y.; Takahashi, T.; Osada, H.			CLCP1 interacts with semaphorin 4B and regulates motility of lung cancer cells	ONCOGENE			English	Article						CLCP1; SEMA4B; lung cancer	POSTSYNAPTIC DENSITY PROTEIN; SUPPRESSES TUMOR-FORMATION; LINE NCI-H460-LNM35; ENDOCYTOSIS; METASTASIS; GENE	We previously established a highly metastatic subline, LNM35, from the NCI-H460 lung cancer cell line, and demonstrated upregulation of a novel gene, CLCP1 ( CUB, LCCL-homology, coagulation factor V/VIII homology domains protein), in LNM35 and lung cancer specimens. In this study, we focused on the potential roles of that gene in cancer metastasis. First, we established stable LNM35 RNAi clones, in which CLCP1 expression was suppressed by RNAi, and found that their motility was significantly reduced, although growth rates were not changed. Next, in vitro selection of a phage display library demonstrated that a phage clone displaying a peptide similar to a sequence within the Sema domain of semaphorin 4B ( SEMA4B) interacted with LNM35. Immunoprecipitation experiments confirmed interaction of CLCP1 with SEMA4B, regulation of CLCP1 protein by ubiquitination and proteasome degradation enhanced in the presence of SEMA4B. These results are the first to indicate that CLCP1 plays a role in cell motility, whereas they also showed that at least one of its ligands is SEMA4B and that their interaction mediates proteasome degradation by CLCP1. Although the physiological role of the interaction between CLCP1 and SEMA4B remains to be investigated, this novel gene may become a target of therapy to inhibit metastasis of lung cancers.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya Univ, Div Mol Carcinogenesis, Ctr Neurol Dis & Canc, Grad Sch Med, Nagoya, Aichi, Japan; Nagoya Univ, Div Surg Oncol, Dept Surg, Grad Sch Med, Nagoya, Aichi, Japan; Aichi Canc Ctr Hosp, Dept Pulm Med, Nagoya, Aichi 464, Japan	Aichi Cancer Center; Nagoya University; Nagoya University; Aichi Cancer Center	Osada, H (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	hosada@aichi-cc.jp	Nagino, Masato/I-7342-2014; Sekido, Yoshitaka/P-9756-2015; Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001; Sekido, Yoshitaka/0000-0002-2428-3848				Bachelder RE, 2003, CANCER RES, V63, P5230; Burkhardt C, 2005, FEBS LETT, V579, P3821, DOI 10.1016/j.febslet.2005.05.079; Castellani V, 2004, MOL CELL NEUROSCI, V26, P89, DOI 10.1016/j.mcn.2004.01.010; Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101; Conrotto P, 2005, BLOOD, V105, P4321, DOI 10.1182/blood-2004-07-2885; Fournier AE, 2000, J CELL BIOL, V149, P411, DOI 10.1083/jcb.149.2.411; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Herold C, 1996, J IMMUNOL, V157, P5262; Inagaki S, 2001, J BIOL CHEM, V276, P9174, DOI 10.1074/jbc.M009051200; Kobuke K, 2001, J BIOL CHEM, V276, P34105, DOI 10.1074/jbc.M105293200; Koshikawa K, 2002, ONCOGENE, V21, P2822, DOI 10.1038/sj.onc.1205405; Kozaki K, 2000, CANCER RES, V60, P2535; Kozaki K, 2001, ONCOGENE, V20, P4228, DOI 10.1038/sj.onc.1204561; Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740; Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545; Osada H, 2004, INT J CANCER, V112, P26, DOI 10.1002/ijc.20395; Tse C, 2002, CANCER RES, V62, P542; Xiang RH, 2002, CANCER RES, V62, P2637; Yanagisawa K, 2000, ONCOGENE, V19, P2305, DOI 10.1038/sj.onc.1203591	19	48	52	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					4025	4031		10.1038/sj.onc.1210183	http://dx.doi.org/10.1038/sj.onc.1210183			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213806				2022-12-17	WOS:000247144500013
J	Takahashi, K; Akiyama, H; Shimazaki, K; Uchida, C; Akiyama-Okunuki, H; Tomita, M; Fukumoto, M; Uchida, T				Takahashi, K.; Akiyama, H.; Shimazaki, K.; Uchida, C.; Akiyama-Okunuki, H.; Tomita, M.; Fukumoto, M.; Uchida, T.			Ablation of a peptidyl prolyl isomerase Pin1 from p53-null mice accelerated thymic hyperplasia by increasing the level of the intracellular form of Notch1	ONCOGENE			English	Article						p53; Notch1; presenilin-1; thymocytes; hyperplasia	CELL-CYCLE; RETINOBLASTOMA PROTEIN; X-CHROMOSOME; P53 PROTEIN; DNA-DAMAGE; GROWTH; APOPTOSIS; GENE; PRESENILIN-1; EXPRESSION	Tumor suppressor p53 is essential for checkpoint control in response to a variety of genotoxics tresses. DNA damage leads to phosphorylation on the Ser/Thr-Pro motifs of p53, which facilitates interaction with Pin1, a pSer/pThr-Prospeci. c peptidyl prolyl isomerase. Pin1 is required for the timely activation of p53, resulting in apoptosis or cell cycle arrest. To investigate the physiological relationship between Pin1 and p53, we created Pin1-/-p53-/-mice. These p53-deficient mice spontaneously developed lymphomas, mainly of thymic origin, as well as generalized lymphoma infiltration into other organs, including the liver, kidneys and lungs. Ablation of Pin1, in addition to p53, accelerated the thymichy perplasia, but the thymocytes in these Pin1-/-p53-/- mice did not infiltrate other organs. The thymocytes in 12-week-old Pin1-/-p53-/- mic e were CD4(-)CD8(-) (double negative) and had significantly higher levels of the intracellular form of Notch1 (NIC) than the thymocytes of p53-/- or wild- type mice. Presenilin-1, a cleavage enzyme for NIC generation from full-length Notch1 was increased in the thymocytes of Pin1-/-p53-/- mice. Pin1 depletion also inhibited the degradation of NIC by proteasomes. These results suggest that both Pin1 and p53 control the normal proliferation and differentiation of thymocytes by regulating the NIC level.	Tohoku Univ, Grad Sch Agr Sci, Sendai, Miyagi 9818555, Japan; Tohoku Univ, Ctr Interdisciplinary Res, Sendai, Miyagi 9818555, Japan; Tohoku Univ, Inst Dev Aging & Canc, Sendai, Miyagi 9818555, Japan; Showa Univ, Sch Pharmaceut Sci, Tokyo 142, Japan; Ibaraki Univ, Univ Hlth Ctr, Mito, Ibaraki 310, Japan	Tohoku University; Tohoku University; Tohoku University; Showa University; Ibaraki University	Uchida, T (corresponding author), Tohoku Univ, Grad Sch Agr Sci, 1-1 Amamiya, Sendai, Miyagi 9818555, Japan.	uchidat@biochem.tohoku.ac.jp		Uchida, Takafumi/0000-0003-3665-4906				Akiyama H, 2005, BIOCHEM BIOPH RES CO, V336, P521, DOI 10.1016/j.bbrc.2005.08.130; Amson R, 2000, P NATL ACAD SCI USA, V97, P5346, DOI 10.1073/pnas.97.10.5346; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Beverly LJ, 2005, CANCER RES, V65, P7159, DOI 10.1158/0008-5472.CAN-05-1664; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fowlkes BJ, 2002, J IMMUNOL, V169, P1817, DOI 10.4049/jimmunol.169.4.1817; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; HAAPAJARVI T, 1995, ONCOGENE, V11, P151; Hasserjian RP, 1996, BLOOD, V88, P970, DOI 10.1182/blood.V88.3.970.bloodjournal883970; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jehn BM, 1999, J IMMUNOL, V162, P635; Katsuda K, 2002, ONCOGENE, V21, P2108, DOI 10.1038/sj.onc.1205272; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lai EC, 2002, CURR BIOL, V12, pR200, DOI 10.1016/S0960-9822(02)00749-2; Laws AM, 2004, EUR J IMMUNOL, V34, P726, DOI 10.1002/eji.200324772; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Lu KP, 1996, NATURE, V380, P544; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Maillard I, 2003, IMMUNITY, V19, P781, DOI 10.1016/S1074-7613(03)00325-X; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P8917, DOI 10.1128/MCB.24.20.8917-8928.2004; Nakase H, 1996, STROKE, V27, P720, DOI 10.1161/01.STR.27.4.720; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Pastorcic M, 2000, J BIOL CHEM, V275, P34938, DOI 10.1074/jbc.M005411200; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; PURDIE CA, 1994, ONCOGENE, V9, P603; Radtke F, 2004, NAT IMMUNOL, V5, P247, DOI 10.1038/ni1045; RASTAN S, 1994, CURR OPIN GENET DEV, V4, P292, DOI 10.1016/S0959-437X(05)80056-5; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; ROGEL A, 1988, BIOCHIM BIOPHYS ACTA, V950, P395; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shaw PE, 2002, EMBO REP, V3, P521, DOI 10.1093/embo-reports/kvf118; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; TAKAGI N, 1974, EXP CELL RES, V86, P127, DOI 10.1016/0014-4827(74)90657-0; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wahl GM, 2002, NAT CELL BIOL, V4, P328; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116	59	48	49	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3835	3845		10.1038/sj.onc.1210153	http://dx.doi.org/10.1038/sj.onc.1210153			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17160015				2022-12-17	WOS:000247026400007
J	Shepard, CR; Kassis, J; Whaley, DL; Kim, HG; Wells, A				Shepard, C. R.; Kassis, J.; Whaley, D. L.; Kim, H. G.; Wells, A.			PLC gamma contributes to metastasis of in situ-occurring mammary and prostate tumors	ONCOGENE			English	Article						phospholipase C-gamma; tumor dissemination; lung metastases; breast carcinoma; polyoma middle T antigen; TRAMP mouse	EPIDERMAL-GROWTH-FACTOR; PHOSPHOLIPASE C-GAMMA; CANCER CELL-MIGRATION; FACTOR RECEPTOR; EGF RECEPTOR; MOTILITY; INVASION; KINASE; CARCINOMA; PROTEIN	Phospholipase C-gamma ( PLC gamma) has been implicated in tumor cell motility required for invasiveness and metastasis. Diminished tumor dissemination has been demonstrated in xenograft models, but studies in naturally-occurring tumors are lacking, having been limited by the timing of the interventions. Therefore, we generated mice that express a doxycycline ( DOX)-inducible dominant-negative fragment of PLC gamma, PLCz; this approach avoids the in utero lethality caused by the absence of PLC gamma. As we targeted two de novo-occurring carcinomas of the mammary ( MMTV-driven polyoma middle T antigen model, PyVmT) and prostate ( TRAMP model) glands, we limited expression to these epithelial cells by driving DOX transactivator from the prostatein C3 promoter. This avoids the confounding variable of potentially abrogating motility in stromal and endothelial cells. These mice developed normally in the presence of DOX, except for limited mammary development if treated before 6 weeks and immaturity of the prostate gland if treated before 2 weeks of age. DOX-mediated induction of PLCz from age 8 to 16 weeks in PyVmT mice decreased the number of lung metastases by > 10-fold ( P < 0.06) without a detectable effect on in situ tumor cell proliferation or tumor size. Lung metastases were also significantly decreased in the TRAMP model in which the mice expressed the PLCz fragment ( P < 0.05). DOX treatment itself had no effect on tumor size or metastasis in control mice, nor did it affect tumor dissemination in nontransgenic littermates. In conclusion, abrogation of the PLC gamma signaling pathway can limit the metastatic potential of carcinomas.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Vet Affairs Med Ctr, Dept Pathol, Pittsburgh, PA USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Alabama System; University of Alabama Birmingham	Wells, A (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, 3550 Terrace St,Scaife Hall,S-713, Pittsburgh, PA 15261 USA.	wellsa@upmc.edu		Wells, Alan/0000-0002-1637-8150				Bodnar RJ, 2006, CIRC RES, V98, P617, DOI 10.1161/01.RES.0000209968.66606.10; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; Dittmar T, 2002, FASEB J, V16, P1823, DOI 10.1096/fj.02-0096fje; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Gingrich JR, 1996, CANCER RES, V56, P4096; Gingrich JR, 1997, CANCER RES, V57, P4687; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; HOMMA Y, 1992, J BIOL CHEM, V267, P21844; Iwabu A, 2004, J BIOL CHEM, V279, P14551, DOI 10.1074/jbc.M311981200; JAKOBSSON PA, 1973, ACTA RADIOL THER PHY, V12, P1; Ji GS, 1998, MOL BIOL CELL, V9, P749, DOI 10.1091/mbc.9.4.749; Jones NP, 2005, J CELL SCI, V118, P2695, DOI 10.1242/jcs.02374; Kassis J, 1999, CLIN CANCER RES, V5, P2251; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Mouneimne G, 2004, J CELL BIOL, V166, P697, DOI 10.1083/jcb.200405156; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Price JT, 1999, CANCER RES, V59, P5475; Reddy CC, 1996, J CELL PHYSIOL, V166, P512, DOI 10.1002/(SICI)1097-4652(199603)166:3<512::AID-JCP6>3.0.CO;2-S; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Tehranian A, 1996, AM J PATHOL, V149, P1177; Thomas Sufi Mary, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P542; Turner T, 1997, CLIN CANCER RES, V3, P2275; Wang WG, 2005, TRENDS CELL BIOL, V15, P138, DOI 10.1016/j.tcb.2005.01.003; Webster MA, 1998, ONCOGENE, V16, P1963, DOI 10.1038/sj.onc.1201707; Wells A, 2000, ADV CANCER RES, V78, P31; Wells A, 2002, ACTA ONCOL, V41, P124, DOI 10.1080/028418602753669481; XIE H, 1995, CLIN EXP METASTAS, V13, P407, DOI 10.1007/BF00118180	38	48	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2007	26	21					3020	3026		10.1038/sj.onc.1210115	http://dx.doi.org/10.1038/sj.onc.1210115			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17130835				2022-12-17	WOS:000246395400007
J	Adam, SJ; Rund, LA; Kuzmuk, KN; Zachary, JF; Schook, LB; Counter, CM				Adam, S. J.; Rund, L. A.; Kuzmuk, K. N.; Zachary, J. F.; Schook, L. B.; Counter, C. M.			Genetic induction of tumorigenesis in Swine	ONCOGENE			English	Article						porcine; cancer; model	CUTANEOUS MELANOMAS; RAS ONCOGENESIS; HUMAN CANCER; TUMOR-CELLS; IN-VIVO; TELOMERASE; TRANSFORMATION; MODELS; GROWTH; REQUIREMENTS	The transition from basic to clinical cancer research for a number of experimental therapeutics is hampered by the lack of a genetically malleable, large animal model. To this end, we genetically engineered primary porcine cells to be tumorigenic by expression of proteins known to perturb pathways commonly corrupted in human cancer. Akin to human cells, these porcine cells were quite resistant to transformation, requiring multiple genetic changes. Moreover, the transformed porcine cells produced tumors when returned to the isogenic host animal. The ability to now rapidly and reproducibly genetically induce tumors of sizes similar to those treated clinically in a large mammal similar to humans in many respects will provide a robust cancer model for preclinical studies dependant on generating large tumors.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Dept Radiat Oncol, Durham, NC 27710 USA; Univ Illinois, Dept Anim Sci, Chicago, IL 60680 USA; Univ Illinois, Inst Genom Biol, Chicago, IL 60680 USA; Univ Illinois, Coll Vet Med, Dept Pathobiol, Urbana, IL 61801 USA	Duke University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Urbana-Champaign	Counter, CM (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Dept Radiat Oncol, 3813,LSRC Bldg,Room C225,Res Dr, Durham, NC 27710 USA.	schook@uiuc.edu; count004@mc.duke.edu		rund, laurie/0000-0003-0761-7196; Schook, Lawrence/0000-0002-6580-8364; Counter, Christopher M/0000-0003-0748-3079	NATIONAL CANCER INSTITUTE [R01CA094184] Funding Source: NIH RePORTER; NCI NIH HHS [CA94184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON LJ, 1968, CANCER, V22, P398, DOI 10.1002/1097-0142(196808)22:2<398::AID-CNCR2820220218>3.0.CO;2-2; Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; BOS JL, 1989, CANCER RES, V49, P4682; BROWN DG, 1970, J AM VET MED ASSOC, V157, P1914; Chudnovsky Y, 2005, NAT GENET, V37, P745, DOI 10.1038/ng1586; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; DEWHIRST MD, 2000, TUMOR MODELS CANC RE, P565; FIEBIG HH, 2000, TUMOR MODELS CANC RE, P113; Goessel G, 2005, P NATL ACAD SCI USA, V102, P15599, DOI 10.1073/pnas.0409730102; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Kendall SD, 2006, CELL CYCLE, V5, P1074, DOI 10.4161/cc.5.10.2734; Kendall SD, 2005, CANCER RES, V65, P9824, DOI 10.1158/0008-5472.CAN-05-1543; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lim KH, 2004, MOL CELL, V15, P491, DOI 10.1016/j.molcel.2004.08.014; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; O'Hayer KM, 2006, METHOD ENZYMOL, V407, P637, DOI 10.1016/S0076-6879(05)07050-3; OXENHANDLER RW, 1982, AM J PATHOL, V109, P259; Pathak S, 2000, INT J ONCOL, V17, P1219; Perez J, 2002, VET PATHOL, V39, P445, DOI 10.1354/vp.39-4-445; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Shay JW, 2002, CANCER CELL, V2, P257, DOI 10.1016/S1535-6108(02)00159-9; Stewart SA, 2000, SEMIN CANCER BIOL, V10, P399, DOI 10.1006/scbi.2000.0339; Swanson KS, 2004, EXP BIOL MED, V229, P866, DOI 10.1177/153537020422900902; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9; Vincent-Naulleau S, 2004, PIGM CELL RES, V17, P24, DOI 10.1046/j.1600-0749.2003.00101.x; WARGOVICH MJ, 1991, J COMP PATHOL, V105, P271, DOI 10.1016/S0021-9975(08)80195-8; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Xie W, 2002, DRUG DISCOV TODAY, V7, P509, DOI 10.1016/S1359-6446(02)02251-1; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110	31	48	49	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					1038	1045		10.1038/sj.onc.1209892	http://dx.doi.org/10.1038/sj.onc.1209892			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16964292				2022-12-17	WOS:000244245400010
J	Eguchi, T; Takaki, T; Itadani, H; Kotani, H				Eguchi, T.; Takaki, T.; Itadani, H.; Kotani, H.			RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene	ONCOGENE			English	Article						ECT2; RB; cytokinesis; DNA damage	CELL-CYCLE PROGRESSION; EXCHANGE FACTOR ECT2; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; E2F; RHO; CYTOKINESIS; FAMILY; GENE; REPLICATION	As alterations in retinoblastoma (RB)/E2F pathway are commonly found in human cancers, the molecular mechanism underlying cell cycle deregulation caused by the mutations in the RB/E2F pathway needs to be investigated extensively. Compared with good understanding of RB/E2F functions in G1-S cell cycle progression, it is not fully understood how an abrogated RB pathway affects the G2-M phase of the cell cycle. Here, we report that disruption of RB accelerated G2-M progression in the presence of DNA damage by elevating the expression of a set of mitotic regulatory genes. We generated RB(+)- and (-)-matched cells using short hairpin RNA. In the RB(-) cells, the G2/M checkpoint mediated by a DNA-damaging agent was over-ridden. With microarray analysis, we found that the expression of key G2-M regulatory genes was upregulated in RB(-) cells. In particular, we demonstrated that the proto-oncogene ECT2 was directly regulated by E2Fs. Furthermore, suppression of ECT2 expression by small interfering RNA in RB(-) cells resulted in cytokinesis arrest, suggesting that RB(-) cells lack the regulation of E2F-mediated cytokinesis. These results indicate that aberrant ECT2 expression, observed in various human tumors, could be the direct result of RB/E2F pathway deficiency, thereby contributing to cell division in cancers.	Merck Res Lab, Banyu Tsukuba Res Inst, Funct Genom, Tsukuba, Ibaraki 3002611, Japan	Merck & Company	Kotani, H (corresponding author), Merck Res Lab, Banyu Tsukuba Res Inst, Funct Genom, Tsukuba, Ibaraki 3002611, Japan.	hidehito_kotani@merck.com						Black EP, 2003, CANCER RES, V63, P3716; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Clemens F, 2005, TOXICOL APPL PHARM, V206, P138, DOI 10.1016/j.taap.2005.02.009; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hill E, 2000, EMBO J, V19, P5711, DOI 10.1093/emboj/19.21.5711; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jiang YY, 2004, J BIOL CHEM, V279, P40511, DOI 10.1074/jbc.M404496200; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Mayhew CN, 2005, CANCER RES, V65, P4568, DOI 10.1158/0008-5472.CAN-04-4221; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Namba R, 2004, MOL CANCER RES, V2, P453; Polager S, 2003, J BIOL CHEM, V278, P1443, DOI 10.1074/jbc.M210327200; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Saito S, 2004, J BIOL CHEM, V279, P7169, DOI 10.1074/jbc.M306725200; Saito S, 2003, J CELL BIOCHEM, V90, P819, DOI 10.1002/jcb.10688; Sakata H, 2000, HEPATOLOGY, V32, P193, DOI 10.1053/jhep.2000.8271; SCHULZE A, 1994, ONCOGENE, V9, P3475; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Wang JYJ, 2001, ACTA ONCOL, V40, P689; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yen CC, 2005, WORLD J GASTROENTERO, V11, P1267, DOI 10.3748/wjg.v11.i9.1267; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804	41	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					509	520		10.1038/sj.onc.1209810	http://dx.doi.org/10.1038/sj.onc.1209810			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862181				2022-12-17	WOS:000243731600004
J	Rosner, M; Freilinger, A; Hengstschlager, M				Rosner, M.; Freilinger, A.; Hengstschlaeger, M.			Akt regulates nuclear/cytoplasmic localization of tuberin	ONCOGENE			English	Article						TSC2; tuberin; Akt; S6K; cell cycle	SCLEROSIS GENE-2 PRODUCT; TUMOR-SUPPRESSOR COMPLEX; MAMMALIAN TARGET; PHOSPHORYLATION; TSC2; RAPAMYCIN; PROTEIN; GROWTH; P27(KIP1); HAMARTIN	The autosomal dominantly inherited disease tuberous sclerosis (TSC) affects similar to 1 in 6000 individuals and is characterized by the development of tumors, named hamartomas, in different organs. TSC1, encoding hamartin, and TSC2, encoding tuberin are tumor suppressor genes responsible for TSC. Hamartin and tuberin form a complex, of which tuberin is assumed to be the functional component. The TSC proteins have been implicated in the control of cell cycle by activating the cyclin-dependent kinase inhibitor p27 and in cell size regulation by inhibiting the mammalian target of rapamycin (mTOR)/p70S6K cascade. Phosphorylation of S939 and T1462 by Akt downregulates tuberin's potential to inhibit mTOR/ p70S6K. Here, we show that this tuberin phosphorylation by Akt does not affect tuberin-mediated control of p27 protein amounts. This demonstrates that regulating p27 protein amounts and mTOR/p7OS6K are separable functions of tuberin. Furthermore, we found that phosphorylation by Akt triggers upregulation of cytoplasmic and downregulation of nuclear tuberin. In cycling cells with high Akt activity, tuberin is predominantly localized to the cytoplasm. In arrested GO cells with downregulated Akt activity, a significant proportion of tuberin is localized to the nucleus. Upon re-entry into the normal ongoing cell cycle, nuclear localization of tuberin is downregulated parallel to the activation of Akt. Recently, the mTOR/p7OS6K cascade has been demonstrated to exist in both the cytoplasm and nucleus. We here also found that tuberin harbors the potential to regulate p70S6K activity in both the cytoplasm and nucleus. This description of functional tuberin in the cytoplasm and the nucleus together with our observation of Akt-controlled and cell cycle-regulated tuberin localization are of particular interest for a further understanding of tuberin's function as a gate keeper of the GO cell status as well as of Akt's activity to control cell proliferation.	Med Univ Vienna, A-1090 Vienna, Austria	Medical University of Vienna	Hengstschlager, M (corresponding author), Med Univ Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	markus.hengstschlaeger@meduniwien.ac.at						Astrinidis A, 2005, ONCOGENE, V24, P7475, DOI 10.1038/sj.onc.1209090; Astrinidis A, 2006, HUM MOL GENET, V15, P287, DOI 10.1093/hmg/ddi444; Bachmann RA, 2006, J BIOL CHEM, V281, P7357, DOI 10.1074/jbc.M512218200; Chong-Kopera H, 2006, J BIOL CHEM, V281, P8313, DOI 10.1074/jbc.C500451200; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Dostie J, 2000, J CELL BIOL, V148, P239, DOI 10.1083/jcb.148.2.239; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Furuya F, 2006, P NATL ACAD SCI USA, V103, P1780, DOI 10.1073/pnas.0510849103; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu H, 2006, P NATL ACAD SCI USA, V103, P4134, DOI 10.1073/pnas.0511342103; Lou Dingyuan, 2001, Molecular Cell Biology Research Communications, V4, P374, DOI 10.1006/mcbr.2001.0307; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; Pan DJ, 2004, TRENDS CELL BIOL, V14, P78, DOI 10.1016/j.tcb.2003.12.006; Pasumarthi KBS, 2000, CIRC RES, V86, P1069, DOI 10.1161/01.RES.86.10.1069; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Rosner M, 2004, J BIOL CHEM, V279, P48707, DOI 10.1074/jbc.M405528200; Rosner M, 2004, AMINO ACIDS, V27, P119, DOI 10.1007/s00726-004-0119-z; Rosner M, 2003, ONCOGENE, V22, P4786, DOI 10.1038/sj.onc.1206776; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Soucek T, 1998, ONCOGENE, V16, P2197, DOI 10.1038/sj.onc.1201743; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wienecke R, 1996, ONCOGENE, V13, P913; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Zhang XW, 2002, J BIOL CHEM, V277, P28127, DOI 10.1074/jbc.M202625200	43	48	48	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					521	531		10.1038/sj.onc.1209812	http://dx.doi.org/10.1038/sj.onc.1209812			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862180				2022-12-17	WOS:000243731600005
J	Maeda, M; Johnson, E; Mandal, SH; Lawson, KR; Keim, SA; Svoboda, RA; Caplan, S; Wahl, JK; Wheelock, MJ; Johnson, KR				Maeda, M.; Johnson, E.; Mandal, S. H.; Lawson, K. R.; Keim, S. A.; Svoboda, R. A.; Caplan, S.; Wahl, J. K., III; Wheelock, M. J.; Johnson, K. R.			Expression of inappropriate cadherins by epithelial tumor cells promotes endocytosis and degradation of E-cadherin via competition for p120(ctn)	ONCOGENE			English	Article						cadherin; endocytosis; p120(ctn)	MICROVASCULAR ENDOTHELIAL-CELLS; SQUAMOUS CARCINOMA-CELLS; N-CADHERIN; MESENCHYMAL TRANSITIONS; DOWN-REGULATION; CANCER CELLS; ADHERENS JUNCTIONS; PLASMA-MEMBRANE; P120 CATENIN; VE-CADHERIN	Cadherin cell-cell adhesion proteins play an important role in modulating the behavior of tumor cells. E-cadherin serves as a suppressor of tumor cell invasion, and when tumor cells turn on the expression of a non-epithelial cadherin, they often express less E-cadherin, enhancing the tumorigenic phenotype of the cells. Here, we show that when A431 cells are forced to express R-cadherin, they dramatically downregulate the expression of endogenous E- and P-cadherin. In addition, we show that this downregulation is owing to increased turnover of the endogenous cadherins via clathrin-dependent endocytosis. p120(ctn) binds to the juxtamembrane domain of classical cadherins and has been proposed to regulate cadherin adhesive activity. One way p120(ctn) may accomplish this is to serve as a rheostat to regulate the levels of cadherin. Here, we show that the degradation of E-cadherin in response to expression of R-cadherin is owing to competition for p120(ctn).	Univ Nebraska, Med Ctr, Dept Oral Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Canc Ctr, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Wheelock, MJ (corresponding author), Univ Nebraska, Med Ctr, Dept Oral Biol, 987696 Nebraska Med Ctr, Omaha, NE 68198 USA.	mwheelock@unmc.edu		Keim, Sarah/0000-0002-7965-9267	NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051188] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA09746, P30-CA36727] Funding Source: Medline; NCRR NIH HHS [P20-RR018759] Funding Source: Medline; NIDCR NIH HHS [R01-DE12308] Funding Source: Medline; NIGMS NIH HHS [R01-GM51188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhtar N, 2001, MOL BIOL CELL, V12, P847, DOI 10.1091/mbc.12.4.847; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; Bussemakers MJG, 2000, INT J CANCER, V85, P446, DOI 10.1002/(SICI)1097-0215(20000201)85:3<446::AID-IJC23>3.3.CO;2-2; D'Souza-Schorey C, 2005, TRENDS CELL BIOL, V15, P19, DOI 10.1016/j.tcb.2004.11.002; Dahl U, 2002, MOL CELL BIOL, V22, P1474, DOI 10.1128/MCB.22.5.1474-1487.2002; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Giroldi Laurence A., 2000, Morphologie, V84, P31; Grignani F, 1998, CANCER RES, V58, P14; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Islam S, 2000, J CELL BIOCHEM, V78, P141, DOI 10.1002/(SICI)1097-4644(20000701)78:1<141::AID-JCB13>3.0.CO;2-R; Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643; Johnson E, 2004, J BIOL CHEM, V279, P31041, DOI 10.1074/jbc.M400024200; JOHNSON KR, 1993, EXP CELL RES, V207, P252, DOI 10.1006/excr.1993.1191; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; Kowalczyk AP, 2004, CURR OPIN CELL BIOL, V16, P522, DOI 10.1016/j.ceb.2004.07.001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; MATSUNAMI H, 1993, J CELL SCI, V106, P401; Miranda KC, 2003, J BIOL CHEM, V278, P43480, DOI 10.1074/jbc.M305525200; Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Nieman MT, 1999, J CELL SCI, V112, P1621; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; Peifer M, 2003, J CELL BIOL, V163, P437, DOI 10.1083/jcb.200310090; Pishvaian MJ, 1999, CANCER RES, V59, P947; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; SACCO PA, 1995, J BIOL CHEM, V270, P20201, DOI 10.1074/jbc.270.34.20201; SUBTIL A, 1994, J CELL SCI, V107, P3461; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Tomita K, 2000, CANCER RES, V60, P3650; Vernon AE, 2004, CURR BIOL, V14, pR719, DOI 10.1016/j.cub.2004.08.048; Wahl JK, 2003, J BIOL CHEM, V278, P17269, DOI 10.1074/jbc.M211452200; WHEELOCK MJ, 1987, J CELL BIOCHEM, V34, P187, DOI 10.1002/jcb.240340305; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Wheelock MJ, 2001, J MAMMARY GLAND BIOL, V6, P275, DOI 10.1023/A:1011319507155; Xiao KY, 2005, MOL BIOL CELL, V16, P5141, DOI 10.1091/mbc.E05-05-0440; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Xiao KY, 2003, J BIOL CHEM, V278, P19199, DOI 10.1074/jbc.M211746200	48	48	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2006	25	33					4595	4604		10.1038/sj.onc.1209396	http://dx.doi.org/10.1038/sj.onc.1209396			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16786001				2022-12-17	WOS:000239457500009
J	Vogt, M; Butz, K; Dymalla, S; Semzow, J; Hoppe-Seyler, F				Vogt, M.; Butz, K.; Dymalla, S.; Semzow, J.; Hoppe-Seyler, F.			Inhibition of Bax activity is crucial for the antiapoptotic function of the human papillomavirus E6 oncoprotein	ONCOGENE			English	Article						cervical cancer; human papillomavirus; apoptosis	P53-INDEPENDENT APOPTOSIS; HUMAN KERATINOCYTES; DOWN-REGULATION; CANCER-CELLS; E7 PROTEIN; TYPE-18 E6; SENESCENCE; EXPRESSION; GENE; P53	Oncogenic types of human papillomaviruses (HPVs) cause cervical cancer in humans. The antiapoptotic viral E6 gene has been identified as a key factor for maintaining the viability of HPV-positive cancer cells. Although E6 has the potential to modulate many apoptosis regulators, the crucial apoptotic pathway blocked by endogenous E6 in cervical cancer cells remained unknown. Using RNA interference (RNAi), here, we show that targeted inhibition of E6 expression in cervical cancer cells leads to the transcriptional stimulation of the PUMA promoter, in a p53-dependent manner. This is linked to the activation and translocation of Bax to the mitochondrial membrane, cytochrome c release into the cytosol, and activation of caspase-3, in a PUMA-dependent manner. Moreover, inhibition of Bax expression by RNAi efficiently reverts the apoptotic phenotype, which results from inhibition of E6 expression. Thus, interference with the p53/PUMA/Bax cascade is crucial for the antiapoptotic function of the viral E6 oncogene in HPV-positive cancer cells.	Deutsch Krebsforschungszentrum, Arbeitsgrp Mol Therapie Virus Assoz Tumore, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Hoppe-Seyler, F (corresponding author), Deutsch Krebsforschungszentrum, Arbeitsgrp Mol Therapie Virus Assoz Tumore, F065,Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	hoppe-seyler@dkfz.de		Hoppe-Seyler, Felix/0000-0002-1864-300X				Aguilar-Lemarroy A, 2002, ONCOGENE, V21, P165, DOI 10.1038/sj.onc.1204979; Baldus SE, 2005, ONCOGENE, V24, P810, DOI 10.1038/sj.onc.1208235; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DeFilippis RA, 2003, J VIROL, V77, P1551, DOI 10.1128/JVI.77.2.1551-1563.2003; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Filippova M, 2004, J BIOL CHEM, V279, P25729, DOI 10.1074/jbc.M401172200; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Gu J, 2004, ONCOGENE, V23, P1300, DOI 10.1038/sj.onc.1207239; Hall AHS, 2003, J VIROL, V77, P6066, DOI 10.1128/JVI.77.10.6066-6069.2003; Hengstermann A, 2005, J VIROL, V79, P9296, DOI 10.1128/JVI.79.14.9296-9300.2005; Horner SM, 2004, J VIROL, V78, P4063, DOI 10.1128/JVI.78.8.4063-4073.2004; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kelley ML, 2005, J VIROL, V79, P3737, DOI 10.1128/JVI.79.6.3737-3747.2005; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kong XT, 2001, J BIOL CHEM, V276, P32990, DOI 10.1074/jbc.M103681200; Liu J, 2004, VIROLOGY, V318, P169, DOI 10.1016/j.virol.2003.09.012; Magal SS, 2005, J GEN VIROL, V86, P611, DOI 10.1099/vir.0.80453-0; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Psyrri A, 2004, CANCER RES, V64, P3079, DOI 10.1158/0008-5472.CAN-03-3739; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yuan HD, 2005, ONCOGENE, V24, P5069, DOI 10.1038/sj.onc.1208691; Zhang HFM, 2005, MOL CELL BIOL, V25, P6247, DOI 10.1128/MCB.25.14.6247-6258.2005; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	36	48	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4009	4015		10.1038/sj.onc.1209429	http://dx.doi.org/10.1038/sj.onc.1209429			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16462759				2022-12-17	WOS:000238802400001
J	Leduc, C; Claverie, P; Eymin, B; Col, E; Khochbin, S; Brambilla, E; Gazzeri, S				Leduc, C.; Claverie, P.; Eymin, B.; Col, E.; Khochbin, S.; Brambilla, E.; Gazzeri, S.			p14(ARF) promotes RB accumulation through inhibition of its Tip60-dependent acetylation	ONCOGENE			English	Article						p14(ARF); RB; acetylation; Tip60; DNA damage	DEGRADATION; P53; PROTEIN; MDM2; DIFFERENTIATION; PATHWAY; TUMORS; DEATH; TIP60; E2F1	p14(ARF) is a tumour suppressor which plays a critical role in p53-dependent or -independent cell growth control. Several studies have recently provided evidence that p14(ARF) can also interfere either directly or indirectly with some components of the RB signalling pathway to mediate its antiproliferative activity. The aim of this study was to explore the existence of direct relationships between p14(ARF) and RB proteins. We show that p14(ARF) promotes the accumulation of a hypoacetylated RB protein, when it is upregulated in a model of stable-inducible clones or physiologically induced following cell exposure to cytotoxic agents. Looking for the mechanisms involved in this process, we demonstrate that the histone acetyl transferase Tip60 directly interacts with RB and stimulates its degradation by the proteasome through acetylation of its C-terminus. Furthermore, and consistent with p14(ARF)-induced RB accumulation, we provide evidence that p14(ARF) prevents Tip60-mediated RB acetylation, therefore precluding its proteasomal degradation. Overall, our results identify a novel mechanism by which p14(ARF) controls the RB pathway to trigger its antiproliferative function.	Univ Grenoble 1, INSERM, U578,Grp Rech Canc Poumon, Inst Albert Bonniot,Fac Med, F-38706 La Tronche, France; Univ Grenoble 1, INSERM, U309, Inst Albert Bonniot,Lab Biol Mol & Cellulaire Dif, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gazzeri, S (corresponding author), Univ Grenoble 1, INSERM, U578,Grp Rech Canc Poumon, Inst Albert Bonniot,Fac Med, F-38706 La Tronche, France.	sylvie.gazzeri@ujf-grenoble.fr	eymin, beatrice/U-4670-2019; Khochbin, Saadi/M-8090-2013; Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/M-1961-2013; gazzeri, sylvie/U-4669-2019	eymin, beatrice/0000-0002-7311-3810; Khochbin, Saadi/0000-0002-0455-0857; Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Caron C, 2005, BIOESSAYS, V27, P408, DOI 10.1002/bies.20210; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Datta A, 2002, MOL CELL BIOL, V22, P8398, DOI 10.1128/MCB.22.24.8398-8408.2002; Eymin B, 2002, ONCOGENE, V21, P2750, DOI 10.1038/sj.onc.1205359; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Lemercier C, 2003, J BIOL CHEM, V278, P4713, DOI 10.1074/jbc.M211811200; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Mason SL, 2002, ONCOGENE, V21, P4220, DOI 10.1038/sj.onc.1205524; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486	23	48	52	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	30					4147	4154		10.1038/sj.onc.1209446	http://dx.doi.org/10.1038/sj.onc.1209446			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501607				2022-12-17	WOS:000239004800002
J	Machida, T; Fujita, T; Ooo, ML; Ohira, M; Isogai, E; Mihara, M; Hirato, J; Tomotsune, D; Hirata, T; Fujimori, M; Adachi, W; Nakagawara, A				Machida, T; Fujita, T; Ooo, ML; Ohira, M; Isogai, E; Mihara, M; Hirato, J; Tomotsune, D; Hirata, T; Fujimori, M; Adachi, W; Nakagawara, A			Increased expression of proapoptotic BMCC1, a novel gene with the BNIP2 and Cdc42GAP homology (BCH) domain, is associated with favorable prognosis in human neuroblastomas	ONCOGENE			English	Article						BMCC1; neuroblastoma; apoptosis; BNIP2; Cdc42GAP; BCH domain	PROGRAMMED CELL-DEATH; ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; RHO-FAMILY GTPASES; SIGNALING PATHWAY; INDUCED APOPTOSIS; SYMPATHETIC NEURONS; BCL-2 PROTEINS; GENOMIC DNA; JUN KINASE	Differential screening of the genes obtained from cDNA libraries of primary neuroblastomas ( NBLs) between the favorable and unfavorable subsets has identified a novel gene BCH motif-containing molecule at the carboxyl terminal region 1 (BMCC1). Its 350 kDa protein product possessed a Bcl2-/adenovirus E1B nineteen kDa-interacting protein 2 (BNIP2) and Cdc42GAP homology domain in the COOH-terminus in addition to P-loop and a coiled-coil region near the NH2-terminus. High levels of BMCC1 expression were detected in the human nervous system as well as spinal cord, brain and dorsal root ganglion in mouse embryo. The immunohistochemical study revealed that BMCC1 was positively stained in the cytoplasm of favorable NBL cells but not in unfavorable ones with MYCN amplification. The quantitative real-time reverse transcription-PCR using 98 primary NBLs showed that high expression of BMCC1 was a significant indicator of favorable NBL. In primary culture of newborn mice superior cervical ganglion ( SCG) neurons, mBMCC1 expression was downregulated after nerve growth factor (NGF)-induced differentiation, and upregulated during the NGF-depletion-induced apoptosis. Furthermore, the proapoptotic function of BMCC1 was also suggested by increased expression in CHP134 NBL cells undergoing apoptosis after treatment with retinoic acid, and by an enhanced apoptosis after depletion of NGF in the SCG neurons obtained from newborn mice transgenic with BMCC1 in primary culture. Thus, BMCC1 is a new member of prognostic factors for NBL and may play an important role in regulating differentiation, survival and aggressiveness of the tumor cells.	Childrens Canc Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Shinshu Univ, Sch Med, Dept Surg, Matsumoto, Nagano 390, Japan; Gunma Univ, Sch Med, Dept Pathol, Maebashi, Gumma 371, Japan; Hisamitsu Pharmaceut Co Inc, Tokyo, Japan	Shinshu University; Gunma University; Hisamitsu Pharmaceutical Co Ltd	Nakagawara, A (corresponding author), Childrens Canc Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp	Fujimori, Maiko/N-2883-2019					BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Burge CB, 1998, CURR OPIN STRUC BIOL, V8, P346, DOI 10.1016/S0959-440X(98)80069-9; Cahill MA, 1996, ONCOGENE, V13, P2087; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Evans A E, 1976, Natl Cancer Inst Monogr, V44, P49; FAVROT MC, 1993, NEW ENGL J MED, V329, P1965, DOI 10.1056/NEJM199312233292615; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Garnier M, 1997, J NEUROSCI, V17, P4591; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Horton P., 1996, INT C INT SYST MOL B, V4, P109; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kaneko M, 1998, MED PEDIATR ONCOL, V31, P1, DOI 10.1002/(SICI)1096-911X(199807)31:1<1::AID-MPO1>3.0.CO;2-H; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; LEE VM, 1980, NEUROSCIENCE, V5, P2239, DOI 10.1016/0306-4522(80)90140-2; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Low BC, 2000, J BIOL CHEM, V275, P37742, DOI 10.1074/jbc.M004897200; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; Nagai M, 2000, INT J ONCOL, V16, P907; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Nakagawara A, 1998, Hum Cell, V11, P115; Nakamura Y, 1998, BIOCHEM BIOPH RES CO, V243, P722, DOI 10.1006/bbrc.1998.8112; Ohira M, 2003, CANCER LETT, V197, P63, DOI 10.1016/S0304-3835(03)00085-5; Ohira M, 2003, ONCOGENE, V22, P5525, DOI 10.1038/sj.onc.1206853; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OLTVAI ZN, 1993, CELL, V74, P619; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; Solovyev VV, 1999, NUCLEIC ACIDS RES, V27, P248, DOI 10.1093/nar/27.1.248; Subramanian T, 1995, ONCOGENE, V11, P2403; Takihara Y, 1997, DEVELOPMENT, V124, P3673; Tanaka T, 1998, CANCER-AM CANCER SOC, V83, P1626, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1626::AID-CNCR19>3.0.CO;2-Y; Vegeto E, 1999, FASEB J, V13, P793, DOI 10.1096/fasebj.13.8.793; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YUAN JY, 1992, DEVELOPMENT, V116, P309; Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728; Zhang BL, 1999, J BIOL CHEM, V274, P2609, DOI 10.1074/jbc.274.5.2609; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhou YT, 2002, J BIOL CHEM, V277, P7483, DOI 10.1074/jbc.M109459200; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	56	48	55	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1931	1942		10.1038/sj.onc.1209225	http://dx.doi.org/10.1038/sj.onc.1209225			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16288218				2022-12-17	WOS:000236224800010
J	Linggi, B; Cheng, QC; Rao, AR; Carpenter, G				Linggi, B; Cheng, QC; Rao, AR; Carpenter, G			The ErbB-4 s80 intracellular domain is a constitutively active tyrosine kinase	ONCOGENE			English	Article						ErbB-4; tyrosine kinase; growth factor	GROWTH-FACTOR RECEPTOR; NUCLEAR EXPRESSION; CELL CARCINOMA; MAMMARY-GLAND; EGF RECEPTOR; CLEAVAGE; ACTIVATION; DIFFERENTIATION; IDENTIFICATION; ASSOCIATION	The ErbB-4 receptor tyrosine kinase homo- and heterodimerizes following heregulin binding, which provokes increased levels of tyrosine autophosphorylation. Unique to the ErbB family, ErbB-4 is then proteolytically cleaved by alpha- and gamma-secretase to produce an 80 kDa intracellular domain (s80 ICD) fragment. This fragment is found in both the cytoplasm and nucleus of many normal and cancer cells and can interact with transcription factors in the cytoplasm and nucleus. Since the s80 ICD lacks ectodomain sequences known to play a major role in dimerization of ErbB family members, we asked whether the s80 ICD is an active tyrosine kinase. Here, we demonstrate that the s80 ICD is a constitutively active tyrosine kinase and can form homodimers. The s80 ICD is autophosphorylated in cells and can phosphorylate an exogenous substrate in vitro. Also, the s80 ICD can coassociate and dimers are detected by chemical cross-linking. This is the first example of constitutive kinase activation and dimerization totally within the cytoplasmic domain of an ErbB receptor and suggests that the s80 ICD may function to phosphorylate substrates in the cytoplasm or nucleus.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 647 Light Hall, Nashville, TN 37232 USA.	graham.carpenter@vanderbilt.edu			NCI NIH HHS [P30 CA6845, T32 CA009582, CA97456] Funding Source: Medline; NIDDK NIH HHS [P30 DK20593, P30 DK020593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097456, T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aifa S, 2005, EXP CELL RES, V302, P108, DOI 10.1016/j.yexcr.2004.08.032; Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; Bei R, 2004, J PATHOL, V204, P317, DOI 10.1002/path.1642; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; Chattopadhyay A, 1999, J BIOL CHEM, V274, P26091, DOI 10.1074/jbc.274.37.26091; Cheng QC, 2003, J BIOL CHEM, V278, P38421, DOI 10.1074/jbc.M302111200; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Hughes DPM, 2004, CANCER RES, V64, P2047, DOI 10.1158/0008-5472.CAN-03-3096; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Landau M, 2004, STRUCTURE, V12, P2265, DOI 10.1016/j.str.2004.10.006; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Penuel E, 2002, J BIOL CHEM, V277, P28468, DOI 10.1074/jbc.M202510200; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; Srinivasan R, 2000, CANCER RES, V60, P1483; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Vaskovsky A, 2000, J NEUROCHEM, V74, P979, DOI 10.1046/j.1471-4159.2000.0740979.x; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200; Zhu HJ, 2003, GROWTH FACTORS, V21, P15, DOI 10.1080/0897719031000096424	33	48	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					160	163		10.1038/sj.onc.1209003	http://dx.doi.org/10.1038/sj.onc.1209003			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170367				2022-12-17	WOS:000234406400018
J	Hahn, MA; Marsh, DJ				Hahn, MA; Marsh, DJ			Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin	ONCOGENE			English	Article						HRPT2; parafibromin; nuclear localization signal; hyperparathyroidism	EXPORT SIGNAL; PROTEIN; HRPT2; HYPERPARATHYROIDISM; MUTATIONS; EXPRESSION; SEQUENCE; COMPLEX; GENE	Parafibromin is a putative tumor suppressor encoded by HRPT2, mutations in which have been implicated in the familial tumor syndrome hyperparathyroidism jaw tumor syndrome (HPT-JT), and sporadic parathyroid carcinoma. Recently, parafibromin has been shown to be an accessory factor for RNA polymerase II as part of the human Paf1 complex, suggesting, as has been shown for its yeast homologue (Cdc73), that it may have a role as an important regulator of transcription. Parafibromin has also been shown to interact with a histone methyltransferase complex that methylates histone H3 and to inhibit proliferation when overexpressed in mammalian cell lines. Despite these findings, the cellular localization of parafibromin has been controversial, with reports of both nuclear and nucleocytoplasmic localization. We have expressed wild-type and mutant parafibromin tagged with enhanced green fluorescent protein and have identified a functional bipartite nuclear localization signal (NLS) at residues 125-139 (nucleotides 373-417), KRAADEV-LAEAKKPR, that is evolutionarily conserved and critical for the nuclear localization of parafibromin. We have also shown that the C-terminal arm of this bipartite NLS plays the primary role in nuclear localization. In support of these findings, specific HRPT2 mutations identified in HPT-JT or sporadic parathyroid carcinoma predicted to truncate parafibromin upstream of or within this NLS disrupt nuclear localization.	Univ Sydney, Royal N Shore Hosp, Dept Mol Med, Kolling Inst Med Res, Sydney, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Marsh, DJ (corresponding author), Univ Sydney, Royal N Shore Hosp, Dept Mol Med, Kolling Inst Med Res, Sydney, NSW 2065, Australia.	debbie_marsh@med.usyd.edu.au	Marsh, Deborah J/I-1491-2014	Marsh, Deborah J/0000-0001-5899-4931				Betz JL, 2002, MOL GENET GENOMICS, V268, P272, DOI 10.1007/s00438-002-0752-8; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Chen JD, 2003, J INTERN MED, V253, P634, DOI 10.1046/j.1365-2796.2003.01168.x; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Howell VM, 2003, J MED GENET, V40, P657, DOI 10.1136/jmg.40.9.657; Hsi ED, 1996, J CLIN ENDOCR METAB, V81, P1736, DOI 10.1210/jc.81.5.1736; Huang TT, 2001, MOL CELL BIOL, V21, P4737, DOI 10.1128/MCB.21.14.4737-4747.2001; Jans DA, 1997, FEBS LETT, V406, P315, DOI 10.1016/S0014-5793(97)00293-7; Linder B, 2000, J MOL BIOL, V299, P369, DOI 10.1006/jmbi.2000.3766; Porter SE, 2005, EUKARYOT CELL, V4, P209, DOI 10.1128/EC.4.1.209-220.2005; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rozenblatt-Rosen O, 2005, MOL CELL BIOL, V25, P612, DOI 10.1128/MCB.25.2.612-620.2005; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Shattuck TM, 2003, NEW ENGL J MED, V349, P1722, DOI 10.1056/NEJMoa031237; Simonds WF, 2004, J CLIN ENDOCR METAB, V89, P96, DOI 10.1210/jc.2003-030675; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tan MH, 2004, CLIN CANCER RES, V10, P6629, DOI 10.1158/1078-0432.CCR-04-0493; van Koningsbruggen S, 2004, J MED GENET, V41, DOI 10.1136/jmg 2003.012781; Villar JC, 2004, FILTR SEPARAT, V41, P32, DOI 10.1016/S0015-1882(04)00282-4; Woodard GE, 2005, ONCOGENE, V24, P1272, DOI 10.1038/sj.onc.1208274; Zhang L, 2003, CANCER GENE THER, V10, P611, DOI 10.1038/sj.cgt.7700608	23	48	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6241	6248		10.1038/sj.onc.1208778	http://dx.doi.org/10.1038/sj.onc.1208778			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16116486				2022-12-17	WOS:000231877100005
J	Garnis, C; Davies, JJ; Buys, TPH; Tsao, MS; MacAulay, C; Lam, S; Lam, WL				Garnis, C; Davies, JJ; Buys, TPH; Tsao, MS; MacAulay, C; Lam, S; Lam, WL			Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression	ONCOGENE			English	Article						array CGH; TRIO; GDNF; 5p; carcinoma in situ; copy number	COMPARATIVE GENOMIC HYBRIDIZATION; ALLELIC DELETION; CARCINOMAS; EXPRESSION; DNA; GENE; 5-ALPHA-REDUCTASE; AMPLIFICATION; FREQUENT; MARKER	Lung cancer is the most widely diagnosed malignancy in the world. Understanding early-stage disease will give insight into its pathogenesis. Despite the fact that pre-invasive lesions are challenging to isolate, and often yield insufficient DNA for the analysis of multiple loci, genomic pro. ling of such lesions will lead to the discovery of causal genetic alterations, which may be otherwise masked by the gross instability associated with tumors. In this study, we report the identification of multiple early genetic events on chromosome 5p in lung cancer progression. Using a high-resolution 5p-specific genomic array, which contains a tiling path of DNA segments for comparative genomic hybridization, nine novel minimal regions of loss and gain were discovered in bronchial carcinoma in situ (CIS) specimens. Within these regions we identified two candidate genes novel to lung cancer. The 0.27 Mbp region at 5p15.2 contains a single gene, Triple Functional Domain, which we determined to be differentially expressed in tumors. The 0.34 Mbp region at 5p13.2 contains Glial Cell Line-Derived Neurotrophic Factor (GDNF), which is a ligand for the RET oncogene product and is normally expressed during lung development (but absent in adult lung tissue). Our data showed not only that GDNF is overexpressed at the transcript level in squamous non-small-cell lung carcinoma, but also that the GDNF protein is present in early-stage lesions. Reactivation of the fetal lung expressed GDNF in early lesions and its amplification in CIS suggests an early role in tumorigenesis. These results highlight the value of examining the genomes of pre-invasive stages of cancer at tiling resolution.	British Columbia Canc Res Ctr, Vancouver, BC V5Z 3L1, Canada; Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada	British Columbia Cancer Agency; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Garnis, C (corresponding author), British Columbia Canc Res Ctr, 601 W 10th Ave, Vancouver, BC V5Z 3L1, Canada.	cgarnis@bccrc.ca	Tsao, Ming Sound/AFQ-7332-2022; Tsao, Ming-Sound/M-3503-2017; Garnis, Cathie/A-3888-2009; MacAulay, Calum/K-1795-2016	Tsao, Ming Sound/0000-0002-9160-5405; MacAulay, Calum/0000-0003-4440-2792				Balsara BR, 1997, CANCER RES, V57, P2116; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; Burger MJ, 2002, INT J CANCER, V100, P228, DOI 10.1002/ijc.10468; Chi B, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-13; Coe BR, 2005, GENE CHROMOSOME CANC, V42, P308, DOI 10.1002/gcc.20137; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Fromont-Hankard G, 2002, ARCH PATHOL LAB MED, V126, P432; Garnis C, 2003, CANCER RES, V63, P8582; Garnis C, 2004, GENE CHROMOSOME CANC, V39, P93, DOI 10.1002/gcc.10294; Garnis C, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-9; HARRIS G, 1992, P NATL ACAD SCI USA, V89, P10787, DOI 10.1073/pnas.89.22.10787; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Krzywinski M, 2004, NUCLEIC ACIDS RES, V32, P3651, DOI 10.1093/nar/gkh700; Lam S, 2000, CANCER-AM CANCER SOC, V89, P2468; Luk C, 2001, CANCER GENET CYTOGEN, V125, P87, DOI 10.1016/S0165-4608(00)00363-0; McPherson JD, 2001, NATURE, V409, P934, DOI 10.1038/35057157; McWilliams A, 2002, ONCOGENE, V21, P6949, DOI 10.1038/sj.onc.1205831; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; RIED T, 1994, CANCER RES, V54, P1801; Saretzki G, 2002, CANCER LETT, V176, P81, DOI 10.1016/S0304-3835(01)00644-9; Siwoski A, 2002, MODERN PATHOL, V15, P889, DOI 10.1097/01.MP.0000024288.63070.4F; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Travis WD, 1999, HISTOLOGICAL TYPING; Ullmann R, 1998, HUM PATHOL, V29, P1145, DOI 10.1016/S0046-8177(98)90428-2; Wang K, 2002, ONCOGENE, V21, P7598, DOI 10.1038/sj.onc.1205953; Watson SK, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-6; Wiebe JP, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-9; Wieland I, 1996, ONCOGENE, V12, P97; WIELAND I, 1994, CANCER RES, V54, P1772; Wistuba II, 2000, CLIN CANCER RES, V6, P2604; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zheng M, 2004, AM J PATHOL, V165, P63, DOI 10.1016/S0002-9440(10)63275-0; Zhu CQ, 2004, CLIN CANCER RES, V10, P1984, DOI 10.1158/1078-0432.CCR-03-0470	35	48	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 14	2005	24	30					4806	4812		10.1038/sj.onc.1208643	http://dx.doi.org/10.1038/sj.onc.1208643			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870700				2022-12-17	WOS:000230477900007
J	Cui, QQ; Lim, SK; Zhao, B; Hoffmann, FM				Cui, QQ; Lim, SK; Zhao, B; Hoffmann, FM			Selective inhibition of TGF-beta responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP	ONCOGENE			English	Article						TGF-beta; peptide aptamer; Smad; FoxH1; Lef1	GROWTH-FACTOR-BETA; TRANSCRIPTION FACTORS; SIGNALING PATHWAYS; SYNERGISTIC COOPERATION; CELL-PROLIFERATION; ENDOTHELIAL-CELLS; INTERACTION MOTIF; SKI ONCOPROTEIN; WNT PATHWAYS; PROLINE-RICH	Transforming growth factor beta (TGF-beta) stimulation results in the assembly of Smad-containing protein complexes that mediate activation or repression of TGF-beta responsive genes. To determine if disruption of specific Smad protein-protein interactions would selectively inhibit responses to TGF-beta or generally interfere with Smad-dependent signaling, we developed three Smad-binding peptide aptamers by introducing Smad interaction motifs from Smad-binding proteins CBP, FoxH1 and Lef1. into the scaffold protein E. coli thioredoxin A (Trx). All three classes of aptamers bound to Smads by GST pulldown assays and co-immunoprecipitation from mammalian cells. Expression of the aptamers in HepG2 cells did not generally inhibit Smad-dependent signaling as evaluated using seven TGF-beta responsive luciferase reporter genes. The Trx-xFoxH1b aptamer inhibited TGF-beta-induced expression from a reporter dependent on the Smad-FoxH1 interaction, A3-lux, by 50%. Trx-xFoxH1b also partially inhibited two reporters not dependent on a Smad-FoxH1 interaction, 3TP-lux and Twntop, and endogenous PAI-1 expression. Trx-Lef1 aptamer only inhibited expression of the Smad-Lef1 responsive reporter gene TwnTop. The Trx-CBP aptamer had no significant effect on reporter gene expression. The results suggest that Smad-binding peptide aptamers can be developed to selectively inhibit TGF-beta-induced gene expression.	Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Hoffmann, FM (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	fmhoffma@wisc.edu		Hoffmann, F. Michael/0000-0002-2770-9656	NATIONAL CANCER INSTITUTE [R01CA090875, T32CA009135, P30CA014520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK064336] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 014520, T32 CA 09135, R01 CA 090875] Funding Source: Medline; NIDDK NIH HHS [R21 DK 064336] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Buerger C, 2003, J BIOL CHEM, V278, P37610, DOI 10.1074/jbc.M301629200; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Chong PA, 2004, J BIOL CHEM, V279, P40707, DOI 10.1074/jbc.M404375200; Colas P, 2000, P NATL ACAD SCI USA, V97, P13720, DOI 10.1073/pnas.97.25.13720; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Crease DJ, 1998, P NATL ACAD SCI USA, V95, P4398, DOI 10.1073/pnas.95.8.4398; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DiChiara MR, 2000, J EXP MED, V192, P695, DOI 10.1084/jem.192.5.695; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Germain S, 2000, GENE DEV, V14, P435; Geyer CR, 1999, P NATL ACAD SCI USA, V96, P8567, DOI 10.1073/pnas.96.15.8567; Goodman RH, 2000, GENE DEV, V14, P1553; Howell M, 2002, DEVELOPMENT, V129, P2823; Hu MC, 2003, DEVELOPMENT, V130, P2753, DOI 10.1242/dev.00478; Hua XX, 2000, J BIOL CHEM, V275, P33205, DOI 10.1074/jbc.C000568200; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Hussein SM, 2003, J BIOL CHEM, V278, P48805, DOI 10.1074/jbc.M305472200; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Inman GJ, 2002, J BIOL CHEM, V277, P51008, DOI 10.1074/jbc.M208532200; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kennedy G, 2003, MOL CELL BIOL, V23, P6901, DOI 10.1128/MCB.23.19.6901-6908.2003; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Long JY, 2004, P NATL ACAD SCI USA, V101, P99, DOI 10.1073/pnas.0307598100; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Nagel-Wolfrum K, 2004, MOL CANCER RES, V2, P170; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Randall RA, 2004, MOL CELL BIOL, V24, P1106, DOI 10.1128/MCB.24.3.1106-1121.2004; Randall RA, 2002, EMBO J, V21, P145, DOI 10.1093/emboj/21.1.145; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Theil T, 2002, DEVELOPMENT, V129, P3045; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317	67	48	60	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3864	3874		10.1038/sj.onc.1208556	http://dx.doi.org/10.1038/sj.onc.1208556			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15750622				2022-12-17	WOS:000229435300002
J	Lu, M; Mira-y-Lopez, R; Nakajo, S; Nakaya, K; Jing, YK				Lu, M; Mira-y-Lopez, R; Nakajo, S; Nakaya, K; Jing, YK			Expression of estrogen receptor alpha, retinoic acid receptor alpha and cellular retinoic acid binding protein II genes is coordinately regulated in human breast cancer cells	ONCOGENE			English	Article						cellular retinoic acid binding protein; retinoic acid receptor; breast cancer; estrogen receptor	ACUTE PROMYELOCYTIC LEUKEMIA; MAMMARY-CARCINOMA; GROWTH-INHIBITION; RAR-ALPHA; 9-CIS-RETINOIC ACID; EPITHELIAL-CELLS; MESSENGER-RNA; HUMAN SKIN; VITAMIN-A; IN-VITRO	Human breast cancer cell lines expressing the estrogen receptor alpha (ER alpha), all-trans-retinoic acid (ATRA) receptor alpha (RAR alpha) and cellular retinoic acid binding protein II (CRABPII) genes are sensitive to ATRA-mediated growth inhibition. To study the relationship among ER alpha, RAR alpha and CRABPII expression, the protein levels of each member were compared in five breast cancer cell lines (T47D, MCF-7, ZR-75-1, Hs587T and MDA-MB-231 cells) and two immortalized nontumorigenic breast epithelial cell lines (MTSV1.7 and MCF-10A). ER alpha, RAR alpha and CRABPII proteins were detected in T47D, MCF-7 and ZR-75-1 cells but not in other tested cell lines. RAR alpha and CRABPII proteins were either reduced or undetectable in T47D/C4:2W and MCF-7/ADR cells with lost expression of ER alpha. Estradiol increased and antiestrogens (tamoxifen and ICI 164,384) downregulated the expression of both RAR alpha and CRABPII proteins in T47D and MCF-7 cells. RAR alpha antagonist Ro-41-5253 inhibited CRABPII expression, but not RAR alpha expression in estradiol-treated T47D and MCF-7 cells. Suppression of ER alpha by small interfering RNA (siRNA) reduced RAR alpha and CRABPII gene expression and siRNA suppression of RAR alpha reduced CRABPII expression while having no effect on ER alpha in T47D cells. Transient transfection of either RAR alpha or ER alpha expression vectors increased CRABPII expression in MDA-MB-231 cells but only RAR alpha, not ER alpha, activated hCRABPII promoter reporter. These results indicate that there is a gene activation pathway in which ERa drives RAR alpha transcription and RAR alpha drives CRABPII transcription in ER alpha-positive human breast cancer cells.	Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA; Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Tokyo, Japan	Icahn School of Medicine at Mount Sinai; Showa University	Jing, YK (corresponding author), Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	yongkui.jing@mssm.edu			NCI NIH HHS [NIH CA54273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA054273, R01CA054273] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANZANO MA, 1994, CANCER RES, V54, P4614; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; ASTROM A, 1992, J BIOL CHEM, V267, P25251; ASTROM A, 1991, J BIOL CHEM, V266, P17662; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; Bucco RA, 1997, BIOCHEMISTRY-US, V36, P4009, DOI 10.1021/bi962094o; BUSCH C, 1990, METHOD ENZYMOL, V189, P315; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; DAWSON MI, 1995, CANCER RES, V55, P4446; DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643; Delva L, 1999, MOL CELL BIOL, V19, P7158; Di W, 1998, J INVEST DERMATOL, V111, P1109, DOI 10.1046/j.1523-1747.1998.00455.x; Fitzgerald P, 1997, CANCER RES, V57, P2642; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; Gottardis MM, 1996, CANCER RES, V56, P5566; Guo XJ, 2000, CARCINOGENESIS, V21, P1925, DOI 10.1093/carcin/21.11.1925; Han QX, 1997, DIAGN MOL PATHOL, V6, P42, DOI 10.1097/00019606-199702000-00007; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JIANG SY, 1992, MOL ENDOCRINOL, V6, P2167, DOI 10.1210/me.6.12.2167; Jing YK, 1997, CANCER RES, V57, P1668; Jing YK, 1996, FASEB J, V10, P1064, DOI 10.1096/fasebj.10.9.8801168; Li XH, 2003, J BIOL CHEM, V278, P35819, DOI 10.1074/jbc.M302551200; Lin XH, 2003, CANCER RES, V63, P498; MACGREGOR TM, 1992, J BIOL CHEM, V267, P7777; Mangelsdorf David J., 1994, P319; Manor D, 2003, CANCER RES, V63, P4426; Nakagawa S, 2003, MOL CARCINOGEN, V38, P106, DOI 10.1002/mc.10150; Niles RM, 2000, NUTRITION, V16, P1084, DOI 10.1016/S0899-9007(00)00436-6; Noy N, 2000, BIOCHEM J, V348, P481, DOI 10.1042/0264-6021:3480481; Ong David E., 1994, P283; Pasquali D, 1997, EUR J ENDOCRINOL, V137, P410, DOI 10.1530/eje.0.1370410; Pink JJ, 1996, BRIT J CANCER, V74, P1227, DOI 10.1038/bjc.1996.521; RISHI AK, 1995, CANCER RES, V55, P4999; ROMAN SD, 1992, CANCER RES, V52, P2236; ROMAN SD, 1993, CANCER RES, V53, P5940; Rosenauer A, 1998, CANCER RES, V58, P5110; ROSS AC, 1993, J AM DIET ASSOC, V93, P1285, DOI 10.1016/0002-8223(93)91956-Q; Rousseau C, 2003, J STEROID BIOCHEM, V86, P1, DOI 10.1016/S0960-0760(03)00255-3; Schneider SM, 2000, CANCER RES, V60, P5479; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; Tallman MS, 2002, BLOOD, V100, P4298, DOI 10.1182/blood-2002-02-0632; TAVAKKOL A, 1992, J INVEST DERMATOL, V99, P146, DOI 10.1111/1523-1747.ep12616781; Van heusden J, 1998, BRIT J CANCER, V77, P26, DOI 10.1038/bjc.1998.5; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; VANDERLEEDE BJM, 1995, MOL CELL ENDOCRINOL, V109, P77, DOI 10.1016/0303-7207(95)03487-R; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Widschwendter M, 1997, INT J CANCER, V71, P497; WIDSCHWENDTER M, 1995, CANCER RES, V55, P2135; Widschwendter M, 1997, CANCER RES, V57, P4158; Yang QF, 2002, BREAST CANCER RES TR, V76, P167, DOI 10.1023/A:1020576606004; ZHAO ZR, 1995, EXP CELL RES, V219, P555, DOI 10.1006/excr.1995.1264	53	48	49	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4362	4369		10.1038/sj.onc.1208661	http://dx.doi.org/10.1038/sj.onc.1208661			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15870697				2022-12-17	WOS:000229976900005
J	Dubrovska, A; Kanamoto, T; Lomnytska, M; Heldin, CH; Volodko, N; Souchelnytskyi, S				Dubrovska, A; Kanamoto, T; Lomnytska, M; Heldin, CH; Volodko, N; Souchelnytskyi, S			TGF ss 1/Smad3 counteracts BRCA1-dependent repair of DNA damage	ONCOGENE			English	Article						Smad3; BRCA1; transforming growth factor-ss; DNA repair; breast cancer	TGF-BETA; CANCER-SUSCEPTIBILITY; COLORECTAL-CANCER; PROGNOSTIC-FACTOR; MUTANT MICE; BRCA1; SMAD4; EXPRESSION; CELLS; GENE	Inactivation of the BRCA1 gene has been found to confer susceptibility to early-onset familial breast and ovarian cancers. BRCA1 regulates DNA repair, chromatin remodeling and affects gene transcription. Transforming growth factor-beta (TGF beta) is a potent regulator of growth, apoptosis and invasiveness of tumor cells, including breast cancer cells. Here we show that Smad3 which is a component of the TGF beta signaling pathway, forms a complex with BRCA1 in vitro and in vivo. The interaction is mediated by the MH1 domain of Smad3 and the G terminal part of BRCA1. We observed a co-localization of Smad3 and BRCA1 in nuclear complexes. We also found that TGF beta 1/Smad3 counteracted BRCA1-dependent repair of DNA double-strand breaks in human breast epithelial cells, as evaluated by BRCA1 nuclear foci formation, single-cell gel electrophoresis and cell survival assays. Thus, TGF beta 1/Smad3 suppresses BRCA1-dependent DNA repair in response to a DNA damaging agent.	Ludwig Inst Canc Res, Biomed Ctr, SE-75124 Uppsala, Sweden; Hiroshima Univ, Dept Ophthalmol & Visual Sci, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348551, Japan; Lviv Natl Med Univ, Dept Oncol & Med Radiol, UA-79031 Lvov, Ukraine	Ludwig Institute for Cancer Research; Hiroshima University; Danylo Halytsky Lviv National Medical University	Souchelnytskyi, S (corresponding author), Ludwig Inst Canc Res, Biomed Ctr, Box 595, SE-75124 Uppsala, Sweden.	serhiy.souchelnytskyi@licr.uu.se	Souchelnytskyi, Serhiy/G-6491-2011; Lomnytska, Marta/GWZ-2220-2022; Dubrovska, Anna/AAE-8514-2019; Souchelnytskyi, Serhiy/J-9446-2014	Souchelnytskyi, Serhiy/0000-0001-8243-9276; Dubrovska, Anna/0000-0002-3375-1500; Lomnytska, Marta/0000-0003-2773-8446				Boulay JL, 2002, BRIT J CANCER, V87, P630, DOI 10.1038/sj.bjc.6600511; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Ewan KB, 2002, CANCER RES, V62, P5627; Glick A, 1999, P NATL ACAD SCI USA, V96, P14949, DOI 10.1073/pnas.96.26.14949; Kanamoto T, 2002, EMBO J, V21, P1219, DOI 10.1093/emboj/21.5.1219; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lomnytska M, 2004, PROTEOMICS, V4, P995, DOI 10.1002/pmic.200300659; Miyajima A, 2003, UROLOGY, V61, P1072, DOI 10.1016/S0090-4295(02)02553-0; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; MURRAY PA, 1993, BRIT J CANCER, V67, P1408, DOI 10.1038/bjc.1993.261; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Preobrazhenska O, 2002, ONCOGENE, V21, P5660, DOI 10.1038/sj.onc.1205732; Pulaski L, 2001, J BIOL CHEM, V276, P14344, DOI 10.1074/jbc.M011019200; Schmied BM, 2000, CARCINOGENESIS, V21, P1121, DOI 10.1093/carcin/21.6.1121; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Souchelnytskyi S, 2002, EXP ONCOL, V24, P3; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang Q, 2000, ONCOGENE, V19, P6152, DOI 10.1038/sj.onc.1203974; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Xiangming C, 2001, CLIN CANCER RES, V7, P277; Xie W, 2002, CANCER RES, V62, P497; Yakmovych I, 2001, FASEB J, V15, P553; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	30	48	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2289	2297		10.1038/sj.onc.1208443	http://dx.doi.org/10.1038/sj.onc.1208443			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735739				2022-12-17	WOS:000227877400002
J	Li, ZG; Shi, HY; Zhang, M				Li, ZG; Shi, HY; Zhang, M			Targeted expression of maspin in tumor vasculatures induces endothelial cell apoptosis	ONCOGENE			English	Article						angiogenesis; maspin; endothelial cells; apoptosis; Bcl-2 family proteins	CYTOCHROME-C RELEASE; MEDIATED APOPTOSIS; BONE METASTASIS; ACTIVATION; PATHWAY; CANCER; ANGIOGENESIS; INHIBITION; DEATH; CASPASE-8	Angiogenesis, the formation of new blood vessels, is required for normal tissue development and pathological conditions such as tumorigenesis. Most solid tumors can not grow beyond a few millimeters without the recruitment of neovessels since cancer cells require access to blood vessels for nutrients and to escape the local environment and metastasize to other tissue and organ sites. Targeting tumor vessel endothelium therefore should serve as an effective therapy for cancers. Maspin is a serpin that exhibits antiangiogenic properties. In this report, we show that when maspin overexpression is targeted in vivo to endothelial cells, it actively induces endothelial cell apoptosis. Intravascular administration of adenovirus-maspin to mice bearing mammary tumors disrupts tumor-induced angiogenesis. Interestingly, tumor neovessels become leaky after maspin treatment, whereas normal mature vessels are not affected by maspin treatment. We further demonstrate that maspin directly induces endothelial cell apoptosis in vitro, and this effect is maspin specific. The induction of apoptosis is accompanied by changes in the expression of Bcl-2 family genes and is blocked by caspase inhibitors. In addition, the apoptotic effect is mediated by intracellular maspin and is dependent on the RSL region of maspin. Furthermore, we have shown that transient overexpression of Bcl-2 protected the HUVECs from maspin-mediated apoptosis, and the presence of both maspin and Bax accelerated the apoptosis process. These findings demonstrate that neovascular endothelial cells are highly sensitive to maspin level inside the cells. This property can be used for targeted therapy against tumor angiogenesis and metastasis.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Zhang, M (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	mzhang@bcm.tmc.edu			NCI NIH HHS [CA79736] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079736] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100; Choi KB, 1998, J BIOL CHEM, V273, P20185, DOI 10.1074/jbc.273.32.20185; Choi WS, 2004, J BIOL CHEM, V279, P20451, DOI 10.1074/jbc.M311164200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Dickinson JL, 1998, CELL DEATH DIFFER, V5, P163, DOI 10.1038/sj.cdd.4400324; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1986, CANCER RES, V46, P467; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Gilot D, 2002, J BIOL CHEM, V277, P49220, DOI 10.1074/jbc.M207325200; Gurtu V, 1997, ANAL BIOCHEM, V251, P98, DOI 10.1006/abio.1997.2220; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; LaVallee TM, 2003, CANCER RES, V63, P468; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XY, 2001, CANCER RES, V61, P1699; Li YS, 2001, CANCER RES, V61, P6906; Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McGettrick AF, 2001, EUR J BIOCHEM, V268, P5868, DOI 10.1046/j.0014-2956.2001.02535.x; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Shi HY, 2002, MOL THER, V5, P755, DOI 10.1006/mthe.2002.0602; Shi HY, 2001, CANCER RES, V61, P6945; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Suminami Y, 2000, BRIT J CANCER, V82, P981, DOI 10.1054/bjoc.1999.1028; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Tuxhorn JA, 2002, CANCER RES, V62, P6021; YANG J, 1997, SCIENCE, V275, P1132; Yuan YH, 2002, CIRCULATION, V105, P2653, DOI 10.1161/01.CIR.0000018947.95555.65; Zhang M, 2000, ONCOGENE, V19, P6053, DOI 10.1038/sj.onc.1204006; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	46	48	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 17	2005	24	12					2008	2019		10.1038/sj.onc.1208449	http://dx.doi.org/10.1038/sj.onc.1208449			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688005				2022-12-17	WOS:000227681900005
J	Weber, HO; Ludwig, RL; Morrison, D; Kotlyarov, A; Gaestel, M; Vousden, KH				Weber, HO; Ludwig, RL; Morrison, D; Kotlyarov, A; Gaestel, M; Vousden, KH			HDM2 phosphorylation by MAPKAP kinase 2	ONCOGENE			English	Article						HDM2; MAPKAP kinase 2; p53; phosphorylation	CELL-CYCLE ARREST; UBIQUITIN-PROTEIN LIGASE; RING-FINGER DOMAIN; NUCLEAR EXPORT; P53 STABILITY; ONCOPROTEIN MDM2; UV-RADIATION; DNA-DAMAGE; DEGRADATION; PATHWAY	p53 stability is regulated by HDM2, a RING domain protein that acts as an E3 ligase to ubiquitinate p53 and target its degradation. Phosphorylation of HDM2 on serine 166 by AKT has been shown to enhance HDM2 activity and promote the degradation of p53. Here, we show that MAPKAP kinase 2 ( MK2) can phosphorylate HDM2 on serine 157 and 166 in vitro. Treatment of cells with anisomycin, which activates MK2, also results in phosphorylation of HDM2 on serine 157 and 166 in vivo. Mutation of the MK2 phosphorylation sites in HDM2 to aspartic acid renders HDM2 slightly more active in the degradation of p53, and mouse cells deficient for MK2 show reduced Mdm2 phosphorylation and elevated levels of p53 protein. Together, our results suggest that MK2 may act to dampen the extent and duration of the p53 response.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; NCI, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Hannover Med Sch, Inst Biochem Physiol Chem, D-30625 Hannover, Germany	Beatson Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Hannover Medical School	Vousden, KH (corresponding author), Beatson Inst Canc Res, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.	k.vousden@beatson.gla.ac.uk	Gaestel, Matthias/A-6560-2013	Gaestel, Matthias/0000-0002-4944-4652	NATIONAL CANCER INSTITUTE [Z01BC010329, ZIABC010329] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bates S, 1999, MOL CARCINOGEN, V24, P7, DOI 10.1002/(SICI)1098-2744(199901)24:1<7::AID-MC2>3.0.CO;2-5; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brignone C, 2004, ONCOGENE, V23, P4121, DOI 10.1038/sj.onc.1207540; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Burch LR, 2004, J MOL BIOL, V337, P115, DOI 10.1016/j.jmb.2003.10.081; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lai ZH, 2001, J BIOL CHEM, V276, P31357, DOI 10.1074/jbc.M011517200; Lawlor MA, 2001, J CELL SCI, V114, P2903; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; LUNA RMD, 1995, NATURE, V378, P203; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meek DW, 2003, MOL CANCER RES, V1, P1017; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Perry ME, 2004, MOL CANCER RES, V2, P9; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; She QB, 2002, ONCOGENE, V21, P1580, DOI 10.1038/sj.onc.1205239; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wu GS, 2004, CANCER BIOL THER, V3, P156, DOI 10.4161/cbt.3.2.614; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	49	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					1965	1972		10.1038/sj.onc.1208389	http://dx.doi.org/10.1038/sj.onc.1208389			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688025				2022-12-17	WOS:000227681900001
J	Reddy, J; Shivapurkar, N; Takahashi, T; Parikh, G; Stastny, V; Echebiri, C; Crumrine, K; Zochbauer-Muller, S; Drach, J; Zheng, YY; Feng, ZD; Kroft, SH; McKenna, RW; Gazdar, AF				Reddy, J; Shivapurkar, N; Takahashi, T; Parikh, G; Stastny, V; Echebiri, C; Crumrine, K; Zochbauer-Muller, S; Drach, J; Zheng, YY; Feng, ZD; Kroft, SH; McKenna, RW; Gazdar, AF			Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors	ONCOGENE			English	Article						cytokine signaling pathway; methylation; hematopoietic tumors	EPSTEIN-BARR-VIRUS; MONOCLONAL GAMMOPATHY; NEGATIVE REGULATOR; HYPERMETHYLATION; SHP1; EVENTS; SOCS-1; SYK; PCR	The perturbations of the cytokine signaling pathway play an important role in lymphoid/hematopoietic tumors. Aberrant promoter methylation is the major mechanism of gene silencing in tumors. We examined 150 lymphoid/ hematopoietic tumors or potential premalignant specimens, 55 control specimens and 12 EBV-transformed B lymphoblastoid cultures and 10 lymphoma/leukemia (L/L) or multiple myeloma ( MM) cell lines for the methylation ( and, in cell lines, of the expression status) of three genes involved in the cytokine signaling pathway. The genes were: SHP1, a protein tyrosine phosphatase; SYK, a protein kinase; and SOCS1, a suppressor of cytokine signaling. Our major findings were: ( 1) one or more of the three genes was frequently methylated in L/L and MM cell lines and there was good concordance ( 90 100%) between methylation and loss of gene expression; ( 2) treatment of L/L cell lines with a demethylating agent resulted in re-expression of SHP1 protein and downregulation of phosphorylated STAT3 in L/L cell lines; ( 3) all 55 control specimens and the lymphoblastoid cultures were negative for methylation of the three genes; ( 4) non-Hodgkin's lymphomas ( 100%), and leukemias (94%) had almost universal methylation of SHP1 and relatively less frequent (<30%) methylation of SOCS1 and SYK; ( 5) MM and monoclonal gammopathy of unknown significance (MGUS) had infrequent methylation of SHP1 (<20%), and occasional methylation of SOCS1 and SYK; and ( 6) comparable methylation frequencies for SOCS1 were observed in MM and MGUS, suggesting that SOCS1 methylation is an early event in MM pathogenesis. At least one gene was methylated in 119 of 130 (93%) of the malignant and 12 of 20 (60%) of the MGUS samples. Our findings demonstrate that the perturbations of cytokine signaling via silencing of these three genes are almost universal in lymphoid/ hematopoietic tumors but the patterns of gene methylated for L/L and plasma cell dyscrasias are different.	UT SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; UT SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Hosp, Dept Med 1, Div Clin Oncol, A-1090 Vienna, Austria; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University Hospital Vienna; Fred Hutchinson Cancer Center	Gazdar, AF (corresponding author), UT SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	adi.gazdar@utsouthwestern.edu	Kroft, Steven/AAE-2543-2020; Zöchbauer-Müller, Sabine/B-8399-2012; Parikh, Gunjan/AAS-1375-2020	Zöchbauer-Müller, Sabine/0000-0002-6777-1729; Parikh, Gunjan/0000-0002-8447-1349	NATIONAL CANCER INSTITUTE [U01CA084971] Funding Source: NIH RePORTER; NCI NIH HHS [5U01CA8497102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Chim CS, 2004, LEUKEMIA, V18, P356, DOI 10.1038/sj.leu.2403216; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; Ganju RK, 2000, J BIOL CHEM, V275, P17263, DOI 10.1074/jbc.M000689200; Goodman PA, 2003, ONCOGENE, V22, P2504, DOI 10.1038/sj.onc.1206313; Guillerm G, 2001, BLOOD, V98, P244, DOI 10.1182/blood.V98.1.244; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jebbink J, 2003, J MOL DIAGN, V5, P15, DOI 10.1016/S1525-1578(10)60446-1; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Krebs DL, 2000, J CELL SCI, V113, P2813; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Kyle RA, 2003, BLOOD, V102, P3759, DOI 10.1182/blood-2003-03-0801; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Oka T, 2002, CANCER RES, V62, P6390; Shivapurkar N, 2002, LANCET, V359, P851, DOI 10.1016/S0140-6736(02)07921-7; Shivapurkar N, 2002, ONCOGENE, V21, P8510, DOI 10.1038/sj.onc.1205941; Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; Wu CY, 2003, GENE, V306, P1, DOI 10.1016/S0378-1119(03)00400-1; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556; Yuan YF, 2001, CANCER RES, V61, P5558	25	48	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					732	736		10.1038/sj.onc.1208032	http://dx.doi.org/10.1038/sj.onc.1208032			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580314				2022-12-17	WOS:000226420400021
J	Sorli, SC; Bunney, TD; Sugden, PH; Paterson, HF; Katan, M				Sorli, SC; Bunney, TD; Sugden, PH; Paterson, HF; Katan, M			Signaling properties and expression in normal and tumor tissues of two phospholipase C epsilon splice variants	ONCOGENE			English	Article						phosphoinositide-specificc phospholipase C epsilon; splice variants; Ras; colorectal tumors; epigenetic silencing	HUMAN CANCERS; RAS EFFECTOR; CYCLIC-AMP; ACTIVATION; GENE; SUPPRESSOR; PROTEIN; PATHWAYS; PLC; PHOSPHORYLATION	Phospholipase Cepsilon (PLCepsilon) is a novel member of phosphoinositide-specific phospholipase C enzymes with a unique regulatory link to Ras GTP-ases. In the present studies, we establish existence of two splice variants (PLCepsilon1a and PLCepsilon1b) derived from human PLCepsilon1 gene. When expressed in COS or HEK293 cells, PLCepsilon1a and PLCepsilon1b have similar potential to be stimulated by diverse signaling pathways via tyrosine kinase and G-protein coupled receptors and share the ability to function as an effector of Ras. The expression pattern shows broader mRNA expression of PLCepsilon1a in normal tissues; furthermore, in most cell lines expressing PLCepsilon, PLCepsilon1a is the only splice variant present. Analysis of normal/tumor matched pairs derived from colon and rectum demonstrates greatly reduced expression levels in tumor tissues. Further studies in a colorectal tumor cell line lacking PLCepsilon show restoration of transcription of PLCepsilon1a and PLCepsilon1b by demethylating agent 5-aza-2'-deoxycytidine, suggesting epigenetic silencing through hypermethylation. In addition, expression of exogenous PLCepsilon in this cell line demonstrates inhibitory effects of PLCepsilon on cell viability and proliferation. Taken together, our findings suggest that regulatory mechanisms controlling expression of PLCepsilon, broadened by diversity introduced by splice variants, could play important role in PLCepsilon regulation in normal and tumor cells.	Inst Canc Res, Chester Beatty Labs, Canc Res UK Ctr Cell & Mol Biol, London SW3 6JB, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst Div, London SW7 2AZ, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Imperial College London	Katan, M (corresponding author), Inst Canc Res, Chester Beatty Labs, Canc Res UK Ctr Cell & Mol Biol, Fulham Rd, London SW3 6JB, England.	matilda@icr.ac.uk		Bunney, Tom/0000-0002-0281-8813				ALVAREZ RA, 1995, GENOMICS, V29, P53, DOI 10.1006/geno.1995.1214; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BOGOYEVITCH MA, 1995, BIOCHEM J, V309, P437, DOI 10.1042/bj3090437; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Ellis MV, 1998, J BIOL CHEM, V273, P11650, DOI 10.1074/jbc.273.19.11650; Esteller M, 2003, ADV EXP MED BIOL, V532, P39; Evellin S, 2002, J BIOL CHEM, V277, P16805, DOI 10.1074/jbc.M112024200; Guy M, 2001, BRIT J CANCER, V84, P520, DOI 10.1054/bjoc.2000.1635; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; Kelley GG, 2004, BIOCHEM J, V378, P129, DOI 10.1042/BJ20031370; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kim MJ, 1998, J BIOL CHEM, V273, P3618, DOI 10.1074/jbc.273.6.3618; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Nagano K, 1999, J BIOL CHEM, V274, P2872, DOI 10.1074/jbc.274.5.2872; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Pyrzynska B, 2002, J BIOL CHEM, V277, P14102, DOI 10.1074/jbc.M104443200; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Song CH, 2002, ONCOGENE, V21, P8105, DOI 10.1038/sj.onc.1206003; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Wells A, 2000, ADV CANCER RES, V78, P31; Wing MR, 2003, J BIOL CHEM, V278, P41253, DOI 10.1074/jbc.M306904200; Wing MR, 2001, J BIOL CHEM, V276, P48257, DOI 10.1074/jbc.C100574200; Wu DM, 2003, EUR J NEUROSCI, V17, P1571, DOI 10.1046/j.1460-9568.2003.02591.x	35	48	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					90	100		10.1038/sj.onc.1208168	http://dx.doi.org/10.1038/sj.onc.1208168			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15558028				2022-12-17	WOS:000226125800011
J	Li, C; Lin, MH; Liu, JW				Li, C; Lin, MH; Liu, JW			Identification of PRC1 as the p53 target gene uncovers a novel function of p53 in the regulation of cytokinesis	ONCOGENE			English	Article						p53; PRC1; ptsp53; cell cycle; cytokinesis; transcriptional regulation	WILD-TYPE P53; TEMPERATURE-SENSITIVE MUTANT; CELL-CYCLE ARREST; TRANSCRIPTIONAL REGULATION; GROWTH ARREST; BINDING; PROTEIN; INHIBITION; MECHANISMS; SENESCENCE	Our previous studies conducted in MCF7-ptsp53 cells have demonstrated that overexpression of the wild-type (wt) p53 at permissive temperature 32degreesC leads to growth arrest at the G2/M phase of the cell cycle. To identify novel p53-regulated genes that are responsible for the p53-induced G2/M arrest, we conducted cDNA microarray analyses. The array results indicated that the mRNA level of protein regulator of cytokinesis (PRC1) was significantly decreased when the p53 transactivation activity was turned on, suggesting that PRC1 transcription could be downregulated by p53. In this study, we have extensively examined the functional role of p53 in the regulation of PRC1, a cell cycle protein that plays important roles during cytokinesis. We demonstrate that increased expression of the wt p53 either by exogenous transfection or chemical induction results in reduced mRNA and protein expression of PRC1 in HCT116 p53(+/+), HCT116 p53(-/-), MCF-7, T47D, and HeLa cells. Importantly, we show that the decreased PRC1 expression is accompanied by the appearance of binucleated cells, indicating the process of cell division after mitosis being inhibited. By isolation and characterization of a 3 kb genomic fragment containing the 5'-flanking region and part of exon 1 of PRC1 gene, we demonstrate that p53 directly suppresses PRC1 gene transcription. We further locate the p53-responsive sequence to the proximal promoter region -214 to -163, relative to the transcriptional start site. The in vivo interaction of p53 with PRC1 gene promoter is further demonstrated by chromatin immunoprecipitation assay. Taken together, these new findings suggest that p53 may have important roles in the regulation of cytokinesis through controlling the transcription of PRC1.	Dept Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Liu, JW (corresponding author), Dept Vet Affairs Palo Alto Hlth Care Syst, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	jingwen.liu@med.va.gov			NCI NIH HHS [1R01CA83648-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; CHENG KC, 1993, ADV CANCER RES, V60, P121; Chun ACS, 2003, J BIOL CHEM, V278, P37439, DOI 10.1074/jbc.M307185200; Dubrez L, 2001, GENE THER, V8, P1705, DOI 10.1038/sj.gt.3301592; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Harris LC, 1996, CANCER RES, V56, P2029; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li C, 2003, BREAST CANCER RES TR, V80, P23, DOI 10.1023/A:1024483017549; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; Mollinari C, 2002, J CELL BIOL, V157, P1175, DOI 10.1083/jcb.200111052; Nakamura S, 2002, ONCOGENE, V21, P2102, DOI 10.1038/sj.onc.1205251; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Straight AF, 2000, CURR BIOL, V10, pR760, DOI 10.1016/S0960-9822(00)00746-6; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Tarapore P, 2000, CANCER INVEST, V18, P148, DOI 10.3109/07357900009038246; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wesierska-Gadek J, 2000, J CELL BIOCHEM, V80, P85; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; YIN XY, 2001, CANCER RES, V61, P6493	35	48	49	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9336	9347		10.1038/sj.onc.1208114	http://dx.doi.org/10.1038/sj.onc.1208114			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15531928				2022-12-17	WOS:000225764100005
J	Willingham, AT; Deveraux, QL; Hampton, GM; Aza-Blanc, P				Willingham, AT; Deveraux, QL; Hampton, GM; Aza-Blanc, P			RNAi and HTS: exploring cancer by systematic loss-of-function	ONCOGENE			English	Article						RNA interference; RNAi; siRNA; high throughput screen	GENOME-WIDE RNAI; RETRACTED ARTICLE. SEE; SHORT-INTERFERING RNAS; HUMAN TUMOR-CELLS; CAENORHABDITIS-ELEGANS; MAMMALIAN-CELLS; LUNG-CANCER; INDUCED APOPTOSIS; GENE-EXPRESSION; EGFR MUTATIONS	Cancer develops through the successive accumulation and selection of genetic and epigenetic alterations, enabling cells to survive, replicate and evade homeostatic control mechanisms such as apoptosis and antiproliferative signals. This transformation process, however, may create vulnerabilities since the accumulation of mutations can expose synthetic lethal gene interactions and oncogene-driven cellular reprogramming ('addiction'), giving rise to new therapeutic avenues. With the completion of the human genome project, it is anticipated that the identification and characterization of genetic networks that regulate cell growth, differentiation, apoptosis and transformation will be fundamental to decoding the complexity of these processes, and ultimately, cancer itself. Genomic methodologies, such as large-scale mRNA profiling using microarrays, have already begun to reveal the molecular basis of cancer heterogeneity and the clinical behavior of tumors. The combination of traditional cell culture techniques with high-throughput screening approaches has given rise to new cellular-genomics methodologies that enable the simultaneous interrogation of thousands of genes in live cells, facilitating true functional pro. ling of biological processes. Among these, RNA interference (RNAi) has the potential to enable rapid genome-wide loss-of-function (LOF) screens in mammalian systems, which until recently has been the sole domain of lower organisms. Here, we present a broad overview of this maturing technology and explore how, within current technical constraints, large-scale LOF use of RNAi can be exploited to uncover the molecular basis of cancer - from the genetics of synthetic lethality and oncogene-dependent cellular addiction to the acquisition of cancer-associated cellular phenotypes.	Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92093 USA	Novartis; Scripps Research Institute	Aza-Blanc, P (corresponding author), Novartis Res Fdn, Genom Inst, 10675 John J Hopkins Dr, San Diego, CA 92121 USA.	pazabla@gnf.org						Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Baghdoyan S, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh074; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Carpenter AE, 2004, NAT REV GENET, V5, P11, DOI 10.1038/nrg1248; Deveraux QL, 2003, SEMIN CANCER BIOL, V13, P293, DOI 10.1016/S1044-579X(03)00043-9; Dolma S, 2003, CANCER CELL, V3, P285, DOI 10.1016/S1535-6108(03)00050-3; Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345; Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5; ECHALIER G, 1970, IN VITRO CELL DEV B, V6, P162; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Hsieh AC, 2004, NUCLEIC ACIDS RES, V32, P893, DOI 10.1093/nar/gkh238; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889; Kawasaki H, 2003, NUCLEIC ACIDS RES, V31, P981, DOI 10.1093/nar/gkg184; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Luo B, 2004, P NATL ACAD SCI USA, V101, P5494, DOI 10.1073/pnas.0400551101; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mittal V, 2004, NAT REV GENET, V5, P355, DOI 10.1038/nrg1323; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pothof J, 2003, GENE DEV, V17, P443, DOI 10.1101/gad.1060703; Reddy A, 2002, CURR OPIN PHARMACOL, V2, P366, DOI 10.1016/S1471-4892(02)00178-9; REN YG, 2004, MOL CELL BIOL   0908; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; Sen G, 2004, NAT GENET, V36, P183, DOI 10.1038/ng1288; Shirane D, 2004, NAT GENET, V36, P190, DOI 10.1038/ng1290; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Smith NA, 2000, NATURE, V407, P319, DOI 10.1038/35030305; Snove O, 2004, BIOCHEM BIOPH RES CO, V319, P256, DOI 10.1016/j.bbrc.2004.04.175; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Torrance CJ, 2001, NAT BIOTECHNOL, V19, P940, DOI 10.1038/nbt1001-940; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653; Yanagawa S, 1998, J BIOL CHEM, V273, P32353, DOI 10.1074/jbc.273.48.32353; Yoshikawa T, 2004, J CONTROL RELEASE, V96, P227, DOI 10.1016/j.jconrel.2004.01.024; Zheng LX, 2004, P NATL ACAD SCI USA, V101, P135, DOI 10.1073/pnas.2136685100; Ziauddin J, 2001, NATURE, V411, P107, DOI 10.1038/35075114	62	48	53	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2004	23	51					8392	8400		10.1038/sj.onc.1208217	http://dx.doi.org/10.1038/sj.onc.1208217			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517021				2022-12-17	WOS:000224815900010
J	Janoueix-Lerosey, I; Novikov, E; Monteiro, M; Gruel, N; Schleiermacher, G; Loriod, B; Nguyen, C; Delattre, O				Janoueix-Lerosey, I; Novikov, E; Monteiro, M; Gruel, N; Schleiermacher, G; Loriod, B; Nguyen, C; Delattre, O			Gene expression profiling of 1p35-36 genes in neuroblastoma	ONCOGENE			English	Article						neuroblastoma; 1p deletion; gene expression profiling; hierarchical clustering	CHROMOSOME-I; SHORT ARM; DELETION; IDENTIFICATION; HYBRIDIZATION; PREDICTION; INSIGHTS; REGIONS; BINDING; PROTEIN	Deletion of the chromosome 1p36 region is a frequent abnormality in neuroblastoma. To gain further insights into the role of this alteration in oncogenesis, we have constructed a specific cDNA microarray representing most known genes and ESTs from the 1p35-36 region and analysed the expression profiles of 15 neuroblastoma cell lines and 28 neuroblastoma tumours. Hierarchical clustering using expression levels of 320 cDNAs from 1p35-36 separated localized or 4S cases without 1p deletion from advanced stages and cell tines. Supervised learning classification enabled to predict reliably the status of chromosome 1p according to its expression profile. Around 15% of the genes or ESTs presented a significantly decreased expression in samples with 1p deletion as compared to 1p-normal samples suggesting that 1p deletion results in a gene dosage effect on a subset of genes critical for the development of 1p-deleted neuroblastoma. Several genes presumed to have functions in neural differentiation (CDC42, VAMP3, CLSTN1), signal transduction in neural cells (GNB1) and cell cycle regulation (STMN1, RPA2, RBAF600, FBXO6, MAD2L2) exhibited a decreased expression in samples presenting 1p deletion. The identification of such genes provides baseline information for further studies to elucidate how these genes could individually or collectively play a critical role in neuroblastoma tumorigenesis.	Inst Curie, U509, INSERM, Sect Rech,Lab Pathol Mol Canc, F-75248 Paris 05, France; Ctr Immunol Marseille Luminy, Equipe TAGC, F-13288 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Delattre, O (corresponding author), Inst Curie, U509, INSERM, Sect Rech,Lab Pathol Mol Canc, Pavillon Trouillet Rossignol 26,Rue Ulm, F-75248 Paris 05, France.	delattre@curie.fr	Monteiro, Marta/B-2833-2011; loriod, beatrice bl/L-2948-2016; Nguyen, Catherine/M-4119-2016; Janoueix-Lerosey, Isabelle/G-1758-2018	loriod, beatrice bl/0000-0001-5801-2264; Nguyen, Catherine/0000-0001-9376-6360; Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; Monteiro C. Antunes, Marta/0000-0002-0327-0917; delattre, olivier/0000-0002-8730-2276				Bauer A, 2001, GENE CHROMOSOME CANC, V31, P228, DOI 10.1002/gcc.1139; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; Bo TH, 2002, GENOME BIOL, V3; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; CHENG NC, 1995, ONCOGENE, V10, P291; COMBARET V, 1995, INT J CANCER, V61, P185, DOI 10.1002/ijc.2910610208; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Dudoit S. F. J. a. S. T. P, 2000, 576 U CAL DEP STAT; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fix A, 2004, GENE CHROMOSOME CANC, V40, P266, DOI 10.1002/gcc.20041; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hepp R, 2001, CELL TISSUE RES, V305, P247, DOI 10.1007/s004410100359; Lastowska M, 2001, J CLIN ONCOL, V19, P3080; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Mukasa A, 2002, ONCOGENE, V21, P3961, DOI 10.1038/sj.onc.1205495; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nadon R, 2002, TRENDS GENET, V18, P265, DOI 10.1016/S0168-9525(02)02665-3; Ohira M, 2003, ONCOGENE, V22, P5525, DOI 10.1038/sj.onc.1206853; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Schleiermacher G, 2003, CANCER GENET CYTOGEN, V141, P32, DOI 10.1016/S0165-4608(02)00644-1; Van Roy N, 2001, GENE CHROMOSOME CANC, V32, P126, DOI 10.1002/gcc.1174; Vogt L, 2001, MOL CELL NEUROSCI, V17, P151, DOI 10.1006/mcne.2000.0937; WESS J, 1995, LIFE SCI, V56, P915, DOI 10.1016/0024-3205(95)00028-5; White PS, 2001, MED PEDIATR ONCOL, V36, P37, DOI 10.1002/1096-911X(20010101)36:1<37::AID-MPO1010>3.0.CO;2-L	30	48	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5912	5922		10.1038/sj.onc.1207784	http://dx.doi.org/10.1038/sj.onc.1207784			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15195138				2022-12-17	WOS:000222941100005
J	Fukamachi, H; Ito, K				Fukamachi, H; Ito, K			Growth regulation of gastric epithelial cells by Runx3	ONCOGENE			English	Article						Runx3; gastric cancer; growth; TGF-beta tumorigeneisis	METHYL-N-NITROSOUREA; TRANSFORMING GROWTH-FACTOR-BETA-1; CLEIDOCRANIAL DYSPLASIA; TUMOR-SUPPRESSOR; TRANSCRIPTION; CANCER; TGF-BETA-1; INDUCTION; MUTATIONS; PROLIFERATION	Runx3 is expressed by gastric epithelial cells throughout development. Mice whose Runx3 gene has been knocked out died soon after birth. In the knockout mouse, gastric epithelia exhibited hyperplasia and epithelial apoptosis was suppressed. Analysis using a primary culture system for the epithelial cells suggested that this is caused by the reduced sensitivity of Runx3 -/- gastric epithelial cells to the growth-inhibiting and apoptosis-inducing activities of TGF-beta. In human and mouse gastric cancer cell lines, RUNX3/Runx3 was silenced due to hypermethylation of CpG islands in the promoter region. Exogenous expression of RUNX3 in the cells that do not express the endogenous gene caused an inhibition of growth both in vivo and in vitro. These observations indicate that Runx3 is a major growth regulator of gastric epithelial cells, and that it is deeply involved in gastric tumorigenesis in both humans and mice.	Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan; Inst Mol & Cell Biol, Singapore 117609, Singapore	University of Tokyo; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Fukamachi, H (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan.	h_fukama@biol.s.u-tokyo.ac.jp						Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Furihata C, 1997, JPN J CANCER RES, V88, P363, DOI 10.1111/j.1349-7006.1997.tb00390.x; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Ichinose M, 1998, JPN J CANCER RES, V89, P516, DOI 10.1111/j.1349-7006.1998.tb03292.x; Kallapur S, 1999, MOL REPROD DEV, V52, P341, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;341::AID-MRD2&gt;3.0.CO;2-N; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Levanon D, 2003, EMBO REP, V4, P560, DOI 10.1038/sj.embor.embor868; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MARTIKAINEN P, 1990, ENDOCRINOLOGY, V127, P2963, DOI 10.1210/endo-127-6-2963; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; Shi MJ, 1998, J IMMUNOL, V161, P6751; TATEMATSU M, 1993, JPN J CANCER RES, V84, P1258, DOI 10.1111/j.1349-7006.1993.tb02831.x; YANAGIHARA K, 1992, CANCER RES, V52, P4042	22	48	53	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4330	4335		10.1038/sj.onc.1207121	http://dx.doi.org/10.1038/sj.onc.1207121			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156189				2022-12-17	WOS:000221586000018
J	Yatabe, Y; Mitsudomi, T; Takahashi, T				Yatabe, Y; Mitsudomi, T; Takahashi, T			Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation	ONCOGENE			English	Article						maspin; non-small-cell lung cancers; intratumor heterogeneity; promoter DNA methylation; cellular properties	THYROID TRANSCRIPTION FACTOR; MAMMARY EPITHELIAL-CELLS; MESSENGER-RNA EXPRESSION; SUPPRESSOR GENE MASPIN; HUMAN BREAST-CANCER; PROGNOSTIC-SIGNIFICANCE; ADENOCARCINOMAS; CARCINOMAS; P53; PATTERNS	Maspin has been demonstrated to be a suppressor of invasion and cell motility in vitro, whereas in vivo analyses have reported that increased expression of maspin is associated with malignant behavior. The present study examined maspin expression in normal lung and non-small-cell lung cancers. Only proximal airway cells in the normal lung expressed maspin, and the expression was associated with decreased methylation. This association was also observed in non-small-cell lung cancers, but the expression was quite different among histologic subtypes; 20 of 21 squamous cell carcinomas showed intense, uniform expression, whereas the expression status varied among adenocarcinomas. Of the 119 adenocarcinomas, 60 were negative, 23 positive and 36 showed a heterogeneous expression pattern. The expression was inversely correlated with markers of peripheral airway cells. Taken together, the results suggest that maspin may be expressed in association with the proximal airway cell type. It is of note that the heterogeneous expression pattern of maspin is quite distinctive, showing geographic positivity in the individual tumors. Separate analysis of methylation status in positive and negative portions of individual tumors provided an instance of intratumor diversity associated with promoter DNA methylation.	Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Nagoya, Aichi 464, Japan; Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi 464, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center	Yatabe, Y (corresponding author), Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Chikusa Ku, Nagoya, Aichi 4648681, Japan.	yyatabe@aichi-cc.jp	Takahashi, Takashi/I-7262-2014; YATABE, Yasushi/J-6461-2014	Takahashi, Takashi/0000-0003-0615-7001; YATABE, Yasushi/0000-0003-1788-559X; Mitsudomi, Tetsuya/0000-0001-9860-8505				Achiwa H, 1999, CLIN CANCER RES, V5, P1001; Bass R, 2002, J BIOL CHEM, V277, P46845, DOI 10.1074/jbc.C200532200; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bieche I, 2003, BRIT J CANCER, V88, P863, DOI 10.1038/sj.bjc.6600812; Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Goldstein NS, 2001, AM J CLIN PATHOL, V116, P319, DOI 10.1309/550P-QLJX-D84W-F6DN; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Greene FL, 2002, AJCC CANC STAGING MA, DOI DOI 10.1007/978-1-4757-3656-4; Hida T, 1998, CANCER RES, V58, P3761; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Jiang N, 2002, ONCOGENE, V21, P4089, DOI 10.1038/sj.onc.1205507; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KAWAI J, 1993, NUCLEIC ACIDS RES, V21, P5604, DOI 10.1093/nar/21.24.5604; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Lau SK, 2002, MODERN PATHOL, V15, P538, DOI 10.1038/modpathol.3880560; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8; Maass N, 2001, CLIN CANCER RES, V7, P812; Marchetti A, 1996, J PATHOL, V179, P254, DOI 10.1002/(SICI)1096-9896(199607)179:3<254::AID-PATH589>3.0.CO;2-J; Markl IDC, 2001, CANCER RES, V61, P5875; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; Nass SJ, 2000, CANCER RES, V60, P4346; Nishio M, 1997, CLIN CANCER RES, V3, P1051; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sood AK, 2002, CLIN CANCER RES, V8, P2924; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; TSUCHIYA E, 1995, J CANCER RES CLIN, V121, P577, DOI 10.1007/BF01197773; Umekita Y, 2002, INT J CANCER, V100, P452, DOI 10.1002/ijc.10500; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; Yatabe Y, 2000, AM J PATHOL, V157, P985, DOI 10.1016/S0002-9440(10)64611-1; Yatabe Y, 2001, P NATL ACAD SCI USA, V98, P10839, DOI 10.1073/pnas.191225998; Yatabe Y, 1998, CANCER RES, V58, P1042; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	43	48	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	2004	23	23					4041	4049		10.1038/sj.onc.1207557	http://dx.doi.org/10.1038/sj.onc.1207557			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15048080				2022-12-17	WOS:000221520200001
J	Gomez-Manzano, C; Balague, C; Alemany, R; Lemoine, MG; Mitlianga, P; Jiang, H; Khan, A; Alonso, M; Lang, FF; Conrad, CA; Liu, TJ; Bekele, BN; Yung, WKA; Fueyo, J				Gomez-Manzano, C; Balague, C; Alemany, R; Lemoine, MG; Mitlianga, P; Jiang, H; Khan, A; Alonso, M; Lang, FF; Conrad, CA; Liu, TJ; Bekele, BN; Yung, WKA; Fueyo, J			A novel E1A-E1B mutant adenovirus induces glioma regression in vivo	ONCOGENE			English	Article						glioma; therapy; E1A; E1B; adenovirus	CONDITIONALLY REPLICATIVE ADENOVIRUS; ONCOLYTIC ADENOVIRUS; CANCER-THERAPY; E1A PROTEINS; EFFICACY; TUMOR; CELLS; TRANSFORMATION; PATHWAY; POTENT	Malignant gliomas are the most frequently occurring primary brain tumors and are resistant to conventional therapy. Conditionally replicating adenoviruses are a novel strategy in glioma treatment. Clinical trials using E1B mutant adenoviruses have been reported recently and E1A mutant replication-competent adenoviruses are in advanced preclinical testing. Here we constructed a novel replication-selective adenovirus (CB1) incorporating a double deletion of a 24 bp Rb-binding region in the E1a gene, and a 903 bp deleted region in the E1b gene that abrogates the expression of a p53-binding E1B-55 kDa protein. CB1 exerted a potent anticancer effect in vitro in U-251 MG, U-373 MG, and D-54 MG human glioma cell lines, as assessed by qualitative and quantitative viability assays. Replication analyses demonstrated that CB1 replicates in vitro in human glioma cells. Importantly, CB1 acquired a highly attenuated replicative phenotype in both serum-starved and proliferating normal human astrocytes. In vivo experiments using intracranially implanted D-54 MG glioma xenografts in nude mice showed that a single dose of CB1 (1.5 x 10(8) PFU/tumor) significantly improved survival. Immunohistochemical analyses of expressed adenoviral proteins confirmed adenoviral replication within the tumors. The CB1 oncolytic adenovirus induces a potent antiglioma effect and could ultimately demonstrate clinical relevance and therapeutic utility.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Alabama Birmingham, Gene Therapy Ctr, Birmingham, AL 35294 USA; Inst Catala Oncol, Barcelona 08907, Spain; Univ Texas, MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Alabama System; University of Alabama Birmingham; Catalan Institute of Oncology; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fueyo, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Box 316,1515 Holcombe Blvd, Houston, TX 77030 USA.	jfueyo@mdanderson.org	Alonso, Marta M/AAI-9457-2020; Mitlianga, Paraskevi/AAU-1541-2020	Alonso, Marta M/0000-0002-7520-7351; Mitlianga, Paraskevi/0000-0003-3145-5596; Fueyo, Juan/0000-0001-6941-2335; Gomez-Manzano, Candelaria/0000-0002-1259-2133	NCI NIH HHS [R01CA90879] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090879] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alemany R, 2000, NAT BIOTECHNOL, V18, P723, DOI 10.1038/77283; BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; Balague C, 2001, J VIROL, V75, P7602, DOI 10.1128/JVI.75.16.7602-7611.2001; Bauerschmitz GJ, 2002, CANCER RES, V62, P1266; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Cripe TP, 2001, CANCER RES, V61, P2953; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; Fueyo J, 2003, J NATL CANCER I, V95, P652, DOI 10.1093/jnci/95.9.652; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Howe JA, 2000, MOL THER, V2, P485, DOI 10.1006/mthe.2000.0206; Jakubczak JL, 2003, CANCER RES, V63, P1490; Johnson L, 2002, CANCER CELL, V1, P325, DOI 10.1016/S1535-6108(02)00060-0; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; Lal S, 2000, J NEUROSURG, V92, P326, DOI 10.3171/jns.2000.92.2.0326; Lamfers MLM, 2002, CANCER RES, V62, P5736; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; Ramachandra M, 2001, NAT BIOTECHNOL, V19, P1035, DOI 10.1038/nbt1101-1035; SHENK T, 1991, ADV CANCER RES, V57, P47; Suzuki K, 2001, CLIN CANCER RES, V7, P120; Tsukuda K, 2002, CANCER RES, V62, P3438; van Beusechem VW, 2002, CANCER RES, V62, P6165; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YOSHIDA K, 1995, CURR TOP MICROBIOL, V199, P113	27	48	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1821	1828		10.1038/sj.onc.1207321	http://dx.doi.org/10.1038/sj.onc.1207321			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	15014451				2022-12-17	WOS:000220129500003
J	Li, HX; Seth, A				Li, HX; Seth, A			An RNF11: Smurf2 complex mediates ubiquitination of the AMSH protein	ONCOGENE			English	Article						RNF11; AMSH; smurf2; TGF-beta; breast cancer; RING-H2-finger domain; PY motif	TGF-BETA RECEPTOR; BREAST-CANCER; LIGASE; EPS15; DEGRADATION; ENDOCYTOSIS; PATHWAY; TARGETS; ENDOSOMES; BRCA1	RING-finger proteins play crucial roles in ubiquitination events involved in diverse cellular processes including signal transduction, differentiation and apoptosis. Most of the RING-finger proteins have E3-ubiquitin ligase activity. RNF11 is a small RING-finger protein and harbors a RING-H2 domain and a PY motif that could facilitate protein: protein interaction(s) involved in oncogenesis. To isolate RNF11 protein partners and determine its role in normal and cancer cells, we performed yeast two-hybrid screening. Among 18 in-frame positive clones, three were found to be ZBRK1, Eps15 and AMSH ( associated molecule with the SH3 domain of STAM). ZBRK1 is a KRAB domain containing Zinc-finger protein and is known to repress target gene transcription in a BRCA1-dependent manner. Eps15 is monoubiquitinated and is part of an essential complex involved in the endocytosis of plasma membrane receptors via the clathrin-mediated internalization pathway. Recent studies have shown that AMSH protein is involved in BMP/TGF-beta signaling pathway by binding to Smad6 and Smad7. The association of RNF11 with these binding partners suggests that it would be involved in biological processes such as gene transcription, BMP/TGF-beta signaling and ubiquitination-associated events. Previously, we have shown that RNF11 interacts with the HECT-type E3 ligases AIP4 and Smurf2. Here, we show that RNF11 binds to AMSH in mammalian cells and that this interaction is independent of the RNF11 RING-finger domain and the PY motif. Our results also demonstrate that AMSH is ubiquitinated by Smurf2 E3 ligase in the presence of RNF11 and that a consequent reduction in its steady-state level requires both RNF11 and Smurf2. RNF11 therefore recruits AMSH to Smurf2 for ubiquitination, leading to its degradation by the 26S proteasome. The potential functions of RNF11-mediated degradation of AMSH in breast cancer are discussed.	Sunnybrook & Womens Coll Hlth Sci Ctr, Lab Mol Pathol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Seth, A (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Lab Mol Pathol, Rm E-423B,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	arun.seth@utoronto.ca						Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Bean AJ, 2000, J BIOL CHEM, V275, P15271, DOI 10.1074/jbc.275.20.15271; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Burger A, 1998, ONCOGENE, V16, P327, DOI 10.1038/sj.onc.1201517; Carbone R, 1997, CANCER RES, V57, P5498; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Ishii N, 2001, MOL CELL BIOL, V21, P8626, DOI 10.1128/MCB.21.24.8626-8637.2001; Itoh F, 2001, EMBO J, V20, P4132, DOI 10.1093/emboj/20.15.4132; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KITCHING R, 2003, UNPUB BIOCH BIOPHYS; Nuber U, 1999, J BIOL CHEM, V274, P7576, DOI 10.1074/jbc.274.11.7576; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Salcini AE, 1999, INT J BIOCHEM CELL B, V31, P805, DOI 10.1016/S1357-2725(99)00042-4; Sorkina T, 1999, J CELL SCI, V112, P317; Subramaniam V, 2003, BRIT J CANCER, V89, P1538, DOI 10.1038/sj.bjc.6601301; Tanaka N, 1999, J BIOL CHEM, V274, P19129, DOI 10.1074/jbc.274.27.19129; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	23	48	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1801	1808		10.1038/sj.onc.1207319	http://dx.doi.org/10.1038/sj.onc.1207319			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14755250				2022-12-17	WOS:000220129500001
J	Krauer, KG; Burgess, A; Buck, M; Flanagan, J; Gabrielli, B				Krauer, KG; Burgess, A; Buck, M; Flanagan, J; Gabrielli, B			The EBNA-3 gene family proteins disrupt the G2/M checkpoint	ONCOGENE			English	Article						EBV; EBNA-3; G2/M checkpoint; chk2	EPSTEIN-BARR-VIRUS; CELL-CYCLE CHECKPOINTS; DNA-DAMAGE CHECKPOINT; NUCLEAR ANTIGEN 3C; HISTONE DEACETYLASE; TYROSINE DEPHOSPHORYLATION; MONOCLONAL-ANTIBODY; B-LYMPHOCYTES; J KAPPA; ACTIVATION	The Epstein - Barr nuclear antigens (EBNA), EBNA-3, -4 and - 6, have previously been shown to act as transcriptional regulators, however, this study identifies another function for these proteins, disruption of the G2/M checkpoint. Lymphoblastoid cell lines (LCLs) treated with a G2/M initiating drug azelaic bishydroxamine ( ABHA) did not show a G2/M checkpoint response, but rather they display an increase in cell death, a characteristic of sensitivity to the cytotoxic effects of the drug. Cell cycle analysis demonstrated that the individual expression of EBNA-3, - 4 or - 6 are capable of disrupting the G2/M checkpoint response induced by ABHA resulting in increased toxicity, whereas EBNA-2, and - 5 were not. EBNA-3 gene family protein expression also disrupted the G2/M checkpoint initiated in response to the genotoxin etoposide and the S phase inhibitor hydroxyurea. The G2 arrest in response to these drugs were sensitive to caffeine, suggesting that ATM/ATR signalling in these checkpoint responses may be blocked by the EBNA-3 family proteins. The function of EBNA-3, - 4 and - 6 proteins appears to be more complex than anticipated and these data suggest a role for these proteins in disrupting the host cell cycle machinery.	Univ Queensland, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Univ Queensland, Joint Oncol Program, Brisbane, Qld 4029, Australia; Univ Queensland, Dept Mol & Cellular Pathol, Brisbane, Qld, Australia	QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland; University of Queensland	Krauer, KG (corresponding author), Univ Queensland, Queensland Inst Med Res, Post Off Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.	keniaK@qimr.edu.au	Burgess, Andrew/H-3339-2019; Burgess, Andrew/C-7952-2009; Gabrielli, Brian G/B-3655-2011	Burgess, Andrew/0000-0003-4536-9226; Burgess, Andrew/0000-0003-4536-9226; Gabrielli, Brian G/0000-0003-3933-1651; Flanagan, James/0000-0003-4955-1383				BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Cannell EJ, 1996, ONCOGENE, V13, P1413; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Cludts I, 1998, J VIROL, V72, P1862, DOI 10.1128/JVI.72.3.1862-1869.1998; Connell M. J. O., 2000, TRENDS CELL BIOL, V10, P296; Darbon JM, 2000, J BIOL CHEM, V275, P15363, DOI 10.1074/jbc.275.20.15363; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Grundhoff AT, 1999, J BIOL CHEM, V274, P19136, DOI 10.1074/jbc.274.27.19136; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Kaykas A, 2000, ONCOGENE, V19, P1400, DOI 10.1038/sj.onc.1203365; Kienzle N, 1996, BIOTECHNIQUES, V20, P612; Kienzle N, 1996, VIROLOGY, V224, P167, DOI 10.1006/viro.1996.0518; Krauer KG, 1996, VIROLOGY, V226, P346, DOI 10.1006/viro.1996.0662; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; LOCK RB, 1992, CANCER RES, V52, P1817; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MARSHALL D, 1995, J VIROL, V69, P3624, DOI 10.1128/JVI.69.6.3624-3630.1995; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MAUNDERS MJ, 1994, J GEN VIROL, V75, P769, DOI 10.1099/0022-1317-75-4-769; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Parker GA, 1996, ONCOGENE, V13, P2541; Parker GA, 2000, ONCOGENE, V19, P700, DOI 10.1038/sj.onc.1203327; PETTI L, 1990, VIROLOGY, V176, P563, DOI 10.1016/0042-6822(90)90027-O; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; Radkov SA, 1999, J VIROL, V73, P5688, DOI 10.1128/JVI.73.7.5688-5697.1999; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Robertson ES, 1996, J VIROL, V70, P3068, DOI 10.1128/JVI.70.5.3068-3074.1996; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCULLEY TB, 1984, J VIROL, V52, P88, DOI 10.1128/JVI.52.1.88-93.1984; Sculley TB, 2002, TRANSPLANTATION, V73, P271, DOI 10.1097/00007890-200201270-00021; Shieh SY, 2000, GENE DEV, V14, P289; SILINS SL, 1994, VIROLOGY, V202, P16, DOI 10.1006/viro.1994.1317; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; SINCLAIR AJ, 1992, CELL GROWTH DIFFER, V3, P557; Sinclair AJ, 1998, HISTOL HISTOPATHOL, V13, P461, DOI 10.14670/HH-13.461; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; Villa LL, 1997, ADV CANCER RES, V71, P321, DOI 10.1016/S0065-230X(08)60102-5; Wade M, 2000, MOL CELL BIOL, V20, P1344, DOI 10.1128/MCB.20.4.1344-1360.2000; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhao B, 1996, J VIROL, V70, P4228, DOI 10.1128/JVI.70.7.4228-4236.1996; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	54	48	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1342	1353		10.1038/sj.onc.1207253	http://dx.doi.org/10.1038/sj.onc.1207253			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14716295				2022-12-17	WOS:000189035800002
J	Liu, WM; Powles, T; Shamash, J; Propper, D; Oliver, T; Joel, S				Liu, WM; Powles, T; Shamash, J; Propper, D; Oliver, T; Joel, S			Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity	ONCOGENE			English	Article						GM-CSF; Epo; apoptosis; chemosensitivity; receptors	COLONY-STIMULATING FACTOR; GM-CSF; IN-VITRO; RECEPTOR EXPRESSION; BCL-2 EXPRESSION; LEUKEMIA CELLS; DOUBLE-BLIND; BONE-MARROW; C-KIT; ERYTHROPOIETIN	The recombinant growth factors (GFs) erythropoietin (Epo) and granulocyte-macrophage colony stimulating factor (GM-CSF) have important roles in the management of cancer patients. However, the effects of these GFs at a cellular level are not well understood. We examined the effect of GFs alone, and in combination with cytotoxic chemotherapy, in a panel of seven cell lines. Flow cytometric analysis showed varying levels of receptor expression, which correlated with phosphorylated MAPK expression. Additionally, there were also concomitant increases in BCL-2 protein levels in those cells with high levels of MAPK activation. Although culturing cells with Epo or GM-CSF did not alter cell viability by themselves, GF pretreatment in cell lines expressing higher receptor levels resulted in a reduced magnitude of cell kill following exposure to cytotoxic IC50 concentrations of cisplatin. Subsequent co-culture with either the MEK inhibitor U0126 or the GM-CSF antagonist E21R negated this induced resistance to cytotoxic chemotherapy, confirming the importance of the GF receptor as well as MAPK in mediating these effects. These results suggest that the use of GFs during chemotherapy may be detrimental in those cancers expressing higher levels of the specific receptor. Conversely, our results also suggest that GFs are safe to use in chemotherapeutic regimens if the cancer cells do not overexpress the particular receptor.	St Bartholomews Hosp, Barry Reed Oncol Lab, New Drug Study Grp, London, England	University of London; Queen Mary University London	Liu, WM (corresponding author), Inst Canc Res, Haddow Labs, Med Sect, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	wai.liu@icr.ac.uk	Liu, Wai/B-7877-2008	Liu, Wai/0000-0001-7099-7510; Oliver, Tim/0000-0002-7879-8943				ABELS R, 1993, EUR J CANC S, V2, P2; Acs G, 2002, CANCER-AM CANCER SOC, V95, P969, DOI 10.1002/cncr.10787; Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; BERDEL WE, 1989, BLOOD, V73, P80; BI SC, 1992, LEUKEMIA, V6, P839; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; BRADBURY D, 1994, LEUKEMIA, V8, P786; Bratthauer G L, 1999, Methods Mol Biol, V115, P203; CHERVENICK PA, 1971, BLOOD-J HEMATOL, V37, P131, DOI 10.1182/blood.V37.2.131.131; Chong ZZ, 2002, J CEREBR BLOOD F MET, V22, P503, DOI 10.1097/00004647-200205000-00001; Clark O, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-23; CLARKE BJ, 1977, P NATL ACAD SCI USA, V74, P1105, DOI 10.1073/pnas.74.3.1105; DASILVA JL, 1990, BLOOD, V75, P577; DeJong MO, 1997, STEM CELLS, V15, P275, DOI 10.1002/stem.150275; DEL PL, 1997, SCIENCE, V278, P687; Dempke W, 2000, ANTICANCER RES, V20, P5155; EVERSON MP, 1989, BLOOD, V74, P1472; Fallowfield L, 2002, BRIT J CANCER, V87, P1341, DOI 10.1038/sj.bjc.6600657; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fukumi S, 2000, MOL CELL BIOCHEM, V206, P43, DOI 10.1023/A:1007056727876; Galea HR, 2002, CLIN EXP IMMUNOL, V129, P247, DOI 10.1046/j.1365-2249.2002.01929.x; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gerharz CD, 2001, UROLOGY, V58, P821, DOI 10.1016/S0090-4295(01)01371-1; Hisakawa H, 2001, BLOOD, V98, P3618, DOI 10.1182/blood.V98.13.3618; Iversen PO, 1996, BLOOD, V88, P2634, DOI 10.1182/blood.V88.7.2634.bloodjournal8872634; Iversen PO, 1996, P NATL ACAD SCI USA, V93, P2785, DOI 10.1073/pnas.93.7.2785; Iversen PO, 1997, J BIOL CHEM, V272, P9877; Kapur R, 2001, J BIOL CHEM, V276, P1099, DOI 10.1074/jbc.M007442200; Kolonics A, 2001, CELL SIGNAL, V13, P743, DOI 10.1016/S0898-6568(01)00201-7; KURZROCK R, 1991, LEUKEMIA, V5, P985; LAUGHLIN MJ, 1993, ANN HEMATOL, V67, P267, DOI 10.1007/BF01696346; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; Liu WM, 1998, CANCER CHEMOTH PHARM, V41, P343, DOI 10.1007/s002800050749; Liu WM, 2002, EUR J CANCER, V38, P842, DOI 10.1016/S0959-8049(02)00016-3; Liu WM, 2002, BRIT J CANCER, V86, P1472, DOI 10.1038/sj.bjc.6600288; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; LOTEM J, 1995, CELL GROWTH DIFFER, V6, P647; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MCCREDIE KB, 1971, SCIENCE, V171, P293, DOI 10.1126/science.171.3968.293; MCGUCKIN CP, 1995, EXP HEMATOL, V23, P14; ORAZI A, 1992, BLOOD, V79, P2610; Park SA, 2001, MOL BRAIN RES, V93, P18, DOI 10.1016/S0169-328X(01)00176-0; Pless M, 1997, BLOOD, V89, P3175, DOI 10.1182/blood.V89.9.3175; Ramshaw HS, 2002, EXP HEMATOL, V30, P1124, DOI 10.1016/S0301-472X(02)00903-7; Sachs L, 1996, P NATL ACAD SCI USA, V93, P4742, DOI 10.1073/pnas.93.10.4742; SEGER R, 1992, J BIOL CHEM, V267, P25628; SHABO Y, 1990, LEUKEMIA, V4, P797; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; STEWARD WP, 1993, LANCET, V342, P153, DOI 10.1016/0140-6736(93)91350-U; Vansteenkiste J, 2002, J NATL CANCER I, V94, P1211; Westenfelder C, 2000, KIDNEY INT, V58, P647, DOI 10.1046/j.1523-1755.2000.00211.x; Westphal G, 2002, TUMORI, V88, P150, DOI 10.1177/030089160208800214; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067	57	48	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					981	990		10.1038/sj.onc.1207294	http://dx.doi.org/10.1038/sj.onc.1207294			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647427				2022-12-17	WOS:000188486600014
J	Cho, NH; Hong, KP; Hong, SH; Kang, S; Chung, KY; Cho, SH				Cho, NH; Hong, KP; Hong, SH; Kang, S; Chung, KY; Cho, SH			MMP expression profiling in recurred stage IB lung cancer	ONCOGENE			English	Article						recurred stage IB lung cancer; MMP-10; MMP-12; c-DNA array; real-time RT-PCR	MATRIX METALLOPROTEINASES; CARCINOMAS; GENES; METASTASIS; INHIBITORS; OVEREXPRESSION; STROMELYSIN-2; COLLAGENASE; GELATINASE; TUMORS	We aimed to clarify the prime role of recurrence in stage I lung cancer. To determine the expression profiles, quantitative RT - PCR and real-time PCR were performed subsequently to evaluate the validity of meaningful molecules identified by 0.12K c-DNA array experiment surveys. In all, 10 lung cancer patients presenting with recurrence of stage IB were selected and compared with 10 stage IB lung cancer patients without recurrence since biopsied 3 years previously. On c-DNA microarray data analysis using pairs of recurred and the corresponding nonrecurred patients, the following genes were found to be upregulated in the recurred cases: matrix metalloproteinase (MMP)-10 in five cases, MMP-12 in two cases, MMP-11, MMP-14, MMP-15, fos, cyclin E2, E2F3, TGF-alpha in each one case. The most frequently upregulated genes in recurred lung cancers were MMP-10 (stromelysin-2) and MMP-12 ( macrophage elastase). On transcriptional assay by quantitative RT - PCR and real-time RT - PCR analysis to validate those molecules, both transcripts of MMP-10 and MMP-12 were significantly more upregulated in recurred stage IB lung cancer than in the non-recurred stage IB lung cancer ( P = 0.004). Transcript levels were identical to c-DNA array data. The protein levels of these entities were also evaluated by immunohistochemistry of archival slides. By immunohistochemistry, MMP-10 monoclonal antibody showed more intense immunoreactivity in the recurred stage IB lung cancer than in the nonrecurred stage IB lung cancer ( P = 0.0313). Our approach revealed that MMP-10 plays an important role in the recurrence in stage IB lung cancer, irrespective of the histologic type.	Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Thorac Surg, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Cho, SH (corresponding author), Yonsei Univ, Coll Med, Dept Pathol, Shinchon Dong 134, Seoul, South Korea.	shjo@yumc.yonsei.ac.kr		KANG, SUKI/0000-0002-9957-3479; jo, namhun/0000-0002-0045-6441				Bolon I, 1997, AM J PATHOL, V150, P1619; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; Cai M, 2002, CLIN CANCER RES, V8, P1152; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; Delebecq TJ, 2000, CLIN CANCER RES, V6, P1086; Fong KM, 1996, CLIN CANCER RES, V2, P1369; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Kerkela E, 2001, BRIT J CANCER, V84, P659, DOI 10.1054/bjoc.2000.1634; Langmann T, 2003, CLIN CHEM, V49, P230, DOI 10.1373/49.2.230; MARTINI N, 1977, J THORAC CARDIOV SUR, V74, P499; MARTINI N, 1995, J THORAC CARDIOV SUR, V109, P120, DOI 10.1016/S0022-5223(95)70427-2; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Murray GI, 2001, J PATHOL, V195, P135, DOI 10.1002/1096-9896(200109)195:2<135::AID-PATH939>3.0.CO;2-G; NAGAKAWA H, 1994, JPN J CANCER RES, V85, P934; NAGASE H, 1998, STROMELYSINS 1 2, P43; Nawrocki B, 1997, INT J CANCER, V72, P556, DOI 10.1002/(SICI)1097-0215(19970807)72:4<556::AID-IJC2>3.3.CO;2-#; OHORI NP, 1992, AM J SURG PATHOL, V16, P675, DOI 10.1097/00000478-199207000-00006; Passlick B, 2000, CLIN CANCER RES, V6, P3944; Rechardt O, 2000, J INVEST DERMATOL, V115, P778, DOI 10.1046/j.1523-1747.2000.00135.x; SHAPIRO SD, 1998, MATRIX METALLOPROTEI, P185; SOINI Y, 1993, AM J PATHOL, V142, P1622; SREENATH T, 1992, CANCER RES, V52, P4942; Thomas P, 2000, J PATHOL, V190, P150; TOKURAKU M, 1995, INT J CANCER, V64, P355, DOI 10.1002/ijc.2910640513; URBANSKI SJ, 1992, BRIT J CANCER, V66, P1188, DOI 10.1038/bjc.1992.434	27	48	53	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					845	851		10.1038/sj.onc.1207140	http://dx.doi.org/10.1038/sj.onc.1207140			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14647437				2022-12-17	WOS:000188304900024
J	Ader, I; Delmas, C; Bonnet, J; Rochaix, P; Favre, G; Toulas, C; Cohen-Jonathan-Moyal, E				Ader, I; Delmas, C; Bonnet, J; Rochaix, P; Favre, G; Toulas, C; Cohen-Jonathan-Moyal, E			Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts	ONCOGENE			English	Article						Rho; glioma; hypoxia; MMP; angiogenesis	FARNESYLTRANSFERASE INHIBITOR; H-RAS; TUMOR-GROWTH; CELL-LINES; NUDE-MICE; IN-VIVO; TRANSGENIC MICE; HELA-CELLS; ANGIOGENESIS; REGRESSION	We previously demonstrated in vitro that inhibiting the biological pathways of the small GTPase Rho radio-sensitizes the human glioma U87 cell line. The aim of this study was to determine if Rho might be involved in the control of in vivo radiosensitivity altogether by controlling cellular radioresistance and by modifying tumor micro-environment. We demonstrate here that the in vivo induction of the dominant negative of Rho, RhoBN19, in U87 xenografts induces a significant decrease of tumor cell survival after irradiation more important than the one we previously observed in vitro. This in vivo increased effect of RhoBN19 expression is due to the improvement of the tumor oxygenation associated with a significant decrease of the vessel density and of the metalloproteinase 2 (MMP2) expression. Moreover, in vitro RhoBN19 expression in U87 cells leads to the inhibition of MMP2 activity. Our results demonstrate for the first time that inhibiting Rho pathways modifies the in vivo radiosensitivity of human glioma cells by controlling intrinsic radioresistance, hypoxia and angiogenesis. These data strongly suggest that Rho should be a major determinant of cellular resistance to ionizing radiation.	Inst Claudius Regaud, Dept Radiotherapie, F-31052 Toulouse, France; Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563, F-31052 Toulouse, France; Inst Claudius Regaud, Anat Pathol Lab, F-31052 Toulouse, France	UNICANCER; Institut Claudius Regaud; UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud	Cohen-Jonathan-Moyal, E (corresponding author), Inst Claudius Regaud, Dept Radiotherapie, 20-24 Rue Pont St Pierre, F-31052 Toulouse, France.		Moyal, Elizabeth/A-9802-2015; Rochaix, Philippe/O-4710-2014; delmas, caroline/O-9241-2014; Toulas, Christine/P-3838-2014; Ader-Perarnau, Isabelle/F-7160-2017; FAVRE, Gilles/K-9189-2014	Moyal, Elizabeth/0000-0002-6593-9276; Rochaix, Philippe/0000-0001-6238-1599; Toulas, Christine/0000-0003-1261-1725; FAVRE, Gilles/0000-0002-2344-1883; ADER, isabelle/0000-0001-5103-8509				ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Ader I, 2002, ONCOGENE, V21, P5998, DOI 10.1038/sj.onc.1205746; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Bernhard EJ, 1996, CANCER RES, V56, P1727; Bernhard EJ, 1998, CANCER RES, V58, P1754; Bernsen HJJA, 1999, J NEURO-ONCOL, V44, P129, DOI 10.1023/A:1006363215260; Bernsen HJJA, 1998, J NEURO-ONCOL, V38, P51, DOI 10.1023/A:1005957201431; Brizel DM, 1996, CANCER RES, V56, P941; Brizel DM, 1997, INT J RADIAT ONCOL, V38, P285, DOI 10.1016/S0360-3016(97)00101-6; Cohen-Jonathan E, 1999, RADIAT RES, V152, P404, DOI 10.2307/3580225; Cohen-Jonathan E, 2000, RADIAT RES, V154, P125, DOI 10.1667/0033-7587(2000)154[0125:FIPTAE]2.0.CO;2; Cohen-Jonathan E, 2001, CANCER RES, V61, P2289; Deb S, 1999, J NEUROSCI RES, V55, P44, DOI 10.1002/(SICI)1097-4547(19990101)55:1<44::AID-JNR6>3.0.CO;2-G; Delmas C, 2002, INT J CANCER, V100, P43, DOI 10.1002/ijc.10439; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; Fenton BM, 1999, BRIT J CANCER, V79, P464, DOI 10.1038/sj.bjc.6690072; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; HOCKEL M, 1994, ADV EXP MED BIOL, V345, P445; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Itoh T, 1998, CANCER RES, V58, P1048; Kakeji Y, 1997, INVEST NEW DRUG, V15, P39, DOI 10.1023/A:1005718628223; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Koike T, 2000, BIOCHEM BIOPH RES CO, V277, P43, DOI 10.1006/bbrc.2000.3630; Kunkel P, 2001, CANCER RES, V61, P6624; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MCKENNA WG, 1991, RADIAT RES, V125, P283, DOI 10.2307/3578111; MCKENNA WG, 1990, INT J RADIAT ONCOL, V18, P849, DOI 10.1016/0360-3016(90)90407-B; Nozue M, 1997, J SURG ONCOL, V66, P30, DOI 10.1002/(SICI)1096-9098(199709)66:1<30::AID-JSO7>3.0.CO;2-O; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; SUN JZ, 1995, CANCER RES, V55, P4243; TEICHER BA, 1995, INT J CANCER, V61, P732, DOI 10.1002/ijc.2910610523; Turcotte S, 2003, J CELL SCI, V116, P2247, DOI 10.1242/jcs.00427; Uchida S, 2000, BIOCHEM BIOPH RES CO, V269, P633, DOI 10.1006/bbrc.2000.2315; VAN AL, 1997, GENE DEV, V11, P2295; van Golen KL, 2000, NEOPLASIA, V2, P418, DOI 10.1038/sj.neo.7900115; Wolff JEA, 1997, KLIN PADIATR, V209, P275, DOI 10.1055/s-2008-1043962; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	41	48	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8861	8869		10.1038/sj.onc.1207095	http://dx.doi.org/10.1038/sj.onc.1207095			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654782				2022-12-17	WOS:000186982200007
J	Aebersold, DM; Landt, O; Berthou, S; Gruber, G; Beer, KT; Greiner, RH; Zimmer, Y				Aebersold, DM; Landt, O; Berthou, S; Gruber, G; Beer, KT; Greiner, RH; Zimmer, Y			Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx	ONCOGENE			English	Article						Met receptor; activating mutation; radiotherapy; head and neck cancer	GROWTH-FACTOR RECEPTOR; SOMATIC MUTATIONS; FACTOR PROTECTS; SCATTER FACTOR; C-MET; RADIATION; DNA; CARCINOMAS; ONCOGENE; KINASE	Aberrant signalling through the hepatocyte growth factor/scatter factor receptor Met has been implicated in various aspects of the development of human cancer including the promotion of tumour invasion, angiogenesis and metastasis. Moreover, experimental data indicate that activation of the Met receptor may be involved in cellular resistance towards antineoplastic treatments such as chemotherapy and ionizing radiation. We determined the prevalence and clinical impact of the Met-activating mutation Y1253D in patients with squamous cell cancer of the oropharynx treated by radical radiotherapy. To screen archival tissue for the presence of a low-abundance point mutation, we developed a sensitive screening method using real-time polymerase chain reaction along with peptide nucleic acid-based DNA clamping and melting curve analysis. By this approach, Met Y1253D was detected in tumours of 15 out of 138 patients (10.9%). Both univariate and multivariate survival analysis revealed Met Y1253D to be significantly associated with impaired local tumour control. Our results provide evidence that the Met-activating mutation Y1253D is present in a notable subset of patients with oropharyngeal cancer and indicate that it may interfere with radioresponsiveness of these tumours, supporting the notion of aberrant Met signalling as a potential target for radiosensitization.	Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland; MOLBIOL, TIB, Berlin, Germany; Inselspital, Dept Radiat Oncol, Bern, Switzerland	University of Bern; University of Bern; University Hospital of Bern	Zimmer, Y (corresponding author), Univ Bern, Dept Clin Res, Murtenstr 35-D-809, CH-3010 Bern, Switzerland.		Aebersold, Daniel Matthias/C-2946-2013	Aebersold, Daniel Matthias/0000-0002-9493-3834				Aebersold DM, 2001, INT J CANCER, V96, P41, DOI 10.1002/1097-0215(20010220)96:1<41::AID-IJC5>3.0.CO;2-F; Bowers DC, 2000, CANCER RES, V60, P4277; CHIARA F, 2003, J BIOL CHEM, V12, P12; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Lindel K, 2001, CANCER-AM CANCER SOC, V92, P805, DOI 10.1002/1097-0142(20010815)92:4<805::AID-CNCR1386>3.0.CO;2-9; Lorenzato A, 2002, CANCER RES, V62, P7025; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Park WS, 1999, CANCER RES, V59, P307; Pietras RJ, 1999, CANCER RES, V59, P1347; Raben David, 2002, Expert Rev Anticancer Ther, V2, P461, DOI 10.1586/14737140.2.4.461; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Sun XY, 2002, NAT BIOTECHNOL, V20, P186, DOI 10.1038/nbt0202-186; To CTT, 1998, ONCOL REP, V5, P1013; Turner BC, 1997, CANCER RES, V57, P3079	19	48	53	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8519	8523		10.1038/sj.onc.1206968	http://dx.doi.org/10.1038/sj.onc.1206968			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627992				2022-12-17	WOS:000186650300015
J	Oksvold, MP; Thien, CBF; Widerberg, J; Chantry, A; Huitfeldt, HS; Langdon, WY				Oksvold, MP; Thien, CBF; Widerberg, J; Chantry, A; Huitfeldt, HS; Langdon, WY			Serine mutations that abrogate ligand-induced ubiquitination and internalization of the EGF receptor do not affect c-Cbl association with the receptor	ONCOGENE			English	Article						receptor tyrosine kinase; endocytosis; down-regulation; ubiquitination	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; DOWN-REGULATION; THREONINE PHOSPHORYLATION; RING FINGER; TRAFFICKING; PATHWAY; GRB2; SITE; DESENSITIZATION	In the present study, we examined EGF-induced internalization, degradation and trafficking of the epidermal growth factor receptor (EGFR) mutated at serines 1046, 1047, 1057 and 1142 located in its cytoplasmic carboxyterminal region. We found the serine-mutated EGFR to be inhibited in EGF-induced internalization and degradation in NIH3T3 cells. We therefore tested the hypothesis that these mutations affect ligand-induced c-Cbl association with the receptor, leading to inhibited receptor ubiquitination. EGF was unable to induce ubiquitination of the serine-mutated EGFR, yet EGF-induced phosphorylation of the c-Cbl-binding site at tyrosine 1045, and c-Cbl-EGFR association, was unaffected. To compare the relevance of these serine residues with tyrosine 1045 in their regulation of c-Cbl binding and receptor ubiquitination, we analysed an EGFR mutated at tyrosine 1045 (Y1045F). EGF-induced c-Cbl-EGFR binding was partially inhibited, and receptor ubiquitination was abrogated in cells expressing Y1045F-EGFR. In contrast, ligand-induced internalization and degradation of the Y1045F mutant was similar to that of wild-type EGFR. Together, our data indicate that the serine residues and tyrosine 1045 are essential for EGF-induced receptor ubiquitination, but only the serine residues are critical for EGFR internalization and degradation.	Univ Oslo, Rikshosp, Inst Pathol, Lab Toxicopathol, N-0027 Oslo, Norway; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Western Australia, Queen Elizabeth II Med Ctr, Dept Pathol, Nedlands, WA 6009, Australia	University of Oslo; National Hospital Norway; University of East Anglia; University of Western Australia	Oksvold, MP (corresponding author), Univ Oslo, Rikshosp, Inst Pathol, Lab Toxicopathol, N-0027 Oslo, Norway.		Thien, Christine/GQP-0424-2022	Thien, Christine/0000-0003-3884-5546				Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Clague MJ, 2001, J CELL SCI, V114, P3075; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; COVERS R, 1998, J BIOL CHEM, V273, P16426; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; ECCLES SA, 1994, INVAS METAST, V14, P337; Feinmesser RL, 1999, J BIOL CHEM, V274, P16168, DOI 10.1074/jbc.274.23.16168; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Franklin WA, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.31520; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; HELIN K, 1991, J BIOL CHEM, V266, P8363; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; LUND KA, 1990, J BIOL CHEM, V265, P20517; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Oksvold MP, 2000, J HISTOCHEM CYTOCHEM, V48, P21, DOI 10.1177/002215540004800103; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; SORKIN A, 1992, J BIOL CHEM, V267, P8672; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Tebar F, 2002, MOL BIOL CELL, V13, P2057, DOI 10.1091/mbc.01-12-0571; THEROUX SJ, 1992, J BIOL CHEM, V267, P7967; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; WILEY HS, 1991, J BIOL CHEM, V266, P11083; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	41	48	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8509	8518		10.1038/sj.onc.1207117	http://dx.doi.org/10.1038/sj.onc.1207117			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627991				2022-12-17	WOS:000186650300014
J	Whitmarsh, RJ; Saginario, C; Zhuo, Y; Hilgenfeld, E; Rappaport, EF; Megonigal, MD; Carroll, M; Liu, M; Osheroff, N; Cheung, NKV; Slater, DJ; Ried, T; Knutsen, T; Blair, IA; Felix, CA				Whitmarsh, RJ; Saginario, C; Zhuo, Y; Hilgenfeld, E; Rappaport, EF; Megonigal, MD; Carroll, M; Liu, M; Osheroff, N; Cheung, NKV; Slater, DJ; Ried, T; Knutsen, T; Blair, IA; Felix, CA			Reciprocal DNA topoisomerase II cleavage events at 5 '-TATTA-3 ' sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing	ONCOGENE			English	Article						t(9;11) translocation; DNA topoisomerase II; secondary leukemia; etoposide; etoposide catechol; etoposide quinone	ACUTE MYELOID-LEUKEMIA; BALANCED CHROMOSOME-ABERRATIONS; ACUTE LYMPHOBLASTIC-LEUKEMIA; SECONDARY ACUTE-LEUKEMIA; CLUSTER REGION; MYELODYSPLASTIC SYNDROMES; RELIGATION REACTION; TRANSLOCATION; GENE; COMPLEX	Few t(9;11) translocations in DNA topoisomerase II inhibitor-related leukemias have been studied in detail and the DNA damage mechanism remains controversial. We characterized the der(11) and der(9) genomic breakpoint junctions in a case of AML following etoposide and doxorubicin. Etoposide-, etoposide metabolite- and doxorubicin-induced DNA topoisomerase II cleavage was examined in normal homologues of the MLL and AF-9 breakpoint sequences using an in vitro assay. Induction of DNA topoisomerase II cleavage complexes in CEM and K562 cell lines was investigated using an in vivo complex of enzyme assay. The translocation occurred between identical 5'-TATTA-3' sequences in MLL intron 8 and AF-9 intron 5 without the gain or loss of bases. The 5'-TATTA-3' sequences were reciprocally cleaved by DNA topoisomerase II in the presence of etoposide, etoposide catechol or etoposide quinone, creating homologous 4-base 5' overhangs that would anneal to form both breakpoint junctions without any processing. der(11) and der(4) translocation breakpoints in a treatment-related ALL at the same site in MLL are consistent with a damage hotspot. Etoposide and both etoposide metabolites induced DNA topoisomerase II cleavage complexes in the hematopoietic cell lines. These results favor the model in which the chromosomal breakage leading to MLL translocations in DNA topoisomerase II inhibitor-related leukemias is a consequence of DNA topoisomerase II cleavage.	Childrens Hosp Philadelphia, Div Oncol, Abramson Res Ctr, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Canc Pharmacol, Philadelphia, PA 19104 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Hosp Univ Penn, Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Josephy Stokes Jr Res Inst, Philadelphia, PA 19104 USA; NCI, Genet Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Memorial Sloan Kettering Cancer Center; Vanderbilt University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Jefferson University	Felix, CA (corresponding author), Childrens Hosp Philadelphia, Div Oncol, Abramson Res Ctr, Rm 902B,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	felix@email.chop.edu	Rappaport, Eric/GRO-4051-2022; Blair, Ian A/B-3320-2010		NCI NIH HHS [CA85469, CA80175, CA77683] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077683, R01CA080175, R01CA085469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; Aplan PD, 1996, BLOOD, V87, P2649, DOI 10.1182/blood.V87.7.2649.bloodjournal8772649; Atlas M, 1998, LEUKEMIA, V12, P1895, DOI 10.1038/sj.leu.2401223; BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; Ben-Yehuda M, 2002, BLOOD, V100, p324A; Betti CJ, 2003, CANCER RES, V63, P1377; Betti CJ, 2001, CANCER RES, V61, P4550; Blanco JG, 2001, P NATL ACAD SCI USA, V98, P10338, DOI 10.1073/pnas.181199898; Bloomfield CD, 2002, GENE CHROMOSOME CANC, V33, P362, DOI 10.1002/gcc.10046; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; Bromberg KD, 2003, J BIOL CHEM, V278, P7406, DOI 10.1074/jbc.M212056200; Bromberg KD, 2001, BIOCHEMISTRY-US, V40, P8410, DOI 10.1021/bi010681q; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Byl JAW, 2001, BIOCHEMISTRY-US, V40, P712, DOI 10.1021/bi0021838; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P6611, DOI 10.1093/nar/18.22.6611; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P4553, DOI 10.1093/nar/18.15.4553; CHARRON M, 1991, CHROMOSOMA, V100, P97, DOI 10.1007/BF00418242; Daheron L, 2001, GENE CHROMOSOME CANC, V31, P382, DOI 10.1002/gcc.1157; DOMER PH, 1995, LEUKEMIA, V9, P1305; FELIX CA, 1995, CANCER RES, V55, P4287; Felix CA, 1999, MOL DIAGN, V4, P269, DOI 10.1016/S1084-8592(99)80002-2; Felix CA, 1997, BLOOD, V90, P4679, DOI 10.1182/blood.V90.12.4679.4679_4679_4686; Felix CA, 2001, MED PEDIATR ONCOL, V36, P525, DOI 10.1002/mpo.1125; Felix CA, 1998, P NATL ACAD SCI USA, V95, P13176, DOI 10.1073/pnas.95.22.13176; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; Gillert E, 1999, ONCOGENE, V18, P4663, DOI 10.1038/sj.onc.1202842; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; KAUFMANN SH, 1998, BIOCHIM BIOPHYS ACTA, V1400, P196; Langer T, 2003, GENE CHROMOSOME CANC, V36, P393, DOI 10.1002/gcc.10167; LEE MP, 1992, NUCLEIC ACIDS RES, V20, P5027, DOI 10.1093/nar/20.19.5027; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lovett BD, 2001, BIOCHEMISTRY-US, V40, P1159, DOI 10.1021/bi002361x; Lovett BD, 2001, P NATL ACAD SCI USA, V98, P9802, DOI 10.1073/pnas.171309898; LOZZIO BB, 1979, LEUKEMIA RES, V3, P363, DOI 10.1016/0145-2126(79)90033-X; Megonigal MD, 1997, P NATL ACAD SCI USA, V94, P11583, DOI 10.1073/pnas.94.21.11583; Megonigal MD, 2000, P NATL ACAD SCI USA, V97, P2814, DOI 10.1073/pnas.050397097; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; MULLER MT, 1988, BIOCHEMISTRY-US, V27, P8369, DOI 10.1021/bi00422a012; NEGRINI M, 1993, CANCER RES, V53, P4489; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; POMMIER Y, 1993, CAUSES CONSEQUENCES, P277; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Raffini LJ, 2002, P NATL ACAD SCI USA, V99, P4568, DOI 10.1073/pnas.062066799; RAFFINI LJ, 2002, P ANR M 2002; RATAIN MJ, 1987, BLOOD, V70, P1412; Reichel M, 2001, ONCOGENE, V20, P2900, DOI 10.1038/sj.onc.1204401; Ross JA, 1996, CANCER CAUSE CONTROL, V7, P581, DOI 10.1007/BF00051700; ROSS JA, 2003, AM SOC CLIN ONCOL, V3, P243; Rowley JD, 2002, GENE CHROMOSOME CANC, V33, P331, DOI 10.1002/gcc.10040; SANDOVAL C, 1993, J CLIN ONCOL, V11, P1039, DOI 10.1200/JCO.1993.11.6.1039; SECKERWALKER LM, 1985, MED PEDIATR ONCOL, V13, P48, DOI 10.1002/mpo.2950130112; Sim SP, 2001, J BIOL CHEM, V276, P31590, DOI 10.1074/jbc.M103962200; Slater DJ, 2002, ONCOGENE, V21, P4706, DOI 10.1038/sj.onc.1205572; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; Strick R, 2000, P NATL ACAD SCI USA, V97, P4790, DOI 10.1073/pnas.070061297; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; SUBRAMANIAN D, 1995, CANCER RES, V55, P2097; SUBRAMANIAN D, 2001, DNA TOPOISOMERASE 2; Super HG, 1997, GENE CHROMOSOME CANC, V20, P185, DOI 10.1002/(SICI)1098-2264(199710)20:2<185::AID-GCC9>3.0.CO;2-#; UZMAN BG, 1966, CANCER, V19, P1725, DOI 10.1002/1097-0142(196611)19:11<1725::AID-CNCR2820191142>3.0.CO;2-T; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WEH HJ, 1986, J CLIN ONCOL, V4, P1518, DOI 10.1200/JCO.1986.4.10.1518; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014; Zhou RH, 1997, CANCER RES, V57, P4699; Zinkevich Vitaly, 2000, Molecular Biology Today, V1, P29	69	48	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8448	8459		10.1038/sj.onc.1207052	http://dx.doi.org/10.1038/sj.onc.1207052			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627986				2022-12-17	WOS:000186650300009
J	Tokumaru, Y; Nomoto, S; Jeronimo, C; Henrique, R; Harden, S; Trink, B; Sidransky, D				Tokumaru, Y; Nomoto, S; Jeronimo, C; Henrique, R; Harden, S; Trink, B; Sidransky, D			Biallelic inactivation of the RIZ1 gene in human gastric cancer	ONCOGENE			English	Article						hypermethylation; RIZ1; gastric cancer tumor suppressor gene; gene silencing	TUMOR-SUPPRESSOR GENE; METHYLTRANSFERASE SUPERFAMILY/; HYPERMETHYLATION; METHYLATION; PROTEIN; INSTABILITY; MEMBER; SERUM; DNA	The distal short arm of chromosome 1 is commonly deleted in a variety of human neoplasms including gastrointestinal cancer. Genetic alterations of the retinoblastoma protein-interacting zing-finger gene (RIZ)1 including loss of heterozygosity (LOH) at 1p36, frame-shift mutations, and promoter hypermethylation were reported previously in several cancers. In this study, we evaluated RIZ1 in 30 primary gastric cancers and found frameshift mutations in two cases (6.7%). Moreover, using real-time quantitative methylation-specific PCR, methylation of the RIZ1 promoter was detected in 11 (37%) cases. In all 11 cases with methylation, inactivation of the second allele occurred through frameshift mutation, LOH or promoter methylation. Our results suggest that RIZ1 is a specific target of inactivation in human gastric cancer.	Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Head & Neck Canc Res Div, Baltimore, MD 21205 USA; Portuguese Inst Oncol, Dept Genet, P-4200072 Oporto, Portugal; Portuguese Inst Oncol, Dept Pathol, P-4200072 Oporto, Portugal	Johns Hopkins University; Universidade de Coimbra; Universidade de Coimbra	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Head & Neck Canc Res Div, 818 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.		Henrique, Rui Manuel Ferreira/I-2757-2013; Jerónimo, Carmen/H-3284-2013	Henrique, Rui Manuel Ferreira/0000-0003-3171-4666; Jerónimo, Carmen/0000-0003-4186-5345; Harden, Susan Victoria/0000-0001-6067-7177	NCI NIH HHS [1 U01 CA84986] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084986] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1997, J CLIN PATHOL; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497; Du Y, 2001, CANCER RES, V61, P8094; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Esteller M, 2000, CANCER RES, V60, P4366; Esteller M, 2001, CANCER RES, V61, P3225; Fang W, 2000, GENE CHROMOSOME CANC, V28, P269, DOI 10.1002/1098-2264(200007)28:3<269::AID-GCC4>3.0.CO;2-K; Jiang GL, 1999, INT J CANCER, V83, P541, DOI 10.1002/(SICI)1097-0215(19991112)83:4<541::AID-IJC17>3.0.CO;2-F; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035; Nomoto S, 2000, GENE CHROMOSOME CANC, V28, P342, DOI 10.1002/1098-2264(200007)28:3<342::AID-GCC13>3.0.CO;2-A; Piao Z, 2000, CANCER RES, V60, P4701; Sakurada K, 2001, GENE CHROMOSOME CANC, V30, P207, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1080>3.0.CO;2-V; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Toyota M, 1999, CANCER RES, V59, P5438; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Usadel H, 2002, CANCER RES, V62, P371; Weith A, 1996, CYTOGENET CELL GENET, V72, P114	20	48	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2003	22	44					6954	6958		10.1038/sj.onc.1206403	http://dx.doi.org/10.1038/sj.onc.1206403			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534544				2022-12-17	WOS:000185843400018
J	Reiss, K; Khalili, K				Reiss, K; Khalili, K			Viruses and cancer: lessons from the human polyomavirus, JCV	ONCOGENE			English	Review						tumorigenesis; T-antigen; oncogene; JC virus; PML	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; HUMAN NEUROTROPIC POLYOMAVIRUS; INSULIN-RECEPTOR SUBSTRATE-1; HUMAN PAPOVAVIRUS JC; SMALL TUMOR-ANTIGEN; PROTEIN T-ANTIGEN; TRANSGENIC MICE; BETA-CATENIN; SIMIAN VIRUS-40; BRAIN-TUMORS	The possible role of eucaryotic viruses in the development of cancer has been the subject of intense investigation during the past 50 years. Thus far, a strong link between some RNA and DNA viruses and various cancers in humans has been established and the transforming activity of several of the viruses in cell culture and their oncogenecity in experimental animals has been well documented. Perhaps, one of the most common themes among the oncogenic viruses rests in the ability of one or more of the viral proteins to deregulate pathways involved in the control of cell proliferation. For example, inactivation of tumor suppressors through their association with viral transforming proteins, and/or impairment of signal transduction pathways upon viral infection and expression of viral proteins are among the key biological events that can either trigger and/or contribute to the process of cancer. In recent years, more attention has been paid to human polyomaviruses, particularly JC virus (JCV), which infects greater than 80% of the human population, due to the ability of this virus to induce a fatal demyelinating disease in the brain, its presence in various tumors of central nervous system (CNS) and non-CNS origin, and the oncogenic potential of this virus in several laboratory animal models. Here, we will focus our attention on JCV and describe several pathways employed by the virus to contribute to and/or accelerate cancer development.	Temple Univ, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA.							Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Berger JR, 1998, ANN NEUROL, V44, P341, DOI 10.1002/ana.410440309; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; Bofill-Mas S, 2001, J VIROL, V75, P10290, DOI 10.1128/JVI.75.21.10290-10299.2001; BOLLAG B, 1989, J VIROL, V63, P863, DOI 10.1128/JVI.63.2.863-872.1989; Bollag B, 2000, VIROLOGY, V274, P165, DOI 10.1006/viro.2000.0451; CARSWELL S, 1986, J VIROL, V60, P1055, DOI 10.1128/JVI.60.3.1055-1061.1986; CASTAIGNE P, 1974, REV NEUROL-FRANCE, V130, P379; Darbinian N, 2001, J CELL PHYSIOL, V189, P334, DOI 10.1002/jcp.10029; Del Valle L, 2002, J NEUROVIROL, V8, P138, DOI 10.1080/13550280290101111; Del Valle L, 2002, CLIN CANCER RES, V8, P1822; Del Valle L, 2001, CANCER RES, V61, P4287; Del Valle L, 2002, JNCI-J NATL CANCER I, V94, P267, DOI 10.1093/jnci/94.4.267; DELVALLE L, 2001, HUMAN POLYOMAVIRUSES, P409; Eberhart CG, 2000, J NEUROPATH EXP NEUR, V59, P333, DOI 10.1093/jnen/59.4.333; Enam S, 2002, CANCER RES, V62, P7093; FAREED GC, 1978, MICROBIOLOGY 1978, P427; Franks RR, 1996, ONCOGENE, V12, P2573; FRISQUE RJ, 1980, J VIROL, V35, P265, DOI 10.1128/JVI.35.1.265-269.1980; Frisque RJ, 1992, MOL NEUROVIROLOGY PA, P25; Gallia GL, 1998, J BIOL CHEM, V273, P32662, DOI 10.1074/jbc.273.49.32662; Gallia GL, 1998, J NEUROVIROL, V4, P175, DOI 10.3109/13550289809114517; Gan DD, 2001, ONCOGENE, V20, P4864, DOI 10.1038/sj.onc.1204670; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Gordon J, 2000, ONCOGENE, V19, P4840, DOI 10.1038/sj.onc.1203849; HAGGERTY S, 1989, J VIROL, V63, P2180, DOI 10.1128/JVI.63.5.2180-2190.1989; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Howard CM, 1998, J NATL CANCER I, V90, P1451, DOI 10.1093/jnci/90.19.1451; KANG SS, 1992, VIROLOGY, V191, P754, DOI 10.1016/0042-6822(92)90251-J; KHALILI K, 1988, P NATL ACAD SCI USA, V85, P354, DOI 10.1073/pnas.85.2.354; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; London W T, 1983, Prog Clin Biol Res, V105, P227; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; Monaco MCG, 1996, J VIROL, V70, P7004, DOI 10.1128/JVI.70.10.7004-7012.1996; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; OHSUMI S, 1986, ACTA PATHOL JAPON, V36, P815; Patti R, 2000, INT J ONCOL, V16, P577; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Polakis P, 2000, GENE DEV, V14, P1837; Prins C, 2001, J NEUROVIROL, V7, P250; RAJ GV, 1995, INT J ONCOL, V7, P801; Reiss Krzysztof, 2002, Expert Opin Ther Targets, V6, P539, DOI 10.1517/14728222.6.5.539; RESNICK J, 1986, J VIROL, V60, P1098, DOI 10.1128/JVI.60.3.1098-1106.1986; Ricciardiello L, 2000, GASTROENTEROLOGY, V119, P1228, DOI 10.1053/gast.2000.19269; Ricciardiello L, 2001, J VIROL, V75, P1996, DOI 10.1128/JVI.75.4.1996-2001.2001; RICHARDSON E, 1961, NEW ENGL J MED, V265, P815, DOI 10.1056/NEJM196110262651701; Safak M, 1999, J VIROL, V73, P10146, DOI 10.1128/JVI.73.12.10146-10157.1999; Safak M, 2001, J VIROL, V75, P1476, DOI 10.1128/JVI.75.3.1476-1486.2001; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Shintaku M, 2000, J NEUROPATH EXP NEUR, V59, P921, DOI 10.1093/jnen/59.10.921; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SIMA AAF, 1983, ANN NEUROL, V14, P183, DOI 10.1002/ana.410140205; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; VARAKIS J, 1978, CANCER RES, V38, P1718; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; WALKER DL, 1978, MICROBIOLOGY, P432; Wang JY, 2001, ONCOGENE, V20, P3857, DOI 10.1038/sj.onc.1204532; WHEAT WH, 1994, MOL CELL BIOL, V14, P5881, DOI 10.1128/MCB.14.9.5881; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZURHEIN GM, 1979, NATL CANCER I MONOGR, V51, P205	67	48	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 29	2003	22	42					6517	6523		10.1038/sj.onc.1206959	http://dx.doi.org/10.1038/sj.onc.1206959			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528276				2022-12-17	WOS:000185700700008
J	Kim, YK; Han, JW; Woo, YN; Chun, JK; Yoo, JY; Cho, EJ; Hong, SY; Lee, HY; Lee, YW; Lee, HW				Kim, YK; Han, JW; Woo, YN; Chun, JK; Yoo, JY; Cho, EJ; Hong, SY; Lee, HY; Lee, YW; Lee, HW			Expression of p21WAF1/Cip1 through Sp1 sites by histone deacetylase inhibitor apicidin requires PI 3-kinasePKC epsilon signaling pathway	ONCOGENE			English	Article						historic deacetylase inhibitor; apicidin; p21(WAF1/Cip1); PI 3-kinase; PKC epsilon	KINASE-C-EPSILON; HUMAN P21(WAF1/CIP1) GENE; GROWTH-FACTOR-BETA; TRANSCRIPTIONAL ACTIVATION; PHOSPHOINOSITIDE 3-KINASE; TRICHOSTATIN-A; INDUCTION; PROMOTER; P53; CHROMATIN	We previously reported that the activation of p21(WAF1/Cip1) transcription by histone deacetylase inhibitor apicidin was mediated through Sp1 sites and pointed to the possible participation of protein kinase C (PKC). In this study, we investigated the role and identity of the specific isoforms of PKC involved and identified phosphatidylinositol 3-kinase (PI 3-kinase) as an upstream effector in HeLa cells. Using an isoform-specific pharmacological inhibitor of PKC, a PKCepsilon dominant-negative mutant, and antisense oligonucleotide to inhibit PKCepsilon specifically, we found that among PKC isoforms, PKCepsilon was required for the p21(WAF1/Cip1) expression by apicidin. In addition to PKCepsilon, PI 3-kinase appeared to participate in the activation of p21(WAF1/Cip1) promoter by apicidin, since inactivation of PI 3-kinase either by transient expression of dominant-negative mutant of PI 3-kinase or its specific inhibitors, LY294002 and wortmannin, attenuated the activation of p21(WAF1/Cip1) promoter and p21(WAF1/Cip1) protein expression by apicidin. Furthermore, membrane translocation of PKCepsilon in response to apicidin was blocked by the PI 3-kinase inhibitor, indicating the role of PI 3-kinase as an upstream molecule of PRO: in the p21(WAF1/Cip1) promoter activation by apicidin. However, the p21(WAF1/Cip1) expression by apicidin appeared to be independent of the histone hyperacetylation, since apicidin-induced histone hyperacetylation of p21(WAF1/Cip1) promoter region was not affected by inhibition of PI 3-kinase and PKC, suggesting that the chromatin remodeling through the histone hyperacetylation alone might not be sufficient for the expression of p21(WAF1/Cip1) by apicidin. Taken together, these results suggest that the PI 3-kinase-PKCepsilon signaling pathway plays a pivotal role in the expression of the p21(WAF1/Cip1) by apicidin.	Sungkyunkwan Univ, Coll Pharm, Dept Biochem & Mol Biol, Suwon 440746, South Korea; Sungkyunkwan Univ, Dept Genet Engn, Suwon 440746, South Korea; Konyang Univ, Coll Med, Dept Pharmacol, Nonsan 320711, South Korea; Seoul Natl Univ, Sch Agr Biotechnol, Suwon 441744, South Korea	Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Konyang University; Konyang University Hospital; Seoul National University (SNU)	Lee, HW (corresponding author), Sungkyunkwan Univ, Coll Pharm, Dept Biochem & Mol Biol, Suwon 440746, South Korea.	hylee@skku.ac.kr	Cho, Eun-Jung/AAR-1785-2020	Cho, Eun-Jung/0000-0002-6610-5329				Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; CHEDID M, 1994, ONCOGENE, V9, P3021; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; COUSENS LS, 1979, J BIOL CHEM, V254, P1716; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Espinos E, 1998, MOL BRAIN RES, V56, P118, DOI 10.1016/S0169-328X(98)00036-9; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200; Han JW, 2000, CANCER RES, V60, P6068; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Kwon SH, 2002, J BIOL CHEM, V277, P2073, DOI 10.1074/jbc.M106699200; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee TH, 2000, ONCOGENE, V19, P3766, DOI 10.1038/sj.onc.1203715; LI YJ, 1995, ONCOGENE, V10, P599; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Park JS, 1999, APPL ENVIRON MICROB, V65, P126; Petersohn D, 1996, EUR J BIOCHEM, V239, P827, DOI 10.1111/j.1432-1033.1996.0827u.x; Petrovics G, 2002, ARCH BIOCHEM BIOPHYS, V397, P217, DOI 10.1006/abbi.2001.2640; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rivero JA, 1998, BIOCHEM BIOPH RES CO, V248, P664, DOI 10.1006/bbrc.1998.9041; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sowa Y, 1999, CANCER RES, V59, P4266; Sternglanz R, 1996, TRENDS BIOCHEM SCI, V21, P357, DOI 10.1016/S0968-0004(96)90120-6; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; TOKER A, 1994, J BIOL CHEM, V269, P32358; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YANO H, 1993, J BIOL CHEM, V268, P25846; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	63	48	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6023	6031		10.1038/sj.onc.1206875	http://dx.doi.org/10.1038/sj.onc.1206875			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955081				2022-12-17	WOS:000185137800011
J	Hayes, SA; Huang, XK; Kambhampati, S; Platanias, LC; Bergan, RC				Hayes, SA; Huang, XK; Kambhampati, S; Platanias, LC; Bergan, RC			p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion	ONCOGENE			English	Article						p38 MAP kinase; transforming growth factor beta; Smad; cell adhesion; prostate cancer	GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; BREAST-CANCER CELLS; TGF-BETA; SIGNAL-TRANSDUCTION; TRANSFORMING GROWTH-FACTOR-BETA-1; INDUCED PHOSPHORYLATION; EXTRACELLULAR-MATRIX; EPITHELIAL-CELLS; CARCINOMA CELLS	Transforming growth factor beta (TGFbeta) regulates cell adhesion, proliferation, and differentiation in a variety of cells. Smad proteins are receptor-activated transcription factors that translocate to the nucleus in response to TGFbeta. We demonstrate here that TGFbeta increases cell adhesion in metastatic PC3-M prostate cancer cells. TGFbeta treatment of PC3-M cells leads to nuclear translocation of R-Smad proteins. We show that Smad proteins are necessary, but not sufficient, for TGFbeta-mediated cell adhesion. After showing that TGFbeta upregulated p38 MAP kinase activity in PC3-M cells, we show that inhibition of p38 MAP kinase partially blocked TGFbeta-mediated increase in cell adhesion, as well as nuclear translocation of Smad3. Finally, we show that Smad3 is phosphorylated by p38 MAP kinase in vitro. These findings implicate crosstalk between the MAP kinase and Smad signaling pathways in TGFbeta's regulation of cell adhesion in human prostate cells. This represents a mechanism by which the pleiotropic effects of TGFbeta may be channeled to modulate cell adhesion.	Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Bergan, RC (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Olson 8524,710 N Fairbanks, Chicago, IL 60611 USA.				NATIONAL CANCER INSTITUTE [R01CA077816, P50CA090386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000260] Funding Source: NIH RePORTER; NCI NIH HHS [CA9407, CA77816, CA90386] Funding Source: Medline; NIA NIH HHS [T32 AG00260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bakin AV, 2002, J CELL SCI, V115, P3193; Bergan R, 1996, CLIN EXP METASTAS, V14, P389, DOI 10.1007/BF00123398; Bergan R, 1996, BLOOD, V88, P731, DOI 10.1182/blood.V88.2.731.bloodjournal882731; Bissell DM, 2001, HEPATOLOGY, V34, P859, DOI 10.1053/jhep.2001.28457; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; Brodin G, 1999, CANCER RES, V59, P2731; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Dennler S, 2002, J LEUKOCYTE BIOL, V71, P731; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Festuccia C, 1999, INT J CANCER, V81, P395, DOI 10.1002/(SICI)1097-0215(19990505)81:3<395::AID-IJC13>3.3.CO;2-M; Galanis A, 2001, J BIOL CHEM, V276, P965, DOI 10.1074/jbc.M007697200; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hayashida T, 1999, KIDNEY INT, V56, P1710, DOI 10.1046/j.1523-1755.1999.00733.x; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hsing AY, 1996, CANCER RES, V56, P5146; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; Karsdal MA, 2001, J BIOL CHEM, V276, P39350, DOI 10.1074/jbc.M008738200; Kim IY, 1996, CLIN CANCER RES, V2, P1255; Kim IY, 1998, CLIN CANCER RES, V4, P1625; Kim IY, 1996, CANCER RES, V56, P44; Kostenuik PJ, 1997, CLIN EXP METASTAS, V15, P41; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kyle E, 1997, MOL PHARMACOL, V51, P193, DOI 10.1124/mol.51.2.193; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LAIHO M, 1992, Critical Reviews in Oncogenesis, V3, P1; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Latil A, 1999, PROSTATE, V40, P225, DOI 10.1002/(SICI)1097-0045(19990901)40:4<225::AID-PROS3>3.0.CO;2-3; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Liu YQ, 2001, PROSTATE CANCER P D, V4, P81, DOI 10.1038/sj.pcan.4500506; Liu YQ, 2000, CLIN EXP METASTAS, V18, P203, DOI 10.1023/A:1006729106034; Lucia MS, 1998, J CELL PHYSIOL, V175, P184, DOI 10.1002/(SICI)1097-4652(199805)175:2<184::AID-JCP8>3.0.CO;2-K; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; MOORADIAN DL, 1990, CANCER RES, V50, P273; Moustakas A, 2001, J CELL SCI, V114, P4359; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Olsson N, 2001, CELL SIGNAL, V13, P483, DOI 10.1016/S0898-6568(01)00176-0; Ozen M, 2000, ANTICANCER RES, V20, P1905; Paine E, 2000, J BIOL CHEM, V275, P11284, DOI 10.1074/jbc.275.15.11284; Paul R, 1997, BRIT J UROL, V79, P37, DOI 10.1111/j.1464-410X.1997.tb00799.x; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Rohlff C, 1998, PROSTATE, V37, P51, DOI 10.1002/(SICI)1097-0045(19980915)37:1<51::AID-PROS8>3.0.CO;2-B; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schnaper HW, 1998, PEDIATR NEPHROL, V12, P790, DOI 10.1007/s004670050550; Sehgal I, 1996, CANCER RES, V56, P3359; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Ungefroren H, 2003, J BIOL CHEM, V278, P11041, DOI 10.1074/jbc.M300035200; VERMA A, 2001, J BIOL CHEM, V31, P31; Wagers AJ, 2000, J IMMUNOL, V165, P5011, DOI 10.4049/jimmunol.165.9.5011; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang L, 2002, J BIOL CHEM, V277, P47257, DOI 10.1074/jbc.M208573200; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; WILDING G, 1989, MOL CELL ENDOCRINOL, V62, P79, DOI 10.1016/0303-7207(89)90115-9; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; Xiao BG, 1996, CLIN EXP IMMUNOL, V103, P475; Yamamoto T, 2001, J CELL BIOCHEM, V82, P591, DOI 10.1002/jcb.1179; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	72	48	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2003	22	31					4841	4850		10.1038/sj.onc.1206730	http://dx.doi.org/10.1038/sj.onc.1206730			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894225				2022-12-17	WOS:000184344600007
J	Ko, J; Lee, YH; Hwang, SY; Lee, YS; Shin, SM; Hwang, JH; Kim, J; Kim, YW; Jang, SW; Ryoo, ZY; Kim, IK; Namkoong, SE; Kim, JW				Ko, J; Lee, YH; Hwang, SY; Lee, YS; Shin, SM; Hwang, JH; Kim, J; Kim, YW; Jang, SW; Ryoo, ZY; Kim, IK; Namkoong, SE; Kim, JW			Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization	ONCOGENE			English	Article						HCCR-2; cervical cancer; p53; oncogene	TUMOR-SUPPRESSOR GENES; CELLS; ASSOCIATION; MICROSCOPY; PROTEINS; INVITRO	Basic studies of oncogenesis have demonstrated that either the elevated production of particular oncogene proteins or the occurrence of qualitative abnormalities in oncogenes can contribute to neoplastic cellular transformation. The purpose of this study was to identify unique oncogenes that are differentially expressed in human cancers and characterize their functions in tumorigenesis. To discover new putative oncogenes, the differential display RT-PCR method was applied using normal cervical tissues, cervical cancer cell lines, cervical cancer tissues, and metastatic tissues. We identified a new human cervical cancer oncogene HCCR-2 that was overexpressed in various human tumors including leukemia, lymphoma, and carcinomas of the breast, kidney, ovary, stomach, colon, and uterine cervix. Ectopic expression of HCCR-2 resulted in direct tumorigenic conversions of NIH/3T3 and Rat1 fibroblasts. Nude mice injected with NIH/3T3 cells stably transfected with HCCR-2 formed tumors in 4 weeks. The resultant tumors display characteristics of an epithelial carcinoma. In HCCR-2 transfected NCI-H460 cells and RKO cells, stabilization of the p53 tumor suppressor occurred without genetic mutation and correlated with functional impairment, as indicated by the defective induction of p53-induced p21(WAF1), MDM2, and bax. These results indicate. that HCCR-2 probably represents a new oncogene that is related to tumorigenesis, functioning as a negative regulator of the p53 tumor suppressor.	Catholic Univ Korea, Coll Med, Mol Genet Lab, Seoul 137040, South Korea; Univ Ulsan, Coll Med, Asan Inst Life Sci, Seoul 138736, South Korea; Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, Taegu 705717, South Korea; Hanyang Univ, Dept Biochem & Mol Biol, Ansan 425791, South Korea; Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul 137040, South Korea; Catholic Univ Korea, Coll Med, Dept Obstet & Gynecol, Seoul 137040, South Korea; Catholic Univ Korea, Coll Med, Dept Anat, Seoul 137040, South Korea; Catholic Univ Korea, Coll Med, Lab Anim Sci, Seoul 137040, South Korea	Catholic University of Korea; University of Ulsan; Yeungnam University; Hanyang University; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Kim, JW (corresponding author), Catholic Univ Korea, Coll Med, Mol Genet Lab, 505 Banpo Dong, Seoul 137040, South Korea.	jinwoo@cmc.cu-k.ac.kr	RYOO, ZAEYOUNG/AAQ-1573-2020					AARONSON SA, 1970, P NATL ACAD SCI USA, V66, P1236, DOI 10.1073/pnas.66.4.1236; AHN KY, 1991, AM J PHYSIOL, V265, pF792; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BUICK RN, 1980, CANCER, V45, P1238, DOI 10.1002/1097-0142(19800315)45:5+<1238::AID-CNCR2820451333>3.0.CO;2-R; BUSBYEARLE RMC, 1994, BRIT J CANCER, V69, P732, DOI 10.1038/bjc.1994.138; CHERIF D, 1990, P NATL ACAD SCI USA, V87, P6639, DOI 10.1073/pnas.87.17.6639; Cooper G.M., 1995, ONCOGENES; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; HUBERT WG, 1993, J VIROL, V67, P2932, DOI 10.1128/JVI.67.5.2932-2937.1993; HUIBREGTSE JM, 1994, COLD SPRING HARB SYM, V59, P237, DOI 10.1101/SQB.1994.059.01.028; Kim J, 1996, AM J PHYSIOL-RENAL, V270, pF575, DOI 10.1152/ajprenal.1996.270.4.F575; Kim JW, 1996, GYNECOL ONCOL, V62, P230, DOI 10.1006/gyno.1996.0221; Leonard C J, 1995, Important Adv Oncol, P33; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PUCHTLER H, 1978, HISTOCHEMISTRY, V57, P177, DOI 10.1007/BF00492078; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; WEINBERG RA, 1994, CA-CANCER J CLIN, V44, P160, DOI 10.3322/canjclin.44.3.160; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	24	48	76	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4679	4689		10.1038/sj.onc.1206624	http://dx.doi.org/10.1038/sj.onc.1206624			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879013				2022-12-17	WOS:000184157000009
J	Snijders, AM; Nowee, ME; Fridlyand, J; Piek, JMJ; Dorsman, JC; Jain, AN; Pinkel, D; van Diest, PJ; Verheijen, RHM; Albertson, DG				Snijders, AM; Nowee, ME; Fridlyand, J; Piek, JMJ; Dorsman, JC; Jain, AN; Pinkel, D; van Diest, PJ; Verheijen, RHM; Albertson, DG			Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in Fallopian tube carcinoma	ONCOGENE			English	Article						array CGH; CCNE1; AKT2; fallopian tube cancer	CYCLIN-E GENE; OVARIAN-CANCER; C-MYC; SOLID TUMORS; AMPLIFICATION; OVEREXPRESSION; ONCOGENE; MICROARRAYS; CDK2; AKT2	Fallopian tube carcinoma (FTC) is a rare, poorly studied and aggressive cancer, associated with poor survival. Since tumorigenesis is related to the acquisition of genetic changes, we used genome-wide array comparative genomic hybridization to analyse copy number aberrations occurring in FTC in order to obtain a better understanding of FTC carcinogenesis and to identify prognostic events and targets for therapy. We used arrays of 2464 genomic clones, providing similar to 1.4 Mb resolution across the genome to map genomic DNA copy number aberrations quantitatively from 14 FTC onto the human genome sequence. All tumors showed a high frequency of copy number aberrations with recurrent gains on 3q, 6p, 7q, 8q, 12p, 17q, 19 and 20q, and losses involving chromosomes 4, 5q, 8p, 16q, 17p, 18q and X. Recurrent regions of amplification included 1p34, 8p11-q11, 8q24, 12p, 17p13, 17q12-q21, 19p13, 19q12-q13 and 19q13. Candidate, known oncogenes mapping to these amplicons included CMYC (8q24), CCNE1 (19q12-q21) and AKT2 (19q13), whereas PIK3CA and KRAS, previously suggested to be candidate driver genes for amplification, mapped outside copy number maxima on 3q and 12p, respectively. The FTC were remarkably homogeneous, with some recurrent aberrations occurring in more than 70% of samples, which suggests a stereotyped pattern of tumor evolution.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; VU Univ, Dept Obstet & Gynaecol, Med Ctr, Amsterdam, Netherlands; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; VU Univ, Dept Pathol, Med Ctr, Amsterdam, Netherlands	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Vrije Universiteit Amsterdam; University of California System; University of California San Francisco; Vrije Universiteit Amsterdam	Albertson, DG (corresponding author), Univ Calif San Francisco, Canc Res Inst, Box 0808, San Francisco, CA 94143 USA.		Piek, Jurgen Martinus Johannes/AAX-2108-2021	Piek, Jurgen Martinus Johannes/0000-0002-0487-0631	NCI NIH HHS [CA83040, CA94407] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083040, R33CA094407] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAMA Y, 1995, JPN J CANCER RES, V86, P617, DOI 10.1111/j.1349-7006.1995.tb02442.x; Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Aziz S, 2001, GYNECOL ONCOL, V80, P341, DOI 10.1006/gyno.2000.6095; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Caduff RF, 1998, AM J SURG PATHOL, V22, P319, DOI 10.1097/00000478-199803000-00006; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheung VG, 2001, NATURE, V409, P953, DOI 10.1038/35057192; Chung TKH, 2000, GYNECOL OBSTET INVES, V49, P47, DOI 10.1159/000010212; DUTRILLAUX B, 1986, INT J CANCER, V38, P475, DOI 10.1002/ijc.2910380404; Geisen C, 2002, J BIOL CHEM, V277, P39909, DOI 10.1074/jbc.M205919200; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HELLSTROM AC, 1994, INT J GYNECOL CANCER, V4, P408, DOI 10.1046/j.1525-1438.1994.04060408.x; Heselmeyer K, 1998, INT J GYNECOL PATHOL, V17, P245, DOI 10.1097/00004347-199807000-00009; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; Karhu R, 1997, CYTOMETRY, V28, P198, DOI 10.1002/(SICI)1097-0320(19970701)28:3<198::AID-CYTO3>3.0.CO;2-A; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; Knight SJL, 2000, AM J HUM GENET, V67, P320, DOI 10.1086/302998; Leeper K, 2002, GYNECOL ONCOL, V87, P52, DOI 10.1006/gyno.2002.6779; Lin L, 2000, CANCER RES, V60, P7021; Manavi M, 1998, GYNECOL ONCOL, V71, P165, DOI 10.1006/gyno.1998.5084; Marone M, 1998, INT J CANCER, V75, P34, DOI 10.1002/(SICI)1097-0215(19980105)75:1<34::AID-IJC6>3.3.CO;2-A; MIZUUCHI H, 1995, CANCER, V76, P86, DOI 10.1002/1097-0142(19950701)76:1<86::AID-CNCR2820760112>3.0.CO;2-L; MONK BJ, 1994, AM J OBSTET GYNECOL, V171, P1193, DOI 10.1016/0002-9378(94)90131-7; Pere H, 1998, CANCER RES, V58, P4274; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; SNIJDERS AM, 2003, IN PRESS ONCOGENE; SolinasToldo S, 1996, CANCER RES, V56, P3803; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Sun PC, 2001, GENOMICS, V75, P17, DOI 10.1006/geno.2001.6587; Wang ZR, 1999, EXP MOL PATHOL, V66, P140, DOI 10.1006/exmp.1999.2259; Weiss MM, 1999, J CLIN PATHOL-MOL PA, V52, P243; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598; Zweemer RP, 2000, GYNECOL ONCOL, V76, P45, DOI 10.1006/gyno.1999.5623; Zweemer RP, 2001, LAB INVEST, V81, P1363, DOI 10.1038/labinvest.3780350	39	48	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4281	4286		10.1038/sj.onc.1206621	http://dx.doi.org/10.1038/sj.onc.1206621			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833150				2022-12-17	WOS:000183979800014
J	Aldred, MA; Morrison, C; Gimm, O; Hoang-Vu, C; Krause, U; Dralle, H; Jhiang, S; Eng, C				Aldred, MA; Morrison, C; Gimm, O; Hoang-Vu, C; Krause, U; Dralle, H; Jhiang, S; Eng, C			Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas	ONCOGENE			English	Article						follicular thyroid cancer; microarray analysis	LONG ARM; TUMORS; MUTATIONS; CANCER; HETEROZYGOSITY; PAPILLARY; INSTABILITY; EXPRESSION; DELETIONS; SUGGESTS	Peroxisome proliferator-activated receptor gamma (PPARgamma) has previously been implicated in the pathogenesis of follicular thyroid carcinoma (FTC), where a translocation with PAX8 has been reported in some 50% of tumors in three small series. The resultant fusion protein inhibits normal PPARgamma function by a dominant-negative mechanism. In a series of 19 FTCs, we identified this translocation in only two tumors (10.5%). However, microarray analysis and semiquantitative RT-PCR demonstrated greatly reduced PPARgamma expression in 13 of 17 (76%) nontranslocation tumors. Immunohistochemical analysis of 142 thyroid tumors showed a statistically significant reduction in PPARgamma immunoreactive protein, not only in FTCs but also in papillary thyroid carcinomas and Hurthle cell carcinomas. This suggests that while the overall frequency of the PAX8-PPARgamma translocation in FTCs may be lower than previously thought, functional downregulation of PPARgamma is a key event in multiple types of thyroid neoplasia and is a possible target for therapeutic intervention.	Ohio State Univ, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Clin Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Univ Halle Wittenberg, Dept Surg, Halle Saale, Germany; Univ Halle Wittenberg, Inst Pathol, Halle Saale, Germany; Ohio State Univ, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; Univ Leicester, Div Med Genet, Leicester, Leics, England; Univ Cambridge, Canc Res UK, Human Canc Genet Res Grp, Cambridge, England	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; University System of Ohio; Ohio State University; University of Leicester; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Eng, C (corresponding author), Ohio State Univ, Human Canc Genet Program, 420 W 12th Ave,Ste 690 TMRF, Columbus, OH 43210 USA.			Eng, Charis/0000-0002-3693-5145	NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA16058] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Clay CE, 2000, PROSTAG OTH LIPID M, V62, P23, DOI 10.1016/S0090-6980(00)00073-3; Dahia PLM, 1997, CANCER RES, V57, P4710; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; Grebe SKG, 1997, J CLIN ENDOCR METAB, V82, P3684, DOI 10.1210/jc.82.11.3684; Halachmi N, 1998, GENE CHROMOSOME CANC, V23, P239, DOI 10.1002/(SICI)1098-2264(199811)23:3<239::AID-GCC5>3.0.CO;2-2; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Marques AR, 2002, J CLIN ENDOCR METAB, V87, P3947, DOI 10.1210/jc.87.8.3947; Martelli ML, 2002, J CLIN ENDOCR METAB, V87, P4728, DOI 10.1210/jc.2001-012054; Nikiforova MN, 2002, AM J SURG PATHOL, V26, P1016, DOI 10.1097/00000478-200208000-00006; Ohta K, 2001, J CLIN ENDOCR METAB, V86, P2170, DOI 10.1210/jc.86.5.2170; Oriola J, 2001, EUR J CANCER, V37, P2470, DOI 10.1016/S0959-8049(01)00302-1; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Smith WM, 2001, HUM GENET, V109, P146, DOI 10.1007/s004390100563; Trovato M, 1999, J CLIN ENDOCR METAB, V84, P3235, DOI 10.1210/jcem.84.9.5986; Tung WS, 1997, GENE CHROMOSOME CANC, V19, P43, DOI 10.1002/(SICI)1098-2264(199705)19:1<43::AID-GCC7>3.0.CO;2-0; Ward LS, 1998, J CLIN ENDOCR METAB, V83, P525, DOI 10.1210/jc.83.2.525; Yeh JJ, 1999, GENE CHROMOSOME CANC, V26, P322, DOI 10.1002/(SICI)1098-2264(199912)26:4<322::AID-GCC6>3.0.CO;2-#; Zedenius J, 1996, HUM GENET, V97, P299, DOI 10.1007/BF02185758; Zhou XP, 2000, J MED GENET, V37, P410, DOI 10.1136/jmg.37.6.410	19	48	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3412	3416		10.1038/sj.onc.1206400	http://dx.doi.org/10.1038/sj.onc.1206400			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776192				2022-12-17	WOS:000183128500007
J	Jia, L; Patwari, Y; Kelsey, SM; Srinivasula, SM; Agrawal, SG; Alnemri, ES; Newland, AC				Jia, L; Patwari, Y; Kelsey, SM; Srinivasula, SM; Agrawal, SG; Alnemri, ES; Newland, AC			Role of Smac in human leukaemic cell apoptosis and proliferation	ONCOGENE			English	Article						apoptosis; apaf-1; caspases; IAPs; smac	TRAIL-INDUCED APOPTOSIS; DRUG-INDUCED APOPTOSIS; CYTOCHROME-C; PROMOTES APOPTOSIS; SMAC/DIABLO; PROTEIN; MITOCHONDRIA; DEATH; OVEREXPRESSION; IDENTIFICATION	Smac (or DIABLO) is a recently identified, novel proapoptotic molecule, which is released from mitochondria into the cytosol during apoptosis. Smac functions by eliminating the caspase-inhibitory properties of the inhibitors of apoptosis proteins (IAP), particularly XIAP. In this study, we stably transfected both full-length (FL) and mature (NIT) Smac genes into the K562 and CEM leukaemic cell lines. Both FL and NIT Smac transfectants increased the sensitivity of leukaemic cells to UV light-induced apoptosis and the activation of caspase-9 and caspase-3. Purified cytosol from the mature Smac transfectants, or the addition of human recombinant Smac protein or N-7 peptide into nontransfected cytosol, showed an increased sensitivity to cytochrome c-induced activation of caspase-3. The mature Smac enhanced the susceptibility of both K562 and CEM cells to TRAIL-induced apoptosis. Overexpression of the mature Smac protein also inhibited proliferation, as detected by reduced colony formation and Ki-67 expression in leukaemic cells. Cell cycle analysis revealed that Smac transfectants displayed significant G0/G1 arrest and reduction in 5-bromo-2'-deoxyuridine (BrdU) incorporation. Smac sensitized human acute myeloid leukaemia blasts to cytochrome c-induced activation of caspase-3. However, Smac failed to overcome Apaf-l-deficiency-mediated resistance to cytochrome c in primary leukaemic blasts. In summary, this study reveals that Smac/DIABLO exhibits a potential role in increasing apoptosis and suppressing proliferation in human leukaemic cells. Importantly, it also indicates that it is crucial to evaluate the levels of Apaf-1 and XIAP proteins in patient samples before using Smac peptide therapy in the treatment of human leukaemia.	St Bartholomews & Royal London Sch Med & Dent, Dept Hematol Oncol, London E1 2AD, England; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	University of London; Queen Mary University London; Jefferson University	Jia, L (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Hematol Oncol, Turner St, London E1 2AD, England.	L.jia@qmul.ac.uk	Alnemri, Emad S/B-4526-2010	Jia, Li/0000-0002-6076-8455				Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Carson JP, 2002, CANCER RES, V62, P18; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Gerlach C, 1998, LAB INVEST, V78, P129; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Jia L, 2001, ONCOGENE, V20, P4817, DOI 10.1038/sj.onc.1204628; Jia L, 2001, BIOCHEM BIOPH RES CO, V283, P1037, DOI 10.1006/bbrc.2001.4895; Jia L, 2001, BLOOD, V98, P414, DOI 10.1182/blood.V98.2.414; Jia L, 1999, BLOOD, V93, P2353, DOI 10.1182/blood.V93.7.2353.407k20_2353_2359; Kabra NH, 2001, P NATL ACAD SCI USA, V98, P6307, DOI 10.1073/pnas.111158698; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu FT, 2002, BRIT J HAEMATOL, V117, P333, DOI 10.1046/j.1365-2141.2002.03418.x; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Partheniou F, 2001, BIOCHEM BIOPH RES CO, V287, P181, DOI 10.1006/bbrc.2001.5582; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Terry NHA, 2001, METHOD CELL BIOL, V63, P355; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Zang DY, 2001, BLOOD, V98, P3058, DOI 10.1182/blood.V98.10.3058; Zhang XD, 2001, CANCER RES, V61, P7339	33	48	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2003	22	11					1589	1599		10.1038/sj.onc.1206322	http://dx.doi.org/10.1038/sj.onc.1206322			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642862				2022-12-17	WOS:000181580500001
J	Chuang, JI; Chang, TY; Liu, HS				Chuang, JI; Chang, TY; Liu, HS			Glutathione depletion-induced apoptosis of Ha-ras-transformed NIH3T3 cells can be prevented by melatonin	ONCOGENE			English	Article						reactive oxygen species; glutathione; melatonine; apoptosis; Ha-ras	CANCER CELLS; BUTHIONINE SULFOXIMINE; SELECTIVE ACTIVATION; NIH/3T3 CELLS; NEWBORN RATS; IN-VITRO; GROWTH; EXPRESSION; ONCOGENE; DEATH	It is well known that intracellular antioxidant glutathione (GSH) plays major roles in the maintenance of redox status and defense of oxidative stress. Ras, a small GTP-binding protein, may send growth-stimulating message to the nucleus through downstream Rac oncoprotein and superoxide (O-2(radical anion)). These findings led us to investigate the effects of GSH and melatonin, a free-radical scavenger, on Ras-Rac-O-2(radical anion)-related growth signal transduction. Our results demonstrate that overexpression of the inducible Ha-ras oncogene by isopropyl-beta-D-thiogalactoside (IPTG) increases the levels of reactive oxygen species (ROS, including O-2(radical anion) and hydrogen peroxide (H2O2)) and GSH in an Ha-ras-transformed NIH/3T3 fibroblast cell line. On the contrary, melatonin significantly suppresses ras-triggered cell growth by inhibiting the increase of ROS and GSH. Moreover, severe apoptosis of this transformed cell line occurred when the cell redox balance between ROS and GSH was dramatically changed in the presence of IPTG and L-buthionine-[S,R]-sulfoximine (BSO, a specific inhibitor of GSH synthetase). That BSO-induced cell apoptosis needs Ras to increase the ROS level was demonstrated by the free-radical scavenger melatonin. It effectively blocked cell apoptosis, but cell growth was also slowed without affecting Ras expression. Based on our studies, two approaches can be applied to treating ras-related cancers. One is utilizing melatonin to suppress cancer cell proliferation, and the other is utilizing BSO to induce cancer-cell apoptosis. Cotreatment of ras-related cancer cells with melatonin and BSO stops cell growth as well as apoptosis. Whether these cancer cells will undergo further regression or become recurrent merits investigation.	Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Parasitol, Tainan 701, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University	Liu, HS (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 701, Taiwan.			Liu, Hsiao-Sheng/0000-0003-0576-7203				ABE M, 1994, J PINEAL RES, V17, P94, DOI 10.1111/j.1600-079X.1994.tb00119.x; Agapito MT, 2001, J PINEAL RES, V31, P23, DOI 10.1034/j.1600-079X.2001.310104.x; Barranco SC, 2000, DIS COLON RECTUM, V43, P1133, DOI 10.1007/BF02236562; Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1124/jpet.112.192138; Blask DE, 1997, CANCER RES, V57, P1909; Chang MY, 1999, EXP CELL RES, V248, P589, DOI 10.1006/excr.1999.4436; Chen ST, 1999, EXP BRAIN RES, V124, P241, DOI 10.1007/s002210050619; Chen ST, 2002, J PINEAL RES, V32, P262, DOI 10.1034/j.1600-079X.2002.01871.x; Chuang JI, 2001, J CHEM NEUROANAT, V21, P215, DOI 10.1016/S0891-0618(01)00109-0; Cos S, 2000, FRONT NEUROENDOCRIN, V21, P133, DOI 10.1006/frne.1999.0194; Granzotto M, 2001, J PINEAL RES, V31, P206, DOI 10.1034/j.1600-079X.2001.310303.x; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; Guha A, 1998, CAN J NEUROL SCI, V25, P267, DOI 10.1017/S0317167100034272; GUO N, 1992, NEUROSCIENCE, V51, P835, DOI 10.1016/0306-4522(92)90524-6; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; ITO M, 1984, J INTERFERON RES, V22, P603; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Karbownik M, 2001, INT J BIOCHEM CELL B, V33, P735, DOI 10.1016/S1357-2725(01)00059-0; Kilic E, 1999, J CEREBR BLOOD F MET, V19, P511, DOI 10.1097/00004647-199905000-00005; Kuo ML, 1996, BIOCHEM PHARMACOL, V52, P481, DOI 10.1016/0006-2952(96)00251-1; Li ZR, 1997, J PINEAL RES, V22, P117, DOI 10.1111/j.1600-079X.1997.tb00312.x; Lissoni P, 1996, ONCOLOGY, V53, P43; LISSONI P, 1999, METATONIN PROMOTION, P175; Liu HS, 1998, BRIT J CANCER, V77, P1777, DOI 10.1038/bjc.1998.296; Marelli MM, 2000, PROSTATE, V45, P238, DOI 10.1002/1097-0045(20001101)45:3<238::AID-PROS6>3.0.CO;2-W; Mayo JC, 1998, J PINEAL RES, V25, P12, DOI 10.1111/j.1600-079X.1998.tb00380.x; Mediavilla MD, 1999, LIFE SCI, V65, P415, DOI 10.1016/S0024-3205(99)00262-3; MEISTER A, 1994, CANCER RES, V54, pS1969; MILLER AC, 1993, MOL CELL BIOL, V13, P4416, DOI 10.1128/MCB.13.7.4416; Neri B, 1998, ANTICANCER RES, V18, P1329; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; Panzer A, 1998, CANCER LETT, V122, P17, DOI 10.1016/S0304-3835(97)00360-1; Petranka J, 1999, J PINEAL RES, V26, P129, DOI 10.1111/j.1600-079X.1999.tb00574.x; Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480; Reiter RJ, 2002, CARDIOVASC DRUG THER, V16, P5, DOI 10.1023/A:1015376328431; Roth JA, 1997, BRAIN RES, V768, P63, DOI 10.1016/S0006-8993(97)00549-0; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Schnelldorfer T, 2000, CANCER-AM CANCER SOC, V89, P1440, DOI 10.1002/1097-0142(20001001)89:7<1440::AID-CNCR5>3.3.CO;2-S; Seyfried J, 1999, NEUROSCI LETT, V264, P1, DOI 10.1016/S0304-3940(99)00107-X; THRALL BD, 1991, CARCINOGENESIS, V12, P1319, DOI 10.1093/carcin/12.7.1319; Toffa S, 1997, J NEURAL TRANSM, V104, P67, DOI 10.1007/BF01271295; Vahrmeijer AL, 2000, BIOCHEM PHARMACOL, V59, P1557, DOI 10.1016/S0006-2952(00)00286-0; WALSH AC, 1995, CANCER LETT, V95, P105, DOI 10.1016/0304-3835(95)03871-S; Weijzen S, 1999, LEUKEMIA, V13, P502, DOI 10.1038/sj.leu.2401367; Xu MF, 2001, J PINEAL RES, V31, P301, DOI 10.1034/j.1600-079X.2001.310403.x	46	48	52	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1349	1357		10.1038/sj.onc.1206289	http://dx.doi.org/10.1038/sj.onc.1206289			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618760				2022-12-17	WOS:000181360900009
J	Garcia, MA; Guerra, S; Gil, JS; Jimenez, V; Esteban, M				Garcia, MA; Guerra, S; Gil, JS; Jimenez, V; Esteban, M			Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L	ONCOGENE			English	Article						E3L; vaccinia virus; dsRNA; PKR; tumor apoptosis	DOUBLE-STRANDED-RNA; NF-KAPPA-B; TETRATRICOPEPTIDE REPEAT PROTEIN; BROAD SPECIES-SPECIFICITY; TUMOR-SUPPRESSOR P53; KINASE PKR; INFECTED CELLS; INTERFERON RESISTANCE; ACTIVATION; GENE	The vaccinia virus (VV) E3L gene encodes a dsRNA binding protein that inhibits activation of the IFN-induced, dsRNA-dependent protein kinase, (PKR), the 2-5A synthetases/RNase L system and other dsRNA dependent pathways, thus leading to efficient VV replication. To analyse E3L effects over cellular metabolism in a virus-free system, we have generated stable mouse 3T3 cell lines expressing E3L. Expression of E3L in NIH3T3 cells results in inhibition of eIF-2alpha phosphorylation and IkappaBalpha degradation in response to dsRNA. Antiviral responses induced by IFN-alpha/beta were partially impaired in 3T3-E3L cells, as determined by a viability assay upon VSV infection. E3L expression also confers resistance to dsRNA-triggered apoptosis. Interestingly, cells expressing E3L grew faster than control cells, and showed increased expression of cyclin A and decreased levels of P27(Kip1). E3L cooperated with H-ras in a focus formation assay, and NIH3T3 E3L cells formed solid tumors when injected in nude mice. Overall, our findings reveal that interference of E3L protein with several cellular pathways, results in promotion of cellular growth, impairment of antiviral activity and resistance to apoptosis.	CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Madrid 28049, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Esteban, M (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Campus Univ Autonoma, Madrid 28049, Spain.		Garcia, Maria Angel MA/I-5116-2016; Gil, Jesus/C-7739-2012; guerra, susana/K-5972-2014	Garcia, Maria Angel MA/0000-0003-2003-3769; Gil, Jesus/0000-0002-4303-6260; guerra, susana/0000-0001-9067-2991; ESTEBAN, MARIANO/0000-0003-0846-2827				ALCAMI A, 1995, J VIROL, V69, P4633; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; BEATTIE E, 1995, J VIROL, V69, P499, DOI 10.1128/JVI.69.1.499-505.1995; Beattie E, 1996, VIRUS GENES, V12, P89, DOI 10.1007/BF00370005; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Brandt TA, 2001, J VIROL, V75, P850, DOI 10.1128/JVI.75.2.850-856.2001; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; CHANG HW, 1992, P NATL ACAD SCI USA, V89, P4825, DOI 10.1073/pnas.89.11.4825; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Geiss G, 2001, J BIOL CHEM, V276, P30178, DOI 10.1074/jbc.C100137200; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Guo JJ, 2000, VIROLOGY, V267, P209, DOI 10.1006/viro.1999.0135; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Kibler KV, 1997, J VIROL, V71, P1992, DOI 10.1128/JVI.71.3.1992-2003.1997; Kim T, 1999, J BIOL CHEM, V274, P30686, DOI 10.1074/jbc.274.43.30686; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Lee SB, 1996, J INTERF CYTOK RES, V16, P1073, DOI 10.1089/jir.1996.16.1073; LEE SB, 1993, VIROLOGY, V193, P1037, DOI 10.1006/viro.1993.1223; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; LU Y, 1995, VIROLOGY, V214, P222, DOI 10.1006/viro.1995.9937; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MEURS EF, 1993, CELL, V62, P379; Murcia-Nicolas A, 1999, VIRUS RES, V59, P1, DOI 10.1016/S0168-1702(98)00114-2; PAEZ E, 1984, VIROLOGY, V134, P12, DOI 10.1016/0042-6822(84)90268-X; PARK H, 1994, P NATL ACAD SCI USA, V11, P4713; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; Rebouillat D, 1999, J INTERF CYTOK RES, V19, P295, DOI 10.1089/107999099313992; Rivas C, 1998, VIROLOGY, V243, P406, DOI 10.1006/viro.1998.9072; Romano PR, 1998, MOL CELL BIOL, V18, P7304, DOI 10.1128/MCB.18.12.7304; Sangfelt O, 1999, ONCOGENE, V18, P2798, DOI 10.1038/sj.onc.1202609; Savinova O, 1999, INT J BIOCHEM CELL B, V31, P175, DOI 10.1016/S1357-2725(98)00140-X; SEN GC, 1992, J BIOL CHEM, V267, P5017; Sharp TV, 1998, VIROLOGY, V250, P302, DOI 10.1006/viro.1998.9365; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Smith EJ, 2001, J BIOL CHEM, V276, P8951, DOI 10.1074/jbc.M008717200; Smith Geoffrey L., 1994, Trends in Microbiology, V2, P81, DOI 10.1016/0966-842X(94)90539-8; Smith GL, 1997, IMMUNOL REV, V159, P137, DOI 10.1111/j.1600-065X.1997.tb01012.x; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; SYMONS JA, 1995, CELL, V81, P551, DOI 10.1016/0092-8674(95)90076-4; Tan SL, 1999, J INTERF CYTOK RES, V19, P543, DOI 10.1089/107999099313677; Tang NM, 1999, MOL CELL BIOL, V19, P4757; WATSON JC, 1991, VIROLOGY, V185, P206, DOI 10.1016/0042-6822(91)90768-7; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Xiang Y, 2002, J VIROL, V76, P5251, DOI 10.1128/JVI.76.10.5251-5259.2002; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; YUWEN H, 1993, VIROLOGY, V195, P732, DOI 10.1006/viro.1993.1424; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355; Zhou AM, 1999, VIROLOGY, V258, P435, DOI 10.1006/viro.1999.9738	64	48	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8379	8387		10.1038/sj.onc.1206036	http://dx.doi.org/10.1038/sj.onc.1206036			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466958	Bronze			2022-12-17	WOS:000179480100001
J	Murakami, Y				Murakami, Y			Functional cloning of a tumor suppressor gene,TSLC1, in human non-small cell lung cancer	ONCOGENE			English	Review						tumor suppressor gene; functional cloning; non-small cell lung cancer; TSLC1; TSLL1; TSLL2	YEAST ARTIFICIAL CHROMOSOME; MICROCELL-MEDIATED TRANSFER; PROSTATE-CANCER; BREAST-CANCER; HUMAN DNA; TUMORIGENIC EXPRESSION; MALIGNANT PHENOTYPE; COLORECTAL CANCERS; MULTIPLE PATHWAYS; CARCINOMA CELLS	The identification of a tumor suppressor gene in non-small cell lung cancer (NSCLC) is one of the most important issues to elucidate the molecular mechanisms of this type of refractory cancer and to establish a novel strategy against it. Since NSCLC, like most other human cancers, develops as a sporadic disease, linkage analysis is not available for gene cloning. This review describes the functional cloning approaches to a tumor suppressor gene in sporadic cancers. Suppression of the malignant phenotype of cancer cells by fusion with a normal fibroblast was the first demonstration of the recessive phenotype of cancer cells in 1969. Evidence of tumor suppressor genes on the specific chromosomes was later provided by functional complementation of the cancer phenotype through microcell-mediated chromosome transfer. Further introduction of more restricted DNA fragments by YAC transfer provides a potent tool to localize the gene to a small segment, appropriate for the subsequent gene cloning. TSLC1, a novel tumor suppressor gene in NSCLC, was identified on chromosome 11q23.2 through a series of functional complementation of A549 cells in tumorigenicity. Two-hit inactivation of the TSLC1 by promoter methylation and gene deletion was observed in 40% of primary NSCLC tumors. The strong tumor suppressor activity of TSLC1, and its possible involvement in cell adhesion, suggest that the functional cloning approach could cast a new light on a group of genes that have not yet been characterized, but are important for general human carcinogenesis as well as tumor suppression.	Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genomics Project, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genomics Project, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.							Ahuja N, 1998, CANCER RES, V58, P5489; ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; Aoe K, 1999, ANTICANCER RES, V19, P291; Arai Y, 1996, GENOMICS, V35, P196, DOI 10.1006/geno.1996.0339; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANERJEE A, 1992, CANCER RES, V52, P6297; BIRCHMEIER W, 1995, BIOESSAYS, V17, P97, DOI 10.1002/bies.950170203; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; Cao Q, 2001, CANCER GENET CYTOGEN, V129, P131, DOI 10.1016/S0165-4608(01)00442-3; CARTER SB, 1967, NATURE, V213, P261, DOI 10.1038/213261a0; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; CAVENEE WK, 1995, SCI AM, V272, P72, DOI 10.1038/scientificamerican0395-72; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; DOWDY SF, 1990, GENE CHROMOSOME CANC, V2, P318, DOI 10.1002/gcc.2870020410; England NL, 1996, CARCINOGENESIS, V17, P1567, DOI 10.1093/carcin/17.8.1567; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Fukuhara H, 2001, ONCOGENE, V20, P5401, DOI 10.1038/sj.onc.1204696; GNIRKE A, 1991, EMBO J, V10, P1629, DOI 10.1002/j.1460-2075.1991.tb07685.x; Gomyo H, 1999, GENOMICS, V62, P139, DOI 10.1006/geno.1999.6001; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRODEN J, 1995, CANCER RES, V55, P1531; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUXLEY C, 1991, GENOMICS, V9, P742, DOI 10.1016/0888-7543(91)90369-P; ICHIKAWA T, 1994, CANCER RES, V54, P2299; ICHIKAWA T, 1992, CANCER RES, V52, P3486; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kanamori M, 2000, ONCOGENE, V19, P1564, DOI 10.1038/sj.onc.1203454; Kawanishi M, 1997, CARCINOGENESIS, V18, P2057, DOI 10.1093/carcin/18.11.2057; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; Kon H, 1998, ONCOGENE, V16, P257, DOI 10.1038/sj.onc.1201488; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; LOH WE, 1992, P NATL ACAD SCI USA, V89, P1755, DOI 10.1073/pnas.89.5.1755; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MINNA J, 2002, ONCOGENE; MISRA BC, 1989, AM J HUM GENET, V45, P565; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; Murakami Y, 1998, MUTAT RES-FUND MOL M, V400, P421, DOI 10.1016/S0027-5107(98)00031-1; Murakami YS, 1996, CANCER RES, V56, P2157; MURAKAMI YS, 1995, CANCER RES, V55, P3389; MURAYAMA F, 1965, BIKEN J, V8, P103; Myohanen SK, 1998, CANCER RES, V58, P591; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; NEGRINI M, 1994, CANCER RES, V54, P1331; NEGRINI M, 1992, ONCOGENE, V7, P2013; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; Nomoto S, 1998, CANCER RES, V58, P1380; OBriant K, 1997, ANTICANCER RES, V17, P3243; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Ohsaki Y, 1996, ONCOLOGY, V53, P327; Ordonez C, 2000, CANCER RES, V60, P3419; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; PACHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109, DOI 10.1073/pnas.87.13.5109; PAVAN WJ, 1990, P NATL ACAD SCI USA, V87, P1300, DOI 10.1073/pnas.87.4.1300; PAVAN WJ, 1990, MOL CELL BIOL, V10, P4163, DOI 10.1128/MCB.10.8.4163; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; Phillips KK, 1996, CANCER RES, V56, P1222; PONTECORVO G, 1976, CYTOGENET CELL GENET, V16, P399, DOI 10.1159/000130642; PRESCOTT DM, 1972, EXP CELL RES, V71, P480, DOI 10.1016/0014-4827(72)90322-9; RASIO D, 1995, CANCER RES, V55, P3988; REEVES RH, 1995, CURRENT PROTOCOLS HU; Robertson G, 1996, CANCER RES, V56, P4487; RODENHUIS S, 1988, CANCER RES, V48, P5738; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; SACHSE R, 1994, ONCOGENE, V9, P39; SANTON JB, 1986, CANCER RES, V46, P4701; SASAKI M, 1994, CANCER RES, V54, P6090; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHEDL A, 1993, NUCLEIC ACIDS RES, V21, P4783, DOI 10.1093/nar/21.20.4783; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; SPENCER F, 1994, GENOMICS, V22, P118, DOI 10.1006/geno.1994.1352; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sunahara M, 1999, ONCOGENE, V18, P3761, DOI 10.1038/sj.onc.1202972; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Tanaka H, 1999, MOL CARCINOGEN, V25, P249, DOI 10.1002/(SICI)1098-2744(199908)25:4<249::AID-MC3>3.0.CO;2-Z; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Todd MC, 1996, ONCOGENE, V13, P2387; WADA M, 1994, BIOCHEM BIOPH RES CO, V200, P1693, DOI 10.1006/bbrc.1994.1647; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Weinberg RA, 1996, SCI AM, V275, P62, DOI 10.1038/scientificamerican0996-62; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WELCH DR, 1994, ONCOGENE, V9, P255; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; White R, 1992, CURR OPIN GENET DEV, V2, P53, DOI 10.1016/S0959-437X(05)80321-1; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Yamori T, 1997, JPN J CANCER RES, V88, P1205, DOI 10.1111/j.1349-7006.1997.tb00350.x; YOSHIDA A, 1994, J SURG ONCOL, V55, P170, DOI 10.1002/jso.2930550308; Yoshida BA, 2000, JNCI-J NATL CANCER I, V92, P1717, DOI 10.1093/jnci/92.21.1717; YOSHIDA MA, 1994, MOL CARCINOGEN, V9, P114, DOI 10.1002/mc.2940090303; Zenklusen JC, 2001, NAT GENET, V27, P392, DOI 10.1038/86891	115	48	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	2002	21	45					6936	6948		10.1038/sj.onc.1205825	http://dx.doi.org/10.1038/sj.onc.1205825			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362275	Bronze			2022-12-17	WOS:000178640200008
J	Catalano, A; Romano, M; Martinotti, S; Procopio, A				Catalano, A; Romano, M; Martinotti, S; Procopio, A			Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen	ONCOGENE			English	Article						SV40; Tag; VEGF; mesothelioma	ANGIOGENESIS; GENE; P53; MESOTHELIOMA; SUPPRESSION; SEQUENCES; RECEPTOR; CELLS	Vascular endothelial growth factor (VEGF), an important angiogenic factor, regulates cell proliferation, differentiation, and apoptosis through activation of its tyrosine-kinase receptors, such as Flt-1 and Flk-1/Kdr. Human malignant mesothelioma cells (HMC), which have wild-type p53, express VEGF and exhibit cell growth increased by VEGF. Here, we demonstrate that early transforming proteins of simian virus (SV) 40, large tumor antigen (Tag) and small tumor antigen (tag). which have been associated with mesotheliomas, enhanced HNIC proliferation by inducing VEGF expression. SV40-Tag expression potently increased VEGF protein and mRNA levels in several HNIC lines. This effect was suppressed by the protein synthesis inhibitor, cycloheximide. Inactivation of the VEGF signal transduction pathway by expression of soluble form of FIt-1 inhibited Flk-1/Kdr activation and HNIC proliferation induced by SV40 early genes. Experiments with SV40 mutants revealed that SV40-Tag, but not -tag, is involved in the VEGF promoter activation. However, concomitant expression of SV40-tag enhanced Tag function. In addition, SV40-Tag expression sustained VEGF induction in colon carcinoma cell line (CCL)-233, which have wild-type p53, but not in CCL-238, which lack functional p53. These data indicate that VEGF regulation by SV40 transforming proteins can represent a key event in SV40 signaling relevant for tumor progression.	Univ Ancona, Fac Med, Inst Expt Pathol, I-60131 Ancona, Italy; Univ Messina, Dept Human Pathol, I-98125 Messina, Italy; Univ G DAnnunzio, Dept Oncol & Neurosci, Chieti, Italy	Marche Polytechnic University; University of Messina; G d'Annunzio University of Chieti-Pescara	Procopio, A (corresponding author), Univ Ancona, Fac Med, Inst Expt Pathol, Via Ranieri, I-60131 Ancona, Italy.	mromano@unich.it; procopio@poscsi.unian.it	Procopio, Antonio Domenico/AAB-2451-2021; Romano, Mario/I-7986-2012	Procopio, Antonio Domenico/0000-0001-6897-8724; Romano, Mario/0000-0001-8512-1458				Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; Browne K, 2001, ANN OCCUP HYG, V45, P327, DOI 10.1016/S0003-4878(01)00029-1; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Claudio PP, 2001, CANCER RES, V61, P462; DeCaprio JA, 1999, BIOLOGICALS, V27, P23, DOI 10.1006/biol.1998.0173; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Gaetano C, 2001, CIRC RES, V88, pE38; Gonin S, 1999, ONCOGENE, V18, P8011, DOI 10.1038/sj.onc.1203319; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Kumar-Singh S, 1999, J PATHOL, V189, P72, DOI 10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0; Orengo AM, 1999, EUR RESPIR J, V13, P527, DOI 10.1183/09031936.99.13352799; Pal S, 2001, CANCER RES, V61, P6952; Paley EL, 1996, CARCINOGENESIS, V17, P939, DOI 10.1093/carcin/17.5.939; Procopio A, 2000, GENE CHROMOSOME CANC, V29, P173, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1019>3.0.CO;2-B; Romano M, 2001, FASEB J, V15, P2326, DOI 10.1096/fj.01-0150com; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; Takayama K, 2000, CANCER RES, V60, P2169; Zhang LL, 2000, CANCER RES, V60, P3655	20	48	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2896	2900		10.1038/sj.onc.1205382	http://dx.doi.org/10.1038/sj.onc.1205382			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973650	Green Published			2022-12-17	WOS:000175063700015
J	Claij, N; Riele, HT				Claij, N; Riele, HT			Methylation tolerance in mismatch repair proficient cells with low MSH2 protein level	ONCOGENE			English	Article						mismatch repair; methylation tolerance; microsatellite instability; mutation frequency; homologous recombination	GENE; PREDISPOSITION; HMSH2-HMSH6; DEFICIENCY; EXPRESSION; RESISTANCE; MUTATIONS; FREQUENCY; HMLH1; HMSH2	Loss of DNA mismatch repair has been found in tumors associated with the familial cancer predisposition syndrome HNPCC (hereditary non-polyposis colorectal cancer) and a subset of sporadic cancers. MSH2 deficiency abolishes the action of the mismatch repair system, resulting in a phenotype which is characterized by an increased accumulation of base substitutions and frameshifts, enhanced recombination between homologous but non-identical DNA sequences, and tolerance to the cytotoxic effects of methylating agents. In this study we describe an embryonic stem cell line in which the level of MSH2 protein is 10-fold reduced compared to that in wild-type cells. Remarkably, these MSH2-low cells were as resistant to killing by methylating agents as cells completely lacking MSH2, while they had retained almost maximal mismatch repair capacity as judged from their anti-mutagenic and anti-recombinogenic capacity and the absence of microsatellite instability. In contrast, MSH2-low cells were highly sensitive to methylation-damage induced mutagenesis. Thus, 10-fold reduced MSH2 protein levels render cells resistant to the toxic and highly sensitive to the mutagenic effects of methylating agents. This condition is not manifested by microsatellite instability and may have implications four both the etiology and treatment of cancer.	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Riele, HT (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	h.t.riele@nki.nl						Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Berardini M, 2000, J BIOL CHEM, V275, P27851; BOCKER T, 1999, BIOCHIM BIOPHYS ACTA, V1423, P1; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Evans E, 2000, MOL CELL BIOL, V20, P7839, DOI 10.1128/MCB.20.21.7839-7844.2000; Fink D, 1998, CLIN CANCER RES, V4, P1; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Friedman HS, 1997, CANCER RES, V57, P2933; Fritzell JA, 1997, CANCER RES, V57, P5143; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; Kane MF, 1997, CANCER RES, V57, P808; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; Lu SL, 1996, JPN J CANCER RES, V87, P279, DOI 10.1111/j.1349-7006.1996.tb00218.x; Lynch HT, 2000, J CLIN ONCOL, V18, p19S; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; Shin KH, 2000, EUR J CANCER, V36, P925, DOI 10.1016/S0959-8049(00)00025-3; Shin KH, 1998, J CANCER RES CLIN, V124, P421, DOI 10.1007/s004320050194; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Umar A, 1998, GENETICS, V148, P1637; Zhu WB, 1998, MUTAT RES-FUND MOL M, V398, P93, DOI 10.1016/S0027-5107(97)00244-3	24	48	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2873	2879		10.1038/sj.onc.1205395	http://dx.doi.org/10.1038/sj.onc.1205395			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973647				2022-12-17	WOS:000175063700012
J	Todd, JL; Rigas, JD; Rafty, LA; Denu, JM				Todd, JL; Rigas, JD; Rafty, LA; Denu, JM			Dual-specificity protein tyrosine phosphatase VHR down-regulates c-Jun N-terminal kinase (JNK)	ONCOGENE			English	Article						JNK; stress kinase; VHR; protein tyrosine phosphatase	MAP KINASE; INDUCED APOPTOSIS; CELL APOPTOSIS; IN-VIVO; ACTIVATION; PATHWAYS; HSP72; SUPPRESSION; MECHANISMS; SUBSTRATE	The JNK group (for c-Jun N-terminal kinase) of mitogen-activated protein kinases (MAP kinases) is activated in cells in response to environmental stress and cytokines. Activation of JNK is the result of dual phosphorylation by specific upstream kinases which phosphorylate the TxY motif. Much less is known concerning the down-regulation by protein phosphatases. Here, we demonstrate that the tyrosine-specific and constitutively-expressed phosphatase VHR (for VH1-Related) down-regulates the JNK signaling pathway at the level of JNK dephosphorylation. VHR was shown to efficiently dephosphorylate JNK and to form a tight complex with activated JNK when the catalytically-inactive C124S VHR mutant was employed as an in vivo substrate trap. Utilizing an in vitro assay, the transcription factor c-Jun specifically inhibited the ability of VHR to dephosphorylate JNK, likely by sterically blocking access to the phosphorylation sites when JNK and c-Jun form a complex. c-Jun has no effect on the ability of VHR to inactivate the ERK MAP kinases or to hydrolyze artificial substrates. The c-Jun inhibition results are discussed in terms of the resistant-nature of JNK dephosphorylation in cellular extracts and in terms of a general model in which VHR may be a general MAP kinase phosphatase whose specificity and activity are dictated by the presence of MAP kinase-associated proteins that inhibit dephosphorylation.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol L224, Portland, OR 97201 USA	Oregon Health & Science University	Denu, JM (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol L224, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	denuj@ohsu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059785, R37GM059785] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 59785] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JarielEncontre I, 1997, MOL BIOL REP, V24, P51, DOI 10.1023/A:1006804723722; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Kondo T, 2000, J BIOL CHEM, V275, P7668, DOI 10.1074/jbc.275.11.7668; Kondo T, 2000, J BIOL CHEM, V275, P8872, DOI 10.1074/jbc.275.12.8872; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; May GHW, 1998, J BIOL CHEM, V273, P33429, DOI 10.1074/jbc.273.50.33429; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; Nguyen AN, 1999, GENE DEV, V13, P1653, DOI 10.1101/gad.13.13.1653; Patel R, 1998, J CELL SCI, V111, P2247; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salvat C, 1998, ONCOGENE, V17, P327, DOI 10.1038/sj.onc.1201922; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Yaglom JA, 1999, J BIOL CHEM, V274, P20223, DOI 10.1074/jbc.274.29.20223	36	48	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2573	2583		10.1038/sj.onc.1205344	http://dx.doi.org/10.1038/sj.onc.1205344			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971192				2022-12-17	WOS:000174918400014
J	Oneyama, C; Nakano, H; Sharma, SV				Oneyama, C; Nakano, H; Sharma, SV			UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug	ONCOGENE			English	Article						UCS15A; SH3; proline-rich domains; Src; Sam68; Grb2	GLUTATHIONE-S-TRANSFERASE; RECEPTOR TYROSINE KINASES; SRC HOMOLOGY-3 DOMAIN; BINDING-PROTEIN; 3-DIMENSIONAL STRUCTURE; NUCLEOTIDE EXCHANGE; E-CADHERIN; GRB2; FAMILY; SAM68	Protein-protein interactions play critical regulatory roles in mediating signal transduction. Previous studies have identified an unconventional, small-molecule, Src signal transduction inhibitor, UCS15A. UCS15A differed from conventional Src-inhibitors in that it did not alter the levels or the tyrosine kinase activity of Src. Our studies suggested that UCS15A exerted its Src-inhibitory effects by a novel mechanism that involved the disruption of protein-protein interactions mediated by Src. In the present study we have examined the ability of UCS15A to disrupt the interaction of Src-SH3 with Sam68, both in vivo and in vitro. This ability of UCS15A was not restricted to Src-SH3 mediated protein-protein interactions, since the drug was capable of disrupting the in vivo interactions of Sam68 with other SH3 domain containing proteins such as Grb2 and PLCgamma. In addition, UCS15A was capable of disrupting other typical SH3-mediated protein-protein interactions such as Grb2-Sos1, cortactin-ZO1, as well as atypical SH3-mediated protein-protein interactions such as Grb2-Gab1. However, UCS15A was unable to disrupt the non-SH3-mediated protein-protein interactions of P-catenin, with E-cadherin and g-catenin. In addition, UCS15A had no effect on the SH2-mediated interaction between Grb2 and activated Epidermal Growth Factor receptor. Thus, the ability of UCS15A, to disrupt protein-protein interactions appeared to be restricted to SH3-mediated protein-protein interactions. In this regard, UCS15A represents the first example of a non-peptide, small molecule agent capable of disrupting SH3-mediated protein-protein interactions. In vitro analyses suggested that UCS15A did not bind to the SH3 domain itself but rather may interact directly with the target proline-rich domains.	Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 194, Japan	Kyowa Kirin Ltd	Sharma, SV (corresponding author), Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, 3-6-6 Asahi Cho,Machida Shi, Tokyo 194, Japan.	ssharma@kyowa.co.jp						Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Combs AP, 1996, J AM CHEM SOC, V118, P287, DOI 10.1021/ja953750v; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Finan PM, 1996, FEBS LETT, V389, P141, DOI 10.1016/0014-5793(96)00552-2; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jabado N, 1998, J IMMUNOL, V161, P2798; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Ladbury JE, 2000, CHEM BIOL, V7, pR3, DOI 10.1016/S1074-5521(00)00067-3; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mano H, 1999, CYTOKINE GROWTH F R, V10, P267, DOI 10.1016/S1359-6101(99)00019-2; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Mayer BJ, 2001, J CELL SCI, V114, P1253; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Nguyen JT, 2000, CHEM BIOL, V7, P463, DOI 10.1016/S1074-5521(00)00130-7; Nguyen JT, 1997, NAT STRUCT BIOL, V4, P256, DOI 10.1038/nsb0497-256; Nishida M, 2001, EMBO J, V20, P2995, DOI 10.1093/emboj/20.12.2995; Pai LM, 1996, J BIOL CHEM, V271, P32411, DOI 10.1074/jbc.271.50.32411; PARKER MW, 1990, J MOL BIOL, V213, P221, DOI 10.1016/S0022-2836(05)80183-4; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pillay I, 1996, CELL GROWTH DIFFER, V7, P1487; Ponting CP, 1999, J MOL BIOL, V289, P729, DOI 10.1006/jmbi.1999.2827; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Sharma SV, 2001, ONCOGENE, V20, P2068, DOI 10.1038/sj.onc.1204296; Shen ZW, 1999, ONCOGENE, V18, P4647, DOI 10.1038/sj.onc.1203079; SMITHGALL TE, 1995, J PHARMACOL TOX MET, V34, P125, DOI 10.1016/1056-8719(95)00082-7; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Summy JM, 2000, ONCOGENE, V19, P155, DOI 10.1038/sj.onc.1203265; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; Yamashita Y, 1996, JPN J CANCER RES, V87, P1106, DOI 10.1111/j.1349-7006.1996.tb03118.x; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864	67	48	54	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2037	2050		10.1038/sj.onc.1205271	http://dx.doi.org/10.1038/sj.onc.1205271			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960376				2022-12-17	WOS:000174827000010
J	Chung, JY; Chavez, PRG; Russell, RM; Wang, XD				Chung, JY; Chavez, PRG; Russell, RM; Wang, XD			Retinoic acid inhibits hepatic Jun N-terminal kinase-dependent signaling pathway in ethanol-fed rats	ONCOGENE			English	Article						alcohol; hepatocyte proliferation and apoptosis; retinoids; mitogen-activated protein kinases	MITOGEN-ACTIVATED PROTEIN; C-JUN; CELL-PROLIFERATION; AP-1; PHOSPHORYLATION; METABOLISM; EXPRESSION; APOPTOSIS; GROWTH; TRANSDUCTION	Retinoic acid (RA) supplementation suppresses ethanol-enhanced hepatocyte hyperproliferation in rats; however, little is known about the mechanism(s). Here, we investigated whether RA affects the protein kinase signaling pathways in the liver tissues of rats fed with a high dose of ethanol for a prolonged period of time (6 months). Results show that there were greater levels of phosphorylated Jun N-terminal kinase (JNK) and phosphorylated c-Jun protein, but not total JNK protein, in livers of ethanol-fed rats vs those of controls. Moreover, ethanol feeding to rats increased the levels of phosphorylated mitogen-activated protein kinase kinase-4 (MKK-4) and decreased the levels of mitogen-activated kinase phosphatase-1 (MKP-1) in liver tissue. However, hepatic levels of phosphorylated-p38 protein and total-p38 protein were not altered by the ethanol treatment. In contrast, all-trans-RA supplementation at two doses in ethanol-fed rats greatly attenuated the ethanol-induced hepatic phosphorylation of MKK-4, phosphorylated-JNK and c-Jun proteins. The level of MKP-1 was increased in ethanol-fed rats supplemented with all-trans-RA. Further, ethanol-induced hepatocyte hyperproliferation, measured by immunostaining for proliferating cell nuclear antigen, were markedly decreased by all-trans-RA supplementation. Interestingly, hepatic apoptosis in the liver of ethanol-fed rats after 6 months of treatment decreased significantly. This decrease of hepatic apoptosis in ethanol-fed rats was prevented by all-trans-RA supplementation in a dose-dependent manner. The results from these studies indicate that restoration of RA homeostasis is critical for the regulation of JNK-dependent signaling pathway and apoptosis in the liver of ethanol-fed rats.	Tufts Univ, USDA, Jean Mayer Human Nutr Res Ctr, Gastrointestinal Nutr Lab,Mol Carcinogenesis Sect, Boston, MA 02111 USA	Tufts University; United States Department of Agriculture (USDA)	Wang, XD (corresponding author), Tufts Univ, USDA, Jean Mayer Human Nutr Res Ctr, Gastrointestinal Nutr Lab,Mol Carcinogenesis Sect, 711 Washington St, Boston, MA 02111 USA.	XWang@hnrc.tufts.edu			NCI NIH HHS [R01CA49195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BARONI GS, 1994, J HEPATOL, V20, P508, DOI 10.1016/S0168-8278(05)80498-2; Boylan JM, 1996, CELL GROWTH DIFFER, V7, P1261; CASINI A, 1991, HEPATOLOGY, V13, P758, DOI 10.1016/0270-9139(91)92576-T; CASINI A, 1994, ALCOHOL ALCOHOLISM, V29, P303; Cebers G, 1996, NEUROREPORT, V8, P217, DOI 10.1097/00001756-199612200-00044; Chen JP, 1998, BIOCHEM J, V334, P669, DOI 10.1042/bj3340669; CHEN N, 2001, CANCER RES, V15, P3908; Chung JG, 2001, CARCINOGENESIS, V22, P1213, DOI 10.1093/carcin/22.8.1213; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIEHL AM, 1988, HEPATOLOGY, V8, P237, DOI 10.1002/hep.1840080208; Ding WQ, 1996, NEUROREPORT, V7, P2191, DOI 10.1097/00001756-199609020-00027; Finch A, 2001, BIOCHEM J, V353, P275, DOI 10.1042/0264-6021:3530275; Fisher GJ, 1999, PHOTOCHEM PHOTOBIOL, V69, P154, DOI 10.1111/j.1751-1097.1999.tb03268.x; Fortunato F, 2000, PANCREAS, V21, P174, DOI 10.1097/00006676-200008000-00011; Fuchs SY, 1996, ONCOGENE, V13, P1531; Gouillon Z.-Q., 1999, Frontiers in Bioscience, V4, pa16, DOI 10.2741/gouillon; Halsted CH, 1996, HEPATOLOGY, V23, P497, DOI 10.1002/hep.510230314; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HOEK JB, 1992, FASEB J, V6, P2386, DOI 10.1096/fasebj.6.7.1563591; Jarvis WD, 1997, FEBS LETT, V412, P9, DOI 10.1016/S0014-5793(97)00705-9; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHARBANDA S, 1993, BIOCHEM PHARMACOL, V45, P675, DOI 10.1016/0006-2952(93)90142-J; Kurie Jonathan M., 1999, Current Opinion in Oncology, V11, P497, DOI 10.1097/00001622-199911000-00011; Lee HY, 1999, MOL CELL BIOL, V19, P1973; Lippman SC, 2000, J NUTR, V130, p479S, DOI 10.1093/jn/130.2.479S; Liu C, 2001, GASTROENTEROLOGY, V120, P179, DOI 10.1053/gast.2001.20877; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Pandey SC, 1996, ALCOHOL CLIN EXP RES, V20, pA67, DOI 10.1111/j.1530-0277.1996.tb01749.x; Pfahl M, 1996, ANNU REV NUTR, V16, P257, DOI 10.1146/annurev.nu.16.070196.001353; Radominska-Pandya A, 2000, J BIOL CHEM, V275, P22324, DOI 10.1074/jbc.M907722199; RESNICOFF M, 1993, J BIOL CHEM, V268, P21777; Seitz HK, 2001, ALCOHOL CLIN EXP RES, V25, p137S, DOI 10.1097/00000374-200105051-00024; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; TAKADA A, 1986, HEPATOLOGY, V6, P65, DOI 10.1002/hep.1840060113; THURSTON AW, 1992, BIOCHEM BIOPH RES CO, V185, P1062, DOI 10.1016/0006-291X(92)91734-8; Uto H, 2001, CANCER RES, V61, P4779; WANDS JR, 1979, GASTROENTEROLOGY, V77, P528; Wang XD, 1998, HEPATOLOGY, V28, P744, DOI 10.1002/hep.510280321; Wang XD, 2001, ALCOHOL IN HEALTH AND DISEASE, P427; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	46	48	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1539	1547		10.1038/sj.onc.1205023	http://dx.doi.org/10.1038/sj.onc.1205023			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896582				2022-12-17	WOS:000173956800009
J	Engedal, N; Korkmaz, CG; Saatcioglu, F				Engedal, N; Korkmaz, CG; Saatcioglu, F			C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP	ONCOGENE			English	Article						prostate cancer; apoptosis; MAPKs; JNK; caspases	ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; NH2-TERMINAL KINASE; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; T-LYMPHOCYTES; STRESS; DEATH; JNK; INHIBITION	In early, androgen dependent stages of prostate cancer, androgen withdrawal, the major course of therapy in prostate cancer, leads to a rapid regression of the tumor as a result of apoptosis. However, prostate cancer invariably progresses to an androgen independent and apoptosis resistant stage for which no curative treatment is available. The molecular details of regression upon androgen withdrawal and progression to a resistant state are largely unknown. Here we show that c-Jun N-terminal Kinase (JNK) is activated strongly and in a sustained fashion by 12-O-tetradecanoylphorbol 13-acetate (TPA) and thapsigargin (TG), two agents which were previously shown to lead to apoptosis in the androgen responsive prostate cancer cell line LNCaP. The time course of JNK induction by both compounds correlated very well with the onset and progression of apoptosis in LNCaP cells. Inhibition of either ERK or p38 pathways did not affect TPA-induced cell death. In the androgen-independent prostate cancer cell lines DU-145 and PC-3, and in the cervical carcinoma cell line HeLaS3, TPA did not lead to apoptosis and there were no significant changes in JNK activity upon TPA treatment. The failure of TPA to induce JNK activity in PC-3, DU-145, and HelaS3 cells was not due to a general defect in JNK signaling since ultraviolet (UV) irradiation dramatically increased JNK activity in all four cell lines. Specific inhibition of JNK by expression of the JNK Inhibitory Protein (JIP) dramatically inhibited both TPA- and TG-induced apoptosis. Furthermore, apoptosis induced by both agents was completely blocked by ectopic expression of the baculovirus caspase-inhibitor P35. Surprisingly, zVAD-fmk, a cell-permeable fluoromethylketone inhibitor of caspases, had no effect on TPA-induced apoptosis, whereas it completely inhibited TG-induced cell death; JNK activity was not affected in either case. This indicates that zVAD-fmk does not inhibit some of the caspases involved in TPA-induced apoptosis, and that despite the common requirement of JNK activation, TPA- and TG-induced cell death are mechanistically different. Furthermore, it also suggests that JNK is either upstream or independent of caspases in LNCaP cells. Collectively, these results indicate that apoptosis in LNCaP cells requires a sustained increase in JNK activity and caspase activation; components of these signaling pathways may be defective in the androgen independent prostate cancer cell lines.	Univ Oslo, Biotechnol Ctr Oslo, N-0349 Oslo, Norway; Univ Oslo, Dept Biochem, N-0349 Oslo, Norway; Univ Oslo, Inst Clin Med, N-0349 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo	Saatcioglu, F (corresponding author), Univ Oslo, Biotechnol Ctr Oslo, Gaustadalleen 21, N-0349 Oslo, Norway.		Engedal, Nikolai/AAJ-8951-2020	Engedal, Nikolai/0000-0003-3718-3464				Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Araki S, 1997, KIDNEY INT, V51, P631, DOI 10.1038/ki.1997.92; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; DAY ML, 1994, CELL GROWTH DIFFER, V5, P735; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Fronsdal K, 2000, PROSTATE, V43, P111, DOI 10.1002/(SICI)1097-0045(20000501)43:2<111::AID-PROS5>3.0.CO;2-4; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Garzotto M, 1998, CANCER RES, V58, P2260; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; Henttu P, 1998, BIOCHEM BIOPH RES CO, V244, P167, DOI 10.1006/bbrc.1998.8238; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huggins C, 1941, CANCER RES, V1, P293; ISAACS JT, 1994, VITAM HORM, V49, P433; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KINZEL V, 1988, CANCER RES, V48, P1759; Kuroki DW, 1996, CANCER RES, V56, P637; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li XO, 1997, J BIOL CHEM, V272, P14996, DOI 10.1074/jbc.272.23.14996; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Magi-Galluzzi C, 1998, VIRCHOWS ARCH, V432, P407, DOI 10.1007/s004280050184; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; Marcelli M, 1999, CANCER RES, V59, P382; McConkey DJ, 1996, CANCER RES, V56, P5594; Miller LK, 1997, J CELL PHYSIOL, V173, P178, DOI 10.1002/(SICI)1097-4652(199711)173:2<178::AID-JCP17>3.3.CO;2-Z; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Montironi R, 1998, UROL INT, V60, P25, DOI 10.1159/000056542; Moore RA, 1944, SURGERY, V16, P152; Nagahara A, 1998, AM J PHYSIOL-GASTR L, V275, pG740, DOI 10.1152/ajpgi.1998.275.4.G740; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Shrode LD, 1997, J BIOL CHEM, V272, P13653, DOI 10.1074/jbc.272.21.13653; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Stattin P, 1998, BRIT J CANCER, V77, P670, DOI 10.1038/bjc.1998.107; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wertz IE, 2000, J BIOL CHEM, V275, P11470, DOI 10.1074/jbc.275.15.11470; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; YOUNG CYF, 1994, ONCOL RES, V6, P203; Zhang PS, 1996, J NEUROSCI RES, V46, P114, DOI 10.1002/(SICI)1097-4547(19961001)46:1<114::AID-JNR14>3.0.CO;2-5; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751; ZHU HJ, 1995, FEBS LETT, V374, P303, DOI 10.1016/0014-5793(95)01116-V	63	48	49	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1017	1027		10.1038/sj.onc.1205167	http://dx.doi.org/10.1038/sj.onc.1205167			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850819				2022-12-17	WOS:000173580100005
J	Forus, A; D'Angelo, A; Henriksen, J; Merla, G; Maelandsmo, GM; Florenes, VA; Olivieri, S; Bjerkehagen, B; Meza-Zepeda, LA; Blanco, FD; Muller, C; Sanvito, F; Kononen, J; Nesland, JM; Fodstad, O; Reymond, A; Kallioniemi, OP; Arrigoni, G; Ballabio, A; Myklebost, O; Zollo, M				Forus, A; D'Angelo, A; Henriksen, J; Merla, G; Maelandsmo, GM; Florenes, VA; Olivieri, S; Bjerkehagen, B; Meza-Zepeda, LA; Blanco, FD; Muller, C; Sanvito, F; Kononen, J; Nesland, JM; Fodstad, O; Reymond, A; Kallioniemi, OP; Arrigoni, G; Ballabio, A; Myklebost, O; Zollo, M			Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas - a possible mechanism for altering the nm23-H1 activity	ONCOGENE			English	Article						PRUNE; nm23; sarcoma; breast	COMPARATIVE GENOMIC HYBRIDIZATION; NUCLEOSIDE DIPHOSPHATE KINASE; HUMAN HEPATOCELLULAR-CARCINOMA; CELL-LINES; MOLECULAR CHARACTERIZATION; TISSUE MICROARRAYS; PROTEIN EXPRESSION; TUMOR PROGRESSION; GENE-EXPRESSION; DROSOPHILA	PRUNE, the human homologue of the Drosophila gene, is located in 1q21.3, a region highly amplified in human sarcomas, malignant tumours of mesenchymal origin. Prune protein interacts with the metastasis suppressor nm23-H1, but shows impaired affinity towards the nm23-H1 S120G mutant associated with advanced neuroblastoma. Based on these observations, we previously suggested that prune may act as a negative regulator of nm23-H1 activity. We found amplification of PRUNE in aggressive sarcoma subtypes, such as leiomyosarcomas and malignant fibrous histiocytomas (NIFH) as well as in the less malignant liposarcomas. PRUNE amplification was generally accompanied by high mRNA and moderate to high protein levels. The sarcoma samples expressed nm23-H1 mostly at low or moderate levels, whereas mRNA and protein levels were moderate to high in breast carcinomas. For the more aggressive sarcoma subtypes, 9/13 patients with PRUNE amplification developed metastases. A similar situation was observed in all breast carcinomas with amplification of PRUNE. Infection of NIH3T3 cells with a PRUNE recombinant retrovirus increased cell proliferation. Possibly, amplification and overexpression of PRUNE has the same effect in the tumours. We suggest that amplification and overexpression of PRUNE could be a mechanism for inhibition of nm23-H1 activity that affect the development or progression of these tumours.	Telethon Inst Genet & Med, I-80131 Naples, Italy; Norwegian Radium Hosp, Dept Tumor Biol, Oslo, Norway; Norwegian Radium Hosp, Dept Pathol, Oslo, Norway; HSR Biomed Sci Pk, Dept Pathol, Milan, Italy; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Univ Tampere, Inst Med Technol, Canc Genet Lab, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Tampere, Finland; Univ Geneva, Sch Med, Div Med Genet, CH-1211 Geneva, Switzerland	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); University of Oslo; University of Oslo; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Tampere University; Tampere University; Tampere University Hospital; University of Geneva	Zollo, M (corresponding author), Telethon Inst Genet & Med, Via Pietro Castellino 111, I-80131 Naples, Italy.	zollo@tigem.it	merla, giuseppe/K-4627-2012; Kallioniemi, Olli P/H-5111-2011; BALLABIO, Andrea/AAL-2672-2020; Myklebost, Ola/E-9335-2010; Meza-Zepeda, Leonardo Andres/CAG-5229-2022	merla, giuseppe/0000-0001-5078-928X; Kallioniemi, Olli P/0000-0002-3231-0332; BALLABIO, Andrea/0000-0003-1381-4604; Myklebost, Ola/0000-0002-2866-3223; Meza-Zepeda, Leonardo Andres/0000-0003-3056-212X; Kononen, Juha/0000-0002-0157-2137; Reymond, Alexandre/0000-0003-1030-8327	Telethon [TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Banfi S, 1996, NAT GENET, V13, P167, DOI 10.1038/ng0696-167; Berner JM, 1997, ONCOGENE, V14, P2935, DOI 10.1038/sj.onc.1201135; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; Caligo MA, 1997, INT J CANCER, V74, P102, DOI 10.1002/(SICI)1097-0215(19970220)74:1<102::AID-IJC18>3.0.CO;2-H; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; Cipollini G, 1997, INT J CANCER, V73, P297, DOI 10.1002/(SICI)1097-0215(19971009)73:2<297::AID-IJC22>3.0.CO;2-B; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; Enzinger FM, 1995, SOFT TISSUE TUMORS, V3rd; FLORENES VA, 1992, CANCER RES, V52, P6088; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P15, DOI 10.1002/gcc.2870140104; Forus A, 1998, BRIT J CANCER, V78, P495, DOI 10.1038/bjc.1998.521; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; Forus A, 2001, CANCER GENET CYTOGEN, V125, P100, DOI 10.1016/S0165-4608(00)00369-1; Gronwald J, 1997, CANCER RES, V57, P481; Hartsough MT, 2001, CANCER RES, V61, P2320; HE J, 1995, CANCER RES, V55, P4833; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; Hirai M, 1999, GENE CHROMOSOME CANC, V25, P261, DOI 10.1002/(SICI)1098-2264(199907)25:3<261::AID-GCC8>3.0.CO;2-#; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KHATIB ZA, 1993, CANCER RES, V53, P5535; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kudoh K, 1999, CLIN CANCER RES, V5, P2526; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P855; Lindsley D.L., 1992, GENOME DROSOPHILA ME; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; Marenholz I, 1996, GENOMICS, V37, P295, DOI 10.1006/geno.1996.0563; MARTINEZ JA, 1995, GUT, V37, P712, DOI 10.1136/gut.37.5.712; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muller W, 1998, CANCER-AM CANCER SOC, V83, P2481, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2481::AID-CNCR11>3.0.CO;2-P; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREVI N, 1975, MUTAT RES, V33, P193, DOI 10.1016/0027-5107(75)90195-5; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pedeutour F, 1999, GENE CHROMOSOME CANC, V24, P30, DOI 10.1002/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.0.CO;2-P; Pilotti S, 1998, J PATHOL, V185, P188; Qin LX, 1999, CANCER RES, V59, P5662; Reymond A, 1999, ONCOGENE, V18, P7244, DOI 10.1038/sj.onc.1203140; ROYDS JA, 1993, J NATL CANCER I, V85, P727, DOI 10.1093/jnci/85.9.727; Royds JA, 1997, BRIT J CANCER, V75, P1195, DOI 10.1038/bjc.1997.204; Roymans D, 2001, EXP CELL RES, V262, P145, DOI 10.1006/excr.2000.5087; Russell RL, 1998, BRIT J CANCER, V78, P710, DOI 10.1038/bjc.1998.566; SANTORO M, 1994, ONCOGENE, V9, P509; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; Schraml P, 1999, CLIN CANCER RES, V5, P1966; Simons A, 2000, CANCER GENET CYTOGEN, V118, P89, DOI 10.1016/S0165-4608(99)00178-8; Srivatsa PJ, 1996, GYNECOL ONCOL, V60, P363, DOI 10.1006/gyno.1996.0056; Subramanian C, 2001, NAT MED, V7, P350, DOI 10.1038/85499; Szymanska J, 1996, GENE CHROMOSOME CANC, V15, P89, DOI 10.1002/(SICI)1098-2264(199602)15:2<89::AID-GCC2>3.0.CO;2-#; Tapper J, 1998, CANCER RES, V58, P2715; Tarkkanen M, 1999, INT J CANCER, V84, P114, DOI 10.1002/(SICI)1097-0215(19990420)84:2<114::AID-IJC4>3.0.CO;2-Q; Timmons L, 1996, GENETICS, V144, P1589; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; Tseng YH, 2001, CANCER RES, V61, P2071; Volorio S, 1998, DNA SEQUENCE, V9, P307, DOI 10.3109/10425179809008469; Weiss SW, 1994, WHO HISTOLOGICAL CLA, V2nd; WHITE CJ, 1899, J CUTAN GENITOURIN, V17, P1; Wong N, 1999, AM J PATHOL, V154, P37, DOI 10.1016/S0002-9440(10)65248-0; Zimonjic DB, 1999, HEPATOLOGY, V29, P1208, DOI 10.1002/hep.510290410	61	48	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6881	6890		10.1038/sj.onc.1204874	http://dx.doi.org/10.1038/sj.onc.1204874			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687967				2022-12-17	WOS:000171641000009
J	Knoepfler, PS; Sykes, DB; Pasillas, M; Kamps, MP				Knoepfler, PS; Sykes, DB; Pasillas, M; Kamps, MP			HoxB8 requires its Pbx-interaction motif to block differentiation of primary myeloid progenitors and of most cell line models of myeloid differentiation	ONCOGENE			English	Article						HoxB8; Pbx; myeloid; differentiation	COOPERATIVE DNA-BINDING; HOMEOBOX GENE; SOMATOSTATIN PROMOTER; ONCOPROTEIN E2A-PBX1; IN-VIVO; PRE-B; LEUKEMIA; PROTEINS; HOMEODOMAIN; EXPRESSION	HoxB8 was the first homeobox gene identified as a cause of leukemia. In murine WEHI3B acute myeloid leukemia (AML) cells, proviral integration leads to the expression of both HoxB8 and Interleukin (IL-3). Enforced expression of HoxB8 blocks differentiation of factor-dependent myeloid progenitors, while IL-3 co-expression induces autocrine proliferation and overt leukemogenicity. Previously, we demonstrated that HoxB8 binds DNA cooperatively with members of the Pbx family of transcription factors, and that HoxB8 makes contact with the Pbx homeodomain through a hexameric sequence designated the Pbx-interaction motif (PIM). E2a-Pbx1, an oncogenic derivative of Pbx1, both retains its ability to heterodimerize with Hox proteins and arrest myeloid differentiation. This observation prompts the question of whether E2a-Pbx1 and Hox oncoproteins use endogenous Hox and Pbx proteins, respectively, to target a common set of cellular genes. Here, we use four different models of neutrophil and macrophage differentiation to determine whether HoxB8 needs to bind DNA or Pbx cofactors in order to arrest myeloid differentiation. The ability of HoxB8 to bind DNA or to bind Pbx was essential (1) to block differentiation of factor-dependent myeloid progenitors from primary marrow; (2) to block IL-6-induced monocytic differentiation of M1-AML cells; and (3) to block granulocytic differentiation of GM-CSF-dependent ECoM-G cells. However, while DNA-binding was required, the HoxB8 Pbx-interaction motif was unnecessary for preventing macrophage differentiation of ECoM-M cells. We conclude that HoxB8 prevents differentiation by directly influencing cellular gene expression, and that the genetic context within a cell dictates whether the effect of HoxB8 is dependent on a physical interaction with Pbx proteins.	Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA; Fred Hutchinson Canc Res Ctr, Dept Basic Sci, Seattle, WA 98109 USA	University of California System; University of California San Diego; Fred Hutchinson Cancer Center	Kamps, MP (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Knoepfler, Paul/0000-0001-5444-334X	NATIONAL CANCER INSTITUTE [R01CA056876] Funding Source: NIH RePORTER; NCI NIH HHS [CA56876] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Calvo KR, 1999, ONCOGENE, V18, P8033, DOI 10.1038/sj.onc.1203377; Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; Care A, 1999, ONCOGENE, V18, P1993, DOI 10.1038/sj.onc.1202498; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DiRocco G, 1997, EMBO J, V16, P3644, DOI 10.1093/emboj/16.12.3644; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAWLEY RG, 1994, ONCOGENE, V9, P1; Izon DJ, 1998, BLOOD, V92, P383, DOI 10.1182/blood.V92.2.383.414k41_383_393; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1994, ONCOGENE, V9, P3159; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lawrence HJ, 1996, STEM CELLS, V14, P281, DOI 10.1002/stem.140281; Lawrence HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/blood.V89.6.1922; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lu Q, 1996, MOL CELL BIOL, V16, P1632; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Passner JM, 1999, NATURE, V397, P714, DOI 10.1038/17833; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; SYKES DB, 2001, IN PRESS BLOOD; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Yaron Y, 2001, J IMMUNOL, V166, P5058, DOI 10.4049/jimmunol.166.8.5058	47	48	52	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5440	5448		10.1038/sj.onc.1204710	http://dx.doi.org/10.1038/sj.onc.1204710			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571641				2022-12-17	WOS:000170781100004
J	Claudio, J; Zhu, YX; Benn, SJ; Shukla, AH; McGlade, CJ; Falcioni, N; Stewart, AK				Claudio, J; Zhu, YX; Benn, SJ; Shukla, AH; McGlade, CJ; Falcioni, N; Stewart, AK			HACS1 encodes a novel SM-SAM adaptor protein differentially expressed in normal and malignant hematopoietic cells	ONCOGENE			English	Article						myeloma; adaptor protein; hematopoietic; SAM domain; SH3 domain	TYROSINE KINASE; HUMAN LEUKEMIA; FUSION; TEL; ACTIVATION; FAMILY; DOMAIN; GENE	SH3 and SAM domains are protein interaction motifs that are predominantly seen in signaling molecules, adaptors, and scaffold proteins. We have identified a novel family of putative adaptor genes that includes HACS1. HACS1 encodes a 441 amino acid protein that is differentially expressed in hematopoietic cells and has restricted expression in human tissues. Its SH3 domain is most similar to the same motif in Crk and its SAM domain shares homology with a family of uncharacterized putative scaffold and adaptor proteins. HACS1 maps to human chromosome 21q11.2 in a region that is frequently disrupted by translocation events in hematopoietic malignancies. Polyclonal antibodies against HACS1 recognized a 49.5 kDa protein whose mRNA is expressed in human immune tissues, bone marrow, heart, lung, placenta and brain. Cell lines and primary cells from acute myeloid leukemias and multiple myeloma patients express HACS1. Immunostaining and cellular fractionation studies localized the HACS1 protein predominantly to the cytoplasm.	Toronto Gen Res Inst, Toronto, ON, Canada; Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Canadian Blood Serv, Toronto Ctr, Toronto, ON M5G 2M1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Canadian Blood Services	Stewart, AK (corresponding author), Princess Margaret Hosp, 610 Univ Ave,Room 5-126, Toronto, ON M5G 2M9, Canada.							ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Claudio JO, 1998, GENOMICS, V50, P44, DOI 10.1006/geno.1998.5308; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Kyba M, 1998, DEV GENET, V22, P74, DOI 10.1002/(SICI)1520-6408(1998)22:1<74::AID-DVG8>3.3.CO;2-V; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rhodes J, 2000, EXP HEMATOL, V28, P305, DOI 10.1016/S0301-472X(99)00148-4; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sheng M, 2000, J CELL SCI, V113, P1851; Shi CS, 2000, BLOOD, V95, P776, DOI 10.1182/blood.V95.3.776.003k23_776_782; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876	17	48	50	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5373	5377		10.1038/sj.onc.1204698	http://dx.doi.org/10.1038/sj.onc.1204698			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536050				2022-12-17	WOS:000170575500013
J	Curtin, JC; Dragnev, KH; Sekula, D; Christie, AJ; Dmitrovsky, E; Spinella, MJ				Curtin, JC; Dragnev, KH; Sekula, D; Christie, AJ; Dmitrovsky, E; Spinella, MJ			Retinoic acid activates p53 in human embryonal carcinoma through retinoid receptor-dependent stimulation of p53 transactivation function	ONCOGENE			English	Article						retinoic acid; differentiation; embryonal carcinoma; teratocarcinoma; p53	GERM-CELL TUMORS; CISPLATIN-INDUCED APOPTOSIS; DNA-DAMAGE; HUMAN TERATOCARCINOMAS; TESTICULAR-TUMORS; GENE-EXPRESSION; DOWN-REGULATION; DIFFERENTIATION; CANCER; PROTEIN	Although retinoids are known to regulate gene transcription by activating retinoid receptors, the targets of retinoid receptors are largely unknown. This study indicates effective all-trans retinoic acid (RA)-induced differentiation of human embryonal carcinoma cells engages p53, Unexpectedly, RA has been found to activate the transactivation function of p53 in the human embryonal carcinoma cell line, NT2/D1, in a retinoid receptor-dependent manner. A derived RA-resistant line, NT2/D1-R1, is deficient in this activity and is co-resistant to cisplatin, This indicates that RA and cisplatin responses may share a common pathway involving p53 in embryonal carcinomas. RA has no effect on p53 steady-state protein levels in either line. RA enhances endogenous p53 transactivation activity in NT2/D1 but not NT2/D1-R1 cells. In addition, RA induces transactivation activity of a gal4-p53 fusion protein, suggesting that RA activates p53 independent of increasing p53 levels or sequence-specific DNA binding. This activity is absent in retinoic acid receptor gamma (RAR gamma)-deficient NT2/D1-R1 cells but can be restored upon co-transfection with specific RARs. Transient transfection of a dominant-negative p53 construct in NT2/D1 cells blocks the RA-mediated transcriptional decline of a differentiation-sensitive reporter plasmid and enhances survival of NT2/D1 cells following cisplatin treatment. Taken together, these findings indicate that RA activates the intrinsic activation function of p53 by a novel mechanism independent of effects on p53 stability or DNA binding and that this activation may be a general mechanism that contributes to RA-mediated G1 arrest.	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Coll, Hitchcock Med Ctr, Dept Med, Lebanon, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Spinella, MJ (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.		Spinella, Michael/B-7210-2014		NCI NIH HHS [R01 CA54494, CA75154, R01 CA87546] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA075154, R01CA054494, R01CA087546] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allemand I, 1999, ONCOGENE, V18, P6521, DOI 10.1038/sj.onc.1203052; Andrews PW, 1998, APMIS, V106, P158, DOI 10.1111/j.1699-0463.1998.tb01331.x; Armstrong Robert B., 1994, P545; Arriola EL, 1999, ONCOGENE, V18, P1457, DOI 10.1038/sj.onc.1202420; Boersma AWM, 1997, CYTOMETRY, V27, P275, DOI 10.1002/(SICI)1097-0320(19970301)27:3<275::AID-CYTO10>3.0.CO;2-Q; Boyle JO, 2001, CLIN CANCER RES, V7, P259; Burger H, 1999, INT J CANCER, V81, P620, DOI 10.1002/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.3.CO;2-J; Burger H, 1997, INT J CANCER, V73, P592, DOI 10.1002/(SICI)1097-0215(19971114)73:4<592::AID-IJC22>3.0.CO;2-A; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Chresta CM, 1996, CANCER RES, V56, P1834; Collins MD, 1999, ANNU REV PHARMACOL, V39, P399, DOI 10.1146/annurev.pharmtox.39.1.399; DMITROVSKY E, 1990, CANCER SURV, V9, P369; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; GUCHELAAR HL, 1993, INT J CANCER, V55, P442, DOI 10.1002/ijc.2910550320; HALL PA, 1997, CURR BIOL, V7, P144; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hecker D, 1996, ONCOGENE, V12, P953; HEIMDAL K, 1993, GENE CHROMOSOME CANC, V6, P92, DOI 10.1002/gcc.2870060205; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HONG WK, 1977, CANCER, V40, P2987, DOI 10.1002/1097-0142(197712)40:6<2987::AID-CNCR2820400634>3.0.CO;2-A; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; Hussain SP, 1998, CANCER RES, V58, P4023; JETTEN AM, 1979, NATURE, V278, P180, DOI 10.1038/278180a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Lutzker SG, 1998, APMIS, V106, P85, DOI 10.1111/j.1699-0463.1998.tb01323.x; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Maerz WJ, 1998, ONCOGENE, V17, P761, DOI 10.1038/sj.onc.1201992; Mangelsdorf David J., 1994, P319; Matin A, 1998, APMIS, V106, P174, DOI 10.1111/j.1699-0463.1998.tb01333.x; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; MILLER WH, 1990, ONCOGENE, V5, P511; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; NASONBURCHENAL K, 1999, RETINOIDS HDB EXPT P, P301; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PENG HQ, 1993, CANCER RES, V53, P3574; PERA MF, 1990, CANCER SURV, V9, P243; Rapley E, 1998, APMIS, V106, P64; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; SCHOTTENFELD D, 1980, AM J EPIDEMIOL, V112, P232, DOI 10.1093/oxfordjournals.aje.a112989; Schwartz D, 1999, CELL GROWTH DIFFER, V10, P665; Shang YF, 1999, J BIOL CHEM, V274, P18005, DOI 10.1074/jbc.274.25.18005; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shin DM, 1997, CLIN CANCER RES, V3, P875; Shin DM, 2000, J NATL CANCER I, V92, P69, DOI 10.1093/jnci/92.1.69; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Spinella MJ, 1998, ONCOGENE, V16, P3471, DOI 10.1038/sj.onc.1201876; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	59	48	48	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2559	2569		10.1038/sj.onc.1204370	http://dx.doi.org/10.1038/sj.onc.1204370			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420666				2022-12-17	WOS:000168652500007
J	Khoury, H; Dankort, DL; Sadekova, S; Naujokas, MA; Muller, WJ; Park, M				Khoury, H; Dankort, DL; Sadekova, S; Naujokas, MA; Muller, WJ; Park, M			Distinct tyrosine autophosphorylation sites mediate induction of epithelial mesenchymal like transition by an activated ErbB-2/Neu receptor	ONCOGENE			English	Article						ErbB-2/Neu; epithelial-mesenchymal transition; morphogenesis; MDCK epithelial cells; Shc	HEPATOCYTE GROWTH-FACTOR; KIDNEY-CELLS REQUIRES; HUMAN BREAST-CANCER; ADAPTER PROTEIN; MAMMARY-GLAND; NEU ONCOGENE; C-MET; KINASE; MORPHOGENESIS; CARCINOMA	Tight control of cell proliferation and morphogenesis is required to ensure normal tissue patterning and prevent cancer formation. Overexpression of the ErbB-2/Neu receptor tyrosine kinase is associated with increased progression in human breast cancer, yet in breast explant cultures, the ErbB-2/Neu receptor contributes to alveolar differentiation. To examine the consequence of deregulated ErbB-2/Neu activation on epithelial morphogenesis, we have expressed a constitutively activated mutant of ErbB-2/Neu in a Madin-Darby canine kidney (MDCK) epithelial cell model. Using two-dimensional cultures we demonstrate that activated ErbB-2/Neu induces breakdown of cell-cell junctions, increased cell motility and dispersal of epithelial colonies. This correlates with reorganization of the actin cytoskeleton and fetal adhesions and loss of insoluble cell-cell junction complexes involving E-cadherin. Interestingly, a constitutively activated ErbB-2/Neu receptor promotes an invasive morphogenic program in MDCK cells in a three-dimensional matrix. We show that two tyrosines in the carboxy-terminal tail of ErbB-2/Neu, involved in the phosphorylation of the Shc adapter protein, are each sufficient to promote epithelial-mesenchymal like transition and enhanced cell motility in two-dimensional culture and cell invasion rather than a morphogenic response in matrix culture. This provides a model system to investigate ErbB-2/Neu induced signaling pathways required for epithelial cell dispersal and invasion versus morphogenesis.	McGill Univ Hosp Ctr, Dept Biochem, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ Hosp Ctr, Dept Med, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ Hosp Ctr, Dept Oncol, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McMaster Univ, Inst Mol Biol & Biotechnol, Dept Biol, Hamilton, ON, Canada	McGill University; McGill University; McGill University; McMaster University	Park, M (corresponding author), McGill Univ Hosp Ctr, Dept Biochem, Mol Oncol Grp, H5-10-687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.			Dankort, David/0000-0002-5862-6829				Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Boyer B, 1996, ACTA ANAT, V156, P227; Brandt BH, 1999, FASEB J, V13, P1939, DOI 10.1096/fasebj.13.14.1939; Chausovsky A, 1998, MOL BIOL CELL, V9, P3195, DOI 10.1091/mbc.9.11.3195; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Klapper LN, 2000, CANCER RES, V60, P3384; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; Pawson T, 2000, GENE DEV, V14, P1027; Pegram MD, 1998, BREAST CANCER RES TR, V52, P65, DOI 10.1023/A:1006111117877; PELICCI G, 1995, ONCOGENE, V10, P1631; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Rauh MJ, 1999, MOL CELL BIOL, V19, P8169; RICCI A, 1995, ONCOGENE, V11, P1519; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; Selli C, 1997, J UROLOGY, V158, P245, DOI 10.1097/00005392-199707000-00079; Sheetz MP, 1999, BIOCHEM SOC SYMP, V65, P233; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; YAMASHITA J, 1994, CANCER RES, V54, P1630; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Zhang XH, 1997, UROLOGY, V50, P636, DOI 10.1016/S0090-4295(97)00258-6; ZHU H, 1994, J BIOL CHEM, V269, P29943	39	48	50	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					788	799		10.1038/sj.onc.1204166	http://dx.doi.org/10.1038/sj.onc.1204166			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314013				2022-12-17	WOS:000166924400002
J	Pestell, KE; Ducruet, AP; Wipf, P; Lazo, JS				Pestell, KE; Ducruet, AP; Wipf, P; Lazo, JS			Small molecule inhibitors of dual specificity protein phosphatases	ONCOGENE			English	Article						tyrosine phosphatases; dual specificity phosphatases; cdc25; cancer	INSULIN SIGNAL-TRANSDUCTION; NON-HODGKINS-LYMPHOMAS; TYROSINE-PHOSPHATASE; CELL-CYCLE; CDC25 PHOSPHATASE; C-MYC; TRYPANOSOMA-BRUCEI; CRYSTAL-STRUCTURE; PHASE-TRANSITION; INTACT-CELLS	One hallmark of neoplasia is the deregulation of eel cycle control mechanisms, which is secondary to altered protein phosphorylation, Dual specificity protein phosphatases uniquely dephosphorylate both phosphoserines/ threonines and phosphotyrosines on the same protein substrate. As a class they regulate intracellular signaling through the mitogen activated and stress activated kinases and govern cellular movement through G1/S and G2/M cell cycle checkpoints by affecting the activity of cyclin-dependent kinases, In particular, the Cdc25 phosphatases, which dephosphorylate cyclin-dependent kinases, are overexpressed in many human tumors and this increased expression is associated with a poor prognosis. In addition to expression levels, the intracellular activity of Cdc25 phosphatases is determined by their subcellular distribution and physical proximity to substrates. Small molecules that either inhibit the catalytic activity or alter the subcellular distribution of these dual specificity protein phosphatases could provide effective tools to interrogate the role of phosphorylation pathways and may afford new approaches to the management of cancer.	Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lazo, JS (corresponding author), Univ Pittsburgh, Dept Pharmacol, Biomed Sci Tower E1340,3550 Terrace & DeSoto St, Pittsburgh, PA 15261 USA.		Wipf, Peter/AAG-1771-2021	Wipf, Peter/0000-0001-7693-5863; Barnes, Katharine/0000-0003-4968-3028	NATIONAL CANCER INSTITUTE [R01CA043917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008424] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43917] Funding Source: Medline; NIGMS NIH HHS [T32 GM08424] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Bakalara N, 1995, EXP PARASITOL, V81, P302, DOI 10.1006/expr.1995.1121; Bakalara N, 1995, EUR J BIOCHEM, V234, P871, DOI 10.1111/j.1432-1033.1995.871_a.x; Barford D, 1996, TRENDS BIOCHEM SCI, V21, P407, DOI 10.1016/S0968-0004(96)10060-8; Bergnes G, 1999, BIOORG MED CHEM LETT, V9, P2849, DOI 10.1016/S0960-894X(99)00497-7; Bernardi R, 2000, ONCOGENE, V19, P2447, DOI 10.1038/sj.onc.1203564; Blanchard JL, 1999, BIOORG MED CHEM LETT, V9, P2537, DOI 10.1016/S0960-894X(99)00431-X; BOLIN I, 1988, MOL MICROBIOL, V2, P237, DOI 10.1111/j.1365-2958.1988.tb00025.x; BRUBAKER RR, 1991, CLIN MICROBIOL REV, V4, P309, DOI 10.1128/CMR.4.3.309-324.1991; BUTLER T, 1985, TXB MED, P1600; Cans C, 1999, ANTICANCER RES, V19, P1241; Cebula RE, 1997, BIOORG MED CHEM LETT, V7, P2015, DOI 10.1016/S0960-894X(97)00357-0; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; Chen W, 2000, BIOCHEMISTRY-US, V39, P10781, DOI 10.1021/bi000909u; COHN P, 1989, ANNU REV BIOCHEM, V58, P453; COOL DE, 1993, MOL CELL BIOCHEM, V128, P143, DOI 10.1007/BF01076765; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; Dixon D, 1998, EXP CELL RES, V240, P236, DOI 10.1006/excr.1998.3940; Dodo K, 2000, BIOORG MED CHEM LETT, V10, P615, DOI 10.1016/S0960-894X(00)00065-2; DRAETTA J, 1997, BIOCHIM BIOPHYS ACTA, V1332, pM53; Ducruet AP, 2000, BIOORGAN MED CHEM, V8, P1451, DOI 10.1016/S0968-0896(00)00069-9; Eckstein JW, 2000, INVEST NEW DRUG, V18, P149, DOI 10.1023/A:1006377913494; El-Subbagh HI, 1999, ARCH PHARM, V332, P19; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Fritzen EL, 2000, BIOORG MED CHEM LETT, V10, P649, DOI 10.1016/S0960-894X(00)00069-X; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Garner-Hamrick PA, 1998, INT J CANCER, V76, P720, DOI 10.1002/(SICI)1097-0215(19980529)76:5<720::AID-IJC18>3.0.CO;2-7; Gasparotto D, 1997, CANCER RES, V57, P2366; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GUNSAKERA SP, 1996, J AM CHEM SOC, V118, P8759; Ham SW, 1998, BIOORG MED CHEM LETT, V8, P2507, DOI 10.1016/S0960-894X(98)00411-9; Ham SW, 1997, BIOORG CHEM, V25, P33, DOI 10.1006/bioo.1996.1052; Hernandez S, 1998, CANCER RES, V58, P1762; Hernandez S, 2000, INT J CANCER, V89, P148, DOI 10.1002/(SICI)1097-0215(20000320)89:2<148::AID-IJC8>3.0.CO;2-R; HORIGUCHI T, 1994, BIOCHEM PHARMACOL, V48, P2139, DOI 10.1016/0006-2952(94)90516-9; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kaniga K, 1996, MOL MICROBIOL, V21, P633, DOI 10.1111/j.1365-2958.1996.tb02571.x; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Kioschis P, 1996, GENOMICS, V33, P365, DOI 10.1006/geno.1996.0212; Kole HK, 1996, J BIOL CHEM, V271, P14302, DOI 10.1074/jbc.271.24.14302; Koufaki M, 1996, J MED CHEM, V39, P2609, DOI 10.1021/jm9509152; Kudo Y, 1997, JPN J CANCER RES, V88, P947, DOI 10.1111/j.1349-7006.1997.tb00313.x; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; Lammer C, 1998, J CELL SCI, V111, P2445; Lammers R, 1997, FEBS LETT, V404, P37, DOI 10.1016/S0014-5793(97)00080-X; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Minassian BA, 1999, ANN NEUROL, V45, P262, DOI 10.1002/1531-8249(199902)45:2<262::AID-ANA20>3.0.CO;2-9; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Otani T, 2000, J ANTIBIOT, V53, P337, DOI 10.7164/antibiotics.53.337; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Peng HR, 2000, BIOORGAN MED CHEM, V8, P299, DOI 10.1016/S0968-0896(99)00284-9; Peng HR, 1998, J MED CHEM, V41, P4677, DOI 10.1021/jm980500r; Reynolds RA, 1999, J MOL BIOL, V293, P559, DOI 10.1006/jmbi.1999.3168; Rice RL, 1997, BIOCHEMISTRY-US, V36, P15965, DOI 10.1021/bi971338h; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Takahashi M, 2000, BIOORG MED CHEM LETT, V10, P2571, DOI 10.1016/S0960-894X(00)00527-8; Tamura K, 2000, CANCER RES, V60, P1317; Tamura K, 1999, ONCOGENE, V18, P6989, DOI 10.1038/sj.onc.1203179; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; WHITE MF, 1994, J BIOL CHEM, V269, P1; Woo ES, 1999, ONCOGENE, V18, P2770, DOI 10.1038/sj.onc.1202614; Wu WG, 1998, CANCER RES, V58, P4082; Xia K, 1999, MOL CELL BIOL, V19, P4819; Zhang WR, 1996, MOL ENDOCRINOL, V10, P575, DOI 10.1210/me.10.5.575; Zhang ZY, 1997, CURR TOP CELL REGUL, V35, P21, DOI 10.1016/S0070-2137(97)80002-7; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007	74	48	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6607	6612		10.1038/sj.onc.1204084	http://dx.doi.org/10.1038/sj.onc.1204084			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426646				2022-12-17	WOS:000167704000007
J	Krosl, J; Sauvageau, G				Krosl, J; Sauvageau, G			AP-1 complex is effector of Hox-induced cellular proliferation and transformation	ONCOGENE			English	Article						Hox; Pbx; AP-1; proliferation; transformation	HEMATOPOIETIC-CELLS CAUSES; BONE-MARROW CELLS; MYELOID-LEUKEMIA; HOMEOBOX GENES; MAMMARY-GLAND; CLUSTER GENES; GROWTH-FACTOR; FRA-1 GENE; EXPRESSION; PROTEIN	Hox gene products, initially characterized as master regulators of embryonic patterning, are also required for proper functioning of adult tissues. There is also a growing body of evidence that links Hox proteins to regulation of cellular proliferation/transformation. However, the underlying molecular mechanisms of Hox-associated transformation and tissue growth have yet to be elucidated. Using a well established model system for studying changes in cellular proliferation induced by Hoxb4, we show that AP-I activity is markedly increased in Hoxb4-transduced cells due to significant upregulation of Jun-B and Fra-1 protein levels, Furthermore, we also show that the specific changes in AP-1 protein expression are necessary for the proliferation effects induced by Hoxb4, and that these changes converge to increase levels of cyclin D1, a known integrator of proliferation signals. Our observations thus link Hox gene products with key elements of the cell cycle machinery.	Clin Res Inst Montreal, Lab Mol Genet Hemopoiet Stem Cells, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Hop Maison Neuve Rosemont, Div Hematol, Montreal, PQ H1T 2M4, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal	Sauvageau, G (corresponding author), Clin Res Inst Montreal, Lab Mol Genet Hemopoiet Stem Cells, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.			Sauvageau, Guy/0000-0002-4333-7266				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Amato SF, 1996, J IMMUNOL, V157, P146; Asahara H, 1999, MOL CELL BIOL, V19, P8219; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; CARE A, 1994, MOL CELL BIOL, V14, P4872, DOI 10.1128/MCB.14.7.4872; Care A, 1996, MOL CELL BIOL, V16, P4842; Chariot A, 1999, ONCOGENE, V18, P4007, DOI 10.1038/sj.onc.1202776; Chen F, 1999, P NATL ACAD SCI USA, V96, P541, DOI 10.1073/pnas.96.2.541; CILLO C, 1994, INVAS METAST, V14, P38; COFFER P, 1994, ONCOGENE, V9, P911; DEVITA G, 1993, EUR J CANCER, V29A, P887, DOI 10.1016/S0959-8049(05)80432-0; FRIEDMANN Y, 1994, CANCER RES, V54, P5981; HERBER, 1994, ONCOGENE, V9, P2105; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lawrence HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/blood.V89.6.1922; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Mamo A, 1999, BLOOD, V94, p250A; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Quaranta MT, 1996, J IMMUNOL, V157, P2462; SALSER SJ, 1994, TRENDS GENET, V10, P159, DOI 10.1016/0168-9525(94)90092-2; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Snowden AW, 1998, BIOCHEM PHARMACOL, V55, P1947, DOI 10.1016/S0006-2952(98)00020-3; Stelnicki EJ, 1998, J INVEST DERMATOL, V110, P110, DOI 10.1046/j.1523-1747.1998.00092.x; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Yueh YG, 1998, P NATL ACAD SCI USA, V95, P9956, DOI 10.1073/pnas.95.17.9956; Zakany J, 1996, NATURE, V384, P69, DOI 10.1038/384069a0; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732	39	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2000	19	45					5134	5141		10.1038/sj.onc.1203897	http://dx.doi.org/10.1038/sj.onc.1203897			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064450				2022-12-17	WOS:000090124100002
J	Dazard, JE; Piette, J; Basset-Seguin, N; Blanchard, JM; Gandarillas, A				Dazard, JE; Piette, J; Basset-Seguin, N; Blanchard, JM; Gandarillas, A			Switch from p53 to MDM2 as differentiating human keratinocytes lose their proliferative potential and increase in cellular size	ONCOGENE			English	Article						cell cycle; mitosis; G2/M; c-myc; endoreplication; checkpoints	P53-MEDIATED TRANSCRIPTIONAL ACTIVITY; GROWTH-FACTOR-BETA; NORMAL HUMAN SKIN; TERMINAL DIFFERENTIATION; WILD-TYPE; IN-VITRO; EPIDERMAL-KERATINOCYTES; MALIGNANT PROGRESSION; MURINE KERATINOCYTES; INVOLUCRIN SYNTHESIS	p53 transcription factor is mutated in most skin cell carcinomas and in more than 50% of all human malignancies, One of its transcriptional targets is MDM2, which in turn down-regulates p53, The role of the p53/MDM2 regulatory loop upon genotoxic stress is well documented, but less is known about its role in normal tissue homeostasis. We have explored this pathway during the different transitions of the human epidermal differentiation programme and after isolating stem cells, transit amplifying cells or differentiating cells from epidermis, Maximum expression of p53 was found in proliferating keratinocytes. A striking and transient induction of MDM2 and a down-modulation of p53 characterized the transition from proliferation to differentiation in primary human keratinocytes. These changes were delayed in late differentiating carcinoma cells, and were clearly different in suspended primary fibroblasts. Interestingly, these changes correlated with an increase in cell size, at the time of irreversible commitment to differentiation. Induction of MDM2 was also associated with suppression of proliferation in normal, or hyperproliferative, psoriatic epidermis, Moreover, both proteins were induced as keratinocytes mere driven to leave the stem cell compartment by c-Myc activation, Overall, our results show a critical regulation of the p53/MDM2 pathway at the epidermal transition from proliferation to differentiation.	Inst Genet Mol, CNRS, UMR 5535, F-34293 Montpellier 5, France; Hop St Louis, Inst Rech Peau, INSERM, U532, F-75010 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Gandarillas, A (corresponding author), Inst Genet Mol, CNRS, UMR 5535, 1919 Route Mende, F-34293 Montpellier 5, France.							ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; Alkhalaf M, 1999, ONCOGENE, V18, P1419, DOI 10.1038/sj.onc.1202448; ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; BASSETSEGUIN N, 1994, J INVEST DERMATOL, V103, P102; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; BURNHAM JC, 1993, B HIST MED, V67, P1; Casenghi M, 1999, EXP CELL RES, V250, P339, DOI 10.1006/excr.1999.4554; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Dazard JE, 1997, ONCOGENE, V14, P1123, DOI 10.1038/sj.onc.1200922; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Di Leonardo A, 1997, CANCER RES, V57, P1013; DROZDOFF V, 1993, J CELL BIOL, V123, P909, DOI 10.1083/jcb.123.4.909; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gandarillas A, 1999, EXP DERMATOL, V8, P71, DOI 10.1111/j.1600-0625.1999.tb00350.x; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; GANDARILLAS A, IN PRESS ONCOGENE; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; HALL PA, 1989, DEVELOPMENT, V106, P619; HALL PA, 1993, ONCOGENE, V8, P203; Hannuksela-Svahn A, 1999, ACTA DERM-VENEREOL, V79, P195; Harvat BL, 1998, J CELL SCI, V111, P1185; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOFFMAN R, 1989, BLOOD, V74, P1196; HOTCHIN NA, 1992, J BIOL CHEM, V267, P14852; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; HOTCHIN NA, 1993, J CELL SCI, V106, P1131; HUDSON DL, 1992, HYBRIDOMA, V11, P367, DOI 10.1089/hyb.1992.11.367; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; JACK EM, 1990, HEPATOLOGY, V11, P286, DOI 10.1002/hep.1840110220; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; JONES MA, 1973, PERSPECT AM HIST, V7, P3; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kallassy M, 1998, MOL CARCINOGEN, V21, P26, DOI 10.1002/(SICI)1098-2744(199801)21:1<26::AID-MC5>3.0.CO;2-N; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laktionov PP, 1999, NUCLEIC ACIDS RES, V27, P2315, DOI 10.1093/nar/27.11.2315; LAVKER RM, 1983, J INVEST DERMATOL S, V81, P121; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Li Q, 1999, MOL CELL BIOL, V19, P5339; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Martinez LA, 1999, ONCOGENE, V18, P397, DOI 10.1038/sj.onc.1202300; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MCKAY IA, 1995, CLIN DERMATOL, V13, P105, DOI 10.1016/0738-081X(95)93817-8; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MILS V, 1994, DIFFERENTIATION, V58, P77, DOI 10.1046/j.1432-0436.1994.5810077.x; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MOLES JP, 1993, ONCOGENE, V8, P583; MOSNER J, 1994, ONCOGENE, V9, P3321; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Nigro JM, 1997, CANCER RES, V57, P3635; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; OLSON DC, 1993, ONCOGENE, V8, P2353; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PARKINSON FK, 1983, CARCINOGENESIS, V4, P857, DOI 10.1093/carcin/4.7.857; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Peled A, 1996, ONCOGENE, V13, P1677; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Prives C, 1999, J PATHOL, V187, P112; Reinke V, 1999, CELL GROWTH DIFFER, V10, P147; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RHEINWALD JG, 1983, HUMAN CARCINOGENESIS, P85; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; Sidransky D, 1996, ANNU REV MED, V47, P285; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SOINI Y, 1994, BRIT J DERMATOL, V131, P514; Traas J, 1998, CURR OPIN PLANT BIOL, V1, P498, DOI 10.1016/S1369-5266(98)80042-3; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WATT FM, 1981, J CELL BIOL, V90, P738, DOI 10.1083/jcb.90.3.738; WATT FM, 1993, DEVELOPMENT, P185; WATT FM, 1982, NATURE, V295, P434, DOI 10.1038/295434a0; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WEINBERG WC, 1994, CANCER RES, V54, P5584; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; [No title captured]	93	48	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3693	3705		10.1038/sj.onc.1203695	http://dx.doi.org/10.1038/sj.onc.1203695			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949923				2022-12-17	WOS:000088568400001
J	Sutherland, LC; Edwards, SE; Cable, HC; Poirier, GG; Miller, BA; Cooper, CS; Williams, GT				Sutherland, LC; Edwards, SE; Cable, HC; Poirier, GG; Miller, BA; Cooper, CS; Williams, GT			LUCA-15-encoded sequence variants regulate CD95-mediated apoptosis	ONCOGENE			English	Article						LUCA-15; CD95; apoptosis; chromosome 3; jurkat; antisense	FLICE-INHIBITORY PROTEIN; EPSTEIN-BARR VIRUS; INDUCED CELL-DEATH; C-ELEGANS; IMMUNE ESCAPE; LUNG-CANCER; FAS; EXPRESSION; TUMORS; RNA	Using an expression cloning system to discover novel genes involved in apoptosis, we identified a 326 bp bone marrow cDNA fragment (termed Je2) that suppresses, upon transfection, CD95-mediated apoptosis in Jurkat T cells, Sequence homology revealed that Je2, maps to 3p21.3, to an intronic region of the candidate TSG LUCA-15 locus. It represents, in fact, an antisense transcript to the 3'-UTR of two novel splice variants of this gene. Overexpression of sequence representing one of these splice variants (a 2.6 kit cDNA termed Clone 26), inhibited proliferation of Jurkat cells and sensitized them to CD95-mediated apoptosis, This study therefore implicates the LUCA-15 gene locus in the control of apoptosis.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pediat,Div Hematol Oncol, Hershey, PA 17033 USA; Keele Univ, Sch Life Sci, Keele ST5 5BG, Staffs, England; Inst Canc Res, Haddow Labs, Sutton SM2 5NG, Surrey, England; CHU Laval, Ctr Rech, Eastern Quebec Peptide Sequencing Facil, Ste Foy, PQ G1V 4G2, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Keele University; University of London; Institute of Cancer Research - UK; Laval University	Sutherland, LC (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pediat,Div Hematol Oncol, Hershey, PA 17033 USA.		Williams, Gwyn/GQY-7555-2022	Williams, Gwyn/0000-0003-4556-9930; Poirier, Guy/0000-0002-4869-1424	NCRR NIH HHS [M01 RR10732] Funding Source: Medline; NIDDK NIH HHS [DK46778] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR010732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046778, R01DK046778] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cock JGRBD, 1998, APOPTOSIS, V3, P17, DOI 10.1023/A:1009603001888; Cook DM, 1996, ONCOGENE, V13, P1789; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Drabkin HA, 1999, ONCOGENE, V18, P2589, DOI 10.1038/sj.onc.1202601; French LE, 1999, J EXP MED, V190, P891, DOI 10.1084/jem.190.7.891; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; GABIG TG, 1994, J BIOL CHEM, V269, P29515; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAATTELA M, 1995, ONCOGENE, V10, P2297; KISSIL JL, 1995, J BIOL CHEM, V270, P27932, DOI 10.1074/jbc.270.46.27932; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Nagata S, 1996, NAT MED, V2, P1306, DOI 10.1038/nm1296-1306; Okura T, 1996, J IMMUNOL, V157, P4277; Peltz SW, 1999, J EXP MED, V190, P1729, DOI 10.1084/jem.190.12.1729; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider TJ, 1999, J EXP MED, V189, P949, DOI 10.1084/jem.189.6.949; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; Sutherland LC, 2000, J IMMUNOL METHODS, V234, P43, DOI 10.1016/S0022-1759(99)00202-1; Sutherland LC, 1997, J IMMUNOL METHODS, V207, P179, DOI 10.1016/S0022-1759(97)00118-X; Tsuruda K, 1999, LEUKEMIA RES, V23, P159, DOI 10.1016/S0145-2126(98)00158-1; Van den Eynde B, 1999, J EXP MED, V190, P1793, DOI 10.1084/jem.190.12.1793; Vanhee-Brossollet C, 1998, GENE, V211, P1, DOI 10.1016/S0378-1119(98)00093-6; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Wei MH, 1996, CANCER RES, V56, P1487; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Williams GT, 1998, TOXICOL LETT, V103, P485, DOI 10.1016/S0378-4274(98)00343-9; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Wyllie AH, 1997, EUR J CELL BIOL, V73, P189; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	40	48	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3774	3781		10.1038/sj.onc.1203720	http://dx.doi.org/10.1038/sj.onc.1203720			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949932				2022-12-17	WOS:000088568400010
J	Swaroop, M; Wang, YX; Miller, P; Duan, HJ; Jatkoe, T; Madore, SJ; Sun, Y				Swaroop, M; Wang, YX; Miller, P; Duan, HJ; Jatkoe, T; Madore, SJ; Sun, Y			Yeast homolog of human SAG/ROC2/Rbx2/Hrt2 is essential for cell growth, but not for germination: chip profiling implicates its role in cell cycle regulation	ONCOGENE			English	Article						RING finger; ubiquitin ligase; growth essential; cell cycle; SCF complex; apoptosis	NF-KAPPA-B; UBIQUITIN-LIGASE COMPLEX; SACCHAROMYCES-CEREVISIAE; INDUCED APOPTOSIS; S-PHASE; BCL-2 FAMILY; DEATH; PROTEIN; KINASE; PATHWAY	In an attempt to understand the signaling pathway mediating redox-induced apoptosis, we cloned SAG, an evolutionarily conserved zinc RING finger gene that, when overexpressed, protects cells from apoptosis induced by redox agents. Here we report functional characterization of SAG by the use of yeast genetics approach. Targeted disruption of ySAG, yeast homolog of human SAG, and subsequent tetrad analysis revealed that ySAG is required for yeast viability. Complementation experiment showed that the lethal phenotype induced by the ySAG deletion is fully rescued by wildtype SAG, but not by several hSAG mutants, Complementation experiment has also confirmed that ySAG is essential for normal vegetative growth, rather than being required for sporulation. Furthermore, cell death induced by SAG deletion was accompanied by cell enlargement and abnormal cell cycle profiling with an increased DNA content. Importantly, SAG was found to be the second family member of Rbx (RING box protein) or ROC (Regulator of cullins) or Hrt that is a component of SCF E3 ubiquitin ligase, Indeed, like ROC1/Rbx1/Hrt1, SAG binds to Cull and SAG-Cull complex has ubiquitin ligase activity to promote poly-ubiquitination of E2/ Cdc34. This ligase activity is required for complementation of death phenotype induced by ySAG disruption. Finally, chip profiling of the entire yeast genome revealed induction of several G1/S as well as G2/M checkpoint control genes upon SAG withdrawal. Thus, SAG appears to control cell cycle progression in yeast by promoting ubiquitination and degradation of cell cycle regulatory proteins.	Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA; Parke Davis Pharmaceut Res, Dept Infect Dis, Ann Arbor, MI USA	Pfizer; Pfizer	Sun, Y (corresponding author), Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA.			Swaroop, Manju/0000-0002-0576-1664				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Boger-Nadjar E, 1998, MOL GEN GENET, V260, P232, DOI 10.1007/s004380050891; Chen A, 2000, J BIOL CHEM, V275, P15432, DOI 10.1074/jbc.M907300199; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Duan HJ, 1999, MOL CELL BIOL, V19, P3145; ESPINOZA FH, 1994, SCIENCE, V266, P1388, DOI 10.1126/science.7973730; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Farr KA, 1998, MOL CELL BIOL, V18, P2738, DOI 10.1128/MCB.18.5.2738; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Goh PY, 1999, MOL CELL BIOL, V19, P5512; Gorbsky GJ, 1997, BIOESSAYS, V19, P193, DOI 10.1002/bies.950190303; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; IIDA H, 1984, J CELL BIOL, V99, P199, DOI 10.1083/jcb.99.1.199; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KASSIR Y, 1991, METHOD ENZYMOL, V194, P94; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Levine K, 1995, Prog Cell Cycle Res, V1, P101; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; MATSUMOTO Y, 1993, YEAST, V9, P929, DOI 10.1002/yea.320090813; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Michael WM, 1998, SCIENCE, V282, P1886, DOI 10.1126/science.282.5395.1886; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Peter ME, 1997, P NATL ACAD SCI USA, V94, P12736, DOI 10.1073/pnas.94.24.12736; PRINTEN JA, 1994, GENETICS, V138, P609; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; ROBINSON LC, 1991, MOL GEN GENET, V230, P241, DOI 10.1007/BF00290674; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SAZER S, 1990, J CELL SCI, V97, P509; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Sun Y, 1997, FEBS LETT, V408, P16, DOI 10.1016/S0014-5793(97)00380-3; Sun Y, 1997, ONCOGENE, V14, P385, DOI 10.1038/sj.onc.1200834; SUN Y, 1990, FREE RADICAL BIO MED, V8, P583, DOI 10.1016/0891-5849(90)90156-D; Swaroop M, 1999, FREE RADICAL BIO MED, V27, P193, DOI 10.1016/S0891-5849(99)00078-7; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; THIELE DJ, 1986, SCIENCE, V231, P854, DOI 10.1126/science.3080806; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang YX, 1999, FEBS LETT, V445, P269, DOI 10.1016/S0014-5793(99)00136-2; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Wyllie A H, 1980, Int Rev Cytol, V68, P251	80	48	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2000	19	24					2855	2866		10.1038/sj.onc.1203635	http://dx.doi.org/10.1038/sj.onc.1203635			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851089				2022-12-17	WOS:000087403600007
J	Thullberg, M; Bartek, J; Lukas, J				Thullberg, M; Bartek, J; Lukas, J			Ubiquitin/proteasome-mediated degradation of p19(INK4d) determines its periodic expression during the cell cycle	ONCOGENE			English	Article						INK4 family; p19(INK4d); cyclin D; CDK4; ubiquitin/proteasome-dependent degradation; retinoblastoma protein	DEPENDENT KINASES CDK4; TUMOR-SUPPRESSOR; RETINOBLASTOMA-PROTEIN; GROWTH SUPPRESSION; INHIBITOR P27; LUNG-CANCER; INK4 FAMILY; TGF-BETA; S-PHASE; P16(INK4A)	Assembly and activity of the proto-oncogenic cyclin D/ CDK4(6) complexes, the major driving force of G1 phase progression, is negatively regulated by a family of INK4 CDK inhibitors p16(INK4a), p15(INK4b), p18(INK4c), and p19(INK4d). Expression of the INK4 family members is controlled at the transcriptional level, through differential response to environmental and intracellular signals such as cytokines, oncogenic overload, or cellular senescence. Here we show that the periodic oscillation of the p19(INK4d) protein during the cell cycle is determined by the ubiquitin/proteasome-dependent mechanism, allowing the protein abundance to follow the changes in its mRNA expression. Within the INK4 family, this regulatory mode appears restricted to p19(INK4d) whose ubiquitination was dependent on the integrity of lysine 62, and binding to CDK4. These results highlight unexpected differences among the INK4 inhibitors, and suggest how p19(INK4d) may help regulate the rate of cyclin D/CDK4(6) complex formation, and thereby timely progression through the mammalian cell division cycle.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen O, Denmark	Danish Cancer Society	Lukas, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen O, Denmark.		Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Amati B, 1999, NAT CELL BIOL, V1, pE91, DOI 10.1038/12087; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bartkova J, 1996, CANCER RES, V56, P5475; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Esposito V, 1997, CANCER RES, V57, P3381; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lukas C, 1999, HYBRIDOMA, V18, P225, DOI 10.1089/027245799315871; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1995, ONCOGENE, V10, P2125; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Pavey S, 1999, CANCER RES, V59, P4185; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; SHAPIRO GI, 1995, CANCER RES, V55, P6200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Thullberg M, 2000, HYBRIDOMA, V19, P63, DOI 10.1089/027245700315806; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Welcker M, 1996, ONCOGENE, V13, P419; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Wolff B, 1999, ONCOGENE, V18, P2663, DOI 10.1038/sj.onc.1202617; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	47	48	49	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2000	19	24					2870	2876		10.1038/sj.onc.1203579	http://dx.doi.org/10.1038/sj.onc.1203579			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851091				2022-12-17	WOS:000087403600009
J	Firon, M; Shaharabany, M; Altstock, RT; Horev, J; Abramovici, A; Resau, JH; Vande Woude, GF; Tsarfaty, I				Firon, M; Shaharabany, M; Altstock, RT; Horev, J; Abramovici, A; Resau, JH; Vande Woude, GF; Tsarfaty, I			Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells	ONCOGENE			English	Article						Met; HGF/SF; dominant negative; tubulogenesis; breast cancer cells	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; HUMAN BREAST-CANCER; C-MET; TYROSINE KINASE; EPITHELIAL-CELLS; FACTOR-RECEPTOR; FACTOR/SCATTER FACTOR; TUMOR PROGRESSION; MET/HGF RECEPTOR	Activation of the Met tyrosine kinase growth factor receptor by its ligand HGF/SF has been shown to increase in vitro invasiveness in epithelial cell lines. To study the effect of Met-HGF/SF signaling in breast cancer cells, we transfected met, hgf/sf and dominant negative (DN) forms of met into the poorly differentiated metastatic murine mammary adenocarcinoma cell line DA3, These cells express moderate levels of endogenous Met, which is rapidly phosphorylated in response to HGF/SF treatment. Met+hgf/sf transfection results in significantly increased tumorigenic and metastatic activity in vivo accompanied by reduced tubule formation. DA3 cells transfected with DN forms of Met (DN-DA3) exhibit reduced Met phosphorylation following exposure to HGF/SF, Furthermore, as compared to the parental cells, the DN-DA3 cells exhibit diminished in vitro scattering and invasiveness, while in vitro they display greatly reduced tumorigenicity and spontaneous metastasis, Tumors emanating from DN-DA3 cells injected to BALB/C mice are highly differentiated and display extensive tubule formation. These results suggest that Met-HGF/SF signaling is a determining factor in the delicate balance between differentiation/tubule formation and tumorigenicity-metastasis.	Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Pathol, IL-69978 Tel Aviv, Israel; NCI, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Ft Detrick, MD 21702 USA	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Tsarfaty, I (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel.			Tsarfaty, Ilan/0000-0002-5230-7093				ALBINI A, 1987, CANCER RES, V47, P3239; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BENZ CC, 1995, GENE, V159, P3, DOI 10.1016/0378-1119(95)00147-X; BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; Beviglia L, 1997, INT J CANCER, V74, P301, DOI 10.1002/(SICI)1097-0215(19970620)74:3<301::AID-IJC12>3.0.CO;2-E; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Clark GM, 1996, DIS BREAST, P461; Cortner J., 1995, V74, P89; CUNHA GR, 1994, CANCER, V74, P1030, DOI 10.1002/1097-0142(19940801)74:3+<1030::AID-CNCR2820741510>3.0.CO;2-Q; DENG G, 1994, CANCER RES, V54, P499; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; FU YX, 1990, CANCER RES, V50, P227; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, ONCOGENE, V13, P853; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lamszus K, 1997, LAB INVEST, V76, P339; Liang TJ, 1996, J CLIN INVEST, V97, P2872, DOI 10.1172/JCI118744; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; NAGY J, 1995, J SURG ONCOL, V60, P95, DOI 10.1002/jso.2930600206; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; PEPPER MS, 1995, EXP CELL RES, V219, P204, DOI 10.1006/excr.1995.1220; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; QIAN XL, 1994, ONCOGENE, V9, P1507; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; Robinson ML, 1995, DEVELOPMENT, V121, P3959; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1995, CANCER RES, V55, P1963; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P163; ROSEN EM, 1993, SYM SOC EXP BIOL, V47, P227; ROSEN EM, 1994, INT J CANCER, V57, P706, DOI 10.1002/ijc.2910570517; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SORIANO JV, 1995, J CELL SCI, V108, P413; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tsarfaty I, 1999, ANAL QUANT CYTOL, V21, P397; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; YAMASHITA J, 1994, CANCER RES, V54, P1630; YAMASHITA J, 1993, RES COMMUN CHEM PATH, V82, P249; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Yao Y, 1996, AM J PATHOL, V149, P1707; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	62	48	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2000	19	20					2386	2397		10.1038/sj.onc.1203557	http://dx.doi.org/10.1038/sj.onc.1203557			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828880				2022-12-17	WOS:000087018400003
J	Bryckaert, M; Guillonneau, X; Hecquet, C; Courtois, Y; Mascarelli, F				Bryckaert, M; Guillonneau, X; Hecquet, C; Courtois, Y; Mascarelli, F			Both FGF1 and Bcl-x synthesis are necessary for the reduction of apoptosis in retinal pigmented epithelial cells by FGF2: role of the extracellular signal-regulated kinase 2	ONCOGENE			English	Article						FGF; Bcl-x; ERK2; apoptosis; retinal pigmented epithelial cells	FIBROBLAST-GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; HUMAN BREAST-CANCER; PEROXYNITRITE-INDUCED APOPTOSIS; FACTOR-I; PHOTORECEPTOR DEGENERATION; NEUROTROPHIC ACTIVITY; PROTOONCOGENE BCL-2; ENDOGENOUS FGF1; PC12 CELLS	Retinal pigmented epithelial (RPE) cells are of central importance in the maintenance of neural retinal function. Changes in the RPE cells associated with repair activities have been described as metaplasia, while RPE cell apoptosis is responsible for the development of a variety of retinal degenerations. We investigated the regulation of the anti-apoptotic properties of the fibroblast growth factors (FGF) 2 in serum-free cultures of RPE cells, In the absence of serum, confluent stationary RPE cells died by apoptosis via a caspase 3-dependent pathway, The addition of FGF2 greatly reduced apoptosis over a 7-day culture period, We demonstrated the involvement of an autocrine loop involving endogenous FGF1 in the mechanisms that govern FGF2-induced resistance to apoptosis by showing: (1) higher levels of apoptosis in cells treated with antisense FGF1 oligonucleotide or after neutralization of excreted FGF1; (2) the long-term activation of FGFR1 and of ERK2, (3) the inhibition of FGFR1 and ERK2 activation and an increase in apoptosis if excreted FGF1 was neutralized, FGF2 also increased the de novo synthesis and the production of Bcl-xl before the onset of apoptosis, Both inhibition of ERK2 activation, which decreased Bcl-xl synthesis, and downregulation of Bcl-x by antisense oligonucleotide treatment inhibited the survival-promoting activity of FGF2, Thus, FGF2-induced cell survival is a progressive adaptive phenomenon involving ERK2 activation by excreted FGF1 and ERK2-dependent Bcl-x production.	Assoc Claude Bernard, CNRS, INSERM, U450, F-75016 Paris, France; IFR Circulat, INSERM, U348, F-75010 Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Mascarelli, F (corresponding author), Assoc Claude Bernard, CNRS, INSERM, U450, 29 Rue Wilhem, F-75016 Paris, France.		Guillonneau, xavier/E-3995-2017; guillonneau, xavier/AAF-9495-2021; Mascarelli, Frederic/L-8916-2018	Guillonneau, xavier/0000-0001-7379-3935; guillonneau, xavier/0000-0001-7379-3935; Bryckaert, Marijke/0000-0003-3398-0976				ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ALTERIO J, 1988, FEBS LETT, V242, P41, DOI 10.1016/0014-5793(88)80981-5; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; CLARENC JP, 1993, J BIOL CHEM, V268, P5600; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COURLIER F, 1997, J MOL EVOL, V44, P43; Davidson FF, 1998, NATURE, V391, P587, DOI 10.1038/35385; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; Desire L, 1998, DEV DYNAM, V212, P63, DOI 10.1002/(SICI)1097-0177(199805)212:1<63::AID-AJA6>3.0.CO;2-0; Enzmann V, 1998, OPHTHALMIC RES, V30, P189, DOI 10.1159/000055473; FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0; FENNEWALD SM, 1995, J BIOL CHEM, V270, P21718, DOI 10.1074/jbc.270.37.21718; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; Funato N, 1997, BIOCHEM BIOPH RES CO, V240, P21, DOI 10.1006/bbrc.1997.7588; Gao H, 1996, EXP EYE RES, V62, P181, DOI 10.1006/exer.1996.0022; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Garland JM, 1998, BLOOD, V92, P1235, DOI 10.1182/blood.V92.4.1235.416k18_1235_1246; GILLARDON F, 1995, J NEUROSCI RES, V41, P708, DOI 10.1002/jnr.490410517; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Guillonneau X, 1997, EXP CELL RES, V233, P198, DOI 10.1006/excr.1997.3542; Guillonneau X, 1998, MOL BIOL CELL, V9, P2785, DOI 10.1091/mbc.9.10.2785; Guillonneau X, 1998, J BIOL CHEM, V273, P22367, DOI 10.1074/jbc.273.35.22367; GUKOVA M, 1995, J BIOL CHEM, V270, P2620; Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203; Isenmann S, 1997, EUR J NEUROSCI, V9, P1763, DOI 10.1111/j.1460-9568.1997.tb01534.x; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Konig A, 1997, LEUKEMIA, V11, P258, DOI 10.1038/sj.leu.2400556; Levin LA, 1997, INVEST OPHTH VIS SCI, V38, P2545; LEZOUALCH F, 1995, J BIOL CHEM, V270, P12100, DOI 10.1074/jbc.270.20.12100; Lindenboim L, 1998, NEUROSCI LETT, V253, P37, DOI 10.1016/S0304-3940(98)00602-8; Liu JF, 1998, EUR J BIOCHEM, V258, P271, DOI 10.1046/j.1432-1327.1998.2580271.x; Liu YZ, 1999, NUCLEIC ACIDS RES, V27, P2086, DOI 10.1093/nar/27.10.2086; MALECAZE F, 1993, J CELL PHYSIOL, V154, P631, DOI 10.1002/jcp.1041540323; Mishima K, 1998, MODERN PATHOL, V11, P886; MONTPIED P, 1993, BIOCHEM BIOPH RES CO, V195, P623, DOI 10.1006/bbrc.1993.2091; Myoken Y, 1996, INT J CANCER, V65, P650, DOI 10.1002/(SICI)1097-0215(19960301)65:5<650::AID-IJC15>3.0.CO;2-B; Navarro P, 1998, EXP CELL RES, V243, P213, DOI 10.1006/excr.1998.4168; Onal MZ, 1997, EUR NEUROL, V38, P141; Papermaster DS, 1997, CELL DEATH DIFFER, V4, P21, DOI 10.1038/sj.cdd.4400210; PARTANEN J, 1992, Progress in Growth Factor Research, V4, P69, DOI 10.1016/0955-2235(92)90005-3; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; Raguenez G, 1999, BIOCHEM BIOPH RES CO, V258, P745, DOI 10.1006/bbrc.1999.0613; Renaud F, 1996, J BIOL CHEM, V271, P2801, DOI 10.1074/jbc.271.5.2801; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; SAHL B, 1999, ANTICANCER RES, V19, P731; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Shin JT, 1996, ARCH BIOCHEM BIOPHYS, V335, P32, DOI 10.1006/abbi.1996.0479; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Spear N, 1998, ARCH BIOCHEM BIOPHYS, V356, P41, DOI 10.1006/abbi.1998.0741; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; VLODAVSKY I, 1982, EXP CELL RES, V140, P149, DOI 10.1016/0014-4827(82)90166-5; Wang Q, 1998, EXP CELL RES, V238, P177, DOI 10.1006/excr.1997.3820; YAZOVITSKAYA EM, 1999, MOL CARCINOG, V25, P1; Yokoyama Y, 1997, J NEUROCHEM, V68, P2212	64	48	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7584	7593		10.1038/sj.onc.1203200	http://dx.doi.org/10.1038/sj.onc.1203200			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602518				2022-12-17	WOS:000084119600020
J	Robles, AI; Wang, XW; Harris, CC				Robles, AI; Wang, XW; Harris, CC			Drug-induced apoptosis is delayed and reduced in XPD lymphoblastoid cell lines: possible role of TFIIH in p53-mediated apoptotic cell death	ONCOGENE			English	Article						DNA helicase; doxorubicin; DNA repair; programmed cell death	NUCLEOTIDE EXCISION-REPAIR; DNA-DAMAGE; XERODERMA-PIGMENTOSUM; IONIZING-RADIATION; POLY(ADP-RIBOSE) POLYMERASE; GAMMA-RADIATION; P53; PHOSPHORYLATION; TRANSCRIPTION; ACTIVATION	The tumor suppressor gene product p53 can bind to and inhibit the helicase activity of the multisubunit transcription-repair factor TFIIH, We previously reported that p53-mediated apoptosis is attenuated in primary human fibroblasts from individuals with Xeroderma Pigmentosum (XP) that harbor mutations in the TFIIH DNA helicases XPD or XPB, In this study we show that apoptosis is reduced and delayed in three XPD Iymphoblastoid cell lines (LCLs), but not in an XPD heterozygote LCL, after exposure to doxorubicin, a DNA-damaging agent and topoisomerase II inhibitor frequently used in cancer therapy. Apoptosis was assessed by quantitation of Annexin V binding to exposed phosphatidylserine residues and by caspase-mediated cleavage of Poly(ADP)Ribose Polymerase (PARP). Apoptosis induced by doxorubicin was suppressed in LCLs retrovirally transduced with the Human Papillomavirus 16 E6 oncoprotein, consistent with the hypothesis that this is a p53-dependent process. PARP cleavage was not delayed in XPD LCLs in response to anti-Fas (CD95) antibody-mediated apoptosis, thus, the defect in the apoptotic pathway in these cells lies upstream of caspase activation. Similar changes in the expression of apoptosis-effector genes, p53, and p53-responsive genes p21(cip/WAF-1/Sid1) p21), gadd45, bcl-2 and bar were observed in normal and XPD LCLs after treatment with doxorubicin, indicating that delayed apoptosis was not a consequence of defective transcription of these genes. Thus, our studies provide further support to the hypothesis that XPD and p53 can functionally interact in a p53-mediated apoptotic pathway.	NCI, Human Carcinogenesis Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, Div Basic Sci, NIH, Bldg 37 Rm 2C05, Bethesda, MD 20892 USA.		Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X; Robles, Ana/0000-0001-5019-4374	DIVISION OF BASIC SCIENCES - NCI [Z01BC005794] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; de Boer J, 1998, MOL CELL, V1, P981, DOI 10.1016/S1097-2765(00)80098-2; de Boer J, 1998, CANCER RES, V58, P89; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gottlieb E, 1996, CELL GROWTH DIFFER, V7, P301; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kubbutat MHG, 1998, TRENDS MICROBIOL, V6, P173, DOI 10.1016/S0966-842X(98)01267-0; LEHMANN AR, 1995, TRENDS BIOCHEM SCI, V20, P402, DOI 10.1016/S0968-0004(00)89088-X; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; MIYASHITA T, 1995, CELL, V80, P293; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889; Sheard MA, 1997, INT J CANCER, V73, P757, DOI 10.1002/(SICI)1097-0215(19971127)73:5<757::AID-IJC24>3.0.CO;2-1; Sheikh MS, 1998, CANCER RES, V58, P1593; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SPETH PAJ, 1988, CLIN PHARMACOKINET, V15, P15, DOI 10.2165/00003088-198815010-00002; Stary A, 1996, CANCER SURV, V26, P155; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Taylor EM, 1997, P NATL ACAD SCI USA, V94, P8658, DOI 10.1073/pnas.94.16.8658; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Whitacre CM, 1997, CANCER RES, V57, P2157; Wolf CM, 1997, EXP CELL RES, V230, P22, DOI 10.1006/excr.1996.3401; Yu YJ, 1998, CANCER RES, V58, P4277	41	48	51	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4681	4688		10.1038/sj.onc.1202862	http://dx.doi.org/10.1038/sj.onc.1202862			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467415				2022-12-17	WOS:000082154400005
J	Wieland, I; Arden, KC; Michels, D; Klein-Hitpass, L; Bohm, M; Viars, CS; Weidle, UH				Wieland, I; Arden, KC; Michels, D; Klein-Hitpass, L; Bohm, M; Viars, CS; Weidle, UH			Isolation of DICE1: A gene frequently affected by LOH and downregulated in lung carcinomas	ONCOGENE			English	Article						chromosome 13; cDNA cloning; DBI-1 homologue; lung cancer; MOMeNT	RETINOBLASTOMA SUSCEPTIBILITY GENE; SQUAMOUS-CELL CARCINOMAS; TUMOR-SUPPRESSOR GENE; FACTOR-I RECEPTOR; DISTINCT REGIONS; CHROMOSOME 13Q; EXON AMPLIFICATION; ALLELIC DELETION; PROSTATE-CANCER; BREAST-CANCER	In the development and progression of sporadic tumors multiple tumor suppressor genes are inactivated that may be distinct from predisposing cancer genes. Previously, a tumor suppressor locus on human chromosome 13q14 that is distinct from the retinoblastoma predisposing gene 1 (RBI) has been identified in lung, head and neck, breast, ovarian and prostate tumors, By an approach that combines genomic difference cloning and positional cloning we isolated the cDNA of a novel gene (DICE1) located at 13q14.12-14.2. The DICE1 gene is highly conserved in evolution and its mRNA is expressed in a nide variety of fetal and adult tissues, The DICE1 cDNA encodes a predicted protein of 887 amino acids corresponding to an 100 kD protein that shows 92.9% identity to the carboxy-terminal half of the mouse EGF repeat transmembrane protein DBI-1. The DBI-1 protein interferes with the mitogenic response to insulin-like growth factor 1 (IGF-I) and is presumably involved in anchorage-dependent growth. When compared to normal lung tissue expression of the DICE1 mRNA aas reduced or undetectable in the majority of non-small cell lung carcinomas analysed, The location of the DICE1 gene in the region of allelic loss, its high evolutionary conservation and the downregulation of expression in carcinoma cells suggests that DICE1 is a candidate tumor suppressor gene in non-small cell lung carcinomas and possibly in other sporadic carcinomas.	Univ Essen Gesamthsch, Sch Med, Inst Cell Biol Canc Res, D-45122 Essen, Germany; Univ Calif San Diego, Dept Med, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Essen Gesamthsch, Sch Med, Dept Urol, D-45122 Essen, Germany; Roche Diagnost GmbH, D-82377 Penzberg, Germany	University of Duisburg Essen; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of Duisburg Essen; Roche Holding	Wieland, I (corresponding author), Univ Klinikum Magdeburg, Inst Human Genet, Leipziger Str 44, D-39120 Magdeburg, Germany.			Wieland, Ilse/0000-0002-8017-3029				ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; BASERGA R, 1995, CANCER RES, V55, P249; Bohm M, 1997, INT J ONCOL, V10, P131; Bohm M, 1997, AM J PATHOL, V151, P63; BOHM M, 1993, CANCER GENET CYTOGEN, V65, P83, DOI 10.1016/0165-4608(93)90211-4; Bohm M, 1997, INT J CANCER, V74, P291; BORG A, 1992, CANCER RES, V52, P2991; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; Cooney KA, 1996, CANCER RES, V56, P1142; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Garkavtsev I, 1997, CYTOGENET CELL GENET, V76, P176, DOI 10.1159/000134539; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENSEL CH, 1990, CANCER RES, V50, P3067; Hoff HB, 1998, EXP CELL RES, V238, P359, DOI 10.1006/excr.1997.3865; KIM TM, 1994, CANCER RES, V54, P605; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Li CD, 1998, ONCOGENE, V16, P481, DOI 10.1038/sj.onc.1201554; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Maestro R, 1996, CANCER RES, V56, P1146; Peralta RC, 1998, INT J CANCER, V78, P600, DOI 10.1002/(SICI)1097-0215(19981123)78:5<600::AID-IJC12>3.0.CO;2-1; SACHSE R, 1994, ONCOGENE, V9, P39; Sambrook J, 1989, MOL CLONING LAB MANU; SCHOTT DR, 1994, CANCER RES, V54, P1393; SELTMANN M, 1994, CYTOGENET CELL GENET, V67, P46, DOI 10.1159/000133795; SHAPIRO GI, 1995, CANCER RES, V54, P5643; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; Tamura K, 1997, INT J CANCER, V74, P45, DOI 10.1002/(SICI)1097-0215(19970220)74:1<45::AID-IJC8>3.0.CO;2-0; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; Wieland I, 1996, ONCOGENE, V12, P97; WIELAND I, 1994, CANCER RES, V54, P1772; WIELAND I, 1992, P NATL ACAD SCI USA, V89, P9705, DOI 10.1073/pnas.89.20.9705; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YOO GH, 1994, CANCER RES, V54, P4603	44	48	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4530	4537		10.1038/sj.onc.1202806	http://dx.doi.org/10.1038/sj.onc.1202806			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467397				2022-12-17	WOS:000082018600002
J	Feshchenko, EA; Shore, SK; Tsygankov, AY				Feshchenko, EA; Shore, SK; Tsygankov, AY			Tyrosine phosphorylation of C-Cbl facilitates adhesion and spreading while suppressing anchorage-independent growth of V-Abl-transformed NIH3T3 fibroblasts	ONCOGENE			English	Article						Abl; Cbl; adhesion; morphology; transformation; tyrosine phosphorylation	CELL ANTIGEN RECEPTOR; PROTOONCOGENE PRODUCT P120(CBL); PHOSPHOTYROSINE-BINDING DOMAIN; PHOSPHOINOSITIDE 3-OH KINASE; INTEGRIN SIGNALING PATHWAY; SRC HOMOLOGY-3 DOMAIN; CRK ADAPTER PROTEINS; ACTIVATED T-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; EGF RECEPTOR	The protooncogenic protein c-Cbl becomes tyrosine phosphorylated in normal cells in response to a variety of external stimuli, as well as in cells transformed by oncogenic protein tyrosine kinases. Tyrosine phosphorylation of c-Cbl upregulates its binding to multiple crucial signaling molecules. However, the biological consequences of c-Cbl-mediated signaling are insufficiently understood. To analyse the biological functions of c-Cbl, we overexpressed wild-type c-Cbl and its tyrosine phosphorylation-defective mutant form in v-Abl-transformed NIH3T3 fibroblasts. In this system, wild-type c-Cbl facilitated adhesion and spreading of v-Abl-transformed fibroblasts on the extracellular matrix, while reducing anchorage independence of these cells, as measured by their colony-forming efficiency in soft agar. Therefore, overexpression of wild-type c-Cbl exhibits an overall transformation-suppressing effect. By contrast, overexpression of a tyrosine phosphorylation-defective form of c-Cbl increases neither adhesion nor anchorage dependence of v-Abl-transformed fibroblasts. Analysis of the role of individual tyrosine phosphorylation sites of c-Cbl in these phenomena indicates that both phosphatidylinositol-3' kinase and the CrkL adaptor protein may be involved in the observed effects of c-Cbl. To summarize, the results presented in this report indicate that c-Cbl is involved in regulation of cell adhesion and cytoskeletal rearrangements, and that these effects of c-Cbl are dependent on its tyrosine phosphorylation.	Temple Univ, Sch Med, Dept Immunol & Microbiol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Tsygankov, AY (corresponding author), Temple Univ, Sch Med, Dept Immunol & Microbiol, 3400 Broad St, Philadelphia, PA 19140 USA.		Tsygankov, Alexander Y/K-6205-2017		NCI NIH HHS [CA78499] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078499] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; Andoniou CE, 1996, ONCOGENE, V12, P1981; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Brizzi MF, 1996, ONCOGENE, V13, P2067; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; HAWLEY RG, 1994, GENE THER, V1, P136; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; KAWATA M, 1988, J BIOL CHEM, V263, P18965; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khwaja A, 1996, ONCOGENE, V12, P2491; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Lakkakorpi PT, 1997, EXP CELL RES, V237, P296, DOI 10.1006/excr.1997.3797; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LI PM, 1993, ONCOGENE, V8, P1731; Liu YC, 1997, J BIOL CHEM, V272, P168; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Manie SN, 1997, EXP HEMATOL, V25, P45; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Merlo JJ, 1998, ANTICANCER RES, V18, P2389; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Nakamura I, 1997, J CELL PHYSIOL, V172, P230, DOI 10.1002/(SICI)1097-4652(199708)172:2<230::AID-JCP10>3.0.CO;2-D; NOBES CD, 1995, J CELL SCI, V108, P225; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Ojaniemi M, 1998, ONCOGENE, V16, P3159, DOI 10.1038/sj.onc.1201859; OKABE M, 1992, BLOOD, V80, P1330; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POWIS G, 1994, CANCER RES, V54, P2419; Rebstein PJ, 1997, EXP CELL RES, V231, P276, DOI 10.1006/excr.1996.3466; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Ribon V, 1996, MOL CELL BIOL, V16, P45; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Salgame P, 1997, NUCLEIC ACIDS RES, V25, P680, DOI 10.1093/nar/25.3.680; Sattler M, 1996, ONCOGENE, V12, P839; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SHORE SK, 1994, J BIOL CHEM, V269, P5413; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHORE SK, 1989, ONCOGENE, V4, P1411; Smit L, 1996, ONCOGENE, V13, P381; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zell T, 1998, CURR BIOL, V8, P814, DOI 10.1016/S0960-9822(98)70323-9	85	48	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	1999	18	25					3703	3715		10.1038/sj.onc.1202672	http://dx.doi.org/10.1038/sj.onc.1202672			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391678				2022-12-17	WOS:000081140200004
J	Fotedar, R; Brickner, H; Saadatmandi, N; Rousselle, T; Diederich, L; Munshi, A; Jung, B; Reed, JC; Fotedar, A				Fotedar, R; Brickner, H; Saadatmandi, N; Rousselle, T; Diederich, L; Munshi, A; Jung, B; Reed, JC; Fotedar, A			Effect of p21(waf1/cip1) transgene on radiation induced apoptosis in T cells	ONCOGENE			English	Article						p21(waf1); transgenic mice; radiation; apoptosis; p53	DEPENDENT KINASE INHIBITOR; NUCLEOTIDE EXCISION-REPAIR; DNA-REPLICATION; CDK INHIBITOR; CYCLE ARREST; IN-VIVO; POTENTIAL MEDIATOR; HUMAN FIBROBLASTS; S-PHASE; P21	The cyclin kinase inhibitor p21(WAF1/Cip1) is upregulated by the tumor suppressor p53. While p21 is central for the G-1 arrest mediated by p53, it is still unclear if p21 also functions as a downstream effector of p53 dependent apoptosis. Apoptosis induced by DNA damage but not dexamethasone is p53 dependent in thymocytes. To investigate the physiological role of p21 in apoptosis, we have generated transgenic mice in which the p21 transgene is targeted for restricted expression in the T cell lineage. Thymocytes from p21 transgenic mice were hypersensitive to cell death induced by DNA damaging agents such as ionizing radiation and UV, but not be dexamethasone. Irradiated p21 transgenic thymocytes had approximately twofold more apoptotic cells as compared to irradiated age matched littermate control mice. Radiation induced death is comparable in thymocytes from p21 + Bcl2 + double transgenic mice and age matched littermate controls, indicating that the Bcl2 transgene rescues the radiation hypersensitivity imposed by p21. However, thymocytes from p53-/- mice even when they expressed the p21 transgene, were resistant to death induced by radiation. Together these results show that thymocytes from p21 transgenic mice are hypersensitive to radiation induced programmed cell death and suggest that the radiation hypersensitivity of p21 transgenic thymocytes involves p53 dependent pathway and signals in addition to p21.	Inst Biol Struct JP Ebel, F-38027 Grenoble 1, France; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; La Jolla Inst Allergy & Immunol, La Jolla, CA 92037 USA; Burnham Inst, La Jolla, CA 92037 USA	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); La Jolla Institute for Immunology; Sanford Burnham Prebys Medical Discovery Institute	Fotedar, A (corresponding author), Inst Biol Struct JP Ebel, 41 Ave Martyrs, F-38027 Grenoble 1, France.				NATIONAL CANCER INSTITUTE [R01CA074435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031453] Funding Source: NIH RePORTER; NCI NIH HHS [CA74435] Funding Source: Medline; NIAID NIH HHS [AI31453] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; BRENOTBOSC F, 1995, CHROMOSOMA, V103, P517, DOI 10.1007/BF00355316; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Fotedar R, 1996, ONCOGENE, V12, P2155; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; JACKSON FH, 1904, P LOND MATH SOC, V3, P1; KATSUMATA M, 1992, P NATL ACAD SCI USA, V89, P11376, DOI 10.1073/pnas.89.23.11376; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kondo Y, 1997, EXP CELL RES, V236, P51, DOI 10.1006/excr.1997.3693; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Linton PJ, 1996, J EXP MED, V184, P1891, DOI 10.1084/jem.184.5.1891; LOWE SW, 1993, NATURE, V362, P837; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; McDonald E, 1996, CANCER RES, V56, P2250; MIYASHITA T, 1995, CELL, V80, P293; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Sekiguchi T, 1998, ONCOGENE, V16, P369, DOI 10.1038/sj.onc.1201539; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	49	48	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3652	3658		10.1038/sj.onc.1202693	http://dx.doi.org/10.1038/sj.onc.1202693			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380888				2022-12-17	WOS:000080891700012
J	Hartmann, BL; Geley, S; Loffler, M; Hattmannstorfer, R; Strasser-Wozak, EMC; Auer, B; Kofler, R				Hartmann, BL; Geley, S; Loffler, M; Hattmannstorfer, R; Strasser-Wozak, EMC; Auer, B; Kofler, R			Bcl-2 interferes with the execution phase, but not upstream events, in glucocorticoid-induced leukemia apoptosis	ONCOGENE			English	Article						glucocorticoid; apoptosis; bcl-2; leukemia; tetracycline-regulated gene expression	POLY(ADP-RIBOSE) POLYMERASE CLEAVAGE; FAMILY PROTEASE INHIBITORS; CERAMIDE-INDUCED APOPTOSIS; LINE CCRF-CEM; CELL-DEATH; CYTOCHROME-C; REGULATED APOPTOSIS; THYMOCYTE APOPTOSIS; REPRESSIVE FUNCTION; DNA FRAGMENTATION	Due to their growth arrest- and apoptosis-inducing ability, glucocorticoids (GC) are widely used in the therapy of various lymphoid malignancies. Cell death is associated with activation of members of the interleukin-1 beta-converting enzyme (ICE) protease/caspase family and, is presumably prevented by the anti-apoptotic protein Bcl-2. To further address the role of Bcl-2 in CC-mediated cytotoxicity, we generated subclones of the GC-sensitive human T-cell acute lymphoblastic leukemia line CCRF-CEM, in which transgenic Bcl-2 expression is regulated by tetracycline. Up to about 48 h, exogenous Bcl-2 almost completely protected these cells from apoptosis, digestion of poly-ADP ribose polymerase (PARP) and generation of Asp-Glu-Val-Asp cleaving (DEVDase) activity. However, when the cells were cultured for another 24 h in the continuous presence of GC, they underwent massive apoptosis that was associated with DEVDase activity and PARP cleavage. Bcl-2 did not markedly affect GC-mediated growth arrest, thereby separating the anti-proliferative from the apoptosis-inducing effect of GC. Moreover, Bcl-2 did not prevent the dramatic reduction in the levels of several mRNAs observed during GC treatment, including the transgenic Bcl-2 mRNA. Thus, Bcl-2 can be placed upstream of effector caspase activation, but downstream of other GC-regulated events, such as growth arrest and the potentially critical repression of steady state levels of multiple mRNA.	Univ Innsbruck, Inst Gen & Expt Pathol, Div Mol Pathophysiol, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Biochem, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck	Kofler, R (corresponding author), Univ Innsbruck, Inst Gen & Expt Pathol, Div Mol Pathophysiol, A-6020 Innsbruck, Austria.							ADELMAN NE, 1983, J EXP MED, V158, P1350, DOI 10.1084/jem.158.4.1350; ALNEMRI ES, 1992, CANCER RES, V52, P491; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; ASHRAF J, 1993, MOL ENDOCRINOL, V7, P631, DOI 10.1210/me.7.5.631; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Benson RSP, 1998, CELL DEATH DIFFER, V5, P432, DOI 10.1038/sj.cdd.4400366; Boulakia CA, 1996, ONCOGENE, V12, P529; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brunet CL, 1998, CELL DEATH DIFFER, V5, P107, DOI 10.1038/sj.cdd.4400334; CARONLESLIE LAM, 1994, FASEB J, V8, P639, DOI 10.1096/fasebj.8.9.8005391; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; Decaudin D, 1997, CANCER RES, V57, P62; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANSSTORMS RB, 1995, J STEROID BIOCHEM, V53, P1, DOI 10.1016/0960-0760(95)00034-W; Geley S, 1997, FEBS LETT, V402, P36, DOI 10.1016/S0014-5793(96)01496-2; Geley S, 1997, ONCOGENE, V15, P2429, DOI 10.1038/sj.onc.1201399; Geley S, 1996, REV PHYSIOL BIOCH P, V128, P1; Geley S, 1996, CANCER RES, V56, P5033; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hala M, 1996, INT J CANCER, V68, P663, DOI 10.1002/(SICI)1097-0215(19961127)68:5<663::AID-IJC17>3.0.CO;2-2; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Ibrado AM, 1996, CANCER RES, V56, P4743; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Melkova Z, 1997, FEBS LETT, V403, P273, DOI 10.1016/S0014-5793(97)00065-3; MEMON SA, 1995, J IMMUNOL, V155, P4644; Messmer UK, 1996, FEBS LETT, V384, P162; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIYASHITA T, 1993, BLOOD, V81, P151; Miyashita T, 1997, BIOCHEM BIOPH RES CO, V233, P781, DOI 10.1006/bbrc.1997.6559; MIYASHITA T, 1992, CANCER RES, V52, P5407; Monney L, 1996, BIOCHEM BIOPH RES CO, V221, P340, DOI 10.1006/bbrc.1996.0597; Moreno MB, 1996, J IMMUNOL, V157, P3845; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NORMAN MR, 1977, CANCER RES, V37, P3785; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; POWERS JH, 1993, CANCER RES, V53, P4059; Robertson NM, 1997, CANCER RES, V57, P43; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SCHWARTZMAN RA, 1994, INT ARCH ALLERGY IMM, V105, P347, DOI 10.1159/000236781; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SGONC R, 1994, INT ARCH ALLERGY IMM, V105, P327, DOI 10.1159/000236777; Shimizu S, 1996, ONCOGENE, V12, P2251; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; STRASSERWOZAK EMC, 1995, CANCER RES, V55, P348; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; THOMPSON EB, 1994, MOL ENDOCRINOL, V8, P665, DOI 10.1210/me.8.6.665; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; THULASI R, 1993, J BIOL CHEM, V268, P18306; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; Urashima M, 1997, BLOOD, V90, P279; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUH YS, 1989, J BIOL CHEM, V264, P10904; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZHIVOTOVSKY B, 1995, EXP CELL RES, V221, P404, DOI 10.1006/excr.1995.1391; Zhou F, 1996, MOL ENDOCRINOL, V10, P306, DOI 10.1210/me.10.3.306; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	77	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					713	719		10.1038/sj.onc.1202339	http://dx.doi.org/10.1038/sj.onc.1202339			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989821				2022-12-17	WOS:000078394400016
J	Muschel, RJ; Soto, DE; McKenna, WG; Bernhard, EJ				Muschel, RJ; Soto, DE; McKenna, WG; Bernhard, EJ			Radiosensitization and apoptosis	ONCOGENE			English	Review						radiation; X-rays; cell cycle; radiosensitization; apoptosis	RADIATION-INDUCED APOPTOSIS; WILD-TYPE P53; TUMOR-CELL LINES; FARNESYL TRANSFERASE INHIBITORS; P53-DEPENDENT G(1) ARREST; IRRADIATED MURINE TUMORS; HUMAN-SKIN FIBROBLASTS; S-PHASE PROGRESSION; HELA-CELLS; H-RAS	The toxicity of radiation to living tissues was discovered soon after the discovery of radioactivity itself and this toxicity is the basis for cancer therapy with radiation. Although this mode of therapy is often effective, its success is far from assured. One major difficulty in the implementation of radiotherapy is that normal tissues are also sensitive to killing by radiation so that treatment is often limited by the tolerance of normal tissues for radiation, Thus methods that sensitize tumor cells while sparing normal tissues could potentially lead to greater success with radiation as a therapy. Oncogenes are frequently altered in tumors, but are not in normal tissue making them potential targets for altering radiosensitivity and apoptosis in tumors.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Muschel, RJ (corresponding author), Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.							Badie B, 1998, J NEURO-ONCOL, V37, P217, DOI 10.1023/A:1005924925149; Barratt RA, 1998, CANCER RES, V58, P2639; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Barth H, 1996, CANCER RES, V56, P2268; BAYREUTHER K, 1988, P NATL ACAD SCI USA, V85, P5112, DOI 10.1073/pnas.85.14.5112; Bernhard EJ, 1996, CANCER RES, V56, P1727; Bernhard EJ, 1996, INT J RADIAT BIOL, V69, P575, DOI 10.1080/095530096145580; Bernhard EJ, 1998, CANCER RES, V58, P1754; Bowen C, 1998, CANCER RES, V58, P3275; Bristow RG, 1996, RADIOTHER ONCOL, V40, P197, DOI 10.1016/0167-8140(96)01806-3; Bristow RG, 1998, ONCOGENE, V16, P1789, DOI 10.1038/sj.onc.1201935; BUSSE PM, 1978, RADIAT RES, V76, P292, DOI 10.2307/3574780; Chang EH, 1997, ARCH OTOLARYNGOL, V123, P507; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; DAVIS MA, 1995, INT J RADIAT BIOL, V67, P509, DOI 10.1080/09553009514550621; DeWeese TL, 1997, INT J RADIAT ONCOL, V37, P145, DOI 10.1016/S0360-3016(96)00448-8; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; FAN SJ, 1995, CANCER RES, V55, P1649; Gallardo D, 1996, CANCER RES, V56, P4891; Gelb MH, 1998, CURR OPIN CHEM BIOL, V2, P40, DOI 10.1016/S1367-5931(98)80034-3; Geng L, 1998, RADIAT RES, V150, P31, DOI 10.2307/3579642; Gibbs JB, 1997, CURR OPIN CHEM BIOL, V1, P197, DOI 10.1016/S1367-5931(97)80010-5; Gjerset RA, 1995, MOL CARCINOGEN, V14, P275, DOI 10.1002/mc.2940140408; Gregoire V, 1997, BRIT J CANCER, V76, P1315, DOI 10.1038/bjc.1997.554; Guo M, 1997, RADIAT RES, V147, P295, DOI 10.2307/3579336; HaasKogan DA, 1996, INT J RADIAT ONCOL, V36, P95, DOI 10.1016/S0360-3016(96)00244-1; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HarmsRingdahl M, 1996, MUTAT RES-REV GENET, V366, P171, DOI 10.1016/S0165-1110(96)90038-X; Hasegawa M, 1997, RADIAT RES, V147, P457, DOI 10.2307/3579503; HENDRY JH, 1982, INT J RADIAT BIOL, V42, P611, DOI 10.1080/09553008214551591; Hendry JH, 1996, INT J RADIAT BIOL, V70, P677, DOI 10.1080/095530096144563; Hendry JH, 1997, RADIAT RES, V148, P254, DOI 10.2307/3579610; HURWITZ C, 1969, BIOPHYS J, V9, P607, DOI 10.1016/S0006-3495(69)86407-6; IJIRI K, 1983, BRIT J CANCER, V47, P175, DOI 10.1038/bjc.1983.25; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; LANG FF, 1963, J NEUROSURG, V125, P98; Lara PC, 1996, INT J RADIAT BIOL, V70, P683, DOI 10.1080/095530096144572; Lawrence TS, 1996, INT J RADIAT BIOL, V70, P273, DOI 10.1080/095530096145003; Lawrence TS, 1996, CANCER RES, V56, P3203; Lebowitz PF, 1997, CANCER RES, V57, P708; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; LING CC, 1989, RADIAT RES, V120, P267, DOI 10.2307/3577713; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; McGinn CJ, 1996, J NATL CANCER I, V88, P1193, DOI 10.1093/jnci/88.17.1193; MCKENNA WG, 1990, CANCER RES, V50, P97; McKenna WG, 1996, ONCOGENE, V12, P237; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Meyn R E, 1997, Oncology (Williston Park), V11, P349; Meyn R.E., 1997, ONCOLOGY WILLISTON P, V11, P356; Meyn R.E., 1997, ONCOLOGY WILLISTON P, V11, P361; Meyn R.E., 1997, ONCOLOGY WILLISTON P, V11, P365; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; Milner AE, 1997, ONCOGENE, V15, P1815, DOI 10.1038/sj.onc.1201355; O'Rourke DM, 1998, P NATL ACAD SCI USA, V95, P10842, DOI 10.1073/pnas.95.18.10842; Ogawa N, 1997, INT J CANCER, V73, P367, DOI 10.1002/(SICI)1097-0215(19971104)73:3<367::AID-IJC11>3.0.CO;2-A; OHYAMA H, 1985, RADIAT RES, V101, P123, DOI 10.2307/3576309; Pirollo KF, 1997, ONCOGENE, V14, P1735, DOI 10.1038/sj.onc.1201116; POWELL SN, 1995, CANCER RES, V55, P1643; Prendergast GC, 1996, CANCER RES, V56, P2626; RADFORD IR, 1991, INT J RADIAT BIOL, V59, P1353, DOI 10.1080/09553009114551221; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P217, DOI 10.1080/09553009414550251; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Rodemann HP, 1996, KIDNEY INT, V49, pS32; RODEMANN HP, 1991, SCANNING MICROSCOPY, V5, P1135; RODEMANN HP, 1991, SCANNING MICROSCOPY, V5, P1142; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Rupnow BA, 1998, CANCER RES, V58, P1779; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SAMID D, 1991, RADIAT RES, V126, P244, DOI 10.2307/3577825; Sebti Said, 1997, Current Opinion in Oncology, V9, P557, DOI 10.1097/00001622-199711000-00011; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Shewach DS, 1996, INVEST NEW DRUG, V14, P257, DOI 10.1007/BF00194528; SINCLAIR WK, 1964, RADIAT RES, V21, P584, DOI 10.2307/3571653; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; STEPHENS LC, 1993, RADIAT RES, V135, P75, DOI 10.2307/3578399; STEPHENS LC, 1991, RADIAT RES, V127, P308, DOI 10.2307/3577946; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; TAUCHI H, 1994, INT J RADIAT BIOL, V65, P449, DOI 10.1080/09553009414550521; THOMPSON LH, 1967, INT J RADIAT BIOL RE, V13, P391; THOMPSON LH, 1969, INT J RADIAT BIOL RE, V15, P347, DOI 10.1080/09553006914550571; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; TSANG NM, 1995, ONCOGENE, V10, P2403; TSANG NM, 1994, RADIAT RES, V140, P172, DOI 10.2307/3578900; VanHouten N, 1997, INT IMMUNOL, V9, P945, DOI 10.1093/intimm/9.7.945; Vidair CA, 1996, CANCER RES, V56, P4116; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Wang L, 1996, RADIAT RES, V146, P259, DOI 10.2307/3579455; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Wouters BG, 1997, CANCER RES, V57, P4703; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAMADA T, 1988, INT J RADIAT BIOL, V53, P65, DOI 10.1080/09553008814550431; YIN DX, 1995, CANCER RES, V55, P4922; Yount GL, 1996, CANCER RES, V56, P500	103	48	56	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 24	1998	17	25					3359	3363		10.1038/sj.onc.1202580	http://dx.doi.org/10.1038/sj.onc.1202580			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916998	Bronze			2022-12-17	WOS:000078048200017
J	Gollahon, LS; Kraus, E; Wu, TA; Yim, SO; Strong, LC; Shay, JW; Tainsky, MA				Gollahon, LS; Kraus, E; Wu, TA; Yim, SO; Strong, LC; Shay, JW; Tainsky, MA			Telomerase activity during spontaneous immortalization of Li-Fraumeni syndrome skin fibroblasts	ONCOGENE			English	Article						p53; telomeres; ALT pathway; senescence; cell hybrids	MAMMARY EPITHELIAL-CELLS; HUMAN PAPILLOMAVIRUS TYPE-16; CELLULAR SENESCENCE; CANCER SYNDROME; TUMOR-ANTIGEN; MUTANT P53; TRANSFORMATION; E6; GROWTH; DNA	Li-Fraumeni Syndrome (LFS) is characterized by heterozygous germline mutations in the p53 gene. Accompanied by genomic instability and loss or mutation of the remaining wild type p53 allele, a low frequency of spontaneous immortalization in LFS fibroblasts occurs. It is believed that the loss of p53 wild type function contributes to immortalization of these LFS fibroblasts, but it is not clear if this is sufficient. Because stabilization of telomere length is also thought to be a necessary step in immortalization, telomerase activity, expression of the telomerase RNA component (hTR) and telomere length were ana:lysed at various passages during the spontaneous immortalization of LFS skin fibroblasts. One LFS strain which immortalized, MDAH087 (087), had no detectable telomerase activity whereas another LFS strain which immortalized, MDAH041 (041), had detectable telomerase activity. In preimmortal cells from both strains, hTR was not detected by in situ hybridization. Immortal 087 cells remained negative for hTR, while immortal 041 cells demonstrated strong hTR in situ hybridization signals. 087 cells had long and heterogenous telomeres whereas telomeres; of 041 cells had short, stable telomere lengths. Tumorigenicity studies in nude mice with ras-transformed 087 and 041 cells resulted in both cell lines giving rise to tumors and retaining telomerase status. Overall these results suggest that strain specificity may be important in telomerase re-activation and that both abrogation of p53 function and a mechanism to maintain telomeres are necessary for immortalization.	Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Expt Pediat, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Gollahon, LS (corresponding author), Texas Tech Univ, Dept Biol Sci, POB 43131, Lubbock, TX 79409 USA.		Shay, Jerry W/F-7878-2011	Tainsky, Michael/0000-0002-0261-831X	NATIONAL CANCER INSTITUTE [T32CA009299, P01CA034936, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA-P01 34936, CA-16672, CA-09299] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; Avilion AA, 1996, CANCER RES, V56, P645; BACCHETTI S, 1995, INT J ONCOL, V7, P423; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; Barrett J. Carl, 1993, P61; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DUNCAN EL, 1993, EXP CELL RES, V205, P337, DOI 10.1006/excr.1993.1095; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gao QS, 1996, CANCER RES, V56, P3129; GILLESPIE PG, 1991, P NATL ACAD SCI USA, V88, P2563, DOI 10.1073/pnas.88.6.2563; Gollahon LS, 1996, ONCOGENE, V12, P715; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Greider CW, 1991, CURR OPIN CELL BIOL, V3, P444, DOI 10.1016/0955-0674(91)90072-7; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Holt Shawn E., 1996, Methods in Cell Science, V18, P237, DOI 10.1007/BF00132889; Hsiao RS, 1997, ANTICANCER RES, V17, P827; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; JORDAN C, 1990, IN SITU HYBRIDIZATIO, P61; Karlsson C, 1996, CANCER RES, V56, P241; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; LEMOINE NR, 1990, ONCOGENE, V5, P1833; MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PIATYSZEK MA, 1996, METHODS CELL SCI, V17, P1; RAINEY WH, 1994, J CLIN ENDOCR METAB, V78, P705, DOI 10.1210/jc.78.3.705; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; ROSS SR, 1978, PERSISTENT VIRUSES, V11, P469; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SASAKI M, 1994, CANCER RES, V54, P6090; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHAY JW, 1993, ONCOGENE, V8, P1407; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1994, METH MOL G, V5, P263; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; TAINSKY MA, 1995, CANCER METAST REV, V14, P43, DOI 10.1007/BF00690210; TSUTSUI T, 1995, CARCINOGENESIS, V16, P25, DOI 10.1093/carcin/16.1.25; Tsutsui T, 1997, MOL CARCINOGEN, V18, P7, DOI 10.1002/(SICI)1098-2744(199701)18:1<7::AID-MC2>3.0.CO;2-F; VANDERHAEGEN BA, 1993, IN VITRO CELL DEV-AN, V29A, P180, DOI 10.1007/BF02634177; WATANABE S, 1993, JPN J CANCER RES, V84, P1043, DOI 10.1111/j.1349-7006.1993.tb02799.x; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; Yashima K, 1998, CLIN CANCER RES, V4, P229	74	48	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					709	717		10.1038/sj.onc.1201987	http://dx.doi.org/10.1038/sj.onc.1201987			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715272				2022-12-17	WOS:000075337200005
J	Petersen, S; Rudolf, J; Bockmuhl, U; Gellert, K; Wolf, G; Dietel, M; Petersen, I				Petersen, S; Rudolf, J; Bockmuhl, U; Gellert, K; Wolf, G; Dietel, M; Petersen, I			Distinct regions of allelic imbalance on chromosome 10q22-q26 in squamous cell carcinomas of the lung	ONCOGENE			English	Article						lung cancer; tumor genetics; loss of heterozygosity	PROSTATE-CANCER; HUMAN GLIOBLASTOMAS; LONG ARM; PROGRESSION; LOCI; HETEROZYGOSITY; GENE; HUMAN-CHROMOSOME-10; ADENOCARCINOMA; ABNORMALITIES	The genetic mechanisms underlying the progression to the metastatic phenotype of lung cancer are poorly understood. We recently showed that small cell lung cancer (SCLC) and metastasizing squamous cell carcinomas are characterized by an increased incidence of allelic loss on chromosome 10q, In the present study we performed a deletion mapping using 24 polymorphic markers on chromosome 10q22-q26 in 39 squamous cell carcinomas (SCC) of the lung identifying 14 metastatic carcinomas (74%) and three non-metastatic SCC (15%) with allelic imbalance. The allelotype analysis indicated three regions of allelic loss that were clustered at the loci Afm086/D10S541, D10S185 and D10S1782/D10S169. A localized microsatellite instability was observed in two carcinomas for the markers D10S1686 and D10S1782, In addition the PTEN/MMAC1 gene was analysed by direct DNA sequencing and Southern blot analysis in 25 and 28 carcinomas, respectively, without detecting any genomic alterations. Similarly, no altered transcript was detected in 15 tumor cell lines and 20 primary tumors by Northern blot analysis or RT-PCR, In summary, three distinct regions of allelic imbalance were identified suggesting that multiple tumor suppressor genes on chromosome 10q contribute to tumor progression and metastases formation of lung cancer.	Univ Hosp Charite, Inst Pathol, D-10098 Berlin, Germany; Univ Hosp Charite, Dept Otorhinolaryngol, D-10098 Berlin, Germany; Univ Hosp Charite, Dept Surg, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Petersen, I (corresponding author), Univ Hosp Charite, Inst Pathol, D-10098 Berlin, Germany.							Bockmuhl U, 1997, CANCER RES, V57, P5213; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; FONG KM, 1995, CANCER RES, V55, P28; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; GRAY IC, 1995, CANCER RES, V55, P4800; Guldberg P, 1997, CANCER RES, V57, P3660; HERBST RA, 1994, CANCER RES, V54, P3111; Ittmann M, 1996, CANCER RES, V56, P2143; KARLBOM AE, 1993, HUM GENET, V92, P169; Kerangueven F, 1997, ONCOGENE, V14, P339, DOI 10.1038/sj.onc.1200818; Komiya A, 1996, GENE CHROMOSOME CANC, V17, P245; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; MOIR DT, 1994, GENOMICS, V22, P1, DOI 10.1006/geno.1994.1338; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MORITA R, 1991, CANCER RES, V51, P5817; Nagase S, 1997, CANCER RES, V57, P1630; Nagase S, 1996, BRIT J CANCER, V74, P1979, DOI 10.1038/bjc.1996.663; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; NIHEI N, 1995, GENE CHROMOSOME CANC, V14, P112, DOI 10.1002/gcc.2870140205; PEIFFER SL, 1995, CANCER RES, V55, P1922; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; Petersen I, 1997, CANCER RES, V57, P2331; Petersen S, 1998, BRIT J CANCER, V77, P270, DOI 10.1038/bjc.1998.43; PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604; RASHEED BKA, 1995, ONCOGENE, V10, P2243; REMPEL SA, 1993, CANCER RES, V53, P2386; Rhei E, 1997, CANCER RES, V57, P3657; SATO S, 1994, CANCER RES, V54, P5652; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; SPEAKS SL, 1992, GENE CHROMOSOME CANC, V5, P239, DOI 10.1002/gcc.2870050311; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; Teng DHF, 1997, CANCER RES, V57, P5221; TESTA JR, 1992, CANCER RES, V52, pS2702; THIBERVILLE L, 1995, CANCER RES, V55, P5133	40	48	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					449	454		10.1038/sj.onc.1201949	http://dx.doi.org/10.1038/sj.onc.1201949			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696038				2022-12-17	WOS:000075043000007
J	Kim, J; Lee, K; Pelletier, J				Kim, J; Lee, K; Pelletier, J			The desmoplastic small round cell tumor t(11;22) translocation produces EWS/WT1 isoforms with differing oncogenic properties	ONCOGENE			English	Article						EWS; WT1; DSRCT; oncogene; transformation; cancer genetics	EWINGS-SARCOMA TRANSLOCATION; WILMS-TUMOR; TRANSCRIPTION FACTOR; GENE FUSION; UROGENITAL DEVELOPMENT; SUPPRESSOR GENE; EWS GENE; WT1; BINDING; MUTATIONS	Structural alterations of the Wilms' tumor locus (WT1) at 11p13 have been implicated in the etiology of two human cancers - Wilms' tumor (WT), a pediatric renal malignancy, and Desmoplastic Small Round Cell Tumor (DSRCT), an aggressive cancer of the abdomenal serosal lining with predilection for male adolescents, Germline mutations within the WT1 tumor suppressor gene predispose to WT and are associated with congenital malformations of the urogenital system, and somatic mutations are associated with initiation of transformation in WTs, In DSRCT, a recurrent translocation, t(11;22)(p13;q12), fuses the amino terminal domain of the EWS1 gene product to three of the four WT1 zinc fingers. Two EWS/WT1 isoforms are generated as a result of an alternative splicing event between zinc fingers III and IV, inserting or removing three amino acids (+/-KTS), We demonstrate that introduction of EWS/ WT1(-KTS) into NIH3T3 cells causes their tumorigenic transformation as determined by: formation of transformed foci on a monolayer of cells; anchorage-independent growth; and tumor formation in nude mice. EWS/WT1(+ KTS) showed no transforming potential in these assays. These results indicate the oncogenic effect of the t(11;22) translocation is mediated by the EWS/ WT1(-KTS) isoform and that fusion of the EWS amino terminal domain to the WT1 DNA binding domain produces a chimeric product showing a gain of function.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong	McGill University; McGill University; Hong Kong University of Science & Technology	Pelletier, J (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.							AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BROWN AD, 1995, ONCOGENE, V10, P1749; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; GERALD WL, 1991, AM J SURG PATHOL, V15, P499, DOI 10.1097/00000478-199106000-00001; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; JEON IS, 1995, ONCOGENE, V10, P1229; Karnieli E, 1996, J BIOL CHEM, V271, P19304, DOI 10.1074/jbc.271.32.19304; KRAUSS RS, 1992, MOL CELL BIOL, V12, P3117, DOI 10.1128/MCB.12.7.3117; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; LADANYI M, 1994, CANCER RES, V54, P2837; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MCMASTER ML, 1995, CELL GROWTH DIFFER, V6, P1609; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; RAUSCHER FJ, 1994, COLD SPRING HARB SYM, V59, P137, DOI 10.1101/SQB.1994.059.01.017; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1995, MOL CELL BIOL, V15, P3516; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	31	48	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					1973	1979		10.1038/sj.onc.1201716	http://dx.doi.org/10.1038/sj.onc.1201716			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591781				2022-12-17	WOS:000073079400009
J	Subramaniam, PS; Cruz, PE; Hobeika, AC; Johnson, HM				Subramaniam, PS; Cruz, PE; Hobeika, AC; Johnson, HM			Type I interferon induction of the Cdk-inhibitor p21(WAF1) is accompanied by ordered G1 arrest, differentiation and apoptosis of the Daudi B-cell line	ONCOGENE			English	Article						interferon alpha; p21(WAF1); B-cell differentiation; apoptosis; cell cycle	SENSITIVE HEMATOPOIETIC-CELLS; RETINOBLASTOMA PROTEIN; C-MYC; INTERLEUKIN-6 SUPPRESS; ONCOGENE EXPRESSION; ALPHA-INTERFERON; DOWN-REGULATION; RB PROTEIN; GROWTH; GENE	We show, in this study, that type I IFN induction of the cyclin-dependent kinase (cdk) inhibitor p21(WAF1) in the human Burkitt lymphoma B cell-line Daudi and ensuing cell cycle arrest correlate with the terminal differentiation of these cells, and is ultimately followed by apoptosis and cell death. The expression of p21(WAF1) paralleled the onset of G1 arrest and the reduction of surface IgM expression which was used as a marker of the differentiation response, and the IFN treated cells acquired a typical plasma cell-like morphology. The type II IFN IFN gamma, which does not inhibit the growth of Daudi cells, did not induce the expression of p21(WAF1), nor affect the expression of surface IgM. The induction of p21(WAF1) which paralleled the inhibition of the phosphorylation of the retinoblastoma protein, pRB, was preceded by the strong reduction in c-myc levels, We propose that the coupled down-regulation of c-myc and induction of p21(WAF1) may be crucial to the induction of differentiation and G1 arrest in Daudi cells by type I IFN. Growth arrest and differentiation was followed by apoptosis and cell death, and was accompanied by the induction of the activity of the apoptotic ICE-family protease CPP32. G1 arrest and differentiation followed by apoptotic cell death are characteristics of terminal differentiation. Thus, our data suggest that the induction of p21(WAF1) and G1 arrest mediated by type I IFN in Daudi cells is part of terminal differentiation response in these cells, highlighting a role for type I IFN as B cell terminal differentiation factors.	Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Subramaniam, PS (corresponding author), Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA.				NATIONAL CANCER INSTITUTE [R01CA069959, R01CA038587] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38587, CA 69959] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERTOLINI JN, 1992, J IMMUNOL, V149, P1771; Blagosklonny MV, 1996, LEUKEMIA RES, V20, P101, DOI 10.1016/0145-2126(95)00103-4; BURKE LC, 1992, ONCOGENE, V7, P783; CLEMENS MJ, 1988, J CELL BIOCHEM, V38, P251, DOI 10.1002/jcb.240380404; COLLINS SJ, 1987, BLOOD, V70, P1233; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EXLEY R, 1987, P NATL ACAD SCI USA, V84, P6467, DOI 10.1073/pnas.84.18.6467; EXLEY R, 1987, INT J CANCER, V40, P53, DOI 10.1002/ijc.2910400110; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; HERMEKING H, 1995, ONCOGENE, V11, P1409; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; NOGUCHI PD, 1992, CURRENT PROTOCOLS IM, V1; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RUBIN BY, 1983, J GEN VIROL, V64, P1743, DOI 10.1099/0022-1317-64-8-1743; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Subramaniam PS, 1997, J INTERF CYTOK RES, V17, P11, DOI 10.1089/jir.1997.17.11; TAMM I, 1987, MECHANISMS INTERFERO, V2, P25; THOMAS NSB, 1991, ONCOGENE, V6, P317; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; TOMITA Y, 1982, INT J CANCER, V30, P161, DOI 10.1002/ijc.2910300206; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; YEN A, 1992, EUR J CELL BIOL, V57, P210; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479	30	48	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1885	1890		10.1038/sj.onc.1201712	http://dx.doi.org/10.1038/sj.onc.1201712			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583686				2022-12-17	WOS:000072994600012
J	Poon, RYC; Hunter, T				Poon, RYC; Hunter, T			Expression of a novel form of p21(Cip1/Waf1) in UV-irradiated and transformed cells	ONCOGENE			English	Article						cell cycle; CDK inhibitor; cyclin; proteasome	CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR GENE; INHIBITS DNA-REPLICATION; PROTEIN-KINASE; CDK INHIBITOR; TERMINAL DIFFERENTIATION; POTENTIAL MEDIATOR; NUCLEAR ANTIGEN; BINDING DOMAINS; MICE DEFICIENT	The tumor suppressor p53 and its target the CDK inhibitor p21 (Cip1/Waf1) are key components of the cellular response to DNA damage. Insight into how p21 is regulated in normal cells, and how it may be deregulated in tumor cells is important for the understanding of tumorigenesis. p21 was induced in normal human diploid fibroblasts after UV irradiation-induced DNA damage, but, at a high dose of UV irradiation, a faster mobility form of p21 on SDS-PAGE (designated p21 Delta) was expressed. Surprisingly, in a variety of growing transformed cell lines, the level of p21 was low but p21 Delta was prominent. We found that p21 Delta appeared to be derived through a loss of around 10 amino acids from the C-terminus of p21, which theoretically would remove the PCNA binding domain, a second cyclin binding domain and the nuclear localization signal sequence. Several characteristics distinguish p21 from p21 Delta. Both the full length p21 and p21 Delta could be stabilized by a proteasome inhibitor, but only the full length p21 was associated with Cdk2 and PCNA. Consistent with this, gel filtration chromatography revealed that all the full length p21 in the cell was complexed to other proteins, whereas a significant portion of p21 Delta was in monomeric form. Moreover, p21 was mainly localized to the nucleus, but p21 Delta was mainly localized to the cytoplasm. We propose that the decrease in p21 and increase in p21 Delta could contribute to the deregulation of the cell cycle, and could be a mechanism involved in cellular transformation.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong; Salk Inst Biol Studies, La Jolla, CA 92037 USA	Hong Kong University of Science & Technology; Salk Institute	Poon, RYC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong.			Poon, Randy/0000-0001-5571-6231	NCI NIH HHS [CA14195, CA39780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195, R35CA039780] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; AUSUBEL RM, 1991, CURRENT PROTOCOLS MO; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHEN L, 1996, NATURE, V16, P4673; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOUBIN F, 1995, ONCOGENE, V10, P2281; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HUPPI K, 1994, ONCOGENE, V9, P3017; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JIANG HP, 1994, ONCOGENE, V9, P3397; KAKUNAGA T, 1978, P NATL ACAD SCI USA, V75, P1334, DOI 10.1073/pnas.75.3.1334; KASTAN MB, 1991, CANCER RES, V51, P6304; LEE KAW, 1994, CELL BIOL LAB HDB; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MICHIELI P, 1994, CANCER RES, V54, P3391; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; MURRAY A, 1993, CELL CYCLE; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; QUELLE DE, 1995, CELL, V83, P993; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; Tchou WW, 1996, J BIOL CHEM, V271, P29556, DOI 10.1074/jbc.271.47.29556; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TROLL W, 1993, PROTEASE INHIBITORS; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XIONG Y, 1992, CELL, V71, P50; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	78	48	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1333	1343		10.1038/sj.onc.1201897	http://dx.doi.org/10.1038/sj.onc.1201897			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546435				2022-12-17	WOS:000072422000012
J	Pacini, F; Vivaldi, A; Santoro, M; Fedele, M; Fusco, A; Romei, C; Basolo, F; Pinchera, A				Pacini, F; Vivaldi, A; Santoro, M; Fedele, M; Fusco, A; Romei, C; Basolo, F; Pinchera, A			Simian virus 40-like DNA sequences in human papillary thyroid carcinomas	ONCOGENE			English	Article						SV40; thyroid cancer; autoimmune thyroiditis; oncogene	LARGE T-ANTIGEN; TRANSGENIC MICE; CHOROID-PLEXUS; RET ONCOGENE; CANCER; TUMORS; CELLS; EXPRESSION; RADIATION; EXPOSURE	Sequences of the SV40 virus, a virus of Asian macaques, have been found in human tumors, such as pleural mesotheliomas, ependimomas and choroid plexus tumors, Transgenic mice carrying the SV40 large T gene under the transcriptional control of the thyroglobulin gene promoter, develop thyroid dedifferentiation and follicular thyroid cell proliferation, leading to thyroid hyperplasia and adenocarcinomas. On these bases we investigated the presence of SV40 DNA sequences in 69 samples of papillary thyroid carcinomas (PTC) and in other thyroid and non-thyroid carcinomas, as well as in benign thyroid diseases. By Southern blot and PCR amplification followed by sequence analysis, we found the presence of SV40-related sequences integrated in the tumoral DNA of three cases of PTC. At least the 203 bp fragment of the aminoterminus of large T antigen, the 294 bp fragment of the VP1 gene and the 483 bp entire regulatory region were present in the tumoral DNA of these patients. SV40 sequences were not found in tissues other than PTC. Our results demonstrate that, in addition to previous findings in mesotheliomas and brain tumors, SV40 is somehow linked to papillary thyroid carcinoma. Although our data do not demonstrate a causative role in the development of PTC, this possibility must be considered and requires further studies.	Univ Pisa, Ist Endocrinol Metodol Clin & Med Lavoro, I-56124 Pisa, Italy; Univ Pisa, Ist Anat Patol, I-56124 Pisa, Italy; Univ Naples Federico II, CNR, Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Ist Nazl Tumori, I-80131 Naples, Italy; Univ Reggio Calabria, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	University of Pisa; University of Pisa; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria	Pacini, F (corresponding author), Univ Pisa, Ist Endocrinol Metodol Clin & Med Lavoro, Via Paradisa 2, I-56124 Pisa, Italy.		Fedele, Monica/C-1417-2015; Basolo, Fulvio/AAC-2727-2019	Fedele, Monica/0000-0002-9171-1312; Basolo, Fulvio/0000-0003-1657-5020; Fusco, Alfredo/0000-0003-3332-5197				ARTHUR RR, 1989, PROG MED VIROL, V36, P42; BALKANY C, 1995, THYROID, V5, P47, DOI 10.1089/thy.1995.5.47; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; Bond JA, 1996, INT J CANCER, V67, P563, DOI 10.1002/(SICI)1097-0215(19960807)67:4<563::AID-IJC16>3.0.CO;2-8; CARBONE M, 1994, ONCOGENE, V9, P1781; CIAMPOLILLO A, 1989, LANCET, V1, P1096; Cristaudo A., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P29; DAS BC, 1992, J MED VIROL, V36, P239, DOI 10.1002/jmv.1890360402; FEIGENBAUM L, 1992, J VIROL, V66, P1176, DOI 10.1128/JVI.66.2.1176-1182.1992; GALANTI MR, 1995, INT J CANCER, V61, P615, DOI 10.1002/ijc.2910610506; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; LEDENT C, 1995, ONCOGENE, V10, P1789; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; Martini F, 1996, CANCER RES, V56, P4820; MELNICK JL, 1962, P SOC EXP BIOL MED, V109, P965, DOI 10.3181/00379727-109-27392; MILLER RW, 1995, ENVIRON HEALTH PERSP, V103, P41, DOI 10.2307/3432343; MORRIS JA, 1961, P SOC EXP BIOL MED, V108, P56, DOI 10.3181/00379727-108-26843; Pettersson B, 1996, INT J CANCER, V65, P13, DOI 10.1002/(SICI)1097-0215(19960103)65:1&lt;13::AID-IJC3&gt;3.0.CO;2-4; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1995, EUR J ENDOCRINOL, V133, P513, DOI 10.1530/eje.0.1330513; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1994, ONCOGENE, V9, P509; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; SORIANO F, 1974, NATURE, V249, P421, DOI 10.1038/249421a0; TAKAHASHI MH, 1995, BRIT J CANCER, V72, P813, DOI 10.1038/bjc.1995.418; WILLIAMS ED, 1979, CLIN ENDOCRINOL META, V8, P193, DOI 10.1016/S0300-595X(79)80017-1; WILLIAMS ED, 1995, J ENDOCRINOL INVEST, V18, P144, DOI 10.1007/BF03349725	31	48	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	1998	16	5					665	669		10.1038/sj.onc.1201552	http://dx.doi.org/10.1038/sj.onc.1201552			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482113				2022-12-17	WOS:000071816600012
J	Drane, P; Barel, M; Balbo, M; Frade, R				Drane, P; Barel, M; Balbo, M; Frade, R			Identification of RB18A, a 205 kDa new p53 regulatory protein which shares antigenic and functional properties with p53	ONCOGENE			English	Article						p53; antigen related	WILD-TYPE P53; DNA-BINDING FUNCTION; LARGE T-ANTIGEN; TRANSCRIPTIONAL ACTIVATION; MONOCLONAL-ANTIBODY; GROWTH SUPPRESSION; CELLULAR PROTEIN; TUMOR-ANTIGEN; IN-VITRO; KINASE-C	Immunological screening with the anti-p53 moAb, PAb1801 of a cDNA expression library, prepared from human B lymphoma cells, led us to identify a new human 205 kDa protein called RB18A for 'Recognized By PAb1801 moAntibody'. Immunoblotting or immunoprecipitation of fusion protein or in vitro translated protein, respectively, demonstrated that RB18A protein was recognized by several anti-p53 moAb reacting with the N or C-terminal domains of p53. Full length sequence of RB18B cDNA and computer analysis demonstrated that despite common antigenic determinants between RB18A and p53 proteins, nucleotide and deduced protein sequences did not reveal any significant homologies. RB18A mRNA was detected in all tissues tested except in kidney. In addition, RB18A protein shared identical functions with p53 protein: binding to DNA or to p53 and self-oligomerization. Furthermore, RB18A regulated p53 specific binding on his DNA consensus binding site. These functions were associated to the C-terminal domain of RB18A protein and more specifically to the PAb421 binding site present in this domain. The activation by RB18A of p53 binding on DNA was induced through an unstable interaction between both proteins. Altogether, our data demonstrated that RB18A protein shares antigenic and functional properties with p53 and regulated p53 functions.	Hop St Antoine, Ctr INSERM, INSERM U354, Immunochim Regulat Cellulaires & Interact Virales, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Frade, R (corresponding author), Hop St Antoine, Ctr INSERM, INSERM U354, Immunochim Regulat Cellulaires & Interact Virales, F-75012 Paris, France.			BAREL, Monique/0000-0001-8171-7027				Arrowsmith CH, 1996, ONCOGENE, V12, P1379; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAREL M, 1991, J IMMUNOL, V147, P1286; BAREL M, 1989, P NATL ACAD SCI USA, V86, P10054, DOI 10.1073/pnas.86.24.10054; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DAUD AI, 1993, AM J PHYSIOL, V264, pH1693, DOI 10.1152/ajpheart.1993.264.5.H1693; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; Kim KK, 1996, J BIOL CHEM, V271, P29255, DOI 10.1074/jbc.271.46.29255; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEGROS Y, 1994, ONCOGENE, V9, P2071; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; Milne DM, 1996, ONCOGENE, V13, P205; MILNER J, 1987, ONCOGENE, V1, P453; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; RADINSKY R, 1994, ONCOGENE, V9, P1877; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Simons A, 1997, ONCOGENE, V14, P145, DOI 10.1038/sj.onc.1200825; SOUSSI T, 1990, ONCOGENE, V5, P945; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929	63	48	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	1997	15	25					3013	3024		10.1038/sj.onc.1201492	http://dx.doi.org/10.1038/sj.onc.1201492			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444950				2022-12-17	WOS:000070968000002
J	Pearson, A; Greenblatt, J				Pearson, A; Greenblatt, J			Modular organization of the E2F1 activation domain and its interaction with general transcription factors TBP and TFIIH	ONCOGENE			English	Review						E2F1; TBP; TFIIH; transactivation	RNA-POLYMERASE-II; TATA-BINDING PROTEIN; EUKARYOTIC DNA-REPLICATION; HYDROPHOBIC AMINO-ACIDS; C-TERMINAL DOMAIN; RETINOBLASTOMA PROTEIN; MOLECULAR-CLONING; GROWTH SUPPRESSION; TRANS-ACTIVATION; PROMOTER DNA	The transcriptional activator E2F1 regulates the expression of genes at the G1/S boundary. We have characterized interactions of the E2F1 activation domain with two general transcription factors, the TATA-box binding protein (TBP) and TFIIH. Two distinct binding sites on E2F1 were identified for TBP (amino acids 386-417 and 415-437) each of which supported activation in mammalian cells when expressed as a fusion to a heterologous DNA-binding domain. Neither of these minimal activation domains independently bound TFIIH; rather, the TFIIH binding site of E2F1 overlaps both domains. Loss of TFIIH-binding by E2F1 resulted in a 60-65% reduction in transactivation, suggesting that the E2F1/TFIIH interaction is important, but not essential, for transactivation. The retinoblastoma protein (Rb) binds directly to E2F1 and represses E2F1-mediated transactivation. We have demonstrated that recombinant Rb can compete with TBP and the p62 subunit of TFIIH for binding to immobilized E2F1. A tumorigenic form of Rb deficient in repressing E2F1-mediated transactivation is likewise deficient in displacing TBP from E2F1. We propose that competition between Rb and both TBP and TFIIH for binding to E2F1 is a mechanism by which Rb inhibits transactivation by E2F1.	UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5G 1L6,CANADA	University of Toronto; University of Toronto				Pearson, Angela/0000-0002-5997-2846				ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; AUERSPERG N, 1964, J NATL CANCER I, V32, P135; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Blair WS, 1996, EMBO J, V15, P1658, DOI 10.1002/j.1460-2075.1996.tb00511.x; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; Blau J, 1996, MOL CELL BIOL, V16, P2044; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; EMILI A, 1995, J BIOL CHEM, V270, P13674, DOI 10.1074/jbc.270.23.13674; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; FORMOSA T, 1991, METHOD ENZYMOL, V208, P24; GE H, 1994, J BIOL CHEM, V269, P17136; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; ING NH, 1992, J BIOL CHEM, V267, P17617; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PAN GH, 1994, J BIOL CHEM, V269, P30101; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PUGH BF, 1992, J BIOL CHEM, V267, P679; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SO AG, 1992, CRIT REV BIOCHEM MOL, V27, P129, DOI 10.3109/10409239209082561; SOPTA M, 1985, J BIOL CHEM, V260, P353; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANAKA M, 1994, MOL CELL BIOL, V14, P6056, DOI 10.1128/MCB.14.9.6056; TANTIN D, 1994, J BIOL CHEM, V269, P17397; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TONG X, 1995, P NATL ACAD SCI USA, V92, P3259, DOI 10.1073/pnas.92.8.3259; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WALKER S, 1993, MOL CELL BIOL, V13, P5233, DOI 10.1128/MCB.13.9.5233; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WEEDA G, 1990, MOL CELL BIOL, V10, P2570, DOI 10.1128/MCB.10.6.2570; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WOONTNER M, 1989, J BIOL CHEM, V265, P8979; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; ZHU H, 1994, J BIOL CHEM, V269, P3489	112	48	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2643	2658		10.1038/sj.onc.1201451	http://dx.doi.org/10.1038/sj.onc.1201451			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400991				2022-12-17	WOS:A1997YH46800002
J	DellaValle, V; Duro, D; Bernard, O; Larsen, CJ				DellaValle, V; Duro, D; Bernard, O; Larsen, CJ			The human protein p19(ARF) is not detected in hemopoietic human cell lines that abundantly express the alternative beta transcript of the p16(INK4a)/MTS1 gene	ONCOGENE			English	Article						p16(INK4a); MTS1; CDKN2; p19(ARF)	ACUTE LYMPHOBLASTIC-LEUKEMIA; P16(INK4)/MTS1 GENE; UNRELATED PROTEINS; FAMILIAL MELANOMA; P16; SENESCENCE; DELETIONS; IMMORTALIZATION; INACTIVATION; P15(INK4B)	The p16/MTS1/CDKN2 gene on human chromosome band 9p21 encodes two unrelated proteins: p16(INK4a), a inhibitor of the cyclin D-dependent kinases and CDK6, and the structurally unrelated p19(ARF) protein that arrests cell growth in G(1)/S and also in G(2)/M. By use of polyclonal antibodies, the human p19(ARF) (hp19(ARF)) protein has been identified in the nucleus of various cells including normal cultured fibroblasts. The level of this protein did not fluctuate throughout the cell cycle and was more elevated in fibroblasts with limited or arrested growth, suggesting that p19(ARF) accumulated in presenescent or senescent cells. Interestingly, hp19(ARF) was not detected in several hemopoietic tumor cell lines (mainly of B-type lymphoid origin) that expressed abundant amounts of the p16 beta transcript. This finding indicates that in certain tumors, the expression of hp19(ARF) RNA and protein may be uncoupled, Furthermore, it suggests that disruption of a translational mechanism may be involved in the inactivation of hp19(ARF).	INST GENET MOL,INSERM,U301,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Bernard, Olivier A./E-5721-2016	Bernard, Olivier/0000-0002-0463-9747				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P995; COLEMAN A, 1994, CANCER RES, V54, P344; COLIGAN JE, 1995, CURRENT PROTOCOLS PR, V1; DURO D, 1995, ONCOGENE, V11, P21; Duro D, 1996, CANCER RES, V56, P848; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Flores JF, 1996, CANCER RES, V56, P5023; Hara E, 1996, MOL CELL BIOL, V16, P859; Hui AM, 1996, HEPATOLOGY, V24, P575, DOI 10.1053/jhep.1996.v24.pm0008781327; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Larsen CJ, 1996, ONCOGENE, V12, P2041; Liggett WH, 1996, CANCER RES, V56, P4119; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MAO L, 1995, CANCER RES, V55, P2995; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; Parry D, 1996, MOL CELL BIOL, V16, P3844; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Reznikoff CA, 1996, CANCER RES, V56, P2886; Sambrook J., 1989, MOL CLONING; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SOULARD M, 1993, NUCLEIC ACIDS RES, V21, P4210, DOI 10.1093/nar/21.18.4210; STONE S, 1995, CANCER RES, V55, P2988; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; WICK ST, 1995, ONCOGENE, V11, P2013; ZHOU M, 1995, LEUKEMIA, V9, P1159	29	48	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2475	2481		10.1038/sj.onc.1201417	http://dx.doi.org/10.1038/sj.onc.1201417			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395243				2022-12-17	WOS:A1997YE96300009
J	Sakamoto, Y; Yoshida, M; Semba, K; Hunter, T				Sakamoto, Y; Yoshida, M; Semba, K; Hunter, T			Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc finger domain	ONCOGENE			English	Article						tumor suppressor gene; phosphorylation; transcription factor; DNA binding	FACTOR-A-CHAIN; GROWTH-FACTOR; SUPPRESSOR GENE; KIDNEY DEVELOPMENT; MOLECULAR-CLONING; UROGENITAL SYSTEM; MAMMALIAN-CELLS; EXPRESSION; SITE; RECOGNITION	The Wilms' tumor suppressor gene, WT1, encodes a transcription factor in the zinc finger family, which binds to GC-rich sequences and functions as a transcriptional activator or repressor, The WT1 protein plays a crucial role in urogenital development in mammals and its function is thought to be conserved during vertebrate evolution, Although accumulating evidence suggests that WT1 regulates a subset of genes including growth factor and growth factor receptor genes, little is known about regulators or signal cascades that could modulate the function of WT1, In this study, we show that the WT1 protein expressed exogenously in fibroblasts was phosphorylated in vivo, and that treatment with forskolin, which activates the cAMP-dependent protein kinase (PKA) in vivo, induced phosphorylation of additional sites in WT1, We identified the forskolin-induced phosphorylation sites as Ser-365 and Ser-393, which lie in the zinc finger domain in zinc fingers 2 and 3, respectively, PKA phosphorylated WT1 at Ser-365 and Ser-393 in vitro, as well as at additional sites, and this phosphorylation abolished the DNA-binding activity of WT1 in vitro. Using WT1 mutants in which Ser-365 and Ser-393 were mutated to Ala individually and in combination, we showed that phosphorylation of these sites was critical for inhibition of DNA binding in vivo, Thus, coexpression of the PKA catalytic subunit with wild type WT1 reduced the level of WT1 DNA-binding activity detected in nuclear extracts, and decreased transcriptional repression activity in vivo, In contrast to wild type WT1, all of the phosphorylation site mutants retained significant DNA-binding activity and repression activity in the presence of PKA, Analysis of the mutants showed that phosphorylation of Ser-365 and Ser-395 had additive inhibitory effects on WT1 DNA-binding in vivo and that phosphorylation at both sites was required for neutralization of repression activity, Therefore, we conclude that PKA modulates the activity of WT1 in vivo through phosphorylation of Ser-365 and Ser-393, which inhibits DNA binding, This in turn results in a decrease in WT1 transcriptional repression, Our findings provide the first evidence that the function of WT1 can be modulated by its phosphorylation in vivo.	SALK INST BIOL STUDIES, MOL BIOL & VIROL LAB, LA JOLLA, CA 92037 USA; UNIV TOKYO, INST MED SCI, DEPT CELLULAR & MOL BIOL, MINATO KU, TOKYO 108, JAPAN	Salk Institute; University of Tokyo					NATIONAL CANCER INSTITUTE [P30CA014195] Funding Source: NIH RePORTER; NCI NIH HHS [CA14195, CA39760] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Algar EM, 1996, ONCOGENE, V12, P1005; ALOI JA, 1995, ENDOCRINOLOGY, V136, P1227, DOI 10.1210/en.136.3.1227; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1985, DNA CLONING PRACTICA; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HEWITT SM, 1995, CANCER RES, V55, P5386; HSU SY, 1995, MOL ENDOCRINOL, V9, P1356, DOI 10.1210/me.9.10.1356; HUFF V, 1993, BIOCHIM BIOPHYS ACTA, V1155, P295, DOI 10.1016/0304-419X(93)90011-Z; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kennedy D, 1996, NAT GENET, V12, P329, DOI 10.1038/ng0396-329; KENT J, 1995, ONCOGENE, V11, P1781; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; Menke AL, 1996, ONCOGENE, V12, P537; MORRIS JF, 1991, ONCOGENE, V6, P2339; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; REDDY JC, 1995, J BIOL CHEM, V270, P29976; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; Semba K, 1996, GENE, V175, P167, DOI 10.1016/0378-1119(96)00143-6; SHARMA PM, 1994, P NATL ACAD SCI USA, V91, P9931, DOI 10.1073/pnas.91.21.9931; SHARMA PM, 1992, CANCER RES, V52, P6407; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1995, ONCOGENE, V10, P1243; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1994, J BIOL CHEM, V269, P12577; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878; Ye Y, 1996, EMBO J, V15, P5606, DOI 10.1002/j.1460-2075.1996.tb00945.x	59	48	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	1997	15	17					2001	2012		10.1038/sj.onc.1201391	http://dx.doi.org/10.1038/sj.onc.1201391			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366517				2022-12-17	WOS:A1997YC28400001
J	Yamaguchi, R; Mazaki, Y; Hirota, K; Hashimoto, S; Sabe, H				Yamaguchi, R; Mazaki, Y; Hirota, K; Hashimoto, S; Sabe, H			Mitosis specific serine phosphorylation and downregulation of one of the focal adhesion protein, paxillin	ONCOGENE			English	Article						focal adhesion proteins; mitosis; paxillin; phosphorylation; protein-degradation	I-KAPPA-B; UBIQUITIN-PROTEASOME PATHWAY; TUMOR-NECROSIS-FACTOR; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; CELL-ADHESION; BINDING-SITE; C-SRC	Mitotic cells typically lack well-formed focal adhesions, As an approach to explore the dynamic process regulating the focal adhesion assembly, we examined states of focal adhesion proteins during mitosis of the cell cycle. We found that the amount of paxillin was significantly reduced during mitosis of the cell cycle, whereas other focal adhesion proteins including talin, vinculin and Focal Adhesion Kinase did not. Proteolytic degradation appeared to be involved in the mitotic reduction, but transcriptional and/or translational controls of the mRNA were not essential for this downregulation. Moreover, concurrent with the decreased protein level, phosphorylation status of paxillin altered during mitosis; mitotic paxillin was phosphorylated primarily on serine and dephosphorylated on tyrosine while interphase one was phosphorylated both on serine and tyrosine. We found that mitotic phosphorylation created an electrophoretically slow-migrating population of paxillin which was barely detected in interphase cells. This mitotic specific modification occurred with both alpha and beta isoforms of paxillin. We also examined the fate of paxillin protein by changing its protein amount. We found that majority of paxillin overexpressed was subjected to the specific modification but not to the downregulation in the mitotic arrested cells. On the other hand, paxillin exogenously expressed at a moderate level was subjected to both the mitotic modification and downregulation. Collectively, we concluded that paxillin's specific serine phosphorylation together with the proteolytic downregulation of a limited fraction of paxillin is taken place during the mitosis of the cell cycle.	JAPAN SCI & TECHNOL CORP, PRECURSORY RES EMBRYON SCI & TECHNOL, SAKYO KU, KYOTO 606, JAPAN; KYOTO UNIV, INST VIRUS RES, KYOTO 606, JAPAN	Japan Science & Technology Agency (JST); Kyoto University			Sabe, Hisataka/A-4066-2012; Sabe, Hisataka/GPF-4385-2022; Hirota, Kiichi/E-9181-2010	Hirota, Kiichi/0000-0003-1110-0827; Yamaguchi, Ryuji/0000-0002-1706-7063; Mazaki, Yuichi/0000-0003-4192-0834				BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Mazaki Y, 1997, J BIOL CHEM, V272, P7437, DOI 10.1074/jbc.272.11.7437; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Moir RD, 1995, INT REV CYTOL, V162B, P141; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PFALLER R, 1995, J BIOL CHEM, V270, P19066, DOI 10.1074/jbc.270.32.19066; POMIES P, 1992, BIOCHEM BIOPH RES CO, V189, P1429, DOI 10.1016/0006-291X(92)90234-C; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; Sabe H, 1995, J BIOL CHEM, V270, P31219, DOI 10.1074/jbc.270.52.31219; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sambrooke J., 1989, MOL CLONING LAB MANU; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SIMOS G, 1992, EMBO J, V11, P4027, DOI 10.1002/j.1460-2075.1992.tb05496.x; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tanaka T, 1996, FEBS LETT, V399, P53, DOI 10.1016/S0014-5793(96)01280-X; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WOOD CK, 1994, J CELL SCI, V107, P709; YAMAGUCHI R, 1994, FEBS LETT, V356, P114, DOI 10.1016/0014-5793(94)01246-6	43	48	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	1997	15	15					1753	1761		10.1038/sj.onc.1201345	http://dx.doi.org/10.1038/sj.onc.1201345			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362441				2022-12-17	WOS:A1997XZ72500001
J	Pognonec, P; Boulukos, KE; Aperlo, C; Fujimoto, M; Ariga, H; Nomoto, A; Kato, H				Pognonec, P; Boulukos, KE; Aperlo, C; Fujimoto, M; Ariga, H; Nomoto, A; Kato, H			Cross-family interaction between the bHLHZip USF and bZip Fra1 proteins results in down-regulation of AP1 activity	ONCOGENE			English	Article						USF; Fra1; AP1; bHLHLZ interaction; transcription	HELIX-LOOP-HELIX; TRANSCRIPTION FACTOR USF; FOS-JUN; C-JUN; GLUCOCORTICOID RECEPTOR; LEUCINE-ZIPPER; DNA-BINDING; FUNCTIONAL ANTAGONISM; ANTITUMOR PROMOTION; INTERACTION CLONING	Heterodimerization among the basic-leucine zipper (bZIP) proteins or among the basic-helix-loop-helix-leucine zipper (bHLHZip) proteins confers a multitude of combinational activities to these transcription factors. To further examine the function of the bHLHZip protein, USF, we screened for cellular proteins which could directly interact with USF using the yeast two-hybrid system, A bZip protein, Fra1, was found to efficiently interact with USF. USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun. Both the bHLHZip and the N-terminal regions of Fra1 are required for efficient interaction with USF, In vivo association between USF and Fra1 has been demonstrated by co-immunoprecipitation. Expression of exogenous USF led to a decrease in AP1-dependent transcription in F9 cells. Co-expression of exogenous Fra1 restored the AP1 activity in a dose-dependent manner, These data show that USF and Fra1 physically and functionally interact demonstrating that cross-talk occurs between factors of distantly related transcription families.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,DEPT BIOL MOL,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MICROBIOL,MINATO KU,TOKYO 108,JAPAN	Hokkaido University; University of Tokyo	Pognonec, P (corresponding author), UNIV NICE,CTR BIOCHIM,PARC VALROSE,F-06108 NICE 2,FRANCE.		Ariga, Hiroyoshi/B-5895-2013	Ariga, Hiroyoshi/0000-0001-7384-2143				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Aperlo C, 1996, EUR J BIOCHEM, V241, P249, DOI 10.1111/j.1432-1033.1996.0249t.x; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; CHANG LA, 1992, NUCLEIC ACIDS RES, V20, P287, DOI 10.1093/nar/20.2.287; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOLETTA VC, 1994, ONCOGENE, V9, P3305; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KERPPOLA T, 1995, NATURE, V373, P199, DOI 10.1038/373199a0; KERPPOLA TK, 1994, ONCOGENE, V9, P675; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; READ ML, 1993, BIOCHEM J, V295, P233, DOI 10.1042/bj2950233; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WISDOM R, 1993, MOL CELL BIOL, V13, P2635, DOI 10.1128/MCB.13.5.2635; YANG-YEN H-F, 1990, New Biologist, V2, P351; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	54	48	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2091	2098		10.1038/sj.onc.1201046	http://dx.doi.org/10.1038/sj.onc.1201046			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160889				2022-12-17	WOS:A1997WW80900011
J	Sweeney, KJ; Sarcevic, B; Sutherland, RL; Musgrove, EA				Sweeney, KJ; Sarcevic, B; Sutherland, RL; Musgrove, EA			Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells	ONCOGENE			English	Article						cyclin D2; cyclin D1; breast cancer; CDK	G1 PHASE PROGRESSION; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; DEPENDENT KINASES; GROWTH-FACTOR; CANCER-CELLS; D1 PROTEIN; DIFFERENTIAL EXPRESSION; HEMATOPOIETIC-CELLS; MAMMALIAN-CELLS	To investigate the possibility of differing roles for cyclins D1 and D2 in breast epithelial cells, we examined the expression, cell cycle regulation and activity of these two G(1) cyclins in both 184 normal breast epithelial cells and T-47D breast cancer cells. Synchromisation studies in 184 cells demonstrated that cyclin D1 and cyclin D2 were differentially regulated during G(1), with cyclin D2 abundance increasing by 3.7-fold but only small changes in cyclin D1 abundance observed. The functional consequences of increased cyclin D2 expression were examined in T-47D cells, which express no detectable cyclin D2, Induced expression of cyclin D2 resulted in increases in cyclin E expression, pRB phosphorylation and the percentage of cells in S-phase, while constitutive expression resulted in a consistent trend toward reduced dependence on serum for continued proliferation. Thus, cyclin D2 is a positive regulator of G(1) progression in breast cells analogous to the well-documented effects of cyclin D1. Indeed, equimolar concentrations of inducible cyclin D1 and D2 resulted in quantitatively similar cell cycle effects. Marked divergence was found, however, in the CDKs activated by the two cyclins in breast epithelial cells. Cyclin D2 complexes contained a higher Cdk2/Cdk4 ratio than cyclin D1 complexes. The cyclin D2-associated kinase activity was largely inhibited by Cdk2-specific inhibitors and could phosphorylate histone H1, a substrate for Cdk2 but not for Cdk4 and Cdk6. Therefore, cyclin D2 preferentially activated Cdk2 in breast epithelial cells. In contrast, Cdk4 and Cdk6 were predominantly responsible for cyclin D1-associated kinase activity as previously reported. Thus, although cyclins D1 and D2 elicited similar effects on breast epithelial cell cycle progression they appeared to achieve this end via activation of different CDKs. This is the first evidence of cyclin D2 activating Cdk2 in mammalian cells thus providing further evidence that D-type cyclins are not necessarily redundant.	ST VINCENTS HOSP, GARVAN INST MED RES, CANC RES PROGRAM, DARLINGHURST, NSW 2010, AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney			Sutherland, Robert L/A-8378-2008	Sarcevic, Boris/0000-0002-8063-1050				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; ANDO K, 1995, ONCOGENE, V10, P751; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1995, ONCOGENE, V10, P775; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1994, ONCOGENE, V9, P71; Botz J, 1996, MOL CELL BIOL, V16, P3401; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DALY RJ, 1991, CELL GROWTH DIFFER, V2, P457; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Geng Y, 1996, ONCOGENE, V12, P1173; GILLETT C, 1994, CANCER RES, V54, P1812; GLAB N, 1994, FEBS LETT, V353, P207, DOI 10.1016/0014-5793(94)01035-8; HARPER JW, 1993, CELL, V75, P805; Higashi H, 1996, EUR J BIOCHEM, V237, P460, DOI 10.1111/j.1432-1033.1996.0460k.x; Hui R, 1996, CLIN CANCER RES, V2, P923; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, ONCOGENE, V8, P3447; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KRANENBURG O, 1995, ONCOGENE, V10, P87; Lilischkis R, 1996, INT J CANCER, V66, P249, DOI 10.1002/(SICI)1097-0215(19960410)66:2<249::AID-IJC19>3.0.CO;2-7; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1995, ONCOGENE, V10, P2125; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Musgrove EA, 1996, J CELL BIOCHEM, V60, P363; MUSGROVE EA, 1989, CANCER RES, V49, P2398; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PALMERO I, 1993, ONCOGENE, V8, P1049; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REDDEL RR, 1984, CANCER RES, V44, P2398; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SWEENEY KJE, 1996, MAMMARY TUMOR CELL C, P141; TAM SW, 1994, ONCOGENE, V9, P2663; TAM SW, 1994, CANCER RES, V54, P5816; TSAI LH, 1993, ONCOGENE, V8, P1593; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	63	48	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	1997	14	11					1329	1340		10.1038/sj.onc.1200951	http://dx.doi.org/10.1038/sj.onc.1200951			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178893				2022-12-17	WOS:A1997WP10900008
J	Besser, D; Bardelli, A; Didichenko, S; Thelen, M; Comoglio, PM; Ponzetto, C; Nagamine, Y				Besser, D; Bardelli, A; Didichenko, S; Thelen, M; Comoglio, PM; Ponzetto, C; Nagamine, Y			Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2	ONCOGENE			English	Article						GRB2; hepatocyte growth factor; plasminogen activator; signal transduction; Tpr-Met	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; RECEPTOR TYROSINE KINASE; DEPENDENT PROTEIN-KINASE; DOMINANT-NEGATIVE MUTANT; PHOSPHATIDYLINOSITOL 3-KINASE; HGF RECEPTOR; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; SH2 DOMAINS	The oncogene Tpr-Met is a constitutively active form of the hepatocyte growth factor/scatter factor (HGF/SF) receptor Met. It comprises the intracellular moiety of Met linked to the dimerization domain of the nuclear envelope protein Tpr, thus functioning as a constitutively activated Met, HGF/SF is responsible for various biological processes including angiogenesis and wound healing, in which secreted serine protease urokinase-type plasminogen activator (uPA) is implicated, The action of HGF/SF on cells is mediated by the autophosphorylation of Met on two carboxyterminal tyrosine Y(1349)VHVNATVY(1356)VNV. The two tyrosine provide docking sites for various effector molecules, suggesting that multiple signaling pathways are activated to exert biological effects of HGF/SF [Ponzetto et al., Cell (1994) 77: 261], We found that Tpr-Met efficiently activates the uPA gene via a SOS/Ras/extracellular signal regulated kinase (ERK)-dependent signaling pathway, Mutation of Y-1356, which abrogates GRB2 binding, reduced the induction to half of the control level, while mutation of Y-1349 showed little effect on uPA induction, suggesting an important but partly replaceable role for GRB2 in Met-dependent uPA gene induction, Mutation of both (YVHV)-V-1349 and (YVNV)-V-1356 into optimal PI 3-kinase sites resulted in a residual induction of about one quarter of the control level, suggesting a potential role for PI 3-kinase, Dose-response analysis of the Tpr-Met showed a biphasic curve, These results suggest that the interplay among different signaling molecules on the receptor is important for full induction of the pathway leading to the activation of the uPA gene.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,I-10126 TURIN,ITALY; UNIV BERN,THEODOR KOCHER INST,CH-3012 BERN,SWITZERLAND; UNIV TURIN,SCH MED,CANC RES INST,I-10126 TURIN,ITALY	Friedrich Miescher Institute for Biomedical Research; University of Turin; University of Bern; University of Turin			Besser, Daniel/A-8304-2012; BARDELLI, Alberto/J-9721-2018	Besser, Daniel/0000-0002-4958-9624; Comoglio, Paolo/0000-0002-7056-5328; BARDELLI, Alberto/0000-0003-1647-5070				BARDELLI A, 1992, ONCOGENE, V7, P1973; Besser D, 1995, ONCOGENE, V11, P2383; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; Blasi F, 1990, Semin Cancer Biol, V1, P117; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOTTERI FM, 1990, J BIOL CHEM, V265, P13327; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; CASSADY AI, 1991, NUCLEIC ACIDS RES, V19, P6839, DOI 10.1093/nar/19.24.6839; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEGEN JL, 1985, J BIOL CHEM, V260, P2426; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GUALANDRIS A, 1995, J CELL PHYSIOL, V162, P400, DOI 10.1002/jcp.1041620312; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; LEE JS, 1994, J BIOL CHEM, V269, P2887; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; LEE JS, 1994, NUCLEIC ACIDS RES, V22, P569, DOI 10.1093/nar/22.4.569; LONGATI P, 1994, ONCOGENE, V9, P49; MENOUD PA, 1993, NUCLEIC ACIDS RES, V21, P1845, DOI 10.1093/nar/21.8.1845; NAGAMINE Y, 1991, EMBO J, V10, P117, DOI 10.1002/j.1460-2075.1991.tb07927.x; NAGAMINE Y, 1995, FIBRINOLYSIS DIS; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RUSCIANO D, 1995, ONCOGENE, V11, P1979; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SONGYANG Z, 1993, CELL, V72, P1; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TIENARI J, 1991, CELL REGUL, V2, P285, DOI 10.1091/mbc.2.4.285; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VONDERAHE D, 1990, NUCLEIC ACIDS RES, V18, P1991, DOI 10.1093/nar/18.8.1991	54	48	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					705	711		10.1038/sj.onc.1200879	http://dx.doi.org/10.1038/sj.onc.1200879			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038378				2022-12-17	WOS:A1997WG43000009
J	Koreth, J; Bakkenist, CJ; McGee, JO				Koreth, J; Bakkenist, CJ; McGee, JO			Allelic deletions at chromosome 11q22-q23.1 and 11q25-qterm are frequent in sporadic breast but not colorectal cancers	ONCOGENE			English	Article						LOH; breast; colorectal; cancer; microsatellites; chromosome 11q	ATAXIA-TELANGIECTASIA; GENETIC ALTERATIONS; CERVICAL-CARCINOMA; MALIGNANT-MELANOMA; OVARIAN-CANCER; LONG ARM; HETEROZYGOSITY; TUMORS; REGION; 11Q23	We identified the chromosome 11q23 region as containing a putative tumour suppressor gene(s) frequently deleted in nonfamilial breast and other cancers. To define this region(s) further, we performed a systematic genetic analysis at chromosome 11q14-qterm in sporadic breast and colorectal cancer, Tumour and constitutional DNA from a panel of 81 cases (51 breast and 30 colorectal cancers) were analysed with multiple microsatellite markers distal to 11q13. Of 51 breast cancers, 31 of 49 informative cases (63%) showed LOH at the 11q22-q23.1 region (similar to 8 Mb). Furthermore, 23 of 45 informative cases (51%) had a deletion at 11q25 (similar to 2 Mb), Overall, LOH on 11q occurred in 37 of 51 breast cancers (72%). Colorectal cancers had LOH at 11q22 in two of 18 informative cases (11%), LOH at 11q23.3 in two of 17 informative cases (12%) and LOH at 11q25 in three of 20 informative cases (15%). Overall, LOH at 11q occurred in five of 30 colorectal cancers (16%), This data shows that chromosome 11q contains at least two independent regions (one novel) frequently deleted in breast cancers. Contrary to previous reports, LOH at distal 11q is not frequent in colorectal cancer. Chromosome 11q22-q23.1 and 11q25-qterm contain putative tumour suppressor genes with a significant role in breast but not colorectal carcinogenesis.	UNIV OXFORD, NUFFIELD DEPT PATHOL & BACTERIOL, JOHN RADCLIFFE HOSP, OXFORD OX3 9DU, ENGLAND	University of Oxford								Baffa R, 1996, CANCER RES, V56, P268; BETHWAITE PB, 1995, BRIT J CANCER, V71, P814, DOI 10.1038/bjc.1995.157; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; CARTER SL, 1994, CANCER RES, V54, P6270; CAWKWELL L, 1993, BRIT J CANCER, V67, P1262, DOI 10.1038/bjc.1993.236; Coleman A., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P196; Davis M, 1996, CANCER RES, V56, P741; DEVILEE P, 1994, GENE CHROMOSOME CANC, V11, P71, DOI 10.1002/gcc.2870110202; FORD D, 1995, BRIT J CANCER, V72, P805, DOI 10.1038/bjc.1995.417; FOULKES WD, 1993, BRIT J CANCER, V67, P268, DOI 10.1038/bjc.1993.51; Gabra H, 1996, CANCER RES, V56, P950; GABRA H, 1995, BRIT J CANCER, V72, P367, DOI 10.1038/bjc.1995.340; GUDMUNDSSON J, 1995, BRIT J CANCER, V72, P696, DOI 10.1038/bjc.1995.396; GUSTAFSON CE, 1994, BRIT J CANCER, V70, P395, DOI 10.1038/bjc.1994.315; HAMPTON GM, 1994, CANCER RES, V54, P4586; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HERBST RA, 1995, CANCER RES, V55, P2494; KELDYSH PL, 1993, GENE CHROMOSOME CANC, V6, P45, DOI 10.1002/gcc.2870060109; KORETH J, 1995, J PATHOL, V176, P11, DOI 10.1002/path.1711760104; LASKEY RA, 1990, RADIOISOTOPES BIOL P, P87; LITT M, 1995, GENOMICS, V27, P101, DOI 10.1006/geno.1995.1011; NEGRINI M, 1994, CANCER RES, V54, P1331; NEGRINI M, 1995, CANCER RES, V55, P3003; PARSHAD R, 1992, HUM GENET, V88, P524, DOI 10.1007/BF00219338; RASIO D, 1995, CANCER RES, V55, P3988; SATO T, 1990, CANCER RES, V50, P7184; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SHAW ME, 1995, GENE CHROMOSOME CANC, V13, P1, DOI 10.1002/gcc.2870130102; STICKLAND JE, 1992, BR J CANCER S17, V66, P3; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TOMLINSON IPM, 1993, GENE CHROMOSOME CANC, V7, P169, DOI 10.1002/gcc.2870070310; Tomlinson IPM, 1996, J CLIN PATHOL, V49, P386, DOI 10.1136/jcp.49.5.386; VANHEYNINGEN V, 1995, CYTOGENET CELL GENET, V69, P128, DOI 10.1159/000133953; WINQVIST R, 1995, CANCER RES, V55, P2660	36	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	1997	14	4					431	437		10.1038/sj.onc.1200847	http://dx.doi.org/10.1038/sj.onc.1200847			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053840				2022-12-17	WOS:A1997WE36400006
J	McMasters, KM; Luna, RMD; Pena, JR; Lozano, G				McMasters, KM; Luna, RMD; Pena, JR; Lozano, G			mdm2 Deletion does not alter growth characteristics of p53-deficient embryo fibroblasts	ONCOGENE			English	Article						G(1) arrest; genomic instability; p53 null cells	WILD-TYPE P53; SOFT-TISSUE SARCOMAS; GENE AMPLIFICATION; MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2; PROTEIN; ABNORMALITIES; LETHALITY; APOPTOSIS; ONCOGENE	The mdma gene encodes a protein that is necessary for the negative regulation of p53 function in vivo. Deletion of the mdm2 gene in mice results in early embryonic death while concomitant mdm2 and p53 deletion results in viable offspring. The viability of these mice prompted us to ask if MDM2, had an important growth regulatory function independent of p53. We established mouse embryo fibroblasts null for both p53 and mdma and compared them with p53-null fibroblasts. The cells did not differ in their growth rates or their ability to bypass a G(1) arrest. Both cell lines formed colonies efficiently when plated at low density and showed a similar degree of genetic instability. Thus, the analysis of several growth parameters indicated no difference between p53-null and p53/mdm2-null cell lines.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT SURG ONCOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA47296] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047296, R29CA047296] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARVEY M, 1993, ONCOGENE, V8, P2457; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; LADANYI M, 1993, CANCER RES, V53, P16; LEACH FS, 1993, CANCER RES, V53, P2231; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUNA RMD, 1995, NATURE, V378, P203; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; QUESNEL B, 1994, EUR J CANCER, V30A, P982, DOI 10.1016/0959-8049(94)90128-7; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SHEIKH MS, 1993, CANCER RES, V53, P3226; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	30	48	49	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1731	1736						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895519				2022-12-17	WOS:A1996VM88700018
J	Juan, TSC; McNiece, IK; Jenkins, NA; Gilbert, DJ; Copeland, NG; Fletcher, FA				Juan, TSC; McNiece, IK; Jenkins, NA; Gilbert, DJ; Copeland, NG; Fletcher, FA			Molecular characterization of mouse and rat CPP32 beta gene encoding a cysteine protease resembling interleukin-1 beta converting enzyme and CED-3	ONCOGENE			English	Article						cysteine protease; apoptosis, CED-3; gene structure	PROGRAMMED CELL-DEATH; IL-1-BETA-CONVERTING ENZYME; C-ELEGANS; POLY(ADP-RIBOSE) POLYMERASE; CAENORHABDITIS-ELEGANS; MAMMALIAN HOMOLOG; MICE DEFICIENT; APOPTOSIS; IDENTIFICATION; INDUCTION	Interleukin-1 beta converting enzyme (ICE) defines a new class of mammalian cysteine protease that shares strong homology with the Caenorhabditis elegans death gene ced-3, Both ICE and CED-3, when introduced into cultured cells, induce apoptosis, indicating that this type of cysteine protease may play an important role in the process of programmed cell death, Here, we report the cloning of a mouse and rat gene encoding a novel cysteine protease. The putative proteins encoded by these cDNAs contain the conserved sequence (QACRG) necessary for covalent linkage to the substrate as well as the three amino acids responsible for substrate binding and catalysis in ICE, Amino acid sequence analysis indicates that this rodent cysteine protease is the homolog of human CPP32 beta, Mouse CPP32 beta mRNA is highly expressed in spleen, and to a lesser degree in brain, lung, liver, and kidney, The mouse CPP32 beta genomic locus spans a region of approximately 20 kb, including seven exons and six introns, Mouse interspecific backcross mapping allowed localization of CPP32 beta to the central region of mouse chromosome 8, linked to Scvr, Lpl, Jund1 and Mlr.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Juan, TSC (corresponding author), AMGEN INC,DEPT DEV HEMATOL,1840 DEHAVILLAND DR,THOUSAND OAKS,CA 91320, USA.							BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; CASANO FJ, 1994, GENOMICS, V20, P474, DOI 10.1006/geno.1994.1203; CERRETTI DP, 1994, GENOMICS, V20, P468, DOI 10.1006/geno.1994.1202; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fichant Gwennaele A., 1992, Human Molecular Genetics, V1, P259, DOI 10.1093/hmg/1.4.259; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Green EL, 1981, GENETICS PROBABILITY, P77; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HOFFMAN B, 1994, ONCOGENE, V9, P1807; JENKINS NA, 1981, J VIROL, V43, P269; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; STEINGRIMSSON E, 1995, GENOMICS, V28, P179, DOI 10.1006/geno.1995.1129; TERAJIMA M, 1994, J BIOCHEM-TOKYO, V116, P1105, DOI 10.1093/oxfordjournals.jbchem.a124634; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	36	48	54	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					749	755						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761296				2022-12-17	WOS:A1996VD43300010
J	Khwaja, A; Hallberg, B; Warne, PH; Downward, J				Khwaja, A; Hallberg, B; Warne, PH; Downward, J			Networks of interaction of p120(cbl) and p130(cas) with Crk and Grb2 adaptor proteins	ONCOGENE			English	Article						Cb1; Grb2; Crk; oncogene; tyrosine phosphorylation	RECEPTOR TYROSINE KINASES; V-CBL ONCOGENE; SH3 DOMAINS; IDENTIFICATION; TRANSFORMATION; ASSOCIATION; TRUNCATION; BINDS; CELLS	P120(cbl), the product of the c-cbl proto-oncogene, has previously been shown to become tyrosine phosphorylated following EGF stimulation of cells, and to bind constitutively to the SH3 domain of the adaptor protein Grb2. Here we show that another adaptor protein, Crk, binds through its SH2 domain to tyrosine phosphorylated p120(cbl). In addition, Crk becomes phosphorylated on tyrosine and serine following EGF treatment of PC12 and other cell lines. In unstimulated cells, while Grb2 is not bound to any tyrosine phosphoprotein, Crk is bound via its SH2 domain to tyrosine phosphorylated p130(cas), the Crk-associated v-Src substrate. Following EGF treatment, Crk dissociates from p130(cas), possibly due to a higher affinity of Crk SH2 for p120(cbl) compared with p130(cas). Interaction between Grb2 and p120(cbl) increases threefold following EGF treatment of cells; in vitro, this induction of Grb2 association with unphosphorylated p120(cbl) can be mimicked by the addition of tyrosine phosphorylated She, suggesting a transfer of information between the SH2 and SH3 domains of Grb2. These data indicate that adaptor proteins can exchange binding partners in response to stimuli, and that different adaptor proteins can bind to the same partners by different mechanisms.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Khwaja, Asim/C-1509-2008	Downward, Julian/0000-0002-2331-4729				ADCOCK MR, 1993, NATURE, V363, P83; ADCOCK MR, 1992, NATURE, V360, P689; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; LEZCANO OMR, 1994, J BIOL CHEM, V269, P17363; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PATCH LA, 1995, J CELL SCI, V108, P1371; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; RANKIN S, 1994, J BIOL CHEM, V269, P704; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; REGNIER DC, 1989, J VIROL, V63, P3678, DOI 10.1128/JVI.63.9.3678-3682.1989; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	48	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2491	2498						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700507				2022-12-17	WOS:A1996UW48700002
J	Varley, JM; McGown, G; Thorncroft, M; Cochrane, S; Morrison, P; Woll, P; Kelsey, AM; Mitchell, ELD; Boyle, J; Birch, JM; Evans, DGR				Varley, JM; McGown, G; Thorncroft, M; Cochrane, S; Morrison, P; Woll, P; Kelsey, AM; Mitchell, ELD; Boyle, J; Birch, JM; Evans, DGR			A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni syndrome	ONCOGENE			English	Article						TP53; Li-Fraumeni; codon 344; tetramerisation domain	NORMAL KIDNEY TISSUE; BREAST-CANCER; P53 MUTATIONS; GERM; CHROMOSOME; GENE	We report details of a family with classic Li-Fraumeni syndrome in which there is a mutation in codon 344 of the tumour suppressor gene TP53, Codon 344 is a key residue within the tetramerisation domain, and the amino acid substitution of a proline for a leucine is predicted to have profound implications for tetramerisation and potentially DNA binding, This is the first report of a mutation at this residue in either sporadic tumours or in the germline and the first report of a germline mutation within the tetramerisation domain, The family does not appear to be remarkable in the spectrum of tumours, and there is loss of the wild-type allele in a leiomyosarcoma from the proband. A cell line has been established from the tumour of the proband and cytogenetic and molecular studies carried out, providing an extensive analysis in this family.	CITY HOSP,DEPT CLIN GENET,NOTTINGHAM NG5 1PB,ENGLAND; QUEENS MED CTR,DEPT MED ONCOL,NOTTINGHAM NG7 2UH,ENGLAND; ROYAL MANCHESTER CHILDRENS HOSP,PAEDIAT & FAMILIAL CANC RES GRP,CRC,MANCHESTER M27 4HA,LANCS,ENGLAND; ROYAL MANCHESTER CHILDRENS HOSP,DEPT HISTOPATHOL,MANCHESTER M27 4HA,LANCS,ENGLAND	University of Nottingham; University of Nottingham; Royal Manchester Children's Hospital; Royal Manchester Children's Hospital	Varley, JM (corresponding author), PATERSON INST CANC RES,DEPT CANC GENET,CRC,WILMSLOW RD,MANCHESTER M20 9BX,LANCS,ENGLAND.		Evans, D Gareth/AAB-4308-2022	Evans, D Gareth/0000-0002-8482-5784; Woll, Penella/0000-0002-1118-0831				BIRCH JM, 1994, BRIT J CANCER, V70, P1176, DOI 10.1038/bjc.1994.468; BIRCH JM, 1990, J PATHOL, V161, P1, DOI 10.1002/path.1711610102; BIRCH JM, 1994, EUR J CANCER, V30A, P1935, DOI 10.1016/0959-8049(94)00383-G; BORRESEN AL, 1992, CANCER RES, V52, P3234; CHEN PC, 1995, CANCER GENET CYTOGEN, V82, P106, DOI 10.1016/0165-4608(94)00213-U; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DILLER L, 1995, J CLIN INVEST, V95, P1606, DOI 10.1172/JCI117834; ELFVING P, 1990, CYTOGENET CELL GENET, V53, P123, DOI 10.1159/000132910; EMANUEL A, 1992, GENE CHROMOSOME CANC, V4, P75, DOI 10.1002/gcc.2870040110; FREBOURG T, 1995, AM J HUM GENET, V56, P608; HOGGARD N, 1995, CHROMOSOME RES, V3, P137, DOI 10.1007/BF00710677; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; ISHIOKA C, 1995, ONCOGENE, V10, P1485; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KYRITSIS AP, 1994, JNCI-J NATL CANCER I, V86, P344, DOI 10.1093/jnci/86.5.344; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCINTYRE JF, 1994, J CLIN ONCOL, V12, P925, DOI 10.1200/JCO.1994.12.5.925; SAMESHIMA Y, 1992, J NATL CANCER I, V84, P703, DOI 10.1093/jnci/84.9.703; SHISEKI M, 1993, CANCER LETT, V73, P51, DOI 10.1016/0304-3835(93)90187-E; SIDRANSKY D, 1992, CANCER RES, V52, P2984; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; VARLEY JM, 1995, J MED GENET, V32, P946; WAGNER J, 1994, JNCI-J NATL CANCER I, V86, P1707, DOI 10.1093/jnci/86.22.1707	25	48	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2437	2442						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649785				2022-12-17	WOS:A1996UQ22000022
J	Wertheim, I; Tangir, J; Muto, MG; Welch, WR; Berkowitz, RS; Chen, WY; Mok, SC				Wertheim, I; Tangir, J; Muto, MG; Welch, WR; Berkowitz, RS; Chen, WY; Mok, SC			Loss of heterozygosity of chromosome 17 in human borderline and invasive epithelial ovarian tumors	ONCOGENE			English	Article						ovary; borderline; loss of heterozygosity; microsatellite instability	GENE-MUTATIONS; FREQUENT LOSS; CANCER LOCUS; P53 GENE; MALIGNANCY; DELETION	Polymerase chain reaction (PCR) analysis of microsatellite polymorphisms corresponding to four loci which map to chromosome 17p and 11 loci which map to chromosome 17q was performed to screen for loss of heterozygosity (LOH) in paired normal and tumor tissues from 27 cases of borderline epithelial ovarian tumors (BEOT) and 32 cases of invasive epithelial ovarian cancers (IOC), LOH was observed in six of 27 (22%) of the borderline tumors and in 29 of 32 (90%) of the invasive ovarian cancers (P<0.001), At all 15 loci studied, a lower percentage of allelic loss was detected in borderline tumors (0-14%) vs invasive cancer (8-93%), At eight loci this difference was statistically significant, For IOC, one common loss region was identified on chromosome 17p and four distinct common loss regions were on chromosome 17q, which supports the notion that multiple tumor suppressors may reside on chromosome 17 in IOC. These data suggest that LOH on chromosome 17 is an infrequent event in BEOT compared with IOC and therefore may not be important in the distinct pathogenesis of BEOT.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV GYNECOL ONCOL,LAB GYNECOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,DIV WOMENS & PERINATAL PATHOL,BOSTON,MA 02115; CHINESE UNIV HONG KONG,DEPT ANAT,SHATIN,HONG KONG	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Chinese University of Hong Kong			Chan, Wood Yee/R-6692-2018	Chan, Wood Yee/0000-0002-7114-1463	NATIONAL CANCER INSTITUTE [R01CA063381] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA63381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERCHUCK A, 1994, GYNECOL ONCOL, V52, P232, DOI 10.1006/gyno.1994.1037; CROPP CS, 1994, CANCER RES, V54, P2548; ECCLES DM, 1992, ONCOGENE, V7, P2069; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GODWIN AK, 1994, AM J HUM GENET, V55, P666; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; International Federation of Gynecology and Obstetrics (FIGO), 1987, AM J OBSTET GYNECOL, V56, P263; JACOBS IJ, 1993, CANCER RES, V53, P1218; KAERN J, 1993, CANCER, V71, P1810, DOI 10.1002/1097-0142(19930301)71:5<1810::AID-CNCR2820710516>3.0.CO;2-V; KUPRYJANCZYK J, 1993, P NATL ACAD SCI USA, V90, P4961, DOI 10.1073/pnas.90.11.4961; LEE JH, 1990, CANCER RES, V50, P2724; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MARKS JR, 1991, CANCER RES, V51, P2979; MOK CH, 1992, CANCER RES, V52, P5119; Mok S. C., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P571; MOK SCH, 1993, CANCER RES, V53, P1489; NAROD SA, 1991, LANCET, V338, P82; PIERETTI M, 1995, HUM PATHOL, V26, P393, DOI 10.1016/0046-8177(95)90139-6; RICE LW, 1990, GYNECOL ONCOL, V39, P195, DOI 10.1016/0090-8258(90)90431-J; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; Sambrook J, 1989, MOL CLONING LAB MANU; SATO T, 1991, CANCER RES, V51, P5118; Serov S., 1973, INT HISTOLOGICAL CLA, V9; TANGIR J, 1996, IN PRESS ONCOGENE; TENERIELLO MG, 1993, CANCER RES, V53, P3103; TSAO SW, 1991, ANTICANCER RES, V11, P1975; WEITZEL JN, 1994, GYNECOL ONCOL, V55, P245, DOI 10.1006/gyno.1994.1285; WERTHEIM I, 1994, J NATL CANCER I, V86, P1549, DOI 10.1093/jnci/86.20.1549	30	48	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2147	2153						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668340				2022-12-17	WOS:A1996UP28300013
J	Guerrero, C; Rojas, JM; Chedid, M; Esteban, LM; Zimonjic, DB; Popescu, NC; deMora, JF; Santos, E				Guerrero, C; Rojas, JM; Chedid, M; Esteban, LM; Zimonjic, DB; Popescu, NC; deMora, JF; Santos, E			Expression of alternative forms of Ras exchange factors GRF and SOS1 in different human tissues and cell lines	ONCOGENE			English	Article						Ras; hGRF; hSOS1; expression; alternative splicing	NUCLEOTIDE-RELEASING FACTOR; RECEPTOR TYROSINE KINASES; SACCHAROMYCES-CEREVISIAE; DROSOPHILA SON; SEVENLESS GENE; IDENTIFICATION; HOMOLOGS; PROTEINS; GRB2; CDNAS	DNA probes and antibodies specific for different coding regions of human SOS1 and GRF genes were used to screen expression of these genes in a variety of adult and fetal human tissues and cell lines. Despite previous reports of the exclusive expression of hGRF RNA in brain, we also observed expression of this gene in various other tissues including lung and pancreas, as web as several tumor cell lines. At least three different hGRF mRNA transcripts were observed depending on the probe used, with the larger transcripts being detected by probes corresponding to the 5' end of the gene while smaller transcripts were detected by probes corresponding to the 3' end. Expression of hSOS1-related transcripts was more ubiquitous and homogeneous than with hGRF, with similar levels of specific transcripts being detected in most tissues and cell lines tested. Three to five different transcripts were detected in human tissues when using probes for the 5' end and middle regions of this gene, whereas only two were detected with probes corresponding to the 3' end. Screening of multiple human tumor cell lines showed ubiquitous expression of three specific transcripts, although the level and ratio of each of these transcripts varied widely among individual cell lines. Consistent with the variety of transcripts detected, several protein forms were also identified in Western immunoblots with antisera raised against specific domains of hSOS1 and human Ras-GRF gene products. Fluorescence in situ chromosomal hybridization suggested that, in both cases, the multiple forms arise from single chromosomal loci. The heterogeneity of hGRF and hSOS1 gene products detected (which appear to retain in most cases a functional catalytic domain), suggests that differentially expressed, alternatively spliced hSOS1 and hGRF forms may contribute to fine regulation of Ras activation in different tissues or at different stages of development.	NCI, DBS, CELLULAR & MOLEC BIOL LAB, NATL INST HLTH, BETHESDA, MD 20892 USA; NCI, DBS, BIOL LAB, NATL INST HLTH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Rojas, José M/D-3718-2018; Rojas, José M./AAA-3354-2021; de Mora, Jaime Font/H-6304-2015; Zimonjic, Drazen/AAX-7513-2020; Guerrero, Carmen/F-1776-2010; de Mora, Jaime Font/AAK-7591-2021	Rojas, José M/0000-0002-5383-3482; Rojas, José M./0000-0002-7547-2825; de Mora, Jaime Font/0000-0002-6816-2095; Guerrero, Carmen/0000-0002-8747-6831; de Mora, Jaime Font/0000-0002-6816-2095				BEALL JA, 1986, J IMMUNOL METHODS, V86, P217, DOI 10.1016/0022-1759(86)90456-4; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHARDIN P, 1994, CYTOGENET CELL GENET, V66, P68, DOI 10.1159/000133667; CHEN LP, 1993, DEV GENET, V14, P339, DOI 10.1002/dvg.1020140503; DALY RJ, 1994, ONCOGENE, V9, P2723; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; FATH I, 1993, NUCLEIC ACIDS RES, V21, P4398, DOI 10.1093/nar/21.18.4398; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FERRARI C, 1994, EXP CELL RES, V210, P353, DOI 10.1006/excr.1994.1048; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MUSACCHIO A, 1994, TRENDS BIOCHEM SCI, V19, P349; POPESCU N, 1994, GENOMICS, V20, P333, DOI 10.1006/geno.1994.1182; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHWEIGHOFFER F, 1993, ONCOGENE, V8, P1477; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; WEBB GC, 1993, GENOMICS, V18, P14, DOI 10.1006/geno.1993.1421; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WEI W, 1994, GENE, V151, P279, DOI 10.1016/0378-1119(94)90671-8; ZIMONJIC DB, 1994, CYTOGENET CELL GENET, V65, P184, DOI 10.1159/000133628; ZIMONJIC DB, 1995, CANCER GENET CYTOGEN, V80, P100, DOI 10.1016/0165-4608(94)00161-4	34	48	49	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1097	1107						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649802				2022-12-17	WOS:A1996UA88400019
J	Mao, C; RayGallet, D; Tavitian, A; MoreauGachelin, F				Mao, C; RayGallet, D; Tavitian, A; MoreauGachelin, F			Differential phosphorylations of Spi-B and Spi-1 transcription factors	ONCOGENE			English	Article						Spi-1; PU.1 and Spi-B; pRb; SAP kinases; ERK1; affinity chromatography	PU.1 REGULATES EXPRESSION; PUTATIVE ONCOGENE SPI-1; DNA-BINDING MOTIF; ETS GENE FAMILY; RETINOBLASTOMA PROTEIN; ACTIVATION DOMAIN; CHAIN GENE; IDENTIFICATION; SEQUENCE; KINASE	Spi-1/PU-1 and Spi-B are hematopoietic transcription factors which, in vitro, display similar affinities for DNA target sequences containing the consensus binding site 5'GGAA-3'. While the role of Spi-1 in the transcriptional regulation of B cell and myeloid specific genes has been largely demonstrated, the biological function of Spi-B still remains to be elucidated. Since Spi-B and Spi-1 are very divergent in their transactivator domain, these domains might acquire functional specificity in vivo by interacting with different co-factors and/or by undergoing different phosphorylations. First, we observed that casein kinase II phosphorylates Spi-B as well as Spi-1, in vitro, Then. by affinity chromatographies and in vitro kinase assays with fusion proteins between glutathione-S-transferase and the transactivator domain of Spi-B, two kinases were identified on their ability to interact and phosphorylate this domain; the MAP kinase ERK1 and the stress activated protein kinase JNK1. The Threonine 56 was defined as the ERK1 phosphorylation site by using phosphoamino-acid analyses and a Spi-B mutant version with the substitution T56 to A56. Strikingly, ERK1 failed to phosphorylate Spi-1, in vitro, whereas JNK1, like CK II, phosphorylated Spi-B and Spi-1. In addition, other purified Spi-B-kinase activities, unidentified as yet, display similar specificity than ERK1 for Spi-B versus Spi-1. Furthermore, the evident interaction of pRb protein with the transactivator domain of Spi-B in an unphosphorylated state disappeared when this domain was first phosphorylated in vitro either by ERK1 or by the purified Spi-B-kinase activities. Our data revealed multiple phosphorylation sites within Spi-B whose some of them appeared specific for Spi-B versus Spi-1 and which may account for differential regulation of their activities.	FAC MED LARIBOISIERE, INSERM, U248, F-75010 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Ray-Gallet, Dominique/A-9224-2019					ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BIRD TA, 1994, J BIOL CHEM, V269, P31836; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; RAYGALLET D, 1995, ONCOGENE, V11, P303; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSS IL, 1994, ONCOGENE, V9, P121; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	55	48	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					863	873						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632909				2022-12-17	WOS:A1996TW68600018
J	vanGrunsven, LA; Thomas, A; Urdiales, JL; Machenaud, S; Choler, P; Durand, I; Rudkin, BB				vanGrunsven, LA; Thomas, A; Urdiales, JL; Machenaud, S; Choler, P; Durand, I; Rudkin, BB			Nerve growth factor-induced accumulation of PC12 cells expressing cyclin D1: Evidence for a G1 phase block	ONCOGENE			English	Article						NGF; PC12; cyclin D1; flow cytometry; cell cycle; differentiation	PHEOCHROMOCYTOMA CELLS; DIFFERENTIATION; DNA; OVEREXPRESSION; PROGRESSION; FIBROBLASTS; METABOLISM; PROTEIN; G(1); LINE	The anti-proliferative effect of nerve growth factor (NGF) on the rat pheochromocytoma cell line PC12 has been previously shown to be accompanied by the accumulation of cells in either the G1 phase with a 2c DNA content, or with a 4c DNA content characteristic for G2/M, as evidenced by flow cytometric analysis of DNA distribution using propidium iodide. Herein, these apparently conflicting results are clarified. The present studies indicate that a simple DNA distribution profile obtained by this technique can confound interpretation of the biological effects of NGF on cell-cycle distribution due to the presence of tetraploid cells. Using cyclin D1 and incorporation of bromodeoxyuridine as markers of respectively, G1 and S phase, we show that PC12 cultures can have a considerable amount of tetraploid cells which, when in the G1 phase, have a 49 DNA content and express cyclin D1. During exposure to NGF, this population increases, reflecting the accumulation of cells in the G1 phase of the cell cycle. The data presented, support the possibility that events affecting the expression or action of G1 regulatory proteins may be involved in the molecular mechanism of the antimitogenic effect of NGF.	ECOLE NORMALE SUPER LYON,BIOL CELLULAIRE & MOLEC LAB,UMR CNRS 49,F-69364 LYON 07,FRANCE; SCHERING PLOUGH CORP,LAB RECH IMMUNOL,F-69570 DARDILLY,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); Merck & Company; Schering Plough Corporation			van Grunsven, Leo/E-5839-2010; Urdiales, José Luis/K-1125-2014; Choler, Philippe/A-7270-2008	van Grunsven, Leo/0000-0002-0990-7034; Urdiales, José Luis/0000-0002-2519-9293; Choler, Philippe/0000-0002-9062-2721; RUDKIN, Brian B./0000-0003-3700-1982				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Barde Y A, 1994, Prog Clin Biol Res, V390, P45; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; DAHMER MK, 1988, ENDOCRINOLOGY, V122, P2109, DOI 10.1210/endo-122-5-2109; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; FUJITA K, 1989, ENVIRON HEALTH PERSP, V80, P127, DOI 10.2307/3430738; GRECO A, 1993, CELL GROWTH DIFFER, V4, P539; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUNNING PW, 1981, J NEUROSCI, V1, P368; IGNATIUS MJ, 1985, J NEUROSCI, V5, P343; JIANG W, 1993, ONCOGENE, V8, P3447; KATO J, 1993, GENE DEV, V7, P331; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1994, ONCOGENE, V9, P2159; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MILANI D, 1993, J GEN VIROL, V74, P2587, DOI 10.1099/0022-1317-74-12-2587; MUNOZ A, 1993, J CELL BIOL, V121, P423, DOI 10.1083/jcb.121.2.423; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAUSCH DM, 1989, J NEUROSCI RES, V24, P49, DOI 10.1002/jnr.490240108; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; TAMARU T, 1994, NEUROSCI LETT, V168, P229, DOI 10.1016/0304-3940(94)90457-X; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103	34	48	48	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					855	862						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632908				2022-12-17	WOS:A1996TW68600017
J	VANETTEN, RA; DEBNATH, J; ZHOU, H; CASASNOVAS, JM				VANETTEN, RA; DEBNATH, J; ZHOU, H; CASASNOVAS, JM			INTRODUCTION OF A LOSS-OF-FUNCTION POINT MUTATION FROM THE SH3 REGION OF THE CAENORHABDITIS-ELEGANS SEM-5 GENE ACTIVATES THE TRANSFORMING ABILITY OF C-ABL IN-VIVO AND ABOLISHES BINDING OF PROLINE-RICH LIGANDS IN-VITRO	ONCOGENE			English	Article						ONCOGENES; ABELSON MURINE LEUKEMIA VIRUS; TYROSINE KINASE; CELL TRANSFORMATION; SRC HOMOLOGY REGION	TYROSINE-PHOSPHORYLATED PEPTIDES; GUANINE-NUCLEOTIDE EXCHANGE; ONCOGENIC ACTIVATION; CRYSTAL-STRUCTURE; ADAPTER PROTEIN; KINASE-ACTIVITY; DOMAIN; GRB2; SRC; RAS	We have introduced two loss-of-function point mutations from highly conserved regions of the src homology 3 (SH3) domains of the Caenorhabditis elegans sem-5 gene into the SH3 domain of the murine type IV c-abl tyrosine kinase proto-oncogene. One of the mutations, P131L, activated abl to transform fibroblasts while tbe other, G128R, did not. When combined with independent activating mutations in the c-abl kinase domain or NH,terminus, the G128R mutation blocked transformation by the double mutant, suggesting that the G128R mutant was unable to transform cells for trivial reasons. The c-Abl G128R mutant, like wild type c-Abi protein, was localized to the nucleus and actin cytoskeleton and had normal tyrosine kinase activity in vitro, while the transforming c-Abl P131L protein was localized exclusively to the cytoplasm and exhibited decreased in vitro kinase activity. By real-time biospecific interaction analysis, the wild type Abl SH3 domain bound to two proteins containing proline-rich motifs with dissociation constants of 0.2 and 17 mu M; the G128R mutant bound with 50-fold lower affinity, and no binding was detected by the P131L mutant. Both mutations completely abolished binding of the Abl SH3 domain to proline-rich target proteins in a filter-binding assay, These results suggest that the transforming activity of Abl is regulated in vivo by an inhibitor protein which associates with the SH3 domain via a proline-rich sequence.	HARVARD UNIV, SCH MED, CTR BLOOD RES, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	VANETTEN, RA (corresponding author), HARVARD UNIV, SCH MED, CTR BLOOD RES, DEPT GENET, 200 LONGWOOD AVE, BOSTON, MA 02115 USA.			Debnath, Jayanta/0000-0002-8745-4069	NIAID NIH HHS [AI 39121] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; BORCHERT TV, 1994, FEBS LETT, V341, P79, DOI 10.1016/0014-5793(94)80244-0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DRUKER BJ, 1992, NEW ENGL J MED, V321, P1383; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEINZEL SS, 1988, J VIROL, V62, P3738, DOI 10.1128/JVI.62.10.3738-3746.1988; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MULLER AJ, 1993, P NATL ACAD SCI USA, V90, P3457, DOI 10.1073/pnas.90.8.3457; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; Potts W M, 1988, Oncogene Res, V3, P343; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SASISEKHARAN V, 1959, ACTA CRYSTALLOGR, V12, P897, DOI 10.1107/S0365110X59002535; SAWYERSMAKER L, 1986, J VIROL, V57, P1182; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	70	48	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					1977	1988						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7539119				2022-12-17	WOS:A1995QZ92600012
J	ANDO, K; GRIFFIN, JD				ANDO, K; GRIFFIN, JD			CDK4 INTEGRATES GROWTH-STIMULATORY AND INHIBITORY SIGNALS DURING G1 PHASE OF HEMATOPOIETIC-CELLS	ONCOGENE			English	Article						HEMATOPOIESIS; CYCLINS; CELL CYCLE, INTERLEUKIN-3; CDK4; TGF-BETA-1; RETINOBLASTOMA	RETINOBLASTOMA-SUSCEPTIBILITY GENE; D-TYPE CYCLINS; TGF-BETA; PROTEIN-KINASES; PRODUCT; EXPRESSION; PROGRESSION; SUBUNIT; ENTRY	Proliferation of hematopoietic cells is controlled by both growth stimulatory and inhibitory cytokines acting primarily in G1, but the mechanism which integrate these disparate signals are unknown. In a myeloid cell line dependent on interleukin-3 (IL-3) for proliferation, expression of the cyclin dependent kinase Cdk4 and D-type cyclin partners, D2 and D3, in mid G1 was found to be directly related to the concentration of IL-3. TGF beta 1, which induces cell cycle arrest in mid-G1, blocked IL-3-induced expression of Cdk4, but had no effect on expression of cyclins D2 or D3. Sublines made to constitutively express Cdk4, but not lines constitutively expressing cyclins D2 or D3, were hyper responsive to IL-3 and resistant to TGF beta 1. Using an in vitro kinase assay with recombinant retinoblastoma protein (Rb) as a substrate, cyclin D2-associated kinase activity was shown to be induced in G1 by IL-3 and inhibited by TGF beta 1. Constitutive expression of Cdk4, but not cyclin D2 or D3, increased cyclin D2-associated Rb kinase activity and this activity could no longer be inhibited by TGF beta 1. Also, in vivo phosphorylation of Rb was inhibited by TGF beta 1 in wild type but not in Cdk4 lines. Cdk2 kinase activity was also decreased by TGF beta 1, and restored by overexpression of Cdk4. These results implicate Cdk4 activity as a mid G1 checkpoint sensitive to both growth stimulatory and inhibitory cytokines.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School								AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATUSHIME H, 1991, CELL, V65, P701; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	31	48	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					751	755						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862452				2022-12-17	WOS:A1995QH61200015
J	DENBAKKER, MA; RIEGMAN, PHJ; HEKMAN, RACP; BOERSMA, W; JANSSEN, PJA; VANDERKWAST, TH; ZWARTHOFF, EC				DENBAKKER, MA; RIEGMAN, PHJ; HEKMAN, RACP; BOERSMA, W; JANSSEN, PJA; VANDERKWAST, TH; ZWARTHOFF, EC			THE PRODUCT OF THE NF2 TUMOR-SUPPRESSOR GENE LOCALIZES NEAR THE PLASMA-MEMBRANE AND IS HIGHLY EXPRESSED IN MUSCLE-CELLS	ONCOGENE			English	Article						NF2; TUMOR SUPPRESSOR GENE; CYTOSKELETON; MUSCLE CELLS	BILATERAL ACOUSTIC NEUROFIBROMATOSIS; TYPE-2 NEUROFIBROMATOSIS; UNITED-KINGDOM; RADIXIN; EZRIN; TALIN; CYTOSKELETON; CONFIRMATION; FAMILY; MOESIN	Neurofibromatosis type 2 (NF2) is a disease resulting in the formation of schwannomas of the eighth cranial nerve, and other central nervous system tumours. A tumour suppressor gene has been found to be responsible for this disorder. The 595 amino acid NF2 protein shows a great deal of homology to a superfamily of membrane organizing proteins. To generate antibodies against the NF2 protein four synthetic peptides (SP) were injected in rabbits. COS cells transfected with an NF2 cDNA construct in an expression vector were used for immunocytochemical staining experiments; lysates of transfected COS cells were used for Western blotting experiments, as were lysates of E. coli cultures transformed with an NF2 cDNA construct subcloned in a prokaryotic expression vector. In western blots all sera detected a band indicating the appropriate molecular weight in lysates of transfected COS cells and E. coli. Immunocytochemical staining experiments indicate that the NF2 protein localizes in or near the cell membrane. Immunohistochemical staining of human tissue sections demonstrated the presence of the NF2 protein in muscle-, and Schwann cells. These results support the hypothesis that the NF2 protein functions as a membrane organizing element.	TNO, MBL, DEPT IMMUNOL, 2280 HV RIJSWIJK, NETHERLANDS	Netherlands Organization Applied Science Research	DENBAKKER, MA (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PATHOL, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		Riegman, Peter/GLS-0041-2022	Van der Kwast, Theodorus/0000-0001-8640-5786				ALGRAIN M, 1993, CURR BIOL, V3, P451, DOI 10.1016/0960-9822(93)90354-Q; ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; [Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; CLAUDIO JO, 1994, HUM MOL GENET, V3, P185; DEPREZ RHL, 1994, AM J HUM GENET, V54, P1022; EVANS DGR, 1992, J MED GENET, V29, P847, DOI 10.1136/jmg.29.12.847; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GUTMANN DH, 1993, NEURON, V10, P335, DOI 10.1016/0896-6273(93)90324-K; GUTMANN DH, 1993, ARCH NEUROL-CHICAGO, V50, P1185, DOI 10.1001/archneur.1993.00540110065007; HARA T, 1994, CANCER RES, V54, P330; HAWKES R, 1986, METHOD ENZYMOL, V121, P484; IRVING RM, 1994, HUM MOL GENET, V3, P347, DOI 10.1093/hmg/3.2.347; JACOBY LB, 1994, HUM MOL GENET, V3, P413, DOI 10.1093/hmg/3.3.413; KUPFER MIK, 1989, ARCH OPHTHALMOL-CHIC, V107, P541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDAU K, 1993, BRIT J OPHTHALMOL, V77, P646, DOI 10.1136/bjo.77.10.646; LOWLY DR, 1993, CIBA F S, V176, P67; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MUGURUMA M, 1990, BIOCHEM BIOPH RES CO, V171, P1217, DOI 10.1016/0006-291X(90)90815-5; MULVIHILL JJ, 1990, ANN INTERN MED, V113, P39, DOI 10.7326/0003-4819-113-1-39; PAKKANEN R, 1988, J CELL BIOCHEM, V38, P65, DOI 10.1002/jcb.240380107; PYKETT MJ, 1994, HUM MOL GENET, V3, P559, DOI 10.1093/hmg/3.4.559; RAGGE NK, 1993, BRIT J OPHTHALMOL, V77, P662, DOI 10.1136/bjo.77.10.662; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; RICCARDI V M, 1989, Neurofibromatosis, V2, P284; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBIO MP, 1994, CANCER RES, V54, P45; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SATO N, 1992, J CELL SCI, V103, P131; STERNBERGER LA, 1979, J HISTOCHEM CYTOCHEM, V27, P1424, DOI 10.1177/27.11.92498; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; VISKOCHIL D, 1993, ANNU REV NEUROSCI, V16, P183, DOI 10.1146/annurev.ne.16.030193.001151; WEBB MAP, 1986, NEW ENGL J MED, V315, P1553; ZEGERS ND, 1991, BIOCHIM BIOPHYS ACTA, V1073, P23, DOI 10.1016/0304-4165(91)90178-J	40	48	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					757	763						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862453				2022-12-17	WOS:A1995QH61200016
J	PEEPER, DS; KEBLUSEK, P; HELIN, K; TOEBES, M; VANDEREB, AJ; ZANTEMA, A				PEEPER, DS; KEBLUSEK, P; HELIN, K; TOEBES, M; VANDEREB, AJ; ZANTEMA, A			PHOSPHORYLATION OF A SPECIFIC CDK SITE IN E2F-1 AFFECTS ITS ELECTROPHORETIC MOBILITY AND PROMOTES PRB-BINDING IN-VITRO	ONCOGENE			English	Article						E2F; PRB; CYCLIN; CDK; PHOSPHORYLATION	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; ADENOVIRUS E1A PROTEINS; CELL-CYCLE; COMPLEX-FORMATION; TRANS-ACTIVATION; S-PHASE; EXPRESSION; P107; RB	The E2F transcription factor family participates in growth control presumably through transcriptional activation of genes that promote entry into S phase. E2F activity is believed to be controlled across the cell cycle by association with various cellular proteins, including the product of the retinoblastoma gene (pRB). We find that E2F-1 proteins are heterogeneously phosphorylated in insect cells, as a result of which they migrate as a doublet on SDS-polyacrylamide gels. This electrophoretic shift is shown to be dependent upon specific phosphorylation of E2F-1 on serine-375 (S375), near the pRB-binding site. Phosphorylation on S375 also occurs in human cells. E2F-1 was most efficiently phosphorylated on this residue by cyclin A/cdc2 kinase, and to a lesser extent by cyclin A/cdk2, irrespective of the presence of the pRB-related p107 protein. Phosphorylation of E2F-1 on S375 greatly enhanced its affinity of PRE in vitro. These results suggest a novel way of regulating E2F-1 activity, namely by cell-cycle-dependent phosphorylation of this transcription factor.	LEIDEN UNIV, DEPT MOLEC CARCINOGENESIS, SYLVIUS LAB, 2333 AL LEIDEN, NETHERLANDS; MASSACHUSETTS GEN HOSP E, CTR CANC, BOSTON, MA 02129 USA	Leiden University; Leiden University - Excl LUMC			Helin, Kristian/K-2526-2019; Peeper, Daniel/AAA-2430-2020; Helin, Kristian/HDM-8306-2022	Helin, Kristian/0000-0003-1975-6097				ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; NEVINS JR, 1992, SCIENCE, V258, P424; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PEEPER DS, 1992, VIROLOGY, V190, P733, DOI 10.1016/0042-6822(92)90911-8; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Summers MD, 1987, TEXAS AGR EXPT STATI; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	60	48	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					39	48						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824278				2022-12-17	WOS:A1995QA98000006
J	LI, NX; SCHLESSINGER, J; MARGOLIS, B				LI, NX; SCHLESSINGER, J; MARGOLIS, B			AUTOPHOSPHORYLATION MUTANTS OF THE EGF-RECEPTOR SIGNAL THROUGH AUXILIARY MECHANISMS INVOLVING SH2 DOMAIN PROTEINS	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; GUANINE-NUCLEOTIDE EXCHANGE; PHOSPHOLIPASE-C-GAMMA; MOTH-EATEN MICE; POINT MUTATION; BINDING-SITE; HEMATOPOIETIC-CELLS; MITOGENIC SIGNAL; PHOSPHORYLATION	Many growth factors bind and activate receptors with intrinsic protein tyrosine kinase activity. Once activated these receptors undergo autophosphorylation allowing them to bind src homology 2 (SH2) domain proteins. We mutated or deleted all known autophosphorylation sites of the Epidermal Growth Factor-Receptor (EGF-receptor) and examined the effects of these mutations on gene expression, MAP kinase activation and mitogenesis. We find that the mutant receptors, although unable to bind SH2 domain proteins, are fully competent to activate all these signaling pathways. Our data indicates that these mutant receptors utilize several different compensatory mechanisms to overcome the lack of autophosphorylation sites. One mechanism is the use of tyrosine phosphorylated cellular proteins as surrogates for binding SH2 domain proteins. We find that all these mutant receptors can induce tyrosine phosphorylation of She which then acts as a binding site for the Grb2/Sos signaling complex. This data indicates that even though autophosphorylation mutants of the EGF-receptor cannot directly bind SH2 domain proteins, they are able to use auxiliary signals that result in activation of SH2 domain proteins crucial for mitogenesis.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University								BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HSIAO WLW, 1992, MOL CARCINOGEN, V5, P140, DOI 10.1002/mc.2940050210; JIANG W, 1992, CANCER RES, V52, P2980; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROTIN D, 1992, J BIOL CHEM, V267, P9678; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SOLER C, 1993, J BIOL CHEM, V268, P22010; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SURMACZ E, 1992, CANCER RES, V52, P4522; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WHITE MF, 1994, J BIOL CHEM, V269, P1; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577	52	48	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3457	3465						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970705				2022-12-17	WOS:A1994PT39200007
J	DARBON, JM; DEVAULT, A; TAVIAUX, S; FESQUET, D; MARTINEZ, AM; GALAS, S; CAVADORE, JC; DOREE, M; BLANCHARD, JM				DARBON, JM; DEVAULT, A; TAVIAUX, S; FESQUET, D; MARTINEZ, AM; GALAS, S; CAVADORE, JC; DOREE, M; BLANCHARD, JM			CLONING, EXPRESSION AND SUBCELLULAR-LOCALIZATION OF THE HUMAN HOMOLOG OF P40(MO15) CATALYTIC SUBUNIT OF CDK-ACTIVATING KINASE	ONCOGENE			English	Article							MATURATION-PROMOTING FACTOR; CYCLIN-DEPENDENT KINASES; PROTEIN-KINASE; CELL-CYCLE; TYROSINE KINASE; FISSION YEAST; NEGATIVE REGULATION; CDC25 PROTEIN; S-PHASE; PHOSPHORYLATION	Transitions of the cell cycle are controlled by cyclin-dependent protein kinases (cdks) whose phosphorylation on the Thr residue included in the conserved sequence YTHEVV dramatically increases the activity. A kinase responsible for this specific phosphorylation, called CAK for cdk-activating kinase, has been recently purified from starfish and Xenopus oocytes and shown to contain the MO15 gene product as a catalytic subunit. In the present paper, we have cloned the human homolog of Xenopus p40(MO15) by probing a HeLa cell cDNA library with degenerate oligonucleotides deduced from Xenopus and starfish MO15 sequences. Human and Xenopus MO15 displayed a strong homology showing 86% identity with regard to amino acid sequences. Northern blot analysis of RNA extracts from a series of human tissues as well as from cultured rodent fibroblasts revealed a unique 1.4 kb MO15 mRNA. No variation in the amount of MO15 transcript or protein was found along the entire course of the fibroblast cell cycle. Fluorescence in situ hybridization on human lymphocyte metaphases showed two distinct chromosomal locations of human MO15 gene at 5q12-q13 and 2q22-q24. By using gene tagging and mammalian cell transfection, we demonstrate that the KRKR motif located at the carboxy terminal end of MO15 is required for nuclear targeting of the protein. Mutation of KRKR to NGER retains MO15 in the cytoplasmic compartment, whilst the wild-type protein is detected exclusively in the nucleus. Interestingly, we demonstrate that the nuclear targeting of MO15 is necessary to confer the protein its CAK activity. In contrast to the wild-type, the NLS-mutated MO15 expressed in Xenopus oocytes is unable to generate CAK as long as the nuclear envelope is not broken. The nuclear localization of both the MO15 gene product and CAK activity may imply that cdks activation primarily occurs in the cell nucleus.	CNRS, UMR 9942, F-34033 MONTPELLIER, FRANCE	Centre National de la Recherche Scientifique (CNRS)	DARBON, JM (corresponding author), CNRS, INSERM, U249, UPR 9008, BP 5051, F-34033 MONTPELLIER, FRANCE.		Fesquet, didier/M-9750-2019; Fesquet, Didier/A-1490-2009; martinez, Anne-marie/R-2751-2017	Fesquet, didier/0000-0001-5657-9689; martinez, Anne-marie/0000-0001-8562-7627				BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; CANCE WG, 1993, INT J CANCER, V54, P571, DOI 10.1002/ijc.2910540409; CLARKE PR, 1991, J CELL SCI, V100, P409; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVAULT A, 1992, J CELL BIOL, V118, P1109, DOI 10.1083/jcb.118.5.1109; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS NL, 1990, NUCLEIC ACIDS RES, V18, P3015, DOI 10.1093/nar/18.10.3015; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; Hunt T, 1991, Semin Cell Biol, V2, P213; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOSAK M, 1984, NUCLEIC ACIDS RES, V12, P857; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LABBE JC, 1991, METHOD ENZYMOL, V200, P291; LABBE JC, 1994, IN PRESS EMBO J; LASKEY RA, 1993, CELL, V74, P585, DOI 10.1016/0092-8674(93)90505-K; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; LORCA T, 1992, J CELL SCI, V102, P55; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; ONOE S, 1993, BIOMED RES-TOKYO, V14, P441, DOI 10.2220/biomedres.14.441; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0	60	48	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1994	9	11					3127	3138						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936635				2022-12-17	WOS:A1994PM65800004
J	PERI, KG; GERVAIS, FG; WEIL, R; DAVIDSON, D; GISH, GD; VEILLETTE, A				PERI, KG; GERVAIS, FG; WEIL, R; DAVIDSON, D; GISH, GD; VEILLETTE, A			INTERACTIONS OF THE SH2 DOMAIN OF LYMPHOCYTE-SPECIFIC TYROSINE PROTEIN-KINASE P56(LCK) WITH PHOSPHOTYROSINE-CONTAINING PROTEINS	ONCOGENE			English	Article								We have previously demonstrated that the non-catalytic Src homology 2 (SH2) domain is required for both positive and negative regulation of the catalytic function of the lymphocyte-specific tyrosine protein kinase p56lck. Indeed, the ability of activated p56lck molecules (tyrosine 505 to phenylalanine 505 mutants) to enhance T-cell receptor (TCR)-induced tyrosine protein phosphorylation is dramatically reduced by deletion of the SH2 domain. Paradoxically, removal of the SH2 sequence also results in constitutive elevation of the catalytic function of wild-type Lck polypeptides, rendering them capable of oncogenic transformation of rodent fibroblasts. As SH2 sequences can mediate binding to phosphotyrosine-containing peptides, the ability of the Lck SH2 domain to interact with tyrosine-phosphorylated proteins was tested. We found that the SH2 sequence of p56lck can bind several of the TCR-regulated tyrosine phosphorylation substrates in vitro. One of the substrates, an 80-kilodalton (kDa) phosphoprotein (p80) showed the tightest binding to the SH2 domain of Lck. Additionally, it was observed that the SH2 domain of Lck can bind a synthetic peptide containing the phosphorylated carboxy-terminal tyrosine 505 of p56lck. Indirect evidence indicating that the SH2 region interacts with the tyrosine-phosphorylated carboxy terminus of Lck in vivo was also obtained. As deletion of the SH2 domain or mutation of tyrosine 505 results in p56lck activation in vivo, it is conceivable that interactions between these two regions impose a conformation that is unfavorable to phosphorylation of intracellular substrates. Collectively, these findings suggest that the SH2 domain modulates the catalytic function of Lck through complex interactions with phosphotyrosine-containing proteins.	MCGILL UNIV, MCGILL CANC CTR,ROOM 715B,MCINTYRE MED SCI BLDG, 3655 DRUMMOND ST, MONTREAL H3G 1Y6, QUEBEC, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3G 1Y6, QUEBEC, CANADA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO M5G 1X5, ONTARIO, CANADA; MCGILL UNIV, DEPT MED, MONTREAL H3G 1Y6, QUEBEC, CANADA; MCGILL UNIV, DEPT ONCOL, MONTREAL H3G 1Y6, QUEBEC, CANADA; MONTREAL GEN HOSP, DEPT MED, DIV MED ONCOL, MONTREAL H3G 1A4, QUEBEC, CANADA	McGill University; McGill University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; McGill University; McGill University; McGill University			Gish, Gerald D/C-7228-2017	Weil, Robert/0000-0001-5235-0932				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGERTON M, 1992, J IMMUNOL, V149, P1847; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HURLEY TR, 1989, ONCOGENE, V4, P265; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; REYNOLDS PJ, 1992, ONCOGENE, V7, P1949; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; STAERZ UD, 1985, J IMMUNOL, V134, P3994; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Veillette A, 1991, Semin Immunol, V3, P143; VEILLETTE A, 1992, ONCOGENE, V7, P971; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	48	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2765	2772						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	7690927				2022-12-17	WOS:A1993LX34300018
J	INOUE, J; TAKAHARA, T; AKIZAWA, T; HINO, O				INOUE, J; TAKAHARA, T; AKIZAWA, T; HINO, O			BCL-3, A MEMBER OF THE I-KAPPA-B PROTEINS, HAS DISTINCT SPECIFICITY TOWARDS THE REL FAMILY OF PROTEINS	ONCOGENE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; ENHANCER-BINDING-PROTEIN; CELL-CYCLE CONTROL; DNA-BINDING; TRANSCRIPTION FACTOR; PROTOONCOGENE BCL-3; MAMMALIAN-CELLS; P65 SUBUNIT; ACTIVATION; INHIBITION	Expression of the bcl-3 gene is demonstrated to be elevated in some B-cell chronic lymphocytic leukemias with a chromosomal translocation, t(14;19)(q32;q13.1). Bcl-3 protein has seven tandem ankyrin repeats that are also found in IkappaB proteins, inhibitors of Rel/NFkappaB transcription factors. In this paper, we demonstrate that Bcl-3 is a member of IkappaB family of proteins with a novel specificity. Bcl-3 preferentially associates with the p50 of NFkappaB, and the nuclear localization signal of p50 is required for this association. Bcl-3 inhibits the DNA-binding activity of p50 homodimers but not that of p50-p65 heterodimers. Transient transfection experiments revealed that appropriate expression of Bcl-3 results in inhibition of the function of p50 homodimers but not that of p50-p65 heterodimers, whereas pp40 and IkappaBgamma inhibit the function of both p50 homodimers and p50-p65 heterodimers. These studies suggest that Bcl-3 could modulate the transcription in a way different from pp40 and IkappaBgamma.	JAPANESE FDN CANC RES,INST CANC,DEPT EXPTL PATHOL,TOSHIMA KU,TOKYO 170,JAPAN; SETSUNAN UNIV,DEPT ANALYT CHEM,HIRAKATA,OSAKA 573,JAPAN	Japanese Foundation for Cancer Research; Setsunan University	INOUE, J (corresponding author), UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN.							BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JOHANNESS A, 1991, CELL, V65, P1281; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHUTZE S, 1992, CELL, V71, P765; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; WULZYN FG, 1992, NATURE, V358, P597; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	40	48	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2067	2073						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336935				2022-12-17	WOS:A1993LP17100006
J	FOOS, G; NATOUR, S; KLEMPNAUER, KH				FOOS, G; NATOUR, S; KLEMPNAUER, KH			TATA-BOX DEPENDENT TRANSACTIVATION OF THE HUMAN HSP70 PROMOTER BY MYB PROTEINS	ONCOGENE			English	Article							ONCOGENE C-MYB; GENE V-MYB; NUCLEOTIDE-SEQUENCE; CELLULAR PROGENITOR; PROTO-ONCOGENE; EXPRESSION; DIFFERENTIATION; DNA; CELLS; CDNA	The oncogene v-myb and its cellular progenitor c-myb encode nuclear, DNA-binding phosphoproteins that function as transcriptional regulators. Previous studies have demonstrated the existence of two distinct transactivation mechanisms for Myb-inducible promoters. One of these mechanisms, exemplified by the chicken mim-1 promoter, involves specific binding of Myb protein to Myb binding sites located upstream of the transcriptional start site. A second mechanism, exemplified by the human HSP70 promoter, does not require the presence of specific Myb binding sites. Here, we have more closely investigated transactivation of the human HSP70 promoter by Myb proteins. Mutational analysis of the human HSP70 promoter failed to show a correlation between Myb-inducibility and the presence of a particular upstream transcription factor binding site, but instead showed that Myb-inducibility was dependent on the presence of a particular type of TATA-box. This suggests that the TATA-box is involved in transactivation by v-Myb and that only a subset of TATA-boxes confers Myb-inducibility. Activation of the HSP70 promoter is dependent on the presence of most of the carboxy terminal amino acid sequences of v-Myb, including the previously identified acidic transactivation domain and a putative leucine-zipper region. Finally, we show that the HSP70 promoter is activated in a Myb binding site independent fashion not only by v-Myb, but also by chicken c-Myb and chicken B-Myb. These observations raise the possibility that the ability to transactivate in a Myb binding-site independent manner is a common property among Myb proteins. Since chicken B-Myb has been shown previously to be unable to transactivate a Myb binding-site containing promoter, such as the mim-1 promoter (Foos et al., 1992), our results also show that both modes of transactivation are independent of each other.	MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,STUBEWEG 51,W-7800 FREIBURG,GERMANY	Max Planck Society								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CRAIG RW, 1984, CANCER RES, V44, P442; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENE JM, 1987, MOL CELL BIOL, V7, P3646, DOI 10.1128/MCB.7.10.3646; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LAM EWF, 1992, ONCOGENE, V7, P1185; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LUM LSY, 1992, MOL CELL BIOL, V12, P2599, DOI 10.1128/MCB.12.6.2599; MCMAHON J, 1988, ONCOGENE, V3, P717; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKANO T, 1992, ONCOGENE, V7, P527; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P165, DOI 10.1128/MCB.10.1.165; THEISEN M, 1986, EMBO J, V5, P719, DOI 10.1002/j.1460-2075.1986.tb04273.x; TOKODORO K, 1988, P NATL ACAD SCI USA, V85, P8900; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	47	48	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1775	1782						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510924				2022-12-17	WOS:A1993LG68200008
J	KATZAV, S				KATZAV, S			SINGLE-POINT MUTATIONS IN THE SH2 DOMAIN IMPAIR THE TRANSFORMING POTENTIAL OF VAV AND FAIL TO ACTIVATE PROTO-VAV	ONCOGENE			English	Article							CYTOPLASMIC SIGNALING PROTEINS; TYROSINE KINASE; V-FPS; GENE-PRODUCT; SRC GENE; PROTOONCOGENE; MUTAGENESIS; DELETIONS; P60C-SRC; CELLS	The importance of an intact Src Homology 2 (SH2) domain for transformation by members of the tyrosine kinase family, including v-src, c-src, c-abl, fps and fyn is well documented. To determine the role of the SH2 domain in transformation by a protein which is not a member of this family, we employed site directed mutagenesis to change four highly conserved residues in the SH2 domain of the vav oncogene and the vav proto-oncogene (proto-vav). Proto-vav encodes a protein that contains one SH2 domain and two Src Homology 3 (SH3) domains, in addition to a number of other motifs usually found in transcriptional factors and guanine nucleotide exchange factors. Substitution of arginine 629 to glycine (R629G) and arginine 647 to leucine (R647L) in vav did not impair its transforming potential in NIH3T3 fibroblasts. By contrast, substitutions of tryptophan 622 to arginine (W622R) and glycine 642 to valine (G642V) in the vav SH2, greatly reduced its transforming potential. Similar point mutations introduced in the SH2 domain of proto-vav did not activate the transforming potential of the normal gene. Interestingly, although all the vav SH2 mutant proteins were constitutively phosphorylated on tyrosine when expressed in NIH3T3 cells, they fail to bind to a phosphorylated epidermal growth factor receptor (EGFR), regardless of their transforming potential.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital					NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BOGUSKI MS, 1992, NATURE, V358, P113, DOI 10.1038/358113a0; BOOKER GW, 1992, NATURE, V358, P685; BUESTLO XR, 1992, SCIENCE, V256, P1196; BUESTLO XR, 1992, NATURE, V356, P69; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GALLAND F, 1992, ONCOGENE, V7, P585; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8952; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAMPS MP, 1988, ONCOGENE, V2, P305; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KATZAV S, 1992, BRIT J HAEMATOL, V81, P141, DOI 10.1111/j.1365-2141.1992.tb08198.x; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PARSONS JT, 1989, CURR TOP MICROBIOL I, V147, P97; ROSENBERG NE, 1988, ADV VIRUS RES, V54, P39; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SEMBA K, 1990, MOL CELL BIOL, V10, P3095, DOI 10.1128/MCB.10.6.3095; ULRICH A, 1990, CELL, V61, P203; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989	40	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1757	1763						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510922				2022-12-17	WOS:A1993LG68200006
J	MILLER, CW; CHUMAKOV, A; SAID, J; CHEN, DL; ASLO, A; KOEFFLER, HP				MILLER, CW; CHUMAKOV, A; SAID, J; CHEN, DL; ASLO, A; KOEFFLER, HP			MUTANT-P53 PROTEINS HAVE DIVERSE INTRACELLULAR ABILITIES TO OLIGOMERIZE AND ACTIVATE TRANSCRIPTION	ONCOGENE			English	Article							WILD-TYPE P53; MAMMALIAN-CELLS; GENE; EXPRESSION; MUTATIONS; SEQUENCE; DOMAIN; TRANSFORMATION; ELEMENT; JUN	Accumulating evidence supports the hypothesis that tumor-suppressor p53 can act as a transcriptional activator. Insertion of high-affinity p53 DNA binding sites up-stream of a promoter yields a p53-responsive vector. Chimeric proteins fusing p53 and the GAL4 DNA-binding domain demonstrate the presence of a transcriptional activating domain in the N-terminus of p53. GAL4-p53 chimeras constructed using naturally occurring p53 mutations at either codon 141 (Tyr-141) or 175 (His-175) of p53 had little ability to activate the reporter gene; in contrast, mutations at either codon 248 (Trp-248) or 273 (His-273) produced greater transcriptional activities than did wild-type p53. GAL4 chimeras can be used to analyse interactions between different domains of p53 and between different p53 alleles; a DNA binding site is defined, and a simple measurement can be made of function. We had expected that coexpression of GAL4 chimeras and p53 alleles would squelch transcriptional activation downstream of GAL binding sites. Surprisingly, coexpression of either p53 (Trp-248) or (His-273) with the GALA-p53 (wild-type, His-273, Trp-248, His-175, Tyr-141) effectors conferred an increase in transcriptional activation as compared with the effector alone. Oligomerization of p53 alleles with GAL4-p53 chimeras could underlie this effect, leading to an increase in transcription-activating motifs near the promoter. To test this possibility, we constructed a GAL4- p53 C-terminal chimera with p53 residues 160-393, lacking the transcriptional activating domain but retaining regions believed to be important in p53 oligomerization. Neither GAL4-p53 (C-terminus) nor p53 expression vectors were able to transactivate G5E1B-CAT alone. Both p53 (His-273) and (Trp-248) co-expressed with GAL4-p53 (C-terminus) were able to transactivate the G5E1B-CAT reporter gene; in contrast, p53 (Tyr-141) was not able to activate transcription. p53 (Tyr-141/His-273) behaved as a dominant negative mutant and inhibited the ability of the combination of p53 (His-273) and GAL4-p53 (C-terminus) to stimulate the reporter gene. Double immunoprecipitation by sequentially using GAL4 and p53 antibodies showed that p53 (His-273) and (Tyr-141/ His-273), but not p53 (Tyr-141), can efficiently oligomerize in vivo to the C-terminal region of p53. Transcriptional activating function of p53 may be modulated by oligomerization; some mutations, such as His-273 and Trp-248, participate in these functions. The p53 proteins with mutations at Tyr-141 and His-175 have lost their abilities to transactivate and oligomerize efficiently in vivo, perhaps resulting in loss of their tumor-suppressor activities. In contrast, mutations in the region of codons 248 and 273 result in p53 proteins with potent abilities to transactivate and oligomerize in vivo, suggesting that these proteins in conjunction with loss of the normal allele of p53 may be able to behave in a similar way to recessive oncogenes.	UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,DEPT PATHOL,LOS ANGELES,CA 90048	Cedars Sinai Medical Center; University of California System; University of California Los Angeles	MILLER, CW (corresponding author), UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DEPT MED,DIV HEMATOL ONCOL,5019 DAVIS BLDG,LOS ANGELES,CA 90048, USA.		Chumakov, Alexey/N-1541-2014	Chumakov, Alexey/0000-0003-2733-3166	NATIONAL CANCER INSTITUTE [P30CA042710, P01CA042710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042792] Funding Source: NIH RePORTER; NCI NIH HHS [CA42710] Funding Source: Medline; NIDDK NIH HHS [DK42792] Funding Source: Medline; PHS HHS [IRT370] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BUSCH SJ, 1990, ONCOGENE, V63, P729; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FIELDS S, 1989, NATURE, V340, P240; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GLASS CK, 1990, CELL, V5, P1549; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1988, ONCOGENE HDB; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1992, BIOCHIM BIOPHYS ACTA, V1119, P11, DOI 10.1016/0167-4838(92)90227-5; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MALKIN D, 1990, SCIENCE, V250, P1236; MEDCALF EA, 1992, ONCOGENE, V7, P71; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SADOWSKI I, 1988, NATURE, V335, P653; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SOUSSI T, 1990, ONCOGENE, V5, P945; STEINMEYER K, 1988, ONCOGENE, V3, P501; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570	47	48	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1815	1824						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510927				2022-12-17	WOS:A1993LG68200013
J	FELIX, CA; STRAUSS, EA; DAMICO, D; TSOKOS, M; WINTER, S; MITSUDOMI, T; NAU, MM; BROWN, DL; LEAHEY, AM; HOROWITZ, ME; POPLACK, DG; COSTIN, D; MINNA, JD				FELIX, CA; STRAUSS, EA; DAMICO, D; TSOKOS, M; WINTER, S; MITSUDOMI, T; NAU, MM; BROWN, DL; LEAHEY, AM; HOROWITZ, ME; POPLACK, DG; COSTIN, D; MINNA, JD			A NOVEL GERMLINE P53 SPLICING MUTATION IN A PEDIATRIC-PATIENT WITH A 2ND MALIGNANT NEOPLASM	ONCOGENE			English	Article							CELLULAR PROTEIN P53; BREAST-CANCER; GENE; TUMOR; RETINOBLASTOMA; IDENTIFICATION; ANTIBODIES; EXPRESSION; COMPLEX	A novel germline p53 splicing mutation was identified in a pediatric patient with two metachronous primary cancers that are constituent tumors of the Li-Fraumeni syndrome. Genomic DNA from the second tumor showed the same mutation and loss of heterozygosity at the p53 locus. The mutant mRNA and protein were present in the tumor tissue. In contrast, in the normal tissues bearing the germline mutation in the heterozygous state, predominantly normal mRNA was expressed and the mutant p53 protein was not detectable. The functional silence and relative lack of mutant p53 mRNA expression in the normal tissues of this patient may be caused by decreased stability or decreased production. If this proves a more general pattern of expression of mutant p53 in individuals with germline mutations, these findings may explain the paucity of tumors in individuals affected with the Li-Fraumeni syndrome.	USN,MED ONCOL BRANCH,BETHESDA,MD 20892; UNIV TEXAS,SW MED CTR,SIMMONS COMPREHENS CANC RES CTR,DALLAS,TX 75235; NCI,PEDIAT BRANCH,BETHESDA,MD 20892; NCI,MED BRANCH,BETHESDA,MD 20892; NCI,PATHOL LAB,BETHESDA,MD 20892	United States Department of Defense; United States Navy; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	FELIX, CA (corresponding author), CHILDRENS HOSP,DEPT PEDIAT,DIV ONCOL,34TH ST & CIVIC CTR BLVD,ROOM 9093,PHILADELPHIA,PA 19104, USA.			Mitsudomi, Tetsuya/0000-0001-9860-8505				ADDISON C, 1990, ONCOGENE, V5, P423; BODNER SM, 1992, ONCOGENE, V7, P743; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; DAMICO D, 1992, ONCOGENE, V7, P339; DEFROMENTEL CC, 1987, INT J CANCER, V39, P185, DOI 10.1002/ijc.2910390211; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FELIX CA, 1992, CANCER RES, V52, P2243; FELIX CA, 1992, J CLIN INVEST, V89, P649; FIDLER AE, 1992, LANCET, V339, P243, DOI 10.1016/0140-6736(92)90042-2; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IAVARONE A, 1992, P NATL ACAD SCI USA, V89, P4207, DOI 10.1073/pnas.89.9.4207; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1969, J NATL CANCER I, V43, P1365; LI FP, 1991, CANCER EPIDEM BIOMAR, V1, P91; LI FP, 1992, J NATL CANCER I, V84, P1156, DOI 10.1093/jnci/84.15.1156; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MEADOWS AT, 1988, B CANCER, V75, P125; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; WINTER SF, 1993, IN PRESS CANCER RES; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZHANG W, 1992, ONCOGENE, V7, P1645	44	48	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1203	1210						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479743				2022-12-17	WOS:A1993KY32800011
J	MORRIS, JDH; CROOK, T; BANDARA, LR; DAVIES, R; LATHANGUE, NB; VOUSDEN, KH				MORRIS, JDH; CROOK, T; BANDARA, LR; DAVIES, R; LATHANGUE, NB; VOUSDEN, KH			HUMAN PAPILLOMAVIRUS TYPE-16 E7 REGULATES E2F AND CONTRIBUTES TO MITOGENIC SIGNALING	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; KINASE-II PHOSPHORYLATION; TRANSCRIPTION FACTOR; DNA-SYNTHESIS; MUTATIONAL ANALYSIS; HUMAN KERATINOCYTES; ADENOVIRUS E1A; RB PROTEIN; 3T3 CELLS; TRANSFORMATION	We have produced human papillomavirus type 16 E7 protein in a bacterial expression system and examined the mitogenic activity of this protein in Swiss 3T3 cells after scrape loading. The ability of E7 to induce cellular DNA synthesis in quiescent mouse fibroblasts is strongly enhanced by the presence of a single growth factor such as insulin. Although only weakly mitogenic, introduction of E7 alone resulted in the rapid induction of the transcriptionally active form of E2F, which was not enhanced further by the addition of insulin. Mutant E7 proteins defective for RB binding failed to induce the active form of E2F or act synergistically with insulin to stimulate DNA synthesis. The ability of E7 to regulate E2F may therefore be necessary, but is not sufficient, for full induction of DNA synthesis.	ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, NORFOLK PL, LONDON W2 1PG, ENGLAND; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	Imperial College London; Ludwig Institute for Cancer Research; MRC National Institute for Medical Research				Davies, Rachel/0000-0002-2162-6219				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BANKS L, 1990, ONCOGENE, V5, P1383; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DURST M, 1987, ONCOGENE, V1, P251; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MCNEIL PL, 1984, J CELL BIOL, V98, P1556, DOI 10.1083/jcb.98.4.1556; METCALFE JC, 1985, J CELL SCI, P199; MORRIS JDH, 1989, ONCOGENE, V4, P27; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; PAGANO M, 1992, ONCOGENE, V7, P1681; PATRIDGE JF, 1991, EMBO J, V10, P3819; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; ROZENGURT E, 1985, J CELL SCI, P229; SATO H, 1989, VIROLOGY, V168, P195, DOI 10.1016/0042-6822(89)90423-6; SHIVJI MKK, 1991, MOL CELL BIOL, V11, P1686, DOI 10.1128/MCB.11.3.1686; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	45	48	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					893	898						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455943				2022-12-17	WOS:A1993KT22000010
J	WILLIAMS, RT; CARBONAROHALL, DA; HALL, FL				WILLIAMS, RT; CARBONAROHALL, DA; HALL, FL			COPURIFICATION OF P34CDC2/P58CYCLIN-A PROLINE-DIRECTED PROTEIN-KINASE AND THE RETINOBLASTOMA TUMOR SUSCEPTIBILITY GENE-PRODUCT - INTERACTION OF AN ONCOGENIC SERINE THREONINE PROTEIN-KINASE WITH A TUMOR-SUPPRESSOR PROTEIN	ONCOGENE			English	Article							CELL-CYCLE CONTROL; HISTONE H-1 KINASE; M-PHASE; OSTEO-SARCOMA; CDC2 PROTEIN; DNA-REPLICATION; E1A PROTEINS; PHOSPHORYLATION; EXPRESSION; P53	Proline-directed protein kinase (PDPK) is characterized as a cytoplasmic oncogenic serine/theonine kinase that is activated by growth factor-mediated mechanisms and is proposed to function in mammalian somatic cells as an S phase promoting factor. The present study was undertaken to assess the hypothesis that p34cdc2/p58cyclin A PDPK is a physiologically relevant form of the p34cdc2 protein kinase that phosphorylates and inactivates the product of the retinoblastoma/osteosarcoma tumor susceptibility gene (Rb protein). In the course of these studies it was determined (fortuitously) that the p34cdc2/p58cyclin A PDPK purified from the cytosol of FM3A mouse mammary carcinoma cells was 'contaminated' by several high molecular weight substrate proteins that essentially co-purified with the protein kinase, one of which was identified as the Rb protein itself (p105Rb). High-resolution fast protein liquid chromatography (FPLC) revealed that the Rb protein co-purified with a particular subset of the PDPK heterodimer, i.e. with a single species of the 58 kDa cyclin A doublet. The subset of PDPK associated with the Rb protein exhibited somewhat lower specific enzyme activity, as judged by in vitro kinase assays and comparative Western blotting. Immunoprecipitation studies confirmed that p105Rb is physically associated with the p34cdc2/p58cyclin A PDPK. Further studies confirmed that the underphosphorylated Rb protein (p105Rb) present in G1 lysates of synchronized human MG63 osteosarcoma cells could be readily phosphorylated by purified PDPK in vitro, resulting in the characteristic shift in the apparent molecular mass (SDS-PAGE) of the Rb protein that is reported to accompany the hyperphosphorylation and functional inactivation of this protein. Moreover, the induction of the cyclin A subunit of PDPK in these synchronized MG63 cells was found to be closely correlated with the cell cycle-dependent phosphorylation of the Rb protein. From these studies it is concluded that the growth factor-sensitive PDPK is a physiological Rb kinase, which may function to inactivate the Rb protein in vivo.	CHILDRENS HOSP, DIV ORTHOPAED SURG, 4650 SUNSET BLVD, LOS ANGELES, CA 90054 USA; UNIV SO CALIF, SCH MED, DEPT MOLEC PHARMACOL & TOXICOL, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH PHARM, LOS ANGELES, CA 90089 USA	Children's Hospital Los Angeles; University of Southern California; University of Southern California								ADDISON C, 1990, ONCOGENE, V5, P423; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; Braun R K, 1989, Proc West Pharmacol Soc, V32, P15; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHAMBERS TC, 1990, J BIOL CHEM, V265, P16940; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; Hall F L, 1989, Proc West Pharmacol Soc, V32, P1; HALL FL, 1990, J BIOL CHEM, V265, P6944; HALL FL, 1991, J BIOL CHEM, V266, P17430; HALL FL, 1991, J BONE JT SURG ORTHO, V15, P454; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Kulp K S, 1990, Proc West Pharmacol Soc, V33, P219; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LANGAN TA, 1980, PROTEIN PHOSPHORYLAT, P70; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MATTHEWS HR, 1984, MOL CELL BIOCHEM, V59, P81; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILLER CW, 1990, CANCER RES, V50, P7950; MINSHULL J, 1989, J CELL SCI, P77; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARLEY JM, 1989, ONCOGENE, V4, P725; Vulliet P R, 1988, Proc West Pharmacol Soc, V31, P255; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YOKOTA J, 1988, ONCOGENE, V3, P471	70	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					423	432						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1532245				2022-12-17	WOS:A1992HK00500004
J	MA, QF; HERSCHMAN, HR				MA, QF; HERSCHMAN, HR			A CORRECTED SEQUENCE FOR THE PREDICTED PROTEIN FROM THE MITOGEN-INDUCIBLE TIS11 PRIMARY RESPONSE GENE	ONCOGENE			English	Article							SWISS 3T3 CELLS; TETRADECANOYL	We previously reported the sequence of a cDNA, TIS11, cloned from TPA-treated Swiss 3T3 cells. Two laboratories have reported sequences for cDNAs that have a region of identity with the TIS11 cDNA, but differ in their 5' and 3' flanking regions. We now report that the original TIS11 cDNA is likely to be a chimeric molecule, and find that the TIS11 gene encodes a protein identical to the TTP and Nup475 genes.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,BIOMED & ENVIRONM SCI LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	HERSCHMAN, HR (corresponding author), UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.				NIGMS NIH HHS [GM24797] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024797] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DUBOIS RN, 1990, J BIOL CHEM, V265, P19186; LAI WS, 1990, J BIOL CHEM, V265, P16556; LIM RW, 1987, ONCOGENE, V1, P263; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; VARNUM BC, 1989, ONCOGENE, V4, P119; YAMAMOTO KR, 1976, ANNU REV BIOCHEM, V45, P721, DOI 10.1146/annurev.bi.45.070176.003445	6	48	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1277	1278						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861870				2022-12-17	WOS:A1991GV26000025
J	MIOZZO, M; PIEROTTI, MA; SOZZI, G; RADICE, P; BONGARZONE, I; SPURR, NK; DELLAPORTA, G				MIOZZO, M; PIEROTTI, MA; SOZZI, G; RADICE, P; BONGARZONE, I; SPURR, NK; DELLAPORTA, G			HUMAN TRK PROTOONCOGENE MAPS TO CHROMOSOME 1Q32-Q41	ONCOGENE			English	Note									IST NAZL TUMORI,DIV EXPTL ONCOL A,VIA G VENEZIAN 1,I-20133 MILAN,ITALY; IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LID,HERTS,ENGLAND	Fondazione IRCCS Istituto Nazionale Tumori Milan			Bongarzone, Italia/B-9544-2017; Radice, Paolo/O-3119-2013; Sozzi, Gabriella/G-8259-2011	Bongarzone, Italia/0000-0003-2530-9170; Pierotti, Marco Alessandro/0000-0002-7431-8332; Radice, Paolo/0000-0001-6298-4111; Sozzi, Gabriella/0000-0001-9360-6914; Miozzo, Monica/0000-0002-6523-4575				AKAO Y, 1987, SOMAT CELL MOLEC GEN, V13, P273, DOI 10.1007/BF01535209; ANDREWS PW, 1985, ANN HUM GENET, V49, P31, DOI 10.1111/j.1469-1809.1985.tb01673.x; BONGARZONE I, 1989, ONCOGENE, V4, P1457; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; DONGHI R, 1989, ONCOGENE, V4, P521; EDWARDS YH, 1985, ANN HUM GENET, V49, P101, DOI 10.1111/j.1469-1809.1985.tb01681.x; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HEISTERKAMP N, 1982, NATURE, V299, P747, DOI 10.1038/299747a0; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; JONES EA, 1976, SOMAT CELL GENET, V2, P483, DOI 10.1007/BF01542686; KATZAV S, 1989, ONCOGENE, V4, P1129; KIELTY CM, 1982, ANN HUM GENET, V46, P307, DOI 10.1111/j.1469-1809.1982.tb01582.x; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MAYALL BH, 1975, AUTOMATION CYTOGENET, P133; NABHOLZ M, 1969, NATURE, V223, P358, DOI 10.1038/223358a0; OLAH E, 1989, CANCER GENET CYTOGEN, V43, P179, DOI 10.1016/0165-4608(89)90029-0; PHILLIPS IR, 1985, ANN HUM GENET, V49, P267, DOI 10.1111/j.1469-1809.1985.tb01702.x; POVEY S, 1980, ANN HUM GENET, V43, P241, DOI 10.1111/j.1469-1809.1980.tb01557.x; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; SEWELL WA, 1988, IMMUNOGENETICS, V28, P278, DOI 10.1007/BF00345506; SOLOMON E, 1979, ANN HUM GENET, V42, P273, DOI 10.1111/j.1469-1809.1979.tb00661.x; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8696; VANHEYNINGEN V, 1975, ANN HUM GENET, V38, P295; WHITEHEAD AS, 1982, P NATL ACAD SCI-BIOL, V79, P5021, DOI 10.1073/pnas.79.16.5021	29	48	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1411	1414						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	2216464				2022-12-17	WOS:A1990EC24100021
J	CARTER, G; HUGHES, DC; CLARK, RE; MCCORMICK, F; JACOBS, A; WHITTAKER, JA; PADUA, RA				CARTER, G; HUGHES, DC; CLARK, RE; MCCORMICK, F; JACOBS, A; WHITTAKER, JA; PADUA, RA			RAS MUTATIONS IN PATIENTS FOLLOWING CYTOTOXIC THERAPY FOR LYMPHOMA	ONCOGENE			English	Article									UNIV COLL CARDIFF, DEPT HAEMATOL, LEUKAEMIA RES FUND PRELEUKAEMIA UNIT, HEATH PK, CARDIFF CF4 4XN, S GLAM, WALES; CETUS CORP, EMERYVILLE, CA 94608 USA	Cardiff University			Hughes, David/AAB-9237-2019; PADUA, Rose Ann/E-8621-2019; Padua, Rose Ann/GVT-5961-2022	Hughes, David/0000-0002-4539-3093; PADUA, Rose Ann/0000-0001-9964-7864; 				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BLAYNEY DW, 1987, NEW ENGL J MED, V316, P710, DOI 10.1056/NEJM198703193161203; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; CARTER G, 1989, CANCER CEL, V7, P143; DEMPSEY JL, 1985, CANCER RES, V45, P2873; EADIE JS, 1984, NATURE, V308, P201, DOI 10.1038/308201a0; FARR CJ, 1988, ONCOGENE, V3, P673; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GOW J, 1988, LEUKEMIA RES, V12, P805, DOI 10.1016/0145-2126(88)90033-1; GUERRERO I, 1986, LEUKEMIA RES, V10, P851, DOI 10.1016/0145-2126(86)90306-1; GUERRERO I, 1984, P NATL ACAD SCI-BIOL, V81, P202, DOI 10.1073/pnas.81.1.202; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; KALDOR JM, 1987, INT J CANCER, V39, P571, DOI 10.1002/ijc.2910390506; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1988, ONCOGENE, V3, P541; LEVINE EG, 1986, CLIN HAEMATOL, V15, P1037; LOECHLER EL, 1984, P NATL ACAD SCI-BIOL, V81, P6271, DOI 10.1073/pnas.81.20.6271; MORLEY AA, 1983, NATURE, V302, P155, DOI 10.1038/302155a0; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; PADUA RA, 1988, LEUKEMIA, V2, P503; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; PEDERSENBJERGAARD J, 1982, NEW ENGL J MED, V307, P965, DOI 10.1056/NEJM198210143071601; PEDERSENBJERGAARD J, 1987, LANCET, V2, P83, DOI 10.1016/S0140-6736(87)92744-9; PEDERSENBJERGAARD J, 1988, CANCER RES, V48, P1812; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SAWEY MJ, 1987, MOL CELL BIOL, V7, P932, DOI 10.1128/MCB.7.2.932; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; SHUKLA VK, 1989, IN PRESS ONCOGENE RE; STEENVOORDEN ACM, 1988, LEUKEMIA, V2, P325; STEVENSON M, 1986, MOL CELL BIOL, V6, P3410, DOI 10.1128/MCB.6.10.3410; STRAUSS GH, 1979, MUTAT RES, V61, P353, DOI 10.1016/0027-5107(79)90140-4; TRICOT G, 1985, BRIT J HAEMATOL, V59, P659, DOI 10.1111/j.1365-2141.1985.tb07361.x; YUNIS JJ, 1989, ONCOGENE, V4, P609; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	39	48	50	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1990	5	3					411	416						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	2179819				2022-12-17	WOS:A1990CW41500020
J	REEVES, BR; SMITH, S; FISHER, C; WARREN, W; KNIGHT, J; MARTIN, C; CHAN, AML; GUSTERSON, BA; WESTBURY, G; COOPER, CS				REEVES, BR; SMITH, S; FISHER, C; WARREN, W; KNIGHT, J; MARTIN, C; CHAN, AML; GUSTERSON, BA; WESTBURY, G; COOPER, CS			CHARACTERIZATION OF THE TRANSLOCATION BETWEEN CHROMOSOME-X AND CHROMOSOME-18 IN HUMAN SYNOVIAL SARCOMAS	ONCOGENE			English	Article									INST CANC RES, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND; ROYAL MARSDEN HOSP, LONDON SW3 6JJ, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	REEVES, BR (corresponding author), INST CANC RES, HADDOW LABS, 15 COTSWOLD RD, SUTTON SM2 5NG, SURREY, ENGLAND.		Chan, Andrew Man-Lok/J-9497-2013; gusterson, barry a/D-3752-2009	Chan, Andrew Man-Lok/0000-0001-9923-5464; 				ALHADEFF B, 1977, CYTOGENET CELL GENET, V19, P236, DOI 10.1159/000130814; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BRIDGE JA, 1988, CANCER, V62, P935, DOI 10.1002/1097-0142(19880901)62:5<935::AID-CNCR2820620514>3.0.CO;2-E; CORSON JM, 1984, HUM PATHOL, V15, P615, DOI 10.1016/S0046-8177(84)80284-1; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER C, 1986, HUM PATHOL, V17, P996, DOI 10.1016/S0046-8177(86)80083-1; FRIEND KK, 1976, SOMAT CELL GENET, V2, P183, DOI 10.1007/BF01542631; FUKUI M, 1985, P NATL ACAD SCI USA, V82, P5954, DOI 10.1073/pnas.82.17.5954; GALLIMORE PH, 1973, CHROMOSOMA, V41, P259, DOI 10.1007/BF00344020; GRIFFIN CA, 1987, CANCER GENET CYTOGEN, V26, P181, DOI 10.1016/0165-4608(87)90148-8; GUSTERSON B, 1985, INT J CANCER, V36, P689; Harnden DG, 1985, INT SYSTEM HUMAN CYT; HEIM S, 1987, CANCER CYTOGENETICS; HEYDERMAN E, 1979, J CLIN PATHOL, V32, P35, DOI 10.1136/jcp.32.1.35; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; ISHIKAWA F, 1986, P NATL ACAD SCI USA, V83, P3209, DOI 10.1073/pnas.83.10.3209; KLEBE RJ, 1970, J CELL BIOL, V45, P74, DOI 10.1083/jcb.45.1.74; LIMON J, 1986, CANCER GENET CYTOGEN, V23, P87, DOI 10.1016/0165-4608(86)90152-4; LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709; MANDAHL N, 1988, CANCER GENET CYTOGEN, V30, P323, DOI 10.1016/0165-4608(88)90202-6; MIETTINEN M, 1983, VIRCHOWS ARCH B, V44, P187, DOI 10.1007/BF02890169; MIETTINEN M, 1984, AM J PATHOL, V117, P18; NOGUERA R, 1988, CANCER GENET CYTOGEN, V33, P311, DOI 10.1016/0165-4608(88)90040-4; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SHENG WW, 1987, CANCER GENET CYTOGEN, V29, P179, DOI 10.1016/0165-4608(87)90048-3; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; SMITH S, 1987, CANCER GENET CYTOGEN, V26, P179, DOI 10.1016/0165-4608(87)90147-6; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; UEDA T, 1988, CANCER GENET CYTOGEN, V30, P183, DOI 10.1016/0165-4608(88)90111-2; WITTE ON, 1986, CANCER SURV, V5, P183; 1988, CYTOGENT CELL GENET, V46, P1	36	48	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1989	4	3					373	378						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2704557				2022-12-17	WOS:A1989U567600014
J	Simon, T; Jackson, E; Giamas, G				Simon, Thomas; Jackson, Ellen; Giamas, Georgios			Breaking through the glioblastoma micro-environment via extracellular vesicles	ONCOGENE			English	Review							GLIOMA-CELLS; ENDOTHELIAL-CELLS; TUMOR-GROWTH; EXOSOMES; BRAIN; RNA; ANGIOGENESIS; SURVIVAL; DELIVERY; PROMOTE	Glioblastoma (GBM) is the most common and most aggressive brain tumour. Prognosis remains poor, despite the combined treatment of radio- and chemotherapy following surgical removal. GBM cells coexist with normal non-neoplastic cells, including endothelial cells, astrocytes and immune cells, constituting a complex and dynamic tumour micro-environment (TME). Extracellular vesicles (EVs) provide a critical means of bidirectional inter-cellular communication in the TME. Through delivery of a diverse range of genomic, lipidomic and proteomic cargo to neighbouring and distant cells, EVs can alter the phenotype and function of the recipient cell. As such, EVs have demonstrated their role in promoting angiogenesis, immune suppression, invasion, migration, drug resistance and GBM recurrence. Moreover, EVs can reflect the phenotype of the cells within the TME. Thus, in conjunction with their accessibility in biofluids, they can potentially serve as a biomarker reservoir for patient prognosis, diagnosis and predictive therapeutic response as well as treatment follow-up. Furthermore, together with the ability of EVs to cross the blood-brain barrier undeterred and through the exploitation of their cargo, EVs may provide an effective mean of drug delivery to the target site. Unveiling the mechanisms by which EVs within the GBM TME are secreted and target recipient cells may offer an indispensable understanding of GBM that holds the potential to provide a better prognosis and overall quality of life for GBM patients.	[Simon, Thomas; Jackson, Ellen; Giamas, Georgios] Univ Sussex, Sch Life Sci, Dept Biochem & Biomed, Brighton BN1 9QG, E Sussex, England	University of Sussex	Simon, T; Giamas, G (corresponding author), Univ Sussex, Sch Life Sci, Dept Biochem & Biomed, Brighton BN1 9QG, E Sussex, England.	t.simon@sussex.ac.uk; g.giamas@sussex.ac.uk	Giamas, Georgios/AAP-3487-2021	Simon, Thomas/0000-0002-3280-2716	Action Against Cancer; Rothschild Foundation; Searle Memorial Charitable Trust; Colin McDavid Family Trust; Bernard Sunley Foundation	Action Against Cancer; Rothschild Foundation; Searle Memorial Charitable Trust; Colin McDavid Family Trust; Bernard Sunley Foundation	This work was supported by Action Against Cancer, The Colin McDavid Family Trust, The Rothschild Foundation, The Bernard Sunley Foundation, The Searle Memorial Charitable Trust, Mr. Alessandro Dusi, and Mr. Milan Markovic.	Abels ER, 2019, CELL REP, V28, P3105, DOI 10.1016/j.celrep.2019.08.036; Andre-Gregoire G, 2017, CELL ADHES MIGR, V11, P164, DOI 10.1080/19336918.2016.1247145; [Anonymous], [No title captured]; Azam Zulfikar, 2019, Acta Oncol, V58, P353, DOI 10.1080/0284186X.2018.1551621; Balachandran B., 2019, COGENT MED, V6, DOI [10.1080/2331205X.2019.1635806, DOI 10.1080/2331205X.2019.1635806]; Banelli B, 2017, INT J GENOMICS, V2017, DOI 10.1155/2017/7639084; Baulch JE, 2016, ENVIRON MOL MUTAGEN, V57, P405, DOI 10.1002/em.21988; Behnan J, 2019, BRAIN, V142, P847, DOI 10.1093/brain/awz044; Benito-Jardon M, 2017, ELIFE, V6, DOI 10.7554/eLife.22264; Berenguer J, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1446660; Brandao M, 2019, GLIA, V67, P779, DOI 10.1002/glia.23520; Bronisz A, 2014, CANCER RES, V74, P738, DOI 10.1158/0008-5472.CAN-13-2650; Brown NF, 2018, BRIT J CANCER, V119, P1171, DOI 10.1038/s41416-018-0258-8; Chandran VI, 2019, J NEURO-ONCOL, V144, P477, DOI 10.1007/s11060-019-03262-4; Chen JWE, 2018, FRONT MATER, V5, DOI 10.3389/fmats.2018.00039; Chetty C, 2012, CELL SIGNAL, V24, P549, DOI 10.1016/j.cellsig.2011.10.008; Cuperlovic-Culf M, ANAL SIMULATION GLIO, pE88, DOI [10.3390/metabo10030088, DOI 10.3390/METAB010030088]; Davis CN, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007191; Davis ME, 2016, CLIN J ONCOL NURS, V20, P2, DOI 10.1188/16.CJON.S1.2-8; De Vleeschouwer S, 2017, GLIOBLASTOMA, P315, DOI 10.15586/codon.glioblastoma.2017.ch16; Domenis R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169932; Erkan EP, 2017, CANCER GENE THER, V24, P38, DOI 10.1038/cgt.2016.78; Fidoamore A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6809105; Gabrusiewicz K, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1412909; Gao XF, 2020, CELL REP, V30, P2489, DOI 10.1016/j.celrep.2020.01.089; Garofalo M, 2019, THERANOSTICS, V9, P5681, DOI 10.7150/thno.34824; Greene C, 2019, FLUIDS BARRIERS CNS, V16, DOI 10.1186/s12987-019-0123-z; Grimaldi A, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00041; Guo XF, 2019, INT J CANCER, V144, P3111, DOI 10.1002/ijc.32052; Guo YW, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00125; Gupta K, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00503; Hallal S, 2019, MOL NEUROBIOL, V56, P4566, DOI 10.1007/s12035-018-1385-1; Harder BG, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00462; Heffernan JM, 2018, FRONT MATER, V5, DOI 10.3389/fmats.2018.00007; Hellwinkel JE, 2015, IMMUNE MODULATION TU, P329; Jena L, 2019, TRANSL RES, V10, P304; Jovanovic N, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55020034; Kesanakurti D, 2013, ONCOGENE, V32, P327, DOI 10.1038/onc.2012.52; Kim Y, 2014, MOL CANCER RES, V12, P1416, DOI 10.1158/1541-7786.MCR-13-0629; Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110; Lam D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40128-1; Lane R, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0560-x; Lang HL, 2017, EUR REV MED PHARMACO, V21, P959; Lang HL, 2017, ONCOL REP, V38, P785, DOI 10.3892/or.2017.5742; Lim EJ, 2017, ONCOTARGET, V8, P1438, DOI 10.18632/oncotarget.13638; Loo HK, 2019, BIOMARK MED, V13, P161, DOI 10.2217/bmm-2018-0463; Lucero R, 2020, CELL REP, V30, P2065, DOI 10.1016/j.celrep.2020.01.073; Ma X, 2017, AM J TRANSL RES, V9, P5012; Mallawaaratchy DM, 2017, J NEURO-ONCOL, V131, P233, DOI 10.1007/s11060-016-2298-3; Margolis L, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000363; Misra S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00201; Mondal A, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00144; Monteiro AR, 2017, CELLS-BASEL, V6, DOI 10.3390/cells6040045; Morad G, 2019, ACS NANO, V13, P13853, DOI 10.1021/acsnano.9b04397; Munoz JL, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00134; Munoz JL, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.60; Nareshkumar RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28745-8; Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024; Ning XF, 2018, MED SCI MONITOR, V24, P2350, DOI 10.12659/MSM.906641; Osti D, 2019, CLIN CANCER RES, V25, P266, DOI 10.1158/1078-0432.CCR-18-1941; Oushy S, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0477; Parker NR, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00055; Parodi A, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11050245; Qian MY, 2020, ONCOGENE, V39, P428, DOI 10.1038/s41388-019-0996-y; Rackov G, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00651; Ramachandran RK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172234; Rempe RG, 2016, J CEREBR BLOOD F MET, V36, P1481, DOI 10.1177/0271678X16655551; Ricklefs F, 2016, CANCER RES, V76, P2876, DOI 10.1158/0008-5472.CAN-15-3432; Ricklefs FL, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar2766; Saint-Pol JAO, TARGETING CROSSING B, pE851, DOI [10.3390/cells9040851, DOI 10.3390/CELLS9040851]; Schiffer D, 2019, CANCERS, V11, DOI 10.3390/cancers11010005; Serlin Y, 2015, SEMIN CELL DEV BIOL, V38, P2, DOI 10.1016/j.semcdb.2015.01.002; Shao HL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7999; Sharma A, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00146; Si WG, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-018-0587-8; Simon T, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0878-x; Simon T, 2017, TRENDS MOL MED, V23, P282, DOI 10.1016/j.molmed.2017.01.002; Simon T, 2014, NEUROMOL MED, V16, P752, DOI 10.1007/s12017-014-8324-8; Simon Thomas, 2020, INT J MOL SCI, V21, P3071; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Spinelli C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1490144; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Sullivan R, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00194; Sun X, 2017, ONCOTARGET, V8, P36137, DOI 10.18632/oncotarget.16661; Svensson KJ, 2011, P NATL ACAD SCI USA, V108, P13147, DOI 10.1073/pnas.1104261108; Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750; Todorova D, 2017, CIRC RES, V120, P1658, DOI 10.1161/CIRCRESAHA.117.309681; Treps L, 2016, ONCOGENE, V35, P2615, DOI 10.1038/onc.2015.317; Treps L, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2017.1359479; van der Vlis TAMB, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0591-4; van der Vos KE, 2016, NEURO-ONCOLOGY, V18, P58, DOI 10.1093/neuonc/nov244; Venkatesh HS, 2017, NATURE, V549, P533, DOI 10.1038/nature24014; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Walker S, 2019, THERANOSTICS, V9, P8001, DOI 10.7150/thno.37097; Wang FF, 2018, EBIOMEDICINE, V37, P68, DOI 10.1016/j.ebiom.2018.10.024; Wang ZF, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1181-4; Watkins S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5196; Wendler F, 2017, ONCOGENE, V36, P877, DOI 10.1038/onc.2016.253; Xue Q, 2017, ONCOL LETT, V13, P1325, DOI 10.3892/ol.2017.5567; Yi Y, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00477; Yin JX, 2019, EBIOMEDICINE, V42, P238, DOI 10.1016/j.ebiom.2019.03.016; Yu TF, 2018, CANCER LETT, V433, P210, DOI 10.1016/j.canlet.2018.06.041; Zeng AL, 2018, CANCER LETT, V436, P10, DOI 10.1016/j.canlet.2018.08.004; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zhao C, 2018, BIOCHEM BIOPH RES CO, V502, P324, DOI 10.1016/j.bbrc.2018.05.140; Zhao X, 2017, ACTA PHARM SIN B, V7, P541, DOI [10.1016/j.apsh.2017.07.002, 10.1016/j.apsb.2017.07.002]	106	47	47	4	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4477	4490		10.1038/s41388-020-1308-2	http://dx.doi.org/10.1038/s41388-020-1308-2		MAY 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32366909	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000530271400003
J	Luo, AP; Zhou, XT; Shi, X; Zhao, YH; Men, Y; Chang, X; Chen, HY; Ding, F; Li, Y; Su, D; Xiao, ZF; Hui, ZG; Liu, ZH				Luo, Aiping; Zhou, Xuantong; Shi, Xing; Zhao, Yahui; Men, Yu; Chang, Xiao; Chen, Hongyan; Ding, Fang; Li, Yi; Su, Dan; Xiao, Zefen; Hui, Zhouguang; Liu, Zhihua			Exosome-derived miR-339-5p mediates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma	ONCOGENE			English	Article							NEOADJUVANT CHEMORADIOTHERAPY; P53-INDUCIBLE MICRORNAS; PROGNOSTIC-SIGNIFICANCE; H2AX PHOSPHORYLATION; TUMOR-SUPPRESSOR; DOWN-REGULATION; DNA-DAMAGE; CANCER; STAGE; EXPRESSION	Cancer cells associated with radioresistance are likely to give rise to local recurrence and distant metastatic relapse. However, it remains unclear whether specific miRNAs have direct roles in radioresistance and/or prognosis. In this study, we find that miR-339-5p promotes radiosensitivity, and is downregulated in radioresistant subpopulations of esophageal cancer cells. Notably, miR-339-5p was selectively secreted into blood via exosomes, and that higher serum miR-339-5p levels were positively associated with radiotherapy sensitivity and good survival. Moreover, miR-339-5p expression was downregulated in the T3/T4 stage compared with T1/T2 stage in esophageal squamous cell carcinoma (ESCC) patients (P = 0.04), and low miR-339-5p expression in tissue was significantly associated with poor overall survival (P = 0.036) and disease-free survival (P = 0.037). Overexpression of miR-339-5p enhanced radiosensitivity in vitro and in vivo. Mechanistically, miR-339-5p enhances radiosensitivity by targeting Cdc25A, and is transcriptionally regulated by Runx3. Correlations were observed between miR-339-5p levels and Cdc25A/Runx3 levels in tissue samples. Intriguingly, combined analysis of miR-339-5p expression with Runx3 increased the separation of the survival curves obtained for either gene alone in the TCGA datasets (P = 0.009). Overall, exosome-derived miR-339-5p mediates radiosensitivity through downregulation of Cdc25A, and predicts pathological response to preoperative radiotherapy in locally advanced ESCC, suggesting it could be a promising non-invasive biomarker for facilitating personalized treatments.	[Luo, Aiping; Zhou, Xuantong; Zhao, Yahui; Chen, Hongyan; Ding, Fang; Li, Yi; Liu, Zhihua] Chinese Acad Med Sci, State Key Lab Mol Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China; [Luo, Aiping; Zhou, Xuantong; Zhao, Yahui; Men, Yu; Chang, Xiao; Chen, Hongyan; Ding, Fang; Li, Yi; Xiao, Zefen; Hui, Zhouguang; Liu, Zhihua] Peking Union Med Coll, Beijing 100021, Peoples R China; [Shi, Xing] Chinese Acad Sci, Beijing Inst Genom, Key Lab Genome Sci & Informat, Beijing 100101, Peoples R China; [Men, Yu; Chang, Xiao; Xiao, Zefen; Hui, Zhouguang] Chinese Acad Med Sci, Dept Radiotherapy, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China; [Su, Dan] Zhejiang Canc Hosp, Dept Pathol, Hangzhou 310022, Zhejiang, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Sciences; Beijing Institute of Genomics, CAS; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Zhejiang Cancer Hospital	Liu, ZH (corresponding author), Chinese Acad Med Sci, State Key Lab Mol Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China.; Xiao, ZF; Hui, ZG; Liu, ZH (corresponding author), Peking Union Med Coll, Beijing 100021, Peoples R China.; Xiao, ZF; Hui, ZG (corresponding author), Chinese Acad Med Sci, Dept Radiotherapy, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China.	xiaozefen@sina.com; huizg@cicams.ac.cn; liuzh@cicams.ac.cn	dong, wang/T-9093-2019; su, dan/GYJ-1940-2022	Chang, Xiao/0000-0003-0560-2441; Zhao, Yahui/0000-0002-9613-1384; Xiao, Zefen/0000-0003-0503-6814	National Key R&D program of China [2016YFC1302100]; National Natural Science Foundation of China [81472791, 81372418]; CAMS Initiative for Innovative Medicine [2016-I2M-1-001]	National Key R&D program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Initiative for Innovative Medicine	We thank Dr. Yutaka Shimada for the generous gifts of ESCC cell lines (KYSE series). This research was supported by National Key R&D program of China (2016YFC1302100), National Natural Science Foundation of China (81472791, 81372418), and CAMS Initiative for Innovative Medicine (2016-I2M-1-001).	Banath JP, 2004, CANCER RES, V64, P7144, DOI 10.1158/0008-5472.CAN-04-1433; Challagundla KB, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv135; Chowdhury D, 2013, NAT REV MOL CELL BIO, V14, P181, DOI 10.1038/nrm3523; Davies L, 2010, CLIN ONCOL-UK, V22, P578, DOI 10.1016/j.clon.2010.05.023; Eriksson D, 2010, TUMOR BIOL, V31, P363, DOI 10.1007/s13277-010-0042-8; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Georges SA, 2008, CANCER RES, V68, P10105, DOI 10.1158/0008-5472.CAN-08-1846; Gupta S, 2014, NATURE, V512, P101, DOI 10.1038/nature13382; Hamai Y, 2017, ANTICANCER RES, V37, P5639, DOI 10.21873/anticanres.11999; Jansson MD, 2015, ONCOGENE, V34, P1908, DOI 10.1038/onc.2014.130; Jorgensen S, 2010, METHODS, V52, P375, DOI 10.1016/j.ymeth.2010.07.002; Kawai T, 2017, ANTICANCER RES, V37, P3301, DOI 10.21873/anticanres.11697; Kim S, 2008, J BIOL CHEM, V283, P18158, DOI 10.1074/jbc.M800186200; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Krishnan V, 2017, ADV EXP MED BIOL, V962, P491, DOI 10.1007/978-981-10-3233-2_29; Long JM, 2014, J BIOL CHEM, V289, P5184, DOI 10.1074/jbc.M113.518241; Maier P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010102; Majidinia M, 2016, DNA REPAIR, V47, P1, DOI 10.1016/j.dnarep.2016.09.003; Melo SA, 2014, CANCER CELL, V26, P707, DOI 10.1016/j.ccell.2014.09.005; Morgan MA, 2015, CLIN CANCER RES, V21, P2898, DOI 10.1158/1078-0432.CCR-13-3229; Nedaeinia R, 2017, CANCER GENE THER, V24, P48, DOI 10.1038/cgt.2016.77; Odenthal M, 2013, INT J CANCER, V133, P2454, DOI 10.1002/ijc.28253; Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Phinney DG, 2017, STEM CELLS, V35, P851, DOI 10.1002/stem.2575; Pichiorri F, 2010, CANCER CELL, V18, P367, DOI 10.1016/j.ccr.2010.09.005; Prathipati P, 2017, STEM CELL REV REP, V13, P79, DOI 10.1007/s12015-016-9696-y; Sakakura C, 2007, ONCOGENE, V26, P5927, DOI 10.1038/sj.onc.1210403; Schwarzenbach H, 2014, NAT REV CLIN ONCOL, V11, P145, DOI 10.1038/nrclinonc.2014.5; Shapiro J, 2015, LANCET ONCOL, V16, P1090, DOI 10.1016/S1470-2045(15)00040-6; Shen B, 2015, FEBS LETT, V589, P3205, DOI 10.1016/j.febslet.2015.09.009; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sjoquist KM, 2011, LANCET ONCOL, V12, P681, DOI 10.1016/S1470-2045(11)70142-5; Takeshita N, 2013, BRIT J CANCER, V108, P644, DOI 10.1038/bjc.2013.8; Tanaka Y, 2013, CANCER-AM CANCER SOC, V119, P1159, DOI 10.1002/cncr.27895; Taneja N, 2004, J BIOL CHEM, V279, P2273, DOI 10.1074/jbc.M310030200; Tellez CS, 2016, CANCER RES, V76, P4741, DOI 10.1158/0008-5472.CAN-15-3367; Ueda R, 2009, P NATL ACAD SCI USA, V106, P10746, DOI 10.1073/pnas.0811817106; Villarroya-Beltri C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3980; Weber CEM, 2016, CANCER RES, V76, P3562, DOI 10.1158/0008-5472.CAN-15-2932; Wu ZS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-542; Yamada C, 2010, J BIOL CHEM, V285, P16693, DOI 10.1074/jbc.M109.055525; Zhang PJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6671	44	47	49	3	34	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					4990	5006		10.1038/s41388-019-0771-0	http://dx.doi.org/10.1038/s41388-019-0771-0			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30858545				2022-12-17	WOS:000472145900008
J	Zhang, JW; Dulak, AM; Hattersley, MM; Willis, BS; Nikkila, J; Wang, A; Lau, A; Reimer, C; Zinda, M; Fawell, SE; Mills, GB; Chen, HW				Zhang, Jingwen; Dulak, Austin M.; Hattersley, Maureen M.; Willis, Brandon S.; Nikkila, Jenni; Wang, Anderson; Lau, Alan; Reimer, Corinne; Zinda, Michael; Fawell, Stephen E.; Mills, Gordon B.; Chen, Huawei			BRD4 facilitates replication stress-induced DNA damage response	ONCOGENE			English	Article							BROMODOMAIN PROTEIN BRD4; ACUTE MYELOID-LEUKEMIA; DOUBLE-STRAND BREAKS; THERAPEUTIC TARGET; OVARIAN-CARCINOMA; ATR KINASE; IN-VIVO; S-PHASE; INHIBITOR; CANCER	Previous reports have demonstrated that select cancers depend on BRD4 to regulate oncogenic gene transcriptional programs. Here we describe a novel role for BRD4 in DNA damage response (DDR). BRD4 associates with and regulates the function of pre-replication factor CDC6 and plays an indispensable part in DNA replication checkpoint signaling. Inhibition of BRD4 by JQ1 or AZD5153 resulted in a rapid, time-dependent reduction in CHK1 phosphorylation and aberrant DNA replication re-initiation. Furthermore, BRD4 inhibition sensitized cancer cells to various replication stress-inducing agents, and synergized with ATR inhibitor AZD6738 to induce cell killing across a number of cancer cell lines. The synergistic interaction between AZD5153 and AZD6738 is translatable to in vivo ovarian cell-line and patient-derived xenograft models. Taken together, our study uncovers a new biological function of BRD4 and provides mechanistic rationale for combining BET inhibitors with DDR-targeted agents for cancer therapy.	[Zhang, Jingwen; Dulak, Austin M.; Hattersley, Maureen M.; Willis, Brandon S.; Reimer, Corinne; Zinda, Michael; Fawell, Stephen E.; Chen, Huawei] AstraZeneca R&D, IMED Biotech Unit, Oncol, Boston, MA 02298 USA; [Nikkila, Jenni; Wang, Anderson; Lau, Alan] AstraZeneca, IMED Biotech Unit, Oncol, Cambridge, England; [Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	AstraZeneca; AstraZeneca; University of Texas System; UTMD Anderson Cancer Center	Chen, HW (corresponding author), AstraZeneca R&D, IMED Biotech Unit, Oncol, Boston, MA 02298 USA.	raymond.chen@astrazeneca.com	Zhang, Jing/GWZ-7332-2022	Wang, Anderson/0000-0002-3571-5095; Mills, Gordon/0000-0002-0144-9614; Lau, Alan/0000-0003-1055-9812	NATIONAL CANCER INSTITUTE [U01CA217842] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA217842] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amorim S, 2016, LANCET HAEMATOL, V3, pE196, DOI 10.1016/S2352-3026(16)00021-1; Baker A, 2016, CANCER RES, V76, P1158, DOI 10.1158/0008-5472.CAN-15-1070; Baratta MG, 2015, P NATL ACAD SCI USA, V112, P232, DOI 10.1073/pnas.1422165112; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Borlado LR, 2008, CARCINOGENESIS, V29, P237, DOI 10.1093/carcin/bgm268; Bradbury RH, 2016, J MED CHEM, V59, P7801, DOI 10.1021/acs.jmedchem.6b00070; Chen R, 2005, BLOOD, V106, P2513, DOI 10.1182/blood-2005-04-1678; Chen YH, 2009, J BIOL CHEM, V284, P182, DOI 10.1074/jbc.M806530200; Chiang CM, 2009, BIOL REP, V1, P98, DOI DOI 10.3410/B1-98; Crafter C, 2015, INT J ONCOL, V47, P446, DOI 10.3892/ijo.2015.3062; Degorce SL, 2016, J MED CHEM, V59, P6281, DOI 10.1021/acs.jmedchem.6b00519; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Dobbelstein M, 2015, NAT REV DRUG DISCOV, V14, P405, DOI 10.1038/nrd4553; Duursma AM, 2005, CELL CYCLE, V4, P1725, DOI 10.4161/cc.4.12.2193; Elsasser S, 1999, MOL BIOL CELL, V10, P3263, DOI 10.1091/mbc.10.10.3263; Etemadmoghadam D, 2013, CLIN CANCER RES, V19, P5960, DOI 10.1158/1078-0432.CCR-13-1337; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Floyd SR, 2013, NATURE, V498, P246, DOI 10.1038/nature12147; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Foote KM, 2015, FUTURE MED CHEM, V7, P873, DOI [10.4155/FMC.15.33, 10.4155/fmc.15.33]; Gelot C, 2015, GENES-BASEL, V6, P267, DOI 10.3390/genes6020267; Gong FD, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006272; Goundiam O, 2015, INT J CANCER, V137, P1890, DOI 10.1002/ijc.29568; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Kilkenny C, 2010, J PHARMACOL PHARMACO, V1, P94, DOI 10.4103/0976-500X.72351; Koltun ES, 2012, BIOORG MED CHEM LETT, V22, P3727, DOI 10.1016/j.bmcl.2012.04.024; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lehar J, 2009, NAT BIOTECHNOL, V27, P659, DOI 10.1038/nbt.1549; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Maruyama T, 2002, MOL CELL BIOL, V22, P6509, DOI 10.1128/MCB.22.18.6509-6520.2002; Montagnoli A, 2008, NAT CHEM BIOL, V4, P357, DOI 10.1038/nchembio.90; Montecucco A, 2007, CANCER LETT, V252, P9, DOI 10.1016/j.canlet.2006.11.005; Nam EA, 2011, J BIOL CHEM, V286, P28707, DOI 10.1074/jbc.M111.248914; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Oehlmann M, 2004, J CELL BIOL, V165, P181, DOI 10.1083/jcb.200311044; Price BD, 2013, CELL, V152, P1344, DOI 10.1016/j.cell.2013.02.011; Puigvert JC, 2016, FEBS J, V283, P232, DOI 10.1111/febs.13574; Rhyasen GW, 2016, MOL CANCER THER, V15, P2563, DOI 10.1158/1535-7163.MCT-16-0141; Rodriguez-Bravo V, 2006, CANCER RES, V66, P8672, DOI 10.1158/0008-5472.CAN-05-4443; Shi JW, 2014, MOL CELL, V54, P728, DOI 10.1016/j.molcel.2014.05.016; Stanlie A, 2014, MOL CELL, V55, P97, DOI 10.1016/j.molcel.2014.05.018; Stathis A, 2016, CANCER DISCOV, V6, P492, DOI 10.1158/2159-8290.CD-15-1335; Toledo LI, 2011, NAT STRUCT MOL BIOL, V18, P721, DOI 10.1038/nsmb.2076; Vendetti FP, 2015, ONCOTARGET, V6, P44289, DOI 10.18632/oncotarget.6247; Walter D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10530; Waring MJ, 2016, NAT CHEM BIOL, V12, P1097, DOI [10.1038/NCHEMBIO.2210, 10.1038/nchembio.2210]; Wu SY, 2007, J BIOL CHEM, V282, P13141, DOI 10.1074/jbc.R700001200; Yang ZY, 2008, MOL CELL BIOL, V28, P967, DOI 10.1128/MCB.01020-07; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	54	47	48	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3763	3777		10.1038/s41388-018-0194-3	http://dx.doi.org/10.1038/s41388-018-0194-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29636547	Green Accepted			2022-12-17	WOS:000438465600001
J	Zuo, Q; Liu, J; Huang, LP; Qin, YF; Hawley, T; Seo, C; Merlino, G; Yu, YL				Zuo, Qiang; Liu, Jing; Huang, Liping; Qin, Yifei; Hawley, Teresa; Seo, Claire; Merlino, Glenn; Yu, Yanlin			AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASES; METASTATIC MELANOMA; ACQUIRED-RESISTANCE; THERAPEUTIC IMPLICATIONS; MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; SIGNALING PATHWAYS; TARGETED THERAPY; MEK INHIBITION; RAF INHIBITION	Multiple genetic mutations within melanoma not only cause lesion-specific responses to targeted therapy but also alter the molecular route of resistance to that therapy. Inactivation of PTEN occurs in up to 30% of melanomas, frequently with a concurrent activating BRAF mutation. PTEN loss regulates both acquired and intrinsic drug resistance. Here we show that AXL/AKT axis mediated-resistance to BRAF inhibitor (BRAFi) depends upon PTEN status in melanoma. Hyperactivation of both ERK and AKT pathways was associated with BRAFi resistance in melanoma with wildtype PTEN. The PTEN-impaired melanoma cells required only the ERK resistance mechanism. Moreover, we identified AXL as a key upstream effector of AKT pathway-associated resistance to BRAFi in melanoma with wildtype PTEN, but not in melanoma with impaired PTEN. Notably, we confirmed that blocking AXL by shRNA and a small molecular inhibitor could rescue the sensitivity of resistant melanoma cells with wildtype PTEN to BRAFi and inhibit their growth in vitro and in vivo. Our study has uncovered a mechanism by which PTEN status contributes to acquired resistance to BRAFi and offers a rational strategy to guide clinical testing in pre-identified subsets of patients who relapse during treatment with BRAFi. The identified protein AXL represents a promising therapeutic target for BRAF mutant melanoma patients with wildtype PTEN.	[Zuo, Qiang; Huang, Liping; Qin, Yifei; Seo, Claire; Merlino, Glenn; Yu, Yanlin] NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Zuo, Qiang; Liu, Jing; Huang, Liping] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou 510515, Guangdong, Peoples R China; [Hawley, Teresa] NCI, Lab Genome Integr, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Southern Medical University - China; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yu, YL (corresponding author), NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	YuY@mail.nih.gov			NIH; NATIONAL CANCER INSTITUTE [ZIABC008756] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by funding from the NIH intramural research program. Thanks, are due to Dr. Miriam Anver for assistance with immunohistochemistry.	Brand TM, 2014, CANCER RES, V74, P5152, DOI 10.1158/0008-5472.CAN-14-0294; Bucheit AD, 2014, CLIN CANCER RES, V20, P5527, DOI 10.1158/1078-0432.CCR-14-1027; Byron SA, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-75; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen G, 2014, HEMATOL ONCOL CLIN N, V28, P523, DOI 10.1016/j.hoc.2014.03.001; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deng W, 2012, PIGM CELL MELANOMA R, V25, DOI 10.1111/j.1755-148X.2011.00950.x; Durban VM, 2013, J CLIN INVEST, V123, P5104, DOI 10.1172/JCI69619; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Giles KM, 2013, MOL CANCER THER, V12, P2541, DOI 10.1158/1535-7163.MCT-13-0170; Girotti MR, 2013, CANCER DISCOV, V3, P158, DOI 10.1158/2159-8290.CD-12-0386; Gopal YNV, 2010, CANCER RES, V70, P8736, DOI 10.1158/0008-5472.CAN-10-0902; Haluska FG, 2006, CLIN CANCER RES, V12, p2301S, DOI 10.1158/1078-0432.CCR-05-2518; Hather G, 2014, CANCER INFORM, V13, P65, DOI 10.4137/CIN.S13974; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; HERBST RA, 1994, CANCER RES, V54, P3111; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Meyer AS, 2015, CELL SYST, V1, P25, DOI 10.1016/j.cels.2015.06.002; Meyer AS, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004155; Miller MA, 2016, CANCER DISCOV, V6, P382, DOI 10.1158/2159-8290.CD-15-0933; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Nathanson KL, 2013, CLIN CANCER RES, V19, P4868, DOI 10.1158/1078-0432.CCR-13-0827; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Ribas A, 2014, LANCET ONCOL, V15, P954, DOI 10.1016/S1470-2045(14)70301-8; Sensi M, 2011, J INVEST DERMATOL, V131, P2448, DOI 10.1038/jid.2011.218; Sheskin DJ., 2011, HDB PARAMETRIC NONPA, V5, DOI [10.2307/2685909, DOI 10.1201/9781420036268]; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Stahl JM, 2003, CANCER RES, V63, P2881; Sullivan Ryan, 2015, Am Soc Clin Oncol Educ Book, P177, DOI 10.14694/EdBook_AM.2015.35.177; Sullivan RJ, 2014, HEMATOL ONCOL CLIN N, V28, P437, DOI 10.1016/j.hoc.2014.02.007; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Yao TW, 2017, ONCOTARGET, V8, P583, DOI 10.18632/oncotarget.11882; Yu YL, 2006, CANCER RES, V66, P1982, DOI 10.1158/0008-5472.CAN-05-2360; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	50	47	48	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3275	3289		10.1038/s41388-018-0205-4	http://dx.doi.org/10.1038/s41388-018-0205-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29551771	Green Accepted			2022-12-17	WOS:000435526600007
J	Liu, XY; Bi, L; Wang, Q; Wen, MX; Li, C; Ren, YD; Jiao, QL; Mao, JH; Wang, CX; Wei, GW; Wang, YS				Liu, Xiaoyan; Bi, Lei; Wang, Qin; Wen, Mingxin; Li, Ce; Ren, Yidan; Jiao, Qinlian; Mao, Jian-Hua; Wang, Chuanxin; Wei, Guangwei; Wang, Yunshan			miR-1204 targets VDR to promotes epithelial-mesenchymal transition and metastasis in breast cancer	ONCOGENE			English	Article							VITAMIN-D-RECEPTOR; PVT1; PROGRESSION; EXPRESSION; PROSTATE; CELLS; EMT; AMPLIFICATION; CONTRIBUTES; CATENIN	Plasmacytoma variant translocation 1 (PVT1) is an lncRNA that plays vital roles in breast cancer (BC) pathogenesis. Increasing evidence suggests that miRNAs that reside in the PVT1 locus are the main driver of the oncogenic roles of PVT1 in cancer. However, the oncogenic role and underlying mechanism of miR-1204, located in the PVT1 locus, in human cancer is still unclear. In this study, we discovered that increased expression of miR-1204 is associated with poor prognosis in BC. Moreover, miR-1204 promotes proliferation, epithelial-mesenchymal transition and invasion of BC cells both in vitro and in vivo. Mechanistic investigations demonstrated that VDR is a novel target gene of miR-1204. Interference of VDR restored miR-1204-mediated BC cell proliferation, tumorigenesis, and metastasis. Collectively, our results demonstrated that the miR-1204-VDR pathway exerts oncogenic effects in BC with potential therapeutic applications in blocking BC development and progression.	[Liu, Xiaoyan; Wen, Mingxin; Wei, Guangwei; Wang, Yunshan] Shandong Univ, Sch Med, Minist Educ, Dept Human Anat, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Liu, Xiaoyan; Wen, Mingxin; Wei, Guangwei; Wang, Yunshan] Shandong Univ, Sch Med, Minist Educ, Key Lab Expt Teratol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Bi, Lei; Mao, Jian-Hua; Wang, Yunshan] Lawrence Berkeley Natl Lab, Biol Syst & Engn Div, Berkeley, CA 94720 USA; [Wang, Qin] Shandong Univ, Qilu Hosp, Dept Anesthesiol, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Li, Ce; Ren, Yidan; Jiao, Qinlian; Wang, Yunshan] Shandong Univ, Sch Ocean, Int Biotechnol R&D Ctr, 180 Wenhua Xi Rd, Weihai 264209, Shandong, Peoples R China; [Bi, Lei] Nanjing Univ Chinese Med, Sch Preclin Med, 138 Xianlin Rd, Nanjing 210023, Jiangsu, Peoples R China; [Wang, Chuanxin] Shandong Univ, Hosp 2, Dept Clin Lab, Jinan 250033, Shandong, Peoples R China	Shandong University; Shandong University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Shandong University; Shandong University; Nanjing University of Chinese Medicine; Shandong University	Wei, GW; Wang, YS (corresponding author), Shandong Univ, Sch Med, Minist Educ, Dept Human Anat, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Wei, GW; Wang, YS (corresponding author), Shandong Univ, Sch Med, Minist Educ, Key Lab Expt Teratol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Wang, YS (corresponding author), Lawrence Berkeley Natl Lab, Biol Syst & Engn Div, Berkeley, CA 94720 USA.; Wang, YS (corresponding author), Shandong Univ, Sch Ocean, Int Biotechnol R&D Ctr, 180 Wenhua Xi Rd, Weihai 264209, Shandong, Peoples R China.	gwwei@yahoo.com; wangyunshan135@126.com	Mao, Jian-Hua/EIZ-8595-2022	Mao, Jian-Hua/0000-0001-9320-6021	China Postdoctoral International Exchange Program; National Natural Science Foundation of China [81402193, 31271461, 81472583, 81528017]; Postdoctoral Innovation Project of Shandong Province [147751]; Postdoctoral Science Foundation of China [2015M570597]; National Key R&D Program of China [2017YFC1308600]; Taishan Scholar Program of Shandong Province	China Postdoctoral International Exchange Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Postdoctoral Innovation Project of Shandong Province; Postdoctoral Science Foundation of China(China Postdoctoral Science Foundation); National Key R&D Program of China; Taishan Scholar Program of Shandong Province	This work was supported by the China Postdoctoral International Exchange Program 2015, National Natural Science Foundation of China (no. 81402193), Postdoctoral Innovation Project of Shandong Province (no. 147751), and Postdoctoral Science Foundation of China (no. 2015M570597) to Y.S. Wang; by National Natural Science Foundation of China (nos. 31271461, 81472583, 81528017), National Key R&D Program of China (No. 2017YFC1308600), and the Taishan Scholar Program of Shandong Province to G.W. Wei.	Ahmadiyeh N, 2010, P NATL ACAD SCI USA, V107, P9742, DOI 10.1073/pnas.0910668107; Barsotti AM, 2012, J BIOL CHEM, V287, P2509, DOI 10.1074/jbc.M111.322875; Beck-Engeser GB, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-4; Bertucci F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037943; Bronsert P, 2014, J PATHOL, V234, P410, DOI 10.1002/path.4416; Bronson PG, 2016, NAT GENET, V48, P1425, DOI 10.1038/ng.3675; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Drake LE, 2014, J PATHOL, V232, P283, DOI 10.1002/path.4298; Dumont N, 2009, CANCER CELL, V16, P3, DOI 10.1016/j.ccr.2009.06.013; Fabbri M, 2012, CANCER RES, V72, P6333, DOI 10.1158/0008-5472.CAN-12-3229; Fromont G, 2013, HUM PATHOL, V44, P1617, DOI 10.1016/j.humpath.2013.01.012; Gu Y, 2016, J PATHOL, V239, P60, DOI 10.1002/path.4697; Guan YH, 2007, CLIN CANCER RES, V13, P5745, DOI 10.1158/1078-0432.CCR-06-2882; Helms MW, 2008, BRIT J CANCER, V99, P774, DOI 10.1038/sj.bjc.6604556; Hsu CY, 2014, J PATHOL, V232, P330, DOI 10.1002/path.4295; Huppi Konrad, 2012, Frontiers in Genetics, V3, P69, DOI 10.3389/fgene.2012.00069; Johnson AL, 2015, ONCOTARGET, V6, P16304, DOI 10.18632/oncotarget.4059; Kong R, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0355-8; Li ZW, 2015, CLIN CANCER RES, V21, P844, DOI 10.1158/1078-0432.CCR-14-2437; M'kacher R, 2003, CANCER GENET CYTOGEN, V143, P32, DOI 10.1016/S0165-4608(02)00823-3; Meng LY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13964; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Mito JK, 2013, J PATHOL, V229, P132, DOI 10.1002/path.4099; Mulrane L, 2013, CANCER RES, V73, P6554, DOI 10.1158/0008-5472.CAN-13-1841; Nagoshi H, 2012, CANCER RES, V72, P4954, DOI 10.1158/0008-5472.CAN-12-0213; Pradhan AK, 2017, CANCER RES, V77, P949, DOI 10.1158/0008-5472.CAN-16-1731; Raffel S, 2016, CANCER CELL, V29, P133, DOI 10.1016/j.ccell.2016.01.007; Schumacher FR, 2007, CANCER RES, V67, P2951, DOI 10.1158/0008-5472.CAN-06-3591; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sotelo J, 2010, P NATL ACAD SCI USA, V107, P3001, DOI 10.1073/pnas.0906067107; Sun Y, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-137; Thorne J, 2008, P NUTR SOC, V67, P115, DOI 10.1017/S0029665108006964; Torres S, 2017, J PATHOL, V242, P39, DOI 10.1002/path.4874; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Wang YS, 2014, CANCER RES, V74, P520, DOI 10.1158/0008-5472.CAN-13-2182	35	47	52	5	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3426	3439		10.1038/s41388-018-0215-2	http://dx.doi.org/10.1038/s41388-018-0215-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29555976	Green Published			2022-12-17	WOS:000436411300008
J	Takahashi, K; Ehata, S; Koinuma, D; Morishita, Y; Soda, M; Mano, H; Miyazono, K				Takahashi, Kei; Ehata, Shogo; Koinuma, Daizo; Morishita, Yasuyuki; Soda, Manabu; Mano, Hiroyuki; Miyazono, Kohei			Pancreatic tumor microenvironment confers highly malignant properties on pancreatic cancer cells	ONCOGENE			English	Article							DISTANT METASTASIS; NESTIN; EXPRESSION; PROLIFERATION; FIBROBLASTS; MARKER; GROWTH; PROGRESSION; PROGNOSIS; EVOLUTION	Tumor microenvironment plays a pivotal role in cancer progression; however, little is known regarding how differences in the microenvironment affect characteristics of cancer cells. Here, we investigated the effects of tumor microenvironment on cancer cells by using mouse tumor models. After three cycles of inoculation and extraction of human pancreatic cancer cells, including SUIT-2 and Panc-1 cells, from tumors, distinct cancer cell lines were established: 3P cells from the pancreas obtained using the orthotopic tumor model and 3sc cells from subcutaneous tissue obtained using the subcutaneous tumor model. On re-inoculation of these cells, the 3sc cells and, more prominently, the 3P cells, exhibited higher tumorigenic activity than the parental cells. The 3P cells specifically exhibited low E-cadherin expression and high invasiveness, suggesting that they were endowed with the highest malignant characteristics. RNA-sequence analysis demonstrated that distinct signaling pathways were activated in each cell line and that the 3P cells acquired a cancer stem cell-like phenotype. Among cancer stem cell-related genes, those specifically expressed in the 3P cells, including NES, may be potential new targets for cancer therapy. The mechanisms underlying the development of highly malignant cancer cell lines were investigated. Individual cell clones within the parental cells varied in tumor-forming ability, indicating the presence of cellular heterogeneity. Moreover, the tumor-forming ability and the gene expression profile of each cell clone were altered after serial orthotopic inoculations. The present study thus suggests that both selection and education processes by tumor microenvironment are involved in the development of highly malignant cancer cells.	[Takahashi, Kei; Ehata, Shogo; Koinuma, Daizo; Morishita, Yasuyuki; Miyazono, Kohei] Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan; [Soda, Manabu; Mano, Hiroyuki] Univ Tokyo, Dept Cellular Signaling, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Miyazono, K (corresponding author), Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp	Koinuma, Daizo/Y-8716-2018	Koinuma, Daizo/0000-0001-5611-2122; Ehata, Shogo/0000-0002-6740-9391; Takahashi-Yamashiro, Kei/0000-0002-7925-6636	Grand for Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development (AMED) [16ck0106193h0001]; KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) [22112002]; KAKENHI from the Japan Society for the Promotion of Science (JSPS), [15K08393, 25-10991]; Yasuda Medical Foundation; Cell Science Research Foundation; Tokyo Society of Medical Sciences; Grants-in-Aid for Scientific Research [17H06326, 15H05774] Funding Source: KAKEN	Grand for Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); KAKENHI from the Japan Society for the Promotion of Science (JSPS),(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Yasuda Medical Foundation; Cell Science Research Foundation(Cell Science Research Foundation, Japan); Tokyo Society of Medical Sciences; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr. Yoko Katsuno, Dr. Yuichiro Yokoyama, and Dr. Yukari Hoshino (The University of Tokyo) for their technical assistance, and Hiroyuki Miyoshi (Keio University) for providing the lentiviral vectors. This work was supported by a Grand for Practical Research for Innovative Cancer Control (16ck0106193h0001) from the Japan Agency for Medical Research and Development (AMED; K.M.), a KAKENHI Grant-in-Aid for Scientific Research on Innovative Areas, Integrative Research on Cancer Microenvironment Network (22112002) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT; K.M.), a KAKENHI Grant-in-Aid for Scientific Research (C; 15K08393; S.E.) and Research Fellowship for Young Scientists (25-10991; K.T.) from the Japan Society for the Promotion of Science (JSPS), Specific Research Grants from Yasuda Medical Foundation (K.M.), The Cell Science Research Foundation (S.E.), and The Tokyo Society of Medical Sciences (S.E.).	Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Arase M, 2014, CANCER SCI, V105, P974, DOI 10.1111/cas.12454; Bachem MG, 2005, GASTROENTEROLOGY, V128, P907, DOI 10.1053/j.gastro.2004.12.036; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Eguchi D, 2013, SURGERY, V154, P573, DOI 10.1016/j.surg.2013.03.010; Ehrmann J, 2005, J CLIN PATHOL, V58, P222, DOI 10.1136/jcp.2004.021238; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hippo Y, 2001, CANCER RES, V61, P889; Horiguchi K, 2009, J BIOL CHEM, V284, P245, DOI 10.1074/jbc.M804777200; Hoshino Y, 2015, AM J PATHOL, V185, P1457, DOI 10.1016/j.ajpath.2015.01.011; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024; Katsuno Y, 2008, ONCOGENE, V27, P6322, DOI 10.1038/onc.2008.232; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Liu CG, 2010, CANCER SCI, V101, P815, DOI 10.1111/j.1349-7006.2009.01422.x; Ma J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.293; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Matsuda Y, 2016, PANCREAS, V45, P93, DOI 10.1097/MPA.0000000000000427; Murai F, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.26; Neradil J, 2015, CANCER SCI, V106, P803, DOI 10.1111/cas.12691; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Perera RM, 2015, CANCER DISCOV, V5, P1247, DOI 10.1158/2159-8290.CD-15-0671; Piras F, 2010, ONCOL REP, V23, P17, DOI 10.3892/or_00000601; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Qian LW, 2003, CANCER LETT, V190, P105, DOI 10.1016/S0304-3835(02)00517-7; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Ryan DP, 2014, NEW ENGL J MED, V371, P2140, DOI 10.1056/NEJMc1412266; Sahlgren CM, 2006, EMBO J, V25, P4808, DOI 10.1038/sj.emboj.7601366; Strojnik T, 2007, SURG NEUROL, V68, P133, DOI 10.1016/j.surneu.2006.10.050; Takahashi K, 2015, CANCER SCI, V106, P867, DOI 10.1111/cas.12685; Takeda K, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14607; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yokoyama Y, 2017, CANCER RES, V77, P4026, DOI 10.1158/0008-5472.CAN-17-0112; Zhao ZW, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0408-8	41	47	50	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2757	2772		10.1038/s41388-018-0144-0	http://dx.doi.org/10.1038/s41388-018-0144-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29511349	Green Published, hybrid			2022-12-17	WOS:000432929800001
J	Ambrosio, S; Sacca, CD; Amente, S; Paladino, S; Lania, L; Majello, B				Ambrosio, S.; Sacca, C. D.; Amente, S.; Paladino, S.; Lania, L.; Majello, B.			Lysine-specific demethylase LSD1 regulates autophagy in neuroblastoma through SESN2-dependent pathway	ONCOGENE			English	Article							EPIGENETIC REGULATION; MTOR; CANCER; TARGET; P53; INHIBITOR; SESTRIN2; EXPRESSION; STRESS; GENES	Autophagy is a physiological process, important for recycling of macromolecules and maintenance of cellular homeostasis. Defective autophagy is associated with tumorigenesis and has a causative role in chemotherapy resistance in leukemia and in solid cancers. Here, we report that autophagy is regulated by the lysine-specific demethylase LSD1/KDM1A, an epigenetic marker whose overexpression is a feature of malignant neoplasia with an instrumental role in cancer development. In the present study, we determine that two different LSD1 inhibitors (TCP and SP2509) as well as selective ablation of LSD1 expression promote autophagy in neuroblastoma cells. At a mechanistic level, we show that LSD1 binds to the promoter region of Sestrin2 (SESN2), a critical regulator of mTORC1 activity. Pharmacological inhibition of LSD1 triggers SESN2 expression that hampers mTORC1 activity, leading to enhanced autophagy. SESN2 overexpression suffices to promote autophagy in neuroblastoma cells, while loss of SESN2 expression reduces autophagy induced by LSD1 inhibition. Our findings elucidate a mechanism whereby LSD1 controls autophagy in neuroblastoma cells through SESN2 transcription regulation, and we suggest that pharmacological targeting of LSD1 may have effective therapeutic relevance in the control of autophagy in neuroblastoma.	[Ambrosio, S.; Sacca, C. D.; Majello, B.] Univ Naples Federico II, Div Genet, Dept Biol, Via Cinthia,Edificio 7, I-80126 Naples, Italy; [Amente, S.; Paladino, S.; Lania, L.] Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Naples, Italy; [Paladino, S.] Ceinge Biotecnol Avanzate Scarl, Naples, Italy	University of Naples Federico II; University of Naples Federico II; CEINGE Biotecnologie Avanzate	Majello, B (corresponding author), Univ Naples Federico II, Div Genet, Dept Biol, Via Cinthia,Edificio 7, I-80126 Naples, Italy.	majello@unina.it	Paladino, Simona/ABH-7826-2020; Paladino, Simona/J-5383-2018; Amente, Stefano/AAU-7605-2020	Paladino, Simona/0000-0001-5332-6774; Amente, Stefano/0000-0003-0612-6096; Majello, Barbara/0000-0003-2789-3585; Sacca, Carmen Daniela/0000-0002-9861-9332	AIRC [IG13173]; Epigenomics Flagship Project-EPIGEN; CNR; MOVIE of Rete delle Biotecnologie, Campania	AIRC(Fondazione AIRC per la ricerca sul cancro); Epigenomics Flagship Project-EPIGEN; CNR(Consiglio Nazionale delle Ricerche (CNR)); MOVIE of Rete delle Biotecnologie, Campania	We thank A Feliciello for helpful discussions, constructive criticisms, Dr M Capasso for help with the R2 package and Dr P Chumakov for providing us the SESN2-Flag expression vector. This work was supported by following grants: AIRC (IG13173 to BM), Epigenomics Flagship Project-EPIGEN, CNR and from Grant MOVIE of the Rete delle Biotecnologie, Campania.	Ambrosio S, 2017, ONCOTARGET, V8, P3854, DOI 10.18632/oncotarget.12924; Amente S, 2015, ONCOTARGET, V6, P14572, DOI 10.18632/oncotarget.3990; Amente S, 2013, BBA-GENE REGUL MECH, V1829, P981, DOI 10.1016/j.bbagrm.2013.05.002; Belounis A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2906-9; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Cam M, 2014, J BIOL CHEM, V289, P4083, DOI 10.1074/jbc.M113.530303; Cimmino F, 2015, SCI REP-UK, V5, DOI 10.1038/srep11158; de Narvajas AAM, 2013, MOL CELL BIOL, V33, P3983, DOI 10.1128/MCB.00813-13; Eisenberg T, 2014, CELL METAB, V19, P431, DOI 10.1016/j.cmet.2014.02.010; Eisenberg-Lerner A, 2009, APOPTOSIS, V14, P376, DOI 10.1007/s10495-008-0307-5; Etani T, 2015, ONCOTARGET, V6, P2865, DOI 10.18632/oncotarget.3067; Feng SJ, 2016, MED SCI MONITOR, V22, P4742, DOI 10.12659/MSM.898825; Fiskus W, 2014, LEUKEMIA, V28, P2155, DOI 10.1038/leu.2014.119; Fullgrabe J, 2014, NAT REV MOL CELL BIO, V15, P65, DOI 10.1038/nrm3716; Gallagher LE, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020024; Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784; Goldschneider D, 2006, NUCLEIC ACIDS RES, V34, P5603, DOI 10.1093/nar/gkl619; Han X, 2014, MOL CELL, V55, P482, DOI 10.1016/j.molcel.2014.06.006; Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092; Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161; Kim H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10025; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006; Lan F, 2008, CURR OPIN CELL BIOL, V20, P316, DOI 10.1016/j.ceb.2008.03.004; Lapierre LR, 2015, AUTOPHAGY, V11, P867, DOI 10.1080/15548627.2015.1034410; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Maiese K, 2016, BRIT J CLIN PHARMACO, V82, P1245, DOI 10.1111/bcp.12804; Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498; Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Parmigiani A, 2014, CELL REP, V9, P1281, DOI 10.1016/j.celrep.2014.10.019; Periz G, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002114; Rebecca VW, 2016, ONCOGENE, V35, P1, DOI 10.1038/onc.2015.99; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Sehgal AR, 2015, LEUKEMIA, V29, P517, DOI 10.1038/leu.2014.349; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Wang JX, 2015, NAT NEUROSCI, V18, P1256, DOI 10.1038/nn.4069; Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268; Wei FZ, 2015, AUTOPHAGY, V11, P2309, DOI 10.1080/15548627.2015.1117734; White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941; Wolfson RL, 2016, SCIENCE, V351, P43, DOI 10.1126/science.aab2674; Zapata PAM, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2388-9; Zhang F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6775; Zhang JB, 2015, AUTOPHAGY, V11, P629, DOI 10.1080/15548627.2015.1023981	51	47	49	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2017	36	48					6701	6711		10.1038/onc.2017.267	http://dx.doi.org/10.1038/onc.2017.267			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FO4AJ	28783174	hybrid, Green Published			2022-12-17	WOS:000416780800005
J	Debebe, A; Medina, V; Chen, CY; Mahajan, IM; Jia, C; Fu, D; He, L; Zeng, N; Stiles, BW; Chen, CL; Wang, M; Aggarwal, KR; Peng, Z; Huang, J; Chen, J; Li, M; Dong, T; Atkins, S; Borok, Z; Yuan, W; Machida, K; Ju, C; Kahn, M; Johnson, D; Stiles, BL				Debebe, A.; Medina, V.; Chen, C-Y; Mahajan, I. M.; Jia, C.; Fu, D.; He, L.; Zeng, N.; Stiles, B. W.; Chen, C-L; Wang, M.; Aggarwal, K-R; Peng, Z.; Huang, J.; Chen, J.; Li, M.; Dong, T.; Atkins, S.; Borok, Z.; Yuan, W.; Machida, K.; Ju, C.; Kahn, M.; Johnson, D.; Stiles, B. L.			Wnt/beta-catenin activation and macrophage induction during liver cancer development following steatosis	ONCOGENE			English	Article							INTESTINAL STEM-CELLS; HEPATOCELLULAR-CARCINOMA; LIPID-METABOLISM; BETA-CATENIN; PERIPORTAL HEPATOCYTES; PROGENITOR CELLS; MICE LACKING; FATTY LIVER; PTEN; EXPRESSION	Obesity confers an independent risk for carcinogenesis. In the liver, steatosis often proceeds cancer formation; however, the mechanisms by which steatosis promotes carcinogenesis is unknown. We hypothesize that steatosis alters the microenvironment to promote proliferation of tumor initiating cells (TICs) and carcinogenesis. We used several liver cancer models to address the mechanisms underlying the role of obesity in cancer and verified these findings in patient populations. Using bioinformatics analysis and verified by biochemical assays, we identified that hepatosteatosis resulting from either Pten deletion or transgenic expression of HCV core/NS5A proteins, promotes the activation of Wnt/beta-catenin. We verified that high fat diet lipid accumulation is also capable of inducing Wnt/beta-catenin. Caloric restriction inhibits hepatosteatosis, reduces Wnt/beta-catenin activation and blocks the expansion of TICs leading to complete inhibition of tumorigenesis without affecting the phosphatase and tensin homologue deleted on chromosome 10 (PTEN) loss regulated protein kinase B (AKT) activation. Pharmacological inhibition or loss of the Wnt/beta-catenin signal represses TIC growth in vitro, and decreases the accumulation of TICs in vivo. In human liver cancers, ontology analysis of gene set enrichment analysis (GSEA)-defined Wnt signature genes indicates that Wnt signaling is significantly induced in tumor samples compared with healthy livers. Indeed, Wnt signature genes predict 90% of tumors in a cohort of 558 patient samples. Selective depletion of macrophages leads to reduction of Wnt and suppresses tumor development, suggesting infiltrating macrophages as a key source for steatosis-induced Wnt expression. These data established Wnt/beta-catenin as a novel signal produced by infiltrating macrophages induced by steatosis that promotes growth of tumor progenitor cells, underlying the increased risk of liver tumor development in obese individuals.	[Debebe, A.; Medina, V.; Chen, C-Y; Mahajan, I. M.; Jia, C.; He, L.; Zeng, N.; Aggarwal, K-R; Peng, Z.; Huang, J.; Chen, J.; Li, M.; Dong, T.; Atkins, S.; Kahn, M.; Stiles, B. L.] Univ Southern Calif, Sch Pharm, Pharmacol & Pharmaceut Sci, PSC 402,1985 Zonal Ave, Los Angeles, CA 90089 USA; [Jia, C.] Tongji Univ, Shanghai Peoples Hosp 10, Dept Nucl Med, Shanghai, Peoples R China; [Fu, D.] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Cent Lab Med Res, Shanghai, Peoples R China; [Stiles, B. W.] CALTECH, Jet Prop Lab, Pasadena, CA USA; [Chen, C-L; Yuan, W.; Machida, K.] Univ Southern Calif, Keck Sch Med, Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; [Wang, M.; Ju, C.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Pharmaceut Sci, Aurora, CO USA; [Borok, Z.] Univ Southern Calif, Keck Sch Med, Will Rogers Inst Pulm Res Ctr, Med, Los Angeles, CA 90033 USA; [Borok, Z.] Univ Southern Calif, Keck Sch Med, Biochem & Mol Biol, Los Angeles, CA 90033 USA; [Borok, Z.; Kahn, M.; Stiles, B. L.] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA; [Johnson, D.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Stiles, B. L.] Univ Southern Calif, Keck Sch Med, Pathol, Los Angeles, CA 90033 USA	University of Southern California; Tongji University; Tongji University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Southern California; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Southern California; University of Southern California; University of Southern California; Baylor College of Medicine; University of Southern California	Stiles, BL (corresponding author), Univ Southern Calif, Sch Pharm, Pharmacol & Pharmaceut Sci, PSC 402,1985 Zonal Ave, Los Angeles, CA 90089 USA.	bstiles@usc.edu	Jia, Chengyou/AAV-1153-2021; peng, zhechu/AAA-5942-2022; Fu, Da/GXF-2656-2022; AVILA, MATIAS A/Y-6342-2019	Peng, Zhechu/0000-0002-9301-7164; AVILA, MATIAS A/0000-0001-6570-3557; Dong, Tiange/0000-0002-0612-4261	NIH [R01CA154986-01, R01 HL112638-01, 1R01AA018857, P50AA11999, R01CA108614-06A1]; NIDDK [R01DK084241-01]; USC center for Liver Disease [P30DK48522]; Norris Comprehensive Cancer Center [P30CA014089]; CIRM; USC; Hastings Foundation; NATIONAL CANCER INSTITUTE [R01CA108614, R01CA154986, P30CA014089] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL112638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI091987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK084241, P30DK048522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM086262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA011999, R01AA018857, R01AA025204] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); USC center for Liver Disease; Norris Comprehensive Cancer Center; CIRM(California Institute for Regenerative Medicine); USC; Hastings Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We acknowledge the technical support from Ms Mungoma, Carrithers, Zhang, Barsky and Mr Li, Dr Bryan W Stiles would like to state that 'this work was done as a private venture and not in the author's capacity as an employee of the Jet Propulsion Laboratory, California Institute of Technology'. This work was supported by NIH grants R01CA154986-01 (BLS). Dr Stiles also acknowledges support from NIDDK (R01DK084241-01). Dr Borok was supported by NIH grant R01 HL112638-01. Dr Machida would like to acknowledge NIH grants 1R01AA018857 and P50AA11999. We acknowledge support from USC center for Liver Disease (P30DK48522) and Norris Comprehensive Cancer Center (P30CA014089). Dr Johnson acknowledges funding from NIH grant R01CA108614-06A1. AD, ZP and VM are partially supported by CIRM pre- and post-doctoral and F32 Developmental Biology training fellowship. NZ acknowledges the support of USC provost postdoctoral fellowship. ZB is Edgington Chair in Medicine and was supported by the Hastings Foundation.	Adinolfi LE, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060803; ALBANES D, 1987, Nutrition and Cancer, V9, P199; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Carpentier R, 2011, GASTROENTEROLOGY, V141, P1432, DOI 10.1053/j.gastro.2011.06.049; Casali A, 2009, CELL STEM CELL, V4, P124, DOI 10.1016/j.stem.2009.01.009; Chen CL, 2016, CELL METAB, V23, P206, DOI 10.1016/j.cmet.2015.12.004; Chen CL, 2013, J CLIN INVEST, V123, P2832, DOI 10.1172/JCI65859; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Domagala-Kulawik J, 2015, TRANSL LUNG CANCER R, V4, P177, DOI 10.3978/j.issn.2218-6751.2015.01.11; Eckert C, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00179; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Font-Burgada J, 2015, CELL, V162, P766, DOI 10.1016/j.cell.2015.07.026; Furuyama K, 2011, NAT GENET, V43, P34, DOI 10.1038/ng.722; Galicia VA, 2010, GASTROENTEROLOGY, V139, P2170, DOI 10.1053/j.gastro.2010.09.002; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Gentzler R, 2016, IMMUNOTHERAPY-UK, V8, P583, DOI 10.2217/imt-2015-0029; Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013; He LN, 2010, AM J PATHOL, V176, P2302, DOI 10.2353/ajpath.2010.090931; He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Inagawa S, 2002, CLIN CANCER RES, V8, P450; Janabi M, 2000, ARTERIOSCL THROM VAS, V20, P1953, DOI 10.1161/01.ATV.20.8.1953; Johnson DL, 2016, TRENDS ENDOCRIN MET, V27, P742, DOI 10.1016/j.tem.2016.04.016; Kalaany NY, 2009, NATURE, V458, P725, DOI 10.1038/nature07782; Kaler P, 2009, ONCOGENE, V28, P3892, DOI 10.1038/onc.2009.247; Lamb JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020090; Lee JS, 2004, GASTROENTEROLOGY, V127, pS51, DOI 10.1053/j.gastro.2004.09.015; Li Y, 2013, J BIOL CHEM, V288, P25007, DOI 10.1074/jbc.M113.450353; Miyabayashi T, 2007, P NATL ACAD SCI USA, V104, P5668, DOI 10.1073/pnas.0701331104; Monga SP, 2015, GASTROENTEROLOGY, V148, P1294, DOI 10.1053/j.gastro.2015.02.056; Moon BC, 2012, ARTERIOSCL THROM VAS, V32, P236, DOI 10.1161/ATVBAHA.111.241356; Palian BM, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004789; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Qian Yan, 2005, Hepatobiliary Pancreat Dis Int, V4, P173; Reddy JK, 2006, AM J PHYSIOL-GASTR L, V290, pG852, DOI 10.1152/ajpgi.00521.2005; Rountree CB, 2009, STEM CELLS, V27, P290, DOI 10.1634/stemcells.2008-0332; Spranger S, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1086862; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Staal FJT, 2010, J CELL BIOCHEM, V109, P844, DOI 10.1002/jcb.22467; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; Sung WK, 2012, NAT GENET, V44, P765, DOI 10.1038/ng.2295; Taniguchi CM, 2006, CELL METAB, V3, P343, DOI 10.1016/j.cmet.2006.04.005; Ueda S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002800; Widelitz Randall B, 2008, Organogenesis, V4, P123; Woo SR, 2015, ANNU REV IMMUNOL, V33, P445, DOI 10.1146/annurev-immunol-032414-112043; Xu XL, 2006, J CLIN INVEST, V116, P1843, DOI 10.1172/JCI27282; Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024	47	47	51	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					6020	6029		10.1038/onc.2017.207	http://dx.doi.org/10.1038/onc.2017.207			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28671671	Green Published, hybrid			2022-12-17	WOS:000413841400010
J	Wang, Q; Ma, J; Lu, Y; Zhang, S; Huang, J; Chen, J; Bei, JX; Yang, K; Wu, G; Huang, K; Chen, J; Xu, S				Wang, Q.; Ma, J.; Lu, Y.; Zhang, S.; Huang, J.; Chen, J.; Bei, J-X; Yang, K.; Wu, G.; Huang, K.; Chen, J.; Xu, S.			CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells	ONCOGENE			English	Article							CYCLE-RELATED KINASE; TRANSCRIPTION FACTOR NRF2; PROTEASOMAL DEGRADATION; PROTEOMIC ANALYSIS; EMERGING ROLE; E3 LIGASE; PROLIFERATION; GENE; CHEMORESISTANCE; CARCINOMA	Radiochemoresistance is considered the main cause of local recurrence and distant metastasis in lung cancer. However, the underlying mechanisms of radiochemoresistance remain to be uncovered. In this study, we determine the functions of cell cyclerelated kinase (CDK20) in radiochemoresistance. CDK20 is a newly identified protein kinase, which plays critical roles in cell growth and proliferation in several types of cancer. Using tandem affinity purification technology, we provide evidences that CDK20 binds to the ubiquitin ligase Kelch-like ECH-associated protein 1 (KEAP1), which targets transcriptional factor nuclear factor erythroid-2-related factor 2 (NRF2) for degradation. We show that this interaction is mediated by an evolutionarily conserved ETGE motif on CDK20. Furthermore, we demonstrate that CDK20 competes with NRF2 for KEAP1 binding, enhances the transcriptional activity of NRF2 and lowers the cellular reactive oxygen species level. Moreover, CDK20-depleted cells display impaired cell proliferation, defective G2/M arrest and increased radiochemosensitivity in lung cancer. These phenotypes induced by CDK20 knockdown are partially dependent on NRF2 inactivation. More importantly, CDK20 is overexpressed in human lung cancer tissues, as determined by immunostaining. Collectively, our results suggest that CDK20 positively modulate the KEAP1-NRF2 cytoprotective pathway to regulate tumor progression and radiochemoresistance, implying that CDK20 is a novel, promising therapeutic target for lung cancer.	[Wang, Q.; Ma, J.; Lu, Y.; Zhang, S.; Huang, J.; Chen, J.; Yang, K.; Wu, G.; Xu, S.] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Hubei, Peoples R China; [Bei, J-X] Sun Yat Sen Univ, Ctr Canc, South China Collaborat Innovat Ctr Canc Med, State Key Lab Oncol,Dept Expt Res, Guangzhou, Guangdong, Peoples R China; [Huang, K.] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Clin Ctr Human Gene Res, Wuhan, Hubei, Peoples R China; [Huang, K.] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Cardiol, Wuhan, Hubei, Peoples R China; [Chen, J.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA	Huazhong University of Science & Technology; State Key Lab Oncology South China; Sun Yat Sen University; Huazhong University of Science & Technology; Huazhong University of Science & Technology; University of Texas System; UTMD Anderson Cancer Center	Yang, K; Xu, S (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Hubei, Peoples R China.	yangkunyu@medmail.com.cn; xsb723@hust.edu.cn	Bei, Jin-Xin/AAO-1259-2020		National Natural Science Foundation of China [81301719, 81372435]; State Key Laboratory of Oncology in South China [HN2014-10]; Wuhan Science and Technology Bureau [2015060101010041]; Department of Defense Era of Hope research scholar award [W81XWH-09-1-0409]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Laboratory of Oncology in South China; Wuhan Science and Technology Bureau; Department of Defense Era of Hope research scholar award(United States Department of Defense)	This work was supported by the National Natural Science Foundation of China (81301719 to SX), Open Funds of State Key Laboratory of Oncology in South China (HN2014-10 to SX), a grant from the Wuhan Science and Technology Bureau (2015060101010041 to SX), the National Natural Science Foundation of China (81372435 to KY) and Department of Defense Era of Hope research scholar award (W81XWH-09-1-0409 to JC).	Addario BJ, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.01.20; An XM, 2010, EUR J CANCER, V46, P1752, DOI 10.1016/j.ejca.2010.04.007; Bai XP, 2016, DRUG METAB REV, V48, P541, DOI 10.1080/03602532.2016.1197239; Camp ND, 2012, J BIOL CHEM, V287, P6539, DOI 10.1074/jbc.M111.316471; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chio IIC, 2016, CELL, V166, P963, DOI 10.1016/j.cell.2016.06.056; Feng H, 2015, J HEPATOL, V62, P1100, DOI 10.1016/j.jhep.2014.11.040; Feng H, 2011, J CLIN INVEST, V121, P3159, DOI 10.1172/JCI45967; Hast BE, 2013, CANCER RES, V73, P2199, DOI 10.1158/0008-5472.CAN-12-4400; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Homma S, 2009, CLIN CANCER RES, V15, P3423, DOI 10.1158/1078-0432.CCR-08-2822; Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644; Lee DF, 2009, MOL CELL, V36, P131, DOI 10.1016/j.molcel.2009.07.025; Lee S, 2012, FREE RADICAL BIO MED, V53, P807, DOI 10.1016/j.freeradbiomed.2012.05.038; Liu Y, 2004, J BIOL CHEM, V279, P4507, DOI 10.1074/jbc.M309995200; Ma JL, 2012, MOL CELL BIOL, V32, P1506, DOI 10.1128/MCB.06271-11; Malumbres M, 2014, GENOME BIOL, V15, DOI 10.1186/gb4184; Malumbres M, 2009, NAT CELL BIOL, V11, P1275, DOI 10.1038/ncb1109-1275; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; Mikell JL, 2015, J THORAC ONCOL, V10, P462, DOI 10.1097/JTO.0000000000000411; Mitsuishi Y, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00200; Ng SSM, 2007, J NATL CANCER I, V99, P936, DOI 10.1093/jnci/djm011; O'Connell MA, 2015, BIOCHEM SOC T, V43, P687, DOI 10.1042/BST20150069; Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Singh A, 2008, CANCER RES, V68, P7975, DOI 10.1158/0008-5472.CAN-08-1401; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Solis LM, 2010, CLIN CANCER RES, V16, P3743, DOI 10.1158/1078-0432.CCR-09-3352; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Tian Y, 2012, ONCOL LETT, V4, P601, DOI 10.3892/ol.2012.828; Wohlbold L, 2006, CELL CYCLE, V5, P546, DOI 10.4161/cc.5.5.2541; Wu GQ, 2009, INT J CANCER, V125, P2631, DOI 10.1002/ijc.24630; Xu S, 2011, ONCOGENE, V30, P2219, DOI 10.1038/onc.2010.596; Xu SB, 2014, MOL CELL PROTEOMICS, V13, P2986, DOI 10.1074/mcp.M113.036699; Xu Y, 2013, CANCER RES, V73, P4406, DOI 10.1158/0008-5472.CAN-12-4297; Yang Y, 2013, EMBO REP, V14, P741, DOI 10.1038/embor.2013.80; Yu Z, 2014, GUT, V63, P1793, DOI 10.1136/gutjnl-2013-305584; Zhan LJ, 2012, FREE RADICAL BIO MED, V53, P758, DOI 10.1016/j.freeradbiomed.2012.05.041; Zhang P, 2010, MOL CANCER THER, V9, P336, DOI 10.1158/1535-7163.MCT-09-0589; Zhou SN, 2013, CRIT REV ONCOL HEMAT, V88, P706, DOI 10.1016/j.critrevonc.2013.09.001	43	47	49	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5321	5330		10.1038/onc.2017.161	http://dx.doi.org/10.1038/onc.2017.161			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28534518				2022-12-17	WOS:000410671700010
J	Tse, BWC; Volpert, M; Ratther, E; Stylianou, N; Nouri, M; McGowan, K; Lehman, ML; McPherson, SJ; Roshan-Moniri, M; Butler, MS; Caradec, J; Gregory-Evans, CY; McGovern, J; Das, R; Takhar, M; Erho, N; Alshalafa, M; Davicioni, E; Schaeffer, EM; Jenkins, RB; Ross, AE; Karnes, RJ; Den, RB; Fazli, L; Gregory, PA; Gleave, ME; Williams, ED; Rennie, PS; Buttyan, R; Gunter, JH; Selth, LA; Russell, PJ; Nelson, CC; Hollier, BG				Tse, B. W. C.; Volpert, M.; Ratther, E.; Stylianou, N.; Nouri, M.; McGowan, K.; Lehman, M. L.; McPherson, S. J.; Roshan-Moniri, M.; Butler, M. S.; Caradec, J.; Gregory-Evans, C. Y.; McGovern, J.; Das, R.; Takhar, M.; Erho, N.; Alshalafa, M.; Davicioni, E.; Schaeffer, E. M.; Jenkins, R. B.; Ross, A. E.; Karnes, R. J.; Den, R. B.; Fazli, L.; Gregory, P. A.; Gleave, M. E.; Williams, E. D.; Rennie, P. S.; Buttyan, R.; Gunter, J. H.; Selth, L. A.; Russell, P. J.; Nelson, C. C.; Hollier, B. G.			Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; RECEPTOR SPLICE VARIANTS; CANCER-CELLS; DEPRIVATION THERAPY; BREAST-CANCER; CASTRATION; EXPRESSION; GROWTH; MECHANISMS; BINDING	Recent evidence has implicated the transmembrane co-receptor neuropilin-1 (NRP1) in cancer progression. Primarily known as a regulator of neuronal guidance and angiogenesis, NRP1 is also expressed in multiple human malignancies, where it promotes tumor angiogenesis. However, non-angiogenic roles of NRP1 in tumor progression remain poorly characterized. In this study, we define NRP1 as an androgen-repressed gene whose expression is elevated during the adaptation of prostate tumors to androgen-targeted therapies (ATTs), and subsequent progression to metastatic castration-resistant prostate cancer (mCRPC). Using short hairpin RNA (shRNA)-mediated suppression of NRP1, we demonstrate that NRP1 regulates the mesenchymal phenotype of mCRPC cell models and the invasive and metastatic dissemination of tumor cells in vivo. In patients, immunohistochemical staining of tissue microarrays and mRNA expression analyses revealed a positive association between NRP1 expression and increasing Gleason grade, pathological T score, positive lymph node status and primary therapy failure. Furthermore, multivariate analysis of several large clinical prostate cancer (PCa) cohorts identified NRP1 expression at radical prostatectomy as an independent prognostic biomarker of biochemical recurrence after radiation therapy, metastasis and cancer-specific mortality. This study identifies NRP1 for the first time as a novel androgen-suppressed gene upregulated during the adaptive response of prostate tumors to ATTs and a prognostic biomarker of clinical metastasis and lethal PCa.	[Tse, B. W. C.; Volpert, M.; Ratther, E.; Stylianou, N.; McGowan, K.; Lehman, M. L.; McPherson, S. J.; Williams, E. D.; Gunter, J. H.; Russell, P. J.; Nelson, C. C.; Hollier, B. G.] Queensland Univ Technol, Australian Prostate Canc Res Ctr, Inst Hlth & Biomed Innovat, Sch Biomed Sci,Princess Alexandra Hosp,Translatio, 37 Kent St, Brisbane, Qld 4102, Australia; [Nouri, M.; Roshan-Moniri, M.; Butler, M. S.; Caradec, J.; Fazli, L.; Gleave, M. E.; Rennie, P. S.; Buttyan, R.] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC, Canada; [Gregory-Evans, C. Y.] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada; [McGovern, J.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Tissue Repair & Regenerat Program, Brisbane, Qld, Australia; [Das, R.; Selth, L. A.] Univ Adelaide, Dame Roma Mitchell Canc Res Labs, Adelaide, SA, Australia; [Das, R.; Selth, L. A.] Univ Adelaide, Freemasons Fdn Ctr Mens Hlth, Discipline Med, Adelaide, SA, Australia; [Takhar, M.; Erho, N.; Alshalafa, M.; Davicioni, E.] GenomeDX Biosci, Vancouver, BC, Canada; [Schaeffer, E. M.] Northwestern Univ, Dept Urol, Chicago, IL 60611 USA; [Jenkins, R. B.] Mayo Clin, Dept Pathol, Rochester, MN USA; [Den, R. B.] Mayo Clin, Lab Med, Rochester, MN USA; [Ross, A. E.] Johns Hopkins Univ, Dept Urol, Brady Urol Inst, Baltimore, MD USA; [Karnes, R. J.] Mayo Clin, Dept Urol, Rochester, MN USA; [Den, R. B.] Thomas Jefferson Univ Hosp, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA; [Gregory, P. A.] SA Pathol & Univ South Australia, Ctr Canc Biol, Adelaide, SA, Australia	Queensland University of Technology (QUT); University of British Columbia; University of British Columbia; Queensland University of Technology (QUT); University of Adelaide; University of Adelaide; GenomeDx Biosciences; Northwestern University; Mayo Clinic; Mayo Clinic; Johns Hopkins University; Mayo Clinic; Jefferson University; Centre for Cancer Biology; SA Pathology; University of South Australia	Hollier, BG (corresponding author), Queensland Univ Technol, Australian Prostate Canc Res Ctr, Inst Hlth & Biomed Innovat, Sch Biomed Sci,Princess Alexandra Hosp,Translatio, 37 Kent St, Brisbane, Qld 4102, Australia.	b.hollier@qut.edu.au	Tse, Brian/X-8909-2019; Stylianou, Nataly/GOP-1782-2022; Williams, Elizabeth D/B-1538-2008; Russell, Pamela/O-8504-2019; Gunter, Jennifer H/B-8960-2016; Gregory, Philip/F-4089-2013; Gregory-Evans, Cheryl Y/G-9550-2011; Selth, Luke/AAH-4823-2021	Tse, Brian/0000-0002-5982-8369; Williams, Elizabeth D/0000-0002-3364-6655; Gunter, Jennifer H/0000-0003-2447-5732; Gregory, Philip/0000-0002-0999-0632; Selth, Luke/0000-0002-4686-1418; Stylianou, Nataly/0000-0002-8006-5730; Nouri, Mannan/0000-0002-7442-9251; Volpert, Marianna/0000-0002-6537-0729; Gleave, Martin/0000-0003-4235-0167; Den, Robert/0000-0002-8653-1763; Butler, Miriam/0000-0002-1582-8383	Cure Cancer Australia Foundation; Cancer Australia PdCCRS grant [108878]; Australian Government Department of Health; Queensland Government National and International Research Alliance Program; Movember Foundation; Prostate Cancer Foundation of Australia through a Movember Revolutionary Team Award; Prostate Cancer Foundation of Australia	Cure Cancer Australia Foundation; Cancer Australia PdCCRS grant; Australian Government Department of Health(Australian GovernmentDepartment of Health & Ageing); Queensland Government National and International Research Alliance Program; Movember Foundation; Prostate Cancer Foundation of Australia through a Movember Revolutionary Team Award; Prostate Cancer Foundation of Australia	We thank Dr Leland Chung and Dr Simon Hayward for kindly providing the C4-2B and BPH-1 cell lines, respectively, used in this study. This research was supported by Cure Cancer Australia Foundation, Prostate Cancer Foundation of Australia and Cancer Australia PdCCRS grant 108878 and the Australian Government Department of Health, Queensland Government National and International Research Alliance Program funding to the Australian-Canadian Prostate Cancer Research Alliance, as well as by the Movember Foundation and the Prostate Cancer Foundation of Australia through a Movember Revolutionary Team Award.	Best CJM, 2005, CLIN CANCER RES, V11, P6823, DOI 10.1158/1078-0432.CCR-05-0585; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Chen MQ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-89; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; Den RB, 2014, INT J RADIAT ONCOL, V89, P1038, DOI 10.1016/j.ijrobp.2014.04.052; Erho N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066855; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Glinka Y, 2011, CARCINOGENESIS, V32, P613, DOI 10.1093/carcin/bgq281; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Hansel DE, 2004, AM J SURG PATHOL, V28, P347, DOI 10.1097/00000478-200403000-00007; Heidenreich A, 2014, EUR UROL, V65, P467, DOI 10.1016/j.eururo.2013.11.002; Hollier BG, 2013, CANCER RES, V73, P1981, DOI 10.1158/0008-5472.CAN-12-2962; Hong TM, 2007, CLIN CANCER RES, V13, P4759, DOI 10.1158/1078-0432.CCR-07-0001; James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5; Jia H, 2010, BRIT J CANCER, V102, P541, DOI 10.1038/sj.bjc.6605539; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Latil A, 2000, INT J CANCER, V89, P167, DOI 10.1002/(SICI)1097-0215(20000320)89:2<167::AID-IJC11>3.0.CO;2-9; Lin D, 2015, ONCOTARGET, V6, P1806, DOI 10.18632/oncotarget.2809; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Lu J, 2015, J UROLOGY, V193, P690, DOI 10.1016/j.juro.2014.08.043; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; McShane LM, 2005, EUR J CANCER, V41, P1690, DOI 10.1016/j.ejca.2005.03.032; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Nouri M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00370; Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018; Patel P, 2010, MATRIX BIOL, V29, P97, DOI 10.1016/j.matbio.2009.10.004; Patnaik A, 2014, CANCER CHEMOTH PHARM, V73, P951, DOI 10.1007/s00280-014-2426-8; Peng Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094422; Pepe MS, 2008, J NATL CANCER I, V100, P1432, DOI 10.1093/jnci/djn326; Pomerantz MM, 2015, NAT GENET, V47, P1346, DOI 10.1038/ng.3419; Qi JF, 2013, CANCER CELL, V23, P332, DOI 10.1016/j.ccr.2013.02.016; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Ross AE, 2015, EUR UROL; Snuderl M, 2013, CELL, V152, P1065, DOI 10.1016/j.cell.2013.01.036; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Sprenger CCT, 2014, HORM CANCER-US, V5, P207, DOI 10.1007/s12672-014-0177-y; Stephenson JM, 2002, INT J CANCER, V101, P409, DOI 10.1002/ijc.10611; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Teng Y, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-453; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Vanaja DK, 2003, CANCER RES, V63, P3877; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; West DC, 2005, J BIOL CHEM, V280, P13457, DOI 10.1074/jbc.M410924200; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE, P385; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Yuan X, 2009, UROL ONCOL-SEMIN ORI, V27, P36, DOI 10.1016/j.urolonc.2008.03.021; Zhang SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-9	53	47	48	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3417	3427		10.1038/onc.2016.482	http://dx.doi.org/10.1038/onc.2016.482			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28092670	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000403340700006
J	Lefort, S; Thuleau, A; Kieffer, Y; Sirven, P; Bieche, I; Marangoni, E; Vincent-Salomon, A; Mechta-Grigoriou, F				Lefort, S.; Thuleau, A.; Kieffer, Y.; Sirven, P.; Bieche, I.; Marangoni, E.; Vincent-Salomon, A.; Mechta-Grigoriou, F.			CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients	ONCOGENE			English	Article							CHEMOKINE RECEPTOR CXCR4; GROWTH-STIMULATING FACTOR; WEAK PARTIAL AGONISTS; TUMOR-GROWTH; FUNCTIONAL EXPRESSION; DUCTAL CARCINOMA; PROGENITOR CELLS; METASTASIS; STEM; MICROENVIRONMENT	The CXCR4 receptor and its ligand CXCL12 (also named stromal cell-derived factor 1, SDF1) have a critical role in chemotaxis and homing, key steps in cancer metastasis. Although myofibroblasts expressing CXCL12 are associated with the presence of axillary metastases in HER2 breast cancers (BC), the therapeutic interest of targeting CXCR4/CXCL12 axis in the different BC subtypes remains unclear. Here, we investigate this question by testing antitumor activity of CXCR4 inhibitors in patient-derived xenografts (PDX), which faithfully reproduce human tumor properties. We observed that two CXCR4 inhibitors, AMD3100 and TN14003, efficiently impair tumor growth and metastasis dissemination in both Herceptin-sensitive and Herceptin-resistant HER2 BC. Conversely, blocking CXCR4/CXCL12 pathway in triple-negative (TN) BC does not reduce tumor growth, and can even increase metastatic spread. Moreover, although CXCR4 inhibitors significantly reduce myofibroblast content in all BC subtypes, they decrease angiogenesis only in HER2 BC. Thus, our findings suggest that targeting CXCR4 could provide some therapeutic interest for HER2 BC patients, whereas it has no impact or could even be detrimental for TN BC patients.	[Lefort, S.; Kieffer, Y.; Sirven, P.; Mechta-Grigoriou, F.] Inst Curie Res Dept, Stress & Canc Lab, LNCC Labelized Team, 26 Rue Ulm, F-75248 Paris 05, France; [Lefort, S.; Kieffer, Y.; Sirven, P.; Mechta-Grigoriou, F.] INSERM, U830, Genet & Biol Canc, F-75248 Paris, France; [Thuleau, A.; Marangoni, E.] Inst Curie Res Dept, Translat Res Dept, Lab Pre Clin Invest, Paris, France; [Bieche, I.] Inst Curie Hosp Grp, Serv Genet, Unite Pharmacognet, Paris, France; [Vincent-Salomon, A.] Hosp Grp Paris, Inst Curie, Dept Pathol, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Mechta-Grigoriou, F (corresponding author), PSL Res Univ, Inst Curie Res Dept, Stress & Canc Lab, LNCC Labelized Team, 26 Rue Ulm, Paris, France.	fatima.mechta-grigoriou@curie.fr	Bièche, Ivan/O-7399-2017; Marangoni, Elisabetta/GSO-3945-2022; MECHTA-GRIGORIOU, Fatima/C-5253-2017	Bièche, Ivan/0000-0002-2430-5429; Marangoni, Elisabetta/0000-0002-3337-6448; MECHTA-GRIGORIOU, Fatima/0000-0002-3751-6989; KIEFFER, Yann/0000-0003-2722-3071; Lefort, Sylvain/0000-0001-7320-4256	Fondation ARC; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Curie	Fondation ARC; Institut National de la Sante et de la Recherche Medicale (Inserm)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Institut Curie	We are grateful to M Cardon from the 'Stress and Cancer' lab, at the Institut Curie, as well as R Leclere, E Martel, M Richardson and A Nicolas from the experimental pathology platform for help and advice. We acknowledge O Mariani from CRB Institut Curie for her help in preparing RNA samples from patient tumors. We are grateful to all members of the animal facilities of Institute Curie for their helpful expertize. SL was supported by funding from the Fondation ARC. The experimental work was also supported by grants from the Institut National de la Sante et de la Recherche Medicale (Inserm) and the Institut Curie. FMG's laboratory is labelized by the Ligue Nationale Contre le Cancer (LNCC). We are very grateful to the LNCC, Institut Curie and Inserm for providing their support these last years. We also thank the Institut National du Cancer (INCa), the FRM and the Fondation ARC (Association pour la Recherche contre le Cancer).	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Ara T, 2003, J IMMUNOL, V170, P4649, DOI 10.4049/jimmunol.170.9.4649; Balkwill F, 2004, SEMIN CANCER BIOL, V14, P171, DOI 10.1016/j.semcancer.2003.10.003; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Cabioglu N, 2005, CANCER RES, V65, P6493, DOI 10.1158/0008-5472.CAN-04-1303; Carion A, 2003, BRIT J HAEMATOL, V122, P918, DOI 10.1046/j.1365-2141.2003.04545.x; Costa A, 2014, SEMIN CANCER BIOL, V25, P23, DOI 10.1016/j.semcancer.2013.12.007; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; De Falco V, 2007, CANCER RES, V67, P11821, DOI 10.1158/0008-5472.CAN-07-0899; Dommange F, 2006, FASEB J, V20, P1913, DOI 10.1096/fj.05-5667fje; Gruosso T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9583; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; Hassan S, 2011, INT J CANCER, V129, P225, DOI 10.1002/ijc.25665; Hori T, 1998, J IMMUNOL, V160, P180; Huang EH, 2009, J SURG RES, V155, P231, DOI 10.1016/j.jss.2008.06.044; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kang H, 2005, BREAST CANCER RES, V7, pR402, DOI 10.1186/bcr1022; Lefort S, 2014, AUTOPHAGY, V10, P2122, DOI 10.4161/15548627.2014.981788; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Liang SX, 2015, ONCOTARGET, V6, P1020, DOI 10.18632/oncotarget.2741; Liang ZX, 2007, BIOCHEM BIOPH RES CO, V363, P542, DOI 10.1016/j.bbrc.2007.09.007; Liang ZX, 2005, CANCER RES, V65, P967; Liekens S, 2010, CURR PHARM DESIGN, V16, P3903, DOI 10.2174/138161210794455003; Ling XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058426; Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murdoch C, 1999, IMMUNOLOGY, V98, P36; Nafi SNM, 2014, ONCOTARGET, V5, P5934; Nagasawa T, 1996, P NATL ACAD SCI USA, V93, P14726, DOI 10.1073/pnas.93.25.14726; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Reyal F, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3095; Rhodes LV, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-295; Saez R, 2006, CLIN CANCER RES, V12, P424, DOI 10.1158/1078-0432.CCR-05-1807; Salvucci O, 2006, BREAST CANCER RES TR, V97, P275, DOI 10.1007/s10549-005-9121-8; Schmid BC, 2004, BREAST CANCER RES TR, V84, P247, DOI 10.1023/B:BREA.0000019962.18922.87; Sharma M, 2014, CELL ADHES MIGR, V8, P384, DOI 10.4161/cam.29285; Singh B, 2010, CLIN EXP METASTAS, V27, P233, DOI 10.1007/s10585-010-9321-4; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tamamura H, 2003, FEBS LETT, V550, P79, DOI 10.1016/S0014-5793(03)00824-X; Toullec A, 2010, EMBO MOL MED, V2, P211, DOI 10.1002/emmm.201000073; Trent JO, 2003, J BIOL CHEM, V278, P47136, DOI 10.1074/jbc.M307850200; Xu TP, 2013, CANCER EPIDEMIOL, V37, P725, DOI 10.1016/j.canep.2013.04.017; Yazhou C, 2004, TUMOR BIOL, V25, P290, DOI 10.1159/000081394; Zhang WB, 2002, J BIOL CHEM, V277, P24515, DOI 10.1074/jbc.M200889200; Zhang ZG, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-49; Zlotnik A, 2006, INT J CANCER, V119, P2026, DOI 10.1002/ijc.22024; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	56	47	47	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1211	1222		10.1038/onc.2016.284	http://dx.doi.org/10.1038/onc.2016.284			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27669438	Green Published, hybrid			2022-12-17	WOS:000395861300005
J	Li, G; Li, M; Hu, J; Lei, R; Xiong, H; Ji, H; Yin, H; Wei, Q; Hu, G				Li, G.; Li, M.; Hu, J.; Lei, R.; Xiong, H.; Ji, H.; Yin, H.; Wei, Q.; Hu, G.			The microRNA-182-PDK4 axis regulates lung tumorigenesis by modulating pyruvate dehydrogenase and lipogenesis	ONCOGENE			English	Article							TARGETING HEXOKINASE 2; AEROBIC GLYCOLYSIS; GLUCOSE-METABOLISM; MIR-182 EXPRESSION; UP-REGULATION; FATTY-ACID; CANCER; CELL; KINASE; MICRORNA	Reprogrammed metabolism is one of the hallmarks of cancer. The dysregulation of glycolysis in cancer has been heavily studied. However, it remains largely unclear how other metabolic processes are regulated in cancer cells. Here we show that microRNA-182 (miR-182) suppresses pyruvate dehydrogenase (PDH) kinase 4 (PDK4) and promotes lung tumorigenesis. miR-182 is dysregulated and inversely correlated with PDK4 in human lung adenocarcinomas. The miR-182-PDK4 axis regulates lung cancer cell growth by modulating the activity of PDH, the gatekeeping enzyme of pyruvate flux into acetyl-CoA, and subsequently de novo lipogenesis of cancer cells. Suppression of lipogenesis by silencing ATP citrate lyase (ACLY) and fatty acid synthase (FASN) or by chemical inhibitors diminishes the effects of miR-182-PDK4 in tumor growth. Alteration of de novo lipogenesis also affects reactive oxygen species (ROS) production and the downstream JNK signaling pathway. Hence, our work suggests that the miR-182-PDK4 axis is a crucial regulator of cancer cell metabolism and a potential target for antitumor therapy.	[Li, G.; Hu, J.; Lei, R.; Hu, G.] Chinese Acad Sci, Key Lab Stem Cell Biol, Inst Hlth Sci, Shanghai Inst Biol Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China; [Li, G.; Hu, J.; Lei, R.; Hu, G.] Shanghai Jiao Tong Univ, Sch Med, 320 Yueyang Rd, Shanghai 200031, Peoples R China; [Li, G.; Hu, J.; Lei, R.; Hu, G.] Univ Chinese Acad Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China; [Li, M.; Yin, H.] Chinese Acad Sci, Key Lab Food Safety Res, Inst Nutr Sci, Shanghai Inst Biol Sci, Shanghai, Peoples R China; [Xiong, H.] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Wuhan, Peoples R China; [Ji, H.] Chinese Acad Sci, State Key Lab Cell Biol, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, Shanghai, Peoples R China; [Wei, Q.] Tongji Univ, Sch Med, Dept Pathol, Shanghai Peoples Hosp 10, 301 Yanchang Rd, Shanghai 200072, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Huazhong University of Science & Technology; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Tongji University	Hu, G (corresponding author), Chinese Acad Sci, Key Lab Stem Cell Biol, Inst Hlth Sci, Shanghai Inst Biol Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.; Hu, G (corresponding author), Shanghai Jiao Tong Univ, Sch Med, 320 Yueyang Rd, Shanghai 200031, Peoples R China.; Hu, G (corresponding author), Univ Chinese Acad Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.; Wei, Q (corresponding author), Tongji Univ, Sch Med, Dept Pathol, Shanghai Peoples Hosp 10, 301 Yanchang Rd, Shanghai 200072, Peoples R China.	weiqing1971@aliyun.com; ghhu@sibs.ac.cn		Hu, Guohong/0000-0002-2980-5166; Li, Gang/0000-0001-9761-1323; yin, hui yong/0000-0001-7049-1560	Ministry of Science and Technology of China [2011CB510105, 2012ZX09506-001-005, 2013CB910904]; National Natural Science Foundation of China [81430070, 81222032, 31371409]; Chinese Academy of Sciences [XDA01040402]; Science and Technology Commission of Shanghai Municipality [14431900800]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences(Chinese Academy of Sciences); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	We thank Dr Weihong Sun at the Tissue Bank of the Institute of Health Sciences for technical support. The study was funded by grants from the Ministry of Science and Technology of China (2011CB510105, 2012ZX09506-001-005 and 2013CB910904), National Natural Science Foundation of China (81430070, 81222032 and 31371409), Chinese Academy of Sciences (XDA01040402) and Science and Technology Commission of Shanghai Municipality (14431900800).	Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chen B, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-228; Chiang CH, 2013, BBA-GEN SUBJECTS, V1830, P3067, DOI 10.1016/j.bbagen.2013.01.009; Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007; Fang R, 2012, J BIOL CHEM, V287, P23227, DOI 10.1074/jbc.M112.373084; Fang ZY, 2012, CELL RES, V22, P565, DOI 10.1038/cr.2011.149; Fei X, 2012, FEBS LETT, V586, P392, DOI 10.1016/j.febslet.2012.01.006; Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094; Grassian AR, 2011, GENE DEV, V25, P1716, DOI 10.1101/gad.16771811; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; Guo WJ, 2015, HEPATOLOGY, V62, P1132, DOI 10.1002/hep.27929; Guttilla IK, 2009, J BIOL CHEM, V284, P23204, DOI 10.1074/jbc.M109.031427; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanke M, 2010, UROL ONCOL-SEMIN ORI, V28, P655, DOI 10.1016/j.urolonc.2009.01.027; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Horie T, 2009, BIOCHEM BIOPH RES CO, V389, P315, DOI 10.1016/j.bbrc.2009.08.136; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kim HR, 2013, BIOCHEM BIOPH RES CO, V437, P225, DOI 10.1016/j.bbrc.2013.06.043; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; LABER B, 1987, BIOCHEM J, V248, P351, DOI 10.1042/bj2480351; Landi MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001651; Lei R, 2014, ONCOGENE, V33, P1287, DOI 10.1038/onc.2013.65; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Liu AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086872; Liu H, 2013, INT J COLORECTAL DIS, V28, P697, DOI 10.1007/s00384-013-1674-0; Ma XY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6212; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; OOKHTENS M, 1984, AM J PHYSIOL, V247, pR146, DOI 10.1152/ajpregu.1984.247.1.R146; Park YY, 2013, HEPATOLOGY, V58, P182, DOI 10.1002/hep.26310; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Qin J, 2014, GENE, V538, P342, DOI 10.1016/j.gene.2013.12.043; Rardin MJ, 2009, ANAL BIOCHEM, V389, P157, DOI 10.1016/j.ab.2009.03.040; SABINE JR, 1967, CANCER RES, V27, P793; Schaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Seo JS, 2012, GENOME RES, V22, P2109, DOI 10.1101/gr.145144.112; Singh Pankaj K, 2011, Mol Cell Pharmacol, V3, P125; Su LJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-140; Sun JB, 2015, INT J CLIN EXP PATHO, V8, P4755; Sun WY, 2015, CANCER RES, V75, P4923, DOI 10.1158/0008-5472.CAN-15-1023; Sun YH, 2010, BIOCHEM BIOPH RES CO, V396, P501, DOI 10.1016/j.bbrc.2010.04.127; Sutendra G, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00038; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Tan XG, 2011, CLIN CANCER RES, V17, P6802, DOI 10.1158/1078-0432.CCR-11-0419; Wang J, 2015, ONCOTARGET, V6, P19456, DOI 10.18632/oncotarget.3318; Wang PY, 2013, ONCOL LETT, V6, P1681, DOI 10.3892/ol.2013.1593; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wei Q, 2015, THORAC CANCER, V6, P2, DOI 10.1111/1759-7714.12164; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang WB, 2014, ONCOTARGET, V5, P740, DOI 10.18632/oncotarget.1608; Zhang S, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-10; Zhu HL, 2014, BIOCHEM BIOPH RES CO, V450, P857, DOI 10.1016/j.bbrc.2014.06.073	57	47	48	4	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					989	998		10.1038/onc.2016.265	http://dx.doi.org/10.1038/onc.2016.265			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27641336				2022-12-17	WOS:000394169100011
J	Teo, WW; Merino, VF; Cho, S; Korangath, P; Liang, X; Wu, RC; Neumann, NM; Ewald, AJ; Sukumar, S				Teo, W. W.; Merino, V. F.; Cho, S.; Korangath, P.; Liang, X.; Wu, R-C; Neumann, N. M.; Ewald, A. J.; Sukumar, S.			HOXA5 determines cell fate transition and impedes tumor initiation and progression in breast cancer through regulation of E-cadherin and CD24	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; RETINOIC ACID RECEPTOR; STEM-CELLS; GENE-EXPRESSION; MAMMARY-GLAND; DIFFERENTIATION; ACTIVATION; INHIBITION; ALPHA; MORPHOGENESIS	Loss of HOXA5 expression occurs frequently in breast cancer and correlates with higher pathological grade and poorer disease outcome. However, how HOX proteins drive differentiation in mammalian cells is poorly understood. In this paper, we investigated cellular and molecular consequences of loss of HOXA5 in breast cancer, and the role played by retinoic acid in HOXA5 function. Analysis of global gene expression data from HOXA5-depleted MCF10A breast epithelial cells, followed by validation, pointed to a role for HOXA5 in maintaining several molecular traits typical of the epithelial lineage such as cell-cell adhesion, tight junctions and markers of differentiation. Depleting HOXA5 in immortalized MCF10A or transformed MCF10A-Kras cells reduced their CD24(+)/CD44(lo) population, enhanced self-renewal capacity and reduced expression of E-cadherin (CDH1) and CD24. In the case of MCF10A-Kras, HOXA5 loss increased branching and protrusive morphology in Matrigel, all features suggestive of epithelial to basal transition. Further, orthotopically implanted xenografts of MCF10A-Kras-scr grew as well-differentiated pseudo-luminal carcinomas, while MCF10A-Kras-shHOXA5 cells formed aggressive, poorly differentiated carcinomas. Conversely, ectopic expression of HOXA5 in aggressive SUM149 or SUM159 breast cancer cells reversed the cellular and molecular alterations observed in the HOXA5-depleted cells. Retinoic acid is a known upstream regulator of HOXA5 expression. HOXA5 depletion in MCF10A cells engineered to express doxycycline-induced shHOXA5 slowed transition of cells from a less differentiated CD24(-)/CD44(+) to the more differentiated CD24(+)/CD44(+) state. This transition was promoted by retinal treatment, which upregulated endogenous HOXA5 expression and caused re-expression of occludin and claudin-7 (CLDN7). Expression of CDH1 and CD24 was transcriptionally upregulated by direct binding of HOXA5 to their promoter sequences as demonstrated by luciferase and ChIP analyses. Thus, loss of HOXA5 in mammary cells leads to loss of epithelial traits, an increase in stemness and cell plasticity, and the acquisition of more aggressive phenotypes.	[Teo, W. W.; Merino, V. F.; Cho, S.; Korangath, P.; Liang, X.; Sukumar, S.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Breast Canc Program, Dept Oncol,Sch Med, 1650 Orleans St,CRB1,143, Baltimore, MD 21231 USA; [Teo, W. W.; Wu, R-C; Sukumar, S.] Johns Hopkins Univ, Sch Med, Grad Program Pathobiol, Baltimore, MD USA; [Neumann, N. M.; Ewald, A. J.] Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD USA; [Liang, X.] Wuhan Univ, Sch Publ Hlth, Wuhan, Peoples R China; [Wu, R-C] Chang Gung Mem Hosp, Dept Anat Pathol, Taoyuan, Taiwan	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Wuhan University; Chang Gung Memorial Hospital	Sukumar, S (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Breast Canc Program, Dept Oncol,Sch Med, 1650 Orleans St,CRB1,143, Baltimore, MD 21231 USA.	saras@jhmi.edu		Neumann, Neil/0000-0001-9779-7754; Teo, Wei Wen/0000-0002-3647-0253; Korangath, Preethi/0000-0002-6623-493X; Cho, Soonweng/0000-0002-1637-2875; Wu, Ren-Chin/0000-0003-1439-0874	Susan G. Komen Foundation Leadership Grant [SAC110050]; Department of Defense Center of Excellence [W81XWH-04-1-0595]; SKCCC Core Grant [P30 CA006973]; AVON Research Foundation Center of Excellence Grant; American Cancer Society [RSG-12-141-01-CSM]; Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007309] Funding Source: NIH RePORTER	Susan G. Komen Foundation Leadership Grant; Department of Defense Center of Excellence(United States Department of Defense); SKCCC Core Grant; AVON Research Foundation Center of Excellence Grant; American Cancer Society(American Cancer Society); Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Akhilesh Pandey and Edward Gabrielson for guidance; Alan Rein for critically reviewing the manuscript; and help from members of the Sukumar lab. This work was supported by the Susan G. Komen Foundation Leadership Grant # SAC110050, the Department of Defense Center of Excellence-W81XWH-04-1-0595 and the SKCCC Core Grant P30 CA006973 to SS and The AVON Research Foundation Center of Excellence Grant to SS/WWT. AJE is supported by awards from the American Cancer Society (RSG-12-141-01-CSM) and from the Breast Cancer Research Foundation.	Alexander T, 2009, ANNU REV CELL DEV BI, V25, P431, DOI 10.1146/annurev.cellbio.042308.113423; Ansari KI, 2012, J MOL ENDOCRINOL, V48, P61, DOI 10.1530/JME-11-0078; Arab HH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011007; Aubin J, 1997, DEV BIOL, V192, P432, DOI 10.1006/dbio.1997.8746; Chen HX, 2007, CANCER RES, V67, P8007, DOI 10.1158/0008-5472.CAN-07-1405; Chen HX, 2004, MOL CELL BIOL, V24, P924, DOI 10.1128/MCB.24.2.924-935.2004; Chute JP, 2006, P NATL ACAD SCI USA, V103, P11707, DOI 10.1073/pnas.0603806103; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Dubrulle J, 2001, CELL, V106, P219, DOI 10.1016/S0092-8674(01)00437-8; Ghiaur G, 2013, P NATL ACAD SCI USA, V110, P16121, DOI 10.1073/pnas.1305937110; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Ginestier C, 2009, CELL CYCLE, V8, P3297, DOI 10.4161/cc.8.20.9761; Henderson KD, 2000, DEV BIOL, V217, P362, DOI 10.1006/dbio.1999.9560; Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108; Jin K, 2015, CANCER DISCOV, V5, P944, DOI 10.1158/2159-8290.CD-15-0090; Jin K, 2012, P NATL ACAD SCI USA, V109, P2736, DOI 10.1073/pnas.1018859108; KAY R, 1991, J IMMUNOL, V147, P1412; Keller PJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2755; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Klopp AH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012180; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; KONDO T, 1992, NUCLEIC ACIDS RES, V20, P5729, DOI 10.1093/nar/20.21.5729; Kramer F, 2000, HUM GENET, V107, P249, DOI 10.1007/s004390000375; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Laursen KB, 2013, NUCLEIC ACIDS RES, V41, P6430, DOI 10.1093/nar/gkt367; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marshall H, 1996, FASEB J, V10, P969, DOI 10.1096/fasebj.10.9.8801179; Martin TA, 2010, INT J MOL MED, V26, P721, DOI 10.3892/ijmm_00000519; May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789; Petkova N, 2013, PROSTATE, V73, P1576, DOI 10.1002/pros.22708; PRATT MAC, 1993, DIFFERENTIATION, V53, P105, DOI 10.1111/j.1432-0436.1993.tb00650.x; Qiao YY, 2011, CANCER RES, V71, P3076, DOI 10.1158/0008-5472.CAN-10-2787; Radisky DC, 2008, CELL STEM CELL, V2, P511, DOI 10.1016/j.stem.2008.05.007; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Raman V, 2000, J BIOL CHEM, V275, P26551, DOI 10.1074/jbc.C000324200; Ribeiro AS, 2015, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00371; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Sleeman KE, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1371; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun R, 2015, BIOMATERIALS, V37, P405, DOI 10.1016/j.biomaterials.2014.10.018; Swisshelm K, 1999, GENE, V226, P285, DOI 10.1016/S0378-1119(98)00553-8; Taylor HS, 1997, BIOL REPROD, V57, P1338, DOI 10.1095/biolreprod57.6.1338; Thiaville MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036054; Thomas S, 2012, CANCER RES, V72, P5600, DOI 10.1158/0008-5472.CAN-11-3666; Tokes AM, 2005, BREAST CANCER RES, V7, pR296, DOI 10.1186/bcr983; Vesuna F, 2009, NEOPLASIA, V11, P1318, DOI 10.1593/neo.91084; Wang HY, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-680; Wang YA, 2005, DEV DYNAM, V234, P892, DOI 10.1002/dvdy.20570; Yan WX, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-62; Zhang HJ, 2011, CANCER RES, V71, P1292, DOI 10.1158/0008-5472.CAN-10-2825; ZWARTKRUIS F, 1993, EXP CELL RES, V205, P422, DOI 10.1006/excr.1993.1108	56	47	51	2	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5539	5551		10.1038/onc.2016.95	http://dx.doi.org/10.1038/onc.2016.95			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27157614	Green Accepted			2022-12-17	WOS:000386998200008
J	Jubierre, L; Soriano, A; Planells-Ferrer, L; Paris-Coderch, L; Tenbaum, SP; Romero, OA; Moubarak, RS; Almazan-Moga, A; Molist, C; Roma, J; Navarro, S; Noguera, R; Sanchez-Cespedes, M; Comella, JX; Palmer, HG; de Toledo, JS; Gallego, S; Segura, MF				Jubierre, L.; Soriano, A.; Planells-Ferrer, L.; Paris-Coderch, L.; Tenbaum, S. P.; Romero, O. A.; Moubarak, R. S.; Almazan-Moga, A.; Molist, C.; Roma, J.; Navarro, S.; Noguera, R.; Sanchez-Cespedes, M.; Comella, J. X.; Palmer, H. G.; Sanchez de Toledo, J.; Gallego, S.; Segura, M. F.			BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways	ONCOGENE			English	Article							SWI/SNF COMPLEX; DNA METHYLATION; BRG1 EXPRESSION; INHIBITION; VORINOSTAT; TRIAL; WIDE; PROLIFERATION; CHEMOTHERAPY; TARGETS	Neuroblastoma (NB) is a neoplasm of the sympathetic nervous system, and is the most common solid tumor of infancy. NBs are very heterogeneous, with a clinical course ranging from spontaneous regression to resistance to all current forms of treatment. High-risk patients need intense chemotherapy, and only 30-40% will be cured. Relapsed or metastatic tumors acquire multi-drug resistance, raising the need for alternative treatments. Owing to the diverse mechanisms that are responsible of NB chemoresistance, we aimed to target epigenetic factors that control multiple pathways to bypass therapy resistance. We found that the SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 4 (SMARCA4/BRG1) was consistently upregulated in advanced stages of NB, with high BRG1 levels being indicative of poor outcome. Loss-of-function experiments in vitro and in vivo showed that BRG1 is essential for the proliferation of NB cells. Furthermore, whole-genome transcriptome analysis revealed that BRG1 controls the expression of key elements of oncogenic pathways such as PI3K/AKT and BCL2, which offers a promising new combination therapy for high-risk NB.	[Jubierre, L.; Soriano, A.; Paris-Coderch, L.; Almazan-Moga, A.; Molist, C.; Roma, J.; Sanchez de Toledo, J.; Gallego, S.; Segura, M. F.] UAB, Lab Translat Res Child & Adolescent Canc, VHIR, Passeig Vall dHebron 119-129, Barcelona 08035, Spain; [Planells-Ferrer, L.; Moubarak, R. S.; Sanchez-Cespedes, M.; Comella, J. X.] UAB, Cell Signaling & Apoptosis Grp, VHIR, Barcelona, Spain; [Tenbaum, S. P.; Palmer, H. G.] VHIO, Stem Cell & Canc Lab, Barcelona, Spain; [Romero, O. A.] Bellvitge Biomed Res Inst IDIBELL Barcelona, Epigenet & Canc Biol Program PEBC, Barcelona, Spain; [Navarro, S.; Noguera, R.] Univ Valencia, Sch Med, Valencia, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Valencia	Segura, MF (corresponding author), UAB, Lab Translat Res Child & Adolescent Canc, VHIR, Passeig Vall dHebron 119-129, Barcelona 08035, Spain.	miguel.segura@vhir.org	Romero, Octavio A./AAA-8078-2020; Jubierre Zapater, Luz/ABD-7848-2021; Gallego, Soledad/ABI-1334-2020; Navarro, Samuel/AAD-2021-2020; Palmer, Héctor G./AAG-8332-2019; Soriano, Aroa/J-9105-2016; Segura, Miguel F/J-4749-2013; Comella, Joan/GQA-4279-2022	Romero, Octavio A./0000-0003-0229-6530; Jubierre Zapater, Luz/0000-0001-9934-1590; Navarro, Samuel/0000-0001-5016-5653; Soriano, Aroa/0000-0001-9659-1471; Segura, Miguel F/0000-0003-0916-3618; Palmer, Hector/0000-0002-9823-5638; Paris Coderch, Laia/0000-0003-2145-5752; Gallego, Soledad/0000-0002-4712-9624; Roma, Josep/0000-0001-7692-6123; Moubarak, Rana/0000-0003-2096-1258	Instituto de Salud Carlos III [CP11/00052, RD12/0036/0016, RD12/0036/0020, RD12/0036/0045, RD12/0036/0012]; European Regional Development Fund (ERDF); Generalitat de Catalunya [2014-SGR-660]; Marie Curie Career Integration Grants	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); European Regional Development Fund (ERDF)(European Commission); Generalitat de Catalunya(Generalitat de Catalunya); Marie Curie Career Integration Grants	We thank members of the Genomics Facility, Statitstics and Bioinformatic Unit, Pathology Laboratory and the Animal Core Facilities of the Vall d'Hebron Research Institute. We thank Dr Mireia Dunac, Dr Jose R Bayascas and Dr Diego Arango for precious advice. We thank Ms Christine O'Hara for text correction. This work was supported by the Instituto de Salud Carlos III (CP11/00052, RD12/0036/0016, RD12/0036/0020, RD12/0036/0045, RD12/0036/0012) co-financed by the European Regional Development Fund (ERDF), Generalitat de Catalunya 2014-SGR-660 and Marie Curie Career Integration Grants.	Alaminos M, 2004, JNCI-J NATL CANCER I, V96, P1208, DOI 10.1093/jnci/djh224; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bai J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059772; Bai J, 2012, J CANCER RES CLIN, V138, P991, DOI 10.1007/s00432-012-1172-8; Bender A, 2011, ONCOGENE, V30, P494, DOI 10.1038/onc.2010.429; Boix J, 1998, EXP CELL RES, V238, P422, DOI 10.1006/excr.1997.3852; Buckley PG, 2011, INT J CANCER, V128, P2296, DOI 10.1002/ijc.25584; Burke MJ, 2014, AM J HEMATOL, V89, P889, DOI 10.1002/ajh.23778; Buscarlet M, 2014, BLOOD, V123, P1720, DOI 10.1182/blood-2013-02-483495; Charlet J, 2012, BIOCHEM PHARMACOL, V83, P858, DOI 10.1016/j.bcp.2012.01.009; Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Fouladi M, 2010, J CLIN ONCOL, V28, P3623, DOI 10.1200/JCO.2009.25.9119; Grau E, 2010, J CANCER RES CLIN, V136, P1415, DOI 10.1007/s00432-010-0796-9; Hummel TR, 2013, PEDIATR BLOOD CANCER, V60, P1452, DOI 10.1002/pbc.24541; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Irwin MS, 2015, PEDIATR CLIN N AM, V62, P225, DOI 10.1016/j.pcl.2014.09.015; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988; Keshelava N, 1998, CANCER RES, V58, P5396; Kumar HR, 2008, PEDIATR SURG INT, V24, P1229, DOI 10.1007/s00383-008-2245-2; Lamers F, 2012, EUR J CANCER, V48, P3093, DOI 10.1016/j.ejca.2012.01.037; Li Yan, 2006, Zhonghua Nan Ke Xue, V12, P629; Lin H, 2010, BRIT J DERMATOL, V163, P502, DOI 10.1111/j.1365-2133.2010.09851.x; Liu XR, 2014, EUR J CANCER, V50, P2251, DOI 10.1016/j.ejca.2014.05.017; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Machida Y, 2001, J BIOCHEM, V129, P43, DOI 10.1093/oxfordjournals.jbchem.a002834; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Numata M, 2013, INT J ONCOL, V42, P403, DOI 10.3892/ijo.2012.1723; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Opel D, 2011, CLIN CANCER RES, V17, P3233, DOI 10.1158/1078-0432.CCR-10-2530; Popovic R, 2012, CANCER DISCOV, V2, P405, DOI 10.1158/2159-8290.CD-12-0076; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Romero OA, 2012, EMBO MOL MED, V4, P603, DOI 10.1002/emmm.201200236; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Segura MF, 2013, CANCER RES, V73, P6264, DOI 10.1158/0008-5472.CAN-13-0122-T; Sentani K, 2001, PATHOBIOLOGY, V69, P315, DOI 10.1159/000064638; Shain AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055119; Shi J, 2013, GENE DEV, V27, P2648, DOI 10.1101/gad.232710.113; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Su JM, 2011, CLIN CANCER RES, V17, P589, DOI 10.1158/1078-0432.CCR-10-0738; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun A, 2007, PROSTATE, V67, P203, DOI 10.1002/pros.20521; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Watanabe T, 2011, BRIT J CANCER, V104, P146, DOI 10.1038/sj.bjc.6606018; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Wyce A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072967; Yang QW, 2007, CLIN CANCER RES, V13, P3191, DOI 10.1158/1078-0432.CCR-06-2846; Yu AL, 2010, NEW ENGL J MED, V363, P1324, DOI 10.1056/NEJMoa0911123; Yuste VJ, 2001, J BIOL CHEM, V276, P22323, DOI 10.1074/jbc.M100072200; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	55	47	50	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5179	5190		10.1038/onc.2016.50	http://dx.doi.org/10.1038/onc.2016.50			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	26996667				2022-12-17	WOS:000384433000009
J	Ingthorsson, S; Andersen, K; Hilmarsdottir, B; Maelandsmo, GM; Magnusson, MK; Gudjonsson, T				Ingthorsson, S.; Andersen, K.; Hilmarsdottir, B.; Maelandsmo, G. M.; Magnusson, M. K.; Gudjonsson, T.			HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; MYOEPITHELIAL CELLS; ERBB RECEPTORS; CLAUDIN-LOW; CANCER; DIFFERENTIATION; EXPRESSION; TRANSFORMATION; ENDOCYTOSIS; HIERARCHY	The members of the epidermal growth factor receptor (EGFR) kinase family are important players in breast morphogenesis and cancer. EGFR2/HER2 and EGFR expression have a prognostic value in certain subtypes of breast cancer such as HER2-amplified, basal-like and luminal type B. Many clinically approved small molecular inhibitors and monoclonal antibodies have been designed to target HER2, EGFR or both. There is, however, still limited knowledge on how the two receptors are expressed in normal breast epithelium, what effects they have on cellular differentiation and how they participate in neoplastic transformation. D492 is a breast epithelial cell line with stem cell properties that can undergo epithelial to mesenchyme transition (EMT), generate luminal-and myoepithelial cells and form complex branching structures in three-dimensional (3D) culture. Here, we show that overexpression of HER2 in D492 (D492(HER2)) resulted in EMT, loss of contact growth inhibition and increased oncogenic potential in vivo. HER2 overexpression, furthermore, inhibited endogenous EGFR expression. Re-introducing EGFR in D492(HER2) (D492(HER2/EGFR)) partially reversed the mesenchymal state of the cells, as an epithelial phenotype reappeared both in 3D cultures and in vivo. The D492(HER2/EGFR) xenografts grow slower than the D492HER2 tumors, while overexpression of EGFR alone (D492(EGFR)) was not oncogenic in vivo. Consistent with the EGFR-mediated epithelial phenotype, overexpression of EGFR drove the cells toward a myoepithelial phenotype in 3D culture. The effect of two clinically approved anti-HER2 and EGFR therapies, trastuzumab and cetuximab, was tested alone and in combination on D492HER2 xenografts. While trastuzumab had a growth inhibitory effect compared with untreated control, the effect of cetuximab was limited. When administered in combination, the growth inhibitory effect of trastuzumab was less pronounced. Collectively, our data indicate that in HER2-overexpressing D492 cells, EGFR can behave as a tumor suppressor, by pushing the cells towards epithelial differentiation.	[Ingthorsson, S.; Hilmarsdottir, B.; Magnusson, M. K.; Gudjonsson, T.] Univ Iceland, Biomed Ctr, Stem Cell Res Unit, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland; [Ingthorsson, S.; Hilmarsdottir, B.; Magnusson, M. K.; Gudjonsson, T.] Landspitali Univ Hosp, Dept Haematol Lab, Reykjavik, Iceland; [Andersen, K.; Maelandsmo, G. M.] Norwegian Radium Hosp, Oslo Univ Hosp, Inst Canc Res, Dept Tumor Biol, Oslo, Norway; [Andersen, K.; Maelandsmo, G. M.] Norwegian Radium Hosp, Oslo Univ Hosp, Canc Stem Cell Innovat Ctr, Oslo, Norway; [Maelandsmo, G. M.] Univ Oslo, Inst Clin Med, KG Jebsen Ctr Breast Canc Res, Oslo, Norway; [Magnusson, M. K.] Univ Iceland, Dept Pharmacol & Toxicol, Reykjavik, Iceland	University of Iceland; Landspitali National University Hospital; University of Oslo; University of Oslo; University of Oslo; University of Iceland	Gudjonsson, T (corresponding author), Univ Iceland, Biomed Ctr, Stem Cell Res Unit, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland.	tgudjons@hi.is	Hilmarsdottir, Bylgja/AAV-7406-2020; Mælandsmo, Gunhild Mari/AFV-4446-2022	Ingthorsson, Saevar/0000-0001-8480-9680; Gudjonsson, Thorarinn/0000-0001-9645-9665; Hilmarsdottir, Bylgja/0000-0001-8693-5541	Landspitali University Hospital Science Fund; University of Iceland Research Fund; Science and Technology Policy Council Research Fund; Grant of Excellence, 'Gongum saman'	Landspitali University Hospital Science Fund; University of Iceland Research Fund; Science and Technology Policy Council Research Fund; Grant of Excellence, 'Gongum saman'	This work was supported from Landspitali University Hospital Science Fund, University of Iceland Research Fund, Science and Technology Policy Council Research Fund and Grant of Excellence, 'Gongum saman', a supporting group for breast cancer research in Iceland. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We are grateful to Petros Gebregziabher and Alexandr Kristian for advicing on and performing the in vivo experiments.	Balk-Moller E, 2014, AM J PATHOL, V184, P1198, DOI 10.1016/j.ajpath.2013.12.013; Barsky SH, 2005, J MAMMARY GLAND BIOL, V10, P249, DOI 10.1007/s10911-005-9585-5; Baulida J, 1996, J BIOL CHEM, V271, P5251; Carpenter RL, 2014, ONCOGENE, V34, P546; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Davis NM, 2014, ONCOTARGET, V5, P4603, DOI 10.18632/oncotarget.2209; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Flageng MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074618; Forster N, 2014, DEV CELL, V28, P147, DOI 10.1016/j.devcel.2013.11.019; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Gudjonsson T, 2002, GENE DEV, V16, P693, DOI 10.1101/gad.952602; Gudjonsson T, 2002, J CELL SCI, V115, P39; Guth U, 2014, BREAST, V23, P26, DOI 10.1016/j.breast.2013.10.007; Gupta P, 2014, MOL ONCOL, V8, P1532, DOI 10.1016/j.molonc.2014.06.006; Haglund K, 2012, J CELL SCI, V125, P265, DOI 10.1242/jcs.091280; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hartman Z, 2013, ONCOGENE, V32, P4169, DOI 10.1038/onc.2012.418; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Hilmarsdottir B, 2015, DEV BIOL, V403, P150, DOI 10.1016/j.ydbio.2015.05.007; Hilmarsdottir B, 2014, GENES-BASEL, V5, P804, DOI 10.3390/genes5030804; Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007; Ingthorsson Saevar, 2010, BMC Res Notes, V3, P184, DOI 10.1186/1756-0500-3-184; Jenndahl LE, 2005, INT J ONCOL, V27, P439; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lee K, 2011, EMBO J, V30, P2662, DOI 10.1038/emboj.2011.159; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Moyret-Lalle C, 2014, WORLD J CLIN ONCOL, V5, P311, DOI 10.5306/wjco.v5.i3.311; Nakagawa M, 2012, BREAST CANCER-TOKYO, V19, P54, DOI 10.1007/s12282-011-0265-6; Oakes SR, 2014, CELL MOL LIFE SCI, V71, P4301, DOI 10.1007/s00018-014-1674-4; Ortega-Cava Cesar F, 2011, J Carcinog, V10, P29, DOI 10.4103/1477-3163.90443; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pinhel I, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3145; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Sabatier R, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-228; Schneider MR, 2016, ONCOGENE, V35, P2949, DOI 10.1038/onc.2015.372; Sigurdsson V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023833; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sobande Folakemi, 2015, Cesk Patol, V51, P80; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sternlicht MD, 2006, DIFFERENTIATION, V74, P365, DOI 10.1111/j.1432-0436.2006.00105.x; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vidi Pierre-Alexandre, 2013, Methods Mol Biol, V945, P193, DOI 10.1007/978-1-62703-125-7_13; Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114; Zhan LX, 2006, CANCER RES, V66, P5201, DOI 10.1158/0008-5472.CAN-05-4081; Zhang MH, 2014, BIOMED REP, V2, P41, DOI 10.3892/br.2013.187; Zwang Yaara, 2009, Traffic, V10, P349, DOI 10.1111/j.1600-0854.2008.00870.x	49	47	48	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4244	4255		10.1038/onc.2015.489	http://dx.doi.org/10.1038/onc.2015.489			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26686087	Green Published, hybrid			2022-12-17	WOS:000382149800009
J	Alayev, A; Salamon, RS; Berger, SM; Schwartz, NS; Cuesta, R; Snyder, RB; Holz, MK				Alayev, A.; Salamon, R. S.; Berger, S. M.; Schwartz, N. S.; Cuesta, R.; Snyder, R. B.; Holz, M. K.			mTORC1 directly phosphorylates and activates ER alpha upon estrogen stimulation	ONCOGENE			English	Article							BREAST-CANCER; RECEPTOR-ALPHA; TUBEROUS SCLEROSIS; MAMMALIAN TARGET; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOCRINE-THERAPY; RAPAMYCIN TOR; CELL-GROWTH; EVEROLIMUS; RAPTOR	Breast cancer is the leading cause of cancer-related deaths among women. Approximately 75% of breast cancers are estrogen receptor-alpha (ER alpha) positive, underscoring the dependence of cancer cells on estrogen for growth and survival. Patients treated with endocrine therapy often develop resistance, either de novo or acquired, which in some cases is caused by aberrations within the growth factor signaling pathways. The mechanistic target of rapamycin complex 1 (mTORC1) has emerged as a critical node in estrogenic signaling. We have previously shown that mTORC1 can phosphorylate and activate ER alpha on S167 via its effector-the 40S ribosomal S6 kinase 1 (S6K1). Presently, we have uncovered a direct link between mTORC1 and ER alpha. We found that ERa binds to regulatory-associated protein of mTOR (Raptor) and causes it to translocate to the nucleus upon estrogen stimulation. In addition, we identified mTOR as the kinase that phosphorylates ERa on S104/106 and activates transcription of ER target genes. Our findings show a direct link between mTORC1 and ER alpha, which further implicates mTORC1 signaling in the pathogenesis of ER-positive breast cancer and provides rationale for FDA-approved use of mTORC1 inhibitors in combination with endocrine agents for treatment of this disease.	[Alayev, A.; Salamon, R. S.; Berger, S. M.; Schwartz, N. S.; Cuesta, R.; Snyder, R. B.; Holz, M. K.] Yeshiva Univ, Dept Biol, 245 Lexington Ave Bio 341, New York, NY 10016 USA; [Holz, M. K.] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA; [Holz, M. K.] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10467 USA	Yeshiva University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Holz, MK (corresponding author), Yeshiva Univ, Dept Biol, 245 Lexington Ave Bio 341, New York, NY 10016 USA.	mholz@yu.edu			NIH [CA151112]; Atol Charitable Trust; LAM Foundation [098P0113]; American Cancer Society [RSG-13-287-01-TBE]; National Cancer Center; NATIONAL CANCER INSTITUTE [R15CA151112] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Atol Charitable Trust; LAM Foundation; American Cancer Society(American Cancer Society); National Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Dr Jonathan M Backer (Albert Einstein College of Medicine) for his help with the kinase assay and Adi Berman for excellent technical assistance. This work was supported by the NIH-CA151112; Atol Charitable Trust; LAM Foundation-098P0113; American Cancer Society-RSG-13-287-01-TBE ( all to MKH) and National Cancer Center-no grant number (to AA).	Alayev A, 2013, J CELL PHYSIOL, V228, P1658, DOI 10.1002/jcp.24351; Bachelot T, 2012, J CLIN ONCOL, V30, P2718, DOI 10.1200/JCO.2011.39.0708; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Baselga J, 2009, J CLIN ONCOL, V27, P2630, DOI 10.1200/JCO.2008.18.8391; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Chambliss KL, 2010, J CLIN INVEST, V120, P2319, DOI 10.1172/JCI38291; Chaveroux C, 2013, CELL METAB, V17, P586, DOI 10.1016/j.cmet.2013.03.003; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Cunningham JT, 2007, NATURE, V450, P736, DOI 10.1038/nature06322; Ellis M, 2004, ONCOLOGIST, V9, P20, DOI 10.1634/theoncologist.9-suppl_3-20; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Fonseca BD, 2015, J BIOL CHEM, V290, P15996, DOI 10.1074/jbc.M114.621730; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Generali D, 2008, CLIN CANCER RES, V14, P2673, DOI 10.1158/1078-0432.CCR-07-1046; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Holz MK, 2005, J BIOL CHEM, V280, P26089, DOI 10.1074/jbc.M504045200; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; James MJ, 2004, J BIOL CHEM, V279, P8911, DOI 10.1074/jbc.M307735200; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200; Le Romancer M, 2011, ENDOCR REV, V32, P597, DOI 10.1210/er.2010-0016; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Madak-Erdogan Z, 2014, MOL CANCER RES, V12, P714, DOI 10.1158/1541-7786.MCR-13-0588; Madak-Erdogan Z, 2011, MOL CELL BIOL, V31, P226, DOI 10.1128/MCB.00821-10; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653; Maruani DM, 2012, ONCOGENE, V31, P5073, DOI 10.1038/onc.2011.657; Miller TW, 2011, J CLIN ONCOL, V29, P4452, DOI 10.1200/JCO.2010.34.4879; Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680; Miller WR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr2931; Oshiro N, 2007, J BIOL CHEM, V282, P20329, DOI 10.1074/jbc.M702636200; Paplomata E, 2014, THER ADV MED ONCOL, V6, P154, DOI 10.1177/1758834014530023; Paplomata E, 2013, BREAST CANCER RES TR, V140, P453, DOI 10.1007/s10549-013-2630-y; Paplomata E, 2013, THER CLIN RISK MANAG, V9, P27, DOI 10.2147/TCRM.S30349; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Petz LN, 2002, ENDOCRINOLOGY, V143, P4583, DOI 10.1210/en.2002-220369; Piccart M, 2014, ANN ONCOL, V25, P2357, DOI 10.1093/annonc/mdu456; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Thomas RS, 2008, J MOL ENDOCRINOL, V40, P173, DOI 10.1677/JME-07-0165; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Yamashita H, 2005, BREAST CANCER RES, V7, pR753, DOI 10.1186/bcr1285; Yamashita H, 2008, ENDOCR-RELAT CANCER, V15, P755, DOI 10.1677/ERC-08-0078; Yamnik RL, 2010, FEBS LETT, V584, P124, DOI 10.1016/j.febslet.2009.11.041; Yamnik RL, 2009, J BIOL CHEM, V284, P6361, DOI 10.1074/jbc.M807532200; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Yu J, 2006, CANCER RES, V66, P9461, DOI 10.1158/0008-5472.CAN-06-1895; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	56	47	47	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3535	3543		10.1038/onc.2015.414	http://dx.doi.org/10.1038/onc.2015.414			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26522726	Green Accepted			2022-12-17	WOS:000379621500006
J	Meng, Z; Jia, LF; Gan, YH				Meng, Z.; Jia, L-F; Gan, Y-H			PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITORS; TRICHOSTATIN-A; MEMBRANE ASSOCIATION; PHOSPHATASE-ACTIVITY; SUPPRESSOR PTEN; PROSTATE-CANCER; PLASMA-MEMBRANE; CELL-MIGRATION; BINDING MOTIF; BREAST-CANCER	Phosphatase and tensin homologue deleted on chromosome 10 (PTEN), an important tumour-suppressor gene, is mutated, downregulated or dysfunctional in many tumours. The phosphatase activity of PTEN depends on membrane translocation (activation). As promising anti-cancer agents, histone deacetylase (HDAC) inhibitors, particularly trichostatin A (TSA), can promote PTEN membrane translocation, but the underlying mechanism remains unknown. In this study, we revealed that non-selective HDAC inhibitors, namely, TSA or suberoylanilide hydroxamic acid (SAHA), induced PTEN membrane translocation through PTEN acetylation at K163 by inhibiting HDAC6. K163 acetylation inhibited the interaction of the PTEN C-tail with the remaining part of PTEN, resulting in PTEN membrane translocation. Overexpression of wild-type PTEN, but not K163-mutated PTEN, facilitated the inhibition of cell proliferation, migration and invasion, as well as xenograft tumour growth, induced by SAHA or tubastatin A, an HDAC6-specific inhibitor. These results indicated that PTEN activation by inhibiting HDAC6 significantly contributed to tumour inhibition. Therefore, non-selective HDAC or HDAC6-specific inhibitors may be more clinically suitable to treat tumours without PTEN mutations or deletions.	[Meng, Z.; Jia, L-F; Gan, Y-H] Peking Univ, Cent Lab, Sch & Hosp Stomatol, 22 Zhongguancun Ave South, Beijing 100081, Peoples R China; [Meng, Z.; Gan, Y-H] Peking Univ, Dept Oral & Maxillofacial Surg, Sch & Hosp Stomatol, Beijing 100081, Peoples R China	Peking University; Peking University	Gan, YH (corresponding author), Peking Univ, Cent Lab, Sch & Hosp Stomatol, 22 Zhongguancun Ave South, Beijing 100081, Peoples R China.	kqyehuagan@bjmu.edu.cn			National Natural Science Foundation of China [81472764, 81271173]; China International Science and Technology Cooperation [2013DFB30360]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China International Science and Technology Cooperation	This work was supported by the National Natural Science Foundation of China (Grant No. 81472764 and 81271173) and China International Science and Technology Cooperation (Grant No. 2013DFB30360).	Altonsy MO, 2012, NUTR CANCER, V64, P1251, DOI 10.1080/01635581.2012.721156; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Butler LM, 2000, CANCER RES, V60, P5165; Chen CS, 2005, J BIOL CHEM, V280, P38879, DOI 10.1074/jbc.M505733200; Dallavalle S, 2012, BIOCHEM PHARMACOL, V84, P756, DOI 10.1016/j.bcp.2012.06.014; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Dekker FJ, 2009, DRUG DISCOV TODAY, V14, P942, DOI 10.1016/j.drudis.2009.06.008; Denning G, 2007, ONCOGENE, V26, P3930, DOI 10.1038/sj.onc.1210175; Donadelli M, 2003, MOL CARCINOGEN, V38, P59, DOI 10.1002/mc.10145; Duan H, 2005, MOL CELL BIOL, V25, P1608, DOI 10.1128/MCB.25.5.1608-1619.2005; Duvic M, 2007, EXPERT OPIN INV DRUG, V16, P1111, DOI 10.1517/13543784.16.7.1111; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Gan YH, 2009, ORAL ONCOL, V45, pE150, DOI 10.1016/j.oraloncology.2009.05.563; Georgescu MM, 2000, CANCER RES, V60, P7033; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Herold C, 2002, J HEPATOL, V36, P233, DOI 10.1016/S0168-8278(01)00257-4; Huang J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1919; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Iijima M, 2004, J BIOL CHEM, V279, P16606, DOI 10.1074/jbc.M312098200; Kim HR, 2006, EXP MOL MED, V38, P616, DOI 10.1038/emm.2006.73; Kou XX, 2013, CARCINOGENESIS, V34, P58, DOI 10.1093/carcin/bgs336; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lee YS, 2008, CANCER RES, V68, P7561, DOI 10.1158/0008-5472.CAN-08-0188; Leslie NR, 2005, BIOCHEM SOC T, V33, P1507, DOI 10.1042/BST0331507; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lumb CN, 2013, BIOPHYS J, V104, P613, DOI 10.1016/j.bpj.2012.12.002; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; Mei SP, 2004, INT J ONCOL, V25, P1509; Meuillet EJ, 2004, ARCH BIOCHEM BIOPHYS, V429, P123, DOI 10.1016/j.abb.2004.04.020; Oehme I, 2013, P NATL ACAD SCI USA, V110, pE2592, DOI 10.1073/pnas.1300113110; Okumura K, 2006, J BIOL CHEM, V281, P26562, DOI 10.1074/jbc.M605391200; Rahdar M, 2009, P NATL ACAD SCI USA, V106, P480, DOI 10.1073/pnas.0811212106; Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646; Squarize CH, 2013, NEOPLASIA, V15, P461, DOI 10.1593/neo.121024; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Tashiro H, 1997, CANCER RES, V57, P3935; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Vazquez F, 2006, P NATL ACAD SCI USA, V103, P3633, DOI 10.1073/pnas.0510570103; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016; Zhang Y, 2008, MOL CELL BIOL, V28, P1688, DOI 10.1128/MCB.01154-06	48	47	48	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2333	2344		10.1038/onc.2015.293	http://dx.doi.org/10.1038/onc.2015.293			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26279303				2022-12-17	WOS:000376165000006
J	Ho, TH; Park, IY; Zhao, H; Tong, P; Champion, MD; Yan, H; Monzon, FA; Hoang, A; Tamboli, P; Parker, AS; Joseph, RW; Qiao, W; Dykema, K; Tannir, NM; Castle, EP; Nunez-Nateras, R; Teh, BT; Wang, J; Walker, CL; Hung, MC; Jonasch, E				Ho, T. H.; Park, I. Y.; Zhao, H.; Tong, P.; Champion, M. D.; Yan, H.; Monzon, F. A.; Hoang, A.; Tamboli, P.; Parker, A. S.; Joseph, R. W.; Qiao, W.; Dykema, K.; Tannir, N. M.; Castle, E. P.; Nunez-Nateras, R.; Teh, B. T.; Wang, J.; Walker, C. L.; Hung, M-C; Jonasch, E.			High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma	ONCOGENE			English	Article							ANTITUMOR-ACTIVITY; SNP MICROARRAYS; METHYLATION; TARGET; SETD2; HYPB/SETD2; MUTATIONS; EVOLUTION; CANCER; REPAIR	Mutations in SETD2, a histone H3 lysine trimethyltransferase, have been identified in clear cell renal cell carcinoma (ccRCC); however it is unclear if loss of SETD2 function alters the genomic distribution of histone 3 lysine 36 trimethylation (H3K36me3) in ccRCC. Furthermore, published epigenomic profiles are not specific to H3K36me3 or metastatic tumors. To determine if progressive SETD2 and H3K36me3 dysregulation occurs in metastatic tumors, H3K36me3, SETD2 copy number (CN) or SETD2 mRNA abundance was assessed in two independent cohorts: metastatic ccRCC (n = 71) and the Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma data set (n = 413). Although SETD2 CN loss occurs with high frequency (490%), H3K36me3 is not significantly impacted by monoallelic loss of SETD2. H3K36me3-positive nuclei were reduced an average of similar to 20% in primary ccRCC (90% positive nuclei in uninvolved vs 70% positive nuclei in ccRCC) and reduced by similar to 60% in metastases (90% positive in uninvolved kidney vs 30% positive in metastases) (P<0.001). To define a kidney-specific H3K36me3 profile, we generated genome-wide H3K36me3 profiles from four cytoreductive nephrectomies and SETD2 isogenic renal cell carcinoma (RCC) cell lines using chromatin immunoprecipitation coupled with high-throughput DNA sequencing and RNA sequencing. SETD2 loss of methyltransferase activity leads to regional alterations of H3K36me3 associated with aberrant RNA splicing in a SETD2 mutant RCC and SETD2 knockout cell line. These data suggest that during progression of ccRCC, a decline in H3K36me3 is observed in distant metastases, and regional H3K36me3 alterations influence alternative splicing in ccRCC.	[Ho, T. H.] Mayo Clin, Div Hematol & Med Oncol, Scottsdale, AZ USA; [Ho, T. H.; Champion, M. D.; Yan, H.] Mayo Clin, Ctr Individualized Med, Rochester, MN USA; [Park, I. Y.; Walker, C. L.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Ctr Translat Canc Res, Houston, TX USA; [Zhao, H.; Tong, P.; Wang, J.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Champion, M. D.] Mayo Clin, Dept Biomed Stat & Informat, Scottsdale, AZ USA; [Yan, H.] Dept Biomed Stat & Informat, Rochester, MN USA; [Monzon, F. A.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Monzon, F. A.; Hoang, A.; Tannir, N. M.; Jonasch, E.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, 1515 Holcombe Blvd,Unit 1374, Houston, TX 77030 USA; [Tamboli, P.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Parker, A. S.] Mayo Clin, Dept Hlth Sci Res, Jacksonville, FL 32224 USA; [Joseph, R. W.] Mayo Clin, Div Hematol & Med Oncol, Jacksonville, FL 32224 USA; [Qiao, W.] Univ Texas MD Anderson Canc Ctr, Div Quantitat Sci, Houston, TX 77030 USA; [Dykema, K.; Teh, B. T.] Van Andel Inst, Ctr Canc Genom & Computat Biol, Grand Rapids, MI USA; [Castle, E. P.; Nunez-Nateras, R.] Mayo Clin, Dept Urol, Scottsdale, AZ USA; [Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Hung, M-C] China Med Univ, Ctr Mol Med, Taichung, Taiwan; [Hung, M-C] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Monzon, F. A.] Invitae, San Francisco, CA USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic; Mayo Clinic Phoenix; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic; Mayo Clinic; University of Texas System; UTMD Anderson Cancer Center; Van Andel Institute; Mayo Clinic; Mayo Clinic Phoenix; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Taiwan	Jonasch, E (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, 1515 Holcombe Blvd,Unit 1374, Houston, TX 77030 USA.	ejonasch@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Joseph, Richard/0000-0001-6102-4661	ASCO Young Investigator Award from the Kidney Cancer Association; Action to Cure Kidney Cancer Organization; MD Anderson Hematology-Oncology Fellowship; NIH grant [K12 CA90628]; Mayo Clinic CR5 grant; Mayo Clinic Center for Individualized Medicine Epigenomics Translational Program; Kathryn H and Roger Penske Career Development Award to Support Medical Research; Mayo Clinic Center for Individualized Medicine; NATIONAL CANCER INSTITUTE [R01CA143811, K12CA090628, R01CA134466, P30CA015083, P30CA016672] Funding Source: NIH RePORTER	ASCO Young Investigator Award from the Kidney Cancer Association; Action to Cure Kidney Cancer Organization; MD Anderson Hematology-Oncology Fellowship; NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Clinic CR5 grant; Mayo Clinic Center for Individualized Medicine Epigenomics Translational Program; Kathryn H and Roger Penske Career Development Award to Support Medical Research; Mayo Clinic Center for Individualized Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ian Davis, W Kimryn Rathmell, Kathryn E Hacker and Jeremy M Simon for helpful discussions and assistance with the genotyping of tissue. THH is supported by funding from the ASCO Young Investigator Award from the Kidney Cancer Association, the Action to Cure Kidney Cancer Organization, the MD Anderson Hematology-Oncology Fellowship, NIH grant K12 CA90628, a Mayo Clinic CR5 grant, the Mayo Clinic Center for Individualized Medicine Epigenomics Translational Program and a Kathryn H and Roger Penske Career Development Award to Support Medical Research. MDC is supported by the Mayo Clinic Center for Individualized Medicine.	Alvarez K, 2010, DIAGN MOL PATHOL, V19, P127, DOI 10.1097/PDM.0b013e3181d527c5; Bai AL, 2010, CANCER RES, V70, P7630, DOI 10.1158/0008-5472.CAN-10-1489; Bonnal S, 2012, NAT REV DRUG DISCOV, V11, P847, DOI 10.1038/nrd3823; Buck MJ, 2013, ONCOGENE; Carvalho S, 2014, ELIFE, V3, DOI 10.7554/eLife.02482; Champion MD, 2014, CHIP RNA SEQPRO STRA; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Edmunds JW, 2008, EMBO J, V27, P406, DOI 10.1038/sj.emboj.7601967; Finley SD, 2012, AAPS J, V14, P500, DOI 10.1208/s12248-012-9363-4; Fontebasso AM, 2013, ACTA NEUROPATHOL, V125, P659, DOI 10.1007/s00401-013-1095-8; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Ho TH, 2004, EMBO J, V23, P3103, DOI 10.1038/sj.emboj.7600300; Hu M, 2010, P NATL ACAD SCI USA, V107, P2956, DOI 10.1073/pnas.0915033107; James LI, 2013, NAT CHEM BIOL, V9, P184, DOI [10.1038/NCHEMBIO.1157, 10.1038/nchembio.1157]; Jonasch E, 2010, CANCER-AM CANCER SOC, V116, P57, DOI 10.1002/cncr.24685; Jonasch E, 2009, J CLIN ONCOL, V27, P4076, DOI 10.1200/JCO.2008.21.3660; Joseph CG, 2014, GENE CHROMOSOME CANC, V53, P15, DOI 10.1002/gcc.22114; Kim HJ, 2009, AM J SURG PATHOL, V33, P1276, DOI 10.1097/PAS.0b013e3181a2aa36; Kolasinska-Zwierz P, 2009, NAT GENET, V41, P376, DOI 10.1038/ng.322; Li F, 2013, CELL, V153, P590, DOI 10.1016/j.cell.2013.03.025; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Linehan WM, 2010, NAT REV UROL, V7, P277, DOI 10.1038/nrurol.2010.47; Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208; Mar BG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4469; Monzon FA, 2011, MODERN PATHOL, V24, P1470, DOI 10.1038/modpathol.2011.107; Pena-LlopiS S, 2012, NAT GENET, V44, P751, DOI 10.1038/ng.2323; Pfister SX, 2014, CELL REP, V7, P2006, DOI 10.1016/j.celrep.2014.05.026; Shen L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-284; Simon JM, 2014, GENOME RES, V24, P241, DOI 10.1101/gr.158253.113; Singh RK, 2012, TRENDS MOL MED, V18, P472, DOI 10.1016/j.molmed.2012.06.006; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020; Vivas-Mejia PE, 2011, CLIN CANCER RES, V17, P3716, DOI 10.1158/1078-0432.CCR-11-0233; Wagner EJ, 2012, NAT REV MOL CELL BIO, V13, P115, DOI 10.1038/nrm3274; Xie P, 2008, CELL SIGNAL, V20, P1671, DOI 10.1016/j.cellsig.2008.05.012	42	47	49	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1565	1574		10.1038/onc.2015.221	http://dx.doi.org/10.1038/onc.2015.221			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26073078	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000373063600009
J	Zhu, Z; Zhao, X; Zhao, L; Yang, H; Liu, L; Li, J; Wu, J; Yang, F; Huang, G; Liu, J				Zhu, Z.; Zhao, X.; Zhao, L.; Yang, H.; Liu, L.; Li, J.; Wu, J.; Yang, F.; Huang, G.; Liu, J.			p54(nrb)/NONO regulates lipid metabolism and breast cancer growth through SREBP-1A	ONCOGENE			English	Article							FATTY-ACID SYNTHASE; ELEMENT-BINDING PROTEIN-1; DE-NOVO LIPOGENESIS; PROSTATE-CANCER; ACTIVATION; EXPRESSION; ANDROGEN; PATHWAY; CELLS; TRANSCRIPTION	Dysregulation of lipid metabolism is common in breast cancer. However, the underlying mechanisms remain elusive and the contribution of aberrant lipid metabolism to the malignant phenotypes of breast cancer is poorly understood. Here, we show that the nuclear protein p54(nrb)/Nono is highly expressed in breast cancer tissues as compared with the adjacent normal tissues in human patients. To determine the functions of p54(nrb) in breast cancer, we performed a biochemical screen and identified SREBP-1a, a master activator for genes involved in lipid biosynthesis, as a novel interacting protein of p54(nrb). In human breast cancer tissues, the levels of p54(nrb) and SREBP-1a proteins were positively correlated with each other. Our biochemical analyses showed that the conserved Y267 residue of p54(nrb) was required for its binding to the nuclear form of SREBP-1a. Interestingly, p54(nrb) binding to nuclear SREBP-1a caused an increase of nuclear SREBP-1a protein stability. As a result, p54(nrb) stimulates SREBP-1-meidated transcription of lipogenic genes and lipid production in breast cancer cells. Moreover, both p54(nrb) and SREBP-1a were required for breast cancer cell growth in vitro, and p54(nrb) binding to nuclear SREBP-1a was also critical for breast tumor development in vivo. Together, we conclude that p54(nrb) is a novel regulator of SREBP-1a in the nucleus, and our data suggest that p54(nrb) regulation of SREBP-1a supports the increased cellular demand of lipids for breast cancer growth. Thus, the SREBP pathway may represent a novel target for treating breast cancer.	[Zhu, Z.; Zhao, X.; Zhao, L.; Liu, L.; Li, J.; Wu, J.; Huang, G.; Liu, J.] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Nucl Med, Shanghai 200127, Peoples R China; [Yang, H.; Huang, G.] Shanghai Jiao Tong Univ, Sch Med, Chinese Acad Sci, Shanghai Inst Biol Sci,Inst Hlth Sci, Shanghai 200030, Peoples R China; [Yang, F.] Albert Einstein Coll Med, Dept Med, New York, NY USA; [Yang, F.] Albert Einstein Coll Med, Dept Dev & Mol Biol, New York, NY USA	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Yeshiva University; Yeshiva University	Huang, G; Liu, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Nucl Med, Shanghai 200127, Peoples R China.	huang2802@163.com; nuclearj@163.com			'973' Project [2012CB932604]; New Drug Discovery Project [2012ZX09506-001-005]; Shanghai First-class Discipline (Medical technology); National Natural Science Foundation of China [81372195, 81471685, 81471687]; Shanghai Pujiang Program [13PJ1406000]; Science and Technology Commission of Shanghai Municipality [134119a5600]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning [1410000157]; Shanghai Municipal Commission of Health and Family Planning [XYQ2013109]; NIH [R01 (DK093623)]	'973' Project(National Basic Research Program of China); New Drug Discovery Project; Shanghai First-class Discipline (Medical technology); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Pujiang Program(Shanghai Pujiang Program); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning; Shanghai Municipal Commission of Health and Family Planning; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The study was supported by research grants from '973' Project (No. 2012CB932604), New Drug Discovery Project (No. 2012ZX09506-001-005), Shanghai First-class Discipline (Medical technology), National Natural Science Foundation of China (No. 81372195, 81471685 and 81471687), Shanghai Pujiang Program (No. 13PJ1406000), Science and Technology Commission of Shanghai Municipality (No. 134119a5600), Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (No. 1410000157) and Shanghai Municipal Commission of Health and Family Planning (XYQ2013109). FY was supported by NIH R01 (DK093623).	Amelio AL, 2007, P NATL ACAD SCI USA, V104, P20314, DOI 10.1073/pnas.0707999105; Calvisi DF, 2011, GASTROENTEROLOGY, V140, P1071, DOI 10.1053/j.gastro.2010.12.006; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Furuta E, 2008, CANCER RES, V68, P1003, DOI 10.1158/0008-5472.CAN-07-2489; Guo DL, 2014, CURR PHARM DESIGN, V20, P2619, DOI 10.2174/13816128113199990486; Guo DL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000446; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hata K, 2008, J CLIN INVEST, V118, P3098, DOI 10.1172/JCI31373; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Ishiguro H, 2003, INT J CANCER, V105, P26, DOI 10.1002/ijc.11021; Ishitani K, 2003, BIOCHEM BIOPH RES CO, V306, P660, DOI 10.1016/S0006-291X(03)01021-0; Kuhajda FP, 2006, CANCER RES, V66, P5977, DOI 10.1158/0008-5472.CAN-05-4673; Kuhnert A, 2012, J CELL BIOCHEM, V113, P1744, DOI 10.1002/jcb.24045; Kuwahara S, 2006, BIOL REPROD, V75, P352, DOI 10.1095/biolreprod.106.051136; Li JN, 2000, EXP CELL RES, V261, P159, DOI 10.1006/excr.2000.5054; Li WH, 2012, CELL CYCLE, V11, P2348, DOI 10.4161/cc.20811; Liu PY, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju113; Lu SY, 2010, INT J CANCER, V126, P416, DOI 10.1002/ijc.24761; MEDES G, 1953, CANCER RES, V13, P27; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Nieva C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046456; Park J, 2014, NAT REV ENDOCRINOL, V10, P455, DOI 10.1038/nrendo.2014.94; Passon DM, 2012, P NATL ACAD SCI USA, V109, P4846, DOI 10.1073/pnas.1120792109; Pavao M, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-15; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Rawson RB, 2003, NAT REV MOL CELL BIO, V4, P631, DOI 10.1038/nrm1174; Rysman E, 2010, CANCER RES, V70, P8117, DOI 10.1158/0008-5472.CAN-09-3871; Schiffnery S, 2011, CARCINOGENESIS, V32, P1176, DOI 10.1093/carcin/bgr103; Shao W, 2012, CELL METAB, V16, P414, DOI 10.1016/j.cmet.2012.09.002; Shav-Tal Y, 2002, FEBS LETT, V531, P109, DOI 10.1016/S0014-5793(02)03447-6; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Williams KJ, 2013, CANCER RES, V73, P2850, DOI 10.1158/0008-5472.CAN-13-0382-T; Yamashita T, 2009, J HEPATOL, V50, P100, DOI 10.1016/j.jhep.2008.07.036; Yang YA, 2003, EXP CELL RES, V282, P132, DOI 10.1016/S0014-4827(02)00023-X; Yecies JL, 2011, CELL METAB, V14, P21, DOI 10.1016/j.cmet.2011.06.002; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/0092-8674(93)90690-R; Zhang Z, 2001, CELL, V106, P465, DOI 10.1016/S0092-8674(01)00466-4; Zhao XP, 2014, DIABETES, V63, P2464, DOI 10.2337/db13-0835; Zhao XP, 2012, J CLIN INVEST, V122, P2417, DOI 10.1172/JCI61462	47	47	51	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1399	1410		10.1038/onc.2015.197	http://dx.doi.org/10.1038/onc.2015.197			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26148231				2022-12-17	WOS:000372196400006
J	Zlatanou, A; Sabbioneda, S; Miller, ES; Greenwalt, A; Aggathanggelou, A; Maurice, MM; Lehmann, AR; Stankovic, T; Reverdy, C; Colland, F; Vaziri, C; Stewart, GS				Zlatanou, A.; Sabbioneda, S.; Miller, E. S.; Greenwalt, A.; Aggathanggelou, A.; Maurice, M. M.; Lehmann, A. R.; Stankovic, T.; Reverdy, C.; Colland, F.; Vaziri, C.; Stewart, G. S.			USP7 is essential for maintaining Rad18 stability and DNA damage tolerance	ONCOGENE			English	Article							UBIQUITIN-SPECIFIC PROTEASE; CELL NUCLEAR ANTIGEN; POLYMERASE-ETA; PCNA MONOUBIQUITINATION; TRANSLESION SYNTHESIS; MAMMALIAN-CELLS; BINDING MOTIF; POL-ETA; S-PHASE; REV1	Rad18 functions at the cross-roads of three different DNA damage response (DDR) pathways involved in protecting stressed replication forks: homologous recombination repair, DNA inter-strand cross-link repair and DNA damage tolerance. Although Rad18 serves to facilitate replication of damaged genomes by promoting translesion synthesis (TLS), this comes at a cost of potentially error-prone lesion bypass. In contrast, loss of Rad18-dependent TLS potentiates the collapse of stalled forks and leads to incomplete genome replication. Given the pivotal nature with which Rad18 governs the fine balance between replication fidelity and genome stability, Rad18 levels and activity have a major impact on genomic integrity. Here, we identify the de-ubiquitylating enzyme USP7 as a critical regulator of Rad18 protein levels. Loss of USP7 destabilizes Rad18 and compromises UV-induced PCNA mono-ubiquitylation and Pol eta recruitment to stalled replication forks. USP7-depleted cells also fail to elongate nascent daughter strand DNA following UV irradiation and show reduced DNA damage tolerance. We demonstrate that USP7 associates with Rad18 directly via a consensus USP7-binding motif and can disassemble Rad18-dependent poly-ubiquitin chains both in vitro and in vivo. Taken together, these observations identify USP7 as a novel component of the cellular DDR involved in preserving the genome stability.	[Zlatanou, A.; Miller, E. S.; Aggathanggelou, A.; Stankovic, T.; Stewart, G. S.] Univ Birmingham, Sch Canc Sci, Vincent Dr, Birmingham B15 2TT, W Midlands, England; [Sabbioneda, S.] CNR, Ist Genet Mol, I-27100 Pavia, Italy; [Greenwalt, A.; Vaziri, C.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA; [Maurice, M. M.] UMCU, Heidelberglaan 100, Utrecht, Netherlands; [Lehmann, A. R.] Univ Sussex, MRC Genome Damage & Stabil Ctr, Brighton, E Sussex, England; [Reverdy, C.; Colland, F.] Hybrigen Pharma, Paris, France	University of Birmingham; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of North Carolina; University of North Carolina Chapel Hill; Unilever; Utrecht University; Utrecht University Medical Center; University of Sussex	Stewart, GS (corresponding author), Univ Birmingham, Sch Canc Sci, Vincent Dr, Birmingham B15 2TT, W Midlands, England.	g.s.stewart@bham.ac.uk	Sabbioneda, Simone/N-7017-2015	Sabbioneda, Simone/0000-0001-8551-5465; Maurice, Madelon/0000-0001-6885-5361; Stankovic, Tatjana/0000-0002-3780-274X; Stewart, Grant/0000-0002-0960-3241	Lister Institute Research Prize; WWCR [13-1012]; CR-UK Senior Research Fellowship [C17183/A13030]; LLR [11045]; AIRC [12710]; 7th Framework Program [CIG 303806]; NIEHS [R01ES009558]; NCI [F31 CA177179]; University of Birmingham; MRC [G0501450] Funding Source: UKRI; Medical Research Council [G0501450] Funding Source: researchfish; Worldwide Cancer Research [13-1012] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [F31CA177179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009558] Funding Source: NIH RePORTER	Lister Institute Research Prize; WWCR; CR-UK Senior Research Fellowship; LLR; AIRC(Fondazione AIRC per la ricerca sul cancro); 7th Framework Program(European Commission); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Birmingham; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Worldwide Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Drs Akira Yasui, Jun Huang, Justin Leung, Junjie Chen and Patricia Kannouche for the kind gift of various Rad18 expression plasmids. We thank Drs Jan van der Knaap, Chris Boutell and Roger Everett for providing recombinant purified WT and catalytically inactive USP7 and Dr Jakob Nilsson for providing the HeLa Flp-In/T-Rex cells. We also thank Dr Malcolm Taylor for critical reading of the manuscript. This work was funded by a Lister Institute Research Prize (AZ and GS), a WWCR project grant (AZ and GS; 13-1012), a CR-UK Senior Research Fellowship (GS and EM; C17183/A13030) and a LLR program grant (AA and TS; 11045), SS was supported by an AIRC Grant 12710 and a 7th Framework Program (CIG 303806). CV was supported by R01ES009558 from the NIEHS. AMG was funded by a pre-doctoral fellowship (F31 CA177179) from the NCI. Lastly, we thank the University of Birmingham for supporting this work.	Bekes M, 2013, CELL REP, V5, P826, DOI 10.1016/j.celrep.2013.10.008; Bergink S, 2009, NATURE, V458, P461, DOI 10.1038/nature07963; Bi XH, 2006, MOL CELL BIOL, V26, P3527, DOI 10.1128/MCB.26.9.3527-3540.2006; Bienko M, 2005, SCIENCE, V310, P1821, DOI 10.1126/science.1120615; Bienko M, 2010, MOL CELL, V37, P396, DOI 10.1016/j.molcel.2009.12.039; Bomar MG, 2010, MOL CELL, V37, P408, DOI 10.1016/j.molcel.2009.12.038; Canning M, 2004, J BIOL CHEM, V279, P38160, DOI 10.1074/jbc.M402885200; Colland F, 2009, MOL CANCER THER, V8, P2286, DOI 10.1158/1535-7163.MCT-09-0097; Day TA, 2010, J CELL BIOL, V191, P953, DOI 10.1083/jcb.201006043; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; Felle M, 2011, NUCLEIC ACIDS RES, V39, P8355, DOI 10.1093/nar/gkr528; Gan GN, 2008, CELL RES, V18, P174, DOI 10.1038/cr.2007.117; Garg P, 2005, P NATL ACAD SCI USA, V102, P18361, DOI 10.1073/pnas.0505949102; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Guo CX, 2006, MOL CELL BIOL, V26, P8892, DOI 10.1128/MCB.01118-06; Hashimoto K, 2012, J BIOL CHEM, V287, P9613, DOI 10.1074/jbc.M111.331728; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Huang J, 2009, NAT CELL BIOL, V11, P592, DOI 10.1038/ncb1865; Huether R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4630; Jacq X, 2013, CELL BIOCHEM BIOPHYS, V67, P25, DOI 10.1007/s12013-013-9635-3; Jansen JG, 2009, MOL CELL BIOL, V29, P3113, DOI 10.1128/MCB.00071-09; Jung YS, 2012, DNA REPAIR, V11, P177, DOI 10.1016/j.dnarep.2011.10.017; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kim H, 2012, NAT STRUCT MOL BIOL, V19, P164, DOI 10.1038/nsmb.2222; LARIMER FW, 1989, J BACTERIOL, V171, P230, DOI 10.1128/jb.171.1.230-237.1989; LAWRENCE CW, 1976, GENETICS, V82, P207; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Lin JR, 2011, MOL CELL, V42, P237, DOI 10.1016/j.molcel.2011.02.026; Masuda Y, 2012, NUCLEIC ACIDS RES, V40, P1065, DOI 10.1093/nar/gkr805; McNally K, 2008, DNA REPAIR, V7, P597, DOI 10.1016/j.dnarep.2007.12.013; Meulmeester E, 2005, CELL CYCLE, V4, P1166, DOI 10.4161/cc.4.9.1981; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Miyase S, 2005, J BIOL CHEM, V280, P515, DOI 10.1074/jbc.M409219200; Nakajima S, 2006, J BIOL CHEM, V281, P34687, DOI 10.1074/jbc.M605545200; Nicholson B, 2011, CELL BIOCHEM BIOPHYS, V60, P61, DOI 10.1007/s12013-011-9185-5; Oh YM, 2007, BIOCHEM BIOPH RES CO, V357, P615, DOI 10.1016/j.bbrc.2007.03.193; Palle K, 2011, CELL CYCLE, V10, P1625, DOI 10.4161/cc.10.10.15617; PARRIS CN, 1992, GENE, V117, P1, DOI 10.1016/0378-1119(92)90482-5; Qian J, 2015, ONCOGENE, V34, P4791, DOI 10.1038/onc.2014.394; Qing P, 2011, J CELL BIOCHEM, V112, P3856, DOI 10.1002/jcb.23317; Reverdy C, 2012, CHEM BIOL, V19, P467, DOI 10.1016/j.chembiol.2012.02.007; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sheng Y, 2006, NAT STRUCT MOL BIOL, V13, P285, DOI 10.1038/nsmb1067; Stary A, 2003, J BIOL CHEM, V278, P18767, DOI 10.1074/jbc.M211838200; Tateishi S, 2003, MOL CELL BIOL, V23, P474, DOI 10.1128/MCB.23.2.474-481.2003; Wagner JM, 2009, MOL PHARMACOL, V76, P208, DOI 10.1124/mol.109.055178; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383; Wood A, 2007, J BIOL CHEM, V282, P20256, DOI 10.1074/jbc.M702366200; Yoon JH, 2012, P NATL ACAD SCI USA, V109, P7799, DOI 10.1073/pnas.1204105109; Zeman MK, 2014, J CELL BIOL, V206, P183, DOI 10.1083/jcb.201311063; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zlatanou A, 2011, MOL CELL, V43, P649, DOI 10.1016/j.molcel.2011.06.023	53	47	48	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					965	976		10.1038/onc.2015.149	http://dx.doi.org/10.1038/onc.2015.149			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25961918	Green Submitted			2022-12-17	WOS:000370823300003
J	Wang, G; Fu, Y; Yang, X; Luo, X; Wang, J; Gong, J; Hu, J				Wang, G.; Fu, Y.; Yang, X.; Luo, X.; Wang, J.; Gong, J.; Hu, J.			Brg-1 targeting of novel miR550a-5p/RNF43/Wnt signaling axis regulates colorectal cancer metastasis	ONCOGENE			English	Article							NUCLEOSOME-REMODELING COMPLEXES; SWI/SNF COMPLEX; HEPATOCELLULAR-CARCINOMA; UBIQUITIN LIGASE; CELL; RNF43; EXPRESSION; MUTATIONS; COMPONENT; FAMILY	Metastasis is one of the main causes of death in patients with colorectal cancer (CRC). Brg-1 is a central component of the SWItch/Sucrose NonFermentable chromatin-remodeling complex, which features a bromodomain and helicase/ATPase activity. The gene encoding Brg-1 is frequently mutated or silenced in human cancers. Several reports have proposed Brg-1 as a tumor suppressor; however, little is known about its role in oncogenesis and metastasis. Here we demonstrated that decreased Brg-1 regulates a novel miR-550a-5p/RNF43/Wnt/beta-catenin signaling pathway, to promote CRC metastasis in vitro and in vivo. In particular, we used high-throughput RNA-sequencing analysis to show that Brg-1 negatively regulates miR-550a-5p in CRC cells. We further found that Brg-1 inhibits the transcriptional activity of miR-550a-5p promoter, and that decreased Brg-1 expression increased miR-550a-5p expression. We also identified ring finger 43 (RNF43), an inhibitor of Wnt/beta-catenin signaling, as a target of miR-550a-5p. Knockdown of Brg-1 by small interfering RNA led to decreased RNF43 expression, increased Wnt signaling and increased CRC cell migration and invasion. This novel pathway defines a new function for Brg-1 and provides potential targets for the treatment of Brg-1 mutant and loss-of-function tumors.	[Wang, G.; Fu, Y.; Yang, X.; Luo, X.; Hu, J.] Huazhong Univ Sci & Technol, Tongji Med Coll, Canc Res Inst, 1095 Jiefang Rd, Wuhan 430030, Peoples R China; [Wang, J.] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Immunol, 1095 Jiefang Rd, Wuhan 430030, Peoples R China; [Gong, J.] Huazhong Univ Sci & Technol, Tongji Hosp, Mol Med Ctr, 1095 Jiefang Rd, Wuhan 430030, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Hu, J (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Canc Res Inst, 1095 Jiefang Rd, Wuhan 430030, Peoples R China.; Hu, J (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Canc Res Inst, 1095 Jiefang Rd, Wuhan 430030, Peoples R China.	jbhu@tjh.tjmu.edu.cn	Wang, Guihua/AAX-3130-2021		National Natural Science foundation [81300411, 81372662]; Fundamental Research Funds for the Central Universities [2015QN144]	National Natural Science foundation(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This study was supported by the National Natural Science foundation (Number. 81300411 and Number. 81372662) and the Fundamental Research Funds for the Central Universities (Number 2015QN144).	Anson M, 2012, J CLIN INVEST, V122, P586, DOI 10.1172/JCI43937; Bai J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059772; Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Dai Y, 2008, CARCINOGENESIS, V29, P1725, DOI 10.1093/carcin/bgn117; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Griffin CT, 2008, DEVELOPMENT, V135, P493, DOI 10.1242/dev.010090; Han D, 2008, DEV BIOL, V315, P136, DOI 10.1016/j.ydbio.2007.12.024; Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110; Katoh H, 2005, J HEPATOL, V43, P863, DOI 10.1016/j.jhep.2005.05.033; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Koizumi Y, 1997, CLIN CANCER RES, V3, P1067; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Lin H, 2010, BRIT J DERMATOL, V163, P502, DOI 10.1111/j.1365-2133.2010.09851.x; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; MCNUTT NS, 1981, LAB INVEST, V44, P309; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Ramirez-Carrozzi VR, 2006, GENE DEV, V20, P282, DOI 10.1101/gad.1383206; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Sentani K, 2001, PATHOBIOLOGY, V69, P315, DOI 10.1159/000064638; Shinada K, 2011, BIOCHEM BIOPH RES CO, V404, P143, DOI 10.1016/j.bbrc.2010.11.082; STRAGAND JJ, 1980, CANCER RES, V40, P2846; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Sugiura T, 2008, EXP CELL RES, V314, P1519, DOI 10.1016/j.yexcr.2008.01.013; Sun A, 2007, PROSTATE, V67, P203, DOI 10.1002/pros.20521; Tian Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048958; Trotter K., 2008, NUCL RECEPT SIGNAL, V6, P1, DOI DOI 10.1621/NRS.06004; Valdman A, 2003, INT J ONCOL, V22, P1003; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Van Rechem C, 2009, BIOCHEM BIOPH RES CO, V385, P586, DOI 10.1016/j.bbrc.2009.05.115; von Figura G, 2014, NAT CELL BIOL, V16, P255, DOI 10.1038/ncb2916; Wang G, 2015, ONCOGENE, V34, P912, DOI 10.1038/onc.2014.30; Wang G, 2012, CELL DEATH DIFFER, V19, P1870, DOI 10.1038/cdd.2012.70; Wang GH, 2013, ANGIOGENESIS, V16, P561, DOI 10.1007/s10456-013-9336-y; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Wong AKC, 2000, CANCER RES, V60, P6171; Xu Y, 2007, J BIOL CHEM, V282, P37429, DOI 10.1074/jbc.M706039200; Yen CC, 2003, INT J ONCOL, V23, P871; Zebisch M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3787; Zou Y, 2013, GENE, V531, P112, DOI 10.1016/j.gene.2013.08.054	45	47	48	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					651	661		10.1038/onc.2015.124	http://dx.doi.org/10.1038/onc.2015.124			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25961913				2022-12-17	WOS:000369548800012
J	Cheng, X; Yang, Y; Fan, Z; Yu, L; Bai, H; Zhou, B; Wu, X; Xu, H; Fang, M; Shen, A; Chen, Q; Xu, Y				Cheng, X.; Yang, Y.; Fan, Z.; Yu, L.; Bai, H.; Zhou, B.; Wu, X.; Xu, H.; Fang, M.; Shen, A.; Chen, Q.; Xu, Y.			MKL1 potentiates lung cancer cell migration and invasion by epigenetically activating MMP9 transcription	ONCOGENE			English	Article							PRO-INFLAMMATORY TRANSCRIPTION; BRAHMA-RELATED GENE-1; TGF-BETA; MRTF-A; MESENCHYMAL TRANSITION; LEUKEMIA 1; MATRIX-METALLOPROTEINASE-9; INDUCTION; CHROMATIN; REPRESSION	Malignant tumors are exemplified by excessive proliferation and aggressive migration/invasion contributing to increased mortality of cancer patients. Matrix metalloproteinase 9 (MMP9) expression is positively correlated with lung cancer malignancy. The mechanism underlying an elevated MMP9 expression is not clearly defined. We demonstrate here that the transcriptional modulator megakaryocytic leukemia 1 (MKL1) was activated by hypoxia and transforming growth factor (TGF-beta), two prominent pro-malignancy factors, in cultured lung cancer cells. MKL1 levels were also increased in more invasive types of lung cancer in humans. Depletion of MKL1 in lung cancer cells attenuated migration and invasion both in vitro and in vivo. Overexpression of MKL1 potentiated the induction of MMP9 transcription by hypoxia and TGF-beta, whereas MKL1 silencing diminished MMP9 expression. Of interest, MKL1 knockdown eliminated histone H3K4 methylation surrounding the MMP9 promoter. Further analyses revealed that MKL1 recruited ASH2, a component of the H3K4 methyltransferase complex, to activate MMP9 transcription. Depletion of ASH2 ameliorated cancer cell migration and invasion in an MMP9-dependent manner. Together our data indicate that MKL1 potentiates lung cancer cell migration and invasion by epigenetically activating MMP9 transcription.	[Cheng, X.; Yang, Y.; Fan, Z.; Yu, L.; Bai, H.; Zhou, B.; Wu, X.; Xu, H.; Fang, M.; Chen, Q.; Xu, Y.] Nanjing Med Univ, Key Lab Cardiovasc Dis, Nanjing 210029, Jiangsu, Peoples R China; [Cheng, X.; Yang, Y.; Fan, Z.; Yu, L.; Bai, H.; Zhou, B.; Wu, X.; Xu, H.; Fang, M.; Chen, Q.; Xu, Y.] Nanjing Med Univ, Dept Pathophysiol, Nanjing 210029, Jiangsu, Peoples R China; [Cheng, X.] Jiangsu Inst Nucl Med, Wuxi, Peoples R China; [Yang, Y.] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing, Jiangsu, Peoples R China; [Fang, M.] Jiangsu Jiankang Vocat Univ, Dept Nursing, Nanjing, Jiangsu, Peoples R China; [Shen, A.] Nantong Univ, Coll Med, Dept Key Lab Inflammat & Mol Targets, Nantong, Peoples R China	Nanjing Medical University; Nanjing Medical University; China Pharmaceutical University; Nantong University	Xu, Y (corresponding author), Nanjing Med Univ, Key Lab Cardiovasc Dis, 140 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.	mmfangnjmu@yahoo.com; yxu2005@gmail.com	wu, xin/GRS-8615-2022; Yu, Liming/AAH-6983-2021; Zhou, Bisheng/K-2160-2019; Zhou, Bisheng/M-3143-2016	Yu, Liming/0000-0002-6702-7625; Zhou, Bisheng/0000-0003-1551-0612	National Basic Science Project of China [2012CB517503]; National Natural Science Foundation of China [31270805, 31200645, 81402550, 91439106]; Natural Science Foundation of Jiangsu Province [BK2012043, BK20140906, BK21041498]; Education Commission of Jiangsu Province [14KJA31001]; Program for New Century Excellent Talents in University of China [NCET-11-0991]; Ministry of Education [212059, 20123234110008]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Basic Science Project of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Education Commission of Jiangsu Province; Program for New Century Excellent Talents in University of China(Program for New Century Excellent Talents in University (NCET)); Ministry of Education; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported, in part, by grants from the National Basic Science Project of China (2012CB517503), National Natural Science Foundation of China (31270805, 31200645, 81402550, 91439106), Natural Science Foundation of Jiangsu Province (BK2012043, BK20140906, BK21041498), Education Commission of Jiangsu Province (14KJA31001), the Program for New Century Excellent Talents in University of China (NCET-11-0991), Ministry of Education (212059, 20123234110008) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD). YX is a fellow at the Collaborative Innovative Center for Cardiovascular Translational Medicine.	Ballerini P, 2003, LEUKEMIA, V17, P1193, DOI 10.1038/sj.leu.2402914; Basu S, 2007, CELL MICROBIOL, V9, P2804, DOI 10.1111/j.1462-5822.2007.00997.x; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Chang C, 2013, MOL CELL BIOL, V33, P3795, DOI 10.1128/MCB.00434-13; Chen DW, 2013, CARDIOVASC RES, V100, P363, DOI 10.1093/cvr/cvt214; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Cock-Rada AM, 2012, CANCER RES, V72, P810, DOI 10.1158/0008-5472.CAN-11-1052; Cox G, 2000, CLIN CANCER RES, V6, P2349; Fang F, 2013, CIRC RES, V113, P986, DOI 10.1161/CIRCRESAHA.113.301296; Fang F, 2011, CIRC RES, V108, P797, DOI 10.1161/CIRCRESAHA.111.240655; Gilles L, 2009, BLOOD, V114, P4221, DOI 10.1182/blood-2009-03-209932; Gurbuz I, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-22; Hampl V, 2013, EMBO MOL MED, V5, P1367, DOI 10.1002/emmm.201202406; Hanna M, 2009, J BIOL CHEM, V284, P23125, DOI 10.1074/jbc.M109.019059; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Illman SA, 2006, J CELL SCI, V119, P3856, DOI 10.1242/jcs.03157; Jakopovic M, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00261; Kaplan A, 2014, NEURON, V81, P333, DOI 10.1016/j.neuron.2013.12.009; Kim JE, 2008, EXP MOL MED, V40, P514, DOI 10.3858/emm.2008.40.5.514; Kim J, 2010, BIOCHEM BIOPH RES CO, V401, P412, DOI 10.1016/j.bbrc.2010.09.068; Kong XC, 2009, J MOL CELL CARDIOL, V46, P292, DOI 10.1016/j.yjmcc.2008.10.023; Larrieu D, 2010, CELL CYCLE, V9, P3984, DOI 10.4161/cc.9.19.13208; Lee SM, 2010, J BIOL CHEM, V285, P22036, DOI 10.1074/jbc.M110.108878; Lin YW, 2013, J PATHOL, V230, P277, DOI 10.1002/path.4179; Lockman K, 2007, CIRC RES, V101, pE115, DOI 10.1161/CIRCRESAHA.107.164178; Lundin A, 2013, CANCER LETT, V338, P89, DOI 10.1016/j.canlet.2012.08.014; Marcus PM, 2000, J NATL CANCER I, V92, P1308, DOI 10.1093/jnci/92.16.1308; Medjkane S, 2009, NAT CELL BIOL, V11, P257, DOI 10.1038/ncb1833; Moutsopoulos NM, 2008, CURR OPIN IMMUNOL, V20, P234, DOI 10.1016/j.coi.2008.04.003; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Osada H, 2005, MOL CARCINOGEN, V44, P233, DOI 10.1002/mc.20135; Pine SR, 2010, P NATL ACAD SCI USA, V107, P2195, DOI 10.1073/pnas.0909390107; Pinto CA, 2003, CLIN CANCER RES, V9, P3098; Rintoul RC, 2001, LANCET ONCOL, V2, P437, DOI 10.1016/S1470-2045(00)00421-6; Risch A, 2008, INT J CANCER, V123, P1, DOI 10.1002/ijc.23605; Robert I, 2009, ONCOGENE, V28, P1626, DOI 10.1038/onc.2009.6; Schaaij-Visser TBM, 2013, BBA-PROTEINS PROTEOM, V1834, P2242, DOI 10.1016/j.bbapap.2013.01.029; Shaposhnikov D, 2013, CELL CYCLE, V12, P1762, DOI 10.4161/cc.24839; Shaposhnikov D, 2012, CELL CYCLE, V11, P141, DOI 10.4161/cc.11.1.18499; Shilatifard A, 2008, CURR OPIN CELL BIOL, V20, P341, DOI 10.1016/j.ceb.2008.03.019; Shilatifard A, 2012, ANNU REV BIOCHEM, V81, P65, DOI 10.1146/annurev-biochem-051710-134100; Sienel W, 2003, INT J CANCER, V103, P647, DOI 10.1002/ijc.10841; Sun LN, 2013, J CELL SCI, V126, P3939, DOI 10.1242/jcs.127381; Sun LN, 2013, JNCI-J NATL CANCER I, V105, P887, DOI 10.1093/jnci/djt118; Takino T, 2003, ONCOGENE, V22, P4617, DOI 10.1038/sj.onc.1206542; Tang ZY, 2013, CELL, V154, P297, DOI 10.1016/j.cell.2013.06.027; Tian WF, 2015, J HEPATOL, V62, P165, DOI 10.1016/j.jhep.2014.07.029; Tian WF, 2013, HEPATOLOGY, V58, P576, DOI 10.1002/hep.26207; Tsai YP, 2014, INT J CANCER, V134, P249, DOI 10.1002/ijc.28190; Ung YC, 2007, JNCI-J NATL CANCER I, V99, P1753, DOI 10.1093/jnci/djm232; Wan M, 2013, J BIOL CHEM, V288, P5039, DOI 10.1074/jbc.M112.424515; Weinl C, 2013, J CLIN INVEST, V123, P2193, DOI 10.1172/JCI64201; Wood SL, 2014, CANCER TREAT REV, V40, P558, DOI 10.1016/j.ctrv.2013.10.001; Xu HH, 2015, J AM SOC NEPHROL, V26, P1648, DOI 10.1681/ASN.2014070678; Yan XL, 2013, HEPATOLOGY, V57, P2274, DOI 10.1002/hep.26257; Yang XF, 2009, J CELL SCI, V122, P2473, DOI 10.1242/jcs.049148; Yang YY, 2014, NUCLEIC ACIDS RES, V42, P10460, DOI 10.1093/nar/gku776; Yang YY, 2013, NUCLEIC ACIDS RES, V41, P6005, DOI 10.1093/nar/gkt311; Yoshio T, 2010, CARCINOGENESIS, V31, P1185, DOI 10.1093/carcin/bgq065; Yu LM, 2014, J CELL SCI, V127, P4645, DOI 10.1242/jcs.152314; Yuan ZB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083895; Zhong Q, 2013, DIABETES, V62, P2559, DOI 10.2337/db12-1141; Zhou JL, 2009, ARTERIOSCL THROM VAS, V29, P921, DOI 10.1161/ATVBAHA.109.187229; Zhou X, 2010, CANCER RES, V70, P4214, DOI 10.1158/0008-5472.CAN-09-2942; Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396	65	47	50	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2015	34	44					5570	5581		10.1038/onc.2015.14	http://dx.doi.org/10.1038/onc.2015.14			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9FX	25746000				2022-12-17	WOS:000364594000006
J	Maric, G; Annis, MG; Dong, Z; Rose, AAN; Ng, S; Perkins, D; MacDonald, PA; Ouellet, V; Russo, C; Siegel, PM				Maric, G.; Annis, M. G.; Dong, Z.; Rose, A. A. N.; Ng, S.; Perkins, D.; MacDonald, P. A.; Ouellet, V.; Russo, C.; Siegel, P. M.			GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin alpha(5)beta(1) for efficient breast cancer metastasis	ONCOGENE			English	Article							GLYCOPROTEIN NONMETASTATIC B; THERAPEUTIC TARGET; DC-HIL; EXPRESSION; OSTEOACTIVIN; PROTEIN; CELLS; ADHESION; ANGIOGENESIS; SIGNATURE	Glycoprotein nmb (GPNMB) promotes breast tumor growth and metastasis and its expression in tumor epithelium correlates with poor prognosis in breast cancer patients. Despite its biological and clinical significance, little is known regarding the molecular mechanisms engaged by GPNMB. Herein, we show that GPNMB engages distinct functional domains and mechanisms to promote primary tumor growth and metastasis. We demonstrate that neuropilin-1 (NRP-1) expression is increased in breast cancer cells that overexpress GPNMB. Interestingly, the GPNMB-driven increase in NRP-1 expression potentiated vascular endothelial growth factor signaling in breast cancer cells and was required for the growth, but not metastasis, of these cells in vivo. Interrogation of RNAseq data sets revealed a positive correlation between GPNMB and NRP-1 levels in human breast tumors. Furthermore, we ascribe pro-growth and pro-metastatic functions of GPNMB to its ability to bind alpha(5)beta(1) integrin and increase downstream signaling in breast cancer cells. We show that GPNMB enhances breast cancer cell adhesion to fibronectin, increases alpha(5)beta(1) expression and associates with this receptor through its RGD motif. GPNMB recruitment into integrin complexes activates Src and Fak signaling pathways in an RGD-dependent manner. Importantly, both the RGD motif and cytoplasmic tail of GPNMB are required to promote primary mammary tumor growth; however, only mutation of the RGD motif impaired the formation of lung metastases. Together, these findings identify novel and distinct molecular mediators of GPNMB-induced breast cancer growth and metastasis.	[Maric, G.; Annis, M. G.; Dong, Z.; Rose, A. A. N.; Ng, S.; Perkins, D.; MacDonald, P. A.; Ouellet, V.; Russo, C.; Siegel, P. M.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [Maric, G.; Annis, M. G.; Dong, Z.; Rose, A. A. N.; MacDonald, P. A.; Ouellet, V.; Russo, C.; Siegel, P. M.] McGill Univ, Dept Med, Montreal, PQ H3A 1A3, Canada; [Ng, S.; Perkins, D.; Siegel, P. M.] McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 1A3, Canada; [Siegel, P. M.] McGill Univ, Dept Biochem, Montreal, PQ H3A 1A3, Canada	McGill University; McGill University; McGill University; McGill University	Siegel, PM (corresponding author), McGill Univ, Goodman Canc Res Ctr, 1160 Pine Ave West,Room 513, Montreal, PQ H3A 1A3, Canada.	peter.siegel@mcgill.ca	Rose, April/AAR-8222-2020	Rose, April/0000-0002-9845-4603; Annis, Matthew/0000-0002-8776-004X	Canadian Institutes for Health Research (CIHR); Fonds de recherche en sante du Quebec (FRSQ) research scholar program; CIHR [MOP-119401]	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Fonds de recherche en sante du Quebec (FRSQ) research scholar program; CIHR(Canadian Institutes of Health Research (CIHR))	We thank members of the Siegel laboratory for their thoughtful discussions regarding the current work and are also grateful to Dr Josie Ursini-Siegel for her critical reading of the manuscript. We acknowledge the Goodman Cancer Research Centre histology core facility (McGill University) for routine histological services. GM acknowledges studentship support from the Canadian Institutes for Health Research (CIHR). PMS was supported by the Fonds de recherche en sante du Quebec (FRSQ) research scholar program (Junior 2) and is currently a McGill University William Dawson Scholar. This research was supported solely by a grant from the CIHR (MOP-119401).	Arjonen A, 2012, TRAFFIC, V13, P610, DOI 10.1111/j.1600-0854.2012.01327.x; Bachelder RE, 2001, CANCER RES, V61, P5736; Bagri A, 2009, CLIN CANCER RES, V15, P1860, DOI 10.1158/1078-0432.CCR-08-0563; Bendell J, 2013, J CLIN ONCOL, V32, P3619; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bradshaw JM, 2010, CELL SIGNAL, V22, P1175, DOI 10.1016/j.cellsig.2010.03.001; Cao Y, 2008, CANCER RES, V68, P8667, DOI 10.1158/0008-5472.CAN-08-2614; Cao Y, 2012, CANCER RES, V72, P3912, DOI 10.1158/0008-5472.CAN-11-4058; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Chung JS, 2009, J IMMUNOL, V183, P5190, DOI 10.4049/jimmunol.0901319; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Furochi H, 2007, FEBS LETT, V581, P5743, DOI 10.1016/j.febslet.2007.11.036; Ganguly KK, 2013, CELL ADHES MIGR, V7, P251, DOI 10.4161/cam.23840; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Hoashi T, 2010, FASEB J, V24, P1616, DOI 10.1096/fj.09-151019; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; Keir CH, 2012, EXPERT OPIN BIOL TH, V12, P259, DOI 10.1517/14712598.2012.642357; Lamagna C, 2006, J LEUKOCYTE BIOL, V80, P705, DOI 10.1189/jlb.1105656; Le Borgne R, 2001, J CELL SCI, V114, P2831; Lehmann BD, 2014, J PATHOL, V232, P142, DOI 10.1002/path.4280; Maric G, 2013, ONCOTARGETS THER, V6, P839, DOI 10.2147/OTT.S44906; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Missan DS, 2012, CRIT REV EUKAR GENE, V22, P309, DOI 10.1615/CritRevEukarGeneExpr.v22.i4.50; Moussa FM, 2014, J CELL BIOCHEM, V115, P1243, DOI 10.1002/jcb.24760; Ngan E, 2013, J CELL SCI, V126, P1981, DOI 10.1242/jcs.118315; Northey JJ, 2013, J BIOL CHEM, V288, P5210, DOI 10.1074/jbc.M112.424804; Parikh AA, 2003, CANCER, V98, P720, DOI 10.1002/cncr.11560; Prat A, 2013, ONCOLOGIST, V18, P123, DOI 10.1634/theoncologist.2012-0397; Rose AAN, 2007, MOL CANCER RES, V5, P1001, DOI 10.1158/1541-7786.MCR-07-0119; Rose AAN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012093; Rose AAN, 2010, CLIN CANCER RES, V16, P2147, DOI 10.1158/1078-0432.CCR-09-1611; Sheng MHC, 2008, FEBS LETT, V582, P1451, DOI 10.1016/j.febslet.2008.03.030; Sheng MHC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035280; Shikano S, 2001, J BIOL CHEM, V276, P8125, DOI 10.1074/jbc.M008539200; Sondag GR, 2014, J CELL PHYSIOL, V229, P955, DOI 10.1002/jcp.24512; Staton CA, 2011, HISTOPATHOLOGY, V59, P274, DOI 10.1111/j.1365-2559.2011.03922.x; Tabaries S, 2011, ONCOGENE, V30, P1318, DOI 10.1038/onc.2010.518; Theos AC, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12084; Tomihari M, 2009, EXP DERMATOL, V18, P586, DOI 10.1111/j.1600-0625.2008.00830.x; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Vaklavas C, 2014, BIODRUGS; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wang L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001161; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wey JS, 2005, BRIT J CANCER, V93, P233, DOI 10.1038/sj.bjc.6602663; Xu H, 2014, CLIN CHEM, V60, P122, DOI 10.1373/clinchem.2013.207167; Yau C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2753	49	47	51	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5494	5504		10.1038/onc.2015.8	http://dx.doi.org/10.1038/onc.2015.8			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25772243				2022-12-17	WOS:000363479700009
J	Jeong, SM; Lee, J; Finley, LWS; Schmidt, PJ; Fleming, MD; Haigis, MC				Jeong, S. M.; Lee, J.; Finley, L. W. S.; Schmidt, P. J.; Fleming, M. D.; Haigis, M. C.			SIRT3 regulates cellular iron metabolism and cancer growth by repressing iron regulatory protein 1	ONCOGENE			English	Article							TRANSFERRIN RECEPTOR; OXIDATIVE STRESS; ACTIVATION; HOMEOSTASIS; RESTRICTION; DEACETYLASE; HYPOXIA; ATAXIA	Iron metabolism is essential for many cellular processes, including oxygen transport, respiration and DNA synthesis, and many cancer cells exhibit dysregulation in iron metabolism. Maintenance of cellular iron homeostasis is regulated by iron regulatory proteins (IRPs), which control the expression of iron-related genes by binding iron-responsive elements (IREs) of target mRNAs. Here, we report that mitochondrial SIRT3 regulates cellular iron metabolism by modulating IRP1 activity. SIRT3 loss increases reactive oxygen species production, leading to elevated IRP1 binding to IREs. As a consequence, IRP1 target genes, such as the transferrin receptor (TfR1), a membrane-associated glycoprotein critical for iron uptake and cell proliferation, are controlled by SIRT3. Importantly, SIRT3 deficiency results in a defect in cellular iron homeostasis. SIRT3 null cells contain high levels of iron and lose iron-dependent TfR1 regulation. Moreover, SIRT3 null mice exhibit higher levels of iron and TfR1 expression in the pancreas. We found that the regulation of iron uptake and TfR1 expression contribute to the tumor-suppressive activity of SIRT3. Indeed, SIRT3 expression is negatively correlated with TfR1 expression in human pancreatic cancers. SIRT3 overexpression decreases TfR1 expression by inhibiting IRP1 and represses proliferation in pancreatic cancer cells. Our data uncover a novel role of SIRT3 in cellular iron metabolism through IRP1 regulation and suggest that SIRT3 functions as a tumor suppressor, in part, by modulating cellular iron metabolism.	[Jeong, S. M.; Lee, J.; Finley, L. W. S.; Haigis, M. C.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Schmidt, P. J.; Fleming, M. D.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA; [Schmidt, P. J.; Fleming, M. D.] Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Haigis, MC (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, SGM 329C,240 Longwood Ave, Boston, MA 02115 USA.	marcia_haigis@hms.harvard.edu		Fleming, Mark/0000-0003-0948-4024; Lee, Jaewon/0000-0002-5677-2398	Takeda Pharmaceuticals; NIH [R01/AG032375]; American Cancer Society New Scholar Award; Glenn Foundation for Medical Research; NATIONAL INSTITUTE ON AGING [R01AG032375] Funding Source: NIH RePORTER	Takeda Pharmaceuticals(Takeda Pharmaceutical Company Ltd); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society New Scholar Award; Glenn Foundation for Medical Research; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Ditte Lee and Annie Lee for technical assistance. We are also grateful to Alec C Kimmelman for providing cell lines and helpful discussions. This work was funded by a grant from Takeda Pharmaceuticals (to MCH). MCH is supported by NIH grant R01/AG032375, the American Cancer Society New Scholar Award and the Glenn Foundation for Medical Research.	Anderson CP, 2012, BBA-MOL CELL RES, V1823, P1468, DOI 10.1016/j.bbamcr.2012.05.010; Anderson SA, 2013, CELL METAB, V17, P282, DOI 10.1016/j.cmet.2013.01.007; Bayeva M, 2012, CELL METAB, V16, P645, DOI 10.1016/j.cmet.2012.10.001; Bell EL, 2011, MOL CELL, V42, P561, DOI 10.1016/j.molcel.2011.05.008; Chen CY, 2013, CELL METAB, V17, P343, DOI 10.1016/j.cmet.2013.01.013; Cheng Y, 2004, CELL, V116, P565, DOI 10.1016/S0092-8674(04)00130-8; Daniels TR, 2006, CLIN IMMUNOL, V121, P144, DOI 10.1016/j.clim.2006.06.010; Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; KOPPENOL WH, 1993, FREE RADICAL BIO MED, V15, P645, DOI 10.1016/0891-5849(93)90168-T; Lobmayr L, 2005, GENE, V354, P157, DOI 10.1016/j.gene.2005.04.040; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; Lu SC, 2009, MOL ASPECTS MED, V30, P42, DOI 10.1016/j.mam.2008.05.005; Muckenthaler MU, 2008, ANNU REV NUTR, V28, P197, DOI 10.1146/annurev.nutr.28.061807.155521; Mueller S, 2005, BIOFACTORS, V24, P171, DOI 10.1002/biof.5520240121; Nunez-Millacura C, 2002, J NEUROCHEM, V82, P240, DOI 10.1046/j.1471-4159.2002.00971.x; O'Donnell KA, 2006, MOL CELL BIOL, V26, P2373, DOI 10.1128/MCB.26.6.2373-2386.2006; Pantopoulos K, 1998, P NATL ACAD SCI USA, V95, P10559, DOI 10.1073/pnas.95.18.10559; Qiu XL, 2010, CELL METAB, V12, P662, DOI 10.1016/j.cmet.2010.11.015; Richardson DR, 2009, BBA-GEN SUBJECTS, V1790, P702, DOI 10.1016/j.bbagen.2008.04.003; Rouault TA, 2006, NAT CHEM BIOL, V2, P406, DOI 10.1038/nchembio807; Ryschich E, 2004, EUR J CANCER, V40, P1418, DOI 10.1016/j.ejca.2004.01.036; Sanchez M, 2011, BLOOD, V118, pE168, DOI 10.1182/blood-2011-04-343541; Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057; Someya S, 2010, CELL, V143, P802, DOI 10.1016/j.cell.2010.10.002; Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Wagner GR, 2012, HUM MOL GENET, V21, P2688, DOI 10.1093/hmg/dds095; Wang J, 2004, MOL CELL BIOL, V24, P954, DOI 10.1128/MCB.24.3.954-965.2004; Wang JA, 2011, BIOCHEM J, V434, P365, DOI 10.1042/BJ20101825; Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537	32	47	49	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2115	2124		10.1038/onc.2014.124	http://dx.doi.org/10.1038/onc.2014.124			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909164	Green Accepted, Green Submitted			2022-12-17	WOS:000353173400011
J	Ray, P; Stacer, AC; Fenner, J; Cavnar, SP; Meguiar, K; Brown, M; Luker, KE; Luker, GD				Ray, P.; Stacer, A. C.; Fenner, J.; Cavnar, S. P.; Meguiar, K.; Brown, M.; Luker, K. E.; Luker, G. D.			CXCL12-gamma in primary tumors drives breast cancer metastasis	ONCOGENE			English	Article							LUNG METASTASIS; CXCR4; EXPRESSION; CHEMOKINE; CELLS; ANGIOGENESIS; ISOFORMS; GROWTH; RECRUITMENT; DISRUPTION	Compelling evidence shows that chemokine C-X-C motif chemokine ligand 12 (CXCL12) drives metastasis in multiple malignancies. Similar to other key cytokines in cancer, CXCL12 exists as several isoforms with distinct biophysical properties that may alter signaling and functional outputs. However, effects of CXCL12 isoforms in cancer remain unknown. CXCL12-alpha, -beta and -gamma showed cell-type-specific differences in activating signaling through G protein-dependent pathways in cell-based assays, while CXCL12-gamma had greatest effects on recruitment of the adapter protein beta-arrestin 2. CXCL12-beta and -gamma also stimulated endothelial tube formation to a greater extent than CXCL12-alpha. To investigate the effects of CXCL12 isoforms on tumor growth and metastasis, we used a mouse xenograft model of metastatic human breast cancer combining CXCR4+ breast cancer cells and mammary fibroblasts secreting an isoform of CXCL12. Altough all CXCL12 isoforms produced comparable growth of mammary tumors, CXCL12-gamma significantly increased metastasis to bone marrow and other sites. Breast cancer cells originating from tumors with CXCL12-gamma fibroblasts upregulated RANKL (receptor activator of nuclear factor-kappa B ligand), contributing to bone marrow tropism of metastatic cancer cells. CXCL12-gamma was expressed in metastatic tissues in mice, and we also detected CXCL12-gamma in malignant pleural effusions from patients with breast cancer. In our mouse model, mammary fibroblasts disseminated to sites of breast cancer metastases, providing another mechanism to increase levels of CXCL12 in metastatic environments. These studies identify CXCL12-gamma as a potent pro-metastatic molecule with important implications for cancer biology and effective therapeutic targeting of CXCL12 pathways.	[Ray, P.; Stacer, A. C.; Fenner, J.; Meguiar, K.; Luker, K. E.; Luker, G. D.] Univ Michigan, Ctr Mol Imaging, Dept Radiol, Ann Arbor, MI 48109 USA; [Cavnar, S. P.; Luker, G. D.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA; [Brown, M.; Luker, G. D.] Univ Michigan, Dept Internal Med, Ctr Comprehens Canc, Breast Oncol Program, Ann Arbor, MI 48109 USA; [Luker, G. D.] Univ Michigan Ctr, Dept Microbiol & Immunol, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Luker, GD (corresponding author), Univ Michigan, Sch Med, Dept Radiol, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA.	gluker@umich.edu		luker, gary/0000-0001-6832-2581	United States National Institutes of Health [R01CA136553, R01CA136829, R01CA142750, P50CA093990]; NSF; Fashion Footwear Association of New York (FFANY)/QVC; NATIONAL CANCER INSTITUTE [R01CA136553, P50CA093990, R01CA142750, R01CA136829] Funding Source: NIH RePORTER	United States National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); Fashion Footwear Association of New York (FFANY)/QVC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the United States National Institutes of Health grants R01CA136553, R01CA136829, R01CA142750 and P50CA093990. SPC was supported by an NSF predoctoral fellowship. Research was also supported by Fashion Footwear Association of New York (FFANY)/QVC presents Shoes on Sale.	Altenburg JD, 2007, J VIROL, V81, P8140, DOI 10.1128/JVI.00268-07; Brown Julie M, 2004, Cancer Treat Res, V118, P149; Cavnar SP, 2014, INTEGR BIOL-UK, V6, P564, DOI 10.1039/c4ib00015c; Chu QYD, 2010, J SURG RES, V159, P689, DOI 10.1016/j.jss.2008.09.020; Chueh BH, 2007, ANAL CHEM, V79, P3504, DOI 10.1021/ac062118p; Deng JH, 2012, CANCER CELL, V21, P642, DOI 10.1016/j.ccr.2012.03.039; Diamond P, 2009, J BONE MINER RES, V24, P1150, DOI [10.1359/jbmr.090210, 10.1359/JBMR.090210]; Dona E, 2013, NATURE, V503, P285, DOI 10.1038/nature12635; Duda DG, 2011, CLIN CANCER RES, V17, P2074, DOI 10.1158/1078-0432.CCR-10-2636; Duda DG, 2010, P NATL ACAD SCI USA, V107, P21677, DOI 10.1073/pnas.1016234107; Ebos JML, 2007, P NATL ACAD SCI USA, V104, P17069, DOI 10.1073/pnas.0708148104; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Gahan JC, 2012, J UROLOGY, V187, P827, DOI 10.1016/j.juro.2011.10.150; Guo P, 2001, CANCER RES, V61, P8569; Ho TK, 2010, J VASC SURG, V51, P689, DOI 10.1016/j.jvs.2009.10.044; Holland J, 2013, CELL REP; Jung YH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2766; Kim HR, 2014, ARTHRITIS RHEUMATOL, V66, P538, DOI 10.1002/art.38286; Kloen P, 1997, CANCER, V80, P2230; Laguri C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001110; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Luker K, 2012, ONCOGENE, V31, P4570, DOI DOI 10.1038/0NC.2011.633; Luker KE, 2008, ANAL CHEM, V80, P5565, DOI 10.1021/ac8005457; Luker KE, 2006, CANCER LETT, V238, P30, DOI 10.1016/j.canlet.2005.06.021; Luker KE, 2009, NEOPLASIA, V11, P1022, DOI 10.1593/neo.09724; Luker KE, 2009, BIOTECHNIQUES, V47, P625, DOI 10.2144/000113126; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Nixon AB, 2013, CLIN CANCER RES, V19, P6957, DOI 10.1158/1078-0432.CCR-13-0926; Odemis V, 2012, GLIA, V60, P372, DOI 10.1002/glia.22271; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Park HR, 2003, J KOREAN MED SCI, V18, P541, DOI 10.3346/jkms.2003.18.4.541; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Rajagopal S, 2010, P NATL ACAD SCI USA, V107, P628, DOI 10.1073/pnas.0912852107; Ray P, INT J BIOCH CELL BIO, V44, P669; Rueda P, 2012, CIRCULATION, V126, P1882, DOI 10.1161/CIRCULATIONAHA.112.113290; Rueda P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002543; Salcedo R, 2003, MICROCIRCULATION, V10, P359, DOI 10.1038/sj.mn.7800200; Sceneay J, 2013, CANCER METAST REV, V32, P449, DOI 10.1007/s10555-013-9420-1; Shcherbo D, 2010, NAT METHODS, V7, P827, DOI [10.1038/NMETH.1501, 10.1038/nmeth.1501]; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Shu HKG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079768; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; Song JW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005756; Stumm R, 2007, J COMP NEUROL, V502, P382, DOI 10.1002/cne.21336; Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756-3282(99)00210-0; Venkiteswaran G, 2013, CELL, V155, P674, DOI 10.1016/j.cell.2013.09.046; Yu L, 2006, GENE, V374, P174, DOI 10.1016/j.gene.2006.02.001; Zannettino ACW, 2005, CANCER RES, V65, P1700, DOI 10.1158/0008-5472.CAN-04-1687; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; Zhang SS, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-85; Zhang XHF, 2013, CELL, V154, P1060, DOI 10.1016/j.cell.2013.07.036	55	47	47	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2043	2051		10.1038/onc.2014.157	http://dx.doi.org/10.1038/onc.2014.157			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909174	Green Accepted			2022-12-17	WOS:000353173400004
J	Li, N; Lee, K; Xi, Y; Zhu, B; Gary, BD; Ramirez-Alcantara, V; Gurpinar, E; Canzoneri, JC; Fajardo, A; Sigler, S; Piazza, JT; Chen, X; Andrews, J; Thomas, M; Lu, W; Li, Y; Laan, DJ; Moyer, MP; Russo, S; Eberhardt, BT; Yet, L; Keeton, AB; Grizzle, WE; Piazza, GA				Li, N.; Lee, K.; Xi, Y.; Zhu, B.; Gary, B. D.; Ramirez-Alcantara, V.; Gurpinar, E.; Canzoneri, J. C.; Fajardo, A.; Sigler, S.; Piazza, J. T.; Chen, X.; Andrews, J.; Thomas, M.; Lu, W.; Li, Y.; Laan, D. J.; Moyer, M. P.; Russo, S.; Eberhardt, B. T.; Yet, L.; Keeton, A. B.; Grizzle, W. E.; Piazza, G. A.			Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and beta-catenin-dependent TCF transcriptional activity	ONCOGENE			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; PROTEIN-KINASE-G; SULINDAC SULFIDE; EXPRESSION; EXISULIND; APOPTOSIS; CANCER; ACTIVATION; PDE10A; LOCALIZATION	The cyclic nucleotide phosphodiesterase 10A (PDE10) has been mostly studied as a therapeutic target for certain psychiatric and neurological conditions, although a potential role in tumorigenesis has not been reported. Here we show that PDE10 is elevated in human colon tumor cell lines compared with normal colonocytes, as well as in colon tumors from human clinical specimens and intestinal tumors from Apc(Min/+) mice compared with normal intestinal mucosa, respectively. An isozyme and tumor-selective role of PDE10 were evident by the ability of small-molecule inhibitors and small interfering RNA knockdown to suppress colon tumor cell growth with reduced sensitivity of normal colonocytes. Stable knockdown of PDE10 by short hairpin RNA also inhibits colony formation and increases doubling time of colon tumor cells. PDE10 inhibition selectively activates cGMP/cGMP-dependent protein kinase signaling to suppress beta-catenin levels and T-cell factor (TCF) transcriptional activity in colon tumor cells. Conversely, ectopic expression of PDE10 in normal and precancerous colonocytes increases proliferation and activates TCF transcriptional activity. These observations suggest a novel role of PDE10 in colon tumorigenesis and that inhibitors may be useful for the treatment or prevention of colorectal cancer.	[Li, N.] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL USA; [Lee, K.; Xi, Y.; Zhu, B.; Gary, B. D.; Ramirez-Alcantara, V.; Canzoneri, J. C.; Fajardo, A.; Sigler, S.; Piazza, J. T.; Chen, X.; Andrews, J.; Thomas, M.; Russo, S.; Keeton, A. B.; Piazza, G. A.] Univ S Alabama, Drug Discovery Res Ctr, Mitchell Canc Inst, Dept Oncol Sci & Pharmacol, Mobile, AL 36004 USA; [Gurpinar, E.] Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL USA; [Lu, W.; Li, Y.] So Res Inst, Drug Discovery Div, Birmingham, AL 35255 USA; [Laan, D. J.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA; [Moyer, M. P.] INCELL Corp LLC, San Antonio, TX USA; [Eberhardt, B. T.; Yet, L.] Univ S Alabama, Dept Chem, Mobile, AL 36004 USA; [Grizzle, W. E.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of South Alabama; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of South Alabama; University of Alabama System; University of Alabama Birmingham	Piazza, GA (corresponding author), Univ S Alabama, Drug Discovery Res Ctr, Mitchell Canc Inst, Dept Oncol Sci & Pharmacol, 1660 Springhill Ave,Suite 3029, Mobile, AL 36004 USA.	gpiazza@health.southalabama.edu	Li, Nan/I-3589-2015; Ramirez-Alcantara, Verónica/AAM-5424-2020	Xi, Yaguang/0000-0003-3681-9352; Piazza, Gary/0000-0003-4418-887X	National Institutes of Health [1R01CA131378, 1R01CA148817, 1R01CA155638]; NATIONAL CANCER INSTITUTE [R01CA155638, R01CA131378, R01CA148817] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R24HL123767] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr Graeme Bolger for critical reading of the manuscript. We also thank Dr Marian from Medical University Vienna, Austria for the generous gift of LT97 adenoma cell line and Dr Dan Dixon from University of Kansas Cancer Center for providing specimens from the Apc<SUP>Min/+</SUP> mouse model. We are also grateful to Dr Darren Browning from Georgia Regents University Cancer Center for providing the CTNNB1 luciferase reporter construct. This work was supported by National Institutes of Health Grants, 1R01CA131378, 1R01CA148817 and 1R01CA155638 to GAP.	Anderson CB, 2002, P NATL ACAD SCI USA, V99, P8683, DOI 10.1073/pnas.122235399; Bender AT, 2006, PHARMACOL REV, V58, P488, DOI 10.1124/pr.58.3.5; Chappie TA, 2007, J MED CHEM, V50, P182, DOI 10.1021/jm060653b; Coskran TM, 2006, J HISTOCHEM CYTOCHEM, V54, P1205, DOI 10.1369/JHC.6A6930.2006; D'Andrea MR, 2005, J HISTOCHEM CYTOCHEM, V53, P895, DOI 10.1369/jhc.5A6625.2005; Deguchi A, 2004, CANCER RES, V64, P3966, DOI 10.1158/0008-5472.CAN-03-3740; Deguchi A, 2002, MOL CANCER THER, V1, P803; Francis SH, 2011, PHYSIOL REV, V91, P651, DOI 10.1152/physrev.00030.2010; Fujishige K, 1999, J BIOL CHEM, V274, P18438, DOI 10.1074/jbc.274.26.18438; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Hou YL, 2006, CANCER LETT, V240, P60, DOI 10.1016/j.canlet.2005.08.035; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Kwon IK, 2010, ONCOGENE, V29, P3423, DOI 10.1038/onc.2010.91; Kwon IK, 2008, CANCER-AM CANCER SOC, V112, P1462, DOI 10.1002/cncr.23334; Li N, 2013, MOL CANCER THER, V12, P1848, DOI 10.1158/1535-7163.MCT-13-0048; Li QJ, 2004, GENOMICS, V83, P231, DOI 10.1016/j.ygeno.2003.08.004; Li X, 2012, ONCOGENE, V31, P4979, DOI 10.1038/onc.2011.655; Liu L, 2001, J PHARMACOL EXP THER, V299, P583; Loughney K, 1999, GENE, V234, P109, DOI 10.1016/S0378-1119(99)00171-7; Lucas KA, 2000, PHARMACOL REV, V52, P375; Marko D, 2000, CHEM RES TOXICOL, V13, P944, DOI 10.1021/tx000090l; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315; Piazza GA, 2001, CANCER RES, V61, P3961; Pitari GM, 2001, P NATL ACAD SCI USA, V98, P7846, DOI 10.1073/pnas.141124698; Pusztai L, 2003, J CLIN ONCOL, V21, P3454, DOI 10.1200/JCO.2003.02.114; Richter M, 2002, EUR J CANCER, V38, P1937, DOI 10.1016/S0959-8049(02)00158-2; Saravani R, 2012, CELL PROLIFERAT, V45, P199, DOI 10.1111/j.1365-2184.2012.00819.x; Savai R, 2010, EXPERT OPIN INV DRUG, V19, P117, DOI 10.1517/13543780903485642; Shailubhai K, 2000, CANCER RES, V60, P5151; Shimizu K, 2009, ANTICANCER RES, V29, P1119; Siuciak JA, 2006, NEUROPHARMACOLOGY, V51, P386, DOI 10.1016/j.neuropharm.2006.04.013; Siuciak JA, 2006, NEUROPHARMACOLOGY, V51, P374, DOI 10.1016/j.neuropharm.2006.01.012; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Soderling SH, 1999, P NATL ACAD SCI USA, V96, P7071, DOI 10.1073/pnas.96.12.7071; Steinbrecher KA, 2000, BIOCHEM BIOPH RES CO, V273, P225, DOI 10.1006/bbrc.2000.2917; Thompson WJ, 2000, CANCER RES, V60, P3338; Tian X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018136; Tinsley HN, 2010, CANCER PREV RES, V3, P1303, DOI 10.1158/1940-6207.CAPR-10-0030; Tinsley HN, 2009, MOL CANCER THER, V8, P3331, DOI 10.1158/1535-7163.MCT-09-0758; Whitehead CM, 2003, MOL CANCER THER, V2, P479; Whitt JD, 2012, CANCER PREV RES, V5, P822, DOI 10.1158/1940-6207.CAPR-11-0559; Xie Z, 2006, NEUROSCIENCE, V139, P597, DOI 10.1016/j.neuroscience.2005.12.042; Zhang LZ, 2008, P NATL ACAD SCI USA, V105, P19532, DOI 10.1073/pnas.0806152105	44	47	49	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1499	1509		10.1038/onc.2014.94	http://dx.doi.org/10.1038/onc.2014.94			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24704829	Green Accepted			2022-12-17	WOS:000351416800003
J	Kuo, PY; Leshchenko, VV; Fazzari, MJ; Perumal, D; Gellen, T; He, T; Iqbal, J; Baumgartner-Wennerholm, S; Nygren, L; Zhang, F; Zhang, W; Suh, KS; Goy, A; Yang, DT; Chan, WC; Kahl, BS; Verma, AK; Gascoyne, RD; Kimby, E; Sander, B; Ye, BH; Melnick, AM; Parekh, S				Kuo, P-Y; Leshchenko, V. V.; Fazzari, M. J.; Perumal, D.; Gellen, T.; He, T.; Iqbal, J.; Baumgartner-Wennerholm, S.; Nygren, L.; Zhang, F.; Zhang, W.; Suh, K. S.; Goy, A.; Yang, D. T.; Chan, W-C; Kahl, B. S.; Verma, A. K.; Gascoyne, R. D.; Kimby, E.; Sander, B.; Ye, B. H.; Melnick, A. M.; Parekh, S.			High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma	ONCOGENE			English	Article							TRANSCRIPTION FACTOR SOX11; BETA-CATENIN DEGRADATION; DEPENDENT PHOSPHORYLATION; PROTEIN-KINASE; FOLLOW-UP; EXPRESSION; PROLIFERATION; ACTIVATION; PATHWAY; GENE	Sex determining region Y-box 11 (SOX11) expression is specific for mantle cell lymphoma ( MCL) as compared with other non-Hodgkin's lymphomas. However, the function and direct-binding targets of SOX11 in MCL are largely unknown. We used high-resolution chromatin immunoprecipitation sequencing to identify the direct target genes of SOX11 in a genome-wide, unbiased manner and elucidate its functional significance. Pathway analysis identified WNT, PKA and TGF-beta signaling pathways as significantly enriched by SOX11-target genes. Quantitative chromatin immunoprecipitation sequencing and promoter reporter assays confirmed that SOX11 directly binds to individual genes and modulates their transcription activities in these pathways in MCL. Functional studies using RNA interference demonstrate that SOX11 directly regulates WNT in MCL. We analyzed SOX11 expression in three independent well-annotated tissue microarrays from the University of Wisconsin (UW), Karolinska Institute and British Columbia Cancer Agency. Our findings suggest that high SOX11 expression is associated with improved survival in a subset of MCL patients, particularly those treated with intensive chemotherapy. Transcriptional regulation of WNT and other biological pathways affected by SOX11-target genes may help explain the impact of SOX11 expression on patient outcomes.	[Kuo, P-Y; Leshchenko, V. V.; Perumal, D.; He, T.; Parekh, S.] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, New York, NY 10029 USA; [Fazzari, M. J.] Yeshiva Univ, Albert Einstein Coll Med, Dept Populat Hlth, Bronx, NY USA; [Fazzari, M. J.] Yeshiva Univ, Albert Einstein Coll Med, Dept Genet, Bronx, NY USA; [Gellen, T.; Verma, A. K.] Yeshiva Univ, Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY USA; [Iqbal, J.; Chan, W-C] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Baumgartner-Wennerholm, S.; Kimby, E.] Karolinska Inst, Ctr Haematol, Dept Med, Stockholm, Sweden; [Baumgartner-Wennerholm, S.; Nygren, L.; Kimby, E.; Sander, B.] Karolinska Univ Hosp, Stockholm, Sweden; [Nygren, L.; Sander, B.] Karolinska Inst, Dept Lab Med, Div Pathol, Stockholm, Sweden; [Zhang, F.; Zhang, W.] Icahn Sch Med Mt Sinai, Dept Med, Bioinformat Lab, New York, NY 10029 USA; [Suh, K. S.; Goy, A.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Genom & Biomarkers Program, Hackensack, NJ USA; [Yang, D. T.; Kahl, B. S.] Univ Wisconsin, Dept Pathol, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Kahl, B. S.] Univ Wisconsin, UW Carbone Canc Ctr, Madison, WI USA; [Gascoyne, R. D.] British Columbia Canc Agcy, Dept Pathol & Expt Therapeut, Vancouver, BC V5Z 4E6, Canada; [Ye, B. H.] Yeshiva Univ, Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY USA; [Melnick, A. M.] Weill Cornell Med Coll, Div Hematol & Oncol, New York, NY USA; [Melnick, A. M.] Weill Cornell Med Coll, Dept Pharmacol, New York, NY USA	Icahn School of Medicine at Mount Sinai; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Nebraska System; University of Nebraska Medical Center; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Icahn School of Medicine at Mount Sinai; Hackensack University Medical Center; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; British Columbia Cancer Agency; Yeshiva University; Albert Einstein College of Medicine; Cornell University; Cornell University	Parekh, S (corresponding author), Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, 1470 Madison Ave 5-114,Box 1079, New York, NY 10029 USA.	samir.parekh@mssm.edu	Goy, Andre/AAS-4464-2020; Melnick, Ari/AAA-5763-2020; Gascoyne, Randy D/A-6009-2013; Goy, Andre/AHC-0473-2022	Goy, Andre/0000-0001-5125-6522; Gascoyne, Randy D/0000-0002-2610-5690; Goy, Andre/0000-0001-5125-6522; Fazzari, Melissa/0000-0002-5674-3589; He, Tianfang/0000-0003-3307-3110; Iqbal, Javeed/0000-0003-3668-0629; Kimby, Eva/0000-0003-3078-6131	Chemotherapy Foundation; NATIONAL CANCER INSTITUTE [P30CA014520, K12CA132783, P30CA013330] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011] Funding Source: NIH RePORTER	Chemotherapy Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank the Epigenomics cores at Weil Cornell Medical College and Albert Einstein College of Medicine for the service support in next generation sequencing. We would also like to thank Eugenia (Jenny) Giannopoulou, PhD, and Olivier Elemento, PhD, for the assistance in ChIP-seq analysis and Chris Benner, PhD, for the support in motif analysis. We are grateful for Stuart A Aaronson, MD, for the expert consultation on WNT signaling pathway and the DN-TCF4 construct and Thomas J Kelly, MD, PhD for the SMAD3 reporter construct. This project was funded in part by the Chemotherapy Foundation (SP), Gabrielle's Angel Foundation (SP), Leukemia and Lymphoma Society Translational Research Project Grant (SP), Paul Calabresi Career Development Award K12-CA132783-01 (SP), the Swedish Cancer Society (BS), the Swedish Research Council (BS), the Cancer Society in Stockholm (BS), the Karolinska Institutet Funds (BS) and the Stockholm County Council (BS). DTY is supported by the Clinical and Translational Science Award (CTSA) program, previously through the National Center for Research Resources grant 1UL1RR025011, and now by the National Center for Advancing Translational Sciences (NCATS), grant 9U54TR000021 (DTY), grant P30 CA014520 from the National Cancer Institute and Forward Lymphoma (DTY).	Asciutti S, 2011, ONCOGENE, V30, P956, DOI 10.1038/onc.2010.475; Badis G, 2009, SCIENCE, V324, P1720, DOI 10.1126/science.1162327; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Brennana DJ, 2009, EUR J CANCER, V45, P1510, DOI 10.1016/j.ejca.2009.01.028; Vegliante MC, 2013, BLOOD, V121, P2175, DOI 10.1182/blood-2012-06-438937; Vegliante MC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021382; Carvajal-Cuenca A, 2012, HAEMATOL-HEMATOL J, V97, P270, DOI 10.3324/haematol.2011.052621; Chen YH, MOD PATHOL, V23, P105; Chung EJ, 2002, BLOOD, V100, P982, DOI 10.1182/blood.V100.3.982; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; de Bont JM, 2008, NEURO-ONCOLOGY, V10, P648, DOI 10.1215/15228517-2008-032; Dictor M, 2009, HAEMATOL-HEMATOL J, V94, P1563, DOI 10.3324/haematol.2009.008474; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; Dy P, 2008, NUCLEIC ACIDS RES, V36, P3101, DOI 10.1093/nar/gkn162; Fernandez V, 2010, CANCER RES, V70, P1408, DOI 10.1158/0008-5472.CAN-09-3419; Geisler CH, 2012, BRIT J HAEMATOL, V158, P355, DOI 10.1111/j.1365-2141.2012.09174.x; Gelebart P, 2008, BLOOD, V112, P5171, DOI 10.1182/blood-2008-02-139212; Giannopoulou EG, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-277; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Greiner TC, 1996, BLOOD, V87, P4302, DOI 10.1182/blood.V87.10.4302.bloodjournal87104302; Grumolato L, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003603; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Kimura Y, 2013, INT J ONCOL, V43, P457, DOI 10.3892/ijo.2013.1982; Kormish JD, 2010, DEV DYNAM, V239, P56, DOI 10.1002/dvdy.22046; Kridel R, 2012, BLOOD, V119, P1963, DOI 10.1182/blood-2011-11-391474; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lee JY, 2004, AM J RESP CELL MOL, V31, P234, DOI 10.1165/rcmb.2003-0447OC; Leshchenko VV, 2010, BLOOD, V116, P1025, DOI 10.1182/blood-2009-12-257485; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Murugan S, 2012, EXP CELL RES, V318, P1134, DOI 10.1016/j.yexcr.2012.03.008; Nygren L, 2012, BLOOD, V119, P4215, DOI 10.1182/blood-2011-12-400580; Oberley MJ, 2013, HISTOPATHOLOGY, V63, P499, DOI 10.1111/his.12207; Pan X, 2009, P NATL ACAD SCI USA, V106, P3788, DOI 10.1073/pnas.0810147106; Rhind N, 2012, COLD SPRING HARB PER, V4, P1; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; Romaguera JE, 2010, BRIT J HAEMATOL, V150, P200, DOI 10.1111/j.1365-2141.2010.08228.x; Sakamoto I, 2000, J BIOL CHEM, V275, P32871, DOI 10.1074/jbc.M004089200; Sernbo S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-405; Sinner D, 2007, MOL CELL BIOL, V27, P7802, DOI 10.1128/MCB.02179-06; Sock E, 2004, MOL CELL BIOL, V24, P6635, DOI 10.1128/mcb.24.15.6635-6644.2004; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wang X, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014085; Weigle B, 2005, ONCOL REP, V13, P139; Wiestner A, 2007, BLOOD, V109, P4599, DOI 10.1182/blood-2006-08-039859; Witzig TE, 2005, J CLIN ONCOL, V23, P6409, DOI 10.1200/JCO.2005.55.017; Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057; Zhang M, 2010, J BIOL CHEM, V285, P8703, DOI 10.1074/jbc.M109.093526; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	55	47	48	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1231	1240		10.1038/onc.2014.44	http://dx.doi.org/10.1038/onc.2014.44			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24681958	Green Accepted			2022-12-17	WOS:000350687100003
J	Martin, Y; Cabrera, E; Amoedo, H; Hernandez-Perez, S; Dominguez-Kelly, R; Freire, R				Martin, Y.; Cabrera, E.; Amoedo, H.; Hernandez-Perez, S.; Dominguez-Kelly, R.; Freire, R.			USP29 controls the stability of checkpoint adaptor Claspin by deubiquitination	ONCOGENE			English	Article							DNA-DAMAGE-RESPONSE; REPEATED PHOSPHOPEPTIDE MOTIFS; CELL-CYCLE; REPLICATION; CHK1; PHOSPHORYLATION; DESTRUCTION; DEGRADATION; ACTIVATION; BINDING	The DNA damage checkpoint is essential for the maintenance of genome integrity after genotoxic stress, and also for cell survival in eukaryotes. Claspin has a key role in the ATR (ATM and Rad3-related)-Chk1 branch of the DNA damage checkpoint and is also required for correct DNA replication. To achieve properly these functions, Claspin is tightly regulated by ubiquitinin-dependent proteasomal degradation, which controls Claspin levels in a DNA-damage- and cell-cycle-dependent manner. Here, we identified a new regulator of Claspin, the ubiquitin-specific peptidase 29, USP29. Downregulation of USP29 destabilizes Claspin, whereas its overexpression promotes an increase in Claspin levels. USP29 interacts with Claspin and is able to deubiquitinate it both in vivo and in vitro. Most importantly, USP29 knockdown results in an impaired phosphorylation of Chk1 after DNA damage and USP29-depleted cells show a major defect in the S-phase progression. With these results, we identified USP29 as a new player in the ATR-Chk1 pathway and the control of DNA replication.	[Martin, Y.; Cabrera, E.; Amoedo, H.; Hernandez-Perez, S.; Dominguez-Kelly, R.; Freire, R.] Hosp Univ Canarias, Unidad Invest, Inst Tecnol Biomed, Tenerife 38320, Spain	Universidad de la Laguna	Freire, R (corresponding author), Hosp Univ Canarias, Unidad Invest, Ofra S-N, Tenerife 38320, Spain.	rfreire@ull.es	Freire, Raimundo/Q-7660-2019; Cabrera, Elisa/GPX-3455-2022	Freire, Raimundo/0000-0003-4473-8894; 	Spanish MINECO [SAF2010-22357, CONSOLIDER-Ingenio 2010 CDS2007-0015]	Spanish MINECO(Spanish Government)	We are grateful to V Smits for careful reading of the manuscript. We thank G Marfany, JW Harper and D Bohmann for helpful reagents. This work was supported by grants from the Spanish MINECO (SAF2010-22357, CONSOLIDER-Ingenio 2010 CDS2007-0015).	Bassermann F, 2008, CELL, V134, P256, DOI 10.1016/j.cell.2008.05.043; Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007; Chini CCS, 2006, J BIOL CHEM, V281, P33276, DOI 10.1074/jbc.M604373200; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Clarke CAL, 2005, BIOCHEM J, V388, P705, DOI 10.1042/BJ20041966; Cummins JM, 2004, NATURE, V428, DOI 10.1038/nature02501; Dominguez-Kelly R, 2011, J CELL BIOL, V194, P567, DOI 10.1083/jcb.201101047; Faustrup H, 2009, J CELL BIOL, V184, P13, DOI 10.1083/jcb.200807137; Freire R, 2006, CELL CYCLE, V5, P2831, DOI 10.4161/cc.5.24.3559; Gao DM, 2009, MOL BIOL CELL, V20, P3305, DOI 10.1091/mbc.E09-01-0092; Jacq X, 2013, CELL BIOCHEM BIOPHYS, V67, P25, DOI 10.1007/s12013-013-9635-3; Perez-Castro AJ, 2012, J CELL SCI, V125, P1152, DOI 10.1242/jcs.091124; Kim JM, 2008, ONCOGENE, V27, P3475, DOI 10.1038/sj.onc.1210994; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(05)00092-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Lee J, 2005, MOL BIOL CELL, V16, P5269, DOI 10.1091/mbc.E05-07-0671; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Liu JH, 2011, EMBO J, V30, P846, DOI 10.1038/emboj.2011.11; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; Meng Z, 2011, MOL BIOL CELL, V22, P2834, DOI 10.1091/mbc.E11-01-0048; Mosbech A, 2013, J BIOL CHEM, V288, P16579, DOI 10.1074/jbc.M113.459917; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Petermann E, 2008, MOL BIOL CELL, V19, P2373, DOI 10.1091/mbc.E07-10-1035; Refolio E, 2011, J CELL SCI, V124, P2488, DOI 10.1242/jcs.081711; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Semple JI, 2007, CELL DEATH DIFFER, V14, P1433, DOI 10.1038/sj.cdd.4402134; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Smits VAJ, 2010, FRONT BIOSCI-LANDMRK, V15, P840, DOI 10.2741/3649; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Uno S, 2011, GENES CELLS, V16, P842, DOI 10.1111/j.1365-2443.2011.01535.x; Verlinden L, 2007, CANCER RES, V67, P6574, DOI 10.1158/0008-5472.CAN-06-3545; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039	37	47	49	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					1058	1063		10.1038/onc.2014.38	http://dx.doi.org/10.1038/onc.2014.38			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632611				2022-12-17	WOS:000350121300012
J	Xu, C; Fan, CD; Wang, X				Xu, C.; Fan, C. D.; Wang, X.			Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase	ONCOGENE			English	Article						Mdm2; p53; NEDD4-1; E3 ligases; degradation; ubiquitination	ACUTE LYMPHOBLASTIC-LEUKEMIA; UBIQUITIN LIGASE; NEGATIVE REGULATOR; PROMOTES; ACTIVATION; CANCER; INACTIVATION; DEGRADATION; ONCOPROTEIN; PATHWAY	Mdm2 is a critical negative regulator of the tumor suppressor protein p53. Mdm2 is an E3 ligase whose overexpression leads to functional inactivation of p53. Mdm2 protein stability is regulated by several mechanisms including RING (Really Interesting New Gene) domain-mediated autoubiquitination. Here we report biochemical identification of NEDD4-1 as an E3 ligase for Mdm2 that contributes to the regulation of Mdm2 protein stability in cells. NEDD4-1 was identified from Jurkat cytosolic fractions using an enzyme-dead Mdm2 mutant protein as a substrate for in vitro E3 ligase assays. We show that lysates from Nedd4-1 knockout (KO) mouse embryonic fibroblasts (MEFs) have significantly diminished E3 ligase activity toward Mdm2 compared with lysates from wildtype (WT) MEFs. Recombinant NEDD4-1 promotes Mdm2 ubiquitination in vitro in a concentration-and time-dependent manner. In cells, NEDD4-1 physically interacts with Mdm2 via the RING domain of Mdm2. Overexpression of NEDD4-1, but not an enzyme-dead NEDD4-1CS mutant, increases ubiquitination of Mdm2. NEDD4-1 catalyzes the formation of K63-type polyubiquitin chains on Mdm2 that are distinct from K48-type polyubiquitination chains mediated by the Mdm2/MdmX complex. Importantly, K63-type polyubiquitination by NEDD4-1 competes with K48-type polyubiquitination on Mdm2 in cells. As a result, NEDD4-1-mediated ubiquitination stabilizes Mdm2. NEDD4-1 knockdown reduces the t(1/2) (half-life) of endogenous Mdm2 from 20 to 12 min in U2OS cells. Nedd4-1 KO MEFs manifest increased p53 levels and activity, a more robust DNA damage response and increased G1 arrest compared with WT MEFs. Similarly, NEDD4-1 knockdown in WT-p53-bearing cells increases basal p53 levels and activity in an Mdm2-dependent manner, causes stronger p53 responses to DNA damage and results in p53-dependent growth inhibition compared with corresponding NEDD4-1-proficient control cells. This study identifies NEDD4-1 as a novel component of the p53/Mdm2 regulatory feedback loop that controls p53 activity during stress responses.	[Xu, C.; Fan, C. D.; Wang, X.] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Wang, X (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	xinjiang.wang@roswellpark.org			Roswell Park Cancer Institute; Roswell Park Core Grant [CA16056]; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER	Roswell Park Cancer Institute; Roswell Park Core Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by start-p funds from Roswell Park Cancer Institute (XW). The Roswell Park Core Grant CA16056 is also gratefully acknowledged. We sincerely thank Dr Baoli Yang for providing Nedd4-1 -/- and parental MEFs; Dr Yosef Shiloh and Dr Jiandong Chen and Dr Dirk P Bohmann for providing DNA constructs; Dr Moshe Oren for antibodies, Bert Vogelstein for providing HCT116-p53 -/- cells and Dr Gigi Lozano for p53/Mdm2 DKO MEFs, respectively. We also thank Dr David Goodrich and other faculty colleagues at the Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute for their critical reading of the manuscript.	Amodio N, 2010, AM J PATHOL, V177, P2622, DOI 10.2353/ajpath.2010.091075; Chen ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Dai BB, 2010, CANCER RES, V70, P2951, DOI 10.1158/0008-5472.CAN-09-3909; Eide PW, 2013, CELL SIGNAL, V25, P12, DOI 10.1016/j.cellsig.2012.08.012; Fan CD, 2013, J BIOL CHEM, V288, P1674, DOI 10.1074/jbc.M112.416339; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Inuzuka H, 2010, CANCER CELL, V18, P147, DOI 10.1016/j.ccr.2010.06.015; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Khor LY, 2009, J CLIN ONCOL, V27, P3177, DOI 10.1200/JCO.2008.19.8267; Lai ZH, 2001, J BIOL CHEM, V276, P31357, DOI 10.1074/jbc.M011517200; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li Q, 2013, CLIN CANCER RES, V19, P34, DOI 10.1158/1078-0432.CCR-12-0053; Linares LK, 2007, NAT CELL BIOL, V9, P331, DOI 10.1038/ncb1545; Linke K, 2008, CELL DEATH DIFFER, V15, P841, DOI 10.1038/sj.cdd.4402309; LUNA RMD, 1995, NATURE, V378, P203; Marks DI, 1996, BLOOD, V87, P1155, DOI 10.1182/blood.V87.3.1155.bloodjournal8731155; Mosesson Y, 2009, DEV CELL, V16, P687, DOI 10.1016/j.devcel.2009.03.015; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang X, J BIOL CHEM, V286, P23725; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Wang ZW, 2012, ONCOTARGET, V3, P1026; Yang JY, 2006, MOL CELL BIOL, V26, P7269, DOI 10.1128/MCB.00172-06; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608	30	47	48	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					342	350		10.1038/onc.2013.557	http://dx.doi.org/10.1038/onc.2013.557			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24413081				2022-12-17	WOS:000348145500008
J	Chen, Z; Zhang, Y; Jia, C; Wang, Y; Lai, P; Zhou, X; Wang, Y; Song, Q; Lin, J; Ren, Z; Gao, Q; Zhao, Z; Zheng, H; Wan, Z; Gao, T; Zhao, A; Dai, Y; Bai, X				Chen, Z.; Zhang, Y.; Jia, C.; Wang, Y.; Lai, P.; Zhou, X.; Wang, Y.; Song, Q.; Lin, Jun; Ren, Z.; Gao, Q.; Zhao, Z.; Zheng, H.; Wan, Z.; Gao, T.; Zhao, A.; Dai, Y.; Bai, X.			mTORC1/2 targeted by n-3 polyunsaturated fatty acids in the prevention of mammary tumorigenesis and tumor progression	ONCOGENE			English	Article						mTORC1; mTORC2; breast cancer; n-3 polyunsaturated fatty acids (n-3 PUFAs); fat-1	BREAST-CANCER; DOCOSAHEXAENOIC ACID; MAMMALIAN TARGET; DIETARY-FAT; GROWTH; OMEGA-3-FATTY-ACIDS; COMPLEX; LONG; OIL; METASTASIS	Although epidemiological and preclinical studies have shown the preventative effects of n-3 polyunsaturated fatty acids (PUFAs) on breast cancer, inconsistencies still remain in the data and the underlying mechanisms remain unclear. In this study, we identified mammalian target of rapamycin (mTOR) signaling, which plays an essential role in cell proliferation and breast tumorigenesis, as a target of n-3 PUFAs. In breast cancer cell lines, n-3 PUFAs rapidly and efficiently suppress both mTOR complex 1 (mTORC1) and mTORC2 and their downstream signaling, and subsequently inhibit cell proliferation and angiogenesis while promoting apoptosis. Further study indicates that stabilization of the mTOR-raptor complex by n-3 PUFAs may contribute to their inhibitory effect on mTORC1. Importantly, four complementary and well-controlled animal models were utilized to identify the role and molecular target of n-3 PUFAs in the prevention of breast carcinogenesis and progression, namely: (1) chemically induced mammary tumor rats with a high dietary intake of n-3 PUFAs; (2) nude mice implanted with mammary tumor cell lines stably expressing fat-1, a desaturase that catalyzes the conversion of n-6 to n-3 PUFAs and produces n-3 PUFAs endogenously; (3) fat-1 transgenic severe combined immune deficiency mice implanted with breast tumor cells; and (4) the fat-1 transgenic mouse mammary tumor virus-polyoma virus middle T oncogene double-hybrid mice, a model of aggressive breast cancer. In summary, dietary and endogenous n-3 PUFAs abrogate the activity of mTORC1/2 pathways in vitro and in vivo and prevent breast carcinogenesis, tumor growth and metastasis. Taken together, our findings convincingly clarify the causal relationship between n-3 PUFAs and breast cancer prevention and establish mTORC1/2 as a target of n-3 PUFAs.	[Chen, Z.; Zhang, Y.; Jia, C.; Lai, P.; Zhou, X.; Song, Q.; Lin, Jun; Bai, X.] Southern Med Univ, Sch Basic Med Sci, Dept Cell Biol, Guangzhou 510515, Guangdong, Peoples R China; [Wang, Y.; Wang, Y.; Ren, Z.; Gao, Q.; Wan, Z.; Zhao, A.; Dai, Y.] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China; [Wang, Y.; Wang, Y.; Ren, Z.; Gao, Q.; Wan, Z.; Zhao, A.; Dai, Y.] Nanjing Med Univ, Jiangsu Key Lab Xenotransplantat, Nanjing, Jiangsu, Peoples R China; [Zhao, Z.] Nankai Univ, Coll Life Sci, Tianjin 300071, Peoples R China; [Zheng, H.] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China; [Gao, T.] Southern Med Univ, Dept Anat & Neurobiol, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China; Nanjing Medical University; Nanjing Medical University; Nankai University; Southern Medical University - China; Southern Medical University - China	Dai, Y (corresponding author), Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.	yifandai08@gmail.com; baixc15@smu.edu.cn	qiancheng, song/C-4159-2014	zhang, yue/0000-0002-6612-8002; Chen, Zhenguo/0000-0003-3280-5201; Song, Qiancheng/0000-0002-9335-5147; Bai, Xiaochun/0000-0001-9631-4781	State Key Development Program for Basic Research of China [2009CB918904, 2013CB945203]; National Natural Sciences Foundation of China [91029727]; Guangdong Natural Science Foundation [s2012010008209]; Program for Changjiang Scholars and Innovative Research Team in University [IRT1142]	State Key Development Program for Basic Research of China(State Key Development Program for Basic Research of China); National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Program for Changjiang Scholars and Innovative Research Team in University(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT))	We greatly appreciate the gift of TSC2<SUP>+/+</SUP> and TSC2<SUP>-/-</SUP> MEFs from Dr David J Kwiatkowski (Brigham and Women's Hospital, Boston, MA, USA). This work was supported by the State Key Development Program for Basic Research of China (2009CB918904, 2013CB945203), National Natural Sciences Foundation of China (91029727), Guangdong Natural Science Foundation (s2012010008209) and Program for Changjiang Scholars and Innovative Research Team in University (IRT1142). TSC2<SUP>+/+</SUP>P53<SUP>-/-</SUP> and TSC2<SUP>-/-</SUP>P53<SUP>-/-</SUP> mouse embryonic fibroblasts (MEF) were provided by Dr David J Kwiatkowski (Brigham and Women's Hospital, Boston, MA, USA).	Bai XC, 2010, CELL MOL LIFE SCI, V67, P239, DOI 10.1007/s00018-009-0163-7; Berquin IM, 2008, CANCER LETT, V269, P363, DOI 10.1016/j.canlet.2008.03.044; BRADEN LM, 1986, LIPIDS, V21, P285, DOI 10.1007/BF02536414; COHEN LA, 1993, LIPIDS, V28, P449, DOI 10.1007/BF02535944; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Engeset D, 2006, INT J CANCER, V119, P175, DOI 10.1002/ijc.21819; GABOR H, 1985, J NATL CANCER I, V74, P1299; Gerber M, 2012, BRIT J NUTR, V107, pS228, DOI 10.1017/S0007114512001614; Gingras AA, 2007, J PHYSIOL-LONDON, V579, P269, DOI 10.1113/jphysiol.2006.121079; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Jiang WQ, 2012, CANCER RES, V72, P3795, DOI 10.1158/0008-5472.CAN-12-1047; Jing K, 2011, AUTOPHAGY, V7, P1348, DOI 10.4161/auto.7.11.16658; JURKOWSKI JJ, 1985, J NATL CANCER I, V74, P1145; Kang JX, 2008, J NUTRIGENET NUTRIGE, V1, P172, DOI 10.1159/000119714; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim EK, 2011, ONCOGENE, V30, P2954, DOI 10.1038/onc.2011.22; Kwiatkowski DJ, 2005, HUM MOL GENET, V14, pR251, DOI 10.1093/hmg/ddi260; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Larsson SC, 2004, AM J CLIN NUTR, V79, P935; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; MacLean CH, 2006, JAMA-J AM MED ASSOC, V295, P403, DOI 10.1001/jama.295.4.403; MacLennan MB, 2013, J NUTR BIOCHEM, V24, P388, DOI 10.1016/j.jnutbio.2012.08.002; Manni A, 2010, CANCER PREV RES, V3, P322, DOI 10.1158/1940-6207.CAPR-09-0173; O'Regan R, 2011, EXPERT OPIN THER TAR, V15, P859, DOI 10.1517/14728222.2011.575362; Olivo SE, 2005, CARCINOGENESIS, V26, P1563, DOI 10.1093/carcin/bgi118; ROSE DP, 1995, JNCI-J NATL CANCER I, V87, P587, DOI 10.1093/jnci/87.8.587; ROSE DP, 1993, JNCI-J NATL CANCER I, V85, P1743, DOI 10.1093/jnci/85.21.1743; Sarbassov DD, 2005, J BIOL CHEM, V280, P39505, DOI 10.1074/jbc.M506096200; SCHATZKIN A, 1989, JAMA-J AM MED ASSOC, V261, P3284, DOI 10.1001/jama.261.22.3284; Signori C, 2011, CANCER RES, V71, P6091, DOI 10.1158/0008-5472.CAN-11-0977; van Veelen W, 2011, ONCOGENE, V30, P2289, DOI 10.1038/onc.2010.630; Warner E, 2011, NEW ENGL J MED, V365, P1025, DOI 10.1056/NEJMcp1101540; Wei D, 2010, DIABETES, V59, P471, DOI 10.2337/db09-0284; Wen ZH, 2013, ONCOGENE, V32, P160, DOI 10.1038/onc.2012.47; Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501; Xia SH, 2006, P NATL ACAD SCI USA, V103, P12499, DOI 10.1073/pnas.0605394103; Yoshida S, 2011, J BIOL CHEM, V286, P32651, DOI 10.1074/jbc.M111.238014; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	39	47	51	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2014	33	37					4548	4557		10.1038/onc.2013.402	http://dx.doi.org/10.1038/onc.2013.402			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3UZ	24096482				2022-12-17	WOS:000342004800002
J	Chen, YH; Gutmann, DH				Chen, Y-H; Gutmann, D. H.			The molecular and cell biology of pediatric low-grade gliomas	ONCOGENE			English	Review						genetically-engineered mice; brain tumor; glioma; pilocytic astrocytoma; astrocyte; neural stem cell	TYPE-1 GENE-PRODUCT; NEURAL STEM-CELLS; MAPK PATHWAY ACTIVATION; OPTIC-NERVE GLIOMA; RADIAL GLIA CELLS; GROWTH-FACTOR; PILOCYTIC ASTROCYTOMAS; PROGENITOR PROLIFERATION; TUMOR PREDISPOSITION; MALIGNANT GLIOMAS	Pilocytic astrocytoma (PA) is the most common glial cell tumor arising in children. Sporadic cases are associated with KIAA1549:BRAF fusion rearrangements, while 15-20% of children develop PA in the context of the neurofibromatosis 1 (NF1) inherited tumor predisposition syndrome. The unique predilection of these tumors to form within the optic pathway and brainstem (NF1-PA) and cerebellum (sporadic PA) raises the possibility that gliomagenesis requires more than biallelic inactivation of the NF1 tumor suppressor gene or expression of the KIAA1549:BRAF transcript. Several etiologic explanations include differential susceptibilities of preneoplastic neuroglial cell types in different brain regions to these glioma-causing genetic changes, contributions from nonneoplastic cells and signals in the tumor microenvironment, and genomic modifiers that confer glioma risk. As clinically-faithful rodent models of sporadic PA are currently under development, Nf1 genetically-engineered mouse (GEM) models have served as tractable systems to study the role of the cell of origin, deregulated intracellular signaling, non-neoplastic cells in the tumor microenvironment and genomic modifiers in gliomagenesis. In this report, we highlight advances in Nf1-GEM modeling and review new experimental evidence that supports the emerging concept that Nf1- and KIAA1549:BRAF-induced gliomas arise from specific cell types in particular brain locations.	[Chen, Y-H; Gutmann, D. H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 South Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu		Gutmann, David/0000-0002-3127-5045	National Institutes of Health [NS065527]; National Brain Tumor Society	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Brain Tumor Society	This work was supported in part by grants from the National Institutes of Health (NS065527) and National Brain Tumor Society (to DHG). Y-HC is a fellow of the American Brain Tumor Association.	Amankulor NM, 2009, J NEUROSCI, V29, P10299, DOI 10.1523/JNEUROSCI.2500-09.2009; Amlin-Van Schaick J, 2012, MAMM GENOME, V23, P277, DOI 10.1007/s00335-011-9380-0; Amlin-Van Schaick JC, 2012, NEURO-ONCOLOGY, V14, P160, DOI 10.1093/neuonc/nor206; ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; Armstrong GT, 2011, NEURO-ONCOLOGY, V13, P223, DOI 10.1093/neuonc/noq178; Assanah M, 2006, J NEUROSCI, V26, P6781, DOI 10.1523/JNEUROSCI.0514-06.2006; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; Bajenaru ML, 2005, ANN NEUROL, V57, P119, DOI 10.1002/ana.20337; Bajenaru ML, 2003, CANCER RES, V63, P8573; Banerjee S, 2011, P NATL ACAD SCI USA, V108, P15996, DOI 10.1073/pnas.1019012108; Bar EE, 2008, J NEUROPATH EXP NEUR, V67, P878, DOI 10.1097/NEN.0b013e3181845622; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Binning MJ, 2008, CANCER RES, V68, P7838, DOI 10.1158/0008-5472.CAN-08-1899; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Calatozzolo C, 2011, CANCER BIOL THER, V11, P242, DOI 10.4161/cbt.11.2.13951; Cin H, 2011, ACTA NEUROPATHOL, V121, P763, DOI 10.1007/s00401-011-0817-z; Costa RM, 2001, NAT GENET, V27, P399, DOI 10.1038/86898; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; Daginakatte GC, 2007, HUM MOL GENET, V16, P1098, DOI 10.1093/hmg/ddm059; Daginakatte GC, 2008, CANCER RES, V68, P10358, DOI 10.1158/0008-5472.CAN-08-2506; Dasgupta B, 2005, CANCER RES, V65, P2755, DOI 10.1158/0008-5472.CAN-04-4058; Dasgupta B, 2003, J NEUROSCI, V23, P8949; Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218; Eisenhardt AE, 2011, INT J CANCER, V129, P2297, DOI 10.1002/ijc.25893; Elkabes S, 1996, J NEUROSCI, V16, P2508; Fanelli M, 2008, ONCOGENE, V27, P358, DOI 10.1038/sj.onc.1210642; Fisher MJ, 2012, NEURO-ONCOLOGY, V14, P790, DOI 10.1093/neuonc/nos076; Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Gronych J, 2011, J CLIN INVEST, V121, P1344, DOI 10.1172/JCI44656; Guillamo JS, 2003, BRAIN, V126, P152, DOI 10.1093/brain/awg016; GUTMANN DH, 1995, CELL GROWTH DIFFER, V6, P315; Gutmann DH, 1999, ANN NEUROL, V46, P777, DOI 10.1002/1531-8249(199911)46:5<777::AID-ANA15>3.0.CO;2-H; GUTMANN DH, 1995, DEV DYNAM, V202, P302, DOI 10.1002/aja.1002020309; Gutmann DH, 2000, NEUROPATH APPL NEURO, V26, P361, DOI 10.1046/j.1365-2990.2000.00258.x; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hasselblatt M, 2011, NEUROPATH APPL NEURO, V37, P803, DOI 10.1111/j.1365-2990.2011.01193.x; Hawkins C, 2011, CLIN CANCER RES, V17, P4790, DOI 10.1158/1078-0432.CCR-11-0034; Hegedus B, 2008, CANCER RES, V68, P1520, DOI 10.1158/0008-5472.CAN-07-5916; Hoshiko M, 2012, J NEUROSCI, V32, P15106, DOI 10.1523/JNEUROSCI.1167-12.2012; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Jacob K, 2009, BRIT J CANCER, V101, P722, DOI 10.1038/sj.bjc.6605179; Jacob K, 2011, CLIN CANCER RES, V17, P4650, DOI 10.1158/1078-0432.CCR-11-0127; Janzarik WG, 2007, NEUROPEDIATRICS, V38, P61, DOI 10.1055/s-2007-984451; Johnson RA, 2010, NATURE, V466, P632, DOI 10.1038/nature09173; Jones DTW, 2009, ONCOGENE, V28, P2119, DOI 10.1038/onc.2009.73; Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kalamarides M, 2011, ONCOGENE, V30, P2333, DOI 10.1038/onc.2010.609; Kaul A, 2012, GENE DEV, V26, P2561, DOI 10.1101/gad.200907.112; Kluwe L, 2001, J NEUROPATH EXP NEUR, V60, P917, DOI 10.1093/jnen/60.9.917; Kostianovsky AM, 2008, J IMMUNOL, V181, P5425, DOI 10.4049/jimmunol.181.8.5425; Lau N, 2000, J NEUROPATH EXP NEUR, V59, P759, DOI 10.1093/jnen/59.9.759; Lee DY, 2012, CANCER CELL, V22, P131, DOI 10.1016/j.ccr.2012.05.036; Lee DY, 2010, GENE DEV, V24, P2317, DOI 10.1101/gad.1957110; Lin EY, 2007, CANCER RES, V67, P5064, DOI 10.1158/0008-5472.CAN-07-0912; Lindberg N, 2009, ONCOGENE, V28, P2266, DOI 10.1038/onc.2009.76; Listernick R, 2007, ANN NEUROL, V61, P189, DOI 10.1002/ana.21107; Liu C, 2011, CELL, V146, P209, DOI 10.1016/j.cell.2011.06.014; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lyustikman Y, 2008, NEOPLASIA, V10, P501, DOI 10.1593/neo.08206; Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8; Markovic DS, 2009, P NATL ACAD SCI USA, V106, P12530, DOI 10.1073/pnas.0804273106; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; Masui K, 2010, GLIA, V58, P1050, DOI 10.1002/glia.20986; Merkle FT, 2004, P NATL ACAD SCI USA, V101, P17528, DOI 10.1073/pnas.0407893101; Pfister S, 2008, J CLIN INVEST, V118, P1739, DOI 10.1172/JCI33656; Pfister Stefan, 2009, Recent Results Cancer Res, V171, P67, DOI 10.1007/978-3-540-31206-2_4; Platten M, 2003, ANN NEUROL, V54, P388, DOI 10.1002/ana.10679; Pong WW, 2013, ANN NEUROL, V73, P303, DOI 10.1002/ana.23813; Raabe EH, 2011, CLIN CANCER RES, V17, P3590, DOI 10.1158/1078-0432.CCR-10-3349; Reilly KM, 2000, NAT GENET, V26, P109, DOI 10.1038/79075; Reilly KM, 2004, P NATL ACAD SCI USA, V101, P13008, DOI 10.1073/pnas.0401236101; Robinson JP, 2010, ONCOGENE, V29, P335, DOI 10.1038/onc.2009.333; Roumier A, 2004, J NEUROSCI, V24, P11421, DOI 10.1523/JNEUROSCI.2251-04.2004; Schindler G, 2011, ACTA NEUROPATHOL, V121, P397, DOI 10.1007/s00401-011-0802-6; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Shalitin S, 2011, HORM RES PAEDIAT, V76, P113, DOI 10.1159/000327584; Sharif S, 2006, J CLIN ONCOL, V24, P2570, DOI 10.1200/JCO.2005.03.8349; Sharma MK, 2005, NEUROLOGY, V65, P1335, DOI 10.1212/01.wnl.0000180409.78098.d7; Sharma MK, 2007, CANCER RES, V67, P890, DOI 10.1158/0008-5472.CAN-06-0973; Sievert AJ, 2009, BRAIN PATHOL, V19, P449, DOI 10.1111/j.1750-3639.2008.00225.x; Simmons GW, 2011, J NEUROPATH EXP NEUR, V70, P51, DOI 10.1097/NEN.0b013e3182032d37; Solga AC, 2014, ONCOGENE, V33, P289, DOI 10.1038/onc.2012.580; Sugiarto S, 2011, CANCER CELL, V20, P328, DOI 10.1016/j.ccr.2011.08.011; Taylor MD, 2005, CANCER CELL, V8, P323, DOI 10.1016/j.ccr.2005.09.001; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; Tchoghandjian A, 2009, BRAIN, V132, P1523, DOI 10.1093/brain/awp048; Tong JY, 2002, NAT NEUROSCI, V5, P95, DOI 10.1038/nn792; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; Wang Y, 2009, CANCER CELL, V15, P514, DOI 10.1016/j.ccr.2009.04.001; Warrington NM, 2007, CANCER RES, V67, P8588, DOI 10.1158/0008-5472.CAN-06-2220; Warrington NM, 2010, CANCER RES, V70, P5717, DOI 10.1158/0008-5472.CAN-09-3769; Watters JJ, 2005, J NEUROSCI RES, V81, P447, DOI 10.1002/jnr.20485; Wesolowska A, 2008, ONCOGENE, V27, P918, DOI 10.1038/sj.onc.1210683; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wimmer K, 2002, J NEUROPATH EXP NEUR, V61, P896, DOI 10.1093/jnen/61.10.896; Wisoff JH, 2011, NEUROSURGERY, V68, P1548, DOI 10.1227/NEU.0b013e318214a66e; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; Yeh TH, 2009, GLIA, V57, P1239, DOI 10.1002/glia.20845; Zhu Y, 2005, DEVELOPMENT, V132, P5577, DOI 10.1242/dev.02162	105	47	47	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2019	2026		10.1038/onc.2013.148	http://dx.doi.org/10.1038/onc.2013.148			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23624918	Bronze			2022-12-17	WOS:000334599100002
J	Shukla, A; Edwards, R; Yang, Y; Hahn, A; Folkers, K; Ding, J; Padmakumar, VC; Cataisson, C; Suh, KS; Yuspa, SH				Shukla, A.; Edwards, R.; Yang, Y.; Hahn, A.; Folkers, K.; Ding, J.; Padmakumar, V. C.; Cataisson, C.; Suh, K. S.; Yuspa, S. H.			CLIC4 regulates TGF-beta-dependent myofibroblast differentiation to produce a cancer stroma	ONCOGENE			English	Article						CLIC; alpha-SMA; p38; microenvironment; PPM1a	EPITHELIAL-MESENCHYMAL TRANSITION; CHLORIDE CHANNEL PROTEIN; MUSCLE ACTIN EXPRESSION; CONTRACTILE ACTIVITY; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; CELL CARCINOMA; FIBROBLASTS; GROWTH; PHOSPHATASE	Cancer stroma has a profound influence on tumor development and progression. The conversion of fibroblasts to activated myofibroblasts is a hallmark of reactive tumor stroma. Among a number of factors involved in this conversion, transforming growth factor (TGF)-beta has emerged as a major regulator. CLIC4, an integral protein in TGF-beta signaling, is highly upregulated in stroma of multiple human cancers, and overexpression of CLIC4 in stromal cells enhances the growth of cancer xenografts. In this study, we show that conditioned media from tumor cell lines induces expression of both CLIC4 and the myofibroblast marker alpha smooth muscle actin (alpha-SMA) in stromal fibroblasts via TGF-beta signaling. Genetic ablation of CLIC4 in primary fibroblasts prevents or reduces constitutive or TGF-beta-induced expression of alpha-SMA and extracellular matrix components that are markers of myofibroblasts. CLIC4 is required for the activation of p38 map kinase by TGF-beta, a pathway that signals myofibroblast conversion in stromal cells. This requirement involves the interaction of CLIC4 with PPM1a, the selective phosphatase of activated p38. Conditioned media from fibroblasts overexpressing CLIC4 increases tumor cell migration and invasion in a TGF-beta-dependent manner and promotes epithelial to mesenchymal transition indicating that high stromal CLIC4 serves to enhance tumor invasiveness and progression. Thus, CLIC4 is significantly involved in the development of a nurturing tumor microenvironment by enhancing TGF-beta signaling in a positive feedback loop. Targeting CLIC4 in tumor stroma should be considered as a strategy to mitigate some of the tumor enhancing effects of the cancer stroma.	[Shukla, A.; Edwards, R.; Yang, Y.; Hahn, A.; Folkers, K.; Padmakumar, V. C.; Cataisson, C.; Yuspa, S. H.] NCI, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD 20892 USA; [Ding, J.] NIA, Neurogenet Lab, Bethesda, MD 20892 USA; [Suh, K. S.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Hackensack University Medical Center	Yuspa, SH (corresponding author), NCI, Lab Canc Biol & Genet, Ctr Canc Res, 37 Convent Dr, Bethesda, MD 20892 USA.	yuspas@mail.nih.gov	Shukla, Anjali/G-4046-2014	Edwards Mayhew, Rebecca/0000-0003-3503-9637	Center for Cancer Research, National Cancer Institute; NATIONAL CANCER INSTITUTE [ZIABC005445] Funding Source: NIH RePORTER	Center for Cancer Research, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Lalage Wakefield, National Cancer Institute, Bethesda for providing Smad3 KO mice and MI, MII, MIII, MIV cell lines, Dr Ed Leof, Department of Biochemistry and Molecular Biology, Mayo Clinic, Minnesota for providing anti-phospho Smad3 antibody and Dr Akira Oshima, National Cancer Institute for help with immunofluorescence. This work was supported by the intramural research program of the Center for Cancer Research, National Cancer Institute.	Adegboyega PA, 2010, HUM PATHOL, V41, P1128, DOI 10.1016/j.humpath.2009.12.014; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bohman S, 2005, J BIOL CHEM, V280, P42397, DOI 10.1074/jbc.M506724200; Brenmoehl J, 2009, WORLD J GASTROENTERO, V15, P1431, DOI 10.3748/wjg.15.1431; Caraci F, 2008, PHARMACOL RES, V57, P274, DOI 10.1016/j.phrs.2008.02.001; Cheng AY, 2000, J BIOL CHEM, V275, P34744, DOI 10.1074/jbc.M006210200; Connolly EC, 2011, CANCER RES, V71, P2339, DOI 10.1158/0008-5472.CAN-10-2941; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; De Wever O, 2008, INT J CANCER, V123, P2229, DOI 10.1002/ijc.23925; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; Evans RA, 2003, EXP CELL RES, V282, P90, DOI 10.1016/S0014-4827(02)00015-0; Fernandez-Salas E, 1999, J BIOL CHEM, V274, P36488, DOI 10.1074/jbc.274.51.36488; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Hinz B, 2001, AM J PATHOL, V159, P1009, DOI 10.1016/S0002-9440(10)61776-2; Hinz B, 2007, J INVEST DERMATOL, V127, P526, DOI 10.1038/sj.jid.5700613; Hu B, 2003, AM J RESP CELL MOL, V29, P397, DOI 10.1165/rcmb.2003-0063OC; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Lichti U, 2008, NAT PROTOC, V3, P799, DOI 10.1038/nprot.2008.50; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Littler DR, 2010, FEBS LETT, V584, P2093, DOI 10.1016/j.febslet.2010.01.027; Littler DR, 2005, FEBS J, V272, P4996, DOI 10.1111/j.1742-4658.2005.04909.x; Littler DR, 2004, J BIOL CHEM, V279, P9298, DOI 10.1074/jbc.M308444200; Liu M, 2011, INT J CANCER, V129, P1795, DOI 10.1002/ijc.26116; Lu SL, 2006, GENE DEV, V20, P1331, DOI 10.1101/gad.1413306; Meyer-ter-Vehn T, 2006, INVEST OPHTH VIS SCI, V47, P1500, DOI 10.1167/iovs.05-0361; Micke P, 2004, LUNG CANCER, V45, pS163, DOI 10.1016/j.lungcan.2004.07.977; Miyazono K, 2009, P JPN ACAD B-PHYS, V85, P314, DOI 10.2183/pjab.85.314; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Padmakumar VC, 2012, AM J PATHOL, V181, P74, DOI 10.1016/j.ajpath.2012.03.025; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Ronnov-Jessen L, 2002, AM J PATHOL, V161, P471, DOI 10.1016/S0002-9440(10)64203-4; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; RonnovJessen L, 1996, J CELL BIOL, V134, P67, DOI 10.1083/jcb.134.1.67; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Saunier EF, 2006, CURR CANCER DRUG TAR, V6, P565, DOI 10.2174/156800906778742460; Shorning BY, 2003, DEV GENES EVOL, V213, P514, DOI 10.1007/s00427-003-0356-2; Shukla A, 2010, NUCLEUS-PHILA, V1, P144; Shukla A, 2009, NAT CELL BIOL, V11, P777, DOI 10.1038/ncb1885; Suh KS, 2005, CURR PHARM DESIGN, V11, P2753, DOI 10.2174/1381612054546806; Suh KS, 2007, CLIN CANCER RES, V13, P121, DOI 10.1158/1078-0432.CCR-06-1562; Sun WJ, 2009, CELL SIGNAL, V21, P95, DOI 10.1016/j.cellsig.2008.09.012; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tlsty TD, 2001, SEMIN CANCER BIOL, V11, P97, DOI 10.1006/scbi.2000.0361; Tsujino T, 2007, CLIN CANCER RES, V13, P2082, DOI 10.1158/1078-0432.CCR-06-2191; Tung JJ, 2009, ANGIOGENESIS, V12, P209, DOI 10.1007/s10456-009-9139-3; Tuxhorn JA, 2002, CANCER RES, V62, P3298; Uemura M, 2005, MOL BIOL CELL, V16, P4214, DOI 10.1091/mbc.E05-02-0149; Ulmasov B, 2009, AM J PATHOL, V174, P1084, DOI 10.2353/ajpath.2009.080625; Yao Q, 2009, ONCOL REP, V22, P541, DOI 10.3892/or_00000469; Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580	54	47	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					842	850		10.1038/onc.2013.18	http://dx.doi.org/10.1038/onc.2013.18			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23416981	Green Accepted			2022-12-17	WOS:000331626900005
J	Patel, RA; Liu, Y; Wang, B; Li, R; Sebti, SM				Patel, R. A.; Liu, Y.; Wang, B.; Li, R.; Sebti, S. M.			Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities	ONCOGENE			English	Article						RKI-18; ROCK1; ROCK2; invasion; migration; MLC-2	RHO-ASSOCIATED KINASE; BREAST-CANCER CELLS; TUMOR-CELLS; GTPASES; PROTEINS; OVEREXPRESSION; INVOLVEMENT; PROGRESSION; EXPRESSION; DISEASE	ROCK1 and ROCK2 mediate important processes such as cell migration, invasion and metastasis, making them good targets for the development of antitumor agents. Recently, using a fragment-based approach and X-ray crystallography, we reported on the design and synthesis of novel Rho-kinase inhibitors (RKIs). Here, we selected a pair of RKIs, the closely related structural analogs RKI-18 (potent; IC50 values of 397 nM (ROCK1) and 349 nM (ROCK2)) and RKI-11 (weak/inactive; IC50 values of 38 mu M (ROCK1) and 45 mu M (ROCK2)), as chemical probes and determined their effects on cytoskeleton organization, signaling, apoptosis, anchorage-dependent and independent growth, migration and invasion. RKI-18 but not RKI-11 suppresses potently the phosphorylation of the ROCK substrate myosin light chain 2 (MLC2) in intact human breast, lung, colon and prostate cancer cells. Furthermore, RKI-18 is highly selective at decreasing the levels of P-MLC2 over those of P-Akt, P-S6 and P-Erk 1/2. RKI-18 suppresses ROCK-mediated actin fiber formation, following stimulation with LPA as well as p21-activated kinase (PAK)-mediated lamellipodia and filopodia formation following bradykinin or PDGF stimulation. Furthermore, RKI-18 but not RKI-11 inhibits migration, invasion and anchorage-independent growth of human breast cancer cells. The fact that the active ROCK inhibitor RKI-18, but not the inactive closely related structural analog RKI-11 is effective at suppressing malignant transformation suggests that inhibition of ROCK with RKI-18 results in preventing migration, invasion and anchorage-independent growth. The potential of this class of RKIs as anti-tumor agents warrants further advanced preclinical studies.	[Patel, R. A.; Liu, Y.; Wang, B.; Li, R.; Sebti, S. M.] H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Dept, Tampa, FL 33612 USA; [Sebti, S. M.] Univ S Florida, Dept Oncol Sci, Tampa, FL USA; [Sebti, S. M.] Univ S Florida, Dept Mol Med, Tampa, FL USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Sebti, SM (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Dept, SRB3-DRDIS,12902 Magnolia Dr, Tampa, FL 33612 USA.	said.sebti@moffitt.org			NCI [U19 CA 067771]; NATIONAL CANCER INSTITUTE [P30CA076292, R01CA098473, U19CA067771] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Nan Sun (Moffitt Cancer Center) and the following Moffitt Cancer Center core facilities: the Chemical Biology Core, the Analytical Microscopy Core and Comparative Medicine Core facility. This work was supported by NCI grant U19 CA 067771.	Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Balasis ME, 2011, CLIN CANCER RES, V17, P2852, DOI 10.1158/1078-0432.CCR-10-2544; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Burbelo P, 2004, BREAST CANCER RES TR, V84, P43, DOI 10.1023/B:BREA.0000018422.02237.f9; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Imamura F, 2000, JPN J CANCER RES, V91, P811, DOI 10.1111/j.1349-7006.2000.tb01018.x; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kleer CG, 2002, AM J PATHOL, V160, P579, DOI 10.1016/S0002-9440(10)64877-8; Lane J, 2008, INT J ONCOL, V33, P585, DOI 10.3892/ijo_00000044; Li B, 2006, FEBS LETT, V580, P4252, DOI 10.1016/j.febslet.2006.06.056; Li RS, 2012, J MED CHEM, V55, P2474, DOI 10.1021/jm201289r; Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008-5472.CAN-09-1541; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Olson MF, 2008, CURR OPIN CELL BIOL, V20, P242, DOI 10.1016/j.ceb.2008.01.002; Patel RA, 2012, CANCER RES, V72, P5025, DOI 10.1158/0008-5472.CAN-12-0954; Redowicz MJ, 1999, ARCH BIOCHEM BIOPHYS, V364, P122, DOI 10.1006/abbi.1999.1112; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Routhier A, 2010, ONCOL REP, V23, P861, DOI 10.3892/or_00000708; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Scott RW, 2007, J MOL MED, V85, P555, DOI 10.1007/s00109-007-0165-6; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Tang Y, 2008, FRONT BIOSCI-LANDMRK, V13, P759, DOI 10.2741/2718; Vigil D, 2012, CANCER RES, V72, P5338, DOI 10.1158/0008-5472.CAN-11-2373; Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065; Ying H, 2006, MOL CANCER THER, V5, P2158, DOI 10.1158/1535-7163.MCT-05-0440; Yoshioka K, 1999, CANCER RES, V59, P2004; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100; Zicha D, 2003, SCIENCE, V300, P142, DOI 10.1126/science.1082026	33	47	50	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					550	555		10.1038/onc.2012.634	http://dx.doi.org/10.1038/onc.2012.634			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23396364	Green Accepted			2022-12-17	WOS:000331125100003
J	Weingarten-Gabbay, S; Khan, D; Liberman, N; Yoffe, Y; Bialik, S; Das, S; Oren, M; Kimchi, A				Weingarten-Gabbay, S.; Khan, D.; Liberman, N.; Yoffe, Y.; Bialik, S.; Das, S.; Oren, M.; Kimchi, A.			The translation initiation factor DAP5 promotes IRES-driven translation of p53 mRNA	ONCOGENE			English	Article						p53; Delta 40p53; DAP5; IRES; translational control	RIBOSOME ENTRY SITE; ENDOPLASMIC-RETICULUM STRESS; PROGRAMMED CELL-DEATH; MEDIATED TRANSLATION; EXPRESSION ANALYSIS; CASPASE CLEAVAGE; FACTOR 4G; ISOFORMS; IDENTIFICATION; INDUCTION	Translational regulation of the p53 mRNA can determine the ratio between p53 and its N-terminal truncated isoforms and therefore has a significant role in determining p53-regulated signaling pathways. Although its importance in cell fate decisions has been demonstrated repeatedly, little is known about the regulatory mechanisms that determine this ratio. Two internal ribosome entry sites (IRESs) residing within the 5'UTR and the coding sequence of p53 mRNA drive the translation of full-length p53 and Delta 40p53 isoform, respectively. Here, we report that DAP5, a translation initiation factor shown to positively regulate the translation of various IRES containing mRNAs, promotes IRES-driven translation of p53 mRNA. Upon DAP5 depletion, p53 and Delta 40p53 protein levels were decreased, with a greater effect on the N-terminal truncated isoform. Functional analysis using bicistronic vectors driving the expression of a reporter gene from each of these two IRESs indicated that DAP5 preferentially promotes translation from the second IRES residing in the coding sequence. Furthermore, p53 mRNA expressed from a plasmid carrying this second IRES was selectively shifted to lighter polysomes upon DAP5 knockdown. Consequently, Delta 40p53 protein levels and the subsequent transcriptional activation of the 14-3-3 sigma gene, a known target of Delta 40p53, were strongly reduced. In addition, we show here that DAP5 interacts with p53 IRES elements in in vitro and in vivo binding studies, proving for the first time that DAP5 directly binds a target mRNA. Thus, through its ability to regulate IRES-dependent translation of the p53 mRNA, DAP5 may control the ratio between different p53 isoforms encoded by a single mRNA.	[Weingarten-Gabbay, S.; Liberman, N.; Yoffe, Y.; Bialik, S.; Kimchi, A.] Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; [Khan, D.; Das, S.] Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; [Oren, M.] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Indian Institute of Science (IISC) - Bangalore; Weizmann Institute of Science	Kimchi, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, 234 Herzl St, IL-76100 Rehovot, Israel.	adi.kimchi@weizmann.ac.il		Khan, Debjit/0000-0001-5568-3361; Oren, Moshe/0000-0003-4311-7172	Flight Attendant Medical Research Institute; European Union FP7 APO-SYS; Indo French Centre for the Promotion of Advanced Research; Department of Biotechnology, India; Council of Scientific and Industrial Research, India	Flight Attendant Medical Research Institute; European Union FP7 APO-SYS; Indo French Centre for the Promotion of Advanced Research; Department of Biotechnology, India(Department of Biotechnology (DBT) India); Council of Scientific and Industrial Research, India(Council of Scientific & Industrial Research (CSIR) - India)	We gratefully acknowledge Dr Robin Fahraeus and Dr Jean-Christophe Bourdon for the p53 cDNA constructs, the Israel Structure Proteomic Center (ISPC) at the Weizmann Institute for supplying recombinant DAP5 protein and Sylvia Wilder for technical help. This work was supported by grants from the Flight Attendant Medical Research Institute (to AK and MO), the European Union FP7 APO-SYS (to AK), the Indo French Centre for the Promotion of Advanced Research (to SD), the Department of Biotechnology, India (to SD), and a pre-doctoral fellowship from the Council of Scientific and Industrial Research, India (to DK). AK and MO are incumbents of the Helena Rubinstein Chair of Cancer Research and the Andre Lwoff Chair in Molecular Biology, respectively.	Bourougaa K, 2010, MOL CELL, V38, P78, DOI 10.1016/j.molcel.2010.01.041; Candeias MM, 2006, ONCOGENE, V25, P6936, DOI 10.1038/sj.onc.1209996; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Grover R, 2008, CELL CYCLE, V7, P2189, DOI 10.4161/cc.7.14.6271; Grover R, 2011, RNA BIOL, V8, P132, DOI 10.4161/rna.8.1.14260; Henis-Korenblit S, 2002, P NATL ACAD SCI USA, V99, P5400, DOI 10.1073/pnas.082102499; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Herbreteau CH, 2005, NAT STRUCT MOL BIOL, V12, P1001, DOI 10.1038/nsmb1011; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; Lewis SM, 2008, NUCLEIC ACIDS RES, V36, P168, DOI 10.1093/nar/gkm1007; Liberman N, 2008, J MOL BIOL, V383, P539, DOI 10.1016/j.jmb.2008.08.013; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Marash L, 2005, CELL DEATH DIFFER, V12, P554, DOI 10.1038/sj.cdd.4401609; Marash L, 2008, MOL CELL, V30, P447, DOI 10.1016/j.molcel.2008.03.018; Marcel V, 2011, CELL DEATH DIFFER, V18, P1815, DOI 10.1038/cdd.2011.120; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Nevins TA, 2003, J BIOL CHEM, V278, P3572, DOI 10.1074/jbc.M206781200; Ohki R, 2007, CANCER SCI, V98, P189, DOI 10.1111/j.1349-7006.2006.00375.x; Powell DJ, 2008, CELL CYCLE, V7, P950, DOI 10.4161/cc.7.7.5626; Pudi R, 2003, J BIOL CHEM, V278, P12231, DOI 10.1074/jbc.M210287200; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Shaughnessy JD, 1997, GENOMICS, V39, P192, DOI 10.1006/geno.1996.4502; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Warnakulasuriyarachchi D, 2004, J BIOL CHEM, V279, P17148, DOI 10.1074/jbc.M308737200; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321; Yang DQ, 2006, ONCOGENE, V25, P4613, DOI 10.1038/sj.onc.1209483; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801	30	47	48	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					611	618		10.1038/onc.2012.626	http://dx.doi.org/10.1038/onc.2012.626			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23318444				2022-12-17	WOS:000331125100009
J	Thu, KL; Radulovich, N; Becker-Santos, DD; Pikor, LA; Pusic, A; Lockwood, WW; Lam, WL; Tsao, MS				Thu, K. L.; Radulovich, N.; Becker-Santos, D. D.; Pikor, L. A.; Pusic, A.; Lockwood, W. W.; Lam, W. L.; Tsao, M-S			SOX15 is a candidate tumor suppressor in pancreatic cancer with a potential role in Wnt/beta-catenin signaling	ONCOGENE			English	Article						SOX15; integrative genomics; tumor suppressor; pancreatic cancer; Wnt pathway	FREQUENT EPIGENETIC INACTIVATION; PROMOTER METHYLATION; WNT PATHWAY; GENE; MUTATIONS; ONCOGENE; BIOLOGY; PROLIFERATION; ANTAGONISTS; EVOLUTION	Pancreatic cancer is among the top five deadliest cancers in developed countries. Better knowledge of the molecular mechanisms contributing to its tumorigenesis is imperative to improve patient prognosis. Identification of novel tumor suppressor genes (TSGs) in pancreatic cancer will reveal new mechanisms of pathway deregulation and will ultimately help improve our understanding of this aggressive disease. According to Knudson's two-hit model, TSGs are classically disrupted by two concerted genetic events. In this study, we combined DNA methylation profiling with copy number and mRNA expression profiling to identify novel TSGs in a set of 20 pancreatic cancer cell lines. These data sets were integrated for each of similar to 12000 genes in each cell line enabling the elucidation of those genes that undergo DNA hypermethylation, copy-number loss and mRNA downregulation simultaneously in multiple cell lines. Using this integrative genomics strategy, we identified SOX15 (sex determining region Y-box 15) as a candidate TSG in pancreatic cancer. Expression of SOX15 in pancreatic cancer cell lines with undetectable expression resulted in reduced viability of cancer cells both in vitro and in vivo demonstrating its tumor suppressive capability. We also found reduced expression, homozygous deletion and aberrant DNA methylation of SOX15 in clinical pancreatic tumor data sets. Furthermore, we deduced a novel role for SOX15 in suppressing the Wnt/b-catenin signaling pathway, which we hypothesize is a pathway through which SOX15 may exert its tumor suppressive effects in pancreatic cancer.	[Thu, K. L.; Becker-Santos, D. D.; Pikor, L. A.; Pusic, A.; Lockwood, W. W.; Lam, W. L.] BC Canc Res Ctr, Vancouver, BC, Canada; [Radulovich, N.; Tsao, M-S] Univ Toronto, Ontario Canc Inst, Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M5S 1A1, Canada; [Radulovich, N.; Tsao, M-S] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	British Columbia Cancer Agency; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Lam, WL (corresponding author), BC Canc Res Ctr, Vancouver, BC, Canada.	wanlam@bccrc.ca; Ming.Tsao@uhn.ca	Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022	Tsao, Ming Sound/0000-0002-9160-5405; Thu, Kelsie/0000-0001-9262-7238	Vanier Canada Graduate Scholarships; University of British Columbia 4YF scholarship; CIHR Jean-Francois Saint Denis Fellowship in Cancer Research; Canadian Cancer Society Research Institute [700809]; Canadian Institutes for Health Research; PMH Foundation; Ontario Ministry of Health and Long Term Care; M Qasim Choksi Chair in Lung Cancer Translational Research	Vanier Canada Graduate Scholarships; University of British Columbia 4YF scholarship; CIHR Jean-Francois Saint Denis Fellowship in Cancer Research(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); PMH Foundation; Ontario Ministry of Health and Long Term Care(Ministry of Health and Long-Term Care, Ontario); M Qasim Choksi Chair in Lung Cancer Translational Research	KLT, NR and LAP are supported by Vanier Canada Graduate Scholarships, DDBS by University of British Columbia 4YF scholarship and WWL by a CIHR Jean-Francois Saint Denis Fellowship in Cancer Research. This work was supported by grants from the Canadian Cancer Society Research Institute (#700809), the Canadian Institutes for Health Research, PMH Foundation and Ontario Ministry of Health and Long Term Care. MST is the M Qasim Choksi Chair in Lung Cancer Translational Research.	Andreeva AV, 2010, GENE CHROMOSOME CANC, V49, P775, DOI 10.1002/gcc.20787; Bachman KE, 1999, CANCER RES, V59, P798; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Beranger F, 2000, J BIOL CHEM, V275, P16103, DOI 10.1074/jbc.275.21.16103; Berger AH, 2011, NATURE, V476, P163, DOI 10.1038/nature10275; Bernard P, 2010, INT J BIOCHEM CELL B, V42, P400, DOI 10.1016/j.biocel.2009.10.017; Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706; Birnbaum DJ, 2011, GENE CHROMOSOME CANC, V50, P456, DOI 10.1002/gcc.20870; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Coe BP, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq548; di Magliano MP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001155; Dihlmann S, 2005, INT J CANCER, V113, P515, DOI 10.1002/ijc.20609; Drew BA, 2012, BBA-REV CANCER, V1825, P37, DOI 10.1016/j.bbcan.2011.10.002; Du YC, 2009, GASTROENTEROLOGY, V137, P1346, DOI 10.1053/j.gastro.2009.06.041; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Gumz ML, 2007, CLIN CANCER RES, V13, P4740, DOI 10.1158/1078-0432.CCR-07-0143; Gustavsson E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-187; Harada T, 2008, ONCOGENE, V27, P1951, DOI 10.1038/sj.onc.1210832; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hong SM, 2012, CLIN CANCER RES, V18, P700, DOI 10.1158/1078-0432.CCR-11-1718; Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307; Ito M, 2010, INT J BIOCHEM CELL B, V42, P449, DOI 10.1016/j.biocel.2009.10.023; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jia Y, 2010, EPIGENETICS-US, V5, P743, DOI 10.4161/epi.5.8.13104; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Joergensen MT, 2011, PANCREAS, V40, P540, DOI 10.1097/MPA.0b013e3182152fdf; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Khojasteh M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-274; Klarmann GJ, 2008, EPIGENETICS-US, V3, P59, DOI 10.4161/epi.3.2.5899; Kongkham PN, 2010, ONCOGENE, V29, P3017, DOI 10.1038/onc.2010.32; Kormish JD, 2010, DEV DYNAM, V239, P56, DOI 10.1002/dvdy.22046; Lee HJ, 2004, MOL CELL BIOL, V24, P8428, DOI 10.1128/MCB.24.19.8428-8436.2004; Licchesi JDF, 2008, CARCINOGENESIS, V29, P895, DOI 10.1093/carcin/bgn017; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; Lochhead PA, 2012, BIOCHEM SOC T, V40, P251, DOI 10.1042/BST20110663; Lockwood WW, 2012, CLIN CANCER RES, V18, P1936, DOI 10.1158/1078-0432.CCR-11-1431; MacGrogan D, 1996, GENOMICS, V35, P55, DOI 10.1006/geno.1996.0322; Mak AB, 2010, MOL CELL PROTEOMICS, V9, P811, DOI 10.1074/mcp.M000002-MCP201; Mann KM, 2012, P NATL ACAD SCI USA, V109, P5934, DOI 10.1073/pnas.1202490109; McCleary-Wheeler AL, 2012, MOL CARCINOGEN, V51, P25, DOI 10.1002/mc.20827; Medina PP, 2009, HUM MOL GENET, V18, P1343, DOI 10.1093/hmg/ddp034; Meeson AP, 2007, EMBO J, V26, P1902, DOI 10.1038/sj.emboj.7601635; Moon Randall T, 2004, Nat Rev Genet, V5, P691, DOI 10.1038/nrg1427; Morris JP, 2010, NAT REV CANCER, V10, P683, DOI 10.1038/nrc2899; Polakis P, 2012, EMBO J, V31, P2737, DOI 10.1038/emboj.2012.126; Qin YR, 2011, CLIN CANCER RES, V17, P46, DOI 10.1158/1078-0432.CCR-10-1155; Radutovich N, 2008, METHOD ENZYMOL, V439, P1, DOI 10.1016/S0076-6879(07)00401-6; Rajan N, 2011, J PATHOL, V224, P309, DOI 10.1002/path.2896; Rubin JS, 2006, FRONT BIOSCI, V11, P2093, DOI 10.2741/1952; Sakai M, 2004, CANCER SCI, V95, P588, DOI 10.1111/j.1349-7006.2004.tb02491.x; Samuel N, 2012, NAT REV GASTRO HEPAT, V9, P77, DOI 10.1038/nrgastro.2011.215; Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178; Savage J, 2009, STEM CELLS, V27, P1231, DOI 10.1002/stem.57; Simon R, 2007, CANCER INFORM, V3, P11; Singh P, 2011, PANCREAS, V40, P644, DOI 10.1097/MPA.0b013e31821ff741; Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tan AC, 2009, MOL ONCOL, V3, P425, DOI 10.1016/j.molonc.2009.03.004; Tennis MA, 2012, P AM THORAC SOC, V9, P83; Tennis MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032921; Thu KL, 2011, J THORAC ONCOL, V6, P1521, DOI 10.1097/JTO.0b013e3182289479; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Vincent A, 2011, CLIN CANCER RES, V17, P4341, DOI 10.1158/1078-0432.CCR-10-3431; White BD, 2012, GASTROENTEROLOGY, V142, P219, DOI 10.1053/j.gastro.2011.12.001; Wu J, 2011, P NATL ACAD SCI USA, V108, P21188, DOI 10.1073/pnas.1118046108; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yan HT, 2007, MOL CELLS, V24, P323; Yao H, 2011, EXPERT OPIN THER TAR, V15, P873, DOI 10.1517/14728222.2011.577418; Ye YW, 2011, CANCER LETT, V307, P124, DOI 10.1016/j.canlet.2011.03.024; Zhang W, 2008, CANCER RES, V68, P2764, DOI 10.1158/0008-5472.CAN-07-6349	72	47	48	0	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					279	288		10.1038/onc.2012.595	http://dx.doi.org/10.1038/onc.2012.595			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318427				2022-12-17	WOS:000330214000002
J	Ivanova, IA; Vermeulen, JF; Ercan, C; Houthuijzen, JM; Saig, FA; Vlug, EJ; van der Wall, E; van Diest, PJ; Vooijs, M; Derksen, PWB				Ivanova, I. A.; Vermeulen, J. F.; Ercan, C.; Houthuijzen, J. M.; Saig, F. A.; Vlug, E. J.; van der Wall, E.; van Diest, P. J.; Vooijs, M.; Derksen, P. W. B.			FER kinase promotes breast cancer metastasis by regulating alpha(6)- and beta(1)-integrin-dependent cell adhesion and anoikis resistance	ONCOGENE			English	Article						breast cancer; cell adhesion; cell migration; FER kinase; metastasis	BONE-MARROW; N-CADHERIN; CORTACTIN; ACTIVATION; MIGRATION; LINES; GENE; PHOSPHORYLATION; CARCINOMA; INTEGRIN	Metastatic breast cancer cannot be treated successfully. Currently, the targeted therapies for metastatic disease are limited to human epidermal growth factor receptor 2 and hormone receptor antagonists. Understanding the mechanisms of breast cancer growth and metastasis is therefore crucial for the development of new intervention strategies. Here, we show that FER kinase (FER) controls migration and metastasis of invasive human breast cancer cell lines by regulating alpha(6)- and beta(1)-integrin-dependent adhesion. Conversely, the overexpression of FER in non-metastatic breast cancer cells induces pro-invasive features. FER drives anoikis resistance, regulates tumour growth and is necessary for metastasis in a mouse model of human breast cancer. In human invasive breast cancer, high FER expression is an independent prognostic factor that correlates with high-grade basal/triple-negative tumours and worse overall survival, especially in lymph node-negative patients. These findings establish FER as a promising target for the prevention and inhibition of metastatic breast cancer.	[Ivanova, I. A.; Vermeulen, J. F.; Ercan, C.; Houthuijzen, J. M.; Saig, F. A.; Vlug, E. J.; van der Wall, E.; van Diest, P. J.; Vooijs, M.; Derksen, P. W. B.] Univ Med Ctr Utrecht, Dept Pathol, NL-3584 CX Utrecht, Netherlands; [van der Wall, E.] Univ Med Ctr Utrecht, Div Internal Med & Dermatol, NL-3584 CX Utrecht, Netherlands; [Vooijs, M.] Maastricht Univ Med Ctr, Dept Radiat Oncol, Maastricht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Maastricht University; Maastricht University Medical Centre (MUMC)	Vooijs, M (corresponding author), Maastricht Univ Med Ctr 1, Dept Radiat Oncol, Postbox 616-23, NL-6200 Maastricht, Netherlands.	marc.vooijs@maastrichtuniversity.nl; pderksen@umcutrecht.nl	Vooijs, Marc/K-3522-2019; Derksen, Patrick/C-6643-2008	Derksen, Patrick/0000-0003-0732-7762; Houthuijzen, Julia/0000-0003-0404-1961	Aegon Inc.; The Netherlands Organization for Scientific Research Grant [NWO-VIDI 917.96.318]; Terry Fox Foundation [700041]	Aegon Inc.; The Netherlands Organization for Scientific Research Grant; Terry Fox Foundation	We thank N Heisterkamp for providing the pUHG10-3(FER) vector, E Danen and A Sonnenberg for anti-integrin antibodies and L Price for help with the Matrigel assays. Luciferase-expressing MDA-MB-231 cells were a kind gift from G van der Pluijm. We are grateful to C Pfauth, T Westphal and the Netherlands Cancer Institute for providing RAG2<SUP>-/-</SUP>;IL2R gamma c<SUP>-/-</SUP> recipient mice. M van Amersfoort and D van der Giezen are acknowledged for expert technical assistance with the mouse experiments and F Morsink for performing the vimentin IHC staining. We also thank S Huveneers for critically reviewing this manuscript. This research is supported by an unrestricted educational grant from Aegon Inc. and The Netherlands Organization for Scientific Research Grant (NWO-VIDI 917.96.318). IA Ivanova is a Research Fellow of the Terry Fox Foundation (Award #700041).	Allard P, 2000, MOL CELL ENDOCRINOL, V159, P63, DOI 10.1016/S0303-7207(99)00205-1; Arregui C, 2000, J CELL BIOL, V149, P1263, DOI 10.1083/jcb.149.6.1263; Bharadwaj S, 2005, ONCOGENE, V24, P8291, DOI 10.1038/sj.onc.1208993; Braun S, 2001, J CLIN ONCOL, V19, P1468, DOI 10.1200/JCO.2001.19.5.1468; Brew CT, 2009, INT J CANCER, V124, P2294, DOI 10.1002/ijc.24210; Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140; Craig AWB, 2002, MOL CELL BIOL, V22, P6363, DOI 10.1128/MCB.22.18.6363-6374.2002; Craig AWB, 2001, MOL CELL BIOL, V21, P603, DOI 10.1128/MCB.21.2.603-613.2001; Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; El Sayegh TY, 2005, MOL BIOL CELL, V16, P5514, DOI 10.1091/mcbE05-05-0410; Fei F, 2010, BMC BIOCHEM, V11, DOI 10.1186/1471-2091-11-48; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Gimeno R, 2004, BLOOD, V104, P3886, DOI 10.1182/blood-2004-02-0656; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Guo CH, 2011, P NATL ACAD SCI USA, V108, P7968, DOI 10.1073/pnas.1105369108; Heath RJW, 2008, J CELL SCI, V121, P1951, DOI 10.1242/jcs.023895; Hoefnagel LDC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2645; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Itoh T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000393; Ivanova IA, 2006, ONCOGENE, V25, P430, DOI 10.1038/sj.onc.1208999; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; KIM L, 1995, MOL CELL BIOL, V15, P4553; LEONE BA, 1988, AM J CLIN ONCOL-CANC, V11, P618, DOI 10.1097/00000421-198812000-00004; Li HY, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-366; MacGrath SM, 2012, J CELL SCI, V125, P1621, DOI 10.1242/jcs.093781; Mills GB, 2009, J CLIN INVEST, V119, P2123, DOI 10.1172/JCI40256; MIYATA Y, CANC SCI, V104, P681; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Pasder O, 2006, ONCOGENE, V25, P4194, DOI 10.1038/sj.onc.1209695; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; ROSEN PP, 1989, J CLIN ONCOL, V7, P355, DOI 10.1200/JCO.1989.7.3.355; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sangrar W, 2007, MOL CELL BIOL, V27, P6140, DOI 10.1128/MCB.01744-06; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Schackmann RCJ, 2011, J CLIN INVEST, V121, P3176, DOI 10.1172/JCI41695; Sung BH, 2011, CURR BIOL, V21, P1460, DOI 10.1016/j.cub.2011.06.065; van Diest PJ, 2002, BMJ-BRIT MED J, V325, P648, DOI 10.1136/bmj.325.7365.648; Vermeulen JF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037864; Vespa A, 2005, MOL BIOL CELL, V16, P4084, DOI 10.1091/mbc.e05-02-0087; Voisset E, 2010, LEUKEMIA, V24, P721, DOI 10.1038/leu.2009.301; Wei C, 2013, ONCOL LETT, V5, P473, DOI 10.3892/ol.2012.1032; Wetterwald A, 2002, AM J PATHOL, V160, P1143, DOI 10.1016/S0002-9440(10)64934-6; Xu G, 2004, J CELL SCI, V117, P3207, DOI 10.1242/jcs.01174; Yoneyama T, 2012, MOL BIOL CELL, V23, P771, DOI 10.1091/mbc.E11-06-0517; Zirngibl R, 2001, EXP CELL RES, V266, P87, DOI 10.1006/excr.2001.5217; Zoubeidi A, 2009, MOL CANCER RES, V7, P142, DOI 10.1158/1541-7786.MCR-08-0117	54	47	51	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2013	32	50					5582	5592		10.1038/onc.2013.277	http://dx.doi.org/10.1038/onc.2013.277			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272LF	23873028	hybrid, Green Published			2022-12-17	WOS:000328461400003
J	Gupta, A; Jha, S; Engel, DA; Ornelles, DA; Dutta, A				Gupta, A.; Jha, S.; Engel, D. A.; Ornelles, D. A.; Dutta, A.			Tip60 degradation by adenovirus relieves transcriptional repression of viral transcriptional activator EIA	ONCOGENE			English	Article						HAT; Tip60; EIA; adenovirus	DNA-DAMAGE RESPONSE; CELL-CYCLE ARREST; HISTONE ACETYLTRANSFERASE; PROTEIN-VII; ACETYLATION; COMPLEX; E1A; CHROMATIN; P53; TRANSFORMATION	Adenoviruses are linear double-stranded DNA viruses that infect human and rodent cell lines, occasionally transform them and cause tumors in animal models. The host cell challenges the virus in multifaceted ways to restrain viral gene expression and DNA replication, and sometimes even eliminates the infected cells by programmed cell death. To combat these challenges, adenoviruses abrogate the cellular DNA damage response pathway. Tip60 is a lysine acetyltransferase that acetylates histones and other proteins to regulate gene expression, DNA damage response, apoptosis and cell cycle regulation. Tip60 is a bona fide tumor suppressor as mice that are haploid for Tip60 are predisposed to tumors. We have discovered that Tip60 is degraded by adenovirus oncoproteins EIB55K and E4orf6 by a proteasome-mediated pathway. Tip60 binds to the immediate early adenovirus promoter and suppresses adenovirus EIA gene expression, which is a master regulator of adenovirus transcription, at least partly through retention of the virally encoded repressor pVII on this promoter. Thus, degradation of Tip60 by the adenoviral early proteins is important for efficient viral early gene transcription and for changes in expression of cellular genes.	[Gupta, A.; Jha, S.; Dutta, A.] Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; [Engel, D. A.] Univ Virginia, Sch Med, Dept Microbiol, Charlottesville, VA 22908 USA; [Ornelles, D. A.] Wake Forest Sch Med, Dept Microbiol & Immunol, Winston Salem, NC USA	University of Virginia; University of Virginia; Wake Forest University	Dutta, A (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, 1300 Jefferson Pk Ave,Box 800733, Charlottesville, VA 22908 USA.	ad8q@virginia.edu	Jha, Sudhakar/B-2308-2009; Dutta, Anindya/P-3203-2016; Jha, Sudhakar/S-3550-2019	Jha, Sudhakar/0000-0002-5093-4843; Dutta, Anindya/0000-0002-4319-0073	US army Postdoctoral fellowship for breast cancer research [DOD-W81XWH1110687];  [RO1 GM084465]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084465] Funding Source: NIH RePORTER	US army Postdoctoral fellowship for breast cancer research; ; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the members of Dutta laboratory for lively discussions and helpful comments. This work was supported by RO1 GM084465 to AD. AG was supported by US army Postdoctoral fellowship for breast cancer research DOD-W81XWH1110687.	Baker A, 2007, J VIROL, V81, P7034, DOI 10.1128/JVI.00029-07; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Bhoumik A, 2008, J BIOL CHEM, V283, P17605, DOI 10.1074/jbc.M802030200; Blackford AN, 2010, P NATL ACAD SCI USA, V107, P12251, DOI 10.1073/pnas.0914605107; Chen JN, 2007, VIROLOGY, V369, P411, DOI 10.1016/j.virol.2007.08.012; Col E, 2005, EMBO J, V24, P2634, DOI 10.1038/sj.emboj.7600734; Dallaire F, 2009, J VIROL, V83, P5329, DOI 10.1128/JVI.00089-09; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Doyon Y, 2004, CURR OPIN GENET DEV, V14, P147, DOI 10.1016/j.gde.2004.02.009; Ferrari R, 2008, SCIENCE, V321, P1086, DOI 10.1126/science.1155546; Ferrari R, 2009, NAT REV GENET, V10, P290, DOI 10.1038/nrg2539; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055; Horwitz GA, 2008, SCIENCE, V321, P1084, DOI 10.1126/science.1155544; Hu YF, 2009, DEV DYNAM, V238, P2912, DOI 10.1002/dvdy.22110; Ikura T, 2007, MOL CELL BIOL, V27, P7028, DOI 10.1128/MCB.00579-07; Jha S, 2008, MOL CELL BIOL, V28, P2690, DOI 10.1128/MCB.01983-07; Jha S, 2010, MOL CELL, V38, P700, DOI 10.1016/j.molcel.2010.05.020; Johnson JS, 2004, J VIROL, V78, P6459, DOI 10.1128/JVI.78.12.6459-6468.2004; Karen KA, 2011, J VIROL, V85, P4135, DOI 10.1128/JVI.02540-10; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Li RF, 2011, CELL HOST MICROBE, V10, P390, DOI 10.1016/j.chom.2011.08.013; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Nevels M, 2001, J VIROL, V75, P3089, DOI 10.1128/JVI.75.7.3089-3094.2001; Niller HH, 2011, CANCER LETT, V305, P200, DOI 10.1016/j.canlet.2010.08.007; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Reitsma JM, 2011, CELL HOST MICROBE, V9, P103, DOI 10.1016/j.chom.2011.01.006; Ruthenburg AJ, 2007, NAT REV MOL CELL BIO, V8, P983, DOI 10.1038/nrm2298; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sapountzi V, 2006, INT J BIOCHEM CELL B, V38, P1496, DOI 10.1016/j.biocel.2006.03.003; Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874; Sha JF, 2010, J VIROL, V84, P4050, DOI 10.1128/JVI.02131-09; Shamay M, 2012, J VIROL, V86, P5179, DOI 10.1128/JVI.00169-12; Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Sun YL, 2007, MOL CELL BIOL, V27, P8502, DOI 10.1128/MCB.01382-07; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0	44	47	49	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5017	5025		10.1038/onc.2012.534	http://dx.doi.org/10.1038/onc.2012.534			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23178490	Green Accepted, Green Submitted			2022-12-17	WOS:000325937900003
J	Rebocho, AP; Marais, R				Rebocho, A. P.; Marais, R.			ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers	ONCOGENE			English	Article						ARAF; BRAF; CRAF; protein complexes; paradoxical activation	B-RAF; C-RAF; HUMAN CANCER; WILD-TYPE; KINASE-ACTIVITY; ONCOGENIC RAS; MUTATIONS; MELANOMA; PHOSPHORYLATION; ACTIVATION	The RAF proteins are cytosolic protein kinases that regulate cell responses to extracellular signals. There are three RAF proteins in cells, ARAF, BRAF and CRAF, and recent studies have shown that the formation of complexes by these different isoforms has an important role in their activation, particularly in response to RAF inhibitors. Here, we investigated the role of ARAF in cancer cell signaling and examined the role of ARAF in mediating paradoxical activation of the MAPK pathway in cells treated with RAF inhibitors. We show that two mutations that occur in ARAF in cancer inactivate the kinase. We also show that ARAF is not functionally redundant with CRAF and cannot substitute for CRAF downstream of RAS. We further show that ARAF binds to and is activated by BRAF and that ARAF also forms complexes with CRAF. Critically, ARAF seems to stabilize BRAF: CRAF complexes in cells treated with RAF inhibitors and thereby regulate cell signaling in a subtle manner to ensure signaling efficiency.	[Rebocho, A. P.; Marais, R.] Inst Canc Res, Div Canc Biol, Signal Transduct Team, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Marais, R (corresponding author), Univ Manchester, Paterson Inst Canc Res, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	Richard.Marais@picr.man.ac.uk		Marais, Richard/0000-0001-7484-4183	Fundacao para a Ciencia e Tecnologia [SFRH/BD/15904/2005]; Institute of Cancer Research; Cancer Research UK [C107/A10433]; Cancer Research UK [17240, 19279] Funding Source: researchfish	Fundacao para a Ciencia e Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission); Institute of Cancer Research; Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	This work was funded by Fundacao para a Ciencia e Tecnologia (SFRH/BD/15904/2005), the Institute of Cancer Research and Cancer Research UK (Ref: C107/A10433). We thank Professor Caroline Springer for providing sorafenib and PD184352.	Blasco RB, 2011, CANCER CELL, V19, P652, DOI 10.1016/j.ccr.2011.04.002; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Emuss V, 2005, CANCER RES, V65, P9719, DOI 10.1158/0008-5472.CAN-05-1683; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hu JC, 2011, P NATL ACAD SCI USA, V108, P6067, DOI 10.1073/pnas.1102554108; Karreth FA, 2011, CANCER DISCOV, V1, P128, DOI 10.1158/2159-8290.CD-10-0044; Lee JW, 2005, APMIS, V113, P54, DOI 10.1111/j.1600-0463.2005.apm1130108.x; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; McKay MM, 2011, CURR BIOL, V21, P563, DOI 10.1016/j.cub.2011.02.033; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Moretti S, 2009, BBA-MOL CELL RES, V1793, P1634, DOI 10.1016/j.bbamcr.2009.09.001; Packer LM, 2011, CANCER CELL, V20, P715, DOI 10.1016/j.ccr.2011.11.004; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429	28	47	48	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 27	2013	32	26					3207	3212		10.1038/onc.2012.330	http://dx.doi.org/10.1038/onc.2012.330			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22926515				2022-12-17	WOS:000321004600011
J	Sorokin, AV; Chen, J				Sorokin, A. V.; Chen, J.			MEMO1, a new IRS1-interacting protein, induces epithelial-mesenchymal transition in mammary epithelial cells	ONCOGENE			English	Article						MEMO1; IRS1; EMT; Snail1; breast cancer	INSULIN-RECEPTOR SUBSTRATE-1; NF-KAPPA-B; PLECKSTRIN-HOMOLOGY DOMAIN; GLYCOGEN-SYNTHASE KINASE-3; HUMAN PANCREATIC-CANCER; GROWTH-FACTOR RECEPTOR; E-CADHERIN; BREAST-CANCER; IRS PROTEINS; SIGNAL-TRANSDUCTION	MEMO1 (mediator of ErbB2-driven cell motility 1) regulates HER2-dependent cell migration. Increased MEMO1 expression is associated with cancer aggressiveness. Here, we found that MEMO1 is also involved in breast carcinogenesis via regulating insulin-like growth factor-I receptor-dependent signaling events. We showed that MEMO1 binds to insulin receptor substrate 1, activates the downstream PI3K/Akt signaling pathway, leads to upregulation of Snail1 and thereby triggers the epithelial-mesenchymal transition (EMT) program. In addition, MEMO1 overexpression is accompanied by growth factor-independent proliferation, anchorage-independent growth in soft agar, and enhanced metastatic potential. Together, these findings suggest that MEMO1 acts as an oncogene and is a potential therapeutic target for cancer treatment.	[Sorokin, A. V.; Chen, J.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Chen, J (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	jchen8@mdanderson.org			Era of Hope Research award [W81XWH-09-1-0409]; Department of Defense [W81XWH-05-1-0470]; MD Anderson's Cancer Center Support Grant [CA016672]	Era of Hope Research award; Department of Defense(United States Department of Defense); MD Anderson's Cancer Center Support Grant	We thank all our colleagues in the Chen laboratory for insightful discussions and technical assistance. We thank Dr Douglas Yee at the University of Minnesota for sharing hIRS2 cDNA and Dr Cosima Baldari at the University of Siena (Italy) for sharing ShcA(p66) cDNA. This work was supported in part by an Era of Hope Research award to JC (W81XWH-09-1-0409). JC is also a recipient of an Era of Hope Scholar award from the Department of Defense (W81XWH-05-1-0470). This work was supported by MD Anderson's Cancer Center Support Grant (CA016672).	Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Backer JM, 1997, EUR J BIOCHEM, V245, P91, DOI 10.1111/j.1432-1033.1997.t01-1-00091.x; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bergmann U, 1996, BIOCHEM BIOPH RES CO, V220, P886, DOI 10.1006/bbrc.1996.0500; Boissan M, 2005, AM J PATHOL, V167, P869, DOI 10.1016/S0002-9440(10)62058-5; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Cantarini MC, 2006, HEPATOLOGY, V44, P446, DOI 10.1002/hep.21272; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dearth RK, 2006, MOL CELL BIOL, V26, P9302, DOI 10.1128/MCB.00260-06; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Del Valle L, 2002, CLIN CANCER RES, V8, P1822; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Fagiani E, 2007, CANCER RES, V67, P3064, DOI 10.1158/0008-5472.CAN-06-2301; Gibson SL, 2007, CELL CYCLE, V6, P631, DOI 10.4161/cc.6.6.3987; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Hanke S, 2009, MOL CELL PROTEOMICS, V8, P519, DOI 10.1074/mcp.M800407-MCP200; Hannafon BN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2839; Hellawell GO, 2002, CANCER RES, V62, P2942; Hemi R, 2002, J BIOL CHEM, V277, P8961, DOI 10.1074/jbc.M109391200; Hoang CD, 2004, CANCER RES, V64, P7479, DOI 10.1158/0008-5472.CAN-04-1898; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Kalinina T, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-295; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim HJ, 2007, MOL CELL BIOL, V27, P3165, DOI 10.1128/MCB.01315-06; Kornmann M, 1998, CANCER RES, V58, P4250; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mardilovich K, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-14; Marone R, 2004, NAT CELL BIOL, V6, P515, DOI 10.1038/ncb1134; Meira M, 2009, J CELL SCI, V122, P787, DOI 10.1242/jcs.032094; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pelicci G, 1996, ONCOGENE, V13, P633; Qiu C, 2008, J BIOL CHEM, V283, P2734, DOI 10.1074/jbc.M703523200; Ravikumar S, 2007, CANCER RES, V67, P9266, DOI 10.1158/0008-5472.CAN-07-2088; Rocha RL, 1997, CLIN CANCER RES, V3, P103; Sabbah M, 2008, DRUG RESIST UPDATE, V11, P123, DOI 10.1016/j.drup.2008.07.001; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; Sorokin AV, 2005, EMBO J, V24, P3602, DOI 10.1038/sj.emboj.7600830; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Szabolcs M, 2009, AM J PATHOL, V174, P276, DOI 10.2353/ajpath.2009.080086; Werner H, 2000, CELL MOL LIFE SCI, V57, P932, DOI 10.1007/PL00000735; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; White MF, 2006, CAN J PHYSIOL PHARM, V84, P725, DOI 10.1139/Y06-008; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Zaoui K, 2008, J CELL BIOL, V183, P401, DOI 10.1083/jcb.200805107; Zaoui K, 2010, P NATL ACAD SCI USA, V107, P18517, DOI 10.1073/pnas.1000975107; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	57	47	47	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 27	2013	32	26					3130	3138		10.1038/onc.2012.327	http://dx.doi.org/10.1038/onc.2012.327			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22824790				2022-12-17	WOS:000321004600003
J	Ward, Y; Lake, R; Martin, PL; Killian, K; Salerno, P; Wang, T; Meltzer, P; Merino, M; Cheng, SY; Santoro, M; Garcia-Rostan, G; Kelly, K				Ward, Y.; Lake, R.; Martin, P. L.; Killian, K.; Salerno, P.; Wang, T.; Meltzer, P.; Merino, M.; Cheng, S-Y; Santoro, M.; Garcia-Rostan, G.; Kelly, K.			CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model	ONCOGENE			English	Article						CD97; LPAR; thyroid cancer; metastasis; vascular invasion; anaplastic	LYSOPHOSPHATIDIC ACID; MAMMARY TUMORIGENESIS; TUMOR PROGRESSION; HORMONE RECEPTOR; EXPRESSION; AUTOTAXIN; INVASION; 7-TRANSMEMBRANE; METASTASIS; CARCINOMA	CD97, a member of the adhesion family of G-protein-coupled receptors (GPCRs), complexes with and potentiates lysophosphatidic acid (LPA) receptor signaling to the downstream effector RHOA. We show here that CD97 was expressed in a majority of thyroid cancers but not normal thyroid epithelium and that the level of CD97 expression was further elevated with progression to poorly differentiated and undifferentiated carcinoma. Intratumoral progression also showed that CD97 expression correlates with invasiveness and dedifferentiation. To determine the functional role of CD97, we produced a transgenic model of thyroglobulin promoter-driven CD97 expression. Transgenic CD97 in combination with Thrb(PV), an established mouse model of thyroid follicular cell carcinogenesis, significantly increased the occurrence of vascular invasion and lung metastasis. Expression of transgenic CD97 in thyroid epithelium led to elevated ERK phosphorylation and increased numbers of Ki67 + cells in developing tumors. In addition, tumor cell cultures derived from CD97 transgenic as compared with non-transgenic mice demonstrated enhanced, constitutive and LPA-stimulated ERK activation. In human thyroid cancer cell lines, CD97 depletion reduced RHO-GTP and decreased LPA-stimulated invasion but not EGF-stimulated invasion, further suggesting that CD97 influences an LPA-associated mechanism of progression. Consistent with the above, CD97 expression in human thyroid cancers correlated with LPA receptor and markers of aggressiveness including Ki67 and pAKT. This study shows an autonomous effect of CD97 on thyroid cancer progression and supports the investigation of this GPCR as a therapeutic target for these cancers.	[Ward, Y.; Lake, R.; Martin, P. L.; Kelly, K.] NCI, Cell & Canc Biol Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Killian, K.; Meltzer, P.] NCI, Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Salerno, P.] NCI, Med Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Wang, T.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; [Merino, M.] NCI, Pathol Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Cheng, S-Y] NCI, Mol Biol Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Santoro, M.] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Naples, Italy; [Garcia-Rostan, G.] Univ Valladolid, Spanish Res Council, Inst Biol & Mol Genet, Valladolid, Spain	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); The Wistar Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Naples Federico II; Universidad de Valladolid	Kelly, K (corresponding author), NCI, Cell & Canc Biol Branch, Ctr Canc Res, Bldg 37 Room 1068, Bethesda, MD 20892 USA.	kellyka@mail.nih.gov	Rostan, Ginesa Garcia/E-4093-2018	Rostan, Ginesa Garcia/0000-0002-9238-1263	Intramural Research Program; Center for Cancer Research; National Cancer Institute; Programa Ramon y Cajal-Ministerio de Ciencia e Innovacion; Social EU Funds; Universidad de Valladolid, Spain; NATIONAL CANCER INSTITUTE [ZIASC009389, ZIABC011191, ZIABC011091] Funding Source: NIH RePORTER	Intramural Research Program; Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Programa Ramon y Cajal-Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Social EU Funds; Universidad de Valladolid, Spain; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Intramural Research Program, Center for Cancer Research, National Cancer Institute and the Programa Ramon y Cajal-Ministerio de Ciencia e Innovacion, Social EU Funds, Universidad de Valladolid, Spain. We acknowledge Barbara J Taylor, Subhadra Banerjee, William G Telford, and Veena Kapoor of the CCR FACS Core Facilities and Christopher D Heger of the CCR Antibody and Protein Purification Unit for their excellent technical support. We thank Drs Cameselle-Teijeiro, X Matias-Guiu, A Herrero and M Fresno-Forcelledo for providing human PDC and UC samples.	Adeniran AJ, 2006, AM J SURG PATHOL, V30, P216, DOI 10.1097/01.pas.0000176432.73455.1b; Aust G, 2002, AM J CLIN PATHOL, V118, P699; Cheng SY, 2011, ONCOGENE; DeLellis RA, 2004, PATHOLOGY GENETICS T; Gray JX, 1996, J IMMUNOL, V157, P5438; Guo R, 2006, ENDOCRINOLOGY, V147, P4883, DOI 10.1210/en.2005-1635; Gupte R, 2011, CHEMMEDCHEM, V6, P922, DOI 10.1002/cmdc.201000425; Horak CE, 2007, CANCER RES, V67, P11751, DOI 10.1158/0008-5472.CAN-07-3175; Jonkers J, 2009, CANCER CELL, V15, P457, DOI 10.1016/j.ccr.2009.05.003; Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997; Kehlen A, 2004, INT J CANCER, V109, P833, DOI 10.1002/ijc.20022; Kjellman P, 2003, THYROID, V13, P371, DOI 10.1089/105072503321669866; Kojic SL, 2011, EXPERT REV ANTICANC, V11, P387, DOI [10.1586/ERA.10.179, 10.1586/era.10.179]; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Lagerstrom MC, 2008, NAT REV DRUG DISCOV, V7, P339, DOI 10.1038/nrd2518; Lin ME, 2010, PROSTAG OTH LIPID M, V91, P130, DOI 10.1016/j.prostaglandins.2009.02.002; Lin SB, 2009, GASTROENTEROLOGY, V136, P1711, DOI 10.1053/j.gastro.2009.01.002; Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027; Loberg RD, 2005, UROLOGY, V66, P1321, DOI 10.1016/j.urology.2005.06.094; MEIER CA, 1993, J CLIN INVEST, V92, P1986, DOI 10.1172/JCI116793; Mustafa T, 2005, CANCER EPIDEM BIOMAR, V14, P108; Nagaiah G, 2011, J ONCOL, V2011, DOI 10.1155/2011/542358; Nikiforov YE, 2011, MODERN PATHOL, V24, pS34, DOI 10.1038/modpathol.2010.167; Saji M, 2011, ONCOGENE, V30, P4307, DOI 10.1038/onc.2011.136; Sipos JA, 2011, CLIN ONCOL-UK, V22, P395; Sobrinho-Simoes M, 2011, DIAGN HISTOPATHOL, V17, P114, DOI DOI 10.1016/J.MPDHP.2010.12.001; Steinert M, 2002, AM J PATHOL, V161, P1657, DOI 10.1016/S0002-9440(10)64443-4; Stortelers C, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-387; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Ward Y, 2011, CANCER RES, V71, P7301, DOI 10.1158/0008-5472.CAN-11-2381; Wiseman SM, 2003, HEAD NECK-J SCI SPEC, V25, P662, DOI 10.1002/hed.10277; Ying H, 2003, CARCINOGENESIS, V24, P1467, DOI 10.1093/carcin/bgg111; Yona S, 2008, TRENDS BIOCHEM SCI, V33, P491, DOI 10.1016/j.tibs.2008.07.005	33	47	48	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2726	2738		10.1038/onc.2012.301	http://dx.doi.org/10.1038/onc.2012.301			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22797060	Bronze, Green Accepted			2022-12-17	WOS:000319808000004
J	Gomez-Casares, MT; Garcia-Alegria, E; Lopez-Jorge, CE; Ferrandiz, N; Blanco, R; Alvarez, S; Vaque, JP; Bretones, G; Caraballo, JM; Sanchez-Bailon, P; Delgado, MD; Martin-Perez, J; Cigudosa, JC; Leon, J				Gomez-Casares, M. T.; Garcia-Alegria, E.; Lopez-Jorge, C. E.; Ferrandiz, N.; Blanco, R.; Alvarez, S.; Vaque, J. P.; Bretones, G.; Caraballo, J. M.; Sanchez-Bailon, P.; Delgado, M. D.; Martin-Perez, J.; Cigudosa, J. C.; Leon, J.			MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1)	ONCOGENE			English	Article						Myc; imatinib; dasatinib; p27; chronic myeloid leukemia; differentiation	DEPENDENT KINASE INHIBITOR; BCR-ABL; C-MYC; ERYTHROID-DIFFERENTIATION; DEGRADATION; P27; EXPRESSION; MECHANISMS; SKP2; ASSOCIATION	Chronic myeloid leukemia (CML) progresses from a chronic to a blastic phase where the leukemic cells are proliferative and undifferentiated. The CML is nowadays successfully treated with BCR-ABL kinase inhibitors as imatinib and dasatinib. In the CML-derived K562 cell line, low concentrations of imatinib induce proliferative arrest and erythroid differentiation. We found that imatinib upregulated the cell cycle inhibitor p27(KIP1) (p27) in a time- and -concentration dependent manner, and that the extent of imatinib-mediated differentiation was severely decreased in cells with depleted p27. MYC (c-Myc) is a transcription factor frequently deregulated in human cancer. MYC is overexpressed in untreated CML and is associated to poor response to imatinib. Using K562 sublines with conditional MYC expression (induced by Zn2+ or activated by 4-hydroxy-tamoxifen) we show that MYC prevented the erythroid differentiation induced by imatinib and dasatinib. The differentiation inhibition is not due to increased proliferation of MYC-expressing clones or enhanced apoptosis of differentiated cells. As p27 overexpression is reported to induce erythroid differentiation in K562, we explored the effect of MYC on imatinib-dependent induction of p27. We show that MYC abrogated the imatinib-induced upregulation of p27 concomitantly with the differentiation inhibition, suggesting that MYC inhibits differentiation by antagonizing the imatinib-mediated upregulation of p27. This effect occurs mainly by p27 protein destabilization. This was in part due to MYC-dependent induction of SKP2, a component of the ubiquitin ligase complex that targets p27 for degradation. The results suggest that, although MYC deregulation does not directly confer resistance to imatinib, it might be a factor that contributes to progression of CML through the inhibition of differentiation. Oncogene (2013) 32, 2239-2246; doi:10.1038/onc.2012.246; published online 18 June 2012	[Gomez-Casares, M. T.; Lopez-Jorge, C. E.] Hosp Univ Dr Negrin, Serv Hematol, Las Palmas Gran Canaria, Spain; [Gomez-Casares, M. T.; Lopez-Jorge, C. E.] Hosp Univ Dr Negrin, Unidad Invest, Las Palmas Gran Canaria, Spain; [Garcia-Alegria, E.; Ferrandiz, N.; Blanco, R.; Vaque, J. P.; Bretones, G.; Caraballo, J. M.; Delgado, M. D.; Leon, J.] Univ Cantabria CSIC SODERCAN, Inst Biomed & Biotecnol Cantabria IBBTEC, Grp Transcript Control & Canc, Dept Biol Mol,Fac Med, Santander 39011, Cantabria, Spain; [Alvarez, S.; Cigudosa, J. C.] CNIO, Human Canc Genet Program, Madrid, Spain; [Sanchez-Bailon, P.; Martin-Perez, J.] CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC); Centro Nacional de Investigaciones Oncologicas (CNIO); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Leon, J (corresponding author), Univ Cantabria CSIC SODERCAN, Inst Biomed & Biotecnol Cantabria IBBTEC, Grp Transcript Control & Canc, Dept Biol Mol,Fac Med, Avda Cardenal Herrera Oria S-N, Santander 39011, Cantabria, Spain.	leonj@unican.es	Leon, Javier/K-4615-2014; Vaqué, José P/H-8413-2015; Martin-Perez, Jorge/A-3522-2008; Ferrandiz-Diaz, Nuria/V-4071-2017; Cigudosa, Juan C/E-4105-2016; CASARES, MARIA TERESA GOMEZ/R-6060-2018; Bretones, Gabriel/AAB-4637-2021; ALEGRIA, EVA GARCIA/O-3498-2018; Delgado, M. Dolores/K-9056-2014	Vaqué, José P/0000-0002-3913-2495; Martin-Perez, Jorge/0000-0002-2292-0057; Ferrandiz-Diaz, Nuria/0000-0002-7410-3470; CASARES, MARIA TERESA GOMEZ/0000-0003-0505-5126; Bretones, Gabriel/0000-0002-1521-5544; ALEGRIA, EVA GARCIA/0000-0003-4159-0206; Delgado, M. Dolores/0000-0003-4682-4040; Leon, Javier/0000-0001-5803-0112	Fundacion Mutua Madrilena;  [SAF11-23796];  [ISCIII-RETIC RD06/0020/0017];  [FIS 11/00397];  [SAF09-09254];  [FIS08-0878];  [FIS08-0440]	Fundacion Mutua Madrilena(Instituto de Salud Carlos III); ; ; ; ; ; 	We thank Pilar Frade, Maria Aramburu and Guillermo Santana for technical assistance, Robert Eisenman, Theodore Lee and Robert Sclafani for constructs, and M Teresa Molero and Carlos Richard for useful comments on the manuscript. Funding for this work was provided by grants SAF11-23796 and ISCIII-RETIC RD06/0020/0017 to JL, FIS 11/00397 to MDD, SAF09-09254 and Fundacion Mutua Madrilena to JMP, FIS08-0878 to SA and FIS08-0440 to JCC.	Acosta JC, 2008, MOL CELL BIOL, V28, P7286, DOI 10.1128/MCB.00752-08; Agarwal A, 2008, BLOOD, V112, P1960, DOI 10.1182/blood-2007-09-113860; Albajar M, 2008, CANCER LETT, V270, P328, DOI 10.1016/j.canlet.2008.05.024; Albajar M, 2011, MOL CANCER RES, V9, P564, DOI 10.1158/1541-7786.MCR-10-0356; Andreu EJ, 2005, CANCER RES, V65, P3264, DOI 10.1158/0008-5472.CAN-04-1357; Bretones G, 2011, J BIOL CHEM, V286, P9815, DOI 10.1074/jbc.M110.165977; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen JY, 2009, LEUKEMIA RES, V33, P1520, DOI 10.1016/j.leukres.2009.03.007; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; DELGADO MD, 1995, ONCOGENE, V10, P1659; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; Gomez-Casares MT, 2004, HAEMATOLOGICA, V89, P241; GOMEZCASARES MT, 1993, LEUKEMIA, V7, P1824; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; Jonuleit T, 2000, BLOOD, V96, P1933, DOI 10.1182/blood.V96.5.1933.h8001933_1933_1939; Kantarjian HM, 2011, CLIN CANCER RES, V17, P1674, DOI 10.1158/1078-0432.CCR-10-2922; Kavalerchik E, 2008, J CLIN ONCOL, V26, P2911, DOI 10.1200/JCO.2008.17.5745; Kossatz U, 2004, GENE DEV, V18, P2602, DOI 10.1101/gad.321004; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; Leon J, 2009, CELL CYCLE, V8, P1148, DOI 10.4161/cc.8.8.8126; Lerga A, 1999, CELL GROWTH DIFFER, V10, P639; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Melo JV, 2007, NAT REV CANCER, V7, P441, DOI 10.1038/nrc2147; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Munoz-Alonso MJ, 2005, J BIOL CHEM, V280, P18120, DOI 10.1074/jbc.M500758200; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; O'Dwyer ME, 2002, ANNU REV MED, V53, P369, DOI 10.1146/annurev.med.53.082901.103853; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Quintas-Cardama A, 2009, BLOOD, V113, P1619, DOI 10.1182/blood-2008-03-144790; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; ROWLEY PT, 1981, EXP HEMATOL, V9, P32; Roy S, 2008, CELL CYCLE, V7, P1828, DOI 10.4161/cc.7.12.6024; Rubbi L, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001314; Savona M, 2008, NAT REV CANCER, V8, P341, DOI 10.1038/nrc2368; Schenone S, 2010, EXPERT OPIN INV DRUG, V19, P931, DOI 10.1517/13543784.2010.499898; Shah NP, 2008, CANCER CELL, V14, P485, DOI 10.1016/j.ccr.2008.11.001; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Wu J, 2008, J NATL CANCER I, V100, P926, DOI 10.1093/jnci/djn188	47	47	48	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2239	2246		10.1038/onc.2012.246	http://dx.doi.org/10.1038/onc.2012.246			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22710719				2022-12-17	WOS:000318062800013
J	Liu, Z; Zanata, SM; Kim, J; Peterson, MA; Di Vizio, D; Chirieac, LR; Pyne, S; Agostini, M; Freeman, MR; Loda, M				Liu, Z.; Zanata, S. M.; Kim, J.; Peterson, M. A.; Di Vizio, D.; Chirieac, L. R.; Pyne, S.; Agostini, M.; Freeman, M. R.; Loda, M.			The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation	ONCOGENE			English	Article						USP2a; DUB; EGFR; endocytosis	EPIDERMAL-GROWTH-FACTOR; DEUBIQUITINATING ENZYME USP2A; RECEPTOR TYROSINE KINASES; CLATHRIN-COATED PITS; DOWN-REGULATION; PROSTATE-CANCER; MEMBRANE-PROTEIN; PLASMA-MEMBRANE; LUNG-CANCER; CELL-GROWTH	Ubiquitination of epidermal growth factor receptor (EGFR) is required for downregulation of the receptor by endocytosis. Impairment of this pathway results in constitutively active EGFR, which is associated with carcinogenesis, particularly in lung cancer. We previously demonstrated that the deubiquitinating enzyme ubiquitin-specific protease 2a (USP2a) has oncogenic properties. Here, we show a new role for USP2a as a regulator of EGFR endocytosis. USP2a localizes to early endosomes and associates with EGFR, stabilizing the receptor, which retains active downstream signaling. HeLa cells transiently expressing catalytically active, but not mutant (MUT), USP2a show increased plasma membrane-localized EGFR, as well as decreased internalized and ubiquitinated EGFR. Conversely, USP2a silencing reverses this phenotype. Importantly, USP2a prevents the degradation of MUT in addition to wild-type EGFR. Finally, we observed that USP2a and EGFR proteins are coordinately overexpressed in non-small cell lung cancers. Taken together, our data indicate that USP2a antagonizes EGFR endocytosis and thus amplifies signaling activity from the receptor. Our findings suggest that regulation of deubiquitination could be exploited therapeutically in cancers overexpressing EGFR. Oncogene (2013) 32, 1660-1669; doi:10.1038/onc.2012.188; published online 18 June 2012	[Liu, Z.; Zanata, S. M.; Peterson, M. A.; Chirieac, L. R.; Pyne, S.; Agostini, M.; Loda, M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Liu, Z.; Zanata, S. M.; Peterson, M. A.; Chirieac, L. R.; Pyne, S.; Agostini, M.; Loda, M.] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02215 USA; [Liu, Z.; Loda, M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Zanata, S. M.] Univ Fed Parana, Dept Basic Pathol, BR-80060000 Curitiba, Parana, Brazil; [Zanata, S. M.] Univ Fed Parana, Dept Cell Biol, BR-80060000 Curitiba, Parana, Brazil; [Kim, J.; Di Vizio, D.; Freeman, M. R.] Childrens Hosp, Urol Dis Res Ctr, Boston, MA 02115 USA; [Kim, J.; Di Vizio, D.; Freeman, M. R.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; [Freeman, M. R.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Loda, M.] Kings Coll London, Div Canc Studies, London WC2R 2LS, England	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Universidade Federal do Parana; Universidade Federal do Parana; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of London; King's College London	Loda, M (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, DA1536,450 Brookline Ave, Boston, MA 02215 USA.	Massimo_loda@dfci.harvard.edu	Agostini, Michelle/I-1275-2012; Chirieac, Lucian R./AAD-2030-2019; Agostini, Michelle/AAD-6610-2022; Zanata, Silvio/AAC-9670-2021	Agostini, Michelle/0000-0002-3648-337X; Zanata, Silvio/0000-0003-2818-6954	National Cancer Institute [RO1CA131945, PO1CA89021, P50 CA90381]; Prostate Cancer Foundation; CAPES, Brazil [3665/10-0]; NATIONAL CANCER INSTITUTE [R00CA131472, P50CA090381, P01CA089021, R01CA131945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK087806] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Prostate Cancer Foundation; CAPES, Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Tomas Kirchhausen for AMSH constructs, Mihee Ji and Erik McCauley for technical assistance, Jane Hayward for help with preparation of the figures, Giulio Draetta and Richard J Flavin for critical reading of the manuscript. This work was supported by the National Cancer Institute (RO1CA131945, PO1CA89021, P50 CA90381 and the Prostate Cancer Foundation). SMZ was supported by CAPES (no. 3665/10-0), Brazil.	Abella JV, 2005, MOL CELL BIOL, V25, P9632, DOI 10.1128/MCB.25.21.9632-9645.2005; Agromayor M, 2006, J BIOL CHEM, V281, P23083, DOI 10.1074/jbc.M513803200; Allende-Vega N, 2010, ONCOGENE, V29, P432, DOI 10.1038/onc.2009.330; Alwan HAJ, 2007, J BIOL CHEM, V282, P1658, DOI 10.1074/jbc.M604711200; Amit I, 2004, GENE DEV, V18, P1737, DOI 10.1101/gad.294904; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Benassi B, 2012, CANCER DISCOV, V2, P236, DOI 10.1158/2159-8290.CD-11-0219; Bowers K, 2006, J BIOL CHEM, V281, P5094, DOI 10.1074/jbc.M508632200; Bunn PA, 2002, SEMIN ONCOL, V29, P38, DOI 10.1053/sonc.2002.35646; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; CERNY T, 1986, BRIT J CANCER, V54, P265, DOI 10.1038/bjc.1986.172; Clague MJ, 2006, TRENDS CELL BIOL, V16, P551, DOI 10.1016/j.tcb.2006.09.002; d'Azzo A, 2005, TRAFFIC, V6, P429, DOI 10.1111/j.1600-0854.2005.00294.x; de Araujo Mariana Eca Guimaraes, 2008, V424, P317, DOI 10.1007/978-1-60327-064-9_25; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Gousseva N, 2003, GENE EXPRESSION, V11, P163, DOI 10.3727/000000003108749053; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Graner E, 2004, CANCER CELL, V5, P253, DOI 10.1016/S1535-6108(04)00055-8; Grovdal LM, 2004, EXP CELL RES, V300, P388, DOI 10.1016/j.yexcr.2004.07.003; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Haslekas C, 2005, MOL BIOL CELL, V16, P5832, DOI 10.1091/mbc.E05-05-0456; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Huang F, 2007, P NATL ACAD SCI USA, V104, P16904, DOI 10.1073/pnas.0707416104; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Hurley JH, 2006, ANNU REV BIOPH BIOM, V35, P277, DOI 10.1146/annurev.biophys.35.040405.102126; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Komada Masayuki, 2008, Curr Drug Discov Technol, V5, P78, DOI 10.2174/157016308783769469; Lenferink AEG, 1997, BIOCHEM J, V327, P859; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lin HJ, 2000, MOL CELL BIOL, V20, P6568, DOI 10.1128/MCB.20.17.6568-6578.2000; Love KR, 2007, NAT CHEM BIOL, V3, P697, DOI 10.1038/nchembio.2007.43; Ma YM, 2007, J BIOL CHEM, V282, P9805, DOI 10.1074/jbc.M611635200; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Metzig M, 2011, INT J CANCER, V129, P607, DOI 10.1002/ijc.26124; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Mizuno E, 2006, TRAFFIC, V7, P1017, DOI 10.1111/j.1600-0854.2006.00452.x; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Naslavsky N, 2004, MOL BIOL CELL, V15, P3542, DOI 10.1091/mbc.E04-02-0151; Niendorf S, 2007, MOL CELL BIOL, V27, P5029, DOI 10.1128/MCB.01566-06; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Polo S, 2004, CURR OPIN CELL BIOL, V16, P156, DOI 10.1016/j.ceb.2004.02.003; Priolo C, 2006, CANCER RES, V66, P8625, DOI 10.1158/0008-5472.CAN-06-1374; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Row PE, 2006, J BIOL CHEM, V281, P12618, DOI 10.1074/jbc.M512615200; Saksena S, 2007, TRENDS BIOCHEM SCI, V32, P561, DOI 10.1016/j.tibs.2007.09.010; Sakurada A, 2006, CLIN LUNG CANCER, V7, pS138, DOI 10.3816/CLC.2006.s.005; Shan J, 2009, MOL CELL, V36, P469, DOI 10.1016/j.molcel.2009.10.018; Shi Y, 2011, J BIOL CHEM, V286, P38960, DOI 10.1074/jbc.M111.231498; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Stevenson LF, 2007, EMBO J, V26, P976, DOI 10.1038/sj.emboj.7601567; Stuffers S, 2009, EXP CELL RES, V315, P1619, DOI 10.1016/j.yexcr.2008.10.013; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Urbe S, 2006, BIOCHEM SOC T, V34, P754, DOI 10.1042/BST0340754; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	61	47	48	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 28	2013	32	13					1660	1669		10.1038/onc.2012.188	http://dx.doi.org/10.1038/onc.2012.188			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22710717	Green Accepted			2022-12-17	WOS:000316855800006
J	Allende-Vega, N; Dayal, S; Agarwala, U; Sparks, A; Bourdon, JC; Saville, MK				Allende-Vega, N.; Dayal, S.; Agarwala, U.; Sparks, A.; Bourdon, J-C; Saville, M. K.			p53 is activated in response to disruption of the pre-mRNA splicing machinery	ONCOGENE			English	Article						p53; spliceosome; splicing; MdmX; Mdm2; TG003	EMERGING ROLE; PROTEIN; CANCER; TRANSCRIPTION; DEGRADATION; STRESS; DOMAIN; MDM2; PHOSPHORYLATION; LOCALIZATION	In this study, we show that interfering with the splicing machinery results in activation of the tumour-suppressor p53. The spliceosome was targeted by small interfering RNA-mediated knockdown of proteins associated with different small nuclear ribonucleoprotein complexes and by using the small-molecule splicing modulator TG003. These interventions cause: the accumulation of p53, an increase in p53 transcriptional activity and can result in p53-dependent G(1) cell cycle arrest. Mdm2 and MdmX are two key repressors of p53. We show that a decrease in MdmX protein level contributes to p53 activation in response to targeting the spliceosome. Interfering with the spliceosome also causes an increase in the rate of degradation of Mdm2. Alterations in splicing are linked with tumour development. There are frequently global changes in splicing in cancer. Our study suggests that p53 activation could participate in protection against potential tumour-promoting defects in the spliceosome. A number of known p53-activating agents affect the splicing machinery and this could contribute to their ability to upregulate p53. Preclinical studies indicate that tumours can be more sensitive than normal cells to small-molecule spliceosome inhibitors. Activation of p53 could influence the selective anti-tumour activity of this therapeutic approach. Oncogene (2013) 32, 1-14; doi:10.1038/onc.2012.38; published online 20 February 2012	[Allende-Vega, N.; Dayal, S.; Agarwala, U.; Sparks, A.; Bourdon, J-C; Saville, M. K.] Univ Dundee, Ninewells Hosp & Med Sch, Med Res Inst, Div Canc Res, Dundee DD1 9SY, Angus, Scotland	University of Dundee	Saville, MK (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Med Res Inst, Div Canc Res, Mail Box 11, Dundee DD1 9SY, Angus, Scotland.	m.k.saville@dundee.ac.uk	JC, Bourdon/A-4439-2008	JC, Bourdon/0000-0003-4623-9386; Allende-Vega, Nerea/0000-0001-5569-6461	Cancer Research UK	Cancer Research UK(Cancer Research UK)	This work was funded by Cancer Research UK.	Alexander R, 2010, BIOCHEM SOC T, V38, P1251, DOI 10.1042/BST0381251; Allende-Vega N, 2010, ONCOGENE, V29, P432, DOI 10.1038/onc.2009.330; Andre F, 2009, LANCET ONCOL, V10, P381, DOI 10.1016/S1470-2045(09)70024-5; Bartel F, 2004, MOL CANCER RES, V2, P29; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Blencowe BJ, 2006, CELL, V126, P37, DOI 10.1016/j.cell.2006.06.023; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Brody Y, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000573; Brooks CL, 2011, FEBS LETT, V585, P2803, DOI 10.1016/j.febslet.2011.05.022; Busa R, 2010, RNA BIOL, V7, P390, DOI 10.4161/rna.7.4.12466; Cao WH, 1998, J BIOL CHEM, V273, P20629, DOI 10.1074/jbc.273.32.20629; Cass DM, 2006, BIOCHEMISTRY-US, V45, P10092, DOI 10.1021/bi060429o; Chandler DS, 2006, CANCER RES, V66, P9502, DOI 10.1158/0008-5472.CAN-05-4271; Cheok CF, 2011, NAT REV CLIN ONCOL, V8, P25, DOI 10.1038/nrclinonc.2010.174; Corrionero A, 2011, GENE DEV, V25, P445, DOI 10.1101/gad.2014311; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; Dayal S, 2009, J BIOL CHEM, V284, P5030, DOI 10.1074/jbc.M805871200; Disher K, 2007, GENOME, V50, P946, DOI 10.1139/G07-074; Egecioglu DE, 2011, RNA, V17, P383, DOI 10.1261/rna.2454711; Fackenthal JD, 2008, DIS MODEL MECH, V1, P37, DOI 10.1242/dmm.000331; Ghosh G, 2011, FEBS J, V278, P587, DOI 10.1111/j.1742-4658.2010.07992.x; Giglio S, 2005, CANCER RES, V65, P9687, DOI 10.1158/0008-5472.CAN-05-0450; Golas MM, 2003, SCIENCE, V300, P980, DOI 10.1126/science.1084155; Grainger RJ, 2005, RNA, V11, P533, DOI 10.1261/rna.2220705; Grosso AR, 2008, EMBO REP, V9, P1087, DOI 10.1038/embor.2008.189; Hernandez H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007202; Hock A, 2010, INT J BIOCHEM CELL B, V42, P1618, DOI 10.1016/j.biocel.2010.06.011; Kaida D, 2007, NAT CHEM BIOL, V3, P576, DOI 10.1038/nchembio.2007.18; Katzenberger RJ, 2006, MOL CELL BIOL, V26, P9256, DOI 10.1128/MCB.01125-06; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kim E, 2008, TRENDS GENET, V24, P7, DOI 10.1016/j.tig.2007.10.001; Kim MY, 2009, BMB REP, V42, P125, DOI 10.5483/BMBRep.2009.42.3.125; Kotake Y, 2007, NAT CHEM BIOL, V3, P570, DOI 10.1038/nchembio.2007.16; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lane DP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001222; Lenos K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/876173; Ljungman M, 2007, CELL CYCLE, V6, P2252, DOI 10.4161/cc.6.18.4751; Makarova OV, 2001, EMBO J, V20, P2553, DOI 10.1093/emboj/20.10.2553; Marcel V, 2010, FEBS LETT, V584, P4463, DOI 10.1016/j.febslet.2010.10.005; Marine JCW, 2007, J CELL SCI, V120, P371, DOI 10.1242/jcs.03362; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Munoz MJ, 2009, CELL, V137, P708, DOI 10.1016/j.cell.2009.03.010; Muraki M, 2004, J BIOL CHEM, V279, P24246, DOI 10.1074/jbc.M314298200; Newman AJ, 2010, CURR OPIN STRUC BIOL, V20, P82, DOI 10.1016/j.sbi.2009.12.003; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Reyal F, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2192; Ritchie DB, 2009, BBA-GENE REGUL MECH, V1789, P624, DOI 10.1016/j.bbagrm.2009.08.010; Ritchie W, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000011; Schaffert N, 2004, EMBO J, V23, P3000, DOI 10.1038/sj.emboj.7600296; Singh J, 2009, NAT STRUCT MOL BIOL, V16, P1128, DOI 10.1038/nsmb.1666; Sleeman J, 2007, J CELL SCI, V120, P1540, DOI 10.1242/jcs.001529; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stevenson LF, 2007, EMBO J, V26, P976, DOI 10.1038/sj.emboj.7601567; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Svejstrup JQ, 2007, TRENDS BIOCHEM SCI, V32, P165, DOI 10.1016/j.tibs.2007.02.005; UTANS U, 1992, GENE DEV, V6, P631, DOI 10.1101/gad.6.4.631; Valadkhan S, 2010, PROTEOMICS, V10, P4128, DOI 10.1002/pmic.201000354; Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang YV, 2007, P NATL ACAD SCI USA, V104, P12365, DOI 10.1073/pnas.0701497104; Ward AJ, 2010, J PATHOL, V220, P152, DOI 10.1002/path.2649; Wilkinson CRM, 2004, CURR BIOL, V14, P2283, DOI 10.1016/j.cub.2004.11.058; Will CL, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003707; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; Zhao XL, 2007, NUCLEIC ACIDS RES, V35, P550, DOI 10.1093/nar/gkl1084	67	47	47	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					1	14		10.1038/onc.2012.38	http://dx.doi.org/10.1038/onc.2012.38			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22349816				2022-12-17	WOS:000313029500001
J	Sambandam, Y; Sundaram, K; Liu, A; Kirkwood, KL; Ries, WL; Reddy, SV				Sambandam, Y.; Sundaram, K.; Liu, A.; Kirkwood, K. L.; Ries, W. L.; Reddy, S. V.			CXCL13 activation of c-Myc induces RANK ligand expression in stromal/preosteoblast cells in the oral squamous cell carcinoma tumor-bone microenvironment	ONCOGENE			English	Article						oral squamous cell carcinoma; CXCL13; RANK ligand; c-Myc; osteoblast	KAPPA-B LIGAND; SOLUBLE RECEPTOR ACTIVATOR; INDUCED OSTEOLYSIS; PROSTATE-CANCER; NECK-CANCER; OSTEOCLAST DIFFERENTIATION; CHEMOKINE RECEPTORS; OSTEOBLASTS; METASTASIS; INVASION	CXC chemokine ligand-13 (CXCL13) has been implicated in oral squamous cell carcinoma (OSCC) tumor progression and osteolysis. The tumor necrosis factor family member RANKL (receptor activator of NF-kappa B ligand), a critical bone resorbing osteoclastogenic factor, has an important role in cancer invasion of bone/osteolysis. Here, we show high-level expression of CXCL13 in primary human OSCC tumor specimens; however, human bone marrow-derived stromal (SAKA-T) and murine preosteoblast (MC3T3-E1) cells produce at very low level. Recombinant CXCL13 (0-15 ng/ml) dose dependently induced CXCR5 expression in SAKA-T and MC3T3-E1 cells. Conditioned media obtained from OSCC cell lines increased the RANKL expression and an antibody against the CXCL13 specific receptor, CXCR5 markedly decreased RANKL expression in these cells. Furthermore, CXCL13 increased hRANKL-Luc promoter activity. Superarray screening identified c-Myc and NFATc3 transcription factors upregulated in CXCL13-stimulated SAKA-T cells. Immunohistochemical analysis of OSCC tumors that developed in athymic mice demonstrated RANKL and NFATc3 expression in tumor and osteoblast cells, however, showed p-c-Myc expression specific to osteoblastic cells at the tumor-bone interface. We further identified NFATc3 expression, but not c-Myc activation in primary human OSCC tumor specimens compared with adjacent normal tissue. Also, CXCL13 significantly increased p-ERK1/2 in SAKA-T and MC3T3-E1 cells. siRNA suppression of c-Myc expression markedly decreased CXCL13-induced RANKL and NFATc3 expression in preosteoblast cells. Chromatin-immuno precipitation assay confirmed p-c-Myc binding to the hRANKL promoter region. In summary, c-Myc activation through CXCL13-CXCR5 signaling axis stimulates RANKL expression in stromal/preosteoblast cells. Thus, our results implicate CXCL13 as a potential therapeutic target to prevent OSCC invasion of bone/osteolysis. Oncogene (2013) 32, 97-105; doi:10.1038/onc.2012.24; published online 13 February 2012	[Sambandam, Y.; Sundaram, K.; Reddy, S. V.] Med Univ S Carolina, Charles P Darby Childrens Res Inst, Charleston, SC 29425 USA; [Liu, A.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [Kirkwood, K. L.; Ries, W. L.] Med Univ S Carolina, Sch Dent Med, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Reddy, SV (corresponding author), Med Univ S Carolina, Charles P Darby Childrens Res Inst, 173 Ashley Ave, Charleston, SC 29425 USA.	reddysv@musc.edu	Reddy, Sakamuri/H-6419-2019; Kirkwood, Keith L/L-4728-2018	Kirkwood, Keith/0000-0003-4519-8973	National Institutes of Health from National Center for Research Resources [C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015455] Funding Source: NIH RePORTER	National Institutes of Health from National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Dr Thomas E Carey, University of Michigan, Ann Arbor, MI for generously providing OSCC cells and Alfredo A Molinolo MD, PhD, NIDCR, NIH for providing the OSCC tumor tissue microarray slides. This work was conducted in a facility constructed with the support from the National Institutes of Health, Grant Number C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources.	Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Brenner JC, 2010, HEAD NECK-J SCI SPEC, V32, P417, DOI 10.1002/hed.21198; Buchholz M, 2006, EMBO J, V25, P3714, DOI 10.1038/sj.emboj.7601246; Chen G, 2006, CANCER-AM CANCER SOC, V107, P289, DOI 10.1002/cncr.21978; Choi S, 2008, J DENT RES, V87, P14, DOI 10.1177/154405910808700104; Darimont C, 2002, CELL GROWTH DIFFER, V13, P59; Deyama Y, 2008, ONCOL REP, V20, P663, DOI 10.3892/or_00000057; El-Haibi CP, 2011, CELL PROLIFERAT, V44, P311, DOI 10.1111/j.1365-2184.2011.00757.x; Funk GF, 2002, HEAD NECK-J SCI SPEC, V24, P165, DOI 10.1002/hed.10004; Habib T, 2007, J CELL BIOL, V179, P717, DOI 10.1083/jcb.200704173; Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Ishikuro M, 2008, BONE, V43, P621, DOI 10.1016/j.bone.2008.05.014; Jimi E, 2011, ORAL DIS, V17, P462, DOI 10.1111/j.1601-0825.2010.01781.x; Kayamori K, 2010, AM J PATHOL, V176, P968, DOI 10.2353/ajpath.2010.090299; Kikuchi T, 2003, J DENT RES, V82, P546, DOI 10.1177/154405910308200712; Lee SK, 2002, J IMMUNOL, V169, P2374, DOI 10.4049/jimmunol.169.5.2374; Legler DF, 1998, J EXP MED, V187, P655, DOI 10.1084/jem.187.4.655; Lisignoli G, 2004, EXP GERONTOL, V39, P659, DOI 10.1016/j.exger.2003.09.030; Lisignoli G, 2003, J CELL PHYSIOL, V194, P71, DOI 10.1002/jcp.10188; Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; Marampon F, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-31; Mikami S, 2009, J PATHOL, V218, P530, DOI 10.1002/path.2567; Mishra A, 2006, INT J CANCER, V119, P2840, DOI 10.1002/ijc.22262; Molinolo AA, 2007, CLIN CANCER RES, V13, P4964, DOI 10.1158/1078-0432.CCR-07-1041; Muller A, 2006, INT J CANCER, V118, P2147, DOI 10.1002/ijc.21514; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379; Nomura T, 2007, ORAL ONCOL, V43, P257, DOI 10.1016/j.oraloncology.2006.03.015; Pandruvada SNM, 2010, INT J CANCER, V126, P2319, DOI 10.1002/ijc.24920; Perez-Sayans M, 2011, ORAL ONCOL, V47, P688, DOI 10.1016/j.oraloncology.2011.05.016; Roccisana JL, 2004, J BIOL CHEM, V279, P10500, DOI 10.1074/jbc.M303727200; Roux S, 2004, LEUKEMIA LYMPHOMA, V45, P1111, DOI 10.1080/10428194310001593193; Singh G, 2010, J BIOL CHEM, V285, P27241, DOI 10.1074/jbc.M110.100438; Singh S, 2009, CANCER LETT, V283, P29, DOI 10.1016/j.canlet.2009.03.022; Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707; Thiolloy S, 2009, CANCER RES, V69, P6747, DOI 10.1158/0008-5472.CAN-08-3949; Uchida D, 2001, INT J CANCER, V93, P489, DOI 10.1002/ijc.1368; Vachani A, 2007, CLIN CANCER RES, V13, P2905, DOI 10.1158/1078-0432.CCR-06-1670; Wilson TJ, 2008, CANCER RES, V68, P5803, DOI 10.1158/0008-5472.CAN-07-5889; Yuvaraj S, 2009, MOL CANCER RES, V7, P1399, DOI 10.1158/1541-7786.MCR-08-0589; Ziober AF, 2006, CLIN CANCER RES, V12, P5960, DOI 10.1158/1078-0432.CCR-06-0535; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	44	47	50	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					97	105		10.1038/onc.2012.24	http://dx.doi.org/10.1038/onc.2012.24			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22330139	Green Accepted			2022-12-17	WOS:000313029500010
J	Kamiyama, H; Suzuki, K; Maeda, T; Koizumi, K; Miyaki, Y; Okada, S; Kawamura, YJ; Samuelsson, JK; Alonso, S; Konishi, F; Perucho, M				Kamiyama, H.; Suzuki, K.; Maeda, T.; Koizumi, K.; Miyaki, Y.; Okada, S.; Kawamura, Y. J.; Samuelsson, J. K.; Alonso, S.; Konishi, F.; Perucho, M.			DNA demethylation in normal colon tissue predicts predisposition to multiple cancers	ONCOGENE			English	Article						DNA demethylation; colon cancer; synchronous; metachronous; epigenetics	COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; LINE-1 HYPOMETHYLATION; METHYLATION; TUMORS; FIELD; MUCOSA; AGE; GUIDELINES; MUTATIONS	Some colon cancer (CC) patients present synchronous cancers at diagnosis and others develop metachronous neoplasms, but the risk factors are unclear for non-hereditary CC. We showed previously that global DNA demethylation increased with aging and correlated with genomic damage in CC, and we show now that preferentially associates to CCs with wild-type p53. This study aimed to elucidate the extent of DNA hypomethylation in patients with single and multiple CC, its relationship with aging, and its potential as predictive tool. We compared by real-time methylation-specific PCR the relative demethylation level (RDL) of long interspersed nucleotide element-1 (LINE-1) sequences in matched cancer tissues and non-cancerous colonic mucosa (NCM) from patients with single and multiple right-sided CCs. Although no RDL difference was found in NCM from single CC patients and healthy volunteers (P = 0.5), there was more demethylation (higher RDL) in NCM from synchronous cancer patients (P = 1.1 x 10(-5)) multiple CCs also were more demethylated than single CCs (P = 0.0014). High NCM demethylation was predictive for metachronous neoplasms (P = 0.003). In multivariate logistic regression analyses RDL was the only independent predictor for metachronous (P = 0.02) and multiple (P = 4.9 x 10(-5)) tumors. The higher LINE-1 demethylation in NCM from patients with multiple (synchronous and metachronous) tumors (P = 9.6 x 10(-7)) was also very significant in patients with tumors without (P = 3.8 x 10(-6)), but not with (P = 0.16) microsatellite instability. NCM demethylation increased with aging in patients with single tumors, but decreased in those with multiple tumors. Moreover, the demethylation difference between patients with single vs multiple tumors appeared higher in younger (P = 3.6 x 10(-4)) than in older (P = 0.0016) patients. These results predict that LINE-1 hypomethylation in NCM can be used as an epigenetic predictive biomarker for multiple CC risk. The stronger association of demethylation in NCM with multiple CC risk from younger patients also suggests an inherited predisposition for the apparent field cancerization effect of somatic demethylation. Oncogene (2012) 31, 5029-5037; doi:10.1038/onc.2011.652; published online 6 February 2012	[Kamiyama, H.; Suzuki, K.; Maeda, T.; Okada, S.; Kawamura, Y. J.; Konishi, F.] Jichi Med Univ, Saitama Med Ctr, Dept Surg, Saitama, Japan; [Koizumi, K.; Miyaki, Y.] Hamamatsu Univ Sch Med, Dept Surg 1, Hamamatsu, Shizuoka 4313192, Japan; [Samuelsson, J. K.; Perucho, M.] Sanford Burnham Med Res Inst SBMRI, La Jolla, CA 92037 USA; [Samuelsson, J. K.; Alonso, S.; Perucho, M.] Inst Predict & Personalized Med Canc IMPPC, Barcelona, Spain; [Perucho, M.] Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain	Jichi Medical University; Hamamatsu University School of Medicine; Sanford Burnham Prebys Medical Discovery Institute; ICREA	Suzuki, K (corresponding author), Jichi Med Univ, Saitama Med Ctr, Dept Surg, Saitama, Japan.	ksuzbnhm@omiya.jichi.ac.jp; mperucho@sanfordburnham.org	Alonso, Sergio/GVR-8346-2022; Alonso, Sergio/G-5145-2011	Alonso, Sergio/0000-0001-6497-892X; Perucho, Manuel/0000-0002-2169-2662	Ministry of Education, Culture, Science, Sports, and Technology of Japan; NIH [R37 CA63585]; Spanish Ministry of Science and Innovation [FIS PI09/02444]; ICREA Funding Source: Custom; NATIONAL CANCER INSTITUTE [R37CA063585] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [21591710] Funding Source: KAKEN	Ministry of Education, Culture, Science, Sports, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); ICREA(ICREA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by grants from the Ministry of Education, Culture, Science, Sports, and Technology of Japan, NIH grant R37 CA63585 and from the Spanish Ministry of Science and Innovation (FIS PI09/02444).	Ahlquist T, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-94; Belshaw NJ, 2010, CARCINOGENESIS, V31, P1158, DOI 10.1093/carcin/bgq077; Bouvier AM, 2008, EUR J CANCER, V44, P522, DOI 10.1016/j.ejca.2008.01.007; Braakhuis BJM, 2003, CANCER RES, V63, P1727; Brenner H, 2007, GUT, V56, P1585, DOI 10.1136/gut.2007.122739; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Estecio MRH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000399; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Gonzalo V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008777; Horii J, 2008, CLIN BIOCHEM, V41, P1440, DOI 10.1016/j.clinbiochem.2008.08.089; Ibrahim AEK, 2011, GUT, V60, P499, DOI 10.1136/gut.2010.223602; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kawakami K, 2011, CANCER SCI, V102, P166, DOI 10.1111/j.1349-7006.2010.01776.x; KIM HG, 1994, AM J PATHOL, V145, P148; Konishi K, 2009, CANCER PREV RES, V2, P814, DOI 10.1158/1940-6207.CAPR-09-0054; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; Menigatti M, 2009, ONCOGENE, V28, P899, DOI 10.1038/onc.2008.444; Nosho K, 2009, GASTROENTEROLOGY, V137, P1609, DOI 10.1053/j.gastro.2009.08.002; Ogino S, 2008, J NATL CANCER I, V100, P1734, DOI 10.1093/jnci/djn359; Paun BC, 2010, CANCER-AM CANCER SOC, V116, P4495, DOI 10.1002/cncr.25348; Perucho M, 1996, BIOL CHEM, V377, P675; Qu GZ, 1999, CANCER GENET CYTOGEN, V109, P34, DOI 10.1016/S0165-4608(98)00143-5; R Development Core Team, 2009, R LANG ENV STAT COMP; Rex DK, 2006, GASTROENTEROLOGY, V130, P1865, DOI 10.1053/j.gastro.2006.03.013; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; Sunami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018884; Suter CM, 2004, INT J COLORECTAL DIS, V19, P95, DOI 10.1007/s00384-003-0539-3; Suzuki K, 2006, CANCER CELL, V9, P199, DOI 10.1016/j.ccr.2006.02.016; Suzuki K, 2003, GASTROENTEROLOGY, V125, P1330, DOI 10.1016/j.gastro.2003.07.006; Svrcek M, 2010, GUT, V59, P1516, DOI 10.1136/gut.2009.194787; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tsao JL, 2000, P NATL ACAD SCI USA, V97, P1236, DOI 10.1073/pnas.97.3.1236; Umar A, 2004, NAT REV CANCER, V4, P153, DOI 10.1038/nrc1278; Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142; Vilar E, 2010, NAT REV CLIN ONCOL, V7, P153, DOI 10.1038/nrclinonc.2009.237; Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987; Worthley DL, 2010, ONCOGENE, V29, P1653, DOI 10.1038/onc.2009.449; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yamashita K, 2003, CANCER CELL, V4, P121, DOI 10.1016/S1535-6108(03)00190-9; Zeimet AG, 2011, GYNECOL ONCOL, V121, P24, DOI 10.1016/j.ygyno.2010.12.332	44	47	47	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	48					5029	5037		10.1038/onc.2011.652	http://dx.doi.org/10.1038/onc.2011.652			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048CU	22310288	Green Accepted			2022-12-17	WOS:000311888600007
J	Cronan, MR; Nakamura, K; Johnson, NL; Granger, DA; Cuevas, BD; Wang, JG; Mackman, N; Scott, JE; Dohlman, HG; Johnson, GL				Cronan, M. R.; Nakamura, K.; Johnson, N. L.; Granger, D. A.; Cuevas, B. D.; Wang, J-G; Mackman, N.; Scott, J. E.; Dohlman, H. G.; Johnson, G. L.			Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis	ONCOGENE			English	Article						MAP3K; metastasis; MAPK network; MEKK2; MLK3	SIGNAL-REGULATED KINASE-5; BREAST-CANCER; PROSTATE-CANCER; TISSUE FACTOR; EXPRESSION; ACTIVATION; ERK5; PROGRESSION; CARCINOMA; APOPTOSIS	Analysis of patient tumors suggests that multiple MAP3 kinases (MAP3Ks) are critical for growth and metastasis of cancer cells. MAP3Ks selectively control the activation of extracellular signal-regulated kinase 1/2 (ERK1/2), Jun N-terminal kinase (JNK), p38 and ERK5 in response to receptor tyrosine kinases and GTPases. We used MDA-MB-231 cells because of their ability to metastasize from the breast fat pad to distant lymph nodes for an orthotopic xenograft model to screen the function of seven MAP3Ks in controlling tumor growth and metastasis. Stable short hairpin RNA (shRNA) knockdown was used to inhibit the expression of each of the seven MAP3Ks, which were selected for their differential regulation of the MAPK network. The screen identified two MAP3Ks, MEKK2 and MLK3, whose shRNA knockdown caused significant inhibition of both tumor growth and metastasis. Neither MEKK2 nor MLK3 have been previously shown to regulate tumor growth and metastasis in vivo. These results demonstrated that MAP3Ks, which differentially activate JNK, p38 and ERK5, are necessary for xenograft tumor growth and metastasis of MDA-MB-231 tumors. The requirement for MAP3Ks signaling through multiple MAPK pathways explains why several members of the MAPK network are activated in cancer. MEKK2 was required for epidermal growth factor receptor and Her2/Neu activation of ERK5, with ERK5 being required for metastasis. Loss of MLK3 expression increased mitotic infidelity and apoptosis in vitro. Knockdown of MEKK2 and MLK3 resulted in increased apoptosis in orthotopic xenografts relative to control tumors in mice, inhibiting both tumor growth and metastasis; MEKK2 and MLK3 represent untargeted kinases in tumor biology for potential therapeutic development. Oncogene (2012) 31, 3889-3900; doi:10.1038/onc.2011.544; published online 5 December 2011	[Cronan, M. R.; Nakamura, K.; Johnson, N. L.; Granger, D. A.; Johnson, G. L.] Univ N Carolina, Dept Pharmacol, Sch Med, Chapel Hill, NC 27599 USA; [Cronan, M. R.; Dohlman, H. G.] Univ N Carolina, Dept Biochem & Biophys, Sch Med, Chapel Hill, NC 27599 USA; [Cronan, M. R.; Nakamura, K.; Johnson, N. L.; Granger, D. A.; Wang, J-G; Mackman, N.; Dohlman, H. G.; Johnson, G. L.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC 27599 USA; [Cuevas, B. D.] Loyola Univ Chicago, Stritch Sch Med, Dept Mol Pharmacol & Therapeut, Maywood, IL USA; [Mackman, N.] Univ N Carolina, McAllister Heart Inst, Sch Med, Div Hematol & Oncol,Dept Med, Chapel Hill, NC 27599 USA; [Scott, J. E.] N Carolina Cent Univ, Dept Pharmaceut Sci, Biomfg Res Inst & Technol Enterprise, Durham, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Loyola University Chicago; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; North Carolina Central University	Johnson, GL (corresponding author), Univ N Carolina, Dept Pharmacol, Sch Med, Chapel Hill, NC 27599 USA.	glj@med.unc.edu		Cronan, Mark/0000-0002-3760-1649; Dohlman, Henrik/0000-0003-2443-0729; Mackman, Nigel/0000-0002-9170-7700	NIH [GM30324, DK37871, GM059167, U54CA156735, CA120881]; University of North Carolina; RNAi Screening Core; Lentiviral shRNA Core; NATIONAL CANCER INSTITUTE [K01CA120881, U54CA156735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324, R01GM059167] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of North Carolina; RNAi Screening Core; Lentiviral shRNA Core; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH Grants GM30324 (GLJ), DK37871 (GLJ), GM059167 (HGD), U54CA156735 (GLJ and JES) and CA120881 (BC) and the University of North Carolina Cancer Research Fund (GLJ). We acknowledge the RNAi Screening Core and Lentiviral shRNA Core for support of this research.	Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; Brancho D, 2005, MOL CELL BIOL, V25, P3670, DOI 10.1128/MCB.25.9.3670-3681.2005; Montero JC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005565; Cazares LH, 2009, CLIN CANCER RES, V15, P5541, DOI 10.1158/1078-0432.CCR-08-2892; Cha HJ, 2006, CELL SIGNAL, V18, P93, DOI 10.1016/j.cellsig.2005.03.028; Chang S, 2011, COMPOS MATH, V147, P375, DOI 10.1112/S0010437X1000504X; Chen J, 2010, ONCOGENE, V29, P4399, DOI 10.1038/onc.2010.198; Cuevas BD, 2007, ONCOGENE, V26, P3159, DOI 10.1038/sj.onc.1210409; Cuevas BD, 2006, ONCOGENE, V25, P4998, DOI 10.1038/sj.onc.1209507; Davidson B, 2006, GYNECOL ONCOL, V102, P453, DOI 10.1016/j.ygyno.2006.01.034; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Fedorov O, 2010, NAT CHEM BIOL, V6, P166, DOI 10.1038/nchembio.297; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Guo ZJ, 2002, MOL CELL BIOL, V22, P5761, DOI 10.1128/MCB.22.16.5761-5768.2002; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Jaeschke A, 2007, MOL CELL, V27, P498, DOI 10.1016/j.molcel.2007.07.008; Kasthuri RS, 2009, J CLIN ONCOL, V27, P4834, DOI 10.1200/JCO.2009.22.6324; Kesavan K, 2004, J CELL PHYSIOL, V199, P140, DOI 10.1002/jcp.10457; Khorana AA, 2008, J THROMB HAEMOST, V6, P1983, DOI 10.1111/j.1538-7836.2008.03156.x; Kim KY, 2004, J BIOL CHEM, V279, P29478, DOI 10.1074/jbc.M313947200; Lee W, 2010, NATURE, V465, P473, DOI 10.1038/nature09004; McCracken SRC, 2008, ONCOGENE, V27, P2978, DOI 10.1038/sj.onc.1210963; Mehta PB, 2003, ONCOGENE, V22, P1381, DOI 10.1038/sj.onc.1206154; Mishra R, 2007, J BIOL CHEM, V282, P30393, DOI 10.1074/jbc.M705895200; Nakamura K, 2010, J BIOL CHEM, V285, P2077, DOI 10.1074/jbc.M109.065102; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rak J, 2010, SEMIN THROMB HEMOST, V36, P888, DOI 10.1055/s-0030-1267043; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Sartorius CA, 2003, BREAST CANCER RES TR, V79, P287, DOI 10.1023/A:1024031731269; Sheridan C, 2008, J BIOL CHEM, V283, P22128, DOI 10.1074/jbc.M800271200; SIDEBOTTOM E, 1983, BRIT J CANCER, V47, P399, DOI 10.1038/bjc.1983.60; Sourvinos G, 1999, ONCOGENE, V18, P4968, DOI 10.1038/sj.onc.1202891; Sticht C, 2008, NEOPLASIA, V10, P462, DOI 10.1593/neo.08164; Sun WY, 2003, MOL CELL BIOL, V23, P2298, DOI 10.1128/MCB.23.7.2298-2308.2003; Tatake RJ, 2008, BIOCHEM BIOPH RES CO, V377, P120, DOI 10.1016/j.bbrc.2008.09.087; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Waldmeier P, 2006, BIOCHEM PHARMACOL, V72, P1197, DOI 10.1016/j.bcp.2006.06.031; Wang X, 2010, HUM PATHOL, V41, P401, DOI 10.1016/j.humpath.2009.08.018; Wo JY, 2011, J CLIN ONCOL, V29, P2619, DOI 10.1200/JCO.2010.29.5907; Yang QK, 2010, CANCER CELL, V18, P258, DOI 10.1016/j.ccr.2010.08.008; Yu JL, 2005, BLOOD, V105, P1734, DOI 10.1182/blood-2004-05-2042; Zen K, 2009, GENE CHROMOSOME CANC, V48, P109, DOI 10.1002/gcc.20624	44	47	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	34					3889	3900		10.1038/onc.2011.544	http://dx.doi.org/10.1038/onc.2011.544			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IV	22139075	Green Accepted, Green Submitted			2022-12-17	WOS:000307925000006
J	Tailler, M; Senovilla, L; Lainey, E; Thepot, S; Metivier, D; Sebert, M; Baud, V; Billot, K; Fenaux, P; Galluzzi, L; Boehrer, S; Kroemer, G; Kepp, O				Tailler, M.; Senovilla, L.; Lainey, E.; Thepot, S.; Metivier, D.; Sebert, M.; Baud, V.; Billot, K.; Fenaux, P.; Galluzzi, L.; Boehrer, S.; Kroemer, G.; Kepp, O.			Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia	ONCOGENE			English	Article						apoptosis; necrosis; myeloblasts; HL-60; HCS	CELL-DEATH; CARDIAC-GLYCOSIDES; MITOCHONDRIAL ALTERATIONS; CANCER-CELLS; DIFFERENTIATION; APOPTOSIS; ASSAYS; INHIBITION; EXPRESSION; GUIDELINES	Despite recent progress in the treatment of acute myeloid leukemia (AML), the prognosis of this rather heterogeneous disease remains poor and novel chemotherapeutics that specifically target leukemic cells must be developed. To address this need at the preclinical level, we implemented a high content imaging-based screen for the identification of small agents that induce AML cell death in vitro. Among a panel of 1040 Food and Drug Administration-approved agents, we identified pyrithione zinc (PZ) and ouabain (OUA) as potential antileukemic compounds. Both PZ and OUA efficiently induced cell death associated with apoptotic chromatin condensation and inhibition of nuclear factor-kappa B survival signaling, leading to reduced expression of antiapoptotic proteins, in several AML cell lines. PZ- and OUA-induced cell death was associated with the permeabilization of the outer mitochondrial membrane and led to the release of cytochrome c followed by caspase activation. Both PZ and OUA exerted significant anticancer effects in vivo, on human AML cells xenografts as well as ex vivo, on CD34(+) (but not CD34(-)) malignant myeloblasts from AML patients. Altogether, our results suggest that PZ and OUA may exhibit antileukemic effects by inducing the apoptotic demise of AML cells. Oncogene (2012) 31, 3536-3546; doi:10.1038/onc.2011.521; published online 21 November 2011	[Kroemer, G.] Inst Gustave Roussy, INSERM, PR1, U848, F-94805 Villejuif, Val De Marne, France; [Tailler, M.; Senovilla, L.; Lainey, E.; Thepot, S.; Metivier, D.; Sebert, M.; Fenaux, P.; Galluzzi, L.; Boehrer, S.; Kepp, O.] Univ Paris Sud, F-94275 Le Kremlin Bicetre, France; [Thepot, S.; Sebert, M.; Fenaux, P.; Boehrer, S.] Univ Paris 13, AP HP, Hop Avicenne, Serv Hematol Clin, Bobigny, France; [Baud, V.; Billot, K.] INSERM, Inst Cochin, U1016, Paris, France; [Baud, V.; Billot, K.] CNRS, UMR8104, Paris, France; [Baud, V.; Billot, K.; Kroemer, G.] Univ Paris 05, Paris, France; [Kroemer, G.] Ctr Rech Cordeliers, Paris, France; [Kroemer, G.] Hop Europe Georges Pompidou, AP HP, Pole Biol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, PR1, U848, 114 Rue Edouard Vaillant, F-94805 Villejuif, Val De Marne, France.	kroemer@orange.fr; oliver.kepp@igr.fr	Galluzzi, Lorenzo/AAG-6294-2019; Galluzzi, Lorenzo/AAG-6432-2019; Kepp, Oliver/N-2763-2017; KROEMER, Guido/B-4263-2013; Galluzzi, Lorenzo/AAH-3286-2021; Kroemer, Guido/AAY-9859-2020; Baud, Veronique/F-7699-2013; Kepp, Oliver/GPX-8627-2022; Galluzzi, Lorenzo/K-2709-2012; THEPOT, Sylvain/L-3078-2015; Senovilla, Laura/AAX-5599-2021; Baud, Veronique/AAL-3950-2020	Kepp, Oliver/0000-0002-6081-9558; KROEMER, Guido/0000-0002-9334-4405; Baud, Veronique/0000-0002-4090-718X; Galluzzi, Lorenzo/0000-0003-2257-8500; Baud, Veronique/0000-0002-4090-718X; thepot, sylvain/0000-0003-3492-2778; Senovilla, Laura/0000-0001-6887-2436	Ligue Nationale contre le Cancer (Equipes labellisee); Agence Nationale pour la Recherche (ANR); European Commission; Fondation pour la Recherche Medicale (FRM); Institut National du Cancer (INCa); Canceropole Ile-de-France; Fondation Bettencourt-Schueller; LabEx Onco-Immunology; Agence Nationale pour la Recherche; Association pour la Recherche sur le Cancer; Belgian InterUniversity Attraction Pole; Universite Paris Descartes; Ligue Nationale contre le Cancer; Apo-Sys	Ligue Nationale contre le Cancer (Equipes labellisee); Agence Nationale pour la Recherche (ANR)(French National Research Agency (ANR)); European Commission(European CommissionEuropean Commission Joint Research Centre); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Canceropole Ile-de-France(Region Ile-de-France); Fondation Bettencourt-Schueller; LabEx Onco-Immunology; Agence Nationale pour la Recherche(French National Research Agency (ANR)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Belgian InterUniversity Attraction Pole(Belgian Federal Science Policy Office); Universite Paris Descartes; Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Apo-Sys(European CommissionEuropean Commission Joint Research Centre)	This work is supported by grants to GK from the Ligue Nationale contre le Cancer (Equipes labellisee), Agence Nationale pour la Recherche (ANR), European Commission (Active p53, Apo-Sys, ChemoRes, ApopTrain), Fondation pour la Recherche Medicale (FRM), Institut National du Cancer (INCa), Canceropole Ile-de-France, Fondation Bettencourt-Schueller and the LabEx Onco-Immunology; to VB from Agence Nationale pour la Recherche, Association pour la Recherche sur le Cancer, Belgian InterUniversity Attraction Pole and Universite Paris Descartes. MT is supported by the Ligue Nationale contre le Cancer. LG is funded by Apo-Sys; KB is supported by Agence Nationale pour la Recherche.	Bielawski K, 2006, BIOL PHARM BULL, V29, P1493, DOI 10.1248/bpb.29.1493; Boehrer S, 2008, BLOOD, V111, P2170, DOI 10.1182/blood-2007-07-100362; Burnett A, 2011, J CLIN ONCOL, V29, P487, DOI 10.1200/JCO.2010.30.1820; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Chan G, 2007, BLOOD, V110, P1079, DOI 10.1182/blood-2007-01-069856; Edwards Bruce S., 2009, V486, P151, DOI 10.1007/978-1-60327-545-3_11; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Galluzzi L, 2007, APOPTOSIS, V12, P803, DOI 10.1007/s10495-007-0720-1; Hahn CK, 2009, CANCER CELL, V16, P281, DOI 10.1016/j.ccr.2009.08.018; Hallbook H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015718; Hoffmann J, 2008, CANCER RES, V68, P5301, DOI 10.1158/0008-5472.CAN-08-0237; Juncker T, 2011, BIOCHEM PHARMACOL, V81, P13, DOI 10.1016/j.bcp.2010.08.025; Kepp O, 2011, NAT REV DRUG DISCOV, V10, P221, DOI 10.1038/nrd3373; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kometiani P, 2005, MOL PHARMACOL, V67, P929, DOI 10.1124/mol.104.007302; Lamore SD, 2011, BIOMETALS, V24, P875, DOI 10.1007/s10534-011-9441-6; Lamore SD, 2010, CELL STRESS CHAPERON, V15, P309, DOI 10.1007/s12192-009-0145-6; Lopez-Lazaro M, 2007, EXPERT OPIN THER TAR, V11, P1043, DOI 10.1517/14728222.11.8.1043; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757; Newman RA, 2008, MOL INTERV, V8, P36, DOI 10.1124/mi.8.1.8; Newman RA, 2006, J EXP THER ONCOL, V5, P167; Perne A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008292; Rouge TD, 2007, CANCER RES, V67, P6253, DOI 10.1158/0008-5472.CAN-07-0538; Smits ELJ, 2011, CANCER IMMUNOL IMMUN, V60, P757, DOI 10.1007/s00262-011-1022-6; Stegmaier K, 2005, BLOOD, V106, P2841, DOI 10.1182/blood-2005-02-0488; Tufi R, 2008, CELL DEATH DIFFER, V15, P274, DOI 10.1038/sj.cdd.4402275; Vicencio JM, 2009, CELL DEATH DIFFER, V16, P1006, DOI 10.1038/cdd.2009.34; Vitale I, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001337; Wald DN, 2008, CANCER RES, V68, P4369, DOI 10.1158/0008-5472.CAN-07-6559; Wang Z, 2009, CANCER RES, V69, P6556, DOI 10.1158/0008-5472.CAN-09-0891; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; Yin W, 2009, BIOCHEM PHARMACOL, V78, P191, DOI 10.1016/j.bcp.2009.03.025; ZHANG LS, 1992, CANCER RES, V52, P4634	34	47	48	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	30					3536	3546		10.1038/onc.2011.521	http://dx.doi.org/10.1038/onc.2011.521			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	979UA	22105358				2022-12-17	WOS:000306844100006
J	Noll, JE; Jeffery, J; Al-Ejeh, F; Kumar, R; Khanna, KK; Callen, DF; Neilsen, PM				Noll, J. E.; Jeffery, J.; Al-Ejeh, F.; Kumar, R.; Khanna, K. K.; Callen, D. F.; Neilsen, P. M.			Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11	ONCOGENE			English	Article						ANKRD11; centrosome aberrations; gain of function; invasion; mutant p53	GAIN-OF-FUNCTION; HUMAN BREAST-CANCER; TUMOR-SUPPRESSOR; CORE DOMAIN; GENETIC INSTABILITY; KAPPA-B; CELLS; COMPLEX; MUTATIONS; PROTEIN	Mutations of p53 in cancer can result in a gain of function associated with tumour progression and metastasis. We show that inducible expression of several p53 'hotspot' mutants promote a range of centrosome abnormalities, including centrosome amplification, increased centrosome size and loss of cohesion, which lead to mitotic defects and multinucleation. These mutant p53-expressing cells also show a change in morphology and enhanced invasive capabilities. Consequently, we sought for a means to specifically target the function of mutant p53 in cancer cells. This study has identified ANKRD11 as a key regulator of the oncogenic potential of mutant p53. Loss of ANKRD11 expression with p53 mutation defines breast cancer patients with poor prognosis. ANKRD11 alleviates the mitotic defects driven by mutant p53 and suppresses mutant p53-mediated mesenchymal-like transformation and invasion. Mechanistically, we show that ANKRD11 restores a native conformation to the mutant p53 protein and causes dissociation of the mutant p53-p63 complex. This represents the first evidence of an endogenous protein with the capacity to suppress the oncogenic properties of mutant p53. Oncogene (2012) 31, 2836-2848; doi:10.1038/onc.2011.456; published online 10 October 2011	[Noll, J. E.; Kumar, R.; Callen, D. F.; Neilsen, P. M.] Univ Adelaide, Canc Therapeut Lab, Discipline Med, Adelaide, SA 5000, Australia; [Jeffery, J.; Al-Ejeh, F.; Khanna, K. K.] Queensland Inst Med Res, Signal Transduct Lab, Brisbane, Qld 4006, Australia; [Neilsen, P. M.] Univ Adelaide, Discipline Med, Sarcoma Res Grp, Adelaide, SA, Australia; [Neilsen, P. M.] Hanson Inst, Adelaide, SA, Australia	University of Adelaide; QIMR Berghofer Medical Research Institute; University of Adelaide; Hanson Institute	Noll, JE (corresponding author), Univ Adelaide, Canc Therapeut Lab, Discipline Med, Frome Rd, Adelaide, SA 5000, Australia.	jacqueline.noll@adelaide.edu.au	Kumar, Raman/AHE-0538-2022; Al-Ejeh, Fares/M-7032-2016; Khanna, Kum Kum/I-1747-2013; Callen, David F/G-1975-2012	Kumar, Raman/0000-0001-7976-8386; Al-Ejeh, Fares/0000-0002-1553-0077; Noll, Jacqueline/0000-0001-7375-635X; Neilsen, Paul/0000-0001-7937-3675; Callen, David/0000-0002-6189-9991; Khanna, Kum Kum/0000-0001-8650-5381	Cancer Council of South Australia and San Remo; NHMRC Program grant; Cancer Council NSW; Cure Cancer Foundation Australia; Cancer Council SA	Cancer Council of South Australia and San Remo(Cancer Council South Australia); NHMRC Program grant(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council NSW(Cancer Council New South Wales); Cure Cancer Foundation Australia; Cancer Council SA(Cancer Council South Australia)	We thank Vivek Mittal for the ecdysone-inducible constructs; Karen Vousden and Patricia Muller for the p63 and p73 constructs; Maria Lung, Sumitra Deb and Chikashi Ishioka for the mutant p53 constructs; Jeffrey Salisbury for the anti-centrin antibody; Anne-Marie Cleton-Jansen for providing patient material; and Darryl Russell and Kira Height for technical assistance. We acknowledge the Cancer Council of South Australia and San Remo for financial support. KKK is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow, and this work is supported by an NHMRC Program grant to KKK. FA is supported by the Cancer Council NSW, the Cure Cancer Foundation Australia and the Cancer Council SA.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Caulin C, 2007, J CLIN INVEST, V117, P1893, DOI 10.1172/JCI31721; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Di Agostino S, 2008, CELL CYCLE, V7, P3440, DOI 10.4161/cc.7.21.6995; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dong PX, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-103; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; Gadea G, 2002, EMBO J, V21, P2373, DOI 10.1093/emboj/21.10.2373; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Hadjihannas MV, 2010, EMBO REP, V11, P317, DOI 10.1038/embor.2010.23; Hansen LL, 1998, CANCER RES, V58, P2166; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Issaeva N, 2003, P NATL ACAD SCI USA, V100, P13303, DOI 10.1073/pnas.1835733100; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kravchenko JE, 2008, P NATL ACAD SCI USA, V105, P6302, DOI 10.1073/pnas.0802091105; Kumar R, 2005, CANCER RES, V65, P11304, DOI 10.1158/0008-5472.CAN-05-0936; Kuukasjarvi T, 1997, CANCER RES, V57, P1597; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Liu DP, 2010, ONCOGENE, V29, P949, DOI 10.1038/onc.2009.376; Liu G, 2006, J CELL BIOCHEM, V97, P448, DOI 10.1002/jcb.20700; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; MILNER J, 1987, ONCOGENE, V1, P453; Muller P, 2008, ONCOGENE, V27, P3371, DOI 10.1038/sj.onc.1211010; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Neilsen PM, 2008, J CELL SCI, V121, P3541, DOI 10.1242/jcs.026351; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Pishas KI, 2011, CLIN CANCER RES, V17, P494, DOI 10.1158/1078-0432.CCR-10-1587; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Roger L, 2006, BIOL CELL, V98, P141, DOI 10.1042/BC20050058; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Schneider G, 2010, ONCOGENE, V29, P2795, DOI 10.1038/onc.2010.46; Scian MJ, 2004, ONCOGENE, V23, P4430, DOI 10.1038/sj.onc.1207553; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Stambolsky P, 2010, CANCER CELL, V17, P273, DOI 10.1016/j.ccr.2009.11.025; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weisz L, 2007, CANCER RES, V67, P2396, DOI 10.1158/0008-5472.CAN-06-2425; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059	48	47	47	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	23					2836	2848		10.1038/onc.2011.456	http://dx.doi.org/10.1038/onc.2011.456			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958YW	21986947	Green Published			2022-12-17	WOS:000305277900004
J	Huang, M; Anand, S; Murphy, EA; Desgrosellier, JS; Stupack, DG; Shattil, SJ; Schlaepfer, DD; Cheresh, DA				Huang, M.; Anand, S.; Murphy, E. A.; Desgrosellier, J. S.; Stupack, D. G.; Shattil, S. J.; Schlaepfer, D. D.; Cheresh, D. A.			EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation	ONCOGENE			English	Article						pancreatic cancer; Rap1; CAS; EGFR; metastasis; tyrosine phosphorylation	GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION SITES; DOWN-REGULATION; INTEGRIN ACTIVATION; TUMOR PROGRESSION; CANCER-CELLS; CROSS-TALK; EXPRESSION; MIGRATION; RAS	Tyrosine kinase receptors have an essential role in various aspects of tumor progression. In particular, epidermal growth factor receptor (EGFR) and its ligands have been implicated in the growth and dissemination of a wide array of human carcinomas. Here, we describe an EGFR-mediated signaling pathway that regulates human pancreatic carcinoma cell invasion and metastasis, yet does not influence the growth of primary tumors. In fact, ligation/activation of EGFR induces Src-dependent phosphorylation of two critical tyrosine residues of p130CAS, leading to the assembly of a Crk-associated substrate (CAS)/Nck1 complex that promotes Ras-associated protein-1 (Rap1) signaling. Importantly, GTP loading of Rap1 is specifically required for pancreatic carcinoma cell migration on vitronectin but not on collagen. Furthermore, Rap1 activation is required for EGFR-mediated metastasis in vivo without impacting primary tumor growth. These findings identify a molecular pathway that promotes the invasive/metastatic properties of human pancreatic carcinomas driven by EGFR. Oncogene (2012) 31, 2783-2793; doi: 10.1038/onc.2011.450; published online 3 October 2011	[Huang, M.; Anand, S.; Murphy, E. A.; Desgrosellier, J. S.; Stupack, D. G.; Cheresh, D. A.] Moores Univ Calif San Diego, Ctr Canc, Dept Pathol, La Jolla, CA 92093 USA; [Shattil, S. J.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Cheresh, DA (corresponding author), Moores Univ Calif San Diego, Ctr Canc, Dept Pathol, Room 2344,3855 Hlth Sci Dr,MC 0803, La Jolla, CA 92093 USA.	dcheresh@ucsd.edu	ANAND, SUDARSHAN/I-5316-2019; Desgrosellier, Jay S/A-8756-2008	ANAND, SUDARSHAN/0000-0002-4969-6884; Huang, Miller/0000-0002-3371-0100	NIH [CA107263, HL56595, HL47900, CA102310, CA045726]; NATIONAL CANCER INSTITUTE [R01CA095262, R01CA045726, R01CA107263, T32CA121938, R01CA102310] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056595] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr Steven K Hanks for the donation of the CAS mutant plasmids and Dr David J Shields for helpful discussion. This work was supported by NIH Grants CA107263 (DGS), HL56595 and HL47900 (SJS), CA102310 (DDS), and CA045726 (DAC).	Bailey CL, 2009, CANCER RES, V69, P4962, DOI 10.1158/0008-5472.CAN-08-4269; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Brabek J, 2005, MOL CANCER RES, V3, P307, DOI 10.1158/1541-7786.MCR-05-0015; Brabek J, 2004, ONCOGENE, V23, P7406, DOI 10.1038/sj.onc.1207965; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Bruns CJ, 2000, CANCER RES, V60, P2926; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Faller BA, 2009, BIOL-TARGETS THER, V3, P419; Frische EW, 2010, DEV BIOL, V340, P1, DOI 10.1016/j.ydbio.2009.12.043; Furstenau DK, 2011, BREAST CANCER RES TR, V129, P361, DOI 10.1007/s10549-010-1227-y; Gao L, 2006, CANCER RES, V66, P7880, DOI 10.1158/0008-5472.CAN-06-0254; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; Gu JG, 2001, J BIOL CHEM, V276, P27090, DOI 10.1074/jbc.M102284200; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Huang JH, 2002, J BIOL CHEM, V277, P27265, DOI 10.1074/jbc.M203063200; Jenei V, 2005, EXP CELL RES, V310, P463, DOI 10.1016/j.yexcr.2005.08.010; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lotz M, 2003, J SURG RES, V109, P123, DOI 10.1016/S0022-4804(02)00100-2; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Matsumoto S, 2006, INT J CANCER, V119, P1491, DOI 10.1002/ijc.21940; Mitra RS, 2008, CANCER RES, V68, P3959, DOI 10.1158/0008-5472.CAN-07-2755; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Morgan MA, 2008, CLIN CANCER RES, V14, P5142, DOI 10.1158/1078-0432.CCR-07-4072; Morgillo F, 2006, CANCER RES, V66, P10100, DOI 10.1158/0008-5472.CAN-06-1684; Ohba Y, 2003, EMBO J, V22, P859, DOI 10.1093/emboj/cdg087; Papouchado B, 2005, MODERN PATHOL, V18, P1329, DOI 10.1038/modpathol.3800427; Payne SL, 2006, J CELL BIOCHEM, V98, P827, DOI 10.1002/jcb.20792; Peace BE, 2003, EXP CELL RES, V289, P317, DOI 10.1016/S0014-4827(03)00280-5; Pryczynicz A, 2008, ANTICANCER RES, V28, P1399; Retta SF, 2006, EUR J CELL BIOL, V85, P283, DOI 10.1016/j.ejcb.2005.09.007; Ricono JM, 2009, CANCER RES, V69, P1383, DOI 10.1158/0008-5472.CAN-08-3612; Rivera F, 2009, CANCER TREAT REV, V35, P335, DOI 10.1016/j.ctrv.2008.11.007; Rivera GM, 2006, P NATL ACAD SCI USA, V103, P9536, DOI 10.1073/pnas.0603786103; Sakakibara A, 2002, J CELL SCI, V115, P4915, DOI 10.1242/jcs.00207; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Shattil SJ, 2010, NAT REV MOL CELL BIO, V11, P288, DOI 10.1038/nrm2871; Shimonaka M, 2003, J CELL BIOL, V161, P417, DOI 10.1083/jcb.200301133; Shin NY, 2004, J BIOL CHEM, V279, P38331, DOI 10.1074/jbc.M404675200; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Tamada M, 2004, DEV CELL, V7, P709, DOI 10.1016/j.devcel.2004.08.021; Thomas RM, 2007, CANCER RES, V67, P6075, DOI 10.1158/0008-5472.CAN-06-4128; Trevino JG, 2006, AM J PATHOL, V168, P962, DOI 10.2353/ajpath.2006.050570; Tsygankova OA, 2007, MOL CELL BIOL, V27, P6647, DOI 10.1128/MCB.00155-07; Tsygankova OM, 2010, MOL CELL BIOL, V30, P3262, DOI 10.1128/MCB.01345-09; Ueno Y, 2008, INT J CANCER, V123, P340, DOI 10.1002/ijc.23465; Wolpin BM, 2007, CANCER RES, V67, P7923, DOI 10.1158/0008-5472.CAN-07-0373; Xu JG, 2007, CELL SIGNAL, V19, P1575, DOI 10.1016/j.cellsig.2007.02.004; Yaman E, 2009, FEBS J, V276, P4607, DOI 10.1111/j.1742-4658.2009.07166.x; Zhang LZ, 2006, CANCER RES, V66, P898, DOI 10.1158/0008-5472.CAN-05-3025	51	47	49	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	22					2783	2793		10.1038/onc.2011.450	http://dx.doi.org/10.1038/onc.2011.450			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	952DB	21963850	Green Accepted			2022-12-17	WOS:000304769000008
J	Goparaju, CM; Blasberg, JD; Volinia, S; Palatini, J; Ivanov, S; Donington, JS; Croce, C; Carbone, M; Yang, H; Pass, HI				Goparaju, C. M.; Blasberg, J. D.; Volinia, S.; Palatini, J.; Ivanov, S.; Donington, J. S.; Croce, C.; Carbone, M.; Yang, H.; Pass, H. I.			Onconase mediated NFK beta downregulation in malignant pleural mesothelioma	ONCOGENE			English	Article						mesothelioma; microRNA; multidrug resistance	CYTOTOXIC RIBONUCLEASE ONCONASE; TYROSINE KINASE INHIBITOR; HUMAN LUNG-CANCER; KAPPA-B; ANTITUMOR RIBONUCLEASE; CELL-LINES; EXPRESSION PROFILES; RADIATION RESPONSE; INDUCED APOPTOSIS; DRUG-RESISTANCE	Treatment of malignant pleural mesothelioma (MPM) with Ranpirnase (Onconase) results in disruption of protein translation and cell apoptosis. We hypothesize that Onconase exerts an effect via downregulation of nuclear factor kappa B (NFK beta) by specific microRNAs (miRNAs) and that interference of this pathway could have implications for MPM resistance to chemotherapy. Three immortalized MPM cell lines (H2959, H2373 and H2591) were exposed to Onconase at 0-20 mu g/ml. Cell counts were measured at 48 and 72 h. Gene expression in miRNA-enriched RNA was validated by reverse transcription-PCR (RT-PCR). The functional implications of miRNA expression were evaluated by transfecting miRNA mimics or inhibitors into MPM cell lines, and performing Matrigel invasion, cell proliferation, soft agar colony formation and scratch closure assays. Effects on NFK beta expression and downstream targets including ABC transporters, BCL-xl and IAP were assessed by RT-PCR and western blotting. Treatment with 20 mu g/ml of Onconase significantly decreased cell count and invasion. Hsa-miR-17* was significantly upregulated and hsa-miR-30c was significantly downregulated by Onconase treatment in all cell lines. Forced expression of hsa-miR-17* mimic and hsa-miR-30c inhibitor each significantly decreased functional activity of Onconase in all assays. NFKB1 (p50) expression and downstream targets were also decreased with Onconase treatment, as well as with forced expression of miRNA mimic and inhibitors. Onconase treatment caused a significant decrease in cell proliferation, invasion and in expression of certain miRNAs. Recapitulation of the resultant miRNA expression pattern with hsa-miR-17* mimic and hsa-miR-30c inhibitor resulted in downregulation of NFKB1 and reduced malignant behavior in functional assays. Thus, Onconase likely exerts its antitumor effect through these miRNAs. Oncogene (2011) 30, 2767-2777; doi: 10.1038/onc.2010.643; published online 14 February 2011	[Goparaju, C. M.; Donington, J. S.; Pass, H. I.] NYU, Med Ctr, Dept Cardiothorac Surg, New York, NY 10016 USA; [Blasberg, J. D.] Columbia Univ Coll Phys & Surg, St Lukes Roosevelt Med Ctr, Dept Gen Surg, New York, NY 10032 USA; [Volinia, S.; Palatini, J.; Croce, C.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Ivanov, S.] Vanderbilt Univ, Med Ctr, Dept Otolaryngol, Nasville, TN USA; [Carbone, M.; Yang, H.] Univ Hawaii, Canc Res Ctr Hawaii, Honolulu, HI 96813 USA	New York University; Columbia University; Mount Sinai St. Luke's; Mount Sinai West; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Vanderbilt University; Cancer Research Center of Hawaii; University of Hawaii System	Pass, HI (corresponding author), NYU, Med Ctr, Dept Cardiothorac Surg, 530 1st Ave,Suite 9V, New York, NY 10016 USA.	Harvey.Pass@nyumc.org	Volinia, Stefano/AAA-9264-2019; Volinia, Stefano/A-3029-2010; Young, Richard A/F-6495-2012	Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893; Young, Richard A/0000-0001-8855-8647; Palatini, Jeffrey/0000-0001-9280-4417; Ivanov, Sergey/0000-0001-9770-7237; Pass, Harvey/0000-0003-3222-3471	NCI/NIH EDRN Biomarker Discovery Laboratory [UO1CA1111295, 1PO1 CA114047-D1A1]; NATIONAL CANCER INSTITUTE [P01CA114047] Funding Source: NIH RePORTER	NCI/NIH EDRN Biomarker Discovery Laboratory(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Ranpirnase was provided by AlphaCell Corporation, Paramus, NJ, USA. We also wish to acknowledge the generous support of Belluck and Fox, LPA for this project. Supported by NCI/NIH EDRN Biomarker Discovery Laboratory Grant UO1CA1111295 to Dr Pass and 1PO1 CA114047-D1A1 to Dr Carbone.	Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Ardelt B, 2007, INT J ONCOL, V31, P663; Ardelt B, 2003, CELL CYCLE, V2, P22, DOI 10.4161/cc.2.1.232; Barnhart BC, 2003, CELL, V114, P148, DOI 10.1016/S0092-8674(03)00561-0; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cao XB, 2007, CANCER BIOL THER, V6, P246, DOI 10.4161/cbt.6.2.3626; Carbone M, 2007, ONCOGENE, V26, P6959, DOI 10.1038/sj.onc.1210515; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Davidson AL, 2008, MICROBIOL MOL BIOL R, V72, P317, DOI 10.1128/MMBR.00031-07; Deptala A, 1998, INT J ONCOL, V13, P11; Dickson KA, 2005, PROG NUCLEIC ACID RE, V80, P349, DOI 10.1016/S0079-6603(05)80009-1; Gillet JP, 2007, BBA-REV CANCER, V1775, P237, DOI 10.1016/j.bbcan.2007.05.002; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gilmore Thomas D, 2003, Cancer Treat Res, V115, P241; Gordon GJ, 2007, J PATHOL, V211, P439, DOI 10.1002/path.2120; Halicka DH, 2002, INT J ONCOL, V21, P1245; Iordanov MS, 2000, CANCER RES, V60, P1983; Jones PM, 2004, CELL MOL LIFE SCI, V61, P682, DOI 10.1007/s00018-003-3336-9; Kasashima K, 2004, BIOCHEM BIOPH RES CO, V322, P403, DOI 10.1016/j.bbrc.2004.07.130; Kaufman AJ, 2008, EXPERT REV ANTICANC, V8, P293, DOI 10.1586/14737140.8.2.293; Kbeck A, 2008, FUTURE ONCOL, V4, P341, DOI 10.2217/14796694.4.3.341; Khokhar NZ, 2001, CLIN CANCER RES, V7, P3199; Kim DH, 2007, ADV EXP MED BIOL, V599, P53; Kobe B, 1996, J MOL BIOL, V264, P1028, DOI 10.1006/jmbi.1996.0694; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lee I, 2008, EXPERT OPIN BIOL TH, V8, P813, DOI 10.1517/14712598.8.6.813 ; Lee I, 2007, IN VIVO, V21, P721; Lee JE, 2008, BIODRUGS, V22, P53, DOI 10.2165/00063030-200822010-00006; Littlejohn JE, 2008, INT J CANCER, V123, P202, DOI 10.1002/ijc.23452; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; MIKULSKI SM, 1992, BRIT J CANCER, V66, P304, DOI 10.1038/bjc.1992.261; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; PASS HI, 1995, ANN THORAC SURG, V59, P835, DOI 10.1016/0003-4975(95)00045-M; Pass HI, 2004, CLIN CANCER RES, V10, P849, DOI 10.1158/1078-0432.CCR-0607-3; Pavlakis N, 2006, EXPERT OPIN BIOL TH, V6, P391, DOI 10.1517/14712598.6.4.391; Porta C, 2008, BIOL-TARGETS THER, V2, P601; RECK M, 2009, J CLIN ONCOL S, V27, pNIL96; Robinson BWS, 2005, NEW ENGL J MED, V353, P1591, DOI 10.1056/NEJMra050152; Robledo R, 1999, J CELL PHYSIOL, V180, P158, DOI 10.1002/(SICI)1097-4652(199908)180:2<158::AID-JCP3>3.0.CO;2-R; Rybak SM, 1996, J NATL CANCER I, V88, P747, DOI 10.1093/jnci/88.11.747; Saxena SK, 2002, J BIOL CHEM, V277, P15142, DOI 10.1074/jbc.M108115200; Shi Z, 2007, CANCER RES, V67, P11012, DOI 10.1158/0008-5472.CAN-07-2686; Shi Z, 2009, ONCOL REP, V21, P483, DOI 10.3892/or_00000248; Shukla S, 2009, DRUG METAB DISPOS, V37, P359, DOI 10.1124/dmd.108.024612; Singh UP, 2007, J MOL BIOL, V371, P93, DOI 10.1016/j.jmb.2007.04.071; Soini Y, 2001, ANN ONCOL, V12, P1239, DOI 10.1023/A:1012292230480; Soini Y, 1999, CLIN CANCER RES, V5, P3508; Symanowski J, 2009, J THORAC ONCOL, V4, P149, DOI 10.1097/JTO.0b013e318194f991; Tsai SY, 2004, INT J ONCOL, V25, P1745; Varkonyi-Gasic E, 2007, PLANT METHODS, V3, DOI 10.1186/1746-4811-3-12; Wang XJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r65; WU YN, 1993, J BIOL CHEM, V268, P10686; Yang HN, 2006, P NATL ACAD SCI USA, V103, P10397, DOI 10.1073/pnas.0604008103; Yang HN, 2008, CURR TREAT OPTION ON, V9, P147, DOI 10.1007/s11864-008-0067-z; Zhao H, 2008, CELL CYCLE, V7, P3258, DOI 10.4161/cc.7.20.6855	57	47	52	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	24					2767	2777		10.1038/onc.2010.643	http://dx.doi.org/10.1038/onc.2010.643			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB	21317924	Green Accepted			2022-12-17	WOS:000291678500007
J	Kim, JA; Lee, J; Margolis, RL; Fotedar, R				Kim, J. A.; Lee, J.; Margolis, R. L.; Fotedar, R.			SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibition	ONCOGENE			English	Article						Cdk1 activation; endoreplication; G2/M progression; JNK; polyploidy; SP600125	POLO-LIKE KINASES; CELL-CYCLE PROGRESSION; N-TERMINAL KINASE; DNA-REPLICATION; DEPENDENT KINASE; MAMMALIAN-CELLS; AURORA-A; CANCER-CELLS; HISTONE H3; MITOSIS	Cell cycle controls ensure that DNA replication (S phase) follows mitosis resulting in two precise copies of the genome. A failure of the control mechanisms can result in multiple rounds of DNA replication without cell division. In endoreplication, cells with replicated genomes bypass mitosis, then replicate their DNA again, resulting in polyploidy. Endoreplication from G2 phase lacks all hallmarks of mitosis. Using synchronized cells, we show that the c-Jun N-terminal kinase (JNK) inhibitor, SP600125, prevents the entry of cells into mitosis and leads to endoreplication of DNA from G2 phase. We show that cells proceed from G2 phase to replicate their DNA in the absence of mitosis. This effect of SP600125 is independent of its suppression of JNK activity. Instead, the inhibitory effect of SP600125 on mitotic entry predominantly occurs upstream of Aurora A kinase and Polo-like kinase 1, resulting in a failure to remove the inhibitory phosphorylation of Cdk1. Importantly, our results directly show that the inhibition of Cdk1 activity and the persistence of Cdk2 activity in G2 cells induces endoreplication without mitosis. Furthermore, endoreplication from G2 phase is independent of p53 control. Oncogene (2010) 29, 1702-1716; doi:10.1038/onc.2009.464; published online 11 January 2010	[Margolis, R. L.; Fotedar, R.] Burnham Inst Med Res, La Jolla, CA 92037 USA; [Kim, J. A.; Lee, J.; Margolis, R. L.; Fotedar, R.] Sidney Kimmel Canc Ctr, San Diego, CA USA	Sanford Burnham Prebys Medical Discovery Institute	Fotedar, R (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rfotedar@burnham.org			National Institutes of Health [CA108947, CA101810, GM068107, GM088716]; NATIONAL CANCER INSTITUTE [R01CA101810, R01CA108947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088716, R01GM068107] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We dedicate this paper in fond memory of Arun Fotedar, a colleague and friend, whose laughter infected us all. We thank Kristian Helin (European Institute of Oncology, Italy) for Cdc6 antibody, Hideo Nishitani (Kyushu University) for Cdt1 antibody and Robert J Schultz (NCI, Bethesda, MD) for UCN-01. This work was supported by grants from the National Institutes of Health to RF (CA108947 and CA101810) and to RM (GM068107 and GM088716).	ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; Arias EE, 2007, GENE DEV, V21, P497, DOI 10.1101/gad.1508907; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Busby EC, 2000, CANCER RES, V60, P2108; Cai DP, 2006, CANCER RES, V66, P9270, DOI 10.1158/0008-5472.CAN-06-1758; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; Damiens E, 2001, ONCOGENE, V20, P3786, DOI 10.1038/sj.onc.1204503; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Di Fiore B, 2007, J CELL BIOL, V177, P425, DOI 10.1083/jcb.200611166; Diffley JFX, 2002, J CELL SCI, V115, P869; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; Fotedar A, 1996, J BIOL CHEM, V271, P31627, DOI 10.1074/jbc.271.49.31627; Georgatos SD, 1997, J CELL SCI, V110, P2129; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; HAMILTON BT, 1982, EUR J CELL BIOL, V28, P190; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI200112466; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hochegger H, 2007, J CELL BIOL, V178, P257, DOI 10.1083/jcb.200702034; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; Kiang L, 2009, MOL CELL BIOL, V29, P4025, DOI 10.1128/MCB.00185-09; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; L'Italien L, 2006, CELL CYCLE, V5, P984, DOI 10.4161/cc.5.9.2721; Laronne A, 2003, MOL BIOL CELL, V14, P3730, DOI 10.1091/mbc.E02-12-0850; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee J, 2009, MOL BIOL CELL, V20, P1891, DOI 10.1091/mbc.E08-08-0818; MacCorkle RA, 2004, J BIOL CHEM, V279, P40112, DOI 10.1074/jbc.M405481200; Machida YJ, 2007, GENE DEV, V21, P184, DOI 10.1101/gad.1495007; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mingo-Sion AM, 2004, ONCOGENE, V23, P596, DOI 10.1038/sj.onc.1207147; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; Miyamoto-Yamasaki Y, 2007, CELL BIOL INT, V31, P1501, DOI 10.1016/j.cellbi.2007.07.002; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; O'Farrell PH, 2001, TRENDS CELL BIOL, V11, P512, DOI 10.1016/S0962-8924(01)02142-0; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Roberts EC, 2002, MOL CELL BIOL, V22, P7226, DOI 10.1128/MCB.22.20.7226-7241.2002; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Schmidt M, 2005, EMBO REP, V6, P866, DOI 10.1038/sj.embor.7400483; Sclafani RA, 2007, ANNU REV GENET, V41, P237, DOI 10.1146/annurev.genet.41.110306.130308; Seki A, 2008, J CELL BIOL, V181, P65, DOI 10.1083/jcb.200712027; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Uetake Y, 2007, CURR BIOL, V17, P2081, DOI 10.1016/j.cub.2007.10.065; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wang M, 2009, J PATHOL, V218, P95, DOI 10.1002/path.2521; Yu Q, 2002, CANCER RES, V62, P5743; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035	60	47	49	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	2010	29	11					1702	1716		10.1038/onc.2009.464	http://dx.doi.org/10.1038/onc.2009.464			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	20062077	Green Accepted			2022-12-17	WOS:000275694700015
J	Sirvent, A; Benistant, C; Pannequin, J; Veracini, L; Simon, V; Bourgaux, JF; Hollande, F; Cruzalegui, F; Roche, S				Sirvent, A.; Benistant, C.; Pannequin, J.; Veracini, L.; Simon, V.; Bourgaux, J-F; Hollande, F.; Cruzalegui, F.; Roche, S.			Src family tyrosine kinases-driven colon cancer cell invasion is induced by Csk membrane delocalization	ONCOGENE			English	Article						tyrosine kinase Src; oncogenic signalling; colorectal cancer; invasion; Csk	ADAPTER PROTEIN; DOWN-REGULATION; BREAST-CANCER; ENRICHED MICRODOMAINS; C-SRC; GROWTH; ACTIVATION; PHOSPHORYLATION; PROLIFERATION; ASSOCIATION	The nonreceptor tyrosine kinases of the Src family (SFK) are frequently deregulated in human colorectal cancer (CRC), and they have been implicated in tumour growth and metastasis. How SFK are activated in this cancer has not been clearly established. Here, we show that the SFK-dependent invasion is induced by inactivation of the negative regulator C-terminal Src kinase, Csk. While the level of Csk was inconsistent with SFK activity in colon cancer cells, its membrane translocation, needed for efficient regulation of membrane-localized SFK activity, was impaired. Accordingly, Csk downregulation did not affect SFK oncogenic activity in these cells, whereas expression of a membrane-localized form of this kinase affected their invasive activity. Downregulation of the transmembrane and rafts-localized Csk-binding protein/phosphoprotein associated with glycosphingolipid-enriched microdomain (PAG), was instrumental for the cytoplasmic accumulation of Csk. Re-expression of PAG in cells from late-stage CRC inhibited SFK invasive activity in a Csk-dependent manner. Conversely, inactivation of its residual expression in early-stage CRC cells promoted SFK invasive activity. Finally, this mechanism was specific to CRC as Csk coupling to SFK was readily detected in breast cancer cells. Therefore, Csk mis-localization defines a novel mechanism for SFK oncogenic activation in CRC cells. Oncogene (2010) 29, 1303-1315; doi:10.1038/onc.2009.450; published online 14 December 2009	[Sirvent, A.; Benistant, C.; Veracini, L.; Simon, V.; Roche, S.] Univ Montpellier I, CNRS, CRBM, UMR5237,Equipe Labellisee Ligue Natl Canc, F-34293 Montpellier 05, France; [Pannequin, J.; Hollande, F.] Univ Montpellier 2, IGF, Montpellier, France; [Pannequin, J.; Hollande, F.] Univ Montpellier I, INSERM, U661, UMR5203, F-34293 Montpellier 05, France; [Bourgaux, J-F] CHU Caremeau, Serv Hepatogastroenterol, Nimes, France; [Cruzalegui, F.] Inst Rech Servier, Div Canc Res & Drug Discovery, Croissy Sur Seine, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Nimes; Servier; Institut de Recherches Internationales Servier	Roche, S (corresponding author), Univ Montpellier I, CNRS, CRBM, UMR5237,Equipe Labellisee Ligue Natl Canc, 1919 Route Mende, F-34293 Montpellier 05, France.	serge.roche@crbm.cnrs.fr	Hollande, Frederic/E-3133-2013; Hollande, Frederic/GLS-4120-2022; Benistant, Christine/M-5771-2018	Hollande, Frederic/0000-0002-7046-8392; roche, serge/0000-0003-3413-3859; pannequin, julie/0000-0002-9956-373X	Servier Laboratories; la Ligue Nationale Contre le Cancer; CNRS; University of Montpellier 1 and 2; l'Association pour la Recherche contre le Cancer (ARC); INCa;  [4025]	Servier Laboratories; la Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); CNRS(Centre National de la Recherche Scientifique (CNRS)); University of Montpellier 1 and 2; l'Association pour la Recherche contre le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); INCa(Institut National du Cancer (INCA) France); 	We thank M Okada, S Parsons, P Mangeat and N Morin for various reagents; C Naudin, G Collin and C Leroy for technical assistance; Sylvain De Rossi and Virginie Georget (Montpellier RIO Imaging platform) for confocal microscopy analysis; and J Hickmann for helpful discussion. This work was supported by Servier Laboratories, la Ligue Nationale Contre le Cancer, the CNRS, the University of Montpellier 1 and 2 and l'Association pour la Recherche contre le Cancer (ARC, n<SUP>o</SUP> 4025). AS was supported by Servier Laboratories and by the INCa. SR and CB are INSERM investigators.	Baumeister U, 2005, EMBO J, V24, P1686, DOI 10.1038/sj.emboj.7600647; Benistant C, 2001, CANCER RES, V61, P1415; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; Boureux A, 2005, J CELL SCI, V118, P3717, DOI 10.1242/jcs.02491; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Cam WR, 2001, CANCER, V92, P61, DOI 10.1002/1097-0142(20010701)92:1<61::AID-CNCR1292>3.0.CO;2-D; Causeret M, 2005, MOL BIOL CELL, V16, P2168, DOI 10.1091/mbc.E04-09-0829; Collin G, 2007, MOL CELL BIOL, V27, P7631, DOI 10.1128/MCB.00543-07; Emaduddin M, 2008, P NATL ACAD SCI USA, V105, P2358, DOI 10.1073/pnas.0712176105; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Horejsi V, 2004, NAT REV IMMUNOL, V4, P603, DOI 10.1038/nri1414; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Ingley E, 2006, J BIOL CHEM, V281, P31920, DOI 10.1074/jbc.M602637200; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Ishizawar RC, 2004, J BIOL CHEM, V279, P23773, DOI 10.1074/jbc.M312368200; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; KOEGL M, 1994, BIOCHEM J, V302, P737, DOI 10.1042/bj3020737; Kunte DP, 2005, FEBS LETT, V579, P3497, DOI 10.1016/j.febslet.2005.05.030; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Leroy C, 2009, CANCER RES, V69, P2279, DOI 10.1158/0008-5472.CAN-08-2354; Liang FB, 2007, J BIOL CHEM, V282, P5413, DOI 10.1074/jbc.M608940200; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Miyagi T, 2008, BBA-GEN SUBJECTS, V1780, P532, DOI 10.1016/j.bbagen.2007.09.016; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; Nusrat A, 2000, J CELL SCI, V113, P1771; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Pannequin J, 2007, GASTROENTEROLOGY, V133, P1554, DOI 10.1053/j.gastro.2007.08.023; Read RD, 2004, MOL CELL BIOL, V24, P6676, DOI 10.1128/mcb.24.15.6676-6689.2004; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Saito K, 2008, BIOCHEM BIOPH RES CO, V366, P969, DOI 10.1016/j.bbrc.2007.12.055; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Sirvent A, 2007, ONCOGENE, V26, P7313, DOI 10.1038/sj.onc.1210543; Smida M, 2007, BLOOD, V110, P596, DOI 10.1182/blood-2006-07-038752; Solheim SA, 2008, J BIOL CHEM, V283, P2773, DOI 10.1074/jbc.M705215200; Stewart RA, 2003, ONCOGENE, V22, P6436, DOI 10.1038/sj.onc.1206820; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Tauzin S, 2008, BLOOD, V111, P2310, DOI 10.1182/blood-2007-05-090985; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Veracini L, 2008, J CELL BIOL, V182, P603, DOI 10.1083/jcb.200705102; Veracini L, 2006, J CELL SCI, V119, P2921, DOI 10.1242/jcs.03015; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zhao MM, 2006, MOL CELL BIOL, V26, P2479, DOI 10.1128/MCB.26.7.2479-2489.2006; Zheng X, 2008, INT J CANCER, V122, P1999, DOI 10.1002/ijc.23321; Zhu S, 2008, ONCOGENE, V27, P2027, DOI 10.1038/sj.onc.1210838; Zhu S, 2007, CANCER RES, V67, P10129, DOI 10.1158/0008-5472.CAN-06-4338	47	47	47	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1303	1315		10.1038/onc.2009.450	http://dx.doi.org/10.1038/onc.2009.450			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	20010872	Green Submitted			2022-12-17	WOS:000275170600006
J	Ming, M; Han, W; Maddox, J; Soltani, K; Shea, CR; Freeman, DM; He, YY				Ming, M.; Han, W.; Maddox, J.; Soltani, K.; Shea, C. R.; Freeman, D. M.; He, Y-Y			UVB-induced ERK/AKT-dependent PTEN suppression promotes survival of epidermal keratinocytes	ONCOGENE			English	Article						PTEN; UVB; keratinocytes; AKT	NONMELANOMA SKIN-CANCER; TUMOR-SUPPRESSOR; GERMLINE MUTATIONS; GENE; APOPTOSIS; PHOSPHORYLATION; TRANSFORMATION; PROGRESSION; PTEN/MMAC1; EXPRESSION	Ultraviolet (UV) radiation in sunlight is the major environmental cause of skin cancer. PTEN (phosphatase and tensin homolog deleted on chromosome 10) is a proven critical tumor suppressor. We report here that UVB downregulates PTEN in primary human keratinocytes, human HaCaT keratinocytes and mouse skin. As compared with normal skin, PTEN levels are reduced in human actinic keratosis, a precancerous skin lesion caused by solar UV. PTEN downregulation is mediated by two mechanisms: (1) PTEN is cleaved by active caspase in apoptotic cells in which AKT activation is reduced; and (2) PTEN transcription is suppressed in surviving cells, and this suppression is independent of caspase activation and occurs in parallel with increased ERK and AKT activation. We report here that the combination of ERK and AKT activation is crucial for PTEN suppression in surviving cells following UVB irradiation. AKT activation is higher in UVB-irradiated surviving cells as compared with unirradiated cells. The ERK and AKT pathways are involved in sustaining PTEN suppression in UVB-exposed cells. Increasing PTEN expression enhances apoptosis of keratinocytes in response to UVB irradiation. Our findings indicate that (1) UVB radiation suppresses PTEN expression in keratinocytes; and (2) the ERK/AKT/PTEN axis may form a positive feedback loop following UVB irradiation. Our identification of PTEN as a critical molecular target of UVB provides new insights into the pathogenesis of skin cancer. Oncogene (2010) 29, 492-502; doi: 10.1038/onc.2009.357; published online 2 November 2009	[Ming, M.; Han, W.; Maddox, J.; Soltani, K.; Shea, C. R.; Freeman, D. M.; He, Y-Y] Univ Chicago, Dermatol Sect, Dept Med, Chicago, IL 60637 USA	University of Chicago	He, YY (corresponding author), Univ Chicago, Dermatol Sect, Dept Med, 5841 S Maryland Ave,MC5067, Chicago, IL 60637 USA.	yyhe@medicine.bsd.uchicago.edu	Shea, Christopher R./AAJ-7143-2021		Department of Medicine and the Section of Dermatology at the University of Chicago; American Skin Association to the University of Chicago Cancer Research Center [P30 CA014599]; Wendy Will Case Cancer Fund Inc.; CTSA [NIH UL1RR024999]; University of Chicago; NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016936] Funding Source: NIH RePORTER	Department of Medicine and the Section of Dermatology at the University of Chicago; American Skin Association to the University of Chicago Cancer Research Center; Wendy Will Case Cancer Fund Inc.; CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); University of Chicago(University of Chicago); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by the Department of Medicine and the Section of Dermatology at the University of Chicago, the American Skin Association to the University of Chicago Cancer Research Center (P30 CA014599), the Wendy Will Case Cancer Fund Inc., the CTSA (NIH UL1RR024999), and the University of Chicago 'Friends of Dermatology' Endowment Fund. We thank Terri Li for PTEN immunohistochemistry. We are grateful to Dr Christopher Kontos for the adenoviral PTEN vector and Dr William Sellers for the HA-PTEN plasmid.	Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; Birck A, 2000, J INVEST DERMATOL, V114, P277, DOI 10.1046/j.1523-1747.2000.00877.x; BODE AM, 2003, SCI STKE, pRE2; Bowden GT, 2004, NAT REV CANCER, V4, P23, DOI 10.1038/nrc1253; Byun DS, 2003, INT J CANCER, V104, P318, DOI 10.1002/ijc.10962; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DIFFEY BL, 1991, CLIN PHYS PHYSIOL M, V12, P311, DOI 10.1088/0143-0815/12/4/001; DIFFEY BL, 1991, PHYS MED BIOL, V36, P299, DOI 10.1088/0031-9155/36/3/001; Erb P, 2008, ADV EXP MED BIOL, V624, P283, DOI 10.1007/978-0-387-77574-6_22; Grzanka D, 2006, NEOPLASMA, V53, P328; Harima Y, 2001, INT J ONCOL, V18, P493; He YY, 2008, PHOTOCHEM PHOTOBIOL, V84, P69, DOI 10.1111/j.1751-1097.2007.00199.x; He YY, 2008, CANCER RES, V68, P3752, DOI 10.1158/0008-5472.CAN-07-6138; He YY, 2006, ONCOGENE, V25, P3680, DOI 10.1038/sj.onc.1209384; He YY, 2006, ONCOGENE, V25, P1521, DOI 10.1038/sj.onc.1209184; He YY, 2004, J INVEST DERMATOL, V122, P533, DOI 10.1046/j.0022-202X.2003.22123.x; Hettinger K, 2007, CELL DEATH DIFFER, V14, P218, DOI 10.1038/sj.cdd.4401946; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Li G, 2002, DEVELOPMENT, V129, P4159; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Polo SE, 2006, CELL, V127, P481, DOI 10.1016/j.cell.2006.08.049; Ramos J, 2004, CANCER EPIDEM BIOMAR, V13, P2006; Rigel DS, 2008, J AM ACAD DERMATOL, V58, pS129, DOI 10.1016/j.jaad.2007.04.034; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 2003, CANCER RES, V63, P674; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Torres J, 2003, J BIOL CHEM, V278, P30652, DOI 10.1074/jbc.M212610200; Vasudevan KM, 2007, CANCER RES, V67, P10343, DOI 10.1158/0008-5472.CAN-07-1827; WEBB AR, 1988, J CLIN ENDOCR METAB, V67, P373, DOI 10.1210/jcem-67-2-373; Wong JW, 2000, J INVEST DERMATOL, V115, P427, DOI 10.1046/j.1523-1747.2000.00077.x	33	47	56	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					492	502		10.1038/onc.2009.357	http://dx.doi.org/10.1038/onc.2009.357			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881543	Green Accepted			2022-12-17	WOS:000274084600003
J	Pena, C; Garcia, JM; Larriba, MJ; Barderas, R; Gomez, I; Herrera, M; Garcia, V; Silva, J; Dominguez, G; Rodriguez, R; Cuevas, J; de Herreros, AG; Casal, JI; Munoz, A; Bonilla, F				Pena, C.; Garcia, J. M.; Larriba, M. J.; Barderas, R.; Gomez, I.; Herrera, M.; Garcia, V.; Silva, J.; Dominguez, G.; Rodriguez, R.; Cuevas, J.; de Herreros, A. G.; Casal, J. I.; Munoz, A.; Bonilla, F.			SNAI1 expression in colon cancer related with CDH1 and VDR downregulation in normal adjacent tissue	ONCOGENE			English	Article						colorectal cancer; epithelial-mesenchymal transition; SNAI1; CDH1; normal adjacent tissue	TRANSCRIPTION FACTOR SNAIL; VITAMIN-D-RECEPTOR; CADHERIN GENE-EXPRESSION; TUMOR PROGRESSION; IN-SITU; BREAST; CARCINOMA; CELLS; HETEROZYGOSITY; TRANSITION	SNAI1, ZEB1, E-cadherin (CDH1), and vitamin D receptor (VDR) genes regulate the epithelial-mesenchymal transition (EMT) that initiates the invasion process of many tumor cells. We hypothesized that this process could also affect the behavior of normal cells adjacent to the tumor. To verify this hypothesis, the expression level of these genes was determined by quantitative RT-PCR in tumor, normal adjacent, and normal distant tissues from 32 colorectal cancer (CC) patients. In addition, we extended the study to human HaCaT normal keratinocytes and SW480-ADH colon cancer cells co-cultured with SW480-ADH cells over-expressing the mouse Snai1 gene. Of 18 CC cases with SNAI1 expression in tumor tissue, five also had SNAI1 in normal adjacent tissue (NAT). Expression of SNAI1 in tumor tissue correlated with downregulation of CDH1 and VDR genes in both tumor (P = 0.047 and P = 0.014, respectively) and NAT lacking SNAI1 expression (P = 0.054 and P = 0.003). ZEB1 expression was directly related to VDR expression in tumor tissue (r = 0.39; P = 0.027) and inversely to CDH1 in NAT (r = -0.46; P = 0.010). CDH1 and VDR were also downregulated in SW480-ADH and MaCaT cells, respectively, when they were co-cultured with Snai1-expressing cells. Furthermore, cytokine analysis showed differences in the conditioned media obtained from the two cell types. These results indicate that histologically normal tissue adjacent to tumor tissue expressing the EMT-inducing gene SNAI1 shows alterations in the expression of epithelial differentiation genes such as CDH1 and VDR. Oncogene (2009) 28, 4375-4385; doi: 10.1038/onc.2009.285; published online 5 October 2009	[Pena, C.; Garcia, J. M.; Gomez, I.; Herrera, M.; Garcia, V.; Silva, J.; Dominguez, G.; Bonilla, F.] Hosp Univ Puerta Hierro Majadahonda, Dept Med Oncol, E-28222 Madrid, Spain; [Larriba, M. J.; Munoz, A.] Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain; [Barderas, R.; Casal, J. I.] CSIC, CIB, Funct Prote Lab, Madrid, Spain; [Rodriguez, R.] Hosp Virgen Salud, Dept Pathol, Toledo, Spain; [Cuevas, J.] Hosp Gen Univ, Dept Pathol, Guadalajara, Spain; [de Herreros, A. G.] Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, Barcelona, Spain	Hospital Puerta de Hierro-Majadahonda; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Complejo Hospitalario de Toledo; Pompeu Fabra University	Bonilla, F (corresponding author), Hosp Univ Puerta Hierro Majadahonda, Dept Med Oncol, C Joaquin Rodrigo,2 Majadahonda, E-28222 Madrid, Spain.	fbonilla.hpth@salud.madrid.org	Munoz, Alberto/O-6393-2014; Casal, Ignacio/M-2312-2014; de Herreros, A Garcia/H-3104-2014; Barderas, Rodrigo/K-3560-2014; LARRIBA, MARIA JESUS/O-4652-2014	Munoz, Alberto/0000-0003-3890-4251; Casal, Ignacio/0000-0003-1085-2840; de Herreros, A Garcia/0000-0001-5270-0808; Barderas, Rodrigo/0000-0003-3539-7469; LARRIBA, MARIA JESUS/0000-0001-9035-7414; Garcia-Barberan, Vanesa/0000-0002-2531-0203	Accion Transversal del Cancer (ISCIII);  [SAF2007-60431];  [CAM: S-GEN/0266/2006];  [ISCIII-RETIC RD06/0020 and /0009]	Accion Transversal del Cancer (ISCIII)(Instituto de Salud Carlos III); ; ; 	We thank M Eaude for help with the English paper. This study was supported by the grants SAF2007-60431, CAM: S-GEN/0266/2006, ISCIII-RETIC RD06/0020 and /0009, and a grant from the Accion Transversal del Cancer (ISCIII).	Aboseif S, 1999, DIFFERENTIATION, V65, P113, DOI 10.1046/j.1432-0436.1999.6520113.x; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Baulida J, 1999, BIOCHEM J, V344, P565, DOI 10.1042/0264-6021:3440565; Blanco MJ, 2007, DEVELOPMENT, V134, P4073, DOI 10.1242/dev.006858; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brown LF, 1999, CLIN CANCER RES, V5, P1041; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; Forsti A, 2001, EUR J CANCER, V37, P1372, DOI 10.1016/S0959-8049(01)00118-6; Franci C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herzig M, 2002, BBA-REV CANCER, V1602, P97, DOI 10.1016/S0304-419X(02)00039-2; Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007; Kurose K, 2001, HUM MOL GENET, V10, P1907, DOI 10.1093/hmg/10.18.1907; Lakhani SR, 1999, J PATHOL, V189, P496, DOI 10.1002/(SICI)1096-9896(199912)189:4&lt;496::AID-PATH485&gt;3.0.CO;2-D; Larson PS, 1998, AM J PATHOL, V152, P1591; Larson PS, 2002, AM J PATHOL, V161, P283, DOI 10.1016/S0002-9440(10)64180-6; Lazarova DL, 2001, CELL GROWTH DIFFER, V12, P319; Li YW, 2000, DIFFERENTIATION, V66, P126, DOI 10.1046/j.1432-0436.2000.660207.x; Li Z, 2002, CANCER RES, V62, P1000; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Locascio A, 2002, J BIOL CHEM, V277, P38803, DOI 10.1074/jbc.M205358200; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Menke A, 2001, CANCER RES, V61, P3508; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nilsson E, 2001, J SOC GYNECOL INVEST, V8, pS17, DOI 10.1016/S1071-5576(00)00099-X; Olumi AF, 1999, CANCER RES, V59, P5002; OTO M, 1993, ANAL BIOCHEM, V213, P19, DOI 10.1006/abio.1993.1379; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pena C, 2005, HUM MOL GENET, V14, P3361, DOI 10.1093/hmg/ddi366; Pena C, 2006, INT J CANCER, V119, P2098, DOI 10.1002/ijc.22083; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Postigo AA, 2003, EMBO J, V22, P2453, DOI 10.1093/emboj/cdg226; Ren ZP, 1996, ONCOGENE, V12, P765; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; SOZZI G, 1991, CANCER RES, V51, P400; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; TOMITA N, 1992, CANCER RES, V52, P6840; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528	50	47	53	3	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2009	28	49					4375	4385		10.1038/onc.2009.285	http://dx.doi.org/10.1038/onc.2009.285			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DT	19802011	Green Submitted			2022-12-17	WOS:000272876400006
J	Shimabe, M; Goyama, S; Watanabe-Okochi, N; Yoshimi, A; Ichikawa, M; Imai, Y; Kurokawa, M				Shimabe, M.; Goyama, S.; Watanabe-Okochi, N.; Yoshimi, A.; Ichikawa, M.; Imai, Y.; Kurokawa, M.			Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells	ONCOGENE			English	Article						Evi-1; Pbx1; leukemogenesis; target gene	MYELOID-TRANSFORMING GENE; DNA-BINDING; STEM-CELLS; PRE-B; TRANSCRIPTION FACTOR-1; TRANSLOCATION PROTEIN; ZINC FINGERS; SELF-RENEWAL; IDENTIFICATION; SEQUENCE	Ecotropic viral integration site-1 (Evi-1) is a nuclear transcription factor, which is essential for the proliferation/maintenance of hematopoietic stem cells (HSCs). Aberrant expression of Evi-1 has been frequently found in myeloid leukemia, and is associated with a poor patient survival. Recently, we reported candidate target genes of Evi-1 shared in HSCs and leukemic cells using gene expression profiling analysis. In this study, we identified Pbx1, a proto-oncogene in hematopoietic malignancy, as a target gene of Evi-1. Overexpression of Evi-1 increased Pbx1 expression in hematopoietic stem/progenitor cells. An analysis of the Pbx1 promoter region revealed that Evi-1 upregulates Pbx1 transcription. Furthermore, reduction of Pbx1 levels through RNAi-mediated knockdown significantly inhibited Evi-1-induced transformation. In contrast, knockdown of Pbx1 did not impair bone marrow transformation by E2A/HLF or AML1/ETO, suggesting that Pbx1 is specifically required for the maintenance of bone marrow transformation mediated by Evi-1. These results indicate that Pbx1 is a target gene of Evi-1 involved in Evi-1-mediated leukemogenesis. Oncogene (2009) 28, 4364-4374; doi: 10.1038/onc.2009.288; published online 21 September 2009	[Kurokawa, M.] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Kurokawa, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kurokawa-tky@umin.ac.jp	Yoshimi, Akihide/I-3792-2019	Yoshimi, Akihide/0000-0002-0664-7281; Imai, Yoichi/0000-0002-2938-6133	Japan Society for the Promotion of Science; Health and Labour Sciences Research; Ministry of Health, Labour and Welfare; Grants-in-Aid for Scientific Research [19679004] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Health and Labour Sciences Research(Ministry of Health, Labour and Welfare, Japan); Ministry of Health, Labour and Welfare(Ministry of Health, Labour and Welfare, Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank T Kitamura for Plat-E packaging cells and pMYs-IG retrovirus vector, H Nakauchi and M Onodera for pGCDNsameGFP retroviral vector, T Inaba for E2A/HLF cDNA, SW Hiebert for AML1/ETO cDNA, D Bohmann for c-Jun cDNA, Y Shimamura for expert technical assistance, and KYOWA KIRIN for cytokines. This work was supported in part by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, and by Health and Labour Sciences Research grants from Ministry of Health, Labour and Welfare.	DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DiMartino JF, 2001, BLOOD, V98, P618, DOI 10.1182/blood.V98.3.618; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; Ficara F, 2008, CELL STEM CELL, V2, P484, DOI 10.1016/j.stem.2008.03.004; FUNABIKI T, 1994, ONCOGENE, V9, P1575; Goyama S, 2008, CELL STEM CELL, V3, P207, DOI 10.1016/j.stem.2008.06.002; Goyama S, 2009, CANCER SCI, V100, P990, DOI 10.1111/j.1349-7006.2009.01152.x; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Jin GA, 2007, BLOOD, V109, P3998, DOI 10.1182/blood-2006-08-041202; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kim SK, 2002, NAT GENET, V30, P430, DOI 10.1038/ng860; Knoepfler PS, 2001, ONCOGENE, V20, P5440, DOI 10.1038/sj.onc.1204710; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 2000, EMBO J, V19, P2958, DOI 10.1093/emboj/19.12.2958; Laricchia-Robbio L, 2008, BLOOD CELL MOL DIS, V40, P141, DOI 10.1016/j.bcmd.2007.07.012; Laricchia-Robbio L, 2009, CANCER RES, V69, P1633, DOI 10.1158/0008-5472.CAN-08-2562; Lawrence HJ, 1996, STEM CELLS, V14, P281, DOI 10.1002/stem.140281; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Lim JH, 2005, HUM MOL GENET, V14, P2027, DOI 10.1093/hmg/ddi207; Liu Y, 2006, ONCOGENE, V25, P3565, DOI 10.1038/sj.onc.1209403; Lugthart S, 2008, BLOOD, V111, P4329, DOI 10.1182/blood-2007-10-119230; Manley NR, 2004, DEV BIOL, V276, P301, DOI 10.1016/j.ydbio.2004.08.030; MANN RS, 1995, BIOESSAYS, V17, P855, DOI 10.1002/bies.950171007; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Nitta E, 2005, ONCOGENE, V24, P6165, DOI 10.1038/sj.onc.1208754; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Ogawa S, 1996, ONCOGENE, V13, P183; Park JT, 2008, CANCER RES, V68, P8852, DOI 10.1158/0008-5472.CAN-08-0517; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PINTADO T, 1985, CANCER, V55, P535, DOI 10.1002/1097-0142(19850201)55:3<535::AID-CNCR2820550311>3.0.CO;2-4; Qiu Y, 2007, AM J PATHOL, V170, P152, DOI 10.2353/ajpath.2007.060722; Sato T, 2008, CANCER SCI, V99, P1407, DOI 10.1111/j.1349-7006.2008.00842.x; Schnabel CA, 2000, ONCOGENE, V19, P608, DOI 10.1038/sj.onc.1203371; Schnabel CA, 2003, DEV BIOL, V254, P262, DOI 10.1016/S0012-1606(02)00038-6; Selleri L, 2001, DEVELOPMENT, V128, P3543; Shiraishi K, 2007, ONCOGENE, V26, P339, DOI 10.1038/sj.onc.1209800; Smith KS, 2002, MOL CELL BIOL, V22, P7678, DOI 10.1128/MCB.22.21.7678-7688.2002; SUZUKAWA K, 1994, BLOOD, V84, P2681; Takeshita M, 2008, LEUKEMIA, V22, P1241, DOI 10.1038/leu.2008.53; TANAKA T, 1994, J BIOL CHEM, V269, P24020; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; van Doorn-Khosrovani SBV, 2003, BLOOD, V101, P837, DOI 10.1182/blood-2002-05-1459; Watanabe-Okochi N, 2008, BLOOD, V111, P4297, DOI 10.1182/blood-2007-01-068346; Yaron Y, 2001, J IMMUNOL, V166, P5058, DOI 10.4049/jimmunol.166.8.5058; Yatsula B, 2005, J BIOL CHEM, V280, P30712, DOI 10.1074/jbc.M504293200; Yuasa H, 2005, EMBO J, V24, P1976, DOI 10.1038/sj.emboj.7600679	48	47	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2009	28	49					4364	4374		10.1038/onc.2009.288	http://dx.doi.org/10.1038/onc.2009.288			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DT	19767769				2022-12-17	WOS:000272876400005
J	Gao, SB; Feng, ZJ; Xu, B; Wu, Y; Yin, P; Yang, Y; Hua, X; Jin, GH				Gao, S-B; Feng, Z-J; Xu, B.; Wu, Y.; Yin, P.; Yang, Y.; Hua, X.; Jin, G-H			Suppression of lung adenocarcinoma through menin and polycomb gene-mediated repression of growth factor pleiotrophin	ONCOGENE			English	Article						lung adenocarcinoma; histone H3 lysine 27; Men1; pleiotrophin; Polycomb	ANAPLASTIC LYMPHOMA KINASE; TYROSINE-PHOSPHATASE-BETA/ZETA; EXPRESSION; CANCER; MLL; IDENTIFICATION; RECEPTOR; FIBROBLASTS; METHYLATION; P18(INK4C)	Menin upregulates transcription of cell-cycle inhibitors to suppress endocrine tumors, but it is poorly understood how menin suppresses non-endocrine tumors such as lung cancer. Here, we show that menin inhibits proliferation of human lung cancer cells and growth of lung cancer in mice. The menin-mediated tumor suppression requires repression of growth factor pleiotrophin (PTN), which binds to its cell surface receptor, anaplastic lymphoma kinase (ALK) that is activated in certain lung adenocarcinomas. Menin represses PTN transcription and PTN-induced proliferation of human lung cancer cells, and menin expression is substantially reduced in primary human lung adenocarcinomas. Notably, menin binds the PTN locus and enhances Polycomb gene Enhancer of Zeste homolog 2 (EZH2)-mediated histone H3 lysine 27 trimethylation (H3K27m3), a negative mark for gene transcription but does not affect histone H3K4 methylation that is usually upregulated by menin in endocrine cells. Together, our findings indicate that menin suppresses lung cancer partly through increasing Polycomb gene-mediated H3K27 methylation and repressing PTN transcription, unraveling a novel, epigenetically regulated PTN-ALK signaling pathway in suppressing lung cancer. Oncogene (2009) 28, 4095-4104; doi:10.1038/onc.2009.273; published online 14 September 2009	[Yang, Y.; Hua, X.] Univ Penn, Dept Canc Biol, Philadelphia, PA 19096 USA; [Gao, S-B; Feng, Z-J; Xu, B.; Wu, Y.; Hua, X.; Jin, G-H] Xiamen Univ, Coll Med, Dept Basic Med Sci, Xiamen 361005, Fujian, Peoples R China; [Yin, P.] Xiamen Univ, Zhongshan Hosp, Dept Pathol, Xiamen, Peoples R China	University of Pennsylvania; Xiamen University; Xiamen University	Hua, X (corresponding author), Univ Penn, Dept Canc Biol, Room 412,BRB2-3,421 Curie Blvd, Philadelphia, PA 19096 USA.	huax@mail.med.upenn.edu; ghjin@xmu.edu.cn		Feng, Zijie/0000-0002-5633-3686	NFSC [30701003]; Natural Science Foundation of Fujian Province of China [C0710044]; National Cancer Institute Short-Term Scientist Exchange Program; National Cancer Institute [R01CA100912, R01CA113962]; NATIONAL CANCER INSTITUTE [R01CA100912, R01CA113962] Funding Source: NIH RePORTER	NFSC(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Fujian Province of China(Natural Science Foundation of Fujian Province); National Cancer Institute Short-Term Scientist Exchange Program; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is in partly supported by NFSC Grants (No 30701003, GH Jin), the Natural Science Foundation of Fujian Province of China (No C0710044, GH Jin), National Cancer Institute Short-Term Scientist Exchange Program (GH Jin), and National Cancer Institute Grants (R01CA100912 and R01CA113962, XH). We appreciate the valuable comments from other members of our laboratories.	Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Chen YX, 2006, P NATL ACAD SCI USA, V103, P1018, DOI 10.1073/pnas.0510347103; Choudhuri R, 1997, CANCER RES, V57, P1814; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Jager R, 2002, BRIT J CANCER, V86, P858, DOI 10.1038/sj.bjc.6600202; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Jin SH, 2003, CANCER RES, V63, P4204; Karnik SK, 2005, P NATL ACAD SCI USA, V102, P14659, DOI 10.1073/pnas.0503484102; La P, 2004, ENDOCRINOLOGY, V145, P3443, DOI 10.1210/en.2004-0124; Lemos MC, 2008, HUM MUTAT, V29, P22, DOI 10.1002/humu.20605; Lu KV, 2005, J BIOL CHEM, V280, P26953, DOI 10.1074/jbc.M502614200; Martin C, 2007, CURR OPIN CELL BIOL, V19, P266, DOI 10.1016/j.ceb.2007.04.002; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Pei XH, 2007, CANCER RES, V67, P3162, DOI 10.1158/0008-5472.CAN-06-4517; Perez-Pinera P, 2007, CELL CYCLE, V6, P2877, DOI 10.4161/cc.6.23.5090; Perez-Pinera P, 2007, J BIOL CHEM, V282, P28683, DOI 10.1074/jbc.M704505200; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Ringrose L, 2007, DEVELOPMENT, V134, P223, DOI 10.1242/dev.02723; Schnepp RW, 2006, CANCER RES, V66, P5707, DOI 10.1158/0008-5472.CAN-05-4518; Schnepp RW, 2004, J BIOL CHEM, V279, P10685, DOI 10.1074/jbc.M308073200; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Yan JZ, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000047; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632	30	47	50	4	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2009	28	46					4095	4104		10.1038/onc.2009.273	http://dx.doi.org/10.1038/onc.2009.273			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AE	19749796	Green Accepted			2022-12-17	WOS:000272560500005
J	Lafferty-Whyte, K; Cairney, CJ; Will, MB; Serakinci, N; Daidone, MG; Zaffaroni, N; Bilsland, A; Keith, WN				Lafferty-Whyte, K.; Cairney, C. J.; Will, M. B.; Serakinci, N.; Daidone, M-G; Zaffaroni, N.; Bilsland, A.; Keith, W. N.			A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT	ONCOGENE			English	Article						telomerase; ALT; mesenchymal; microarray; signalling; c-Myc	MAINTENANCE MECHANISMS; IN-VITRO; TRANSFORMATION; SARCOMAS; TUMORS; LIPOSARCOMAS; ASSOCIATION; PROGNOSIS; CULTURE; HTR	Telomere length is maintained by two known mechanisms, the activation of telomerase or alternative lengthening of telomeres (ALT). The molecular mechanisms regulating the ALT phenotype are poorly understood and it is unknown how the decision of which pathway to activate is made at the cellular level. We have shown earlier that active repression of telomerase gene expression by chromatin remodelling of the promoters is one mechanism of regulation; however, other genes and signalling networks are likely to be required to regulate telomerase and maintain the ALT phenotype. Using gene expression profiling, we have uncovered a signature of 1305 genes to distinguish telomerase-positive and ALT cell lines. By combining this with the gene expression profiles of liposarcoma tissue samples, we refined this signature to 297 genes. A network analysis of known interactions between genes within this signature revealed a regulatory signalling network consistent with a model of human telomerase reverse transcriptase (hTERT) repression in ALT cell lines and liposarcomas. This network expands on our existing knowledge of hTERT regulation and provides a platform to understand differential regulation of hTERT in different tumour types and normal tissues. We also show evidence to suggest a novel mesenchymal stem cell origin for ALT immortalization in cell lines and mesenchymal tissues. Oncogene (2009) 28, 3765-3774; doi:10.1038/onc.2009.238; published online 17 August 2009	[Lafferty-Whyte, K.; Cairney, C. J.; Will, M. B.; Bilsland, A.; Keith, W. N.] Univ Glasgow, Ctr Oncol & Appl Pharmacol, Canc Res UK Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; [Serakinci, N.] So Denmark Univ, Inst Reg Hlth Serv, Telomere & Aging Grp, Vejle, Denmark; [Daidone, M-G; Zaffaroni, N.] Ist Nazl Tumori, Unit 10, Dept Expt Oncol & Labs, Fdn IRCCS, I-20133 Milan, Italy	Beatson Institute; University of Glasgow; University of Southern Denmark; Fondazione IRCCS Istituto Nazionale Tumori Milan	Keith, WN (corresponding author), Univ Glasgow, Ctr Oncol & Appl Pharmacol, Canc Res UK Beatson Labs, Alexander Stone Bldg,Garscube Estate,Switchback R, Glasgow G61 1BD, Lanark, Scotland.	n.keith@beatson.gla.ac.uk	Zaffaroni, Nadia/J-8178-2016; Cairney, Claire/H-6989-2012; Daidone, Maria Grazia/E-9232-2017; Bilsland, Alan/G-2629-2010; Keith, Nicol/D-3325-2009	Zaffaroni, Nadia/0000-0002-4669-0890; Daidone, Maria Grazia/0000-0002-4786-1321; Keith, Nicol/0000-0001-7862-3580; Cairney, Claire/0000-0001-6531-245X; Bilsland, Alan/0000-0003-0957-3908; SERAKINCI, Nedime/0000-0002-1884-0839	Cancer Research UK; European Community [LSHC-CT-2004-502943, LSHC-CT-2005-0018806]; Glasgow University [Health-F2-2007-200950]; Italian Association for Cancer Research	Cancer Research UK(Cancer Research UK); European Community(European Commission); Glasgow University; Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Cancer Research UK, European Community Grants LSHC-CT-2004-502943, LSHC-CT-2005-0018806 and Health-F2-2007-200950 Glasgow University and Italian Association for Cancer Research.	Atkinson SP, 2005, CANCER RES, V65, P7585, DOI 10.1158/0008-5472.CAN-05-1715; Bernardo ME, 2007, CANCER RES, V67, P9142, DOI 10.1158/0008-5472.CAN-06-4690; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Cairney CJ, 2008, BRIT J CANCER, V98, P1467, DOI 10.1038/sj.bjc.6604328; Cairney CJ, 2008, BIOCHIMIE, V90, P13, DOI 10.1016/j.biochi.2007.07.025; Chen YJ, 2006, CANCER RES, V66, P6473, DOI 10.1158/0008-5472.CAN-06-0910; Costa A, 2006, CANCER RES, V66, P8918, DOI 10.1158/0008-5472.CAN-06-0273; Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394; Hakin-Smith V, 2003, LANCET, V361, P836, DOI 10.1016/S0140-6736(03)12681-5; Hao Huang, 2008, J Exp Clin Cancer Res, V27, P27, DOI 10.1186/1756-9966-27-27; Henson JD, 2005, CLIN CANCER RES, V11, P217; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Huang PR, 2008, BBA-MOL CELL RES, V1783, P193, DOI 10.1016/j.bbamcr.2007.08.006; Jiang WQ, 2007, ONCOGENE, V26, P4635, DOI 10.1038/sj.onc.1210260; Johnson JE, 2005, CLIN CANCER RES, V11, P5347, DOI 10.1158/1078-0432.CCR-05-0684; Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377; Mehle C, 1996, ONCOGENE, V13, P161; Miura M, 2006, STEM CELLS, V24, P1095, DOI 10.1634/stemcells.2005-0403; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Rubio D, 2005, CANCER RES, V65, P3035, DOI 10.1158/0008-5472.CAN-04-4194; Serakinci N, 2004, ONCOGENE, V23, P5095, DOI 10.1038/sj.onc.1207651; Serakinci N, 2006, REGEN MED, V1, P125, DOI 10.2217/17460751.1.1.125; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Ulaner GA, 2004, GENE CHROMOSOME CANC, V41, P155, DOI 10.1002/gcc.20074; Ulaner GA, 2003, CANCER RES, V63, P1759; Wang Y, 2005, CYTOTHERAPY, V7, P509, DOI 10.1080/14653240500363216; Wu CL, 2007, CANCER RES, V67, P8216, DOI 10.1158/0008-5472.CAN-07-0999; Yeager TR, 1999, CANCER RES, V59, P4175; Zhao YM, 2008, BIOCHEM BIOPH RES CO, V369, P1114, DOI 10.1016/j.bbrc.2008.03.011; Zhong ZH, 2007, J BIOL CHEM, V282, P29314, DOI 10.1074/jbc.M701413200; Zhou YF, 2006, CANCER RES, V66, P10849, DOI 10.1158/0008-5472.CAN-06-2146; Zimmermann S, 2003, LEUKEMIA, V17, P1146, DOI 10.1038/sj.leu.2402962	32	47	50	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	43					3765	3774		10.1038/onc.2009.238	http://dx.doi.org/10.1038/onc.2009.238			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512KT	19684619	Green Accepted			2022-12-17	WOS:000271248400001
J	Boehrer, S; Ades, L; Tajeddine, N; Hofmann, WK; Kriener, S; Bug, G; Ottmann, OG; Ruthardt, M; Galluzzi, L; Fouassier, C; Tailler, M; Olaussen, KA; Gardin, C; Eclache, V; de Botton, S; Thepot, S; Fenaux, P; Kroemer, G				Boehrer, S.; Ades, L.; Tajeddine, N.; Hofmann, W. K.; Kriener, S.; Bug, G.; Ottmann, O. G.; Ruthardt, M.; Galluzzi, L.; Fouassier, C.; Tailler, M.; Olaussen, K. A.; Gardin, C.; Eclache, V.; de Botton, S.; Thepot, S.; Fenaux, P.; Kroemer, G.			Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome	ONCOGENE			English	Article						leukemogenesis; apoptosis; cell cycle; ATM; Chk-1	ATM ACTIVATION; CELL-LINES; CLASSIFICATION; APOPTOSIS; KINASE; CHECKPOINT; PATHWAYS; COMPLEX; BARRIER; TARGET	The molecular mechanisms responsible for the evolution from the preleukemic entities of low-risk myelodysplastic syndrome (MDS) to the less favorable forms of high-risk MDS, as well as those enabling transformation to acute myeloid leukemia (AML), are still incompletely understood. Abundant evidence from solid tumors demonstrates that preneoplastic lesions activate signaling pathways of a DNA damage response (DDR), which functions as an 'anticancer barrier' hindering tumorigenesis. Testing the hypothesis that subgroups of MDS and AML differ with respect to DDR, we first assessed markers of DDR (phosphorylation of ATM, Chk-1, Chk-2 and H2AX) in cell lines representing different entities of MDS (P39, MOLM-13) and AML (MV4-11, KG-1) before and after gamma-irradiation. Although gamma-irradiation induced apoptosis and G(2)/M arrest and a concomitant increase in the phosphorylation of ATM, Chk-1 and H2AX in MDS-derived cell lines, this radiation response was attenuated in the AML-derived cell lines. It is noteworthy that KG-1, but not P39 cells exhibit signs of an endogenous activation of the DDR. Similarly, we found that the frequency of P-ATM(+) cells detectable in bone marrow (BM) biopsies increased in samples from patients with AML as compared with high-risk MDS samples and significantly correlated with the percentage of BM blasts. In contrast, the frequency of gamma-H2AX(+) cells was heterogeneous in all subgroups of AML and MDS. Whereas intermediate-1 MDS samples contained as little P-Chk-1 and P-Chk-2 as healthy controls, staining for both checkpoint kinases increased in intermediate-2 and high-risk MDS, yet declined to near-to-background levels in AML samples. Thus the activation of Chk-1 and Chk-2 behaves in accord with the paradigm established for solid tumors, whereas ATM is activated during and beyond transformation. In conclusion, we demonstrate the heterogeneity of the DDR response in MDS and AML and provide evidence for its selective suppression in AML because of the uncoupling between activated ATM and inactive checkpoint kinases. Oncogene (2009) 28, 2205-2218; doi: 10.1038/onc.2009.69; published online 27 April 2009	[Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Boehrer, S.; Ades, L.; Tajeddine, N.; Galluzzi, L.; Fouassier, C.; Tailler, M.; Olaussen, K. A.; Fenaux, P.; Kroemer, G.] Univ Paris 11, Paris, France; [Boehrer, S.; Ades, L.; Fouassier, C.; Gardin, C.; Eclache, V.; Thepot, S.; Fenaux, P.] Univ Paris 13, Hop Avicenne, AP HP, Serv Hematol Clin, Bobigny, France; [Hofmann, W. K.] Univ Hosp Benjamin Franklin, Charite, Dept Hematol & Oncol, Berlin, Germany; [Kriener, S.] Goethe Univ Frankfurt, Dept Pathol, Frankfurt, Germany; [Bug, G.; Ottmann, O. G.; Ruthardt, M.] Goethe Univ Frankfurt, Dept Hematol & Oncol, Frankfurt, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Goethe University Frankfurt; Goethe University Frankfurt	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Kroemer, Guido/AAY-9859-2020; Galluzzi, Lorenzo/AAG-6294-2019; Ades, lionel/T-6882-2019; Bug, Gesine/H-8827-2013; Galluzzi, Lorenzo/AAH-3286-2021; Ottmann, Oliver G/D-5007-2016; KROEMER, Guido/B-4263-2013; Galluzzi, Lorenzo/K-2709-2012	Ottmann, Oliver G/0000-0001-9559-1330; KROEMER, Guido/0000-0002-9334-4405; Galluzzi, Lorenzo/0000-0003-2257-8500; Ruthardt, Martin/0000-0003-1021-3811; Olaussen, Ken/0000-0002-3115-8914	Deutsche Forschungsgemeinschaft; Assistance Publique-Hopitaux de Paris; Caisse Nationale d'Assurance Maladie des Professions Independantes; Canceropole Ile-de-France,; Institut National du Cancer; Fondation de France; Association Laurette Fugain; Cent pour Sang la Vie; Agence National de la Recherche; European Commission (ApoSys, ChemoRes., Apopt-Train, RIGHT); Gutermuth-Stiftung	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Assistance Publique-Hopitaux de Paris; Caisse Nationale d'Assurance Maladie des Professions Independantes; Canceropole Ile-de-France,(Region Ile-de-France); Institut National du Cancer(Institut National du Cancer (INCA) France); Fondation de France(Fondation de France); Association Laurette Fugain; Cent pour Sang la Vie; Agence National de la Recherche(French National Research Agency (ANR)); European Commission (ApoSys, ChemoRes., Apopt-Train, RIGHT)(European CommissionEuropean Commission Joint Research Centre); Gutermuth-Stiftung	SB and LA contributed equally to this paper. SB receives a scholarship from the Deutsche Forschungsgemeinschaft, LA receives a scholarship from Assistance Publique-Hopitaux de Paris and Caisse Nationale d'Assurance Maladie des Professions Independantes. GK is supported by Canceropole Ile-de-France, Institut National du Cancer, Fondation de France, Association Laurette Fugain, Cent pour Sang la Vie, Agence National de la Recherche and the European Commission (ApoSys, ChemoRes., Apopt-Train, RIGHT). The project was carried out with the support from the Gutermuth-Stiftung. SB, LA, NT, LG, CF, MT and KAO. performed and analysed the experiments. WKH., SK., GB, OGO., MR, CG, VE, SdeB., ST and PF provided bone marrow biopsies and patient data. SB and GK designed the study and wrote the paper.	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartkova J, 2007, ONCOGENE, V26, P7414, DOI 10.1038/sj.onc.1210553; Bartkova J, 2005, CELL CYCLE, V4, P838, DOI 10.4161/cc.4.6.1742; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; Boehrer S, 2008, BLOOD, V111, P2170, DOI 10.1182/blood-2007-07-100362; Braun T, 2006, BLOOD, V107, P1156; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Coquelle A, 2006, BIOCHEM PHARMACOL, V72, P1396, DOI 10.1016/j.bcp.2006.04.014; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Fan C, 2006, BBA-MOL CELL RES, V1763, P1090, DOI 10.1016/j.bbamcr.2006.08.026; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Grimwade D., 2004, Annals of Hematology, V83, pS45; Grimwade D, 2001, BEST PRACT RES CL HA, V14, P497, DOI 10.1053/beha.2001.0152; Grimwade D, 2001, BLOOD, V98, P1312, DOI 10.1182/blood.V98.5.1312; Grosjean-Raillard J, 2009, ONCOGENE, V28, P1099, DOI 10.1038/onc.2008.457; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Horibe S, 2007, LEUKEMIA, V21, P2195, DOI 10.1038/sj.leu.2404748; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Klaus M, 2004, CANCER GENET CYTOGEN, V155, P47, DOI 10.1016/j.cancergencyto.2004.03.008; KOEFFLER HP, 1980, BLOOD, V56, P344; LANGE B, 1987, BLOOD, V70, P192; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; Matsuo Y, 1997, LEUKEMIA, V11, P1469, DOI 10.1038/sj.leu.2400768; NAGAI M, 1984, GANN, V75, P1100; Nuciforo PG, 2007, CARCINOGENESIS, V28, P2082, DOI 10.1093/carcin/bgm108; Parker JE, 2001, INT J HEMATOL, V73, P416, DOI 10.1007/BF02994003; Parker JE, 1998, BRIT J HAEMATOL, V101, P220; Parker JE, 2000, LEUKEMIA LYMPHOMA, V40, P1, DOI 10.3109/10428190009054877; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Slovak ML, 2000, BLOOD, V96, P4075, DOI 10.1182/blood.V96.13.4075; Thiriet C, 2005, MOL CELL, V18, P617, DOI 10.1016/j.molcel.2005.05.008; Tort F, 2006, CANCER RES, V66, P10258, DOI 10.1158/0008-5472.CAN-06-2178; Vardiman JW, 2002, BLOOD, V100, P2292, DOI 10.1182/blood-2002-04-1199; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; ZAMZAMI N, 2003, METH MOL B, V282, P103	42	47	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	22					2205	2218		10.1038/onc.2009.69	http://dx.doi.org/10.1038/onc.2009.69			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453VF	19398952				2022-12-17	WOS:000266640300003
J	Wang, H; Song, K; Krebs, TL; Yang, J; Danielpour, D				Wang, H.; Song, K.; Krebs, T. L.; Yang, J.; Danielpour, D.			Smad7 is inactivated through a direct physical interaction with the LIM protein Hic-5/ARA55	ONCOGENE			English	Article						Smad; TGF-beta; prostate; Smad2; Smad7; Hic-5	GROWTH-FACTOR-BETA; PLASMINOGEN-ACTIVATOR INHIBITOR-1; FACTOR-KAPPA-B; TGF-BETA; MALIGNANT-TRANSFORMATION; RECEPTOR COACTIVATOR; HIC-5; SUPPRESSION; EXPRESSION; APOPTOSIS	We recently reported that hydrogen peroxide-inducible clone-5 (Hic-5, also named androgen receptor-associated protein 55) can bind to the transforming growth factor-beta (TGF-beta)-signaling regulator Smad3, thereby inhibiting certain Smad3-dependent TGF-beta responses. We now show that Hic-5 can also control TGF-beta responses through an alternative mechanism involving Smad7, a key negative regulator of TGF-beta signaling. Hic-5 binds directly to Smad7. This interaction requires the LIM3 domain of Hic-5, and enhances TGF-beta signaling through causing loss of Smad7 protein but not mRNA. Enforced expression of Hic-5 reverses the ability of Smad7 to suppress TGF-beta-induced phosphorylation of Smads 2 and 3 and activation of the plasminogen activator inhibitor-1 promoter (in NRP-154 and PC3 prostate carcinoma and WPMY-1 prostate myofibroblast cell lines). Lentiviral-mediated small-hairpin RNA silencing of endogenous Hic-5 reduced TGF-beta responses in PC3 and WPMY-1 cells. Further work suggests that the level of Smad7 is modulated by its physical interaction with Hic-5 and targeted to a degradation pathway not likely to be proteasomal. Our findings support that Hic-5 functions as a cell-type-specific activator of TGF-beta signaling through its ability to physically interact with and neutralize Smad7. Oncogene (2008) 27, 6791-6805; doi:10.1038/onc.2008.291;published online 1 September 2008	[Wang, H.; Song, K.; Krebs, T. L.; Danielpour, D.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Div Gen Med Sci Oncol, Dept Pharmacol,Sch Med, Cleveland, OH 44106 USA; [Yang, J.] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Danielpour, D (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Div Gen Med Sci Oncol, Dept Pharmacol,Sch Med, Wolstein Res Bldg,Room 3532,2103 Cornell Rd, Cleveland, OH 44106 USA.	david.danielpour@case.edu			NCI [1R01CA102074, 1R01CA092102]; NATIONAL CANCER INSTITUTE [R01CA092102, R01CA102074] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Joan Massague for 3TP-lux plasmid, Dr Bert Vogelstein for SBE4<INF>BV</INF>-luciferase plasmid, Dr Kohei Miyazono for full-length mouse Flag-Smad7-pcDNA3 plasmid, Dr Bing-Cheng Wang for the pcDNA3-Myc plasmid, Dr Ryosuke Takahashi and Dr Yu-Chung Yang for HA-ubiquitin plasmid, Dr Malcolm Whitman for ARE-lux and Myc-FAST-1. This work was supported by NCI grants 1R01CA102074 and 1R01CA092102.	Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chipuk JE, 2002, J BIOL CHEM, V277, P26412, DOI 10.1074/jbc.M201244200; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; DABIRI G, 2008, J INVEST DE IN PRESS; DANIELPOUR D, 1994, CANCER RES, V54, P3413; Danielpour D, 2005, EUR J CANCER, V41, P846, DOI 10.1016/j.ejca.2004.12.027; Dong CM, 2002, P NATL ACAD SCI USA, V99, P3908, DOI 10.1073/pnas.062010399; Durand MK, 2004, THROMB HAEMOSTASIS, V91, P438, DOI 10.1160/TH03-12-0784; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Fujita H, 1998, J BIOL CHEM, V273, P26516, DOI 10.1074/jbc.273.41.26516; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heitzer MD, 2006, CANCER RES, V66, P7326, DOI 10.1158/0008-5472.CAN-05-2379; Heitzer MD, 2006, MOL ENDOCRINOL, V20, P56, DOI 10.1210/me.2005-0065; Hong S, 2007, CANCER RES, V67, P9577, DOI 10.1158/0008-5472.CAN-07-1179; Horrevoets AJG, 2004, BRIT J HAEMATOL, V125, P12, DOI 10.1111/j.1365-2141.2004.04844.x; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim SG, 2005, MOL BIOL CELL, V16, P4672, DOI 10.1091/mbc.E05-01-0054; Koinuma D, 2003, EMBO J, V22, P6458, DOI 10.1093/emboj/cdg632; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Lallemand F, 2005, J BIOL CHEM, V280, P27645, DOI 10.1074/jbc.M500188200; Lallemand F, 2001, ONCOGENE, V20, P879, DOI 10.1038/sj.onc.1204167; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; MASSAGUE J, 1992, MOL REPROD DEV, V32, P99, DOI 10.1002/mrd.1080320204; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mazars A, 2001, J BIOL CHEM, V276, P36797, DOI 10.1074/jbc.M101672200; Mori K, 2006, J BIOL CHEM, V281, P22048, DOI 10.1074/jbc.M513111200; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nishiya N, 2001, MOL CELL BIOL, V21, P5332, DOI 10.1128/MCB.21.16.5332-5345.2001; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; Rahimi RA, 2007, J CELL BIOCHEM, V102, P593, DOI 10.1002/jcb.21501; Rahman MM, 2003, P NATL ACAD SCI USA, V100, P5124, DOI 10.1073/pnas.0530097100; Shibanuma M, 2003, MOL BIOL CELL, V14, P1158, DOI 10.1091/mbc.02-06-0099; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Simonsson M, 2005, J BIOL CHEM, V280, P21797, DOI 10.1074/jbc.M503134200; Song K, 2006, J BIOL CHEM, V281, P7765, DOI 10.1074/jbc.M511781200; Song K, 2003, J BIOL CHEM, V278, P38342, DOI 10.1074/jbc.M304583200; Song K, 2003, CANCER RES, V63, P4358; Song KY, 2006, EMBO J, V25, P58, DOI 10.1038/sj.emboj.7600917; Tang BW, 1999, CANCER RES, V59, P4834; Thomas SM, 1999, J CELL SCI, V112, P181; Tumbarello DA, 2007, J CELL PHYSIOL, V211, P736, DOI 10.1002/jcp.20991; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang H, 2005, J BIOL CHEM, V280, P5154, DOI 10.1074/jbc.M411575200; Wang X, 2002, J BIOL CHEM, V277, P15426, DOI 10.1074/jbc.M111218200; Wicks SJ, 2005, ONCOGENE, V24, P8080, DOI 10.1038/sj.onc.1208944; Wilkes MC, 2006, J BIOL CHEM, V281, P27846, DOI 10.1074/jbc.M603721200; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; WRANA JL, 1992, COLD SPRING HARB SYM, V57, P81, DOI 10.1101/SQB.1992.057.01.011; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; YANG J, 2008, ONCOGENE IN PRESS; Yue JB, 1999, ONCOGENE, V18, P2033, DOI 10.1038/sj.onc.1202521; Zhang SP, 2007, MOL CELL BIOL, V27, P4488, DOI 10.1128/MCB.01636-06; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	59	47	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2008	27	54					6791	6805		10.1038/onc.2008.291	http://dx.doi.org/10.1038/onc.2008.291			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IS	18762808	Green Accepted			2022-12-17	WOS:000261108000001
J	Hoskins, EE; Gunawardena, RW; Habash, KB; Wise-Draper, TM; Jansen, M; Knudsen, ES; Wells, SI				Hoskins, E. E.; Gunawardena, R. W.; Habash, K. B.; Wise-Draper, T. M.; Jansen, M.; Knudsen, E. S.; Wells, S. I.			Coordinate regulation of Fanconi anemia gene expression occurs through the Rb/E2F pathway	ONCOGENE			English	Article						Fanconi anemia; Rb protein family; E2F; transcription	CERVICAL-CARCINOMA CELLS; HUMAN-PAPILLOMAVIRUS E7; OVARIAN-CANCER; DNA-REPLICATION; POCKET PROTEINS; MESSENGER-RNA; FA PATHWAY; IN-VIVO; BRCA1; TUMOR	Fanconi anemia (FA) is a genome instability syndrome that is characterized by progressive bone marrow failure and a high risk of cancer. FA patients are particularly susceptible to leukemia as well as squamous cell carcinomas (SCCs) of the head and neck, anogenital region and skin. Thirteen complementation groups and the corresponding FA genes have been identified, and their protein products assemble into nuclear core complexes during DNA-damage responses. Much progress has been made in our understanding of post-translational FA protein modi. cations and physical interactions. By contrast, little is known about the control of protein availability at the level of transcription. We report here that multiple FA proteins were downregulated during the proliferative arrest of primary human keratinocytes and HeLa cells, and that the observed regulation was at a transcriptional level. Proliferative stimuli such as expression of HPV16 E7 as well as E2F1 overexpression in primary cells resulted in coordinate FA upregulation. To de. ne the underlying mechanism, we examined the endogenous FANCD2 promoter, and detected regulated binding of members of the E2F/Rb family in chromatin immunoprecipitation assays. Finally, a 1 kb promoter fragment was sufficient to confer E2F/Rb regulation in reporter assays. Taken together, our data demonstrate FA gene co-regulation in synchrony with the cell cycle and suggest that deregulated expression of individual FA genes-in addition to FA gene mutation-may promote FA-related human cancer.	[Hoskins, E. E.; Habash, K. B.; Wise-Draper, T. M.; Wells, S. I.] Cincinnati Childrens Hosp, Med Ctr, Div Hematol Oncol, Cincinnati, OH 45229 USA; [Gunawardena, R. W.; Knudsen, E. S.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA; [Jansen, M.] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Expt Hematol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Jefferson University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Wells, SI (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Hematol Oncol, 3333 Burnet Ave,TCHRF Room S7-206, Cincinnati, OH 45229 USA.	Susanne.Wells@cchmc.org		Wise-Draper, Trisha/0000-0002-7279-4028	NATIONAL CANCER INSTITUTE [R01CA116316, R01CA104213, R01CA102357] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA116316-01A1, R01 CA102357-01A1, CA104213, R01 CA102357, R01 CA116316, CA102357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alter BP, 2003, CANCER-AM CANCER SOC, V97, P425, DOI 10.1002/cncr.11046; Angus SP, 2004, MOL CELL BIOL, V24, P5404, DOI 10.1128/MCB.24.12.5404-5420.2004; Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; Bagby GC, 2006, SEMIN HEMATOL, V43, P147, DOI 10.1053/j.seminhematol.2006.04.005; Bindra RS, 2007, CANCER METAST REV, V26, P249, DOI 10.1007/s10555-007-9061-3; Bindra RS, 2006, CANCER BIOL THER, V5, P1400, DOI 10.4161/cbt.5.10.3454; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Chang YJE, 2002, J VIROL, V76, P8864, DOI 10.1128/JVI.76.17.8864-8874.2002; Chen CC, 2007, J MOL MED, V85, P497, DOI 10.1007/s00109-006-0153-2; Chen Q, 2005, BLOOD, V106, P698, DOI 10.1182/blood-2004-11-4286; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Dhillon VS, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-33; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; Dressman HK, 2007, J CLIN ONCOL, V25, P517, DOI 10.1200/JCO.2006.06.3743; Duensing S, 2004, INT J CANCER, V109, P157, DOI 10.1002/ijc.11691; Fehrmann Frauke, 2005, Methods Mol Biol, V292, P317; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Gunawardena RW, 2004, J BIOL CHEM, V279, P29278, DOI 10.1074/jbc.M400395200; Gurtan AM, 2006, DNA REPAIR, V5, P1119, DOI 10.1016/j.dnarep.2006.05.009; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Johung K, 2007, J VIROL, V81, P2102, DOI 10.1128/JVI.02348-06; Kennedy RD, 2005, GENE DEV, V19, P2925, DOI 10.1101/gad.1370505; Kennedy RD, 2007, J CLIN INVEST, V117, P1440, DOI 10.1172/JCI31245; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kobayashi Teruaki, 1994, Journal of Dermatological Science, V8, P171, DOI 10.1016/0923-1811(94)90050-7; Kutler DI, 2003, BLOOD, V101, P1249, DOI 10.1182/blood-2002-07-2170; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leveille F, 2006, DNA REPAIR, V5, P556, DOI 10.1016/j.dnarep.2006.01.005; Marsit CJ, 2004, ONCOGENE, V23, P1000, DOI 10.1038/sj.onc.1207256; Mathew CG, 2006, ONCOGENE, V25, P5875, DOI 10.1038/sj.onc.1209878; Meijer GA, 2007, CELL ONCOL, V29, P181; Mulloy JC, 2005, P NATL ACAD SCI USA, V102, P4016, DOI 10.1073/pnas.0404701102; Nakahara T, 2005, J VIROL, V79, P13150, DOI 10.1128/JVI.79.20.13150-13165.2005; Narayan G, 2004, CANCER RES, V64, P2994, DOI 10.1158/0008-5472.CAN-04-0245; Niedzwiedz W, 2004, MOL CELL, V15, P607, DOI 10.1016/j.molcel.2004.08.009; Oberley MJ, 2003, J BIOL CHEM, V278, P42466, DOI 10.1074/jbc.M307733200; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Pagano G, 2003, BIOESSAYS, V25, P589, DOI 10.1002/bies.10283; Patel KJ, 2007, DNA REPAIR, V6, P885, DOI 10.1016/j.dnarep.2007.02.002; Pejovic T, 2006, CANCER RES, V66, P9017, DOI 10.1158/0008-5472.CAN-06-0222; Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947; Reimer D, 2007, CLIN CANCER RES, V13, P144, DOI 10.1158/1078-0432.CCR-06-0780; Russell PA, 2000, INT J CANCER, V87, P317, DOI 10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B; Siddiqui H, 2003, MOL CELL BIOL, V23, P7719, DOI 10.1128/MCB.23.21.7719-7731.2003; Spardy N, 2007, J VIROL, V81, P13265, DOI 10.1128/JVI.01121-07; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Tategu M, 2007, GENE REGUL SYST BIO, V1, P1; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; van der Heijden MS, 2005, CLIN CANCER RES, V11, P7508, DOI 10.1158/1078-0432.CCR-05-1048; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Wells SI, 2003, P NATL ACAD SCI USA, V100, P7093, DOI 10.1073/pnas.1232309100; Wise-Draper TM, 2005, J VIROL, V79, P14309, DOI 10.1128/JVI.79.22.14309-14317.2005; Wreesmann VB, 2007, ORL-J OTO-RHIN-LARYN, V69, P218, DOI 10.1159/000101542; Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942	59	47	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2008	27	35					4798	4808		10.1038/onc.2008.121	http://dx.doi.org/10.1038/onc.2008.121			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18438432	Green Accepted			2022-12-17	WOS:000258445100005
J	Lopez-Serra, L; Ballestar, E; Ropero, S; Setien, F; Billard, LM; Fraga, MF; Lopez-Nieva, P; Alaminos, M; Guerrero, D; Dante, R; Esteller, M				Lopez-Serra, L.; Ballestar, E.; Ropero, S.; Setien, F.; Billard, L-M; Fraga, M. F.; Lopez-Nieva, P.; Alaminos, M.; Guerrero, D.; Dante, R.; Esteller, M.			Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins	ONCOGENE			English	Article						DNA methylation; epigenetics; methyl-CpG-binding domain proteins; tumor suppressor genes; RNA interference	HISTONE DEACETYLASE COMPLEX; DNA METHYLATION; RETT-SYNDROME; TRANSCRIPTIONAL REPRESSION; CHROMOSOMAL-PROTEIN; CANCER-CELLS; MECP2; MBD2; IDENTIFICATION; ASSOCIATION	Methyl-cytosine-phosphate-guanine (CpG)-binding domain (MBD) proteins are bound to hypermethylated promoter CpG islands of tumor suppressor genes in human cancer cells, although a direct causal relationship at the genome-wide level between MBD presence and gene silencing remains to be demonstrated. To this end, we have inhibited the expression of MBD proteins in HeLa cells by short hairpin RNAs; and studied the functional consequences of MBD depletion using microarray-based expression analysis in conjunction with extensive bisulfite genomic sequencing and chromatin immunoprecipitation. The removal of MBDs results in a release of gene silencing associated witha loss of MBD occupancy in 5'-CpG islands without any change in the DNA methylation pattern. Our results unveil new targets for epigenetic inactivation mediated by MBDs in transformed cells, such as the cell adhesion protein gamma-parvin and the fibroblast growth factor 19, where we also demonstrate their bona. de tumor suppressor features. Our data support a fundamental role for MBD proteins in the direct maintenance of transcriptional repression of tumor suppressors and identify new candidate genes for epigenetic disruption in cancer cells.	[Esteller, M.] Spanish Natl Canc Res Ctr CNIO, Canc Epigenet Lab, Mol Pathol Program, Madrid, Spain; [Billard, L-M; Dante, R.] Ctr Leon Berard, INSERM, U590, Oncol Mol Lab, F-69373 Lyon, France; [Alaminos, M.] Univ Granada, Dept Histol, Granada, Spain; [Alaminos, M.] Fdn Hosp Clin, Granada, Spain; [Guerrero, D.] Ctr Invest Biomed, Serv Navarro Salud, Navarra, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; University of Granada; Servicio Navarro de Salud - Osasunbidea	Esteller, M (corresponding author), Spanish Natl Canc Res Ctr CNIO, Canc Epigenet Lab, Mol Pathol Program, C Melchor Fernandez Almagro 3, Madrid, Spain.	mesteller@cnio.es	Nieva, Pilar López/R-9516-2019; ALAMINOS, MIGUEL/N-9960-2016; Esteller, Manel/L-5956-2014; Ballestar, Esteban/ABG-8561-2020; Fraga, Mario F/H-7824-2017	Nieva, Pilar López/0000-0001-6369-2444; ALAMINOS, MIGUEL/0000-0003-4876-2672; Esteller, Manel/0000-0003-4490-6093; Fraga, Mario F/0000-0001-8450-2603; Ballestar, Esteban/0000-0002-1400-2440				Bakker J, 2002, J BIOL CHEM, V277, P22573, DOI 10.1074/jbc.M203009200; Ballestar E, 2005, BIOCHEM CELL BIOL, V83, P374, DOI 10.1139/o05-035; Ballestar E, 2005, HUM GENET, V116, P91, DOI 10.1007/s00439-004-1200-0; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Bernard D, 2006, ONCOGENE, V25, P1358, DOI 10.1038/sj.onc.1209179; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fatemi M, 2006, J CELL SCI, V119, P3033, DOI 10.1242/jcs.03099; Fournier C, 2002, EMBO J, V21, P6560, DOI 10.1093/emboj/cdf655; Fraga MF, 2003, NUCLEIC ACIDS RES, V31, P1765, DOI 10.1093/nar/gkg249; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hutchins AS, 2002, MOL CELL, V10, P81, DOI 10.1016/S1097-2765(02)00564-6; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jordan C, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-36; Klose RJ, 2005, MOL CELL, V19, P667, DOI 10.1016/j.molcel.2005.07.021; Koizume S, 2002, NUCLEIC ACIDS RES, V30, P4770, DOI 10.1093/nar/gkf593; LAN MS, 1994, DNA CELL BIOL, V13, P505, DOI 10.1089/dna.1994.13.505; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Olski TM, 2001, J CELL SCI, V114, P525; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; Zhao XY, 2003, P NATL ACAD SCI USA, V100, P6777, DOI 10.1073/pnas.1131928100	39	47	47	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2008	27	25					3556	3566		10.1038/sj.onc.1211022	http://dx.doi.org/10.1038/sj.onc.1211022			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223687				2022-12-17	WOS:000256468500007
J	Deep, G; Oberlies, NH; Kroll, DJ; Agarwal, R				Deep, G.; Oberlies, N. H.; Kroll, D. J.; Agarwal, R.			Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway	ONCOGENE			English	Article						androgen receptor; prostate specific antigen; prostate cancer; isosilybin B	CANCER CELLS; FLAVONOID ANTIOXIDANT; INDUCED APOPTOSIS; SILYBUM-MARIANUM; P53 ACTIVATION; MILK THISTLE; G(1) ARREST; IN-VIVO; SILYMARIN; GROWTH	The identification and development of novel nontoxic phytochemicals that target androgen and androgen receptor (AR) signaling remains a priority for prostate cancer (PCA) control. In the present study, we assessed the antiandrogenic efficacy of isosilybin B employing human PCA LNCaP ( mutated AR), 22Rv1 ( mutated AR) and LAPC4 ( wild-type AR) cells. Isosilybin B (10-90 mu M) treatment decreased the AR and prostate specific antigen (PSA) levels in LNCaP, 22Rv1 and LAPC4 cells, but not in non-neoplastic human prostate epithelial PWR-1E cells. Isosilybin B treatment also inhibited synthetic androgen R1881-induced nuclear localization of AR, PSA expression and cell growth, and caused G(1) arrest. In mechanistic studies identifying AR degradation, isosilybin B caused increased phosphorylation of Akt (Ser-473 and Thr-308) and Mdm2 (Ser-166), which was linked with AR degradation as pretreatment with PI3K inhibitor (LY294002)-restored AR level. Further, overexpression of kinase-dead Akt largely reversed isosilybin B mediated-AR degradation suggesting a critical role of Akt in AR degradation. Antibody pull-down results also indicated that isosilybin B treatment enhances the formation of complex between Akt, Mdm2 and AR, which promotes phosphorylation-dependent AR ubiquitination and its degradation by proteasome. Together, present findings identify a novel mechanism for isosilybin B-mediated anticancer effects in human PCA cells.	[Deep, G.; Agarwal, R.] Univ Colorado, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; [Oberlies, N. H.; Kroll, D. J.] Ctr Organ & Med Chem, Nat Prod Lab, Res Triangle Pk, NC USA; [Agarwal, R.] Univ Colorado, Ctr Canc, Denver, CO 80262 USA	University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Denver	Agarwal, R (corresponding author), Univ Colorado, Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th St,Box C238, Denver, CO 80262 USA.	Rajesh.Agarwal@uchsc.edu	Deep, Gagan/H-1853-2012; Oberlies, Nicholas/D-8162-2011	Oberlies, Nicholas/0000-0002-0354-8464	NCI NIH HHS [R01 CA104286] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104286] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernard D, 2003, J CLIN INVEST, V112, P1724; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Chen SY, 2006, P NATL ACAD SCI USA, V103, P15969, DOI 10.1073/pnas.0604193103; Cinar B, 2005, CANCER RES, V65, P2547, DOI 10.1158/0008-5472.CAN-04-3411; Davis-Searles PR, 2005, CANCER RES, V65, P4448, DOI 10.1158/0008-5472.CAN-04-4662; Deep G, 2006, ONCOGENE, V25, P1053, DOI 10.1038/sj.onc.1209146; Deep G, 2007, CARCINOGENESIS, V28, P1533, DOI 10.1093/carcin/bgm069; Dhanalakshmi S, 2005, J BIOL CHEM, V280, P20375, DOI 10.1074/jbc.M414640200; Gioeli D, 2006, MOL ENDOCRINOL, V20, P503, DOI 10.1210/me.2005-0351; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Haag P, 2005, J STEROID BIOCHEM, V96, P251, DOI 10.1016/j.jsbmb.2005.04.029; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kim NC, 2003, ORG BIOMOL CHEM, V1, P1684, DOI 10.1039/b300099k; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Lee DK, 2003, J CLIN ENDOCR METAB, V88, P4043, DOI 10.1210/jc.2003-030261; Lee HJ, 2003, CELL MOL LIFE SCI, V60, P1613, DOI 10.1007/s00018-003-2309-3; Liao ZM, 2005, PROSTATE, V64, P186, DOI 10.1002/pros.20224; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Mendoza N, 2002, CANCER RES, V62, P5485; Miyamoto H, 2005, MOL CARCINOGEN, V44, P1, DOI 10.1002/mc.20121; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; Nagabhushan M, 1996, CANCER RES, V56, P3042; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Paajarvi G, 2004, FASEB J, V18, P476, DOI 10.1096/fj.04-2745fje; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Pliskova M, 2005, TOXICOLOGY, V215, P80, DOI 10.1016/j.tox.2005.06.020; Reddy GPV, 2006, J CELL BIOCHEM, V98, P1408, DOI 10.1002/jcb.20927; Seidlova-Wuttke D, 2003, J STEROID BIOCHEM, V86, P179, DOI 10.1016/S0960-0760(03)00270-X; Sharifi Nima, 2006, Am J Ther, V13, P166, DOI 10.1097/00045391-200603000-00013; Singh RP, 2006, MOL CARCINOGEN, V45, P436, DOI 10.1002/mc.20223; Singh RP, 2002, ANTIOXID REDOX SIGN, V4, P655, DOI 10.1089/15230860260220166; Tong QS, 2003, CHINESE MED J-PEKING, V116, P1515; Wang L, 2004, J BIOL CHEM, V279, P32444, DOI 10.1074/jbc.M313963200; Wellington K, 2001, BIODRUGS, V15, P465, DOI 10.2165/00063030-200115070-00005; Wen Y, 2000, CANCER RES, V60, P6841; Yang L, 2005, J BIOL CHEM, V280, P33558, DOI 10.1074/jbc.M504461200; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zi XL, 1998, CLIN CANCER RES, V4, P1055; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	42	47	48	4	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	28					3986	3998		10.1038/onc.2008.45	http://dx.doi.org/10.1038/onc.2008.45			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18332867				2022-12-17	WOS:000257089000010
J	Silva, FP; Hamamoto, R; Kunizaki, M; Tsuge, M; Nakamura, Y; Furukawa, Y				Silva, F. Pittella; Hamamoto, R.; Kunizaki, M.; Tsuge, M.; Nakamura, Y.; Furukawa, Y.			Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells	ONCOGENE			English	Article						SMYD3; methyltransferase; cancer	SET DOMAIN; HISTONE METHYLATION	Histone methylation is involved in the regulation of gene expression and DNA replication through alteration of chromatin structure. We earlier showed that SMYD3, a histone H3-lysine 4-specific methyltransferase, is frequently upregulated in human colorectal, liver and breast cancer compared to their matched non-cancerous cells, and that its activity is associated with the growth of these tumors. In the present study, we found that human cancer cells express both the full-length and a cleaved form of SMYD3 protein. Amino acid sequence analysis uncovered that the cleaved form lacks the 34 amino acids in the N-terminal region of the full-length protein. Interestingly, the cleaved protein and mutant protein containing substitutions at glycines 15 and 17, two highly conserved amino acids in the N-terminal region, revealed a higher histone methyltransferase (HMTase) activity compared to the full-length protein. Furthermore, the N-terminal region is responsible for the association with heat shock protein 90 alpha (HSP90 alpha). These data indicate that the N-terminal region plays an important role for the regulation of its methyltransferase activity and suggest that a structural change of the protein through the cleavage of the region or interaction with HSP90a may be involved in the modulation. These findings may help for a better understanding of the mechanisms that modulate the HMTase activity of SMYD3, and contribute to the development of novel anticancer drugs targeting SMYD3 methyltransferase activity.	[Furukawa, Y.] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Promot Genome Based Med Project,Minato Ku, Tokyo 1088639, Japan; [Silva, F. Pittella; Hamamoto, R.; Kunizaki, M.; Tsuge, M.; Nakamura, Y.] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo, Japan	University of Tokyo; University of Tokyo	Furukawa, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Promot Genome Based Med Project,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	furukawa@ims.u-tokyo.ac.jp	Hamamoto, Ryuji/AAF-9600-2019; Silva, Fabio Pittella/B-2621-2013; Tsuge, Masataka/G-5246-2019	Hamamoto, Ryuji/0000-0002-2632-1334; Silva, Fabio Pittella/0000-0002-9644-7098; Tsuge, Masataka/0000-0001-7591-8287				Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Fasulo L, 2000, J NEUROCHEM, V75, P624, DOI 10.1046/j.1471-4159.2000.0750624.x; Fontecave M, 2004, TRENDS BIOCHEM SCI, V29, P243, DOI 10.1016/j.tibs.2004.03.007; Greiner D, 2005, NAT CHEM BIOL, V1, P143, DOI 10.1038/nchembio721; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Hamamoto R, 2006, CANCER SCI, V97, P113, DOI 10.1111/j.1349-7006.2006.00146.x; Jacobs SA, 2002, NAT STRUCT BIOL, V9, P833, DOI 10.1038/nsb861; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Marmorstein R, 2003, TRENDS BIOCHEM SCI, V28, P59, DOI 10.1016/S0968-0004(03)00007-0; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Rawlings ND, 2006, NUCLEIC ACIDS RES, V34, pD270, DOI 10.1093/nar/gkj089; Tresaugues L, 2006, J MOL BIOL, V359, P1170, DOI 10.1016/j.jmb.2006.04.050; Tsuge M, 2005, NAT GENET, V37, P1104, DOI 10.1038/ng1638; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Yang XJ, 2005, ONCOGENE, V24, P1653, DOI 10.1038/sj.onc.1208173; Zhang X, 2002, CELL, V111, P117, DOI 10.1016/S0092-8674(02)00999-6	18	47	50	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2008	27	19					2686	2692		10.1038/sj.onc.1210929	http://dx.doi.org/10.1038/sj.onc.1210929			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	17998933				2022-12-17	WOS:000255259500003
J	Ozeri-Galai, E; Schwartz, M; Rahat, A; Kerem, B				Ozeri-Galai, E.; Schwartz, M.; Rahat, A.; Kerem, B.			Interplay between ATM and ATR in the regulation of common fragile site stability	ONCOGENE			English	Article						fragile sites; replication stress; ATM; ATR; double strand breaks; Chk1	DNA-DAMAGE RESPONSE; ONCOGENE-INDUCED SENESCENCE; IONIZING-RADIATION; PREFERENTIAL TARGETS; PHOSPHORYLATION; REPLICATION; ACTIVATION; CHECKPOINT; BREAKS; RECOMBINATION	Common fragile sites are specific genomic loci that form constrictions and gaps on metaphase chromosomes under conditions that slow, but do not arrest, DNA replication. These sites have been shown to have a role in various chromosomal rearrangements in tumors. Different DNA damage response proteins were shown to regulate fragile site stability, including ataxia-telangiectasia and Rad3-related (ATR) and its effector Chk1. Here, we investigated the role of ataxia-telangiectasia mutated (ATM), the main transducer of DNA double-strand break (DSB) signal, in this regulation. We demonstrate that replication stress conditions, which induce fragile site expression, lead to DNA fragmentation and recruitment of phosphorylated ATM to nuclear foci at DSBs. We further show that ATM plays a role in maintaining fragile site stability, which is revealed only in the absence of ATR. However, the activation of ATM under these replication stress conditions is ATR independent. Following conditions that induce fragile site expression both ATR and ATM phosphorylate Chk1, suggesting that both proteins regulate fragile site expression probably via their effect on Chk1 activation. Our findings provide new insights into the interplay between ATR and ATM pathways in response to partial replication inhibition and in the regulation of fragile site stability.	[Ozeri-Galai, E.; Schwartz, M.; Rahat, A.; Kerem, B.] Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Kerem, B (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel.	kerem@cc.huji.ac.il		Schwartz, Michal/0000-0001-5442-0201				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Arlt MF, 2006, DNA REPAIR, V5, P1126, DOI 10.1016/j.dnarep.2006.05.010; Arlt MF, 2003, CYTOGENET GENOME RES, V100, P92, DOI 10.1159/000072843; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bester AC, 2006, GENE THER, V13, P1057, DOI 10.1038/sj.gt.3302752; Bolderson E, 2004, HUM MOL GENET, V13, P2937, DOI 10.1093/hmg/ddh316; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; CHENG CH, 1993, BIOCHEMISTRY-US, V32, P8568, DOI 10.1021/bi00084a025; Cuadrado M, 2006, J EXP MED, V203, P297, DOI 10.1084/jem.20051923; Cuadrado M, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-7; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Durkin SG, 2006, ONCOGENE, V25, P4381, DOI 10.1038/sj.onc.1209466; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; GLOVER TW, 1987, AM J HUM GENET, V41, P882; GLOVER TW, 1988, AM J HUM GENET, V43, P265; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; HECHT F, 1984, CLIN GENET, V26, P169; Hellman A, 2000, MOL CELL BIOL, V20, P4420, DOI 10.1128/MCB.20.12.4420-4427.2000; Ho GPH, 2006, MOL CELL BIOL, V26, P7005, DOI 10.1128/MCB.02018-05; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Le Beau MM, 1998, HUM MOL GENET, V7, P755, DOI 10.1093/hmg/7.4.755; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schwartz M, 2006, CANCER LETT, V232, P13, DOI 10.1016/j.canlet.2005.07.039; Schwartz M, 2005, GENE DEV, V19, P2715, DOI 10.1101/gad.340905; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Thorland EC, 2003, ONCOGENE, V22, P1225, DOI 10.1038/sj.onc.1206170; Wang L, 1997, GENOMICS, V41, P485, DOI 10.1006/geno.1997.4690; Yoo HY, 2007, J BIOL CHEM, V282, P17501, DOI 10.1074/jbc.M701770200; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	46	47	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2008	27	15					2109	2117		10.1038/sj.onc.1210849	http://dx.doi.org/10.1038/sj.onc.1210849			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17934520				2022-12-17	WOS:000254621300001
J	Jones, L; Tilli, MT; Assefnia, S; Torre, K; Halama, ED; Parrish, A; Rosen, EM; Furth, PA				Jones, L. P.; Tilli, M. T.; Assefnia, S.; Torre, K.; Halama, E. D.; Parrish, A.; Rosen, E. M.; Furth, P. A.			Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ER alpha-negative and ER alpha-positive mammary preneoplasia and cancer	ONCOGENE			English	Article						breast cancer; mouse model; brca1; estrogen; ER alpha	INSULIN-RECEPTOR SUBSTRATE-2; SUSCEPTIBILITY GENE BRCA1; BREAST-CANCER; EPITHELIAL-CELLS; TRANSGENIC MICE; MOUSE MODEL; DUCTAL MORPHOGENESIS; TUMOR-FORMATION; GROWTH; PROGESTERONE	BRCA1 can regulate estrogen receptor-alpha (ER alpha) activity. This study tested the hypotheses that Brca1 loss in mammary epithelium alters the estrogenic growth response and that exposure to increased estrogen or ER alpha collaborates with Brca1 deficiency to accelerate preneoplasia and cancer development. Longer ductal extension was found in mammary glands of Brca1(f/f;MMTV-Cre) mice during puberty as compared to wild-type mice. Terminal end bud differentiation was impaired in Brca1 mutant mice with preservation of prolactin-induced alveolar differentiation. Exogenous estrogen stimulated an abnormal sustained increase in mammary epithelial cell proliferation and the appearance of ER alpha-negative preneoplasia in postpubertal Brca1 mutant mice. Carcinogenesis was investigated using Brca1(f/f;MMTV-Cre) mice hemizygous for p53. Exogenous estrogen increased the percentage of mice with multiple hyperplastic alveolar nodules. Targeted conditional ER alpha overexpression in mammary epithelial cells of mice that were Brca1 mutant and hemizygous for p53 increased the percentage of mice exhibiting multiple hyperplastic nodules, invasive mammary cancers and cancer multiplicity. Significantly more than half of the preneoplasia and cancers were ER alpha negative even as their initiation was promoted by ER alpha overexpression.	[Jones, L. P.; Tilli, M. T.; Assefnia, S.; Torre, K.; Halama, E. D.; Parrish, A.; Rosen, E. M.; Furth, P. A.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA	Georgetown University	Furth, PA (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA.	paf3@georgetown.edu			DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005024] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA112176, T32CA009686] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA112176-05, T32 CA009686, R01 CA112176, 2T32CA09686-08, N01-CN-05024, R01CA08000] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930; Bachelier R, 2005, ONCOL REP, V14, P1117; Bocchinfuso WP, 1997, J MAMMARY GLAND BIOL, V2, P323, DOI 10.1023/A:1026339111278; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Cui XJ, 2003, ONCOGENE, V22, P6937, DOI 10.1038/sj.onc.1206803; Cullinane CA, 2005, INT J CANCER, V117, P988, DOI 10.1002/ijc.21273; Deans AJ, 2004, ONCOGENE, V23, P6136, DOI 10.1038/sj.onc.1207805; Decensi A, 2003, J MAMMARY GLAND BIOL, V8, P19, DOI 10.1023/A:1025779120649; Dembinski T. C., 1987, The mammary gland. Development, regulation, and function., P355; El Etreby MF, 1998, BREAST CANCER RES TR, V51, P149, DOI 10.1023/A:1006078032287; Fan SJ, 2002, CANCER RES, V62, P141; Fendrick JL, 1998, J MAMMARY GLAND BIOL, V3, P7, DOI 10.1023/A:1018766000275; Foulkes WD, 2004, CLIN CANCER RES, V10, P2029, DOI 10.1158/1078-0432.CCR-03-1061; Frech MS, 2005, CANCER RES, V65, P681; FRECH MS, 2005, BREAST CANC ONLINE, V8; Furuta S, 2005, P NATL ACAD SCI USA, V102, P9176, DOI 10.1073/pnas.0503793102; Furuta S, 2006, CANCER CELL, V10, P13, DOI 10.1016/j.ccr.2006.05.022; Ginsburg E., 2000, METHODS MAMMARY GLAN, P147; Grimm SL, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1520; Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874; Heppner GH, 2000, BREAST CANCER RES, V2, P331; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Jones LP, 2005, ONCOGENE, V24, P3554, DOI 10.1038/sj.onc.1208426; Krzysiek Jozef, 2003, Ginekol Pol, V74, P767; Liang YY, 2003, INT J ONCOL, V23, P369; Ma YX, 2006, MOL ENDOCRINOL, V20, P14, DOI 10.1210/me.2004-0488; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milewicz T, 2005, GROWTH HORM IGF RES, V15, P140, DOI 10.1016/j.ghir.2004.12.006; Poole AJ, 2006, SCIENCE, V314, P1467, DOI 10.1126/science.1130471; Raafat AM, 1999, ENDOCRINOLOGY, V140, P2570, DOI 10.1210/en.140.6.2570; Razandi M, 2004, MOL CELL BIOL, V24, P5900, DOI 10.1128/MCB.24.13.5900-5913.2004; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Ruan WF, 2005, ENDOCRINOLOGY, V146, P1170, DOI 10.1210/en.2004-1360; Shukla V, 2006, CANCER RES, V66, P7151, DOI 10.1158/0008-5472.CAN-05-4570; Silberstein GB, 2001, MICROSC RES TECHNIQ, V52, P155, DOI 10.1002/1097-0029(20010115)52:2<155::AID-JEMT1001>3.0.CO;2-P; Tilli MT, 2003, AM J PATHOL, V163, P1713, DOI 10.1016/S0002-9440(10)63529-8; Vassen L, 1999, MOL ENDOCRINOL, V13, P485; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	39	47	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					794	802		10.1038/sj.onc.1210674	http://dx.doi.org/10.1038/sj.onc.1210674			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653086	Green Accepted			2022-12-17	WOS:000252884500008
J	Syljuasen, RG				Syljuasen, R. G.			Checkpoint adaptation in human cells	ONCOGENE			English	Review						cell cycle checkpoints; genomic instability; ionizing radiation; G2-arrest; cell death; repair of DNA damage	DOUBLE-STRAND BREAK; DNA-DAMAGE CHECKPOINT; PHOSPHORYLATED HISTONE H2AX; POLO-LIKE KINASE; IONIZING-RADIATION; G2/M ARREST; MITOTIC CHROMOSOMES; CYCLE CHECKPOINTS; HELA-CELLS; RECOVERY	Checkpoint adaptation was originally described in Saccharomyces Cerevisiae as the ability to divide following a sustained checkpoint arrest in the presence of unrepairable DNA breaks. A process of checkpoint adaptation was also reported in Xenopus in response to the replication inhibitor aphidicolin. Recently, we showed that checkpoint adaptation also occurs in human cells. Although cells undergoing checkpoint adaptation will frequently die in subsequent cell cycles owing to excessive DNA damage, some of the cells may be able to survive and proliferate with damaged DNA. Thus, checkpoint adaptation in human cells may potentially promote genomic instability and lead to cancer. Here, I discuss the current evidence for checkpoint adaptation in human cells and possible mechanisms and implications of this phenomenon.	Danish Canc Soc, Inst Canc Biol, Copenhagen, Denmark; Danish Canc Soc, Ctr Genotox Stress Res, Copenhagen, Denmark	Danish Cancer Society; Danish Cancer Society	Syljuasen, RG (corresponding author), Univ Copenhagen, BRIC Bioctr, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark.	rs@cancer.dk						Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carballo JA, 2006, BIOL RES, V39, P331, DOI 10.4067/S0716-97602006000200015; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Chu K, 2002, RADIAT RES, V158, P667, DOI 10.1667/0033-7587(2002)158[0667:CVTLCA]2.0.CO;2; Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3; De Souza CPC, 2000, EXP CELL RES, V257, P11, DOI 10.1006/excr.2000.4872; den Elzen N, 2004, CELL CYCLE, V3, P529; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Forand A, 2004, BIOL REPROD, V71, P643, DOI 10.1095/biolreprod.104.027466; Forrester HB, 2000, RADIAT RES, V154, P625, DOI 10.1667/0033-7587(2000)154[0625:CVTLAO]2.0.CO;2; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Galgoczy DJ, 2001, MOL CELL BIOL, V21, P1710, DOI 10.1128/MCB.21.5.1710-1718.2001; HALL EJ, 2006, RADIOBIOLOGY RADILOG; Harrison JC, 2006, ANNU REV GENET, V40, P209, DOI 10.1146/annurev.genet.40.051206.105231; Ianzini F, 1997, INT J RADIAT BIOL, V72, P409, DOI 10.1080/095530097143185; Kao GD, 1997, CANCER RES, V57, P753; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kim SM, 2005, J BIOL CHEM, V280, P38355, DOI 10.1074/jbc.M508673200; Klokov D, 2006, RADIOTHER ONCOL, V80, P223, DOI 10.1016/j.radonc.2006.07.026; Koniaras K, 2001, ONCOGENE, V20, P7453, DOI 10.1038/sj.onc.1204942; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Lee SE, 2001, CURR BIOL, V11, P1053, DOI 10.1016/S0960-9822(01)00296-2; Lee SE, 2003, MOL CELL BIOL, V23, P8913, DOI 10.1128/MCB.23.23.8913-8923.2003; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Linke SP, 1997, CANCER RES, V57, P1171; Loffler H, 2006, EXP CELL RES, V312, P2633, DOI 10.1016/j.yexcr.2006.06.008; Lu CR, 2006, MOL CELL, V23, P121, DOI 10.1016/j.molcel.2006.05.023; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lupardus PJ, 2004, CELL, V117, P555, DOI 10.1016/j.cell.2004.05.005; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Maity A, 1996, ONCOGENE, V13, P1647; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MUSCHEL RJ, 1992, RADIAT RES, V132, P153, DOI 10.2307/3578520; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Suzuki M, 2006, RADIAT RES, V165, P269, DOI 10.1667/RR3508.1; Syljuasen RG, 2006, CANCER RES, V66, P10253, DOI 10.1158/0008-5472.CAN-06-2144; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; THOMPSON LH, 1969, INT J RADIAT BIOL RE, V15, P347, DOI 10.1080/09553006914550571; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; van Vugt MATM, 2005, CANCER RES, V65, P7037, DOI 10.1158/0008-5472.CAN-05-1054; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Yoo HY, 2006, GENE DEV, V20, P772, DOI 10.1101/gad.1398806; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9	53	47	47	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5833	5839		10.1038/sj.onc.1210402	http://dx.doi.org/10.1038/sj.onc.1210402			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17384683				2022-12-17	WOS:000249123100001
J	Wakasugi, T; Izumi, H; Uchiumi, T; Suzuki, H; Arao, T; Nishio, K; Kohno, K				Wakasugi, T.; Izumi, H.; Uchiumi, T.; Suzuki, H.; Arao, T.; Nishio, K.; Kohno, K.			ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes	ONCOGENE			English	Article						ZNF143; p73; Rad51; FEN-1; cisplatin; DNA repair	BOX-BINDING-PROTEIN; CANCER-CELL-LINES; DRUG-RESISTANCE; DAMAGING AGENTS; EXPRESSION; ACTIVATOR; YB-1; STAF	Zinc-finger protein 143 ( ZNF143) is a human homolog of Xenopus transcriptional activator staf that is involved in selenocystyl tRNA transcription. We previously showed that ZNF143 expression is induced by treatment with DNA-damaging agents and that it preferentially binds to cisplatin-modified DNA. In this study, the potential function of ZNF143 was investigated. ZNF143 was overexpressed in cisplatin-resistant cells. ZNF143 knockdown in prostate cancer caused increased sensitivity for cisplatin, but not for oxaliplatin, etoposide and vincristine. We also showed that ZNF143 is associated with tumor suppressor gene product p73 but not with p53.p73 could stimulate the binding of ZNF143 to both ZNF143 binding site and cisplatin-modified DNA, and modulate the function of ZNF143. We provide a direct evidence that both Rad51 and flap endonuclease-1 are target genes of ZNF143 and overexpressed in cisplatin-resistant cells. Taken together, these experiments demonstrate that an interplay of ZNF143, p73 and ZNF143 target genes is involved in DNA repair gene expression and cisplatin resistance.	Univ Occupat & Environm Hlth, Sch Med, Dept Biol Mol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Otorhinolaryngol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Kinki Univ, Sch Med, Dept Genome Biol, Osaka, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; Kindai University (Kinki University)	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Biol Mol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	k-kohno@med.uoeh-u.ac.jp						Altaha R, 2004, INT J MOL MED, V14, P959; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; FUJII R, 1994, JPN J CANCER RES, V85, P426, DOI 10.1111/j.1349-7006.1994.tb02376.x; Imamura T, 2001, J BIOL CHEM, V276, P7534, DOI 10.1074/jbc.M008143200; Ise T, 1999, CANCER RES, V59, P342; Ishiguchi H, 2004, INT J CANCER, V111, P900, DOI 10.1002/ijc.20358; Izumi H, 2003, BIOCHEM J, V373, P713, DOI 10.1042/BJ20021902; Keshelava N, 2001, CANCER RES, V61, P6185; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Kohno K, 2005, EUR J CANCER, V41, P2577, DOI 10.1016/j.ejca.2005.08.007; Kuwano M, 2004, MOL CANCER THER, V3, P1485; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Murakami T, 2001, INT J CANCER, V93, P869, DOI 10.1002/ijc.1418; Myslinski E, 1998, J BIOL CHEM, V273, P21998, DOI 10.1074/jbc.273.34.21998; Ohga T, 1996, CANCER RES, V56, P4224; Raymond E, 2002, MOL CANCER THER, V1, P227; Rincon JC, 1998, NUCLEIC ACIDS RES, V26, P4846, DOI 10.1093/nar/26.21.4846; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; Spiro C, 2003, MOL CELL BIOL, V23, P6063, DOI 10.1128/MCB.23.17.6063-6074.2003; Sugaya M, 2002, CHEST, V122, P282, DOI 10.1378/chest.122.1.282; Tanabe M, 2003, CANCER RES, V63, P8592; TEW KD, 1994, CANCER RES, V54, P4313; Torigoe Takayuki, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P15, DOI 10.2174/1568011053352587; Uramoto H, 2003, BIOCHEM J, V371, P301, DOI 10.1042/BJ20021646; Uramoto H, 2002, J BIOL CHEM, V277, P31694, DOI 10.1074/jbc.M200266200; Vikhanskaya F, 2001, CANCER RES, V61, P935; Wood RD, 2005, MUTAT RES-FUND MOL M, V577, P275, DOI 10.1016/j.mrfmmm.2005.03.007; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7	31	47	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2007	26	36					5194	5203		10.1038/sj.onc.1210326	http://dx.doi.org/10.1038/sj.onc.1210326			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17297437				2022-12-17	WOS:000248674200003
J	Schniewind, B; Groth, S; Muerkoster, SS; Sipos, B; Schaefer, H; Kalthoff, H; Fandrich, F; Ungefroren, H				Schniewind, B.; Groth, S.; Mueerkoester, S. Sebens; Sipos, B.; Schaefer, H.; Kalthoff, H.; Faendrich, F.; Ungefroren, H.			Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function	ONCOGENE			English	Article						TGF-beta; pancreatic carcinoma; ALK5; smad; metastasis	GROWTH-FACTOR-BETA; CANCER-CELLS; BREAST-CANCER; TRANSCRIPTIONAL REPRESSION; MESENCHYMAL TRANSITION; MAMMARY TUMORIGENESIS; ENHANCED EXPRESSION; SIGNALING PATHWAY; BONE METASTASIS; C-MYC	In the present study, we have analysed the effects of transforming growth factor-beta (TGF-beta) signaling on the growth behavior of pancreatic carcinoma cells in vitro and on their tumorigenicity in vivo. Ectopic expression of dominant-negative mutants of the TGF-beta type II receptor or type 1 receptor/activin receptor-like kinase 5(ALK5) in TGF-beta-sensitive pancreatic ductal adenocarcinoma PANC-1 cells prevented the TGF-beta-induced activation of transfected Smad-responsive reporter genes and growth arrest. The growth-inhibitory effect was mimicked by stable expression of kinase-active ALK5( A LK5- T204D), and was dependent on ALK5's ability to activate Smad signaling, as a ALK5-derived mutant with an intact kinase domain but deficient in its ability to activate Smads (RImL45) failed to suppress proliferation in the absence of added TGF-beta. Moreover, this mutant often displayed opposite effects to those of ALK5-TD and blocked various ligand-induced responses in vitro, indicating that it acts in a dominant-negative fashion to inhibit endogenous wild-type receptors. ALK5-TD-, but not RImL45-TD-transduced cells underwent epithelial-to-mesenchymal transition, exhibited a higher ratio of thrombospondin-1 to vascular endothelial growth factor-A expression and upregulated various metastasis-associated genes. Upon orthotopic transplantation of PANC-1 clones into immunodeficient mice, ALK5-TD, but not RImL45-TD, greatly reduced tumor size and induced the formation of liver metastases in otherwise non-metastatic PANC-1 cells. These results suggest a causal, dominant role for the endogenous Smad2/3 signaling pathway in the tumor suppressor and prometastatic activities of TGF-beta in pancreatic tumor cells.	UKSH, Dept Gen Surg & Thorac Surg, Kiel, Germany; Dept Med 1, Lab Mol Gastroenterol & Hepatol, Kiel, Germany; Dept Pathol, Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital	Ungefroren, H (corresponding author), Univ Hosp Kiel, Arnold Heller Str 7, D-24105 Kiel, Germany.	hungefroren@chirurgie-sh.de	Sebens, Susanne/C-1222-2010; Ungefroren, Hendrik/E-2933-2010; Kalthoff, Holger/B-1618-2010; Schäfer, Heiner/C-1055-2011; Faendrich, Fred/B-1705-2010					Arnold NB, 2005, J BIOL CHEM, V280, P21858, DOI 10.1074/jbc.M500583200; Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Bottinger EP, 1997, CANCER RES, V57, P5564; Chen WB, 2002, J BIOL CHEM, V277, P36118, DOI 10.1074/jbc.M203709200; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Dai JL, 1998, CANCER RES, V58, P4592; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Duda DG, 2003, ONCOGENE, V22, P6857, DOI 10.1038/sj.onc.1206751; Ellenrieder V, 2001, INT J CANCER, V93, P204, DOI 10.1002/ijc.1330; Ellenrieder V, 2001, CANCER RES, V61, P4222; Fensterer H, 2004, GENE CHROMOSOME CANC, V39, P224, DOI 10.1002/gcc.20000; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; FRIESS H, 1993, CANCER RES, V53, P2704; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; Goggins M, 1998, CANCER RES, V58, P5329; Grau AM, 1997, CANCER RES, V57, P3929; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Iglesias M, 2000, ONCOGENE, V19, P4134, DOI 10.1038/sj.onc.1203764; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kang YB, 2006, J CELL BIOCHEM, V98, P1380, DOI 10.1002/jcb.20928; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kuang CZ, 2006, P NATL ACAD SCI USA, V103, P1858, DOI 10.1073/pnas.0508977103; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; Muraoka-Cook RS, 2006, ONCOGENE, V25, P3408, DOI 10.1038/sj.onc.1208964; Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S; Nakagawa T, 2004, KIDNEY INT, V66, P605, DOI 10.1111/j.1523-1755.2004.00780.x; Nicolas FJ, 2003, ONCOGENE, V22, P3698, DOI 10.1038/sj.onc.1206420; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Peng BL, 2002, CLIN CANCER RES, V8, P3628; Reiss M, 1997, BREAST CANCER RES TR, V45, P81, DOI 10.1023/A:1005865812918; Rowland-Goldsmith MA, 2002, MOL CANCER THER, V1, P161; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Tian F, 2004, CANCER RES, V64, P4523, DOI 10.1158/0008-5472.CAN-04-0030; Ungefroren H, 2005, J BIOL CHEM, V280, P2644, DOI 10.1074/jbc.M411925200; UNGEFROREN H, 2007, INT J CANC; Voss M, 1999, INT J ONCOL, V14, P93; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927	56	47	49	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4850	4862		10.1038/sj.onc.1210272	http://dx.doi.org/10.1038/sj.onc.1210272			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297450				2022-12-17	WOS:000248170400010
J	Quignon, F; Rozier, L; Lachages, AM; Bieth, A; Simili, M; Debatisse, M				Quignon, F.; Rozier, L.; Lachages, A. -M.; Bieth, A.; Simili, M.; Debatisse, M.			Sustained mitotic block elicits DNA breaks: one-step alteration of ploidy and chromosome integrityin mammalian cells	ONCOGENE			English	Article						double strand breaks; chromosome rearrangements; mitotic slippage; DNA damage checkpoint; spindle checkpoint; tetraploidy	GENOMIC INSTABILITY; P53; TETRAPLOIDY; INHIBITION; ANEUPLOIDY; REREPLICATION; FIBROBLASTS; CHECKPOINTS; MECHANISM; APOPTOSIS	Following prolonged mitotic spindle disruption by microtubule poisons, mammalian cells delay their entry into anaphase, then progressively slip out of mitosis and become tetraploid. Normal cells then stop cycling before S-phase onset, but the mechanisms underlying this arrest are still unclear. Here we show that a double block prevents endo-reduplication. First, cells that exit mitosis without a functional microtubule network are driven toward G0. Reconstitution of the network unmasks a second block that relies on DNA double-strand breaks occurring early in the G1 phase that follows the mitotic block. We propose that a stress signal elicited upon mitotic impairment triggers breakage, which couples the leaky spindle checkpoint to the stringent DNA damage response. Consistent with this finding, cells defective for the damage response continue cycling and acquire, within a single cell cycle, both chromosome rearrangements and abnormal chromosome numbers that remarkably mimic the complex genetic hallmark of tumorigenesis.	Univ Paris 06, Sect Rech, UMR 7147, Inst Curie,CNRS, F-75248 Paris 05, France; CNR, Inst Fisiol Clin, Area Ric, I-56100 Pisa, Italy	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; Consiglio Nazionale delle Ricerche (CNR)	Debatisse, M (corresponding author), Univ Paris 06, Sect Rech, UMR 7147, Inst Curie,CNRS, 26 Rue Ulm, F-75248 Paris 05, France.	michelle.debatisse@curie.fr	Quignon, Frédérique/P-4249-2017	Lachages, Anne-Marie/0000-0003-1771-1880				Aardema MJ, 1998, MUTAT RES-REV MUTAT, V410, P3, DOI 10.1016/S1383-5742(97)00029-X; Anglana M, 2001, J BIOL CHEM, V276, P36639, DOI 10.1074/jbc.M104501200; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Casenghi M, 1999, EXP CELL RES, V250, P339, DOI 10.1006/excr.1999.4554; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Dutrillaux B, 1995, ADV CANCER RES, V67, P59, DOI 10.1016/S0065-230X(08)60710-1; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Halappanavar SS, 2004, CELL CYCLE, V3, P335; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Khan SH, 1998, CANCER RES, V58, P396; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Mantel CR, 2002, CELL CYCLE, V1, P327, DOI 10.4161/cc.1.5.150; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Martin SS, 2004, BBA-MOL CELL RES, V1692, P145, DOI 10.1016/j.bbamcr.2004.02.008; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; Pusapati RV, 2006, P NATL ACAD SCI USA, V103, P1446, DOI 10.1073/pnas.0507367103; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; STUBBLEFIELD ELTON, 1964, SYMP INT SOC CELL BIOL, V3, P223; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; Tritarelli A, 2004, MOL BIOL CELL, V15, P3751, DOI 10.1091/mbc.E03-12-0900; Tsuiki H, 2001, ONCOGENE, V20, P420, DOI 10.1038/sj.onc.1204126; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6	31	47	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					165	172		10.1038/sj.onc.1209787	http://dx.doi.org/10.1038/sj.onc.1209787			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16832348				2022-12-17	WOS:000243398300001
J	Huang, Y; Li, X; Jiang, J; Frank, SJ				Huang, Y.; Li, X.; Jiang, J.; Frank, S. J.			Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells	ONCOGENE			English	Article; Proceedings Paper	86th Annual Meeting of the Endocrine-Society	JUN 12-15, 2004	New Orleans, LA	Endocrine Soc		prolactin; EGFR; signaling; phosphorylation; synergy	JAK2 TYROSINE KINASE; EGF-RECEPTOR; MAMMARY-GLAND; ERBB RECEPTORS; ACTIVATING PROTEIN-1; EPITHELIAL-CELLS; MESSENGER-RNA; HORMONE; INVOLVEMENT; EXPRESSION	Prolactin (PRL) is a polypeptide hormone produced by the anterior pituitary gland and other sites that acts both systemically and locally to cause lactation and other biological effects by interacting with the PRL receptor, a Janus kinase (JAK)2-coupled cytokine receptor family member, and activating downstream signal pathways. Recent evidence suggests PRL is a player in the pathogenesis and progression of breast cancer. Epidermal growth factor (EGF) also has effects on breast tissue, working through its receptors, epidermal growth factor receptor (EGFR) and ErbB-2 (c-neu, HER2), both intrinsic tyrosine kinase growth factor receptors. EGFR promotes pubertal breast ductal morphogenesis in mice, and both EGFR and ErbB-2 are relevant in pathogenesis and behavior of breast and other human cancers. Previous studies showed that PRL and EGF synergize to enhance motility in the human breast cancer cell line, T47D. In this study, we explored crosstalk between the PRL and EGF signaling pathways in T47D cells, with an ultimate aim of understanding how these two important factors might work together in vivo to affect breast cancer behavior. Both PRL and EGF caused robust signaling in T47D cells; PRL acutely activated JAK2, signal transducer and activator of transcription-5 (STAT5), and extracellular signal-regulated kinase-1 and -2 (ERK1 and ERK2), whereas EGF caused EGFR activation and consequent src homology collagen (SHC) activation and ERK activation. Notably, PRL also caused phosphorylation of the EGFR and ErbB-2 at sites detected by PTP101, an antibody that recognizes threonine phosphorylation at consensus motifs for ERK-induced phosphorylation. PRL-induced PTP101-reactive phosphorylation was prevented by pretreatment with PD98059, an ERK pathway inhibitor. Furthermore, PRL synergized with EGF in activating SHC and ERK and transactivating a luciferase reporter driven by c-fos gene enhancer elements, suggesting that PRL allowed markedly enhanced EGF signaling. This was accompanied by substantial inhibition of EGF-induced EGFR downregulation when PRL and EGF cotreatment was compared to EGF treatment alone. This effect of PRL was abrogated by ERK pathway inhibitor pretreatment. Our data suggest that PRL synergistically augments EGF signaling in T47D breast cancer cells at least in part by lessening EGF-induced EGFR downregulation and that this effect requires PRL-induced ERK activity and threonine phosphorylation of EGFR.	Univ Alabama Birmingham, Dept Med, Div Endocrinol Diabet & Metab, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Vet Affairs Med Ctr, Endocrinol Sect, Med Serv, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Frank, SJ (corresponding author), Univ Alabama Birmingham, Dept Med, Div Endocrinol Diabet & Metab, 1530 3rd Ave S,BDB 861, Birmingham, AL 35294 USA.	sjfrank@uab.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046395, R29DK046395, R01DK046395] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46395] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; ANDERSON E, 1993, EUR J CANCER, V29A, P209, DOI 10.1016/0959-8049(93)90178-I; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Badache A, 2001, CANCER RES, V61, P383; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Ben-Jonathan N, 2002, TRENDS ENDOCRIN MET, V13, P245, DOI 10.1016/S1043-2760(02)00603-3; BenJonathan N, 1996, ENDOCR REV, V17, P639, DOI 10.1210/edrv-17-6-639; BERGER MS, 1988, CANCER RES, V48, P1238; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; BONNETERRE J, 1988, EUR J CANCER CLIN ON, V24, P1851, DOI 10.1016/0277-5379(88)90097-1; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Chen NY, 2002, INT J ONCOL, V20, P813; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Chughtai N, 2002, J BIOL CHEM, V277, P31107, DOI 10.1074/jbc.M200156200; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Clevenger CV, 2001, LUPUS, V10, P706, DOI 10.1191/096120301717164949; Das R, 1996, BREAST CANCER RES TR, V40, P141, DOI 10.1007/BF01806209; Das R, 1996, ONCOGENE, V13, P1139; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eisenberg A, 2004, FEBS LETT, V565, P139, DOI 10.1016/j.febslet.2004.03.089; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FENTON SE, 1993, MOL BIOL CELL, V4, P773, DOI 10.1091/mbc.4.8.773; Fenton SE, 1997, EXP CELL RES, V236, P285, DOI 10.1006/excr.1997.3727; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Freeman ME, 2000, PHYSIOL REV, V80, P1523, DOI 10.1152/physrev.2000.80.4.1523; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; GINSBURG E, 1995, CANCER RES, V55, P2591; Goffin V, 2005, ENDOCR REV, V26, P400, DOI 10.1210/er.2004-0016; Goffin V, 1999, MOL CELL ENDOCRINOL, V151, P79, DOI 10.1016/S0303-7207(99)00023-4; Goffin V, 2002, ANNU REV PHYSIOL, V64, P47, DOI 10.1146/annurev.physiol.64.081501.131049; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Grimm SL, 2002, MOL ENDOCRINOL, V16, P2675, DOI 10.1210/me.2002-0239; Gutzman JH, 2005, MOL ENDOCRINOL, V19, P1765, DOI 10.1210/me.2004-0339; Gutzman JH, 2004, MOL ENDOCRINOL, V18, P3064, DOI 10.1210/me.2004-0187; Hankinson SE, 1999, J NATL CANCER I, V91, P629, DOI 10.1093/jnci/91.7.629; Haraguchi S, 1997, MOL CELL ENDOCRINOL, V129, P145, DOI 10.1016/S0303-7207(97)04053-7; Harari PM, 2004, ENDOCR-RELAT CANCER, V11, P689, DOI 10.1677/erc.1.00600; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Horseman ND, 1999, J MAMMARY GLAND BIOL, V4, P79, DOI 10.1023/A:1018708704335; Hovey RC, 2001, DEV DYNAM, V222, P192, DOI 10.1002/dvdy.1179; Huang Y, 2004, ENDOCRINOLOGY, V145, P3297, DOI 10.1210/en.2003-1658; Huang Y, 2004, MOL ENDOCRINOL, V18, P1471, DOI 10.1210/me.2003-0418; Huang Y, 2003, J BIOL CHEM, V278, P18902, DOI 10.1074/jbc.M300939200; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Jiang J, 1998, BIOCHEM BIOPH RES CO, V253, P774, DOI 10.1006/bbrc.1998.9793; Johnson JL, 1996, J BIOL CHEM, V271, P21574, DOI 10.1074/jbc.271.35.20981; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kim SO, 2002, ENDOCRINOLOGY, V143, P4856, DOI 10.1210/en.2002-220565; Kim SO, 1999, J BIOL CHEM, V274, P36015, DOI 10.1074/jbc.274.50.36015; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Laskin JJ, 2004, CANCER TREAT REV, V30, P1, DOI 10.1016/j.ctrv.2003.10.002; LI X, 2005, ENDOCRINE SOC PROGRA, P3; Lichtner RB, 2003, BIOMED PHARMACOTHER, V57, P447, DOI 10.1016/j.biopha.2003.09.006; Lichtner RB, 2001, CANCER RES, V61, P5790; LIN CR, 1984, SCIENCE, V224, P843, DOI 10.1126/science.6326261; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Llovera M, 2000, ONCOGENE, V19, P4695, DOI 10.1038/sj.onc.1203846; Llovera M, 2000, EXP GERONTOL, V35, P41, DOI 10.1016/S0531-5565(99)00078-9; Maus MV, 1999, ENDOCRINOLOGY, V140, P5447, DOI 10.1210/en.140.11.5447; MCMURRAY RW, 1995, J RHEUMATOL, V22, P2084; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Quijano VJ, 1998, J BIOL CHEM, V273, P1200, DOI 10.1074/jbc.273.2.1200; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; RUI H, 1994, J BIOL CHEM, V269, P5364; RUI H, 2000, CYTOKINE REFERENCE O, P267; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; Shilo BZ, 2003, EXP CELL RES, V284, P140, DOI 10.1016/S0014-4827(02)00094-0; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; TAKISHIMA K, 1988, BIOCHEM BIOPH RES CO, V157, P740, DOI 10.1016/S0006-291X(88)80312-7; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; Vonderhaar BK, 1999, ENDOCR-RELAT CANCER, V6, P389, DOI 10.1677/erc.0.0060389; Wennbo H, 1997, ENDOCRINOLOGY, V138, P4410, DOI 10.1210/en.138.10.4410; Wiepz GJ, 1997, J CELL PHYSIOL, V173, P44, DOI 10.1002/(SICI)1097-4652(199710)173:1<44::AID-JCP6>3.0.CO;2-J; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Wiley HS, 2003, TRENDS CELL BIOL, V13, P43; Xie W, 1997, MOL ENDOCRINOL, V11, P1766, DOI 10.1210/me.11.12.1766; Yamauchi T, 2000, J BIOL CHEM, V275, P33937, DOI 10.1074/jbc.M000743200; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yamauchi T, 1998, ENDOCR J, V45, pS27, DOI 10.1507/endocrj.45.Suppl_S27	100	47	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7565	7576		10.1038/sj.onc.1209740	http://dx.doi.org/10.1038/sj.onc.1209740			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16785991				2022-12-17	WOS:000242655500002
J	Huang, Y; Zhao, Q; Zhou, CX; Gu, ZM; Li, D; Xu, HZ; Sims, PJ; Zhao, KW; Chen, GQ				Huang, Y.; Zhao, Q.; Zhou, C-X; Gu, Z-M; Li, D.; Xu, H-Z; Sims, P. J.; Zhao, K-W; Chen, G-Q			Antileukemic roles of human phospholipid scramblase 1 gene, evidence from inducible PLSCR1-expressing leukemic cells	ONCOGENE			English	Article						PLSCR1; proliferation; differentiation; apoptosis; leukemia; gene regulation	KINASE-C-DELTA; GROWTH-FACTOR RECEPTOR; UV-INDUCED APOPTOSIS; PLASMA-MEMBRANE; MYELOID-LEUKEMIA; RETINOIC ACID; C/EBP-ALPHA; INDUCED-DIFFERENTIATION; TRANSBILAYER MOVEMENT; MEDIATED DEGRADATION	Phospholipid scramblase 1 (PLSCR1) is a multiply palmitoylated protein which is localized in either the cell membrane or nucleus depending on its palmitoylated state. The increasing evidence showed the biological roles of PLSCR1 in cell signaling, maturation and apoptosis. To investigate the functions of PLSCR1 in leukemic cells, we generated an inducible PLSCR1-expressing cell line using myeloid leukemic U937 cells. In this cell line, PLSCR1 was tightly regulated and induced upon tetracycline withdrawal. Our results showed that inducible PLSCR1 expression arrested the proliferation of U937 cells at G(1) phase. Meanwhile, PLSCR1-overexpressing U937 cells also underwent granulocyte-like differentiation with increased sensitivity to etoposide-induced apoptosis. Furthermore, we also found that PLSCR1 induction increased cyclin-dependent kinase inhibitors p27(Kip1) and p21(Cip1) proteins, together with downregulation of S phase kinase-associated protein 2 (SKP2), an F-box subunit of the ubiquitin-ligase complex that targets proteins for degradation. Additionally, PLSCR1 induction significantly decreased c-Myc protein and antiapoptotic Bcl-2 protein. Although the exact mechanism by which PLSCR1 regulates these cellular events and gene expression remains unresolved, our results suggest that PLSCR1 plays the antagonistic role regarding leukemia development. These data will shed new insights into understanding the biochemical and biological functions of PLSCR1 protein.	Shanghai Jiao Tong Univ, Sch Med, Key Lab Cell Differentiat & Apoptosis Chinese Min, Dept Pathophysiol, Shanghai 200025, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Inst Hlth Sci, Shanghai Inst Biol Sci, Shanghai 200030, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Grad Sch, Chinese Acad Sci, Shanghai 200030, Peoples R China; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Jiao Tong University; Scripps Research Institute	Chen, GQ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Key Lab Cell Differentiat & Apoptosis Chinese Min, Dept Pathophysiol, 280,Chong Qing S Rd, Shanghai 200025, Peoples R China.	chengq@shsmu.edu.cn	Li, Dong/C-7344-2011	chen, guo qiang/0000-0003-4936-2363	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076215, R01HL036946] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL036946, HL076215] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bailey K, 2005, BBA-MOL CELL BIOL L, V1733, P199, DOI 10.1016/j.bbalip.2004.12.013; Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; Ben-Efraim I, 2004, BIOCHEMISTRY-US, V43, P3518, DOI 10.1021/bi0356911; Boer J, 1998, MOL CELL BIOL, V18, P1236, DOI 10.1128/MCB.18.3.1236; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen MH, 2005, J BIOL CHEM, V280, P10599, DOI 10.1074/jbc.M413194200; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Friedman AD, 2002, J CELL BIOCHEM, V86, P624, DOI 10.1002/jcb.10271; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; Jiang Y, 2005, LEUKEMIA, V19, P1239, DOI 10.1038/sj.leu.2403734; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Kasukabe T, 1998, BIOCHEM BIOPH RES CO, V249, P449, DOI 10.1006/bbrc.1998.9190; Kasukabe T, 1997, BLOOD, V89, P2975, DOI 10.1182/blood.V89.8.2975; Kikuchi J, 1997, BLOOD, V89, P3980, DOI 10.1182/blood.V89.11.3980; Koschmieder S, 2005, INT J HEMATOL, V81, P368, DOI 10.1532/IJH97.05051; LARSSON LG, 1994, ONCOGENE, V9, P1247; Li LW, 1999, MOL CELL BIOL, V19, P8547; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Mitani K, 2004, ONCOGENE, V23, P4263, DOI 10.1038/sj.onc.1207777; Munoz-Alonso MJ, 2005, J BIOL CHEM, V280, P18120, DOI 10.1074/jbc.M500758200; Nakajima H, 1996, LEUKEMIA RES, V20, P665, DOI 10.1016/0145-2126(96)00020-3; Nakamaki T, 2002, EXP HEMATOL, V30, P421, DOI 10.1016/S0301-472X(02)00779-8; Nanjundan M, 2003, J BIOL CHEM, V278, P37413, DOI 10.1074/jbc.M306182200; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Rots NY, 1999, BLOOD, V93, P2721, DOI 10.1182/blood.V93.8.2721.408k28_2721_2729; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Silverman RH, 2002, CANCER RES, V62, P397; Song MG, 2005, BLOOD, V105, P3714, DOI 10.1182/blood-2004-10-4011; Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305; Steinman RA, 2002, ONCOGENE, V21, P3403, DOI 10.1038/sj.onc.1205325; Sun J, 2002, BIOCHEMISTRY-US, V41, P6338, DOI 10.1021/bi025610l; Sun J, 2001, J BIOL CHEM, V276, P28984, DOI 10.1074/jbc.M102505200; Wang ZL, 1998, EXP CELL RES, V244, P105, DOI 10.1006/excr.1998.4191; Wiedmer T, 2003, BIOCHEMISTRY-US, V42, P1227, DOI 10.1021/bi026679w; Yamanaka R, 1998, INT J MOL MED, V1, P213; Yokoyama A, 2004, LEUKEMIA RES, V28, P149, DOI 10.1016/S0145-2126(03)00189-9; Yu A, 2003, J BIOL CHEM, V278, P9706, DOI 10.1074/jbc.M204614200; Zhao J, 1998, BIOCHEMISTRY-US, V37, P6361, DOI 10.1021/bi980218m; Zhao KW, 2005, J BIOL CHEM, V280, P42707, DOI 10.1074/jbc.M506178200; Zhao KW, 2004, BLOOD, V104, P3731, DOI 10.1182/blood-2004-04-1630; Zhou QS, 2005, J BIOL CHEM, V280, P35062, DOI 10.1074/jbc.M504821200; Zhou QS, 2002, BLOOD, V99, P4030, DOI 10.1182/blood-2001-12-0271; ZHU J, 1995, LEUKEMIA, V9, P302	49	47	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6618	6627		10.1038/sj.onc.1209677	http://dx.doi.org/10.1038/sj.onc.1209677			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16702944				2022-12-17	WOS:000241569700006
J	Cuevas, BD; Winter-Vann, AM; Johnson, NL; Johnson, GL				Cuevas, B. D.; Winter-Vann, A. M.; Johnson, N. L.; Johnson, G. L.			MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer	ONCOGENE			English	Article						breast cancer; metastasis; kinase; proteinase; MAPK; knockout	UROKINASE PLASMINOGEN-ACTIVATOR; HUMAN-BREAST-CANCER; DEFICIENT MICE; GROWTH-FACTOR; REDUCED METASTASIS; GENE DISRUPTION; ERK/MAP KINASE; MESSENGER-RNA; IN-VITRO; EXPRESSION	Mammary tumor cells are required to degrade the surrounding matrix and disseminate in order to metastasize, and both of these processes are controlled by a tumor cell-signaling network that remains poorly defined. MEKK1 is a MAPKKK that regulates both the extracellular signal regulated kinase (ERK1/2) and the c-Jun amino terminal kinase (JNK) signaling pathways. MEKK1 signaling regulates migration through control of cell adhesion and is required for inducible expression of urokinase-type plasminogen activator (uPA). MEKK1-deficient mice with mammary gland-targeted expression of the polyoma middle T antigen (PyMT) transgene develop primary mammary tumors at a rate and frequency similar to wild-type littermates, indicating that MEKK1 deficiency does not affect PyMT-mediated transformation. However, MEKK1-/- mice display significantly delayed tumor cell dissemination and lung metastasis. Delayed MEKK1-dependent tumor dissemination is associated with markedly reduced tumor uPA expression, gelatinase activity, and prolonged tumor basement membrane integrity. siRNA-mediated MEKK1 knockdown inhibits uPA activity, cell migration and invasion in MDA-MB-231 human breast cancer cells. Thus MEKK1 controls tumor progression by regulating both the migration and proteolysis aspects of tumor cell invasiveness. To our knowledge, this is the first example of a MAPKKK that regulates metastasis through control of tumor invasiveness.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Cuevas, BD (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, 1108 Mary Ellen Jones Bldg,Campus Box 7365, Chapel Hill, NC 27599 USA.	bruce_cuevas@med.unc.edu; glj@med.unc.edu	, Pathology Services Core/CEZ-2246-2022		NIDDK NIH HHS [DK37871] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed F, 2002, CANCER RES, V62, P7166; Almholt K, 2005, INT J CANCER, V113, P525, DOI 10.1002/ijc.20631; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Balduyck M, 2000, CLIN EXP METASTAS, V18, P171, DOI 10.1023/A:1006762425323; Bianco FJ, 1998, CLIN CANCER RES, V4, P3011; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; Bugge TH, 1998, ONCOGENE, V16, P3097, DOI 10.1038/sj.onc.1201869; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Christensen L, 1996, INT J CANCER, V66, P441; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; Cuevas BD, 2005, ONCOGENE, V24, P801, DOI 10.1038/sj.onc.1208239; Cuevas BD, 2003, EMBO J, V22, P3346, DOI 10.1093/emboj/cdg322; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; DAVIES B, 1993, CANCER RES, V53, P5365; Duffy MJ, 2004, ANN CLIN BIOCHEM, V41, P370, DOI 10.1258/0004563041731529; Duffy MJ, 2004, CLIN BIOCHEM, V37, P541, DOI 10.1016/j.clinbiochem.2004.05.013; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; ELYAZIDI I, 1995, ANTICANCER RES, V15, P783; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FIDLER IJ, 1991, ACTA ONCOL, V30, P669, DOI 10.3109/02841869109092438; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Frederiks WM, 2004, J HISTOCHEM CYTOCHEM, V52, P711, DOI 10.1369/jhc.4R6251.2004; Fuchs SY, 1996, ONCOGENE, V13, P1531; Gelder MEV, 2004, CANCER RES, V64, P4563, DOI 10.1158/0008-5472.CAN-03-3848; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hamasaki T, 1998, UROL RES, V26, P371, DOI 10.1007/s002400050071; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Itoh T, 1998, CANCER RES, V58, P1048; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001; Lijnen HR, 1998, ARTERIOSCL THROM VAS, V18, P1035, DOI 10.1161/01.ATV.18.7.1035; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Manders P, 2004, CANCER-AM CANCER SOC, V101, P486, DOI 10.1002/cncr.20374; Nielsen BS, 1996, LAB INVEST, V74, P168; Nielsen BS, 2001, LAB INVEST, V81, P1485, DOI 10.1038/labinvest.3780363; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; Schweinitz A, 2004, J BIOL CHEM, V279, P33613, DOI 10.1074/jbc.M314151200; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; Sieuwerts AM, 1999, BREAST CANCER RES TR, V55, P9, DOI 10.1023/A:1006190729866; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Tanaka Y, 2004, GYNECOL ONCOL, V94, P725, DOI 10.1016/j.ygyno.2004.06.012; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Witowsky J, 2003, J BIOL CHEM, V278, P5941, DOI 10.1074/jbc.M212363200; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	49	47	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					4998	5010		10.1038/sj.onc.1209507	http://dx.doi.org/10.1038/sj.onc.1209507			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568086				2022-12-17	WOS:000239921300005
J	Goldsmith, KC; Liu, X; Dam, V; Morgan, BT; Shabbout, M; Cnaan, A; Letai, A; Korsmeyer, SJ; Hogarty, MD				Goldsmith, K. C.; Liu, X.; Dam, V.; Morgan, B. T.; Shabbout, M.; Cnaan, A.; Letai, A.; Korsmeyer, S. J.; Hogarty, M. D.			BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma	ONCOGENE			English	Article						apoptosis; neuroblastoma; Bcl-2 homologues; programmed cell death; MYCN	HUMAN NEURO-BLASTOMA; CELL-LINES; CANCER-CELLS; IN-VIVO; P53; PROTEINS; DOMAINS; TUMOR; RESISTANCE; MUTATIONS	The major impediment to cure for many malignancies is the development of therapy resistance with resultant tumor progression. Genetic alterations leading to subversion of inherent apoptosis pathways are common themes in therapy resistance. Bcl-2 family proteins play a critical role in regulating mitochondrial apoptosis that governs chemotherapeutic effects, and defective engagement of these pathways contributes to treatment failure. We have studied the efficacy of BH3 peptidomimetics consisting of the minimal death, or BH3, domains of the proapoptotic BH3-only proteins Bid and Bad to induce apoptosis using neuroblastoma (NB) as a model system. We demonstrate that BH3 peptides, modified with an arginine homopolymer for membrane transduction (called r8-BidBH3 and r8-BadBH3, respectively), potently induce apoptosis in NB cells, including those with MYCN amplification. Cell death is caspase 9 dependent, consistent with a requirement for the intrinsic mitochondrial pathway. Substitutions at highly conserved residues within the r8-BidBH3 peptide abolish apoptotic efficacy supporting activity through specific BH domain interactions. Concomitant exposure to r8-BadBH3 and r8-BidBH3 at sublethal monotherapy doses revealed potent synergy consistent with a competitive displacement model, whereby BH3 peptides displace sequestered BH3 proteins to induce cell death. Further, BH3 peptides demonstrate antitumor efficacy in a xenograft model of NB in the absence of additional genotoxic or trophic stressors. These data provide proof of principle that targeted re-engagement of apoptosis pathways may be of therapeutic utility, and BH3-like compounds are attractive lead agents to re-establish therapy-induced apoptosis in refractory malignancies.	Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	Hogarty, MD (corresponding author), Childrens Hosp Philadelphia, Div Oncol, 9 N ARC,Suite 902C,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	hogartym@email.chop.edu			NATIONAL CANCER INSTITUTE [P01CA097323] Funding Source: NIH RePORTER; NCI NIH HHS [CA97323] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIEDLER JL, 1976, J NATL CANCER I, V57, P683, DOI 10.1093/jnci/57.3.683; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cooperman J, 2004, STEM CELLS, V22, P1111, DOI 10.1634/stemcells.22-6-1111; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Dive C, 1992, Semin Cancer Biol, V3, P417; FEDER MK, 1983, J NATL CANCER I, V70, P1051; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hersey P, 2003, J CELL PHYSIOL, V196, P9, DOI 10.1002/jcp.10256; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1; Keshelava N, 2001, CANCER RES, V61, P6185; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Moreau C, 2003, J BIOL CHEM, V278, P19426, DOI 10.1074/jbc.M209472200; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; SCHLESINGER HR, 1976, CANCER RES, V36, P3094; SCHMECHEL D, 1978, NATURE, V276, P834, DOI 10.1038/276834a0; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; Tajiri T, 2003, CLIN CANCER RES, V9, P3345; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; Tweddle DA, 2001, CANCER RES, V61, P8; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108	39	47	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4525	4533		10.1038/sj.onc.1209489	http://dx.doi.org/10.1038/sj.onc.1209489			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16568093				2022-12-17	WOS:000239457500003
J	Burnworth, B; Popp, S; Stark, HJ; Steinkraus, V; Broecker, EB; Hartschuh, W; Birek, C; Boukamp, P				Burnworth, B.; Popp, S.; Stark, H-J; Steinkraus, V.; Broecker, E. B.; Hartschuh, W.; Birek, C.; Boukamp, P.			Gain of 11q/cyclin D1 overexpression is an essential early step in skin cancer development and causes abnormal tissue organization and differentiation	ONCOGENE			English	Article						keratoacanthoma; cdk4; p21; aberrant differentiation; tumorigenicity	COMPARATIVE GENOMIC HYBRIDIZATION; SQUAMOUS-CELL CARCINOMA; CYCLIN D1; P53 MUTATIONS; CHROMOSOMAL-ABERRATIONS; ORGANOTYPIC COCULTURE; KERATINOCYTES HACAT; GENE; PROGRESSION; EXPRESSION	Non-melanoma skin cancers, in particular keratoacanthomas (KAs) and squamous cell carcinomas (SCCs), have become highly frequent tumor types especially in immune-suppressed transplant patients. Nevertheless, little is known about essential genetic changes. As a paradigm of 'early' changes, that is, changes still compatible with tumor regression, we studied KAs by comparative genomic hybridization and show that gain of chromosome 11q is not only one of the most frequent aberration (8/18), but in four tumors also the only aberration. Furthermore, 11q gain correlated with amplification of the cyclin D1 locus (10/14), as determined by fluorescence in situ hybridization, and overexpression of cyclin D1 protein (25/31), as detected by immunohistochemistry. For unraveling the functional consequence, we overexpressed cyclin D1 in HaCaT skin keratinocytes. These cells only gained little growth advantage in conventional and in organotypic cocultures. However, although the control vector-transfected cells formed a well-stratified and orderly differentiated epidermis-like epithelium, they showed deregulation of tissue architecture with an altered localization of proliferation and impaired differentiation. The most severe phenotype was seen in a clone that additionally upregulated cdk4 and p21. These cells lacked terminal differentiation, exhibited a more autonomous growth in vitro and in vivo and even formed tumors in two injection sites with a growth pattern resembling that of human KAs. Thus, our results identify 11q13 gain/cyclin D1 overexpression as an important step in KA formation and point to a function that exceeds its known role in proliferation by disrupting tissue organization and thereby allowing abnormal growth.	DKFZ, German Canc Res Ctr, Genet Skin Carcinogenesis, D-69120 Heidelberg, Germany; Dermatologicum Hamburg, Hamburg, Germany; Univ Wurzburg, Wurzburg, Germany; Heidelberg Univ, Heidelberg, Germany; Univ Manitoba, Fac Dent, Winnipeg, MB, Canada	Helmholtz Association; German Cancer Research Center (DKFZ); Dermatologikum Hamburg; University of Wurzburg; Ruprecht Karls University Heidelberg; University of Manitoba	Boukamp, P (corresponding author), DKFZ, German Canc Res Ctr, Genet Skin Carcinogenesis, Neuenheimer Feld 280,Postfach 101949, D-69120 Heidelberg, Germany.	p.boukamp@dkfz-heidelberg.de						Arnold A, 2005, J CLIN ONCOL, V23, P4215, DOI 10.1200/JCO.2005.05.064; Ashton KJ, 2003, ARCH DERMATOL, V139, P876, DOI 10.1001/archderm.139.7.876; Billingsley E M, 1999, J Cutan Med Surg, V3, P193; Boukamp P, 1997, GENE CHROMOSOME CANC, V19, P201, DOI 10.1002/(SICI)1098-2264(199708)19:4<201::AID-GCC1>3.0.CO;2-0; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Boukamp P, 1999, ONCOGENE, V18, P5638, DOI 10.1038/sj.onc.1202934; Boukamp Petra, 2005, J Dtsch Dermatol Ges, V3, P493, DOI 10.1111/j.1610-0387.2005.05037.x; Cerezo A, 2003, J INVEST DERMATOL, V121, P110, DOI 10.1046/j.1523-1747.2003.12304.x; Clausen OPF, 2002, J INVEST DERMATOL, V119, P1367, DOI 10.1046/j.1523-1747.2002.19613.x; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005; Freedberg IM EA, 1999, FITZPATRICKS DERMATO; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Hosokawa Y, 1998, GENE CHROMOSOME CANC, V22, P66, DOI 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5; Jin YS, 1999, GENE CHROMOSOME CANC, V26, P295, DOI 10.1002/(SICI)1098-2264(199912)26:4<295::AID-GCC3>3.0.CO;2-W; Jin YS, 2002, CANCER GENET CYTOGEN, V136, P48, DOI 10.1016/S0165-4608(01)00517-9; JOHNSON TM, 1992, J AM ACAD DERMATOL, V26, P467, DOI 10.1016/0190-9622(92)70074-P; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Lesage D, 2005, INT J CANCER, V115, P171, DOI 10.1002/ijc.20907; Ling G, 2001, AM J PATHOL, V159, P1247, DOI 10.1016/S0002-9440(10)62511-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; Oyama T, 1998, CANCER RES, V58, P2876; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; Popp S, 2002, INT J CANCER, V99, P352, DOI 10.1002/ijc.10321; Popp S, 2000, J INVEST DERMATOL, V115, P1095, DOI 10.1046/j.1523-1747.2000.00173.x; QUINN AG, 1994, GENE CHROMOSOME CANC, V11, P222, DOI 10.1002/gcc.2870110404; Rehman I, 1996, ONCOGENE, V12, P2483; Ren ZP, 1996, ONCOGENE, V12, P765; ROTZER D, 2006, IN PRESS ONCOGENE; Schoop VM, 1999, J INVEST DERMATOL, V112, P343, DOI 10.1046/j.1523-1747.1999.00524.x; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shoker BS, 2001, BRIT J CANCER, V84, P1064, DOI 10.1054/bjoc.2001.1705; Stark HJ, 2004, EUR J CELL BIOL, V83, P631, DOI 10.1078/0171-9335-00435; Utikal J, 2005, CANCER LETT, V219, P197, DOI 10.1016/j.canlet.2004.07.011; Utikal J, 2005, INT J ONCOL, V26, P597; Waring AJ, 1996, BRIT J CANCER, V73, P649, DOI 10.1038/bjc.1996.113; Zahnow CA, 2002, BREAST CANCER RES, V4, P109, DOI 10.1186/bcr428	44	47	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4399	4412		10.1038/sj.onc.1209474	http://dx.doi.org/10.1038/sj.onc.1209474			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16547504				2022-12-17	WOS:000239326000003
J	Kanzawa, T; Iwado, E; Aoki, H; Iwamaru, A; Hollingsworth, EF; Sawaya, R; Kondo, S; Kondo, Y				Kanzawa, T.; Iwado, E.; Aoki, H.; Iwamaru, A.; Hollingsworth, E. F.; Sawaya, R.; Kondo, S.; Kondo, Y.			Ionizing radiation induces apoptosis and inhibits neuronal differentiation in rat neural stem cells via the c-Jun NH2-terminal kinase (JNK) pathway	ONCOGENE			English	Article						neural stem cells; ionizing radiation; JNK; apoptosis; neuronal differentiation	BCL-2 FAMILY-MEMBERS; PROGENITOR CELLS; PRECURSOR CELLS; CYTOCHROME-C; EICOSAPENTAENOIC ACID; GAMMA-IRRADIATION; NERVOUS-SYSTEM; GROWTH-FACTOR; MAP KINASES; ADULT-RAT	A substantial number of neural stem cells ( NSCs) continue to proliferate and generate neurons in the central nervous system throughout life. Ionizing radiation, an important adjuvant therapy for glioma patients, may damage NSCs and cause neuronal deficits, such as cognitive dysfunction and memory impairment. However, the precise mechanism of radiation effects on death and differentiation of NSCs remains largely unknown. Here, we found that radiation induced apoptosis in NSCs via the mitochondrial pathway, upregulating the ratio of Bax to Bcl-2 and releasing cytochrome c into the cytoplasm. Radiation also inhibited neuronal differentiation of NSCs by 50%. Of the three stress-associated mitogen-activated protein kinases ( MAPKs), only c-Jun NH2-terminal kinase ( JNK) was activated in NSCs after radiation. Interestingly, JNK inhibition by the specific inhibitor SP600125 rescued NSCs from apoptosis and improved neuronal differentiation. Furthermore, we examined whether radiation directly inhibits neuronal differentiation or not. Radiation did not affect the promoter activity of NeuroD, a basic helix-loop-helix transcription factor that regulates the expression of neuronal differentiation markers. Radiation induced more apoptosis in NeuroD-positive cells than NeuroD-negative cells. We concluded that radiation activates JNK and induces apoptosis, especially in neural progenitor cells, resulting in the inhibition of neurogenesis. Our findings raise the possibility that JNK inhibition has therapeutic potential in protecting NSCs from the adverse effects of radiation.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Kondo, Y (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, BSRB1004, Houston, TX 77030 USA.	yaskondo@mdanderson.org		KANZAWA, TAKAO/0000-0002-8165-5652	NCI NIH HHS [CA088936, CA108558] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088936, R01CA108558] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bieberich E, 2003, J CELL BIOL, V162, P469, DOI 10.1083/jcb.200212067; Bjorkblom B, 2005, J NEUROSCI, V25, P6350, DOI 10.1523/JNEUROSCI.1517-05.2005; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chang LF, 2003, DEV CELL, V4, P521, DOI 10.1016/S1534-5807(03)00094-7; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Cho JH, 2004, MOL NEUROBIOL, V30, P35, DOI 10.1385/MN:30:1:035; Ciccolini F, 1998, J NEUROSCI, V18, P7869; CROSSEN JR, 1994, J CLIN ONCOL, V12, P627, DOI 10.1200/JCO.1994.12.3.627; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Diez del Corral R, 2001, NAT REV NEUROSCI, V2, P835; Eminel S, 2004, J BIOL CHEM, V279, P55385, DOI 10.1074/jbc.M405858200; Erlandsson A, 2001, J NEUROSCI, V21, P3483, DOI 10.1523/JNEUROSCI.21-10-03483.2001; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harada J, 2004, J NEUROCHEM, V88, P1026, DOI 10.1046/j.1471-4159.2003.02219.x; Harris CA, 2001, J BIOL CHEM, V276, P37754; Huang HP, 2000, MOL CELL BIOL, V20, P3292, DOI 10.1128/MCB.20.9.3292-3307.2000; Jacotot E, 1999, ANN NY ACAD SCI, V887, P18, DOI 10.1111/j.1749-6632.1999.tb07919.x; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Kondo S, 1996, ONCOGENE, V13, P1773; KONDO S, 1992, NEUROSURGERY, V30, P506; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Limoli CL, 2004, RADIAT RES, V161, P17, DOI 10.1667/RR3112; Lonergan PE, 2002, J BIOL CHEM, V277, P20804, DOI 10.1074/jbc.M202387200; Lynch AM, 2003, J BIOL CHEM, V278, P51075, DOI 10.1074/jbc.M307970200; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Peissner W, 1999, MOL BRAIN RES, V71, P61, DOI 10.1016/S0169-328X(99)00170-9; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; Rueda D, 2002, J BIOL CHEM, V277, P46645, DOI 10.1074/jbc.M206590200; Shamblott MJ, 2001, P NATL ACAD SCI USA, V98, P113, DOI 10.1073/pnas.021537998; Surma-aho O, 2001, NEUROLOGY, V56, P1285, DOI 10.1212/WNL.56.10.1285; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Verheij M, 1998, RADIOTHER ONCOL, V47, P225, DOI 10.1016/S0167-8140(98)00007-3; Verheij M, 2000, CELL TISSUE RES, V301, P133, DOI 10.1007/s004410000188; Waetzig V, 2005, TRENDS PHARMACOL SCI, V26, P455, DOI 10.1016/j.tips.2005.07.006; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Zhao WQ, 2003, J NEUROSCI RES, V72, P334, DOI 10.1002/jnr.10591	48	47	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3638	3648		10.1038/sj.onc.1209414	http://dx.doi.org/10.1038/sj.onc.1209414			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16491125				2022-12-17	WOS:000238448300003
J	Wojcik, EJ; Sharifpoor, S; Miller, NA; Wright, TG; Watering, R; Tremblay, E; Swan, K; Mueller, CR; Elliott, BE				Wojcik, EJ; Sharifpoor, S; Miller, NA; Wright, TG; Watering, R; Tremblay, E; Swan, K; Mueller, CR; Elliott, BE			A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells	ONCOGENE			English	Article						HGF expression; Src; Stat3; breast carcinoma cells	HEPATOCYTE GROWTH-FACTOR; FACTOR GENE PROMOTER; FACTOR SCATTER FACTOR; FACTOR EXPRESSION; BREAST-CARCINOMA; DNA-BINDING; SIGNAL TRANSDUCERS; MET/HGF RECEPTOR; MET RECEPTOR; CANCER	In the normal breast, hepatocyte growth factor (HGF) is primarily expressed by stromal cells, and stimulates in a paracrine manner epithelial cells expressing the HGF receptor ( Met). In invasive human breast carcinomas, HGF and Met are frequently overexpressed, possibly establishing an autocrine HGF/Met loop that promotes tumour cell invasion. However, the mechanisms leading to autocrine HGF expression in carcinoma cells are not known. We previously demonstrated a cooperative effect between c-Src and Stat3 in the activation of HGF transcription in mammary carcinoma cells. The present report defines a novel Stat3 consensus site at nt - 95 in the HGF promoter that is highly conserved in human and mouse, and is required for c-Src and Stat3 to activate HGF transcription in breast epithelial cells. DNA - protein binding studies demonstrated high affinity binding of a Stat3-containing complex to the nt -95 site. Endogenous Stat3 binding to this region of the HGF promoter in carcinoma cells expressing HGF was demonstrated using a chromatin immunoprecipitation assay. In addition, coexpression of Stat3 and activated c-Src caused increased expression of endogenous HGF mRNA and protein and marked cell scattering in breast epithelial cells. Our results delineate a novel c-Src/Stat3-dependent mechanism that regulates HGF promoter activity, and is linked to transformation of mammary epithelial cells.	Queens Univ, Inst Canc Res, Dept Pathol & Lab Med, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Elliott, BE (corresponding author), Queens Univ, Inst Canc Res, Dept Pathol & Lab Med, Div Canc Biol & Genet, 10 Stuart St, Kingston, ON K7L 3N6, Canada.	elliottb@post.queensu.ca						Andermarcher E, 1996, DEV GENET, V18, P254, DOI 10.1002/(SICI)1520-6408(1996)18:3<254::AID-DVG6>3.0.CO;2-8; Atlas E, 2000, ONCOGENE, V19, P1933, DOI 10.1038/sj.onc.1203516; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Bell AW, 1998, J BIOL CHEM, V273, P6900, DOI 10.1074/jbc.273.12.6900; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Braunstein J, 2003, J BIOL CHEM, V278, P34133, DOI 10.1074/jbc.M304531200; BUSSOLINO F, 1992, J CELL BIOL, V119, P929; BYERS S, 1994, BREAST CANCER RES TR, V31, P203, DOI 10.1007/BF00666154; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Dolled-Filhart M, 2003, CLIN CANCER RES, V9, P594; Elliott BE, 2002, CAN J PHYSIOL PHARM, V80, P91, DOI 10.1139/y02-010; Gallego MI, 2003, ONCOGENE, V22, P8498, DOI 10.1038/sj.onc.1207063; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Hung W, 2001, J BIOL CHEM, V276, P12395, DOI 10.1074/jbc.M010715200; Jiang JG, 2000, BIOCHEM BIOPH RES CO, V272, P882, DOI 10.1006/bbrc.2000.2848; Jiang JG, 2000, ONCOGENE, V19, P2786, DOI 10.1038/sj.onc.1203581; Jiang JG, 1997, MOL CELL BIOL, V17, P5758, DOI 10.1128/MCB.17.10.5758; Jiang JG, 2001, J BIOL CHEM, V276, P25049, DOI 10.1074/jbc.M101611200; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Klosek SK, 2004, ONCOL REP, V12, P293; LIU YH, 1994, J BIOL CHEM, V269, P4152; LIU YH, 1994, MOL CELL BIOL, V14, P7046, DOI 10.1128/MCB.14.11.7046; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Olivero M, 1996, BRIT J CANCER, V74, P1862, DOI 10.1038/bjc.1996.646; Paz K, 2004, ONCOGENE, V23, P8455, DOI 10.1038/sj.onc.1207803; PLASCHKESCHLUTTER A, 1995, J BIOL CHEM, V270, P830, DOI 10.1074/jbc.270.2.830; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Siegfried JM, 1997, CANCER RES, V57, P433; Tomida M, 2004, ONCOGENE, V23, P679, DOI 10.1038/sj.onc.1207190; Trovato M, 2004, EUR J HISTOCHEM, V48, P291; Tuck AB, 1996, AM J PATHOL, V148, P225; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378; WANG Y, 1994, AM J PATHOL, V144, P675; Watson CJ, 2001, J MAMMARY GLAND BIOL, V6, P115, DOI 10.1023/A:1009524817155; YAMASHITA J, 1994, CANCER RES, V54, P1630; Yang J, 2005, CANCER RES, V65, P939; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang YW, 2002, ONCOGENE, V21, P217, DOI 10.1038/sj/onc/1205004	50	47	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2773	2784		10.1038/sj.onc.1209306	http://dx.doi.org/10.1038/sj.onc.1209306			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16407846				2022-12-17	WOS:000237272900008
J	Bark-Jones, SJ; Webb, HM; West, MJ				Bark-Jones, SJ; Webb, HM; West, MJ			EBV EBNA 2 stimulates CDK9-dependent transcription and RNA polymerase II phosphorylation on serine 5	ONCOGENE			English	Article						CDK9; CTD; EBNA 2; phosphorylation; serine 5; serine 2	EPSTEIN-BARR-VIRUS; CARBOXYL-TERMINAL DOMAIN; DEPENDENT KINASE INHIBITOR; SIGNAL-BINDING-PROTEIN; LYMPHOCYTE GROWTH TRANSFORMATION; NUCLEAR-PROTEIN-2 ACIDIC DOMAIN; LATENT MEMBRANE-PROTEIN; HUMAN LEUKEMIA-CELLS; FACTOR P-TEFB; RBP-J-KAPPA	EBNA 2 is one of only. v e viral genes essential for the infection and immortalization of human B cells by the cancer-associated virus Epstein-Barr virus (EBV). EBNA 2 activates cellular and viral transcription and associates with components of the basal transcription apparatus and a number of coactivators. We provide the first evidence to show that the mechanism of transcriptional activation by EBNA 2 also involves phosphorylation of the C-terminal domain (CTD) of RNA polymerase II (pol II). We found that transcriptional activation by EBNA 2 was inhibited by a dominant-negative mutant of the pol II CTD kinase, CDK9, and by low concentrations of the CDK9 inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole. Moreover, using chromatin immunoprecipitation assays we demonstrated that EBNA 2 stimulates both pol II recruitment and pol II phosphorylation on serine 5 of the CTD in vivo. These results identify a new step in the transcription cycle that is subject to regulation by a key EBV-encoded transcription factor and highlight CDK9 inhibitors as potential anti-EBV agents.	Univ Sussex, Sch Life Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England	University of Sussex	West, MJ (corresponding author), Univ Sussex, Sch Life Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England.	m.j.west@sussex.ac.uk		West, Michelle/0000-0002-9497-9365	Wellcome Trust [064014] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABBOT SD, 1990, J VIROL, V64, P2126, DOI 10.1128/JVI.64.5.2126-2134.1990; Alazard N, 2003, J VIROL, V77, P8166, DOI 10.1128/JVI.77.14.8166-8172.2003; ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; ALLDAY MJ, 1989, J GEN VIROL, V70, P1755, DOI 10.1099/0022-1317-70-7-1755; Andersson Jan, 2000, Herpes, V7, P76; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; COHEN JI, 1991, J VIROL, V65, P5880, DOI 10.1128/JVI.65.11.5880-5885.1991; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; COHEN JI, 1992, P NATL ACAD SCI USA, V89, P8030, DOI 10.1073/pnas.89.17.8030; Decker RH, 2001, CELL DEATH DIFFER, V8, P715, DOI 10.1038/sj.cdd.4400868; Deng Z, 2003, J VIROL, V77, P11992, DOI 10.1128/JVI.77.22.11992-12001.2003; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Eberhardy SR, 2002, J BIOL CHEM, V277, P40156, DOI 10.1074/jbc.M207441200; Gold MO, 1998, J VIROL, V72, P4448, DOI 10.1128/JVI.72.5.4448-4453.1998; Gold MO, 1996, NUCLEIC ACIDS RES, V24, P3771, DOI 10.1093/nar/24.19.3771; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; Herrmann CH, 1996, NUCLEIC ACIDS RES, V24, P501, DOI 10.1093/nar/24.3.501; Isel C, 1999, J MOL BIOL, V290, P929, DOI 10.1006/jmbi.1999.2933; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; Kim YK, 2002, MOL CELL BIOL, V22, P4622, DOI 10.1128/MCB.22.13.4622-4637.2002; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; Lee MA, 1999, J VIROL, V73, P2974, DOI 10.1128/JVI.73.4.2974-2982.1999; LING PD, 1993, P NATL ACAD SCI USA, V90, P9237, DOI 10.1073/pnas.90.20.9237; Litz J, 2003, CLIN CANCER RES, V9, P4586; Ma YH, 2003, MOL CANCER THER, V2, P73; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Nelson PJ, 2003, J ANTIMICROB CHEMOTH, V51, P921, DOI 10.1093/jac/dkg175; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Ping YH, 1999, J BIOL CHEM, V274, P7399, DOI 10.1074/jbc.274.11.7399; Ramanathan Y, 2001, J BIOL CHEM, V276, P10913, DOI 10.1074/jbc.M010975200; Sadaie AR, 2004, ANTIVIR RES, V61, P1, DOI 10.1016/j.antiviral.2003.09.004; Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139, DOI 10.1016/S1040-8428(00)00124-4; SJOBLOM A, 1995, J GEN VIROL, V76, P2679, DOI 10.1099/0022-1317-76-11-2679; SKARE J, 1985, J VIROL, V55, P286, DOI 10.1128/JVI.55.2.286-297.1985; Spilianakis C, 2003, EMBO J, V22, P5125, DOI 10.1093/emboj/cdg496; Swaminathan S, 1996, VIROLOGY, V217, P532, DOI 10.1006/viro.1996.0148; Tian YN, 2003, J BIOL CHEM, V278, P44041, DOI 10.1074/jbc.M306443200; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; TONG X, 1995, J VIROL, V69, P585, DOI 10.1128/JVI.69.1.585-588.1995; TONG X, 1995, MOL CELL BIOL, V15, P4735; TONG X, 1995, P NATL ACAD SCI USA, V92, P3259, DOI 10.1073/pnas.92.8.3259; TSANG SF, 1991, J VIROL, V65, P6765, DOI 10.1128/JVI.65.12.6765-6771.1991; Van Veldhuizen PJ, 2005, CANCER CHEMOTH PHARM, V56, P39, DOI 10.1007/s00280-004-0969-9; WALTZER L, 1994, EMBO J, V13, P5633, DOI 10.1002/j.1460-2075.1994.tb06901.x; WANG F, 1990, J VIROL, V64, P3407, DOI 10.1128/JVI.64.7.3407-3416.1990; Wang L, 2000, P NATL ACAD SCI USA, V97, P430, DOI 10.1073/pnas.97.1.430; Wendtner CM, 2004, SEMIN HEMATOL, V41, P224, DOI 10.1053/j.seminhematol.2004.05.004; West MJ, 2004, J VIROL, V78, P9431, DOI 10.1128/JVI.78.17.9431-9445.2004; West MJ, 1999, EMBO J, V18, P1378, DOI 10.1093/emboj/18.5.1378; WOISETSCHLAEGER M, 1991, P NATL ACAD SCI USA, V88, P3942, DOI 10.1073/pnas.88.9.3942; Wu DY, 1996, J VIROL, V70, P6020, DOI 10.1128/JVI.70.9.6020-6028.1996; Yu CR, 2002, CLIN CANCER RES, V8, P2976; Yue W, 2005, J VIROL, V79, P5880, DOI 10.1128/JVI.79.9.5880-5885.2005; Yue W, 2004, J VIROL, V78, P3542, DOI 10.1128/JVI.78.7.3542-3552.2004; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622; ZIMBERSTROBL U, 1994, EMBO J, V13, P4973, DOI 10.1002/j.1460-2075.1994.tb06824.x	64	47	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1775	1785		10.1038/sj.onc.1209205	http://dx.doi.org/10.1038/sj.onc.1209205			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16314842				2022-12-17	WOS:000236013700009
J	Kobayashi, Y; Ohtsuki, M; Murakami, T; Kobayashi, T; Sutheesophon, K; Kitayama, H; Kano, Y; Kusano, E; Nakagawa, H; Furukawa, Y				Kobayashi, Y; Ohtsuki, M; Murakami, T; Kobayashi, T; Sutheesophon, K; Kitayama, H; Kano, Y; Kusano, E; Nakagawa, H; Furukawa, Y			Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma	ONCOGENE			English	Article						melanoma; histone deacetylase inhibitor; Raf; MAP kinase; Rap1; apoptosis	ACTIVATED PROTEIN-KINASE; DEPENDENT ACTIVATION; BRAF MUTATIONS; T-CELL; B-RAF; DEPSIPEPTIDE FR901228; ONCOGENIC MUTATIONS; CYCLIN D1; GENE; EXPRESSION	Histone deacetylase ( HDAC) inhibitors are expected to be effective for refractory cancer because their mechanism of action differs from that of conventional antineoplastic agents. In this study, we examined the effect of the HDAC inhibitor FK228 on malignant melanoma, as well as its molecular mechanisms. FK228 was highly effective against melanoma compared with other commonly used drugs. By comparing the gene expression profiles of melanoma cells and normal melanocytes, we defined a subset of genes specifically upregulated in melanoma cells by FK228, which included Rap1, a small GTP-binding protein of the Ras family. The expression of Rap1 mRNA and protein increased in FK228-treated melanoma cells in both a dose- and a time-dependent manner. A decrease in the phosphorylation of c-Raf, MEK1/2, and ERK1/2 was accompanied by an increase in Rap1 expression in both FK228-treated and Rap1-overexpressing cells. Inhibition of Rap1 upregulation by small interfering RNA ( siRNA) abrogated the induction of apoptosis and suppression of ERK1/2 phosphorylation in FK228-treated melanoma cells. These results indicate that the cytotoxic effects of FK228 are mediated via the upregulation of Rap1. Furthermore, we found that Rap1 was overexpressed and formed a complex with B-Raf in melanoma cell lines with a V599E mutation of B-Raf. The siRNA-mediated abrogation of Rap1 overexpression increased the viability of these cells, suggesting that Rap1 is also an endogenous regulator of Ras-MAP kinase signaling in melanomas.	Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Dept Dermatol, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Div Organ Transplantat, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Dept Nephrol, Minami Kawachi, Tochigi 3290498, Japan; Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto, Japan; Tochigi Canc Ctr, Div Med Oncol, Utsunomiya, Tochigi, Japan; Jikei Univ, Sch Med, Dept Dermatol, Minato Ku, Tokyo, Japan	Jichi Medical University; Jichi Medical University; Jichi Medical University; Jichi Medical University; Kyoto University; Tochigi Prefectural Cancer Center; Jikei University	Furukawa, Y (corresponding author), Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.	furuyu@jichi.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; BYERS HR, 1991, AM J PATHOL, V139, P423; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; D'Silva NJ, 2003, J CELL PHYSIOL, V196, P532, DOI 10.1002/jcp.10331; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Derjuga A, 2001, J BIOL CHEM, V276, P37815; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Francken AB, 2004, ANN SURG ONCOL, V11, P426, DOI 10.1245/ASO.2004.07.014; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Furumai R, 2002, CANCER RES, V62, P4916; Gore SD, 2002, CLIN CANCER RES, V8, P963; Helmbach H, 2001, INT J CANCER, V93, P617, DOI 10.1002/ijc.1378; Henderson C, 2003, J BIOL CHEM, V278, P12579, DOI 10.1074/jbc.M213093200; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Hubbard SR, 2004, CELL, V116, P764, DOI 10.1016/S0092-8674(04)00256-9; Ishida D, 2003, CANCER CELL, V4, P55, DOI 10.1016/S1535-6108(03)00163-6; Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; Kim DH, 2003, J BIOCHEM MOL BIOL, V36, P110; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klisovic DD, 2003, INVEST OPHTH VIS SCI, V44, P2390, DOI 10.1167/iovs.02-1052; Kumar R, 2004, J INVEST DERMATOL, V122, P342, DOI 10.1046/j.0022-202X.2004.22225.x; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Maeda T, 2000, BLOOD, V96, P3847, DOI 10.1182/blood.V96.12.3847.h8003847_3847_3856; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Melnick A, 2002, CURR OPIN HEMATOL, V9, P322, DOI 10.1097/00062752-200207000-00010; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Ribeiro-Neto F, 2002, P NATL ACAD SCI USA, V99, P5418, DOI 10.1073/pnas.082122499; Sandor V, 2002, CLIN CANCER RES, V8, P718; Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schmidt A, 2001, MOL CELL BIOL, V21, P438, DOI 10.1128/MCB.21.2.438-448.2001; Skov S, 2003, BLOOD, V101, P1430, DOI 10.1182/blood-2002-07-2073; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Somech R, 2004, CANCER TREAT REV, V30, P461, DOI 10.1016/j.ctrv.2004.04.006; Sutheesophon K, 2005, J CELL PHYSIOL, V203, P387, DOI 10.1002/jcp.20235; SWOPE VB, 1995, EXP CELL RES, V217, P453, DOI 10.1006/excr.1995.1109; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; UEDA H, 1994, J ANTIBIOT, V47, P301; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	57	47	50	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					512	524		10.1038/sj.onc.1209072	http://dx.doi.org/10.1038/sj.onc.1209072			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16186804				2022-12-17	WOS:000234897400003
J	Veeramani, S; Igawa, T; Yuan, TC; Lin, FF; Lee, MS; Lin, JS; Johansson, SL; Lin, MF				Veeramani, S; Igawa, T; Yuan, TC; Lin, FF; Lee, MS; Lin, JS; Johansson, SL; Lin, MF			Expression of p66(Shc) protein correlates with proliferation of human prostate cancer cells	ONCOGENE			English	Article						p66(Shc); prostatic acid phosphatase; prostate cancer; cell proliferation	66-KDA SHC ISOFORM; ACID-PHOSPHATASE; CARCINOMA-CELLS; SIGNALING PATHWAY; OXIDATIVE STRESS; BREAST-CANCER; LIFE-SPAN; ANDROGEN; KINASE; ESTABLISHMENT	p66(Shc), an isoform of Shc adaptor proteins, is shown to mediate various signals, including cellular stress. However, little is known about its involvement in carcinogenesis. We previously showed that p66(Shc) protein level is upregulated by steroid hormones in human carcinoma cells and is higher in prostate cancer (PCa) specimens than adjacent noncancerous cells. In this study, we investigated the role of p66(Shc) protein in PCa cell proliferation. Among different PCa cell lines tested, p66(Shc) protein level showed positive correlation with cell proliferation, that is, rapid-growing cells expressed higher p66(Shc) protein than slow-growing cells. Exposure of slow-growing LNCaP C-33 cells to epidermal growth factor (EGF) and 5 alpha-dihydrotestosterone (DHT) led to upregulation of proliferation and p66(Shc) protein level. Conversely, growth suppression of fast-growing cells by cellular form of prostatic acid phosphatase (cPAcP) expression, a negative growth regulator, downregulated their p66(Shc) protein level. Additionally, increased expression of p66(Shc) protein by cDNA transfection in LNCaP C-33 cells resulted in increased cell proliferation. Cell cycle analyses showed higher percentage of p66(Shc)-overexpressing cells at S phase (24%) than control cells (17%), correlating with their growth rates. On the other hand, transient knock-down of p66(Shc) expression by RNAi in rapidly growing cells decreased their proliferation as evidenced by the reduced cell growth as well as S phase in p66(Shc)-knocked down cells. The p66(Shc) signaling in cell growth regulation is apparently mediated by extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK). Thus, our results indicate a novel role for p66(Shc) in prostate carcinogenesis, in part, promoting cell proliferation.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA; Univ Nebraska, Coll Med, Med Ctr, Sect Urol Surg, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.	mlin@unmc.edu	Lin, Jamie/F-4278-2015; Veeramani, Suresh/P-7838-2019	Lin, Jamie/0000-0002-7073-9658; LEE, MING-SHYUE/0000-0002-5884-4535; LEE, MING-SHYUE/0000-0002-8673-5088; Veeramani, Suresh/0000-0001-9217-0872	NCI NIH HHS [CA88184, P30 CA36727] Funding Source: Medline; NCRR NIH HHS [P20RR01879, P20RR017675] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727, R01CA088184] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Davol PA, 2003, CANCER RES, V63, P6772; Gioeli D, 1999, CANCER RES, V59, P279; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; IIZUMI T, 1987, J UROLOGY, V137, P1304, DOI 10.1016/S0022-5347(17)44488-0; Jackson JG, 2000, CLIN CANCER RES, V6, P1135; KAIGHN ME, 1979, INVEST UROL, V17, P16; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Lee MS, 2004, ONCOGENE, V23, P3048, DOI 10.1038/sj.onc.1207451; Lee MS, 2004, INT J CANCER, V108, P672, DOI 10.1002/ijc.11621; Lim SD, 2005, PROSTATE, V62, P200, DOI 10.1002/pros.20137; LIN MF, 1993, ARCH BIOCHEM BIOPHYS, V300, P384, DOI 10.1006/abbi.1993.1052; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; LIN MF, 1992, CANCER RES, V52, P4600; Lin MF, 2001, J UROLOGY, V166, P1943, DOI 10.1016/S0022-5347(05)65725-4; Liu SL, 2002, ARCH BIOCHEM BIOPHYS, V406, P173, DOI 10.1016/S0003-9861(02)00430-7; LOOR R, 1981, CANCER LETT, V14, P63, DOI 10.1016/0304-3835(81)90010-0; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Meng TC, 2000, ONCOGENE, V19, P2664, DOI 10.1038/sj.onc.1203576; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Navone NM, 1997, CLIN CANCER RES, V3, P2493; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Orsini F, 2004, J BIOL CHEM, V279, P25689, DOI 10.1074/jbc.M401844200; Pacini S, 2004, MOL CELL BIOL, V24, P1747, DOI 10.1128/MCB.24.4.1747-1757.2004; PONTES JE, 1981, J UROLOGY, V126, P187, DOI 10.1016/S0022-5347(17)54440-7; Price DT, 1999, J UROLOGY, V162, P1537, DOI 10.1016/S0022-5347(05)68354-1; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ripple MO, 1997, JNCI-J NATL CANCER I, V89, P40, DOI 10.1093/jnci/89.1.40; Ripple MO, 1999, JNCI-J NATL CANCER I, V91, P1227, DOI 10.1093/jnci/91.14.1227; SAKAI H, 1993, J UROLOGY, V149, P1020, DOI 10.1016/S0022-5347(17)36285-7; SOLIN T, 1990, BIOCHIM BIOPHYS ACTA, V1048, P72, DOI 10.1016/0167-4781(90)90024-V; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; TELFORD WG, 1991, CELL PROLIFERAT, V24, P447, DOI 10.1111/j.1365-2184.1991.tb01173.x; Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513; Ventura A, 2004, J BIOL CHEM, V279, P2299, DOI 10.1074/jbc.M307655200; Xie YM, 1996, BIOCHEM BIOPH RES CO, V221, P140, DOI 10.1006/bbrc.1996.0559; Yang CPH, 2000, CANCER RES, V60, P5171	39	47	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 3	2005	24	48					7203	7212		10.1038/sj.onc.1208852	http://dx.doi.org/10.1038/sj.onc.1208852			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16170380				2022-12-17	WOS:000232990100009
J	Fujimoto, E; Sato, H; Shirai, S; Nagashima, Y; Fukumoto, K; Hagiwara, H; Negishi, E; Ueno, K; Omori, Y; Yamasaki, H; Hagiwara, K; Yano, T				Fujimoto, E; Sato, H; Shirai, S; Nagashima, Y; Fukumoto, K; Hagiwara, H; Negishi, E; Ueno, K; Omori, Y; Yamasaki, H; Hagiwara, K; Yano, T			Connexin32 as a tumor suppressor gene in a metastatic renal cell carcinoma cell line	ONCOGENE			English	Article						connexin32; tumor suppressor gene; Src; VEGF; metastatic renal cell carcinoma	JUNCTIONAL INTERCELLULAR COMMUNICATION; ENDOTHELIAL GROWTH-FACTOR; MOLECULAR TARGETS; KINASE-ACTIVITY; HEPG2 CELL; EXPRESSION; GAP; PHENOTYPE; CANCER; MOUSE	Connexin genes expressing gap junction proteins have tumor-suppressive effects on primary cancers with certain cell specificity, but the suppressive effects on metastatic cancers are still conflicting. In this study, we show that connexin32 (Cx32) has a strong tumor-suppressive effect on a human metastatic renal cell carcinoma cell line (Caki-1 cell). Cx32 expression in Caki-1 cells reduced in vitro malignant phenotypes of the cells such as anchorage independency and invasion capacity. Furthermore, the Cx32 expression drastically reduced the development of Caki-1 cells in nude mice. We also determined that Cx32 reduced the malignant phenotypes in Caki-1 cells mainly through the inactivation of Src signaling. Especially, Cx32-dependent inactivation of Src decreased the production of vascular epithelial growth factor (VEGF) via the suppression of signal transducers and activators of transcription 3 (Stat3) activation, and we confirmed this result using short interfering RNA. In nude mice, Cx32-transfected Caki-1 cells showed lower serum level of VEGF comparing mock transfectant, and the development of the cells in nude mice positively related to the VEGF level. These data suggest that Cx32 acts as a tumor suppressor gene in Caki-1 cells and that the tumor suppressive effect partly depends on the inhibition of Src-Stat3-VEGF signal pathway.	Natl Inst Hlth & Nutr, Dept Food Sci Res Hlth, Shinjuku Ku, Tokyo 1628636, Japan; Chiba Univ, Fac Pharmaceut Sci, Chiba 2608675, Japan; Yokohama City Univ, Sch Med, Dept Pathol, Kanagawa 2360004, Japan; Japan Human Sci Fdn, Chuo Ku, Tokyo 1030001, Japan; Akita Univ, Sch Med, Dept Pathol, Akita 0108543, Japan; Kwansei Gakuin Univ, Fac Sci & Technol, Sanda, Hyogo 6691337, Japan	National Institute of Health & Nutrition - Japan; Chiba University; Yokohama City University; Akita University; Kwansei Gakuin University	Yano, T (corresponding author), Natl Inst Hlth & Nutr, Dept Food Sci Res Hlth, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628636, Japan.	yano@nih.go.jp	Nagashima, Yoji/AAA-2591-2021; Yano, Tomohiro/J-2166-2016	Yano, Tomohiro/0000-0002-9490-3424; Sato, Hiromi/0000-0001-8815-4829				BOND SL, 1994, CELL GROWTH DIFFER, V5, P179; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; FITZGERALD DJ, 1990, TERATOGEN CARCIN MUT, V10, P89; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Fujimoto E, 2004, MOL CARCINOGEN, V40, P135, DOI 10.1002/mc.20025; Genda T, 2000, LAB INVEST, V80, P387, DOI 10.1038/labinvest.3780043; Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072; Grunstein J, 1999, CANCER RES, V59, P1592; Hirai A, 2003, AM J NEPHROL, V23, P172, DOI 10.1159/000070653; HOLDER JW, 1993, CANCER RES, V53, P3475; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; KORHONEN M, 1994, CANCER RES, V54, P4532; Laird AD, 2003, MOL CANCER THER, V2, P461; Mareel MM, 1997, ENCY CANC, V2, P1072; Martyn KD, 1997, CELL GROWTH DIFFER, V8, P1015; Mesnil M, 2002, BIOL CELL, V94, P493, DOI 10.1016/S0248-4900(02)00025-4; Motzer RJ, 2000, J UROLOGY, V163, P408, DOI 10.1016/S0022-5347(05)67889-5; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; NICOLSON GL, 1988, P NATL ACAD SCI USA, V85, P473, DOI 10.1073/pnas.85.2.473; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Omori Y, 1999, CARCINOGENESIS, V20, P1913, DOI 10.1093/carcin/20.10.1913; PAUL DL, 1995, CURR OPIN CELL BIOL, V7, P665, DOI 10.1016/0955-0674(95)80108-1; Rae RS, 1998, MOL CARCINOGEN, V22, P120, DOI 10.1002/(SICI)1098-2744(199806)22:2<120::AID-MC7>3.0.CO;2-Q; Ren ZY, 2002, J BIOL CHEM, V277, P38486, DOI 10.1074/jbc.M112438200; SIMPSON I, 1977, SCIENCE, V195, P294, DOI 10.1126/science.831276; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; STAUFFER KA, 1991, J CELL BIOL, V115, P141, DOI 10.1083/jcb.115.1.141; TROSKO JE, 1993, LIFE SCI, V53, P1, DOI 10.1016/0024-3205(93)90606-4; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Wiener JR, 1999, CLIN CANCER RES, V5, P2164; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Yano T, 2003, KIDNEY INT, V63, P381, DOI 10.1046/j.1523-1755.2003.00745.x; Yano T, 2001, MOL CARCINOGEN, V31, P101, DOI 10.1002/mc.1045; Yano T, 2001, CARCINOGENESIS, V22, P1593, DOI 10.1093/carcin/22.10.1593; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	41	47	54	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3684	3690		10.1038/sj.onc.1208430	http://dx.doi.org/10.1038/sj.onc.1208430			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782139	Bronze			2022-12-17	WOS:000229221800016
J	An, JB; Fisher, M; Rettig, MB				An, JB; Fisher, M; Rettig, MB			VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappa B-dependent mechanism	ONCOGENE			English	Article						bortezomib; renal cell carcinoma; von Hippel-Lindau tumor suppressor gene; NF-kappa B; RNA interference	PROTEASOME INHIBITOR PS-341; GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR GENE; DRUG-RESISTANCE; CANCER; APOPTOSIS; ACTIVATION; PRODUCT; PATHWAY; MYELOMA	In renal cell carcinomas (RCC), NF-kappaB blockade is required for maximal bortezomib-induced apoptosis, and expression of the von Hippel-Lindau (VHL) tumor suppressor protein downregulates NF-kappaB. Thus, we hypothesized that expression of wild-type (wt) VHL sensitizes RCC cells to bortezomib by reducing constitutive NF-kappaB activity. Using isogenic paired cell lines with and without expression of wtVHL, we have confirmed that VHL expression reduces constitutive NF-kappaB activity. Moreover, VHL expression confers markedly heightened sensitivity to the growth inhibitory effects of bortezomib in vitro. The bortezomib IC50 values were greater than two logs lower in the VHL-expressing cell lines compared to the VHL-deficient counterparts. By manipulating the level of constitutive NF-kappaB activity in an isogenic pair of RCC cell lines independently of VHL expression, we were able to demonstrate that the VHL sensitization effect is due to downregulation of NF-kappaB activity. These findings offer the enticing possibility of using VHL status as a molecular marker to identify RCC patients who may be sensitive to bortezomib. In particular, RCC patients who have non-clear-cell histologies as well as approximately 25% of clear-cell RCCs manifest expression of wtVHL and represent a subpopulation of patients that is apt to respond to bortezomib.	VAGLAHS, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rettig, MB (corresponding author), VAGLAHS, 11301 Wilshire Blvd,Bldg 304,Room E1-113, Los Angeles, CA 90073 USA.	matthew.rettig@med.va.gov						Adams J, 1999, CANCER RES, V59, P2615; An JB, 2004, MOL CANCER THER, V3, P727; An JB, 2003, CLIN CANCER RES, V9, P4537; ATKINS MB, 2004, UP TO DATE; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; CHEN F, 1995, CANCER RES, V55, P4804; Cusack JC, 2001, CANCER RES, V61, P3535; Davis NB, 2004, J CLIN ONCOL, V22, P115, DOI 10.1200/JCO.2004.07.165; de Paulsen N, 2001, P NATL ACAD SCI USA, V98, P1387, DOI 10.1073/pnas.031587498; Frankel A, 2000, CLIN CANCER RES, V6, P3719; Glaspy JA, 2002, SEMIN ONCOL, V29, P41, DOI 10.1053/sonc.2002.33083; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Godley P, 2002, CURR OPIN ONCOL, V14, P280, DOI 10.1097/00001622-200205000-00005; Gunaratnam L, 2003, J BIOL CHEM, V278, P44966, DOI 10.1074/jbc.M305502200; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Mitchell BS, 2003, NEW ENGL J MED, V348, P2597, DOI 10.1056/NEJMp030092; Nathan PD, 2002, LANCET ONCOL, V3, P89, DOI 10.1016/S1470-2045(02)00650-2; Oya M, 2001, ONCOGENE, V20, P3888, DOI 10.1038/sj.onc.1204525; Pavlovich CP, 2003, UROL CLIN N AM, V30, P437, DOI 10.1016/S0094-0143(03)00023-5; Qi H, 2003, CANCER RES, V63, P7076; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288	25	47	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1563	1570		10.1038/sj.onc.1208348	http://dx.doi.org/10.1038/sj.onc.1208348			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15608669				2022-12-17	WOS:000227218200009
J	Downward, J				Downward, J			Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells	ONCOGENE			English	Article						RNA interference; screening; transformation; library; oncogenesis	GENE-EXPRESSION; STABLE SUPPRESSION; CANCER; DESIGN; VECTOR; INHIBITION; APOPTOSIS; SIRNAS; SYSTEM; P53	Over the past decade, 'RNA interference' has emerged as a natural mechanism of silencing of gene expression. This ancient cellular antiviral response can be manipulated to provide an effective research tool to knock down the level of expression of selected target genes, providing a very powerful new method for the analysis of cell signalling pathways. Systematic silencing of genes on a genome-wide scale using large rationally designed libraries targeting many thousands of genes provides a novel functional genomics approach to the investigation of many aspects of mammalian cell behaviour, including oncogenic transformation. Here, the different approaches taken to use RNA interference libraries to study the cancer phenotype will be considered, including both selective and high throughput screens and the use of both vector-based and synthetic oligonucleotide-based methods for inducing RNA interference. The advantages and drawbacks of the competing methodologies will be discussed. RNA interference library technology holds great promise for enabling somatic cell genetics in tissue culture systems. Whether it can provide significant new insights into cancer will be its greatest challenge.	Canc Res UK London Res Inst, London WC2A 3PX, England	Cancer Research UK	Downward, J (corresponding author), Canc Res UK London Res Inst, 44 Lincolns Inn Fields, London WC2A 3PX, England.	downward@cancer.org.uk	Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				Abbas-Terki T, 2002, HUM GENE THER, V13, P2197, DOI 10.1089/104303402320987888; Arts GJ, 2003, GENOME RES, V13, P2325, DOI 10.1101/gr.1332603; Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brummelkamp TR, 2003, NAT REV CANCER, V3, P781, DOI 10.1038/nrc1191; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chen YC, 2003, CANCER RES, V63, P4801; Chi JT, 2003, P NATL ACAD SCI USA, V100, P6343, DOI 10.1073/pnas.1037853100; Cui WW, 2004, COMPUT METH PROG BIO, V75, P67, DOI 10.1016/j.cmpb.2003.09.002; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng127; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; Dirac AMG, 2003, J BIOL CHEM, V278, P11731, DOI 10.1074/jbc.C300023200; Downward J, 2004, BRIT MED J, V328, P1245, DOI 10.1136/bmj.328.7450.1245; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Gupta S, 2004, P NATL ACAD SCI USA, V101, P1927, DOI 10.1073/pnas.0306111101; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Kumar R, 2003, GENOME RES, V13, P2333, DOI 10.1101/gr.1575003; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Silva JM, 2004, P NATL ACAD SCI USA, V101, P6548, DOI 10.1073/pnas.0400165101; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Wang LQ, 2004, BIOINFORMATICS, V20, P1818, DOI 10.1093/bioinformatics/bth164; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Zhao LJ, 2003, GENE, V316, P137, DOI 10.1016/S0378-1119(03)00750-9	37	47	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2004	23	51					8376	8383		10.1038/sj.onc.1208073	http://dx.doi.org/10.1038/sj.onc.1208073			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517019				2022-12-17	WOS:000224815900008
J	Oh, SM; Pyo, CW; Kim, Y; Choi, SY				Oh, SM; Pyo, CW; Kim, Y; Choi, SY			Neutrophil lactoferrin upregulates the human p53 gene through induction of NF-kappa B activation cascade	ONCOGENE			English	Article						lactoferrin; p53; NF-kappa B	TUMOR-NECROSIS-FACTOR; NUCLEAR-FACTOR; KINASE CASCADES; BINDING; TRANSCRIPTION; EXPRESSION; ALPHA; GRANULOPOIESIS; LOCALIZATION; SEQUENCE	Neutrophil lactoferrin (Lf) was previously shown to act as a transcriptional activator in various mammalian cells. Here, we describe that Lf specifically transactivates the p53 tumor suppressor gene through the activation of nuclear factor-kappaB (NF-kappaB) and consequently regulates p53-responsive oncogenes. In HeLa cervical carcinoma cells stably expressing Lf (HeLa-Lf), expression of mdm2 and p21(waf1/cip1) as well as p53 was greatly enhanced. Transient expression of Lf also markedly transactivates transcription of a p53 promoter-driven reporter and NF-kappaB-driven reporters in various mammalian cells. However, mutation of the NF-kappaB site or treatment with an NF-kappaB inhibitor abrogated the transactivation, suggesting that NF-kappaB should play an essential role in the Lf-induced transactivation. Increased binding activity and nuclear translocation of p65 in response to Lf strongly support these findings. Furthermore, Lf-mediated NF-kappaB activation is diminished in IKKalpha- or IKKbeta-deficient mouse embryonic fibroblast cells. The activation of both IKKs and NF-kappaB by Lf is over-ridden by the expression of dominant-negative mutants of NIK, MEKK 1, IKKalpha and IKKbeta. Collectively, we conclude that overexpressed Lf directly relays signals to upstream components responsible for NF-kappaB activation, thereby leading to the activation of NF-kappaB target genes.	Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; Univ Ulsan, Coll Med, Genome Res Ctr Birth Defects & Genet Disorders, Seoul 138736, South Korea	Korea University; University of Ulsan	Choi, SY (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, 5-1 Anam Dong, Seoul 136701, South Korea.	sychoi@korea.ac.kr						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAGBY GC, 1989, BLOOD CELLS, V15, P386; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; GALBRAITH PR, 1986, CLIN INVEST MED, V9, P1; GARRE C, 1992, J CELL PHYSIOL, V153, P477, DOI 10.1002/jcp.1041530306; GINSBERG D, 1990, ONCOGENE, V5, P1285; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HE JL, 1995, NATURE, V373, P721, DOI 10.1038/373721a0; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; MIKOGAMI T, 1994, AM J PHYSIOL, V267, pG308, DOI 10.1152/ajpgi.1994.267.2.G308; Oh SM, 2001, J BIOL CHEM, V276, P42575, DOI 10.1074/jbc.M107724200; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; SHAU HY, 1992, J LEUKOCYTE BIOL, V51, P343, DOI 10.1002/jlb.51.4.343; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Suzuki YA, 2002, BIOCHEM CELL BIOL, V80, P75, DOI 10.1139/o01-228; WENG HQ, 1995, J BIOL CHEM, V270, P13637, DOI 10.1074/jbc.270.23.13637; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	28	47	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8282	8291		10.1038/sj.onc.1208021	http://dx.doi.org/10.1038/sj.onc.1208021			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378004				2022-12-17	WOS:000224749500010
J	Seo, T; Park, J; Lim, C; Choe, J				Seo, T; Park, J; Lim, C; Choe, J			Inhibition of nuclear factor kappa B activity by viral interferon regulatory factor 3 of Kaposi's sarcoma-associated herpesvirus	ONCOGENE			English	Article						KSHV; VIRF3; NF-kappa B; IKK	IKK-ALPHA; INDUCED APOPTOSIS; DNA-SEQUENCES; TUMOR-SUPPRESSOR; MICE LACKING; BETA; ACTIVATION; SUBUNIT; PROTEIN; TNF	Nuclear factor-kappaB (NF-kappaB) is a transcription factor that plays an important role in the immune system and cell death. Many viral proteins modulate NF-kappaB to escape host immune surveillance, promote cell survival, and enhance viral replication. In the present study, we show that NF-kappaB activity is downmodulated by viral interferon regulatory factor 3 (vIRF3), which is encoded by Kaposi's sarcoma-associated herpesvirus open-reading frame K10.5. vIRF3 repressed NF-kappaB-dependent transcription in a dose-dependent manner and inhibited the activation of NF-kappaB induced by tumor necrosis factor (TNF)-alpha. In vivo studies showed vIRF3 inhibited IkappaB kinase beta (IKKbeta) activity, but not IKKalpha activity, resulting in reduced IkappaB phosphorylation. Immunofluorescence assays showed that vIRF3 interfered with nuclear translocation of NF-kappaB. In addition, consistent with the inhibition of NF-kappaB activity, vIRF3 sensitized cells to TNF-alpha-induced apoptosis. While vIRF3 interacts with IKKbeta in vitro and in 293T cells, we were unable to demonstrate vIRF3-IKKbeta interaction in BCBL-1 cells. Our results indicate that vIRF3 can regulate the host immune system and apoptosis via inhibition of NF-kappaB activity.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Choe, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.	jchoe@kaist.ac.kr	Lim, Chunghun/AAB-1253-2020; Choe, Joonho/F-3066-2011	Lim, Chunghun/0000-0001-8473-9272; 				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bakker TR, 1999, INT J CANCER, V80, P320; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Brown HJ, 2003, J VIROL, V77, P8532, DOI 10.1128/JVI.77.15.8532-8540.2003; Burysek L, 1999, J VIROL, V73, P7334; Burysek L, 1999, J HUMAN VIROL, V2, P19; Burysek L, 2001, J VIROL, V75, P2345, DOI 10.1128/JVI.75.5.2345-2352.2001; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Ganem D, 1997, CELL, V91, P157, DOI 10.1016/S0092-8674(00)80398-0; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Hu JD, 2002, J INTERF CYTOK RES, V22, P1017, DOI 10.1089/107999002760624242; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Li M, 2000, MOL CELL BIOL, V20, P8254, DOI 10.1128/MCB.20.21.8254-8263.2000; Li MT, 1998, J VIROL, V72, P5433, DOI 10.1128/JVI.72.7.5433-5440.1998; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Lubyova B, 2004, J BIOL CHEM, V279, P7643, DOI 10.1074/jbc.M309485200; Lubyova B, 2000, J VIROL, V74, P8194, DOI 10.1128/JVI.74.17.8194-8201.2000; Moore PS, 1998, TRENDS GENET, V14, P144, DOI 10.1016/S0168-9525(98)01408-5; Nakamura H, 2001, J VIROL, V75, P7572, DOI 10.1128/JVI.75.16.7572-7582.2001; Ouaaz F, 1999, J EXP MED, V189, P999, DOI 10.1084/jem.189.6.999; Rivas C, 2001, J VIROL, V75, P429, DOI 10.1128/JVI.75.1.429-438.2001; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Seo T, 2002, J VIROL, V76, P8797, DOI 10.1128/JVI.76.17.8797-8807.2002; Seo T, 2001, J VIROL, V75, P6193, DOI 10.1128/JVI.75.13.6193-6198.2001; Seo T, 2000, BIOCHEM BIOPH RES CO, V270, P23, DOI 10.1006/bbrc.2000.2393; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Spitkovsky D, 2002, J BIOL CHEM, V277, P25576, DOI 10.1074/jbc.M201884200; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VAN AD, 1996, SCIENCE, V274, P787; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zimring JC, 1998, J VIROL, V72, P701, DOI 10.1128/JVI.72.1.701-707.1998	55	47	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6146	6155		10.1038/sj.onc.1207807	http://dx.doi.org/10.1038/sj.onc.1207807			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208654				2022-12-17	WOS:000223261000014
J	Guillemard, V; Saragovi, HU				Guillemard, V; Saragovi, HU			Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity	ONCOGENE			English	Article						prodrug; chemotherapy; resistance; target; selectivity; efficacy	GROWTH-FACTOR RECEPTOR; MULTIDRUG-RESISTANCE; MONOCLONAL-ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CELLS; DOXORUBICIN; CANCER; TRANSPORTERS; PERIODATE; OXIDATION	Doxorubicin intercalates into DNA, causes double-strand breaks, and leads to apoptotic death. Limitations to the efficacy and therapeutic index of doxorubicin include poor tumor selectivity, high systemic toxicity, and the development of resistance, especially p-glycoprotein (p-gp)mediated. We chemically coupled doxorubicin to a monoclonal antibody directed to the insulin-like growth factor-1 receptor, a receptor highly overexpressed in most tumors and validated as a tumor target. The prodrug conjugate bounded to tumor cells selectively, and accumulated efficiently and only in receptor-expressing cells. The conjugate was processed to release free doxorubicin inside target cells leading to selective toxicity, had >200-fold improved therapeutic index, and in vivo reduced tumor load with no systemic toxicity. Importantly, the prodrug conjugate is not subject to p-gp efflux and can bypass resistance in vivo. Our studies de. ne a strategy to develop improved and more selective anticancer agents.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Ctr Canc, Montreal, PQ H3T 1E2, Canada	McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University	Saragovi, HU (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond Ave,1320, Montreal, PQ H3G 1Y6, Canada.	uri@pharma.mcgill.ca			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038569] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS38569] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Berezov A, 2002, J BIOL CHEM, V277, P28330, DOI 10.1074/jbc.M202880200; Berezov A, 2001, J MED CHEM, V44, P2565, DOI 10.1021/jm000527m; Casares S, 2001, NAT BIOTECHNOL, V19, P142, DOI 10.1038/84404; da Rocha Adriana B., 2001, Current Opinion in Pharmacology, V1, P364; Fakata KL, 1998, LIFE SCI, V62, P2441, DOI 10.1016/S0024-3205(98)00227-6; Fritzer M, 1996, BIOCHEM PHARMACOL, V51, P489, DOI 10.1016/0006-2952(95)02225-2; Garsky VM, 2001, J MED CHEM, V44, P4216, DOI 10.1021/jm0101996; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Guillemard V, 2001, CANCER RES, V61, P694; Hage DS, 1997, BIOCONJUGATE CHEM, V8, P914, DOI 10.1021/bc970112o; Hailey J, 2002, MOL CANCER THER, V1, P1349; KATO H, 1993, J BIOL CHEM, V268, P2655; King HD, 1999, BIOCONJUGATE CHEM, V10, P279, DOI 10.1021/bc980100i; Langer M, 2001, J MED CHEM, V44, P1341, DOI 10.1021/jm001065f; Maliartchouk S, 1997, J NEUROSCI, V17, P6031; Matsui H, 2002, LEUKEMIA, V16, P813, DOI 10.1038/sj.leu.2402459; Monneret C, 2001, EUR J MED CHEM, V36, P483, DOI 10.1016/S0223-5234(01)01244-2; MOSCOW JA, 1988, J NATL CANCER I, V80, P14, DOI 10.1093/jnci/80.1.14; Munns J, 1998, BRIT J UROL, V82, P284; Nagy A, 1998, P NATL ACAD SCI USA, V95, P1794, DOI 10.1073/pnas.95.4.1794; Omelyanenko V, 1996, J DRUG TARGET, V3, P357, DOI 10.3109/10611869608996827; Salerno M, 2002, BIOCHEM PHARMACOL, V63, P1471, DOI 10.1016/S0006-2952(02)00895-X; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Screaton RA, 1997, J CELL BIOL, V137, P939, DOI 10.1083/jcb.137.4.939; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Stan AC, 1999, CANCER RES, V59, P115; Tan B, 2000, CURR OPIN ONCOL, V12, P450, DOI 10.1097/00001622-200009000-00011; TANNOCK IF, 1992, BASIC SCI ONCOLOGY, P305; TEWEY KM, 1984, J BIOL CHEM, V259, P9182; TRAIL PA, 1993, SCIENCE, V261, P212, DOI 10.1126/science.8327892; WOLFE CAC, 1995, ANAL BIOCHEM, V231, P123, DOI 10.1006/abio.1995.1511; Yang XD, 1999, CANCER RES, V59, P1236	36	47	58	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3613	3621		10.1038/sj.onc.1207463	http://dx.doi.org/10.1038/sj.onc.1207463			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15034547				2022-12-17	WOS:000221101700013
J	Deshayes, F; Lapree, G; Portier, A; Richard, Y; Pencalet, P; Mahieu-Caputo, D; Horellou, P; Tsapis, A				Deshayes, F; Lapree, G; Portier, A; Richard, Y; Pencalet, P; Mahieu-Caputo, D; Horellou, P; Tsapis, A			Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor	ONCOGENE			English	Article						glioblastomas; APRIL; proliferation; APRIL receptor; malignancy	NECROSIS-FACTOR FAMILY; MATURATION ANTIGEN; BCMA GENE; GROWTH; MEMBER; TACI; LIGAND; SUPERFAMILY; SYSTEM; DEATH	A proliferation-inducing ligand (APRIL) of the tumour necrosis factor (TNF) family is produced in small amounts in many tissues and more abundantly in tumours. APRIL has been reported to promote cell growth in vivo and in vitro. It was recently shown that the production of APRIL in some glioblastoma cell lines does not lead to an increase in cell growth. In this study, we investigated the production of APRIL and its ability to increase the proliferation of eight human glioblastoma cell lines. We found that APRIL was produced in the eight human glioblastoma cell lines tested but not in the normal embryonic astrocyte counterparts of glioblastomas. Flow cytometry demonstrated the presence of a specific APRIL-binding receptor on the cell surface in all the glioblastoma cell lines tested. This receptor was also present on normal embryonic and adult astrocytes and embryonic neural progenitor cells. Moreover, the addition of recombinant human APRIL resulted in an increase in proliferation rate of normal adult astrocytes and in four of eight cell lines tested. Addition of the soluble recombinant TNF-receptor-homologue B-cell maturation (BCMA) chimeric protein, which binds APRIL, confirmed the involvement of APRIL in the growth of malignant glioblastoma cell lines.	INSERM, U131, F-92140 Clamart, France; Hop Foch, Serv Neurochirurg, F-92150 Suresnes, France; Hop Antoine Beclere, INSERM, F-92140 Clamart, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Hospital Foch; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Tsapis, A (corresponding author), INSERM, U131, 32 Rue Carnets, F-92140 Clamart, France.	andreas.tsapis@ipsc.u-psud.fr	Horellou, Philippe/B-4290-2019; RICHARD, Yolande/B-7926-2008	Horellou, Philippe/0000-0003-2467-8177; RICHARD, Yolande/0000-0001-8560-9250				Barbero S, 2003, CANCER RES, V63, P1969; CHAMAK B, 1989, DEVELOPMENT, V106, P483; DAVIES LG, 1986, BASIC METHODS MOL BI; Goswami S, 1998, J NEUROCHEM, V71, P1837; Gravestein LA, 1998, SEMIN IMMUNOL, V10, P423, DOI 10.1006/smim.1998.0144; Gross JA, 2000, NATURE, V404, P995, DOI 10.1038/35010115; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Held-Feindt J, 2003, J NEURO-ONCOL, V63, P117, DOI 10.1023/A:1023943405292; Kelly K, 2000, CANCER RES, V60, P1021; LAABI Y, 1992, EMBO J, V11, P3897, DOI 10.1002/j.1460-2075.1992.tb05482.x; LAABI Y, 1994, NUCLEIC ACIDS RES, V22, P1147, DOI 10.1093/nar/22.7.1147; Lopez-Fraga M, 2001, EMBO REP, V2, P945, DOI 10.1093/embo-reports/kve198; Madry C, 1998, INT IMMUNOL, V10, P1693, DOI 10.1093/intimm/10.11.1693; Marsters SA, 2000, CURR BIOL, V10, P785, DOI 10.1016/S0960-9822(00)00566-2; MILOUX B, 1994, GENE, V149, P341, DOI 10.1016/0378-1119(94)90173-2; Rennert P, 2000, J EXP MED, V192, P1677, DOI 10.1084/jem.192.11.1677; Ridet JL, 1999, HUM GENE THER, V10, P271, DOI 10.1089/10430349950019057; Roth W, 2001, CELL DEATH DIFFER, V8, P403, DOI 10.1038/sj.cdd.4400827; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Shu HB, 1999, J LEUKOCYTE BIOL, V65, P680, DOI 10.1002/jlb.65.5.680; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Thompson JS, 2000, J EXP MED, V192, P129, DOI 10.1084/jem.192.1.129; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Wu YM, 2000, J BIOL CHEM, V275, P35478, DOI 10.1074/jbc.M005224200; Xia XZ, 2000, J EXP MED, V192, P137, DOI 10.1084/jem.192.1.137; Yu G, 2000, NAT IMMUNOL, V1, P252, DOI 10.1038/79802	27	47	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3005	3012		10.1038/sj.onc.1207350	http://dx.doi.org/10.1038/sj.onc.1207350			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14691452				2022-12-17	WOS:000220845200004
J	Nagano, K; Masters, JR; Akpan, A; Yang, A; Corless, S; Wood, C; Hastie, C; Zvelebil, M; Cramer, R; Naaby-Hansen, S				Nagano, K; Masters, JR; Akpan, A; Yang, A; Corless, S; Wood, C; Hastie, C; Zvelebil, M; Cramer, R; Naaby-Hansen, S			Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons	ONCOGENE			English	Article						prostate cancer; interferon treatment; growth inhibitory effect of interferon	NUCLEAR RIBONUCLEOPROTEIN-K; HNRNP-K; ENDOPLASMIC-RETICULUM; IFN-GAMMA; C-SRC; CANCER; GENE; PHOSPHORYLATION; PATHWAYS; NMI	Protein expression and de novo synthesis in normal and prostate cancer cell lines derived from the same patient were compared by proteomic analysis, and the effects of INFalpha and INFgamma ( INF = interferon) determined. The expressions of several INF-inducible proteins, including MxA, Nmi, PA28a and IFP53, were downregulated in the cancer cells. INFgamma induced a more than twofold increase or decrease in the synthesis rates of almost twice as many proteins in the cancer cell line. The positive regulator of INF-induced transcription ISGF3gamma was upregulated in the cancer cells and inversely regulated by INFalpha and INFgamma in the normal and cancer cells. Moreover, ISGF3gamma's induction by INFgamma in the cancer cells was more enhanced by simultaneous stimulation with EGF, than its induction in the normal cells. In all, 31 differentially regulated proteins were identified by mass spectrometry analysis, several of which are involved in chaperone-assisted protein folding in the endoplasmic reticulum ( ER) or in regulated protein degradation. Our results suggest that the exclusion of proteins by the ER quality control system, crosstalk between the EGF- and INF-induced signalling pathways and the regulation of INF-inducible genes are all altered in the prostate cancer cells. The combination of upregulated activity in the growth-promoting PI3K/Akt pathway, suppression of Nmi and overexpression of hnRNP-K and c-myc proteins may explain why the prostate cancer cells were found to be more resistant to the growth inhibitory effects of INFgamma.	Royal Free & UCL, Ludwig Inst Canc Res, Sch Med, London W1W 7BS, England; Royal Free & UCL, Prostate Canc Res Ctr, Sch Med, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London, England	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London	Naaby-Hansen, S (corresponding author), Royal Free & UCL, Ludwig Inst Canc Res, Sch Med, Coutauld Bldg,91 Riding House St, London W1W 7BS, England.	soren@ludwig.ucl.ac.uk	Masters, John R/C-5694-2011; aukim-hastie, claire/A-7485-2011	Zvelebil, Marketa/0000-0001-8018-5591; Cramer, Rainer/0000-0002-8037-2511				Bannasch D, 1999, ONCOGENE, V18, P6810, DOI 10.1038/sj.onc.1203090; Bao JX, 1996, ONCOGENE, V12, P2171; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; Benvenuti S, 2002, MOL CELL PROTEOMICS, V1, P280, DOI 10.1074/mcp.M100028-MCP200; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; Braddock DT, 2002, EMBO J, V21, P3476, DOI 10.1093/emboj/cdf352; Bright RK, 1997, CANCER RES, V57, P995; Da Silva N, 2002, BLOOD, V100, P3536, DOI 10.1182/blood.V100.10.3536; Delom F, 2001, J BIOL CHEM, V276, P21337, DOI 10.1074/jbc.M101086200; ENTWISTLE A, 1994, J MICROSC-OXFORD, V175, P238, DOI 10.1111/j.1365-2818.1994.tb03490.x; Frigerio L, 2000, CURR BIOL, V10, pR674, DOI 10.1016/S0960-9822(00)00680-1; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; Isaacs W, 2002, CANCER CELL, V2, P113, DOI 10.1016/S1535-6108(02)00103-4; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Kuratsukuri K, 2000, UROL ONCOL, V5, P265, DOI 10.1016/S1078-1439(00)00086-7; MAKI RG, 1990, P NATL ACAD SCI USA, V87, P5658, DOI 10.1073/pnas.87.15.5658; Mandal M, 2001, J BIOL CHEM, V276, P9699, DOI 10.1074/jbc.M008514200; Naaby-Hansen S, 2001, TRENDS PHARMACOL SCI, V22, P376, DOI 10.1016/S0165-6147(00)01663-1; NAABYHANSEN S, 2003, PROTEOMICS ANAL PROS, P277; Nakaya T, 2001, BIOCHEM BIOPH RES CO, V283, P1150, DOI 10.1006/bbrc.2001.4913; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; Page MJ, 1999, P NATL ACAD SCI USA, V96, P12589, DOI 10.1073/pnas.96.22.12589; Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Roberts WW, 2001, UROLOGY, V57, P1033, DOI 10.1016/S0090-4295(01)00978-5; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Sampath P, 2003, MOL CELL BIOL, V23, P1509, DOI 10.1128/MCB.23.5.1509-1519.2003; Scadden ADJ, 2001, METHOD ENZYMOL, V341, P126, DOI 10.1016/S0076-6879(01)41149-9; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Sueoka E, 1999, CANCER RES, V59, P1404; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; Vigneswaran N, 2000, HUM PATHOL, V31, P931, DOI 10.1053/hupa.2000.9035; WEIJERMAN PC, 1994, CANCER RES, V54, P5579; Wojciak-Stothard B, 1999, J CELL BIOL, V145, P1293, DOI 10.1083/jcb.145.6.1293; Wu YX, 2000, J CELL BIOCHEM, V79, P311, DOI 10.1002/1097-4644(20001101)79:2<311::AID-JCB140>3.0.CO;2-Z; Yu ZB, 2002, J BIOL CHEM, V277, P40247, DOI 10.1074/jbc.M207608200; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	45	47	49	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1693	1703		10.1038/sj.onc.1207297	http://dx.doi.org/10.1038/sj.onc.1207297			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14647428				2022-12-17	WOS:000220029300005
J	Wang, HC; Boecker, W; Wang, HY; Wang, X; Guan, J; Thompson, LH; Nickoloff, JA; Iliakis, G				Wang, HC; Boecker, W; Wang, HY; Wang, X; Guan, J; Thompson, LH; Nickoloff, JA; Iliakis, G			Caffeine inhibits homology-directed repair of I-SceI-induced DNA double-strand breaks	ONCOGENE			English	Article						caffeine; DNA; double-strand breaks (DSB); repair; homology-directed repair; homologous recombination; nonhomologous end joining	IRRADIATED HELA-CELLS; MAMMALIAN-CELLS; IONIZING-RADIATION; PROTEIN-KINASE; INDUCED RADIOSENSITIZATION; CHROMOSOME BREAKS; DAMAGE CHECKPOINT; RAD51 PARALOGS; CULTURED HUMAN; X-IRRADIATION	We recently reported that two Chinese hamster mutants deficient in the RAD51 paralogs XRCC2 and XRCC3 show reduced radiosensitization after treatment with caffeine, thus implicating homology-directed repair (HDR) of DNA double- strand breaks (DSBs) in the mechanism of caffeine radiosensitization. Here, we investigate directly the effect of caffeine on HDR initiated by DSBs induced by a rare cutting endonuclease (I-SceI) into one of two direct DNA repeats. The results demonstrate a strong inhibition by caffeine of HDR in wild-type cells, and a substantial reduction of this effect in HDR-deficient XRCC3 mutant cells. Inhibition of HDR and cell radiosensitization to killing shows similar dependence on caffeine concentration suggesting a cause - effect relationship between these effects. UCN-01, a kinase inhibitor that effectively abrogates checkpoint activation in irradiated cells, has only a small effect on HDR, indicating that similar to radiosensitization, inhibition of checkpoint signaling is not sufficient for HDR inhibition. Recombination events occurring during treatment with caffeine are characterized by rearrangements reminiscent to those previously reported for the XRCC3 mutant, and immunofluorescence microscopy demonstrates significantly reduced formation of IR-specific RAD51 foci after caffeine treatment. In summary, our results identify inhibition of HDR as a significant contributor to caffeine radiosensitization.	Univ Duisburg Gesamthsch, Essen Med Sch, Inst Med Radiat Biol, D-45122 Essen, Germany; Thomas Jefferson Univ, Jefferson Med Coll, Dept Radiat Oncol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94551 USA; Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA	University of Duisburg Essen; Jefferson University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of New Mexico	Iliakis, G (corresponding author), Univ Duisburg Gesamthsch, Essen Med Sch, Inst Med Radiat Biol, IG1 Bldg,Room A4-37, D-45122 Essen, Germany.	Georg.Iliakis@uni-essen.de			NCI NIH HHS [CA56706, CA77693, CA42026] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077693, R01CA056706, R01CA042026] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asaad NA, 2000, ONCOGENE, V19, P5788, DOI 10.1038/sj.onc.1203953; BEETHAM KL, 1984, RADIAT RES, V100, P104, DOI 10.2307/3576526; BEETHAM KL, 1986, RADIAT RES, V107, P272, DOI 10.2307/3576814; BEETHAM KL, 1984, RADIAT RES, V100, P585, DOI 10.2307/3576421; BEETHAM KL, 1982, J CELL PHYSIOL, V113, P385, DOI 10.1002/jcp.1041130306; Bernhard EJ, 1996, INT J RADIAT BIOL, V69, P575, DOI 10.1080/095530096145580; Bill CA, 2001, MUTAT RES-DNA REPAIR, V487, P41; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Brenneman MA, 2000, MUTAT RES-DNA REPAIR, V459, P89, DOI 10.1016/S0921-8777(00)00002-1; Brenneman MA, 2002, MOL CELL, V10, P387, DOI 10.1016/S1097-2765(02)00595-6; Busby EC, 2000, CANCER RES, V60, P2108; BUSSE PM, 1977, RADIAT RES, V71, P666, DOI 10.2307/3574634; BUSSE PM, 1978, RADIAT RES, V76, P292, DOI 10.2307/3574780; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; CHEONG N, 1994, MUTAT RES, V314, P77, DOI 10.1016/0921-8777(94)90063-9; DOMON M, 1969, RADIAT RES, V39, P207, DOI 10.2307/3572642; FAN SJ, 1995, CANCER RES, V55, P1649; FRANKENBERGSCHWAGER M, 1990, RADIAT ENVIRON BIOPH, V29, P273, DOI 10.1007/BF01210408; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; FURCINITTI PS, 1983, RADIAT RES, V95, P197, DOI 10.2307/3576085; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; GRIFFITHS TD, 1978, INT J RADIAT BIOL, V33, P493, DOI 10.1080/09553007814550401; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Haaf T, 1999, J CELL BIOL, V144, P11, DOI 10.1083/jcb.144.1.11; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HARVEY AN, 1994, MUTAT RES, V304, P203, DOI 10.1016/0027-5107(94)90212-7; ILIAKIS G, 1983, INT J RADIAT BIOL, V43, P649, DOI 10.1080/09553008314550741; ILIAKIS G, 1983, RADIAT RES, V95, P87, DOI 10.2307/3576074; ILIAKIS G, 1991, BIOESSAYS, V13, P641; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Johnson RD, 2001, BIOCHEM SOC T, V29, P196, DOI 10.1042/BST0290196; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; JUNG T, 1992, INT J RADIAT BIOL, V62, P161, DOI 10.1080/09553009214551971; KASTAN MB, 1991, CANCER RES, V51, P6304; KIHLMAN BA, 1977, CAFFEINE CHROMOSOMES, P1; KIMLER BF, 1982, INT J RADIAT BIOL, V41, P47, DOI 10.1080/09553008214550041; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liu N, 2002, NUCLEIC ACIDS RES, V30, P1009, DOI 10.1093/nar/30.4.1009; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; LUCKEHUHLE C, 1983, INT J RADIAT BIOL, V43, P123, DOI 10.1080/09553008314550131; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Miller KA, 2002, J BIOL CHEM, V277, P8406, DOI 10.1074/jbc.M108306200; MURNANE JP, 1980, NATURE, V285, P326, DOI 10.1038/285326a0; MURNANE JP, 1995, CANCER METAST REV, V14, P17, DOI 10.1007/BF00690208; MUSK SRR, 1991, RADIAT RES, V125, P262, DOI 10.2307/3578108; MUSK SRR, 1990, INT J RADIAT BIOL, V57, P1105, DOI 10.1080/09553009014551221; PAINTER RB, 1980, J MOL BIOL, V143, P289, DOI 10.1016/0022-2836(80)90191-6; PALAYOOR ST, 1995, RADIAT RES, V141, P235, DOI 10.2307/3579000; Peterson SR, 1997, J BIOL CHEM, V272, P10227; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; POWELL SN, 1995, CANCER RES, V55, P1643; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Raderschall E, 2002, J CELL SCI, V115, P153; Ribeiro JCC, 1999, INT J RADIAT BIOL, V75, P481, DOI 10.1080/095530099140410; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; ROWLEY R, 1992, RADIAT RES, V129, P224, DOI 10.2307/3578161; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shinomiya N, 1997, CYTOMETRY, V27, P365, DOI 10.1002/(SICI)1097-0320(19970401)27:4<365::AID-CYTO8>3.3.CO;2-F; STACKHOUSE MA, 1993, RADIAT RES, V136, P241, DOI 10.2307/3578617; Taghian DG, 1997, MOL CELL BIOL, V17, P6386, DOI 10.1128/MCB.17.11.6386; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tambini CE, 1997, GENOMICS, V41, P84, DOI 10.1006/geno.1997.4636; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; TAYLOR YC, 1993, INT J RADIAT BIOL, V64, P57, DOI 10.1080/09553009314551111; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; THOMPSON LH, 2003, EUKARYOTIC DNA DAMAG; TIMSON J, 1977, MUTAT RES, V47, P1, DOI 10.1016/0165-1110(77)90016-1; TOLMACH LJ, 1980, RADIAT RES, V82, P374, DOI 10.2307/3575387; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; TOMASOVIC SP, 1978, RADIAT RES, V74, P112, DOI 10.2307/3574761; TSO POP, 1964, P NATL ACAD SCI USA, V51, P17, DOI 10.1073/pnas.51.1.17; Valenzuela MT, 2000, RADIOTHER ONCOL, V54, P261, DOI 10.1016/S0167-8140(99)00180-2; WALDREN CA, 1978, RADIAT RES, V73, P95, DOI 10.2307/3574576; WALTERS RA, 1974, BIOPHYS J, V14, P99, DOI 10.1016/S0006-3495(74)70002-9; Wang HC, 2003, RADIAT RES, V159, P420, DOI 10.1667/0033-7587(2003)159[0420:CCNESH]2.0.CO;2; Wang HC, 2001, ONCOGENE, V20, P2212, DOI 10.1038/sj.onc.1204350; Wang X, 2003, RADIAT RES, V159, P426, DOI 10.1667/0033-7587(2003)159[0426:CIRIIO]2.0.CO;2; Wiese C, 2002, NUCLEIC ACIDS RES, V30, P1001, DOI 10.1093/nar/30.4.1001; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	84	47	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					824	834		10.1038/sj.onc.1207168	http://dx.doi.org/10.1038/sj.onc.1207168			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737117				2022-12-17	WOS:000188304900021
J	Celetti, A; Cerrato, A; Merolla, F; Vitagliano, D; Vecchio, G; Grieco, M				Celetti, A; Cerrato, A; Merolla, F; Vitagliano, D; Vecchio, G; Grieco, M			H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization	ONCOGENE			English	Article						H4(D10S170); RET/PTC1; ERK; apoptosis; stress; carcinogenesis; thyroid; TUNEL	FACTOR RECEPTOR-BETA; IN-VIVO; CELLS; PROTOONCOGENE; BAX; ACTIVATION; APOPTOSIS; ONCOGENE; PROTEINS; TUMORS	Human thyroid papillary carcinomas are characterized by rearrangements of the RET protooncogene with a number of heterologous genes, which generate the RET/papillary thyroid carcinoma (PTC) oncogenes. One of the most frequent variants of these recombination events is the fusion of the intracellular kinase-encoding domain of RET to the first 101 amino acids of a gene named H4(D10S170). We have characterized the H4(D10S170) gene product, showing that it is a ubiquitously expressed 55 KDa nuclear and cytosolic protein that is phosphorylated following serum stimulation. This phosphorylation was found to depend on mitogen-activated protein kinase (MAPK) Erk1/2 activity and to be associated to the relocation of H4(D10S170) from the nucleus to the cytosol. Overexpression of the H4(D10S170) gene was able to induce apoptosis of thyroid follicular epithelial cells; conversely a carboxy-terminal truncated H4(D10S170) mutant H4(1-101), corresponding to the portion included in the RET/PTC1 oncoprotein, behaved as dominant negative on the proapoptotic function and nuclear localization of H4(D10S170). Furthermore, conditional expression of the H4(D10S170)-dominant negative truncated mutant protected cells from stress-induced apoptosis. The substitution of serine 244 with alanine abrogated the apoptotic function of H4(D10S170). These data suggest that loss of the H4(D10S170) gene function might have a role in thyroid carcinogenesis by impairing apoptosis.	Magna Graecia Univ Catanzaro, Dipartimento Med Sperimentale & Clin, Policlin Materdomini, I-88100 Catanzaro, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, CNR, Ist Endocrinol & Oncol Sperimentale, Naples, Italy	Magna Graecia University of Catanzaro; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II	Grieco, M (corresponding author), Magna Graecia Univ Catanzaro, Dipartimento Med Sperimentale & Clin, Policlin Materdomini, Via T Campanella 115, I-88100 Catanzaro, Italy.	mgrieco@unicz.it	Cerrato, Aniello/AAY-1484-2020; Celetti, Angela/AAY-7172-2020; vitagliano, donata/B-8976-2012	Grieco, Michele/0000-0002-4212-7814				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Baron U, 2000, METHOD ENZYMOL, V327, P401, DOI 10.1016/S0076-6879(00)27292-3; Bouillet P, 2002, J CELL SCI, V115, P1567; Bounacer A, 1997, BIOCHIMIE, V79, P619, DOI 10.1016/S0300-9084(97)82012-3; Bounacer A, 1997, ONCOGENE, V15, P1263, DOI 10.1038/sj.onc.1200206; Butt AJ, 2000, J BIOL CHEM, V275, P39174, DOI 10.1074/jbc.M908888199; Castellone MD, 2003, ONCOGENE, V22, P246, DOI 10.1038/sj.onc.1206112; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIECO M, 1994, ONCOGENE, V9, P2531; ITO T, 1993, CANCER RES, V53, P2940; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Jossart GH, 1996, CYTOGENET CELL GENET, V75, P254, DOI 10.1159/000134495; Kulkarni S, 2000, CANCER RES, V60, P3592; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Mitchell KO, 2000, CANCER RES, V60, P6318; Mizuno T, 2000, ONCOGENE, V19, P438, DOI 10.1038/sj.onc.1203343; Moysich KB, 2002, LANCET ONCOL, V3, P269, DOI 10.1016/S1470-2045(02)00727-1; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; Pierotti MA, 2001, CANCER LETT, V166, P1, DOI 10.1016/S0304-3835(01)00439-6; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; Portella G, 1996, ONCOGENE, V13, P2021; Rabes HM, 2000, CLIN CANCER RES, V6, P1093; Sakakura C, 1996, INT J CANCER, V67, P101, DOI 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; Santoro M, 2002, ANN NY ACAD SCI, V963, P116, DOI 10.1111/j.1749-6632.2002.tb04102.x; Schlumberger M, 1999, CR ACAD SCI III-VIE, V322, P205, DOI 10.1016/S0764-4469(99)80045-6; Schwaller J, 2001, BLOOD, V97, P3910, DOI 10.1182/blood.V97.12.3910; Sheils OM, 2000, J PATHOL, V192, P32; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Tong Q, 1997, J BIOL CHEM, V272, P9043; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tuttle RM, 2000, SEMIN NUCL MED, V30, P133, DOI 10.1053/nm.2000.5412; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Wang JW, 2003, MOL ENDOCRINOL, V17, P1425, DOI 10.1210/me.2003-0041; ZHAN QM, 1994, ONCOGENE, V9, P3743	39	47	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					109	121		10.1038/sj.onc.1206981	http://dx.doi.org/10.1038/sj.onc.1206981			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712216				2022-12-17	WOS:000187895300012
J	Prokop, A; Wrasidlo, W; Lode, H; Herold, R; Lang, F; Henze, G; Dorken, B; Wieder, T; Daniel, PT				Prokop, A; Wrasidlo, W; Lode, H; Herold, R; Lang, F; Henze, G; Dorken, B; Wieder, T; Daniel, PT			Induction of apoptosis by enediyne antibiotic calicheamicin theta II proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner	ONCOGENE			English	Article						calicheamicin; apoptosis; caspase-3; Bax; Bcl-2; cytochrome c; mitochondria; BJAB; Jurkat; HCT116	DRUG-INDUCED APOPTOSIS; ACUTE MYELOID-LEUKEMIA; CYTOCHROME-C RELEASE; SQUAMOUS-CELL CARCINOMA; HUMAN-MELANOMA CELLS; GEMTUZUMAB OZOGAMICIN; DEATH RECEPTOR; IDENTIFIES PATIENTS; OCCURS DOWNSTREAM; BAX/BCL-2 RATIO	Calicheamicin thetaII is a member of the enediyne class of antitumor antibiotics that bind to DNA and induce apoptosis. These compounds differ, however, from conventional anticancer drugs as they bind in a sequence-specific manner noncovalently to DNA and cause sequence-selective oxidation of deoxyriboses and bending of the DNA helix. Calicheamicin is clinically employed as immunoconjugate to antibodies directed against, for example, CD33 in the case of gemtuzumab ozogamicin. Here, we show by the use of the unconjugated drug that calicheamicin-induced apoptosis is independent from death-receptor/FADD-mediated signals. Moreover, calicheamicin triggers apoptosis in a p53-independent manner as shown by the use of p53 knockout cells. Cell death proceeds via activation of mitochondrial permeability transition, cytochrome c release and activation of caspase-9 and -3. The overexpression of Bcl-x(L) or Bcl-2 strongly inhibited calicheamicin-induced apoptosis. Knockout of Bax abrogated cell death after calicheamicin treatment. Thus, the activation of mitochondria and execution of cell death occur through a fully Bax-dependent mechanism. Interestingly, caspase inhibition by the pancaspase-inhibitor zVAD-fmk interfered with mitochondrial activation by calicheamicin. This places caspase activation upstream of the mitochondria and indicates that calicheamicin-triggered apoptosis is enhanced through death receptor-independent activation of the caspase cascade, that is, an amplification loop that is required for full activation of the mitochondrial pathway.	Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Humboldt Univ, Univ Med Ctr Charite, Dept Gen pediat, D-13353 Berlin, Germany; Humboldt Univ, Univ Med Ctr Charite, Dept Pediat Oncol Hematol, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Daniel, PT (corresponding author), Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch, D-13125 Berlin, Germany.			Herold, Ralf/0000-0002-8148-6748				Ameisen JC, 2002, CELL DEATH DIFFER, V9, P367, DOI 10.1038/sj.cdd.4400950; Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cortazzo M, 1996, CANCER RES, V56, P1199; Daniel PT, 1999, ANAL BIOCHEM, V266, P110, DOI 10.1006/abio.1998.2929; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; DANIEL PT, 2003, IN PRESS ESSAYS BIOC, V39; de Vetten MP, 2000, BRIT J HAEMATOL, V111, P277, DOI 10.1046/j.1365-2141.2000.02402.x; DHEIN J, 1992, J IMMUNOL, V149, P3166; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Fadok VA, 2001, CELL DEATH DIFFER, V8, P582, DOI 10.1038/sj.cdd.4400856; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Guner D, 2003, INT J CANCER, V103, P445, DOI 10.1002/ijc.10850; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Hiatt A, 1994, Bioorg Med Chem, V2, P315, DOI 10.1016/S0968-0896(00)82187-2; Koonin EV, 2002, CELL DEATH DIFFER, V9, P394, DOI 10.1038/sj.cdd.4400991; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Linenberger ML, 2001, BLOOD, V98, P988, DOI 10.1182/blood.V98.4.988; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MAIESE WM, 1989, J ANTIBIOT, V42, P558, DOI 10.7164/antibiotics.42.558; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; Mrozek A, 2003, CELL DEATH DIFFER, V10, P461, DOI 10.1038/sj.cdd.4401193; Nabhan C, 2002, CLIN LYMPHOMA, V2, pS19, DOI 10.3816/CLM.2002.s.004; Nicolaou KC, 1994, CHEM BIOL, V1, P57, DOI 10.1016/1074-5521(94)90041-8; NICOLAOU KC, 1994, ANGEW CHEM INT EDIT, V33, P183, DOI 10.1002/anie.199401831; NICOLAOU KC, 1993, P NATL ACAD SCI USA, V90, P3142, DOI 10.1073/pnas.90.8.3142; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Roucou X, 2001, CELL DEATH DIFFER, V8, P875, DOI 10.1038/sj.cdd.4400910; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, J CELL SCI, V114, P4161; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Salzberg AA, 2000, BIOCHEMISTRY-US, V39, P7605, DOI 10.1021/bi992227g; Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817; Schor NF, 1999, BRAIN RES, V831, P125, DOI 10.1016/S0006-8993(99)01414-6; Sievers EL, 1999, BLOOD, V93, P3678, DOI 10.1182/blood.V93.11.3678; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Smaili SS, 2001, CELL DEATH DIFFER, V8, P909, DOI 10.1038/sj.cdd.4400889; Sturm I, 2003, CELL DEATH DIFFER, V10, P477, DOI 10.1038/sj.cdd.4401194; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Thorson JS, 2000, CURR PHARM DESIGN, V6, P1841, DOI 10.2174/1381612003398564; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; van der Velden VHJ, 2001, BLOOD, V97, P3197, DOI 10.1182/blood.V97.10.3197; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Von Ahsen O, 2000, CELL DEATH DIFFER, V7, P1192, DOI 10.1038/sj.cdd.4400782; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; Wieder T, 1997, FEBS LETT, V411, P260, DOI 10.1016/S0014-5793(97)00717-5; Wieder T, 2001, LEUKEMIA, V15, P1735, DOI 10.1038/sj.leu.2402284; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	71	47	51	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9107	9120		10.1038/sj.onc.1207196	http://dx.doi.org/10.1038/sj.onc.1207196			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14647446				2022-12-17	WOS:000187149100001
J	Pignatelli, M; Cocca, C; Santos, A; Perez-Castillo, A				Pignatelli, M; Cocca, C; Santos, A; Perez-Castillo, A			Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line	ONCOGENE			English	Article						BRCA1; PPAR gamma; regulation	PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); SUBCELLULAR-LOCALIZATION; PROMOTER REGION; SPORADIC BREAST; OVARIAN-CANCER; INHIBITION; COMPLEX; DIFFERENTIATION; TRANSCRIPTION	BRCA1 has been linked to the genetic susceptibility of a majority of familial breast and ovarian cancers. Several lines of evidence indicate that BRCA1 is a tumor suppressor and its expression is downregulated in sporadic breast and ovarian cancer cases. Therefore, the identification of genes involved in the regulation of BRCA1 gene expression might lead to new insights into the pathogenesis and treatment of these tumors. Peroxisome proliferator-activated receptor gamma (PPARgamma) is a member of the nuclear receptor superfamily that has well-established roles in the regulation of adipocyte development and glucose homeostasis. More recently, it has been shown that ligands of PPARgamma have a potent antitumorigenic activity in breast cancer cells. In the present study we have found that two distinct ligands of PPARgamma; 15-deoxy-Delta-(12,14)-prostaglandin J(2). (15dPG-J(2)) and rosiglitazone, increase the levels of BRCA1 protein in human MCF-7 breast cancer cells. Immunofluorescence microscopy analysis showed that, after treatment with 15dPG-J(2), the BRCA1 protein is mainly localized in the nucleus. Functional analysis by transient transfection of different 5'-flanking region fragments, as well as gel mobility shift assays and mutagenic analysis, suggests that the effects of 15dPG-J(2) and rosiglitazone are mediated through a functional DR1 located between the nucleotides -241 and -229, which is a canonical PPARgamma type response element. Our data suggest that PPARgamma is a crucial gene regulating BRCA1 gene expression and might therefore be important for the BRCA1 regulatory pathway involved in the pathogenesis of sporadic breast and ovarian cancer.	Univ Autonoma Madrid, Inst Invest Biomed, CSIC, E-28049 Madrid, Spain; Univ Complutense Madrid, Dept Bioquim & Biol Mol, Fac Med, E-28040 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Complutense University of Madrid	Perez-Castillo, A (corresponding author), Univ Buenos Aires, Dept Radioisotopos, Fac Farm & Bioquim, RA-1053 Buenos Aires, DF, Argentina.		Santos, Angel/K-3744-2014; Perez-Castillo, Ana/A-9505-2015; izadi, emad/M-1118-2019	Santos, Angel/0000-0002-7551-8483; Perez-Castillo, Ana/0000-0002-2632-5853				Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Lebovitz HE, 2001, RECENT PROG HORM RES, V56, P265, DOI 10.1210/rp.56.1.265; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Menendez-Hurtado A, 2000, ENDOCRINOLOGY, V141, P4164, DOI 10.1210/en.141.11.4164; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; Picard F, 2002, ANNU REV NUTR, V22, P167, DOI 10.1146/annurev.nutr.22.010402.102808; Pignatelli M, 2001, J CELL SCI, V114, P4117; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Suen TC, 1999, J BIOL CHEM, V274, P31297, DOI 10.1074/jbc.274.44.31297; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994	30	47	49	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5446	5450		10.1038/sj.onc.1206824	http://dx.doi.org/10.1038/sj.onc.1206824			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934104	Bronze			2022-12-17	WOS:000184735000009
J	Ma, CL; Lin, H; Leonard, SS; Shi, XL; Ye, JP; Luo, J				Ma, CL; Lin, H; Leonard, SS; Shi, XL; Ye, JP; Luo, J			Overexpression of ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human mammary epithelial and breast cancer cells in vitro	ONCOGENE			English	Article						alcohol; growth factors; metastasis; reactive oxygen species; signal transduction	N-TERMINAL KINASE; RECEPTOR TYROSINE KINASES; EPIDERMAL-GROWTH-FACTOR; ALCOHOL-CONSUMPTION; ESTROGEN-RECEPTOR; PC12 CELLS; REGULATED KINASE; OXIDATIVE STRESS; CARCINOMA-CELLS; RAT HEPATOCYTES	Both epidemiological and experimental studies indicate that ethanol is a tumor promoter and may promote metastasis of breast cancer. However, the molecular mechanisms underlying ethanol-mediated tumor promotion remain unknown. Overexpression of ErbB proteins in breast cancer patients is generally associated with poor prognosis. The ErbB proteins are a family of receptor kinases that include four closely related members: epidermal growth factor receptor (EGFR/ErbB1), ErbB2/neu, ErbB3, and ErbB4. Particularly, ErbB2 plays a pivotal role in ErbB-mediated activities. Here we demonstrated that amplification of ErbB2 expression sensitized a specific cellular response to ethanol. Human breast cancer cells or mammary epithelial cells with a high expression of ErbB2 exhibited an enhanced response to ethanol-stimulated cell invasion in vitro. Ethanol also stimulated cell proliferation; however, this stimulation was independent of ErbB2 levels. Ethanol triggered divergent intracellular signaling among cells expressing different ErbB2 levels. In the cells overexpressing ErbB2, ethanol was more effective in the activation of c-Jun NH2 terminal protein kinases (JNKs) and p38 mitogen-activated protein kinase (p38 MAPK) as well as the induction of reactive oxygen species (ROS) than the cells with normal ErbB2 expression. Blockage of either JNKs or p38 MAPK activation eliminated ethanol-mediated cell invasion. In contrast, the reduction of hydrogen peroxide concentration by catalase exposure had little effect on ethanol-induced cell invasion. These results indicated that ethanol-induced cell invasion was primarily mediated by JNKs and p38 MAPK, whereas the involvement of ROS formation might be minimal. Our study suggests that overexpression of ErbB2 may augment ethanol-elicited signaling and promote ethanol-stimulated tumor metastasis.	W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; Xijing Hosp, Dept Dermatol, Xian 710032, Peoples R China; NIOSH, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA; Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	West Virginia University; Air Force Military Medical University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Luo, J (corresponding author), W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA.		Ye, Jianping/N-1998-2017; Shi, Xianglin/B-8588-2012; Luo, Jia/E-4674-2012	Ye, Jianping/0000-0003-3875-365X; Luo, Jia/0000-0002-6968-3618	NATIONAL CANCER INSTITUTE [R01CA090385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R03AA012968] Funding Source: NIH RePORTER; NCI NIH HHS [CA90385] Funding Source: Medline; NIAAA NIH HHS [AA12968] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Alford D, 1998, J CELL SCI, V111, P521; Bailey SM, 1998, HEPATOLOGY, V28, P1318, DOI 10.1002/hep.510280521; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Bowlin SJ, 1997, INT J EPIDEMIOL, V26, P915, DOI 10.1093/ije/26.5.915; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; Castro GD, 2001, TOXICOLOGY, V160, P11, DOI 10.1016/S0300-483X(00)00433-9; Chen YR, 2001, ONCOGENE, V20, P367, DOI 10.1038/sj.onc.1204105; Denkert C, 2002, CLIN EXP METASTAS, V19, P79, DOI 10.1023/A:1013857325012; Dhar A, 2002, MOL CELL BIOCHEM, V234, P185, DOI 10.1023/A:1015948505117; Doll R, 1981, J NATL CANCER I, V66, P1192; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; Fan SJ, 2000, CANCER RES, V60, P5635; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Hauck CR, 2001, CANCER RES, V61, P7079; HIATT RA, 1990, MED ONCOL TUMOR PHAR, V7, P143; Hoek JB, 2002, ALCOHOL, V27, P63, DOI 10.1016/S0741-8329(02)00215-X; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Izevbigie EB, 2002, EXP BIOL MED, V227, P260, DOI 10.1177/153537020222700406; Jurgensmeier JM, 1997, INT J CANCER, V70, P587; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; Kulisz A, 2002, AM J PHYSIOL-LUNG C, V282, pL1324, DOI 10.1152/ajplung.00326.2001; Kuper H, 2000, BRIT J CANCER, V83, P949, DOI 10.1054/bjoc.2000.1360; LACROIX H, 1989, ONCOGENE, V4, P145; Lakka SS, 2000, CLIN EXP METASTAS, V18, P245, DOI 10.1023/A:1006724826083; Li YX, 2001, FREE RADICAL BIO MED, V30, P389, DOI 10.1016/S0891-5849(00)00484-6; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LONGNECKER MP, 1994, CANCER CAUSE CONTROL, V5, P73, DOI 10.1007/BF01830729; Luo J, 1999, J NEUROSCI, V19, P10014, DOI 10.1523/jneurosci.19-22-10014.1999; Luo J, 2003, J BIOL CHEM, V278, P4542, DOI 10.1074/jbc.M208295200; Luo J, 1997, ALCOHOL CLIN EXP RES, V21, P1186, DOI 10.1111/j.1530-0277.1997.tb04436.x; Luo J, 1999, ALCOHOL CLIN EXP RES, V23, P644, DOI 10.1111/j.1530-0277.1999.tb04166.x; Luo J, 2000, BREAST CANCER RES TR, V63, P61, DOI 10.1023/A:1006436315284; Mansat-De Mas V, 1999, MOL PHARMACOL, V56, P867, DOI 10.1124/mol.56.5.867; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCANN A, 1989, IRISH J MED SCI, V158, P137, DOI 10.1007/BF02943053; Meng QH, 2000, BIOCHEM BIOPH RES CO, V273, P448, DOI 10.1006/bbrc.2000.2942; MUFTI SI, 1993, J CANCER RES CLIN, V119, P304, DOI 10.1007/BF01212730; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Olayioye MA, 2001, EXP CELL RES, V267, P81, DOI 10.1006/excr.2001.5242; PANTEL K, 1993, JNCI-J NATL CANCER I, V85, P1419, DOI 10.1093/jnci/85.17.1419; Park MJ, 2002, J NEUROSURG, V97, P112, DOI 10.3171/jns.2002.97.1.0112; PATERSON MC, 1991, CANCER RES, V51, P556; PLANT ML, 1992, INT J ADDICT, V27, P107, DOI 10.3109/10826089209068733; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; Reinke LA, 2002, FREE RADICAL BIO MED, V32, P953, DOI 10.1016/S0891-5849(02)00795-5; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; ROSENBERG L, 1993, EPIDEMIOL REV, V15, P133, DOI 10.1093/oxfordjournals.epirev.a036097; Sano M, 2001, CIRC RES, V89, P661, DOI 10.1161/hh2001.098873; Schmidt-Ullrich RK, 1999, RADIAT ONCOL INVESTI, V7, P321, DOI 10.1002/(SICI)1520-6823(1999)7:6<321::AID-ROI2>3.0.CO;2-Q; SHI XL, 1991, ARCH BIOCHEM BIOPHYS, V289, P355, DOI 10.1016/0003-9861(91)90423-G; Shin EY, 2001, EXP MOL MED, V33, P276, DOI 10.1038/emm.2001.45; Shin M, 2002, BBA-MOL CELL RES, V1589, P311, DOI 10.1016/S0167-4889(02)00195-7; Simon C, 2001, EXP CELL RES, V271, P344, DOI 10.1006/excr.2001.5374; Singletary K, 1997, ALCOHOL CLIN EXP RES, V21, P334; Singletary KW, 2001, JAMA-J AM MED ASSOC, V286, P2143, DOI 10.1001/jama.286.17.2143; Singletary KW, 2001, CANCER LETT, V165, P131, DOI 10.1016/S0304-3835(01)00419-0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Sun YB, 2002, J CELL PHYSIOL, V192, P225, DOI 10.1002/jcp.10132; Swanson CA, 1997, EPIDEMIOLOGY, V8, P231, DOI 10.1097/00001648-199705000-00001; Talvensaari-Mattila A, 1998, CANCER-AM CANCER SOC, V83, P1153, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1153::AID-CNCR14>3.0.CO;2-4; Tan M, 1997, CANCER RES, V57, P1199; TAUCHI K, 1989, VIRCHOWS ARCH A, V416, P65, DOI 10.1007/BF01606471; Tombes RM, 1998, BIOCHEM J, V330, P1451; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vaeth PAC, 1998, ALCOHOL CLIN EXP RES, V22, P928; Verma M, 1999, Cancer Biochem Biophys, V17, P1; Watabiki T, 2000, ALCOHOL CLIN EXP RES, V24, p117S, DOI 10.1111/j.1530-0277.2000.tb00025.x; Weiss HA, 1996, BRIT J CANCER, V73, P1298, DOI 10.1038/bjc.1996.248; Wright RM, 1999, FREE RADICAL BIO MED, V26, P348, DOI 10.1016/S0891-5849(98)00204-4; Ye JP, 1996, MOL CELL BIOL, V16, P6178; Zhu YF, 2001, BREAST CANCER RES TR, V69, P29, DOI 10.1023/A:1012293507534; Zhu YF, 2001, INT J ONCOL, V18, P1299	76	47	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5281	5290		10.1038/sj.onc.1206675	http://dx.doi.org/10.1038/sj.onc.1206675			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917629				2022-12-17	WOS:000184734900007
J	Mayer, F; Stoop, H; Sen, S; Bokemeyer, C; Oosterhuis, JW; Looijenga, LH				Mayer, F; Stoop, H; Sen, S; Bokemeyer, C; Oosterhuis, JW; Looijenga, LH			Aneuploidy of human testicular germ cell tumors is associated with amplification of centrosomes	ONCOGENE			English	Article						germ cell tumors; aneuploidy; centrosomes; STK15	COMPARATIVE GENOMIC HYBRIDIZATION; CARCINOMA IN-SITU; ENDODERMAL SINUS TUMORS; SPERMATOCYTIC SEMINOMA; MITOTIC KINASE; CHROMOSOMAL INSTABILITY; ALKALINE-PHOSPHATASE; CYTOGENETIC ANALYSIS; CANCER PROGRESSION; FLOW-CYTOMETRY	Testicular germ cell tumors occur in three age groups. Seminomas and nonseminomas of adults, including mature teratomas, and the precursor carcinoma in situ (CIS) are aneuploid. This also holds true for yolk sac tumors of newborn and infants, while the mature teratomas of this age are diploid. In contrast, spermatocytic seminomas occurring in the elderly contain both diploid and polyploid cells. Aneuploidy has been associated with centrosome aberrations, sometimes related to overexpression of STK15. Aneuploidy of non-neoplastic germ cells has been demonstrated in the context of male infertility, a risk factor for the development of seminoma/nonseminoma. We investigated aneuploidy, centrosome aberrations and the role of STK15 in different types of testicular germ cell tumors as well as in normal and disturbed spermatogenesis. The aneuploid seminomas and nonseminomas tumors (including CIS) showed increased numbers of centrosomes, without STK15 amplification or overexpression. Four out of six infantile teratomas had normal centrosomes, the remaining two and an infantile yolk sac tumor showed a heterogeneous pattern of cells with normal or amplified centrosomes. Spermatocytic seminomas had two, four or eight centrosomes. Germ cells in seminiferous tubules with disturbed spermatogenesis shared both aneuploidy and centrosome abnormalities with seminomas/nonseminomas and showed a more intense STK15 staining than those with normal spermatogenesis and CIS. Therefore, aneuploidy of testicular germ cell tumors is associated with amplified centrosomes probably unrelated to STK15.	Dr Daniel Den Hoed Canc Ctr, Pathol Lab Expt Pathooncol, Josophine Nefkens Inst, Erasmus Med Ctr, NL-3000 DR Rotterdam, Netherlands; Med Univ Klin Tubingen, Abt Onkol Hamatol Immunol & Rheumatol, D-72076 Tubingen, Germany; Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Houston, TX 77030 USA	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Texas System; UTMD Anderson Cancer Center	Looijenga, LH (corresponding author), Dr Daniel Den Hoed Canc Ctr, Pathol Lab Expt Pathooncol, Josophine Nefkens Inst, Erasmus Med Ctr, Bldg Be Room 430B,POB 1738, NL-3000 DR Rotterdam, Netherlands.		Looijenga, Leendert/B-8145-2019	Looijenga, Leendert/0000-0002-8146-1911				Acar H, 2000, UROL INT, V64, P202, DOI 10.1159/000030531; Burke A, 1993, J UROL PATHOL, V1, P21; CLAUSEN OPF, 1991, CYTOMETRY, V12, P77, DOI 10.1002/cyto.990120111; CUMMINGS OW, 1994, HUM PATHOL, V25, P54, DOI 10.1016/0046-8177(94)90171-6; DEGRAAFF WE, 1992, LAB INVEST, V66, P166; DEKKER I, 1992, CANCER, V69, P993, DOI 10.1002/1097-0142(19920215)69:4<993::AID-CNCR2820690427>3.0.CO;2-8; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; EBLE JN, 1994, HUM PATHOL, V25, P1035, DOI 10.1016/0046-8177(94)90062-0; ELNAGGAR AK, 1992, AM J SURG PATHOL, V16, P611, DOI 10.1097/00000478-199206000-00009; Faulkner SW, 2000, BRIT J CANCER, V83, P729, DOI 10.1054/bjoc.2000.1334; FLOYD C, 1988, CANCER-AM CANCER SOC, V61, P409, DOI 10.1002/1097-0142(19880115)61:2<409::AID-CNCR2820610234>3.0.CO;2-6; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; GILLIS AJM, 1994, LAB INVEST, V71, P874; GIWERCMAN A, 1993, LANCET, V341, P384, DOI 10.1016/0140-6736(93)90199-Q; GIWERCMAN A, 1992, SCAND J UROL NE S148, V26, P1; Glick A, 1999, P NATL ACAD SCI USA, V96, P14949, DOI 10.1073/pnas.96.26.14949; Goepfert TM, 2002, CANCER RES, V62, P4115; Gustafson LM, 2000, LARYNGOSCOPE, V110, P1798; HIGGINS MJ, 1985, CHROMOSOMA, V93, P77, DOI 10.1007/BF01259449; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Jacobsen R, 2000, BMJ-BRIT MED J, V321, P789, DOI 10.1136/bmj.321.7264.789; Jacobsen R, 2000, HUM REPROD, V15, P1958, DOI 10.1093/humrep/15.9.1958; Katayama H, 1999, J NATL CANCER I, V91, P1160, DOI 10.1093/jnci/91.13.1160; Kersemaekers AMF, 2002, J CLIN ONCOL, V20, P1551, DOI 10.1200/JCO.20.6.1551; Kimura M, 1999, J BIOL CHEM, V274, P7334, DOI 10.1074/jbc.274.11.7334; Korn WM, 1996, GENE CHROMOSOME CANC, V17, P78, DOI 10.1002/(SICI)1098-2264(199610)17:2<78::AID-GCC2>3.0.CO;2-Y; Kuo KK, 2000, HEPATOLOGY, V31, P59, DOI 10.1002/hep.510310112; Lahdetie J, 1997, AM J MED GENET, V71, P115; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; LOOIJENGA LHJ, 1990, CYTOGENET CELL GENET, V53, P216, DOI 10.1159/000132934; LOOIJENGA LHJ, 1994, LAB INVEST, V71, P490; Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090; Looijenga LHJ, 2000, J PATHOL, V191, P187, DOI 10.1002/(SICI)1096-9896(200006)191:2<187::AID-PATH584>3.0.CO;2-T; LOOIJENGA LHJ, 1991, LAB INVEST, V64, P113; LOOIJENGA LHJ, 1993, LAB INVEST, V68, P211; Lutz W, 2001, J BIOL CHEM, V276, P20774, DOI 10.1074/jbc.M101324200; MATOSKA J, 1990, AM J CLIN PATHOL, V94, P89, DOI 10.1093/ajcp/94.1.89; Meek DW, 2000, PATHOL BIOL, V48, P246; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Moller H, 1999, BMJ-BRIT MED J, V318, P559, DOI 10.1136/bmj.318.7183.559; Mostert M, 2000, LAB INVEST, V80, P1055, DOI 10.1038/labinvest.3780110; Mostert MMC, 1996, CANCER GENET CYTOGEN, V89, P146, DOI 10.1016/0165-4608(96)00043-X; MOSTOFI FK, 1998, HISTOLOGICAL TYPING; MULLER J, 1987, INT J ANDROL, V10, P147, DOI 10.1111/j.1365-2605.1987.tb00176.x; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; Ottesen AM, 1997, GENE CHROMOSOME CANC, V20, P412; Ouyang XS, 2001, BBA-MOL CELL RES, V1541, P212, DOI 10.1016/S0167-4889(01)00157-4; Perlman EJ, 2000, J PEDIAT HEMATOL ONC, V22, P100, DOI 10.1097/00043426-200003000-00003; PERLMAN EJ, 1994, PEDIATR PATHOL, V14, P695, DOI 10.3109/15513819409023342; Pihan GA, 2001, CANCER RES, V61, P2212; Robbins WA, 1997, NAT GENET, V16, P74, DOI 10.1038/ng0597-74; Roelofs H, 1999, J PATHOL, V189, P236; ROSAI J, 1969, CANCER-AM CANCER SOC, V24, P103, DOI 10.1002/1097-0142(196907)24:1<103::AID-CNCR2820240114>3.0.CO;2-1; Rosenberg C, 1997, CYTOMETRY, V29, P113, DOI 10.1002/(SICI)1097-0320(19971001)29:2<113::AID-CYTO3>3.0.CO;2-E; Rosenberg C, 1999, LAB INVEST, V79, P1447; Rosenberg C, 1998, GENE CHROMOSOME CANC, V23, P286, DOI 10.1002/(SICI)1098-2264(199812)23:4<286::AID-GCC2>3.0.CO;2-6; SCULLY RE, 1961, CANCER-AM CANCER SOC, V14, P788, DOI 10.1002/1097-0142(199007/08)14:4<788::AID-CNCR2820140414>3.0.CO;2-3; SCULLY RE, 1978, TUMORS OVARY MALDEVE, P226; Sen S, 2002, JNCI-J NATL CANCER I, V94, P1320; Shi Q, 2000, CYTOGENET CELL GENET, V90, P79, DOI 10.1159/000015668; Stoop H, 2001, LAB INVEST, V81, P919, DOI 10.1038/labinvest.3780302; Summersgill B, 2001, BRIT J CANCER, V85, P213, DOI 10.1054/bjoc.2001.1889; Summersgill B, 1998, BRIT J CANCER, V77, P305, DOI 10.1038/bjc.1998.47; TALERMAN A, 1974, J UROLOGY, V112, P212, DOI 10.1016/S0022-5347(17)59689-5; Tatsuka M, 1998, CANCER RES, V58, P4811; TRUE LD, 1988, AM J SURG PATHOL, V12, P75, DOI 10.1097/00000478-198802000-00001; Van Dyk Q, 2000, HUM REPROD, V15, P1529; vanEchten J, 1995, CANCER GENET CYTOGEN, V85, P133, DOI 10.1016/0165-4608(95)00151-4; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	74	47	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3859	3866		10.1038/sj.onc.1206469	http://dx.doi.org/10.1038/sj.onc.1206469			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813459				2022-12-17	WOS:000183612000005
J	Varallo, VM; Gan, BS; Seney, S; Ross, DC; Roth, JH; Richards, RS; McFarlane, RM; Alman, B; Howard, JC				Varallo, VM; Gan, BS; Seney, S; Ross, DC; Roth, JH; Richards, RS; McFarlane, RM; Alman, B; Howard, JC			Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro	ONCOGENE			English	Article						Dupuytren's contracture; fibromatosis; beta-catenin; extracellular matrix	TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; E-CADHERIN; CONTRACTURE; COMPLEX; CANCER; FIBROMATOSIS; ABNORMALITIES; ASSOCIATION; INHIBITION	Dupuytren's disease (DD) is a superficial fibromatosis of the hand. Although the molecular mechanisms responsible for this disease are unknown, recent studies suggest that beta-catenin may be a key factor involved in fibromatosis. In this study, we analysed the in vivo and in vitro expression levels of beta-catenin in DD, using surgical specimens and primary cell lines. Although no somatic mutations (exon 3) of beta-catenin were detected, Western blot analysis revealed high levels of beta-catenin in diseased palmar fascia, and low to undetectable levels of beta-catenin in patient-matched normal palmar fascia. Immunohistochemistry analysis showed high levels of beta-catenin expression within the disease fascia, as well as cytoplasmic and nuclear accumulations of the protein. Immunoprecipitation of beta-catenin from seven patient lesions showed the protein to be tyrosine phosphorylated. Lastly, Western analysis of three patient-matched (disease and normal fascia) primary cell cultures showed significantly elevated levels of beta-catenin in disease cells cultured in three-dimensional collagen lattices. This is the first extensive in vivo and in vitro characterization of beta-catenin in DD, and the first to suggest that the extracellular matrix may play an important role in modulating beta-catenin stability in DD.	Univ Western Ontario, Hand & Upper Limb Ctr, Cell & Mol Biol Lab, London, ON, Canada; Univ Western Ontario, Lawson Hlth Res Inst, London, ON, Canada; Univ Western Ontario, Dept Surg, London, ON, Canada; Hosp Sick Children, Dept Surg, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Howard, JC (corresponding author), St Josephs Hlth Care, Hand & Upper Limb Ctr, Cell & Mol Biol Lab, 268 Grosvenor St, London, ON N6A 4V2, Canada.							Abraham SC, 2002, HUM PATHOL, V33, P39, DOI 10.1053/hupa.2002.30196; AN HS, 1988, J HAND SURG-AM, V13A, P872, DOI 10.1016/0363-5023(88)90262-6; ARAFA M, 1992, J HAND SURG-BRIT EUR, V17B, P221, DOI 10.1016/0266-7681(92)90095-J; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BONNICI AV, 1992, J HAND SURG-BRIT EUR, V17B, P349, DOI 10.1016/0266-7681(92)90128-O; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Burge P, 1997, J BONE JOINT SURG BR, V79B, P206, DOI 10.1302/0301-620X.79B2.6990; Burge P, 1999, HAND CLIN, V15, P63; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cheon SS, 2002, P NATL ACAD SCI USA, V30, P30; Dal Cin P, 1999, CANCER GENET CYTOGEN, V108, P137, DOI 10.1016/S0165-4608(98)00126-5; De Wever I, 2000, MODERN PATHOL, V13, P1080, DOI 10.1038/modpathol.3880200; Dupuytren B, 1834, LANCET, V2, P222; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Gudmundsson KG, 2002, J CLIN EPIDEMIOL, V55, P5, DOI 10.1016/S0895-4356(01)00413-9; Hanai J, 2002, J CELL BIOL, V158, P529, DOI 10.1083/jcb.200203064; Hanai J, 2002, J BIOL CHEM, V277, P16464, DOI 10.1074/jbc.M112274200; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Kloen P, 1999, BRIT J PLAST SURG, V52, P629, DOI 10.1054/bjps.1999.3187; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuhn MA, 2002, J SURG RES, V103, P146, DOI 10.1006/jsre.2001.6350; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; MCFARLANE RM, 1991, J HAND SURG-AM, V16A, P775, DOI 10.1016/S0363-5023(10)80134-0; MIKKELSEN OA, 1978, HAND, V10, P1, DOI 10.1016/S0072-968X(78)80019-9; Mikkelsen OA, 1999, J HAND SURG-BRIT EUR, V24B, P515, DOI 10.1054/jhsb.1999.0229; Montgomery E, 2001, MODERN PATHOL, V14, P695, DOI 10.1038/modpathol.3880374; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; NOBLE J, 1992, J HAND SURG-BRIT EUR, V17B, P71, DOI 10.1016/0266-7681(92)90015-T; NOBLE J, 1984, J BONE JOINT SURG BR, V66, P322, DOI 10.1302/0301-620X.66B3.6725338; Polakis P, 2000, GENE DEV, V14, P1837; Rayan GM, 1999, HAND CLIN, V15, P87; Ross DC, 1999, HAND CLIN, V15, P53; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; SERGOVICH FR, 1983, NEW ENGL J MED, V308, P162; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Shibata T, 1996, ONCOGENE, V13, P883; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; SKOOG T, 1960, PLAST RECONSTR SURG, V31, P258; Tejpar S, 1999, ONCOGENE, V18, P6615, DOI 10.1038/sj.onc.1203041; Wang HM, 2001, J CELL PHYSIOL, V187, P188, DOI 10.1002/jcp.1068; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; WURSTERHILL DH, 1988, AM J HUM GENET, V43, P285	43	47	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3680	3684		10.1038/sj.onc.1206415	http://dx.doi.org/10.1038/sj.onc.1206415			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802275				2022-12-17	WOS:000183551000002
J	Tourneur, L; Mistou, S; Michiels, FM; Devauchelle, V; Renia, L; Feunteun, J; Chiocchia, G				Tourneur, L; Mistou, S; Michiels, FM; Devauchelle, V; Renia, L; Feunteun, J; Chiocchia, G			Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells	ONCOGENE			English	Article						FADD; Fas ligand; thyroid; tumor	FLICE-INHIBITORY PROTEIN; COLON-CANCER CELLS; IMMUNE EVASION; DEATH PATHWAY; TRANSGENIC EXPRESSION; LYMPHOCYTE APOPTOSIS; LIGAND EXPRESSION; ENTRY SITE; PROLIFERATION; CD95	Downregulation of proapoptotic molecules like Fas or caspase 8, or upregulation of antiapoptotic molecules like FLICE inhibitory protein has been suggested to be a regulatory mechanism set up by tumor cells to block the death signal received via death receptors. In an in-depth study of the Fas/FasL-signaling pathway in thyroid tumor development, we have demonstrated that tumor cells specifically downregulate the multideath receptor adapter Fas-associated death domain (FADD). The regulation of FADD expression occurred only at the protein level. Furthermore, in the absence of FADD, Fas-signaling resulted in accelerated growth of thyrocytes. Since thyrocytes also acquired FasL expression during tumor development, the absence of FADD protein could lead to greater resistance to numerous death receptor-mediated apoptosis, stimulation of their own proliferation through Fas/FasL interaction, and the capacity to counter-attack the infiltrating lymphocytes.	Univ Paris 05, Inst Cochin, Dept Immunol, IFR 116,CNRS,UMR 8104,INSERM,U567, F-75014 Paris, France; Inst Gustave Roussy, Oncol Mol Lab, CNRS, Unite Rech Associee 1158, F-94805 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Chiocchia, G (corresponding author), Univ Paris 05, Inst Cochin, Dept Immunol, IFR 116,CNRS,UMR 8104,INSERM,U567, 27 Rue Fbg St Jacques, F-75014 Paris, France.		Renia, Laurent/E-2117-2011; Feunteun, Jean/AAZ-1267-2020; CHIOCCHIA, Gilles R/F-6287-2013	Renia, Laurent/0000-0003-0349-1557; CHIOCCHIA, Gilles R/0000-0001-9973-0940; Feunteun, Jean/0000-0003-1212-9189				Baker JR, 1999, J CLIN ENDOCR METAB, V84, P2593, DOI 10.1210/jc.84.8.2593; Batteux F, 2000, J IMMUNOL, V164, P1681, DOI 10.4049/jimmunol.164.4.1681; Bernstein J, 1997, J BIOL CHEM, V272, P9356; Bretz JD, 1999, J BIOL CHEM, V274, P23627, DOI 10.1074/jbc.274.33.23627; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Desbarats J, 2000, NAT MED, V6, P920, DOI 10.1038/78688; Desbarats J, 1999, P NATL ACAD SCI USA, V96, P8104, DOI 10.1073/pnas.96.14.8104; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Droin N, 2001, ONCOGENE, V20, P260, DOI 10.1038/sj.onc.1204066; Droin N, 2000, CANCER RES, V60, P7039; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; Favre-Felix N, 2000, J IMMUNOL, V164, P5023, DOI 10.4049/jimmunol.164.10.5023; Freiberg RA, 1997, J INVEST DERMATOL, V108, P215, DOI 10.1111/1523-1747.ep12334273; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Hiromatsu Y, 1999, J CLIN ENDOCR METAB, V84, P2896, DOI 10.1210/jc.84.8.2896; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kim PKM, 1996, J IMMUNOL, V157, P5461; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; MAZIER D, 1985, SCIENCE, V227, P440, DOI 10.1126/science.3880923; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; Miller DL, 1998, FEBS LETT, V434, P417, DOI 10.1016/S0014-5793(98)01025-4; Mitsiades N, 1999, J CLIN ENDOCR METAB, V84, P2924, DOI 10.1210/jc.84.8.2924; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; Nagata S, 1996, NAT MED, V2, P1306, DOI 10.1038/nm1296-1306; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OWENSCHAUB LB, 1993, J IMMUNOTHER, V14, P234, DOI 10.1097/00002371-199310000-00011; Pomerance M, 2000, J BIOL CHEM, V275, P40539, DOI 10.1074/jbc.M002097200; Restifo NP, 2000, NAT MED, V6, P493, DOI 10.1038/74955; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; SUAREZ HG, 1991, ONCOGENE, V6, P677; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tourneur U, 2001, J IMMUNOL, V167, P1338, DOI 10.4049/jimmunol.167.3.1338; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	46	47	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2795	2804		10.1038/sj.onc.1206399	http://dx.doi.org/10.1038/sj.onc.1206399			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743602				2022-12-17	WOS:000182569300010
J	Kroger, A; Dallugge, A; Kirchhoff, S; Hauser, H				Kroger, A; Dallugge, A; Kirchhoff, S; Hauser, H			IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo	ONCOGENE			English	Article						interferon regulatory factor-1 (IRF-1); cell proliferation; reversion of tumorigenicity; interferon	REGULATORY FACTOR-I; TRANSCRIPTION FACTOR IRF-1; HIGHER EUKARYOTIC CELLS; NATURAL-KILLER-CELLS; GROWTH INHIBITION; PROTEIN-KINASE; LYSYL OXIDASE; DNA-DAMAGE; INTERFERON; GENE	The expression of the transcriptional activator and tumor suppressor IRF-1 induces multiple effects that counteract the growth of tumor cells in vitro and in vivo. These include the inhibition of cell proliferation, the secretion of interferon-beta (IFN-beta), the induction of apoptosis specifically in certain cell types and the induction of a strong T-cell response. Here, we show that apart from its immune-activating properties, IRF-1 expression leads to a reversion of the tumorigenic phenotype of NIH3T3 cells transformed by different oncogenes. This was analysed in detail in a cell line in which the expression of c-Ha-ras and c-myc is under the control of a doxycycline-regulated promoter allowing to switch between the normal and oncogenic cell status. In the same cells, a beta-estradiol activatable IRF-1 fusion protein is expressed. After IRF-1 activation the oncogene-mediated acceleration of the cell cycle is reverted. Further, a complete IRF-1-mediated reversion of the oncogenic phenotype is observed in soft-agar growth assays. IRF-1 activation induces IFN-beta secretion; however, the observed effects are not mediated by IFN-beta. Inhibition of tumor growth is observed in nude mice as long as IRF-1 is active, indicating that neither B-nor T-cells must become activated for tumor growth suppression.	GBF, German Res Ctr Biotechnol, Dept Gene Regulat & Differentiat, D-38124 Braunschweig, Germany	Helmholtz Association; Helmholtz-Center for Infection Research	Hauser, H (corresponding author), GBF, German Res Ctr Biotechnol, Dept Gene Regulat & Differentiat, Mascheroder Weg 1, D-38124 Braunschweig, Germany.							Andoh A, 2002, J IMMUNOL, V169, P1683, DOI 10.4049/jimmunol.169.4.1683; Baasner S, 1996, ONCOGENE, V13, P901; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; DINTER H, 1987, EUR J BIOCHEM, V166, P103, DOI 10.1111/j.1432-1033.1987.tb13488.x; Futaki M, 1996, LEUKEMIA RES, V20, P601, DOI 10.1016/0145-2126(96)00013-6; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRESSER I, 1989, ACTA ONCOL, V28, P347, DOI 10.3109/02841868909111205; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; Hobart M, 1996, TRANSPLANTATION, V62, P1895, DOI 10.1097/00007890-199612270-00037; Horiuchi M, 1997, J BIOL CHEM, V272, P11952, DOI 10.1074/jbc.272.18.11952; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KIRCHHOFF S, 1995, TRENDS GENET, V11, P219, DOI 10.1016/S0168-9525(00)89053-8; Kirchhoff S, 1999, ONCOGENE, V18, P3725, DOI 10.1038/sj.onc.1202704; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; Kirchhoff S, 1999, EUR J BIOCHEM, V261, P546, DOI 10.1046/j.1432-1327.1999.00308.x; Kroger A, 2002, J INTERF CYTOK RES, V22, P5, DOI 10.1089/107999002753452610; Kroger A, 2001, CANCER RES, V61, P2609; Kwissa M, 2000, J MOL MED-JMM, V78, P495, DOI 10.1007/s001090000135; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; Ohteki T, 1998, J EXP MED, V187, P967, DOI 10.1084/jem.187.6.967; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; Qin XQ, 2001, MOL THER, V4, P356, DOI 10.1006/mthe.2001.0464; Salkowski CA, 1996, J IMMUNOL, V156, P3107; Sambrook J, 1989, MOL CLONING LAB MANU; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tamura Tomohiko, 1997, Leukemia (Basingstoke), V11, P439; Tan RSP, 1996, CANCER RES, V56, P2417; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TANIGUCHI T, 1997, BIOCHIM BIOPHYS ACTA, V1333, P9; Unsinger J, 2001, MOL THER, V4, P484, DOI 10.1006/mthe.2001.0480; Yim JH, 1997, J IMMUNOL, V158, P1284	50	47	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					1045	1056		10.1038/sj.onc.1206260	http://dx.doi.org/10.1038/sj.onc.1206260			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592391				2022-12-17	WOS:000180926100010
J	Bougeard, G; Brugieres, L; Chompret, A; Gesta, P; Charbonnier, F; Valent, A; Martin, C; Raux, G; Feunteun, J; Bressac-de Paillerets, B; Frebourg, T				Bougeard, G; Brugieres, L; Chompret, A; Gesta, P; Charbonnier, F; Valent, A; Martin, C; Raux, G; Feunteun, J; Bressac-de Paillerets, B; Frebourg, T			Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene	ONCOGENE			English	Article						TP53; Li-Fraumeni syndrome; deletion; PCR	GERMLINE MUTATION; HCHK2 MUTATIONS; P53; PTEN	The absence of detectable germline TP53 mutations in a fraction of families with Li-Fraumeni syndrome (LFS) has suggested the involvement of other genes, but this hypothesis remains controversial. The density of Alu repeats within the TP53 gene led us to search genomic rearrangements of TP53 in families without detectable TP53 mutation. To this aim, we adapted the quantitative multiplex PCR of short fluorescent fragments (QMPSF) method to the analysis of the 11 exons of TP53. We analysed 98 families, either fulfilling (six families) or partially meeting (92 families) the criteria for LFS, and in which classical methods had failed to reveal TP53 alterations. We identified, in a large family fulfilling the criteria for LITS, a complete heterozygous deletion of TP53. Additional QMPSF analyses indicated that this deletion, which partially removed the centromeric FLJ10385 locus, covered approximately 45 kb. This deletion was shown to result from a complex rearrangement involving two distinct Alu-mediated recombinations. We conclude that TP53 germline rearrangements occur as rare events, but must be considered in LFS families without detectable point TP53 mutation.	IFRMP, Fac Med, INSERM, EMI 9906, F-76183 Rouen, France; Inst Gustave Roussy, Dept Pediat, F-94805 Villejuif, France; Ctr Hosp, F-79021 Niort, France; CHU Rouen, Dept Genet, Rouen, France; Inst Gustave Roussy, Dept Cellular Genom Canc, F-94805 Villejuif, France; Inst Gustave Roussy, UMR 8125, F-94805 Villejuif, France; Inst Gustave Roussy, Dept Biol Clin, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; CHU de Rouen; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Frebourg, T (corresponding author), IFRMP, Fac Med, INSERM, EMI 9906, F-76183 Rouen, France.		Paillerets, Brigitte Bressac-de/D-8954-2018; Frebourg, Thierry/AAK-8390-2020; BOUGEARD, Gaëlle/ABI-6642-2020; Feunteun, Jean/AAZ-1267-2020	Paillerets, Brigitte Bressac-de/0000-0003-0245-8608; BOUGEARD, Gaëlle/0000-0002-1475-0254; CHARBONNIER, Francoise/0000-0002-4875-2506; Feunteun, Jean/0000-0003-1212-9189				Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; BELL DW, 2000, SCIENCE, V289, P359; BIRCH JM, 1994, BRIT J CANCER, V70, P1176, DOI 10.1038/bjc.1994.468; BIRCH JM, 1994, CANCER RES, V54, P1298; Bougeard G, 2001, J MED GENET, V38, P253, DOI 10.1136/jmg.38.4.253; Brown LTR, 2000, CANCER GENET CYTOGEN, V123, P65, DOI 10.1016/S0165-4608(00)00303-4; Burt EC, 1999, BRIT J CANCER, V80, P9, DOI 10.1038/sj.bjc.6690313; Charbonnier F, 2000, CANCER RES, V60, P2760; Charbonnier F, 2002, CANCER RES, V62, P848; Chompret A, 2002, BIOCHIMIE, V84, P75, DOI 10.1016/S0300-9084(01)01361-X; Chompret A, 2001, J MED GENET, V38, P43, DOI 10.1136/jmg.38.1.43; Eeles RA, 1995, CANCER SURV, V25, P101; LI FP, 1988, CANCER RES, V48, P5358; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Mighell AJ, 1997, FEBS LETT, V417, P1, DOI 10.1016/S0014-5793(97)01259-3; PLUMMER SJ, 1994, ONCOGENE, V9, P3273; Portwine C, 2000, J Med Genet, V37, pE13, DOI 10.1136/jmg.37.8.e13; Slebos RJC, 1998, CANCER RES, V58, P5333; Sodha N, 2000, Science, V289, P359; Stone JG, 1999, CANCER LETT, V147, P181, DOI 10.1016/S0304-3835(99)00291-8; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Vahteristo P, 2001, CANCER RES, V61, P5718; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328	23	47	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					840	846		10.1038/sj.onc.1206155	http://dx.doi.org/10.1038/sj.onc.1206155			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584563				2022-12-17	WOS:000180864300006
J	Le, XF; Hittelman, WN; Liu, JX; McWatters, A; Li, C; Mills, GB; Bast, RC				Le, XF; Hittelman, WN; Liu, JX; McWatters, A; Li, C; Mills, GB; Bast, RC			Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr(421) and Ser(424) via multiple signaling pathways in mitosis	ONCOGENE			English	Article						paclitaxel; p70S6K; phosphorylation; activation; mitosis	PROTEIN-KINASE; REGULATORY MECHANISM; GROWTH-REGULATION; MESSENGER-RNA; CELL-CYCLE; IN-VIVO; RAPAMYCIN; P70(S6K); ACTIVATION; INHIBITION	The 70kDa ribosomal S6 kinase (p70S6K) is important for cell growth and survival. Activation of p70S6K requires sequential phosphorylation of multiple serine and threonine sites often triggered by growth factors and hormones. Here, we report that paclitaxel, a microtubule-damaging agent, induces phosphorylation of p70S6K at threonine 421 and serine 424 (T421/S424) in a concentration-and time-dependent manner in multiple breast and ovarian cancer cell lines demonstrated by a T421/S424 phospho-p70S6K antibody. Phosphoamino-acid analysis and Western blot analysis by serine-/threonine-specific antibodies further confirms that both serine and threonine residues are phosphorytated in p70S6K following treatment with paclitaxel. Paclitaxel-induced p70S6K(T421/S424) phosphorylation requires both de novo RNA and protein synthesis via multiple signaling pathways including ERK1/2 MAP kinase, JNK, PKC, Ca++, PI3K, and mammalian target of rapamycin (mTOR). Despite phosphorylation of p70S6K, paclitaxel inactivates this kinase in a concentration- and time-dependent manner as illustrated by in vitro kinase assay. Inhibitors of mTOR, PI3K, and Ca++ impair p70S6K activity, whereas inhibitors of JNK and PKC stimulate p70S6K activity. Inhibition of PKC and JNK prevents paclitaxel-induced p70S6K inactivation. Moreover, the paclitaxel-induced phosphorylation and low activity of p70S6K mainly occurs during mitosis. In summary, paclitaxel is able to induce p70S6K(T421)/(S424) phosphorylation and decrease its activity in mitotic cells via multiple signaling pathways. Our data suggest that paclitaxel-induced p70S6K(T421)/S-424 phosphorylation and kinase inactivation are differentially regulated. Our data also indicate that paclitaxel may exert its antitumor effect, at least in part, via inhibition of p70S6K.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Bast, RC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Box 355, Houston, TX 77030 USA.		Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NATIONAL CANCER INSTITUTE [R01CA039930] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39930] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BOONSTRA J, 1981, J CELL PHYSIOL, V107, P75, DOI 10.1002/jcp.1041070110; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Grammer TC, 1996, CANCER SURV, V27, P271; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Le XF, 2001, ONCOGENE, V20, P8258, DOI 10.1038/sj.onc.1205039; Le XF, 1999, J BIOL CHEM, V274, P21651, DOI 10.1074/jbc.274.31.21651; Li C, 1998, CANCER RES, V58, P2404; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Nakamura M, 2001, CURR BIOL, V11, P1512, DOI 10.1016/S0960-9822(01)00456-0; PANDITA TK, 1994, CYTOGENET CELL GENET, V67, P94, DOI 10.1159/000133807; Papst PJ, 1998, J BIOL CHEM, V273, P15077, DOI 10.1074/jbc.273.24.15077; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; SOUZA CPE, 2000, CELL, V102, P293; TEMPLETON DJ, 2001, CURR BIOL, V8, P69; Thomas G, 2000, NAT CELL BIOL, V2, pE71, DOI 10.1038/35010581; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zhou XZ, 1999, CELL MOL LIFE SCI, V56, P788, DOI 10.1007/s000180050026	48	47	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					484	497		10.1038/sj.onc.1206175	http://dx.doi.org/10.1038/sj.onc.1206175			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555062				2022-12-17	WOS:000180538200002
J	Payton, M; Scully, S; Chung, G; Coats, S				Payton, M; Scully, S; Chung, G; Coats, S			Deregulation of Cyclin E2 expression and associated kinase activity in primary breast tumors	ONCOGENE			English	Article						Cyclin E2; Cyclin E1; Cdk2; breast tumor	CANCER; SURVIVAL; CDK2	The increased expression of G, cyclins has been associated with the many types of human tumors. In primary solid tumors however, the expression and activity of cyclin E2, the newest member of the G, cyclin family, is largely unknown. In this study we have analysed the expression of the E-type cyclins in primary solid tumors from breast, lung, uterus, ovary, colon, and rectal tissues. Relative gene expression was analysed by quantitative real-time reverse transcription polymerase chain reaction (Taqman). The levels of cyclin El and cyclin E2 were significantly elevated (23 vs 38%, respectively) in primary breast tumor samples relative to normal breast tissue controls. We also observed an inverse correlation between the expression of cyclin E1/E2 and estrogen receptor in breast tumors. Our results demonstrate that the expression and associated catalytic activity for both cyclin El and cyclin E2 is elevated in primary breast tumors when compared to normal breast tissue. The increased level of cyclin E2 in breast tumors suggests that, similar to cyclin El, it may contribute to the pathogenesis of breast cancer.	Amgen Inc, Dept Canc Biol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Pathol, Thousand Oaks, CA 91320 USA	Amgen; Amgen	Coats, S (corresponding author), Amgen Inc, Dept Canc Biol, 1 Amgen Ctr Dr,Mailstop 5-2A, Thousand Oaks, CA 91320 USA.							BORTNER DM, 1997, MOL CELL BIOL, V17, P435; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; Geng Y, 2001, P NATL ACAD SCI USA, V98, P13138, DOI 10.1073/pnas.231487798; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; Gudas JM, 1999, MOL CELL BIOL, V19, P612; KEYOMARSI K, 1994, CANCER RES, V54, P380; Loden M, 1999, ONCOGENE, V18, P2557, DOI 10.1038/sj.onc.1202488; Miracco C, 2000, INT J CANCER, V88, P411, DOI 10.1002/1097-0215(20001101)88:3<411::AID-IJC13>3.3.CO;2-G; Muller-Tidow C, 2001, CANCER RES, V61, P647; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Payton M, 2002, INT J BIOCHEM CELL B, V34, P315, DOI 10.1016/S1357-2725(01)00137-6; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Shaaban AM, 2002, AM J PATHOL, V160, P597, DOI 10.1016/S0002-9440(10)64879-1; Zariwala M, 1998, ONCOGENE, V17, P2787, DOI 10.1038/sj.onc.1202505	14	47	61	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8529	8534		10.1038/sj.onc.1206035	http://dx.doi.org/10.1038/sj.onc.1206035			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466974	Bronze			2022-12-17	WOS:000179480100017
J	Horie, K; Tomida, A; Sugimoto, Y; Yasugi, T; Yoshikawa, H; Taketani, Y; Tsuruo, T				Horie, K; Tomida, A; Sugimoto, Y; Yasugi, T; Yoshikawa, H; Taketani, Y; Tsuruo, T			SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin	ONCOGENE			English	Article						SUMO-1; topoisomerase I; camptothecin	UBIQUITIN-LIKE PROTEINS; COVALENT MODIFICATION; SUBCELLULAR-LOCALIZATION; MECHANISM; IDENTIFICATION; EXPRESSION; REPLICATION; INVOLVEMENT; SUMOYLATION; ACTIVATION	DNA topoisomerase I (Topo1) manages the topological state of DNA. Cleavable complexes, the covalent Topo1-DNA intermediates, become DNA damaged when the catalytic cycles are inhibited by the anti-tumor drug camptothecin (CPT). Intriguingly, Topo1 is modified rapidly and extensively with SUMO-1, a ubiquitin-like protein, in response to CPT. This study shows that the sumoylation enhances the cleavable complex formation and apoptosis induced by CPT. Indeed, substitutions of Lys117 and Lys153, identified as Topo1 sumoylation sites, reduced the CPT-induced cleavable complexes without influencing its in vitro catalytic activity. Consistent with this observation, CPT-induced cleavable complexes of wild-type Topo1 increased in a sumoylation-dependent manner. We also found that Topo1 sumoylation occurred independently of CPT when Topo1 was inactivated by mutation of the catalytic Tyr723. These findings suggested that Topo1 inactivation by CPT treatment can trigger Topo1 sumoylation, leading to enhanced cleavable complex formation.	Univ Tokyo, Inst Mol & Cellular Biosci, Lab Cell Growth & Regulat, Bunkyo Ku, Tokyo 1130032, Japan; Univ Tokyo, Fac Med, Dept Obstet & Gynecol, Bunkyo Ku, Tokyo 1130033, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan; Univ Tsukuba, Inst Clin Med, Dept Obstet & Gynecol, Tsukuba, Ibaraki 3058575, Japan	University of Tokyo; University of Tokyo; Japanese Foundation for Cancer Research; University of Tsukuba	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Cell Growth & Regulat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	ttsuruo@iam.u-tokyo.ac.jp						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BJORNSTI MA, 1989, CANCER RES, V49, P6318; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; DARPA P, 1990, CANCER RES, V50, P6919; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; Desai SD, 2001, CANCER RES, V61, P5926; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Duprez E, 1999, J CELL SCI, V112, P381; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Haas AL, 1997, FASEB J, V11, P1257; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; HOLM C, 1989, CANCER RES, V49, P6365; HSIANG YH, 1988, CANCER RES, V48, P1722; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Mashima T, 1999, ONCOGENE, V18, P2423, DOI 10.1038/sj.onc.1202558; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Mo YY, 2002, J BIOL CHEM, V277, P2958, DOI 10.1074/jbc.M108263200; Mo YY, 2000, J BIOL CHEM, V275, P41107, DOI 10.1074/jbc.M003135200; Mo YY, 2000, EXP CELL RES, V256, P480, DOI 10.1006/excr.2000.4864; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pommier Y, 1999, DRUG RESIST UPDATE, V2, P307, DOI 10.1054/drup.1999.0102; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; ROCA J, 1995, TRENDS BIOCHEM SCI, V20, P156, DOI 10.1016/S0968-0004(00)88993-8; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; SQUIRES S, 1993, CANCER RES, V53, P2012; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; Subramanian D, 2000, METH MOL B, V95, P137; SUBRAMANIAN D, 1995, CANCER RES, V55, P2097; Subramanian D, 1998, CANCER RES, V58, P976; SUBRAMANIAN D, 1995, ONCOL RES, V7, P461; SUGIMOTO Y, 1990, CANCER RES, V50, P6925; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	59	47	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2002	21	52					7913	7922		10.1038/sj.onc.1205917	http://dx.doi.org/10.1038/sj.onc.1205917			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439742				2022-12-17	WOS:000179097200001
J	Winey, M; Huneycutt, BJ				Winey, M; Huneycutt, BJ			Centrosomes and checkpoints: the MPS1 family of kinases	ONCOGENE			English	Review						MPS1 kinase; spindle pole body (SPB); centrosome; spindle assembly checkpoint	SPINDLE POLE BODY; DUPLICATION GENE MPS1; PROTEIN-KINASE; BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; MITOTIC CHECKPOINT; ASSEMBLY CHECKPOINT; COMPONENT SPC110P; MITOSIS; COMPLEX		Univ Colorado, MCD Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Winey, M (corresponding author), Univ Colorado, MCD Biol, 347 UCB, Boulder, CO 80309 USA.				NIGMS NIH HHS [GM51312] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051312] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Adams IR, 2000, TRENDS CELL BIOL, V10, P329, DOI 10.1016/S0962-8924(00)01798-0; Ball CA, 2000, NUCLEIC ACIDS RES, V28, P77, DOI 10.1093/nar/28.1.77; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; Brady DM, 2000, CURR BIOL, V10, P675, DOI 10.1016/S0960-9822(00)00515-7; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Castillo AR, 2002, J CELL BIOL, V156, P453, DOI 10.1083/jcb.200111025; Chial HJ, 1999, BIOL CELL, V91, P439, DOI 10.1016/S0248-4900(99)80085-9; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; DONALDSON A, 1995, J CELL BIOL, V132, P887; DOUVILLE EMJ, 1992, MOL CELL BIOL, V12, P2681, DOI 10.1128/MCB.12.6.2681; Fesquet D, 1999, EMBO J, V18, P2424, DOI 10.1093/emboj/18.9.2424; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Fraschini R, 2001, MOL GENET GENOMICS, V266, P115, DOI 10.1007/s004380100533; FRIEDMAN D, 1995, J CELL BIOL, V132, P903; Friedman DB, 2001, J BIOL CHEM, V276, P17958, DOI 10.1074/jbc.M010461200; Gillett ES, 2001, DEV CELL, V1, P162, DOI 10.1016/S1534-5807(01)00032-6; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; HE X, 1997, J CELL SCI, V111, P1635; HOGG D, 1994, ONCOGENE, V9, P89; Hoyt MA, 2000, CELL, V102, P267, DOI 10.1016/S0092-8674(00)00031-3; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jones MH, 2001, P NATL ACAD SCI USA, V98, P13675, DOI 10.1073/pnas.241417098; Jones MH, 1999, MOL BIOL CELL, V10, P2377, DOI 10.1091/mbc.10.7.2377; Knop M, 1997, EMBO J, V16, P6985, DOI 10.1093/emboj/16.23.6985; KRISAK L, 1994, GENE DEV, V8, P2151, DOI 10.1101/gad.8.18.2151; LAUZE E, 1995, EMBO J, V14, P1655, DOI 10.1002/j.1460-2075.1995.tb07154.x; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LINDBERG RA, 1993, ONCOGENE, V8, P351; Luca FC, 1998, MOL BIOL CELL, V9, P29, DOI 10.1091/mbc.9.1.29; Luca FC, 2001, MOL CELL BIOL, V21, P6972, DOI 10.1128/MCB.21.20.6972-6983.2001; Mah AS, 2001, P NATL ACAD SCI USA, V98, P7325, DOI 10.1073/pnas.141098998; Millband DN, 2002, MOL CELL BIOL, V22, P2728, DOI 10.1128/MCB.22.8.2728-2742.2002; MILLS GB, 1992, J BIOL CHEM, V267, P16000; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; O'Connell KF, 2001, CELL, V105, P547, DOI 10.1016/S0092-8674(01)00338-5; Pereira G, 1998, MOL BIOL CELL, V9, P775, DOI 10.1091/mbc.9.4.775; POCH O, 1994, MOL GEN GENET, V243, P641, DOI 10.1007/BF00279573; Schramm C, 2000, EMBO J, V19, P421, DOI 10.1093/emboj/19.3.421; Schutz AR, 1998, MOL BIOL CELL, V9, P759, DOI 10.1091/mbc.9.4.759; Schutz AR, 1997, J CELL BIOL, V136, P969, DOI 10.1083/jcb.136.5.969; Shonn MA, 2000, SCIENCE, V289, P300, DOI 10.1126/science.289.5477.300; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Straight PD, 2000, MOL BIOL CELL, V11, P3525, DOI 10.1091/mbc.11.10.3525; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Sundberg HA, 1997, MOL BIOL CELL, V8, P2575, DOI 10.1091/mbc.8.12.2575; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Wigge PA, 1998, J CELL BIOL, V141, P967, DOI 10.1083/jcb.141.4.967; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745; WINEY M, 1993, J CELL BIOL, V122, P743, DOI 10.1083/jcb.122.4.743; Zhu H, 2000, NAT GENET, V26, P283, DOI 10.1038/81576; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	53	47	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	2002	21	40					6161	6169		10.1038/sj.onc.1205712	http://dx.doi.org/10.1038/sj.onc.1205712			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214245				2022-12-17	WOS:000177840500004
J	Slater, DJ; Hilgenfeld, E; Rappaport, EF; Shah, N; Meek, RG; Williams, WR; Lovett, BD; Osheroff, N; Autar, RS; Ried, T; Felix, CA				Slater, DJ; Hilgenfeld, E; Rappaport, EF; Shah, N; Meek, RG; Williams, WR; Lovett, BD; Osheroff, N; Autar, RS; Ried, T; Felix, CA			MLL-SEPTIN6 fusion recurs in novel translocation of chromosomes 3, X, and 11 in infant acute myelomonocytic leukaemia and in t(X;11) in infant acute myeloid leukaemia, and MLL genomic breakpoint in complex MLL-SEPTIN6 rearrangement is a DNA topoisomerase II cleavage site	ONCOGENE			English	Article						MLL; SEPTIN6; complex translocation; infant leukaemia; spectral karyotype; DNA topoisomerase II	ACUTE LYMPHOBLASTIC-LEUKEMIA; PARTNER GENE; MYELODYSPLASTIC SYNDROME; DROSOPHILA-TRITHORAX; HUMAN HOMOLOG; FUSES MLL; 11Q23; AF-4; IDENTIFICATION; SEPTINS	We examined the MLL translocation in two cases of infant AML with X chromosome disruption. The G-banded karyotype in the first case suggested t(X;3)(q22;p21)ins(X;11)(q22;q13q25). Southern blot analysis showed one MLL rearrangement. Panhandle PCR approaches were used to identify the MLL fusion transcript and MLL genomic breakpoint junction. SEPTIN6 from chromosome band Xq24 was the partner gene of MLL. MLL exon 7 was joined in-frame to SEPTIN6 exon 2 in the fusion transcript. The MLL genomic breakpoint was in intron 7; the SEPTIN6 genomic breakpoint was in intron 1. Spectral karyotyping revealed a complex rearrangement disrupting band 11q23. FISH with a probe for MLL confirmed MLL involvement and showed that the MLL-SEPTIN6 junction was on the der(X). The MLL genomic breakpoint was a functional DNA topoisomerase 11 cleavage site in an in vitro assay. In the second case, the karyotype revealed t(X;11)(q22;q23). Southern blot analysis showed two MLL rearrangements. cDNA panhandle PCR detected a transcript fusing MLL exon 8 in-frame to SEPTIN6 exon 2. MLL and SEPTIN6 are vulnerable to damage to form recurrent translocations in infant AML. Identification of SEPTIN6 and the SEPTIN family members hCDCrel and MSF as partner genes of MLL suggests a common pathway to leukaemogenesis.	Childrens Hosp Philadelphia, Div Oncol, Abramson Res Ctr, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Sch Med, Philadelphia, PA 19104 USA; NCI, Div Genet, Bethesda, MD 20892 USA; Geisinger Med Ctr, Div Hematol Oncol, Dept Pediat, Danville, PA 17822 USA; Alfred I Dupont Inst, Dept Hematol Oncol, Dept Pediat, Wilmington, DE 19899 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Geisinger Medical Center; Nemours Alfred I. duPont Hospital for Children; Vanderbilt University	Felix, CA (corresponding author), Childrens Hosp Philadelphia, Div Oncol, Abramson Res Ctr, Rm 902B,3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	felix@email.chop.edu	Rappaport, Eric/GRO-4051-2022		NATIONAL CANCER INSTITUTE [R01CA080175, R01CA085469, R01CA077683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NCI NIH HHS [CA77683, CA85469, CA80175] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYTON PM, 2001, TRANSCRIPTION FACTOR; Beites CL, 2001, METHOD ENZYMOL, V329, P499; BERNARD OA, 1994, ONCOGENE, V9, P1039; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Borkhardt A, 2001, GENE CHROMOSOME CANC, V32, P82, DOI 10.1002/gcc.1169; Borkhardt A, 2000, P NATL ACAD SCI USA, V97, P9168, DOI 10.1073/pnas.150079597; CHAPLIN T, 1995, BLOOD, V86, P2073, DOI 10.1182/blood.V86.6.2073.bloodjournal8662073; Cooper JA, 1996, J CELL BIOL, V134, P1345, DOI 10.1083/jcb.134.6.1345; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Daheron L, 2001, GENE CHROMOSOME CANC, V31, P382, DOI 10.1002/gcc.1157; Eguchi M, 2001, GENE CHROMOSOME CANC, V32, P212, DOI 10.1002/gcc.1185; Felix CA, 1999, MOL DIAGN, V4, P269, DOI 10.1016/S1084-8592(99)80002-2; Felix CA, 1997, BLOOD, V90, P4679, DOI 10.1182/blood.V90.12.4679.4679_4679_4686; Felix CA, 1998, J PEDIAT HEMATOL ONC, V20, P299, DOI 10.1097/00043426-199807000-00004; FELIX CA, 2000, HEMATOLOGY 2000 ED P, P294; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; FORD AM, 1993, NATURE, V363, P358, DOI 10.1038/363358a0; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; Fuchs U, 2001, P NATL ACAD SCI USA, V98, P8756, DOI 10.1073/pnas.121433898; Gale KB, 1997, P NATL ACAD SCI USA, V94, P13950, DOI 10.1073/pnas.94.25.13950; Gillert E, 1999, ONCOGENE, V18, P4663, DOI 10.1038/sj.onc.1202842; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Harrison CJ, 1998, LEUKEMIA, V12, P811, DOI 10.1038/sj.leu.2401017; Hayette S, 2000, ONCOGENE, V19, P4446, DOI 10.1038/sj.onc.1203789; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; HURET JL, 2001, ATLAS GENET CYTOGENE; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Kartmann B, 2001, J CELL SCI, V114, P839; Kinoshita A, 2000, J COMP NEUROL, V428, P223, DOI 10.1002/1096-9861(20001211)428:2<223::AID-CNE3>3.0.CO;2-M; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lovett BD, 2001, P NATL ACAD SCI USA, V98, P9802, DOI 10.1073/pnas.171309898; Macville M, 1997, HISTOCHEM CELL BIOL, V108, P299, DOI 10.1007/s004180050169; MAHMOUD HH, 1995, MED PEDIATR ONCOL, V24, P77, DOI 10.1002/mpo.2950240203; Megonigal MD, 2000, P NATL ACAD SCI USA, V97, P9597, DOI 10.1073/pnas.150241797; Megonigal MD, 2000, P NATL ACAD SCI USA, V97, P2814, DOI 10.1073/pnas.050397097; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; Mitelman F., 1995, ISCN INT SYSTEM HUMA; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Nakata Y, 1999, LEUKEMIA RES, V23, P85, DOI 10.1016/S0145-2126(98)00131-3; Nilson I, 1997, BRIT J HAEMATOL, V98, P157, DOI 10.1046/j.1365-2141.1997.1522966.x; Ono R, 2002, CANCER RES, V62, P333; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Pegram LD, 2000, BLOOD, V96, P4360; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; PRASAD R, 1993, CANCER RES, V53, P5624; Ross JA, 1996, CANCER CAUSE CONTROL, V7, P581, DOI 10.1007/BF00051700; Ross JA, 1998, INT J CANCER, V78, P26; Roulston Diane, 1997, P325; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Russell SEH, 2000, CANCER RES, V60, P4729; Sano K, 2000, BLOOD, V95, P1066, DOI 10.1182/blood.V95.3.1066.003k11_1066_1068; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Smith MA, 1999, J CLIN ONCOL, V17, P569, DOI 10.1200/JCO.1999.17.2.569; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Super HG, 1997, GENE CHROMOSOME CANC, V20, P185, DOI 10.1002/(SICI)1098-2264(199710)20:2<185::AID-GCC9>3.0.CO;2-#; SUPER HJG, 1994, BLOOD, V83, P641; Taki T, 1999, P NATL ACAD SCI USA, V96, P14535, DOI 10.1073/pnas.96.25.14535; Taki T, 1999, CANCER RES, V59, P4261; Taki T, 1996, ONCOGENE, V13, P2121; Taki T, 1998, BLOOD, V92, P1125, DOI 10.1182/blood.V92.4.1125.416k40_1125_1130; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Tatsumi K, 2001, GENE CHROMOSOME CANC, V30, P230, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1084>3.0.CO;2-J; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSE W, 1995, BLOOD, V85, P650, DOI 10.1182/blood.V85.3.650.bloodjournal853650; Woods WG, 1996, BLOOD, V87, P4979, DOI 10.1182/blood.V87.12.4979.bloodjournal87124979	72	47	49	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2002	21	30					4706	4714		10.1038/sj.onc.1205572	http://dx.doi.org/10.1038/sj.onc.1205572			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096348				2022-12-17	WOS:000176625100013
J	Noujaim, D; van Golen, CM; van Golen, KL; Grauman, A; Feldman, EL				Noujaim, D; van Golen, CM; van Golen, KL; Grauman, A; Feldman, EL			N-Myc and Bcl-2 coexpression induces MMP-2 secretion and activation in human neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; N-Myc; Bcl-2; MMP; invasion; tumorigenesis	MATRIX-METALLOPROTEINASE INHIBITORS; AMYOTROPHIC-LATERAL-SCLEROSIS; SIGNAL-REGULATED KINASE; GROWTH-FACTOR RECEPTOR; MATRIX-METALLOPROTEINASE-9 EXPRESSION; IV COLLAGENASE; TUMOR-CELLS; BREAST-CANCER; IGF-I; INVASION	Neuroblastoma is a peripheral nervous system tumor that accounts for 8-10% of all solid childhood tumors. N-Myc is the most reliable prognostic indicator for neuroblastoma. Bcl-2 is detected in 40-60% of primary neuroblastoma tumors and demonstrates anti-apoptotic action by conferring resistance to chemotherapy and radiation treatment. In neuroblastoma cell lines, the coexpression of N-Myc and Bcl-2 leads to increased tumorigenic properties. Matrix metalloproteinases (MMPs) are endopeptidases that degrade a wide range of basement membrane components, a process important for tumor invasion. This study investigates the effect of N-Myc and Bcl-2 on MMP expression and activation. MMP-2 expression and secretion are increased in SHEP neuroblastoma cells expressing Bcl-2 alone (SHEP/Bcl-2 cells) or both N-Myc and Bcl-2 (SHEP/N-Myc/Bcl-2 cells). MMP-2 activity is increased in the SHEP/N-Myc/Bcl-2 cells yet remains unchanged in SHEP/Bcl-2 cells. TIMP-2 expression is high in SHEP/Bcl-2 cells, which likely inhibits MMP-2 activity, and absent in SHEP/N-Myc/Bcl-2 cells, allowing MMP-2 activity. Invasion is increased in SHEP/N-Myc/Bcl-2 cells and prevented by the use of a pharmacologic MMP-2 inhibitor. These data imply that N-Myc and Bcl-2 cooperate to increase the expression, secretion, and activation of MMP-2, which likely leads to a more tumorigenic phenotype due to increased MMP-2 mediated invasion.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol, 4414 Kresge 3,200 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	efeldman@umich.edu		Feldman, Eva/0000-0002-9162-2694	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007222, R01NS036778] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS36778, T32 NS07222] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ara T, 1998, J PEDIATR SURG, V33, P1272, DOI 10.1016/S0022-3468(98)90167-1; Ara T, 2000, J PEDIATR SURG, V35, P432, DOI 10.1016/S0022-3468(00)90208-2; Barille S, 1999, J IMMUNOL, V163, P5723; Beuche W, 2000, NEUROREPORT, V11, P3419, DOI 10.1097/00001756-200011090-00003; BIEDLER JL, 1988, ADV NEUROBLASTOMA RE, V2, P265; Bjornland K, 2001, J PEDIATR SURG, V36, P1040, DOI 10.1053/jpsu.2001.24735; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Butler AA, 1998, CANCER RES, V58, P3021; Castleberry RP, 1997, PEDIATR CLIN N AM, V44, P919, DOI 10.1016/S0031-3955(05)70537-X; Chambaut-Guerin AM, 2000, J NEUROCHEM, V74, P508, DOI 10.1046/j.1471-4159.2000.740508.x; Chen WT, 1999, ANN NY ACAD SCI, V878, P361, DOI 10.1111/j.1749-6632.1999.tb07695.x; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; Cianfarani S, 1997, EUR J PEDIATR, V156, P256, DOI 10.1007/s004310050595; Corvi R, 1997, J NEURO-ONCOL, V31, P25, DOI 10.1023/A:1005721027709; Crowe DL, 2001, NEOPLASIA, V3, P27, DOI 10.1038/sj.neo.7900135; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; DEVEAS RG, 1995, J CANCER RES CLIN, V121, P275, DOI 10.1007/BF01209593; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; Easton RM, 1998, MOL CELL NEUROSCI, V11, P334, DOI 10.1006/mcne.1998.0690; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Elliott S, 2001, DRUG AGING, V18, P87, DOI 10.2165/00002512-200118020-00002; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; George SJ, 2000, EXPERT OPIN INV DRUG, V9, P993, DOI 10.1517/13543784.9.5.993; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jasty R, 2001, NEOPLASIA, V3, P304, DOI 10.1038/sj.neo.7900171; Kahari VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260; Kanayama Hiro-omi, 2001, Journal of Medical Investigation, V48, P31; Kelly T, 2000, LEUKEMIA LYMPHOMA, V37, P273, DOI 10.3109/10428190009089428; Khasigov PZ, 2001, BIOCHEMISTRY-MOSCOW+, V66, P130, DOI 10.1023/A:1002879128392; Kurata H, 2000, EXP CELL RES, V254, P180, DOI 10.1006/excr.1999.4738; Lakka SS, 2000, CLIN EXP METASTAS, V18, P245, DOI 10.1023/A:1006724826083; Leventhal Phillip S., 1999, V17, P425; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; LEVENTHAL PS, 1995, EXP CELL RES, V221, P179, DOI 10.1006/excr.1995.1365; Lim GP, 1996, J NEUROCHEM, V67, P251; Long L, 1998, CANCER RES, V58, P3243; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; McLennan SV, 2000, KIDNEY INT, V58, pS81, DOI 10.1046/j.1523-1755.2000.07713.x; Mitsiades N, 2001, CANCER RES, V61, P577; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Nagase H, 1998, Cell Res, V8, P179; PHILIP T, 1992, AM J PEDIAT HEMATOL, V14, P97; Ravanti L, 2000, INT J MOL MED, V6, P391; Ribatti D, 1998, INT J CANCER, V77, P449; Ribatti D, 2001, LIFE SCI, V68, P1161, DOI 10.1016/S0024-3205(00)01030-4; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P; Singleton JR, 1996, CANCER RES, V56, P4522; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Sugiura T, 1999, J CELL BIOL, V146, P1375, DOI 10.1083/jcb.146.6.1375; Sugiura Y, 1998, CANCER RES, V58, P2209; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; Taguchi K, 1997, JPN J CANCER RES, V88, P394, DOI 10.1111/j.1349-7006.1997.tb00395.x; Thant AA, 2001, CLIN EXP METASTAS, V18, P423, DOI 10.1023/A:1010921730952; van Golen CM, 2000, CELL DEATH DIFFER, V7, P654, DOI 10.1038/sj.cdd.4400693; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Yu AE, 1996, BIOCHEM CELL BIOL, V74, P823, DOI 10.1139/o96-088; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	62	47	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4549	4557		10.1038/sj.onc.1205552	http://dx.doi.org/10.1038/sj.onc.1205552			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085233				2022-12-17	WOS:000176476700009
J	Yakicier, MC; Legoix, P; Vaury, C; Gressin, L; Tubacher, E; Capron, F; Bayer, J; Degott, C; Balabaud, C; Zucman-rossi, J				Yakicier, MC; Legoix, P; Vaury, C; Gressin, L; Tubacher, E; Capron, F; Bayer, J; Degott, C; Balabaud, C; Zucman-rossi, J			Identification of homozygous deletions at chromosome 16q23 in Aflatoxin B1 exposed hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; loss of heterozygosity; tumor suppressor gene; chromosome 16; homozygous deletion; WWOX/FOR gene	FRAGILE SITE FRA16D; BETA-CATENIN GENE; P53 GENE; MULTIPLE-MYELOMA; BREAST-CANCER; REGION; HETEROZYGOSITY; MUTATIONS; FREQUENT; CELLS	Loss of heterozygosity (LOH) represents the most frequent genetic alteration observed in hepatocellular carcinoma (HCC). Chromosome 16q is of particular interest as it exhibits LOH in 29% of HCC tumors and is frequently lost in breast, prostate, ovarian and gastric carcinomas. We genotyped 157 HCC tumors for 17 microsatellite markers distributed on chromosome 16q and determined a common region of LOH localized between the markers D16S518 and D16S504. By refining the boundaries of two interstitial LOH and two homozygous deletions, the critical region was delimited to 180 kb between D16S3096 and D16S3029. This region is located in intron 8 of the WWOX/FOR gene, but a search for mutations in all coding exons of this gene in 27 HCC tumors and cell lines did not reveal any tumor somatic alterations. Furthermore, by RT-PCR, no abnormal transcripts of this WWOX/FOR gene was detected in nine HCC cell lines. Finally, analysis of the p53 gene mutations with the clinical parameters of all tumors revealed that the two homozygous deletions have occurred in tumors presenting a R249S mutation. Our data revealed a relationship between chromosome 16q homozygous deletions and R249S p53 mutations in tumors where the patient had been exposed to Aflatoxin B1 (P = 0.002). These results are consistent with a role of Aflatoxin B1 in the instability of chromosome 16q at the fragile site FRA16D. However, the nature of the specific gene that is altered during hepato carcino genesis remains to be elucidated.	INSERM, U434, F-75010 Paris, France; Hop Antoine Beclere, Serv Anat Pathol, F-92140 Clamart, France; Hop Beaujon, F-92110 Clichy, France; Hop St Andre, F-33000 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Bordeaux	Zucman-rossi, J (corresponding author), INSERM, U434, CEPH 27 Rue Juliette Dodu, F-75010 Paris, France.		zucman-rossi, Jessica/B-5098-2009; j, zucman-rossi/AAV-3594-2021	zucman-rossi, Jessica/0000-0002-5687-0334; j, zucman-rossi/0000-0002-5687-0334				Autrup H., 1988, IARC SCI PUBL, V89, P63; Bando K, 2000, GENE CHROMOSOME CANC, V28, P38, DOI 10.1002/(SICI)1098-2264(200005)28:1<38::AID-GCC5>3.0.CO;2-A; Bednarek AK, 2000, CANCER RES, V60, P2140; Bluteau O, 1999, GASTROEN CLIN BIOL, V23, P1225; Boige V, 1997, CANCER RES, V57, P1986; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; Chen TP, 1996, CANCER RES, V56, P5605; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; Chou YHW, 1998, CANCER LETT, V123, P1, DOI 10.1016/S0304-3835(97)00276-0; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Driouch K, 1997, GENE CHROMOSOME CANC, V19, P185, DOI 10.1002/(SICI)1098-2264(199707)19:3<185::AID-GCC8>3.0.CO;2-U; ECKL PM, 1987, CARCINOGENESIS, V8, P1077, DOI 10.1093/carcin/8.8.1077; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; ELZAWAHRI M, 1977, ANN NUTR ALIMENT, V31, P859; FABRY L, 1981, TOXICOL LETT, V7, P245, DOI 10.1016/0378-4274(81)90076-X; *FAO, 1991, FAO PAHO, P3; Feo F, 2000, CRIT REV ONCOGENESIS, V11, P19; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; IWABUCHI H, 1995, CANCER RES, V55, P6172; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Latil A, 1997, CANCER RES, V57, P1058; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.3.CO;2-N; Marchio AS, 2000, ONCOGENE, V19, P3733, DOI 10.1038/sj.onc.1203713; Miyoshi Y, 1998, CANCER RES, V58, P2524; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; ODA T, 1992, CANCER RES, V52, P6358; Okabe H, 2000, HEPATOLOGY, V31, P1073, DOI 10.1053/he.2000.6409; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; Paige AJW, 2000, CANCER RES, V60, P1690; Piao Z, 1999, BRIT J CANCER, V80, P850, DOI 10.1038/sj.bjc.6690431; Preisler V, 2000, MUTAGENESIS, V15, P91, DOI 10.1093/mutage/15.1.91; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sengstag C, 1996, CANCER RES, V56, P5457; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; Wong N, 2000, CLIN CANCER RES, V6, P4000; Zucman-Rossi J, 1996, GENOMICS, V38, P247, DOI 10.1006/geno.1996.0625	41	47	56	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5232	5238		10.1038/sj.onc.1204674	http://dx.doi.org/10.1038/sj.onc.1204674			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526514				2022-12-17	WOS:000170464000019
J	Glaser, T; Wagenknecht, B; Weller, M				Glaser, T; Wagenknecht, B; Weller, M			Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells	ONCOGENE			English	Article						glioma; apoptosis; p21; CD95; cytochrome c	CYTOCHROME-C RELEASE; 3/P21 COMPLEX-FORMATION; DEATH RECEPTORS; CASPASE CASCADE; ACTIVATION; PROTEIN; CLEAVAGE; MITOCHONDRIA; INHIBITOR; BCL-2	Human glioma cell lines differ in their requirement for the inhibition of protein synthesis to activate the CD95-dependent killing pathway. CD95 ligand (CD95L) induced mitochondrial cytochrome c release and processing of caspases 3, 7, 8 and 9 in LN-18 cells in the absence of an inhibitor of protein synthesis, cycloheximide (CHX). These biochemical changes were observed in LN-229 cells only in the presence of CHX. The viral caspase inhibitor, cytokine response modifier (crm)-A, inhibited mitochondrial cytochrome c release, caspase processing and cell death under all conditions. Ectopic expression of BCL-X-L prevented processing of caspase 8 in LN-18 cells but not in LN-229 cells. Thus, caspase 8 activation is amplified through the release of cytochrome c in LN-18 cells but occurs mainly at the receptor in LN-229 cells. In contrast to BCL-2, BCL-X-L, X-linked inhibitor-of-apoptosis protein (XIAP) and FLICE-inhibitory protein (FLIP), the levels of the cyclin-dependent kinase (CDK) inhibitor, p21(Waf/Cip1), rapidly decreased in response to CHX. P21 antisense oligonucleotides promoted caspase activation and mitochondrial cytochrome c release and induced strong sensitization to CD95-mediated apoptosis. These data place potentiating effects of CHX (i) to the activation of caspase 8 at the receptor in LN-229 cells as well as (ii) to a down-stream target at least in LN-18 cells, but probably both cell lines, that may be identical with p21(Waf/Cip1).	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.			Weller, Michael/0000-0002-1748-174X				Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; Fulda S, 2000, CANCER RES, V60, P3947; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Glaser T, 1999, ONCOGENE, V18, P5044, DOI 10.1038/sj.onc.1202882; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Granville DJ, 1999, AM J PATHOL, V155, P1021, DOI 10.1016/S0002-9440(10)65202-9; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hueber A, 1998, FEBS LETT, V432, P155, DOI 10.1016/S0014-5793(98)00855-2; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kondo S, 1998, ONCOGENE, V17, P2585, DOI 10.1038/sj.onc.1202194; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Leverkus M, 2000, CANCER RES, V60, P553; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Naumann U, 1998, ONCOGENE, V17, P1567, DOI 10.1038/sj.onc.1202071; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432-1327.1998.2570242.x; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Ruan S, 1998, CANCER RES, V58, P1538; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Suzuki A, 2000, CELL DEATH DIFFER, V7, P721, DOI 10.1038/sj.cdd.4400706; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; Wagenknecht B, 1998, CELL DEATH DIFFER, V5, P894, DOI 10.1038/sj.cdd.4400435; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang ZL, 1999, CANCER RES, V59, P1259; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Weller M, 1998, INT J CANCER, V79, P640; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; WELLER M, 1995, CANCER RES, V55, P2963; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang YK, 1999, INT J CANCER, V83, P790, DOI 10.1002/(SICI)1097-0215(19991210)83:6<790::AID-IJC15>3.0.CO;2-6; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	59	47	47	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4757	4767		10.1038/sj.onc.1204498	http://dx.doi.org/10.1038/sj.onc.1204498			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521188				2022-12-17	WOS:000170271800001
J	Furukawa, T; Adachi, Y; Fujisawa, J; Kambe, T; Yamaguchi-Iwai, Y; Sasaki, R; Kuwahara, J; Ikehara, S; Tokunaga, R; Taketani, S				Furukawa, T; Adachi, Y; Fujisawa, J; Kambe, T; Yamaguchi-Iwai, Y; Sasaki, R; Kuwahara, J; Ikehara, S; Tokunaga, R; Taketani, S			Involvement of PLAGL2 in activation of iron deficient- and hypoxia-induced gene expression in mouse cell lines	ONCOGENE			English	Article						PLAGL; PLAG; iron; hypoxia; HIF-1	ZINC-FINGER PROTEIN; LACTATE-DEHYDROGENASE-A; INDUCIBLE FACTOR-1; TRANSCRIPTIONAL ACTIVATION; PLEOMORPHIC ADENOMAS; ERYTHROPOIETIN GENE; BINDING-PROTEIN; IDENTIFICATION; ZAC1; DEFEROXAMINE	We searched iron-deficient inducible cDNA, using subtraction cloning and mRNA from desferrioxamine-treated mouse macrophage Raw264.7 cells. We identified a pleomorphic adenoma gene like 2 (PLAGL2), one of PLAG superfamily proteins exhibiting antiproliferative properties on tumor cells. Mouse PLAGL2 consists of 496 amino acids with seven C2H2 zinc-fingers. PLAGL2 mRNA was induced in RAW264.7 cells, mouse erythroleukemia cells and Balb/c 3T3 cells when they were treated with desferrioxamine. Hypoxia also increased PLAGL2 mRNA. Expression of PLAGL2 in COS-7 cells led to nuclear localization. PLAGL2 had potential binding ability to GC-rich oligonucleotide and activated transcription of a gene with the binding sequence in transient reporter assay, a finding consistent with a case seen in a PLAGL2 homolog, ZAC-1. Transient co-transfection of PLAGL2 or ZAC1 cDNA and a reporter containing a lactate dehydrogenase A (LDHA) promoter carrying the hypoxia inducible factor-1 responsive element led to an increase in the basal transcription in Balb/c 3T3 and HepG2 cells. Activation in transcription from the LDHA promoter increased by desferrioxamine treatment or hypoxia was further enhanced when PLAGL2 was expressed. We propose that PLAGL2 is involved in the cell cycle arrest and apoptosis of tumor cells by regulating iron depletion- or hypoxia-inducible gene expression.	Kansai Med Univ, Dept Hyg, Moriguchi, Osaka 5708506, Japan; Kansai Med Univ, Dept Microbiol, Moriguchi, Osaka 5708506, Japan; Kansai Med Univ, Dept Pathol 1, Moriguchi, Osaka 5708506, Japan; Kyoto Univ, Dept Life Sci, Kyoto 60601, Japan; Univ Tokushima, Fac Pharmaceut Sci, Inst Med Resources, Tokushima 7708505, Japan; Kyoto Inst Technol, Dept Biotechnol, Kyoto 6068585, Japan	Kansai Medical University; Kansai Medical University; Kansai Medical University; Kyoto University; Tokushima University; Kyoto Institute of Technology	Furukawa, T (corresponding author), Kansai Med Univ, Dept Hyg, Moriguchi, Osaka 5708506, Japan.	furukawa@takii.kmu.ac.jp						Abdollahi A, 1997, CANCER RES, V57, P2029; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Kadota Y, 1997, MOL BRAIN RES, V46, P265, DOI 10.1016/S0169-328X(97)00023-5; Kambe T, 1998, BLOOD, V91, P1185, DOI 10.1182/blood.V91.4.1185; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Kas K, 1997, GENOMICS, V43, P349, DOI 10.1006/geno.1997.4819; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Mohri T, 1999, EXP CELL RES, V253, P533, DOI 10.1006/excr.1999.4720; NOCKA KH, 1988, CANCER RES, V48, P3571; Piras G, 2000, MOL CELL BIOL, V20, P3308, DOI 10.1128/MCB.20.9.3308-3315.2000; QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106; SELF AJ, 1995, METHOD ENZYMOL, V258, P3; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Taketani S, 1998, J BIOL CHEM, V273, P31388, DOI 10.1074/jbc.273.47.31388; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; Voz ML, 1998, ONCOGENE, V16, P1409, DOI 10.1038/sj.onc.1201660; Wang F, 1999, ANTICANCER RES, V19, P445; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Ye Z, 1999, BIOCHEM BIOPH RES CO, V264, P709, DOI 10.1006/bbrc.1999.1554; Zhang YM, 1997, GENE CHROMOSOME CANC, V18, P310, DOI 10.1002/(SICI)1098-2264(199704)18:4<310::AID-GCC10>3.0.CO;2-K	34	47	51	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4718	4727		10.1038/sj.onc.1204647	http://dx.doi.org/10.1038/sj.onc.1204647			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498794				2022-12-17	WOS:000170208600012
J	Del Bello, B; Valentini, MA; Zunino, F; Comporti, M; Maellaro, E				Del Bello, B; Valentini, MA; Zunino, F; Comporti, M; Maellaro, E			Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells	ONCOGENE			English	Article						Bcl-2 cleavage; hydrogen peroxide; cisplatin; apoptosis; melanoma cells	MALIGNANT-MELANOMA; PROTEIN EXPRESSION; DEATH; INHIBITION; RELEASE; FAMILY; BAX	Although the anti-apoptotic effect of Bcl-2 is well established, the role of Bcl-2 in tumour response to therapy and drug resistance is still unclear. The posttranslational modifications of Bcl-2 are likely involved in the control of the apoptotic pathway. In the present study we have investigated the role of Bcl-2 in cellular response to oxidative stress (hydrogen peroxide) and cisplatin using a clone of human metastatic melanoma, which, in spite of Bcl-2 (over)expression, exhibited a moderate chemosensitivity. With both treatments melanoma cells died through an apoptotic process, associated with detachment of cells from the monolayer. In the floating apoptotic cells generated by either hydrogen peroxide or cisplatin, along with morphological and biochemical features of apoptosis, we detected a significant Bcl-2 cleavage, yielding the Bax-like fragment of 23 kDa. Preincubation of cells with the caspase-3/-7 inhibitor DEVD-CHO completely suppressed Bcl-2 cleavage, thus confirming that such a specific proteolysis requires activation of caspase-3/-7. The oxidant- and cisplatin-induced processing of Bcl-2 documented in the present study may represent a regulatory mechanism to circumvent the survival function of Bcl-2 upon apoptosis triggering and to enhance apoptotic response. Since the Bcl-2 cleavage should be regarded as a pro-apoptotic event, Bcl-2 expression is expected to increase susceptibility to apoptosis. Thus, such a pathway could be exploited to improve the efficacy of cytotoxic therapy of melanomas expressing Bcl-2.	Univ Siena, Dept Pathophysiol & Expt Med, I-53100 Siena, Italy; Ist Nazl Tumori, I-20133 Milan, Italy	University of Siena; Fondazione IRCCS Istituto Nazionale Tumori Milan	Maellaro, E (corresponding author), Univ Siena, Dept Pathophysiol & Expt Med, Via A Moro, I-53100 Siena, Italy.	maellaro@unisi.it						Beale PJ, 2000, BRIT J CANCER, V82, P436; Brockhaus F, 1998, EXP CELL RES, V238, P33, DOI 10.1006/excr.1997.3778; CERRONI L, 1995, AM J DERMATOPATH, V17, P7, DOI 10.1097/00000372-199502000-00002; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHU G, 1994, J BIOL CHEM, V269, P787; Del Bello B, 1999, FASEB J, V13, P69; Fadeel B, 1999, LEUKEMIA, V13, P719, DOI 10.1038/sj.leu.2401411; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Hirotani M, 1999, J BIOL CHEM, V274, P20415, DOI 10.1074/jbc.274.29.20415; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Maellaro E, 2000, J CELL SCI, V113, P2671; Marin MC, 1996, ONCOGENE, V12, P2259; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Reed JC, 1997, APOPTOSIS AND CANCER, P64; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Rigel DS, 1996, J AM ACAD DERMATOL, V35, P1012, DOI 10.1016/S0190-9622(96)90139-5; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; Serrone L, 1999, MELANOMA RES, V9, P51, DOI 10.1097/00008390-199902000-00007; Tang LR, 1998, CLIN CANCER RES, V4, P1865; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRON VA, 1995, AM J PATHOL, V146, P643; VANDENOORD JJ, 1994, AM J PATHOL, V145, P294; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; Yamamoto AM, 1998, LEUKEMIA, V12, P1467, DOI 10.1038/sj.leu.2401132; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386	32	47	49	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4591	4595		10.1038/sj.onc.1204618	http://dx.doi.org/10.1038/sj.onc.1204618			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494156				2022-12-17	WOS:000170074900018
J	Obexer, P; Certa, U; Kofler, R; Helmberg, A				Obexer, P; Certa, U; Kofler, R; Helmberg, A			Expression profiling of glucocorticoid-treated T-ALL cell lines: rapid repression of multiple genes involved in RNA-, protein- and nucleotide synthesis	ONCOGENE			English	Article						chemotherapy; gene chip; glucocorticoid; leukemia; pathophysiology	SPINAL MUSCULAR-ATROPHY; RECEPTOR MESSENGER-RNA; KAPPA-B ACTIVITY; INDUCED APOPTOSIS; TRANSCRIPTIONAL ACTIVATION; FK506-BINDING IMMUNOPHILIN; REGULATED APOPTOSIS; DOWN-REGULATION; COMPLETE CDNA; DNA-BINDING	To arrive at a better understanding of the effects of the glucocorticoid component of chemotherapy protocols on lymphocytic leukemia cells, we analysed early responses of T-lymphocytic leukemia cell lines Jurkat and CEM-C7, both of which undergo apoptosis in response to dexamethasone, via gene chips. Among genes identified as repressed, a notable cluster seemed to be of importance for the processes of transcription, mRNA splicing and protein synthesis. Consequently, we assessed time-resolved uptake of uridine and methionine to monitor RNA and protein synthesis, along with parameters quantifying apoptosis, Repression of uptake to about 65% of that in untreated cells preceded the first sign of apoptosis by several hours in both cell lines, In addition to this general repression of RNA and protein synthesis, several genes were found to be regulated that may contribute to synergistic action of glucocorticoids with other components of frequently used chemotherapy protocols such as antimetabolites, methotrexate and alkylating agents.	Univ Innsbruck, Sch Med, Inst Pathophysiol, A-6020 Innsbruck, Austria; F Hoffmann La Roche & Co Ltd, Roche Genet, CH-4070 Basel, Switzerland	University of Innsbruck; Roche Holding	Helmberg, A (corresponding author), Univ Innsbruck, Sch Med, Inst Pathophysiol, A-6020 Innsbruck, Austria.	arno.helmberg@uibk.ac.at						ALBERS MW, 1993, ANN NY ACAD SCI, V696, P54; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Altmeyer A, 1997, IMMUNITY, V7, P667, DOI 10.1016/S1074-7613(00)80387-8; ANTAKLY T, 1989, CANCER RES, V49, pS2230; ASHRAF J, 1991, J STEROID BIOCHEM, V38, P561, DOI 10.1016/0960-0760(91)90313-T; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baxter J D, 2000, Adv Intern Med, V45, P317; BAXTER JD, 1971, SCIENCE, V171, P189, DOI 10.1126/science.171.3967.189; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BURNSTEIN KL, 1994, MOL ENDOCRINOL, V8, P1764, DOI 10.1210/me.8.12.1764; CARONLESLIE LAM, 1994, FASEB J, V8, P639, DOI 10.1096/fasebj.8.9.8005391; Chabncr BA, 1996, PHARMACOL BASIS THER, P1233; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; CHAUDHARY N, 1991, P NATL ACAD SCI USA, V88, P8189, DOI 10.1073/pnas.88.18.8189; CHEN MJ, 1984, J BIOL CHEM, V259, P3933; Chen QF, 1998, GENOMICS, V48, P121, DOI 10.1006/geno.1997.5141; CRUZEN ME, 1994, DNA SEQUENCE, V4, P243, DOI 10.3109/10425179409020847; DAYAN A, 1995, GENE, V165, P307, DOI 10.1016/0378-1119(95)00321-V; DENTON RR, 1993, ENDOCRINOLOGY, V133, P248, DOI 10.1210/en.133.1.248; EISEN LP, 1988, J BIOL CHEM, V263, P12044; ELISEI R, 1993, J ENDOCRINOL INVEST, V16, P533, DOI 10.1007/BF03348900; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; FOLEY GE, 1967, BIOCHEM PHARMACOL, V16, P659, DOI 10.1016/0006-2952(67)90078-0; Geley S, 1996, REV PHYSIOL BIOCH P, V128, P1; Geley S, 1996, CANCER RES, V56, P5033; GIPP JJ, 1995, BIOCHEM BIOPH RES CO, V206, P584, DOI 10.1006/bbrc.1995.1083; Godowski P.J., 1989, UCLA S MOL CELLULAR, P197; GOMI M, 1990, CANCER RES, V50, P1873; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; Hartmann BL, 1999, ONCOGENE, V18, P713, DOI 10.1038/sj.onc.1202339; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; HELMBERG A, 1990, J IMMUNOL, V145, P4332; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HONORE B, 1995, J BIOL CHEM, V270, P28780; HORTSCH M, 1988, NUCLEIC ACIDS RES, V16, P361, DOI 10.1093/nar/16.1.361; HSIEH SL, 1991, BIOCHEM J, V278, P809, DOI 10.1042/bj2780809; HUANG SH, 1994, DNA CELL BIOL, V13, P461, DOI 10.1089/dna.1994.13.461; Iwahana H, 1996, BIOCHEM BIOPH RES CO, V219, P249, DOI 10.1006/bbrc.1996.0213; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Lipsitt DR, 1999, GEN HOSP PSYCHIAT, V21, P1; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MITA K, 1995, GENE, V159, P285, DOI 10.1016/0378-1119(95)00081-G; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; Ramdas J, 1999, CANCER RES, V59, P1378; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Reichardt HM, 1998, MOL CELL ENDOCRINOL, V146, P1, DOI 10.1016/S0303-7207(98)00208-1; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHIMMER BP, 1996, PHARMACOL BASIS THER, P1465; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; SEELIG HP, 1995, ARTHRITIS RHEUM-US, V38, P1389, DOI 10.1002/art.1780381006; SIBLEY CH, 1974, CELL, V2, P213, DOI 10.1016/0092-8674(74)90013-0; SILLEKENS PTG, 1988, NUCLEIC ACIDS RES, V16, P8307, DOI 10.1093/nar/16.17.8307; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; Thompson EB, 1999, TRENDS ENDOCRIN MET, V10, P353, DOI 10.1016/S1043-2760(99)00187-3; THULASI R, 1993, J BIOL CHEM, V268, P18306; Tonko M, 2001, FASEB J, V15, P693, DOI 10.1096/fj.00-0327com; TSUI FWL, 1987, NUCLEIC ACIDS RES, V15, P3349, DOI 10.1093/nar/15.8.3349; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Webster JC, 1999, TRENDS ENDOCRIN MET, V10, P396, DOI 10.1016/S1043-2760(99)00186-1; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; Yoon JB, 1996, MOL CELL BIOL, V16, P1; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	74	47	48	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4324	4336		10.1038/sj.onc.1204573	http://dx.doi.org/10.1038/sj.onc.1204573			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466613				2022-12-17	WOS:000169912600006
J	Wallace, M; Coates, PJ; Wright, EG; Ball, KL				Wallace, M; Coates, PJ; Wright, EG; Ball, KL			Differential post-translational modification of the tumour suppressor proteins Rb and p53 modulate the rates of radiation-induced apoptosis in vivo	ONCOGENE			English	Article						Rb; p21; p53; apoptosis; genetic variation; radiation	CELL-CYCLE ARREST; RETINOBLASTOMA GENE-PRODUCT; DRUG-RESISTANT CELLS; HUMAN CANCER-CELLS; DNA-DAMAGE; P53-MEDIATED APOPTOSIS; THYMOCYTE APOPTOSIS; MEDIATED APOPTOSIS; HEPATOMA-CELLS; G(1) ARREST	Ionizing radiation induces p53-dependent apoptosis in the spleen, providing a model system to study p53 regulated events in a normal cell type. We have developed an in vivo model that identifies genetic differences in the regulation of p53-mediated apoptosis and addresses whether altered post-translational events in the p53-p21/Rb axis modulate the sensitivity of cells to radiation-induced cell death in vivo. Splenocytes from mice with distinct genetic backgrounds (DBA/2 and C57BL/6) exhibit differences in the rate of apoptosis, Whilst no obvious strain differences in protein levels of Bcl-2 or the cyclin-CDKs were observed, early posttranslational regulatory events in the p53-p21/Rb axis showed striking differences in the two mouse strains. Cells from C57BL/6 animals undergo more rapid apoptosis after irradiation resulting from elevated levels and rapid induction of p53, pronounced Rb-cleavage, and the absence of a sustained induction of p21, In contrast, cells from DBA/2 animals have a reduced rate of apoptosis following irradiation with elevated levels of hyperphosphorylated Rb and a sustained induction of the p21 protein that is coincident with the C-terminal phosphorylation of p53, These data suggest that quantitative differences in the level of p21 protein can affect the rate of apoptosis in vivo, consistent with the view that p21 is an anti-apoptotic effector of p53, However, striking differences in the Rb protein-caspase cleavage or hyperphosphorylation - in the same cell type, but in different genetic backgrounds, demonstrates that p53-dependent apoptosis can be modulated in vivo by genetic factors that impinge upon the pro- or antiapoptotic potential of Rh, In addition, we show that Rb cleavage is p53-dependent and that its phosphorylation status can be uncoupled from p21 expression. This study highlights the possibility that genetic factors can be identified that affect differential sensitivity of cells to ionizing radiation in vivo.	Univ Dundee, Sch Med, Dept Surg & Mol Oncol, CRC Labs, Dundee DD1 9SY, Scotland; Univ Dundee, Sch Med, Dept Mol & Cellular Pharmacol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Ball, KL (corresponding author), Univ Dundee, Sch Med, Dept Surg & Mol Oncol, CRC Labs, Dundee DD1 9SY, Scotland.		Coates, Philip J/H-6854-2019	Coates, Philip J/0000-0003-1518-6306				ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; An B, 1996, FEBS LETT, V399, P158, DOI 10.1016/S0014-5793(96)01311-7; An B, 1996, CANCER RES, V56, P438; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Ball K L, 1997, Prog Cell Cycle Res, V3, P125; Ball KL, 1996, EUR J BIOCHEM, V237, P854, DOI 10.1111/j.1432-1033.1996.0854p.x; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; Blaydes JP, 2000, ONCOGENE, V19, P3829, DOI 10.1038/sj.onc.1203773; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Bowen C, 1998, CANCER RES, V58, P3275; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; DEDEIRY WS, 1994, CANCER RES, V54, P1169; DOU QP, 1995, CANCER RES, V55, P5222; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Dou QP, 1997, J CELL BIOCHEM, V64, P586; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Esposito F, 2000, FEBS LETT, V470, P211, DOI 10.1016/S0014-5793(00)01318-1; Fan GS, 1996, ONCOGENE, V12, P1909; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Freemerman AJ, 1997, LEUKEMIA, V11, P504, DOI 10.1038/sj.leu.2400625; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HAUPT Y, 1995, ONCOGENE, V10, P1563; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; Komarova EA, 2000, ONCOGENE, V19, P3791, DOI 10.1038/sj.onc.1203717; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MERRITT AJ, 1994, CANCER RES, V54, P614; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MIYASHITA T, 1995, CELL, V80, P293; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; Muschel RJ, 1998, ONCOGENE, V17, P3359, DOI 10.1038/sj.onc.1202580; NOMURA T, 1992, J RADIAT RES, V33, P109, DOI 10.1269/jrr.33.SUPPLEMENT_109; NOMURA T, 1982, NATURE, V296, P575, DOI 10.1038/296575a0; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432-1327.1998.2570242.x; RODERICK TH, 1963, RADIAT RES, V20, P631, DOI 10.2307/3571354; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Tian H, 2000, CANCER RES, V60, P679; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang H, 1996, ONCOGENE, V13, P373; Wang J, 1997, CANCER RES, V57, P351; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824; Weil MM, 1997, GENOMICS, V45, P626, DOI 10.1006/geno.1997.4999; Whitaker LL, 1997, ONCOGENE, V15, P1069, DOI 10.1038/sj.onc.1201277; Wilson JW, 1998, AM J PATHOL, V153, P899, DOI 10.1016/S0002-9440(10)65631-3; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	68	47	47	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3597	3608		10.1038/sj.onc.1204496	http://dx.doi.org/10.1038/sj.onc.1204496			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439323				2022-12-17	WOS:000169400200001
J	D'Agnano, I; Valentini, A; Fornari, C; Bucci, B; Starace, G; Felsani, A; Citro, G				D'Agnano, I; Valentini, A; Fornari, C; Bucci, B; Starace, G; Felsani, A; Citro, G			Myc down-regulation induces apoptosis in M14 melanoma cells by increasing p27(kip1) levels	ONCOGENE			English	Article						c-myc; melanoma; p27; apoptosis	ANTISENSE OLIGODEOXYNUCLEOTIDES ENHANCE; KINASE INHIBITOR P27(KIP1); C-MYC; CYCLE PROGRESSION; GROWTH ARREST; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; GENE-EXPRESSION; IN-VITRO; PROTEIN; DEATH	In recent years, increasing evidence indicated the importance of a deregulated c-myc gene in the melanoma pathogenesis, We have previously demonstrated that treatment of melanoma cells with c-myc antisense oligodeoxynucleotides can inhibit cell proliferation and activate apoptosis, To gain insight into the mechanisms activated by Myc down-regulation, we have now developed an experimental model that allows modulating Myc protein expression in melanoma cells. This was achieved by originating stable melanoma cell clones expressing ecdysone-inducible c-myc antisense RNA. We show that the induction of c-myc antisense RNA in M14 melanoma cells leads to an inhibition of cell proliferation characterized by accumulation of cells in the G(1) phase of the cell cycle (up to 80%) and activation of apoptosis (50%), These data are associated with an increase of p27(kipl) levels and a significant reduction of the cdk2-associated kinase activity, In addition, we show that an ectopic overexpression of p27(kiPl) in this experimental model can enhance the apoptotic rate. Our results indicate that down-regulation of Myc protein induces a G(1) arrest and activates apoptosis by increasing p27(kipl) content in melanoma cells, that are known to be defective for the p16-cyclinD/cdk4-pRb G(1) checkpoint. This is particularly relevant for identifying new therapeutic strategies based on the re-establishment of the apoptotic pathways in cancer cells.	CNR, Ist Tecnol Biomed, I-00137 Rome, Italy; CNR, Ist Med Sperimentale, I-00137 Rome, Italy; Ist Regina Elena, I-00158 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Consiglio Nazionale delle Ricerche (CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	D'Agnano, I (corresponding author), CNR, Ist Tecnol Biomed, V Marx 43, I-00137 Rome, Italy.		Felsani, Armando/D-1784-2010; bucci, barbara/K-6694-2012; D'Agnano, Igea/AAR-7282-2020	Felsani, Armando/0000-0001-8851-6295; D'Agnano, Igea/0000-0002-2646-9224				Bartkova J, 1996, CANCER RES, V56, P5475; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; Citro G, 1998, CANCER RES, V58, P283; Crooke ST, 1996, ANTISENSE NUCLEIC A, V6, P145, DOI 10.1089/oli.1.1996.6.145; D'Agnano I, 1998, ENVIRON MOL MUTAGEN, V32, P56, DOI 10.1002/(SICI)1098-2280(1998)32:1<56::AID-EM7>3.0.CO;2-9; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Dang CV, 1999, MOL CELL BIOL, V19, P1; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Ezhevsky SA, 1996, MOL BIOL CELL, V7, P553, DOI 10.1091/mbc.7.4.553; FISCHER G, 1994, J EXP MED, V179, P221, DOI 10.1084/jem.179.1.221; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; Katayose Y, 1997, CANCER RES, V57, P5441; KIMURA S, 1995, CANCER RES, V55, P1379; KRIEG AM, 1995, ANTISENSE RES DEV, V5, P241, DOI 10.1089/ard.1995.5.241; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leonetti C, 1996, JNCI-J NATL CANCER I, V88, P419, DOI 10.1093/jnci/88.7.419; LESNIKOWSKI ZJ, 1990, NUCLEIC ACIDS RES, V18, P2109, DOI 10.1093/nar/18.8.2109; Maelandsmo GM, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.181; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Ross DA, 1998, BRIT J SURG, V85, P46; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Schlagbauer-Wadl H, 1999, J INVEST DERMATOL, V112, P332, DOI 10.1046/j.1523-1747.1999.00506.x; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schraml P, 1999, CLIN CANCER RES, V5, P1966; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SKORSKI T, 1995, J EXP MED, V182, P1645, DOI 10.1084/jem.182.6.1645; Stein CA, 1998, ANTISENSE NUCLEIC A, V8, P129, DOI 10.1089/oli.1.1998.8.129; Stein CA, 1996, J NATL CANCER I, V88, P391, DOI 10.1093/jnci/88.7.391; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VanWardenburg RCAM, 1997, INT J CANCER, V73, P544, DOI 10.1002/(SICI)1097-0215(19971114)73:4<544::AID-IJC15>3.0.CO;2-9; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wu M, 1999, J IMMUNOL, V163, P6530	43	47	49	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2814	2825		10.1038/sj.onc.1204392	http://dx.doi.org/10.1038/sj.onc.1204392			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420693				2022-12-17	WOS:000168712000009
J	Nelsen, CJ; Hansen, LK; Rickheim, DG; Chen, CS; Stanley, MW; Krek, W; Albrecht, JH				Nelsen, CJ; Hansen, LK; Rickheim, DG; Chen, CS; Stanley, MW; Krek, W; Albrecht, JH			Induction of hepatocyte proliferation and liver hyperplasia by the targeted expression of cyclin E and skp2	ONCOGENE			English	Article						cyclins; gene therapy; liver regeneration; polyploidy; skp2	CELL-CYCLE; ECTOPIC EXPRESSION; DEPENDENT KINASES; GROWTH-FACTOR; ADENOVIRUS; REGENERATION; DEGRADATION; PROGRESSION; P27(KIP1); REPLICATION	Cells in culture become competent to replicate in the absence of growth factor after progressing beyond the late G1 restriction point, suggesting that a set of genes expressed during G1 phase is sufficient to trigger completion of the cell cycle. However, this has not been demonstrated in an in vivo system. In this study, we examined whether transfection of genes associated with the G1/S transition could trigger hepatocyte replication. Co-transfection of cyclin E and skp2 synergistically promoted cell cycle progression in cultured primary hepatocytes in the absence of mitogen or in the presence of growth inhibitors. Furthermore, transfection of hepatocytes in vivo with cyclin E and skp2 promoted abundant hepatocyte replication and hyperplasia of the liver. These studies confirm that transfection with a small number of genes can trigger proliferation of quiescent hepatocytes in vivo, and suggest that therapies to enhance liver regeneration by targeting cell cycle control genes may be feasible.	Hennepin Cty Med Ctr, Dept Med 865B, Minneapolis, MN 55415 USA; Hennepin Cty Med Ctr, Dept Pathol, Minneapolis, MN 55415 USA; Minneapolis Med Res Fdn Inc, Minneapolis, MN 55404 USA; Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; FMI, CH-4058 Basel, Switzerland	Hennepin County Medical Center; Hennepin County Medical Center; Minneapolis Medical Research Foundation; University of Minnesota System; University of Minnesota Twin Cities; Friedrich Miescher Institute for Biomedical Research	Albrecht, JH (corresponding author), Hennepin Cty Med Ctr, Dept Med 865B, 701 Pk Ave, Minneapolis, MN 55415 USA.			Hansen, Linda/0000-0003-3651-0419	NIDDK NIH HHS [DK54921, DK56222] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK056222, R01DK054921] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albrecht JH, 1999, AM J PHYSIOL-GASTR L, V277, pG1207, DOI 10.1152/ajpgi.1999.277.6.G1207; Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Amati B, 1999, NAT CELL BIOL, V1, pE91, DOI 10.1038/12087; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Bilodeau M, 1999, FEBS LETT, V452, P247, DOI 10.1016/S0014-5793(99)00629-8; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chowdhury JR, 1999, SEMIN LIVER DIS, V19, P1, DOI 10.1055/s-2007-1007092; Coelho CM, 2000, J CELL SCI, V113, P2927; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; Datar SA, 2000, EMBO J, V19, P4543, DOI 10.1093/emboj/19.17.4543; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Delhaye M, 1996, HEPATOLOGY, V23, P1003, DOI 10.1002/hep.510230510; Ehrenfried JA, 1997, SURGERY, V122, P927, DOI 10.1016/S0039-6060(97)90334-2; FANG JWS, 1994, LANCET, V343, P820, DOI 10.1016/S0140-6736(94)92025-7; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Gao CH, 1999, HEPATOLOGY, V30, P1405, DOI 10.1002/hep.510300602; Garcia P, 2000, ONCOGENE, V19, P1820, DOI 10.1038/sj.onc.1203494; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Ginsberg HS, 1996, B NEW YORK ACAD MED, V73, P53; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hansen LK, 1999, J CELL SCI, V112, P2971; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Ilan Y, 1999, SEMIN LIVER DIS, V19, P49, DOI 10.1055/s-2007-1007097; Jaumot M, 1999, HEPATOLOGY, V29, P385, DOI 10.1002/hep.510290226; KAWASAKI S, 1992, GASTROENTEROLOGY, V102, P1351; Kay MA, 1997, MOL MED TODAY, V3, P108, DOI 10.1016/S1357-4310(96)10062-9; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Leone G, 1999, P NATL ACAD SCI USA, V96, P6626, DOI 10.1073/pnas.96.12.6626; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Phaneuf D, 2000, MOL MED, V6, P96, DOI 10.1007/BF03401777; Rai RM, 1998, P NATL ACAD SCI USA, V95, P13829, DOI 10.1073/pnas.95.23.13829; Roberts JM, 1999, CELL, V98, P129, DOI 10.1016/S0092-8674(00)81007-7; Rudolph KL, 2000, SCIENCE, V287, P1253, DOI 10.1126/science.287.5456.1253; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEER CJ, 1995, FASEB J, V9, P1396, DOI 10.1096/fasebj.9.14.7589980; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TARAO K, 1994, CANCER, V73, P1149, DOI 10.1002/1097-0142(19940215)73:4<1149::AID-CNCR2820730405>3.0.CO;2-9; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045	48	47	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1825	1831		10.1038/sj.onc.1204248	http://dx.doi.org/10.1038/sj.onc.1204248			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313930				2022-12-17	WOS:000167908400003
J	Jones, SM; Kazlauskas, A				Jones, SM; Kazlauskas, A			Connecting signaling and cell cycle progression in growth factor-stimulated cells	ONCOGENE			English	Review						PDGF; cell cycle progression; signal transduction	RECEPTOR TYROSINE KINASES; FORKHEAD TRANSCRIPTION FACTOR; FACTOR-BETA-RECEPTOR; SRC FAMILY KINASES; BALB/C 3T3 CELLS; DNA-SYNTHESIS; RESTRICTION POINT; DEPENDENT KINASE; RAS ACTIVITY; PHOSPHATIDYLINOSITOL-3 KINASE	A widely used model system to investigate cell proliferation is stimulation of serum-arrested cells with growth factors. Recent data suggest that there are two waves of growth factor-dependent signaling events required for a proliferative response. One is an acute burst of signaling, which occurs immediately after growth factor stimulation and lasts for 30-60 min. The other occurs in a different time frame (8-12 h post stimulation), and involves activation of cyclin dependent kinases (Cdks), In addition to a general overview of growth factor-dependent signaling,,ve present our 'two wave' hypothesis for how signaling and cell cycle progression are linked.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute; Harvard University; Harvard Medical School	Kazlauskas, A (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.							Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Balciunaite E, 2000, CURR BIOL, V10, P261, DOI 10.1016/S0960-9822(00)00358-4; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DeMali KA, 1999, J BIOL CHEM, V274, P19551, DOI 10.1074/jbc.274.28.19551; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HELDIN CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, pR79; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; Hooshmand-Rad R, 1998, J CELL SCI, V111, P607; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; Hubbard SR, 1999, PROG BIOPHYS MOL BIO, V71, P343, DOI 10.1016/S0079-6107(98)00047-9; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; JONES S, 2000, UNPUB; Jones SM, 1999, CURR BIOL, V9, P512, DOI 10.1016/S0960-9822(99)80235-8; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kirschner M W, 1992, Important Adv Oncol, P3; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MORI S, 1993, J BIOL CHEM, V268, P577; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rimerman RA, 2000, J BIOL CHEM, V275, P14736, DOI 10.1074/jbc.M910241199; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rose DW, 1998, ONCOGENE, V17, P889, DOI 10.1038/sj.onc.1201997; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; Schlesinger TK, 1999, BIOCHEM J, V344, P519, DOI 10.1042/0264-6021:3440519; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; STILES CD, 1979, J CELL PHYSIOL, V99, P395, DOI 10.1002/jcp.1040990314; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Winston JT, 1996, ONCOGENE, V12, P127; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	100	47	47	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2000	19	49					5558	5567		10.1038/sj.onc.1203858	http://dx.doi.org/10.1038/sj.onc.1203858			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114735				2022-12-17	WOS:000165659300002
J	Miyake, M; Inufusa, H; Adachi, M; Ishida, H; Hashida, H; Tokuhara, T; Kakehi, Y				Miyake, M; Inufusa, H; Adachi, M; Ishida, H; Hashida, H; Tokuhara, T; Kakehi, Y			Suppression of pulmonary metastasis using adenovirally motility related protein-1 (MRP-1/CD9) gene delivery	ONCOGENE			English	Article						MRP-1/CD9; adenovirus; gene therapy; metastasis	CELL MOTILITY; BREAST-CANCER; TRANSMEMBRANE-4 SUPERFAMILY; TM4SF PROTEINS; POOR-PROGNOSIS; BRAIN-TUMORS; LUNG-CANCER; IN-VIVO; EXPRESSION; THERAPY	Previously we showed that MRP-1/CD9 might prevent tumor metastasis by suppression of cell motility and invasion of tissue barriers. The present study explored the possibility of preventing metastasis of mouse melanoma BL6 by expression of MRP-1/CD9 through gene transfer. A replication-deficient adenovirus vector was used for the in vivo transfer of MRP-1/CD9 cDNA, Intratumor injection of an adenovirus vector (rAd-MRP-1/CD9) expressing MRP-1/CD9 resulted in a 73.7% reduction in the number of pulmonary metastases of mice and the median survival time of mice treated with rAd-MRP-1/CD9 was significantly longer than those treated with the rAd-beta -gal vector (103.2+/-8.5 days vs 71.2+/-5.2 days, P<0.001 respectively). These results support the expression of MRP-1/CD9 through gene transfer as a therapeutic strategy for preventing metastases and prolonging survival, and support the feasibility of gene transfer in a clinically relevant setting.	Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Kita Ku, Osaka 5308480, Japan; Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Oncol 5, Kita Ku, Osaka 5308480, Japan; Kinki Univ, Sch Med, Dept Surg 1, Osaka 5898511, Japan; Kyoto Univ, Dept Urol & Pathol, Kyoto 6068501, Japan	Kitano Hospital; Kitano Hospital; Kindai University (Kinki University); Kyoto University	Miyake, M (corresponding author), Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Kita Ku, 13-3 Kamiyama Cho, Osaka 5308480, Japan.							Adachi M, 1998, J CLIN ONCOL, V16, P1397, DOI 10.1200/JCO.1998.16.4.1397; BARNES R, 1991, AM J PATHOL, V139, P245; Bonnekoh B, 1998, J INVEST DERMATOL, V110, P867, DOI 10.1046/j.1523-1747.1998.00221.x; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; Cajot JF, 1997, CANCER RES, V57, P2593; CHEN SH, 1995, P NATL ACAD SCI USA, V92, P2577, DOI 10.1073/pnas.92.7.2577; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; Curiel DT, 1996, AM J RESP CELL MOL, V14, P1; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Harris MP, 1996, CANCER GENE THER, V3, P121; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kondo K, 1998, CANCER RES, V58, P2014; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; MIYAKE M, 1991, BIOCHEMISTRY-US, V30, P3328, DOI 10.1021/bi00227a023; MIYAKE M, 1995, CANCER RES, V55, P4127; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; Miyake M, 1996, CANCER RES, V56, P1244; Mori M, 1998, CLIN CANCER RES, V4, P1507; OLDFIELD EH, 1993, HUM GENE THER, V4, P39, DOI 10.1089/hum.1993.4.1-39; RADFORD KJ, 1995, INT J CANCER, V62, P631, DOI 10.1002/ijc.2910620523; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Sho M, 1998, INT J CANCER, V79, P509, DOI 10.1002/(SICI)1097-0215(19981023)79:5<509::AID-IJC11>3.0.CO;2-X; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Tachibana I, 1999, J CELL BIOL, V146, P893, DOI 10.1083/jcb.146.4.893; TOH Y, 1994, J BIOL CHEM, V269, P22958; Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186	33	47	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2000	19	46					5221	5226		10.1038/sj.onc.1203919	http://dx.doi.org/10.1038/sj.onc.1203919			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077438				2022-12-17	WOS:000165059700002
J	Baksh, S; DeCaprio, JA; Burakoff, SJ				Baksh, S; DeCaprio, JA; Burakoff, SJ			Calcineurin regulation of the mammalian G(0)/G(1) checkpoint element, cyclin dependent kinase 4	ONCOGENE			English	Article						cell cycle; calcineurin; cdk4; cyclin activating kinase; Jurkat cells	RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; PHOSPHORYLATION; PHOSPHATASE; FAMILY; CELLS; NFAT; CDK4	Cyclin dependent kinase 4 (cdk8) activity is controlled by the binding of regulatory subunits and inhibitory factors, as well as tyrosine and serine/threonine phosphorylation, More recently the influence of calcium levels have been demonstrated. Using transient transfections in Jurkat cells, we observed specific binding between cdk4 and the calcium and calmodulin activated serine/threonine phosphatase, calcineurin. Furthermore, we demonstrated that the inhibition of the phosphatase activity of calcineurin with FK506 and cyclosporin A resulted in an overall increase in cdk4 kinase activity, suggesting that the phosphatase activity of calcineurin was inhibitory to the kinase activity of cdkA In contrast, we were not able to observe a similar effect on the kinase activity of either cdk6 or cdk2, indicating that the phosphatase activity of calcineurin was specific for cdk4, In addition, using an in vitro phosphatase assay for calcineurin, we observed that the exogenous addition of calcineurin resulted in the dephosphorylation of cdk4, an event that downregulated the kinase activity of cdk4 Calcineurin could, therefore, play an opposing role to the action of the cyclin activating kinase complex, an enzyme that upregulates the kinase activity of cdk4, an important G(0)/G(1) checkpoint element in mammalian cells.	Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Burakoff, SJ (corresponding author), Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.		Baksh, Shairaz/GRX-2106-2022					Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; FRUMAN DA, 1992, EUR J IMMUNOL, V22, P2513, DOI 10.1002/eji.1830221008; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Jinno S, 1999, ONCOGENE, V18, P565, DOI 10.1038/sj.onc.1202347; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KREK W, 1995, METHOD ENZYMOL, V254, P114; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mizunuma M, 1998, NATURE, V392, P303, DOI 10.1038/32695; Mondragon A, 1997, BIOCHEMISTRY-US, V36, P4934, DOI 10.1021/bi9631935; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	23	47	49	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2000	19	24					2820	2827		10.1038/sj.onc.1203585	http://dx.doi.org/10.1038/sj.onc.1203585			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851085				2022-12-17	WOS:000087403600003
J	Madireddi, MT; Dent, P; Fisher, PB				Madireddi, MT; Dent, P; Fisher, PB			Regulation of mda-7 gene expression during human melanoma differentiation	ONCOGENE			English	Article						human melanoma; posttranscriptional gene regulation; 3 '-UTR; AUUUA	MESSENGER-RNA STABILITY; C-FOS PROTEIN; INTERFERON-GAMMA; GM-CSF; GROWTH; CELLS; TRANSCRIPTION; PROGRESSION; CANCER; MECHANISMS	]Induction of irreversible growth arrest and terminal differentiation in human melanoma cells following treatment with recombinant human fibroblast interferon (IFN-beta) and mezerein (MEZ) results in elevated expression of a specific melanoma differentiation associated gene, mda-7. Experiments were conducted to define the mechanism involved in the regulation of mda-7 expression in differentiating human melanoma cells. The mda-7 gene is actively transcribed in uninduced HO-1 human melanoma cells and the rate of transcription of nInn-7 is not significantly enhanced by treatment with IFN-beta, MEZ or IFN-beta+MEZ. The high basal activity of the mda-7 promoter in uninduced melanoma cells and the absence of enhancing effect upon treatment with differentiation inducers is corroborated by transfection studies using the promoter region of mda-7 linked to a luciferase reporter gene containing the SV40 polyadenylation signal sequence. RT-PCR analysis detects the presence of low levels of mda-7 transcripts in uninduced and concomitant increases in differentiation inducer treated HO-1 cells. However, steady-state mda-7 mRNA is detected only in IFN-beta+MEZ and to a lesser degree in MEZ, treated cells, We show that induction of terminal differentiation of HO-1 cells with IFN-beta + MEZ dramatically increases the half-life of mcCn-7 mRNA while treatment with cycloheximide results in detectable mda-7 mRNA in control and inducer treated cells. These observations confirm constitative activity of the mda-7 promoter in HO-1 cells irrespective of differentiation status suggesting posttranscriptional processes as important determinants of mda-7 expression during terminal differentiation, The 3' UTR region of mda-7 contains AU-rich elements (ARE) that contribute to rapid mda-7 mRNA turnover during proliferation and reversible differentiation, a process controlled by a labile protein factor(s), Substitution of the SV40 polyadenylation signal sequence in the luciferase reporter plasmid with the mda-7-ARE-3'-UTR renders the Luciferase message unstable,when expressed in proliferating and reversibly differentiated melanoma cells. In contrast, the luciferase message is stabilized when the mda-7-ARE-3'-UTR construct is expressed in terminally differentiated HO-1 cells. These results provide compelling evidence that mda-7 expression during terminal differentiation in human melanoma cells is regulated predominantly at a posttranscriptional level.	Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Neurosurg, New York, NY 10032 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Urol, New York, NY 10032 USA	Columbia University; Columbia University; Virginia Commonwealth University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.				NCI NIH HHS [CA35675] Funding Source: Medline; NIDDK NIH HHS [R01DK52825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; FISHER PB, 1985, INTERFERON RES, V5, P11; Fontes AM, 1999, CURR TOP DEV BIOL, V44, P171; GOEDDEL DV, 1981, NATURE, V290, P20, DOI 10.1038/290020a0; Gopalkrishnan RV, 1999, NUCLEIC ACIDS RES, V27, P4775, DOI 10.1093/nar/27.24.4775; Huang F, 1999, GENE, V236, P125, DOI 10.1016/S0378-1119(99)00244-9; Huang F, 1999, ONCOGENE, V18, P3546, DOI 10.1038/sj.onc.1202715; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P1293, DOI 10.1073/pnas.76.3.1293; ISHIKAWA M, 1989, INT J CANCER, V43, P134, DOI 10.1002/ijc.2910430125; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P197; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; JIANG HP, 1995, ONCOGENE, V10, P1855; Kang DC, 1998, P NATL ACAD SCI USA, V95, P13788, DOI 10.1073/pnas.95.23.13788; Kang DC, 1998, INT J ONCOL, V13, P1117; KROWCZYNSKA A, 1985, J MOL BIOL, V181, P231, DOI 10.1016/0022-2836(85)90087-7; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MADIREDDI M, 2000, IN PRESS CANC GENE T; MILLER AD, 1984, CELL, V36, P51; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; NEDWIN GE, 1985, J IMMUNOL, V135, P2492; Patterson A, 1999, DRUG AGING, V14, P75, DOI 10.2165/00002512-199914020-00001; RAJ NBK, 1981, P NATL ACAD SCI-BIOL, V78, P7426, DOI 10.1073/pnas.78.12.7426; RJAGOPALAN LE, 1997, PROG NUCL ACID RES M, V256, P257; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; SACHS L, 1980, P NATL ACAD SCI-BIOL, V77, P6152, DOI 10.1073/pnas.77.10.6152; SCOTT RE, 1985, P NATL ACAD SCI USA, V82, P2995, DOI 10.1073/pnas.82.9.2995; Scott RE, 1997, PHARMACOL THERAPEUT, V73, P51, DOI 10.1016/S0163-7258(96)00120-9; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; Spicher A, 1998, MOL CELL BIOL, V18, P7371, DOI 10.1128/MCB.18.12.7371; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; Wada RK, 1997, CANCER LETT, V121, P181, DOI 10.1016/S0304-3835(97)00351-0; WAXMAN S, 1995, DIFFERENTIATION THER; WAXMAN S, 1991, STATUS DIFFERENTIATI; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	42	47	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 2	2000	19	10					1362	1368		10.1038/sj.onc.1203424	http://dx.doi.org/10.1038/sj.onc.1203424			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713678				2022-12-17	WOS:000085743800013
J	Cass, LA; Meinkoth, JL				Cass, LA; Meinkoth, JL			Ras signaling through PI3K confers hormone-independent proliferation that is compatible with differentiation	ONCOGENE			English	Article						cAMP; PI3K; differentiation; proliferation; thyroid cells	THYROID EPITHELIAL-CELLS; ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; DNA-SYNTHESIS; GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; NA+/I SYMPORTER; SKELETAL MYOGENESIS; DISTINCT EFFECTORS; GENE-EXPRESSION	Hormones are specialized mitogens that stimulate proliferation in their differentiated target cells. Thyrotropin (TSH), the physiologic regulator of thyroid cells, stimulates cAMP-mediated proliferation and thyroidspecific gene expression. The mitogenic effects of TSH require Ras, therefore Ras activation should be compatible with the maintenance of thyroid differentiation. However, expression of activated Ras extinguishes the differentiated phenotype of thyroid cells, One explanation for this apparent paradox is the selective utilization of Res effector pathways. We tested the hypothesis that Ras signaling through PI3K mediates the mitogenic effects of TSH in cells which retain their differentiated character. Expression of a Ras effector mutant (RasV12S35) that signals preferentially through Raf-1, although sufficient to confer TSH-independent proliferation, abolished hormone-regulated expression of thyroglobulin and the sodium/iodide symporter, In contrast, expression of a Ras mutant (RasV12C40) that binds selectively to PI3K conferred TSH-independent proliferation without marked effects on thyroid-specific gene expression. Unlike the inhibitory effects of TSH on the proliferation of RasV12S35-expressing cells, TSH enhanced RasV12C40-stimulated proliferation by further increasing the activity of p70s6k, an important mediator of the mitogenic effects of TSH and RasV12C40. These results demonstrate that channeling Ras-dependent signals to PI3K confers TSH with the ability to stimulate proliferation in differentiated cells.	Univ Penn, Dept Pharmacol, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Meinkoth, JL (corresponding author), Univ Penn, Dept Pharmacol, Sch Med, 36th St & Hamilton Walk, Philadelphia, PA 19104 USA.		Meinkoth, Judy L/G-2900-2010		NIDDK NIH HHS [DK02494, DK45696] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K02DK002494, R01DK045696] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; AVVEDIMENTO EV, 1989, CELL, V58, P1135, DOI 10.1016/0092-8674(89)90511-4; BATTISTA S, 1995, ONCOGENE, V11, P2029; Busca R, 1996, J BIOL CHEM, V271, P31824, DOI 10.1074/jbc.271.50.31824; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cass LA, 1998, ENDOCRINOLOGY, V139, P1991, DOI 10.1210/en.139.4.1991; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cobellis G, 1998, ONCOGENE, V17, P2047, DOI 10.1038/sj.onc.1202130; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; Downey P, 1997, BUCINA HIST BRAS SOC, V2, P1; Dumont F J, 1996, Life Sci, V58, P373; FAGIN JA, 1994, ANNU REV MED, V45, P45; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Goi T, 1999, MOL CELL BIOL, V19, P1731; Heldin N E, 1991, Thyroidology, V3, P127; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KAMINSKY SM, 1994, P NATL ACAD SCI USA, V91, P3789, DOI 10.1073/pnas.91.9.3789; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kita Y, 1998, J CELL SCI, V111, P907; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kupperman E, 1996, ENDOCRINOLOGY, V137, P96, DOI 10.1210/en.137.1.96; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Levy O, 1997, P NATL ACAD SCI USA, V94, P5568, DOI 10.1073/pnas.94.11.5568; MARIAS R, 1996, CANCER SURV, V27, P101; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Matsuguchi T, 1998, ONCOGENE, V17, P2701, DOI 10.1038/sj.onc.1202201; MEINKOTH JL, 1991, THYROIDOLOGY, V3, P97; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Missero C, 1998, MOL CELL ENDOCRINOL, V140, P37, DOI 10.1016/S0303-7207(98)00027-6; Ohmori M, 1998, MOL ENDOCRINOL, V12, P727, DOI 10.1210/me.12.5.727; Ohno M, 1999, MOL CELL BIOL, V19, P2051; OKADA T, 1994, J BIOL CHEM, V269, P3568; Ptasznik A, 1997, J CELL BIOL, V137, P1127, DOI 10.1083/jcb.137.5.1127; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Uyttersprot N, 1997, MOL CELL ENDOCRINOL, V131, P195, DOI 10.1016/S0303-7207(97)00108-1; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458	61	47	48	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 17	2000	19	7					924	932		10.1038/sj.onc.1203393	http://dx.doi.org/10.1038/sj.onc.1203393			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702801				2022-12-17	WOS:000085567700010
J	Gartel, AL; Najmabadi, F; Goufman, E; Tyner, AL				Gartel, AL; Najmabadi, F; Goufman, E; Tyner, AL			A role for E2F1 in Ras activation of p21((WAF1/CIP1)) transcription	ONCOGENE			English	Article						p21; Ras; E2F; transient transfection; CAT assay	CELL-CYCLE PROGRESSION; INHIBITOR P21 GENE; S-PHASE ENTRY; RETINOBLASTOMA PROTEIN; CHLORAMPHENICOL ACETYLTRANSFERASE; DEREGULATED EXPRESSION; P53; D1; P21(WAF1/CIP1); APOPTOSIS	We recently reported that E2F1 could transactivate the p21 promoter via cis-acting elements between -119 to +16 bp of the p21 gene. Here we show that activated V12-H-Ras can induce the p21 promoter through the same region of the p21 promoter by a p53-independent mechanism in NIH3T3 cells. In contrast, activated Ras was not able to induce the p21 promoter in E2F1(-/-) fibroblasts, suggesting that E2F1 is required for induction of the p21 promoter by activated Ras, Cotransfection of increasing concentrations of dominant negative E2F1 alone, or with dominant negative DP1 into NIH3T3 cells suppressed induction of the p21 promoter by activated Pas. These data suggest that p53-independent induction of the p21 promoter by activated Ras is mediated at least in part by E2F1.	Univ Illinois, Coll Med, Dept Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gartel, AL (corresponding author), Univ Illinois, Coll Med, Dept Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.		Goufman, Eugene/AAG-6882-2019	Tyner, Angela/0000-0001-7448-8625	NIDDK NIH HHS [R01 DK056283-05, DK48836, R01 DK056283] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056283, R01DK048836] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan JG, 1997, ONCOGENE, V14, P2595, DOI 10.1038/sj.onc.1201105; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Halaban R, 1998, ONCOGENE, V16, P2489, DOI 10.1038/sj.onc.1201773; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Liu Y, 1996, CANCER RES, V56, P31; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MURRAY IA, 1991, NUCLEIC ACIDS RES, V19, P6648; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; SCHULZE A, 1994, ONCOGENE, V9, P3475; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Wang ZM, 1998, P NATL ACAD SCI USA, V95, P15583, DOI 10.1073/pnas.95.26.15583; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wu CL, 1996, MOL CELL BIOL, V16, P3698; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	45	47	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 17	2000	19	7					961	964		10.1038/sj.onc.1203411	http://dx.doi.org/10.1038/sj.onc.1203411			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702805				2022-12-17	WOS:000085567700014
J	Tarafa, G; Villanueva, A; Farre, L; Rodriguez, J; Musulen, E; Reyes, G; Seminago, R; Olmedo, E; Paules, AB; Peinado, MA; Bachs, O; Capella, G				Tarafa, G; Villanueva, A; Farre, L; Rodriguez, J; Musulen, E; Reyes, G; Seminago, R; Olmedo, E; Paules, AB; Peinado, MA; Bachs, O; Capella, G			DCC and SMAD4 alterations in human colorectal and pancreatic tumor dissemination	ONCOGENE			English	Article						pancreatic cancer; colorectal cancer; DCC; Smad4; Smad2	SUPPRESSOR GENE; CHROMOSOME 18Q; MUTATIONAL ANALYSIS; COLON-CANCER; ALLELIC LOSS; DPC4 SMAD4; NUDE-MICE; IN-VIVO; EXPRESSION; CARCINOMA	Chromosome 18q is lost a high proportion of colorectal and pancreatic cancers. Three candidate tumor suppressor genes, DCC, Smad4 and Smad2 have been identified in this chromosome region. DCC and Smad4 aberrations have been previously identified in pancreatic and colorectal tumors. The aim of this study was to compare the presence of concurrent genetic aberrations in DCC and neighboring Smad4 and Smad2 genes during colorectal and pancreatic distal dissemination. We have used a panel of orthotopically implanted colorectal and pancreatic xenografts and corresponding metastases. We have shown that while LOH at DCC locus occurred at a similar frequency in both tumors, diminished DCC protein expression was exclusively present in colorectal tumors harboring intragenic DCC LOH, In contrast, in pancreatic xenografts loss of DCC protein and mRNA expression was restricted to metastases, Smad4 gene aberrations were detected at a similar frequency in both tumors and were selected for during distal dissemination. Acquisition of alterations in both genes occurred independently. Our results suggest that both DCC and Smad4 contribute to pancreatic and colorectal distal dissemination. However, the role of DCC may differ between both tumor types.	Hosp Santa Creu & Sant Pau, Inst Recerca, Lab Invest Gastrointestinal, Barcelona 08025, Spain; Hosp Santa Creu & Sant Pau, S Cirurgia Vasc, Barcelona 08025, Spain; Consorci Hosp Parc Tauli, Serv Patol, Sabadell 08023, Spain; Univ Barcelona, Serv Cient Tecn, Barcelona 08028, Spain; Univ Barcelona, IDIBAPS, Inst Invest Biomed August Pi & Sunyer, Fac Med,Dept Biol Cellular, E-08036 Barcelona, Spain; Inst Recerca Oncol, Dept Canc & Metastasi, Barcelona 08907, Spain; Inst Catala Oncol, Mol Biol Lab, Barcelona 08907, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Hospital of Santa Creu i Sant Pau; Hospital of Santa Creu i Sant Pau; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Catalan Institute of Oncology	Capella, G (corresponding author), Inst Catala Oncol, Mol Biol Lab, Av Gran Via S-N,Km 2,7, Barcelona 08907, Spain.		Musulen, Eva/AAI-9169-2020; Capella, Gabriel/I-1879-2015; Peinado, Miguel A./A-5591-2008; Tarafa, Gemma/H-2517-2013; OLMEDO, EVA/K-6810-2014	Musulen, Eva/0000-0002-9667-6464; Capella, Gabriel/0000-0002-4669-7320; Peinado, Miguel A./0000-0002-4090-793X; Tarafa, Gemma/0000-0003-1734-7740; OLMEDO, EVA/0000-0003-0558-1513; Farre, Lourdes/0000-0002-3168-1940				BUURENVANSEGGEL.VH, 1998, GENE CHROMOSOME CANC, V21, P30; CARELLA G, 1991, ENV HLTH PERSPECT, V93, P125; Chen YQ, 1999, ONCOGENE, V18, P2747, DOI 10.1038/sj.onc.1202629; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fabre M, 1999, INT J CANCER, V81, P799, DOI 10.1002/(SICI)1097-0215(19990531)81:5<799::AID-IJC22>3.0.CO;2-W; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FU XY, 1991, P NATL ACAD SCI USA, V88, P9345, DOI 10.1073/pnas.88.20.9345; Goi T, 1998, BRIT J CANCER, V77, P466, DOI 10.1038/bjc.1998.74; Gotley DC, 1996, ONCOGENE, V13, P787; Gupta PK, 1997, CANCER RES, V57, P1188; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HAHN SA, 1995, CANCER RES, V55, P4670; HOHNE MW, 1992, CANCER RES, V52, P2616; Hoque ATMS, 1997, GUT, V40, P120, DOI 10.1136/gut.40.1.120; IINO H, 1994, CANCER, V73, P1324, DOI 10.1002/1097-0142(19940301)73:5<1324::AID-CNCR2820730503>3.0.CO;2-W; ITOH F, 1993, INT J CANCER, V53, P260, DOI 10.1002/ijc.2910530215; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; Kong XT, 1997, CANCER RES, V57, P3772; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Maesawa C, 1996, EUR J CANCER, V32A, P896, DOI 10.1016/0959-8049(96)00010-X; Martinez-Lopez E, 1998, GASTROENTEROLOGY, V114, P1180, DOI 10.1016/S0016-5085(98)70423-8; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Papadimitrakopoulou VA, 1998, CLIN CANCER RES, V4, P539; PARRY PJ, 1991, NUCLEIC ACIDS RES, V19, P6983, DOI 10.1093/nar/19.24.6983-a; PEINADO MA, 1993, INT J ONCOL, V2, P123; Reyes G, 1996, CANCER RES, V56, P5713; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Schmitt CA, 1998, BRIT J CANCER, V77, P588, DOI 10.1038/bjc.1998.95; Shibata D, 1996, NEW ENGL J MED, V335, P1727, DOI 10.1056/NEJM199612053352303; SIMON B, 1994, GASTROENTEROLOGY, V106, P1645, DOI 10.1016/0016-5085(94)90422-7; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Takei K, 1998, CANCER RES, V58, P3700; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Ueda T, 1997, GENE CHROMOSOME CANC, V20, P140, DOI 10.1002/(SICI)1098-2264(199710)20:2<140::AID-GCC4>3.0.CO;2-3; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118	40	47	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2000	19	4					546	555		10.1038/sj.onc.1203353	http://dx.doi.org/10.1038/sj.onc.1203353			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698524				2022-12-17	WOS:000085104200008
J	Chu, W; Pak, BJ; Bani, MR; Kapoor, M; Lu, SJ; Tamir, A; Kerbel, RS; Ben-David, Y				Chu, W; Pak, BJ; Bani, MR; Kapoor, M; Lu, SJ; Tamir, A; Kerbel, RS; Ben-David, Y			Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications	ONCOGENE			English	Article						malignant melanoma; drug resistance; tyrosinase-related protein-2; chemotherapy; cis-diamminedichloroplatinuim(II)	HUMAN OVARIAN-CANCER; DOPACHROME TAUTOMERASE; DNA-REPAIR; CELL-LINES; IN-VITRO; CISPLATIN; GENE; OVEREXPRESSION; CHEMOTHERAPY; GLUTATHIONE	A major obstacle in the systemic treatment of advanced malignant melanoma is its intrinsic resistance to conventionally used chemotherapeutic agents. In order to investigate the mechanisms of this intrinsic resistance, we have previously utilized retroviral insertional mutagenesis on an early-stage, drug sensitive human melanoma cell line (WM35) to establish mutated cell lines that exhibited increased resistance to cis-diamminedichloroplatinum(II) (CDDP), Here, we demonstrate that this increased resistance to CDDP is mediated by the over-expression of tyrosinase-related protein-2 (TYRP2), an enzyme that normally functions in the biosynthesis of the pigment, melanin. Northern and Western blot analyses revealed that the expression of TYRP2 in the virally-derived cell lines as well as in a panel of human melanoma cell lines positively correlated with their levels of resistance to CDDP, Furthermore, enforced expression of TYRP2 in WM35 cells by transfection elevated their resistance to CDDP, The increased CDDP resistance in the virally-derived clones and TYRP2 transfectants was accompanied by a reduction in CDDP-induced apoptosis, Interestingly, the virally-derived CDDP-resistant clones also showed cross resistance to carboplatin and methotrexate, but not taxol, suggesting that TYRP2 over-expression may confer resistance specifically to DNA damaging agents, Overall, these results demonstrate a novel mechanism of drug resistance in human melanoma cells that is mediated by the over-expression of TYRP2, Since TYRP2 is expressed only in cells of melanocytic lineage, this may represent the first report of a lineage-specific mechanism of drug resistance, In summary, these findings suggest a significant role for TYRP2 in the intrinsic drug resistance phenotype of human melanoma cells and may have important implications in the development of chemosensitization strategies for the clinical management of this disease.	Sunnybrook & Womens Coll Hlth Sci Ctr, Div Canc Biol Res, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Ben-David, Y (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Div Canc Biol Res, Res Bldg,Room S2-18,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Bani, Maria Rosa/AAB-3397-2020	Bani, Maria Rosa/0000-0001-8178-1432	NATIONAL CANCER INSTITUTE [R01CA041233] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PA, 1985, CANCER RES, V45, P6250; AROCA P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P266, DOI 10.1016/0304-4165(90)90088-E; BALCH CM, 1989, CANCER PRINCIPLES PR, V2, P1499; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BATIST G, 1986, J BIOL CHEM, V261, P5544; BERND A, 1994, MELANOMA RES, V4, P287, DOI 10.1097/00008390-199410000-00003; BORCHERS AH, 1990, CANCER RES, V50, P1786; Chan HSL, 1997, CANCER RES, V57, P2325; CHU G, 1990, P NATL ACAD SCI USA, V87, P3324, DOI 10.1073/pnas.87.9.3324; CHU G, 1994, J BIOL CHEM, V269, P787; Citro G, 1998, CANCER RES, V58, P283; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Dolan ME, 1999, CLIN CANCER RES, V5, P2059; Fillpits M, 1997, BRIT J CANCER, V75, P208; HO RCS, 1995, CANCER, V75, P735, DOI 10.1002/1097-0142(19950115)75:2+<735::AID-CNCR2820751418>3.0.CO;2-Q; ISHIKAWA T, 1994, J BIOL CHEM, V269, P29085; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; Kawakami Y, 1998, J IMMUNOTHER, V21, P237, DOI 10.1097/00002371-199807000-00001; Koo HM, 1999, JNCI-J NATL CANCER I, V91, P236, DOI 10.1093/jnci/91.3.236; Kung H J, 1991, Curr Top Microbiol Immunol, V171, P1; KURODA H, 1991, INT J CANCER, V47, P732, DOI 10.1002/ijc.2910470518; LAI GM, 1988, BIOCHEM PHARMACOL, V37, P4597, DOI 10.1016/0006-2952(88)90325-5; LAI GM, 1989, JNCI-J NATL CANCER I, V81, P535, DOI 10.1093/jnci/81.7.535; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Legrand O, 1998, LEUKEMIA, V12, P1327, DOI 10.1038/sj.leu.2401096; LEONARD LJ, 1988, BIOCHEMISTRY-US, V27, P6156, DOI 10.1021/bi00416a049; LORICO A, 1988, CANCER RES, V48, P2036; LU SJ, 1995, CANCER RES, V55, P1139; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; MORIWAKI S-I, 1992, Journal of Dermatological Science, V4, P6, DOI 10.1016/0923-1811(92)90049-H; ORLOW SJ, 1995, P NATL ACAD SCI USA, V92, P10152, DOI 10.1073/pnas.92.22.10152; Overwijk WW, 1999, P NATL ACAD SCI USA, V96, P2982, DOI 10.1073/pnas.96.6.2982; Parkhurst MR, 1998, CANCER RES, V58, P4895; PAWELEK JM, 1990, BIOCHEM BIOPH RES CO, V166, P1328, DOI 10.1016/0006-291X(90)91011-G; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; Tief K, 1998, MOL BRAIN RES, V53, P307, DOI 10.1016/S0169-328X(97)00301-X; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; Young RC, 1989, DRUG RESISTANCE CANC; ZHEN WP, 1992, MOL CELL BIOL, V12, P3689, DOI 10.1128/MCB.12.9.3689	41	47	48	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					395	402		10.1038/sj.onc.1203315	http://dx.doi.org/10.1038/sj.onc.1203315			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656687				2022-12-17	WOS:000084873700010
J	Grishin, A; Sinha, S; Roginskaya, V; Boyer, MJ; Gomez-Cambronero, J; Zuo, S; Kurosaki, T; Romero, G; Corey, SJ				Grishin, A; Sinha, S; Roginskaya, V; Boyer, MJ; Gomez-Cambronero, J; Zuo, S; Kurosaki, T; Romero, G; Corey, SJ			Involvement of Shc and Cbl-PI 3-kinase in Lyn-dependent proliferative signaling pathways for G-CSF	ONCOGENE			English	Article						G-CSF; Lyn; PI 3-kinase; Cbl; Shc	COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASES; FACTOR-RECEPTOR; ANTIGEN RECEPTOR; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; P21(RAS) ACTIVATION; DISTINCT REGIONS; GROWTH-FACTOR; B-CELLS	Granulocyte colony-stimulating factor (G-CSF) is the major hematopoietic factor which controls the production and differentiation of granulocytes. The G-CSF receptor (G-CSFR) belongs to the superfamily of the cytokine receptors, which transduce signals via the activation of cytosolic protein tyrosine kinases (PTK), To determine the role of specific PTK in G-CSF signaling we expressed the human G-CSFR in cell lines derived from DT40 B cells, which lack either the Src-related Lyn or Syk, Wild-type (wt) and syk-deficient cells underwent increased DNA synthesis in response to G-CSF; lyn-deficient cells did not. The purpose of these studies is to identify Lyn's downstream effectors in mediating DNA synthesis, While G-CSF stimulated Pas activity in all cell lines, G-CSF failed to induce the tyrosine phosphorylation of Shc in lyn-deficient cells. G-CSF induced a statistically significant activation of Erk1/Erk2 Kinase or p90Rsk only in the wt cells. G-CSF induced the tyrosine phosphorylation of Cbl and increased activity of PI 3-kinase in wild-type and syk-deficient, but non in lyn-deficient, cells. Inhibition of Shc by over-expression of its SH2 or PTB domains or PI 3-kinase by either treatment with wortmannin or expression of the CblY731F mutant decreased G-CSF-induced DNA synthesis, Thus, the Lyn, Cbl-PI 3-kinase, and Shc/non-Pas-dependent pathways correlate with the ability of cells to respond to G-CSF with increased DNA synthesis.	Childrens Hosp Pittsburgh, Div Hematol Oncol, Pittsburgh, PA 15213 USA; Wright State Univ, Sch Med, Dept Physiol & Biophys, Dayton, OH 45401 USA; Kansai Med Univ, Dept Mol Genet, Inst Liver Res, Moriguchi, Osaka 570, Japan; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Ohio; Wright State University Dayton; Kansai Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Corey, SJ (corresponding author), Childrens Hosp Pittsburgh, Div Hematol Oncol, 3705 5th Ave, Pittsburgh, PA 15213 USA.		Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Gomez-Cambronero, Julian/0000-0002-7581-9227				BALDARI CT, 1995, ONCOGENE, V10, P1141; BASHEY A, 1994, BLOOD, V83, P949, DOI 10.1182/blood.V83.4.949.bloodjournal834949; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Corey SJ, 1998, J BIOL CHEM, V273, P3230, DOI 10.1074/jbc.273.6.3230; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DombroskyFerlan PM, 1997, ONCOGENE, V14, P2019, DOI 10.1038/sj.onc.1201031; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; Dorsch M, 1997, J EXP MED, V186, P1947, DOI 10.1084/jem.186.12.1947; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; Hashimoto A, 1999, J BIOL CHEM, V274, P20139, DOI 10.1074/jbc.274.29.20139; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Joseph DE, 1996, J BIOL CHEM, V271, P13088, DOI 10.1074/jbc.271.22.13088; KAWAUCHI K, 1994, J IMMUNOL, V152, P3306; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; NAGATA S, 1986, NATURE, V319, P415, DOI 10.1038/319415a0; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; PAN CX, 1993, J BIOL CHEM, V268, P25818; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	45	47	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					97	105		10.1038/sj.onc.1203254	http://dx.doi.org/10.1038/sj.onc.1203254			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644984				2022-12-17	WOS:000084844300011
J	Nur-E-Kamal, MSA; Kamal, JM; Qureshi, MM; Maruta, H				Nur-E-Kamal, MSA; Kamal, JM; Qureshi, MM; Maruta, H			The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-Ras-induced transformation	ONCOGENE			English	Article						CDC42; ACK; NGF; neurite outgrowth; Ras transformation; tumor suppressor	PROTEIN; BRADYKININ; GTPASE; GAP; ACTIVATION; DOMAIN; GROWTH	Based on the previous experiments with the N17 mutant of CDC42, it has been speculated, but not proved as yet, that CDC42 is required for Ras-induced malignant transformation of fibroblasts. However, since this inhibitor could sequester many GDP-dissociation stimulators (GDSs), such as DBL, OST and Tiam-1 which activate not only CDC42, but also Rho or Rac, in fact it is not a specific inhibitor that inactivates only CDC42, Thus, we have taken the minimum CDC42-binding domain (residues 504-545, called ACK42) of the Tyr-kinase ACK-1 that binds only CDC42 in the GTP-bound form, and thereby blocking the interactions of CDC42-GTP with its downstream effecters such as ACKs, PAKs and N-WASP, First of all, using the ACK42-GST fusion protein as a specific ligand for the GTP-CDC42 complex, we have revealed that CDC42 is activated by oncogenic Ras mutants such as v-Ha-Ras in NIH3T3 fibroblasts, and similarly in PC12 cells by both NGF (Nerve Growth Factor) and EGF (Epidermal Growth Factor) which activate the endogenous normal Ras, providing the first direct evidence that CDC42 acts downstream of Ras and NGF/EGF. Furthermore, over-expression of ACK42 completely reversed Ras-induced malignant phenotypes such as focus formation and anchorage/serum-independent growth of the fibroblasts, and a cell-permeable derivative of ACK42 called WR-ACK42 strongly inhibited the growth of Ras transformants, with little effect on the parental normal cell growth, and also abolished Ras-induced filopodium/microspike formation of the fibroblasts which is CDC42-dependent. These observations unambiguously proved for the first time that the RAS-induced activation of CDC42 is indeed essential for Ras to transform the fibroblasts, and furthermore suggest that ACK42 or its peptidomimetics are potentially useful for genotherapy or chemotherapy of Ras-associated cancer.	Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia; Univ Med & Dent New Jersey, RW Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; UAE Univ, Fac Med & Hlth Sci, Dept Biochem, Al Ain 17666, U Arab Emirates	Ludwig Institute for Cancer Research; Rutgers State University New Brunswick; Rutgers State University Medical Center; United Arab Emirates University	Maruta, H (corresponding author), Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia.							Aramori I, 1997, MOL PHARMACOL, V51, P171, DOI 10.1124/mol.51.2.171; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; DOWNWARD J, 1988, P NATL ACAD SCI USA, V85, P5774, DOI 10.1073/pnas.85.16.5774; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FRIDMAN M, 1994, J BIOL CHEM, V269, P30105; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Leblanc V, 1998, MOL CELL BIOL, V18, P5567, DOI 10.1128/MCB.18.9.5567; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MARUTA H, 1998, MOL B INT U, V3, P151; MARUTA H, 1996, REGULATION RAS SIGNA, P139; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Wang DZM, 1997, CANCER RES, V57, P2478; Williams EJ, 1997, J BIOL CHEM, V272, P22349, DOI 10.1074/jbc.272.35.22349; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819	27	47	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7787	7793						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618719				2022-12-17	WOS:000084256900008
J	Kongkanuntn, R; Bubb, VJ; Sansom, OJ; Wyllie, AH; Harrison, DJ; Clarke, AR				Kongkanuntn, R; Bubb, VJ; Sansom, OJ; Wyllie, AH; Harrison, DJ; Clarke, AR			Dysregulated expression of beta-catenin marks early neoplastic change in Apc mutant mice, but not all lesions arising in Msh2 deficient mice	ONCOGENE			English	Article						beta-catenin; Apc; p53; Msh2; intestine; pancreas	WNT SIGNALING PATHWAY; INTESTINAL ADENOMAS; NEGATIVE REGULATOR; COLORECTAL-CANCER; SOMATIC MUTATIONS; DESMOID TUMORS; GENE; CARCINOMA; COMPLEX; AXIN	We have analysed the pattern of beta-catenin expression by immunohistochemistry in mice singly or multiply mutant for Ape, p53 and Msh2. We observed increased expression of beta-catenin in all intestinal lesions arising on an Apc(Min) +/- background. In all categories of lesion studied mosaic patterns of beta-catenin expression were observed, with the proportion of cells showing enhanced expression decreasing with increasing lesion size. p53 statics did not alter these patterns. We also show that beta-catenin dysregulation marks pancreatic abnormalities occurring in Apc(Min) +/- and (Apc(Min) +/-, p53-/-) mice. In these mice both adenomas and adenocarcinomas of the pancreas arose and were characterized by increased expression of beta-catenin, We have extended these analyses to intestinal lesions arising in mice mutant for the mismatch repair gene Msh2, In these mice, increased expression of beta-catenin was again observed. However, in contrast with Apc(Min) +/- mice, a subset of lesions retained normal expression. Taken together, these findings show that increased expression of beta-catenin is an efficient marker of early neoplastic change in both murine intestine and pancreas in Ape mutant mice. However, we also show that dysregulation of beta-catenin is not an obligate step in the development of intestinal lesions, and therefore that genetic events other than the loss of Ape function may initiate the transition from normal to neoplastic epithelium.	Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Clarke, AR (corresponding author), Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.		clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Clarke, Alan/0000-0002-4281-426X; Sansom, Owen J./0000-0001-9540-3010				Alman BA, 1997, AM J PATHOL, V151, P329; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P1; Chen HY, 1997, J CELL SCI, V110, P345; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; de Wind N, 1998, CANCER RES, V58, P248; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Going JJ, 1996, J PATHOL, V179, P121; HORII A, 1992, CANCER RES, V52, P6696; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Inomata M, 1996, CANCER RES, V56, P2213; KASHIWABA M, 1994, J CANCER RES CLIN, V120, P727, DOI 10.1007/BF01194271; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LUONGO C, 1994, CANCER RES, V54, P5947; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; NAKATSURU S, 1992, HUM MOL GENET, V1, P559, DOI 10.1093/hmg/1.8.559; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Reitmair AH, 1996, CANCER RES, V56, P2922; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sheng HM, 1998, CARCINOGENESIS, V19, P543, DOI 10.1093/carcin/19.4.543; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shoemaker AR, 1997, BIOCHIM BIOPHYS ACTA, V1332, P25; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Sparks AB, 1998, CANCER RES, V58, P1130; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Takayama T, 1996, AM J PATHOL, V148, P39; THOMPSON AM, 1993, BRIT J CANCER, V68, P64, DOI 10.1038/bjc.1993.287; vanOordt CWV, 1997, CARCINOGENESIS, V18, P2197, DOI 10.1093/carcin/18.11.2197	43	47	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7219	7225		10.1038/sj.onc.1203181	http://dx.doi.org/10.1038/sj.onc.1203181			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602475				2022-12-17	WOS:000084119400005
J	Kikyo, M; Tanaka, K; Kamei, T; Ozaki, K; Fujiwara, T; Inoue, E; Takita, Y; Ohya, Y; Takai, Y				Kikyo, M; Tanaka, K; Kamei, T; Ozaki, K; Fujiwara, T; Inoue, E; Takita, Y; Ohya, Y; Takai, Y			An FH domain-containing Bnr1p is a multifunctional protein interacting with a variety of cytoskeletal proteins in Saccharomyces cerevisiae	ONCOGENE			English	Article						Rho; formin-like protein; septins	GTP-BINDING PROTEIN; ACTIN CYTOSKELETON; EXCHANGE PROTEINS; ESCHERICHIA-COLI; SHUTTLE VECTORS; CELL DIVISION; BUD SITE; YEAST; BNI1P; CYTOKINESIS	Proteins containing formin homology domains, FH1 and FH2, are involved in cytokinesis or establishment of cell polarity in a variety of organisms. Bni1p and Bnr1p are FPF proteins and potential targets of the Rho family small GTP-binding proteins in S. cerevisiae. We have shown that Bnr1p is localized at the bud neck to interact with Hof1p, involved in cytokinesis. We report here that the overexpression of BNR1 causes a cytokinesis deficiency which is similar to the phenotypes of the septin mutants, including cdc3, cdc10, cdc11, and cdc12. The region required for the septin mutant phenotypes was mapped to Bnr1p (35-500), which coincided,vith the region required for the bud-neck localization. To further isolate a gene interacting with BNI1 or BNR1, a multicopy suppressor of the bni1 bnr1 mutant was isolated. This gene encoded Smy1p, a kinesin-related protein. Bnr1p, but not Bni1p, directly interacted with the C-terminal region of Smy1p. The Smy1p-interacting region of Bnr1p was mapped to a region containing the FH2 domain. Bnr1p also directly interacted with Bud6p, a novel actin-binding protein. Bnr1p is thus a multifunctional protein which interacts with the septin system, a microtubule-dependent motor protein, and the actin system, to regulate cytoskeletal functions in S. cerevisiae.	Osaka Univ, Grad Sch Med, Fac Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Bunkyo Ku, Tokyo 1130033, Japan	Osaka University; University of Tokyo	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Biochem & Mol Biol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Kuroda, Kumi O/A-3312-2013; Yashiroda, Yoko/C-8769-2014	Kuroda, Kumi O./0000-0001-7037-1753				BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carroll CW, 1998, J CELL BIOL, V143, P709, DOI 10.1083/jcb.143.3.709; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; DIGUAN C, 1988, GENE, V67, P21, DOI 10.1016/0378-1119(88)90004-2; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; FLESCHER EG, 1993, J CELL BIOL, V122, P373, DOI 10.1083/jcb.122.2.373; FRAZIER JA, 1997, CURR BIOL, V7, P414; Fujiwara T, 1998, MOL BIOL CELL, V9, P1221, DOI 10.1091/mbc.9.5.1221; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Giot L, 1997, MOL BIOL CELL, V8, P987, DOI 10.1091/mbc.8.6.987; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Kamei T, 1998, J BIOL CHEM, V273, P28341, DOI 10.1074/jbc.273.43.28341; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lillie SH, 1998, J CELL BIOL, V140, P873, DOI 10.1083/jcb.140.4.873; LILLIE SH, 1992, NATURE, V356, P358, DOI 10.1038/356358a0; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Longtine MS, 1998, J CELL BIOL, V143, P719, DOI 10.1083/jcb.143.3.719; Mino A, 1998, BIOCHEM BIOPH RES CO, V251, P732, DOI 10.1006/bbrc.1998.9541; NAKATSURU S, 1994, BIOCHEM BIOPH RES CO, V202, P82, DOI 10.1006/bbrc.1994.1896; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SANDERS SL, 1994, CURR BIOL, V4, P907, DOI 10.1016/S0960-9822(00)00201-3; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Tanaka K, 1998, CURR OPIN CELL BIOL, V10, P112, DOI 10.1016/S0955-0674(98)80093-8; Umikawa M, 1998, ONCOGENE, V16, P2011, DOI 10.1038/sj.onc.1201724; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	39	47	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					7046	7054		10.1038/sj.onc.1203184	http://dx.doi.org/10.1038/sj.onc.1203184			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597305				2022-12-17	WOS:000083901900011
J	Abdollahi, A; Bao, R; Hamilton, TC				Abdollahi, A; Bao, R; Hamilton, TC			LOT1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein	ONCOGENE			English	Article						LOT1; ovary; epidermal growth factor; EGFR; TGF-alpha; cancer	SURFACE EPITHELIAL-CELLS; HUMAN-BREAST-CANCER; OVARIAN-CANCER; OKADAIC ACID; TRANSCRIPTIONAL ACTIVATION; SPONTANEOUS TRANSFORMATION; TYROSINE PHOSPHORYLATION; MYELOID DIFFERENTIATION; INCESSANT OVULATION; SIGNAL-TRANSDUCTION	We previously reported cloning the rLot1 gene, and its human homolog (hLOT1), through analysis of differential gene expression in normal and malignant rat ovarian surface epithelial cells. Both human and rat ovarian carcinoma cell lines exhibited lost or decreased expression of this gene. Interestingly, the LOT1 gene localized at band q25 of human chromosome 6 which is a frequent site for LOH in many solid tumors including ovarian cancer. In this report we have further characterized the potential role of LOT1 in malignant transformation and developed evidence that the gene is a novel target of growth factor signaling pathway. Assays using transient transfections showed that LOT1 is a nuclear protein and may act as a transcription factor. In vitro and lit vivo studies involving ovarian cancer cell lines revealed that expression of LOT1 is directly associated with inhibition of cellular proliferation and induction of morphological transformations. Additionally, we show that in normal rat ovarian surface epithelial cells Lot1 gene expression is responsive to growth factor stimulation. Its mRNA is strongly down-regulated by epidermal growth factor receptor (EGFR) ligands, namely EGF and TGF-alpha. Blocking the ligand-activated EGFR signal transduction pathway by the specific EGF receptor inhibitor, tyrphostin AG1478, and the MEK inhibitor, PD098059, restores the normal level of Lot1 gene expression. It appears that the regulation of Lot1 gene is unique to these ligands, as well as the growth promoting agent TPA, since other factors either did not affect Lot1 expression, or the effect was modest and transient. Altogether, the results suggest that Lot1 expression is primarily mediated via EGF receptor or a related pathway and it may regulate the growth promoting signals as a zinc-finger motif containing nuclear transcription factor.	Fox Chase Canc Ctr, Dept Med Oncol, Ovarian Canc Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Abdollahi, A (corresponding author), Fox Chase Canc Ctr, Dept Med Oncol, Ovarian Canc Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NCI NIH HHS [CA56916] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056916] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 1999, J SOC GYNECOL INVEST, V6, P32, DOI 10.1016/S1071-5576(98)00048-3; Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; AHARONOV A, 1978, J BIOL CHEM, V253, P3970; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Batt DB, 1998, J BIOL CHEM, V273, P3408, DOI 10.1074/jbc.273.6.3408; BAUKNECHT T, 1986, CANCER RES, V46, P2614; BERCHUCK A, 1990, OBSTET GYNECOL, V75, P255; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CARPENTER G, 1976, J CELL PHYSIOL, V88, P227, DOI 10.1002/jcp.1040880212; CARPENTER G, 1981, HDB EXPT PHARM, V57, P90; CASAGRANDE JT, 1979, LANCET, V2, P170; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; Cheng AY, 1998, CANCER RES, V58, P3611; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Colitti CV, 1998, ONCOGENE, V16, P555, DOI 10.1038/sj.onc.1201523; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; COURNEY A, 1988, CELL, V55, P741; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Emkey R, 1997, J BIOL CHEM, V272, P31172, DOI 10.1074/jbc.272.49.31172; ESKRAND A, 1994, ONCOGENE, V9, P2313; FATHALLA MF, 1971, LANCET, V2, P163; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; GODWIN AK, 1992, J NATL CANCER I, V84, P592, DOI 10.1093/jnci/84.8.592; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1984, NATURE, V311, P414, DOI 10.1038/311414a0; Ilekis JV, 1997, GYNECOL ONCOL, V65, P36, DOI 10.1006/gyno.1996.4526; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; KOMMOSS F, 1990, J PATHOL, V162, P223, DOI 10.1002/path.1711620308; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MELLON K, 1995, J UROLOGY, V153, P919, DOI 10.1016/S0022-5347(01)67604-3; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOON SO, 1984, P NATL ACAD SCI-BIOL, V81, P2298, DOI 10.1073/pnas.81.8.2298; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORISHIGE KI, 1991, CANCER RES, V51, P5322; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PONTECORVI A, 1988, EMBO J, V7, P1489, DOI 10.1002/j.1460-2075.1988.tb02967.x; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; Rani CSS, 1997, J BIOL CHEM, V272, P10777; ROBERTS D, 1999, UNPUB; RODRIGUEZ GC, 1991, AM J OBSTET GYNECOL, V164, P745, DOI 10.1016/0002-9378(91)90508-O; SAINSBURY JRC, 1985, LANCET, V1, P364; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SCAMBIA G, 1992, J CLIN ONCOL, V10, P529, DOI 10.1200/JCO.1992.10.4.529; SHECHTER Y, 1978, P NATL ACAD SCI USA, V75, P5788, DOI 10.1073/pnas.75.12.5788; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TANAKA K, 1989, CANCER GENET CYTOGEN, V43, P1, DOI 10.1016/0165-4608(89)90122-2; TESTA JR, 1994, CANCER RES, V54, P2778; THRASHBINGHAM CA, 1995, CANCER RES, V55, P6189; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; YAMAMOTO T, 1986, CANCER RES, V46, P414; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU L, 1988, CELL, V55, P1005	85	47	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6477	6487		10.1038/sj.onc.1203067	http://dx.doi.org/10.1038/sj.onc.1203067			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597250				2022-12-17	WOS:000083709200010
J	Murphy, KL; Kittrell, FS; Gay, JP; Jager, R; Medina, D; Rosen, JM				Murphy, KL; Kittrell, FS; Gay, JP; Jager, R; Medina, D; Rosen, JM			Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice	ONCOGENE			English	Article						Bcl-2; mammary tumorigenesis; DMBA; transgenic mice	CELL-DEATH; EPITHELIAL-CELLS; DNA-DAMAGE; MUTANT P53; APOPTOSIS; TUMORIGENESIS; OVEREXPRESSION; GLAND; PROLIFERATION; MORPHOGENESIS	Bcl-2 is known to have dual antiproliferative and antiapoptotic roles. Overexpression of Bcl-2 in the mammary gland using a whey acidic protein (WAP) promoter-driven Bcl-2 transgene inhibits apoptosis in the mammary gland during pregnancy, lactation, and involution, and also counteracts apoptosis induced by overexpression of a mutant p53 transgene (WAP-p53 172 R-L), WAP-Bcl-2 mice and nontransgenic controls were treated with the carcinogen dimethylbenz(a)anthracene (DMBA), Surprisingly, the nontransgenic mice developed mammary tumors with decreased latency. Tumors arising in WAP-Bcl-2 mice displayed substantially reduced levels of proliferation relative to those seen in nontransgenic mice (P<0.015), perhaps resulting in the observed increase in tumor latency following carcinogen treatment. This WAP-Bcl-2 mouse tumor model reflects the situation seen in some human breast cancers overexpressing Bcl-2, where expression of Bcl-2 has been shown to correlate with a lower proliferative index in tumors.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany	Baylor College of Medicine; Baylor College of Medicine; Helmholtz Association; Karlsruhe Institute of Technology	Rosen, JM (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Jager, Richard/B-9478-2009	Jager, Richard/0000-0002-1623-1917	NATIONAL CANCER INSTITUTE [R01CA016303, R37CA016303] Funding Source: NIH RePORTER; NCI NIH HHS [CA16303] Funding Source: Medline; NIGMS NIH HHS [GM08231] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; CHRISTOV K, 1993, CARCINOGENESIS, V14, P2019, DOI 10.1093/carcin/14.10.2019; Friedrich K, 1995, PATHOL RES PRACT, V191, P1114, DOI 10.1016/S0344-0338(11)80656-4; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LI BL, 1994, CELL GROWTH DIFFER, V5, P711; LI BL, 1995, MOL CARCINOGEN, V14, P75, DOI 10.1002/mc.2940140203; LU PJ, 1995, J CELL BIOL, V129, P1363, DOI 10.1083/jcb.129.5.1363; LunaMore S, 1996, PATHOL RES PRACT, V192, P27, DOI 10.1016/S0344-0338(96)80126-9; MARIN MC, 1994, ONCOGENE, V9, P3107; MEDINA D, 1974, J NATL CANCER I, V53, P213, DOI 10.1093/jnci/53.1.213; Merlo GR, 1997, CELL GROWTH DIFFER, V8, P251; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610; Siziopikou KP, 1996, CANCER, V77, P499, DOI 10.1002/(SICI)1097-0142(19960201)77:3<499::AID-CNCR11>3.0.CO;2-#; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TEIXEIRA C, 1995, CANCER RES, V55, P3902	23	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6597	6604		10.1038/sj.onc.1203099	http://dx.doi.org/10.1038/sj.onc.1203099			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597264				2022-12-17	WOS:000083709200024
J	Watabe, M; Kakeya, H; Osada, H				Watabe, M; Kakeya, H; Osada, H			Requirement of protein kinase (Krs/MST) activation for MT-21-induced apoptosis	ONCOGENE			English	Article						apoptosis; Krs/MST; caspase; protein kinase	FAS-MEDIATED APOPTOSIS; INTERLEUKIN-1-BETA CONVERTING-ENZYME; HUMAN NEUROBLASTOMA-CELLS; LEUKEMIA U937 CELLS; PROTEOLYTIC ACTIVATION; SIGNALING PATHWAYS; LAMIN-A; CLEAVAGE; DEATH; PROTEASES	Fas is a well characterized apoptosis-inducing factor. One of our synthetic compounds, MT-21, induced apoptosis in human leukemia HL-60 cells similar to Fas, MT-21 activated caspase-3, an important cysteine aspartic protease for apoptosis induction. MT-21 also activated c-Jun-NH2-terminal kinase (JNK), a member of mitogen activated protein kinase (MAPK) superfamily that is involved in the regulation of cell growth, differentiation and cell death. Moreover, MT-21 treatment resulted in the activation of a 36 kDa kinase which uses myelin basic protein (MBP) as a substrate. However, MAPK and p38 were not activated by treatment with MT-21. The 36 kDa MBP kinase was shown to be a proteolytic product derived from the Krs protein with a molecular weight of 60 kDa. The Krs protein is a Ser/Thr protein kinase whose activity is enhanced by digestion of its C-terminal regulatory domain by caspase-3, When a kinase-inactive mutant form of Krs protein was overexpressed in HL-60 cells, JNK activation and apoptosis induction by MT-21 were suppressed. Furthermore, overexpression of dominant negative c-Jun also suppressed apoptosis induction by MT-21. These findings indicate that MT-21 induces apoptosis by the activation of JNK via the Krs protein, which is activated by caspase cleavage.	RIKEN, Inst Phys & Chem Res, Lab Antibiot, Wako, Saitama 3510198, Japan	RIKEN	Osada, H (corresponding author), RIKEN, Inst Phys & Chem Res, Lab Antibiot, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Osada, Hiroyuki/N-4305-2014; Osada, Hiroyuki/AAY-6254-2020; Kakeya, Hideaki/B-3527-2012	Kakeya, Hideaki/0000-0002-4293-7331				Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cahill MA, 1996, ONCOGENE, V13, P2087; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Crouch DH, 1996, ONCOGENE, V12, P2689; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530, DOI 10.1093/nar/23.21.4530; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Hasegawa J, 1996, CANCER RES, V56, P1713; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KAKEYA H, 1995, J ANTIBIOT, V48, P733, DOI 10.7164/antibiotics.48.733; Kakeya H, 1997, J MED CHEM, V40, P391, DOI 10.1021/jm960719a; Kakeya H, 1998, CANCER RES, V58, P4888; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; Lu ML, 1996, P NATL ACAD SCI USA, V93, P8977, DOI 10.1073/pnas.93.17.8977; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Simizu S, 1996, CANCER RES, V56, P4978; Takahashi A, 1996, J BIOL CHEM, V271, P32487, DOI 10.1074/jbc.271.51.32487; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; THORNBERRY NA, 1995, PROTEIN SCI, V4, P3; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Watabe M, 1996, J BIOL CHEM, V271, P14067, DOI 10.1074/jbc.271.24.14067; Watabe M, 1998, ONCOGENE, V16, P779, DOI 10.1038/sj.onc.1201592; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	47	47	50	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5211	5220		10.1038/sj.onc.1202901	http://dx.doi.org/10.1038/sj.onc.1202901			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498871				2022-12-17	WOS:000082555700010
J	Ayoubi, TAY; Jansen, E; Meulemans, SMP; Van de Ven, WJM				Ayoubi, TAY; Jansen, E; Meulemans, SMP; Van de Ven, WJM			Regulation of HMGIC expression: an architectural transcription factor involved in growth control and development	ONCOGENE			English	Article						HMGIC; gene expression; promoter activity; growth factors; solid tumor formation	BENIGN MESENCHYMAL TUMORS; GENE-EXPRESSION; DNA-BINDING; ADIPOCYTE DIFFERENTIATION; FUNCTIONAL INTERACTION; CHROMOSOMAL-PROTEINS; C GENE; DISTINCT; INHIBITION; DOMAIN	The HMGIC gene has been implicated in the control of cell proliferation and development. We show here that HMGIC has multiple mRNA isoforms that arise by transcription initiation from alternative tandem promoters. These transcripts are not only differentially expressed between cell lines, but they can also differ within an individual cell line, in response to particular stimuli. Whereas quiescent 3T3-L1 preadipocytes express low levels of HMGIC mRNA, stimulation by serum results in a dramatic upregulation with the characteristics of a delayed-early response gene. Characterization of involved signal transduction pathways showed that both FGF-1 and PDGF-BB are strong inducers of HMGIC expression mediated via both the PI-3 kinase and MAP kinase pathways. In order to characterize the regulatory elements, sequences upstream of the translation initiation site of HMGIC were assayed for promoter activity. The HMGIC 5' flanking sequences had constitutive promoter activity in all cell lines tested, suggesting that HMGIC is regulated by negative regulatory elements that were not present in the 5'-flanking regions analysed here.	Univ Leuven VIB, Ctr Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven	Jansen, E (corresponding author), Univ Leuven VIB, Ctr Human Genet, Mol Oncol Lab, Herestr 49, B-3000 Louvain, Belgium.							ANDREWS PW, 1988, BIOCHIM BIOPHYS ACTA, V948, P17, DOI 10.1016/0304-419X(88)90003-0; ASHAR HR, 1995, CELL, V82, P57; Ashar HR, 1996, GENOMICS, V31, P207, DOI 10.1006/geno.1996.0033; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; CHAU KY, 1995, NUCLEIC ACIDS RES, V23, P4262, DOI 10.1093/nar/23.21.4262; Chiappetta G, 1998, CANCER RES, V58, P4193; Currie RA, 1997, J BIOL CHEM, V272, P30880, DOI 10.1074/jbc.272.49.30880; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Elferink CJ, 1996, BIOTECHNIQUES, V20, P470; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; Geurts JMW, 1997, CANCER GENET CYTOGEN, V95, P198, DOI 10.1016/S0165-4608(96)00411-6; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; HYUN SW, 1994, J BIOL CHEM, V269, P364; Ishwad CS, 1997, HUM GENET, V99, P103; Jansen E, 1997, J BIOL CHEM, V272, P2500; JANSEN E, 1999, GENE THER MOL BIOL, V3, P387; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Kazmierczak B, 1998, GENE CHROMOSOME CANC, V23, P279, DOI 10.1002/(SICI)1098-2264(199812)23:4<279::AID-GCC1>3.0.CO;2-1; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LEGER H, 1995, MOL CELL BIOL, V15, P3738; Levitzki A, 1996, CURR OPIN CELL BIOL, V8, P239, DOI 10.1016/S0955-0674(96)80071-8; Manfioletti G, 1995, GENE, V167, P249, DOI 10.1016/0378-1119(95)00666-4; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; Moore DD, 1995, GLOB MOB SURV; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; PARK K, 1992, J BIOL CHEM, V267, P10810; REEVES R, 1990, J BIOL CHEM, V265, P8573; SCHAEFER BC, 1995, ANAL BIOCHEM, V227, P255, DOI 10.1006/abio.1995.1279; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SMAS CM, 1995, BIOCHEM J, V309, P697, DOI 10.1042/bj3090697; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Zhou XJ, 1996, NUCLEIC ACIDS RES, V24, P4071, DOI 10.1093/nar/24.20.4071	41	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5076	5087		10.1038/sj.onc.1202881	http://dx.doi.org/10.1038/sj.onc.1202881			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490844				2022-12-17	WOS:000082497100007
J	Vigna, E; Gramaglia, D; Longati, P; Bardelli, A; Comoglio, PM				Vigna, E; Gramaglia, D; Longati, P; Bardelli, A; Comoglio, PM			Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET	ONCOGENE			English	Article						MET-receptor; Tpr-Met; transformation	HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE RECEPTOR; SCATTER FACTOR-RECEPTOR; C-MET; CONSTITUTIVE ACTIVATION; INVASIVE-GROWTH; REGULATORY SITE; HGF-RECEPTOR; CELL-LINE; TRANSFORMATION	TPR-MET, a transforming counterpart of the c-MET proto-oncogene detected in experimental and human cancer, results from fusion of the MET kinase domain with a dimerization motif encoded by TPR. In this rearrangement the exons encoding the Met extracellular, transmembrane and juxtamembrane domains are lost. The juxtamembrane domain has been suggested to be a regulatory region endowed with negative feedback control. To understand whether its absence is critical for the generation of the Tpr-Met transforming potential, we produced a chimeric molecule (Tpr-juxtaMet) with a conserved juxtamembrane domain. The presence of the domain (aa 962-1009) strongly inhibited Tpr-Met dependent cell transformation. Cell proliferation, anchorage-independent growth, motility and invasion were also impaired. The enzymatic behavior of Tpr-Met and Tpr-juxtaMet was the same, while Tpr-juxtaMet ability to associate cytoplasmic signal transducers and to elicit downstream signaling was severely impaired. These data indicate that the presence of the juxtamembrane domain counterbalances the Tpr-Met transforming potential and therefore the loss of the exon encoding the juxtamembrane domain is crucial in the generation of the active TPR-MET oncogene.	Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Turin, Italy	University of Turin	Vigna, E (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, Str Prov 142,Km 3-95, I-10060 Turin, Italy.		GRAMAGLIA, DANIELA/A-6354-2012; BARDELLI, Alberto/J-9721-2018	Gramaglia, Daniela/0000-0001-6259-0059; BARDELLI, Alberto/0000-0003-1647-5070; Vigna, Elisa/0000-0001-9787-5732; Comoglio, Paolo/0000-0002-7056-5328				ALBINI A, 1987, CANCER RES, V47, P3239; Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GANDINO L, 1990, ONCOGENE, V5, P721; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; KATMATKAR S, 1996, J BIOL CHEM, V271, P26755; LEE CC, 1995, J BIOL CHEM, V270, P507, DOI 10.1074/jbc.270.2.507; LEE CC, 1994, J BIOL CHEM, V269, P19457; Liang TJ, 1996, J CLIN INVEST, V97, P2872, DOI 10.1172/JCI118744; LONGATI P, 1994, ONCOGENE, V9, P49; Michieli P, 1996, ONCOGENE, V12, P775; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RADHA V, 1994, BIOCHEM J, V299, P4600; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; SOMAN NR, 1990, P NATL ACAD SCI USA, V87, P738, DOI 10.1073/pnas.87.2.738; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; Villa-Moruzzi E, 1998, BIOCHEM J, V336, P235, DOI 10.1042/bj3360235; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; ZHEN Z, 1994, ONCOGENE, V9, P1691	39	47	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4275	4281		10.1038/sj.onc.1202791	http://dx.doi.org/10.1038/sj.onc.1202791			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435641				2022-12-17	WOS:000081542400012
J	Koga, H; Matsui, S; Hirota, T; Takebayashi, S; Okumura, K; Saya, H				Koga, H; Matsui, S; Hirota, T; Takebayashi, S; Okumura, K; Saya, H			A human homolog of Drosophila lethal(3)malignant brain tumor (1(3)mbt) protein associates with condensed mitotic chromosomes	ONCOGENE			English	Article						h-1(3)mbt; PcG; tumor suppressor gene; multinucleated cells; Cre-mediated gene activation system	EFFICIENT GENE ACTIVATION; POLYCOMB-GROUP PROTEINS; CRE RECOMBINASE; AXIAL SKELETON; BREAST-CANCER; HUMAN GENOME; ZINC-FINGER; CELL-CYCLE; MELANOGASTER; EXPRESSION	The lethal(3)malignant brain tumor (D-l(3)mbt) gene is considered to be one of the tumor suppressor genes of Drosophila, and its recessive mutations are associated with malignant transformation of the neuroblasts in the larval brain. The structure of D-l(3)mbt protein is similar to Drosophila sex comb on midleg (Scm) protein which is a member of Polycomb group (PcG) proteins. We have isolated here the first human homolog of the D-l(3)mbt gene, designated h-l(3)mbt. Radiation hybrid mapping and fluorescence in situ hybridization (FISH) analysis localized the h-l(3)mbt gene to chromosome 20q12. The k-l(3)mbt transcript is expressed in most of the human adult normal tissues and cultured cell lines. However, some cancer cells markedly reduce the h-l(3)mbt protein expression. Immunocytochemical study revealed that the h-l(3)mbt protein shows a speckled and scattered distribution in interphase nuclei and completely associates with condensed chromosomes in mitotic cells. This subcellular localization has been shown to be different from that of Bmi1 protein which is a component of PcG complex. Furthermore, overexpression of h-l(3)mbt protein by using a Cre-mediated gene activation system leads to failures of proper chromosome segregation and cytokinesis, which result in formation of multinuclei in U251MG cells. These observations suggest that h-l(3)mbt protein has functions distinct from those of PcG proteins and may play a role in proper progression of cell division.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Mie Univ, Fac Bioresources, Biol Chem Lab, Tsu, Mie 5148507, Japan	Kumamoto University; Mie University	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Saya, Hideyuki/J-4325-2013					ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Akasaka T, 1996, DEVELOPMENT, V122, P1513; Alkema MJ, 1997, J MOL BIOL, V273, P993, DOI 10.1006/jmbi.1997.1372; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bornemann D, 1996, DEVELOPMENT, V122, P1621; Buchenau P, 1998, J CELL BIOL, V141, P469, DOI 10.1083/jcb.141.2.469; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GATEFF E, 1993, MECH DEVELOP, V41, P15, DOI 10.1016/0925-4773(93)90052-Y; GATEFF E, 1989, Critical Reviews in Oncogenesis, V1, P221; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; Guan XY, 1996, CANCER RES, V56, P3446; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Jones CA, 1998, MOL CELL BIOL, V18, P2825, DOI 10.1128/MCB.18.5.2825; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; KELLUM R, 1995, J CELL SCI, V108, P1407; Kodjabachian L, 1998, EMBO J, V17, P1063, DOI 10.1093/emboj/17.4.1063; Makino K, 1997, ONCOGENE, V14, P2425, DOI 10.1038/sj.onc.1201087; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; Nakamura H, 1998, ONCOGENE, V16, P1009, DOI 10.1038/sj.onc.1201618; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; Tanner MM, 1996, CANCER RES, V56, P3441; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; van Lohuizen M, 1998, CELL MOL LIFE SCI, V54, P71, DOI 10.1007/s000180050126; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; vanderLugt NMT, 1996, MECH DEVELOP, V58, P153, DOI 10.1016/S0925-4773(96)00570-9; WATSON KL, 1994, J CELL SCI, P19; WISMAR J, 1995, MECH DEVELOP, V53, P141, DOI 10.1016/0925-4773(95)00431-9; Yamamoto Y, 1997, DEVELOPMENT, V124, P3385	37	47	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	1999	18	26					3799	3809		10.1038/sj.onc.1202732	http://dx.doi.org/10.1038/sj.onc.1202732			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445843				2022-12-17	WOS:000081171700001
J	Loden, M; Nielsen, NH; Roos, G; Emdin, SO; Landberg, G				Loden, M; Nielsen, NH; Roos, G; Emdin, SO; Landberg, G			Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation	ONCOGENE			English	Article						breast cancer; cyclin E; p27; p21; retinoblastoma protein; kinase activity	UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE; INHIBITOR P27; P53 PROTEIN; FUNCTIONAL INACTIVATION; E OVEREXPRESSION; ABNORMAL P53; MICE LACKING; G(1) CYCLINS; P27(KIP1)	The cell cycle machinery is regulated by cyclin dependent kinases and sets of activating and inhibitory proteins, The G1-S control mechanism is often deregulated in tumours supposedly leading to increased kinase activity, phosphorylation of substrates and subsequent S phase entrance. Increased kinase activity has been proposed to be essential in cell cycle aberrations, but few studies have actually shown enhanced kinase activity related to specific cell cycle defects in primary tumours, In the present study we have determined the cyclin E dependent kinase activity (cyclin E-kinase) in 59 primary breast cancers, using an H1-kinase assay, and related the activity to the expression of cyclin E, p27 and p21, In a subgroup of 48 tumours, we further characterized the association between cyclin E-kinase, in vivo phosphorylation of the retinoblastoma protein (pRb) and proliferation. The cyclin E-kinase correlated significantly with cyclin E content and inversely with p27 and p21 expression. P27, but not p21, was associated with low cyclin E-kinase in specimens with normal/low levels of cyclin E, At elevated cyclin E levels, suppression of cyclin E-kinase seemed to require high levels of both p21 and p27, The cyclin E-kinase correlated with the phosphorylation status of pRb as well as with proliferation. Surprisingly, pRb phosphorylation did not correlate with proliferation. Our results support that pRb is a substrate for cyclin E-kinase in primary breast cancer and that deregulation of cyclin E and p27 act through increased CDK-kinase activity, but cyclin E associated events beside pRb phosphorylation might be rate-limiting for entrance into S phase.	Umea Univ, Dept Pathol, S-90187 Umea, Sweden; Umea Univ, Dept Surg, S-90187 Umea, Sweden; Umea Univ, Dept Oncol, S-90187 Umea, Sweden	Umea University; Umea University; Umea University	Landberg, G (corresponding author), Umea Univ, Dept Pathol, S-90187 Umea, Sweden.							Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bukholm IK, 1997, J PATHOL, V181, P140, DOI 10.1002/(SICI)1096-9896(199702)181:2<140::AID-PATH745>3.0.CO;2-A; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Ellis PA, 1997, BRIT J CANCER, V76, P480, DOI 10.1038/bjc.1997.413; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Ferrando AA, 1996, HUM GENET, V97, P91; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang M, 1997, INT J CANCER, V74, P529, DOI 10.1002/(SICI)1097-0215(19971021)74:5<529::AID-IJC9>3.0.CO;2-5; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Landberg G, 1997, APMIS, V105, P575, DOI 10.1111/j.1699-0463.1997.tb05056.x; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LUKAS J, 1995, CANCER RES, V55, P4818; Lukas J, 1997, AM J PATHOL, V150, P167; LUKAS J, 1997, GENE DEV, V11, P1492; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MOUSSES S, 1995, HUM MOL GENET, V4, P1089, DOI 10.1093/hmg/4.6.1089; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; NIELSEN NH, 1999, IN PRESS BREAST CANC; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Sgambato A, 1996, CANCER RES, V56, P1389; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Tan P, 1997, CANCER RES, V57, P1259; Wakasugi E, 1997, AM J CLIN PATHOL, V107, P684; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yasui W, 1996, VIRCHOWS ARCH, V429, P13; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456	48	47	48	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2557	2566		10.1038/sj.onc.1202488	http://dx.doi.org/10.1038/sj.onc.1202488			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353599				2022-12-17	WOS:000079907100003
J	Abujiang, P; Mori, TJ; Takahashi, T; Tanaka, F; Kasyu, I; Hitomi, S; Hiai, H				Abujiang, P; Mori, TJ; Takahashi, T; Tanaka, F; Kasyu, I; Hitomi, S; Hiai, H			Loss of heterozygosity (LOH) at 17q and 14q in human lung cancers	ONCOGENE			English	Article						pulmonary adenoma; lung cancer; LOH; tumor suppressor gene	EPITHELIAL OVARIAN-TUMORS; HUMAN PROSTATE-CANCER; CHROMOSOME 17Q; BREAST CARCINOMAS; SOMATIC MUTATIONS; SUPPRESSOR LOCI; BRCA1; GENE; ALLELOTYPE	Our recent linkage study of urethane-induced pulmonary adenomas in SMXA RI strains of mouse revealed two host resistance genes, Par1 (chromosome 11) and Par3 (chromosome 12). The map positions of Par1 and Par3 correspond to human 17q11-23 and 14q11-24, based on synteny between mouse and human. In this study, we examined the loss of heterozygosity (LOH) in these two homologous human chromosomal regions in 30 primary lung adenocarcinoma samples with matched normal DNA. Using 15 highly polymorphic markers, two commonly deleted regions were identified on human chromosomes 14 and 17, respectively. At 17q21, nine (53%) of 17 informative tumors showed LOH between D17S588 and D17S518. On the other hand, at 14q11-12, seven (32%) of 22 informative tumors showed LOH at loci between D14S261 and D14S80. Subsequently, we examined 25 squamous cell carcinomas (SQ) and 24 small cell carcinomas (SCC). At 14q11-12, six (38%) of 16 informative SQ and five (42%) of 12 informative SCC showed LOH. In contrast, at 17q11-23, one (7%) of 15 informative SQ and two (14%) of 14 SCC showed LOH. Therefore, the gene on 17q seemed to affect selectively adenocarcinomas, whereas the other gene on 14q, all three types of lung carcinomas. These observations indicate that a comparative genetic analysis provides a promising approach to survey genes involved in multifactorial process of human lung carcinogenesis.	Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068051, Japan; Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 464, Japan; Kyoto Univ, Chest Dis Res Inst, Dept Thorac Surg, Sakyo Ku, Kyoto 606, Japan	Kyoto University; Aichi Cancer Center; Kyoto University	Hiai, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068051, Japan.		Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001				ABUJIANG P, 1997, CANCER RES, V57, P2904; ABUJIANG P, 1996, CANCER RES, V56, P3716; Canzian F, 1996, CANCER RES, V56, P3331; CARBONE DP, 1992, ADV INTERNAL MED, V37, P153; CHANG WYH, 1995, CANCER RES, V55, P3246; CLIBY W, 1993, CANCER RES, V53, P2393; CLIBY W, 1993, GYNECOL ONCOL, V50, P34, DOI 10.1006/gyno.1993.1160; CROPP CS, 1993, CANCER RES, V53, P5617; Dragani TA, 1995, ADV CANCER RES, V67, P83, DOI 10.1016/S0065-230X(08)60711-3; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; FONG KM, 1995, CANCER RES, V55, P4268; GAO X, 1995, CANCER RES, V55, P1002; GAO X, 1995, ONCOGENE, V11, P1241; Jandrig B, 1996, INT J CANCER, V68, P188, DOI 10.1002/(SICI)1097-0215(19961009)68:2<188::AID-IJC8>3.0.CO;2-U; MALKINSON AM, 1992, CANCER RES, V52, pS2670; Manenti G, 1997, CANCER RES, V57, P4164; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; Niederacher D, 1997, GENE CHROMOSOME CANC, V18, P181, DOI 10.1002/(SICI)1098-2264(199703)18:3<181::AID-GCC5>3.0.CO;2-Y; SATO T, 1993, GENOMICS, V17, P762, DOI 10.1006/geno.1993.1402; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; THRASHBINGHAM CA, 1995, P NATL ACAD SCI USA, V92, P2854, DOI 10.1073/pnas.92.7.2854; TSUCHIYA E, 1992, CANCER RES, V52, P2478; Wertheim I, 1996, ONCOGENE, V12, P2147; ZHANG J, 1995, CHINESE MED J, V75, P211	24	47	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	1998	17	23					3029	3033		10.1038/sj.onc.1202230	http://dx.doi.org/10.1038/sj.onc.1202230			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881705				2022-12-17	WOS:000077427800010
J	Izawa, I; Amano, M; Chihara, K; Yamamoto, T; Kaibuchi, K				Izawa, I; Amano, M; Chihara, K; Yamamoto, T; Kaibuchi, K			Possible involvement of the inactivation of the Rho-Rho-kinase pathway in oncogenic Ras-induced transformation	ONCOGENE			English	Article						Ras; Rho; Rho-kinase; cell adhesion	ACTIN STRESS FIBERS; BINDING PROTEIN-RHO; SERINE-THREONINE KINASE; CELL-CELL ADHESION; PUTATIVE TARGET; FOCAL ADHESIONS; CDC42 GTPASES; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; TIGHT JUNCTIONS	Recent evidence has strongly suggested the involvement of Rho family small guanosine triphosphatases (GTPases) in Ras-induced transformation. To further clarify the role of Rho family GTPases in Ras-induced transformation, we examined the effects of dominant active or dominant negative forms of Rho family GTPases on the morphological changes induced by oncogenic Ras (Ras(V12)) in Rat1 fibroblasts. The cells expressing Ras(V12) showed the severe disruption of actin stress fibers and cell adhesions. The coexpression of dominant active form of Rho (Rho(V14)) reverted not only the formation of stress fibers and focal adhesions but also cell-cell adhesions in Ras-transformed Rat1 cells. In addition, the coexpression of constitutively activated Rho-kinase, a downstream effector of Rho, restored the assembly of stress fibers and focal adhesions. Treatment of Rat cells with lysophosphatidic acid, which is known to activate the Rho-Rho-kinase pathway, enhanced the stress fiber formation, whereas it failed to induce the stress fiber formation in the cells expressing Ras(V12). These results suggest that the Rho-Rho-kinase pathway may be inactivated in the cells expressing Ras(V12), and this may contribute to oncogenic Ras-induced transformation.	Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Yokohama, Kanagawa 2360004, Japan	Nara Institute of Science & Technology; Kirin Brewery Company Limited	Kaibuchi, K (corresponding author), Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan.		Amano, Mutsuki/M-4820-2014	Amano, Mutsuki/0000-0002-0662-1524				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HAN L, 1995, MOL CELL BIOL, V15, P1319; Harlow E LD, 1988, ANTIBODIES LAB MANUA; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329	54	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 3	1998	17	22					2863	2871		10.1038/sj.onc.1202213	http://dx.doi.org/10.1038/sj.onc.1202213			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879992	Bronze			2022-12-17	WOS:000077286400006
J	Bai, RY; Jahn, T; Schrem, S; Munzert, G; Weidner, KM; Wang, JYJ; Duyster, J				Bai, RY; Jahn, T; Schrem, S; Munzert, G; Weidner, KM; Wang, JYJ; Duyster, J			The SH2-containing adapter protein GRB10 interacts with BCR-ABL	ONCOGENE			English	Article						SH2; CML; Grb10; Bcr-Abl; yeast two-hybrid; tyrosine kinase; signal transduction	ACUTE LYMPHOBLASTIC-LEUKEMIA; RECEPTOR TYROSINE KINASE; PHILADELPHIA-CHROMOSOME; SH2 DOMAIN; C-ABL; HEMATOPOIETIC-CELLS; INSULIN-RECEPTOR; BINDING ACTIVITY; TRANSFORMATION; ONCOGENE	Bcr-Abl is an oncogenic tyrosine kinase expressed in tumor cells of CML and a subset of ALL which in its unregulated and activated state is thought to cause cell transformation and leukemia. Bcr-Abl contains several autophosphorylation sites which serve as potential docking sites for SH2-containing signaling molecules; Mutational analysis has indicated that these autophosphorylation sites play a critical role in the transforming capability of Bcr-Abl, It has been shown that the SH2-containing adapter protein Grb(2) binds to the autophosphorylation site Tyr(p)177 whereby it couples Bcr-Abl to the Ras pathway. The biological consequences of this interaction, however, are presently unclear, A Tyr177-mutated Bcr-Abl which lacks the ability to interact with the Grb2-SH2 domain still transforms myeloid cells and generates tumors in nude mice. We performed a yeast two-hybrid screen to identify signaling proteins which bind to distinct Bcr-Abl autophosphorylation sites. Autophosphorylation of Bcr-Abl in yeast was accomplished by using the DNA binding protein LexA which permits dimerization and crossphosphorylation of the fused bait. Using a LexA-Bcr-Abl full length fusion protein as bait, we identified several SH2-containing proteins. Among them we confirmed molecules already shown by others to interact with Bcr-Abl, irt vivo, including Grb2, PI-3-kinase and Crk indicating that dimerization in yeast leads to autophosphorylation of tyrosine residues crucial for Bcr-Abl signaling in vivo. More importantly, we identified the SH2-containing protein Grb10 as a new binding partner for Bcr-Abl. This binding occurs in a phosphotyrosine-dependent manner at Bcr sites of Bcr-Abl. Both Abl and Bcr alone, as well as a kinase-defective Bcr-Abl, failed to interact with Grb10 in yeast. Mutational analysis uncovered a new SH2 binding site in Bcr-Abl located between Bcr aa242-446, which is different from the Grb2 binding site. Binding could be demonstrated in vitro and also in vivo as shown by co-immunoprecipitation analysis in CML cells. Using a temperature sensitive Bcr-Abl stably overexpressed in hematopoetic cells, we demonstrated that complex formation of Grb10 with Bcr-Abl was kinase activation-dependent in vivo. Notably, a Bcr-Abl mutant protein (Bcr/1-242-Abl) which lacks the ability to interact with Grb10 partially alleviated IL-3 dependence of Ba/F3 cells, indicating that the Grb10/Bcr-Abl interaction is important for Bcr-Abl-induced IL-3 independence of Ba/F3 cells. In addition, the Bcr/1-242-Abl mutant has a reduced capacity to induce focus formation in fibroblasts.	Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, D-81675 Munich, Germany; Univ Ulm, Dept Hematol & Oncol, D-89069 Ulm, Germany; Boehringer Mannheim GmbH, Dept Therapeut Biotechnol, D-8122 Penzberg, Germany; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	Technical University of Munich; University of Munich; Ulm University; University of California System; University of California San Diego; University of California System; University of California San Diego	Duyster, J (corresponding author), Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, Ismaningerstr 22, D-81675 Munich, Germany.			schrem, stanley/0000-0003-2909-0794	NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA043054, R37 CA043054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson SM, 1996, BLOOD, V87, P238; Bedi Atul, 1995, Blood, V86, P1148; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOTOH A, 1995, EXP HEMATOL, V23, P1153; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; KIPREOS ET, 1987, P NATL ACAD SCI USA, V84, P1345, DOI 10.1073/pnas.84.5.1345; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; LUTO TG, 1990, SCIENCE, V247, P1079; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; OOI J, 1995, ONCOGENE, V10, P1621; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079	48	47	48	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	1998	17	8					941	948		10.1038/sj.onc.1202024	http://dx.doi.org/10.1038/sj.onc.1202024			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747873	Bronze			2022-12-17	WOS:000075560900002
J	Klotzsche, O; Etzrodt, D; Hohenberg, H; Bohn, W; Deppert, W				Klotzsche, O; Etzrodt, D; Hohenberg, H; Bohn, W; Deppert, W			Cytoplasmic retention of mutant tsp53 is dependent on an intermediate filament protein (Vimentin) scaffold	ONCOGENE			English	Article						nuclear exclusion; cytoplasmic anchorage; temperature sensitive mutant p53; vimentin; intermediate filaments; C6 rat glioma cells	HEAT-SHOCK PROTEINS; P53 PROTEIN; NUCLEAR EXCLUSION; CELL-LINES; KINASE-C; LOCALIZATION; MUTATIONS; PHOSPHORYLATION; ASSOCIATION; EXPRESSION	The temperature-sensitive mutant tsp(val135) accumulates in the cytoplasm of cells kept at the non-permissive temperature (39 degrees C), but is rapidly transported into the cell nucleus at the permissive temperature (30 degrees C). tsp53 thus may serve as a model for analysing cellular parameters influencing the subcellular location of p53. Here we provide evidence that retention of tsp53 in the cytoplasm at the non-permissive temperature is due to cytoskeletal anchorage of the p53 protein. Two sublines of C6 rat glioma cells differing in their expression of the intermediate filament protein vimentin (vimentin expressing or vimentin negative cells) were stably transfected with a vector encoding tsp53, Whereas cells of vimentin expressing C6 subclones retained tsp53 in the cytoplasm at the non-permissive temperature, cells of vimentin negative subclones exclusively harbored the tsp53 within their nuclei. Intermediate filament deficient cells that had been reconstituted with a full length vimentin protein again shelved a cytoplasmic localization of tsp53, whereas in cells expressing a C-terminally truncated (tail-less) vimentin tsp53 localized to the nucleus, We conclude that cytoplasmic sequestration of tsp53 requires an intact intermediate filament system.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Bohn, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							ALBERS K, 1992, INT REV CYTOL, V134, P243, DOI 10.1016/S0074-7696(08)62030-6; ALI IU, 1994, CANCER RES, V54, P1; BADER BL, 1991, J CELL BIOL, V115, P1293, DOI 10.1083/jcb.115.5.1293; BOHN W, 1992, EXP CELL RES, V201, P1, DOI 10.1016/0014-4827(92)90341-5; BOHN W, 1993, J STRUCT BIOL, V111, P48, DOI 10.1006/jsbi.1993.1035; CHENG TJ, 1994, J CELL BIOCHEM, V54, P100, DOI 10.1002/jcb.240540111; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CIESIELSKITRESKA J, 1991, J NEUROSCI RES, V29, P362, DOI 10.1002/jnr.490290312; Deppert W, 1996, J CELL BIOCHEM, V62, P172, DOI 10.1002/(SICI)1097-4644(199608)62:2<172::AID-JCB5>3.0.CO;2-P; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DEPPERT W, 1994, INT CONGR SER, V1050, P11; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ECKELT A, 1992, EUR J CELL BIOL, V58, P319; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; Foisner R, 1995, J STRUCT BIOL, V115, P304, DOI 10.1006/jsbi.1995.1055; GANNON JV, 1991, NATURE, V349, P802; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HEINS S, 1994, CURR OPIN CELL BIOL, V6, P25, DOI 10.1016/0955-0674(94)90112-0; HENNEKES H, 1990, MOL GEN GENET, V221, P33, DOI 10.1007/BF00280364; HERRMANN H, 1992, J MOL BIOL, V223, P637, DOI 10.1016/0022-2836(92)90980-X; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; Knippschild U, 1996, ONCOGENE, V12, P1755; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIAO J, 1995, J BIOL CHEM, V270, P915, DOI 10.1074/jbc.270.2.915; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCCORMICK MB, 1993, J CELL BIOL, V122, P395, DOI 10.1083/jcb.122.2.395; MEDCALF EA, 1992, ONCOGENE, V7, P71; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Nebe B, 1997, CYTOMETRY, V28, P66, DOI 10.1002/(SICI)1097-0320(19970501)28:1<66::AID-CYTO8>3.0.CO;2-F; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; OKABE S, 1988, J CELL BIOL, V107, P651, DOI 10.1083/jcb.107.2.651; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PORTER PL, 1992, AM J PATHOL, V140, P145; ROSER K, 1991, EXP CELL RES, V197, P200, DOI 10.1016/0014-4827(91)90423-R; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; STAUFENBIEL M, 1983, EUR J CELL BIOL, V31, P341; STEINMEYER K, 1988, ONCOGENE, V3, P501; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TAKAHASHI K, 1994, ONCOGENE, V9, P183; TRAUB P, 1983, J CELL SCI, V63, P43; TRONCOSO JC, 1990, J STRUCT BIOL, V103, P2, DOI 10.1016/1047-8477(90)90080-V; ZERRAHN J, 1992, ONCOGENE, V7, P1371	60	47	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3423	3434		10.1038/sj.onc.1202155	http://dx.doi.org/10.1038/sj.onc.1202155			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692550				2022-12-17	WOS:000074544100009
J	Risse-Hackl, G; Adamkiewicz, J; Wimmel, A; Schuermann, M				Risse-Hackl, G; Adamkiewicz, J; Wimmel, A; Schuermann, M			Transition from SCLC to NSCLC phenotype is accompanied by an increased TRE-binding activity and recruitment of specific AP-1 proteins	ONCOGENE			English	Article						AP-1; Jun; Fos; Fra-1, Ras; lung cancer; transdifferentiation	TRANSCRIPTION FACTOR AP-1; PROGRAMMED CELL-DEATH; FOS-RELATED ANTIGEN; C-FOS; LUNG-CANCER; JUN PROTEINS; TUMOR PROGRESSION; GENE-EXPRESSION; PROMOTER ACTIVITY; GROWTH-FACTORS	Transitions from small cell (SCLC) to non-small cell lung cancer (NSCLC) cells have been documented both in vitro and in vivo and are thought to be an important step during tumor progression of human small cell lung cancer towards a treatment-resistant tumor state. We have screened NSCLC and SCLC cell lines for differences in the composition of nuclear transcription factors using consensus oligonucleotide sequences (SRE, Ets, TRE, CRE, B-motif, GAS, E-box), We found NSCLC cells to exhibit significantly higher AP-1 binding activity than SCLC cells consistent with the increased expression of CD44, an AP-1 target gene. To gain more insight into the molecular mechanisms underlying these differences, we analysed SCLC cell lines (NCI-N592 and NCI-H69) which were phenotypically transformed into NSCLC-type cells by transfection with activated H-l ns and c-myc oncogenes, In these cells, I as-induced transition is accompanied by a strong induction of AP-l-binding activity along with increased expression of CD 44 mRNA and protein. When analysing the composition of the AP-1 complex in more detail and comparing ras-induced versus phorbol ester-induced changes, we found Fra-1 to be the major component induced in ras-transfected but not in phorbol-ester treated or non-treated parental SCLC cells. This finding is paralleled by the observation that among the various members of the Fos and Jun family analysed (c-Fos, FosB, Fra-1, Fra-2, c-Jun, JunD, JunB) fra-1 is the only gene to be exclusively expressed in NSCLC cells but not in cells of SCLC origin. Our data, thus, point to a histiotype-related mechanism of recruitment among AP-1 proteins which may have bearings on the fate of lung cancer development.	Univ Marburg, Hamatol Onkol Abt, Zentrum Innere Med, D-35033 Marburg, Germany; Univ Marburg, Inst Molekularbiol & Tumorforsch, D-35037 Marburg, Germany	Philipps University Marburg; Philipps University Marburg	Schuermann, M (corresponding author), Univ Marburg, Hamatol Onkol Abt, Zentrum Innere Med, Baldingerstr, D-35033 Marburg, Germany.							ADAMKIEWICZ J, 1990, ONCOGENE, V5, P525; ADAMKIEWICZ J, 1993, INT J ONCOL, V2, P503; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; Barr LF, 1996, CELL GROWTH DIFFER, V7, P1149; BARR LF, 1991, CANCER RES, V51, P5514; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; BURGER C, 1994, MOL CELL DIFFER, V2, P373; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1990, CRIT REV ONCOGEN, V1, P6184; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FALCO JP, 1990, J CLIN INVEST, V85, P1740, DOI 10.1172/JCI114630; Givehchian M, 1996, ONCOGENE, V12, P1137; GOLDSTONE SD, 1994, ONCOGENE, V9, P2305; HANNAN RD, 1993, J MOL CELL CARDIOL, V25, P1137, DOI 10.1006/jmcc.1993.1127; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOFMANN M, 1993, CANCER RES, V53, P1516; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; JAMAL HH, 1994, ONCOGENE, V9, P417; Kalemkerian GP, 1993, LUNG CANCER, P57; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; MABRY M, 1988, P NATL ACAD SCI USA, V85, P6523, DOI 10.1073/pnas.85.17.6523; MABRY M, 1991, CANCER CELL-MON REV, V3, P53; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUI M, 1990, ONCOGENE, V5, P249; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MELAMED D, 1993, CELL GROWTH DIFFER, V4, P689; MIANO JM, 1993, AM J PATHOL, V142, P715; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NOMURA N, 1990, NUCLEIC ACIDS RES, V18, P3047, DOI 10.1093/nar/18.10.3047; PARK K, 1992, J BIOL CHEM, V267, P10810; PENNO MB, 1994, CANCER RES, V54, P1381; PERSICO AM, 1993, MOL BRAIN RES, V20, P91, DOI 10.1016/0169-328X(93)90113-4; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROGGLI VL, 1985, HUM PATHOL, V16, P569, DOI 10.1016/S0046-8177(85)80106-4; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SATO H, 1993, ONCOGENE, V8, P395; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; SIDEROVSKI DP, 1990, DNA CELL BIOL, V9, P579, DOI 10.1089/dna.1990.9.579; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STEPHENS JM, 1993, MOL CELL BIOCHEM, V123, P63, DOI 10.1007/BF01076476; STJOHN T, 1990, CELL, V60, P45, DOI 10.1016/0092-8674(90)90714-P; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TROEN BR, 1991, CELL GROWTH DIFFER, V2, P23; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; WANG ZQ, 1993, J BONE MINER RES, V8, P839; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WIMMEL A, 1997, LUNG CANCER, V16, P239; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	70	47	49	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3057	3068		10.1038/sj.onc.1201845	http://dx.doi.org/10.1038/sj.onc.1201845			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662339				2022-12-17	WOS:000074125300013
J	Johnson, D; Frame, MC; Wyke, JA				Johnson, D; Frame, MC; Wyke, JA			Expression of the v-Src oncoprotein in fibroblasts disrupts normal regulation of the CDK inhibitor p27 and inhibits quiescence	ONCOGENE			English	Article						v-Src; p27; cellular transformation; CDK activity	DEPENDENT KINASE INHIBITOR; HUMAN CYCLIN-E; CELL-CYCLE; PROTEIN-KINASE; MICE LACKING; MAMMALIAN FIBROBLASTS; PHASE-TRANSITION; P27(KIP1); G(1); MITOGENESIS	To determine how an oncogenic tyrosine kinase disturbs cell cycle control we examined expression of cell cycle proteins and growth of fibroblasts reversibly transformed by a temperature sensitive mutant of v-Src (ts LA 29). ts LA 29 Rat-1 cells and normal Rat-1 cells had similar growth rates but the transformed cells traversed the G(1) phase of the cell cycle more rapidly and failed to exit cycle efficiently in response to serum starvation and cell confluence. Cyclin D1 and cyclin E levels were not elevated in growing ts LA 29 Rat-1 cells and the abbreviated GI was further accelerated by overexpression of cyclin E. A fall in cyclin E and cyclin A dependent kinase activities in Rat-1 cells in response to inhibitory growth conditions was abrogated in ts LA 29 Rat-1 cells and correlated with lack of p27 accumulation or cyclin A down regulation, the latter due to sustained cyclin A promoter activity. The expression of p27 mRNA was lower in ts LA 29 Rat-1 cells than Rat-1 cells and was elevated following v-Src inactivation concurrent with an increase in p27 promoter activity and temporary cell cycle exit. The suppression of mRNA or transcription is a novel way an oncoprotein can induce down regulation of p27 and contributes to the G(1) shortening and perturbed cell cycle regulation of the v-Src transformed cells.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Johnson, D (corresponding author), Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie CRC Labs, Mol Med Ctr, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.							BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FRAME MC, 1994, MOL BIOL CELL, V5, P1177, DOI 10.1091/mbc.5.11.1177; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kramer A, 1996, J BIOL CHEM, V271, P6579; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; PINES J, 1995, CELL CYCLE CONTROL, P144; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Spirin KS, 1996, CANCER RES, V56, P2400; Steeg PS, 1997, NAT MED, V3, P152, DOI 10.1038/nm0297-152; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1993, ONCOGENE, V8, P1593; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; WELHAM MJ, 1990, ONCOGENE, V5, P161; WHITE MK, 1988, MOL CELL BIOL, V8, P138, DOI 10.1128/MCB.8.1.138; WIMMEL A, 1994, ONCOGENE, V9, P995; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; WYKE AW, 1993, CELL GROWTH DIFFER, V4, P671; WYKE AW, 1995, CELL GROWTH DIFFER, V6, P1225; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZerfassThome K, 1996, ONCOGENE, V13, P2323	62	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					2017	2028		10.1038/sj.onc.1201727	http://dx.doi.org/10.1038/sj.onc.1201727			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591786				2022-12-17	WOS:000073079400014
J	Zhang, Y; Fujita, N; Oh-hara, T; Morinaga, Y; Nakagawa, T; Yamada, M; Tsuruo, T				Zhang, Y; Fujita, N; Oh-hara, T; Morinaga, Y; Nakagawa, T; Yamada, M; Tsuruo, T			Production of interleukin-11 in bone-derived endothelial cells and its role in the formation of osteolytic bone metastasis	ONCOGENE			English	Article						endothelial cells; interleukin-11; bone metastasis; bone resorption	OSTEOCLAST DEVELOPMENT; MOLECULAR-CLONING; BREAST-CANCER; HEMATOPOIETIC CYTOKINE; MONOCLONAL-ANTIBODIES; SIGNAL-TRANSDUCTION; MARROW CULTURES; IN-VITRO; RESORPTION; RECEPTOR	The interactions of the cells in the bone microenvironment play important roles in bone remodeling, Osteoblasts are involved in the bone remodeling through the production of soluble factors that regulate proliferation and differentiation of osteoclasts and through cell-cell interactions. Histological studies have suggested that endothelial cells are also associated with some osteolytic bone diseases, However, it is still unclear how endothelial cells contribute to bone resorption, We established bone-derived endothelial cells (BDECs) to study their roles in bone remodeling, The established BDECs promoted bone resorption in a murine neonatal calvaria organ culture system by secreting a soluble bone resorption-inducing factor(s) when stimulated by several inflammatory cytokines. This bone resorption-inducing factor was identified as interleukin-ll (IL-11). IL-11 is known to enhance bone resorption by promoting osteoclastogenesis and by suppressing the activity of osteoblasts, The production of IL-11 in BDECs was also promoted by conditioned medium of human melanoma A375M cells, Because A375M cells formed osteolytic bone metastasis in vivo, BDECs might be involved in pathological osteolysis by producing IL-11, These results suggest that endothelial cells in bone play important roles in the promotion of bone resorption by secreting IL-11 in physiological and pathological conditions.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 113, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 170, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 113, Japan.		Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264				ALAM ASMT, 1992, ENDOCRINOLOGY, V130, P3617, DOI 10.1210/en.130.6.3617; Bellido T, 1996, J CLIN INVEST, V97, P431, DOI 10.1172/JCI118432; Burki F, 1987, Prog Clin Biol Res, V243A, P569; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CHEREL M, 1995, BLOOD, V86, P2534; COLLINOSDOBY P, 1994, J CELL BIOCHEM, V55, P304, DOI 10.1002/jcb.240550306; DICKSON GR, 1990, BONE, V11, P205, DOI 10.1016/8756-3282(90)90215-K; DICKSON GR, 1987, HISTOCHEMISTRY, V87, P569, DOI 10.1007/BF00492472; ELIAS JA, 1995, ENDOCRINOLOGY, V136, P489, DOI 10.1210/en.136.2.489; FORMIGLI L, 1995, J CELL PHYSIOL, V162, P199, DOI 10.1002/jcp.1041620206; FUJITA N, 1993, CANCER RES, V53, P5022; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; GUENTHER HL, 1986, ENDOCRINOLOGY, V119, P193, DOI 10.1210/endo-119-1-193; HENDRIX MJC, 1990, CANCER RES, V50, P4121; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HUGHES FJ, 1993, CALCIFIED TISSUE INT, V53, P362, DOI 10.1007/BF01351844; JAFFE H, ARCH SURG, V20, P355; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Lee SH, 1996, ONCOGENE, V13, P2131; MANOLAGAS SC, 1995, BONE, V17, pS63, DOI 10.1016/8756-3282(95)00180-L; MARTIN TJ, 1994, J CELL BIOCHEM, V56, P357, DOI 10.1002/jcb.240560312; MATSUDA T, 1988, EUR J IMMUNOL, V18, P951, DOI 10.1002/eji.1830180618; Morinaga Y, 1997, INT J CANCER, V71, P422, DOI 10.1002/(SICI)1097-0215(19970502)71:3<422::AID-IJC20>3.0.CO;2-G; Morris JC, 1996, EXP HEMATOL, V24, P1369; Noguchi K, 1996, ONCOGENE, V13, P39; OHISHI K, 1995, CLIN EXP METASTAS, V13, P287, DOI 10.1007/BF00133484; OHNUKI Y, 1980, CANCER RES, V40, P524; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PERKEL VS, 1990, CANCER RES, V50, P6902; Romas E, 1996, J EXP MED, V183, P2581, DOI 10.1084/jem.183.6.2581; ROODMAN GD, 1993, CALCIFIED TISSUE INT, V53, pS94, DOI 10.1007/BF01673412; SABATINI M, 1988, P NATL ACAD SCI USA, V85, P5235, DOI 10.1073/pnas.85.14.5235; SASAKI A, 1995, CANCER RES, V55, P3551; SOSKOLNE WA, 1979, CELL TISSUE RES, V203, P487; SUDA T, 1995, BONE, V17, pS87, DOI 10.1016/8756-3282(95)00185-G; SUEN Y, 1994, BLOOD, V84, P4125, DOI 10.1182/blood.V84.12.4125.bloodjournal84124125; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; TASHJIAN AH, 1985, P NATL ACAD SCI USA, V82, P4535, DOI 10.1073/pnas.82.13.4535; TATSUTA T, 1992, J BIOL CHEM, V267, P20383; TRUETA J, 1963, J BONE JOINT SURG BR, V45, P402, DOI 10.1302/0301-620X.45B2.402; VILLANUEVA JE, 1990, J BONE MINER RES, V5, P733; WILKINS BS, 1995, J PATHOL, V177, P295, DOI 10.1002/path.1711770312; Yamada M, 1997, CANCER CHEMOTH PHARM, V40, P31, DOI 10.1007/s002800050621; YANG L, 1994, J BIOL CHEM, V269, P32732; YIN TG, 1993, J IMMUNOL, V151, P2555; YONEDA T, 1994, BREAST CANCER RES TR, V32, P73, DOI 10.1007/BF00666208; ZAIDI M, 1993, BONE, V14, P97, DOI 10.1016/8756-3282(93)90234-2	50	47	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					693	703		10.1038/sj.onc.1201581	http://dx.doi.org/10.1038/sj.onc.1201581			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488033				2022-12-17	WOS:000071931800001
J	Huguet, C; Crepieux, P; Laudet, V				Huguet, C; Crepieux, P; Laudet, V			Rel/NF-kappa B transcription factors and I kappa B inhibitors: Evolution from a unique common ancestor	ONCOGENE			English	Article						ankyrin repeat protein; rel homology domain; NF-AT; molecular phylogeny	CANDIDATE PROTOONCOGENE BCL-3; CHICKEN SPLEEN-CELLS; DNA-BINDING SUBUNIT; C-REL; PROTO-ONCOGENE; GENE FAMILY; V-REL; FUNCTIONAL-CHARACTERIZATION; SIGNAL-TRANSDUCTION; PRECURSOR P105	From the sequences of Rel/NF-kappa B and I kappa B proteins, we constructed an alignment of their Rel Homology Domain (RHD) and ankyrin repeat domain, Using this alignment, we performed tree reconstruction with both distance matrix and parsimony analysis and estimated the branching robustness using bootstrap resampling methods, We defined four subfamilies of Rel/NF-kappa B transcription factors: (i) cRel, RelA, ReLB, Dorsal and Dif; (ii) NF-kappa B1 and NF-kappa B2; (iii) Relish and (iv) NF-AT factors, the most divergent members, Subfamilies I and II are clustered together whereas Relish diverged earlier than other Rel/NF-kappa B proteins, Three subfamilies of I kappa B inhibitors were also defined: (i) NF-kappa B1 and NF-kappa B2; (ii) close to subfamily I, the short I kappa B proteins I kappa B alpha. I kappa B beta and Bcl-3; (iii) Relish that diverged earlier than other I kappa B inhibitors, Our definition of groups and subfamilies fits to structural and functional features of the Rel/NF-kappa B and I kappa B proteins, We also showed that ankyrin repeats of NF-kappa B1, NF-kappa B2 and Relish are short I kappa B-specific ankyrin motifs. These proteins defining a link between Rel/NF-kappa B and I kappa B families, we propose that all these factors evolved from a common ancestral RHD-ankyrin structure within a unique superfamily, explaining the specificities of interaction between the different Rel/NF-kappa B dimers and the various I kappa B inhibitors.	INST BIOL LILLE,IFR3,UMR319,LAB MECANISMES DEV & CANCERISAT,F-59021 LILLE,FRANCE; INST BIOL LILLE,IFR3,LAB REGULAT PROC INVAS ANGIOGENESE & APOPTOSE,EP560,F-59021 LILLE,FRANCE				Crepieux, Pascale/X-3217-2019					[Anonymous], 1993, MEGA MOL EVOLUTIONAR; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ATCHLEY WR, 1995, P NATL ACAD SCI USA, V92, P10217, DOI 10.1073/pnas.92.22.10217; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BIRKENMEIER CS, 1993, J BIOL CHEM, V268, P9533; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWNELL E, 1989, ONCOGENE, V4, P935; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; Chytil M, 1996, CURR OPIN STRUC BIOL, V6, P91, DOI 10.1016/S0959-440X(96)80100-X; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DUBREUIL RR, 1994, P NATL ACAD SCI USA, V91, P10285, DOI 10.1073/pnas.91.22.10285; Dushay MS, 1996, P NATL ACAD SCI USA, V93, P10343, DOI 10.1073/pnas.93.19.10343; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Fryxell KJ, 1996, TRENDS GENET, V12, P364, DOI 10.1016/S0168-9525(96)80020-5; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; Gilmore TD, 1996, ONCOGENE, V13, P1367; GRUMONT RJ, 1989, ONCOGENE RES, V4, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; Heron E, 1995, GENOMICS, V30, P493, DOI 10.1006/geno.1995.1270; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HILLIS DM, 1992, J HERED, V83, P189, DOI 10.1093/oxfordjournals.jhered.a111190; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; Huguet C, 1994, Cell Death Differ, V1, P71; IKEDA T, 1993, GENE, V133, P237, DOI 10.1016/0378-1119(93)90645-J; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; ITO CY, 1995, GENOMICS, V29, P490, DOI 10.1006/geno.1995.9977; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; KAO KR, 1991, P NATL ACAD SCI USA, V88, P2697, DOI 10.1073/pnas.88.7.2697; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; MULLER CW, 1996, NATURE STRUCTURE BIO, V3, P244; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NAUMANN M, 1993, ONCOGENE, V8, P2275; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PHILIPPE H, 1993, NUCLEIC ACIDS RES, V21, P5264, DOI 10.1093/nar/21.22.5264; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; Suyang H, 1996, MOL CELL BIOL, V16, P5444; SUZUKI K, 1995, NUCLEIC ACIDS RES, V23, P4664, DOI 10.1093/nar/23.22.4664; SWOFFORD DL, 1991, PHYLOGENETICAL ANAL; TANNAHILL D, 1995, INT J DEV BIOL, V39, P549; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	81	47	51	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2965	2974		10.1038/sj.onc.1201471	http://dx.doi.org/10.1038/sj.onc.1201471			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416840				2022-12-17	WOS:A1997YK37700009
J	Haas, K; Johannes, C; Geisen, C; Schmidt, T; Karsunky, H; BlassKampmann, S; Obe, G; Moroy, T				Haas, K; Johannes, C; Geisen, C; Schmidt, T; Karsunky, H; BlassKampmann, S; Obe, G; Moroy, T			Malignant transformation by cyclin E and Ha-Ras correlates with lower sensitivity towards induction of cell death but requires functional Myc and CDK4	ONCOGENE			English	Article						cyclin E; malignant transformation; Myc; CDK inhibitors; polyploidy	RETINOBLASTOMA-PROTEIN; COLORECTAL CARCINOMAS; PHASE-TRANSITION; KINASE-ACTIVITY; BREAST-CANCER; E GENE; C-MYC; D1; FIBROBLASTS; INHIBITION	We demonstrate in this paper that the G1 phase specific cell cycle regulator cyclin E is able to provoke focus formation when cotransfected with activated Ha-ras into primary rat embryo fibroblasts (REFs). Cyclin E/Ha-ras transformed cells are highly tumorigenic in synergeneic rats, are able to form colonies in soft agar and show protection towards apoptosis upon serum starvation or DNA damage compared to cells transformed by the combination of Myc, cyclin D1 or SV40 large T-antigen and Ha-ras. Lines that were established after cyclin El Ha-ras or cyclin D1/Ha-ras transformation contain a large percentage of polyploid cells, This was not observed in cells transformed with other oncoproteins and Ha-ras pointing to an involvement of D-and E type cyclins in genomic instability. The cyclin dependent kinase inhibitors p21 and p27 but also p16 completely abrogate focus formation by cyclin E and Ha-ras suggesting that the oncogenic activity of cyclin E still requires functional G1 specific cyclin/CDK complexes. Moreover, inhibition of Myc function also blocks the oncogenic activity of cyclin E indicating a requirement of Myc for cyclin E function, The findings presented here demonstrate that cyclin E can act as an oncoprotein with a potential involvement in genomic instability and the prevention of cell death, Our data also present more evidence for a strict functional interdependency between G1 cyclin/CDK complexes and c-Myc.	UNIV ESSEN GESAMTHSCH KLINIKUM,IFZ,INST ZELLBIOL TUMORFORSCH,D-45172 ESSEN,GERMANY; UNIV ESSEN GESAMTHSCH,GENET ABT,D-45172 ESSEN,GERMANY	University of Duisburg Essen; University of Duisburg Essen			Moroy, Tarik/D-9923-2011					Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Botz J, 1996, MOL CELL BIOL, V16, P3401; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Datta NS, 1996, MOL BIOL CELL, V7, P209, DOI 10.1091/mbc.7.2.209; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Draetta G.F., 1997, CURR BIOL, V7, P50; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Geng Y, 1996, ONCOGENE, V12, P1173; GONG JP, 1994, CANCER RES, V54, P4285; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; HALL M, 1995, ONCOGENE, V11, P1581; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HU J, 1992, MOL CELL BIOL, V12, P971; JIANG W, 1993, ONCOGENE, V8, P3447; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KERKHOFF E, 1995, EMBO J, V14, P1892, DOI 10.1002/j.1460-2075.1995.tb07181.x; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P940; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEACH FS, 1993, CANCER RES, V53, P1986; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Mumberg D, 1996, ONCOGENE, V13, P2493; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SoferLevi Y, 1996, ONCOGENE, V13, P2431; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WANG ZY, 1995, BLOOD, V86, P3783, DOI 10.1182/blood.V86.10.3783.bloodjournal86103783; Zhang Y, 1996, J BIOL CHEM, V271, P4266	54	47	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2615	2623		10.1038/sj.onc.1201434	http://dx.doi.org/10.1038/sj.onc.1201434			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399649				2022-12-17	WOS:A1997YG73200011
J	Jares, P; Fernandez, PL; Nadal, A; Cazorla, M; Hernandez, L; Pinyol, M; Hernandez, S; Traserra, J; Cardesa, A; Campo, E				Jares, P; Fernandez, PL; Nadal, A; Cazorla, M; Hernandez, L; Pinyol, M; Hernandez, S; Traserra, J; Cardesa, A; Campo, E			p16(MTS1/CDK4I) mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx	ONCOGENE			English	Article						p16(MTS1/CDK4I); LOH 9p21-23; larynx; squamous cell carcinoma	KINASE-4 INHIBITOR GENE; CYCLIN D1 FUNCTION; HUMAN CANCERS; SOMATIC MUTATIONS; NONSMALL CELL; GEL-ELECTROPHORESIS; ALTERED EXPRESSION; PRIMARY TUMORS; LUNG CANCERS; CDKN2 GENE	We have examined the presence of p16(MTS1/CDK4I) gene deletions, mutations and methylation status, and 9p21-23 deletions in a series of 46 squamous cell carcinomas of the larynx and paired normal mucosa previously characterized for cyclin D1 gene amplification and overexpression. pRb expression was also examined by immunohistochemistry. p16(MTS1/CDK4I) mutations were found in 10/46 (22%) carcinomas and hypermethylation in 2/31 (7%). Loss of heterozygosity at 9p21-23 was found in 24 out of 42 (57%) carcinomas examined. All p16(MTS1/CDK4I) mutated cases and the two hypermethylated carcinomas showed 9p21-23 loss of heterozygosity. The loss of heterozygosity correlated with advanced local invasion (P = 0.0045), lymph node metastases (P = 0.0326), stage IV of the tumors (P = 0.0058), and existence of cyclin D1 amplification/overexpression (P < 0.03). Only one out of 37 carcinomas was negative for pRb expression. No alterations in p16 gene or 9p21-23 loss of heterozygosity were detected in this case. These findings indicate that p16(MTS1/CDK4I) is frequently inactivated by gene mutation, hypermethylation, and allelic deletions in a significant subset of squamous cell carcinomas of larynx. Since 9p21-233 loss of heterozygosity was more frequently detected than p16(MTS1/CDK4I) mutations, and mutated carcinomas invariably had loss of heterozygosity, allelic losses probably precede the p16(MTS1/CDK4I) mutations. Their association with cyclin D1 deregulation in advanced carcinomas could indicate a possible cooperative effect in the progression of these neoplasms.	UNIV BARCELONA,HOSP CLIN & PROV BARCELONA,DEPT ANAT PATHOL,E-08007 BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN & PROV BARCELONA,DEPT OTOLARYNGOL,E-08007 BARCELONA,SPAIN; UNIV LLEIDA,DEPT BASIC MED SCI,LLEIDA,SPAIN; HOSP CASA MATERNITAT,BARCELONA,SPAIN	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; Universitat de Lleida			Hernandez-Llodra, S/H-6863-2014; Hernandez, Luis/D-4684-2018; Jares, Pedro/T-3778-2019; Fernandez, Pedro L/H-2594-2017; Campo, Elias/AAC-5593-2019	Hernandez-Llodra, S/0000-0003-3963-3756; Hernandez, Luis/0000-0002-4854-3069; Campo, Elias/0000-0001-9850-9793; JARES, PEDRO/0000-0002-8401-579X; Fernandez, Pedro Luis/0000-0002-8618-4597				American Joint Committee on Cancer, 1992, MAN STAG CANC; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; DOLCETTI R, 1992, INT J CANCER, V52, P178, DOI 10.1002/ijc.2910520204; EMMERTBUCK MR, 1994, AM J PATHOL, V145, P1285; GERADTS J, 1994, INT J CANCER, V58, P161, DOI 10.1002/ijc.2910580203; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; HERMAN JG, 1995, CANCER RES, V55, P4525; Jares P, 1996, AM J PATHOL, V148, P1591; JARES P, 1994, CANCER RES, V54, P4813; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kwiatkowski David J., 1993, Cytogenetics and Cell Genetics, V64, P93, DOI 10.1159/000133566; LO KW, 1995, CANCER RES, V55, P2039; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, CANCER RES, V55, P4818; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MEREDITH SD, 1995, ARCH OTOLARYNGOL, V121, P790; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MICHALIDES R, 1995, CANCER RES, V55, P975; MORI T, 1994, CANCER RES, V54, P3396; NADAL A, 1995, J PATHOL, V175, P181, DOI 10.1002/path.1711750205; NAWROZ H, 1994, CANCER RES, V54, P1152; NEVILLE EM, 1995, ONCOGENE, V11, P581; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; OTO M, 1993, ANAL BIOCHEM, V213, P19, DOI 10.1006/abio.1993.1379; Pinyol M, 1997, BLOOD, V89, P272, DOI 10.1182/blood.V89.1.272.272_272_280; POLLOCK PM, 1995, ONCOGENE, V11, P663; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; PUIG S, 1995, AM J HUM GENET, V57, P395; Sambrook J, 1989, MOL CLONING LAB MANU; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHIMIZU T, 1995, INT J CANCER, V63, P616, DOI 10.1002/ijc.2910630503; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TAM SW, 1994, ONCOGENE, V9, P2663; TUYNS AJ, 1988, INT J CANCER, V41, P483, DOI 10.1002/ijc.2910410403; Ueki K, 1996, CANCER RES, V56, P150; VANDERRIET P, 1994, CANCER RES, V54, P1156; VANDYKE DL, 1994, GENE CHROMOSOME CANC, V9, P192, DOI 10.1002/gcc.2870090308; Yang R, 1996, BIOCHEM BIOPH RES CO, V218, P254, DOI 10.1006/bbrc.1996.0045; ZHANG SY, 1994, CANCER RES, V54, P5050; ZHOU XL, 1994, ONCOGENE, V9, P3737	50	47	48	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1445	1453		10.1038/sj.onc.1201309	http://dx.doi.org/10.1038/sj.onc.1201309			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333020				2022-12-17	WOS:A1997XW41100008
J	Fei, ZL; Xu, SQ; Dews, M; Baserga, R				Fei, ZL; Xu, SQ; Dews, M; Baserga, R			Co-operation of Simian virus 40 T antigen and insulin receptor substrate-1 in protection from apoptosis induced by interleukin-3 withdrawal	ONCOGENE			English	Article						T antigen; IRS-1; apoptosis	GROWTH-FACTOR-I; LARGE TUMOR-ANTIGEN; HEMATOPOIETIC-CELLS; TRANSFORMING ACTIVITY; PHOSPHORYLATION; FIBROBLASTS; EXPRESSION; IGF-1; MITOGENESIS; INHIBITION	32D cells are interleukin-3 (IL-3) dependent murine hemopoietic cells, that undergo apoptosis after IL-3 withdrawal. An overexpressed insulin-like growth factor I receptor (IGF-IR) protects these cells from apoptosis induced by IL-3 withdrawal. When 32D cells are stably transfected with plasmids expressing either IRS-1 (a major substrate of the IGF-IR) or the Simian virus 40 large T antigen, singly, they still undergo apoptosis after IL-3 withdrawal, although IRS-1 offers partial protection. The cells, however, are fully protected when they are stably transfected with both IRS-1 and SV40 T antigen. Protection from apoptosis in these cells is characterized by the stabilization of the Stat1 and Stat5 protein levels, whose synthesis is inhibited when IL-3 is withdrawn.	THOMAS JEFFERSON UNIV,KIMMEL CANC CTR,PHILADELPHIA,PA 19107	Jefferson University					NCI NIH HHS [CM 33694] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARONICA MG, 1996, ONCOGENE, V13, P1917; ASKEW DS, 1991, ONCOGENE, V6, P1915; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1997, VITAM HORM, V53, P65, DOI 10.1016/S0083-6729(08)60704-9; BLANDINO G, 1995, ONCOGENE, V10, P731; Campos SP, 1996, J BIOL CHEM, V271, P24418, DOI 10.1074/jbc.271.40.24418; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DAmbrosio C, 1996, CANCER RES, V56, P4013; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HALDAR S, 1994, BIOCHEM CELL BIOL, V72, P455, DOI 10.1139/o94-061; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Hongo A, 1996, ONCOGENE, V12, P1231; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IHLE JN, 1995, NATURE, V377, P291; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; Jung YK, 1996, J BIOL CHEM, V271, P5112; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Lenahan MK, 1996, ONCOGENE, V12, P1847; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Morrione A, 1996, CANCER RES, V56, P3165; MYERS MG, 1994, J BIOL CHEM, V269, P28783; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; Parrizas M, 1997, J BIOL CHEM, V272, P154; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; RUBIN R, 1995, LAB INVEST, V73, P311; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Singleton JR, 1996, CANCER RES, V56, P4522; Soddu S, 1996, MOL CELL BIOL, V16, P487; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; ULLRICH A, 1986, EMBO J, V5, P503; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V369, P1; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; Yenush L, 1996, MOL CELL BIOL, V16, P2509; Zhou-Li Fei, 1995, Molecular and Cellular Biology, V15, P4232; ZUMSTEIN PP, 1985, P NATL ACAD SCI USA, V82, P3169, DOI 10.1073/pnas.82.10.3169	66	47	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					961	970		10.1038/sj.onc.1201265	http://dx.doi.org/10.1038/sj.onc.1201265			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285691				2022-12-17	WOS:A1997XR76700009
J	Mundt, M; Hupp, T; Fritsche, M; Merkle, C; Hansen, S; Lane, D; Groner, B				Mundt, M; Hupp, T; Fritsche, M; Merkle, C; Hansen, S; Lane, D; Groner, B			Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential	ONCOGENE			English	Article						p53 phosphorylation; allosteric activation; in vitro transcription; specific DNA binding; latent and activated p53	DNA-BINDING FUNCTION; TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; CASEIN KINASE-II; CELL-CYCLE; PHOSPHORYLATION; TRANSCRIPTION; ACTIVATION; PROMOTER; DOMAIN	The tumor suppressor protein p53 is a transcription factor frequently inactivated in human cancers. We have studied the DNA binding potential and the transcriptional activity of p53 variants and p53 protein complexes in in vitro transcription assays, p53 specific transcription was measured via introduction of radioactive UTP into G-free cassette transcripts regulated by promoter sequences containing p53 response elements. Latent and activated p53 fractions were prepared from insect cells infected with p53 encoding baculoviruses by chromatography on heparin columns, p53 fractions distinguishable by their specifc DNA binding activities and their recognition by monoclonal antibody PAb421 were obtained. Specific DNA binding and binding to PAb421 are mutually exclusive. The C-terminus of p53 can be phosphorylated by casein kinase II, protein kinase C and cyclin dependent kinases. The antibody PAb421 binds within the PKC phosphorylation site of p53 and is able to activate DNA binding of latent p53 in vitro. Activation of p53 by PAb421 also results in enhanced transactivation in vitro. Dephosphorylation of latent p53 with phosphatase 2A does not change these properties. This suggests that a conformational change in the carboxyl terminal domain of p53 controls the transactivation potential of p53.	INST EXPT CANC RES, TUMOR BIOL CTR, D-79106 FREIBURG, GERMANY; UNIV DUNDEE, DEPT PATHOL, NINEWELLS HOSP & MED SCH, DUNDEE DD1 4HN, SCOTLAND; UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND	University of Dundee; University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ABARZUA P, 1995, CANCER RES, V55, P3490; ADDISON C, 1990, ONCOGENE, V5, P423; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUCHS B, 1995, ONCOGENE, V10, P789; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GUDAS JM, 1994, CELL GROWTH DIFFER, V5, P295; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLEINHITPASS L, 1991, NUCLEIC ACIDS RES, V19, P1227, DOI 10.1093/nar/19.6.1227; KUGLER W, 1990, NUCLEIC ACIDS RES, V18, P6943, DOI 10.1093/nar/18.23.6943; LANE DP, 1995, PHILOS T ROY SOC B, V347, P83, DOI 10.1098/rstb.1995.0013; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Milne DM, 1996, ONCOGENE, V13, P205; MILNER J, 1990, ONCOGENE, V5, P1683; MOLINARI M, 1995, ONCOGENE, V10, P1849; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PRICE BD, 1993, ONCOGENE, V8, P3055; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0	43	47	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	1997	15	2					237	244		10.1038/sj.onc.1201174	http://dx.doi.org/10.1038/sj.onc.1201174			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244359				2022-12-17	WOS:A1997XK37200012
J	Suy, S; Anderson, WB; Dent, P; Chang, E; Kasid, U				Suy, S; Anderson, WB; Dent, P; Chang, E; Kasid, U			Association of Grb2 with Sos and Ras with Raf-1 upon gamma irradiation of breast cancer cells	ONCOGENE			English	Article						ionizing radiation; Grb2; Sos; Ras; Raf; MAPK; breast cancer	GUANINE-NUCLEOTIDE EXCHANGE; MAP KINASE-KINASE; SIGNAL-TRANSDUCTION PATHWAY; SERINE-THREONINE KINASE; NIH 3T3 CELLS; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; ONCOGENIC P21(RAS); INDUCED ACTIVATION; MAMMALIAN-CELLS	Raf-1 protein serine/threonine kinase has been implicated in growth and damage-responsive signal transduction pathways. Several reports indicate an important role of Ras protein in the growth factor-induced activation of Raf-1. Here we investigated the possible involvement of Ras in ionizing radiation-induced activation of Raf-1. Irradiation of MDA-MB 231 human breast cancer cells caused an increase in GTP-binding and hydrolysis on Ras, and co-immunoprecipitations of endogenous Grb2 with Sos and Raf-1 with Ras. An increase in the level of membrane-bound Raf-1, and tyrosine-phosphorylation of Raf-1 were observed after irradiation. Consistent with these changes, irradiation of cells stimulated the catalytic activity of Raf-1, Finally, radiation treatment of breast cancer cells led to an increase in the phosphorylation and activity of the mitogen-activated protein kinase. Based on these biochemical modifications in vivo, me conclude that Raf-1 functions as an effector of Ras in the radiation-responsive signal transduction pathway leading to the activities of Raf-1 and mitogen-activated protein kinase.	GEORGETOWN UNIV,DEPT RADIAT MED,WASHINGTON,DC 20007; GEORGETOWN UNIV,DEPT OTOLARYNGOL HEAD & NECK SURG,WASHINGTON,DC 20007; GEORGETOWN UNIV,LOMBARDI CANC CTR,DEPT BIOCHEM & MOL BIOL,WASHINGTON,DC 20007; NCI,CELLULAR ONCOL LAB,NIH,BETHESDA,MD 20892; UNIV VIRGINIA,DEPT MED,HOWARD HUGHES MED INST,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	Georgetown University; Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; University of Virginia; University of Virginia					NATIONAL CANCER INSTITUTE [R55CA068322, P30CA051008, R01CA058984] Funding Source: NIH RePORTER; NCI NIH HHS [CA58984, CA68322, P30 CA51008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bernhard EJ, 1996, CANCER RES, V56, P1727; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DOWNWARD J, 1995, METHOD ENZYMOL, V255, P110; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; KASID U, 1993, ADV CANCER RES, V61, P195, DOI 10.1016/S0065-230X(08)60959-8; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOLCH W, 1991, NATURE, V349, P536; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARIAS R, 1993, CELL, V73, P381; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCORMICK F, 1993, SCIENCE, V363, P15; MCKENNA WG, 1990, CANCER RES, V50, P97; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PIROLLO KF, 1989, INT J RADIAT BIOL, V55, P783, DOI 10.1080/09553008914550831; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAPP UR, 1991, ONCOGENE, V6, P495; Reed J C, 1993, Semin Immunol, V5, P327, DOI 10.1006/smim.1993.1039; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Soldatenkov VA, 1997, CANCER J SCI AM, V3, P13; SOZERI O, 1992, ONCOGENE, V7, P2259; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	68	47	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					53	61		10.1038/sj.onc.1201165	http://dx.doi.org/10.1038/sj.onc.1201165			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233777				2022-12-17	WOS:A1997XH58600006
J	DAdamo, DR; Novick, S; Kahn, JM; Leonardi, P; Pellicer, A				DAdamo, DR; Novick, S; Kahn, JM; Leonardi, P; Pellicer, A			rsc: A novel oncogene with structural and functional homology with the gene family of exchange factors for Ral	ONCOGENE			English	Article						oncogene; exchange factors; Ral; Ral-GDS; gene transfer	NUCLEOTIDE DISSOCIATION STIMULATOR; H-RAS; MOLECULAR-CLONING; CEREVISIAE CDC25; ACTIVATION; IDENTIFICATION; INVOLVEMENT; PROTEIN; GTPASE; MODEL	A novel oncogene, rsc (rabbit squamous cell carcinoma), has been identified from a DMBA-induced rabbit squamous cell carcinoma using gene transfer and the nude mouse tumorigenesis assay. A full-length cDNA has been isolated and sequenced. use has potent tumorigenic activity in nude mice (latency <4 weeks), but does not induce focus formation or anchorage independent growth. The oncogene resulted from the fusion of rHR 23A (a rabbit homologue of yeast Rad 23) with a member of the ral-GDS family which we named rgr (ral-GDS related). Deletion analysis demonstrated that the oncogenic potential resides in the Rgr portion of the gene. Rgr is 40% identical overall to Ral-GDS, with identity increasing to 72% over a 100 amino acid region of the catalytic domain. Biochemical experiments indicate that Rgr has GTP/GDP exchange activity for Ral, providing evidence that this pathway is associated with tumorigenesis. The linkage between the Ral pathway and tumorigenesis by a molecule in the Ral-GDS gene family (Ral-GDS being a known effector for Ras) will open the way for the characterization of this pathway and provide an important tool to understand its biological function.	NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University			MARTINEZ, ANTONIO PELLICER/C-4832-2015	Pellicer, Angel/0000-0002-5062-0692	NCI NIH HHS [CA50434] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050434] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ALTINGMEES M, 1992, STRAT MOL BIOL, V5, P58; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BEALE AJ, 1963, LANCET, V2, P640; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Bouck N, 1979, Methods Enzymol, V58, P296; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P511; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHENG JF, 1984, J MOL BIOL, V176, P1, DOI 10.1016/0022-2836(84)90379-6; COROMINAS M, 1991, ONCOGENE, V6, P645; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; Fogh J, 1978, NUDE MOUSE EXPT CLIN; Ghadially F.N., 1988, GHADIALLYS ULTRASTRU, V3rd; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; GUERRERO I, 1984, P NATL ACAD SCI-BIOL, V81, P202, DOI 10.1073/pnas.81.1.202; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; Leon J., 1993, RAS SUPERFAMILY GTPA, P3; Mangues R, 1992, Semin Cancer Biol, V3, P229; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MEAD DA, 1991, BIO-TECHNOL, V9, P657, DOI 10.1038/nbt0791-657; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NEWCOMB EW, 1988, CANCER RES, V48, P5514; NOVICK SC, 1994, THESIS; Park SH, 1995, ONCOGENE, V11, P2349; Sambrook J, 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1993, BRIT J CANCER, V68, P460, DOI 10.1038/bjc.1993.370; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; WATKINS D, 1994, CANCER GENET CYTOGEN, V72, P130, DOI 10.1016/0165-4608(94)90128-7; WEI W, 1993, CLONING ANAL FULL LE; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1996, ONCOGENE, V13, P353	49	47	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 20	1997	14	11					1295	1305		10.1038/sj.onc.1200950	http://dx.doi.org/10.1038/sj.onc.1200950			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178890				2022-12-17	WOS:A1997WP10900005
J	Taniguchi, T; Okamoto, K; Reeve, AE				Taniguchi, T; Okamoto, K; Reeve, AE			Human p57(KIP2) defines a new imprinted domain on chromosome 11p but is not a tumour suppressor gene in Wilms tumour	ONCOGENE			English	Article						Wilms tumour; genomic imprinting; H19; IGF2; p57(KIP2)	GROWTH-FACTOR-II; DEPENDENT KINASE INHIBITOR; H19 GENE; MOUSE; RELAXATION; LOCUS; HETEROZYGOSITY; DELETION; DISRUPTION; CARCINOMA	Mouse p57(Kip2) arrests cells in G(1) by functioning as a strong inhibitor of several G(1) cyclin/Cdk complexes (Lee et al., 1995; Matsuoka et al., 1995; Sherr and Roberts, 1995), Human p57(K1P2) has been suggested to be a tumour suppressor gene because of its location at 11p15.5 which frequently undergoes maternal allele LOH in several types of cancer (Matsuoka et al., 1995; Sherr and Roberts, 1995; Hatada and Mukai, 1995), This suggestion was supported by the discovery that mouse p57(Kip2) is imprinted with expression from only the maternally inherited allele (Hatada and Mukai, 1995), Interestingly, p57(K1P2) is several hundred kilobases from the imprinted H19 and IGF2 genes which are involved in growth regulation (Hoovers et al., 1995), Here we show that human p57(K1P2) is imprinted with expression from the maternal allele, However, unlike the mouse, the imprinting is incomplete with significant expression from the paternal allele depending on the tissue examined, We have also shown that the imprinting of p57(K1P2) occurs independently of the H19/IGF2 domain and thus there must be at least two imprinted domains in 11p15.5. Finally, by examining Wilms tumours we have shown that following maternal 11p LOH, p57(K1P2) was expressed from the paternal allele, Therefore, p57(K1P2) cannot function as an imprinted tumour suppressor gene, at least in Wilms tumour.	UNIV OTAGO,DEPT BIOCHEM,CANC GENET LAB,DUNEDIN,NEW ZEALAND	University of Otago								BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BYRNE JA, 1993, GENE CHROMOSOME CANC, V7, P1; Chung WY, 1996, HUM MOL GENET, V5, P1101, DOI 10.1093/hmg/5.8.1101; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235; Hatada I, 1996, HUM MOL GENET, V5, P783, DOI 10.1093/hmg/5.6.783; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HOOVERS JMN, 1995, P NATL ACAD SCI USA, V92, P12346; JEN J, 1994, CANCER RES, V54, P6353; Jinno Y, 1996, HUM MOL GENET, V5, P1155, DOI 10.1093/hmg/5.8.1155; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; MACKAY J, 1988, BRIT J CANCER, V58, P710, DOI 10.1038/bjc.1988.295; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, NAT GENET, V5, P408, DOI 10.1038/ng1293-408; Orlow I, 1996, CANCER RES, V56, P1219; PAL N, 1990, ONCOGENE, V5, P1665; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; Reid LH, 1996, CANCER RES, V56, P1214; Saitoh S, 1996, P NATL ACAD SCI USA, V93, P7811, DOI 10.1073/pnas.93.15.7811; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61	39	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1201	1206		10.1038/sj.onc.1200934	http://dx.doi.org/10.1038/sj.onc.1200934			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121769	Bronze			2022-12-17	WOS:A1997WM78200009
J	Greco, A; Villa, R; Pierotti, MA				Greco, A; Villa, R; Pierotti, MA			Genomic organization of the human NTRK1 gem	ONCOGENE			English	Article						NTRK1 gene; tyrosine kinase receptor; intron exon structure	TRK PROTOONCOGENE; GROWTH-FACTOR; KINASE GENE; RECEPTOR; ONCOGENE; FUSION; MUTATIONS; DOMAIN	The NTRK1 gene encodes one of the receptors for the Nerve Growth Factors and it is located at 1q21-22. Rearrangements of NTRK1 are frequently detected in human papillary thyroid carcinoma and lead to the formation of chimeric oncogenes, similarly to what observed for the other neurotrophin receptor RET. In addition, the two receptor genes are target of point mutations associated with different human diseases. RET is affected by germ line and somatic mutations in MEN2A, MEN2B tumor syndromes and in the abnormal developmental Hirschsprung disease, whereas mutations of NTRK1 have been reported very recently in patients with congenital insensitivity to pain with anidrosis (CIPA). With the aim to provide a tool for searching mutations along the whole NTRK1 gene, we have determined its genomic organization. Our results demonstrated that NTRK1 is contained within 25 Kb of DNA and is organized in 17 exons, one of which is alternatively spliced. The sequence of the 5' flanking region indicates a high content in C/G, the absence of TATA box, the presence of several putative binding sites for Sp1, AP1, AP2, AP3, ATF and GCF transcription factors.			Greco, A (corresponding author), IST NAZL TUMORI,DIV EXPT ONCOL A,VIA VENEZIAN 1,I-20133 MILAN,ITALY.		Greco, Angela/C-1953-2017	Greco, Angela/0000-0003-2994-0349; Fontecha, Juliana/0000-0002-2215-7362; Pierotti, Marco Alessandro/0000-0002-7431-8332; Villa, Riccardo/0000-0001-8385-800X				BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARKER PA, 1993, J BIOL CHEM, V268, P15150; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GRECO A, 1993, GENOMICS, V18, P397, DOI 10.1006/geno.1993.1482; Indo Y, 1996, NAT GENET, V13, P485, DOI 10.1038/ng0896-485; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.biochem.55.1.1119; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; WEIER HUG, 1995, GENOMICS, V26, P390, DOI 10.1016/0888-7543(95)80226-C	21	47	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2463	2466						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957089				2022-12-17	WOS:A1996VX10800020
J	Molinari, M; Okorokov, AL; Milner, J				Molinari, M; Okorokov, AL; Milner, J			Interaction with damaged DNA induces selective proteolytic cleavage of p53 to yield 40 kDa and 35 kDa fragments competent for sequence-specific DNA binding	ONCOGENE			English	Article						p53; damaged DNA; DNA binding proteolysis	WILD-TYPE P53; ACTIVATED PROTEIN-KINASE; TUMOR-SUPPRESSOR P53; C-TERMINAL DOMAIN; CRYSTAL-STRUCTURE; SINGLE STRANDS; GROWTH ARREST; NUCLEIC-ACIDS; CELL-CYCLE; CONFORMATION	The p53 protein binds sites of primary DNA damage via its C-terminus. This interaction in some way activates sequence-specific binding (via the central core domain) and transactivation of p53 target genes. We now show that interaction with non-specific DNA, but not specific DNA targets, induces selective proteolysis of p53 to give a 40 kDa fragment, comprising the core plus C-terminus, and a 35 KDa conformationally intact core domain. Proteolytic cleavage was limited and yielded roughly equivalent proportions of full length p53 and the 40 kDa and 35 kDa fragments. Significantly, both 40 kDa and 35 kDa products were activated for sequence-specific DNA binding. Similar p53-related products were induced by exposure of cells to DNA damage. We propose that some functions of p53 can be activated by proteolytic processing and that this may be important in the cellular response to DNA damage.	UNIV YORK,DEPT BIOL,YCRC P53 RES GRP,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK				Okorokov, Andrei/0000-0003-2477-3254				BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BRAIN R, 1994, ONCOGENE, V9, P1775; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; FAN SJ, 1995, CANCER RES, V55, P1649; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1994, ONCOGENE, V9, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HESKETH R, 1995, ONCOGENE FACTS BOOK; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUANG L, 1996, IN PRESS P NATL ACAD, V96; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KIM B, 1993, CELL, V73, P1165, DOI 10.1016/0092-8674(93)90645-7; KURIYAN J, 1995, STRUCTURE, V3, P135, DOI 10.1016/S0969-2126(01)00143-5; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, ONCOGENE, V5, P1683; MOLINARI M, 1995, ONCOGENE, V10, P1849; MUMMENBRAUER T, 1996, IN PRESS CELL; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PAILLARD S, 1993, PROTEINS, V15, P330, DOI 10.1002/prot.340150310; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WALKER GC, 1995, TRENDS BIOCHEM SCI, V20, P416, DOI 10.1016/S0968-0004(00)89091-X; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497	54	47	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2077	2086						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950974				2022-12-17	WOS:A1996VV14500004
J	Dosch, J; Kaina, B				Dosch, J; Kaina, B			Induction of c-fos, c-jun, junB and junD mRNA and AP-1 by alkylating mutagens in cells deficient and proficient for the DNA repair protein O-6-methylguanine-DNA methyltransferase (MGMT) and its relationship to cell death, mutation induction and chromosomal instability	ONCOGENE			English	Article						Fos; Jun; alkyltransferase; DNA repair; inducible response	METHYLATION DAMAGE; MISMATCH BINDING; GENE; ACTIVATION; EXPRESSION; AGENTS; UV; DIFFERENTIATION; TRANSCRIPTION; METALLOTHIONEIN	An early and immediate response of cells upon irradiation with UV light and various other forms of genotoxic stress is the induction of the proto-oncogenes c-fos and c-jun, To address the questions of whether (a) methylating agents that are powerful carcinogens are effective in induction of fos and jun mRNAs, (b) induction is affected by the repair capacity of the cells, and (c) induction is accompanied by genotoxic effects, the levels of c-fos, c-jun, junB and junD mRNA were analysed in isogenic Chinese hamster cell lines deficient (phenotypically Mex(-)) and proficient (Mex(+)) for the DNA repair protein O-6-methylguanine-DNA methyltransferase (MGMT) after treatment with N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and methyl methanesulfonate (MMS), Both methylating agents were very effective in inducing fos and jun mRNAs, although they differ markedly in their potency to induce O-6-methylguanine in DNA, Most responsive were c-fos and c-jun (up to 80-fold increases in mRNA level) whereas junB (up to ninefold) and junD (up to twofold) displayed an intermediate and weak response, respectively, No difference in the dose-dependence of induction of these mRNAs was observed between Mex(-) and Mex(+) cells indicating that the critical genotoxic and mutagenic lesion induced by MNNG, i.e. O-6-methylguanine, which is rapidly repaired by MGMT, does not act as a trigger for this response, Induction of fos and jun mRNAs by MNNG and MMS was accompanied by a dose-dependent increase in the activity of the transcription factor AP-1, To induce fos and jun mRNAs as well as AP-1, doses of MNNG were required which were more than 50-fold higher than those inducing gene mutations, recombination events (SCEs) and reproductive cell death, and fivefold higher than those inducing chromosomal aberrations in Mex(-) cells, Therefore, the immediate induction of fos and jun mRNAs and AP-1 in Mex(-) cells upon their exposure to MNNG appears not to be essential for the generation of MNNG-induced mutagenic and genotoxic effects, which is possibly due to the high genotoxic potential of non-repaired O-6-methylguanine, However, for MMS and UV light, which was included in this study for comparison, c-fos, c-jun, junB and junD mRNA as well as AP-1 induction paralleled the dose-response for induction of cell killing effects, recombination and chromosomal breakage indicating that increased expression of Fos and Jun is related to the generation of MMS and UV-induced genetic changes, These data are in line with a model according to which the induced c-Fos and Jun proteins are involved in defense against UV radiation and other DNA damaging agents.	UNIV MAINZ,INST TOXICOL,DIV APPL TOXICOL,D-55131 MAINZ,GERMANY	Johannes Gutenberg University of Mainz								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BUSCHER M, 1988, ONCOGENE, V3, P301; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; FRITZ G, 1993, J BIOL CHEM, V268, P21102; GRIFFIN S, 1994, BIOCHEMISTRY-US, V33, P4787, DOI 10.1021/bi00182a006; GROMBACHER T, 1995, BBA-MOL BASIS DIS, V1270, P63, DOI 10.1016/0925-4439(94)00073-Y; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HOLT J, 1986, P NATL ACAD SCI USA, P4794; KAINA B, 1993, ENVIRON MOL MUTAGEN, V22, P283, DOI 10.1002/em.2850220418; KAINA B, 1991, CARCINOGENESIS, V12, P1857; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEAF CD, 1989, CANCER SURV, V8, P323; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; NAKABEPPU Y, 1985, J BIOL CHEM, V260, P7281; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PEGG AE, 1992, FASEB J, V6, P2302, DOI 10.1096/fasebj.6.6.1544541; Peto R., 1984, IARC SCI PUBL, V57, P627; PRESTAYKO AW, 1981, NITROSOUREAS CURRENT; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SAFFHILL R, 1985, BIOCHIM BIOPHYS ACTA, V823, P111, DOI 10.1016/0304-419X(85)90009-5; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SKLAR R, 1981, NATURE, V289, P417, DOI 10.1038/289417a0; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; ZHUKOVSKAYA N, 1994, CARCINOGENESIS, V15, P2189, DOI 10.1093/carcin/15.10.2189	38	47	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1927	1935						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934539				2022-12-17	WOS:A1996VR79500012
J	Braverman, RH; Cooper, HL; Lee, HS; Prasad, GL				Braverman, RH; Cooper, HL; Lee, HS; Prasad, GL			Anti-oncogenic effects of tropomyosin: Isoform specificity and importance of protein coding sequences	ONCOGENE			English	Article						tropomyosin; isoforms; tumor suppressor	STIMULATES TYROSINE PHOSPHORYLATION; CHICKEN-EMBRYO FIBROBLASTS; MAMMARY EPITHELIAL-CELLS; NON-MUSCLE TROPOMYOSINS; CARDIAC TROPONIN-T; TRANSFORMED-CELLS; ALPHA-TROPOMYOSIN; BETA-TROPOMYOSIN; GROWTH-FACTOR; HYPERTROPHIC CARDIOMYOPATHY	Suppression of muscle type isoforms of tropomyosin (TM) is a common biochemical event in malignantly transformed cells. To evaluate the role of TM proteins and isoform specificity in cellular transformation, cDNAs that consist of coding sequences of TM1 (product of beta gene) and TM2 (product of alpha gene), but lacking untranslated regions (UTRs), have been expressed separately in DT (v-Ki-ras transformed NIH3T3) cells, and elevated levels of the corresponding proteins were detected. DT cells which over express TM2 manifest growth in soft agar. Elevated levels of TM1 protein in DT cells resulted in flattened cell morphology and complete abolition of anchorage independent growth. Tumorigenesis in athymic nude mice was observed in the absence of transduced TM1 mRNA. Thus, expression of TM1 protein is sufficient for tumor suppression: the UTRs of TM1 are not required for the tumor suppressive effects. Expression of TM2 protein, on the other hand, has no effect on the transformed phenotype of DT cells. These data indicate that isoforms 1 and 2 of TMs perform distinct physiological roles.	NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; BHATTACHARYA B, 1988, ONCOGENE RES, V3, P51; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; CANONNEHERGAUX F, 1994, NEUROCHEM INT, V25, P545, DOI 10.1016/0197-0186(94)90153-8; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLAYTON L, 1988, J MOL BIOL, V201, P507, DOI 10.1016/0022-2836(88)90633-X; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COOPER HL, 1987, CANCER RES, V47, P4493; COTE GP, 1983, MOL CELL BIOCHEM, V57, P127, DOI 10.1007/BF00849190; DREES B, 1995, J CELL BIOL, V128, P383, DOI 10.1083/jcb.128.3.383; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GRAMATIKOFF K, 1995, BIOL CHEM H-S, V376, P321; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hammell RL, 1996, J BIOL CHEM, V271, P4236; HENDRICKS M, 1984, MOL CELL BIOL, V4, P1823, DOI 10.1128/MCB.4.9.1823; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; HITCHCOCKDEGREGORI SE, 1994, ADV EXP MED BIOL, V358, P85; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; JAMMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111; KAHN P, 1979, J CELL BIOL, V82, P1, DOI 10.1083/jcb.82.1.1; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; LEAVITT J, 1986, MOL CELL BIOL, V6, P2721, DOI 10.1128/MCB.6.7.2721; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LEONARDI CL, 1982, BIOCHIM BIOPHYS ACTA, V720, P154, DOI 10.1016/0167-4889(82)90007-6; LIANG NG, 1995, NAT GENET, V9, P75; LIBRI D, 1990, MOL CELL BIOL, V10, P5036, DOI 10.1128/MCB.10.10.5036; LIBRI D, 1990, J BIOL CHEM, V265, P3471; LIN JJC, 1985, J CELL BIOL, V100, P692, DOI 10.1083/jcb.100.3.692; LIU H, 1989, CELL, V57, P233, DOI 10.1016/0092-8674(89)90961-6; MACLEOD AR, 1987, BIOESSAYS, V6, P208, DOI 10.1002/bies.950060504; MAEKAWA S, 1994, BIOCHEM MOL BIOL INT, V33, P661; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MCINNES C, 1988, BIOCHIM BIOPHYS ACTA, V951, P117, DOI 10.1016/0167-4781(88)90031-0; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MULLAUER L, 1993, ONCOGENE, V8, P2531; MUTHUCHAMY M, 1993, MOL CELL BIOL, V13, P3311, DOI 10.1128/MCB.13.6.3311; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V25, P267, DOI 10.1002/cm.970250307; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V26, P248, DOI 10.1002/cm.970260308; Payne M R, 1985, Cell Muscle Motil, V6, P141; PITTENGER MF, 1995, J CELL SCI, V108, P3253; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; PRASAD GL, 1994, EUR J BIOCHEM, V224, P1, DOI 10.1111/j.1432-1033.1994.tb19988.x; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; PRASAD GL, 1991, BIOCHEM BIOPH RES CO, V177, P1068, DOI 10.1016/0006-291X(91)90647-P; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; STAMM S, 1993, P NATL ACAD SCI USA, V90, P9857, DOI 10.1073/pnas.90.21.9857; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; TAKENAGA K, 1988, MOL CELL BIOL, V8, P5561, DOI 10.1128/MCB.8.12.5561; TAKENAGA K, 1994, CANCER LETT, V87, P47, DOI 10.1016/0304-3835(94)90408-1; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; TIKOO A, 1994, J BIOL CHEM, V269, P23387; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WEINBERGER RP, 1993, J CELL BIOL, V120, P205, DOI 10.1083/jcb.120.1.205; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WHITTLE N, 1987, PROTEIN ENG, V1, P499, DOI 10.1093/protein/1.6.499; WIRTH PJ, 1992, ELECTROPHORESIS, V13, P305, DOI 10.1002/elps.1150130163	66	47	50	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					537	545						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760295				2022-12-17	WOS:A1996VB32800011
J	deBruijn, DRH; Baats, E; Zechner, U; deLeeuw, B; Balemans, M; Weghuis, DO; HirningFolz, U; vanKessel, AG				deBruijn, DRH; Baats, E; Zechner, U; deLeeuw, B; Balemans, M; Weghuis, DO; HirningFolz, U; vanKessel, AG			Isolation and characterization of the mouse homolog of SYT, a gene implicated in the development of human synovial sarcomas	ONCOGENE			English	Article						synovial sarcoma; mouse Syt gene SH2-; SH3-binding domains; annexin-like repeats; chromosome 18	KRUPPEL-ASSOCIATED BOX; DICTYOSTELIUM-DISCOIDEUM; BINDING PROTEIN; ANNEXIN-VII; TRANSLOCATION; BREAKPOINT; IDENTIFICATION; CHROMOSOME; CLONING; XP11.2	In a previous study we reported the isolation of the human synovial sarcoma-associated t(X;18) breakpoint. As a result of this translocation, the SYT gene on chromosome 18 fuses to either the SSX1 or the SSX2 gene on the X chromosome, depending on the exact location of the breakpoint within band Xp11.2. As yet, little is known about the modes of action of the SYT and SSX genes and their respective (fusion) products. Here we report the isolation of the mouse homolog of SYT, its full length cDNA sequence, its chromosomal localization, and its spatio-temporal expression patterns in adult and embryonic tissues. The SYT gene was found to be well conserved during evolution and is part of a region of synteny between the human and mouse chromosomes 18. In early embryogenesis, Syt is ubiquitously expressed. In later stages, the expression becomes confined to cartilage tissues, specific neuronal cells and some epithelial derived tissues. In mature testis, expression was specifically observed in primary spermatocytes.	UNIV ULM, DEPT MED GENET, D-7900 ULM, GERMANY	Ulm University	deBruijn, DRH (corresponding author), UNIV NIJMEGEN HOSP, DEPT HUMAN GENET, POB 9101, NL-6500 HB NIJMEGEN, NETHERLANDS.		van Kessel, Ad Geurts/A-2810-2010; Olde Weghuis, Danielle/C-4674-2016; Zechner, Ulrich/G-2116-2010; de Bruijn, D.R.H./L-4233-2015					CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; DEBRUIJN DRH, 1994, DIFFERENTIATION, V58, P141; DELEEUW B, 1993, ONCOGENE, V8, P1457; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; DELEEUW B, 1994, HUM MOL GENET, V3, P745, DOI 10.1093/hmg/3.5.745; DELEEUW B, 1994, CANCER GENET CYTOGEN, V73, P89, DOI 10.1016/0165-4608(94)90191-0; DELEEUW B, 1993, GENE CHROMOSOME CANC, V6, P182, DOI 10.1002/gcc.2870060309; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; GRANT CE, 1990, GENE, V96, P213, DOI 10.1016/0378-1119(90)90255-P; GREENWOOD M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P429, DOI 10.1016/0167-4781(91)90137-B; JANZ M, 1995, J PATHOL, V175, P391, DOI 10.1002/path.1711750405; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; OAKBERG EF, 1956, AM J ANAT, V99, P391, DOI 10.1002/aja.1000990303; OVERHAUSER J, 1995, CYTOGENET CELL GENET, V71, P106; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SHIPLEY JM, 1994, ONCOGENE, V9, P1447; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; WEGHUIS DO, 1994, GENE CHROMOSOME CANC, V9, P288; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; ZHANGKECK ZY, 1993, BIOCHEM J, V289, P735, DOI 10.1042/bj2890735	21	47	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	1996	13	3					643	648						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760306				2022-12-17	WOS:A1996VB32800022
J	Vadiveloo, PK; Vairo, G; Novak, U; Royston, AK; Whitty, G; Filonzi, EL; Cragoe, EJ; Hamilton, JA				Vadiveloo, PK; Vairo, G; Novak, U; Royston, AK; Whitty, G; Filonzi, EL; Cragoe, EJ; Hamilton, JA			Differential regulation of cell cycle machinery by various antiproliferative agents is linked to macrophage arrest at distinct G1 checkpoints	ONCOGENE			English	Article						cyclin; cdk; IFN gamma; dimethylamiloride; lipopolysaccharide; cAMP	STIMULATING FACTOR-I; DEPENDENT PROTEIN-KINASES; GROWTH-FACTOR-BETA; C-MYC EXPRESSION; S-PHASE ENTRY; TRANSCRIPTION FACTOR; TGF-BETA; RETINOBLASTOMA PROTEIN; HEMATOPOIETIC-CELLS; SIGNAL TRANSDUCTION	There is currently much interest in the mechanisms of action of antiproliferative agents and their effects on cell cycle machinery. In the present study we examined the mechanisms of action of four unrelated agents known to inhibit proliferation of CSF-1-stimulated bone marrow-derived macrophages (BMM). We report that 8-bromo-cAMP (8Br-cAMP) and lipopolysaccharide (LPS) potently reduced CSF-1-stimulated cyclin D1 protein, and cyclin-dependent kinase (cdk) 4 mRNA and protein levels, while the inhibitory effects of the Na+/ H+ antiport inhibitor 5-(N',N'-dimethyl) amiloride (DMA) and interferon gamma (IFN gamma) were only weak. All agents repressed CSF-1-stimulated retinoblastoma protein phosphorylation. Furthermore, 8Br-cAMP and to a lesser extent IFN gamma, also reduced CSF-1-stimulated levels of E2F DNA binding activity in a macrophage cell line, BAC1.2F5. An explanation for the different effects of the agents is that 8Br-cAMP and LPS were found to arrest BMM in early/mid-G1, while IFN gamma and DMA arrested cells in late G1 or early S phase. These data indicate that (1) different antiproliferative agents can arrest the same cell type at distinct checkpoints in G1 and (2) effects of antiproliferative agents on cell cycle machinery is Linked to the position at which they arrest cells in G1.	WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA	Walter & Eliza Hall Institute	Vadiveloo, PK (corresponding author), UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT MED,MELBOURNE,VIC 3050,AUSTRALIA.			Hamilton, John A/0000-0002-9493-9224				ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; ANDO K, 1995, ONCOGENE, V10, P751; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BORTNER DM, 1991, GENE DEV, V5, P1777, DOI 10.1101/gad.5.10.1777; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCKS BG, 1992, J BIOL CHEM, V267, P12307; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CRAGOE EJ, 1967, J MED CHEM, V10, P66, DOI 10.1021/jm00313a014; DEGREGORI J, 1995, MOL CELL BIOL, V15, P5846; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; GAGELIN C, 1994, BIOCHEM BIOPH RES CO, V205, P923, DOI 10.1006/bbrc.1994.2753; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAMILTON JA, 1992, J IMMUNOL, V148, P4028; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KO TC, 1995, ONCOGENE, V10, P177; KREK W, 1995, METHOD ENZYMOL, V254, P114; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NEVINS JR, 1992, SCIENCE, V258, P424; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; OKAMOTO Y, 1993, BIOCHEM BIOPH RES CO, V195, P84, DOI 10.1006/bbrc.1993.2013; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SCHWARZBAUM S, 1984, J IMMUNOL, V132, P1158; SEWING A, 1993, J CELL SCI, V104, P545; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; VAIRO G, 1985, BIOCHEM BIOPH RES CO, V132, P430, DOI 10.1016/0006-291X(85)91040-X; VAIRO G, 1991, J IMMUNOL, V146, P3469; VAIRO G, 1990, J BIOL CHEM, V265, P2692; VAIRO G, 1995, ONCOGENE, V10, P1969; VAIRO G, 1992, J BIOL CHEM, V267, P19043; VAIRO G, 1990, J BIOL CHEM, V265, P16929; VAIRO G, 1991, IMMUNOL TODAY, V12, P362, DOI 10.1016/0167-5699(91)90067-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIE Y, 1993, BRIT J HAEMATOL, V84, P392, DOI 10.1111/j.1365-2141.1993.tb03092.x	68	47	47	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					599	608						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760301				2022-12-17	WOS:A1996VB32800017
J	Welcker, M; Lukas, J; Strauss, M; Bartek, J				Welcker, M; Lukas, J; Strauss, M; Bartek, J			Enhanced protein stability: A novel mechanism of D-type cyclin over-abundance identified in human sarcoma cells	ONCOGENE			English	Article						cell cycle; proto-oncogene; D-cyclin protein stability; retinoblastoma protein; multistep tumorigenesis	HUMAN BREAST-CANCER; G1 PHASE PROGRESSION; D-CDK COMPLEXES; RETINOBLASTOMA-PROTEIN; DEPENDENT KINASES; GENE-PRODUCT; G(1) CONTROL; EXPRESSION; AMPLIFICATION; LOCALIZATION	The mammalian D-type cyclins promote progression through a G1 checkpoint by phosphorylating the retinoblastoma protein (pRB), and can contribute to oncogenesis via their deregulated expression achieved through gene amplification, chromosomal rearrangement, or retroviral integration. We now report a novel mechanism of tumour-associated D-cyclin over-abundance, resulting from enhanced protein stability. In two human cell lines established from a single uterine sarcoma biopsy, pRB-positive SK-UT-1B and pRB-deficient SK-UT-1, aberrant accumulation of functional cyclins D1, and D2 and D3 occurred in the absence of gene amplification and/or elevated mRNA expression. The abundance of D-cyclin proteins remained elevated throughout the cell cycle, and pulse-chase experiments revealed six to 10-fold prolongation of their protein half-lives as compared with either diploid fibroblasts or control U-2-OS sarcoma cells. These results point to a critical regulatory role of D-type cyclin turnover, and contribute to refinement of current views of the role played by the cyclin D-CDK-p16-pRB pathway in cell cycle control and tumorigenesis.	DANISH CANC SOC, DIV CANC BIOL, DK-2100 COPENHAGEN O, DENMARK; MAX PLANCK GESELL, D-13122 BERLIN, GERMANY	Danish Cancer Society; Max Planck Society			Bartek, Jiri/G-5870-2014	Welcker, Markus/0000-0001-6723-4790; Lukas, Jiri/0000-0001-9087-506X				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1995, CANCER RES, V55, P949; BARTKOVA J, 1995, ONCOGENE, V10, P775; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1994, ONCOGENE, V9, P71; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; GILLETT C, 1994, CANCER RES, V54, P1812; HUNT T, 1991, NATURE, V349, P100, DOI 10.1038/349100a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KATO J, 1993, GENE DEV, V7, P331; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1994, ONCOGENE, V9, P2159; LUKAS J, 1995, ONCOGENE, V10, P2125; LUKAS J, 1995, CANCER RES, V55, P4818; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PETERS G, 1994, J CELL SCI, P89; SCHUURING E, 1992, ONCOGENE, V7, P355; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; TAM SW, 1994, ONCOGENE, V9, P2663; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	47	47	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	1996	13	2					419	425						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710382				2022-12-17	WOS:A1996VA25200022
J	Wieland, I; Bohm, M; Arden, KC; Ammermuller, T; Bogatz, S; Viars, CS; Rajewsky, MF				Wieland, I; Bohm, M; Arden, KC; Ammermuller, T; Bogatz, S; Viars, CS; Rajewsky, MF			Allelic deletion mapping on chromosome 5 in human lung carcinomas	ONCOGENE			English	Article						microdissection; PCR-SSCP; microsatellite markers; APC; del-27; tumor suppressor gene	POLYMERASE CHAIN-REACTION; SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; DIFFERENCE CLONING; HUMAN DNA; CANCER; HYBRIDIZATION; P53; HETEROZYGOSITY; ADENOCARCINOMA	We analysed allelic deletions on chromosome 5 in microdissected human non-small cell lung cancers. Thirty-four primary squamous cell carcinomas, 15 primary adenocarcinomas and five regional lymph node metastases were investigated for loss of heterozygosity (LOH) in chromosomal region 5p15-q21. The sites analysed included the APC tumor suppressor gene at 5q21, five polymorphic microsatellite markers and the putative tumor suppressor locus del-27, that was assigned to chromosomal region 5p13-12 by fluorescence in situ hybridization (FISH) analysis. Allelic deletions encompassed larger genomic regions more often in squamous cell carcinomas than in adenocarcinomas. The del-27 amd APC regions were identified as two distinct regions with the highest LOH frequencies within 5p15-q21. In squamous cell carcinomas LOH frequencies were 73% at the del-27 and 70% at the APC locus. In adenocarcinomas LOH at the del-27 and APC loci occurred in 38% of the informative cases. Allelic deletion of the APC gene and at the del-27 locus was also detected in the metastases. The results suggest involvement of at least two tumor suppressor genes on chromosome 5 in lung tumorigenesis.	UNIV ESSEN GESAMTHSCH,SCH MED,INST CELL BIOL CANC RES,D-45122 ESSEN,GERMANY; UNIV CALIF SAN DIEGO,DEPT MED,LUDWIG INST CANC RES,LA JOLLA,CA 92093	University of Duisburg Essen; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Wieland, I (corresponding author), UNIV ESSEN GESAMTHSCH,SCH MED,INST CELL BIOL CANC RES,VIRCHOWSTR 173,D-45122 ESSEN,GERMANY.			Wieland, Ilse/0000-0002-8017-3029				AHSEE KW, 1994, CANCER RES, V54, P1617; ALLAN GJ, 1994, HUM MUTAT, V3, P283, DOI 10.1002/humu.1380030317; ASHTONRICKARDT PG, 1991, ONCOGENE, V6, P1881; BOHM M, 1994, CLIN EXP METASTAS, V12, P55, DOI 10.1007/BF01784334; BOHM M, 1993, CANCER GENET CYTOGEN, V65, P83, DOI 10.1016/0165-4608(93)90211-4; BOS JL, 1989, CANCER RES, V49, P4682; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; DALY MC, 1993, ONCOGENE, V8, P1721; DAMICO D, 1992, CANCER RES, V52, P1996; FONG KM, 1995, CANCER RES, V55, P220; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HENSEL CH, 1990, CANCER RES, V50, P3067; HORII A, 1992, CANCER RES, V52, P6696; HOSOE S, 1994, CANCER RES, V54, P1787; JACKY PB, 1991, ACT CYTOGENETICS LAB, P89; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; KOK K, 1994, CANCER RES, V54, P4183; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; LOEB LA, 1994, CANCER RES, V54, P5059; MERLO A, 1994, CANCER RES, V54, P640; MIURA I, 1992, CANCER RES, V52, P1322; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; POWELL SM, 1994, GASTROENTEROLOGY, V107, P1759, DOI 10.1016/0016-5085(94)90818-4; RIED T, 1994, CANCER RES, V54, P1801; RODRIGUEZ E, 1994, CANCER RES, V54, P3398; Sambrook J., 1989, MOL CLONING LAB MANU; SATO S, 1994, CANCER RES, V54, P5652; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHISEKI M, 1994, CANCER RES, V54, P5643; SPEICHER MR, 1995, CANCER RES, V55, P1010; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TESTA JR, 1993, CANCER DETECT PREV, V17, P267; TSUCHIYA E, 1992, CANCER RES, V52, P2478; WASHIMI O, 1995, CANCER RES, V55, P514; WEBER JL, 1989, AM J HUM GENET, V44, P388; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; White B. A., 1993, PCR PROTOCOLS CURREN; WIELAND I, 1990, P NATL ACAD SCI USA, V87, P2720, DOI 10.1073/pnas.87.7.2720; WIELAND I, 1994, CANCER RES, V54, P1772; WIELAND I, 1992, P NATL ACAD SCI USA, V89, P9705, DOI 10.1073/pnas.89.20.9705; WLODARSKA I, 1994, CYTOGENET CELL GENET, V65, P179, DOI 10.1159/000133627; YOKOYAMA S, 1992, CANCER RES, V52, P873	47	47	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					97	102						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552404				2022-12-17	WOS:A1996TQ01400012
J	FALASCA, M; SILLETTA, MG; CARVELLI, A; DIFRANCESCO, AL; FUSCO, A; RAMAKRISHNA, V; CORDA, D				FALASCA, M; SILLETTA, MG; CARVELLI, A; DIFRANCESCO, AL; FUSCO, A; RAMAKRISHNA, V; CORDA, D			SIGNALING PATHWAYS INVOLVED IN THE MITOGENIC ACTION OF LYSOPHOSPHATIDYLINOSITOL	ONCOGENE			English	Article						PHOSPHOLIPASE A(2); LYSOLIPIDS; LYSOPHOSPHATIDIC ACID; GLYCEROPHOSPHOINOSITOLS; THYROID; FRTL5 CELLS	FRTL-5 THYROID-CELLS; GROWTH FACTOR-I; LYMPHOCYTE-T ACTIVATION; GTP-BINDING PROTEINS; MURINE SARCOMA-VIRUS; EPITHELIAL-CELLS; IODIDE EFFLUX; ARACHIDONIC-ACID; PHOSPHOLIPASE-C; PERTUSSIS TOXIN	Lysophosphatidylinositol has been previously shown to stimulate cell proliferation in differentiated and in K-ras transformed thyroid cells. Increased levels of lysophosphatidylinositol, but not lysophosphatidylcholine or lysophosphatidylethanolamine, are present in thyroid as well as in other ras-transformed cell lines. We have now investigated the mechanism of action of this lysolipid by analysing its effects in a differentiated thyroid cell line. Lysophosphatidylinositol did not increase the levels of cAMP, the main stimulator of cell proliferation in the thyroid, whereas it stimulated phosphoinositide breakdown, mobilization of cytosolic Ca2+ and arachidonic acid release, suggesting that it activates both phospholipases C and A(2). None of the effects of lysophosphatidylinositol were prevented by pretreatment of cells with pertussis toxin. Instead, the tyrosine kinase inhibitors, tyrphostins AG18 and AG561, completely blocked its mitogenic action. The effects of lysophosphatidylinositol were distinguishable from those of the well known mitogen lysophosphatidic acid, which affected differently the signalling pathways analysed and was not mitogenic in ras-transformed cells. These results suggest that the mitogenic activity of lysophosphatidylinositol is associated with the activation of phospholipase C and phospholipase A(2) and is relatively specific for ras-transformed cells.	IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,CELLULAR & MOLEC ENDOCRINOL LAB,I-66030 SANTA MARIA IMBAR,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CHIM,I-88100 CALABRIA,ITALY	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Universita Mediterranea di Reggio Calabria			Corda, Daniela/K-6385-2016; Falasca, Marco/S-4020-2016	Corda, Daniela/0000-0002-3614-751X; Falasca, Marco/0000-0002-9801-7235; Fusco, Alfredo/0000-0003-3332-5197				ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; ALONSO T, 1990, BIOCHEM BIOPH RES CO, V171, P14, DOI 10.1016/0006-291X(90)91349-W; AMBESIIMPIOMBAT.FS, 1989, FRTL5 TODAY; AMBESIIMPIOMBAT.FS, 1980, P NATL ACAD SCI USA, V77, P3455; ASAOKA Y, 1991, BIOCHEM BIOPH RES CO, V178, P1378, DOI 10.1016/0006-291X(91)91046-F; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BARAN DT, 1987, ENDOCRINOLOGY, V122, P930; BENTON AM, 1982, BLOOD, V60, P642; BERMAN MI, 1987, ARCH BIOCHEM BIOPHYS, V253, P249, DOI 10.1016/0003-9861(87)90658-8; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIZZARRI C, 1990, P NATL ACAD SCI USA, V87, P4889, DOI 10.1073/pnas.87.12.4889; BIZZARRI C, 1994, EUR J BIOCHEM, V219, P837, DOI 10.1111/j.1432-1033.1994.tb18565.x; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BONE EA, 1986, ENDOCRINOLOGY, V119, P2193, DOI 10.1210/endo-119-5-2193; BURCH RM, 1986, J BIOL CHEM, V261, P1236; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CHIARIOTTI L, 1992, ONCOGENE, V7, P2507; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; COLLETTA G, 1983, MOL CELL BIOL, V3, P2099, DOI 10.1128/MCB.3.11.2099; CONDORELLI G, 1992, ENDOCRINOLOGY, V130, P1615, DOI 10.1210/en.130.3.1615; CORDA D, 1985, J BIOL CHEM, V260, P9230; CORDA D, 1989, ADV EXP MED BIOL, V261, P245; CORDA D, 1985, EXP EYE RES, V40, P575, DOI 10.1016/0014-4835(85)90079-X; CORDA D, 1987, ENDOCRINOLOGY, V120, P1152, DOI 10.1210/endo-120-3-1152; Cucchi P., 1992, Acta Medica Romana, V30, P176; DIGIROLAMO M, 1991, ACTA ENDOCRINOL-COP, V125, P192, DOI 10.1530/acta.0.1250192; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; FIELD JB, 1987, BIOCHEM J, V247, P519, DOI 10.1042/bj2470519; FUJIMOTO J, 1992, ENDOCRINOLOGY, V130, P1587, DOI 10.1210/en.130.3.1587; FUSCO A, 1982, CANCER RES, V42, P618; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gennis R. B., 1989, BIOMEMBRANE, P235; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOWE LR, 1993, J BIOL CHEM, V268, P20717; IACOVELLI L, 1993, J BIOL CHEM, V268, P20402; JALINK K, 1990, J BIOL CHEM, V265, P12232; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; LOMBARDI A, 1988, ENDOCRINOLOGY, V123, P1544, DOI 10.1210/endo-123-3-1544; LORENZET R, 1992, THROMB HAEMOSTASIS, V68, P357; MALAGODI MH, 1974, EUR J PHARMACOL, V27, P25, DOI 10.1016/0014-2999(74)90198-8; MARCOCCI C, 1987, ENDOCRINOLOGY, V120, P1127, DOI 10.1210/endo-120-3-1127; MARSH D, 1993, BIOMEMBRANE, V1, P1; MARTIN SC, 1992, J MEMBRANE BIOL, V125, P243; MCHOWAT J, 1993, J BIOL CHEM, V268, P15605; METZ SA, 1988, AM J MED, V85, P9, DOI 10.1016/0002-9343(88)90393-2; MOOLENAAR WH, 1992, REV PHYSIOL BIOCH P, V119, P47; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; OKAJIMA F, 1988, ENDOCRINOLOGY, V123, P1035, DOI 10.1210/endo-123-2-1035; OKAJIMA F, 1989, J BIOL CHEM, V264, P13029; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SATO K, 1992, BIOCHEM J, V283, P281, DOI 10.1042/bj2830281; SCHUMACHER KA, 1979, THROMB HAEMOSTASIS, V42, P631; SHINITZKY M, 1976, BIOCHIM BIOPHYS ACTA, V433, P133, DOI 10.1016/0005-2736(76)90183-8; SMALLRIDGE RC, 1991, ENDOCRINOLOGY, V129, P542, DOI 10.1210/endo-129-1-542; TAHARA K, 1991, J BIOL CHEM, V266, P440; TAKAHASHI S, 1990, ENDOCRINOLOGY, V126, P736, DOI 10.1210/endo-126-2-736; TAKAHASHI SI, 1991, J BIOL CHEM, V266, P7834; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TORNQUIST K, 1991, MOL CELL ENDOCRINOL, V79, P147, DOI 10.1016/0303-7207(91)90105-2; TORNQUIST K, 1992, J CELL PHYSIOL, V150, P90, DOI 10.1002/jcp.1041500113; TRAMONTANO D, 1986, ENDOCRINOLOGY, V119, P940, DOI 10.1210/endo-119-2-940; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; VALENTE WA, 1983, ENDOCRINOLOGY, V112, P71, DOI 10.1210/endo-112-1-71; VALITUTTI S, 1991, CELL SIGNAL, V3, P321, DOI 10.1016/0898-6568(91)90061-X; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; VITTI P, 1983, J CLIN ENDOCR METAB, V57, P782, DOI 10.1210/jcem-57-4-782; VOGT W, 1963, BIOCHEM PHARMACOL, V12, P415, DOI 10.1016/0006-2952(63)90074-1; WANG WQ, 1992, J CHROMATOGR-BIOMED, V581, P139, DOI 10.1016/0378-4347(92)80457-2; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1108, DOI 10.1210/endo-114-4-1108; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346	76	47	49	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2113	2124						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784056				2022-12-17	WOS:A1995RB70300006
J	EYCHENE, A; DUSANTERFOURT, I; BARNIER, JV; PAPIN, C; CHARON, M; GISSELBRECHT, S; CALOTHY, G				EYCHENE, A; DUSANTERFOURT, I; BARNIER, JV; PAPIN, C; CHARON, M; GISSELBRECHT, S; CALOTHY, G			EXPRESSION AND ACTIVATION OF B-RAF KINASE ISOFORMS IN HUMAN AND MURINE LEUKEMIA-CELL LINES	ONCOGENE			English	Article						B-RAF; C-RMIL; RAF-1; SERINE THREONINE KINASE; HEMATOPOIETIC CELLS	COLONY-STIMULATING FACTOR; SERINE-THREONINE KINASE; PROTEIN-KINASE; GROWTH-FACTOR; RAPID PHOSPHORYLATION; C-RAF; SIGNAL TRANSDUCTION; PROTOONCOGENE; ERYTHROPOIETIN; INTERLEUKIN-3	The B-raf/c-Rmil proto-oncogene belongs to the raf/mil family of serine/threonine protein kinases. It encodes multiple protein isoforms previously shown to be expressed predominantly in neural tissues. We report here that B-Raf proteins of 95 and 72 kDa are also expressed in various human and murine hematopoietic cell lines. Their relative level of expression is variable depending on the cell line examined. The highest level of expression of p95(B-raf) was found in UT-7 cells, a human pluripotent cell line established from a patient with a megakaryoblastic leukemia. These cells are able to differentiate toward erythroid or myeloid lineage phenotypes in presence of erythropoietin (EPO) or granulocyte-macrophage colony-stimulating factor (GM-CSF) respectively. We show that treatment of UT-7 cells with EPO, GM-CSF or stem cell factor (SCF) rapidly induces phosphorylation of p95(B-raf) as indicated by a shift of electrophoretic mobility. This increase in phosphorylation is correlated with a three-fold increase of B-Raf kinase activity. B-Raf activation also increases in a dose-dependent manner in response to EPO and GM-CSF. We also show that both p95(B-raf) and p72(B-raf) can be activated by IL-3 in murine BAF-3 pro-B cells and by anti-CD3 in human Jurkat cells, respectively. These observations provide the first evidence that the B-Raf kinase is involved in signal transduction pathways regulating proliferation and differentiation of hematopoietic cells of both myeloid and lymphoid lineages.	HOP COCHIN,ICGM,INSERM,U363,F-75674 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	EYCHENE, A (corresponding author), CTR UNIV ORSAY,INST CURIE,LAB 110,CNRS,URA 1443,F-91405 ORSAY,FRANCE.		Eychene, Alain/M-8838-2017; Dusanter-Fourt, Isabelle/P-4558-2017	Dusanter-Fourt, Isabelle/0000-0002-9286-1021; EYCHENE, Alain/0000-0002-6818-7225				BRENNSCHEIDT U, 1994, CELL GROWTH DIFFER, V5, P367; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUSCHER D, 1993, ONCOGENE, V8, P3323; CALOGERAKI I, 1993, BIOCHEM BIOPH RES CO, V193, P1324, DOI 10.1006/bbrc.1993.1770; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; EYCHENE A, 1992, ONCOGENE, V7, P1657; EYCHENE A, 1992, ONCOGENE, V7, P1315; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FELDER MP, 1991, J VIROL, V65, P3633, DOI 10.1128/JVI.65.7.3633-3640.1991; HEIDECKER G, 1991, ADV CANCER RES, V58, P53; HERMINE O, 1992, BLOOD, V80, P3060; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; KANAKURA Y, 1991, BLOOD, V77, P243; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOMATSU N, 1991, CANCER RES, V51, P341; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; MIHALY A, 1993, BRAIN RES, V627, P225, DOI 10.1016/0006-8993(93)90325-H; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; OWAKI H, 1993, EMBO J, V12, P4367, DOI 10.1002/j.1460-2075.1993.tb06121.x; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; RAMOSMORALES F, 1994, IN PRESS ONCOGENE, V9; RAPP UR, 1991, ONCOGENE, V6, P495; RIEDEL D, 1993, EUR J IMMUNOL, V23, P3146, DOI 10.1002/eji.1830231216; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SOZERI O, 1992, ONCOGENE, V7, P2259; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; STORM SM, 1990, ONCOGENE, V5, P345; TAMAKI T, 1992, CANCER RES, V52, P566; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6934, DOI 10.1073/pnas.85.18.6934; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	47	47	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1159	1165						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7535416				2022-12-17	WOS:A1995QN35300017
J	ZENKLUSEN, JC; OSHIMURA, M; BARRETT, JC; CONTI, CJ				ZENKLUSEN, JC; OSHIMURA, M; BARRETT, JC; CONTI, CJ			INHIBITION OF TUMORIGENICITY OF A MURINE SQUAMOUS-CELL CARCINOMA (SCC) CELL-LINE BY A PUTATIVE TUMOR-SUPPRESSOR GENE ON HUMAN-CHROMOSOME-7	ONCOGENE			English	Article							IDENTIFICATION; EXPRESSION; DELETION; CANCER; NEUROFIBROMATOSIS; HETEROZYGOSITY; CLONING; DISEASE; HYBRIDS; GROWTH	Alterations in oncogenes and tumor suppressor genes (TSG) are considered to be critical steps in oncogenesis. However information on putative TSG involved in the developement of squamous cell carcinomas (SCC) is very limited. In this study we confirmed the existence of a tumor suppressor gene (TSG) on human chromosome 7 (hchr 7) that suppresses the tumorigenicity of squamous cell carcinomas (SCCs). We injected seven clones of CH72 cells (a murine SCC-derived cell line) bearing a hchr 7 (CH72/hchr 7) introduced by microcell fusion, two clones bearing human chromosome 12 (CH72/hchr 12) and parental CH72 cells into athymic Balb/c nude mice. The sizes of the tumors were determined twice a week until tumors reached 12 mm diameter. In situ hybridization for centromeric repetitive sequences of the transferred chromosomes were performed on the cell lines injected and the tumors arising after the injection. Southern blots and polymerase chain reaction (PCR) amplifications of near terminal sequences and (CA) microsatellite repeats were done to test the integrity of the introduced chromosomes. Five out of seven CH72/ hchr 7 clones had a twofold and threefold longer latency periods than CH72 cells. The remaining CH72/hchr 7 clones (MF 6 and 13 no. 4) had latency periods similar to that of parental CH72; MF 6 had a deletion in the introduced chromosome 7 involving q31.3-q31.3, whereas the other hybrid (MF 13 no. 4) seemed to have an intact hchr 7. Tumor-derived cells from CH72/hchr 7 hybrids with a delayed latency had lost centromeric and telomeric sequences of Chr 7. In constrast, tumors derived from the MF 6 and MF 13 no. 4 as well as the CH72/hchr 12 clones retained the introduced human chromosome as shown by chromosome 7 or 12 centromeric and telomeric sequences. These results indicate that the tumorigenicity of CH72 murine SCC cells was suppressed by hchr 7 and that the CH72/hchr 7 regain the tumorigenic phenotype after loss of the introduced chromosome, suggesting the presence of a TSG on hchr 7.	UNIV TEXAS,MD ANDERSON CANC CTR,DIV RES,SMITHVILLE,TX 78957; TOTTORI UNIV,SCH LIFE SCI,DEPT MOLEC & CELL GENET,YONAGO,TOTTORI,JAPAN; NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709	University of Texas System; UTMD Anderson Cancer Center; Tottori University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)					NCI NIH HHS [CA53123] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053123] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1986, CANCER GENET CYTOGEN, V20, P223, DOI 10.1016/0165-4608(86)90077-4; ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, V1, pCH2; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CONTI CJ, 1988, CANCER RES, V48, P435; CONWAY K, 1992, CANCER RES, V52, P6487; DORNISKELLER H, 1987, CELL, V51, P319; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOLKMAN J, 1983, SCIENCE, V221, P719, DOI 10.1126/science.6192498; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HANSEN MF, 1987, CANCER RES, V47, P5518; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KORC M, 1986, P NATL ACAD SCI USA, V83, P5141, DOI 10.1073/pnas.83.14.5141; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEFRANC MP, 1986, P NATL ACAD SCI USA, V83, P9596, DOI 10.1073/pnas.83.24.9596; MYERS JC, 1981, P NATL ACAD SCI-BIOL, V78, P3516, DOI 10.1073/pnas.78.6.3516; NEUMAN WL, 1992, BLOOD, V79, P1501; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; OSLO P, 1992, CANCER GENET CYTOGEN, V59, P73; PORTEOUS DJ, 1989, GENOMICS, V5, P680, DOI 10.1016/0888-7543(89)90108-0; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SHANNON KM, 1992, BLOOD, V79, P1311; TANAKA K, 1990, SCIENCE, V247, P568; THEUNE S, 1991, GENOMICS, V9, P511, DOI 10.1016/0888-7543(91)90418-E; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WHITE R, 1985, NATURE, V318, P382, DOI 10.1038/318382a0; ZAR JH, 1992, BIOSTATISTICAL ANAL, pCH16	37	47	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2817	2825						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084587				2022-12-17	WOS:A1994PG82200007
J	WU, LT; YEE, A; LIU, L; CARBONAROHALL, D; VENKATESAN, N; TOLO, VT; HALL, FL				WU, LT; YEE, A; LIU, L; CARBONAROHALL, D; VENKATESAN, N; TOLO, VT; HALL, FL			MOLECULAR-CLONING OF THE HUMAN CAK1 GENE ENCODING A CYCLIN-DEPENDENT KINASE-ACTIVATING KINASE	ONCOGENE			English	Article							HUMAN OSTEOSARCOMA CELLS; PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; TYROSINE PHOSPHATASE; CATALYTIC SUBUNIT; PHOSPHORYLATION; P34CDC2; IDENTIFICATION; INHIBITOR; P34(CDC2)	Cyclin-dependent, proline-directed protein kinases normally function to execute critical cell cycle transitions; abnormal expression and/or viral subversion of the positive (cyclins) and negative (Pic1) regulatory subunits may contribute to neoplastic transformation and tumorigenesis. In addition to the binding of regulatory subunits, the enzymatic activities of the cyclin-dependent kinases, Cdc2 and Cdk2, are tightly regulated by site-specific protein phosphorylation events, Recent studies have identified a critical phosphorylation site (Thr-161) located within kinase Subdomain VIII that is necessary for Cdc2 activation, and enzymatic activities capable of carrying out this heterologous phosphorylation event have been detected in both Xenopus oocytes and human somatic cells. In this report, we characterize by molecular cloning a human homologue of the Xenopus Cdk-activating kinase (Cak, encoded by MO15); the novel human gene is designated (HS)CAK1. While only 75% identity is observed at the nucleotide level, the deduced amino acid sequence encoded by (HS)CAK1 is approximately 87% identical to that of the Xenopus MO15 gene in corresponding regions. The catalytic domain of (HS)Cak1, defined by conserved kinase Subdomains I through XI, exhibits considerable homology with (HS)Cdc2, suggesting that this kinase cascade involves closely related enzymes. Immunological studies with anti-Cak antibodies confirm the presence of specific immunoreactivity in highly purified preparations of the human Cdc2-activating kinase. The molecular characterization of (HS)CAK1 should facilitate studies of its physiological regulation, as well as its potential utility as a target for therapeutic intervention in the treatment of proliferative disorders.	CHILDRENS HOSP LOS ANGELES, RES INST, DIV ORTHOPAED SURG, LOS ANGELES, CA 90027 USA; UNIV SO CALIF, SCH PHARM, DEPT MOLEC PHARMACOL & TOXICOL, LOS ANGELES, CA 90033 USA	Children's Hospital Los Angeles; University of Southern California					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049715] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01GM49715-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BRECHOT C, 1993, CURR OPIN GENET DEV, V3, P11, DOI 10.1016/S0959-437X(05)80335-1; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; DOU QP, 1993, CANCER RES, V53, P1493; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ERSHLER MA, 1993, GENE, V124, P305, DOI 10.1016/0378-1119(93)90411-U; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUERRUCCI M-A, 1991, Protein Sequences and Data Analysis, V4, P337; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARPER JW, 1993, CELL, V75, P805; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PINES J, 1990, New Biologist, V2, P389; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; WHITE BA, 1982, J BIOL CHEM, V257, P8569; Williams R. T., 1993, Molecular Biology of the Cell, V4, p239A; WILLIAMS RT, 1993, J BIOL CHEM, V268, P8871; WILLIAMS RT, 1992, ONCOGENE, V7, P423; WU LT, 1993, INT J ONCOL, V3, P859; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	45	47	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					2089	2096						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208556				2022-12-17	WOS:A1994NR68500036
J	CARE, A; MATTIA, G; MONTESORO, E; PAROLINI, I; RUSSO, G; COLOMBO, MP; PESCHLE, C				CARE, A; MATTIA, G; MONTESORO, E; PAROLINI, I; RUSSO, G; COLOMBO, MP; PESCHLE, C			C-FES EXPRESSION IN ONTOGENIC DEVELOPMENT AND HEMATOPOIETIC DIFFERENTIATION	ONCOGENE			English	Article							SERUM-FREE CULTURE; TYROSINE PHOSPHORYLATION; PROTO-ONCOGENE; BETA-SUBUNIT; GM-CSF; GROWTH; CDNA; PROGENITORS; RECEPTORS; EMBRYOS	The c-fes protein (NCP92) is a tyrosine-specific protein kinase, capable of both autophosphorylation and phosphorylation of other substrates. We have analysed c-fes RNA expression in human/murine ontogenetic development and in homogenous populations of embryonic and adult human hematopoietic cells. c-fes expression has been observed in rapidly proliferating embryonic-fetal tissues originating from different germinal layers, but not in adult non-hematopoietic tissues. In particular, a spatially and temporally regulated transcription was observed in the central nervous system and in developing cartilage. Expression in hematopoietic cells was evaluated in progenitors purified from embryonic-fetal liver and adult peripheral blood differentiating gradually and specifically along the erythroid or granulomonocytic lineage. In both embryonic and adult hematopoietic cells c-fes was abundantly expressed in undifferentiated progenitors of both lineages, as well as in differentiated granulomonocytic precursors, but not in erythroblasts. This expression pattern correlates with that of GM-CSF and in part IL-3 receptors (Testa et al., 1993 and our unpublished results). Altogether, these results suggest a possible role for c-fes in signal transduction, in both embryonic non-hematopoietic tissues and embryonic/ adult hematopoietic cells, following interaction of growth factors with their tyrosine-kinase negative receptors (i.e., GM-CSF and IL-3 receptors in adult hematopoietic cells and other hypothetical growth factor(s) receptors during embryonic development).	IST SUPER SANITA, DEPT HEMATOL ONCOL, I-00161 ROME, ITALY; OSPED AVELLINO, DIV OBSTET & GYNECOL, I-83100 AVELLINO, ITALY; IST NAZL STUDIO & CURA TUMORI, DIV EXPTL ONCOL D, I-20133 MILAN, ITALY; THOMAS JEFFERSON UNIV, THOMAS JEFFERSON CANC INST, PHILADELPHIA, PA 19107 USA	Istituto Superiore di Sanita (ISS); Fondazione IRCCS Istituto Nazionale Tumori Milan; Jefferson University			Colombo, Mario P./V-7166-2017; CARE', Alessandra/H-5090-2016; Mattia, Gianfranco/K-5194-2016; parolini, Isabella/J-9955-2016; felli, nadia/G-2088-2012	Colombo, Mario P./0000-0003-0042-7955; CARE', Alessandra/0000-0003-4106-3342; Mattia, Gianfranco/0000-0001-7047-6360; parolini, Isabella/0000-0001-9863-1051; felli, nadia/0000-0001-6763-3361				ALCALAY M, 1990, ONCOGENE, V5, P267; BISHOP JM, 1982, MRNA TUMOR VIRUSES M, P267; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; ELIASON JF, 1986, J CELL PHYSIOL, V128, P231, DOI 10.1002/jcp.1041280214; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HOGAN B, 1986, MOL CLONING LABORATO; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LANFRANCONE L, 1989, INT J CANCER, P35; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; MIGLIACCIO G, 1986, J CLIN INVEST, V78, P51, DOI 10.1172/JCI112572; Moore, 1982, DEV HUMAN; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PESCHLE C, 1985, NATURE, V313, P235, DOI 10.1038/313235a0; PLACZEK M, 1990, DEVELOPMENT, V110, P19; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Sambrook J., 1989, MOL CLONING LAB MANU; SORENSEN PHB, 1989, BLOOD, V73, P406; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; TESTA U, 1993, BLOOD, V81, P1442; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VALTIERI M, 1989, BLOOD, V74, P460; YEE SP, 1989, P NATL ACAD SCI USA, V86, P5873, DOI 10.1073/pnas.86.15.5873	29	47	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					739	747						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108116				2022-12-17	WOS:A1994MW55100008
J	MERLO, GR; VENESIO, T; TAVERNA, D; MARTE, BM; CALLAHAN, R; HYNES, NE				MERLO, GR; VENESIO, T; TAVERNA, D; MARTE, BM; CALLAHAN, R; HYNES, NE			GROWTH SUPPRESSION OF NORMAL MAMMARY EPITHELIAL-CELLS BY WILD-TYPE P53	ONCOGENE			English	Article							HUMAN BREAST-CANCER; CELLULAR TUMOR-ANTIGEN; BETA-CASEIN GENE; MUTANT P53; EMBRYO FIBROBLASTS; SV40 DNA; MUTATIONS; PROTEIN; TRANSFORMATION; EXPRESSION	p53 mutations are frequent in human breast cancer. In order to understand the role of p53 in the context of the accumulation of mutations in breast cancer, a model of non transformed mammary cells was sought. The HC11 cells are immortalized, non transformed rodent mammary epithelial cells which synthesize milk proteins following stimulation with lactogenic hormones. p53 protein was readily detected in HC11 protein extracts with the PAb421 antibody. Two mutations were identified in the p53 cDNA from HC11 cells: a missense mutation at codon 138, substituting Trp for Cys, and a microdeletion, codon 123 to 130, of exon 5. The latter results from an intronic mutation of the splice acceptor site at the intron 4/exon 5 junction. The mutations affect separate p53 alleles, and no wt allele was found. Wt p53 was introduced into HC11 cells by means of a retroviral vector, under the control of a Cd++-inducible promoter. In the presence of CdSO4 a dramatic growth inhibition was observed. A temperature-sensitive mutant p53 gene was also transfected into HC11 cells. This resulted in a marked inhibition of cells growth at 32 degrees C, when the p53 is in the wt conformation, while no effect was observed at 37 degrees C, when the mutant conformation is predominant. wt p53-mediated inhibition of monolayer growth does not involve induction of programmed cell death and does not activate de novo synthesis of differentiation-specific milk proteins. We conclude that mutations in the p53 gene likely played a role in their immortalization. The HC11 cells provide a model for assessing the cooperative action of other mutations in mammary tumorigenesis.	USL 1,S GIOVANNI HOSP,I-10123 TURIN,ITALY; NCI,ONCOGENET SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	MERLO, GR (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.		; taverna, daniela/J-8358-2016	Venesio, Tiziana/0000-0002-9035-056X; taverna, daniela/0000-0002-6365-527X				ANDERSEN RD, 1987, MOL CELL BIOL, V7, P3574, DOI 10.1128/MCB.7.10.3574; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BARTEK J, 1990, INT J CANCER, V45, P1105, DOI 10.1002/ijc.2910450620; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CALLAHAN R, 1992, CANCER, V69, P1582, DOI 10.1002/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO;2-Y; CASEY G, 1991, ONCOGENE, V6, P1791; CEPKO CL, 1992, CURRENT PROTOCOLS MO; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG J, 1992, CANCER RES, V52, P222; CZOSNEK HH, 1984, MOL CELL BIOL, V4, P1638, DOI 10.1128/MCB.4.8.1638; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DAVIDOFF AM, 1991, CANCER RES, V51, P2605; DEVILEE P, 1990, CYTOGENET CELL GENET, V53, P52, DOI 10.1159/000132893; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GARCIA I, 1991, CANCER RES, V51, P294; GONOS ES, 1992, INT J ONCOL, V1, P209; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HAPP B, 1993, CELL GROWTH DIFFER, V4, P9; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; ISOLA J, 1992, J NATL CANCER I, V84, P1109, DOI 10.1093/jnci/84.14.1109; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATOZAKI T, 1992, CANCER RES, V52, P4335; MAZARS R, 1992, CANCER RES, V52, P3918; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MEDINA D, 1993, CARCINOGENESIS, V14, P25, DOI 10.1093/carcin/14.1.25; MERLO GR, 1993, INT J CANCER, V54, P531, DOI 10.1002/ijc.2910540402; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MONTENARH M, 1992, ONCOGENE, V7, P1673; OSBORNE RJ, 1991, CANCER RES, V51, P6194; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; REDMOND SMS, 1988, ONCOGENE, V2, P259; ROVINSKI B, 1988, ONCOGENE, V2, P445; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SATO T, 1990, CANCER RES, V50, P7184; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; TAYLOR WR, 1992, ONCOGENE, V7, P1383; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VARLEY JM, 1991, ONCOGENE, V6, P413; VENESIO T, 1992, CELL GROWTH DIFFER, V3, P63; VOJTESEK B, 1993, J CELL SCI, V105, P607; WANG NP, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367	65	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					443	453						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290256				2022-12-17	WOS:A1994MW24800011
J	MOSCOW, JA; HE, R; GNARRA, JR; KNUTSEN, T; WENG, YK; ZHAO, WP; WHANGPENG, J; LINEHAN, WM; COWAN, KH				MOSCOW, JA; HE, R; GNARRA, JR; KNUTSEN, T; WENG, YK; ZHAO, WP; WHANGPENG, J; LINEHAN, WM; COWAN, KH			EXAMINATION OF HUMAN TUMORS FOR RHOA MUTATIONS	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; GLUTATHIONE-PEROXIDASE GENE; LUNG-CANCER; SHORT ARM; ADP-RIBOSYLTRANSFERASE; DNA-SEQUENCE; REGION 3P21; CHROMOSOME-3; HETEROZYGOSITY; LOCALIZATION	rhoA encodes a ras-related GTP-binding protein that is thought to play a role in cytoskeletal organization. Recent evidence has suggested both that rhoA could act either as a dominant oncogene, since transfection of both normal and activated who genes confer a transformed phenotype on fibroblast cells in culture, or as a recessive tumor suppressor gene, by virtue, in part, of its chromosomal location at 3p21, a site deleted in many human malignancies. In either case, a role for rhoA in the oncogenesis of human tumors would be supported by the finding of rhoA mutations in tumors. We therefore examined human tumors and cell lines for mutations in the protein coding regions of rhoA by RNAase protection analysis. We first examined the expression of rhoA in renal cell carcinoma cell lines in which 3p21 was heterozygously deleted or retained. We found no evidence for rhoA mutations in these specimens. We also examined RNA from lung, breast, colon or ovarian tumors and also found no evidence of activating rhoA mutations. Furthermore, there was no relation between the level of rhoA mRNA expression and the presence or absence of 3p21 deletions in the renal cell carcinoma specimens. Thus, although rhoA has transforming potential in vitro, there is no evidence that it is activated by mutation in human malignancies, or that it could act as a tumor suppressor gene in tumors in which 3p21 is deleted.	NCI,PEDIAT BRANCH,BETHESDA,MD 20892; NCI,SURG BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	MOSCOW, JA (corresponding author), NCI,MED BRANCH,BETHESDA,MD 20892, USA.			Gnarra, James/0000-0002-6369-3110				ANGLARD P, 1992, CANCER RES, V52, P348; ANGLARD P, 1991, CANCER RES, V51, P1071; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; AVRAHAM H, 1990, BIOCHEM BIOPH RES CO, V168, P114, DOI 10.1016/0006-291X(90)91682-I; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; CANNIZZARO LA, 1990, GENOMICS, V6, P197, DOI 10.1016/0888-7543(90)90557-B; CARRITT B, 1986, AM J HUM GENET, V38, P428; CHADA S, 1990, GENOMICS, V6, P268, DOI 10.1016/0888-7543(90)90566-D; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; DOROSHOW JH, 1990, PHARMACOL THERAPEUT, V47, P359, DOI 10.1016/0163-7258(90)90062-7; DUTRILLAUX B, 1981, HUM GENET, V57, P93; Flohe L., 1989, GLUTATHIONE CHEM BIO, P644; FUJIMOTO E, 1988, NUCLEIC ACIDS RES, V16, P10943, DOI 10.1093/nar/16.22.10943; GANLY PS, 1992, GENOMICS, V12, P221, DOI 10.1016/0888-7543(92)90369-4; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; KARGER S, 1991, GUIDELINES CANCER CY; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEDUC F, 1989, AM J HUM GENET, V44, P282; MCBRIDE O W, 1988, Biofactors, V1, P285; MIURA Y, 1993, J BIOL CHEM, V268, P510; MOHR C, 1990, FEBS LETT, V275, P168, DOI 10.1016/0014-5793(90)81464-Y; MOSCOW JA, 1992, J BIOL CHEM, V267, P5949; MOSCOW JA, 1989, CANCER RES, V49, P1422; MOSCOW JA, IN PRESS; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; OGOROCHI T, 1989, BIOCHEM BIOPH RES CO, V163, P1175, DOI 10.1016/0006-291X(89)92344-9; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; PERONA R, 1993, ONCOGENE, V8, P1285; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J., 1989, MOL CLONING LAB MANU; SHIMIZU M, 1990, ONCOGENE, V5, P185; SZUCS S, 1986, CANCER GENET CYTOGEN, V26, P369; TJIO JH, 1962, STAIN TECHNOL, V37, P17, DOI 10.3109/10520296209114563; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOSHIDA MA, 1986, CANCER RES, V46, P2139; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	47	47	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					189	194						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302578				2022-12-17	WOS:A1994MW24700023
J	KANDA, H; TAJIMA, H; LEE, GH; NOMURA, K; OHTAKE, K; MATSUMOTO, K; NAKAMURA, T; KITAGAWA, T				KANDA, H; TAJIMA, H; LEE, GH; NOMURA, K; OHTAKE, K; MATSUMOTO, K; NAKAMURA, T; KITAGAWA, T			HEPATOCYTE GROWTH-FACTOR TRANSFORMS IMMORTALIZED MOUSE-LIVER EPITHELIAL-CELLS	ONCOGENE			English	Article							ANCHORAGE-INDEPENDENT GROWTH; SCATTER FACTOR; HEPATOCELLULAR-CARCINOMA; MET PROTOONCOGENE; MOLECULAR-CLONING; HEPATIC-FAILURE; HEPATOPOIETIN-A; KINASE-ACTIVITY; MELANOMA-CELLS; C-MET	Transforming activity of hepatocyte growth factor (HGF) was demonstrated utilizing immortalized but not fully transformed mouse hepatocytes (MLE-10). Rat HGF cDNA, expressed under the control of a cytomegalovirus promoter, was transfected together with the neomycin resistance gene (PSV2neo) into MLE-10 cells by the calcium phosphate method, and propagated G418-resistant colonies were harvested colony by colony. After checking for integration and expression of exogenous HGF, five cell lines (MLE-10-HGF-1 approximately 5) were established. Three cell lines transfected with the vector only (MLE-10-CMV-1 approximately 3) were also established in the same manner. All MLE-10-HGF cell lines grew much faster than the MLE-10-CMV and original MLE-10 cells in culture and produced large colonies in soft agar, which colony production was blocked by the addition of anti-HGF antibody to the agar. After addition of HGF, original and MLE-10-CMV lines produced colonies in soft agar. The high-HGF-production lines (MLE-10-HGF-4 and -5) also gave rise to tumors within 2 weeks when implanted into the nude mice subcutis. In contrast, all MLE-10-CMV and original MLE-10 cells were negative in these growth assays. A rough parallelism between the level of HGF expression and the growth rate in both soft agar and nude mice subcutis was evident among MLE-10-HGF cell lines. Those with higher HGF production tended to grow in a scattered fashion in culture. High-affinity HGF receptor, HGFR/met, was expressed in MLE-10 and all the derived cell lines. Since HGF and/or HGFR/met gene expression is seen in various tumors and the serum HGF level is elevated in patients with hepatic disease, the present results indicate a possible significance of HGF and its receptor system in carcinogenesis, most probably via autocrine and/or paracrine mechanisms.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DIV BIOCHEM,SUITA,OSAKA 565,JAPAN	Osaka University	KANDA, H (corresponding author), JAPANESE FDN CANC RES,INST CANC,DEPT PATHOL,KAMI IKEBUKURO 1-37-1,TOSHIMA KU,TOKYO 170,JAPAN.							BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAN AML, 1988, ONCOGENE, V2, P593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURLONG RA, 1991, J CELL SCI, V100, P173; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HALABAN R, 1992, ONCOGENE, V7, P2195; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; HIGUCHI O, 1991, BIOCHEM BIOPH RES CO, V176, P599, DOI 10.1016/S0006-291X(05)80226-8; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KANDA H, 1983, CARCINOGENESIS, V14, P1061; KONISHI T, 1991, BIOCHEM BIOPH RES CO, V180, P765, DOI 10.1016/S0006-291X(05)81131-3; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LEE GH, 1989, CANCER RES, V49, P403; LEE GH, 1987, HEPATOLOGY, V7, P937, DOI 10.1002/hep.1840070524; LEE GH, 1991, INT J CANCER, V47, P60, DOI 10.1002/ijc.2910470112; LINDROOS P, 1992, CARCINOGENESIS, V13, P139, DOI 10.1093/carcin/13.1.139; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MICHALOPOULOS GK, 1992, HEPATOLOGY, V15, P149, DOI 10.1002/hep.1840150125; MIYAZAKI M, 1992, CELL BIOL INT REP, V16, P145, DOI 10.1016/S0309-1651(06)80108-6; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; NALDINI L, 1991, ONCOGENE, V6, P501; NISHINO T, 1991, BIOCHEM BIOPH RES CO, V181, P323, DOI 10.1016/S0006-291X(05)81421-4; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SHIMODA A, 1992, ACTA HEPATOL JPN, V33, P766; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAHARA E, 1990, J CANCER RES CLIN, V116, P121, DOI 10.1007/BF01612665; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; TOMIYA T, 1992, HEPATOLOGY, V15, P1, DOI 10.1002/hep.1840150102; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; YOSHINAGA Y, 1992, JPN J CANCER RES, V83, P1257, DOI 10.1111/j.1349-7006.1992.tb02755.x; ZARNEGAR R, 1989, CANCER RES, V49, P3314	51	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3047	3053						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414505				2022-12-17	WOS:A1993MC09300020
J	MICHIELS, L; VANDERRAUWELAERT, E; VANHASSELT, F; KAS, K; MERREGAERT, J				MICHIELS, L; VANDERRAUWELAERT, E; VANHASSELT, F; KAS, K; MERREGAERT, J			FAU CDNA ENCODES A UBIQUITIN-LIKE-S30 FUSION PROTEIN AND IS EXPRESSED AS AN ANTISENSE SEQUENCE IN THE FINKEL-BISKIS-REILLY MURINE SARCOMA-VIRUS	ONCOGENE			English	Article							V-FOS; C-FOS; NUCLEOTIDE-SEQUENCE; CELLULAR GENES; FBR-MUSV; CELLS; IDENTIFICATION; TRANSFORMATION; INTERFERON; ONCOGENE	The Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) is capable of inducing osteosarcomas in susceptible mice. This retrovirus transduced sequences derived from the transcription factor c-fos and from an unrelated mouse sequence called fox. Here, we describe the cloning and sequence analysis of human and mouse cellular cDNAs hybridizing to the fox sequence. The cloned cDNAs encode for a single ubiquitin-like (Fubi) protein fused in frame to S30, a protein of the small ribosomal subunit. Fubi conserved amino acid residues known to be involved in the ATP-dependent proteolytic activity of ubiquitin. Moreover, the fau gene is conserved in several species, while its mRNA is ubiquitously expressed in different mouse tissues. Surprisingly, FBR-MuSV transduced the complete but mutated open reading frame (ORF) in its reversed transcriptional orientation. This is the first report about a retrovirus in which an antisense sequence to a cellular gene, which we called fau (FBR-MuSV-associated ubiquitously expressed gene), is discovered. Rat-2 cells transfected with plasmids containing v-fau/fox recombinants of FBR-MuSV revealed a twofold increase of the transformation capacity of FBR-MuSV 'in vitro' because of the fau antisense sequence. Newly formed retropseudogenes were identified in three out of eight primary radiation-induced osteosarcomas. This high incidence of creating retropseudogenes in these Sr-90-induced bone tumours may contribute to the mechanism by which FBR-MuSV, originally isolated from such tumours, acquired the fau gene in its reverse orientation.	UNIV INSTELLING ANTWERP,DEPT BIOCHEM,MOLEC BIOTECHNOL LAB,UNIVERSITEITSPLEIN 1,B-2610 WILRIJK,BELGIUM	University of Antwerp			Michiels, Luc/AGH-3847-2022	Michiels, Luc/0000-0001-5065-2048				AHRENS PB, 1990, J GEN VIROL, V71, P1675, DOI 10.1099/0022-1317-71-8-1675; BANERJI J, 1990, P NATL ACAD SCI USA, V87, P2374, DOI 10.1073/pnas.87.6.2374; BENTVELZEN P, 1978, J NATL CANCER I, V60, P401, DOI 10.1093/jnci/60.2.401; BUTT TR, 1988, J BIOL CHEM, V263, P16364; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; DAVIE JR, 1990, BIOCHEMISTRY-US, V29, P4752, DOI 10.1021/bi00472a002; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FINKEL MP, 1973, BONE CERTAIN ASPECTS, P353; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; GUARINO LA, 1990, P NATL ACAD SCI USA, V87, P409, DOI 10.1073/pnas.87.1.409; GUIS D, 1990, MOL CELL BIOL, V10, P4243; HAAS AL, 1987, J BIOL CHEM, V262, P11315; JANOWSKI M, 1990, INT J RADIAT BIOL, V57, P677, DOI 10.1080/09553009014550851; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JENUWEIN T, 1985, CELL, V41, P629, DOI 10.1016/S0092-8674(85)80035-0; JIANCHILL JL, 1969, J VIROL, V4, P549; KAS K, 1992, BIOCHEM BIOPH RES CO, V187, P927, DOI 10.1016/0006-291X(92)91286-Y; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LOEB KR, 1992, J BIOL CHEM, V267, P7806; LUND PK, 1985, J BIOL CHEM, V260, P7609; MATTHIAS PD, 1983, EMBO J, V2, P1487, DOI 10.1002/j.1460-2075.1983.tb01612.x; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MERREGAERT J, 1984, CR SOC BIOL, V178, P171; MEYERS G, 1991, VIROLOGY, V180, P602, DOI 10.1016/0042-6822(91)90074-L; MEYERS G, 1989, NATURE, V341, P491, DOI 10.1038/341491a0; MICHIELS L, 1986, VIRUS RES, V5, P11, DOI 10.1016/0168-1702(86)90062-6; MICHIELS L, 1984, INT J CANCER, V33, P511, DOI 10.1002/ijc.2910330415; MICHIELS L, 1992, THESIS U ANTWERP; MILLER AD, 1984, CELL, V36, P51; MONIA BP, 1990, BIO-TECHNOL, V8, P209, DOI 10.1038/nbt0390-209; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; REDMAN KL, 1989, NATURE, V338, P438, DOI 10.1038/338438a0; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SWAIN A, 1992, SCIENCE, V255, P841, DOI 10.1126/science.1371365; TONOLIO D, 1988, P NATL ACAD SCI USA, V85, P851; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VANDERRAUWELAERT E, 1988, ONCOGENE, V2, P215; WISDOM R, 1990, MOL CELL BIOL, V10, P5626, DOI 10.1128/MCB.10.11.5626; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	49	47	57	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2537	2546						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395683				2022-12-17	WOS:A1993LT36800026
J	PAQUISFLUCKLINGER, V; MICHIELS, JF; VIDAL, F; ALQUIER, C; POINTIS, G; BOURDON, V; CUZIN, F; RASSOULZADEGAN, M				PAQUISFLUCKLINGER, V; MICHIELS, JF; VIDAL, F; ALQUIER, C; POINTIS, G; BOURDON, V; CUZIN, F; RASSOULZADEGAN, M			EXPRESSION IN TRANSGENIC MICE OF THE LARGE T-ANTIGEN OF POLYOMAVIRUS INDUCES SERTOLI-CELL TUMORS AND ALLOWS THE ESTABLISHMENT OF DIFFERENTIATED CELL-LINES	ONCOGENE			English	Article							C-MYC GENE; EARLY REGION; VIRUS; MOUSE; ONCOGENE; PROTEIN; INVITRO; TUMORS; TRANSFORMATION; FIBROBLASTS	The large T antigen of polyomavirus (PyLT) efficiently immortalizes rodent fibroblasts, but, unlike SV40 T antigen, it is not sufficient to achieve complete oncogenic transformation. We analysed a series of transgenic mouse families that express the PyLT protein under control of the viral enhancer-promoter region. In all of them, the transgene was expressed in the seminiferous epithelium of the testis (Sertoli and germ cells), with no pathological consequences during most of the animals' lives. However, every old male developed large bilateral tumours of the testes, generated by the proliferation of Sertoli cell derivatives. Cell lines could be readily established both from the tumours and from the still apparently normal testis before the onset of tumoral growth. They retained in vitro morphological and ultrastructural features characteristic of Sertoli cells. But, in addition to this major Sertoli component, the maintenance of a cellular contingent of germinal origin was suggested by the expression of genes that are normally transcribed during the premeiotic and early meiotic stages of spermatogenesis (LDH-X, Hox1.4 and c-kit). The two cell types remained tightly associated, even at tate passages in culture, and could not be separated by conventional cloning procedures. This association in culture of the two cell types whose interaction is critical for spermatogenesis may provide a useful toot for its molecular analysis.	FAC SCI NICE,INSERM,UNITE 273,F-06108 NICE 2,FRANCE; UNIV NICE,FAC MED,F-06100 NICE,FRANCE; FAC MED NORD,INSERM,UNITE 270,F-91007 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			Rassoulzadegan, Minoo/O-7939-2016					ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BAUTCH VL, 1989, MOL BIOL MED, V6, P309; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; DAWE CJ, 1987, AM J PATHOL, V127, P243; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Finch C.E., 1994, LONGEVITY SENESCENCE; FRIEDMANN T, 1979, CELL, V17, P715, DOI 10.1016/0092-8674(79)90278-2; GALIANA E, 1990, J NEUROSCI RES, V26, P269, DOI 10.1002/jnr.490260302; GALLIOT B, 1989, DEVELOPMENT, V107, P343; HADLEY MA, 1985, J CELL BIOL, V101, P1511, DOI 10.1083/jcb.101.4.1511; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HINTZ M, 1977, DEV BIOL, V57, P375, DOI 10.1016/0012-1606(77)90222-6; HOFFMAN MC, 1992, EXP CELL RES, V201, P417; Hogan B., 1986, MANIPULATING MOUSE E; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5086; JENSEN NA, 1989, MOL BIOL MED, V6, P493; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KRIPPL B, 1988, NUCLEIC ACIDS RES, V16, P8963, DOI 10.1093/nar/16.18.8963; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Leonard Davis G., 1986, BASIC METHODS MOL BI; Maniatis T., 1982, MOL CLONING; MANOVA K, 1990, DEVELOPMENT, V110, P1057; MATHER JP, 1980, BIOL REPROD, V23, P243, DOI 10.1095/biolreprod23.1.243; MOUGNEAU E, 1988, ONCOGENE RES, V2, P177; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; PAUL D, 1988, EXP CELL RES, V175, P354, DOI 10.1016/0014-4827(88)90199-1; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; Russell L. D., 1990, HISTOLOGICAL HISTOPA; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SILVER J, 1978, CELL, V15, P485, DOI 10.1016/0092-8674(78)90018-1; SOEDA E, 1979, CELL, V17, P357, DOI 10.1016/0092-8674(79)90162-4; STEINBERGER A, 1975, METHOD ENZYMOL, P283; TAHRIJOUTEI A, 1989, ENDOCRINOLOGY, V125, P605, DOI 10.1210/endo-125-2-605; TAKASE M, 1988, ENDOCRINOL JAPON, V35, P285; VANDENELSEN P, 1982, GENE, V18, P175, DOI 10.1016/0378-1119(82)90115-9; WANG R, 1991, J VIROL, V65, P5174, DOI 10.1128/JVI.65.10.5174-5183.1991; WINOCOUR E, 1963, VIROLOGY, V19, P158, DOI 10.1016/0042-6822(63)90005-9; WOLGEMUTH DJ, 1987, P NATL ACAD SCI USA, V84, P5813, DOI 10.1073/pnas.84.16.5813; ZERLIN M, 1987, ONCOGENE, V1, P19; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	44	47	49	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2087	2094						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393161				2022-12-17	WOS:A1993LP17100008
J	YAMAMOTO, K; SETO, M; AKAO, Y; IIDA, S; NAKAZAWA, S; OSHIMURA, M; TAKAHASHI, T; UEDA, R				YAMAMOTO, K; SETO, M; AKAO, Y; IIDA, S; NAKAZAWA, S; OSHIMURA, M; TAKAHASHI, T; UEDA, R			GENE REARRANGEMENT AND TRUNCATED MESSENGER-RNA IN CELL-LINES WITH 11Q23 TRANSLOCATION	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHROMOSOME; BREAKPOINT; LYMPHOMA; FUSION; T(4-11)(Q21-Q23); AMPLIFICATION; HETEROGENEITY; NEOPLASIA; T(11-14)	We have previously demonstrated that the breakpoints of t(11;19)(q23;p13) leukemias are within 360 kb of the CD3 gene. One of the phage clones, 6n, which was isolated from the yeast artificial chromosome clone yB22B2 containing CD3, was found to be within 60 kb of t(11;19) breakpoints. In this study, gene walking was conducted and two phage clones (lambdaHp8-3 and lambdaHp23-13) were isolated from a human placenta genomic library. Southern blot analysis with a genomic probe from lambdaHp8-3 detected gene rearrangements in t(4;11) and t(11;19) cell lines with BamHI digestion. Subsequently, using reiterated sequence-free probes from both ends of 6n that detected transcriptional units in various hematopoietic cells, we isolated cDNA clones. These cDNA clones were classified into two groups (designated MLL-a and MLL-b), which do not hybridize to each other. Northern blot analysis with MLL-a cDNA detected 15-, 14- and 12-kb mRNAs, while MLL-b detected the additional 9.7- and 5-kb mRNAs in peripheral blood lymphocytes. MLL-b cDNA detected a truncated form of 12.5-kb mRNA in t(4;11) cell lines and a truncated form of 10-kb or 9.2-kb mRNA in t(11;19) cell lines. MLL-a did not demonstrate a truncated form of mRNA, but the stronger 14-kb signal was noted in t(4;11) cells, while this signal was very weak in t(11;19) cells. By Southern blot analysis, MLL-b cDNA detected gene rearrangement in cell lines with t(4;11) and t(11;19), whereas MLL-a did not. Furthermore, chimeric cDNA clones were isolated from cDNA libraries of t(4;11) and t(11;19) cell lines with a MLL-b cDNA probe. These results indicate that the MLL-b cDNA is derived from the common target gene involved in 11q23 translocation with 4q21 or 19p13.	AICHI CANC CTR,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; YAMANASHI MED COLL,DEPT PEDIAT,YAMANASHI 40938,JAPAN; TOTTORI UNIV,SCH LIFE SCI,DEPT MOLEC & CELL GENET,YONAGO,TOTTORI 684,JAPAN; AICHI CANC CTR,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Aichi Cancer Center; University of Yamanashi; Tottori University; Aichi Cancer Center								ABE R, 1984, CANCER GENET CYTOGEN, V13, P121, DOI 10.1016/0165-4608(84)90053-0; ABE T, 1990, JPN J CLIN HEMATOL, V31, P1304; AKAO Y, 1991, CANCER RES, V51, P6708; AKAO Y, 1991, CANCER RES, V51, P1574; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CHEN CS, 1991, BLOOD, V78, P2498; CIMINO G, 1991, CANCER RES, V51, P6712; COTTER FE, 1991, GENE CHROMOSOME CANC, V3, P8, DOI 10.1002/gcc.2870030103; DAIBATA M, 1987, JPN J CANCER RES, V78, P1182; DAS S, 1991, GENE CHROMOSOME CANC, V3, P44, DOI 10.1002/gcc.2870030108; GIBBONS B, 1990, BRIT J HAEMATOL, V74, P264, DOI 10.1111/j.1365-2141.1990.tb02581.x; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KUBONISHI I, 1986, CANCER, V58, P1453, DOI 10.1002/1097-0142(19861001)58:7<1453::AID-CNCR2820580713>3.0.CO;2-B; MITANI K, 1989, AM J HEMATOL, V31, P253, DOI 10.1002/ajh.2830310407; MITELMAN F, 1984, NATURE, V310, P325, DOI 10.1038/310325a0; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, BLOOD, V77, P440; ROWLEY JD, 1990, CANCER RES, V50, P3816; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; SAVAGE PD, 1988, CYTOGENET CELL GENET, V49, P289, DOI 10.1159/000132680; SETO M, 1992, ONCOGENE, V7, P1401; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; VANDERPOEL SZ, 1991, P NATL ACAD SCI USA, V88, P10735; YUNIS JJ, 1989, GENOMICS, V5, P84, DOI 10.1016/0888-7543(89)90090-6; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	27	47	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					479	485						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426751				2022-12-17	WOS:A1993KN00600027
J	FALETTO, DL; TSARFATY, I; KMIECIK, TE; GONZATTI, M; SUZUKI, T; WOUDE, GFV				FALETTO, DL; TSARFATY, I; KMIECIK, TE; GONZATTI, M; SUZUKI, T; WOUDE, GFV			EVIDENCE FOR NONCOVALENT CLUSTERS OF THE C-MET PROTOONCOGENE PRODUCT	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; SCATTER FACTOR; SIGNAL TRANSDUCTION; TYROSINE KINASES; PURIFICATION; HEPATOCYTES; CELLS; DIMERIZATION; MECHANISM; MOBILITY	The met proto-oncogene is a member of the tyrosine kinase growth factor receptor family and is the receptor for hepatocyte growth factor (HGF) or scatter factor. The primary met product is a 150 kDa precursor that is glycosylated to generate a 170 kDa (p170met) proreceptor protein. The mature form of the receptor is generated by cleavage of p170met to yield a disulfide-linked 140 kDa beta-subunit (p140met) and a 45 kDa alpha-subunit (p45met). Both products are glycosylated. Under non-reducing conditions both p170met and the alpha, beta-disulfide-linked protein are detected as a 185 kDa product (p185met), but only alpha-beta heterodimeric p185met is cross-linked and rendered resistant to disulfide reduction with membrane-impermeable 6.4 angstrom. linker length cross-linking reagents. These data indicate that the p170 precursor is not on the cell surface. Cross-linking experiments using 12-angstrom linker reagents yield multimeric forms of alpha-beta heterodimeric p185met greater than 500 kDa in size. These multimeric forms are produced in all cell lines tested regardless of the levels of protein expressed. These data suggest that alpha-beta heterodimeric p185met occurs in clusters or patches on the cell surface. Immunohistochemical analysis of met protein in the absence of ligand reveals a clustered staining pattern on the cell surface.	FUKUSHIMA MED SCH,DEPT PATHOL 2,FUKUSHIMA 96012,JAPAN	Fukushima Medical University	WOUDE, GFV (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,POB B,FREDERICK,MD 21702, USA.			Tsarfaty, Ilan/0000-0002-5230-7093; Kmiecik, Thomas/0000-0002-1367-443X; Gonzatti, Mary Isabel/0000-0003-4266-2988	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASAMI O, 1991, J BIOCHEM-TOKYO, V109, P8; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAN AML, 1988, ONCOGENE, V2, P593; COCHET C, 1988, J BIOL CHEM, V263, P3290; GEIGER B, 1991, Current Biology, V1, P237, DOI 10.1016/0960-9822(91)90068-8; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HAMILTON TC, 1983, CANCER RES, V43, P5379; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; MOTOYAMA T, 1979, Acta Medica et Biologica, V27, P49; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P163; ROSEN EM, 1990, P SOC EXP BIOL MED, V195, P34; ROSEN EM, 1990, INVAS METAST, V10, P49; ROSEN EM, 1990, J CELL SCI, V96, P639; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SELDEN C, 1986, BIOCHEM BIOPH RES CO, V139, P361; SHIMIZU I, 1991, J BIOCHEM-TOKYO, V109, P14, DOI 10.1093/oxfordjournals.jbchem.a123335; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; STOKER M, 1985, J CELL SCI, V77, P209; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; VANBELZEN N, 1988, J CELL PHYSIOL, V134, P413, DOI 10.1002/jcp.1041340312; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; ZARNEGAR R, 1989, CANCER RES, V49, P3314	40	47	48	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1149	1157						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1317541				2022-12-17	WOS:A1992HU64200012
J	KITAGAWA, M; SAITOH, S; OGINO, H; OKABE, T; MATSUMOTO, H; OKUYAMA, A; TAMAI, K; OHBA, Y; YASUDA, H; NISHIMURA, S; TAYA, Y				KITAGAWA, M; SAITOH, S; OGINO, H; OKABE, T; MATSUMOTO, H; OKUYAMA, A; TAMAI, K; OHBA, Y; YASUDA, H; NISHIMURA, S; TAYA, Y			CDC2-LIKE KINASE IS ASSOCIATED WITH THE RETINOBLASTOMA PROTEIN	ONCOGENE			English	Article							LARGE-T-ANTIGEN; ADENOVIRUS E1A PROTEINS; DNA-BINDING ACTIVITY; CELL-CYCLE; GENE-PRODUCT; SUSCEPTIBILITY GENE; RB GENE; TERMINAL REGION; OSTEO-SARCOMA; PHOSPHORYLATION	The growth-suppressive activity of the retinoblastoma (RB) protein is suggested to be regulated by phosphorylation. In studies on the kinase that phosphorylates the RB proteins, we have previously found that RB proteins can be phosphorylated by purified cdc2 kinase. In this study, we noted that RB proteins immunoprecipitated from human cell lysates are weakly phosphorylated in the absence of purified cdc2 kinase. Immunoblot analysis showed the presence of p34cdc2 in the immunoprecipitates with anti-RB monoclonal antibody. In addition, the coprecipitated kinase was found to have the same substrate specificity as cdc2 kinase. The associated kinase activity was particularly high in cells arrested in G1/S and S phase by aphidicolin. Furthermore, RB proteins were shown to be phosphorylated in nuclear extracts by some endogenous cdc2-like kinase(s). These results suggest that cdc2-like kinase is the main kinase for phosphorylation of RB proteins in vivo.	NATL CANC CTR, RES INST, DIV BIOL, TOKYO 104, JAPAN; MBL CO LTD, INA LABS, INA, NAGANO 396, JAPAN; KANAZAWA UNIV, FAC PHARMACEUT SCI, DIV BIOL, KANAZAWA, ISHIKAWA 920, JAPAN	National Cancer Center - Japan; Kanazawa University	KITAGAWA, M (corresponding author), BANYU PHARMACEUT CO LTD, TSUKUBA RES INST, OKUBO 3, TSUKUBA 30033, JAPAN.		Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BENEDICT WF, 1983, SCIENCE, V219, P973, DOI 10.1126/science.6336308; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; HUNT T, 1991, NATURE, V349, P100, DOI 10.1038/349100a0; IOANNIDES CG, 1987, P NATL ACAD SCI USA, V84, P4244, DOI 10.1073/pnas.84.12.4244; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TAYA Y, 1986, EMBO J, V5, P1215, DOI 10.1002/j.1460-2075.1986.tb04349.x; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TAYA Y, 1990, GENETIC BASIS FOR CARCINOGENESIS, P171; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YASUDA H, 1981, BIOCHEMISTRY-US, V20, P4414, DOI 10.1021/bi00518a028; YASUDA H, 1990, BIOCHEM BIOPH RES CO, V172, P371, DOI 10.1016/0006-291X(90)90682-D; YOKOTA J, 1988, ONCOGENE, V3, P471; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	69	47	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1992	7	6					1067	1074						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594240				2022-12-17	WOS:A1992HU64200003
J	CROW, DS; KURATA, WE; LAU, AF				CROW, DS; KURATA, WE; LAU, AF			PHOSPHORYLATION OF CONNEXIN43 IN CELLS CONTAINING MUTANT SRC ONCOGENES	ONCOGENE			English	Note							JUNCTIONAL INTERCELLULAR COMMUNICATION; INTER-CELLULAR COMMUNICATION; CHICKEN-EMBRYO FIBROBLASTS; AVIAN-SARCOMA VIRUS; GENE-PRODUCT; GAP JUNCTION; TYROSINE PHOSPHORYLATION; TRANSFORMED-CELLS; PLASMA-MEMBRANE; V-SRC	Disruption of gap junctional communication (measured by intercellular dye transfer) in cultured fibroblasts by pp60v-src is correlated with phosphorylation of the gap junction protein, connexin43 (cx43), on tyrosine. In this report, we examine the functional relevance of these observations by studying cx43 phosphorylation in cells containing kinase-active, non-myristylated pp60(2A527F) or pp60v-src temperature sensitive (ts) for transformation. Non-transformed cells expressing pp60(2A527F) transferred fluorescent dye at high levels and contained cx43 that was phosphorylated predominately on serine. In contrast, cells transformed by kinase-active, myristylated pp60(527F) did not transfer dye and contained cx43 proteins which were phosphorylated on serine and tyrosine. Additionally, activation of ts pp60v-src tyrosine kinase activity upon shift of cells to the permissive temperature was correlated with a rapid increase in the phosphorylated tyrosine content of cx43 proteins and loss of gap junctional communication. These combined results suggested that cx43 is a substrate of pp60v-src whose phosphorylation on tyrosine may be involved in the disruption of gap junctional communication observed in Rous sarcoma virus (RSV)-transformed cells.	UNIV HAWAII,CANC RES CTR,HONOLULU,HI 96813	Cancer Research Center of Hawaii; University of Hawaii System					NCI NIH HHS [CA 52098] Funding Source: Medline; NCRR NIH HHS [RR030601] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKINSON MM, 1981, J CELL BIOL, V91, P573, DOI 10.1083/jcb.91.2.573; AZARNIA R, 1989, ONCOGENE, V4, P1161; AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P207, DOI 10.1007/BF01871630; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; CHANG CC, 1985, P NATL ACAD SCI USA, V82, P5360, DOI 10.1073/pnas.82.16.5360; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; DOWNING JR, 1991, ONCOGENE, V6, P607; FILSON AJ, 1990, CELL GROWTH DIFFER, V1, P661; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; HUNTER T, 1979, COLD SPRING HARB SYM, V44, P931; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KOZMA LM, 1990, MOL CELL BIOL, V10, P837, DOI 10.1128/MCB.10.2.837; LAU AF, 1986, VIROLOGY, V151, P86, DOI 10.1016/0042-6822(86)90106-6; LAU AF, 1989, ONCOGENE RES, V1, P185; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; LOEWENSTEIN WR, 1984, BIOCH SOC S, V50, P43; MEHTA PP, 1986, CELL, V44, P187, DOI 10.1016/0092-8674(86)90497-6; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; SAEZ JC, 1986, P NATL ACAD SCI USA, V83, P2473, DOI 10.1073/pnas.83.8.2473; SPRAY DC, 1981, SCIENCE, V211, P712, DOI 10.1126/science.6779379; STAGG RB, 1990, ENDOCR REV, V11, P302, DOI 10.1210/edrv-11-2-302; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; WARNER A, 1988, J CELL SCI, V89, P1; WENDLER PA, 1989, ONCOGENE, V4, P231; WILLINGHAM MC, 1979, CELL, V18, P125, DOI 10.1016/0092-8674(79)90361-1; YAMASAKI H, 1988, CANCER RES, V48, P3490; YOUNG JDE, 1987, CELL, V48, P733, DOI 10.1016/0092-8674(87)90071-7	36	47	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					999	1003						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1315016				2022-12-17	WOS:A1992HP64200021
J	ROELINK, H; WAGENAAR, E; NUSSE, R				ROELINK, H; WAGENAAR, E; NUSSE, R			AMPLIFICATION AND PROVIRAL ACTIVATION OF SEVERAL WNT GENES DURING PROGRESSION AND CLONAL VARIATION OF MOUSE MAMMARY-TUMORS	ONCOGENE			English	Article							ONCOGENE INT-1; NUCLEOTIDE-SEQUENCE; TRANSGENIC MICE; CELL-LINE; VIRUS; EXPRESSION; REGION; TUMORIGENESIS; INTEGRATION; GROWTH	Mammary tumors in the GR strain are caused by a dominant locus containing an endogenous mouse mammary tumor provirus. Expression of this locus results in high virus titers, inducing tumors that progress from a hormone-dependent to a hormone-independent tumor state. We previously studied the activation of the Wnt-1 and int-2 oncogenes in several series of transplanted GR tumors and found that hormone-dependent early passages are generally oligoclonal for proviral integration at these genes. We have now re-examined several such tumor series for activation of other Wnt genes. In one series, the transition to hormone-independent growth was marked by the loss of the oligoclonal genotype and outgrowth of a hormone-independent cell population, clonal for the activation of Wnt-3. We show two examples of series of transplanted tumors that in later hormone-independent passages contain an amplified and overexpressed Wnt-2 gene, a novel mode of activation of these genes.	STANFORD UNIV,BECKMAN CTR,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,BECKMAN CTR,DEPT DEV BIOL,STANFORD,CA 94305; NETHERLANDS CANC INST,DIV MOLEC BIOL,1066 CX AMSTERDAM,NETHERLANDS	Howard Hughes Medical Institute; Stanford University; Stanford University; Netherlands Cancer Institute								BROOKES S, 1989, NUCLEIC ACIDS RES, V17, P4037, DOI 10.1093/nar/17.11.4037; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; DEAN M, 1987, Genomics, V1, P167, DOI 10.1016/0888-7543(87)90009-7; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; GALLAHAN D, 1987, J VIROL, V61, P66, DOI 10.1128/JVI.61.1.66-74.1987; GALLAHAN D, 1987, J VIROL, V61, P218, DOI 10.1128/JVI.61.1.218-220.1987; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; MCMAHON JA, 1989, DEVELOPMENT, V107, P643; MESTER J, 1987, J VIROL, V61, P1073, DOI 10.1128/JVI.61.4.1073-1078.1987; MICHALIDES R, 1981, CELL, V23, P165, DOI 10.1016/0092-8674(81)90281-6; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; Sambrook J., 1989, MOL CLONING LAB MANU; SCHUURING E, 1990, ONCOGENE, V5, P459; SLUYSER M, 1974, CANCER RES, V34, P3253; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANDEVIJVER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P33, DOI 10.1016/0304-419X(91)90005-6; VANNIE R, 1977, INT J CANCER, V19, P588; VANNIE R, 1981, MAMMARY TUMORS MOUSE, P202; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; WHITE R, 1985, NATURE, V318, P382, DOI 10.1038/318382a0; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x	31	47	48	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					487	492						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549363				2022-12-17	WOS:A1992HK00500013
J	DARLAND, T; SAMUELS, M; EDWARDS, SA; SUKHATME, VP; ADAMSON, ED				DARLAND, T; SAMUELS, M; EDWARDS, SA; SUKHATME, VP; ADAMSON, ED			REGULATION OF EGR-1 (ZFP-6) AND C-FOS EXPRESSION IN DIFFERENTIATING EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article							GENE-EXPRESSION; PROTO-ONCOGENE; 3T3 CELLS; TRANSCRIPTIONAL ACTIVATION; CULTURED-CELLS; GROWTH-FACTORS; ENCODES; SERUM; JUN; PRODUCT	The Egr-1 gene (zfp-6) encodes a 'zinc finger'-type transcription factor that is one of the early growth response genes induced, together with c-fos proto-oncogene, in many cell types. Our earlier work indicated that Egr-1 and c-fos may also play roles in differentiation and we now present data to show some features of their regulation. Transcriptional regulation accounts at least partly for the increased steady-state levels of Egr-1 mRNA in differentiating teratocarcinoma cells; this rate increases threefold over the 7-10 days of differentiation of P]9 embryonal carcinoma cells with both 0.5% DMSO (to give predominantly cardiac muscle) and 1-mu-M retinoic acid (to give nerve and glial cells). The stability of Egr-1 transcripts remains the same (T1/2 = 90 min) in undifferentiated EC and differentiated cell products. In contrast, transcripts for c-fos are barely detectable in EC cells and increase 20-fold during differentiation. The basis for this is a marked increase in stability of c-fos mRNA after differentiation. The protein products of both genes parallel the steady-state levels of their mRNAs, but both proteins become more stable in differentiated cells. This is particularly marked for c-Fos protein, which appears as a distinct 58 kDa species in terminally differentiated P19 cells. Both Egr-1 and c-Fos proteins remain at high constitutive levels in differentiated cells indicating a distinct role for these transcription factors. For instance, it appears that this form of Fos protein may not repress the synthesis of the Egr-1 gene as it does during transient expression of serum-stimulated genes.	LA JOLLA CANC RES FDN,10901 N TORREY PINES RD,LA JOLLA,CA 92037; MEHARRY MED COLL,NASHVILLE,TN 37208; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	Sanford Burnham Prebys Medical Discovery Institute; Meharry Medical College; Howard Hughes Medical Institute; University of Chicago			Sukhatme, Vikas/W-2776-2019		NCI NIH HHS [P30CA 30199] Funding Source: Medline; NICHD NIH HHS [R01 HD 21957] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021957] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA030199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON ED, 1984, DIFFERENTIATION, V27, P152, DOI 10.1111/j.1432-0436.1984.tb01421.x; ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAPETANAKI Y, 1990, ONCOGENE, V5, P645; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CURRAN T, 1984, CELL, V36, P259; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; EDWARDS SA, 1986, EXP CELL RES, V165, P473, DOI 10.1016/0014-4827(86)90600-2; EDWARDS SA, 1988, DEV BIOL, V129, P91, DOI 10.1016/0012-1606(88)90164-9; EDWARDS SA, 1991, UNPB DEV BIOL; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KASIK JW, 1987, MOL CELL BIOL, V7, P3349, DOI 10.1128/MCB.7.9.3349; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; Maniatis T., 1982, MOL CLONING; MARX JL, 1987, SCIENCE, V237, P854, DOI 10.1126/science.3039659; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; PATWARDHAN S, 1991, ONCOGENE, V6, P917; RAUSCHER FJ, 1988, NATURE, V334, P314; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITH SC, 1987, J CELL PHYSIOL, V131, P74, DOI 10.1002/jcp.1041310112; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAYLOR R, 1990, J NIH RES, V2, P49; VERMA IM, 1987, ADV CANCER RES, V49, P29, DOI 10.1016/S0065-230X(08)60793-9; VOSATKA RJ, 1989, J CELL PHYSIOL, V138, P493, DOI 10.1002/jcp.1041380308; WATERS CM, 1990, ONCOGENE, V5, P669	46	47	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1367	1376						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1909429				2022-12-17	WOS:A1991GX27200012
J	AGUZZI, A; KLEIHUES, P; HECKL, K; WIESTLER, OD				AGUZZI, A; KLEIHUES, P; HECKL, K; WIESTLER, OD			CELL TYPE-SPECIFIC TUMOR-INDUCTION IN NEURAL TRANSPLANTS BY RETROVIRUS-MEDIATED ONCOGENE TRANSFER	ONCOGENE			English	Article							MIDDLE-T-ONCOGENE; EMBRYONAL CARCINOMA-CELLS; CENTRAL NERVOUS-SYSTEM; ROUS SARCOMA VIRUS; TRANSGENIC MICE; EXPRESSION; PP60C-SRC; PROTEIN; VECTOR; DIFFERENTIATION	Using a neural transplantation model which mimics structural and functional properties of the normal rat brain to a high extent, we have taken a novel approach to study the transforming potential of activated oncogenes in the developing brain. Single cell suspensions prepared from fetal rat brains were infected with replication-defective retroviral vectors encoding oncogenes and stereotaxically injected into the caudoputamen of adult F344 rats. Rats carrying transplants expressing the polyoma middle T antigen developed endothelial hemangiomas in the graft which in 70% of the recipient animals led to fatal cerebral hemorrhage within 13-50 days after transplantation. Expression of the v-src gene caused astrocytic and mesenchymal tumors with a 70% incidence after latency periods of 2-6 months, but no endothelial lesions. It was found by in situ hybridization that these oncogenes are expressed in all cell types present in the graft. This indicates that cell-type specific transformation is due to differential susceptibility of the respective target cell to the oncogenes, rather than selective integration or expression of the retroviral construct. The highly efficient gene transfer by retroviral vectors into fetal brain transplants provides a challenging experimental strategy to study differentiation and oncogenesis in the CNS.	UNIV ZURICH, DEPT PATHOL, NEUROPATHOL LAB, SCHMELZBERGSTR 12, CH-8091 ZURICH, SWITZERLAND	University of Zurich			Aguzzi, Adriano/A-3351-2008	Aguzzi, Adriano/0000-0002-0344-6708				AGUZZI A, 1990, New Biologist, V2, P533; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BIGNER DD, 1977, EXPT TUMORS CENTRAL; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7194, DOI 10.1093/nar/15.17.7194; BOULTER CA, 1988, ONCOGENE, V2, P207; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; BURGER PC, 1988, CANCER RES, V48, P2871; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CEPKO CL, 1989, ANNU REV NEUROSCI, V12, P47, DOI 10.1146/annurev.ne.12.030189.000403; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLOYD MW, 1975, J NATL CANCER I, V54, P1479, DOI 10.1093/jnci/54.6.1479; CONE RD, 1984, P NATL ACAD SCI-BIOL, V81, P6349, DOI 10.1073/pnas.81.20.6349; EDWARDS PAW, 1988, ONCOGENE, V2, P407; GAGE FH, 1984, DEV NEUROSCI-BASEL, V6, P137, DOI 10.1159/000112341; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; HAGUENAU F, 1971, JNCI-J NATL CANCER I, V46, P539; IVANKOVIC S, 1968, Z KREBSFORSCH KLIN O, V71, P320, DOI 10.1007/BF00524414; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; KATSUKI M, 1988, SCIENCE, V241, P593, DOI 10.1126/science.2456614; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; Kleihues P, 1976, Int Rev Exp Pathol, V15, P153; KLEIHUES P, 1984, PROG EXP TUMOR RES, V27, P1; LEBEAU JM, 1987, MOL CELL BIOL, V7, P4115, DOI 10.1128/MCB.7.11.4115; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; MONTESANO R, 1990, IN PRESS CELL; PERANTONI AO, 1987, P NATL ACAD SCI USA, V84, P6317, DOI 10.1073/pnas.84.17.6317; READHEAD C, 1987, CELL, V48, P703, DOI 10.1016/0092-8674(87)90248-0; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; STOUT JT, 1985, NATURE, V317, P250, DOI 10.1038/317250a0; STUHLMANN H, 1984, P NATL ACAD SCI-BIOL, V81, P7151, DOI 10.1073/pnas.81.22.7151; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; VICK NA, 1971, J NEUROPATH EXP NEUR, V30, P354, DOI 10.1097/00005072-197107000-00004; WIESTLER OD, 1988, J IMMUNOL METHODS, V110, P153, DOI 10.1016/0022-1759(88)90098-1; WIESTLER OD, 1988, MOL CELL BIOL, V8, P502, DOI 10.1128/MCB.8.1.502; WIESTLER OD, 1988, EXP CELL BIOL, V56, P190; WILLIAMS RL, 1988, CELL, V52, P121; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7	41	47	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1991	6	1					113	118						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1992439				2022-12-17	WOS:A1991EY03900015
J	CAPETANAKI, Y; KUISK, I; ROTHBLUM, K; STARNES, S				CAPETANAKI, Y; KUISK, I; ROTHBLUM, K; STARNES, S			MOUSE VIMENTIN - STRUCTURAL RELATIONSHIP TO FOS, JUN, CREB AND TPR	ONCOGENE			English	Article											CAPETANAKI, Y (corresponding author), BAYLOR UNIV,DEPT CELL BIOL,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039617] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39617-01] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BALCAREK JM, 1985, NUCLEIC ACIDS RES, V13, P5527, DOI 10.1093/nar/13.15.5527; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BLACKSHEAR PJ, 1988, FASEB J, V2, P2957, DOI 10.1096/fasebj.2.14.2972578; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BROWNING ET, 1981, J CELL BIOL, V90, P803, DOI 10.1083/jcb.90.3.803; CAPETANAKI Y, 1989, P NATL ACAD SCI USA, V86, P4882, DOI 10.1073/pnas.86.13.4882; CAPETANAKI Y, 1989, IN PRESS J CELL BIOL; CAPETANAKI YG, 1982, MOL CELL BIOL, V2, P258, DOI 10.1128/MCB.2.3.258; CAPETANAKI YG, 1983, CELL, V35, P411, DOI 10.1016/0092-8674(83)90174-5; CAPETANAKI YG, 1984, COLD SPRING HARB SYM, P415; CHAN D, 1989, P NATL ACAD SCI USA, V86, P2747, DOI 10.1073/pnas.86.8.2747; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CRESS AE, 1988, J BIOL CHEM, V263, P19678; CRICK FHC, 1952, NATURE, V170, P882, DOI 10.1038/170882b0; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; CURRAN T, 1984, CELL, V36, P259; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V5, P89; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; DODEMONT HJ, 1982, EMBO J, V1, P167, DOI 10.1002/j.1460-2075.1982.tb01142.x; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; DRAGER UC, 1983, NATURE, V303, P169, DOI 10.1038/303169a0; EVANS RM, 1988, FEBS LETT, V234, P73, DOI 10.1016/0014-5793(88)81306-1; EVANS RM, 1988, EUR J CELL BIOL, V46, P152; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERRARI S, 1986, MOL CELL BIOL, V6, P3614, DOI 10.1128/MCB.6.11.3614; FRANKE WW, 1987, CELL, V48, P3, DOI 10.1016/0092-8674(87)90345-X; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GARD DL, 1982, MOL CELL BIOL, V2, P1104, DOI 10.1128/MCB.2.9.1104; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEIGER B, 1980, P NATL ACAD SCI USA, V77, P4679; GEISLER N, 1982, EMBO J, V1, P1649, DOI 10.1002/j.1460-2075.1982.tb01368.x; GEISLER N, 1983, EMBO J, V2, P1295, DOI 10.1002/j.1460-2075.1983.tb01584.x; GEISLER N, 1988, EMBO J, V7, P15, DOI 10.1002/j.1460-2075.1988.tb02778.x; GEISLER N, 1981, P NATL ACAD SCI-BIOL, V78, P4120, DOI 10.1073/pnas.78.7.4120; GEORGATOS SD, 1987, J CELL BIOL, V105, P117, DOI 10.1083/jcb.105.1.117; GEORGATOS SD, 1987, J CELL BIOL, V105, P105, DOI 10.1083/jcb.105.1.105; GIBSON CW, 1986, MOL CELL BIOCHEM, V71, P61; GOLDMAN R, 1985, ANN NY ACAD SCI, V455, P1, DOI 10.1111/j.1749-6632.1985.tb50400.x; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GRANGER BL, 1979, CELL, V18, P1053, DOI 10.1016/0092-8674(79)90218-6; GRANGER BL, 1982, CELL, V30, P263, DOI 10.1016/0092-8674(82)90032-0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HANUKOGLU I, 1982, CELL, V31, P243, DOI 10.1016/0092-8674(82)90424-X; HERMANN H, 1989, DEVELOPMENT, V105, P279; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HORWITZ B, 1981, EXP CELL RES, V134, P281, DOI 10.1016/0014-4827(81)90427-4; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V150, P1006, DOI 10.1016/0006-291X(88)90728-0; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; INAGAKI M, 1988, J BIOL CHEM, V263, P5970; ISHIKAWA F, 1986, P NATL ACAD SCI USA, V83, P3209, DOI 10.1073/pnas.83.10.3209; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KHILLAN JS, 1987, GENE DEV, V1, P1327, DOI 10.1101/gad.1.10.1327; KING HWS, 1988, ONCOGENE, V2, P617; KNAPP B, 1986, NUCLEIC ACIDS RES, V14, P751, DOI 10.1093/nar/14.2.751; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KUHN S, 1987, J CELL SCI, V87, P543; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; LAURILA P, 1981, EXP CELL RES, V131, P41, DOI 10.1016/0014-4827(81)90403-1; LAWRENCE CB, 1988, COMPUT APPL BIOSCI, V4, P25; LAWRENCE CB, 1986, B MATH BIOL, V48, P569; LAZARIDES E, 1982, ANNU REV BIOCHEM, V51, P219, DOI 10.1146/annurev.bi.51.070182.001251; LEHTO VP, 1978, NATURE, V272, P175, DOI 10.1038/272175a0; LEWIS SA, 1985, NUCLEIC ACIDS RES, V81, P2743; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARCHIORI F, 1988, BIOCHIM BIOPHYS ACTA, V971, P332; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MOLDERS H, 1987, ONCOGENE, V1, P377; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NGAI J, 1984, J CELL BIOL, V99, P306, DOI 10.1083/jcb.99.1.306; OCONNOR CM, 1981, CELL, V23, P135, DOI 10.1016/0092-8674(81)90278-6; OLSON EN, 1989, ONCOGENE, V4, P907; OSBORN M, 1982, COLD SPRING HARB SYM, V46, P413; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PAULING L, 1953, NATURE, V171, P59, DOI 10.1038/171059a0; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; QUAX W, 1985, CELL, V43, P327, DOI 10.1016/0092-8674(85)90038-8; QUAXJEUKEN YEFM, 1983, P NATL ACAD SCI-BIOL, V80, P3548, DOI 10.1073/pnas.80.12.3548; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1987, ONCOGENE HDB, P213; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RITTLING SR, 1987, MOL CELL BIOL, V7, P3908, DOI 10.1128/MCB.7.11.3908; RITTLING SR, 1989, NUCLEIC ACIDS RES, V17, P1619, DOI 10.1093/nar/17.4.1619; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHOEMAN RL, 1988, J BIOL CHEM, V263, P18744; SIEBERT PD, 1985, J BIOL CHEM, V260, P3868; SINGH B, 1987, J VIROL, V61, P3625, DOI 10.1128/JVI.61.11.3625-3629.1987; SINGH B, 1989, IN PRESS ONCOGENE; SPRUILL WA, 1983, P NATL ACAD SCI-BIOL, V80, P993, DOI 10.1073/pnas.80.4.993; SPRUILL WA, 1983, P NATL ACAD SCI-BIOL, V80, P760, DOI 10.1073/pnas.80.3.760; STARGER JM, 1978, J CELL BIOL, V78, P93, DOI 10.1083/jcb.78.1.93; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEINERT PM, 1983, NATURE, V302, P794, DOI 10.1038/302794a0; TAPSCOTT SJ, 1981, DEV BIOL, V86, P40, DOI 10.1016/0012-1606(81)90313-4; TEMPEST PR, 1986, CARCINOGENESIS, V7, P2051, DOI 10.1093/carcin/7.12.2051; TRAUB P, 1987, Z NATURFORSCH C, V42, P47; TRAUB P, 1983, J BIOL CHEM, V258, P1456; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WOODCOCK CLF, 1980, J CELL BIOL, V85, P881, DOI 10.1083/jcb.85.3.881; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YEN SH, 1981, J CELL BIOL, V88, P115, DOI 10.1083/jcb.88.1.115; ZEHNER ZE, 1983, P NATL ACAD SCI-BIOL, V80, P911, DOI 10.1073/pnas.80.4.911; ZEHNER ZE, 1987, J BIOL CHEM, V262, P8112	125	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1990	5	5					645	655						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	2140597				2022-12-17	WOS:A1990DG37400003
J	IWAMOTO, T; TAKAHASHI, M; ITO, M; HAMAGUCHI, M; ISOBE, K; MISAWA, N; ASAI, JP; YOSHIDA, T; NAKASHIMA, I				IWAMOTO, T; TAKAHASHI, M; ITO, M; HAMAGUCHI, M; ISOBE, K; MISAWA, N; ASAI, JP; YOSHIDA, T; NAKASHIMA, I			ONCOGENICITY OF THE RET TRANSFORMING GENE IN MMTV/RET TRANSGENIC MICE	ONCOGENE			English	Article									NAGOYA UNIV,SCH MED,DEPT PATHOL 1,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DIS MECHANISM & CONTROL RES INST,SHOWA KU,NAGOYA,AICHI 466,JAPAN; AICHI CANC CTR,RES CTR,EXPTL PATHOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Nagoya University; Nagoya University; Aichi Cancer Center	IWAMOTO, T (corresponding author), NAGOYA UNIV,SCH MED,DEPT IMMUNOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN.		TAKAHASHI, Masahide/I-7244-2014; isobe, ken-ichi/A-6685-2011; Takahashi, Masahide/AAN-4770-2020	isobe, ken-ichi/0000-0002-8150-2496; Takahashi, Masahide/0000-0002-2803-2683				ANDERSON MLM, 1985, NUCLEIC ACID HYBRIDI, P73; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; Davis LG, 1986, BASIC METHODS MOL BI, P42; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HOGAN B, 1986, MANIPULATING MOUSE E, P79; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; LAND H, 1986, ONCOGENES GROWTH CON, P304; MAJORS JE, 1981, NATURE, V289, P253, DOI 10.1038/289253a0; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6	23	47	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					535	542						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	1691479				2022-12-17	WOS:A1990DB85300012
J	MAHADEVAN, LC; WILLS, AJ; HIRST, EA; RATHJEN, PD; HEATH, JK				MAHADEVAN, LC; WILLS, AJ; HIRST, EA; RATHJEN, PD; HEATH, JK			2-AMINOPURINE ABOLISHES EGF-STIMULATED AND TPA-STIMULATED PP33 PHOSPHORYLATION AND C-FOS INDUCTION WITHOUT AFFECTING THE ACTIVATION OF PROTEIN KINASE-C	ONCOGENE			English	Article											MAHADEVAN, LC (corresponding author), UNIV OXFORD,DEPT BIOCHEM,S PARKS RD,OXFORD OX1 3QU,ENGLAND.							ALEXANDER DR, 1989, BIOCHEM J, V260, P893, DOI 10.1042/bj2600893; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BERRIDGE MJ, 1988, COLD SPRING HARB SYM, V53, P927, DOI 10.1101/SQB.1988.053.01.107; BLAKELEY MD, 1989, BIOCHEM J, V258, P177; BRAVO R, 1986, ONCOGENES GROWTH CON, P253; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOWNES CP, 1986, MOL ASPECTS CELLULAR, V4, P3; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; ERIKSON E, 1986, J BIOL CHEM, V261, P350; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GANZ MB, 1989, NATURE, V337, P648, DOI 10.1038/337648a0; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALL DJ, 1989, MOL CELL BIOL, V9, P1705, DOI 10.1128/MCB.9.4.1705; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HEATH JK, 1986, EMBO J, V5, P1809, DOI 10.1002/j.1460-2075.1986.tb04430.x; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HOCKBERGER P, 1989, NATURE, V338, P340, DOI 10.1038/338340a0; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUNTER T, 1988, COLD SPRING HARB SYM, V53, P131, DOI 10.1101/SQB.1988.053.01.019; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; JONES SD, 1988, COLD SPRING HARB SYM, V53, P531, DOI 10.1101/SQB.1988.053.01.061; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LIM RW, 1987, ONCOGENE, V1, P263; MAHADEVAN LC, 1987, EMBO J, V6, P921, DOI 10.1002/j.1460-2075.1987.tb04839.x; MAHADEVAN LC, 1989, ONCOGENE, V4, P699; MAHADEVAN LC, 1988, ONCOGENE, V2, P249; MAHADEVAN LC, 1989, IN PRESS RECEPTORS P; Maniatis T., 1982, MOL CLONING; MIYAMOTO NG, 1985, EMBO J, V5, P2577; MOOLENAAR WH, 1986, ONCOGENES GROWTH CON, P160; MOON SO, 1984, P NATL ACAD SCI-BIOL, V81, P2298, DOI 10.1073/pnas.81.8.2298; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1988, COLD SPRING HARB SYM, V53, P935; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SARDET C, 1988, COLD SPRING HARB SYM, V53, P1011, DOI 10.1101/SQB.1988.053.01.116; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WEI C, 1987, CELL, V50, P1047; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	68	47	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					327	335						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	2107492				2022-12-17	WOS:A1990CW41500010
J	WELHAM, MJ; WYKE, JA; LANG, A; WYKE, AW				WELHAM, MJ; WYKE, JA; LANG, A; WYKE, AW			MITOGENESIS INDUCED BY PP60V-SRC IS NOT ACCOMPANIED BY INCREASED EXPRESSION OF IMMEDIATE EARLY RESPONSE GENES	ONCOGENE			English	Article									BEATSON INST CANC RES,GARSCUBE ESTATE,SWITCHBACK RD,GLASGOW G61 1BD,SCOTLAND; ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND LABS,LONDON EC1A 7BN,ENGLAND	Beatson Institute; Cancer Research UK; University of London; Queen Mary University London								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BARBER JR, 1987, MOL CELL BIOL, V7, P201; BELL JG, 1975, J GEN VIROL, V27, P127, DOI 10.1099/0022-1317-27-2-127; Bjerrum OJ, 1986, **NON-TRADITIONAL**, V86th, P315; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHANG JD, 1988, CARCINOGENESIS, V9, P17, DOI 10.1093/carcin/9.1.17; CHIARUGI V, 1987, ONCOGENE, V2, P37; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cleveland J L, 1988, Oncogene Res, V3, P357; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1984, CELL, V36, P259; DURKIN JP, 1985, J CELL PHYSIOL, V125, P51, DOI 10.1002/jcp.1041250108; DURKIN JP, 1984, BIOCHEM BIOPH RES CO, V123, P411, DOI 10.1016/0006-291X(84)90245-6; DURKIN JP, 1984, J CELL PHYSIOL, V120, P135, DOI 10.1002/jcp.1041200205; EICK D, 1987, ONCOGENE, V2, P61; Fourney R.M., 1988, FOCUS, V10, P5; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GILLESPIE DAF, 1985, CELL, V41, P279, DOI 10.1016/0092-8674(85)90081-9; GILMER TM, 1983, J VIROL, V45, P462, DOI 10.1128/JVI.45.1.462-465.1983; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAY GM, 1988, J BIOL CHEM, V263, P10714; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAYASHI K, 1987, NUCLEIC ACIDS RES, V15, P6419, DOI 10.1093/nar/15.16.6419; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KARNITZ L, 1989, MOL CELL BIOL, V9, P1929, DOI 10.1128/MCB.9.5.1929; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; KRUEGER JG, 1980, VIROLOGY, V101, P25, DOI 10.1016/0042-6822(80)90480-8; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KRZYZEK RA, 1980, J VIROL, V36, P805, DOI 10.1128/JVI.36.3.805-815.1980; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LINDSTEN T, 1988, EMBO J, V7, P2787, DOI 10.1002/j.1460-2075.1988.tb03133.x; Maniatis T., 1982, MOL CLONING; MEHMET H, 1988, ONCOGENE RES, V3, P281; MEHMET H, 1989, ONCOGENE RES, V4, P215; MULLER R, 1987, ONCOGENE RES, V2, P19; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PURCHIO AF, 1978, P NATL ACAD SCI USA, V75, P1567, DOI 10.1073/pnas.75.3.1567; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SAKSELA K, 1989, EMBO J, V8, P149, DOI 10.1002/j.1460-2075.1989.tb03359.x; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SEFTON BM, 1986, CURR TOP MICROBIOL, V123, P39; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; VANDERVALK J, 1987, J BIOL CHEM, V262, P2431; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; WELHAM MJ, 1988, THESIS U LONDON UK; WHITE MK, 1988, MOL CELL BIOL, V8, P135; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; WYKE JA, 1987, BIOCHIM BIOPHYS ACTA, V907, P47, DOI 10.1016/0304-419X(87)90018-7; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	70	47	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1990	5	2					161	169						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU029	2108404				2022-12-17	WOS:A1990CU02900001
J	SALOME, N; VANHILLE, B; DUPONCHEL, N; MENEGUZZI, G; CUZIN, F; ROMMELAERE, J; CORNELIS, JJ				SALOME, N; VANHILLE, B; DUPONCHEL, N; MENEGUZZI, G; CUZIN, F; ROMMELAERE, J; CORNELIS, JJ			SENSITIZATION OF TRANSFORMED RAT-CELLS TO PARVOVIRUS MVMP IS RESTRICTED TO SPECIFIC ONCOGENES	ONCOGENE			English	Article									INST PASTEUR,CNRS,URA 0156,INSERM,U186,ONCOL MOLEC LAB,BP 245,F-59019 LILLE,FRANCE; UNIV NICE,CTR BIOCHIM,INSERM,U273,F-06034 NICE,FRANCE; UNIV LIBRE BRUXELLES,DEPT BIOL MOLEC,B-1640 RHODE ST GENESE,BELGIUM	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Universite Libre de Bruxelles			SALOME, NATHALIE/P-6408-2016	Meneguzzi, Guerrino/0000-0002-1609-6540; SALOME, NATHALIE/0000-0002-0349-0258				ANDERSON MJ, 1987, PROG MED VIROL, V34, P55; ASTELL CR, 1987, J GEN VIROL, V68, P885, DOI 10.1099/0022-1317-68-3-885; ASTELL CR, 1983, NUCLEIC ACIDS RES, V11, P999, DOI 10.1093/nar/11.4.999; BABISS LE, 1986, VIROLOGY, V154, P180, DOI 10.1016/0042-6822(86)90440-X; BANDO H, 1987, J VIROL, V61, P553, DOI 10.1128/JVI.61.2.553-560.1987; BERG L, 1986, CELL, V46, P753, DOI 10.1016/0092-8674(86)90351-X; BERGMAN P, 1988, ONCOGENE, V2, P453; BINETRUY B, 1987, CANCER CELL, V5, P223; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN YQ, 1989, CARCINOGENESIS, V10, P163, DOI 10.1093/carcin/10.1.163; CHEN YQ, 1986, CANCER RES, V46, P3574; CORNELIS JJ, 1988, J VIROL, V62, P3438, DOI 10.1128/JVI.62.9.3438-3444.1988; CORNELIS JJ, 1988, J VIROL, V62, P1679, DOI 10.1128/JVI.62.5.1679-1686.1988; COTMORE SF, 1987, ADV VIRUS RES, V33, P91, DOI 10.1016/S0065-3527(08)60317-6; CUKOR G, 1983, BIOL ADENO ASS VIRUS, P33; DUPRESSOIR T, 1989, CANCER RES, V49, P3203; FAISST S, 1989, J VIROL, V63, P2152, DOI 10.1128/JVI.63.5.2152-2158.1989; GRISONI M, 1984, VIROLOGY, V135, P406, DOI 10.1016/0042-6822(84)90196-X; GUETTA E, 1986, J NATL CANCER I, V76, P1177; GUETTA E, 1989, IN PRESS J VIROL; HAUGEN TH, 1988, EMBO J, V7, P4245, DOI 10.1002/j.1460-2075.1988.tb03322.x; HOWLEY PM, 1987, PAPOVAVIRIDAE, V2, P141; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; KATZ E, 1986, CANCER RES, V46, P3023; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MARTIN P, 1986, EMBO J, V5, P1529, DOI 10.1002/j.1460-2075.1986.tb04393.x; MCKAY IA, 1986, MOL CELL BIOL, V6, P3382, DOI 10.1128/MCB.6.10.3382; MENEGUZZI G, 1984, EMBO J, V3, P365, DOI 10.1002/j.1460-2075.1984.tb01813.x; MERCHLINSKY MJ, 1983, J VIROL, V47, P227, DOI 10.1128/JVI.47.1.227-232.1983; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; MOUSSET S, 1982, NATURE, V300, P537, DOI 10.1038/300537a0; MOUSSET S, 1986, BIOCHIMIE, V68, P951, DOI 10.1016/S0300-9084(86)81058-6; OSTROVE JM, 1981, VIROLOGY, V113, P521, DOI 10.1016/0042-6822(81)90180-X; OZAWA K, 1988, J VIROL, V62, P2884, DOI 10.1128/JVI.62.8.2884-2889.1988; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; RHODE SL, 1987, J VIROL, V61, P1448, DOI 10.1128/JVI.61.5.1448-1456.1987; ROMMELAERE J, 1989, IN PRESS ONCOSUPPRES; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SIEGL G, 1983, BIOL PATHOGENICITY A, P297; TATTERSALL P, 1978, PARVOVIRUSES INTRO R, P3; THORNER L, 1988, J VIROL, V62, P2474, DOI 10.1128/JVI.62.7.2474-2482.1988; TOOLAN H, 1965, NATURE, V208, P812, DOI 10.1038/208812a0; TULLIS GE, 1988, J VIROL, V62, P2736, DOI 10.1128/JVI.62.8.2736-2744.1988; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANHILLE B, 1989, IN PRESS VIROLOGY, V170; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917	50	47	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1990	5	1					123	130						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2157178				2022-12-17	WOS:A1990CM62000017
J	ALEXANDER, WS; BERNARD, O; CORY, S; ADAMS, JM				ALEXANDER, WS; BERNARD, O; CORY, S; ADAMS, JM			LYMPHOMAGENESIS IN E-MU-MYC TRANSGENIC MICE CAN INVOLVE RAS MUTATIONS	ONCOGENE			English	Article									ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Cory, Suzanne/E-1642-2013; Adams, Jerry M/E-1199-2013	Cory, Suzanne/0000-0002-6818-3451; Adams, Jerry/0000-0002-4360-8628	NCI NIH HHS [CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; CLEVELAND JL, 1986, J CELL BIOCHEM, V30, P195, DOI 10.1002/jcb.240300303; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CORY S, 1983, EMBO J, V2, P697, DOI 10.1002/j.1460-2075.1983.tb01487.x; DIAMOND LE, 1988, MOL CELL BIOL, V8, P2233, DOI 10.1128/MCB.8.5.2233; EVA A, 1986, CARCINOGENESIS, V7, P1931, DOI 10.1093/carcin/7.11.1931; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GUERRERO I, 1985, P NATL ACAD SCI USA, V82, P7810, DOI 10.1073/pnas.82.23.7810; Hariharan I K, 1988, Oncogene Res, V3, P387; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; ISHIKAWA F, 1986, P NATL ACAD SCI USA, V83, P3209, DOI 10.1073/pnas.83.10.3209; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LANGDON WY, 1988, ONCOGENE RES, V3, P271; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARK GE, 1986, P NATL ACAD SCI USA, V83, P6312, DOI 10.1073/pnas.83.17.6312; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; PERUCHO M, 1980, COLD SPRING HARB SYM, V45, P829, DOI 10.1101/SQB.1981.045.01.101; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS E, 1983, P NATL ACAD SCI-BIOL, V80, P4679, DOI 10.1073/pnas.80.15.4679; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TOKSOZ D, 1987, ONCOGENE, V1, P409	37	47	48	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					575	581						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2657573				2022-12-17	WOS:A1989U768800007
J	WILKS, AF; KURBAN, RR				WILKS, AF; KURBAN, RR			ISOLATION AND STRUCTURAL-ANALYSIS OF MURINE C-FES CDNA CLONES	ONCOGENE			English	Article											WILKS, AF (corresponding author), ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,PARKVILLE,VIC 3050,AUSTRALIA.		Wilks, Andrew F/R-5542-2019	Wilks, Andrew F/0000-0002-8554-2399				BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DIAMOND B, 1978, J IMMUNOL, V121, P1329; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FELDMAN RA, 1987, ONCOGENE RES, V1, P441; FELDMAN RA, 1986, MOL CELL BIOL, V6, P1065, DOI 10.1128/MCB.6.4.1065; FOSTER DA, 1986, MOL CELL BIOL, V6, P325, DOI 10.1128/MCB.6.1.325; FOSTER DA, 1985, CELL, V42, P105, DOI 10.1016/S0092-8674(85)80106-9; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HAMPE A, 1982, CELL, V30, P775, DOI 10.1016/0092-8674(82)90282-3; HANAFUSA T, 1980, P NATL ACAD SCI-BIOL, V77, P3009, DOI 10.1073/pnas.77.5.3009; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; HUANG CC, 1984, J VIROL, V50, P125, DOI 10.1128/JVI.50.1.125-131.1984; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MATHEYPREVOT B, 1982, CELL, V28, P897, DOI 10.1016/0092-8674(82)90069-1; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; METCALF D, 1982, INT J CANCER, V30, P773, DOI 10.1002/ijc.2910300616; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROEBROEK AJM, 1987, J VIROL, V61, P2009, DOI 10.1128/JVI.61.6.2009-2016.1987; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA M, 1982, CELL, V30, P787, DOI 10.1016/0092-8674(82)90283-5; SODROSKI JG, 1984, P NATL ACAD SCI-BIOL, V81, P3039, DOI 10.1073/pnas.81.10.3039; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; ULLRICH A, 1984, NATURE, V289, P258; WARNER NL, 1969, J NATL CANCER I, V43, P963; WARNER NL, 1979, IMMUNOBIOLOGY IMNUNO, P223; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; YOUNG JC, 1984, J VIROL, V52, P913, DOI 10.1128/JVI.52.3.913-918.1984	40	47	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					289	294						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	3060793				2022-12-17	WOS:A1988Q436700007
J	Mu, ML; Niu, WX; Zhang, XM; Hu, SS; Niu, CS				Mu, Maolin; Niu, Wanxiang; Zhang, Xiaoming; Hu, Shanshan; Niu, Chaoshi			LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN/AKT/p21 pathway	ONCOGENE			English	Article							LONG NONCODING RNA; CANCER; CELLS; PROLIFERATION; DYSREGULATION; RESISTANCE; RECEPTOR; HOTAIR; LEADS	Glioma is the most common malignant tumor in the central nervous system. Altered long noncoding RNAs (lncRNAs) are playing regulatory roles in physiological and pathogenic processes in cancer. Here, we uncovered a differentially expressed lncRNA called brain cytoplasmic RNA 1 (BCYRN1), and elucidated its function and molecular mechanism in the progression and development of glioma. Three fresh tumor tissues from glioma patients and three normal brain tissues from craniocerebral trauma patients were prepared for high-throughput RNA sequencing. Differential RNA transcripts and BCYRN1 were identified by RT-qPCR in glioma samples and controls. CCK-8, colony formation assays, flow cytometry, TUNEL assays, cell migration assays, wound-healing assays, and xenograft model were established to investigate the biological function of BCYRN1 both in vitro and in vivo. Various bioinformatics analysis, dual-luciferase reporter assays, biotinylated RNA pulldown assays, and rescue experiments were conducted to reveal the underlying mechanisms of competitive endogenous RNAs (ceRNAs). 183 lncRNAs were identified with significant dysregulation in glioma and randomly selected differential RNAs were further confirmed by RT-qPCR. Among them, BCYRN1 was the most downregulated lncRNA, and its low expression positively correlated with glioma progression. Functionally, BCYRN1 overexpression inhibited cell proliferation, migration in glioma cell lines, whereas BCYRN1 depletion resulted in the opposite way. MiR-619-5p was further confirmed as the direct target of BCYRN1. Mechanistically, miR-619-5p specifically targeted the CUE domain containing protein 2 (CUEDC2), and BCYRN1/miR-619-5p suppressed glioma tumorigenesis by inactivating PTEN/AKT/p21 pathway in a CUEDC2-dependent manner. Overall, our data presented that the reduced expression of BCYRN1 was associated with poor patient outcome in glioma. BCYRN1 functioned as a ceRNA to inhibit glioma progression by sponging miR-619-5p to regulate CUEDC2 expression and PTEN/AKT/p21 pathway. Our results indicated that BCYRN1 exerted tumor suppressor potential and might be a candidate in the diagnosis and treatment of glioma.	[Mu, Maolin; Niu, Wanxiang; Zhang, Xiaoming; Hu, Shanshan; Niu, Chaoshi] Univ Sci & Technol China, Affiliated Hosp USTC 1, Div Life Sci & Med, Dept Neurosurg, Hefei 230001, Anhui, Peoples R China; [Mu, Maolin; Niu, Wanxiang; Zhang, Xiaoming; Hu, Shanshan; Niu, Chaoshi] Anhui Key Lab Brain Funct & Dis, Hefei 230001, Anhui, Peoples R China; [Hu, Shanshan; Niu, Chaoshi] Anhui Prov Stereotact Neurosurg Inst, Hefei 230001, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS	Hu, SS; Niu, CS (corresponding author), Univ Sci & Technol China, Affiliated Hosp USTC 1, Div Life Sci & Med, Dept Neurosurg, Hefei 230001, Anhui, Peoples R China.; Hu, SS; Niu, CS (corresponding author), Anhui Key Lab Brain Funct & Dis, Hefei 230001, Anhui, Peoples R China.; Hu, SS; Niu, CS (corresponding author), Anhui Prov Stereotact Neurosurg Inst, Hefei 230001, Anhui, Peoples R China.	hss923@ustc.edu.cn; niuchaoshi@ustc.edu.cn			National Natural Science Foundation of China [:81902525]; Natural Science Foundation of Anhui Province [1908085QH336]; USTC Research Funds of the Double First-Class Initiative [YD9100002002]; Fundamental Research Funds for the Central Universities [WK9110000033]; Special Fund Project for Guiding Local Science and Technology Development by the Central Government [2017070802D144]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Anhui Province(Natural Science Foundation of Anhui Province); USTC Research Funds of the Double First-Class Initiative; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Special Fund Project for Guiding Local Science and Technology Development by the Central Government	This study was support by the National Natural Science Foundation of China (No:81902525), Natural Science Foundation of Anhui Province (No: 1908085QH336), USTC Research Funds of the Double First-Class Initiative (No: YD9100002002), the Fundamental Research Funds for the Central Universities (No: WK9110000033) and Special Fund Project for Guiding Local Science and Technology Development by the Central Government (No: 2017070802D144).	Ahir BK, 2019, CELL SIGNAL, V53, P22, DOI 10.1016/j.cellsig.2018.09.014; Balci T, 2016, GENE, V590, P120, DOI 10.1016/j.gene.2016.06.024; Bartel DP, 2018, CELL, V173, P20, DOI 10.1016/j.cell.2018.03.006; Booy EP, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0679-7; Bossi L, 2016, NAT REV MICROBIOL, V14, P775, DOI 10.1038/nrmicro.2016.129; Casamassimi A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081652; Chen G, 2019, J CELL PHYSIOL, V234, P18688, DOI 10.1002/jcp.28509; Chen Y, 2014, CELL REP, V7, P1982, DOI 10.1016/j.celrep.2014.05.007; D'Amico RS, 2017, WORLD NEUROSURG, V103, P538, DOI 10.1016/j.wneu.2017.04.041; Deguchi S, 2017, ONCOGENE, V36, P4629, DOI 10.1038/onc.2017.88; Dhir A, 2015, NAT STRUCT MOL BIOL, V22, P319, DOI 10.1038/nsmb.2982; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Ge XL, 2019, ONCOGENE, V38, P3061, DOI 10.1038/s41388-018-0645-x; Han MZ, 2020, BRAIN, V143, P512, DOI 10.1093/brain/awz406; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hu L, 2017, ONCOGENE, V36, P1145, DOI 10.1038/onc.2016.281; Hu SS, 2016, NAT STRUCT MOL BIOL, V23, P1011, DOI 10.1038/nsmb.3302; Hu SS, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2681925; Hu T, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0183-3; Hua JJ, 2019, TRENDS GENET, V35, P840, DOI 10.1016/j.tig.2019.08.004; Huang TZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12885; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Jia P, 2016, CANCER LETT, V381, P359, DOI 10.1016/j.canlet.2016.08.009; Karreth FA, 2013, CANCER DISCOV, V3, P1113, DOI 10.1158/2159-8290.CD-13-0202; Katsushima K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13616; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704; Lauria A, 2020, NUCLEIC ACIDS RES, V48, P1730, DOI 10.1093/nar/gkz1208; Lee JT, 2013, CELL, V152, P1308, DOI 10.1016/j.cell.2013.02.016; Li F, 2017, INT J ONCOL, V51, P115, DOI 10.3892/ijo.2017.4009; Li HY, 2008, NAT IMMUNOL, V9, P533, DOI 10.1038/ni.1600; Li LL, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00849-7; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Lien EC, 2017, CURR OPIN CELL BIOL, V45, P62, DOI 10.1016/j.ceb.2017.02.007; Liu K, 2020, ONCOGENE, V39, P3075, DOI 10.1038/s41388-020-1213-8; Luo S, 2016, CELL STEM CELL, V18, P637, DOI 10.1016/j.stem.2016.01.024; McDonel P, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a032151; Pan X, 2011, NAT MED, V17, P708, DOI 10.1038/nm.2369; Pastori C, 2015, P NATL ACAD SCI USA, V112, P8326, DOI 10.1073/pnas.1424220112; Peng J, 2018, ONCOL LETT, V15, P5809, DOI 10.3892/ol.2018.8015; Qiu G, 2016, ONCOL LETT, V12, P5036, DOI 10.3892/ol.2016.5312; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Shao M, 2018, CANCER GENET-NY, V226, P23, DOI 10.1016/j.cancergen.2018.05.001; Singh R, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.168; Slack FJ, 2019, CELL, V179, P1033, DOI 10.1016/j.cell.2019.10.017; Sun B, 2019, ONCOGENE, V38, P6142, DOI 10.1038/s41388-019-0867-6; Sun QY, 2018, TRENDS GENET, V34, P142, DOI 10.1016/j.tig.2017.11.005; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Thomas C, 2011, NAT MED, V17, P658, DOI 10.1038/nm0611-658; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Wang AC, 2019, J CANCER, V10, P1800, DOI 10.7150/jca.29889; Wang RJ, 2018, CANCER RES, V78, P4812, DOI 10.1158/0008-5472.CAN-18-0532; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Westphal M, 2011, NAT REV NEUROSCI, V12, P495, DOI 10.1038/nrn3060; Wu D, 2016, ONCOL LETT, V11, P1189, DOI 10.3892/ol.2015.3983; Wu PF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10025-2; Wu QY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0812-6; Yu W, 2020, CANCER MANAG RES, V12, P1151, DOI 10.2147/CMAR.S227327; Zhai HB, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190505; Zhang JX, 2013, NEURO-ONCOLOGY, V15, P1595, DOI 10.1093/neuonc/not131; Zhang PJ, 2007, EMBO J, V26, P1831, DOI 10.1038/sj.emboj.7601602; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhang XY, 2016, AM J TRANSL RES, V8, P3409	66	46	46	3	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2020	39	45					6879	6892		10.1038/s41388-020-01466-x	http://dx.doi.org/10.1038/s41388-020-01466-x		SEP 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ON7IM	32978519	hybrid, Green Published			2022-12-17	WOS:000572714000002
J	Jiang, MM; Zhang, WW; Zhang, R; Liu, PP; Ye, YN; Yu, WW; Guo, XJ; Yu, JP				Jiang, Mengmeng; Zhang, Wenwen; Zhang, Rui; Liu, Pengpeng; Ye, Yingnan; Yu, Wenwen; Guo, Xiaojing; Yu, Jinpu			Cancer exosome-derived miR-9 and miR-181a promote the development of early-stage MDSCs via interfering with SOCS3 and PIAS3 respectively in breast cancer	ONCOGENE			English	Article							SUPPRESSOR-CELLS; EXPRESSION; MICRORNA-9; METHYLATION; METASTASIS; ACTIVATION; INFECTION; RESPONSES; INVASION	We previously identified that the development of early-stage myeloid-derived suppressor cells (eMDSCs) in breast cancer with high IL-6 (IL-6(high)) expression was correlated with the SOCS3 deficiency-dependent hyperactivation of the JAK/STAT signaling pathway. However, the regulatory mechanisms have not yet been elucidated. In this study, we aimed to investigate how the posttranscriptional regulation mediated by cancer exosome-derived miRNAs affected the JAK/STAT signaling pathway and the development of eMDSCs. Using miRNA microarray, we screened miR-9 and miR-181a which were exclusively upregulated in eMDSCs and inversely associated with SOCS3 expression. We found both miRNAs promoted the amplification of immature eMDSCs with the strong suppression on T-cell immunity in mice and humans. Furthermore, miR-9 and miR-181a promoted 4T1 tumor growth and immune escape via enhancing eMDSCs infiltration in situ. But miR-9 and miR-181a stimulated eMDSCs development by separately inhibiting SOCS3 and PIAS3, two crucial regulators in the negative feedback loop of the JAK/STAT signaling pathway. Elevated miR-9 and miR-181a in eMDSCs was derived from tumor-derived exosomes, and blocking the exosome release could fully attenuate the miRNA-mediated regulation on eMDSCs development. In summary, our findings indicated that tumor exosome-derived miR-9 and miR-181a activated the JAK/STAT signaling pathway via targeting SOCS3 and PIAS3, respectively, and thus promoted the expansion of eMDSCs which might provide potential therapeutic target for IL-6(high) breast cancer treatment.	[Jiang, Mengmeng; Zhang, Wenwen; Zhang, Rui; Liu, Pengpeng; Ye, Yingnan; Yu, Jinpu] Tianjin Med Univ Canc Inst & Hosp, Canc Mol Diagnost Core, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Key Lab Canc Prevent &, Tianjin, Peoples R China; [Jiang, Mengmeng] Tianjin Third Central Hosp, Dept Oncol, Tianjin, Peoples R China; [Zhang, Wenwen; Zhang, Rui; Liu, Pengpeng; Ye, Yingnan; Yu, Wenwen; Yu, Jinpu] Tianjin Med Univ Canc Inst & Hosp, Dept Immunol, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China; [Yu, Wenwen; Yu, Jinpu] Key Lab Canc Immunol & Biotherapy, Tianjin, Peoples R China; [Guo, Xiaojing] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Breast Canc Breast Canc Prevent & Therapy, Dept Breast Pathol & Lab, Tianjin, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University	Yu, JP (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Canc Mol Diagnost Core, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Key Lab Canc Prevent &, Tianjin, Peoples R China.; Yu, JP (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Dept Immunol, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China.; Yu, JP (corresponding author), Key Lab Canc Immunol & Biotherapy, Tianjin, Peoples R China.	yujinpu@tjmuch.com			National Natural Science Foundation of China [81872143, 81472473, 81772840]; National Science and Technology Support Program of China [2015BAI12B15]; Project of Science and Technology of Tianjin [13ZCZCSY20300, 18JCQNJC82700]; Key Project of Tianjin Health and Family Planning Commission [16KG126]; National Science and Technology Major Project [2018ZX09201-015]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Support Program of China; Project of Science and Technology of Tianjin; Key Project of Tianjin Health and Family Planning Commission; National Science and Technology Major Project	This work was supported by National Natural Science Foundation of China (Grant No.81872143, 81472473, 81772840), National Science and Technology Support Program of China (Grant No.2015BAI12B15), National Science and Technology Major Project (Grant No.2018ZX09201-015), Project of Science and Technology of Tianjin (Grant No.13ZCZCSY20300, 18JCQNJC82700) and Key Project of Tianjin Health and Family Planning Commission (Grant No.16KG126). We appreciate the efforts of Dr Juntian Liu and Dr Shixia Li of Department of Preventive Health Screening Center in sample collection. We thank Dr Xiubao Ren of Department of Biotherapy for support of Flow cytometry. We also thank Prof Weijia Zhang of Department of Medicine of Icahn School of Medicine at Mount Sinai for constructive comments to our manuscript.	Al-Mahmood S, 2018, DRUG DELIV TRANSL RE, V8, P1483, DOI 10.1007/s13346-018-0551-3; Arora T, 2003, J BIOL CHEM, V278, P21327, DOI 10.1074/jbc.C300119200; Baroni S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.224; Bhatia A, 2014, EXPERT REV CLIN IMMU, V10, P41, DOI 10.1586/1744666X.2014.865519; Bjornetro T, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1567219; Boosani CS, 2015, MOL BIOL REP, V42, P853, DOI 10.1007/s11033-015-3860-3; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Cao Q, 2013, PHYSIOL GENOMICS, V45, P1206, DOI 10.1152/physiolgenomics.00122.2013; Dudda JC, 2013, IMMUNITY, V38, P742, DOI 10.1016/j.immuni.2012.12.006; Guo XF, 2018, ONCOGENE, V37, P4239, DOI 10.1038/s41388-018-0261-9; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Isomoto H, 2009, DIGESTION, V79, P2, DOI 10.1159/000167859; Jang MH, 2017, HUM PATHOL, V68, P69, DOI 10.1016/j.humpath.2017.08.026; Jiang MM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01840; Jiang MM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00070; Khatibi S, 2017, GROWTH FACTORS, V35, P100, DOI 10.1080/08977194.2017.1363746; Lao MX, 2016, J IMMUNOL, V196, P596, DOI 10.4049/jimmunol.1403254; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Lu CM, 2011, BLOOD, V117, P4293, DOI 10.1182/blood-2010-12-322503; McClure C, 2017, IMMUNOL CELL BIOL, V95, P42, DOI 10.1038/icb.2016.63; Niu J, 2016, ONCOGENE, V35, P1302, DOI 10.1038/onc.2015.189; Orangi E, 2019, GENE, V687, P272, DOI 10.1016/j.gene.2018.11.036; Pu SM, 2016, SCI REP-UK, V6, DOI 10.1038/srep23115; Pyzer AR, 2016, INT J CANCER, V139, P1915, DOI 10.1002/ijc.30232; Ru Peng, 2011, Genes Cancer, V2, P720, DOI 10.1177/1947601911425832; Sade-Feldman M, 2016, CLIN CANCER RES, V22, P5661, DOI 10.1158/1078-0432.CCR-15-3104; Seif F, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0177-y; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Sporn JC, 2019, J SURG RES, V233, P426, DOI 10.1016/j.jss.2018.08.020; Tian J, 2015, J IMMUNOL, V195, P1301, DOI 10.4049/jimmunol.1500209; Tischoff I, 2007, GUT, V56, P1047, DOI 10.1136/gut.2006.111633; Tussie-Luna MI, 2002, P NATL ACAD SCI USA, V99, P12807, DOI 10.1073/pnas.192464499; Xu Z, 2017, FEBS J, V284, P2410, DOI 10.1111/febs.14133; Yang L, 2018, J NEUROIMMUNE PHARM, V13, P330, DOI 10.1007/s11481-018-9779-4; Yu JP, 2014, J IMMUNOL, V193, P2574, DOI 10.4049/jimmunol.1400833; Yu JP, 2013, J IMMUNOL, V190, P3783, DOI 10.4049/jimmunol.1201449; Zhang WW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01699; Zhang X, 2014, J VIRAL HEPATITIS, V21, P264, DOI 10.1111/jvh.12137; Zhao Y, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1004983; Zhen J, 2019, BIOMED PHARMACOTHER, V116, DOI 10.1016/j.biopha.2019.109016; Zheng HB, 2015, INT J CLIN EXP MED, V8, P20263; Zhou ZP, 2010, STEM CELLS, V28, P620, DOI 10.1002/stem.301; Zhu KP, 2019, MOL THER, V27, P518, DOI 10.1016/j.ymthe.2019.01.001	43	46	46	3	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4681	4694		10.1038/s41388-020-1322-4	http://dx.doi.org/10.1038/s41388-020-1322-4		MAY 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32398867				2022-12-17	WOS:000532103100002
J	Kiavue, N; Cabel, L; Melaabi, S; Bataillon, G; Callens, C; Lerebours, F; Pierga, JY; Bidard, FC				Kiavue, Nicolas; Cabel, Luc; Melaabi, Samia; Bataillon, Guillaume; Callens, Celine; Lerebours, Florence; Pierga, Jean-Yves; Bidard, Francois-Clement			ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics	ONCOGENE			English	Review							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; CELL LUNG-CANCER; GENOMIC CHARACTERIZATION; BREAST; ACTIVATION; DOMAIN; TUMOR; HER3; LANDSCAPE	HER3, a member of the EGFR family of receptor tyrosine kinases coded by the ERBB3 gene, plays an important role in cancer, despite its lack of intrinsic kinase activity. As with genes coding for potential heterodimeric partners of HER3, EGFR, and HER2, oncogenic mutations of ERBB3 have been explored by several studies. In this review, we discuss the evidence presenting ERBB3 somatic mutations as potential tumoral drivers. We then show that ERBB3 mutations are not uncommon in many cancer types. Finally, we present the recent results of several studies evaluating different therapeutic approaches for treating patients with oncogenic ERBB3 mutations.	[Kiavue, Nicolas; Cabel, Luc; Melaabi, Samia; Bataillon, Guillaume; Callens, Celine; Lerebours, Florence; Pierga, Jean-Yves; Bidard, Francois-Clement] PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France; [Cabel, Luc; Bidard, Francois-Clement] Versailles St Quentin en Yvelines Univ, Paris Saclay Univ, Paris, France; [Pierga, Jean-Yves] Paris Descartes Univ, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite	Bidard, FC (corresponding author), PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France.; Bidard, FC (corresponding author), Versailles St Quentin en Yvelines Univ, Paris Saclay Univ, Paris, France.	francois-clement.bidard@curie.fr						Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Bidard FC, 2015, ANN ONCOL, V26, P1704, DOI 10.1093/annonc/mdv217; Bose R, 2009, EXP CELL RES, V315, P649, DOI 10.1016/j.yexcr.2008.07.031; Brand TM, 2018, CANCER RES, V78, P2383, DOI 10.1158/0008-5472.CAN-17-1672; Braunstein EM, 2016, LEUKEMIA, V30, P2242, DOI 10.1038/leu.2016.173; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Burk RD, 2017, NATURE, V543, P378, DOI 10.1038/nature21386; Burstein HJ, 2010, J CLIN ONCOL, V28, P1301, DOI 10.1200/JCO.2009.25.8707; Cabel L, 2018, JCO PRECIS ONCOL, V2, P1, DOI 10.1200/PO.17.00243; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chae J, 2018, BMB REP, V51, P584, DOI 10.5483/BMBRep.2018.51.11.091; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chang MT, 2018, CANCER DISCOV, V8, P174, DOI 10.1158/2159-8290.CD-17-0321; Chang MT, 2016, NAT BIOTECHNOL, V34, P155, DOI 10.1038/nbt.3391; Chiou VL, 2015, J CLIN ONCOL, V33, P3541, DOI 10.1200/JCO.2015.61.6870; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Choudhury NJ, 2016, J CLIN ONCOL, V34, P2165, DOI 10.1200/JCO.2015.66.3047; Collier TS, 2013, J BIOL CHEM, V288, P25254, DOI 10.1074/jbc.M113.474882; Connell CM, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2017-000279; DeMatteo RP, 2009, LANCET, V373, P1097, DOI 10.1016/S0140-6736(09)60500-6; Deniziaut G, 2016, ONCOTARGET, V7, P73337, DOI 10.18632/oncotarget.11819; Desmedt C, 2016, J CLIN ONCOL, V34, P1872, DOI 10.1200/JCO.2015.64.0334; Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Frazier NM, 2019, ONCOGENE, V38, P1936, DOI 10.1038/s41388-018-0537-0; Gaborit N, 2016, HUM VACC IMMUNOTHER, V12, P576, DOI 10.1080/21645515.2015.1102809; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Hanninen UA, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007200; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Hutcheson IR, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2848; Hyman DM, 2018, NATURE, V554, P189, DOI 10.1038/nature25475; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Jaiswal BS, 2013, CANCER CELL, V23, P603, DOI 10.1016/j.ccr.2013.04.012; Jeong EG, 2006, INT J CANCER, V119, P2986, DOI 10.1002/ijc.22257; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Kennedy SP, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00088; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Kumar A, 2008, J CLIN ONCOL, V26, P1742, DOI 10.1200/JCO.2007.12.1178; Li M, 2018, GUT; Li ML, 2014, NAT GENET, V46, P872, DOI 10.1038/ng.3030; Littlefield P, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005786; Loree JM, 2018, JNCI-J NATL CANCER I, V110, P1409, DOI 10.1093/jnci/djy067; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Migden MR, 2018, NEW ENGL J MED, V379, P341, DOI 10.1056/NEJMoa1805131; Milewska M, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758834017746040; Mishra R, 2018, ONCOTARGET, V9; Mishra R, 2018, ONCOL REV, V12, P45, DOI 10.4081/oncol.2018.355; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Narayan M, 2009, CANCER RES, V69, P2191, DOI 10.1158/0008-5472.CAN-08-1056; Narkis G, 2007, AM J HUM GENET, V81, P589, DOI 10.1086/520770; Petrelli F, 2017, BREAST CANCER RES TR, V166, P339, DOI 10.1007/s10549-017-4419-x; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Ross JS, 2018, CANCER-AM CANCER SOC, V124, P1358, DOI 10.1002/cncr.31125; Schrock AB, 2017, JAMA ONCOL, V3, P1546, DOI 10.1001/jamaoncol.2017.1051; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Sithanandam G, 2008, CANCER GENE THER, V15, P413, DOI 10.1038/cgt.2008.15; Skoulidis F, 2015, CANCER DISCOV, V5, P860, DOI 10.1158/2159-8290.CD-14-1236; Steinkamp MP, 2014, MOL CELL BIOL, V34, P965, DOI 10.1128/MCB.01605-13; Strickley JD, 2018, EXP HEMATOL ONCOL, V7, DOI 10.1186/s40164-018-0111-z; Tamura S, 2018, BLADDER CANCER, V4, P77, DOI 10.3233/BLC-170144; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Umelo I, 2016, ONCOTARGET, V7, P3068, DOI 10.18632/oncotarget.6585; Verlingue L, 2018, EUR J CANCER, V92, P1, DOI 10.1016/j.ejca.2017.12.020; Wang SZE, 2006, CANCER CELL, V10, P25, DOI 10.1016/j.ccr.2006.05.023; Wang ZX, 2017, METHODS MOL BIOL, V1652, P3, DOI 10.1007/978-1-4939-7219-7_1; Watson P, 2005, FAM CANCER, V4, P245, DOI 10.1007/s10689-004-7994-z; Yin MX, 2015, ACTA BIOCH BIOPH SIN, V47, P39, DOI 10.1093/abbs/gmu111; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	81	46	49	3	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					487	502		10.1038/s41388-019-1001-5	http://dx.doi.org/10.1038/s41388-019-1001-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31519989				2022-12-17	WOS:000509718300001
J	Lan, Q; Peyvandi, S; Duffey, N; Huang, YT; Barras, D; Held, W; Richard, F; Delorenzi, M; Sotiriou, C; Desmedt, C; Lorusso, G; Ruegg, C				Lan, Qiang; Peyvandi, Sanam; Duffey, Nathalie; Huang, Yu-Ting; Barras, David; Held, Werner; Richard, Francois; Delorenzi, Mauro; Sotiriou, Christos; Desmedt, Christine; Lorusso, Girieca; Ruegg, Curzio			Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer	ONCOGENE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; IMMUNE-MEDIATED DORMANCY; CELLS; METASTASIS; MECHANISMS; EXPRESSION; RESISTANCE; PATHWAY; SITE	Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer patients, in particular in estrogen receptor negative (ER-) cancers, by reducing rates of recurrences. It is assumed that the benefits of (neo)adjuvant chemotherapy are due to the killing of disseminated, residual cancer cells, however, there is no formal evidence for it. Here, we provide experimental evidence that ER- breast cancer cells that survived high-dose Doxorubicin and Methotrexate based chemotherapies elicit a state of immunological dormancy. Hallmark of this dormant phenotype is the sustained activation of the IRF7/IFN-beta/IFNAR axis subsisting beyond chemotherapy treatment. Upregulation of IRF7 in treated cancer cells promoted resistance to chemotherapy, reduced cell growth and induced switching of the response from a myeloid derived suppressor cell-dominated immune response to a CD4(+)/CD8(+) T cell-dependent anti-tumor response. IRF7 silencing in tumor cells or systemic blocking of IFNAR reversed the state of dormancy, while spontaneous escape from dormancy was associated with loss of IFN-beta production. Presence of IFN-beta in the circulation of ER- breast cancer patients treated with neoadjuvant Epirubicin chemotherapy correlated with a significantly longer distant metastasis-free survival. These findings establish chemotherapy-induced immunological dormancy in ER- breast cancer as a novel concept for (neo)adjuvant chemotherapy activity, and implicate sustained activation of the IRF7/IFN-beta/IFNAR pathway in this effect. Further, IFN-beta emerges as a potential predictive biomarker and therapeutic molecule to improve outcome of ER- breast cancer patients treated with (neo)adjuvant chemotherapy.	[Lan, Qiang; Peyvandi, Sanam; Duffey, Nathalie; Huang, Yu-Ting; Lorusso, Girieca; Ruegg, Curzio] Univ Fribourg, Pathol Unit, Dept Oncol Microbiol & Immunol OMI, Fac Sci & Med, CH-1700 Fribourg, Switzerland; [Lan, Qiang; Huang, Yu-Ting; Lorusso, Girieca; Ruegg, Curzio] Ecole Polytech Fed Lausanne, NCCR, Swiss Inst Expt Canc Res ISREC, Mol Oncol, CH-1015 Lausanne, Switzerland; [Barras, David; Delorenzi, Mauro] SIB, CH-1015 Lausanne, Switzerland; [Held, Werner; Delorenzi, Mauro] Ludwig Inst Canc Res, CH-1066 Epalinges, Switzerland; [Held, Werner; Delorenzi, Mauro] Univ Lausanne, Dept Fundamental Oncol, CH-1011 Lausanne, Switzerland; [Richard, Francois; Sotiriou, Christos; Desmedt, Christine] Univ Libre Bruxelles, Breast Canc Translat Res Lab, Inst Jules Bordet, B-1000 Brussels, Belgium; [Ruegg, Curzio] Swiss Integrat Ctr Human Hlth, Fribourg, Switzerland; [Lan, Qiang] Univ Helsinki, Dev Biol Program, Inst Biotechnol, Helsinki, Finland	University of Fribourg; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; Swiss Institute of Bioinformatics; Ludwig Institute for Cancer Research; University of Lausanne; Institut Jules Bordet; Universite Libre de Bruxelles; University of Helsinki	Ruegg, C (corresponding author), Univ Fribourg, Pathol Unit, Dept Oncol Microbiol & Immunol OMI, Fac Sci & Med, CH-1700 Fribourg, Switzerland.; Ruegg, C (corresponding author), Ecole Polytech Fed Lausanne, NCCR, Swiss Inst Expt Canc Res ISREC, Mol Oncol, CH-1015 Lausanne, Switzerland.; Ruegg, C (corresponding author), Swiss Integrat Ctr Human Hlth, Fribourg, Switzerland.	curzio.ruegg@unifr.ch	RICHARD, François/AAA-4193-2021; Desmedt, Christine/P-7438-2017	RICHARD, François/0000-0003-4353-3619; Lorusso, Girieca/0000-0002-2807-3207; Desmedt, Christine/0000-0002-5223-5579; Lan, Qiang/0000-0002-7765-6767	Swiss National Science Foundation [31003A_159824]; Swiss Cancer League [KFS-2814-08-2011]; Medic Foundation; Molecular Oncology Program of the National Center of Competence in Research (NCCR)	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League; Medic Foundation; Molecular Oncology Program of the National Center of Competence in Research (NCCR)	We thank Dr. J. Sleeman (Medical Faculty at Heidelberg University, Mannheim, Germany) for providing D2A1/D2.0R cells, Dr. Fred R. Miller (Michigan Cancer Foundation, Detroit, MI, USA) for providing 4T1 cells, Dr. Khalil Zaman (Department of Oncology), University Hospital, University of Lausanne, Lausanne, Switzerland) for providing chemotherapeutic drugs. This work was supported by grants from Swiss National Science Foundation (31003A_159824), The Swiss Cancer League (KFS-2814-08-2011); the Medic Foundation, the Molecular Oncology Program of the National Center of Competence in Research (NCCR), a research instrument of the Swiss National Science Foundation.	Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Anampa J, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0439-8; Barkan D, 2011, JOVE-J VIS EXP, DOI 10.3791/2914; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bidwell BN, 2012, NAT MED, V18, P1224, DOI 10.1038/nm.2830; Castiello L, 2018, CANCER IMMUNOL RES, V6, P658, DOI 10.1158/2326-6066.CIR-17-0675; DEMICHELI R, 1994, J NATL CANCER I, V86, P45; Demicheli R, 2001, SEMIN CANCER BIOL, V11, P297, DOI 10.1006/scbi.2001.0385; Demicheli R, 2007, NAT CLIN PRACT ONCOL, V4, P699, DOI 10.1038/ncponc0999; Desmedt C, 2008, CLIN CANCER RES, V14, P5158, DOI 10.1158/1078-0432.CCR-07-4756; Desmedt C, 2011, J CLIN ONCOL, V29, P1578, DOI 10.1200/JCO.2010.31.2231; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Dunn GP, 2005, NAT IMMUNOL, V6, P722, DOI 10.1038/ni1213; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Dushyanthen S, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0431-3; Ejlertsen B, 2016, DAN MED J, V63; Erdal E, 2017, GENE DEV, V31, P353, DOI 10.1101/gad.289769.116; Forero A, 2016, CANCER IMMUNOL RES, V4, P390, DOI 10.1158/2326-6066.CIR-15-0243; Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012; Goodison S, 2003, CLIN CANCER RES, V9, P3808; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Ignatiadis M, 2012, J CLIN ONCOL, V30, P1996, DOI 10.1200/JCO.2011.39.5624; Joensuu H, 2012, ANN ONCOL, V23, P40, DOI 10.1093/annonc/mds194; Kim ST, 2013, AM J CLIN ONCOL-CANC, V36, P224, DOI 10.1097/COC.0b013e3182467d90; Kim TK, 2000, CANCER RES, V60, P1153; Kim YA, 2016, BREAST CANCER RES TR, V156, P597, DOI 10.1007/s10549-016-3786-z; Klauber-DeMore N, 2001, CLIN CANCER RES, V7, P2434; Kroemer G, 2015, NAT MED, V21, P1128, DOI 10.1038/nm.3944; Lee HJ, 2016, J CLIN PATHOL, V69, P422, DOI 10.1136/jclinpath-2015-203089; Legrier M-E, 2015, BRIT J CANCER, V114, P177; Liu L, 2018, CLIN CANCER RES, V24, P2370, DOI 10.1158/1078-0432.CCR-17-2545; Liu YY, 2018, J CLIN INVEST, V128, P1057, DOI 10.1172/JCI96329; Ma Y, 2013, IMMUNITY, V38, P729, DOI 10.1016/j.immuni.2013.03.003; Monnier Y, 2008, CANCER RES, V68, P7323, DOI 10.1158/0008-5472.CAN-08-0841; MORRIS VL, 1993, CLIN EXP METASTAS, V11, P103, DOI 10.1007/BF00880071; Munzone E, 2012, ANN ONCOL, V23, P305, DOI 10.1093/annonc/mdr309; Naumov GN, 2002, CANCER RES, V62, P2162; Paez D, 2012, CLIN CANCER RES, V18, P645, DOI 10.1158/1078-0432.CCR-11-2186; Perez EA, 2015, J CLIN ONCOL, V33, P701, DOI 10.1200/JCO.2014.57.6298; Romero I, 2014, CANCER RES, V74, P6750, DOI 10.1158/0008-5472.CAN-14-2406; Rubovszky G, 2017, J BREAST CANCER, V20, P119, DOI 10.4048/jbc.2017.20.2.119; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Shultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017; Sisirak V, 2012, CANCER RES, V72, P5188, DOI 10.1158/0008-5472.CAN-11-3468; Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Stanton SE, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0165-6; Teng MWL, 2008, J LEUKOCYTE BIOL, V84, P988, DOI 10.1189/jlb.1107774; Teschendorff AE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r157; Wang K, 2016, ONCOTARGET, V7, P44288, DOI 10.18632/oncotarget.9988; Weichselbaum RR, 2008, P NATL ACAD SCI USA, V105, P18490, DOI 10.1073/pnas.0809242105	53	46	48	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2814	2829		10.1038/s41388-018-0624-2	http://dx.doi.org/10.1038/s41388-018-0624-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30546090	Green Published, hybrid			2022-12-17	WOS:000464121600011
